PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ishikawa, K; Takenaga, K; Akimoto, M; Koshikawa, N; Yamaguchi, A; Imanishi, H; Nakada, K; Honma, Y; Hayashi, J				Ishikawa, Kaori; Takenaga, Keizo; Akimoto, Miho; Koshikawa, Nobuko; Yamaguchi, Aya; Imanishi, Hirotake; Nakada, Kazuto; Honma, Yoshio; Hayashi, Jun-Ichi			ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis	SCIENCE			English	Article							LUNG-CARCINOMA CELLS; PREVENTION; MOUSE; TUMORIGENICITY; PARAGANGLIOMA; APOPTOSIS; BINDING; GENOME; CANCER; MTDNA	Mutations in mitochondrial DNA ( mtDNA) occur at high frequency in human tumors, but whether these mutations alter tumor cell behavior has been unclear. We used cytoplasmic hybrid ( cybrid) technology to replace the endogenous mtDNA in a mouse tumor cell line that was poorly metastatic with mtDNA from a cell line that was highly metastatic, and vice versa. Using assays of metastasis in mice, we found that the recipient tumor cells acquired the metastatic potential of the transferred mtDNA. The mtDNA conferring high metastatic potential contained G13997A and 13885insC mutations in the gene encoding NADH ( reduced form of nicotinamide adenine dinucleotide) dehydrogenase subunit 6 (ND6). These mutations produced a deficiency in respiratory complex I activity and were associated with overproduction of reactive oxygen species ( ROS). Pretreatment of the highly metastatic tumor cells with ROS scavengers suppressed their metastatic potential in mice. These results indicate that mtDNA mutations can contribute to tumor progression by enhancing the metastatic potential of tumor cells.	[Ishikawa, Kaori; Yamaguchi, Aya; Imanishi, Hirotake; Nakada, Kazuto; Hayashi, Jun-Ichi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; [Ishikawa, Kaori; Nakada, Kazuto] Univ Tsukuba, Tsukuba Adv Res Alliance Ctr, Tsukuba, Ibaraki 3058572, Japan; [Ishikawa, Kaori] Japan Soc Promot Sci, Chiyoda Ku, Tokyo 1028472, Japan; [Takenaga, Keizo; Koshikawa, Nobuko] Chiba Canc Ctr, Res Inst, Div Chemotherapy, Chuo Ku, Chiba 2608717, Japan; [Takenaga, Keizo; Akimoto, Miho; Honma, Yoshio] Shimane Univ, Fac Med, Izumo, Shimane 6938501, Japan	University of Tsukuba; University of Tsukuba; Japan Society for the Promotion of Science; Chiba Cancer Center; Shimane University	Hayashi, J (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.	jih45@sakura.cc.tsukuba.ac.jp		ISHIKAWA, Kaori/0000-0001-9895-5996				ALLEN JA, 1980, NATURE, V287, P244, DOI 10.1038/287244a0; Augenlicht LH, 2001, NAT GENET, V28, P104, DOI 10.1038/88800; BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; Czarnecka AM, 2006, J APPL GENET, V47, P67, DOI 10.1007/BF03194602; DeFlora S, 1996, INT J CANCER, V67, P842, DOI 10.1002/(SICI)1097-0215(19960917)67:6<842::AID-IJC14>3.0.CO;2-3; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Gallardo ME, 2006, HUM MUTAT, V27, P575, DOI 10.1002/humu.20338; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; Koshikawa N, 2006, ONCOGENE, V25, P917, DOI 10.1038/sj.onc.1209128; Koshikawa N, 2003, ONCOGENE, V22, P6717, DOI 10.1038/sj.onc.1206765; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Salas A, 2005, PLOS MED, V2, P1158, DOI 10.1371/journal.pmed.0020296; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Shitara H, 1998, GENETICS, V148, P851; Takasu M, 1999, CLIN EXP METASTAS, V17, P409, DOI 10.1023/A:1006632819086; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	26	1001	1045	2	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2008	320	5876					661	664		10.1126/science.1156906	http://dx.doi.org/10.1126/science.1156906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	295DD	18388260	Green Submitted			2022-12-28	WOS:000255454300045
J	Belloc, E; Mendez, R				Belloc, Eulalia; Mendez, Raul			A deadenylation negative feedback mechanism governs meiotic metaphase arrest	NATURE			English	Article							CYTOSTATIC FACTOR ARREST; ANAPHASE-PROMOTING COMPLEX; ZINC-FINGER PROTEINS; CYTOPLASMIC POLYADENYLATION; MESSENGER-RNA; XENOPUS-LAEVIS; POSITIVE FEEDBACK; BINDING PROTEIN; II TRANSITION; MEIOSIS-I	In vertebrate oocytes, meiotic progression is driven by the sequential translational activation of maternal messenger RNAs stored in the cytoplasm. This activation is mainly induced by the cytoplasmic elongation of their poly( A) tails, which is mediated by the cytoplasmic polyadenylation element ( CPE) present in their 39 untranslated regions(1,2). In Xenopus oocytes, sequential phase-specific translation of CPE- regulated mRNAs is required to activate the maturation- promoting factor, which in turn mediates entry into the two consecutive meiotic metaphases ( MI and MII)(3-6). Here we report a genome- wide functional screening to identify previously unknown mRNAs cytoplasmically polyadenylated at meiotic phase transitions. A significant fraction of transcripts containing, in addition to CPEs, ( A+U)- rich element ( ARE) sequences ( characteristic of mRNAs regulated by deadenylation(7)) were identified. Among these is the mRNA encoding C3H-4, an ARE- binding protein that we find to accumulate in MI and the ablation of which induces meiotic arrest. Our results suggest that C3H- 4 recruits the CCR4 deadenylase complex to ARE-containing mRNAs and this, in turn, causes shortening of poly( A) tails. We also show that the opposing activities of the CPEs and the AREs define the precise activation times of the mRNAs encoding the anaphase- promoting complex inhibitors Emi1 and Emi2 during distinct phases of the meiotic cycle. Taken together, our results show that an 'early' wave of cytoplasmic polyadenylation activates a negative feedback loop by activating the synthesis of C3H- 4, which in turn would recruit the deadenylase complex to mRNAs containing both CPEs and AREs. This negative feedback loop is required to exit from metaphase into interkinesis and for meiotic progression.	[Belloc, Eulalia; Mendez, Raul] Pompeu Fabra Univ, Ctr Genom Regulat, Barcelona 08003, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG)	Mendez, R (corresponding author), Pompeu Fabra Univ, Ctr Genom Regulat, C Dr Aiguader 88, Barcelona 08003, Spain.	raul.mendez@crg.es		Mendez, Raul/0000-0002-1952-6905				Aoki K, 2003, J BIOL CHEM, V278, P48491, DOI 10.1074/jbc.M308328200; Ballantyne S, 1997, MOL BIOL CELL, V8, P1633, DOI 10.1091/mbc.8.8.1633; Brandman O, 2005, SCIENCE, V310, P496, DOI 10.1126/science.1113834; Castro A, 2003, J BIOL CHEM, V278, P2236, DOI 10.1074/jbc.M207894200; Charlesworth A, 2004, J BIOL CHEM, V279, P17650, DOI 10.1074/jbc.M313837200; Charlesworth A, 2000, DEV BIOL, V227, P706, DOI 10.1006/dbio.2000.9922; Collart MA, 2003, GENE, V313, P1, DOI 10.1016/S0378-1119(03)00672-3; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; Ferrell JE, 1999, BIOESSAYS, V21, P866, DOI 10.1002/(SICI)1521-1878(199910)21:10<866::AID-BIES9>3.0.CO;2-1; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Inoue D, 2007, NATURE, V446, P1100, DOI 10.1038/nature05688; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Liu J, 2007, ONCOGENE, V26, P1286, DOI 10.1038/sj.onc.1210203; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Mendez R, 2000, MOL CELL, V6, P1253, DOI 10.1016/S1097-2765(00)00121-0; Mendez R, 2002, EMBO J, V21, P1833, DOI 10.1093/emboj/21.7.1833; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Morita M, 2007, MOL CELL BIOL, V27, P4980, DOI 10.1128/MCB.02304-06; Nishiyama T, 2007, NATURE, V446, P1096, DOI 10.1038/nature05696; Ohe M, 2007, DEV BIOL, V303, P157, DOI 10.1016/j.ydbio.2006.10.044; Parry DH, 2003, CURR BIOL, V13, P647, DOI 10.1016/S0960-9822(03)00242-2; Pique M, 2008, CELL, V132, P434, DOI 10.1016/j.cell.2007.12.038; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Richter JD, 2007, TRENDS BIOCHEM SCI, V32, P279, DOI 10.1016/j.tibs.2007.04.004; SIMON R, 1994, MOL CELL BIOL, V14, P7867, DOI 10.1128/MCB.14.12.7867; Tung JJ, 2007, CELL CYCLE, V6, P725, DOI 10.4161/cc.6.6.3936; Tung JJ, 2005, P NATL ACAD SCI USA, V102, P4318, DOI 10.1073/pnas.0501108102; Voeltz GK, 1998, MOL CELL BIOL, V18, P7537, DOI 10.1128/MCB.18.12.7537; Wu L, 1997, MOL CELL BIOL, V17, P6402, DOI 10.1128/MCB.17.11.6402; Yang ZY, 2005, MOL CELL BIOL, V25, P4062, DOI 10.1128/MCB.25.10.4062-4074.2005	34	78	79	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2008	452	7190					1017	U11		10.1038/nature06809	http://dx.doi.org/10.1038/nature06809			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291PF	18385675				2022-12-28	WOS:000255208600044
J	Berezovsky, J; Mikkelsen, MH; Stoltz, NG; Coldren, LA; Awschalom, DD				Berezovsky, J.; Mikkelsen, M. H.; Stoltz, N. G.; Coldren, L. A.; Awschalom, D. D.			Picosecond coherent optical manipulation of a single electron spin in a quantum dot	SCIENCE			English	Article							SPECTRA; FIELDS	Most schemes for quantum information processing require fast single- qubit operations. For spin-based qubits, this involves performing arbitrary coherent rotations of the spin state on time scales much faster than the spin coherence time. By applying off- resonant, picosecond- scale optical pulses, we demonstrated the coherent rotation of a single electron spin through arbitrary angles up to p radians. We directly observed this spin manipulation using time- resolved Kerr rotation spectroscopy and found that the results are well described by a model that includes the electron-nuclear spin interaction. Measurements of the spin rotation as a function of laser detuning and intensity confirmed that the optical Stark effect is the operative mechanism.	[Berezovsky, J.; Mikkelsen, M. H.; Stoltz, N. G.; Coldren, L. A.; Awschalom, D. D.] Univ Calif Santa Barbara, Ctr Spintron & Quantum Computat, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Awschalom, DD (corresponding author), Univ Calif Santa Barbara, Ctr Spintron & Quantum Computat, Santa Barbara, CA 93106 USA.	awsch@physics.ucsb.edu	Mikkelsen, Maiken H/D-8211-2011	Mikkelsen, Maiken H/0000-0002-0487-7585				Atature M, 2007, NAT PHYS, V3, P101, DOI 10.1038/nphys521; Berezovsky J, 2006, SCIENCE, V314, P1916, DOI 10.1126/science.1133862; Carter SG, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.201308; Chen PC, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.075320; Clark SM, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.040501; COHENTANNOUDJI C, 1972, PHYS REV A-GEN PHYS, V5, P968, DOI 10.1103/PhysRevA.5.968; COHENTANNOUDJI C, 1977, J PHYS B-AT MOL OPT, V10, P345, DOI 10.1088/0022-3700/10/3/005; COMBESCOT M, 1988, PHYS REV LETT, V61, P117, DOI 10.1103/PhysRevLett.61.117; Combescot M, 2004, SOLID STATE COMMUN, V132, P129, DOI 10.1016/j.ssc.2004.06.025; Economou SE, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.205415; Gammon D, 2001, PHYS REV LETT, V86, P5176, DOI 10.1103/PhysRevLett.86.5176; Greilich A, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.233301; Gupta JA, 2001, SCIENCE, V292, P2458, DOI 10.1126/science.1061169; GURUDEV MV, 2006, PHYS REV B, V74, DOI UNSP 125306; Imamoglu A, 1999, PHYS REV LETT, V83, P4204, DOI 10.1103/PhysRevLett.83.4204; JOFFRE M, 1989, PHYS REV LETT, V62, P74, DOI 10.1103/PhysRevLett.62.74; Koppens FHL, 2006, NATURE, V442, P766, DOI 10.1038/nature05065; Meier F., 1984, OPTICAL ORIENTATION; Mikkelsen MH, 2007, NAT PHYS, V3, P770, DOI 10.1038/nphys736; Nowack KC, 2007, SCIENCE, V318, P1430, DOI 10.1126/science.1148092; Papageorgiou G, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.085311; Pryor CE, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2206679; ROSATZIN M, 1990, PHYS REV A, V42, P1839, DOI 10.1103/PhysRevA.42.1839; SUTER D, 1991, PHYS REV LETT, V67, P2001, DOI 10.1103/PhysRevLett.67.2001; Unold T, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.157401; VONLEHMEN A, 1987, PHYS REV B, V35, P6479, DOI 10.1103/PhysRevB.35.6479; Wu Y, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.097402; [No title captured]	28	427	429	3	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					349	352		10.1126/science.1154798	http://dx.doi.org/10.1126/science.1154798			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420929				2022-12-28	WOS:000255026100036
J	Callender, C; Quinn, I; Tymoczko, D				Callender, Clifton; Quinn, Ian; Tymoczko, Dmitri			Generalized voice-leading spaces	SCIENCE			English	Article								Western musicians traditionally classify pitch sequences by disregarding the effects of five musical transformations: octave shift, permutation, transposition, inversion, and cardinality change. We model this process mathematically, showing that it produces 32 equivalence relations on chords, 243 equivalence relations on chord sequences, and 32 families of geometrical quotient spaces, in which both chords and chord sequences are represented. This model reveals connections between music- theoretical concepts, yields new analytical tools, unifies existing geometrical representations, and suggests a way to understand similarity between chord types.	[Tymoczko, Dmitri] Princeton Univ, Dept Mus, Princeton, NJ 08544 USA; [Callender, Clifton] Florida State Univ, Coll Mus, Tallahassee, FL 32306 USA; [Quinn, Ian] Yale Univ, Dept Mus, New Haven, CT 06520 USA	Princeton University; State University System of Florida; Florida State University; Yale University	Tymoczko, D (corresponding author), Princeton Univ, Dept Mus, Princeton, NJ 08544 USA.	dmitri@princeton.edu						BOTT R, 1952, FUND MATH, V39, P264; Callender Clifton., 2004, MUSIC THEORY ONLINE, V10, P3; Cohn Richard., 2003, MUSIC THEORY ONLINE, V9; HAIMO E, 1996, MUSIC THEORY SPECTRU, V18; Klumpenhouwer Henry., 1991, THESIS HARVARD U; Lewin David, 1987, GEN MUSICAL INTERVAL; Mazzola G., 2002, TOPOS MUSIC; MORRIS RD, 1993, MUSIC THEOR SPECTRUM, V15, P205, DOI 10.1525/mts.1993.15.2.02a00040; Quinn Ian, 2001, PERSPECT NEW MUSIC, V39, P108; Rameau J.-P., 1971, TREATISE ON HARMONY; RAN Z, 1993, INT MATH RES, P93; Straus JN, 2003, MUSIC THEOR SPECTRUM, V25, P305, DOI 10.1525/mts.2003.25.2.305; Tuffley C., 2002, ALGEBR GEOM TOPOL, V2, P1119, DOI [10.2140/agt.2002.2.1119, DOI 10.2140/AGT.2002.2.1119]; TYMOCZKO D, 2004, ANN M SOC MUS THEOR; Tymoczko D, 2006, SCIENCE, V313, P72, DOI 10.1126/science.1126287	15	83	83	3	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					346	348		10.1126/science.1153021	http://dx.doi.org/10.1126/science.1153021			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420928				2022-12-28	WOS:000255026100035
J	Galkin, VE; Yu, X; Bielnicki, J; Heuser, J; Ewing, CP; Guerry, P; Egelman, EH				Galkin, Vitold E.; Yu, Xiong; Bielnicki, Jakub; Heuser, John; Ewing, Cheryl P.; Guerry, Patricia; Egelman, Edward H.			Divergence of quaternary structures among bacterial flagellar filaments	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; MOTILITY; TRANSFORMATIONS; MUTATIONS; SEQUENCE	It has been widely assumed that the atomic structure of the flagellar filament from Salmonella typhimurium serves as a model for all bacterial flagellar filaments given the sequence conservation in the coiled- coil regions responsible for polymerization. On the basis of electron microscopic images, we show that the flagellar filaments from Campylobacter jejuni have seven protofilaments rather than the 11 in S. typhimurium. The vertebrate Toll- like receptor 5 ( TLR5) recognizes a region of bacterial flagellin that is involved in subunit- subunit assembly in Salmonella and many other pathogenic bacteria, and this short region has diverged in Campylobacter and related bacteria, such as Helicobacter pylori, which are not recognized by TLR5. The driving force in the change of quaternary structure between Salmonella and Campylobacter may have been the evasion of TLR5.	[Galkin, Vitold E.; Yu, Xiong; Bielnicki, Jakub; Egelman, Edward H.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Heuser, John] Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; [Ewing, Cheryl P.; Guerry, Patricia] USN, Enter Dis Dept, Med Res Ctr, Silver Spring, MD 20910 USA	University of Virginia; Washington University (WUSTL); United States Department of Defense; United States Navy	Egelman, EH (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Box 800733, Charlottesville, VA 22908 USA.	egelman@virginia.edu	Egelman, Edward H/A-2488-2009; Guerry, Patricia/A-8024-2011; Galkin, Vitold/AAD-2844-2019	Egelman, Edward/0000-0003-4844-5212	NIAID NIH HHS [AI043559] Funding Source: Medline; NIBIB NIH HHS [EB001567] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001567] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Andersen-Nissen E, 2005, P NATL ACAD SCI USA, V102, P9247, DOI 10.1073/pnas.0502040102; Asakura S, 1970, Adv Biophys, V1, P99; Beatson SA, 2006, TRENDS MICROBIOL, V14, P151, DOI 10.1016/j.tim.2006.02.008; CALLADINE CR, 1975, NATURE, V255, P121, DOI 10.1038/255121a0; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; Frank MK, 2002, NAT STRUCT BIOL, V9, P877, DOI 10.1038/nsb854; GUERRY P, 1991, J BACTERIOL, V173, P4757, DOI 10.1128/jb.173.15.4757-4764.1991; Guerry P, 2007, TRENDS MICROBIOL, V15, P456, DOI 10.1016/j.tim.2007.09.006; Heuser J, 1981, Methods Cell Biol, V22, P97; HOTANI H, 1982, J MOL BIOL, V156, P791, DOI 10.1016/0022-2836(82)90142-5; HYMAN HC, 1991, J MOL BIOL, V220, P79, DOI 10.1016/0022-2836(91)90382-G; KAMIYA R, 1976, J MOL BIOL, V106, P167, DOI 10.1016/0022-2836(76)90306-5; KAMIYA R, 1976, J MOL BIOL, V108, P513, DOI 10.1016/S0022-2836(76)80133-7; KANTO S, 1991, J MOL BIOL, V219, P471, DOI 10.1016/0022-2836(91)90187-B; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Orlova A, 2007, NAT STRUCT MOL BIOL, V14, P921, DOI 10.1038/nsmb1300; Ramos HC, 2004, TRENDS MICROBIOL, V12, P509, DOI 10.1016/j.tim.2004.09.002; Shibata S, 2005, J MOL BIOL, V352, P510, DOI 10.1016/j.jmb.2005.07.023; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Woodward JD, 2008, J STRUCT BIOL, V161, P111, DOI 10.1016/j.jsb.2007.09.019; Yamashita I, 1998, NAT STRUCT BIOL, V5, P125; Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830	25	86	89	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					382	385		10.1126/science.1155307	http://dx.doi.org/10.1126/science.1155307			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420936				2022-12-28	WOS:000255026100046
J	Valgimigli, M; Campo, G; Percoco, G; Bolognese, L; Vassanelli, C; Colangelo, S; de Cesare, N; Rodriguez, AE; Ferrario, M; Moreno, R; Piva, T; Sheiban, I; Pasquetto, G; Prati, F; Nazzaro, MS; Parrinello, G; Ferrari, R				Valgimigli, Marco; Campo, Gianluca; Percoco, Gianfranco; Bolognese, Leonardo; Vassanelli, Corrado; Colangelo, Salvatore; de Cesare, Nicoletta; Rodriguez, Alfredo E.; Ferrario, Maurizio; Moreno, Raul; Piva, Tommaso; Sheiban, Imad; Pasquetto, Giampaolo; Prati, Francesco; Nazzaro, Marco S.; Parrinello, Giovanni; Ferrari, Roberto		MULTISTRATEGY Investigators	Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction - The MULTISTRATEGY randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BARE-METAL STENT; CORONARY INTERVENTION; PLATELET-AGGREGATION; REPERFUSION; THERAPY; BOLUS; INHIBITION; IIB/IIIA; THROMBOCYTOPENIA; METAANALYSIS	Context Abciximab infusion and uncoated- stent implantation is a complementary treatment strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST- segment elevation myocardial infarction ( STEMI). It is uncertain whether there may be similar benefits in replacing abciximab with high- dose bolus tirofiban. Similarly, the use of drug- eluting stents in this patient population is currently discouraged because of conflicting results on efficacy reported in randomized trials and safety concerns reported by registries. Objective To evaluate the effect of high- dose bolus tirofiban and of sirolimus-eluting stents as compared with abciximab infusion and uncoated- stent implantation in patients with STEMI undergoing percutaneous coronary intervention. Design, Setting, and Patients An open- label, 2 x 2 factorial trial of 745 patients presenting with STEMI or new left bundle- branch block at 16 referral centers in Italy, Spain, and Argentina between October 2004 and April 2007. Interventions High- dose bolus tirofiban vs abciximab infusion and sirolimus-eluting stent vs uncoated stent implantation. Main Outcome Measures For drug comparison, at least 50% ST- segment elevation resolution at 90 minutes postintervention with a prespecified noninferiority margin of 9% difference ( relative risk, 0.89); for stent comparison, the rate of major adverse cardiac events, defined as the composite of death from any cause, reinfarction, and clinically driven target- vessel revascularization within 8 months. Results ST- segment resolution occurred in 302 of 361 patients ( 83.6%) who had received abciximab infusion and 308 of 361 ( 85.3%) who had received tirofiban infusion ( relative risk, 1.020; 97.5% confidence interval, 0.958- 1.086; P <. 001 for noninferiority). Ischemic and hemorrhagic outcomes were similar in the tirofiban and abciximab groups. At 8 months, major adverse cardiac events occurred in 54 patients ( 14.5%) with uncoated stents and 29 ( 7.8%) with sirolimus stents ( P=. 004), predominantly reflecting a reduction of revascularization rates ( 10.2% vs 3.2%). The incidence of stent thrombosis was similar in the 2 stent groups. Conclusions In patients with STEMI undergoing percutaneous coronary intervention, compared with abciximab, tirofiban therapy was associated with noninferior resolution of ST- segment elevation at 90 minutes following coronary intervention, whereas sirolimus- eluting stent implantation was associated with a significantly lower risk of major adverse cardiac events than uncoated stents within 8 months after intervention. Trial Registration clinicaltrials. gov Identifier: NCT00229515.	[Valgimigli, Marco; Campo, Gianluca; Percoco, Gianfranco; Ferrari, Roberto] Univ Ferrara, Cardiovasc Inst, I-44100 Ferrara, Italy; [Valgimigli, Marco; Ferrari, Roberto] IRCCS, Salvatore Maugeri Fdn, Cardiovasc Res Ctr, Brescia, Italy; [Bolognese, Leonardo] San Donato Hosp, Cardiovasc Dept, Arezzo, Italy; [Vassanelli, Corrado] Univ Verona, Dept Biomed & Surg Sci, Cardiol Sect, I-37100 Verona, Italy; [Colangelo, Salvatore] San Giovanni Bosco Hosp, Cardiovasc Intervent Lab, Turin, Italy; [de Cesare, Nicoletta] Policlin S Marco, Bergamo, Italy; [Rodriguez, Alfredo E.] Otamendi Hosp, Buenos Aires, DF, Argentina; [Ferrario, Maurizio] Policlin San Matteo, Ist Ricovero & Cura Carattere Sci, I-27100 Pavia, Italy; [Moreno, Raul] La Paz Univ Hosp, Madrid, Spain; [Piva, Tommaso] Azienda Osped Univ, Osped Riuniti Umberto I GM Lancisi, Ancona, Italy; [Sheiban, Imad] Univ Turin, San Giovanni Battista Hosp, Turin, Italy; [Pasquetto, Giampaolo] Civ Hosp, Dept Cardiol, Venice, Italy; [Prati, Francesco] Univ Cattolica Sacro Cuore, Dept Cardiovasc Med, I-00168 Rome, Italy; [Nazzaro, Marco S.] San Camillo Hosp, Rome, Italy; [Parrinello, Giovanni] Univ Brescia, Med Stat Unit, Brescia, Italy	University of Ferrara; Arcispedale Sant'Anna; IRCCS Fatebenefratelli; Istituti Clinici Scientifici Maugeri IRCCS; IRCCS Policlinico San Donato; University of Verona; IRCCS Fondazione San Matteo; Hospital Universitario La Paz; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Brescia	Valgimigli, M (corresponding author), Univ Ferrara, Cardiovasc Inst, Azienda Opedal, Corso Giovecca 203, I-44100 Ferrara, Italy.	vlgmrc@unife.it	Moreno, Raul/AAB-9983-2021; FERRARI, ROBERTO/ABD-5169-2020; Valgimigli, Marco/AAE-9103-2019	Valgimigli, Marco/0000-0002-4353-7110; Ferrari, Roberto/0000-0003-2046-9175; Moreno, Raul/0000-0001-7179-1426; Campo, Gianluca/0000-0002-5150-188X				Antoniucci D, 2004, CIRCULATION, V109, P1704, DOI 10.1161/01.CIR.0000126284.40075.98; Antoniucci D, 2003, J AM COLL CARDIOL, V42, P1879, DOI 10.1016/j.jacc.2003.07.017; Applegate RJ, 2008, J AM COLL CARDIOL, V51, P607, DOI 10.1016/j.jacc.2007.08.064; Aster RH, 2006, J THROMB HAEMOST, V4, P678, DOI 10.1111/j.1538-7836.2006.01829.x; Austin PC, 2004, AM STAT, V58, P131, DOI 10.1198/0003130043277; Bolognese L, 2006, J AM COLL CARDIOL, V47, P522, DOI 10.1016/j.jacc.2005.11.012; Campo G, 2006, J AM COLL CARDIOL, V48, P2178, DOI 10.1016/j.jacc.2005.12.085; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Danzi GB, 2006, AM J CARDIOL, V97, P489, DOI 10.1016/j.amjcard.2005.09.080; Danzi GB, 2004, AM J CARDIOL, V94, P35, DOI 10.1016/j.amjcard.2004.03.026; De Luca G, 2005, JAMA-J AM MED ASSOC, V293, P1759, DOI 10.1001/jama.293.14.1759; Dong J, 2002, CIRCULATION, V105, P2946, DOI 10.1161/01.CIR.0000022604.56986.FF; Ernst NMSKJ, 2004, J AM COLL CARDIOL, V44, P1187, DOI 10.1016/j.jacc.2004.06.050; Farb A, 2007, NEW ENGL J MED, V356, P984, DOI 10.1056/NEJMp068304; Frossard M, 2004, CIRCULATION, V110, P1392, DOI 10.1161/01.CIR.0000141575.92958.9C; Gershlick AH, 2005, NEW ENGL J MED, V353, P2758, DOI 10.1056/NEJMoa050849; Huczek Z, 2007, AM HEART J, V154, P62, DOI 10.1016/j.ahj.2007.03.021; Laarman GJ, 2006, NEW ENGL J MED, V355, P1105, DOI 10.1056/NEJMoa062598; Lele M, 2001, CIRCULATION, V104, P582, DOI 10.1161/hc3101.092199; Merlini PA, 2004, CIRCULATION, V109, P2203, DOI 10.1161/01.CIR.0000127867.41621.85; Montalescot G, 2007, EUR HEART J, V28, P443, DOI 10.1093/eurheartj/ehl472; Nordmann AJ, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005313; O'Neill WW, 2007, J AM COLL CARDIOL, V50, P397, DOI 10.1016/j.jacc.2007.01.099; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; Pinto DS, 2006, J AM COLL CARDIOL, V48, P32, DOI 10.1016/j.jacc.2006.02.060; Reininger AJ, 2000, THROMB HAEMOSTASIS, V83, P217; Roe MT, 2001, J AM COLL CARDIOL, V37, P9, DOI 10.1016/S0735-1097(00)01101-3; Sauerbrei W, 1999, J ROY STAT SOC C-APP, V48, P313, DOI 10.1111/1467-9876.00155; Schneider DJ, 2003, AM J CARDIOL, V91, P334, DOI 10.1016/S0002-9149(02)03163-6; Schroder R, 2004, CIRCULATION, V110, pE506, DOI 10.1161/01.CIR.0000147778.05979.E6; Spaulding C, 2006, NEW ENGL J MED, V355, P1093, DOI 10.1056/NEJMoa062006; Spertus JA, 2006, CIRCULATION, V113, P2803, DOI 10.1161/CIRCULATIONAHA.106.618066; Stoel MG, 2008, CATHETER CARDIO INTE, V71, P283, DOI 10.1002/ccd.21334; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; Topol EJ, 2003, J AM COLL CARDIOL, V42, P1886, DOI 10.1016/j.jacc.2003.09.010; Topol EJ, 2001, NEW ENGL J MED, V344, P1888, DOI 10.1056/NEJM200106213442502; Valgimigli M, 2005, JAMA-J AM MED ASSOC, V293, P2109, DOI 10.1001/jama.293.17.2109; Valgimigli M, 2004, J AM COLL CARDIOL, V44, P14, DOI 10.1016/j.jacc.2004.03.042; Valgimigli M, 2007, AM HEART J, V154, P39, DOI 10.1016/j.ahj.2007.03.023; Valgimigli M, 2006, NEW ENGL J MED, V355, P2484; vantHof AWJ, 1997, LANCET, V350, P615, DOI 10.1016/S0140-6736(96)07120-6; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482	42	209	225	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1788	1799		10.1001/jama.299.15.joc80026	http://dx.doi.org/10.1001/jama.299.15.joc80026			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18375998	Bronze			2022-12-28	WOS:000254954800023
J	Ebeling, PR				Ebeling, Peter R.			Osteoporosis in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; RANDOMIZED CONTROLLED-TRIAL; NURSING-HOME RESIDENTS; X-RAY ABSORPTIOMETRY; HIP FRACTURE RISK; OLDER MEN; VERTEBRAL FRACTURE; ELDERLY-MEN; ANDROGEN SUPPLEMENTATION; PARATHYROID-HORMONE		RMH WH, Dept Med, Footscray, Vic 3011, Australia; Univ Melbourne, Western Hosp, Dept Endocrinol, Footscray, Vic 3011, Australia	University of Melbourne; Western Hospital	Ebeling, PR (corresponding author), RMH WH, Dept Med, Gordon St, Footscray, Vic 3011, Australia.	peterre@unimelb.edu.au		Ebeling, Peter/0000-0002-2921-3742				ABBASI AA, 1995, AM J MED SCI, V310, P229; Amory JK, 2004, J CLIN ENDOCR METAB, V89, P503, DOI 10.1210/jc.2003-031110; Anderson FH, 1997, J BONE MINER RES, V12, P472, DOI 10.1359/jbmr.1997.12.3.472; Anderson FH, 1996, BONE, V18, P171, DOI 10.1016/8756-3282(95)00441-6; Benito M, 2005, J BONE MINER RES, V20, P1785, DOI 10.1359/JBMR.050606; Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157; Brown JP, 2003, CAN MED ASSOC J, V168, P676; Brown JP, 2003, CAN MED ASSOC J, V168, P400; Brown JP, 2003, CAN MED ASSOC J, V168, P544; Brown JP, 2002, CAN MED ASSOC J, V167, pS1; Chang JT, 2004, BRIT MED J, V328, P680, DOI 10.1136/bmj.328.7441.680; Chang KP, 2004, J BONE MINER RES, V19, P532, DOI 10.1359/JBMR.040109; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; De Laet CEDH, 2002, J BONE MINER RES, V17, P2231, DOI 10.1359/jbmr.2002.17.12.2231; Ebeling PR, 1998, DRUG AGING, V13, P421, DOI 10.2165/00002512-199813060-00002; Ebeling PR, 2001, J CLIN ENDOCR METAB, V86, P4098, DOI 10.1210/jc.86.9.4098; Ferrar L, 1999, OSTEOPOROSIS INT, V10, P167, DOI 10.1007/s001980050212; Ferrar L, 2007, J BONE MINER RES, V22, P1434, DOI 10.1359/jbmr.070608; Fink HA, 2006, J CLIN ENDOCR METAB, V91, P3908, DOI 10.1210/jc.2006-0173; Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725; FINKELSTEIN JS, 1989, J CLIN ENDOCR METAB, V69, P776, DOI 10.1210/jcem-69-4-776; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; Jiang HX, 2005, J BONE MINER RES, V20, P494, DOI 10.1359/JBMR.041133; Johnell O, 2001, CALCIFIED TISSUE INT, V69, P182, DOI 10.1007/s00223-001-1045-7; Jones G, 1996, OSTEOPOROSIS INT, V6, P233, DOI 10.1007/BF01622740; Kanis JA, 2007, OSTEOPOROSIS INT, V18, P1033, DOI 10.1007/s00198-007-0343-y; Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI 10.1007/s00198-004-1640-3; Kanis JA, 2002, OSTEOPOROSIS INT, V13, P527, DOI 10.1007/s001980200069; Kanis JA, 2001, CALCIFIED TISSUE INT, V69, P218, DOI 10.1007/s00223-001-1046-6; Kaptoge S, 2006, OSTEOPOROSIS INT, V17, P1369, DOI 10.1007/s00198-005-0067-9; Kaufman JM, 2005, OSTEOPOROSIS INT, V16, P510, DOI 10.1007/s00198-004-1713-3; Khosla S, 2006, J BONE MINER RES, V21, P124, DOI 10.1359/JBMR.050916; KHOSLA S, 1994, BONE, V15, P551, DOI 10.1016/8756-3282(94)90280-1; Kiel DP, 2007, JAMA-J AM MED ASSOC, V298, P413, DOI 10.1001/jama.298.4.413; Kukuljan S, 2006, J BONE MINER RES, V21, pS184; Kurland ES, 2004, OSTEOPOROSIS INT, V15, P992, DOI 10.1007/s00198-004-1636-z; Leib ES, 2004, J CLIN DENSITOM, V7, P1, DOI 10.1385/JCD:7:1:1; Lewiecki EM, 2006, J CLIN ENDOCR METAB, V91, P4215, DOI 10.1210/jc.2006-1178; Looker AC, 2008, J BONE MINER RES, V23, P143, DOI 10.1359/JBMR.071003; Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941; Meier C, 2005, J BONE MINER RES, V20, P579, DOI 10.1359/JBMR.041207; Meier C, 2008, ARCH INTERN MED, V168, P47, DOI 10.1001/archinternmed.2007.2; Michaelsson K, 2007, PLOS MED, V4, P1094, DOI 10.1371/journal.pmed.0040199; Miller P, 2007, J BONE MINER RES, V22, pS26; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; O'Neill TW, 2002, J BONE MINER RES, V17, P2214, DOI 10.1359/jbmr.2002.17.12.2214; ONeill TW, 1996, J BONE MINER RES, V11, P1010; Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9; Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902; Riggs BL, 2008, J BONE MINER RES, V23, P205, DOI 10.1359/JBMR.071020; Ringe JD, 2006, RHEUMATOL INT, V26, P427, DOI 10.1007/s00296-005-0004-4; Rosen CJ, 2001, J CLIN ENDOCR METAB, V86, P957, DOI 10.1210/jc.86.3.957; Sambrook PN, 2002, MED J AUSTRALIA, V176, pS1; Schousboe JT, 2007, JAMA-J AM MED ASSOC, V298, P629, DOI 10.1001/jama.298.6.629; Seeman E, 2006, OSTEOPOROSIS INT, V17, P1577, DOI 10.1007/s00198-006-0160-8; SMITH EP, 1995, NEW ENGL J MED, V332, P131; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P1966, DOI 10.1210/jc.84.6.1966; Szulc P, 2001, CALCIFIED TISSUE INT, V69, P229, DOI 10.1007/s00223-001-1059-1; Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140-6736(07)61342-7; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; Vieth R, 2001, AM J CLIN NUTR, V73, P288	61	255	267	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1474	1482		10.1056/NEJMcp0707217	http://dx.doi.org/10.1056/NEJMcp0707217			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282CY	18385499				2022-12-28	WOS:000254546400008
J	van 't Veer, LJ; Bernards, R				van 't Veer, Laura J.; Bernards, Rene			Enabling personalized cancer medicine through analysis of gene-expression patterns	NATURE			English	Review							NEGATIVE BREAST-CANCER; TRASTUZUMAB RESISTANCE; PROGNOSTIC SIGNATURE; ONCOGENIC PATHWAYS; MICROARRAY; STRATEGY; PREDICT; CHEMOSENSITIVITY; REPRODUCIBILITY; CHEMOTHERAPY	Therapies for patients with cancer have changed gradually over the past decade, moving away from the administration of broadly acting cytotoxic drugs towards the use of more- specific therapies that are targeted to each tumour. To facilitate this shift, tests need to be developed to identify those individuals who require therapy and those who are most likely to benefit from certain therapies. In particular, tests that predict the clinical outcome for patients on the basis of the genes expressed by their tumours are likely to increasingly affect patient management, heralding a new era of personalized medicine.	[van 't Veer, Laura J.; Bernards, Rene] Agendia BV, NL-1066 EC Amsterdam, Netherlands; [van 't Veer, Laura J.] Netherlands Canc Inst, Div Pathol, NL-1066 CX Amsterdam, Netherlands; [van 't Veer, Laura J.; Bernards, Rene] Netherlands Canc Inst, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands; [Bernards, Rene] Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; [Bernards, Rene] Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	Agendia; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Agendia BV, Louwesweg 6, NL-1066 EC Amsterdam, Netherlands.	r.bernards@nki.nl		Bernards, Rene/0000-0001-8677-3423				Abe O, 1998, LANCET, V352, P930; Ach RA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-148; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bild AH, 2006, NAT REV CANCER, V6, P735, DOI 10.1038/nrc1976; Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Coombes KR, 2007, NAT MED, V13, P1276, DOI 10.1038/nm1107-1276b; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Dressman HK, 2006, CLIN CANCER RES, V12, P819, DOI 10.1158/1078-0432.CCR-05-1447; Ein-Dor L, 2006, P NATL ACAD SCI USA, V103, P5923, DOI 10.1073/pnas.0601231103; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364; Harris LN, 2007, CLIN CANCER RES, V13, P1198, DOI 10.1158/1078-0432.CCR-06-1304; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hornberger J, 2005, AM J MANAG CARE, V11, P313; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104; Ma XJ, 2006, J CLIN ONCOL, V24, P4611, DOI 10.1200/JCO.2006.06.6944; Mook Stella, 2007, Cancer Genomics & Proteomics, V4, P147; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Rhodes A, 2000, J CLIN PATHOL, V53, P125, DOI 10.1136/jcp.53.2.125; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sparano JA, 2006, CLIN BREAST CANCER, V7, P347, DOI 10.3816/CBC.2006.n.051; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697; Yu JX, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-182	50	399	417	0	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2008	452	7187					564	570		10.1038/nature06915	http://dx.doi.org/10.1038/nature06915			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385730				2022-12-28	WOS:000254567200034
J	Kestenbaum, B; Rudser, KD; de Boer, IH; Peralta, CA; Fried, LF; Shlipak, MG; Palmas, W; Stehman-Breen, C; Siscovick, DS				Kestenbaum, Bryan; Rudser, Kyle D.; de Boer, Ian H.; Peralta, Carmen A.; Fried, Linda F.; Shlipak, Michael G.; Palmas, Walter; Stehman-Breen, Catherine; Siscovick, David S.			Differences in kidney function and incident hypertension: The multi-ethnic study of atherosclerosis	ANNALS OF INTERNAL MEDICINE			English	Article							SERUM CYSTATIN-C; GLOMERULAR-FILTRATION-RATE; RENAL-DISEASE; BLOOD-PRESSURE; BIRTH-WEIGHT; CREATININE; RISK; PROTEINURIA; POPULATION; PREVALENCE	Background: Kidney disease and hypertension commonly coexist, yet the direction of their association is still debated. Objective: To evaluate whether early kidney dysfunction, measured by serum cystatin C levels and urinary albumin excretion, predates hypertension in adults without clinically recognized kidney or cardiovascular disease. Design: Observational cohort study using data from 2000 to 2005. Setting: The MESA (Multi-Ethnic Study of Atherosclerosis), a community-based study of subclinical cardiovascular disease in adults age 45 to 84 years. Participants: 2767 MESA participants without prevalent hypertension, cardiovascular disease, or clinically recognized kidney disease (an estimated glomerular filtration rate <60 mL/min per 1.73 m(2) or microalbuminuria). Measurements: Cystatin C was measured by using a nephelometer, and urinary albumin and creatinine were measured from a spot morning collection. The primary outcome was incident hypertension, defined as systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, or use of an anti hypertensive medication. Results: During a median follow-up of 3.1 years, 19.7% of the cohort (545 participants) developed hypertension. After adjustment for established hypertension risk factors, each 15-nmol/L increase in cystatin C was associated with a statistically significant 15% greater incidence of hypertension (P = 0.017). The highest sex-specific quartile of urinary albumin-creatinine ratio was associated with a statistically insignificant 16% greater incidence of hypertension (P = 0.192) compared with the lowest quartile. No statistical evidence suggested a multiplicative interaction. Limitations: Unmeasured characteristics may have confounded observed associations of kidney markers with hypertension. Follow-up was relatively short. Hypertension that may have occurred between study visits or hypertension that was not captured by standard cuff measurements may have been missed. Conclusion: Differences in kidney function, indicated by cystatin C levels, are associated with incident hypertension among individuals without clinical kidney or cardiovascular disease. These population-based findings complement experimental work implicating early kidney damage in the pathogenesis of essential hypertension.	[Kestenbaum, Bryan] Univ Washington, Harborview Med Ctr, Div Nephrol, Seattle, WA 98104 USA; San Francisco VA Med Ctr, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA; Columbia Univ, New York, NY USA; Amgen Inc, Thousand Oaks, CA USA; Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Columbia University; Amgen; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kestenbaum, B (corresponding author), Univ Washington, Harborview Med Ctr, Div Nephrol, Room 10EH11,325 9Th Ave, Seattle, WA 98104 USA.	brk@u.washington.edu	de Boer, Ian/GYJ-3282-2022		DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095165, N01HC095162, N01HC095169, N01HC095160, N01HC095163, N01HC095161, N01HC095159, N01HC095164] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000422, UL1TR000423] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025015] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL095169, R44HL095169, R21HL095165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK063274] Funding Source: NIH RePORTER	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; Andoh TF, 2001, AM J TRANSPLANT, V1, P222, DOI 10.1046/j.1600-6135.ajt10305.x; Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113; BORST JGG, 1963, LANCET, V1, P677; Brantsma AH, 2006, J AM SOC NEPHROL, V17, P331, DOI 10.1681/ASN.2005111153; Buckalew VM, 1996, AM J KIDNEY DIS, V28, P811, DOI 10.1016/S0272-6386(96)90380-7; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Coll E, 2000, AM J KIDNEY DIS, V36, P29, DOI 10.1053/ajkd.2000.8237; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; DAHL LK, 1975, CIRC RES, V36, P692, DOI 10.1161/01.RES.36.6.692; Erlandsen EJ, 1999, SCAND J CLIN LAB INV, V59, P1, DOI 10.1080/00365519950185940; Foley RN, 2005, MAYO CLIN PROC, V80, P1270, DOI 10.4065/80.10.1270; Genuth S, 2003, DIABETES CARE, V26, P3160; GUYTON AC, 1972, AM J MED, V52, P584, DOI 10.1016/0002-9343(72)90050-2; HARVEY JM, 1992, LANCET, V340, P1435, DOI 10.1016/0140-6736(92)92624-O; Howie AJ, 1996, J HUM HYPERTENS, V10, P691; Hsu CY, 2005, ARCH INTERN MED, V165, P923, DOI 10.1001/archinte.165.8.923; Huxley R, 2002, LANCET, V360, P659, DOI 10.1016/S0140-6736(02)09834-3; Johnson RJ, 2002, NEW ENGL J MED, V346, P913, DOI 10.1056/NEJMra011078; Julius S, 1996, CLIN EXP HYPERTENS, V18, P305, DOI 10.3109/10641969609088965; Keller G, 2003, NEW ENGL J MED, V348, P101, DOI 10.1056/NEJMoa020549; Knight EL, 2004, KIDNEY INT, V65, P1416, DOI 10.1111/j.1523-1755.2004.00517.x; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Luyckx VA, 2005, KIDNEY INT, V68, pS68, DOI 10.1111/j.1523-1755.2005.09712.x; Mattix HJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341034; NEWMAN DJ, 1995, KIDNEY INT, V47, P312, DOI 10.1038/ki.1995.40; *NIH N I DIAB DIG, 2006, US REN DAT SYST ANN; NORRELUND H, 1994, HYPERTENSION, V24, P301, DOI 10.1161/01.HYP.24.3.301; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; SCHWAB SJ, 1987, ARCH INTERN MED, V147, P943, DOI 10.1001/archinte.147.5.943; Shlipak MG, 2005, NEW ENGL J MED, V352, P2049, DOI 10.1056/NEJMoa043161; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; Wang TJ, 2005, CIRCULATION, V111, P1370, DOI 10.1161/01.CIR.0000158434.69180.2D; WILEY V, 1993, BIOSTATISTICS METHOD; Zelmanovitz T, 1998, DIABETES CARE, V21, P1076, DOI 10.2337/diacare.21.7.1076	39	93	100	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2008	148	7					501	508		10.7326/0003-4819-148-7-200804010-00006	http://dx.doi.org/10.7326/0003-4819-148-7-200804010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284IV	18378946	Green Accepted			2022-12-28	WOS:000254701000002
J	Robbins, J; Gensler, G; Hind, J; Logemann, JA; Lindblad, AS; Brandt, D; Baum, H; Lilienfeld, D; Kosek, S; Lundy, D; Dikeman, K; Kazandjian, M; Gramigna, GD; McGarvey-Toler, S; Gardner, PJM				Robbins, JoAnne; Gensler, Gary; Hind, Jacqueline; Logemann, Jeri A.; Lindblad, Anne S.; Brandt, Diane; Baum, Herbert; Lilienfeld, David; Kosek, Steven; Lundy, Donna; Dikeman, Karen; Kazandjian, Marta; Gramigna, Gary D.; McGarvey-Toler, Susan; Gardner, Patricia J. Miller			Comparison of 2 interventions for liquid aspiration on pneumonia incidence	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; RISK-FACTORS; PARKINSONS-DISEASE; MORTALITY; INFECTIONS; POSTURE; DESIGN	Background: Aspiration pneumonia is common among frail elderly persons with dysphagia. Although interventions to prevent aspiration are routinely used in these patients, little is known about the effectiveness of those interventions. Objective: To compare the effectiveness of chin-down posture and 2 consistencies (nectar or honey) of thickened liquids on the 3-month cumulative incidence of pneumonia in patients with dementia or Parkinson disease. Design: Randomized, controlled, parallel-design trial in which patients were enrolled for 3-month periods from 9 June 1998 to 19 September 2005. Setting: 47 hospitals and 79 subacute care facilities. Patients: 515 patients age 50 years or older with dementia or Parkinson disease who aspirated thin liquids (demonstrated video-fluoroscopically). Of these, 504 were followed until death or for 3 months. Intervention: Participants were randomly assigned to drink all liquids in a chin-down posture (n = 259) or to drink nectar-thick (n = 133) or honey-thick (n = 123) liquids in a head-neutral position. Measurements: The primary outcome was pneumonia diagnosed by chest radiography or by the presence of 3 respiratory indicators. Results: 52 participants had pneumonia, yielding an overall estimated 3-month cumulative incidence of 11%. The 3-month cumulative incidence of pneumonia was 0.098 and 0.116 in the chin-down posture and thickened-liquid groups, respectively (hazard ratio, 0.84 [95% Cl, 0.49 to 1.45]; P = 0.53). The 3-month cumulative incidence of pneumonia was 0.084 in the nectar-thick liquid group compared with 0.150 in the honey-thick liquid group (hazard ratio, 0.50 [Cl, 0.23 to 1.09]; P = 0.083). More patients assigned to thickened liquids than those assigned to the chin-down posture intervention had dehydration (6% vs. 2%), urinary tract infection (6% vs. 3%), and fever (4% vs. 2%). Limitations: A no-treatment control group was not included. Follow-up was limited to 3 months. Care providers were not blinded, and differences in cumulative pneumonia incidence between interventions had wide Cls. Conclusion: No definitive conclusions about the superiority of any of the tested interventions can be made. The 3-month cumulative incidence of pneumonia was much lower than expected in this frail elderly population. Future investigation of chin-down posture combined with nectar-thick liquid may be warranted to determine whether this combination better prevents pneumonia than either intervention independently.	[Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin 11G, Madison, WI 53705 USA; Univ Wisconsin, Madison, WI USA; EMMES Corp & Amer Speech Language Hearing Assoc, Rockville, MD USA; Northwestern Univ, Evanston, IL USA; ORC Macro, Calverton, MD USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA; Univ Miami, Hosp & Clin, Miami, FL 33152 USA; New York Hosp, Queens Med Ctr, Flushing, NY USA; Vet Affairs Boston Healthcare Syst, W Roxbury, MA USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; Emmes Corporation; Northwestern University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Miami; NewYork-Presbyterian Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Robbins, J (corresponding author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin 11G, 2500 Overlook Terrace, Madison, WI 53705 USA.	jrobbin2@wisc.edu	Kazandjian, Marta/GWN-1271-2022		NCRR NIH HHS [M01 RR003186-190295, M01 RR003186, M01 RR003186-16S10295, M01 RR003186-160295, M01 RR003186-170295, M01 RR003186-140295, M01 RR003186-180295, M01 RR003186-15S30295, M01 RR003186-150295] Funding Source: Medline; NIDCD NIH HHS [DC03206, U01 DC003206] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [U01DC003206] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Baine WB, 2001, AM J PUBLIC HEALTH, V91, P1121, DOI 10.2105/AJPH.91.7.1121; Brandt DK, 2006, CLIN TRIALS, V3, P457, DOI 10.1177/1740774506070731; CHERNOFF R, 1994, NUTR REV, V52, pS3; Chidester JC, 1997, J AM DIET ASSOC, V97, P23, DOI 10.1016/S0002-8223(97)00011-4; DEMETS DL, 1982, BIOMETRIKA, V69, P661; *ECRI I, 1999, AHCPR PUBL; FEINBERG M J, 1990, Dysphagia, V5, P61, DOI 10.1007/BF02412646; Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521; FONDA D, 1995, DYSPHAGIA, V10, P165, DOI 10.1007/BF00260971; Gambassi G, 1999, NEUROLOGY, V53, P508, DOI 10.1212/WNL.53.3.508; Gambassi G, 1999, J NEUROL NEUROSUR PS, V67, P59, DOI 10.1136/jnnp.67.1.59; GROBER ME, 1995, J AM GERIATR SOC, V43, P528, DOI 10.1111/j.1532-5415.1995.tb06100.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LACROIX AZ, 1989, PUBLIC HEALTH REP, V104, P350; LAN KKG, 1988, BIOMETRICS, V44, P579, DOI 10.2307/2531870; Langmore SE, 1998, DYSPHAGIA, V13, P69, DOI 10.1007/PL00009559; LIPSKY BA, 1986, ARCH INTERN MED, V146, P2179, DOI 10.1001/archinte.146.11.2179; Loeb M, 1999, ARCH INTERN MED, V159, P2058, DOI 10.1001/archinte.159.17.2058; Logemanin JA, 2008, J SPEECH LANG HEAR R, V51, P173, DOI 10.1044/1092-4388(2008/013); LOGEMANN JA, 1994, OTOLARYNG HEAD NECK, V110, P222, DOI 10.1177/019459989411000212; Logemann Jeri A., 1993, Dysphagia, V8, P230, DOI 10.1007/BF01354543; Louis ED, 1997, ARCH NEUROL-CHICAGO, V54, P260, DOI 10.1001/archneur.1997.00550150024011; NAKAZAWA H, 1993, CHEST, V103, P1636, DOI 10.1378/chest.103.5.1636b; Niederman MS, 1998, CLIN THER, V20, P820, DOI 10.1016/S0149-2918(98)80144-6; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pick N, 1996, J AM GERIATR SOC, V44, P763, DOI 10.1111/j.1532-5415.1996.tb03731.x; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; RASLEY A, 1993, AM J ROENTGENOL, V160, P1005, DOI 10.2214/ajr.160.5.8470567; ROBBINS JA, 1986, ANN NEUROL, V19, P283, DOI 10.1002/ana.410190310; SHANAHAN TK, 1993, ARCH PHYS MED REHAB, V74, P736, DOI 10.1016/0003-9993(93)90035-9; WELCH MV, 1993, ARCH PHYS MED REHAB, V74, P178	31	160	164	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2008	148	7					509	518		10.7326/0003-4819-148-7-200804010-00007	http://dx.doi.org/10.7326/0003-4819-148-7-200804010-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284IV	18378947	Green Accepted			2022-12-28	WOS:000254701000003
J	Folbre, N				Folbre, Nancy			Economics - When a commodity is not exactly a commodity	SCIENCE			English	Editorial Material									Univ Massachusetts, Dept Econ, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Folbre, N (corresponding author), Univ Massachusetts, Dept Econ, Amherst, MA 01003 USA.	folbre@econs.umass.edu						AKERLOF G, 1982, Q J ECON, V97, P4; Barak A, 2007, COMPUT HUM BEHAV, V23, P971, DOI 10.1016/j.chb.2005.08.001; Baumol W., 1967, AM ECON REV, V57, P3; BOWLES S, 1985, AM ECON REV, V75, P16; Castle NG, 2007, GERONTOLOGIST, V47, P650, DOI 10.1093/geront/47.5.650; England P, 2002, SOC PROBL, V49, P455, DOI 10.1525/sp.2002.49.4.455; Folbre N, 2006, POLIT SOC, V34, P11, DOI 10.1177/0032329205284754; FOLBRE N, 2000, J ECON PERSPECT, V14, P4; Fomby P, 2007, AM SOCIOL REV, V72, P181, DOI 10.1177/000312240707200203; Gachter Simon, 2001, SURVEYS EXPT EC BARG, P95; HOLMSTROM B, 1994, AM ECON REV, V84, P4; KANE R, 2007, J AM GERIATR SOC, V55, P6; Keynes J.M., 1973, GEN THEORY EMPLOYMEN; KREPS DM, 1997, AM ECON REV, V87, P2; Pineau J, 2003, ROBOT AUTON SYST, V42, P271, DOI 10.1016/S0921-8890(02)00381-0; *STAT ABSTR US, 2008, PRIC IND PERS CONS E; STIGLITZ JE, 1987, J EC LIT, V25	17	8	8	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1769	1770		10.1126/science.1153904	http://dx.doi.org/10.1126/science.1153904			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	279ZF	18369128				2022-12-28	WOS:000254394000026
J	Carbonell, E; de Castro, JMB; Pares, JM; Perez-Gonzalez, A; Cuenca-Bescos, G; Olle, A; Mosquera, M; Huguet, R; van der Made, J; Rosas, A; Sala, R; Vallverdu, J; Garcia, N; Granger, DE; Martinon-Torres, M; Rodriguez, XP; Stock, GM; Verges, JM; Allue, E; Burjachs, F; Caceres, I; Canals, A; Benito, A; Diez, C; Lozano, M; Mateos, A; Navazo, M; Rodriguez, J; Rosell, J; Arsuaga, JL				Carbonell, Eudald; Bermudez de Castro, Jose M.; Pares, Josep M.; Perez-Gonzalez, Alfredo; Cuenca-Bescos, Gloria; Olle, Andreu; Mosquera, Marina; Huguet, Rosa; van der Made, Jan; Rosas, Antonio; Sala, Robert; Vallverdu, Josep; Garcia, Nuria; Granger, Darryl E.; Martinon-Torres, Maria; Rodriguez, Xose P.; Stock, Greg M.; Verges, Josep M.; Allue, Ethel; Burjachs, Francesc; Caceres, Isabel; Canals, Antoni; Benito, Alfonso; Diez, Carlos; Lozano, Marina; Mateos, Ana; Navazo, Marta; Rodriguez, Jesus; Rosell, Jordi; Arsuaga, Juan L.			The first hominin of Europe	NATURE			English	Article							SIMA DEL ELEFANTE; GRAN DOLINA; MIDDLE-PLEISTOCENE; ATAPUERCA BURGOS; HUMAN SETTLEMENT; LITHIC INDUSTRY; CAVE SEDIMENTS; SPAIN; SITE; SIERRA	The earliest hominin occupation of Europe is one of the most debated topics in palaeoanthropology. However, the purportedly oldest of the Early Pleistocene sites in Eurasia lack precise age control and contain stone tools rather than human fossil remains(1-5). Here we report the discovery of a human mandible associated with an assemblage of Mode 1 lithic tools and faunal remains bearing traces of hominin processing, in stratigraphic level TE9 at the site of the Sima del Elefante, Atapuerca, Spain(6-8). Level TE9 has been dated to the Early Pleistocene ( approximately 1.2 - 1.1 Myr), based on a combination of palaeomagnetism, cosmogenic nuclides and biostratigraphy. The Sima del Elefante site thus emerges as the oldest, most accurately dated record of human occupation in Europe, to our knowledge. The study of the human mandible suggests that the first settlement of Western Europe could be related to an early demographic expansion out of Africa. The new evidence, with previous findings in other Atapuerca sites ( level TD6 from Gran Dolina(9-13)), also suggests that a speciation event occurred in this extreme area of the Eurasian continent during the Early Pleistocene, initiating the hominin lineage represented by the TE9 and TD6 hominins.	[Carbonell, Eudald; Olle, Andreu; Mosquera, Marina; Huguet, Rosa; Sala, Robert; Vallverdu, Josep; Rodriguez, Xose P.; Verges, Josep M.; Allue, Ethel; Burjachs, Francesc; Caceres, Isabel; Canals, Antoni; Lozano, Marina; Rosell, Jordi] Univ Rovira & Virgili, Inst Catala Paleoecol Humana & Evoluc Social, Area Prehistoria, Tarragona 43005, Spain; [Bermudez de Castro, Jose M.; Pares, Josep M.; Perez-Gonzalez, Alfredo; Martinon-Torres, Maria; Mateos, Ana; Rodriguez, Jesus] Ctr Nacl Invest Evoluc Humana, Burgos 09004, Spain; [Pares, Josep M.; Stock, Greg M.] Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA; [Perez-Gonzalez, Alfredo; Benito, Alfonso] Univ Complutense Madrid, Dept Geodinam, Fac Ciencias Geol, E-28040 Madrid, Spain; [Cuenca-Bescos, Gloria] Univ Zaragoza, Fac Ciencias, Area Paleontol, E-50009 Zaragoza, Spain; [van der Made, Jan; Rosas, Antonio] CSIC, Museo Nacl Ciencias Nat, Dept Paleobiol, E-28006 Madrid, Spain; [Garcia, Nuria; Arsuaga, Juan L.] Univ Complutense Madrid, Dept Paleontol, Fac Ciencias Geol, E-28040 Madrid, Spain; [Garcia, Nuria; Arsuaga, Juan L.] UCM, ISCII Evoluc & Comportamiento Humanos, Ctr Invest, Madrid 28029, Spain; [Granger, Darryl E.] Purdue Univ, Dept Earth & Atmospher Sci, W Lafayette, IN 47907 USA; [Stock, Greg M.] Yosemite Natl Pk, El Portal, CA 95318 USA; [Burjachs, Francesc] Inst Catalana Recerca & Estud Avancats, Tarragona 43005, Spain; [Diez, Carlos; Navazo, Marta] Univ Burgos, Lab Prehistoria, Burgos 09001, Spain	Universitat Rovira i Virgili; Catalan Institute of Human Paleo-Ecology & Social Evolution (IPHES); Centro Nacional de Investigacion de La Evolucion Humana (CENIEH); University of Michigan System; University of Michigan; Complutense University of Madrid; University of Zaragoza; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Museo Nacional de Ciencias Naturales (MNCN); Complutense University of Madrid; Complutense University of Madrid; Purdue University System; Purdue University; Purdue University West Lafayette Campus; ICREA; Universidad de Burgos	Carbonell, E (corresponding author), Univ Rovira & Virgili, Inst Catala Paleoecol Humana & Evoluc Social, Area Prehistoria, Placa Imperial Tarraco 1, Tarragona 43005, Spain.	eudald.carbonell@urv.cat; jm.ber@cenieh.es	van der Made, Jan/G-3614-2015; Sala Ramos, Robert/L-5674-2014; RODRIGUEZ, XOSE-PEDRO/A-1069-2008; Rodriguez-Alvarez, Xose-Pedro/B-9057-2009; Vergès Bosch, Josep Maria/G-4490-2015; Poch, Josep Vallverdú i/B-7121-2014; Carbonell, Eudald/G-3003-2015; Burjachs, Francesc/G-2064-2015; Gloria, Cuenca-Bescós/A-3616-2013; Canals Salomó, Antoni/D-3395-2014; Ollé, Andreu/D-6837-2013; Lozano, Marina/G-7293-2015; Benito-Calvo, Alfonso/G-3897-2015; Rodríguez, Jesús/AAB-3336-2020; Rosas, Antonio/D-9742-2016; Cáceres, Isabel/G-2636-2015; Huguet, Rosa/H-5713-2015; Mosquera, Marina/B-1140-2014; d�ez, carlos/B-2126-2008; Rosell, Jordi/G-8705-2015	van der Made, Jan/0000-0002-4807-4338; Sala Ramos, Robert/0000-0002-7168-824X; Rodriguez-Alvarez, Xose-Pedro/0000-0002-1852-2283; Vergès Bosch, Josep Maria/0000-0003-1807-7463; Poch, Josep Vallverdú i/0000-0002-3177-3263; Burjachs, Francesc/0000-0002-7200-9552; Gloria, Cuenca-Bescós/0000-0001-5125-9651; Canals Salomó, Antoni/0000-0002-4240-0921; Ollé, Andreu/0000-0002-8643-5536; Lozano, Marina/0000-0002-6304-7848; Benito-Calvo, Alfonso/0000-0002-6363-1753; Rodríguez, Jesús/0000-0002-2834-0694; Rosas, Antonio/0000-0002-5829-9952; Cáceres, Isabel/0000-0001-8487-2591; Mosquera, Marina/0000-0003-4823-6154; Rosell, Jordi/0000-0002-6758-6291; Bermudez de Castro, Jose Maria/0000-0003-1314-3273; Martinon-Torres, Maria/0000-0002-2750-4554; Mateos, Ana/0000-0002-0676-9836; Navazo, Marta/0000-0002-3602-2741; diez, j.carlos/0000-0002-3856-1837; Arsuaga, Juan Luis/0000-0001-5361-2295	ICREA Funding Source: Custom	ICREA(ICREA)		Arsuaga JL, 1997, J HUM EVOL, V33, P109, DOI 10.1006/jhev.1997.0132; ARSUAGA JL, 1993, NATURE, V362, P534, DOI 10.1038/362534a0; Arsuaga JL, 1997, J HUM EVOL, V33, P105, DOI 10.1006/jhev.1997.0169; Arzarello M, 2007, NATURWISSENSCHAFTEN, V94, P107, DOI 10.1007/s00114-006-0173-3; Bermudez De Castro J. M., 1997, Science (Washington D C), V276, P1392, DOI 10.1126/science.276.5317.1392; Bischoff JL, 2007, J ARCHAEOL SCI, V34, P763, DOI 10.1016/j.jas.2006.08.003; Brauer G, 1996, J HUM EVOL, V30, P445, DOI 10.1006/jhev.1996.0037; Carbonell E, 2005, P NATL ACAD SCI USA, V102, P5674, DOI 10.1073/pnas.0501841102; CARBONELL E, 1995, SCIENCE, V269, P826, DOI 10.1126/science.7638598; Carbonell E, 1999, J HUM EVOL, V37, P313, DOI 10.1006/jhev.1999.0282; Carbonell E, 1996, J ANTHROPOL RES, V52, P107, DOI 10.1086/jar.52.1.3630238; Carbonell E, 1999, J HUM EVOL, V37, P309, DOI 10.1006/jhev.1999.0333; Carbonell E, 2001, ANTHROPOLOGIE, V105, P259; Carbonell E, 1999, J HUM EVOL, V37, P653, DOI 10.1006/jhev.1999.0336; Carbonell E, 1999, J ANTHROPOL ARCHAEOL, V18, P119, DOI 10.1006/jaar.1998.0331; Carbonell E., 1999, ATAPUERCA OCUPACIONE, P1; CARBONELL E, 1999, ATAPUERCA OCUPACIONE, P19; Carbonell E, 2006, CR PALEVOL, V5, P291, DOI 10.1016/j.crpv.2005.12.002; Cuenca-Bescos G, 1999, J HUM EVOL, V37, P353, DOI 10.1006/jhev.1999.0306; CUENCABESCOS G, 2004, ZONA ARQUEOLOGICA, V4, P150; DAY MH, 1973, AM J PHYS ANTHROPOL, V39, P341, DOI 10.1002/ajpa.1330390303; de Lumley H., 1988, ANTHROPOLOGIE, V92, P501; Despriee J, 2006, CR PALEVOL, V5, P821, DOI 10.1016/j.crpv.2006.03.001; Diez JC, 1999, J HUM EVOL, V37, P623, DOI 10.1006/jhev.1999.0346; Fernandez-Jalvo Y, 1999, J HUM EVOL, V37, P591, DOI 10.1006/jhev.1999.0324; Fernandez-Jalvo Y, 1996, SCIENCE, V271, P277, DOI 10.1126/science.271.5247.277; GABUNIA L, 1995, NATURE, V373, P509, DOI 10.1038/373509a0; GARCIA N, IN PRESS PALAEONTO A; Gliozzi E, 1997, RIV ITAL PALEONTOL S, V103, P369, DOI 10.13130/2039-4942/5299; Granger DE, 2001, GEOL SOC AM BULL, V113, P825, DOI 10.1130/0016-7606(2001)113<0825:PPIOTG>2.0.CO;2; HOWELL FC, 1960, CURR ANTHROPOL, V1, P195, DOI 10.1086/200100; Huguet R., 2001, ANTHROPOLOGIE, V105, P237, DOI [10.1016/S0003-5521(01) 80015-7, DOI 10.1016/S0003-5521(01)80015-7]; Huguet R., 2007, THESIS U ROVIRA VIRG; Kaifu Y, 2005, AM J PHYS ANTHROPOL, V128, P497, DOI 10.1002/ajpa.10427; Marquez B, 2001, ANTHROPOLOGIE, V105, P281; Martinon-Torres M, 2007, P NATL ACAD SCI USA, V104, P13279, DOI 10.1073/pnas.0706152104; Oms O, 2000, P NATL ACAD SCI USA, V97, P10666, DOI 10.1073/pnas.180319797; Pares JM, 2006, J HUM EVOL, V50, P163, DOI 10.1016/j.jhevol.2005.08.011; PARES JM, 1995, SCIENCE, V269, P830, DOI 10.1126/science.7638599; Peretto C, 1998, ANTHROPOLOGIE, V102, P343; Rofes J, 2006, RIV ITAL PALEONTOL S, V112, P301, DOI 10.13130/2039-4942/6343; Rosas A., 2006, Estudios Geologicos (Madrid), V62, P327; Rosas A, 1998, AM J PHYS ANTHROPOL, V107, P145, DOI 10.1002/(SICI)1096-8644(199810)107:2<145::AID-AJPA2>3.3.CO;2-8; Rosas A, 2001, ANTHROPOLOGIE, V105, P301; Rosell Jordi, 1998, Quaternaire, V9, P355; SCHRENK F, 1993, NATURE, V365, P833, DOI 10.1038/365833a0; Stock GM, 2004, GEOLOGY, V32, P193, DOI 10.1130/G20197.1; Tobias P.V., 1991, OLDUVAI GORGE, V4; WHITE TD, 1981, S AFR J SCI, V77, P445; WOOD B, 1992, J HUM EVOL, V22, P351, DOI 10.1016/0047-2484(92)90065-H; WOOD BA, 1988, J ANAT, V156, P107; Zagwijn W.H., 1998, Mededelingen Nederlands Instituut voor Toegepaste Geowetenschappen TNO, V60, P19	52	476	494	1	206	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 27	2008	452	7186					465	U7		10.1038/nature06815	http://dx.doi.org/10.1038/nature06815			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279FU	18368116	Green Published, Green Accepted			2022-12-28	WOS:000254341300030
J	Gonzales, R; Corbett, KK; Wirtz, V; Dreser, A				Gonzales, Ralph; Corbett, Kitty K.; Wirtz, Veronika; Dreser, Anahl			Making a difference - Drug resistant infections in poor countries - A shrinking window of opportunity	BRITISH MEDICAL JOURNAL			English	Editorial Material							ANTIMICROBIAL RESISTANCE		[Gonzales, Ralph] Univ Calif San Francisco, Clin & Translat Sci Inst, Multidisciplinary Career Dev Program KL2, San Francisco, CA 94143 USA; [Corbett, Kitty K.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada; [Wirtz, Veronika; Dreser, Anahl] Inst Nacl Salud Publ, Ctr Hlth Syst Res, Cuernavaca, Morelos, Mexico	University of California System; University of California San Francisco; Simon Fraser University; Instituto Nacional de Salud Publica	Gonzales, R (corresponding author), Univ Calif San Francisco, Clin & Translat Sci Inst, Multidisciplinary Career Dev Program KL2, San Francisco, CA 94143 USA.	ralphg@medicine.ucsf.edu	Wirtz, Veornika/AAG-9712-2019	Wirtz, Veronika J./0000-0002-0863-8768; Dreser, Anahi/0000-0001-9019-2330				Avorn J, 2000, ANN INTERN MED, V133, P128, DOI 10.7326/0003-4819-133-2-200007180-00012; Bavestrello L, 2002, REV MED CHILE, V130, P1265; Byarugaba DK, 2004, INT J ANTIMICROB AG, V24, P105, DOI 10.1016/j.ijantimicag.2004.02.015; Hart CA, 1998, BRIT MED J, V317, P647, DOI 10.1136/bmj.317.7159.647; Okeke IN, 1999, EMERG INFECT DIS, V5, P18, DOI 10.3201/eid0501.990103; Planta MB, 2007, J AM BOARD FAM MED, V20, P533, DOI 10.3122/jabfm.2007.06.070019; SALVATIERRAGONZ.R, 1999, REV PANAM INFECT S1, V3; Shojania KG, 2005, HEALTH AFFAIR, V24, P138, DOI 10.1377/hlthaff.24.1.138; WIRTZ V, 2007, 12 NAT M RES LEON GU; World Health Organization, 2001, WHOCDSCSDRDRS20019, P9	10	5	5	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					948	+		10.1136/bmj.39534.553044.94	http://dx.doi.org/10.1136/bmj.39534.553044.94			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397943	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000255540900036
J	Reiss-Brennan, B; Savitz, LA; Briot, P; Cannon, W				Reiss-Brennan, Brenda; Savitz, Lucy A.; Briot, Pascal; Cannon, Wayne			Making a difference - Excessive drinking in young women - Reducing harm through quality improvement	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							REDUCTION		[Reiss-Brennan, Brenda; Cannon, Wayne] Intermt Healthcare, Primary Care Clin Programs, Salt Lake City, UT 84111 USA; [Savitz, Lucy A.; Briot, Pascal] Intermt Healthcare, Inst Hlth Care Delivery Res, Salt Lake City, UT 84111 USA	Intermountain Healthcare; Intermountain Medical Center; Intermountain Healthcare; Intermountain Medical Center	Reiss-Brennan, B (corresponding author), Intermt Healthcare, Primary Care Clin Programs, 36 S State St, Salt Lake City, UT 84111 USA.	Brenda.reiss-brennan@imail.org						Bonomo Y, 2001, J PAEDIATR CHILD H, V37, P5, DOI 10.1046/j.1440-1754.2001.00623.x; Hingson RW, 2006, ARCH PEDIAT ADOL MED, V160, P739, DOI 10.1001/archpedi.160.7.739; Institute of Medicine, 2006, IMPR QUAL HLTH CAR M; KAPLAN HI, 2003, KAPLAN SADDOCKS SYNO; Kessler RC, 2005, NEW ENGL J MED, V352, P2515, DOI 10.1056/NEJMsa043266; Marlatt GA, 2002, ADDICT BEHAV, V27, P867, DOI 10.1016/S0306-4603(02)00294-0; Reiss-Brennan B, 2006, J MANAGE CARE PHARM, V12, pS14, DOI 10.18553/jmcp.2006.12.S2-A.S14; Santelli JS, 1998, FAM PLANN PERSPECT, V30, P271, DOI 10.2307/2991502; Sawwaf M., 2018, SUBSTANCE ABUSE WOME; STRANG J, 1993, PSYCHOACTIVE DRUGS H, P3; U.S. Department of Health and Human Services, 2007, SURG GEN CALL ACT PR; Weitzman ER, 2005, J EPIDEMIOL COMMUN H, V59, P303, DOI 10.1136/jech.2004.024711	12	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	2008	336	7650					952	+		10.1136/bmj.39520.730370.94	http://dx.doi.org/10.1136/bmj.39520.730370.94			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397939	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000255540900040
J	Walsh, T; McClellan, JM; McCarthy, SE; Addington, AM; Pierce, SB; Cooper, GM; Nord, AS; Kusenda, M; Malhotra, D; Bhandari, A; Stray, SM; Rippey, CF; Roccanova, P; Makarov, V; Lakshmi, B; Findling, RL; Sikich, L; Stromberg, T; Merriman, B; Gogtay, N; Butler, P; Eckstrand, K; Noory, L; Gochman, P; Long, R; Chen, ZG; Davis, S; Baker, C; Eichler, EE; Meltzer, PS; Nelson, SF; Singleton, AB; Lee, MK; Rapoport, JL; King, MC; Sebat, J				Walsh, Tom; McClellan, Jon M.; McCarthy, Shane E.; Addington, Anjene M.; Pierce, Sarah B.; Cooper, Greg M.; Nord, Alex S.; Kusenda, Mary; Malhotra, Dheeraj; Bhandari, Abhishek; Stray, Sunday M.; Rippey, Caitlin F.; Roccanova, Patricia; Makarov, Vlad; Lakshmi, B.; Findling, Robert L.; Sikich, Linmarie; Stromberg, Thomas; Merriman, Barry; Gogtay, Nitin; Butler, Philip; Eckstrand, Kristen; Noory, Laila; Gochman, Peter; Long, Robert; Chen, Zugen; Davis, Sean; Baker, Carl; Eichler, Evan E.; Meltzer, Paul S.; Nelson, Stanley F.; Singleton, Andrew B.; Lee, Ming K.; Rapoport, Judith L.; King, Mary-Claire; Sebat, Jonathan			Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia	SCIENCE			English	Article							CHILDHOOD-ONSET SCHIZOPHRENIA; NEURONAL MIGRATION; COMMON DISEASE; NMDA RECEPTOR; SUSCEPTIBILITY; GLUTAMATE; NEUREGULIN; EXPRESSION; NEUROTRANSMITTERS; DIFFERENTIATION	Schizophrenia is a devastating neurodevelopmental disorder whose genetic influences remain elusive. We hypothesize that individually rare structural variants contribute to the illness. Microdeletions and microduplications >100 kilobases were identified by microarray comparative genomic hybridization of genomic DNA from 150 individuals with schizophrenia and 268 ancestry-matched controls. All variants were validated by high- resolution platforms. Novel deletions and duplications of genes were present in 5% of controls versus 15% of cases and 20% of young- onset cases, both highly significant differences. The association was independently replicated in patients with childhood- onset schizophrenia as compared with their parents. Mutations in cases disrupted genes disproportionately from signaling networks controlling neurodevelopment, including neuregulin and glutamate pathways. These results suggest that multiple, individually rare mutations altering genes in neurodevelopmental pathways contribute to schizophrenia.	[McClellan, Jon M.] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA; [Walsh, Tom; Pierce, Sarah B.; Stray, Sunday M.; Lee, Ming K.; King, Mary-Claire] Univ Washington, Dept Med, Seattle, WA 98195 USA; [McCarthy, Shane E.; Kusenda, Mary; Malhotra, Dheeraj; Bhandari, Abhishek; Roccanova, Patricia; Makarov, Vlad; Lakshmi, B.; Sebat, Jonathan] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Addington, Anjene M.; Stromberg, Thomas; Gogtay, Nitin; Butler, Philip; Eckstrand, Kristen; Noory, Laila; Gochman, Peter; Long, Robert; Rapoport, Judith L.] NIMH, Child Psychiat Branch, NIH, Bethesda, MD 20892 USA; [Cooper, Greg M.; Nord, Alex S.; Rippey, Caitlin F.; Baker, Carl; Eichler, Evan E.; King, Mary-Claire] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; [Kusenda, Mary] SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA; [Findling, Robert L.] Case Med Ctr, Dept Psychiat, Cleveland, OH 44106 USA; [Sikich, Linmarie] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA; [Merriman, Barry; Chen, Zugen; Nelson, Stanley F.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; [Davis, Sean; Meltzer, Paul S.] NCI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; [Singleton, Andrew B.] NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	McClellan, JM (corresponding author), Univ Washington, Dept Psychiat, Seattle, WA 98195 USA.	drjack@u.washington.edu	Gogtay, Nitin/A-3035-2008; Davis, Sean/AAD-1801-2021; Cooper, Gregory/D-6914-2011; Nelson, Stanley F/D-4771-2009; Singleton, Andrew B/C-3010-2009; Eckstrand, Kristen/AAV-4858-2020; Gogtay, Nitin/GRR-1980-2022	Davis, Sean/0000-0002-8991-6458; Cooper, Gregory/0000-0001-5509-9923; Nelson, Stanley F/0000-0002-2082-3114; Eckstrand, Kristen/0000-0002-6506-3649; Pierce, Sarah/0000-0001-6739-7135; Addington, Anjene/0000-0001-7770-299X; Nord, Alexander/0000-0003-4259-7514; Gochman, Peter/0000-0003-0791-3155; Sebat, Jonathan/0000-0002-9087-526X; Walsh, Tom/0000-0002-8875-0310; King, Mary-Claire/0000-0001-9426-1743	Howard Hughes Medical Institute Funding Source: Medline; Intramural NIH HHS Funding Source: Medline; NCRR NIH HHS [RR000046, UL1 RR025014, M01 RR000046, RR025014] Funding Source: Medline; NICHD NIH HHS [HD043569, R01 HD043569] Funding Source: Medline; NIMH NIH HHS [MH061355, U01 MH061464, MH061464, U01 MH061528, MH061528] Funding Source: Medline; NINDS NIH HHS [U24 NS052108, NS052108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC011091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000949] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beart PM, 2007, BRIT J PHARMACOL, V150, P5, DOI 10.1038/sj.bjp.0706949; Benzel I, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-31; Bernard-Trifilo JA, 2005, J NEUROCHEM, V93, P834, DOI 10.1111/j.1471-4159.2005.03062.x; Buxbaum JD, 2008, MOL PSYCHIATR, V13, P162, DOI 10.1038/sj.mp.4001991; Chubb JE, 2008, MOL PSYCHIATR, V13, P36, DOI 10.1038/sj.mp.4002106; Esper RM, 2006, BRAIN RES REV, V51, P161, DOI 10.1016/j.brainresrev.2005.11.006; Friedman JI, 2008, MOL PSYCHIATR, V13, P261, DOI 10.1038/sj.mp.4002049; Friedman JM, 2006, AM J HUM GENET, V79, P500, DOI 10.1086/507471; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Ghiani CA, 2007, NEUROCHEM RES, V32, P363, DOI 10.1007/s11064-006-9213-9; Giehl KM, 2007, PROG EXP TUMOR RES, V39, P1, DOI 10.1159/000100041; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Heng JIT, 2007, EUR J NEUROSCI, V26, P537, DOI 10.1111/j.1460-9568.2007.05694.x; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Idol JR, 2008, J AUTISM DEV DISORD, V38, P668, DOI 10.1007/s10803-007-0435-8; Kamnasaran D, 2003, J MED GENET, V40, P325, DOI 10.1136/jmg.40.5.325; Kirov G, 2008, HUM MOL GENET, V17, P458, DOI 10.1093/hmg/ddm323; Kumar RA, 2008, HUM MOL GENET, V17, P628, DOI 10.1093/hmg/ddm376; Law AJ, 2007, HUM MOL GENET, V16, P129, DOI 10.1093/hmg/ddl449; Lee JA, 2006, NEURON, V52, P103, DOI 10.1016/j.neuron.2006.09.027; Li B, 2007, NEURON, V54, P583, DOI 10.1016/j.neuron.2007.03.028; Liu H, 2002, P NATL ACAD SCI USA, V99, P16859, DOI 10.1073/pnas.232186099; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Lupski JR, 2005, PLOS GENET, V1, P627, DOI 10.1371/journal.pgen.0010049; MacIntyre D, 2003, MOL PSYCHIATR, V8, P275, DOI 10.1038/sj.mp.4001232; Makoff A, 1996, MOL BRAIN RES, V40, P165, DOI 10.1016/0169-328X(96)00110-6; Manent JB, 2007, NEUROSCIENTIST, V13, P268, DOI 10.1177/1073858406298918; McClellan JM, 2007, BRIT J PSYCHIAT, V190, P194, DOI 10.1192/bjp.bp.106.025585; Mi HY, 2007, NUCLEIC ACIDS RES, V35, pD247, DOI 10.1093/nar/gkl869; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; Norton N, 2006, AM J MED GENET B, V141B, P96, DOI 10.1002/ajmg.b.30236; Rapoport J L, 2000, Curr Psychiatry Rep, V2, P410, DOI 10.1007/s11920-000-0024-4; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; Sammut S, 2007, J NEUROCHEM, V103, P1145, DOI 10.1111/j.1471-4159.2007.04811.x; Seal JL, 2006, J MED GENET, V43, P887, DOI 10.1136/jmg.2006.043380; Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; Smith RE, 2001, AM J PSYCHIAT, V158, P1393, DOI 10.1176/appi.ajp.158.9.1393; Sporn A, 2004, MOL PSYCHIATR, V9, P225, DOI 10.1038/sj.mp.4001477; Szatmari P, 2007, NAT GENET, V39, P319, DOI 10.1038/ng1985; Wang JQ, 2007, J NEUROCHEM, V100, P1, DOI 10.1111/j.1471-4159.2006.04208.x; Weiss LA, 2008, NEW ENGL J MED, V358, P667, DOI 10.1056/NEJMoa075974	42	1307	1354	0	185	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2008	320	5875					539	543		10.1126/science.1155174	http://dx.doi.org/10.1126/science.1155174			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292EM	18369103				2022-12-28	WOS:000255249300053
J	Liu, L; Botos, I; Wang, Y; Leonard, JN; Shiloach, J; Segal, DM; Davies, DR				Liu, Lin; Botos, Istvan; Wang, Yan; Leonard, Joshua N.; Shiloach, Joseph; Segal, David M.; Davies, David R.			Structural basis of toll-like receptor 3 signaling with double-stranded RNA	SCIENCE			English	Article							CRYSTAL-STRUCTURE; BINDING; RECOGNITION	Toll- like receptor 3 ( TLR3) recognizes double- stranded RNA ( dsRNA), a molecular signature of most viruses, and triggers inflammatory responses that prevent viral spread. TLR3 ectodomains ( ECDs) dimerize on oligonucleotides of at least 40 to 50 base pairs in length, the minimal length required for signal transduction. To establish the molecular basis for ligand binding and signaling, we determined the crystal structure of a complex between two mouse TLR3- ECDs and dsRNA at 3.4 angstrom resolution. Each TLR3- ECD binds dsRNA at two sites located at opposite ends of the TLR3 horseshoe, and an intermolecular contact between the two TLR3- ECD C- terminal domains coordinates and stabilizes the dimer. This juxtaposition could mediate downstream signaling by dimerizing the cytoplasmic Toll interleukin- 1 receptor ( TIR) domains. The overall shape of the TLR3- ECD does not change upon binding to dsRNA.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; [Wang, Yan; Leonard, Joshua N.; Segal, David M.] NCI, Expt Immunol Branch, Bethesda, MD 20892 USA; [Shiloach, Joseph] NIDDKD, Biotechnol Unit, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Davies, DR (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	david.davies@nih.gov	Leonard, Joshua/B-7649-2009	Leonard, Joshua/0000-0003-4359-6126; Botos, Istvan/0000-0002-7702-6749	NATIONAL CANCER INSTITUTE [ZIABC009254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZICDK015500, Z01DK034002] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 BC009254-33] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bell JK, 2006, P NATL ACAD SCI USA, V103, P8792, DOI 10.1073/pnas.0603245103; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200; Gay NJ, 2007, ANNU REV BIOCHEM, V76, P141, DOI 10.1146/annurev.biochem.76.060305.151318; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Leonard JN, 2008, P NATL ACAD SCI USA, V105, P258, DOI 10.1073/pnas.0710779105; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Sun JC, 2006, J BIOL CHEM, V281, P11144, DOI 10.1074/jbc.M510442200; Takada E, 2007, MOL IMMUNOL, V44, P3633, DOI 10.1016/j.molimm.2007.04.021; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522	15	533	553	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					379	381		10.1126/science.1155406	http://dx.doi.org/10.1126/science.1155406			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420935	Green Accepted			2022-12-28	WOS:000255026100045
J	Gosse, NJ; Nevin, LM; Baier, H				Gosse, Nathan J.; Nevin, Linda M.; Baier, Herwig			Retinotopic order in the absence of axon competition	NATURE			English	Article							RETINOTECTAL PROJECTION; RETINAL AXONS; NEURAL MAP; IN-VIVO; ZEBRAFISH RETINA; EPHRIN-AS; GRADIENTS; GROWTH; MODEL; CONNECTIONS	The retinotectal projection has long been studied experimentally and theoretically, as a model for the formation of topographic brain maps(1-3). Neighbouring retinal ganglion cells ( RGCs) project their axons to neighbouring positions in the optic tectum, thus reestablishing a continuous neural representation of visual space. Mapping along this axis requires chemorepellent signalling from tectal cells, expressing ephrin- A ligands, to retinal growth cones, expressing EphA receptors(4). High concentrations of ephrin A, increasing from anterior to posterior, prevent temporal axons from invading the posterior tectum. However, the force that drives nasal axons to extend past the anterior tectum and terminate in posterior regions remains to be identified. We tested whether axon - axon interactions, such as competition, are required for posterior tectum innervation. By transplanting blastomeres from a wild- type ( WT) zebrafish into a lakritz ( lak) mutant, which lacks all RGCs(5), we created chimaeras with eyes that contained single RGCs. These solitary RGCs often extended axons into the tectum, where they branched to form a terminal arbor. Here we show that the distal tips of these arbors were positioned at retinotopically appropriate positions, ruling out an essential role for competition in innervation of the ephrin- A- rich posterior tectum. However, solitary arbors were larger and more complex than under normal, crowded conditions, owing to a lack of pruning of proximal branches during refinement of the retinotectal projection. We conclude that dense innervation is not required for targeting of retinal axons within the zebrafish tectum but serves to restrict arbor size and shape.	[Gosse, Nathan J.; Baier, Herwig] Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94158 USA; [Nevin, Linda M.; Baier, Herwig] Univ Calif San Francisco, Neurosci Program, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Baier, H (corresponding author), Univ Calif San Francisco, Program Dev Biol, 1550 4th St, San Francisco, CA 94158 USA.	herwig.baier@ucsf.edu	Nevin, Linda/AAL-6321-2021	Nevin, Linda/0000-0003-4095-8574	NATIONAL EYE INSTITUTE [R01EY012406, R01EY013855] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012406-08, R01 EY013855-02, R01 EY012406-06A2, R01 EY013855-08, R01 EY012406, R01 EY013855, R01 EY012406-09, R01 EY013855-07, R01 EY012406-07, R01 EY013855-01A1, R01 EY013855-05, R01 EY013855-04, R01 EY013855-03, R01 EY013855-06] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Baier H, 1996, DEVELOPMENT, V123, P415; Brennan C, 1997, DEVELOPMENT, V124, P655; Carvalho RF, 2006, NAT NEUROSCI, V9, P322, DOI 10.1038/nn1655; Flanagan JG, 2006, CURR OPIN NEUROBIOL, V16, P59, DOI 10.1016/j.conb.2006.01.010; FRASER SE, 1990, J NEUROBIOL, V21, P51, DOI 10.1002/neu.480210105; GIERER A, 1983, PROC R SOC SER B-BIO, V218, P77, DOI 10.1098/rspb.1983.0027; Goodhill GJ, 2007, NEURON, V56, P301, DOI 10.1016/j.neuron.2007.09.027; Goodhill GJ, 2005, NETWORK-COMP NEURAL, V16, P5, DOI 10.1080/09548980500254654; Haas K, 2001, NEURON, V29, P583, DOI 10.1016/S0896-6273(01)00235-5; Hansen MJ, 2004, NEURON, V42, P717, DOI 10.1016/j.neuron.2004.05.009; Honda H, 2003, J NEUROSCI, V23, P10368; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Hua JY, 2005, NATURE, V434, P1022, DOI 10.1038/nature03409; Ichijo H, 1998, J NEUROSCI, V18, P5008; Kay JN, 2005, DEVELOPMENT, V132, P2573, DOI 10.1242/dev.01831; Kay JN, 2001, NEURON, V30, P725, DOI 10.1016/S0896-6273(01)00312-9; Lemke G, 2005, ANNU REV CELL DEV BI, V21, P551, DOI 10.1146/annurev.cellbio.20.022403.093702; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Picker A, 1999, DEVELOPMENT, V126, P2967; Poggi L, 2005, J CELL BIOL, V171, P991, DOI 10.1083/jcb.200509098; Rashid T, 2005, NEURON, V47, P57, DOI 10.1016/j.neuron.2005.05.030; Reber M, 2004, NATURE, V431, P847, DOI 10.1038/nature02957; Ruthazer ES, 2004, J NEUROBIOL, V59, P134, DOI 10.1002/neu.10344; Smear MC, 2007, NEURON, V53, P65, DOI 10.1016/j.neuron.2006.12.013; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STUERMER CAO, 1988, J NEUROSCI, V8, P4513; Tsigankov DN, 2006, J COMPUT NEUROSCI, V21, P101, DOI 10.1007/s10827-006-9575-7; VONBOXBERG Y, 1993, NEURON, V10, P345; Willshaw D, 2006, DEVELOPMENT, V133, P2705, DOI 10.1242/dev.02430; Xiao T, 2005, DEVELOPMENT, V132, P2955, DOI 10.1242/dev.01861; Yates PA, 2004, J NEUROBIOL, V59, P95, DOI 10.1002/neu.10341	31	65	66	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2008	452	7189					892	U9		10.1038/nature06816	http://dx.doi.org/10.1038/nature06816			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18368050	Green Accepted			2022-12-28	WOS:000255026000052
J	Davis, S; Papalia, MA; Norman, RJ; O'Neill, S; Redelman, M; Williamson, M; Stuckey, BGA; Wlodarczyk, J; Gard'ner, K; Humberstone, A				Davis, Susan; Papalia, Mary-Anne; Norman, Robert J.; O'Neill, Sheila; Redelman, Margaret; Williamson, Margaret; Stuckey, Bronwyn G. A.; Wlodarczyk, John; Gard'ner, Karen; Humberstone, Andrew			Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women	ANNALS OF INTERNAL MEDICINE			English	Article							SURGICALLY MENOPAUSAL WOMEN; DESIRE DISORDER; ANDROGEN LEVELS; PATCH; DYSFUNCTION; AGE	Background: it is not known whether premenopausal women who report low sexual satisfaction and have low circulating testosterone levels will benefit from testosterone therapy. Objective: To evaluate the effects of exogenous testosterone in premenopausal women reporting diminished sexual function. Design: Randomized, double-blind, placebo-controlled, close-ranging trial. Setting: 6 Australian medical centers. Patients: 261 women age 35 to 46 years who reported a decrease in satisfying sexual activity relative to their younger years and had a morning serum free testosterone level less than 3.8 pmol/L (<1.1 pg/mL). Intervention: 3 different doses of testosterone administered by a metered-dose transdermal spray for 16 weeks or placebo. Measurements: The primary outcome was the mean number of self-reported satisfactory sexual events (SSEs) over 28 days at week 16. The frequency of SSEs, total number of sexual events (every 4 weeks), scores from the modified Sabbatsberg Sexual Self-Rating Scale and the Psychological General Well-Being Index, and safety variables were also measured. Results: The number of SSEs increased during the treatment period in the active treatment groups and the placebo group. The mean number of SSEs over 28 days at week 16 was statistically significantly greater for women treated with the intermediate dose of testosterone therapy (one 90-mu L spray) than for women treated with placebo. The least-squares mean was 2.48 versus 1.70 SSEs, respectively (event rate ratio, 1.49 [95% CI, 1.01 to 2.18]; P = 0.04). The frequency of SSEs in women treated with low and high doses of testosterone did not differ from that in women who took placebo. The rate ratios based on the least-squares mean rates of SSEs during weeks 4 to 16 for each treatment group showed statistically significant or borderline significant increases in all testosterone groups compared with the placebo group. The rate ratios for the one 56-mu L spray, one 90-mu L spray, and two 90-mu L sprays treatment groups were 1.34 (CI, 0.97 to 1.85; P = 0.081), 1.48 (CI, 1.07 to 2.06; P = 0.018), and 1.38 (CI, 1.00 to 1.92; P = 0.052), respectively. At week 16, 95% of women treated with the one 90-mu L dose had a free testosterone level less than the upper limit of the reference range for women. The most frequently reported adverse event was hypertrichosis, which was dose-related and mostly confined to the application site. No clinically relevant changes in blood test values, serum biochemical variables, or vital signs occurred. Limitation: The study duration was short, and the placebo effect was strong. Conclusion: A daily 90-mu L dose of transdermal testosterone improves self-reported sexual satisfaction for premenopausal women with reduced libido and low serum-free testosterone levels by a mean of 0.8 SSE per month. The rate of SSEs with higher and lower testosterone doses did not differ from that with placebo.	[Davis, Susan] Monash Univ, Alfred Hosp, Dept Med, Womens Hlth Program, Prahran, Vic 3181, Australia; Univ Adelaide, Sch Paediat & Reprod Hlth, Res Ctr Reprod Hlth, Adelaide, SA, Australia; Royal Hosp Women, Randwick, NSW, Australia; John Wlodarczyk Consultancy Serv, Sydney, NSW, Australia; Sydney Ctr Sexual & Relationship Therapy, Sydney, NSW, Australia; Princess Alexandra Hosp, Brisbane, Qld, Australia; Univ Western Australia, Sir Charles Gairdner Hosp, Perth, WA 6009, Australia; Acrux Ltd, Melbourne, Vic, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; University of Adelaide; University of Western Australia; Acrux	Davis, S (corresponding author), Monash Univ, Alfred Hosp, Dept Med, Womens Hlth Program, Commercial Rd, Prahran, Vic 3181, Australia.		Davis, Susan R/A-3111-2009; Norman, Robert J/A-1155-2007; Davis, Susan D/GZL-2361-2022	Davis, Susan R/0000-0002-2955-0415; Norman, Robert J/0000-0002-3118-3896; 				BECK AT, 1987, BDI II MANUAL; Bell RJ, 2006, MENOPAUSE, V13, P65, DOI 10.1097/01.gme.0000191212.58856.96; Bradford A, 2007, J SEX MED, V4, P1345, DOI 10.1111/j.1743-6109.2007.00578.x; Braunstein GD, 2005, ARCH INTERN MED, V165, P1582, DOI 10.1001/archinte.165.14.1582; Burger HG, 2000, J CLIN ENDOCR METAB, V85, P2832, DOI 10.1210/jc.85.8.2832; Buster JE, 2005, OBSTET GYNECOL, V105, P944, DOI 10.1097/01.AOG.0000158103.27672.0d; DAVIS SR, 1995, MATURITAS, V21, P227, DOI 10.1016/0378-5122(94)00898-H; Davis SR, 2005, JAMA-J AM MED ASSOC, V294, P91, DOI 10.1001/jama.294.1.91; Davis SR, 2006, MENOPAUSE, V13, P387, DOI 10.1097/01.gme.0000179049.08371.c7; Davison SL, 2005, J CLIN ENDOCR METAB, V90, P3847, DOI 10.1210/jc.2005-0212; Dennerstein L, 2005, FERTIL STERIL, V84, P174, DOI 10.1016/j.fertnstert.2005.01.119; Dupuy H.J., 1984, ASSESSMENT QUALITY L, P170; EICKHOFF JC, 2008, STAT MED        0125; Fedor-Freybergh P, 1977, Acta Obstet Gynecol Scand Suppl, V64, P1; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; GARRATT AM, 1995, BRIT J OBSTET GYNAEC, V102, P311, DOI 10.1111/j.1471-0528.1995.tb09138.x; Goldstat R, 2003, MENOPAUSE, V10, P390, DOI 10.1097/01.GME.0000060256.03945.20; HUMBERSTONE A, 2003, P END SOC 85 ANN M 1; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; Lobo RA, 2003, FERTIL STERIL, V79, P1341, DOI 10.1016/S0015-0282(03)00358-3; PALATSI R, 1984, ACTA DERM-VENEREOL, V64, P517; Shabsigh R, 2007, CURR MED RES OPIN, V23, P2453, DOI 10.1185/030079907X219616; Shifren JL, 2006, MENOPAUSE, V13, P770, DOI 10.1097/01.gme.0000227400.60816.52; Shifren JL, 2000, NEW ENGL J MED, V343, P682, DOI 10.1056/NEJM200009073431002; ZUMOFF B, 1995, J CLIN ENDOCR METAB, V80, P1429, DOI 10.1210/jc.80.4.1429	25	97	96	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2008	148	8					569	577		10.7326/0003-4819-148-8-200804150-00001	http://dx.doi.org/10.7326/0003-4819-148-8-200804150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290LF	18413618				2022-12-28	WOS:000255123600001
J	Greco, G; Powell-Jackson, T; Borghi, J; Mills, A				Greco, Giulia; Powell-Jackson, Timothy; Borghi, Josephine; Mills, Anne			Countdown to 2015: assessment of donor assistance to maternal, newborn, and child health between 2003 and 2006	LANCET			English	Article							AID ALLOCATION; SCALING-UP	Background To track donor assistance to maternal, newborn, and child health-related activities is necessary to assess progress towards Millennium Development Goals 4 and 5 and to foster donor accountability. Our aim was to analyse aid flows to maternal, newborn, and child health for 2005 and 2006 and trends between 2003 and 2006. Methods We analysed and coded the complete aid activities database for 2005 and 2006 with methods that we developed previously to track official development assistance. For the 68 Countdown priority countries, we report two indicators for use in monitoring donor disbursements: official development assistance to child health per child and official development assistance to maternal and neonatal health per livebirth. Findings Donor disbursements increased from US$2119 million in 2003 to $3482 million in 2006; funding for child health increased by 63% and that for maternal and newborn health increased by 66%. In the 68 priority countries, child-related disbursements increased from a mean of $4 per child in 2003 to $7 per child in 2006; disbursements for maternal and neonatal health increased from $7 per livebirth in 2003 to $12 per livebirth in 2006. Nonetheless, disbursements fell in some countries. After adjustment for other determinants, countries with higher under-5 mortality received more official development assistance per child, but official development assistance to maternal and newborn health did not seem to be well targeted towards countries with the greatest maternal health needs. Interpretation Donor resource tracking should be continued to help hold donors accountable and encourage targeting of resources to countries with greatest needs. Funding Partnership for Maternal, Newborn and Child Health.	[Greco, Giulia; Powell-Jackson, Timothy; Borghi, Josephine; Mills, Anne] Univ London London Sch Hyg & Trop Med, Hlth Econ & Financing Programme, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Mills, A (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Econ & Financing Programme, Keppel St, London WC1E 7HT, England.	anne.mills@lshtm.ac.uk		Greco, Giulia/0000-0002-5448-9521; Borghi, Josephine/0000-0002-0482-5451; Mills, Anne/0000-0001-9863-9950				Alesina A, 2002, AM ECON REV, V92, P1126, DOI 10.1257/00028280260344669; Alesina A, 2000, J ECON GROWTH, V5, P33, DOI 10.1023/A:1009874203400; Bobba M, 2007, AID EFFECTIVENESS PO; Bulir A, 2003, IMF STAFF PAPERS, V50, P64; Chauvet, 2003, EUROPEAN J POLITICAL, V19, P33, DOI 10.1016/S0176-2680(02)00128-3; Collier P, 2002, EUR ECON REV, V46, P1475, DOI 10.1016/S0014-2921(01)00187-8; GRECO G, 2007, EC FINANCIAL ANAL SC; Johns B, 2007, B WORLD HEALTH ORGAN, V85, P256, DOI 10.2471/BLT.06.032037; Lane C, 2007, HEALTH AFFAIR, V26, P935, DOI 10.1377/hlthaff.26.4.935; Llavador HG, 2001, J DEV ECON, V64, P147, DOI 10.1016/S0304-3878(00)00128-0; MAIZELS A, 1984, WORLD DEV, V12, P879, DOI 10.1016/0305-750X(84)90046-9; Neumayer E, 2003, SOC SCI QUART, V84, P650, DOI 10.1111/1540-6237.8403010; *OECD, STAT ANN 2007 DEV CO; Powell-Jackson T, 2006, LANCET, V368, P1077, DOI 10.1016/S0140-6736(06)69338-0; Stenberg K, 2007, B WORLD HEALTH ORGAN, V85, P305, DOI 10.2471/BLT.06.032052; Svensson J, 2000, J INT ECON, V51, P437, DOI 10.1016/S0022-1996(99)00014-8; WHITE H, 1995, DEV CHANGE, V26, P163, DOI 10.1111/j.1467-7660.1995.tb00547.x	17	75	76	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1268	1275		10.1016/S0140-6736(08)60561-9	http://dx.doi.org/10.1016/S0140-6736(08)60561-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	286XH	18406861				2022-12-28	WOS:000254878900028
J	Eggleston, CM				Eggleston, Carrick M.			Toward new uses for hematite	SCIENCE			English	Editorial Material							ELECTRODES		Univ Wyoming, Dept Geol & Geophys, Laramie, WY 82071 USA	University of Wyoming	Eggleston, CM (corresponding author), Univ Wyoming, Dept Geol & Geophys, Laramie, WY 82071 USA.	carrick@uwyo.edu						Galvez N, 1999, CLAY CLAY MINER, V47, P304, DOI 10.1346/CCMN.1999.0470306; Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607; HOROWITZ G, 1983, J ELECTROANAL CHEM, V159, P421, DOI 10.1016/S0022-0728(83)80638-X; Kay A, 2006, J AM CHEM SOC, V128, P15714, DOI 10.1021/ja064380l; LIU LY, 1986, IEEE T ELECTRON DEV, V33, P1593, DOI 10.1109/T-ED.1986.22712; SHINAR R, 1983, J ELECTROCHEM SOC, V130, P392, DOI 10.1149/1.2119717; Squyres SW, 2004, SCIENCE, V306, P1709, DOI 10.1126/science.1104559; Vargas M, 1998, NATURE, V395, P65, DOI 10.1038/25720; Wang Y, 2007, J PHYS D APPL PHYS, V40, P3925, DOI 10.1088/0022-3727/40/13/003; Yanina SV, 2008, SCIENCE, V320, P218, DOI 10.1126/science.1154833	10	52	56	8	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					184	185		10.1126/science.1157189	http://dx.doi.org/10.1126/science.1157189			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403697				2022-12-28	WOS:000254836700027
J	Pagel, M				Pagel, Mark			Rise of the digital machine	NATURE			English	Editorial Material									Univ Reading, Sch Biol Sci, Reading RG6 6AJ, Berks, England; Santa Fe Inst, Santa Fe, NM 87501 USA	University of Reading; The Santa Fe Institute	Pagel, M (corresponding author), Univ Reading, Sch Biol Sci, Reading RG6 6AJ, Berks, England.							Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Gell-Mann M., 1994, QUARK JAGUAR ADVENTU; Mattick JS, 2003, BIOESSAYS, V25, P930, DOI 10.1002/bies.10332; Nowak MA, 2005, NATURE, V437, P1291, DOI 10.1038/nature04131	4	5	5	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2008	452	7188					699	699		10.1038/452699a	http://dx.doi.org/10.1038/452699a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401394	Bronze			2022-12-28	WOS:000254792500029
J	Vijayalakshmi, K; Griffiths, A; Hasan, A; O'Sullivan, J				Vijayalakshmi, Kunadian; Griffiths, Amanda; Hasan, Asif; O'Sullivan, John			Lesson of the week - Late hazards after repair of coarctation of the aorta	BRITISH MEDICAL JOURNAL			English	Article							TERM-FOLLOW-UP; SURGICAL-CORRECTION		[Vijayalakshmi, Kunadian; Griffiths, Amanda; Hasan, Asif; O'Sullivan, John] Freeman Rd Hosp, Newcastle Upon Tyne Hosp NHS Trust, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Vijayalakshmi, K (corresponding author), Freeman Rd Hosp, Newcastle Upon Tyne Hosp NHS Trust, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	kunadianvijay@aol.com						Bouchart F, 2000, ANN THORAC SURG, V70, P1483, DOI 10.1016/S0003-4975(00)01999-8; COHEN M, 1989, CIRCULATION, V80, P840, DOI 10.1161/01.CIR.80.4.840; CRAFOORD C, 1945, J THORAC SURG, V14, P347; de Bono J, 2005, INT J CARDIOL, V104, P176, DOI 10.1016/j.ijcard.2004.11.011; Hoimyr H, 2006, EUR J CARDIO-THORAC, V30, P910, DOI 10.1016/j.ejcts.2006.09.016; KAPPETEIN AP, 1994, J THORAC CARDIOV SUR, V107, P87; STEWART AB, 1993, BRIT HEART J, V69, P65; Toro-Salazar OH, 2002, AM J CARDIOL, V89, P541, DOI 10.1016/S0002-9149(01)02293-7; von Kodolitsch Y, 2002, J AM COLL CARDIOL, V39, P617, DOI 10.1016/S0735-1097(01)01784-3	9	0	0	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 5	2008	336	7647					772	773		10.1136/bmj.39472.693356.47	http://dx.doi.org/10.1136/bmj.39472.693356.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284JW	18390530	Green Published			2022-12-28	WOS:000254703700037
J	Dantas, G; Sommer, MOA; Oluwasegun, RD; Church, GM				Dantas, Gautam; Sommer, Morten O. A.; Oluwasegun, Rantimi D.; Church, George M.			Bacteria subsisting on antibiotics	SCIENCE			English	Article							RESISTANCE GENES; MOLECULAR-MECHANISMS; DATABASE; SOIL; BENZYLPENICILLIN; DIVERSITY; RESISTOME; NITROGEN; CARBON; ARB	Antibiotics are a crucial line of defense against bacterial infections. Nevertheless, several antibiotics are natural products of microorganisms that have as yet poorly appreciated ecological roles in the wider environment. We isolated hundreds of soil bacteria with the capacity to grow on antibiotics as a sole carbon source. Of 18 antibiotics tested, representing eight major classes of natural and synthetic origin, 13 to 17 supported the growth of clonal bacteria from each of 11 diverse soils. Bacteria subsisting on antibiotics are surprisingly phylogenetically diverse, and many are closely related to human pathogens. Furthermore, each antibiotic- consuming isolate was resistant to multiple antibiotics at clinically relevant concentrations. This phenomenon suggests that this unappreciated reservoir of antibiotic- resistance determinants can contribute to the increasing levels of multiple antibiotic resistance in pathogenic bacteria.	[Dantas, Gautam; Sommer, Morten O. A.; Oluwasegun, Rantimi D.; Church, George M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Sommer, Morten O. A.] Harvard Univ, Program Biophys, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University	Church, GM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.			church, george/0000-0001-6232-9969; Sommer, Morten Otto Alexander/0000-0003-4005-5674; Dantas, Gautam/0000-0003-0455-8370				ABDELM.Y, 1961, NATURE, V189, P775, DOI 10.1038/189775a0; Alekshun MN, 2007, CELL, V128, P1037, DOI 10.1016/j.cell.2007.03.004; Cole JR, 2007, NUCLEIC ACIDS RES, V35, pD169, DOI 10.1093/nar/gkl889; D'Costa VM, 2007, CURR OPIN MICROBIOL, V10, P481, DOI 10.1016/j.mib.2007.08.009; D'Costa VM, 2006, SCIENCE, V311, P374, DOI 10.1126/science.1120800; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Fredrickson JK, 2000, APPL ENVIRON MICROB, V66, P2006, DOI 10.1128/AEM.66.5.2006-2011.2000; JOHNSEN J, 1977, ARCH MICROBIOL, V115, P271, DOI 10.1007/BF00446452; KAMEDA Y, 1961, NATURE, V191, P1122, DOI 10.1038/1911122a0; Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293; Marshall CG, 1998, ANTIMICROB AGENTS CH, V42, P2215, DOI 10.1128/AAC.42.9.2215; McAllister KA, 1996, BIODEGRADATION, V7, P1, DOI 10.1007/BF00056556; Parke JL, 2001, ANNU REV PHYTOPATHOL, V39, P225, DOI 10.1146/annurev.phyto.39.1.225; Projan SJ, 2007, ANTIMICROB AGENTS CH, V51, P1133, DOI 10.1128/AAC.01370-06; Riesenfeld CS, 2004, ENVIRON MICROBIOL, V6, P981, DOI 10.1111/j.1462-2920.2004.00664.x; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Wheeler DL, 2000, NUCLEIC ACIDS RES, V28, P10, DOI 10.1093/nar/28.1.10	18	387	426	19	318	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2008	320	5872					100	103		10.1126/science.1155157	http://dx.doi.org/10.1126/science.1155157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388292	Green Published			2022-12-28	WOS:000254633000040
J	Stamler, JS; Sun, QA; Hess, DT				Stamler, Jonathan S.; Sun, Qi-An; Hess, Douglas T.			A SNO storm in skeletal muscle	CELL			English	Editorial Material							S-NITROSYLATION; NITRIC-OXIDE; RECEPTOR; CHANNEL; O-2	Dysregulated S-nitrosylation of proteins characterizes a broad array of human disorders, but its role in disease etiology is not well understood. Two new studies (Durham et al., 2008; Bellinger et al., 2008) now show that hyper-S-nitrosylation of the ryanodine receptor calcium release channel (RyR1) in skeletal muscle disrupts calcium ion flux. This disruption underlies the impaired contractility and cellular damage of skeletal muscle during strenuous exercise and in a spectrum of congenital muscle disorders including malignant hyperthermia.	[Stamler, Jonathan S.; Sun, Qi-An; Hess, Douglas T.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Stamler, Jonathan S.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	staml001@mc.duke.edu		Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [R01-HL059130] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059130] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aracena-Parks P, 2006, J BIOL CHEM, V281, P40354, DOI 10.1074/jbc.M600876200; Bellinger AM, 2008, P NATL ACAD SCI USA, V105, P2198, DOI 10.1073/pnas.0711074105; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Gonzalez DR, 2007, P NATL ACAD SCI USA, V104, P20612, DOI 10.1073/pnas.0706796104; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Palmer LA, 2007, J CLIN INVEST, V117, P2592, DOI 10.1172/JCI29444; REID MB, 1994, J CLIN INVEST, V94, P2468, DOI 10.1172/JCI117615; Sun JH, 2003, J BIOL CHEM, V278, P8184, DOI 10.1074/jbc.M211940200; Wappler F, 2001, ANESTHESIOLOGY, V94, P95, DOI 10.1097/00000542-200101000-00019	9	26	26	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 4	2008	133	1					33	35		10.1016/j.cell.2008.03.013	http://dx.doi.org/10.1016/j.cell.2008.03.013			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394987	Bronze			2022-12-28	WOS:000254641300006
J	Xing, YN; Li, Z; Chen, Y; Stock, JB; Jeffrey, PD; Shi, YG				Xing, Yongna; Li, Zhu; Chen, Yu; Stock, Jeffry B.; Jeffrey, Philip D.; Shi, Yigong			Structural mechanism of demethylation and inactivation of protein phosphatase 2A	CELL			English	Article							TERMINAL LEUCINE RESIDUE; PP2A CATALYTIC SUBUNIT; CARBOXYL METHYLATION; REGULATORY SUBUNITS; BOVINE BRAIN; A-SUBUNIT; ASSOCIATION; METHYLTRANSFERASE; METHYLESTERASE; ESTERIFICATION	Protein phosphatase 2A (PP2A) is an important serine/ threonine phosphatase that plays a role in many biological processes. Reversible carboxyl methylation of the PP2A catalytic subunit is an essential regulatory mechanism for its function. Demethylation and negative regulation of PP2A is mediated by a PP2A-specific methylesterase PME-1, which is conserved from yeast to humans. However, the underlying mechanism of PME-1 function remains enigmatic. Here we report the crystal structures of PME-1 by itself and in complex with a PP2A heterodimeric core enzyme. The structures reveal that PME-1 directly binds to the active site of PP2A and that this interaction results in the activation of PME-1 by rearranging the catalytic triad into an active conformation. Strikingly, these interactions also lead to inactivation of PP2A by evicting the manganese ions that are required for the phosphatase activity of PP2A. These observations identify a dual role of PME-1 that regulates PP2A activation, methylation, and holoenzyme assembly in cells.	[Xing, Yongna; Li, Zhu; Chen, Yu; Stock, Jeffry B.; Jeffrey, Philip D.; Shi, Yigong] Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Shi, YG (corresponding author), Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA.	ygshi@princeton.edu		Jeffrey, Philip/0000-0002-4351-5341; Li, Zhu/0000-0003-1536-9401; Shi, Yigong/0000-0003-2030-168X	NATIONAL CANCER INSTITUTE [R01CA123155, K01CA124856] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA123155, K01 CA124856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Chen Y, 2007, NAT STRUCT MOL BIOL, V14, P527, DOI 10.1038/nsmb1254; Cho US, 2007, PLOS BIOL, V5, P1810, DOI 10.1371/journal.pbio.0050202; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; De Baere I, 1999, BIOCHEMISTRY-US, V38, P16539, DOI 10.1021/bi991646a; Fellner T, 2003, GENE DEV, V17, P2138, DOI 10.1101/gad.259903; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; Hombauer H, 2007, PLOS BIOL, V5, P1355, DOI 10.1371/journal.pbio.0050155; Ikehara T, 2007, BIOCHEM BIOPH RES CO, V354, P1052, DOI 10.1016/j.bbrc.2007.01.085; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kloeker S, 1997, BIOCHEM J, V327, P481, DOI 10.1042/bj3270481; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; LEE J, 1993, J BIOL CHEM, V268, P19192; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; Lee JA, 2007, J BIOL CHEM, V282, P30974, DOI 10.1074/jbc.M704861200; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Longin S, 2004, BIOCHEM J, V380, P111, DOI 10.1042/BJ20031643; Longin S, 2008, EXP CELL RES, V314, P68, DOI 10.1016/j.yexcr.2007.07.030; Longin S, 2007, J BIOL CHEM, V282, P26971, DOI 10.1074/jbc.M704059200; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mumby M., 2001, SCI STKE, pe1; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; SHELDRICK G, 1991, PATTERSON INTERPRETA; Sontag E, 2004, J NEUROPATH EXP NEUR, V63, P1080, DOI 10.1093/jnen/63.10.1080; Sontag E, 2007, J NEUROSCI, V27, P2751, DOI 10.1523/JNEUROSCI.3316-06.2007; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Vafai SB, 2002, FEBS LETT, V518, P1, DOI 10.1016/S0014-5793(02)02702-3; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wei HJ, 2001, J BIOL CHEM, V276, P1570, DOI 10.1074/jbc.M008694200; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672; XIE HY, 1994, BIOCHEM BIOPH RES CO, V203, P1710, DOI 10.1006/bbrc.1994.2383; XIE HY, 1993, J BIOL CHEM, V268, P13364; XIE HY, 1994, J BIOL CHEM, V269, P1981; Xing Y, 2006, CELL, V127, P341, DOI 10.1016/j.cell.2006.09.025; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yu H, 2007, P NATL ACAD SCI USA, V104, P17245, DOI 10.1073/pnas.0708582104; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185	52	139	155	1	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2008	133	1					154	163		10.1016/j.cell.2008.02.041	http://dx.doi.org/10.1016/j.cell.2008.02.041			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394995	Bronze			2022-12-28	WOS:000254641300016
J	Li, W; Howard, JD; Parrish, TB; Gottfried, JA				Li, Wen; Howard, James D.; Parrish, Todd B.; Gottfried, Jay A.			Aversive learning enhances perceptual and cortical discrimination of indiscriminable odor cues	SCIENCE			English	Article							HUMAN AUDITORY-CORTEX; PIRIFORM CORTEX; ORBITOFRONTAL CORTEX; OLFACTORY CORTEX; PLASTICITY; AMYGDALA; REPRESENTATIONS; ENANTIOMERS; MODULATION; MECHANISMS	Learning to associate sensory cues with threats is critical for minimizing aversive experience. The ecological benefit of associative learning relies on accurate perception of predictive cues, but how aversive learning enhances perceptual acuity of sensory signals, particularly in humans, is unclear. We combined multivariate functional magnetic resonance imaging with olfactory psychophysics to show that initially indistinguishable odor enantiomers ( mirror- image molecules) become discriminable after aversive conditioning, paralleling the spatial divergence of ensemble activity patterns in primary olfactory ( piriform) cortex. Our findings indicate that aversive learning induces piriform plasticity with corresponding gains in odor enantiomer discrimination, underscoring the capacity of fear conditioning to update perceptual representation of predictive cues, over and above its well- recognized role in the acquisition of conditioned responses. That completely indiscriminable sensations can be transformed into discriminable percepts further accentuates the potency of associative learning to enhance sensory cue perception and support adaptive behavior.	[Li, Wen; Howard, James D.; Parrish, Todd B.; Gottfried, Jay A.] Northwestern Univ, Feinberg Sch Med, Cognit Neurol & Alzheimers Dis Ctr, Chicago, IL 60611 USA; [Parrish, Todd B.] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Chicago, IL 60611 USA; [Gottfried, Jay A.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Gottfried, Jay A.] Northwestern Univ, Dept Psychol, Evanston, IL 60208 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University	Li, W (corresponding author), Northwestern Univ, Feinberg Sch Med, Cognit Neurol & Alzheimers Dis Ctr, Chicago, IL 60611 USA.	wenli@northwestern.edu	Li, Wen/AAU-8505-2020	Parrish, Todd/0000-0002-1184-1572	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC007653] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC007653, K08 DC007653-03, K08 DC007653] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Balleine BW, 2005, PHYSIOL BEHAV, V86, P717, DOI 10.1016/j.physbeh.2005.08.061; Buchel C, 1998, NEURON, V20, P947, DOI 10.1016/S0896-6273(00)80476-6; Edeline JM, 1999, PROG NEUROBIOL, V57, P165, DOI 10.1016/S0301-0082(98)00042-2; Everitt B.J., 2000, AMYGDALA FUNCTIONAL, P353; Gottfried JA, 2006, NEURON, V49, P467, DOI 10.1016/j.neuron.2006.01.007; Haberly L. B., 1998, SYNAPTIC ORG BRAIN; Hall G, 2003, Q J EXP PSYCHOL-B, V56, P43, DOI 10.1080/02724990244000151; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Holland PC, 2004, CURR OPIN NEUROBIOL, V14, P148, DOI 10.1016/j.conb.2004.03.007; Illig KR, 2005, J COMP NEUROL, V488, P224, DOI 10.1002/cne.20595; Kadohisa M, 2006, P NATL ACAD SCI USA, V103, P15206, DOI 10.1073/pnas.0604313103; LaBar KS, 1998, NEURON, V20, P937, DOI 10.1016/S0896-6273(00)80475-4; Laska M, 1999, CHEM SENSES, V24, P161, DOI 10.1093/chemse/24.2.161; Li W, 2006, NEURON, V52, P1097, DOI 10.1016/j.neuron.2006.10.026; Linster C, 2001, J NEUROSCI, V21, P9837, DOI 10.1523/JNEUROSCI.21-24-09837.2001; McLaren IPL, 2000, ANIM LEARN BEHAV, V28, P211, DOI 10.3758/BF03200258; Morris JS, 1998, P ROY SOC B-BIOL SCI, V265, P649, DOI 10.1098/rspb.1998.0343; Ohl FW, 2005, CURR OPIN NEUROBIOL, V15, P470, DOI 10.1016/j.conb.2005.07.002; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; Polley DB, 2004, P NATL ACAD SCI USA, V101, P16351, DOI 10.1073/pnas.0407586101; Polyn SM, 2005, SCIENCE, V310, P1963, DOI 10.1126/science.1117645; Schoenbaum G, 1999, J NEUROSCI, V19, P1876; Weinberger NM, 2007, LEARN MEMORY, V14, P1, DOI 10.1101/lm.421807; Wilson D. A., 2006, LEARNING SMELL; Zelano C, 2005, NAT NEUROSCI, V8, P114, DOI 10.1038/nn1368; Zou ZH, 2005, P NATL ACAD SCI USA, V102, P7724, DOI 10.1073/pnas.0503027102	26	228	231	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1842	1845		10.1126/science.1152837	http://dx.doi.org/10.1126/science.1152837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369149	Green Accepted			2022-12-28	WOS:000254394000051
J	Sylantyev, S; Savtchenko, LP; Niu, YP; Ivanov, AI; Jensen, TP; Kullmann, DM; Xiao, MY; Rusakov, DA				Sylantyev, Sergiy; Savtchenko, Leonid P.; Niu, Yin-Ping; Ivanov, Anton I.; Jensen, Thomas P.; Kullmann, Dimitri M.; Xiao, Min-Yi; Rusakov, Dmitri A.			Electric fields due to synaptic currents sharpen excitatory transmission	SCIENCE			English	Article							CA1 PYRAMIDAL NEURONS; RAT HIPPOCAMPAL SLICES; MULTIVESICULAR RELEASE; PERFORANT PATH; TIME COURSE; SYNAPSES; GLUTAMATE; CLEFT; CELLS; EPSCS	The synaptic response waveform, which determines signal integration properties in the brain, depends on the spatiotemporal profile of neurotransmitter in the synaptic cleft. Here, we show that electrophoretic interactions between AMPA receptor- mediated excitatory currents and negatively charged glutamate molecules accelerate the clearance of glutamate from the synaptic cleft, speeding up synaptic responses. This phenomenon is reversed upon depolarization and diminished when intracleft electric fields are weakened through a decrease in the AMPA receptor density. In contrast, the kinetics of receptor- mediated currents evoked by direct application of glutamate are voltage- independent, as are synaptic currents mediated by the electrically neutral neurotransmitter GABA. Voltage- dependent temporal tuning of excitatory synaptic responses may thus contribute to signal integration in neural circuits.	[Sylantyev, Sergiy; Savtchenko, Leonid P.; Jensen, Thomas P.; Kullmann, Dimitri M.; Rusakov, Dmitri A.] UCL, Inst Neurol, London WC1N 3BG, England; [Savtchenko, Leonid P.] Dnepropetrovsk Natl Univ, Lab Biophys & Bioelect, Dnepropetrovsk, Ukraine; [Niu, Yin-Ping; Xiao, Min-Yi] Gothenburg Univ, Inst Neurosci & Physiol, Gothenburg, Sweden; [Ivanov, Anton I.] INSERM, INMED, U29, F-13258 Marseille, France	University of London; University College London; Ministry of Education & Science of Ukraine; Oles Honchar Dnipro National University; University of Gothenburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Rusakov, DA (corresponding author), UCL, Inst Neurol, Queen Sq, London WC1N 3BG, England.	d.rusakov@ion.ucl.ac.uk	Kullmann, Dimitri M/A-3162-2009; Rusakov, Dmitri A/E-1987-2011; Rusakov, Dmitri/AAH-4529-2021	Kullmann, Dimitri M/0000-0001-6696-3545; Rusakov, Dmitri A/0000-0001-9539-9947; Rusakov, Dmitri/0000-0001-9539-9947; Jensen, Thomas/0000-0002-2560-6784; Ivanov, Anton/0000-0002-8650-6322; Sylantyev, Sergiy/0000-0002-1358-0601	Medical Research Council [G0400627(76527), G0400627, G0400627(71256), G0600368(77987), G0600368, G116/147] Funding Source: Medline; Wellcome Trust [071179] Funding Source: Medline; MRC [G0600368, G0400627, G116/147] Funding Source: UKRI; Medical Research Council [G0601943B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Andrasfalvy BK, 2001, J NEUROSCI, V21, P9151, DOI 10.1523/JNEUROSCI.21-23-09151.2001; Arnth-Jensen N, 2002, NAT NEUROSCI, V5, P325, DOI 10.1038/nn825; Cathala L, 2005, NAT NEUROSCI, V8, P1310, DOI 10.1038/nn1534; Christie JM, 2006, J NEUROSCI, V26, P210, DOI 10.1523/JNEUROSCI.4307-05.2006; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; ECCLES JC, 1958, PROC R SOC SER B-BIO, V148, P38, DOI 10.1098/rspb.1958.0003; Franks KM, 2002, BIOPHYS J, V83, P2333, DOI 10.1016/S0006-3495(02)75248-X; Hausser M, 2000, SCIENCE, V290, P739, DOI 10.1126/science.290.5492.739; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; Hines ML, 2001, NEUROSCIENTIST, V7, P123, DOI 10.1177/107385840100700207; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KNEISLER TB, 1995, HIPPOCAMPUS, V5, P151, DOI 10.1002/hipo.450050302; Magee JC, 2000, NAT NEUROSCI, V3, P895, DOI 10.1038/78800; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P151, DOI 10.1113/jphysiol.1972.sp009839; MCBAIN C, 1992, J NEUROPHYSIOL, V68, P16, DOI 10.1152/jn.1992.68.1.16; Migliore M, 2003, J COMPUT NEUROSCI, V14, P185, DOI 10.1023/A:1021906818333; Nicholson DA, 2006, NEURON, V50, P431, DOI 10.1016/j.neuron.2006.03.022; Nielsen TA, 2004, NEURON, V42, P757, DOI 10.1016/j.neuron.2004.04.003; Raghavachari S, 2004, J NEUROPHYSIOL, V92, P2456, DOI 10.1152/jn.00258.2004; Raman IM, 1995, BIOPHYS J, V69, P1868, DOI 10.1016/S0006-3495(95)80057-3; Savtchenko LP, 2007, P NATL ACAD SCI USA, V104, P1823, DOI 10.1073/pnas.0606636104; Savtchenko LP, 2000, BIOPHYS J, V78, P1119, DOI 10.1016/S0006-3495(00)76670-7; Scimemi A, 2004, J NEUROSCI, V24, P4767, DOI 10.1523/JNEUROSCI.0364-04.2004; TAKEUCHI A, 1959, J NEUROPHYSIOL, V22, P395, DOI 10.1152/jn.1959.22.4.395; Veruki ML, 2003, J PHYSIOL-LONDON, V549, P759, DOI 10.1113/jphysiol.2003.039982; Wadiche JI, 2001, NEURON, V32, P301, DOI 10.1016/S0896-6273(01)00488-3	27	57	57	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1845	1849		10.1126/science.1154330	http://dx.doi.org/10.1126/science.1154330			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369150	Green Accepted			2022-12-28	WOS:000254394000052
J	Dighiero, G; Hamblin, TJ				Dighiero, G.; Hamblin, T. J.			Chronic lymphocytic leukaemia	LANCET			English	Review							STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; HEAVY-CHAIN GENE; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; HIGH-DOSE METHYLPREDNISOLONE; INDUCED CYTIDINE DEAMINASE; VARIABLE-REGION MUTATIONS; PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; B29 CD79B GENE	Chronic lymphocytic leukaemia is the commonest form of leukaemia in Europe and North America, and mainly, though not exclusively, affects older individuals. It has a very variable course, with survival ranging from months to decades. Major progress has been made in identification of molecular and cellular markers that could predict disease progression in patients with chronic lymphocytic leukaemia. In particular, the mutational profile of immunoglobulin genes and some cytogenetic abnormalities are important predictors of prognosis. However, these advances have raised new questions about the biology, prognosis, and management of chronic lymphocytic leukaemia, some of which are addressed here. In particular, we discuss how better understanding of the function of the B-cell receptor, the nature of genetic lesions, and the balance between proliferation and apoptosis have affected our ability to assess prognosis and to manage chronic lymphocytic leukaemia. Available treatments generally induce remission, although nearly all patients relapse, and chronic lymphocytic leukaemia remains an incurable disease. Advances in molecular biology have enhanced our understanding of the pathophysiology of the disease and, together with development of new therapeutic agents, have made management of chronic lymphocytic leukaemia more rational and more effective than previously. Unfortunately, we know of no way that chronic lymphocytic leukaemia can be prevented. Early detection is practised widely, but seemingly makes no difference to the patient's eventual outcome.	[Dighiero, G.] Inst Pasteur Montevideo, Montevideo, Uruguay; [Hamblin, T. J.] Univ Southampton, Sch Med, Canc Sci Div, Southampton, Hants, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur de Montevideo; University of Southampton	Hamblin, TJ (corresponding author), Royal Bournemouth Hosp, Dept Haematol, Castle Lane E, Bournemouth BH7 7DW, Dorset, England.	terjoha@aol.com						ALBESIANO E, 2003, BLOOD, V102, P375; Alfarano A, 1999, BLOOD, V93, P2327, DOI 10.1182/blood.V93.7.2327.407a08_2327_2335; [Anonymous], 1999, J Natl Cancer Inst, V91, P861; Austen B, 2005, BLOOD, V106, P3175, DOI 10.1182/blood-2004-11-4516; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Binet JL, 2006, BLOOD, V107, P859, DOI 10.1182/blood-2005-04-1677; Boelens J, 2007, LEUKEMIA RES, V31, P719, DOI 10.1016/j.leukres.2006.05.024; Bosch F, 2002, BRIT J HAEMATOL, V119, P976, DOI 10.1046/j.1365-2141.2002.03959.x; Bottcher S, 2004, LEUKEMIA, V18, P1637, DOI 10.1038/sj.leu.2403478; Brown JR, 2006, BIOL BLOOD MARROW TR, V12, P1056, DOI 10.1016/j.bbmt.2006.06.004; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Buhl AM, 2006, BLOOD, V107, P2904, DOI 10.1182/blood-2005-07-2615; Byrd JC, 2003, BLOOD, V101, P6, DOI 10.1182/blood-2002-04-1258; Byrd JC, 2005, BLOOD, V105, P49, DOI 10.1182/blood-2004-03-0796; Byrd JC, 2006, J CLIN ONCOL, V24, P437, DOI 10.1200/JCO.2005.03.1021; Byrd JC, 2007, BLOOD, V109, P399, DOI 10.1182/blood-2006-05-020735; Caballero D, 2005, CLIN CANCER RES, V11, P7757, DOI 10.1158/1078-0432.CCR-05-0941; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Caligaris-Cappio F, 2003, BRIT J HAEMATOL, V123, P380, DOI 10.1046/j.1365-2141.2003.04679.x; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Campas C, 2003, BLOOD, V101, P3674, DOI 10.1182/blood-2002-07-2339; CARTWRIGHT RA, 1987, BRIT J CANCER, V56, P79, DOI 10.1038/bjc.1987.158; Castro JE, 2005, BLOOD, V106, P2506, DOI 10.1182/blood-2005-03-1099; Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Cavo M, 2006, NEW ENGL J MED, V354, P1076, DOI 10.1056/NEJMe058322; Chanan-Khan A, 2006, J CLIN ONCOL, V24, P5343, DOI 10.1200/JCO.2005.05.0401; Chen LG, 2005, BLOOD, V105, P2036, DOI 10.1182/blood-2004-05-1715; Cheson BD, 2006, CANCER IMMUNOL IMMUN, V55, P188, DOI 10.1007/s00262-005-0010-0; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Chiorazzi N, 2003, ANNU REV IMMUNOL, V21, P841, DOI 10.1146/annurev.immunol.21.120601.141018; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; *COMM REV HLTH EFF, 2003, VET AG OR 2002, P373; Crespo M, 2006, CLIN CANCER RES, V12, P726, DOI 10.1158/1078-0432.CCR-05-1531; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Cutrona G, 2006, EUR J IMMUNOL, V36, P558, DOI 10.1002/eji.200526355; CUTTNER J, 1992, CANCER INVEST, V10, P103, DOI 10.3109/07357909209032771; Damle RN, 2007, BLOOD, V110, P3352, DOI 10.1182/blood-2007-04-083832; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Deaglio S, 2005, BLOOD, V105, P3042, DOI 10.1182/blood-2004-10-3873; Deaglio S, 2001, LEUKEMIA RES, V25, P1, DOI 10.1016/S0145-2126(00)00093-X; Deaglio S, 2007, BLOOD, V110, P4012, DOI 10.1182/blood-2007-06-094029; Del Giudice I, 2005, CANCER-AM CANCER SOC, V104, P2124, DOI 10.1002/cncr.21437; Delgado J, 2006, BLOOD, V107, P1724, DOI 10.1182/blood-2005-08-3372; Dicker F, 2006, BLOOD, V108, P3152, DOI 10.1182/blood-2006-02-005322; Dighiero G, 1998, NEW ENGL J MED, V338, P1506, DOI 10.1056/NEJM199805213382104; Dighiero G, 2003, LEUKEMIA, V17, P2385, DOI 10.1038/sj.leu.2403154; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dreger P, 2005, LEUKEMIA, V19, P1029, DOI 10.1038/sj.leu.2403745; Dreger P, 2004, BLOOD, V103, P2850, DOI 10.1182/blood-2003-05-1549; Drexler HG, 2003, LEUKEMIA, V17, P416, DOI 10.1038/sj.leu.2402799; DYER MJS, 1994, BLOOD, V83, P3682; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; Faderl S, 2006, BLOOD, V108, p803A, DOI 10.1182/blood.V108.11.2836.2836; Forconi F, 2000, BLOOD, V96, p330A; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; Ghia P, 2003, BLOOD, V101, P1262, DOI 10.1182/blood-2002-06-1801; Ghiotto F, 2004, J CLIN INVEST, V113, P1008, DOI 10.1172/JCI200419399; Gobessi S, 2007, BLOOD, V109, P2032, DOI 10.1182/blood-2006-03-011759; Goldin Lynn R, 2007, Hematology Am Soc Hematol Educ Program, P339; Granziero L, 2001, BLOOD, V97, P2777, DOI 10.1182/blood.V97.9.2777; Grever MR, 2007, J CLIN ONCOL, V25, P799, DOI 10.1200/JCO.2006.08.3089; Gribben JG, 2005, BLOOD, V106, P4389, DOI 10.1182/blood-2005-05-1778; Hainsworth JD, 2003, J CLIN ONCOL, V21, P1746, DOI 10.1200/JCO.2003.09.027; Hamblin T, 2002, ANN HEMATOL, V81, P299, DOI 10.1007/s00277-002-0476-1; Hamblin T, 2006, LEUKEMIA RES, V30, P1063, DOI 10.1016/j.leukres.2005.11.022; Hamblin TJ, 2008, LEUKEMIA RES, V32, P523, DOI 10.1016/j.leukres.2007.08.015; Hamblin TJ, 2002, BLOOD, V99, P1023, DOI 10.1182/blood.V99.3.1023; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Haslinger C, 2004, J CLIN ONCOL, V22, P3937, DOI 10.1200/JCO.2004.12.133; Heintel D, 2005, LEUKEMIA, V19, P1216, DOI 10.1038/sj.leu.2403748; Herve M, 2005, J CLIN INVEST, V115, P1636, DOI 10.1172/JCI24387; Hillmen P, 2007, J CLIN ONCOL, V25, P5616, DOI 10.1200/JCO.2007.12.9098; Josefsson P, 2007, BLOOD, V109, P4973, DOI 10.1182/blood-2006-11-054916; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; Kalla C, 2007, EUR J CANCER, V43, P1328, DOI 10.1016/j.ejca.2007.02.005; Kay NE, 2007, BLOOD, V109, P405, DOI 10.1182/blood-2006-07-033274; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; Keating MJ, 1998, BLOOD, V92, P1165, DOI 10.1182/blood.V92.4.1165.416k03_1165_1171; Kienle D, 2006, BLOOD, V107, P2090, DOI 10.1182/blood-2005-04-1483; Kienle DL, 2005, J CLIN ONCOL, V23, P3780, DOI 10.1200/JCO.2005.02.568; KIPPS TJ, 1993, BLOOD, V81, P2475; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; Kojima K, 2006, BLOOD, V108, P993, DOI 10.1182/blood-2005-12-5148; Krober A, 2002, BLOOD, V100, P1410, DOI 10.1182/blood.V100.4.1410.h81602001410_1410_1416; LAGNEAUX L, 1993, BLOOD, V82, P2379; Landgren O, 2007, BLOOD, V109, P2198, DOI 10.1182/blood-2006-08-044008; Lanham S, 2003, BLOOD, V101, P1087, DOI 10.1182/blood-2002-06-1822; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; LINET MS, 1989, AM J EPIDEMIOL, V130, P655, DOI 10.1093/oxfordjournals.aje.a115387; Lozanski G, 2004, BLOOD, V103, P3278, DOI 10.1182/blood-2003-10-3729; MACMAHON B, 1957, BLOOD, V12, P1; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Maloum K, 2000, BLOOD, V96, P377, DOI 10.1182/blood.V96.1.377.013k56f_377_379; Marti GE, 2003, CYTOM PART B-CLIN CY, V52B, P1, DOI 10.1002/cyto.b.10013; Marti GE, 2005, BRIT J HAEMATOL, V130, P325, DOI 10.1111/j.1365-2141.2005.05550.x; Marti G, 2006, CYTOM PART B-CLIN CY, V70B, P197, DOI 10.1002/cyto.b.20137; Matthews C, 2006, EUR J HAEMATOL, V77, P309, DOI 10.1111/j.1600-0609.2006.00707.x; MATUTES E, 1994, LEUKEMIA, V8, P1640; McCarthy H, 2003, BLOOD, V101, P4903, DOI 10.1182/blood-2002-09-2906; Messmer BT, 2004, J EXP MED, V200, P519, DOI 10.1084/jem.20040544; Messmer BT, 2005, J CLIN INVEST, V115, P755, DOI 10.1172/JCI200523409; MICHALLET M, 1991, BONE MARROW TRANSPL, V7, P275; MICHEL F, 1993, J IMMUNOL, V150, P3624; Milligan DW, 2005, BLOOD, V105, P397, DOI 10.1182/blood-2004-01-0298; Mone AP, 2006, LEUKEMIA, V20, P272, DOI 10.1038/sj.leu.2404014; Montillo M, 2006, J CLIN ONCOL, V24, P2337, DOI 10.1200/JCO.2005.04.6037; Montserrat Emili, 2002, Hematol J, V3, P7; Moreton P, 2005, J CLIN ONCOL, V23, P2971, DOI 10.1200/JCO.2005.04.021; MULLERHERMELINK HK, 2001, WHO CLASSIFICATION T, P127; MYINT H, 1995, BRIT J HAEMATOL, V91, P341, DOI 10.1111/j.1365-2141.1995.tb05300.x; NCI, 2011, SEER CANC STAT REV 1; Nolz JC, 2005, LEUKEMIA, V19, P1018, DOI 10.1038/sj.leu.2403726; Noy A, 2001, BLOOD, V97, P1929, DOI 10.1182/blood.V97.7.1929; Ocana E, 2007, HAEMATOLOGICA, V92, P349, DOI 10.3324/haematol.10649; Oppezzo P, 2005, BLOOD, V106, P650, DOI 10.1182/blood-2004-08-3344; Oppezzo P, 2005, BLOOD, V105, P2495, DOI 10.1182/blood-2004-09-3644; Oppezzo P, 2003, BLOOD, V101, P4029, DOI 10.1182/blood-2002-10-3175; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; OSCIER DG, 2005, BLOOD, V108, P299; Osuji NC, 2005, HAEMATOLOGICA, V90, P1435; Paneesha S, 2005, BRIT J HAEMATOL, V128, P145, DOI 10.1111/j.1365-2141.2004.05250.x; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; Payelle-Brogard B, 2006, LEUKEMIA, V20, P877, DOI 10.1038/sj.leu.2404155; Payelle-Brogard B, 1999, BLOOD, V94, P3516, DOI 10.1182/blood.V94.10.3516.422k09_3516_3522; Payelle-Brogard B, 2002, BRIT J HAEMATOL, V118, P976, DOI 10.1046/j.1365-2141.2002.03759.x; Pepper C, 2007, LEUKEMIA, V21, P687, DOI 10.1038/sj.leu.2404587; Pettitt AR, 2006, LEUKEMIA, V20, P1441, DOI 10.1038/sj.leu.2404265; PRITSCH O, 1993, BLOOD, V82, P3103; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Rassenti LZ, 2004, NEW ENGL J MED, V351, P893, DOI 10.1056/NEJMoa040857; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Rawstron AC, 2007, LEUKEMIA, V21, P956, DOI 10.1038/sj.leu.2404584; Rawstron AC, 2002, BLOOD, V100, P635, DOI 10.1182/blood.V100.2.635; Rawstron AC, 2002, BLOOD, V100, P2289, DOI 10.1182/blood-2002-03-0892; Rawstron AC, 2001, BLOOD, V98, P29, DOI 10.1182/blood.V98.1.29; Reiniger L, 2006, LEUKEMIA, V20, P1089, DOI 10.1038/sj.leu.2404183; Ricca I, 2007, LEUKEMIA, V21, P697, DOI 10.1038/sj.leu.2404544; Richardson SJ, 2006, BLOOD, V107, P3584, DOI 10.1182/blood-2005-04-1718; Ritgen M, 2003, BLOOD, V101, P2049, DOI 10.1182/blood-2002-06-1744; Robak T, 2006, BLOOD, V108, P473, DOI 10.1182/blood-2005-12-4828; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; SCHROEDER HW, 1994, IMMUNOL TODAY, V15, P288, DOI 10.1016/0167-5699(94)90009-4; Schroers R, 2005, LEUKEMIA, V19, P750, DOI 10.1038/sj.leu.2403707; Sellick GS, 2006, SEMIN ONCOL, V33, P195, DOI 10.1053/j.seminoncol.2006.01.013; Stamatopoulos K, 2007, BLOOD, V109, P259, DOI 10.1182/blood-2006-03-012948; Steurer M, 2006, CANCER TREAT REV, V32, P377, DOI 10.1016/j.ctrv.2006.05.002; Stevenson FK, 2004, BLOOD, V103, P4389, DOI 10.1182/blood-2003-12-4312; Teeling JL, 2006, J IMMUNOL, V177, P362, DOI 10.4049/jimmunol.177.1.362; Thompson AA, 1997, BLOOD, V90, P1387, DOI 10.1182/blood.V90.4.1387.1387_1387_1394; Thornton PD, 2003, ANN HEMATOL, V82, P759, DOI 10.1007/s00277-003-0710-5; Thorselius M, 2006, BLOOD, V107, P2889, DOI 10.1182/blood-2005-06-2227; Tobin G, 2002, BLOOD, V99, P2262, DOI 10.1182/blood.V99.6.2262; van't Veer MB, 2006, HAEMATOLOGICA, V91, P56; Vasconcelos Y, 2005, LEUKEMIA, V19, P2002, DOI 10.1038/sj.leu.2403865; Vasconcelos Y, 2003, J CLIN ONCOL, V21, P3928, DOI 10.1200/JCO.2003.02.134; Vrhovac R, 1998, BLOOD, V91, P4694, DOI 10.1182/blood.V91.12.4694.412k09_4694_4700; Vuillier F, 2005, BLOOD, V105, P2933, DOI 10.1182/blood-2004-09-3643; Weiss N S, 1979, Natl Cancer Inst Monogr, P139; Wendtner CM, 2004, LEUKEMIA, V18, P1093, DOI 10.1038/sj.leu.2403354; Wierda W, 2006, CANCER-AM CANCER SOC, V106, P337, DOI 10.1002/cncr.21554; Wierda W, 2005, J CLIN ONCOL, V23, P4070, DOI 10.1200/JCO.2005.12.516; Wierda WG, 2007, BLOOD, V109, P4679, DOI 10.1182/blood-2005-12-051458; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306; Willimott S, 2007, HAEMATOLOGICA, V92, P1359, DOI 10.3324/haematol.11340; Winkler D, 2005, LEUKEMIA, V19, P1211, DOI 10.1038/sj.leu.2403778; Zucchetto A, 2006, J CELL PHYSIOL, V207, P354, DOI 10.1002/jcp.20570	167	230	243	0	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2008	371	9617					1017	1029		10.1016/S0140-6736(08)60456-0	http://dx.doi.org/10.1016/S0140-6736(08)60456-0			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358929				2022-12-28	WOS:000254206000030
J	Keller, AS; Stewart, SA; Eppel, S				Keller, Allen S.; Stewart, Samantha A.; Eppel, Shari			Health and human rights under assault in Zimbabwe	LANCET			English	Editorial Material									[Keller, Allen S.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Stewart, Samantha A.] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; [Keller, Allen S.; Stewart, Samantha A.] Bellevue NYU Program Survivors Torture, New York, NY 10016 USA; [Eppel, Shari] Solidar Peace Trust, Johannesburg, South Africa	New York University; New York University	Keller, AS (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10016 USA.	ask45@aol.com						[Anonymous], 2008, BBC NEWS        0220; FABRICIUS P, 2008, MBEKI BRIEF SADC LEA; Garcia S, 2007, ZIMBABWE EXODUS TOO; *HUM RIGHTS WATCH, 2007, BASH DISS ESC VIOL S; *OP SOC IN S AFR, 2007, BELL NYU PROGR SURV; Pincock S, 2005, LANCET, V366, P363, DOI 10.1016/S0140-6736(05)67012-2; *S AFR MED ASS, 2007, SA DOCT PLEAD ZIMB O; Solidarity Peace Trust, 2007, DESTR ENG VIOL MED P; World Health Organization, 2007, WORLD HLTH REP 2007; *WORLD MED ASS, 2007, WORLD MED ASS RES HL	10	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1057	1058		10.1016/S0140-6736(08)60467-5	http://dx.doi.org/10.1016/S0140-6736(08)60467-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	280RA	18374828				2022-12-28	WOS:000254442700010
J	Singh, SK; Kagalwala, MN; Parker-Thornburg, J; Adams, H; Majumder, S				Singh, Sanjay K.; Kagalwala, Mohamedi N.; Parker-Thornburg, Jan; Adams, Henry; Majumder, Sadhan			REST maintains self-renewal and pluripotency of embryonic stem cells	NATURE			English	Article							TRANSCRIPTIONAL REGULATION; NEURONAL DIFFERENTIATION; REST/NRSF; CHROMATIN; NETWORK; GENES; TUMORS; NANOG	The neuronal repressor REST ( RE1- silencing transcription factor; also called NRSF) is expressed at high levels in mouse embryonic stem ( ES) cells(1), but its role in these cells is unclear. Here we show that REST maintains self- renewal and pluripotency in mouse ES cells through suppression of the microRNA miR- 21. We found that, as with known self- renewal markers, the level of REST expression is much higher in self- renewing mouse ES cells than in differentiating mouse ES ( embryoid body, EB) cells. Heterozygous deletion of Rest ( Rest(+/-)) and its short- interfering-RNA- mediated knockdown in mouse ES cells cause a loss of self- renewal - even when these cells are grown under self- renewal conditions - and lead to the expression of markers specific for multiple lineages. Conversely, exogenously added REST maintains self- renewal in mouse EB cells. Furthermore, Rest(+/-) mouse ES cells cultured under self- renewal conditions express substantially reduced levels of several self- renewal regulators, including Oct4 ( also called Pou5f1), Nanog, Sox2 and c- Myc, and exogenously added REST in mouse EB cells maintains the self- renewal phenotypes and expression of these self- renewal regulators. We also show that in mouse ES cells, REST is bound to the gene chromatin of a set of miRNAs that potentially target self- renewal genes. Whereas mouse ES cells and mouse EB cells containing exogenously added REST express lower levels of these miRNAs, EB cells, Rest(+/-) ES cells and ES cells treated with short interfering RNA targeting Rest express higher levels of these miRNAs. At least one of these REST- regulated miRNAs, miR- 21, specifically suppresses the self- renewal of mouse ES cells, corresponding to the decreased expression of Oct4, Nanog, Sox2 and c- Myc. Thus, REST is a newly discovered element of the interconnected regulatory network that maintains the self- renewal and pluripotency of mouse ES cells.	[Singh, Sanjay K.; Kagalwala, Mohamedi N.; Adams, Henry; Majumder, Sadhan] Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA; [Parker-Thornburg, Jan] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Majumder, Sadhan] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Majumder, Sadhan] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; [Singh, Sanjay K.; Kagalwala, Mohamedi N.; Majumder, Sadhan] Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Houston, TX 77030 USA; [Majumder, Sadhan] Univ Texas Houston, Grad Sch Biomed Sci, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Majumder, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA.	smajumder@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA097124, R01CA081255] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081255, CA81255, R01 CA097124-07, CA97124, R01 CA081255-10, R01 CA097124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Ballas N, 2005, CURR OPIN NEUROBIOL, V15, P500, DOI 10.1016/j.conb.2005.08.015; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Cai JL, 2006, STEM CELLS, V24, P516, DOI 10.1634/stemcells.2005-0143; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Conaco C, 2006, P NATL ACAD SCI USA, V103, P2422, DOI 10.1073/pnas.0511041103; Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032; Cui RT, 2005, J BIOL CHEM, V280, P39152, DOI 10.1074/jbc.M504655200; Fuller GN, 2005, MOL CANCER THER, V4, P343; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Kaji K, 2006, NAT CELL BIOL, V8, P285, DOI 10.1038/ncb1372; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Majumder S, 2006, CELL CYCLE, V5, P1929, DOI 10.4161/cc.5.17.2982; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; Ooi L, 2007, NAT REV GENET, V8, P544, DOI 10.1038/nrg2100; Pan GJ, 2007, CELL RES, V17, P42, DOI 10.1038/sj.cr.7310125; Pritsker M, 2006, P NATL ACAD SCI USA, V103, P6946, DOI 10.1073/pnas.0509861103; Su XH, 2004, MOL CELL BIOL, V24, P8018, DOI 10.1128/MCB.24.18.8018-8025.2004; Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Watanabe Y, 2004, GENE DEV, V18, P889, DOI 10.1101/gad.1179004; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Zhou Q, 2007, P NATL ACAD SCI USA, V104, P16438, DOI 10.1073/pnas.0701014104	24	253	274	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2008	453	7192					223	U11		10.1038/nature06863	http://dx.doi.org/10.1038/nature06863			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297BP	18362916	Bronze, Green Accepted			2022-12-28	WOS:000255592400040
J	Stacey, D; Hawker, G; Dervin, G; Tomek, I; Cochran, N; Tugwell, P; O'Connor, AM				Stacey, Dawn; Hawker, Gillian; Dervin, Geoff; Tomek, Ivan; Cochran, Nan; Tugwell, Peter; O'Connor, Annette M.			Making a difference - Management of chronic pain - Improving shared decision making in osteoarthritis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							AIDS		[Stacey, Dawn; O'Connor, Annette M.] Univ Ottawa, Sch Nursing, Ottawa, ON, Canada; [Hawker, Gillian] Univ Toronto, Div Rheumatol, Toronto, ON, Canada; [Dervin, Geoff] Univ Ottawa, Dept Surg, Div Orthopaed Surg, Ottawa, ON K1N 6N5, Canada; [Tomek, Ivan] Dartmouth Hitchcock Med Ctr, Dept Orthopaed Surg, Lebanon, NH 03766 USA; [Tomek, Ivan] Dartmouth Med Sch, Lebanon, NH USA; [Cochran, Nan] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med & Community & Family Med, Hanover, NH 03756 USA; [Tugwell, Peter] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [O'Connor, Annette M.] Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada	University of Ottawa; University of Toronto; University of Ottawa; Dartmouth College; Dartmouth College; Dartmouth College; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Stacey, D (corresponding author), Univ Ottawa, Sch Nursing, Ottawa, ON, Canada.	dawn.stacey@uottawa.ca	Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556				Coulter A, 2007, BMJ-BRIT MED J, V335, P24, DOI 10.1136/bmj.39246.581169.80; *DARTM HITCHC MED, 2008, QUAL REP KNEE REPL; Elwyn G, 2006, BMJ-BRIT MED J, V333, P417, DOI 10.1136/bmj.38926.629329.AE; Gravel K, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-16; LLEWELLYNTHOMAS HA, 2003, MED DECIS MAKING, V23, P551; *NAT STEER GROUP D, 2005, IMPL PAT DEC AIDS UR; O'Connor AM, 2007, HEALTH AFFAIR, V26, P716, DOI 10.1377/hlthaff.26.3.716; Silvia KA, 2006, HEALTH EXPECT, V9, P255, DOI 10.1111/j.1369-7625.2006.00393.x; Weinstein JN, 2007, HEALTH AFFAIR, V26, P726, DOI 10.1377/hlthaff.26.3.726; Weng HLH, 2007, ARTHRIT RHEUM-ARTHR, V57, P568, DOI 10.1002/art.22670	10	26	26	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	2008	336	7650					954	+						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296KC	18397937	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000255540900042
J	Gallarda, BW; Bonanomi, D; Muller, D; Brown, A; Alaynick, WA; Andrews, SE; Lemke, G; Pfaff, SL; Marquardt, T				Gallarda, Benjamin W.; Bonanomi, Dario; Mueller, Daniel; Brown, Arthur; Alaynick, William A.; Andrews, Shane E.; Lemke, Greg; Pfaff, Samuel L.; Marquardt, Till			Segregation of axial motor and sensory pathways via heterotypic trans-axonal signaling	SCIENCE			English	Article							CHICK HINDLIMB; LOCOMOTOR CIRCUITS; EMBRYONIC CHICK; PROJECTIONS; LIMB	Execution of motor behaviors relies on circuitries effectively integrating immediate sensory feedback to efferent pathways controlling muscle activity. It remains unclear how, during neuromuscular circuit assembly, sensory and motor projections become incorporated into tightly coordinated, yet functionally separate pathways. We report that, within axial nerves, establishment of discrete afferent and efferent pathways depends on coordinate signaling between coextending sensory and motor projections. These heterotypic axon-axon interactions require motor axonal EphA3/EphA4 receptor tyrosine kinases activated by cognate sensory axonal ephrin-A ligands. Genetic elimination of trans-axonal ephrin-A -> EphA signaling in mice triggers drastic motor-sensory miswiring, culminating in functional efferents within proximal afferent pathways. Effective assembly of a key circuit underlying motor behaviors thus critically depends on trans-axonal signaling interactions resolving motor and sensory projections into discrete pathways.	[Gallarda, Benjamin W.; Bonanomi, Dario; Alaynick, William A.; Andrews, Shane E.; Pfaff, Samuel L.] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; [Mueller, Daniel; Marquardt, Till] Univ Gottingen, Sch Med, Dev Neurobiol Lab, European Neurosci Inst Gottingen,Max Planck Soc, D-37077 Gottingen, Germany; [Mueller, Daniel; Marquardt, Till] European Neurosci Inst Gottingen, Deutsche Forschungsgemeinschaft Emmy Noether Grp, D-37077 Gottingen, Germany; [Brown, Arthur] Univ Western Ontario, Biotherapeut Res Grp, Robarts Res Inst, Dept Anat & Cell Biol, London, ON N6A 5K8, Canada; [Lemke, Greg] Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA	Salk Institute; Max Planck Society; University of Gottingen; Western University (University of Western Ontario); Salk Institute	Pfaff, SL (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pfaff@salk.edu; till.marquardt@mpi-mail.mpg.de	Bonanomi, Dario/K-3450-2016; Brown, Arthur/K-8328-2013	Bonanomi, Dario/0000-0003-4517-1244; Brown, Arthur/0000-0002-8725-3195; Gallarda, Benjamin/0000-0002-2968-2549	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054172, P01NS031249] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS054172-04, P01 NS031249, R01 NS054172, R01 NS054172-02, R01 NS054172-05, R01 NS054172-03, NS054172-01A2, NS031249-14A1, R01 NS054172-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Chen HH, 2003, CURR OPIN NEUROBIOL, V13, P96, DOI 10.1016/S0959-4388(03)00006-0; Dong ZP, 1999, J NEUROSCI RES, V56, P334, DOI 10.1002/(SICI)1097-4547(19990515)56:4<334::AID-JNR2>3.0.CO;2-#; ECCLES JC, 1981, APPL NEUROPHYSIOL, V44, P5; Feinstein P, 2004, CELL, V117, P817, DOI 10.1016/j.cell.2004.05.011; Goulding M, 2005, CURR OPIN NEUROBIOL, V15, P14, DOI 10.1016/j.conb.2005.01.017; Gramsbergen A, 1999, DEV BRAIN RES, V112, P217, DOI 10.1016/S0165-3806(98)00184-9; Helmbacher F, 2000, DEVELOPMENT, V127, P3313; Honig MG, 1998, DEVELOPMENT, V125, P995; Honig MG, 1996, DEV BIOL, V175, P325, DOI 10.1006/dbio.1996.0118; Kiehn O, 2006, ANNU REV NEUROSCI, V29, P279, DOI 10.1146/annurev.neuro.29.051605.112910; Klein R, 2004, CURR OPIN CELL BIOL, V16, P580, DOI 10.1016/j.ceb.2004.07.002; Kramer ER, 2006, NEURON, V50, P35, DOI 10.1016/j.neuron.2006.02.020; LANDMESSER L, 1986, DEV BIOL, V118, P511, DOI 10.1016/0012-1606(86)90023-0; Landmesser LT, 2001, INT J DEV NEUROSCI, V19, P175, DOI 10.1016/S0736-5748(00)00090-3; Lee SK, 2004, DEVELOPMENT, V131, P3295, DOI 10.1242/dev.01179; Luo LQ, 2007, NEURON, V56, P284, DOI 10.1016/j.neuron.2007.10.014; Marquardt T, 2005, CELL, V121, P127, DOI 10.1016/j.cell.2005.01.020; MCLACHLAN EM, 1993, NATURE, V363, P543, DOI 10.1038/363543a0; Myers CP, 2005, NEURON, V46, P37, DOI 10.1016/j.neuron.2005.02.022; Quina LA, 2005, J NEUROSCI, V25, P11595, DOI 10.1523/JNEUROSCI.2837-05.2005; Shirasaki R, 2006, NEURON, V50, P841, DOI 10.1016/j.neuron.2006.04.030; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TOSNEY KW, 1989, J EXP ZOOL, V251, P232, DOI 10.1002/jez.1402510211; Vaidya A, 2003, MOL CELL BIOL, V23, P8092, DOI 10.1128/MCB.23.22.8092-8098.2003; Wang G, 1999, DEV BIOL, V208, P324, DOI 10.1006/dbio.1999.9212	26	72	74	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					233	236		10.1126/science.1153758	http://dx.doi.org/10.1126/science.1153758			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403711	Green Accepted			2022-12-28	WOS:000254836700044
J	Parkin, SSP; Hayashi, M; Thomas, L				Parkin, Stuart S. P.; Hayashi, Masamitsu; Thomas, Luc			Magnetic domain-wall racetrack memory	SCIENCE			English	Review							NANOWIRES; MOTION; FERROMAGNETS; PROPAGATION; DYNAMICS; STRIPS	Recent developments in the controlled movement of domain walls in magnetic nanowires by short pulses of spin-polarized current give promise of a nonvolatile memory device with the high performance and reliability of conventional solid-state memory but at the low cost of conventional magnetic disk drive storage. The racetrack memory described in this review comprises an array of magnetic nanowires arranged horizontally or vertically on a silicon chip. Individual spintronic reading and writing nanodevices are used to modify or read a train of similar to 10 to 100 domain walls, which store a series of data bits in each nanowire. This racetrack memory is an example of the move toward innately three-dimensional microelectronic devices.	[Parkin, Stuart S. P.; Hayashi, Masamitsu; Thomas, Luc] IBM Corp, Almaden Res Ctr, San Jose, CA 95120 USA	International Business Machines (IBM)	Parkin, SSP (corresponding author), IBM Corp, Almaden Res Ctr, 650 Harry Rd, San Jose, CA 95120 USA.	parkin@almaden.ibm.com	Parkin, Stuart/D-2521-2012; Hayashi, Masamitsu/N-8033-2019; Hayashi, Masamitsu/H-2809-2011	Parkin, Stuart/0000-0003-4702-6139; Hayashi, Masamitsu/0000-0003-2134-2563; Hayashi, Masamitsu/0000-0003-2134-2563				Barnes SE, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.107204; Beach GSD, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.057203; Beach GSD, 2005, NAT MATER, V4, P741, DOI 10.1038/nmat1477; BERGER L, 1988, J APPL PHYS, V63, P1663, DOI 10.1063/1.339899; BERGER L, 1986, PHYS REV B, V33, P1572, DOI 10.1103/PhysRevB.33.1572; Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; Feigenson M, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.247204; Hayashi M, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.197207; Hayashi M, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.037204; Hayashi M, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.207205; Hayashi M, 2007, NAT PHYS, V3, P21, DOI 10.1038/nphys464; Hubert A., 1998, MAGNETIC DOMAINS ANA; Klaui M, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.106601; Laribi S, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2746952; Li Z, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.207203; Malozemoff A.P., 1979, MAGNETIC DOMAIN WALL; Matick R.E., 1977, COMPUTER STORAGE SYS; McMichael RD, 1997, IEEE T MAGN, V33, P4167, DOI 10.1109/20.619698; Middelhoek S., 1976, PHYS COMPUTER MEMORY; Mott NF, 1936, THEORY PROPERTIES ME; Nakatani Y, 2005, J MAGN MAGN MATER, V290, P750, DOI 10.1016/j.jmmm.2004.11.355; Parkin S, 2003, P IEEE, V91, P661, DOI 10.1109/JPROC.2003.811807; Parkin S. S. P., 2004, U.S. Patents, Patent No. [US6920062, 6920062]; Parkin S. S. P., 2004, U. S. Patents, Patent No. [7,031,178, 7236386]; Parkin SSP, 2004, NAT MATER, V3, P862, DOI 10.1038/nmat1256; PARKIN SSP, 1991, PHYS REV LETT, V66, P2152, DOI 10.1103/PhysRevLett.66.2152; PARKIN SSP, 2004, Patent No. 6898132; Parkin SSP, 2004, U. S. Patents, Patent No. [7,031,178, 7031178]; Parkin SSP, 2004, ( 2004- 2007) U. S. Patents, Patent No. [Patents 6,834,005, 6834005, 6,834,005]; Ravelosona D, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2450664; Ravelosona D, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.117203; Saitoh E, 2004, NATURE, V432, P203, DOI 10.1038/nature03009; Slonczewski JC, 1996, J MAGN MAGN MATER, V159, pL1, DOI 10.1016/0304-8853(96)00062-5; Tatara G, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.086601; Thiaville A, 2005, EUROPHYS LETT, V69, P990, DOI 10.1209/epl/i2004-10452-6; Thomas L, 2007, SCIENCE, V315, P1553, DOI 10.1126/science.1137662; Thomas L, 2006, NATURE, V443, P197, DOI 10.1038/nature05093; Vernier N, 2004, EUROPHYS LETT, V65, P526, DOI 10.1209/epl/i2003-10112-5; Yamanouchi M, 2004, NATURE, V428, P539, DOI 10.1038/nature02441; Zhang S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.127204	41	3319	3386	36	961	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					190	194		10.1126/science.1145799	http://dx.doi.org/10.1126/science.1145799			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403702				2022-12-28	WOS:000254836700032
J	Buckley, B				Buckley, Byron			Wound healing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												byron_buckley@yahoo.com							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2008	299	14					1647	1647		10.1001/jama.299.14.1647	http://dx.doi.org/10.1001/jama.299.14.1647			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285AL	18398068				2022-12-28	WOS:000254749600001
J	Ellsberg, M; Jansen, HAFM; Heise, L; Watts, CH; Garcia-Moreno, C				Ellsberg, Mary; Jansen, Henrica A. F. M.; Heise, Lori; Watts, Charlotte H.; Garcia-Moreno, Claudia		WHO Multicountry Study Womens Hlth	Intimate partner violence and women's physical and mental health in the WHO multi-country study on women's health and domestic violence: an observational study	LANCET			English	Article							RISK-FACTORS; REPRODUCTIVE HEALTH; PREVALENCE; INJURY; CONSEQUENCES; COMMON; DISORDERS; MORTALITY; DISTRESS; RECALL	Background This article summarises findings from ten countries from the WHO multi-country study on women's health and domestic violence against women. Methods Standardised population-based surveys were done between 2000 and 2003. Women aged 15-49 years were interviewed about their experiences of physically and sexually violent acts by a current or former intimate male partner, and about selected symptoms associated with physical and mental health. The women reporting physical violence by a partner were asked about injuries that resulted from this type of violence. Findings 24097 women completed interviews. Pooled analysis of all sites found significant associations between lifetime experiences of partner violence and self-reported poor health (odds ratio 1 . 6 [95% CI 1 . 5-1.8]), and with specific health problems in the previous 4 weeks: difficulty walking (1.6 [1.5-1.8]), difficulty with daily activities (1 . 6 [1.5-1.8]), pain (1 . 6 [1.5-1.7]), memory loss (1 . 8 [1.6-2. 0]), dizziness (1 . 7 [1.6-1.8]), and vaginal discharge (1. 8 [1.7-2. 0]). For all settings combined, women who reported partner violence at least once in their life reported significantly more emotional distress, suicidal thoughts (2.9 [2. 7-3.2]), and suicidal attempts (3.8 [3.3-4. 5]), than non-abused women. These significant associations were maintained in almost all of the sites. Between 19% and 55% of women who had ever been physically abused by their partner were ever injured. Interpretation In addition to being a breach of human rights, intimate partner violence is associated with serious public-health consequences that should be addressed in national and global health policies and programmes. Funding WHO; Governments of the Netherlands, Norway, Sweden, Switzerland, and UK; Rockefeller Foundation; Urban Primary Health Care project of the Government of Bangladesh; Swedish Agency for Research Cooperation with Developing Countries (SAREC/Sida); United Nations Fund for Population Activities (UNFPA); and Trocaire.	[Jansen, Henrica A. F. M.; Garcia-Moreno, Claudia] WHO, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland; [Ellsberg, Mary; Heise, Lori] PATH, Washington, DC USA; [Watts, Charlotte H.] London Sch Hyg & Trop Med, London WC1, England	World Health Organization; University of London; London School of Hygiene & Tropical Medicine	Garcia-Moreno, C (corresponding author), WHO, Dept Reprod Hlth & Res, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	garciamorenoc@who.int	Heise, LORI/AAI-6251-2020; Franca-Junior, Ivan/C-4110-2012	Franca-Junior, Ivan/0000-0002-7004-7301; Rodrigues, Laura Cunha/0000-0001-9008-660X				[Anonymous], 1999, PUTTING WOMENS SAFET; [Anonymous], 1999, ENDING VIOLENCE WOME; Beusenberg M., 1994, WHOMNHPSF948; Bonomi AE, 2006, AM J PREV MED, V30, P458, DOI 10.1016/j.amepre.2006.01.015; Campbell J, 2002, ARCH INTERN MED, V162, P1157, DOI 10.1001/archinte.162.10.1157; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; Carbone-Lopez K, 2006, PUBLIC HEALTH REP, V121, P382, DOI 10.1177/003335490612100406; Eberhard-Gran M, 2007, J GEN INTERN MED, V22, P1668, DOI 10.1007/s11606-007-0389-8; Ellsberg M, 1999, AM PSYCHOL, V54, P30, DOI 10.1037/0003-066X.54.1.30; Ellsberg M, 2002, LANCET, V359, P1599, DOI 10.1016/S0140-6736(02)08521-5; Ellsberg M, 2001, STUD FAMILY PLANN, V32, P1, DOI 10.1111/j.1728-4465.2001.00001.x; Ellsberg M., 2005, RES VIOLENCE WOMEN P; Fanslow JL, 1998, ANN EMERG MED, V32, P341, DOI 10.1016/S0196-0644(98)70011-3; Fischbach RL, 1997, SOC SCI MED, V45, P1161, DOI 10.1016/S0277-9536(97)00022-1; Fryers T, 2003, SOC PSYCH PSYCH EPID, V38, P229, DOI 10.1007/s00127-003-0627-2; Garcia-Moreno C, 2006, LANCET, V368, P1260, DOI 10.1016/S0140-6736(06)69523-8; Golding JM, 1996, PSYCHOL WOMEN QUART, V20, P101, DOI 10.1111/j.1471-6402.1996.tb00667.x; Hassan Fatma, 2004, Inj Control Saf Promot, V11, P111, DOI 10.1080/15660970412331292333; Helweg-Larsen K, 2003, SCAND J PUBLIC HEALT, V31, P51, DOI 10.1080/14034940210133708; Jansen HAFM, 2004, VIOLENCE AGAINST WOM, V10, P831, DOI 10.1177/1077801204265554; Jones AS, 2006, WOMEN HEALTH ISS, V16, P252, DOI 10.1016/j.whi.2006.06.007; Kishor S, 2004, DOMESTIC VIOLENCE 9; KOSS MP, 1993, J INTERPERS VIOLENCE, V8, P198, DOI 10.1177/088626093008002004; Kyriacou DN, 1999, NEW ENGL J MED, V341, P1892, DOI 10.1056/NEJM199912163412505; Loxton D, 2006, J INTERPERS VIOLENCE, V21, P1092, DOI 10.1177/0886260506290290; Mccaw B, 2007, WOMEN HEALTH, V45, P1, DOI 10.1300/J013v45n02_01; McDonough P, 1997, AM J PUBLIC HEALTH, V87, P1476, DOI 10.2105/AJPH.87.9.1476; Mock C, 1999, INT J EPIDEMIOL, V28, P750, DOI 10.1093/ije/28.4.750; MORENO CG, 2003, HLTH HUMAN RIGHTS, V6, P112; Moshiro C, 2005, INJURY PREV, V11, P48, DOI 10.1136/ip.2004.005645; Parish WL, 2004, INT FAM PLAN PERSPEC, V30, P174, DOI 10.1363/3017404; Patel V, 2006, ARCH GEN PSYCHIAT, V63, P404, DOI 10.1001/archpsyc.63.4.404; Plichta SB, 1996, AM J OBSTET GYNECOL, V174, P903, DOI 10.1016/S0002-9378(96)70323-X; Plichta SB, 2001, WOMEN HEALTH ISS, V11, P244, DOI 10.1016/S1049-3867(01)00085-8; Rand M R, 1997, Bur Justice Stat Spec Rep, P1; Romito P, 2005, SOC SCI MED, V60, P1717, DOI 10.1016/j.socscimed.2004.08.026; Salam MA, 2006, MATERN CHILD HLTH J, V10, P83, DOI 10.1007/s10995-005-0030-6; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; Thompson MP, 2003, VIOLENCE AGAINST WOM, V9, P438, DOI 10.1177/1077801202250955; UN Department of Economic and Social Affairs Statistics Division, 2006, WORLDS WOM 2005 PROG; Vic Health, 2004, HLTH COSTS VIOL MEAS; Vizcarra Beatriz, 2004, Inj Control Saf Promot, V11, P125, DOI 10.1080/15660970412331292351; Vos T, 2006, B WORLD HEALTH ORGAN, V84, P739, DOI 10.2471/BLT.06.030411; World Health Organization, 2005, WHO MULT STUD WOM HL; World Health Organization, 2002, WORLD REPORT VIOLENC	45	1164	1186	2	241	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 5	2008	371	9619					1165	1172		10.1016/S0140-6736(08)60522-X	http://dx.doi.org/10.1016/S0140-6736(08)60522-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	287ZM	18395577				2022-12-28	WOS:000254956000025
J	Lakatos, P; Karmos, G; Mehta, AD; Ulbert, I; Schroeder, CE				Lakatos, Peter; Karmos, George; Mehta, Ashesh D.; Ulbert, Istvan; Schroeder, Charles E.			Entrainment of neuronal oscillations as a mechanism of attentional selection	SCIENCE			English	Article							AUDITORY-CORTEX; EVOKED-POTENTIALS; VISUAL-CORTEX; SYNCHRONIZATION; MODULATION; FREQUENCY; SEARCH; BRAIN; POWER; V1	Whereas gamma- band neuronal oscillations clearly appear integral to visual attention, the role of lower- frequency oscillations is still being debated. Mounting evidence indicates that a key functional property of these oscillations is the rhythmic shifting of excitability in local neuronal ensembles. Here, we show that when attended stimuli are in a rhythmic stream, delta- band oscillations in the primary visual cortex entrain to the rhythm of the stream, resulting in increased response gain for task- relevant events and decreased reaction times. Because of hierarchical cross- frequency coupling, delta phase also determines momentary power in higher- frequency activity. These instrumental functions of low- frequency oscillations support a conceptual framework that integrates numerous earlier findings.	[Lakatos, Peter; Schroeder, Charles E.] Nathan S Kline Inst Psychiat Res, Cognit Neurosci & Schizophrenia Program, Orangeburg, NY 10962 USA; [Lakatos, Peter; Karmos, George; Ulbert, Istvan] Hungarian Acad Sci, Inst Psychol, H-1394 Budapest, Hungary; [Karmos, George; Ulbert, Istvan] Peter Pazmany Catholic Univ, Fac Informat Technol, H-1083 Budapest, Hungary; [Mehta, Ashesh D.] Long Isl Jewish Med Ctr, Comprehens Epilepsy Ctr, New Hyde Pk, NY 11040 USA; [Schroeder, Charles E.] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA	Nathan Kline Institute for Psychiatric Research; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Northwell Health; Columbia University	Schroeder, CE (corresponding author), Nathan S Kline Inst Psychiat Res, Cognit Neurosci & Schizophrenia Program, Orangeburg, NY 10962 USA.	schrod@nki.rfmh.org	Ulbert, Istvan/F-2213-2010	Lakatos, Peter/0000-0003-0221-4021	NIMH NIH HHS [MH060358] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060358] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brosch M, 2005, J NEUROSCI, V25, P6797, DOI 10.1523/JNEUROSCI.1571-05.2005; Buzsaki G, 2005, HIPPOCAMPUS, V15, P827, DOI 10.1002/hipo.20113; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Canolty RT, 2006, SCIENCE, V313, P1626, DOI 10.1126/science.1128115; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; Ding J, 2006, CEREB CORTEX, V16, P1016, DOI 10.1093/cercor/bhj044; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Fell J, 2003, BRAIN RES REV, V42, P265, DOI 10.1016/S0165-0173(03)00178-4; Fries P, 2005, TRENDS COGN SCI, V9, P474, DOI 10.1016/j.tics.2005.08.011; Fries P, 2003, TRENDS NEUROSCI, V26, P123, DOI 10.1016/S0166-2236(03)00023-7; Fries P, 2001, SCIENCE, V291, P1560, DOI 10.1126/science.1055465; GALAMBOS R, 1981, P NATL ACAD SCI-BIOL, V78, P2643, DOI 10.1073/pnas.78.4.2643; Jack AI, 2006, NEURON, V51, P135, DOI 10.1016/j.neuron.2006.06.003; Kim YJ, 2007, NAT NEUROSCI, V10, P117, DOI 10.1038/nn1821; KLEIN R, 1988, NATURE, V334, P430, DOI 10.1038/334430a0; Lakatos P, 2005, J NEUROPHYSIOL, V94, P1904, DOI 10.1152/jn.00263.2005; Lakatos P, 2007, NEURON, V53, P279, DOI 10.1016/j.neuron.2006.12.011; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; McAdams CJ, 1999, J NEUROSCI, V19, P431, DOI 10.1523/JNEUROSCI.19-01-00431.1999; Mehta SD, 2000, CEREB CORTEX, V10, P343, DOI 10.1093/cercor/10.4.343; Miniussi C, 1999, BRAIN, V122, P1507, DOI 10.1093/brain/122.8.1507; Morgan ST, 1996, P NATL ACAD SCI USA, V93, P4770, DOI 10.1073/pnas.93.10.4770; Palva S, 2007, TRENDS NEUROSCI, V30, P150, DOI 10.1016/j.tins.2007.02.001; REGAN D, 1977, J OPT SOC AM, V67, P1475, DOI 10.1364/JOSA.67.001475; WALTER WG, 1964, NATURE, V203, P380, DOI 10.1038/203380a0; Womelsdorf T, 2006, NATURE, V439, P733, DOI 10.1038/nature04258; Womelsdorf T, 2007, SCIENCE, V316, P1609, DOI [10.1126/science.1139597, 10.1126/science.1139178]	27	1089	1102	2	156	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					110	113		10.1126/science.1154735	http://dx.doi.org/10.1126/science.1154735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388295				2022-12-28	WOS:000254633000043
J	Thorgeirsson, TE; Geller, F; Sulem, P; Rafnar, T; Wiste, A; Magnusson, KP; Manolescu, A; Thorleifsson, G; Stefansson, H; Ingason, A; Stacey, SN; Bergthorsson, JT; Thorlacius, S; Gudmundsson, J; Jonsson, T; Jakobsdottir, M; Saemundsdottir, J; Olafsdottir, O; Gudmundsson, LJ; Bjornsdottir, G; Kristjansson, K; Skuladottir, H; Isaksson, HJ; Gudbjartsson, T; Jones, GT; Mueller, T; Gottsater, A; Flex, A; Aben, KKH; de Vegt, F; Mulders, PFA; Isla, D; Vidal, MJ; Asin, L; Saez, B; Murillo, L; Blondal, T; Kolbeinsson, H; Stefansson, JG; Hansdottir, I; Runarsdottir, V; Pola, R; Lindblad, B; van Rij, AM; Dieplinger, B; Haltmayer, M; Mayordomo, JI; Kiemeney, LA; Matthiasson, SE; Oskarsson, H; Tyrfingsson, T; Gudbjartsson, DF; Gulcher, JR; Jonsson, S; Thorsteinsdottir, U; Kong, A; Stefansson, K				Thorgeirsson, Thorgeir E.; Geller, Frank; Sulem, Patrick; Rafnar, Thorunn; Wiste, Anna; Magnusson, Kristinn P.; Manolescu, Andrei; Thorleifsson, Gudmar; Stefansson, Hreinn; Ingason, Andres; Stacey, Simon N.; Bergthorsson, Jon T.; Thorlacius, Steinunn; Gudmundsson, Julius; Jonsson, Thorlakur; Jakobsdottir, Margret; Saemundsdottir, Jona; Olafsdottir, Olof; Gudmundsson, Larus J.; Bjornsdottir, Gyda; Kristjansson, Kristleifur; Skuladottir, Halla; Isaksson, Helgi J.; Gudbjartsson, Tomas; Jones, Gregory T.; Mueller, Thomas; Gottsater, Anders; Flex, Andrea; Aben, Katja K. H.; de Vegt, Femmie; Mulders, Peter F. A.; Isla, Dolores; Vidal, Maria J.; Asin, Laura; Saez, Berta; Murillo, Laura; Blondal, Thorsteinn; Kolbeinsson, Halldor; Stefansson, Jon G.; Hansdottir, Ingunn; Runarsdottir, Valgerdur; Pola, Roberto; Lindblad, Bengt; van Rij, Andre M.; Dieplinger, Benjamin; Haltmayer, Meinhard; Mayordomo, Jose I.; Kiemeney, Lambertus A.; Matthiasson, Stefan E.; Oskarsson, Hogni; Tyrfingsson, Thorarinn; Gudbjartsson, Daniel F.; Gulcher, Jeffrey R.; Jonsson, Steinn; Thorsteinsdottir, Unnur; Kong, Augustine; Stefansson, Kari			A variant associated with nicotine dependence, lung cancer and peripheral arterial disease	NATURE			English	Article							GENETIC INFLUENCE; LOWER-EXTREMITY; FAGERSTROM TEST; RISK-FACTORS; SMOKING; CARCINOMA; SMOKERS; STATISTICS; ADDICTION; ISCHEMIA	Smoking is a leading cause of preventable death, causing about 5 million premature deaths worldwide each year(1,2). Evidence for genetic influence on smoking behaviour and nicotine dependence (ND)(3-8) has prompted a search for susceptibility genes. Furthermore, assessing the impact of sequence variants on smoking-related diseases is important to public health(9,10). Smoking is the major risk factor for lung cancer (LC)(11-14) and is one of the main risk factors for peripheral arterial disease (PAD)(15-17). Here we identify a common variant in the nicotinic acetylcholine receptor gene cluster on chromosome 15q24 with an effect on smoking quantity, ND and the risk of two smoking- related diseases in populations of European descent. The variant has an effect on the number of cigarettes smoked per day in our sample of smokers. The same variant was associated with ND in a previous genomewide association study that used low- quantity smokers as controls(18,19), and with a similar approach we observe a highly significant association with ND. A comparison of cases of LC and PAD with population controls each showed that the variant confers risk of LC and PAD. The findings provide a case study of a gene - environment interaction(20), highlighting the role of nicotine addiction in the pathology of other serious diseases.	[Thorgeirsson, Thorgeir E.; Geller, Frank; Sulem, Patrick; Rafnar, Thorunn; Wiste, Anna; Magnusson, Kristinn P.; Manolescu, Andrei; Thorleifsson, Gudmar; Stefansson, Hreinn; Ingason, Andres; Stacey, Simon N.; Bergthorsson, Jon T.; Thorlacius, Steinunn; Gudmundsson, Julius; Jonsson, Thorlakur; Jakobsdottir, Margret; Saemundsdottir, Jona; Olafsdottir, Olof; Gudmundsson, Larus J.; Bjornsdottir, Gyda; Kristjansson, Kristleifur; Gudbjartsson, Daniel F.; Gulcher, Jeffrey R.; Thorsteinsdottir, Unnur; Kong, Augustine; Stefansson, Kari] deCODE Genet, IS-101 Reykjavik, Iceland; [Wiste, Anna] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA; [Skuladottir, Halla] Landspital Univ Hosp, Dept Med Oncol, IS-101 Reykjavik, Iceland; [Isaksson, Helgi J.] Landspital Univ Hosp, Dept Pathol, IS-101 Reykjavik, Iceland; [Gudbjartsson, Tomas] Landspital Univ Hosp, Dept Cardiothorac Surg, IS-101 Reykjavik, Iceland; [Kolbeinsson, Halldor; Stefansson, Jon G.] Landspital Univ Hosp, Dept Gen Adult Psychiat, IS-101 Reykjavik, Iceland; [Jonsson, Steinn] Landspital Univ Hosp, Dept Med, IS-101 Reykjavik, Iceland; [Jones, Gregory T.; van Rij, Andre M.] Univ Otago, Dept Surg, Dunedin Sch Med, Dunedin 9054, New Zealand; [Mueller, Thomas; Dieplinger, Benjamin; Haltmayer, Meinhard] Konventhosp Barmherzige Brueder, Dept Lab Med, A-4020 Linz, Austria; [Gottsater, Anders; Lindblad, Bengt] Malmo Univ Hosp, MAS, Ctr Vasc Dis, S-20502 Malmo, Sweden; [Flex, Andrea; Pola, Roberto] Univ Cattolica Sacro Cuore, Sch Med, Lab Vasc Biol & Genet, A Gemelli Univ Hosp, I-00168 Rome, Italy; [Aben, Katja K. H.; de Vegt, Femmie; Kiemeney, Lambertus A.] Radboud Univ Nijmegen Med Ctr, Dept Epidemiol & Biostat, NL-6500 HB Nijmegen, Netherlands; [Aben, Katja K. H.; Kiemeney, Lambertus A.] Comprehens Canc Ctr E, NL-6501 BG Nijmegen, Netherlands; [Mulders, Peter F. A.; Kiemeney, Lambertus A.] Radboud Univ Nijmegen Med Ctr, Dept Urol, NL-6525 GA Nijmegen, Netherlands; [Isla, Dolores; Vidal, Maria J.; Mayordomo, Jose I.] Univ Hosp, Div Med Oncol, Zaragoza 5009, Spain; [Asin, Laura; Mayordomo, Jose I.] Nanotechnol Inst Aragon, Zaragoza 5009, Spain; [Saez, Berta; Mayordomo, Jose I.] Hlth Sci Inst, Zaragoza 5009, Spain; [Murillo, Laura] Hosp Reina Sofia, Div Med Oncol, Tudela 31500, Spain; [Blondal, Thorsteinn] Primary Hlth Care Ctr, Dept Lung Dis, IS-101 Reykjavik, Iceland; [Hansdottir, Ingunn; Runarsdottir, Valgerdur; Tyrfingsson, Thorarinn] Vogur SAA Addict Treatment Ctr, IS-112 Reykjavik, Iceland; [Pola, Roberto] IRCCS, OASI Inst Res & Care, I-94018 Troina, EN, Italy; [Matthiasson, Stefan E.; Stefansson, Kari] Univ Iceland, Sch Med, IS-101 Reykjavik, Iceland; [Oskarsson, Hogni] Therapeia, IS-101 Reykjavik, Iceland	Emory University; Landspitali National University Hospital; Landspitali National University Hospital; Landspitali National University Hospital; Landspitali National University Hospital; Landspitali National University Hospital; University of Otago; Konventhospital Der Barmherzigen Bruder; Lund University; Skane University Hospital; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Radboud University Nijmegen; Radboud University Nijmegen; Miguel Servet University Hospital; Servicio Navarro de Salud - Osasunbidea; IRCCS Oasi Maria SS; University of Iceland	Thorgeirsson, TE (corresponding author), deCODE Genet, IS-101 Reykjavik, Iceland.	thorgeir@decode.is; kari.stefansson@decode.is	Stefansson, Kari/AAE-7187-2019; Hansdottir, Ingunn/A-6735-2012; Aben, Katja KH/G-9686-2016; Manolescu, Andrei/G-4565-2014; Ingason, Andres/G-6817-2012; Flex, Andrea/K-7305-2016; Magnusson, Kristinn P Pétur/X-4907-2019; Losada, Maria Vidal/AAJ-8633-2021; Mulders, Peter F.A./H-8076-2014; Magnusson, Kristinn/A-6479-2011; Mayordomo, Jose/K-3453-2013; ASIN, LAURA/H-7276-2017; Kiemeney, Lambertus A./D-3357-2009; de Vegt, F./L-4704-2015	Aben, Katja KH/0000-0002-0214-2147; Manolescu, Andrei/0000-0002-0713-4664; Flex, Andrea/0000-0003-2664-4165; Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Losada, Maria Vidal/0000-0003-1992-5727; Magnusson, Kristinn/0000-0003-4528-6826; ASIN, LAURA/0000-0003-0641-3407; Kiemeney, Lambertus A./0000-0002-2368-1326; de Vegt, F./0000-0001-8728-3397; Geller, Frank/0000-0002-9238-3269; Stefansson, Hreinn/0000-0002-9331-6666; Thorgeirsson, Thorgeir/0000-0002-5149-7040; Saez, Berta/0000-0003-0753-1165; Skuladottir, Halla/0000-0001-8703-9407; Pola, Roberto/0000-0001-5224-2931; Isla, Dolores/0000-0002-2483-198X; Bergthorsson, Jon Thor/0000-0002-0560-2639; Jones, Gregory T/0000-0002-6950-4210; Steinthorsdottir, Valgerdur/0000-0003-1846-6274; Bjornsdottir, Gyda/0000-0002-8100-0306; Kong, Augustine/0000-0001-8193-5438; Gudbjartsson, Daniel/0000-0002-5222-9857	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA017932] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA017932] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Barani J, 2005, J VASC SURG, V42, P75, DOI 10.1016/j.jvs.2005.03.025; Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801; BERRETTINI W, IN PRESS MOL PSYCHIA; Bierut LJ, 2007, HUM MOL GENET, V16, P24, DOI 10.1093/hmg/ddl441; Bierut LJ, 2007, JAMA-J AM MED ASSOC, V297, P809, DOI 10.1001/jama.297.8.809; Carlsten C, 2006, JAMA-J AM MED ASSOC, V296, P2480, DOI 10.1001/jama.296.20.2480; CARMELLI D, 1992, NEW ENGL J MED, V327, P829, DOI 10.1056/NEJM199209173271201; Devlin B, 2004, NAT GENET, V36, P1129, DOI 10.1038/ng1104-1129; DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; Flex A, 2002, EUR J VASC ENDOVASC, V24, P264, DOI 10.1053/ejvs.2002.1711; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; Gulcher JR, 2000, EUR J HUM GENET, V8, P739, DOI 10.1038/sj.ejhg.5200530; Haiman CA, 2006, NEW ENGL J MED, V354, P333, DOI 10.1056/NEJMoa033250; HEATH AC, 1993, ADDICT BEHAV, V18, P19, DOI 10.1016/0306-4603(93)90005-T; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; Kendler KS, 1999, PSYCHOL MED, V29, P299, DOI 10.1017/S0033291798008022; Li MD, 2003, ADDICTION, V98, P23, DOI 10.1046/j.1360-0443.2003.00295.x; Madden PAF, 1999, BEHAV GENET, V29, P423, DOI 10.1023/A:1021674804714; Mueller T, 2005, J VASC SURG, V41, P808, DOI 10.1016/j.jvs.2005.01.039; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; PLOMIN R, 1977, PSYCHOL BULL, V84, P309, DOI 10.1037/0033-2909.84.2.309; Powell JT, 1997, ATHEROSCLEROSIS, V129, P41, DOI 10.1016/S0021-9150(96)06012-1; Price JF, 1999, EUR HEART J, V20, P344, DOI 10.1053/euhj.1998.1194; Rose JE, 1996, ANNU REV MED, V47, P493; RUSSELL MAH, 1990, BRIT J ADDICT, V85, P293; Rutherford RB, 1997, J VASC SURG, V26, P517, DOI 10.1016/S0741-5214(97)70045-4; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438; Stellman SD, 2003, ANN EPIDEMIOL, V13, P294, DOI 10.1016/S1047-2797(02)00420-9; STOLERMAN IP, 1995, PSYCHOPHARMACOLOGY, V117, P2, DOI 10.1007/BF02245088; TASC Working Group, 2000, EUR J VASC ENDOVASC, V19, pS1; Thorgeirsson TE, 2003, AM J HUM GENET, V72, P1221, DOI 10.1086/375141; Vink JM, 2005, ADDICT BEHAV, V30, P575, DOI 10.1016/j.addbeh.2004.05.023; *WHO, EC TOB CONTR; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; 2005, MMWR MORB MORTAL WKL, V54, P625	39	1136	1173	1	155	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2008	452	7187					638	U9		10.1038/nature06846	http://dx.doi.org/10.1038/nature06846			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385739	Green Accepted			2022-12-28	WOS:000254567200047
J	Keeling, RF				Keeling, Ralph F.			Atmospheric science - Recording Earth's vital signs	SCIENCE			English	Editorial Material							CARBON-DIOXIDE		Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Keeling, RF (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	rkeeling@ucsd.edu						BACASTOW RB, 1976, NATURE, V261, P116, DOI 10.1038/261116a0; BACASTOW RB, 1985, J GEOPHYS RES-ATMOS, V90, P10529, DOI 10.1029/JD090iD06p10529; Bryden HL, 2005, NATURE, V438, P655, DOI 10.1038/nature04385; KEELING CD, 1960, TELLUS, V12, P200, DOI 10.1111/j.2153-3490.1960.tb01300.x; Keeling CD, 1998, ANNU REV ENERG ENV, V23, P25, DOI 10.1146/annurev.energy.23.1.25; KEELING CD, 1957, P C REC RES CLIM COM, P43; Le Quere C, 2008, SCIENCE, V319, DOI 10.1126/science.1147315; Zickfeld K, 2008, SCIENCE, V319, DOI [10.1126/science.1146886, 10.1126/science.1149077]	8	54	57	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1771	1772		10.1126/science.1156761	http://dx.doi.org/10.1126/science.1156761			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369129				2022-12-28	WOS:000254394000027
J	Assie, G; LaFramboise, T; Platzer, P; Eng, C				Assie, Guillaume; LaFramboise, Thomas; Platzer, Petra; Eng, Charis			Frequency of germline genomic homozygosity associated with cancer cases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; WIDE ASSOCIATION; COLORECTAL-CANCER; HUMAN-POPULATIONS; RISK; HETEROZYGOSITY; STROMA; SCAN; EPITHELIUM; CARCINOMA	Context Cancer is a multigenic disease resulting from both germline susceptibility and somatic events. While studying loss of heterozygosity ( LOH) in cancer tissues, we anecdotally observed a low frequency of heterozygosity in cancer patients compared with controls, raising the question whether homozygosity could play a role in cancer predisposition. Objectives To determine the frequency of germline homozygosity in a large series of patients with 3 different types of solid tumors compared with population- based controls. Design, Setting, and Patients Germline and corresponding tumor DNA isolated from 385 patients with carcinomas ( 147 breast, 116 prostate, and 122 head and neck carcinomas) were subjected to whole genome ( 345- microsatellite marker) LOH analysis. Main Outcome Measures Frequency of homozygosity at microsatellite markers in cancer cases vs controls and frequency of somatic LOH in cancers at loci with the highest homozygosity. Results We identified 16 loci in common among the 3 cancer types, with significantly increased germline homozygosity frequencies in the cancer patients compared with controls ( P <. 001). In the cases who happened to be germline heterozygous at these 16 loci, we found a mean ( SD) LOH frequency of 58% ( 4.2%) compared with 50% ( 7.5%) at 197 markers without increased germline homozygosity ( P <. 001). Across the genome, this relationship holds as well ( r= 0.46; 95% confidence interval, 0.37-0.53; P <. 001). We validated the association of specific loci with high germline homozygosity frequencies in an independent, single- nucleotide polymorphism - based, public data set of 205 lung carcinomas from white individuals ( P <. 05 to P <. 001) as well as the correlation between genome- wide germline homozygosity and LOH frequencies ( r= 0.21; 95% confidence interval, 0.18- 0.24; P <. 001). Conclusions In our study of 4 different types of solid tumors ( our data for 3 types validated in a fourth type), increased germline homozygosity occurred at specific loci. When the germline was heterozygous at these loci, high frequencies of LOH/ allelic imbalance occurred at these loci in the corresponding carcinomas.	[Assie, Guillaume; LaFramboise, Thomas; Platzer, Petra; Eng, Charis] Cleveland Clin Fdn, Genom Med Inst, Cleveland, OH 44195 USA; [Assie, Guillaume; Platzer, Petra; Eng, Charis] Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; [Eng, Charis] Cleveland Clin Fdn, Tausig Canc Inst, Cleveland, OH 44195 USA; [LaFramboise, Thomas; Eng, Charis] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; [Eng, Charis] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Assie, G (corresponding author), Cleveland Clin Fdn, Genom Med Inst, 9500 Euclid Ave,NE-50, Cleveland, OH 44195 USA.	engc@ccf.org		Eng, Charis/0000-0002-3693-5145; Assie, Guillaume/0000-0001-9590-0906	NATIONAL CANCER INSTITUTE [P01CA097189] Funding Source: NIH RePORTER; NCI NIH HHS [1P50/U54CA113001-01, 1P01CA97189-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Bhattacharya P, 2002, CANCER LETT, V188, P207, DOI 10.1016/S0304-3835(02)00430-5; Broman KW, 1999, AM J HUM GENET, V65, P1493, DOI 10.1086/302661; Clark AG, 1999, AM J HUM GENET, V65, P1489, DOI 10.1086/302668; Cox A, 2007, NAT GENET, V39, P352, DOI 10.1038/ng1981; Deligezer U, 2005, IN VIVO, V19, P889; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Fukino K, 2004, CANCER RES, V64, P7231, DOI 10.1158/0008-5472.CAN-04-2866; Fukino K, 2007, JAMA-J AM MED ASSOC, V297, P2103, DOI 10.1001/jama.297.19.2103; Gibson J, 2006, HUM MOL GENET, V15, P789, DOI 10.1093/hmg/ddi493; Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; *R DEV COR TEAM, 2007, R LANG ENV STAT COMP, P5149; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Rudan I, 2003, J MED GENET, V40, P925, DOI 10.1136/jmg.40.12.925; Rudan I, 1999, HUM BIOL, V71, P173; Sarquis MS, 2006, J CLIN ENDOCR METAB, V91, P262, DOI 10.1210/jc.2005-1880; SHAMI SA, 1991, LANCET, V338, P954, DOI 10.1016/0140-6736(91)91828-I; Simon-Sanchez J, 2007, HUM MOL GENET, V16, P1, DOI 10.1093/hmg/ddl436; SIMPSON JL, 1981, AM J OBSTET GYNECOL, V141, P629, DOI 10.1016/S0002-9378(15)33302-0; Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085; Weber F, 2007, JAMA-J AM MED ASSOC, V297, P187, DOI 10.1001/jama.297.2.187; WEBER JL, 1989, AM J HUM GENET, V44, P388; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022; Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089	34	41	43	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2008	299	12					1437	1445		10.1001/jama.299.12.1437	http://dx.doi.org/10.1001/jama.299.12.1437			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278MY	18364486				2022-12-28	WOS:000254292200018
J	Nordlinger, B; Sorbye, H; Glimelius, B; Poston, GJ; Schlag, PM; Rougier, P; Bechstein, WO; Primrose, JN; Euan, TW; Finch-Jones, M; Jaeck, D; Mirza, D; Parks, RW; Collette, L; Praet, M; Bethe, U; Van Cutsem, E; Scheithauer, W; Gruenberger, T				Nordlinger, Bernard; Sorbye, Halfdan; Glimelius, Bengt; Poston, Graeme J.; Schlag, Peter M.; Rougier, Philippe; Bechstein, Wolf O.; Primrose, John N.; Euan, T. Walpole; Finch-Jones, Meg; Jaeck, Daniel; Mirza, Darius; Parks, Rowan W.; Collette, Laurence; Praet, Michel; Bethe, Ullrich; Van Cutsem, Eric; Scheithauer, Werner; Gruenberger, Thomas		EORTC Gastrointestinal Tract Canc; Canc Res UK; ALM-CAO; AGITG; FFCD	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial	LANCET			English	Article							HEPATIC ARTERIAL INFUSION; ADJUVANT CHEMOTHERAPY; SURGICAL RESECTION; PLUS IRINOTECAN; FOLINIC ACID; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; 5-FLUOROURACIL; CARCINOMA	Background Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common. We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Methods This parallel-group study reports the trial's final data for progression-free survival for a protocol unspecified interim time-point, while overall survival is still being monitored. 364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group). Patients were centrally randomised by minimisation, adjusting for Centre and risk score. The primary objective was to detect a hazard ratio (HR) of 0.71 or less for progression-free survival. Primary analysis was by intention to treat. Analyses were repeated for all eligible (171 vs 171) and resected patients (151 vs 152). This trial is registered with ClinicalTrials.gov, number NCT00006479. Findings In the perioperative chemotherapy group, 151 (83%) patients were resected after a median of six (range 1-6) preoperative cycles and 115 (63%) patients received a median six (1-8) postoperative cycles. 152 (84%) patients were resected in the surgery group. The absolute increase in rate of progression-free survival at 3 years was 7.3% (from 28.1% [95-66% CI 21.3-35.51 to 35.4% [28.1-42.7]; HR 0 . 79 [0.62-1.02]; p=0.058) in randomised patients; 8 . 1% (from 28.1% [21.2-36.6] to 36.2% [28.7-43.8]; HR 0 . 77 [0-60-1 . 001; p=0 . 041) in eligible patients; and 9.2% (from 33.2% [25.3-41.2] to 42.4% [34.0-50.5]; HR 0.73 [0.55-0.97]; p=0.025) in patients undergoing resection. 139 patients died (64 in perioperative chemotherapy group vs 75 in surgery group). Reversible postoperative complications occurred more often after chemotherapy than after surgery (40/159 [25%] vs 27/170 [16%]; p=0.04). After surgery we recorded two deaths in the surgery alone group and one in the perioperative chemotherapy group. Interpretation Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected. patients. Funding Swedish Cancer Society, Cancer Research UK, Ligue Nationale Contre le Cancer, US National Cancer Institute, Sanofi-Aventis.	[Nordlinger, Bernard; Rougier, Philippe] Ctr Hosp Univ Ambroise Pare, Assistance Publ Hop Paris, Dept Surg, Boulogne, France; [Nordlinger, Bernard; Rougier, Philippe] Ctr Hosp Univ Ambroise Pare, Assistance Publ Hop Paris, Dept Oncol, Boulogne, France; [Sorbye, Halfdan] Univ Bergen, Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; [Glimelius, Bengt] Uppsala Univ, Dept Oncol Radiol & Clin Immunol, Uppsala, Sweden; [Glimelius, Bengt] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden; [Poston, Graeme J.] Aintree Univ Hosp NHS Fdn Trust, Liverpool L9 7AL, Merseyside, England; [Schlag, Peter M.] Humboldt Univ, Robert Roessle Klin, Dept Surg, Berlin, Germany; [Bechstein, Wolf O.] Univ Frankfurt Klinikum, Dept Gen & Vasc Surg, D-6000 Frankfurt, Germany; [Primrose, John N.] Univ Southampton, Southampton Gen Hosp, Univ Dept Surg, Southampton, Hants, England; [Euan, T. Walpole] Univ Queensland, Princess Alexandra Hosp, Australasian Gastrointestinal Trials Grp, Brisbane, Qld, Australia; [Finch-Jones, Meg] Bristol Royal Infirm & Gen Hosp, Bristol, Avon, England; [Jaeck, Daniel] Hop Univ Hautepierre, Strasbourg, France; [Mirza, Darius] Univ Hosp Birmingham, Birmingham, W Midlands, England; [Parks, Rowan W.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland; [Collette, Laurence; Praet, Michel; Bethe, Ullrich] Eortc Data Ctr, Brussels, Belgium; [Van Cutsem, Eric] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium; [Scheithauer, Werner; Gruenberger, Thomas] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria; [Scheithauer, Werner; Gruenberger, Thomas] Med Univ Vienna, Ctr Canc, Vienna, Austria; [Scheithauer, Werner; Gruenberger, Thomas] Med Univ Vienna, Dept Gen Surg, Vienna, Austria	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Bergen; Haukeland University Hospital; Uppsala University; Karolinska Institutet; Aintree University Hospitals NHS Foundation Trust; Humboldt University of Berlin; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Southampton; University of Queensland; Bristol Royal Infirmary; CHU Strasbourg; University of Birmingham; Royal Infirmary of Edinburgh; University of Edinburgh; European Organisation for Research & Treatment of Cancer; KU Leuven; University Hospital Leuven; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Nordlinger, B (corresponding author), Ctr Hosp Univ Ambroise Pare, Dept Digest Surg, 9 Ave Charles de Gaulle, F-92104 Boulogne, France.	bernard.nordlinger@apr.aphp.fr	Walpole, Euan T/B-4005-2014; Van+Cutsem, Eric/ABE-1762-2021; Gruenberger, Thomas/ABA-1661-2020; Bechstein, Wolf/H-5457-2019	Walpole, Euan T/0000-0001-6105-9039; Gruenberger, Thomas/0000-0002-2671-0540; Bechstein, Wolf/0000-0002-3267-8145; Primrose, John/0000-0002-2069-7605; Raoul, Jean-Luc/0000-0001-6305-8953; Dousset, Bertrand/0000-0003-2526-7345; Bethe, Ullrich/0000-0001-9979-1671; Collette, Laurence/0000-0003-2518-7281	Cancer Research UK Funding Source: Medline; NCI NIH HHS [5U10-CA11488-28, 5U10 CA11488-31, 5U10 CA11488-37, U10 CA011488, 5U10-CA11488-29, 5U10 CA11488-34, 5U10 CA11488-30, 5U10 CA11488-33, 5U10 CA11488-36, 5U10 CA11488-32, 5U10 CA11488-35] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam R, 2004, ANN SURG, V240, P1052, DOI 10.1097/01.sla.0000145964.08365.01; Adam R, 2003, ANN SURG, V238, P871, DOI 10.1097/01.sla.0000098112.04758.4e; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Bilchik AJ, 2005, J CLIN ONCOL, V23, P9073, DOI 10.1200/JCO.2005.03.2334; Charnsangavej C, 2006, ANN SURG ONCOL, V13, P1261, DOI 10.1245/s10434-006-9023-y; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004; FREEDMAN LS, 1976, BIOMETRICS, V32, P691, DOI 10.2307/2529759; Giacchetti S, 1999, ANN ONCOL, V10, P663, DOI 10.1023/A:1008347829017; Hoff PM, 2007, J CLIN ONCOL, V25, P1639, DOI 10.1200/JCO.2006.09.8384; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; HWANG IK, 1990, STAT MED, V9, P1439, DOI 10.1002/sim.4780091207; Janunger KG, 2002, EUR J SURG, V168, P597, DOI 10.1080/11024150201680005; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI, P163; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karoui M, 2006, ANN SURG, V243, P1, DOI 10.1097/01.sla.0000193603.26265.c3; Kemeny MM, 2002, J CLIN ONCOL, V20, P1499, DOI 10.1200/JCO.20.6.1499; Kemeny N, 1999, NEW ENGL J MED, V341, P2039, DOI 10.1056/NEJM199912303412702; Kokudo N, 2007, J CLIN ONCOL, V25, P1299, DOI 10.1200/JCO.2006.09.9069; Lorenz M, 1998, ANN SURG, V228, P756, DOI 10.1097/00000658-199812000-00006; Mitry E, 2006, J CLIN ONCOL, V24, p152S; National Cancer Institute, 1999, COMM TOX CRIT VERS 2; *NCI, EORTC PROT 40051 BOS; Nordlinger B, 1996, CANCER, V77, P1254, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.3.CO;2-R; Portier G, 2006, J CLIN ONCOL, V24, P4976, DOI 10.1200/JCO.2006.06.8353; Rubbia-Brandt L, 2004, ANN ONCOL, V15, P460, DOI 10.1093/annonc/mdh095; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vauthey JN, 2006, J CLIN ONCOL, V24, P2065, DOI 10.1200/JCO.2005.05.3074	30	1416	1485	1	71	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2008	371	9617					1007	1016		10.1016/S0140-6736(08)60455-9	http://dx.doi.org/10.1016/S0140-6736(08)60455-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358928	Green Submitted, Green Published			2022-12-28	WOS:000254206000029
J	Mccoy, D; Mwansambo, C; Costello, A; Khan, A				McCoy, David; Mwansambo, Charles; Costello, Anthony; Khan, Azad			Academic partnerships between rich and poor countries	LANCET			English	Editorial Material									[McCoy, David; Costello, Anthony] UCL, Inst Global Hlth, London WC1N 1EH, England; [Mwansambo, Charles] Kamuzu Cent Hosp, Dept Paediat, Lilongwe, Malawi; [Khan, Azad] Diabet Assoc Bangladesh, Dhaka, Bangladesh	University of London; University College London	Mccoy, D (corresponding author), UCL, Inst Global Hlth, London WC1N 1EH, England.	d.mccoy@ucl.ac.uk						[Anonymous], 2006, PLOS MED, V3, P707, DOI 10.1371/journal.pmed.0030291; Bennett S, 2007, SOUND CHOICES ENHANC; *COMM RES PARTN DE, 1998, GUID RES PARTN DEV C; Costello A, 2000, BRIT MED J, V321, P827, DOI 10.1136/bmj.321.7264.827; Martin JN, 1999, COMMUN THEOR, V9, P1, DOI 10.1111/j.1468-2885.1999.tb00160.x; McCoy D, 2004, LANCET, V364, P1630, DOI 10.1016/S0140-6736(04)17319-4; Mutume G., 2003, AFRICA RECOVERY, V17, P1; Pang TK, 2004, B WORLD HEALTH ORGAN, V82, P720; *WELLC TRUST, 2007, RES CAP STRENGTH AFR	9	23	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1055	1057		10.1016/S0140-6736(08)60466-3	http://dx.doi.org/10.1016/S0140-6736(08)60466-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	280RA	18374827				2022-12-28	WOS:000254442700009
J	Tam, OH; Aravin, AA; Stein, P; Girard, A; Murchison, EP; Cheloufi, S; Hodges, E; Anger, M; Sachidanandam, R; Schultz, RM; Hannon, GJ				Tam, Oliver H.; Aravin, Alexei A.; Stein, Paula; Girard, Angelique; Murchison, Elizabeth P.; Cheloufi, Sihem; Hodges, Emily; Anger, Martin; Sachidanandam, Ravi; Schultz, Richard M.; Hannon, Gregory J.			Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes	NATURE			English	Article							PIWI; PROTEIN; MILI; BIOGENESIS; MICRORNAS; MECHANISM	Pseudogenes populate the mammalian genome as remnants of artefactual incorporation of coding messenger RNAs into transposon pathways(1). Here we show that a subset of pseudogenes generates endogenous small interfering RNAs (endo-siRNAs) in mouse oocytes. These endo-siRNAs are often processed from double-stranded RNAs formed by hybridization of spliced transcripts from protein-coding genes to antisense transcripts from homologous pseudogenes. An inverted repeat pseudogene can also generate abundant small RNAs directly. A second class of endosiRNAs may enforce repression of mobile genetic elements, acting together with Piwi-interacting RNAs. Loss of Dicer, a protein integral to small RNA production, increases expression of endosiRNA targets, demonstrating their regulatory activity. Our findings indicate a function for pseudogenes in regulating gene expression by means of the RNA interference pathway and may, in part, explain the evolutionary pressure to conserve argonautemediated catalysis in mammals.	[Tam, Oliver H.; Aravin, Alexei A.; Girard, Angelique; Murchison, Elizabeth P.; Cheloufi, Sihem; Hodges, Emily; Sachidanandam, Ravi; Hannon, Gregory J.] Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; [Tam, Oliver H.; Aravin, Alexei A.; Girard, Angelique; Murchison, Elizabeth P.; Cheloufi, Sihem; Hodges, Emily; Sachidanandam, Ravi; Hannon, Gregory J.] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA; [Stein, Paula; Anger, Martin; Schultz, Richard M.] Univ Penn, Dept Biol, Lynch Labs 205, Philadelphia, PA 19104 USA	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; University of Pennsylvania	Hannon, GJ (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	hannon@cshl.edu	Anger, Martin/A-3152-2015; Anger, Martin/R-9917-2019; Hannon, Gregory/AAB-3568-2019; Stein, Paula/ABE-9388-2020; sachidanandam, ravi/Q-6916-2019	Anger, Martin/0000-0003-0128-1054; Anger, Martin/0000-0003-0128-1054; Stein, Paula/0000-0002-2040-4593; sachidanandam, ravi/0000-0001-9844-4459; Hodges, Emily/0000-0001-6513-610X; Cheloufi, Sihem/0000-0002-1726-4796; Tam, Oliver/0000-0002-1023-3655; Murchison, Elizabeth Proby/0000-0001-7462-8907	Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [P01 CA013106-34] Funding Source: Medline; NIGMS NIH HHS [R01 GM062534, R01 GM062534-07, R01 GM062534-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062534] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen E, 2005, CELL, V121, P207, DOI 10.1016/j.cell.2005.04.004; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Aravin AA, 2007, SCIENCE, V318, P761, DOI 10.1126/science.1146484; Aravin AA, 2007, SCIENCE, V316, P744, DOI 10.1126/science.1142612; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bettegowda A, 2007, FRONT BIOSCI-LANDMRK, V12, P3713, DOI 10.2741/2346; Brennecke J, 2007, CELL, V128, P1089, DOI 10.1016/j.cell.2007.01.043; Carmell MA, 2007, DEV CELL, V12, P503, DOI 10.1016/j.devcel.2007.03.001; D'Errico Ilenia, 2004, Briefings in Functional Genomics & Proteomics, V3, P157, DOI 10.1093/bfgp/3.2.157; Deng W, 2002, DEV CELL, V2, P819, DOI 10.1016/S1534-5807(02)00165-X; Gunawardane LS, 2007, SCIENCE, V315, P1587, DOI 10.1126/science.1140494; Houwing S, 2007, CELL, V129, P69, DOI 10.1016/j.cell.2007.03.026; Joshua-Tor L, 2006, COLD SPRING HARB SYM, V71, P67, DOI 10.1101/sqb.2006.71.048; Korneev SA, 1999, J NEUROSCI, V19, P7711; Kuramochi-Miyagawa S, 2004, DEVELOPMENT, V131, P839, DOI 10.1242/dev.00973; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lee JSM, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-189; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Murchison EP, 2007, GENE DEV, V21, P682, DOI 10.1101/gad.1521307; MURCHISON EP, IN PRESS GENOME RES; Saito K, 2006, GENE DEV, V20, P2214, DOI 10.1101/gad.1454806; SCHULTZ RM, 1983, DEV BIOL, V97, P264, DOI 10.1016/0012-1606(83)90085-4; Schwarz DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008; Stein P, 2005, DEV BIOL, V286, P464, DOI 10.1016/j.ydbio.2005.08.015; Stitzel ML, 2007, SCIENCE, V316, P407, DOI 10.1126/science.1138236; Tang F, 2007, GENE DEV, V21, P644, DOI 10.1101/gad.418707; Vagin VV, 2006, SCIENCE, V313, P320, DOI 10.1126/science.1129333; Weil D, 1997, GENE, V187, P115, DOI 10.1016/S0378-1119(96)00733-0; ZHOU BS, 1992, CANCER RES, V52, P4280	29	782	832	2	82	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 22	2008	453	7194					534	U8		10.1038/nature06904	http://dx.doi.org/10.1038/nature06904			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18404147	Green Accepted			2022-12-28	WOS:000256023700045
J	Park, DH; Son, HY				Park, Do Hyun; Son, Hyun-Young			Clonorchis sinensis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Park, Do Hyun; Son, Hyun-Young] Univ Ulsan, Coll Med, Seoul 138736, South Korea	University of Ulsan	Park, DH (corresponding author), Univ Ulsan, Coll Med, Seoul 138736, South Korea.	dhpark@amc.seoul.kr							0	2	2	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					E18	E18		10.1056/NEJMicm054461	http://dx.doi.org/10.1056/NEJMicm054461			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288DO	18420495				2022-12-28	WOS:000254966600010
J	Wheeler, DA; Srinivasan, M; Egholm, M; Shen, Y; Chen, L; McGuire, A; He, W; Chen, YJ; Makhijani, V; Roth, GT; Gomes, X; Tartaro, K; Niazi, F; Turcotte, CL; Irzyk, GP; Lupski, JR; Chinault, C; Song, XZ; Liu, Y; Yuan, Y; Nazareth, L; Qin, X; Muzny, DM; Margulies, M; Weinstock, GM; Gibbs, RA; Rothberg, JM				Wheeler, David A.; Srinivasan, Maithreyan; Egholm, Michael; Shen, Yufeng; Chen, Lei; McGuire, Amy; He, Wen; Chen, Yi-Ju; Makhijani, Vinod; Roth, G. Thomas; Gomes, Xavier; Tartaro, Karrie; Niazi, Faheem; Turcotte, Cynthia L.; Irzyk, Gerard P.; Lupski, James R.; Chinault, Craig; Song, Xing-zhi; Liu, Yue; Yuan, Ye; Nazareth, Lynne; Qin, Xiang; Muzny, Donna M.; Margulies, Marcel; Weinstock, George M.; Gibbs, Richard A.; Rothberg, Jonathan M.			The complete genome of an individual by massively parallel DNA sequencing	NATURE			English	Article							STRUCTURAL VARIATION; GENE	The association of genetic variation with disease and drug response, and improvements in nucleic acid technologies, have given great optimism for the impact of 'genomic medicine'. However, the formidable size of the diploid human genome(1), approximately 6 gigabases, has prevented the routine application of sequencing methods to deciphering complete individual human genomes. To realize the full potential of genomics for human health, this limitation must be overcome. Here we report the DNA sequence of a diploid genome of a single individual, James D. Watson, sequenced to 7.4- fold redundancy in two months using massively parallel sequencing in picolitre- size reaction vessels. This sequence was completed in two months at approximately one-hundredth of the cost of traditional capillary electrophoresis methods. Comparison of the sequence to the reference genome led to the identification of 3.3 million single nucleotide polymorphisms, of which 10,654 cause amino- acid substitution within the coding sequence. In addition, we accurately identified small-scale ( 2 - 40,000 base pair ( bp)) insertion and deletion polymorphism as well as copy number variation resulting in the large- scale gain and loss of chromosomal segments ranging from 26,000 to 1.5 million base pairs. Overall, these results agree well with recent results of sequencing of a single individual(2) by traditional methods. However, in addition to being faster and significantly less expensive, this sequencing technology avoids the arbitrary loss of genomic sequences inherent in random shotgun sequencing by bacterial cloning because it amplifies DNA in a cell- free system. As a result, we further demonstrate the acquisition of novel human sequence, including novel genes not previously identified by traditional genomic sequencing. This is the first genome sequenced by next- generation technologies. Therefore it is a pilot for the future challenges of 'personalized genome sequencing'.	[Wheeler, David A.; Chen, Lei; Song, Xing-zhi; Liu, Yue; Yuan, Ye; Nazareth, Lynne; Qin, Xiang; Muzny, Donna M.; Weinstock, George M.; Gibbs, Richard A.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [McGuire, Amy] Baylor Coll Med, Ctr Eth & Hlth Policy, Houston, TX 77030 USA; [Lupski, James R.; Chinault, Craig; Weinstock, George M.; Gibbs, Richard A.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Lupski, James R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Lupski, James R.] Texas Childrens Hosp, Texas Med Ctr, Houston, TX 77030 USA; [Srinivasan, Maithreyan; Egholm, Michael; He, Wen; Chen, Yi-Ju; Makhijani, Vinod; Roth, G. Thomas; Gomes, Xavier; Tartaro, Karrie; Niazi, Faheem; Turcotte, Cynthia L.; Irzyk, Gerard P.; Margulies, Marcel; Rothberg, Jonathan M.] Roche Diagnost, Bradford, CT 06405 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Roche Holding	Rothberg, JM (corresponding author), Roche Diagnost, 454 Life Sci,20 Commercial St, Bradford, CT 06405 USA.	agibbs@bcm.tmc.edu; jonathan.rothberg@gmail.com	Weinstock, George M/C-6314-2013; Wheeler, David A/M-9740-2018	Weinstock, George M/0000-0002-2997-4592; Wheeler, David A/0000-0002-9056-6299	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003273] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bennettt EA, 2004, GENETICS, V168, P933, DOI 10.1534/genetics.104.031757; BITTLES AH, 1994, NAT GENET, V8, P117, DOI 10.1038/ng1094-117; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Halligan DL, 2003, TRENDS GENET, V19, P57, DOI 10.1016/S0168-9525(02)00045-8; Havlak P, 2004, GENOME RES, V14, P721, DOI 10.1101/gr.2264004; Kidd JM, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030063; Korbel JO, 2007, SCIENCE, V318, P420, DOI 10.1126/science.1149504; LANDER E S, 1988, Genomics, V2, P231; Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254; Lupski JR, 2007, NEW ENGL J MED, V356, P1169, DOI 10.1056/NEJMcibr067658; Lupski JR, 2005, PLOS GENET, V1, P627, DOI 10.1371/journal.pgen.0010049; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; McGuire AL, 2008, NAT REV GENET, V9, P152, DOI 10.1038/nrg2302; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Richards S, 2005, GENOME RES, V15, P1, DOI 10.1101/gr.3059305; Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212; VOGEL F, 1986, HUMAN GENETICS PROBL, P487; Weber JL, 2002, AM J HUM GENET, V71, P854, DOI 10.1086/342727	21	1241	1353	14	239	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2008	452	7189					872	U5		10.1038/nature06884	http://dx.doi.org/10.1038/nature06884			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18421352	hybrid			2022-12-28	WOS:000255026000048
J	Ohta, K; Onoda, S; Hirose, K; Sinmyo, R; Shimizu, K; Sata, N; Ohishi, Y; Yasuhara, A				Ohta, Kenji; Onoda, Suzue; Hirose, Kei; Sinmyo, Ryosuke; Shimizu, Katsuya; Sata, Nagayoshi; Ohishi, Yasuo; Yasuhara, Akira			The electrical conductivity of post-perovskite in Earth's D" layer	SCIENCE			English	Article							LOWER-MANTLE; SILICATE PEROVSKITE; PHASE-TRANSITION; D''-LAYER; IRON; MGSIO3; CORE	Recent discovery of a phase transition from perovskite to post- perovskite suggests that the physical properties of Earth's lowermost mantle, called the D'' layer, may be different from those of the overlying mantle. We report that the electrical conductivity of ( Mg0.9Fe0.1) SiO3 post- perovskite is >10(2) siemens per meter and does not vary greatly with temperature at the conditions of the D'' layer. A post- perovskite layer above the core- mantle boundary would, by electromagnetic coupling, enhance the exchange of angular momentum between the fluid core and the solid mantle, which can explain the observed changes in the length of a day on decadal time scales. Heterogeneity in the conductivity of the lowermost mantle is likely to depend on changes in chemistry of the boundary region, not fluctuations in temperature.	[Ohta, Kenji; Hirose, Kei; Sinmyo, Ryosuke] Tokyo Inst Technol, Dept Earth & Planetary Sci, Tokyo 1528551, Japan; [Onoda, Suzue; Shimizu, Katsuya] Osaka Univ, Ctr Quantum Sci & Technol Extreme Condit, Osaka 5608531, Japan; [Hirose, Kei; Sata, Nagayoshi] Japan Agcy Marine Earth Sci & Technol, Inst Res Earth Evolut, Yokosuka, Kanagawa 2370061, Japan; [Ohishi, Yasuo] Japan Synchrotron Radiat Res Inst, Sayo, Hyogo 6795198, Japan; [Yasuhara, Akira] JEOL Ltd, Tokyo 1968558, Japan	Tokyo Institute of Technology; Osaka University; Japan Agency for Marine-Earth Science & Technology (JAMSTEC); Japan Synchrotron Radiation Research Institute; Jeol Ltd; JEOL Japan	Hirose, K (corresponding author), Tokyo Inst Technol, Dept Earth & Planetary Sci, 2-12-1 Ookayama, Tokyo 1528551, Japan.	kei@geo.titech.ac.jp	Hirose, Kei/C-2165-2009; Sinmyo, Ryosuke/M-9534-2019; Sinmyo, Ryosuke/C-6193-2014; Ohta, Kenji/C-2825-2009	Hirose, Kei/0000-0003-4366-7721; Sinmyo, Ryosuke/0000-0001-5799-3400; Sinmyo, Ryosuke/0000-0001-5799-3400; Ohta, Kenji/0000-0002-6107-8720; Shimizu, Katsuya/0000-0003-0560-8325; Yasuhara, Akira/0000-0002-6796-0773				Badro J, 2003, SCIENCE, V300, P789, DOI 10.1126/science.1081311; Badro J, 2004, SCIENCE, V305, P383, DOI 10.1126/science.1098840; Bloxham J, 1998, ANNU REV EARTH PL SC, V26, P501, DOI 10.1146/annurev.earth.26.1.501; Buffett BA, 2000, SCIENCE, V290, P1338, DOI 10.1126/science.290.5495.1338; Holme R, 1998, GEODYNAMICS, V28, P139; Iitaka T, 2004, NATURE, V430, P442, DOI 10.1038/nature02702; Katsura T, 1998, NATURE, V395, P493, DOI 10.1038/26736; Lay T, 2004, GEOPHYS MONOGR SER, V150, P25, DOI 10.1029/150GM04; LI XY, 1990, J GEOPHYS RES-SOLID, V95, P5067, DOI 10.1029/JB095iB04p05067; Lin JF, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030523; Mao WL, 2005, P NATL ACAD SCI USA, V102, P9751, DOI 10.1073/pnas.0503737102; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; Nagao H, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001786; Oganov AR, 2004, NATURE, V430, P445, DOI 10.1038/nature02701; Ohta K, 2007, P JPN ACAD B-PHYS, V83, P97, DOI 10.2183/pjab.83.97; Olsen N, 1999, GEOPHYS J INT, V138, P179, DOI 10.1046/j.1365-246x.1999.00854.x; Ono S, 2006, EARTH PLANET SC LETT, V246, P326, DOI 10.1016/j.epsl.2006.04.017; SHANKLAND TJ, 1993, NATURE, V366, P453, DOI 10.1038/366453a0; Shimizu K, 2002, NATURE, V419, P597, DOI 10.1038/nature01098; Sinmyo R, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL025858; Takeuchi N, 2007, GEOPHYS J INT, V169, P1153, DOI 10.1111/j.1365-246X.2007.03405.x; Tateno S, 2007, PHYS EARTH PLANET IN, V160, P319, DOI 10.1016/j.pepi.2006.11.010; Wysession ME, 1998, GEODYNAMICS, V28, P273; Xu YS, 1998, SCIENCE, V282, P922, DOI 10.1126/science.282.5390.922; Zhang FW, 2006, EARTH PLANET SC LETT, V249, P436, DOI 10.1016/j.epsl.2006.07.023	25	91	99	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					89	91		10.1126/science.1155148	http://dx.doi.org/10.1126/science.1155148			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388291				2022-12-28	WOS:000254633000036
J	Sawyers, CL				Sawyers, Charles L.			The cancer biomarker problem	NATURE			English	Review							CIRCULATING TUMOR-CELLS; PROSTATE-CANCER; LUNG ADENOCARCINOMAS; BREAST-CANCER; MUTATIONS; EXPRESSION; SIGNATURES; RESISTANCE; GEFITINIB; ERLOTINIB	Genomic technologies offer the promise of a comprehensive understanding of cancer. These technologies are being used to characterize tumours at the molecular level, and several clinical successes have shown that such information can guide the design of drugs targeted to a relevant molecule. One of the main barriers to further progress is identifying the biological indicators, or biomarkers, of cancer that predict who will benefit from a particular targeted therapy.	[Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Human Oncol & Pathogenesis Program, New York, NY 10065 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Sawyers, CL (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10065 USA.	sawyersc@mskcc.org	Sawyers, Charles/G-5327-2016		Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Carroll KJ, 2007, PHARM STAT, V6, P253, DOI 10.1002/pst.269; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Committee on Developing Biomarker-Based Tools for Cancer Screening Diagnosis and Treatment, 2007, CANC BIOM PROM CHALL; Coombes KR, 2007, NAT MED, V13, P1276, DOI 10.1038/nm1107-1276b; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102; Dowsett M, 2007, JNCI-J NATL CANCER I, V99, P167, DOI 10.1093/jnci/djk020; Hunter DJ, 2008, NEW ENGL J MED, V358, P105, DOI 10.1056/NEJMp0708162; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Mehrian-Shai R, 2007, P NATL ACAD SCI USA, V104, P5563, DOI 10.1073/pnas.0609139104; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Ratain MJ, 2007, CLIN CANCER RES, V13, P6545, DOI 10.1158/1078-0432.CCR-07-2133; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Shaffer DR, 2007, CLIN CANCER RES, V13, P2023, DOI 10.1158/1078-0432.CCR-06-2701; SHAH N, 2006, BLOOD, V108; Shah NP, 2007, J CLIN INVEST, V117, P2562, DOI 10.1172/JCI30890; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Wang XJ, 2005, NEW ENGL J MED, V353, P1224, DOI 10.1056/NEJMoa051931	27	696	774	6	352	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2008	452	7187					548	552		10.1038/nature06913	http://dx.doi.org/10.1038/nature06913			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385728				2022-12-28	WOS:000254567200032
J	Datta, SD; Koutsky, LA; Ratelle, S; Unger, ER; Shlay, J; McClain, T; Weaver, B; Kerndt, P; Zenilman, J; Hagensee, M; Suhr, CJ; Weinstock, H				Datta, S. Deblina; Koutsky, Laura A.; Ratelle, Sylvie; Unger, Elizabeth R.; Shlay, Judith; McClain, Tracie; Weaver, Beth; Kerndt, Peter; Zenilman, Jonathan; Hagensee, Michael; Suhr, Cristen J.; Weinstock, Hillard			Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005	ANNALS OF INTERNAL MEDICINE			English	Article							PREVALENCE; AGE; PERSISTENCE	Background: Millions of women in the United States receive cervical screening in sexually transmitted disease (STD), family planning, and primary care clinical settings. Objective: To inform current cervical screening programs. Design: Measurement of abnormal Papanicolaou (Pap) tests and high-risk human papillomavirus (HPV) infection among demographically diverse women who received routine cervical screening from January 2003 to December 2005 in the United States. Setting: 26 STD, family planning, and primary care clinics in 6 U.S. cities. Patients: 9657 women age 14 to 65 years receiving routine cervical screening. Measurements: Pap test results and high-risk HPV prevalence by Hybrid Capture 2 assay (Digene, Gaithersburg, Maryland). Results: Among 9657 patients, overall high-risk HPV prevalence by Hybrid Capture 2 testing was 23% (95% Cl, 22% to 24%). Prevalence was highest among women age 14 to 19 years (35% [Cl, 32% to 38%]) and lowest among women age 50 to 65 years (6% [Cl, 4% to 8%]). Prevalence by clinic type (adjusted for age and city) ranged from 26% (Cl, 24% to 29%) in STD clinics to 17% (Cl, 16% to 20%) in primary care clinics. Women younger than 30 years of age whose Pap test showed atypical squamous cells of undetermined significance had a high-risk HPV prevalence of 53%; women 30 years of age or older with normal Pap tests had a 9% prevalence. Values did not vary substantially by clinic type. Limitation: Hybrid Capture 2 and Pap testing were noncentralized, and consent was required for enrollment. Conclusion: High-risk HPV was widespread among women receiving cervical screening in the United States. Many women 30 years of age or older with normal Pap tests would need follow-up if Hybrid Capture 2 testing is added to cytology screening.	[Datta, S. Deblina] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Washington, Seattle, WA 98195 USA; Massachusetts Dept Publ Hlth, Boston, MA USA; Denver Publ Hlth, Denver, CO USA; Cty Los Angeles Dept Hlth Serv, Los Angeles, CA USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA	Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; Massachusetts Department of Public Health; Johns Hopkins University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Datta, SD (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA.	ddatta@cdc.gov		Unger, Elizabeth/0000-0002-2925-5635				ACOG Comm Obstet Practice, 2003, OBSTET GYNECOL, V102, P415; Armitage P., 2002, STAT METHODS MED RES; Bosch FX, 2002, VIRUS RES, V89, P183, DOI 10.1016/S0168-1702(02)00187-9; Castle PE, 2005, J INFECT DIS, V191, P1808, DOI 10.1086/428779; Datta SD, 2007, ANN INTERN MED, V147, P89, DOI 10.7326/0003-4819-147-2-200707170-00007; Dunne EF, 2007, JAMA-J AM MED ASSOC, V297, P813, DOI 10.1001/jama.297.8.813; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; Franceschi S, 2006, INT J CANCER, V119, P2677, DOI 10.1002/ijc.22241; GOTTLIEB SL, 2008, IN PRESS SEX TRANSM; Kulasingam SL, 2006, JNCI-J NATL CANCER I, V98, P92, DOI 10.1093/jnci/djj009; Kulasingam SL, 2002, JAMA-J AM MED ASSOC, V288, P1749, DOI 10.1001/jama.288.14.1749; Manhart LE, 2006, SEX TRANSM DIS, V33, P502, DOI 10.1097/01.olq.0000204545.89516.0a; Moscicki AB, 2004, J INFECT DIS, V190, P37, DOI 10.1086/421467; Naucler P, 2007, NEW ENGL J MED, V357, P1589, DOI 10.1056/NEJMoa073204; Saraiya M, 2007, OBSTET GYNECOL, V109, P360, DOI 10.1097/01.AOG.0000254165.92653.e8; Saslow D, 2002, CA-CANCER J CLIN, V52, P342, DOI 10.3322/canjclin.52.6.342; US Cancer Statistics Working Group, 2007, US CANC STAT 2004 IN; *US PREV ERV TASK, 2003, SCREEN CERV CANC; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wright TC, 2007, AM J OBSTET GYNECOL, V197, P346, DOI 10.1016/j.ajog.2007.07.047; Xi LF, 2006, J NATL CANCER I, V98, P1045, DOI 10.1093/jnci/djj297; Yabroff KR, 2005, J RURAL HEALTH, V21, P149, DOI 10.1111/j.1748-0361.2005.tb00075.x	22	112	119	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2008	148	7					493	500		10.7326/0003-4819-148-7-200804010-00004	http://dx.doi.org/10.7326/0003-4819-148-7-200804010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284IV	18378945				2022-12-28	WOS:000254701000001
J	Miserez, A; Schneberk, T; Sun, CJ; Zok, FW; Waite, JH				Miserez, Ali; Schneberk, Todd; Sun, Chengjun; Zok, Frank W.; Waite, J. Herbert			The transition from stiff to compliant materials in squid beaks	SCIENCE			English	Article							INSECT-CUTICLE; CROSS-LINKING; GRADIENTS; PROTEINS; MASS	The beak of the Humboldt squid Dosidicus gigas represents one of the hardest and stiffest wholly organic materials known. As it is deeply embedded within the soft buccal envelope, the manner in which impact forces are transmitted between beak and envelope is a matter of considerable scientific interest. Here, we show that the hydrated beak exhibits a large stiffness gradient, spanning two orders of magnitude from the tip to the base. This gradient is correlated with a chemical gradient involving mixtures of chitin, water, and His- rich proteins that contain 3,4- dihydroxyphenyl- L- alanine ( dopa) and undergo extensive stabilization by histidyl- dopa cross- link formation. These findings may serve as a foundation for identifying design principles for attaching mechanically mismatched materials in engineering and biological applications.	[Miserez, Ali; Zok, Frank W.] Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; [Miserez, Ali; Schneberk, Todd; Sun, Chengjun; Waite, J. Herbert] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; [Miserez, Ali; Schneberk, Todd; Sun, Chengjun; Waite, J. Herbert] Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Zok, FW (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.	zok@engineering.ucsb.edu; waite@lifesci.ucsb.edu	Miserez, Ali/D-1074-2010; Schneberk, Todd/AAA-5800-2020; Miserez, Ali/CAF-2662-2022	Miserez, Ali/0000-0003-0864-8170; Schneberk, Todd/0000-0003-1642-2075; Miserez, Ali/0000-0003-0864-8170	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015415, R01DE014672] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE015415-01, DE015415, R01 DE015415-04, R01 DE014672, R01 DE015415, R01 DE015415-03] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSEN SO, 1979, ANNU REV ENTOMOL, V24, P29, DOI 10.1146/annurev.en.24.010179.000333; BARNES RD, 1966, INVERTEBRATE ZOOLOGY; Benjamin M, 2006, J ANAT, V208, P471, DOI 10.1111/j.1469-7580.2006.00540.x; BRUNET PCJ, 1980, INSECT BIOCHEM, V10, P467, DOI 10.1016/0020-1790(80)90082-7; Hook F, 2001, ANAL CHEM, V73, P5796, DOI 10.1021/ac0106501; HOPKINS TL, 1992, ANNU REV ENTOMOL, V37, P273, DOI 10.1146/annurev.en.37.010192.001421; Iconomidou VA, 2005, INSECT BIOCHEM MOLEC, V35, P553, DOI 10.1016/j.ibmb.2005.01.017; Imbeni V, 2005, NAT MATER, V4, P229, DOI 10.1038/nmat1323; Kerwin JL, 1999, ANAL BIOCHEM, V268, P229, DOI 10.1006/abio.1998.3069; KINLOCH AJ, 1987, ADHES ADHES, P206; Lee H, 2007, NATURE, V448, P338, DOI 10.1038/nature05968; Liu B, 2006, J AM CHEM SOC, V128, P15228, DOI 10.1021/ja065794h; Miessner M, 2001, BIOMACROMOLECULES, V2, P369, DOI 10.1021/bm005652u; Miserez A, 2007, ACTA BIOMATER, V3, P139, DOI 10.1016/j.actbio.2006.09.004; Moses DN, 2006, J BIOL CHEM, V281, P34826, DOI 10.1074/jbc.M603429200; MURRAY NJ, 1994, EUR J BIOCHEM, V219, P923, DOI 10.1111/j.1432-1033.1994.tb18574.x; Neville A. C., 1993, BIOL FIBROUS COMPOSI; Nishino T, 1999, J POLYM SCI POL PHYS, V37, P1191, DOI 10.1002/(SICI)1099-0488(19990601)37:11<1191::AID-POLB13>3.0.CO;2-H; Raabe D, 2005, ACTA MATER, V53, P4281, DOI 10.1016/j.actamat.2005.05.027; SCHAEFER J, 1987, SCIENCE, V235, P1200, DOI 10.1126/science.3823880; Sun CJ, 2005, J BIOL CHEM, V280, P39332, DOI 10.1074/jbc.M508674200; Suresh S, 2001, SCIENCE, V292, P2447, DOI 10.1126/science.1059716; Sweeney AM, 2007, J R SOC INTERFACE, V4, P685, DOI 10.1098/rsif.2006.0210; Uyeno TA, 2005, J MORPHOL, V264, P211, DOI 10.1002/jmor.10330; Vincent JFV, 2002, COMPOS PART A-APPL S, V33, P1311, DOI 10.1016/S1359-835X(02)00167-7; VINCENT JFV, 1987, J INSECT PHYSIOL, V33, P973, DOI 10.1016/0022-1910(87)90010-2; Waite JH, 2004, BIOCHEMISTRY-US, V43, P7653, DOI 10.1021/bi049380h	27	294	310	5	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1816	1819		10.1126/science.1154117	http://dx.doi.org/10.1126/science.1154117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369144	Green Accepted			2022-12-28	WOS:000254394000044
J	Venteicher, AS; Meng, ZJ; Mason, PJ; Veenstra, TD; Artandi, SE				Venteicher, Andrew S.; Meng, Zhaojing; Mason, Philip J.; Veenstra, Timothy D.; Artandi, Steven E.			Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly	CELL			English	Article							DOMINANT DYSKERATOSIS-CONGENITA; CHROMATIN REMODELING COMPLEX; SMALL NUCLEOLAR RNPS; REVERSE-TRANSCRIPTASE; RNA COMPONENT; LENGTH; CELLS; PROTEINS; RIBONUCLEOPROTEINS; PURIFICATION	Telomerase is a multisubunit ribonucleoprotein (RNP) complex that adds telomere repeats to the ends of chromosomes. Three essential telomerase components have been identified thus far: the telomerase reverse transcriptase (TERT), the telomerase RNA component (TERC), and the TERC-binding protein dyskerin. Few other proteins are known to be required for human telomerase function, limiting our understanding of both telomerase regulation and mechanisms of telomerase action. Here, we identify the ATPases pontin and reptin as telomerase components through affinity purification of TERT from human cells. Pontin interacts directly with both TERT and dyskerin, and the amount of TERT bound to pontin and reptin peaks in S phase, evidence for cell-cycle-dependent regulation of TERT. Depletion of pontin and reptin markedly impairs telomerase RNP accumulation, indicating an essential role in telomerase assembly. These findings reveal an unanticipated requirement for additional enzymes in telomerase biogenesis and suggest alternative approaches for inhibiting telomerase in cancer.	[Venteicher, Andrew S.; Artandi, Steven E.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Venteicher, Andrew S.; Artandi, Steven E.] Stanford Univ, Sch Med, Program Biophys, Stanford, CA 94305 USA; [Artandi, Steven E.] Stanford Univ, Sch Med, Program Canc Biol, Stanford, CA 94305 USA; [Meng, Zhaojing; Veenstra, Timothy D.] NCI, Lab Proteom & Analyt Technol, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21702 USA; [Mason, Philip J.] Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Stanford University; Stanford University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Washington University (WUSTL)	Artandi, SE (corresponding author), Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.	sartandi@stanford.edu	Venteicher, Andrew/AAN-5666-2021; Mason, Philip J/B-1087-2008	Venteicher, Andrew/0000-0003-0643-0493; 	NATIONAL CANCER INSTITUTE [R01CA111691, R01CA106995, R01CA125453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400, N01CO12400, R01 CA125453, R01 CA125453-02, CA125453, R01 CA111691, R01 CA111691-03, R01 CA106995, CA111691] Funding Source: Medline; NIGMS NIH HHS [T32 GM007365, GM07365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allsopp RC, 2003, BLOOD, V102, P517, DOI 10.1182/blood-2002-07-2334; Armanios M, 2005, P NATL ACAD SCI USA, V102, P15960, DOI 10.1073/pnas.0508124102; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; Collins K, 2006, NAT REV MOL CELL BIO, V7, P484, DOI 10.1038/nrm1961; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Fu D, 2006, GENE DEV, V20, P531, DOI 10.1101/gad.1390306; Fu D, 2007, MOL CELL, V28, P773, DOI 10.1016/j.molcel.2007.09.023; Gallant P, 2007, TRENDS CELL BIOL, V17, P187, DOI 10.1016/j.tcb.2007.02.005; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Jady BE, 2006, MOL BIOL CELL, V17, P944, DOI 10.1091/mbc.E05-09-0904; Jonsson ZO, 2004, MOL CELL, V16, P465, DOI 10.1016/j.molcel.2004.09.033; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Marcand S, 2000, CURR BIOL, V10, P487, DOI 10.1016/S0960-9822(00)00450-4; Marrone A, 2005, CURR OPIN GENET DEV, V15, P249, DOI 10.1016/j.gde.2005.04.004; Matias PM, 2006, J BIOL CHEM, V281, P38918, DOI 10.1074/jbc.M605625200; Meier UT, 2005, CHROMOSOMA, V114, P1, DOI 10.1007/s00412-005-0333-9; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Newman DR, 2000, RNA, V6, P861, DOI 10.1017/S1355838200992446; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Prathapam R, 2005, NAT STRUCT MOL BIOL, V12, P252, DOI 10.1038/nsmb900; Rottbauer W, 2002, CELL, V111, P661, DOI 10.1016/S0092-8674(02)01112-1; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Schnapp G, 1998, NUCLEIC ACIDS RES, V26, P3311, DOI 10.1093/nar/26.13.3311; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Tomlinson RL, 2006, MOL BIOL CELL, V17, P955, DOI 10.1091/mbc.E05-09-0903; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy TJ, 2006, BLOOD, V107, P2680, DOI 10.1182/blood-2005-07-2622; Wang F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454; Watkins NJ, 2004, MOL CELL, V16, P789, DOI 10.1016/j.molcel.2004.11.012; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Witkin KL, 2004, GENE DEV, V18, P1107, DOI 10.1101/gad.1201704; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469; Yong JS, 2004, TRENDS CELL BIOL, V14, P226, DOI 10.1016/j.tcb.2004.03.010	45	236	242	0	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 21	2008	132	6					945	957		10.1016/j.cell.2008.01.019	http://dx.doi.org/10.1016/j.cell.2008.01.019			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358808	Green Accepted, Bronze			2022-12-28	WOS:000254273600014
J	Barreiro, A; Rurali, R; Hernandez, ER; Moser, J; Pichler, T; Forro, L; Bachtold, A				Barreiro, Amelia; Rurali, Riccardo; Hernandez, Eduardo R.; Moser, Joel; Pichler, Thomas; Forro, Laszlo; Bachtold, Adrian			Subnanometer motion of cargoes driven by thermal gradients along carbon nanotubes	SCIENCE			English	Article							ELECTRICAL BREAKDOWN; MASS-TRANSPORT; BEARING; MOTORS	An important issue in nanoelectromechanical systems is developing small electrically driven motors. We report on an artificial nanofabricated motor in which one short carbon nanotube moves relative to another coaxial nanotube. A cargo is attached to an ablated outer wall of a multiwalled carbon nanotube that can rotate and/ or translate along the inner nanotube. The motion is actuated by imposing a thermal gradient along the nanotube, which allows for subnanometer displacements, as opposed to an electromigration or random walk effect.	[Hernandez, Eduardo R.] CSIC, Inst Ciencia Mat Barcelona, E-08193 Bellaterra, Spain; [Barreiro, Amelia; Moser, Joel; Bachtold, Adrian] Univ Autonoma Barcelona, Ctr Invest Nanociencia & Nanotecnol, CSIC, Inst Catala Nanotecnol, E-08193 Bellaterra, Spain; [Barreiro, Amelia; Moser, Joel; Bachtold, Adrian] Univ Autonoma Barcelona, Ctr Nacl Microelect, E-08193 Bellaterra, Spain; [Rurali, Riccardo] Univ Autonoma Barcelona, Dept Elect Engn, E-08193 Barcelona, Spain; [Pichler, Thomas] Univ Vienna, Fac Phys, A-01090 Vienna, Austria; [Forro, Laszlo] Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia de Materiales de Barcelona (ICMAB); Autonomous University of Barcelona; Barcelona Institute of Science & Technology; Catalan Institute of Nanoscience & Nanotechnology (ICN2); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion en Nanomateriales y Nanotecnologia (CINN); CSIC-ICN - Centro de Investigacion en Nanociencia y Nanotecnologia (CIN2); Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Microelectronica (CNM); CSIC - Instituto de Microelectronica de Barcelona (IMB-CNM); Autonomous University of Barcelona; University of Vienna; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Hernandez, ER (corresponding author), CSIC, Inst Ciencia Mat Barcelona, Campus UAB, E-08193 Bellaterra, Spain.	ehe@icmab.es; adrian.bachtold@cnm.es	barreiro, amelia/B-8702-2011; Pichler, Thomas/E-4351-2013; Rurali, Riccardo/D-3676-2011; Bachtold, Adrian/C-1389-2014; Hernandez, Eduardo R/B-1285-2008; Moser, Joel/E-3768-2018	Pichler, Thomas/0000-0001-5377-9896; Rurali, Riccardo/0000-0002-4086-4191; Bachtold, Adrian/0000-0002-6145-2479; Hernandez, Eduardo R/0000-0002-1164-2856; Moser, Joel/0000-0003-2149-8568				Astumian RD, 2002, PHYS TODAY, V55, P33, DOI 10.1063/1.1535005; BEGTRUP GE, 2007, PHYS REV LETT, V99; Bourlon B, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.026804; Bourlon B, 2004, NANO LETT, V4, P709, DOI 10.1021/nl035217g; Chen S, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2155116; Collins PC, 2001, SCIENCE, V292, P706, DOI 10.1126/science.1058782; Collins PG, 2001, PHYS REV LETT, V86, P3128, DOI 10.1103/PhysRevLett.86.3128; Deshpande VV, 2006, NANO LETT, V6, P1092, DOI 10.1021/nl052513f; Fennimore AM, 2003, NATURE, V424, P408, DOI 10.1038/nature01823; Golberg D, 2007, ADV MATER, V19, P1937, DOI 10.1002/adma.200700126; Kay ER, 2007, ANGEW CHEM INT EDIT, V46, P72, DOI 10.1002/anie.200504313; Kis A, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.025501; Kolmogorov AN, 2000, PHYS REV LETT, V85, P4727, DOI 10.1103/PhysRevLett.85.4727; Kottas GS, 2005, CHEM REV, V105, P1281, DOI 10.1021/cr0300993; Lozovik YE, 2003, PHYS LETT A, V313, P112, DOI 10.1016/S0375-9601(03)00649-2; Regan BC, 2004, NATURE, V428, P924, DOI 10.1038/nature02496; Roukes M, 2001, PHYS WORLD, V14, P25; Saito R, 2001, CHEM PHYS LETT, V348, P187, DOI 10.1016/S0009-2614(01)01127-7; Schoen PAE, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2748367; Schoen PAE, 2006, NANO LETT, V6, P1910, DOI 10.1021/nl060982r; Servantie J, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.125428; Svensson K, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.145901; Tangney P, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.195901; TERSOFF J, 1988, PHYS REV LETT, V61, P2879, DOI 10.1103/PhysRevLett.61.2879; Tu ZC, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.033404; van den Heuvel MGL, 2007, SCIENCE, V317, P333, DOI 10.1126/science.1139570; Yu MF, 2000, J PHYS CHEM B, V104, P8764, DOI 10.1021/jp002828d	27	296	304	7	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2008	320	5877					775	778		10.1126/science.1155559	http://dx.doi.org/10.1126/science.1155559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VB	18403675				2022-12-28	WOS:000255644400034
J	Seung, KB; Park, DW; Kim, YH; Lee, SW; Lee, CW; Hong, MK; Park, SW; Yun, SC; Gwon, HC; Jeong, MH; Jang, Y; Kim, HS; Kim, PJ; Seong, IW; Park, HS; Ahn, T; Chae, IH; Tahk, SJ; Chung, WS; Park, SJ				Seung, Ki Bae; Park, Duk-Woo; Kim, Young-Hak; Lee, Seung-Whan; Lee, Cheol Whan; Hong, Myeong-Ki; Park, Seong-Wook; Yun, Sung-Cheol; Gwon, Hyeon-Cheol; Jeong, Myung-Ho; Jang, Yangsoo; Kim, Hyo-Soo; Kim, Pum Joon; Seong, In-Whan; Park, Hun Sik; Ahn, Taehoon; Chae, In-Ho; Tahk, Seung-Jea; Chung, Wook-Sung; Park, Seung-Jung			Stents versus coronary-artery bypass grafting for left main coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROPENSITY SCORE METHODS; DRUG-ELUTING STENTS; PERCUTANEOUS TREATMENT; SURGERY; SURVIVAL; IMPLANTATION; STENOSIS; TERM; INTERVENTION; IMMEDIATE	Background: Several studies have compared the treatment effects of coronary stenting and coronary-artery bypass grafting (CABG). However, there are limited data regarding the long-term outcomes of these two interventions for patients with unprotected left main coronary artery disease. Methods: We evaluated 1102 patients with unprotected left main coronary artery disease who underwent stent implantation and 1138 patients who underwent CABG in Korea between January 2000 and June 2006. We compared adverse outcomes (death; a composite outcome of death, Q-wave myocardial infarction, or stroke; and target-vessel revascularization) with the use of propensity-score matching in the overall cohort and in separate subgroups according to type of stent. Results: In the overall matched cohort, there was no significant difference between the stenting and CABG groups in the risk of death (hazard ratio for the stenting group, 1.18; 95% confidence interval [CI], 0.77 to 1.80) or the risk of the composite outcome (hazard ratio for the stenting group, 1.10; 95% CI, 0.75 to 1.62). The rates of target-vessel revascularization were significantly higher in the group that received stents than in the group that underwent CABG (hazard ratio, 4.76; 95% CI, 2.80 to 8.11). Comparisons of the group that received bare-metal stents with the group that underwent CABG and of the group that received drug-eluting stents with the group that underwent CABG produced similar results, although there was a trend toward higher rates of death and the composite end point in the group that received drug-eluting stents. Conclusions: In a cohort of patients with unprotected left main coronary artery disease, we found no significant difference in rates of death or of the composite end point of death, Q-wave myocardial infarction, or stroke between patients receiving stents and those undergoing CABG. However, stenting, even with drug-eluting stents, was associated with higher rates of target-vessel revascularization than was CABG.	[Park, Duk-Woo; Kim, Young-Hak; Lee, Seung-Whan; Lee, Cheol Whan; Hong, Myeong-Ki; Park, Seong-Wook; Park, Seung-Jung] Univ Ulsan, Coll Med, Dept Cardiol, Cardiac Ctr,Asan Med Ctr, Seoul 138736, South Korea; [Seung, Ki Bae; Kim, Pum Joon] Catholic Univ Korea, St Marys Hosp, Gangnam, South Korea; [Chung, Wook-Sung] Yeoido, Seoul, South Korea; [Yun, Sung-Cheol] Univ Ulsan, Coll Med, Asan Med Ctr, Div Biostat, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Ctr Med Res & Informat, Seoul 138736, South Korea; [Gwon, Hyeon-Cheol] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Jeong, Myung-Ho] Chonnam Natl Univ Hosp, Kwangju, South Korea; [Jang, Yangsoo] Yonsei Univ, Severance Hosp, Seoul 120749, South Korea; [Kim, Hyo-Soo] Seoul Natl Univ Hosp, Seoul 110744, South Korea; [Chae, In-Ho] Seoul Natl Univ Hosp, Bundang, South Korea; [Seong, In-Whan] Chungnam Natl Univ Hosp, Taejon, South Korea; [Park, Hun Sik] Kyung Pook Natl Univ Hosp, Taegu, South Korea; [Ahn, Taehoon] Gachon Univ, Gil Med Ctr, Inchon, South Korea; [Tahk, Seung-Jea] Ajou Univ, Med Ctr, Suwon 441749, South Korea	University of Ulsan; Catholic University of Korea; Catholic University Korea Hospital; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Chonnam National University; Chonnam National University Hospital; Yonsei University; Yonsei University Health System; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Chungnam National University; Chungnam National University Hospital; Gachon University; Ajou University	Park, SJ (corresponding author), Univ Ulsan, Coll Med, Dept Cardiol, Cardiac Ctr,Asan Med Ctr, 388-1 Poongnap Dong, Seoul 138736, South Korea.	sjpark@amc.seoul.kr	Jang, Yang Soo/D-4803-2012; Kim, Hyo Soo/J-2753-2012; 안, 태훈/GON-9067-2022	안, 태훈/0000-0003-1544-1784; Jeong, Jin-Ok/0000-0003-0763-4754; Jang, Yangsoo/0000-0002-2169-3112; Seong, In-Whan/0000-0003-4628-0258				Austin PC, 2006, STAT MED, V25, P2084, DOI 10.1002/sim.2328; Black A, 2001, J AM COLL CARDIOL, V37, P832, DOI 10.1016/S0735-1097(00)01176-1; CARACCIOLO EA, 1995, CIRCULATION, V91, P2335, DOI 10.1161/01.CIR.91.9.2335; CHAITMAN BR, 1981, AM J CARDIOL, V48, P765, DOI 10.1016/0002-9149(81)90156-9; Chieffo A, 2005, CIRCULATION, V111, P791, DOI 10.1161/01.CIR.0000155256.88940.F8; Chieffo A, 2006, CIRCULATION, V113, P2542, DOI 10.1161/CIRCULATIONAHA.105.595694; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Dzavik V, 2001, AM HEART J, V142, P119, DOI 10.1067/mhj.2001.116072; EAGLE KA, 2005, CIRCULATION, V111, P2014; Eagle Kim A, 2004, Circulation, V110, pe340; Klein JP., 2003, SURVIVAL ANAL TECHNI; Lee MS, 2006, J AM COLL CARDIOL, V47, P864, DOI 10.1016/j.jacc.2005.09.072; Palmerini T, 2006, AM J CARDIOL, V98, P54, DOI 10.1016/j.amjcard.2006.01.070; Park SJ, 2001, J AM COLL CARDIOL, V38, P1054, DOI 10.1016/S0735-1097(01)01491-7; Park SJ, 1998, J AM COLL CARDIOL, V31, P37, DOI 10.1016/S0735-1097(97)00425-7; Park SJ, 2005, J AM COLL CARDIOL, V45, P351, DOI 10.1016/j.jacc.2004.10.039; Park SJ, 2002, AM J CARDIOL, V90, P374, DOI 10.1016/S0002-9149(02)02492-X; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Sanmartin M, 2007, AM J CARDIOL, V100, P970, DOI 10.1016/j.amjcard.2007.04.037; Silvestri M, 2000, J AM COLL CARDIOL, V35, P1543, DOI 10.1016/S0735-1097(00)00588-X; Smith SC, 2006, CIRCULATION, V113, pE166, DOI 10.1161/CIRCULATIONAHA.106.173220; TAKARO T, 1982, CIRCULATION, V66, P14, DOI 10.1161/01.CIR.66.1.14; Therneau TM, 2000, MODELING SURVIVAL DA; Valgimigli M, 2005, CIRCULATION, V111, P1383, DOI 10.1161/01.CIR.0000158486.20865.8B; YUSUF, 1994, LANCET, V344, P1446; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	26	376	406	1	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	2008	358	17					1781	1792		10.1056/NEJMoa0801441	http://dx.doi.org/10.1056/NEJMoa0801441			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291PL	18378517				2022-12-28	WOS:000255209200004
J	Eldridge, S; Ashby, D; Bennett, C; Wakelin, M; Feder, G				Eldridge, Sandra; Ashby, Deborah; Bennett, Catherine; Wakelin, Melanie; Feder, Gene			Internal and external validity of cluster randomised trials: systematic review of recent trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEALTH INTERVENTIONS; CONSORT STATEMENT; SAMPLE-SIZE; DESIGN; FRAMEWORK; PREVENTION; BIAS	Objectives To assess aspects of the internal validity of recently published cluster randomised trials and explore the reporting of information useful in assessing the external validity of these trials. Design Review of 34 cluster randomised trials in primary care published in 2004 and 2005 in seven journals (British Medical Journal, British Journal of General Practice, Family Practice, Preventive Medicine, Annals of Internal Medicine, Journal of General Internal Medicine, Pediatrics). Data sources National Library of Medicine (Medline) via PubMed. Data extraction To assess aspects of internal validity we extracted data on appropriateness of sample size calculations and analyses, methods of identifying and recruiting individual participants, and blinding. To explore reporting of information useful in assessing external validity we extracted data on cluster eligibility, cluster inclusion and retention, cluster generalisability, and the feasibility and acceptability of the intervention to health providers in clusters. Results 21 (62%) trials accounted for clustering in sample size calculations and 36 (88%) in the analysis; about a quarter were potentially biased because of procedures surrounding recruitment and identification of patients; individual participants were blind to allocation status in 19 (56%) and outcome assessors were blind in 15 (44%). In almost half the reports, information relating to generalisability of clusters was poorly reported, and in two fifths there was no information about the feasibility and acceptability of the intervention. Conclusions Cluster randomised trials are essential for evaluating certain types of interventions. Issues affecting their internal validity, such as appropriate sample size calculations and analysis, have been widely disseminated and are now better addressed by researchers. Blinding of those identifying and recruiting patients to allocation status is recommended but is not always carried out. There may be fewer barriers to internal validity in trials in which individual participants are not recruited. External validity seems poorly addressed in many trials, yet is arguably as important as internal validity in judging quality as a basis for healthcare intervention.	[Eldridge, Sandra; Bennett, Catherine; Wakelin, Melanie; Feder, Gene] Barts & London Queen Marys Sch Med & Dent, Ctr Hlth Sci, London E1 2AT, England; [Ashby, Deborah] Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Eldridge, S (corresponding author), Barts & London Queen Marys Sch Med & Dent, Ctr Hlth Sci, London E1 2AT, England.	s.eldridge@qmul.ac.uk		Feder, Gene/0000-0002-7890-3926				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Bland J Martin, 2004, BMC Med Res Methodol, V4, P21, DOI 10.1186/1471-2288-4-21; Bonell C, 2006, BMJ-BRIT MED J, V333, P346, DOI 10.1136/bmj.333.7563.346; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Campbell MK, 1998, BMJ-BRIT MED J, V317, P1171, DOI 10.1136/bmj.317.7167.1171; Chuang JH, 2000, J AM MED INFORM ASSN, P146; Davidson KW, 2003, ANN BEHAV MED, V26, P161, DOI 10.1207/S15324796ABM2603_01; Delgado-Rodriguez M, 2004, J EPIDEMIOL COMMUN H, V58, P635, DOI 10.1136/jech.2003.008466; Donaldson M, 1994, DEFINING PRIMARY CAR; Donner A, 1996, J CLIN EPIDEMIOL, V49, P435, DOI 10.1016/0895-4356(95)00511-0; DONNER A, 1990, INT J EPIDEMIOL, V19, P795, DOI 10.1093/ije/19.4.795; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Dzewaltowski DA, 2004, HEALTH PROMOT INT, V19, P235, DOI 10.1093/heapro/dah211; Eldridge Sandra M, 2004, Clin Trials, V1, P80, DOI 10.1191/1740774504cn006rr; Eldridge SM, 2005, CLIN TRIALS, V2, P91, DOI 10.1191/1740774505cn070oa; Farrin A, 2005, CLIN TRIALS, V2, P119, DOI 10.1191/1740774505cn073oa; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Glasgow RE, 2001, PATIENT EDUC COUNS, V44, P119, DOI 10.1016/S0738-3991(00)00186-5; Godwin Marshall, 2003, BMC Med Res Methodol, V3, P28, DOI 10.1186/1471-2288-3-28; Hayes RJ, 2000, STAT METHODS MED RES, V9, P95, DOI 10.1191/096228000670953670; Isaakidis P, 2003, AM J EPIDEMIOL, V158, P921, DOI 10.1093/aje/kwg232; Kerry SM, 1998, BRIT MED J, V316, P549, DOI 10.1136/bmj.316.7130.549; Kerry SM, 1998, FAM PRACT, V15, P80, DOI 10.1093/fampra/15.1.80; Kerry SM, 1998, FAM PRACT, V15, P84, DOI 10.1093/fampra/15.1.84; Kjaergard LL, 2002, AM J GASTROENTEROL, V97, P2708; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Mant D., 1997, NATL WORKING GROUP R; Murray DM, 1998, DESIGN ANAL GROUP RA; Nation M, 2003, AM PSYCHOL, V58, P449, DOI 10.1037/0003-066X.58.6-7.449; Oakley A, 2006, BRIT MED J, V332, P413, DOI 10.1136/bmj.332.7538.413; Puffer S, 2003, BMJ-BRIT MED J, V327, P785, DOI 10.1136/bmj.327.7418.785; Rabin BA, 2006, AM J PREV MED, V31, pS24, DOI 10.1016/j.amepre.2006.06.009; Rothwell PM, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010009; Schulz KF, 2002, JAMA-J AM MED ASSOC, V288, P2406, DOI 10.1001/jama.288.19.2406; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 2002, LANCET, V359, P696, DOI 10.1016/S0140-6736(02)07816-9; SIMPSON JM, 1995, AM J PUBLIC HEALTH, V85, P1378, DOI 10.2105/AJPH.85.10.1378; Smith PJ, 1997, J CLIN EPIDEMIOL, V50, P137, DOI 10.1016/S0895-4356(96)00338-1; Ukoumunne OC, 1999, HLTH TECHNOLOGY ASSE, V3, piii, DOI [DOI 10.3310/HTA3050, DOI 10.3310/hta3050]; Varnell SP, 2004, AM J PUBLIC HEALTH, V94, P393, DOI 10.2105/AJPH.94.3.393	41	141	144	2	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2008	336	7649					876	880		10.1136/bmj.39517.495764.25	http://dx.doi.org/10.1136/bmj.39517.495764.25			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290QH	18364360	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000255136800034
J	Markowitz, AJ; Rabow, MW				Markowitz, Amy J.; Rabow, Michael W.			Management of intractable nausea and vomiting in patients at the end of life - "I was feeling nauseous all of the time ... nothing was working"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Wood GJ, 2007, JAMA-J AM MED ASSOC, V298, P1196, DOI 10.1001/jama.298.10.1196	1	2	2	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1826	1826		10.1001/jama.299.15.1826	http://dx.doi.org/10.1001/jama.299.15.1826			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18413877				2022-12-28	WOS:000254954800027
J	Turner, BJ; Hollenbeak, CS; Weiner, M; Ten Have, T; Tang, SSK				Turner, Barbara J.; Hollenbeak, Christopher S.; Weiner, Mark; Ten Have, Thomas; Tang, Simon S. K.			Effect of unrelated comorbid conditions on hypertension management	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-CARE; MULTIMORBIDITY; ADHERENCE; INERTIA	Background: Quality-of-care assessment at a single visit can be affected by whether a patient's comorbid conditions are related or unrelated to a specific measure. Objective: To examine the association of unrelated comorbid conditions with treatment of uncontrolled hypertension in primary care visits. Design: Examination of a database derived from electronic medical records collected during routine care of a cohort of primary care patients. Setting: 6 primary care practices in Philadelphia, Pennsylvania. Patients: 15459 patients with uncontrolled hypertension who made 70557 visits to 200 clinicians from January 2004 through December 2006. Measurements: Intensification of any anti hypertensive treatment before the next visit was assessed. Patient and clinician information were obtained from electronic medical records and administrative data. Unrelated comorbid conditions included 28 conditions, such as arthritis and emphysema, whereas related comorbid conditions included vascular diseases. Generalized estimating equation logistic regression models were used to adjust for patient, health care, and provider characteristics and for clustering. Variation in the effect of unrelated comorbid conditions was examined at the visit, patient, and provider level. Results: At study visits, patients had a mean of 2.2 (SD, 1.8) unrelated comorbid conditions. The adjusted odds of treatment intensification decreased with the number of unrelated comorbid conditions, from 0.85 (95% CI, 0.80 to 0.90) for 1 to 0.59 (CI, 0.51 to 0.69) for 7 or more versus none. The relationship between treatment intensification and unrelated comorbid conditions persisted at the visit, patient, and provider levels (P < 0.001). Limitations: The reasons for not intensifying treatments are unknown. The recorded blood pressure may be inaccurate. Physicians may vary in their recording of comorbid conditions. Conclusion: Patients with more unrelated comorbid conditions were less likely to have uncontrolled hypertension addressed at a visit. The effect of different types of comorbid conditions on meeting quality-of-care measures merits further investigation.	[Turner, Barbara J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Pfizer, New York, NY USA; Penn State Coll Med, Hershey, PA USA	University of Pennsylvania; Pfizer; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Turner, BJ (corresponding author), Univ Penn, Sch Med, 1123 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	bturner@mail.med.upenn.edu	Hollenbeak, Christopher S./A-5309-2019	Hollenbeak, Christopher S./0000-0002-3362-814X; Ten Have, Thomas/0000-0003-0026-3073				Baldwin LM, 2006, MED CARE, V44, P745, DOI 10.1097/01.mlr.0000223475.70440.07; Berlowitz DR, 1998, MED CARE, V36, P928, DOI 10.1097/00005650-199806000-00015; Bokhour BG, 2006, J GEN INTERN MED, V21, P577, DOI 10.1111/j.1525-1497.2006.00397.x; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; *CTR MED MED SERV, PFS FED REG NOT; Durso SC, 2006, JAMA-J AM MED ASSOC, V295, P1935, DOI 10.1001/jama.295.16.1935; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Grant RW, 2004, DIABETIC MED, V21, P150, DOI 10.1111/j.1464-5491.2004.01095.x; Hayward RA, 2007, AM J MANAG CARE, V13, P126; Higashi T, 2007, NEW ENGL J MED, V356, P2496, DOI 10.1056/NEJMsa066253; Ho PM, 2006, ARCH INTERN MED, V166, P1836, DOI 10.1001/archinte.166.17.1836; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; Kaboli PJ, 2004, AM J MANAG CARE, V10, P872; Kerr EA, 2001, AM J MANAG CARE, V7, P1033; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Min LC, 2007, MED CARE, V45, P480, DOI 10.1097/MLR.0b013e318030fff9; Okonofua EC, 2006, HYPERTENSION, V47, P345, DOI 10.1161/01.HYP.0000200702.76436.4b; Oliveria SA, 2002, ARCH INTERN MED, V162, P413, DOI 10.1001/archinte.162.4.413; Piette JD, 2006, DIABETES CARE, V29, P725, DOI 10.2337/diacare.29.03.06.dc05-2078; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Ritchie C, 2007, MED CARE, V45, P477, DOI 10.1097/MLR.0b013e318074d3c1; Rodondi N, 2006, ANN INTERN MED, V144, P475, DOI 10.7326/0003-4819-144-7-200604040-00006; Turner BJ, 2004, ANN INTERN MED, V140, P528, DOI 10.7326/0003-4819-140-7-200404060-00013; Vasan RS, 2005, ANN INTERN MED, V142, P393, DOI 10.7326/0003-4819-142-6-200503150-00005; Wang PS, 2005, HYPERTENSION, V46, P273, DOI 10.1161/01.HYP.0000172753.96583.e1; Werner RM, 2007, J GEN INTERN MED, V22, P1206, DOI 10.1007/s11606-007-0230-4; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635; Yelin E., 2007, Morbidity and Mortality Weekly Report, V56, P4	29	98	98	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2008	148	8					578	586		10.7326/0003-4819-148-8-200804150-00002	http://dx.doi.org/10.7326/0003-4819-148-8-200804150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290LF	18413619				2022-12-28	WOS:000255123600002
J	Chokshi, DA; Kesselheim, AS				Chokshi, Dave A.; Kesselheim, Aaron S.			Rethinking global access to vaccines	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DEVELOPING-COUNTRIES; HUMAN-PAPILLOMAVIRUS; PUBLIC-HEALTH; ROTAVIRUS; EFFICACY; OPPORTUNITIES; IMMUNIZATION; TECHNOLOGY; CHALLENGES; SAFETY		[Chokshi, Dave A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Kesselheim, Aaron S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA USA	University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Chokshi, DA (corresponding author), Univ Penn, Sch Med, 3434 Sansom St, Philadelphia, PA 19104 USA.	daveash@med.upenn.edu	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666; Chokshi, Dave/0000-0001-7467-4591				AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761; Agosti JM, 2007, NEW ENGL J MED, V356, P1908, DOI 10.1056/NEJMp078053; Alliance for Health Policy and Systems Research, 2004, STRENGTH HLTH SYST D; Basu S, 2006, NATURE, V440, P605, DOI 10.1038/440605d; Behforouz HL, 2004, CLIN INFECT DIS, V38, pS429, DOI 10.1086/421408; Birn AE, 2005, LANCET, V366, P514, DOI 10.1016/S0140-6736(05)66479-3; BLOOM DE, 2005, WORLD ECON, V6, P25; BROOKE S, 2006, HPV VACCINES REGULAT; Buekens P, 2004, JAMA-J AM MED ASSOC, V291, P2639, DOI 10.1001/jama.291.21.2639; Chokshi DA, 2007, JAMA-J AM MED ASSOC, V298, P1934, DOI 10.1001/jama.298.16.1934; Clemens J, 2005, NAT MED, V11, pS12, DOI 10.1038/nm1225; Cohen J, 2001, SCIENCE, V293, P1576, DOI 10.1126/science.293.5535.1576; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; *GAVI, 2005, GLOB VACC SUPPL CHAN; *GAVI ALL, 2007, ACC DEV INTR PRIOR N; *HIB IN, 2007, SER I IND OBT 1 EV I; Kim S-Y, 2007, B WORLD HEALTH ORGAN, V85, P821; KNOBLER S, 2002, CONSIDERATIONS VIRAL, P33; Madon T, 2007, SCIENCE, V318, P1728, DOI 10.1126/science.1150009; Mahmoud A, 2004, SCIENCE, V305, P147, DOI 10.1126/science.305.5681.147; *MED SANS FRONT, GIL TEN ACC PROGR DE; *MEN VACC PROJ, 2007, IMPR MEN VACC AFR CO; Milstlen JB, 2006, HEALTH AFFAIR, V25, P1061, DOI 10.1377/hlthaff.25.4.1061; Morel CM, 2005, SCIENCE, V309, P401, DOI 10.1126/science.1115538; Outterson K, 2008, HEALTH AFFAIR, V27, P130, DOI 10.1377/hlthaff.27.1.130; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562; Parashar UD, 2006, EMERG INFECT DIS, V12, P304; *PATH, 2006, CERV CANC VACC PROJ; Peny JM, 2005, VACCINE, V23, P4610, DOI 10.1016/j.vaccine.2005.04.044; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; Salicrup LA, 2006, BIOTECHNOL ADV, V24, P69, DOI 10.1016/j.biotechadv.2005.06.004; Sanders D, 2006, PLOS MED, V3, P719, DOI 10.1371/journal.pmed.0030186; SEKHRI, 2006, FORECASTING GLOBAL H; SEN AK, 2003, VACCINE S2, V21, pS114; Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; World Health Organization, 2005, WORLD HLTH REP 2005; World Health Organization, 2004, REV GLOB BURD DIS 20; 2007, WHO WEEKLY EPIDEMIOL, V82, P285; 2007, ROTAVIRUS VACCINE PR	41	18	19	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2008	336	7647					750	753		10.1136/bmj.39497.598044.BE	http://dx.doi.org/10.1136/bmj.39497.598044.BE			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284JW	18390526	Green Published			2022-12-28	WOS:000254703700030
J	Costello, A; Grant, M; Horton, R				Costello, Anthony; Grant, Malcolm; Horton, Richard			The Lancet-UCL Commission: health effects of climate change	LANCET			English	Editorial Material							ENERGY		[Costello, Anthony; Grant, Malcolm] UCL, London, England; [Horton, Richard] Lancet, London NW1 7BY, England	University of London; University College London	Costello, A (corresponding author), UCL, London, England.	a.costello@ich.ucl.ac.uk						Corbyn Zoe, 2008, TIMES HIGHER ED 0124, P9; Haines A, 2006, LANCET, V367, P2101, DOI 10.1016/S0140-6736(06)68933-2; Horton R, 2007, LANCET, V370, P921, DOI 10.1016/S0140-6736(07)61258-6; McMichael AJ, 2006, LANCET, V367, P859, DOI 10.1016/S0140-6736(06)68079-3; Stern N. H., 2006, STERN REV EC CLIMATE; Wilkinson P, 2007, LANCET, V370, P965, DOI 10.1016/S0140-6736(07)61252-5	6	10	11	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 5	2008	371	9619					1145	1147		10.1016/S0140-6736(08)60502-4	http://dx.doi.org/10.1016/S0140-6736(08)60502-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395563				2022-12-28	WOS:000254956000008
J	Grimwood, K; Kirkwood, CD				Grimwood, Keith; Kirkwood, Carl D.			Human rotavirus vaccines: too early for the strain to tell	LANCET			English	Editorial Material							1ST 2 YEARS; DOUBLE-BLIND; EFFICACY; INFANTS; SAFETY; GASTROENTERITIS; LIFE		[Grimwood, Keith] Royal Childrens Hosp, Queensland Paediat Infect Dis Lab, Discipline Paediat & Child Hlth, Brisbane, Qld 4029, Australia; [Grimwood, Keith] Univ Queensland, Brisbane, Qld 4029, Australia; [Kirkwood, Carl D.] Univ Melbourne, Royal Childrens Hosp, Enter Virus Grp, Murdoch Childrens Res Inst,Dept Paediat, Melbourne, Vic, Australia	Royal Children's Hospital Brisbane; University of Queensland; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Grimwood, K (corresponding author), Royal Childrens Hosp, Queensland Paediat Infect Dis Lab, Discipline Paediat & Child Hlth, Brisbane, Qld 4029, Australia.	Keith_Grimwood@health.qld.gov.au	Grimwood, Keith/F-9334-2011	Grimwood, Keith/0000-0003-3174-9834				Bresee JS, 2005, J INFECT DIS, V192, pS1, DOI 10.1086/431515; Castello Alejandro A, 2004, Pediatr Infect Dis J, V23, pS168, DOI 10.1097/01.inf.0000142466.57262.2a; Glass RI, 2005, J INFECT DIS, V192, pS160, DOI 10.1086/431504; Gurgel RQ, 2007, EMERG INFECT DIS, V13, P1571, DOI 10.3201/eid1310.070412; Linhares AC, 2008, LANCET, V371, P1181, DOI 10.1016/S0140-6736(08)60524-3; Nakagomi T, 2008, ARCH VIROL, V153, P591, DOI 10.1007/s00705-007-0028-z; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; Santos N, 2005, REV MED VIROL, V15, P29, DOI 10.1002/rmv.448; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; Vesikari T, 2007, LANCET, V370, P1757, DOI 10.1016/S0140-6736(07)61744-9; Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664; World Health Organization, 2007, Wkly Epidemiol Rec, V82, P285	12	33	34	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2008	371	9619					1144	1145		10.1016/S0140-6736(08)60501-2	http://dx.doi.org/10.1016/S0140-6736(08)60501-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395562				2022-12-28	WOS:000254956000007
J	Murray, CJL; Frenk, J				Murray, Christopher J. L.; Frenk, Julio			Health metrics and evaluation: strengthening the science	LANCET			English	Article							PUBLIC-HEALTH; TUBERCULOSIS-CONTROL; INTERVENTIONS; ORGANIZATION; STATISTICS; DISABILITY; FRAMEWORK; EDUCATION; COVERAGE; LESSONS	With the growing importance of health in the global agenda comes the responsibility to develop a scientific foundation of metrics and evaluation. The scope of this emerging field can be viewed in terms of key topics, including health outcomes, other social outcomes related to health systems, health services, resource inputs, evaluations of programmes and systems, and analyses to support policy choice. It can also be defined in terms of key activities that are needed to strengthen the scientific basis of the field: development of new methods, instruments, software, and hardware; setting global norms and standards for data collection; increasing the availability of high-quality primary data; systematic analysis and synthesis of existing datasets; strengthening national capacity to obtain, analyse, and use data; and reporting and disseminating results. We explore in depth topics with major scientific challenges and institutional and cultural barriers that are slowing the development of the field. Cutting across the various topical areas and disciplinary approaches to these problems are some common scientific issues, including limited comparability of measurement, uncorrected known biases in data, no standard approach to missing data, unrealistic uncertainty estimates, and the use of disease models that have not been properly validated. Only through concerted action will it be possible to assure the production, reproduction, and use of knowledge that is crucial to the advancement of global health.	[Murray, Christopher J. L.; Frenk, Julio] Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA; [Murray, Christopher J. L.] Univ Washington, Sch Med, Seattle, WA 98195 USA; [Frenk, Julio] Bill & Melinda Gates Fdn, Global Hlth Programme, Seattle, WA USA; [Frenk, Julio] Carso Hlth Inst, Mexico City, DF, Mexico	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; Bill & Melinda Gates Foundation	Murray, CJL (corresponding author), Inst Hlth Metr & Evaluat, Box 358210,2301 5th Ave Suite 600, Seattle, WA 98121 USA.	cjlm@u.washington.edu						Adam T, 2005, BMJ-BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107; [Anonymous], 1987, CANCER RES, V47, P5782; Boerma JT, 2007, LANCET, V369, P779, DOI 10.1016/S0140-6736(07)60364-X; Bradshaw D, 2003, INITIAL BURDEN DIS E; BROOKMEYER R, 1989, STAT MED, V8, P23, DOI 10.1002/sim.4780080105; Buckovich SA, 1999, J AM MED INFORM ASSN, V6, P122, DOI 10.1136/jamia.1999.0060122; Buekens P, 2004, JAMA-J AM MED ASSOC, V291, P2639, DOI 10.1001/jama.291.21.2639; CARPENTER SR, 1989, ECOLOGY, V70, P1142, DOI 10.2307/1941382; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; CHIN J, 1991, B WORLD HEALTH ORGAN, V69, P399; Collins FS, 2003, SCIENCE, V300, P286, DOI 10.1126/science.1084564; Diallo Khassoum, 2003, Hum Resour Health, V1, P3, DOI 10.1186/1478-4491-1-3; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EISNER R, 1988, J ECON LIT, V26, P1611; Evans DB, 2001, BRIT MED J, V323, P307, DOI 10.1136/bmj.323.7308.307; Ezzati M, 2006, J ROY SOC MED, V99, P250, DOI 10.1258/jrsm.99.5.250; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; FRENK J, 1992, SOC SCI MED, V35, P1397, DOI 10.1016/0277-9536(92)90043-P; FRENK J, 1993, ANNU REV PUBL HEALTH, V14, P469, DOI 10.1146/annurev.pu.14.050193.002345; Friedrichsen G.W.S., 1966, OXFORD DICT ENGLISH; Gakidou E, 2006, LANCET, V368, P1920, DOI 10.1016/S0140-6736(06)69568-8; Greene W, 2004, HEALTH ECON, V13, P959, DOI 10.1002/hec.938; Gupta Neeru, 2003, Int J Equity Health, V2, P11, DOI 10.1186/1475-9276-2-11; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Hays RD, 2000, MED CARE, V38, P28; HOLLAND PW, 1986, J AM STAT ASSOC, V81, P945, DOI 10.2307/2289064; Holland PW., 1993, DIFFERENTIAL ITEM FU, DOI DOI 10.4324/9780203357811; IMBENS GW, 2005, RECENT DEV ECONOMETR; Jacobs R, 2006, MEASURING EFFICIENCY; Jamison DT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1; Kapteyn A, 2007, AM ECON REV, V97, P461, DOI 10.1257/aer.97.1.461; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; Kawabata K, 2000, B WORLD HEALTH ORGAN, V78, P716; Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0; King G, 2004, AM POLIT SCI REV, V98, P191, DOI 10.1017/S000305540400108X; King G, 2001, AM POLIT SCI REV, V95, P49, DOI 10.1017/S0003055401000235; King G, 2000, AM J POLIT SCI, V44, P347, DOI 10.2307/2669316; King G, 2007, INT STUD QUART, V51, P183, DOI 10.1111/j.1468-2478.2007.00445.x; Kirkwood B, 2004, BRIT MED J, V328, P966, DOI 10.1136/bmj.328.7446.966; Kohatsu ND, 2004, AM J PREV MED, V27, P417, DOI 10.1016/j.amepre.2004.07.019; Laxminarayan R, 2006, LANCET, V367, P1193, DOI 10.1016/S0140-6736(06)68440-7; Lozano R, 2006, LANCET, V368, P1729, DOI 10.1016/S0140-6736(06)69566-4; *MACR INT, MEAS DEM HLTH SURV; Madon T, 2007, SCIENCE, V318, P1728, DOI 10.1126/science.1150009; Mathers CD, 2001, B WORLD HEALTH ORGAN, V79, P1076; McCabe C, 2000, PHARMACOECONOMICS, V17, P501, DOI 10.2165/00019053-200017050-00007; Mcdowell I., 2006, MEASURING HLTH GUIDE, V3, P37, DOI [DOI 10.1093/ACPROF:OSO/9780195165678.001.0001, 10.1093/acprof:oso/9780195165678.001.0001]; Miguel E, 2004, ECONOMETRICA, V72, P159, DOI 10.1111/j.1468-0262.2004.00481.x; Morris SS, 2004, LANCET, V364, P2030, DOI 10.1016/S0140-6736(04)17515-6; Mullan F, 2005, NEW ENGL J MED, V353, P1810, DOI 10.1056/NEJMsa050004; Murray, 2002, SUMMARY MEASURES POP, P205; Murray C, 2007, LANCET, V369, P1768, DOI 10.1016/S0140-6736(07)60792-2; Murray CJL, 2007, LANCET, V370, P1040, DOI 10.1016/S0140-6736(07)61478-0; Murray CJL, 2007, LANCET, V369, P862, DOI 10.1016/S0140-6736(07)60415-2; Murray CJ, 2003, HLTH SYSTEMS PERFORM, P705; Murray CJL, 2000, B WORLD HEALTH ORGAN, V78, P717; Murray CJL, 1998, INT J TUBERC LUNG D, V2, pS9; Murray CJL, 1997, LANCET, V349, P1347, DOI 10.1016/S0140-6736(96)07494-6; *ORG EC COOP DEV, 2002, MEAS IMPR HLTH SYST; Organisation for Economic Co-operation and Development, HLTH CAR QUAL IND PR; Organization for Economic Cooperation and Development, 2000, SYST HLTH ACC; Pond B, 2006, LANCET, V367, P1448, DOI 10.1016/S0140-6736(06)68346-3; Popper K., 1959, LOGIC SCI DISCOVERY; Powe NR, 1995, CONTROL CLIN TRIALS, V16, P377, DOI 10.1016/S0197-2456(95)00075-5; RAVISHANKAR N, 2008, PHIT PARTNERSHIP IMP; Rivera JA, 2004, JAMA-J AM MED ASSOC, V291, P2563, DOI 10.1001/jama.291.21.2563; Rychetnik L, 2004, J EPIDEMIOL COMMUN H, V58, P538, DOI 10.1136/jech.2003.011585; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Salomon J.A., 2003, HLTH SYSTEMS PERFORM, P301; Salomon JA, 2004, BMJ-BRIT MED J, V328, P258, DOI 10.1136/bmj.37963.691632.44; Salomon JA, 2002, AM J EPIDEMIOL, V156, P761, DOI 10.1093/aje/kwf100; Salomon JA, 2001, B WORLD HEALTH ORGAN, V79, P596; Savedoff W., 2003, HLTH SYSTEMS PERFORM; Sgaier SK, 2007, SCIENCE, V318, P1074, DOI 10.1126/science.1149157; Shaw C, 2001, BRIT MED J, V322, P851, DOI 10.1136/bmj.322.7290.851; Sheldon TA, 1996, HEALTH ECON, V5, P1; Shengelia B, 2005, SOC SCI MED, V61, P97, DOI 10.1016/j.socscimed.2004.11.055; Stephan PE, 1996, J ECON LIT, V34, P1199; SZRETER S, 1991, SOC HIST MED, V4, P435, DOI 10.1093/shm/4.3.435; United Nations, 1983, MAN X IND TECHN DEM; Victora CG, 2004, AM J PUBLIC HEALTH, V94, P400, DOI 10.2105/AJPH.94.3.400; Vujicic M, 2006, INT J HEALTH PLAN M, V21, P101, DOI 10.1002/hpm.834; *WHO, HLTH METR NETW; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization, 2019, INT STAT CLASS DIS R, V11th Edn; World Health Organization, CHOOSING INT AR COST; World Health Organization (WHO), 2002, REV GLOB BURD DIS GB; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; World Health Organization (WHO), 2006, WORLD HLTH REP 2006	90	70	72	1	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2008	371	9619					1191	1199		10.1016/S0140-6736(08)60526-7	http://dx.doi.org/10.1016/S0140-6736(08)60526-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	287ZM	18395581				2022-12-28	WOS:000254956000029
J	Dabby, DS				Dabby, Diana S.			Music theory - Creating musical variation	SCIENCE			English	Editorial Material									[Dabby, Diana S.] Franklin W Olin Coll Engn, Needham, MA 02492 USA	Franklin W. Olin College of Engineering	Dabby, DS (corresponding author), Franklin W Olin Coll Engn, Needham, MA 02492 USA.	diana.dabby@olin.edu						Anderson Emily, 1985, LETT MOZART HIS FAMI; Cage John, 1963, VARIATIONS; DABBY DS, 1996, CHAOS, V6, P2; HAWKINS S., 2003, ANAL POPULAR MUSIC, P80, DOI DOI 10.1017/CBO9780511482014; HENRI P, 1963, VARIATIONS DOOR SIGH; PHILLIPS PS, 1984, MUSIC ANAL, V3, P69, DOI 10.2307/854038; REED N, 1983, THESIS EASTMAN SCH M; RIEPEL JOSEPH, 1752, ANFANGSGRUNDE MUSICA; Schoenberg Arnold., 1967, FUNDAMENTALMUSICAL; Sisman Elaine., 1993, HAYDN CLASSICAL TRAD; Stravinsky, 1966, THEMES EPISODES	11	1	1	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2008	320	5872					62	63		10.1126/science.1153825	http://dx.doi.org/10.1126/science.1153825			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	283JR	18388283				2022-12-28	WOS:000254633000028
J	Pasquale, EB				Pasquale, Elena B.			Eph-ephrin bidirectional signaling in physiology and disease	CELL			English	Review							RECEPTOR TYROSINE KINASE; COLORECTAL-CANCER PROGRESSION; STEM-CELL NICHE; AXON GUIDANCE; HIPPOCAMPAL NEUROGENESIS; SYNAPSE FORMATION; MELANOMA-CELLS; GROWTH-FACTOR; NIPAH VIRUS; EXPRESSION	Receptor tyrosine kinases of the Eph family bind to cell surface-associated ephrin ligands on neighboring cells. The ensuing bidirectional signals have emerged as a major form of contact-dependent communication between cells. New findings reveal that Eph receptors and ephrins coordinate not only developmental processes but also the normal physiology and homeostasis of many adult organs. Imbalance of Eph/ephrin function may therefore contribute to a variety of diseases. The challenge now is to better understand the complex and seemingly paradoxical signaling mechanisms of Eph receptors and ephrins, which will enable effective strategies to target these proteins in the treatment of diseases such as diabetes and cancer.	Burnham Inst Med Res, La Jolla, CA 92037 USA; [Pasquale, Elena B.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Pasquale, EB (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	elenap@burnham.org						Aasheim HC, 2000, BLOOD, V95, P221, DOI 10.1182/blood.V95.1.221.001k01_221_230; Alfaro D, 2007, EUR J IMMUNOL, V37, P2596, DOI 10.1002/eji.200737097; Alford SC, 2007, EXP CELL RES, V313, P4170, DOI 10.1016/j.yexcr.2007.07.019; Aoto J, 2007, J NEUROSCI, V27, P7508, DOI 10.1523/JNEUROSCI.0705-07.2007; Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408; Bahi A, 2005, MOL CELL NEUROSCI, V28, P275, DOI 10.1016/j.mcn.2004.09.011; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Beg AA, 2007, NEURON, V55, P768, DOI 10.1016/j.neuron.2007.07.036; Bonaparte MI, 2005, P NATL ACAD SCI USA, V102, P10652, DOI 10.1073/pnas.0504887102; Bourgin C, 2007, J CELL BIOL, V178, P1295, DOI 10.1083/jcb.200610139; Bouzioukh F, 2007, J NEUROSCI, V27, P11279, DOI 10.1523/JNEUROSCI.3393-07.2007; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Campbell TN, 2006, BIOCHEM BIOPH RES CO, V350, P623, DOI 10.1016/j.bbrc.2006.09.085; Chen J, 2006, EXP EYE RES, V82, P664, DOI 10.1016/j.exer.2005.09.004; Chumley MJ, 2007, J NEUROSCI, V27, P13481, DOI 10.1523/JNEUROSCI.4158-07.2007; Clevers H, 2006, CANCER RES, V66, P2, DOI 10.1158/0008-5472.CAN-05-3849; Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11; Dalva MB, 2007, NAT REV NEUROSCI, V8, P206, DOI 10.1038/nrn2075; Davy A, 2006, PLOS BIOL, V4, P1763, DOI 10.1371/journal.pbio.0040315; Dravis C, 2007, HEARING RES, V223, P93, DOI 10.1016/j.heares.2006.10.007; Du J, 2007, CURR PHARM DESIGN, V13, P2507; Easty DJ, 2000, MELANOMA RES, V10, P401, DOI 10.1097/00008390-200010000-00001; Egea J, 2007, TRENDS CELL BIOL, V17, P230, DOI 10.1016/j.tcb.2007.03.004; Fabes J, 2007, EUR J NEUROSCI, V26, P2496, DOI 10.1111/j.1460-9568.2007.05859.x; Fang BW, 2008, J CELL SCI, V121, P358, DOI 10.1242/jcs.017145; Fawcett JP, 2007, P NATL ACAD SCI USA, V104, P20973, DOI 10.1073/pnas.0710316105; Foubert P, 2007, J CLIN INVEST, V117, P1527, DOI 10.1172/JCI28338; Freywald A, 2006, J IMMUNOL, V176, P4066, DOI 10.4049/jimmunol.176.7.4066; Fu WY, 2007, NAT NEUROSCI, V10, P67, DOI 10.1038/nn1811; Guo H, 2006, CANCER RES, V66, P7050, DOI 10.1158/0008-5472.CAN-06-0004; Hafner C, 2003, INT J ONCOL, V23, P1553; Hafner C, 2005, WORLD J GASTROENTERO, V11, P4024, DOI 10.3748/wjg.v11.i26.4024; Hashimoto T, 2007, KIDNEY INT, V72, P954, DOI 10.1038/sj.ki.5002454; Heroult M, 2006, EXP CELL RES, V312, P642, DOI 10.1016/j.yexcr.2005.10.028; Hess AR, 2007, DEV DYNAM, V236, P3283, DOI 10.1002/dvdy.21190; Himanen JP, 2007, CURR OPIN CELL BIOL, V19, P534, DOI 10.1016/j.ceb.2007.08.004; Hjorthaug HS, 2007, EUR J IMMUNOL, V37, P2326, DOI 10.1002/eji.200737111; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Hu M, 2004, MOL CANCER RES, V2, P533; Ireton RC, 2005, CURR CANCER DRUG TAR, V5, P149, DOI 10.2174/1568009053765780; Ivanov AI, 2006, IUBMB LIFE, V58, P389, DOI 10.1080/15216540600756004; Iwasato T, 2007, CELL, V130, P742, DOI 10.1016/j.cell.2007.07.022; Kaidi A, 2007, GUT, V56, P1637, DOI 10.1136/gut.2007.131540; Kayser MS, 2006, J NEUROSCI, V26, P12152, DOI 10.1523/JNEUROSCI.3072-06.2006; Kida YS, 2007, P NATL ACAD SCI USA, V104, P6708, DOI 10.1073/pnas.0608946104; Konstantinova I, 2007, CELL, V129, P359, DOI 10.1016/j.cell.2007.02.044; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Larsen AB, 2007, MOL CANCER RES, V5, P283, DOI 10.1158/1541-7786.MCR-06-0321; Lee HS, 2006, NAT CELL BIOL, V8, P55, DOI 10.1038/ncb1344; Lim BK, 2008, NAT NEUROSCI, V11, P160, DOI 10.1038/nn2033; Litterst C, 2007, J BIOL CHEM, V282, P16155, DOI 10.1074/jbc.M611449200; Liu X, 2006, J NEUROSCI, V26, P3087, DOI 10.1523/JNEUROSCI.4797-05.2006; Luo LQ, 2007, NEURON, V56, P284, DOI 10.1016/j.neuron.2007.10.014; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Menges CW, 2008, ONCOGENE, V27, P2934, DOI 10.1038/sj.onc.1210957; Meyer S, 2005, INT J ONCOL, V27, P1197; Munoz JJ, 2006, J IMMUNOL, V177, P804, DOI 10.4049/jimmunol.177.2.804; Nakanishi H, 2007, P NATL ACAD SCI USA, V104, P14442, DOI 10.1073/pnas.0703211104; Negrete OA, 2005, NATURE, V436, P401, DOI 10.1038/nature03838; Negrete Oscar A, 2006, PLoS Pathog, V2, pe7; Noren NK, 2007, CANCER RES, V67, P3994, DOI 10.1158/0008-5472.CAN-07-0525; Noren NK, 2004, CELL SIGNAL, V16, P655, DOI 10.1016/j.cellsig.2003.10.006; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Picco V, 2007, DEVELOPMENT, V134, P1491, DOI 10.1242/dev.003939; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Richter M, 2007, J NEUROSCI, V27, P14205, DOI 10.1523/JNEUROSCI.2746-07.2007; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Schmitt AM, 2006, NATURE, V439, P31, DOI 10.1038/nature04334; Segura I, 2007, NAT NEUROSCI, V10, P301, DOI 10.1038/nn1858; Sharfe N, 2008, MOL IMMUNOL, V45, P1208, DOI 10.1016/j.molimm.2007.09.019; Shi L, 2007, P NATL ACAD SCI USA, V104, P16347, DOI 10.1073/pnas.0706626104; Shi W, 2008, DEVELOPMENT, V135, P931, DOI 10.1242/dev.011940; Tanaka M, 2007, J CELL SCI, V120, P2179, DOI 10.1242/jcs.008607; Tolias KF, 2007, P NATL ACAD SCI USA, V104, P7265, DOI 10.1073/pnas.0702044104; Tremblay ME, 2007, J COMP NEUROL, V501, P691, DOI 10.1002/cne.21263; Wegmeyer H, 2007, NEURON, V55, P756, DOI 10.1016/j.neuron.2007.07.038; Wimmer-Kleikamp SH, 2005, IUBMB LIFE, V57, P421, DOI 10.1080/15216540500138337; Wu Jiangping, 2005, Curr Opin Hematol, V12, P292, DOI 10.1097/01.moh.0000166497.26397.9f; Wu Z, 2007, P NATL ACAD SCI USA, V104, P15132, DOI 10.1073/pnas.0707001104; Yamaguchi Y, 2004, CURR OPIN NEUROBIOL, V14, P288, DOI 10.1016/j.conb.2004.04.003; Yu G, 2006, J BIOL CHEM, V281, P10222, DOI 10.1074/jbc.M510320200; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012; Zhou L, 2007, J NEUROSCI, V27, P5127, DOI 10.1523/JNEUROSCI.1170-07.2007; Zhuang GL, 2007, J BIOL CHEM, V282, P2683, DOI 10.1074/jbc.M608509200	90	944	976	4	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2008	133	1					38	52		10.1016/j.cell.2008.03.011	http://dx.doi.org/10.1016/j.cell.2008.03.011			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394988	Bronze			2022-12-28	WOS:000254641300007
J	Teschner, D; Borsodi, J; Wootsch, A; Revay, Z; Havecker, M; Knop-Gericke, A; Jackson, SD; Schlogl, R				Teschner, Detre; Borsodi, Janos; Wootsch, Attila; Revay, Zsolt; Haevecker, Michael; Knop-Gericke, Axel; Jackson, S. David; Schloegl, Robert			The roles of subsurface carbon and hydrogen in palladium-catalyzed alkyne hydrogenation	SCIENCE			English	Article							HETEROGENEOUS CATALYSIS; METHANOL OXIDATION; NANOPARTICLES; IMPURITIES; ETHENE	Alkynes can be selectively hydrogenated into alkenes on solid palladium catalysts. This process requires a strong modification of the near- surface region of palladium, in which carbon ( from fragmented feed molecules) occupies interstitial lattice sites. In situ x- ray photoelectron spectroscopic measurements under reaction conditions indicated that much less carbon was dissolved in palladium during unselective, total hydrogenation. Additional studies of hydrogen content using in situ prompt gamma activation analysis, which allowed us to follow the hydrogen content of palladium during catalysis, indicated that unselective hydrogenation proceeds on hydrogen- saturated beta- hydride, whereas selective hydrogenation was only possible after decoupling bulk properties from the surface events. Thus, the population of subsurface sites of palladium, by either hydrogen or carbon, governs the hydrogenation events on the surface.	[Teschner, Detre; Borsodi, Janos; Haevecker, Michael; Knop-Gericke, Axel; Schloegl, Robert] Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany; [Borsodi, Janos; Wootsch, Attila; Revay, Zsolt] Hungarian Acad Sci, Inst Isotopes, H-1525 Budapest, Hungary; [Jackson, S. David] Univ Glasgow, WestCHEM, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland	Max Planck Society; Fritz Haber Institute of the Max Planck Society; Hungarian Academy of Sciences; University of Glasgow	Teschner, D (corresponding author), Max Planck Gesell, Fritz Haber Inst, Faradayweg 4-6, D-14195 Berlin, Germany.	teschner@fhi-berlin.mpg.de	Jackson, Samuel/AAD-1958-2022; Jackson, Samuel D/F-8095-2011; Wootsch, Attila/AAO-6847-2021	Jackson, Samuel/0000-0003-1257-5533; Jackson, Samuel D/0000-0003-1257-5533; Wootsch, Attila/0000-0002-2755-5394	Engineering and Physical Sciences Research Council [GR/R50899/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Al-Ammar A. S., 1977, J CHEM SOC F1, V74, P5195; Bluhm H, 2004, J PHYS CHEM B, V108, P14340, DOI 10.1021/jp040080j; Blume R, 2007, PHYS CHEM CHEM PHYS, V9, P3648, DOI 10.1039/b700986k; BOND GC, 1962, J CATAL, V1, P74, DOI 10.1016/0021-9517(62)90011-8; Borodzinki A, 2006, CATAL REV, V48, P91, DOI 10.1080/01614940500364909; de Vries J. G., 2007, HDB HOMOGENEOUS HYDR; FRIESKE H, 1973, BER BUNSEN PHYS CHEM, V77, P48; Hansen PL, 2002, SCIENCE, V295, P2053, DOI 10.1126/science.1069325; Honkala K, 2005, SCIENCE, V307, P555, DOI 10.1126/science.1106435; IMBIHL R, 1995, CHEM REV, V95, P697, DOI 10.1021/cr00035a012; Jackson SD, 1996, J CATAL, V162, P10, DOI 10.1006/jcat.1996.0255; Johanek V, 2004, SCIENCE, V304, P1639, DOI 10.1126/science.1097513; JOHNSON AD, 1992, SCIENCE, V257, P223, DOI 10.1126/science.257.5067.223; Khan NA, 2006, CATAL LETT, V108, P159, DOI 10.1007/s10562-006-0041-y; Kim M, 2001, SCIENCE, V292, P1357, DOI 10.1126/science.1059478; Ledentu V, 2000, J AM CHEM SOC, V122, P1796, DOI 10.1021/ja983975g; Marshall R, 2005, J MOL CATAL A-CHEM, V226, P227, DOI 10.1016/j.molcata.2004.10.031; Michaelides A, 1999, J CHEM PHYS, V111, P1343, DOI 10.1063/1.479392; Molnar A, 2001, J MOL CATAL A-CHEM, V173, P185, DOI 10.1016/S1381-1169(01)00150-9; Molnar G., 2004, HDB PROMPT GAMMA ACT; NIELSEN LP, 1991, PHYS REV B, V44, P13156, DOI 10.1103/PhysRevB.44.13156; Rose MK, 2001, J CHEM PHYS, V115, P10927, DOI 10.1063/1.1420732; Teschner D, 2006, J CATAL, V242, P26, DOI 10.1016/j.jcat.2006.05.030; Yudanov IV, 2004, PHYS CHEM CHEM PHYS, V6, P116, DOI 10.1039/b311054k	24	666	676	17	480	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2008	320	5872					86	89		10.1126/science.1155200	http://dx.doi.org/10.1126/science.1155200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388290				2022-12-28	WOS:000254633000035
J	Chin, L; Gray, JW				Chin, Lynda; Gray, Joe W.			Translating insights from the cancer genome into clinical practice	NATURE			English	Review							BREAST-CANCER; SUSCEPTIBILITY GENE; TYROSINE KINASE; RECEPTOR GENE; MOUSE MODELS; LUNG-CANCER; CELL-LINES; MUTATIONS; DNA; AMPLIFICATION	Cancer cells have diverse biological capabilities that are conferred by numerous genetic aberrations and epigenetic modifications. Today's powerful technologies are enabling these changes to the genome to be catalogued in detail. Tomorrow is likely to bring a complete atlas of the reversible and irreversible alterations that occur in individual cancers. The challenge now is to work out which molecular abnormalities contribute to cancer and which are simply 'noise' at the genomic and epigenomic levels. Distinguishing between these will aid in understanding how the aberrations in a cancer cell collaborate to drive pathophysiology. Past successes in converting information from genomic discoveries into clinical tools provide valuable lessons to guide the translation of emerging insights from the genome into clinical end points that can affect the practice of cancer medicine.	[Chin, Lynda] Dana Farber Canc Inst, Boston, MA 02115 USA; [Chin, Lynda] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Gray, Joe W.] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Chin, L (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	lynda_chin@dfci.harvard.edu	Gray, Joe/AAX-9549-2020		NATIONAL CANCER INSTITUTE [U54CA112970] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA112970, U54 CA112970-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bignell GR, 2007, GENOME RES, V17, P1296, DOI 10.1101/gr.6522707; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Blackhall F, 2006, LANCET ONCOL, V7, P499, DOI 10.1016/S1470-2045(06)70725-2; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Bradford TJ, 2006, UROL ONCOL-SEMIN ORI, V24, P538, DOI 10.1016/j.urolonc.2006.07.004; Cameron D, 2008, BREAST CANCER RES TR, V112, P533, DOI 10.1007/s10549-007-9885-0; CAMPBELL PJ, IN PRESS NATURE GENE; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Collas P, 2008, FRONT BIOSCI-LANDMRK, V13, P929, DOI 10.2741/2733; Collins FS, 2007, SCI AM, V296, P50, DOI 10.1038/scientificamerican0307-50; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dai ZY, 2002, GENOME RES, V12, P1591, DOI 10.1101/gr.197402; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demetri GD, 2001, SEMIN ONCOL, V28, P19, DOI 10.1053/sonc.2001.29181; DRMANAC R, 1993, SCIENCE, V260, P1649, DOI 10.1126/science.8503011; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Ewart-Toland A, 2005, CARCINOGENESIS, V26, P1368, DOI 10.1093/carcin/bgi085; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Greshock J, 2007, CANCER RES, V67, P10173, DOI 10.1158/0008-5472.CAN-07-2102; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hodgson JG, 2005, CANCER RES, V65, P9695, DOI 10.1158/0008-5472.CAN-05-0755; HODI F, IN PRESS J CLIN ORTH; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Korbel JO, 2007, SCIENCE, V318, P420, DOI 10.1126/science.1149504; Leary RJ, 2007, NAT PROTOC, V2, P1973, DOI 10.1038/nprot.2007.276; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Maser RS, 2007, MOL CELL BIOL, V27, P2253, DOI 10.1128/MCB.01354-06; Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nowell PC, 2007, J CLIN INVEST, V117, P2033, DOI 10.1172/JCI31771; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pegram M, 2000, SEMIN ONCOL, V27, P13; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Porreca GJ, 2007, NAT METHODS, V4, P931, DOI 10.1038/NMETH1110; Quintas-Cardama A, 2007, NAT REV DRUG DISCOV, V6, P834, DOI 10.1038/nrd2324; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; Scappini B, 2004, CANCER-AM CANCER SOC, V100, P1459, DOI 10.1002/cncr.20131; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Uren AG, 2005, ONCOGENE, V24, P7656, DOI 10.1038/sj.onc.1209043; van Steensel B, 2003, BIOTECHNIQUES, V35, P346; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wong KK, 2007, CLIN CANCER RES, V13, p4593S, DOI 10.1158/1078-0432.CCR-07-0369; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030	91	223	234	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2008	452	7187					553	563		10.1038/nature06914	http://dx.doi.org/10.1038/nature06914			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385729	Green Accepted, Green Submitted			2022-12-28	WOS:000254567200033
J	Al-Alawi, I; Schwartz, S				Al-Alawi, Irfan; Schwartz, Stephen			Radical Muslim doctors and what they mean for the NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Al-Alawi, Irfan] Ctr Islam Pluralism, London, England; [Schwartz, Stephen] Ctr Islam Pluralism, Washington, DC USA		Al-Alawi, I (corresponding author), Ctr Islam Pluralism, London, England.	schwartz@islamicpluralism.eu							0	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR	2008	336	7648					834	834		10.1136/bmj.39282.655035.4E	http://dx.doi.org/10.1136/bmj.39282.655035.4E			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	292ER	18403550	Green Published			2022-12-28	WOS:000255249800050
J	Dekker, J				Dekker, Job			Gene regulation in the third dimension	SCIENCE			English	Editorial Material							CHROMOSOME CONFORMATION CAPTURE; BETA-GLOBIN LOCUS; X-INACTIVATION; ORGANIZATION; EXPRESSION; TRANSCRIPTION; MOUSE		Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Dekker, J (corresponding author), Univ Massachusetts, Sch Med, Program Gene Funct & Express, 364 Plantat St, Worcester, MA 01605 USA.	Job.Dekker@umassmed.edu			NHGRI NIH HHS [R01 HG003143, R01 HG003143-04, HG003143] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003143] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bacher CP, 2006, NAT CELL BIOL, V8, P293, DOI 10.1038/ncb1365; Chuang CH, 2006, CURR BIOL, V16, P825, DOI 10.1016/j.cub.2006.03.059; Dekker J, 2006, NAT METHODS, V3, P17, DOI 10.1038/NMETH823; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dostie J, 2006, GENOME RES, V16, P1299, DOI 10.1101/gr.5571506; Dundr M, 2007, J CELL BIOL, V179, P1095, DOI 10.1083/jcb.200710058; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Fuss SH, 2007, CELL, V130, P373, DOI 10.1016/j.cell.2007.06.023; Grass JA, 2006, MOL CELL BIOL, V26, P7056, DOI 10.1128/MCB.01033-06; Jing HI, 2008, MOL CELL, V29, P232, DOI 10.1016/j.molcel.2007.11.020; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103; Lomvardas S, 2006, CELL, V126, P403, DOI 10.1016/j.cell.2006.06.035; Simonis M, 2007, NAT METHODS, V4, P895, DOI 10.1038/NMETH1114; Simonis M, 2006, NAT GENET, V38, P1348, DOI 10.1038/ng1896; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Vernimmen D, 2007, EMBO J, V26, P2041, DOI 10.1038/sj.emboj.7601654; Wallace JA, 2007, CURR OPIN GENET DEV, V17, P400, DOI 10.1016/j.gde.2007.08.005; West AG, 2005, HUM MOL GENET, V14, pR101, DOI 10.1093/hmg/ddi104; Wold B, 2008, NAT METHODS, V5, P19, DOI 10.1038/NMETH1157; Xu N, 2006, SCIENCE, V311, P1149, DOI 10.1126/science.1122984; Zhao Z, 2006, NAT GENET, V38, P1341, DOI 10.1038/ng1891; Zhou GL, 2006, MOL CELL BIOL, V26, P5096, DOI 10.1128/MCB.02454-05	25	178	185	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1793	1794		10.1126/science.1152850	http://dx.doi.org/10.1126/science.1152850			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369139	Green Accepted, Green Submitted			2022-12-28	WOS:000254394000036
J	Kim, IJ; Zhang, YF; Yamagata, M; Meister, M; Sanes, JR				Kim, In-Jung; Zhang, Yifeng; Yamagata, Masahito; Meister, Markus; Sanes, Joshua R.			Molecular identification of a retinal cell type that responds to upward motion	NATURE			English	Article							GANGLION-CELLS; ADHESION MOLECULES; SELECTIVE UNITS; MOUSE; MORPHOLOGIES; PARALLEL; RECEPTOR	The retina contains complex circuits of neurons that extract salient information from visual inputs. Signals from photoreceptors are processed by retinal interneurons, integrated by retinal ganglion cells ( RGCs) and sent to the brain by RGC axons. Distinct types of RGC respond to different visual features, such as increases or decreases in light intensity ( ON and OFF cells, respectively), colour or moving objects(1-5). Thus, RGCs comprise a set of parallel pathways from the eye to the brain. The identification of molecular markers for RGC subsets will facilitate attempts to correlate their structure with their function, assess their synaptic inputs and targets, and study their diversification. Here we show, by means of a transgenic marking method, that junctional adhesion molecule B ( JAM- B) marks a previously unrecognized class of OFF RGCs in mice. These cells have asymmetric dendritic arbors aligned in a dorsal- to- ventral direction across the retina. Their receptive fields are also asymmetric and respond selectively to stimuli moving in a soma- to- dendrite direction; because the lens reverses the image of the world on the retina, these cells detect upward motion in the visual field. Thus, JAM- B identifies a unique population of RGCs in which structure corresponds remarkably to function.	[Kim, In-Jung; Zhang, Yifeng; Yamagata, Masahito; Meister, Markus; Sanes, Joshua R.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Kim, In-Jung; Zhang, Yifeng; Yamagata, Masahito; Meister, Markus; Sanes, Joshua R.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Meister, M (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	meister@fas.harvard.edu; sanesj@mcb.harvard.edu	Yamagata, Masahito/H-6695-2016	Yamagata, Masahito/0000-0001-8193-2931; Meister, Markus/0000-0003-2136-6506				AMTHOR FR, 1989, J COMP NEUROL, V280, P72, DOI 10.1002/cne.902800107; Badea TC, 2004, J COMP NEUROL, V480, P331, DOI 10.1002/cne.20304; BARLOW HB, 1965, J PHYSIOL-LONDON, V178, P477, DOI 10.1113/jphysiol.1965.sp007638; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Branda CS, 2004, DEV CELL, V6, P7, DOI 10.1016/S1534-5807(03)00399-X; Braz JM, 2002, P NATL ACAD SCI USA, V99, P15148, DOI 10.1073/pnas.222546999; Buffelli M, 2003, NATURE, V424, P430, DOI 10.1038/nature01844; Chichilnisky EJ, 2001, NETWORK-COMP NEURAL, V12, P199, DOI 10.1088/0954-898X/12/2/306; Coombs J, 2006, NEUROSCIENCE, V140, P123, DOI 10.1016/j.neuroscience.2006.02.079; CRONER LJ, 1995, VISION RES, V35, P7, DOI 10.1016/0042-6989(94)E0066-T; Demb JB, 2007, NEURON, V55, P179, DOI 10.1016/j.neuron.2007.07.001; DRAGER UC, 1975, J NEUROPHYSIOL, V38, P690, DOI 10.1152/jn.1975.38.3.690; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Fox MA, 2007, J COMP NEUROL, V503, P280, DOI 10.1002/cne.21381; Ghosh KK, 2004, J COMP NEUROL, V469, P70, DOI 10.1002/cne.10985; Giolli RA, 2006, PROG BRAIN RES, V151, P407, DOI 10.1016/S0079-6123(05)51013-6; Haverkamp S, 2000, J COMP NEUROL, V424, P1; Jakobs TC, 2003, J COMP NEUROL, V465, P361, DOI 10.1002/cne.10845; Jeon CJ, 1998, J NEUROSCI, V18, P8936; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; Lin B, 2000, EUR J NEUROSCI, V12, P4155, DOI 10.1111/j.1460-9568.2000.01311.x; Ling CY, 1998, VISUAL NEUROSCI, V15, P559; Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; Nelson R, 2003, VISUAL NEUROSCIENCES, P260; OYSTER CW, 1967, SCIENCE, V155, P841, DOI 10.1126/science.155.3764.841; Rice DS, 2000, J COMP NEUROL, V424, P327, DOI 10.1002/1096-9861(20000821)424:2<327::AID-CNE10>3.0.CO;2-6; RODIECK RW, 1991, VISUAL NEUROSCI, V6, P95, DOI 10.1017/S095252380001049X; Roska B, 2001, NATURE, V410, P583, DOI 10.1038/35069068; Shen K, 2004, CELL, V116, P869, DOI 10.1016/S0092-8674(04)00251-X; Sun WZ, 2002, J COMP NEUROL, V451, P115, DOI 10.1002/cne.10323; Taylor WR, 2003, TRENDS NEUROSCI, V26, P379, DOI 10.1016/S0166-2236(03)00167-X; Wassle H, 2004, NAT REV NEUROSCI, V5, P747, DOI 10.1038/nrn1497; Weber C, 2007, NAT REV IMMUNOL, V7, P467, DOI 10.1038/nri2096; Yamagata M, 2002, CELL, V110, P649, DOI 10.1016/S0092-8674(02)00910-8; Yamagata M, 2008, NATURE, V451, P465, DOI 10.1038/nature06469	37	292	297	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 27	2008	452	7186					478	U11		10.1038/nature06739	http://dx.doi.org/10.1038/nature06739			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279FU	18368118				2022-12-28	WOS:000254341300033
J	Wagner, GP; Kenney-Hunt, JP; Pavlicev, M; Peck, JR; Waxman, D; Cheverud, JM				Wagner, Gunter P.; Kenney-Hunt, Jane P.; Pavlicev, Mihaela; Peck, Joel R.; Waxman, David; Cheverud, James M.			Pleiotropic scaling of gene effects and the 'cost of complexity'	NATURE			English	Article							QUANTITATIVE TRAIT LOCI; MUTATION-SELECTION BALANCE; MURINE GROWTH; MODULARITY; MICE; EVOLVABILITY; ARCHITECTURE; EVOLUTION	As perceived by Darwin, evolutionary adaptation by the processes of mutation and selection is difficult to understand for complex features that are the product of numerous traits acting in concert, for example the eye or the apparatus of flight. Typically, mutations simultaneously affect multiple phenotypic characters. This phenomenon is known as pleiotropy. The impact of pleiotropy on evolution has for decades been the subject of formal analysis(1-6). Some authors have suggested that pleiotropy can impede evolutionary progress ( a so- called 'cost of complexity'(5)). The plausibility of various phenomena attributed to pleiotropy depends on how many traits are affected by each mutation and on our understanding of the correlation between the number of traits affected by each gene substitution and the size of mutational effects on individual traits. Here we show, by studying pleiotropy in mice with the use of quantitative trait loci ( QTLs) affecting skeletal characters, that most QTLs affect a relatively small subset of traits and that a substitution at a QTL has an effect on each trait that increases with the total number of traits affected. This suggests that evolution of higher organisms does not suffer a 'cost of complexity' because most mutations affect few traits and the size of the effects does not decrease with pleiotropy.	[Wagner, Gunter P.] Yale Univ, Dept Ecol & Evolut Biol, New Haven, CT 06520 USA; [Kenney-Hunt, Jane P.; Pavlicev, Mihaela; Cheverud, James M.] Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA; [Peck, Joel R.; Waxman, David] Univ Sussex, Sch Life Sci, Ctr Study Evolut, Brighton BN1 9QG, E Sussex, England	Yale University; Washington University (WUSTL); University of Sussex	Wagner, GP (corresponding author), Yale Univ, Dept Ecol & Evolut Biol, New Haven, CT 06520 USA.	gunter.wagner@yale.edu; cheverud@pcg.wustl.edu	; Pavlicev, Mihaela/O-4460-2015	Kenney-Hunt, Jane/0000-0002-4143-5022; Peck, Joel/0000-0003-0421-8739; Pavlicev, Mihaela/0000-0001-8439-9351; Wagner, Gunter/0000-0002-3097-002X				CHAI CK, 1956, GENETICS, V41, P165; Cheverud JM, 2001, MAMM GENOME, V12, P3, DOI 10.1007/s003350010218; Cheverud JM, 2001, HEREDITY, V87, P52, DOI 10.1046/j.1365-2540.2001.00901.x; Cheverud JM, 1996, GENETICS, V142, P1305; Ehrich TH, 2003, J EXP ZOOL PART B, V296B, P58, DOI 10.1002/jez.b.00009; Eppig JT, 2005, NUCLEIC ACIDS RES, V33, pD471, DOI 10.1093/nar/gki113; Fisher R.A., 1930, GENETICAL THEORY NAT; HALEY CS, 1992, HEREDITY, V69, P315, DOI 10.1038/hdy.1992.131; Hansen TF, 2003, BIOSYSTEMS, V69, P83, DOI 10.1016/S0303-2647(02)00132-6; Hermisson J, 2004, GENETICS, V168, P2271, DOI 10.1534/genetics.104.029173; KENNEYHUNT JP, IN PRESS GENETICS; Knott SA, 2000, GENETICS, V156, P899; Martin G, 2006, EVOLUTION, V60, P893; Orr HA, 2000, EVOLUTION, V54, P13, DOI 10.1111/j.0014-3820.2000.tb00002.x; Rechenberg I., 1973, EVOLUTIONSSTRATEGIE; TURELLI M, 1985, GENETICS, V111, P165; Vaughn TT, 1999, GENET RES, V74, P313, DOI 10.1017/S0016672399004103; Waddington C., 1957, STRATEGY GENES; WAGNER GP, 1989, GENETICS, V122, P223; WAGNER GP, 1988, J EVOLUTION BIOL, V1, P45, DOI 10.1046/j.1420-9101.1988.1010045.x; Wagner GP, 1996, EVOLUTION, V50, P967, DOI [10.2307/2410639, 10.1111/j.1558-5646.1996.tb02339.x]; Wagner GP, 2007, NAT REV GENET, V8, P921, DOI 10.1038/nrg2267; Waxman D, 1998, SCIENCE, V279, P1210, DOI 10.1126/science.279.5354.1210; Welch JJ, 2003, EVOLUTION, V57, P1723, DOI 10.1554/02-673; Wingreen NS, 2003, GENETICS, V164, P1221; Xu SZ, 2003, GENETICS, V165, P2259	26	160	162	2	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2008	452	7186					470	U9		10.1038/nature06756	http://dx.doi.org/10.1038/nature06756			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279FU	18368117				2022-12-28	WOS:000254341300031
J	Lupien, M; Eeckhoute, J; Meyer, CA; Wang, QB; Zhang, Y; Li, W; Carroll, JS; Liu, XS; Brown, M				Lupien, Mathieu; Eeckhoute, Jerome; Meyer, Clifford A.; Wang, Qianben; Zhang, Yong; Li, Wei; Carroll, Jason S.; Liu, X. Shirley; Brown, Myles			FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription	CELL			English	Article							ESTROGEN-RECEPTOR-ALPHA; CELL-CYCLE PROGRESSION; BREAST-CANCER; GENE-EXPRESSION; BINDING-SITES; HUMAN GENOME; CHROMATIN SIGNATURES; COMPACTED CHROMATIN; ANDROGEN RECEPTOR; LOCATION ANALYSIS	Complex organisms require tissue-specific transcriptional programs, yet little is known about how these are established. The transcription factor FoxA1 is thought to contribute to gene regulation through its ability to act as a pioneer factor binding to nucleosomal DNA. Through genome-wide positional analyses, we demonstrate that FoxA1 cell type-specific functions rely primarily on differential recruitment to chromatin predominantly at distant enhancers rather than proximal promoters. This differential recruitment leads to cell type-specific changes in chromatin structure and functional collaboration with lineage-specific transcription factors. Despite the ability of FoxA1 to bind nucleosomes, its differential binding to chromatin sites is dependent on the distribution of histone H3 lysine 4 dimethylation. Together, our results suggest that methylation of histone H3 lysine 4 is part of the epigenetic signature that defines lineage-specific FoxA1 recruitment sites in chromatin. FoxA1 translates this epigenetic signature into changes in chromatin structure thereby establishing lineage-specific transcriptional enhancers and programs.	[Lupien, Mathieu; Eeckhoute, Jerome; Wang, Qianben; Carroll, Jason S.; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02115 USA; [Lupien, Mathieu; Eeckhoute, Jerome; Wang, Qianben; Carroll, Jason S.; Brown, Myles] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Lupien, Mathieu; Eeckhoute, Jerome; Wang, Qianben; Carroll, Jason S.; Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Meyer, Clifford A.; Zhang, Yong; Li, Wei; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Meyer, Clifford A.; Zhang, Yong; Li, Wei; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health	Brown, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02115 USA.	myles_brown@dfci.harvard.edu	Wang, Qianben/E-4267-2011; Brown, Myles/B-6906-2008; Brown, Myles/AAX-5332-2021; Eeckhoute, Jerome/AAN-8219-2021; Zhang, Yong/B-4838-2011; Li, Wei/A-8544-2009	Brown, Myles/0000-0002-8213-1658; Eeckhoute, Jerome/0000-0002-7222-9264; Zhang, Yong/0000-0001-6316-2734; Carroll, Jason/0000-0003-3643-0080; Lupien, Mathieu/0000-0003-0929-9478; Li, Wei/0000-0001-9931-5990	NCI NIH HHS [P01 CA080111, P01 CA080111-070002, P01 CA080111-100002, P01 CA080111-080002, P01 CA080111-060002, P01 CA8011105, P50 CA089393-080012, P01 CA080111-010002, P50 CA089393-070012, P50 CA089393-060012, P50 CA089393, P01 CA080111-090002] Funding Source: Medline; NHGRI NIH HHS [R01 HG004069-02, R01 HG004069, 1R01 HG004069-02] Funding Source: Medline; NIDDK NIH HHS [R01 DK074967-01A1, R01DK074967, R56 DK074967-01, R56 DK074967, R01 DK074967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089393, P01CA080111] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK074967, R01DK074967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606; Bossard P, 2000, DEVELOPMENT, V127, P4915; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Friedman JR, 2006, CELL MOL LIFE SCI, V63, P2317, DOI 10.1007/s00018-006-6095-6; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Geles KG, 2006, P NATL ACAD SCI USA, V103, P2594, DOI 10.1073/pnas.0510764103; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Ji XW, 2006, NUCLEIC ACIDS RES, V34, pW551, DOI 10.1093/nar/gkl322; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Lin L, 2002, CANCER RES, V62, P5273; Liu XS, 2002, NAT BIOTECHNOL, V20, P835, DOI 10.1038/nbt717; Lupien M, 2007, MOL ENDOCRINOL, V21, P797, DOI 10.1210/me.2006-0074; Marr MT, 2006, GENE DEV, V20, P1458, DOI 10.1101/gad.1418806; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299; Olson EN, 2006, SCIENCE, V313, P1922, DOI 10.1126/science.1132292; Schrem H, 2002, PHARMACOL REV, V54, P129, DOI 10.1124/pr.54.1.129; Schwartz B, 2007, ONCOGENE, V26, P4049, DOI 10.1038/sj.onc.1210193; Sekiya T, 2007, MOL CELL, V28, P291, DOI 10.1016/j.molcel.2007.10.002; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; So AYL, 2007, PLOS GENET, V3, P927, DOI 10.1371/journal.pgen.0030094; Son CG, 2005, GENOME RES, V15, P443, DOI 10.1101/gr.3124505; Spear BT, 2006, CELL MOL LIFE SCI, V63, P2922, DOI 10.1007/s00018-006-6258-5; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Workman CT, 2005, NUCLEIC ACIDS RES, V33, pW389, DOI 10.1093/nar/gki439	53	704	732	3	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2008	132	6					958	970		10.1016/j.cell.2008.01.018	http://dx.doi.org/10.1016/j.cell.2008.01.018			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358809	Green Accepted, Bronze			2022-12-28	WOS:000254273600015
J	Doll, D; Bowley, DM				Doll, Dietrich; Bowley, Douglas M.			Veterans' health-surviving acute injuries is not enough	LANCET			English	Editorial Material							TRAUMATIC BRAIN-INJURY; HOMELESS VETERANS; RECEIPT; IRAQ		[Doll, Dietrich; Bowley, Douglas M.] Charite Univ Med Berlin, Teaching Hosp, Mil Hosp Berlin, D-10115 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Doll, D (corresponding author), Charite Univ Med Berlin, Teaching Hosp, Mil Hosp Berlin, D-10115 Berlin, Germany.	ddoll@gmx.de	Doll, med. Dr. phil. Dietrich/H-6633-2019	Doll, med. Dr. phil. Dietrich/0000-0001-9832-4545				Adams J, 2007, J HEALTH CARE POOR U, V18, P173, DOI 10.1353/hpu.2007.0000; Chen JH, 2007, PSYCHIAT QUART, V78, P63, DOI 10.1007/s11126-006-9027-6; Cunningham M., 2007, VITAL MISSION ENDING; Dandeker C, 2006, ARMED FORCES SOC, V32, P161, DOI 10.1177/0095327X05279177; *DEP VET AFF, 2006, FACT SHEET VA SERV R; Greenberg G, 2007, MIL MED, V172, P461, DOI 10.7205/MILMED.172.5.461; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; *NAT ALL END HOM, 2006, FACT CHECK VET HOM; PERL L, 2007, CRS REPORT C VET HOM; Sherer M, 2008, ARCH PHYS MED REHAB, V89, P42, DOI 10.1016/j.apmr.2007.08.128; Thoresen S, 2006, ARCH SUICIDE RES, V10, P353, DOI 10.1080/13811110600791106; ZOROYA G, 2008, 20 000 VETS BRAIN IN; 2007, LANCET, V370, P1879	15	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR-APR	2008	371	9618					1053	1055		10.1016/S0140-6736(08)60465-1	http://dx.doi.org/10.1016/S0140-6736(08)60465-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18374826				2022-12-28	WOS:000254442700008
J	Ghildiyal, M; Seitz, H; Horwich, MD; Li, CJ; Du, TT; Lee, S; Xu, J; Kittler, ELW; Zapp, ML; Weng, ZP; Zamore, PD				Ghildiyal, Megha; Seitz, Herve; Horwich, Michael D.; Li, Chengjian; Du, Tingting; Lee, Soohyun; Xu, Jia; Kittler, Ellen L. W.; Zapp, Maria L.; Weng, Zhiping; Zamore, Phillip D.			Endogenous siRNAs derived from transposons and mRNAs in Drosophila somatic cells	SCIENCE			English	Article							SMALL INTERFERING RNAS; ARGONAUTE PROTEINS; MELANOGASTER; COMPONENTS; GERMLINE; CLEAVAGE; PIWI	Small interfering RNAs ( siRNAs) direct RNA interference ( RNAi) in eukaryotes. In flies, somatic cells produce siRNAs from exogenous double- stranded RNA ( dsRNA) as a defense against viral infection. We identified endogenous siRNAs ( endo- siRNAs), 21 nucleotides in length, that correspond to transposons and heterochromatic sequences in the somatic cells of Drosophila melanogaster. We also detected endo- siRNAs complementary to messenger RNAs ( mRNAs); these siRNAs disproportionately mapped to the complementary regions of overlapping mRNAs predicted to form double- stranded RNA in vivo. Normal accumulation of somatic endo- siRNAs requires the siRNA- generating ribonuclease Dicer- 2 and the RNAi effector protein Argonaute2 ( Ago2). We propose that endo- siRNAs generated by the fly RNAi pathway silence selfish genetic elements in the soma, much as Piwi- interacting RNAs do in the germ line.	[Ghildiyal, Megha; Seitz, Herve; Horwich, Michael D.; Li, Chengjian; Du, Tingting; Zamore, Phillip D.] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA; [Lee, Soohyun] Boston Univ, Program Bioinformat, Boston, MA 02215 USA; [Xu, Jia] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; [Kittler, Ellen L. W.; Zapp, Maria L.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; [Kittler, Ellen L. W.; Zapp, Maria L.] Univ Massachusetts, Sch Med, Ctr AIDS Res, Worcester, MA 01605 USA; [Weng, Zhiping] Univ Massachusetts, Sch Med, Program Bioinformat & Integrat Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Boston University; Boston University; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Zamore, PD (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.	phillip.zamore@umassmed.edu	Ghildiyal, Megha/F-7980-2014; Seitz, Hervé/AAE-6487-2019; Zamore, Phillip D/A-8941-2013; Xu, Jia/F-7750-2012	Seitz, Hervé/0000-0001-8172-5393; Lee, Soohyun/0000-0002-3594-6213; Xu, Jia/0000-0003-3921-018X; Zamore, Phillip/0000-0002-4505-9618	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003367] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043208, P30AI042845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065236, R01GM062862, R01GM080625, R37GM062862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F30AG030283] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NHGRI NIH HHS [HG003367, R01 HG003367, R01 HG003367-03] Funding Source: Medline; NIAID NIH HHS [R01 AI043208-08, P30 AI042845-119008, R01 AI043208, P30 AI042845] Funding Source: Medline; NIA NIH HHS [F30 AG030283-03, F30AG030283, F30 AG030283-02, F30 AG030283-04] Funding Source: Medline; NIGMS NIH HHS [GM65236, R01 GM065236-07, GM62862, R01 GM065236-08, R01 GM080625-02, R01 GM080625-03, R37 GM062862, R01 GM062862-08, R01 GM062862, R01 GM062862-09, R01 GM065236, R37 GM062862-11, GM080625, R01 GM080625] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brennecke J, 2007, CELL, V128, P1089, DOI 10.1016/j.cell.2007.01.043; CSINK AK, 1994, GENETICS, V138, P153; CZECH B, 2008, NATURE; Desset S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001526; Gunawardane LS, 2007, SCIENCE, V315, P1587, DOI 10.1126/science.1140494; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Haynes KA, 2006, CURR BIOL, V16, P2222, DOI 10.1016/j.cub.2006.09.035; Horwich MD, 2007, CURR BIOL, V17, P1265, DOI 10.1016/j.cub.2007.06.030; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; KAWAMURA Y, 2008, NATURE; Lee YS, 2003, METHODS, V30, P322, DOI 10.1016/S1046-2023(03)00051-3; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; OKAMURA K, 2008, NATURE; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; Pelisson A, 2007, J VIROL, V81, P1951, DOI 10.1128/JVI.01980-06; Rehwinkel J, 2006, MOL CELL BIOL, V26, P2965, DOI 10.1128/MCB.26.8.2965-2975.2006; Saito K, 2007, GENE DEV, V21, P1603, DOI 10.1101/gad.1563607; Seitz H, 2008, CURR BIOL, V18, P147, DOI 10.1016/j.cub.2007.12.049; Sunkar R, 2005, NUCLEIC ACIDS RES, V33, P4443, DOI 10.1093/nar/gki758; Tchurikov NA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000476; Vagin VV, 2006, SCIENCE, V313, P320, DOI 10.1126/science.1129333; Yang N, 2006, NAT STRUCT MOL BIOL, V13, P763, DOI 10.1038/nsmb1141; Yin H, 2007, NATURE, V450, P304, DOI 10.1038/nature06263; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	24	457	478	3	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2008	320	5879					1077	1081		10.1126/science.1157396	http://dx.doi.org/10.1126/science.1157396			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18403677	Green Accepted			2022-12-28	WOS:000256059800046
J	Semenza, GL				Semenza, Gregg L.			O-2 sensing: Only skin deep?	CELL			English	Editorial Material							GENE-EXPRESSION; HYPOXIA; PROTEIN	The transcription factor HIF-1 mediates adaptive responses to hypoxia, and its activity is negatively regulated by O-2-dependent binding of the von Hippel-Lindau (VHL) protein. In this issue, Boutin et al. (2008) use conditional knockout mice to demonstrate that sensing of O-2 by keratinocytes in the epidermis leads to alterations in cutaneous blood flow that affect the production of the hormone erythropoietin, thereby modulating red blood cell production and the O-2-carrying capacity of blood.	[Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Pediat, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Med, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Oncol, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Radiat Oncol, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Pediat, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu						Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kline DD, 2002, P NATL ACAD SCI USA, V99, P821, DOI 10.1073/pnas.022634199; Patel SA, 2008, CELL DEATH DIFFER, V15, P628, DOI 10.1038/cdd.2008.17; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Stockmann C, 2006, CLIN EXP PHARMACOL P, V33, P968, DOI 10.1111/j.1440-1681.2006.04474.x; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	9	20	21	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 18	2008	133	2					206	208		10.1016/j.cell.2008.04.004	http://dx.doi.org/10.1016/j.cell.2008.04.004			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	289JY	18423190	Bronze			2022-12-28	WOS:000255052000008
J	Elmen, J; Lindow, M; Schutz, S; Lawrence, M; Petri, A; Obad, S; Lindholm, M; Hedtjarn, M; Hansen, HF; Berger, U; Gullans, S; Kearney, P; Sarnow, P; Straarup, EM; Kauppinen, S				Elmen, Joacim; Lindow, Morten; Schutz, Sylvia; Lawrence, Matthew; Petri, Andreas; Obad, Susanna; Lindholm, Marie; Hedtjarn, Maj; Hansen, Henrik Frydenlund; Berger, Urs; Gullans, Steven; Kearney, Phil; Sarnow, Peter; Straarup, Ellen Marie; Kauppinen, Sakari			LNA-mediated microRNA silencing in non-human primates	NATURE			English	Article							ANIMAL DEVELOPMENT; IN-VIVO; SPECIFICITY; MODULATION; EXPRESSION	microRNAs ( miRNAs) are small regulatory RNAs that are important in development and disease(1-3) and therefore represent a potential new class of targets for therapeutic intervention(4). Despite recent progress in silencing of miRNAs in rodents(5,6), the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS- formulated locked- nucleic- acid- modified oligonucleotide ( LNA- antimiR) effectively antagonizes the liver- expressed miR- 122 in non- human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA- antimiR to African green monkeys resulted in uptake of the LNA- antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR- 122. This was accompanied by depletion of mature miR- 122 and dose- dependent lowering of plasma cholesterol. Efficient silencing of miR- 122 was achieved in primates by three doses of 10 mg kg(-1) LNA- antimiR, leading to a long- lasting and reversible decrease in total plasma cholesterol without any evidence for LNA- associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA- antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a new class of therapeutics for disease-associated miRNAs.	[Elmen, Joacim; Lindow, Morten; Petri, Andreas; Obad, Susanna; Lindholm, Marie; Hedtjarn, Maj; Kearney, Phil; Straarup, Ellen Marie; Kauppinen, Sakari] Santaris Pharma, DK-2970 Horsholm, Denmark; [Schutz, Sylvia; Sarnow, Peter] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Lawrence, Matthew; Gullans, Steven] RxGen Inc, Hamden, CT 06517 USA; [Berger, Urs] UB In situ, Natick, MA 01760 USA; [Kauppinen, Sakari] Univ Copenhagen, Dept Cellular & Mol Med, Wilhelm Johannsen Ctr Funct Genome Res, DK-2200 Copenhagen N, Denmark	Stanford University; University of Copenhagen	Kauppinen, S (corresponding author), Santaris Pharma, Boge Allee 3, DK-2970 Horsholm, Denmark.	sk@santaris.com	Lindholm, Marie W/B-8736-2015	Lindholm, Marie W/0000-0003-4309-3203; Kearney, Phil/0000-0001-7408-1067; Wikstrom Lindholm, Marie/0000-0002-0975-2394; Sarnow, Peter/0000-0002-2043-2770				Abelson JF, 2005, SCIENCE, V310, P317, DOI 10.1126/science.1116502; Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Eisenberg I, 2007, P NATL ACAD SCI USA, V104, P17016, DOI 10.1073/pnas.0708115104; Elmen J, 2008, NUCLEIC ACIDS RES, V36, P1153, DOI 10.1093/nar/gkm1113; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Krutzfeldt J, 2007, NUCLEIC ACIDS RES, V35, P2885, DOI 10.1093/nar/gkm024; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Pedersen IM, 2007, NATURE, V449, P919, DOI 10.1038/nature06205; Randall G, 2007, P NATL ACAD SCI USA, V104, P12884, DOI 10.1073/pnas.0704894104; Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311; Triboulet R, 2007, SCIENCE, V315, P1579, DOI 10.1126/science.1136319; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; Yang BF, 2007, NAT MED, V13, P486, DOI 10.1038/nm1569	25	1303	1429	0	157	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2008	452	7189					896	U10		10.1038/nature06783	http://dx.doi.org/10.1038/nature06783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18368051				2022-12-28	WOS:000255026000053
J	Hartzband, P; Groopman, J				Hartzband, Pamela; Groopman, Jerome			Off the record - Avoiding the pitfalls of going electronic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Hartzband, Pamela; Groopman, Jerome] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Hartzband, Pamela; Groopman, Jerome] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Hartzband, P (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.								0	128	128	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1656	1658		10.1056/NEJMp0802221	http://dx.doi.org/10.1056/NEJMp0802221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288DO	18420497				2022-12-28	WOS:000254966600002
J	Sparano, JA; Wang, ML; Martino, S; Jones, V; Perez, EA; Saphner, T; Wolff, AC; Sledge, GW; Wood, WC; Davidson, NE				Sparano, Joseph A.; Wang, Molin; Martino, Silvana; Jones, Vicky; Perez, Edith A.; Saphner, Tom; Wolff, Antonio C.; Sledge, George W., Jr.; Wood, William C.; Davidson, Nancy E.			Weekly paclitaxel in the adjuvant treatment of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	30th Annual San Antonio Breast Cancer Symposium	DEC 13-16, 2007	San Antonio, TX	San Antonio Canc Inst, Baylor Coll Med			PHASE-III; CHEMOTHERAPY; DOCETAXEL; OUTCOMES	Background: We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer. Methods: We enrolled 4950 women with axillary lymph node-positive or high-risk, lymph node-negative breast cancer. After randomization, all patients first received 4 cycles of intravenous doxorubicin and cyclophosphamide at 3-week intervals and were then assigned to intravenous paclitaxel or docetaxel given at 3-week intervals for 4 cycles or at 1-week intervals for 12 cycles. The primary end point was disease-free survival. Results: As compared with patients receiving standard therapy (paclitaxel every 3 weeks), the odds ratio for disease-free survival was 1.27 among those receiving weekly paclitaxel (P=0.006), 1.23 among those receiving docetaxel every 3 weeks (P=0.02), and 1.09 among those receiving weekly docetaxel (P=0.29) (with an odds ratio >1 favoring the groups receiving experimental therapy). As compared with standard therapy, weekly paclitaxel was also associated with improved survival (odds ratio, 1.32; P=0.01). An exploratory analysis of a subgroup of patients whose tumors expressed no human epidermal growth factor receptor type 2 protein found similar improvements in disease-free and overall survival with weekly paclitaxel treatment, regardless of hormone-receptor expression. Grade 2, 3, or 4 neuropathy was more frequent with weekly paclitaxel than with paclitaxel every 3 weeks (27% vs. 20%). Conclusions: Weekly paclitaxel after standard adjuvant chemotherapy with doxorubicin and cyclophosphamide improves disease-free and overall survival in women with breast cancer. (ClinicalTrials.gov number, NCT00004125.).	[Sparano, Joseph A.; Wang, Molin; Saphner, Tom; Wolff, Antonio C.; Sledge, George W., Jr.; Wood, William C.; Davidson, Nancy E.] Eastern Cooperat Oncol Grp, Philadelphia, PA USA; [Martino, Silvana] SW Oncol Grp, Ann Arbor, MI USA; [Jones, Vicky] Canc & Leukemia Grp, Chicago, IL USA; [Perez, Edith A.] N Cent Canc Treatment Grp, Rochester, MN USA	Southwest Oncology Group	Sparano, JA (corresponding author), Montefiore Med Ctr, Weiler Div, 1825 Eastchester Rd,2 South,Rm 47, Bronx, NY 10461 USA.	jsparano@montefiore.org	Wolff, Antonio C./T-8796-2019	Wolff, Antonio C./0000-0003-3734-1063; Sparano, Joseph/0000-0002-9031-2010	NCI NIH HHS [U10 CA021115-25S2, U10 CA021115-28S1, CA25224, U10 CA023318, U10 CA037403-19S1, U10 CA037403-19, U10 CA037403-16, U10 CA021115-29S1, U10 CA037403-21S1, U10 CA021115-34S1, CA14958, U10 CA037403-19S2, CA11789, U10 CA014958-28, U10 CA021115-28, U10 CA021115-27, P30 CA013330, U10 CA025224, U24 CA114737, U10 CA021115-32, CA23318, CA49883, CA32012, U10 CA037403-21S4, U24 CA114737-04, U10 CA037403-18, CA21115, CA16116, U10 CA016116, P30 CA013330-359020, U24 CA114737-01, U10 CA021115-26, U10 CA014958-32, U10 CA037403-17S1, U10 CA037403-23, U10 CA021115-34, U10 CA037403-21S3, U10 CA021115, U10 CA014958-33, P30 CA013330-369020, U10 CA037403-16S2, U10 CA037403-21, U10 CA021115-30, U10 CA021115-33S2, U10 CA049883, U10 CA014958-30, U10 CA037403-22A1, U10 CA014958, U10 CA021115-25S1, U10 CA021115-31, U24 CA114737-03, U10 CA037403-17, U10 CA066636, U10 CA021115-33, U10 CA014958-31, U10 CA037403-16S1, U10 CA037403, U10 CA037403-20, U10 CA014958-34, CA66636, U10 CA021115-33S1, U10 CA021115-25S3, U10 CA021115-32S1, U10 CA021115-29, U24 CA114737-05, U10 CA037403-21S2, U10 CA014958-29, U24 CA114737-02, U10 CA021115-25] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA049883, U10CA011789, U10CA016116, U10CA037403, R01CA032012, U10CA014958, P30CA013330, U24CA114737, U10CA025224, U10CA066636, U10CA021115, U10CA023318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; BADVE SS, 2007, J CLIN ONCOL S, V25, pS730; Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P1658, DOI 10.1001/jama.295.14.1658; Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P2356; Calabro F, 2007, EUR UROL, V51, P17, DOI 10.1016/j.eururo.2006.08.013; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Hayes DF, 2007, NEW ENGL J MED, V357, P1496, DOI 10.1056/NEJMoa071167; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Jones SE, 2005, J CLIN ONCOL, V23, P5542, DOI 10.1200/JCO.2005.02.027; Mamounas EP, 2005, J CLIN ONCOL, V23, P3686, DOI 10.1200/JCO.2005.10.517; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; Rivera E, 2006, J CLIN ONCOL, V24, p21S; RODRIGUEZLESCUR.AM, 2007, J CLIN ONCOL S, V25, pS589; Seidman AD, 2004, J CLIN ONCOL, V22, p6S; Sparano J A, 2000, Clin Breast Cancer, V1, P32, DOI 10.3816/CBC.2000.n.002	16	687	710	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1663	1671		10.1056/NEJMoa0707056	http://dx.doi.org/10.1056/NEJMoa0707056			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	288DO	18420499	Green Accepted			2022-12-28	WOS:000254966600004
J	Tyson, JE; Parikh, NA; Langer, J; Green, C; Higgins, RD				Tyson, Jon E.; Parikh, Nehal A.; Langer, John; Green, Charles; Higgins, Rosemary D.		Natl Inst Child Hlth & Human Dev N	Intensive care for extreme prematurity - Moving beyond gestational age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROSS MOTOR FUNCTION; BIRTH-WEIGHT; DATING FORMULAS; POPULATION; CHILDREN; DELIVERY; DETERMINANTS; THRESHOLD; DECISIONS; BIOMETRY	Background: Decisions regarding whether to administer intensive care to extremely premature infants are often based on gestational age alone. However, other factors also affect the prognosis for these patients. Methods: We prospectively studied a cohort of 4446 infants born at 22 to 25 weeks' gestation (determined on the basis of the best obstetrical estimate) in the Neonatal Research Network of the National Institute of Child Health and Human Development to relate risk factors assessable at or before birth to the likelihood of survival, survival without profound neurodevelopmental impairment, and survival without neurodevelopmental impairment at a corrected age of 18 to 22 months. Results: Among study infants, 3702 (83%) received intensive care in the form of mechanical ventilation. Among the 4192 study infants (94%) for whom outcomes were determined at 18 to 22 months, 49% died, 61% died or had profound impairment, and 73% died or had impairment. In multivariable analyses of infants who received intensive care, exposure to antenatal corticosteroids, female sex, singleton birth, and higher birth weight (per each 100-g increment) were each associated with reductions in the risk of death and the risk of death or profound or any neurodevelopmental impairment; these reductions were similar to those associated with a 1-week increase in gestational age. At the same estimated likelihood of a favorable outcome, girls were less likely than boys to receive intensive care. The outcomes for infants who underwent ventilation were better predicted with the use of the above factors than with use of gestational age alone. Conclusions: The likelihood of a favorable outcome with intensive care can be better estimated by consideration of four factors in addition to gestational age: sex, exposure or nonexposure to antenatal corticosteroids, whether single or multiple birth, and birth weight. (ClinicalTrials.gov numbers, NCT00063063 and NCT00009633.).	[Tyson, Jon E.; Parikh, Nehal A.; Green, Charles] Univ Texas Houston, Sch Med, Ctr Clin Res & Evidence Based Med, Houston, TX 77030 USA; [Langer, John] Res Triangle Inst, Res Triangle Pk, NC 27709 USA; [Higgins, Rosemary D.] NICHHD, Bethesda, MD 20892 USA	University of Texas System; University of Texas Health Science Center Houston; Research Triangle Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Tyson, JE (corresponding author), Univ Texas Houston, Sch Med, Ctr Clin Res & Evidence Based Med, MSB 2-106,6431 Fannin St, Houston, TX 77030 USA.	jon.e.tyson@uth.tmc.edu	Parikh, Nehal/AAB-9981-2022	Parikh, Nehal/0000-0002-1375-1247	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD034216, U10HD021385, U10HD027853, U10HD021373, U10HD021364, U10HD027851, U10HD027856, U10HD027904, U10HD027871, U10HD040461, U10HD027880, U10HD040492, U10HD040689] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD040521, U10HD027881, U10HD021415, U10HD040498, U10HD034167, U10HD021397, U01HD036790] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044, M01RR000125, M01RR006022, M01RR000070, M01RR000039, M01RR008084, M01RR000997, UL1RR024148, M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS048152] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000454] Funding Source: Medline; NCRR NIH HHS [M01 RR000997, M01 RR 00044, M01 RR 00750, M01 RR 00997, M01 RR006022, M01 RR000125, M01 RR000750, M01 RR000044, M01 RR008084, M01 RR000070, M01 RR 06022, UL1 RR024148, M01 RR000039, M01 RR 00070, M01 RR 00039, M01 RR 08084, UL1 RR24148, M01 RR 00125] Funding Source: Medline; NICHD NIH HHS [U10 HD27881, U10 HD021385, U10 HD40492, U10 HD034216, U10 HD27851, U10 HD027856, U10 HD40689, U10 HD021373, U01 HD036790, U10 HD21364, U10 HD34216, U10 HD021364, U10 HD027880, U10 HD040521, U10 HD040498, U10 HD21385, U10 HD21373, U10 HD21415, U01 HD36790, U10 HD21397, U10 HD027851, U10 HD027871, U10 HD27853, U10 HD40461, U10 HD034167, U10 HD27856, U10 HD021397, U10 HD027904, U10 HD027853, U10 HD040492, U10 HD040689, U10 HD40498, U10 HD27871, U10 HD40521, U10 HD27880, U10 HD27904, U10 HD040461] Funding Source: Medline; NINDS NIH HHS [K23 NS048152, K23 NS048152-04, 5K23NS048152-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ambalavanan N, 2005, PEDIATRICS, V116, P1367, DOI 10.1542/peds.2004-2099; American College of Obstetricians and Gynecologists, 2002, OBSTET GYNECOL, V100, P617; [Anonymous], 2006, Lancet, V368, P1844; [Anonymous], CONS PRIC IND INFL C; Atkins DL, 2006, PEDIATRICS, V117, pE955, DOI 10.1542/peds.2006-0206; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; Blackmon LR, 2004, PEDIATRICS, V114, P1362, DOI 10.1542/peds.2004-1915; Bottoms SF, 1997, AM J OBSTET GYNECOL, V176, P960, DOI 10.1016/S0002-9378(97)70386-7; Callaghan WM, 2007, PAEDIATR PERINAT EP, V21, P79, DOI 10.1111/j.1365-3016.2007.00864.x; Chervenak FA, 1998, AM J OBSTET GYNECOL, V178, P678, DOI 10.1016/S0002-9378(98)70477-6; Donovan EF, 1999, J PEDIATR-US, V135, P147, DOI 10.1016/S0022-3476(99)70015-6; Doyle LW, 2001, PEDIATRICS, V108, P134, DOI 10.1542/peds.108.1.134; Finer NN, 2004, PEDIATRICS, V114, P651, DOI 10.1542/peds.2004-0394; Gjessing HK, 1999, AM J PUBLIC HEALTH, V89, P213, DOI 10.2105/AJPH.89.2.213; Higgins RD, 2005, PEDIATRICS, V115, P1392, DOI 10.1542/peds.2004-1989; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; Lorenz JM, 2000, J PEDIATR-US, V137, P593, DOI 10.1067/mpd.2000.110532; Lynch CD, 2007, PAEDIATR PERINAT EP, V21, P86, DOI 10.1111/j.1365-3016.2007.00865.x; MacDonald H, 2002, PEDIATRICS, V110, P1024, DOI 10.1542/peds.110.5.1024; Mongelli M, 1996, AM J OBSTET GYNECOL, V174, P278, DOI 10.1016/S0002-9378(96)70408-8; Morin I, 2005, BJOG-INT J OBSTET GY, V112, P145, DOI 10.1111/j.1471-0528.2004.00311.x; Mul T, 1996, ULTRASOUND OBST GYN, V8, P397; Nutting PA, 2005, ANN FAM MED, V3, P529, DOI 10.1370/afm.371; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Paris JJ, 2005, PEDIATRICS, V115, P1415, DOI 10.1542/peds.2004-1950; Partridge J C, 2001, J Perinatol, V21, P27; Peerzada JM, 2004, J PEDIATR-US, V145, P492, DOI 10.1016/j.jpeds.2004.06.018; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Saigal S, 2003, ARCH PEDIAT ADOL MED, V157, P261, DOI 10.1001/archpedi.157.3.261; Saltvedt S, 2004, ULTRASOUND OBST GYN, V24, P42, DOI 10.1002/uog.1047; Schmitt SK, 2006, PEDIATRICS, V117, P154, DOI 10.1542/peds.2005-0484; Sheldon T, 2001, BRIT MED J, V322, P1383, DOI 10.1136/bmj.322.7299.1383; SNIDJERS T, 2002, MULTILEVEL ANAL INTR; Stark AR, 2007, PEDIATRICS, V119, P401, DOI 10.1542/peds.2006-3180; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Tyson JE, 2003, CLIN PERINATOL, V30, P363, DOI 10.1016/S0095-5108(03)00028-9; Tyson JE, 1996, JAMA-J AM MED ASSOC, V276, P1645, DOI 10.1001/jama.276.20.1645; Vohr BR, 2005, PEDIATRICS, V116, P123, DOI 10.1542/peds.2004-1810; Wilcox AJ, 2000, BRIT MED J, V321, P1259, DOI 10.1136/bmj.321.7271.1259	40	631	652	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1672	1681		10.1056/NEJMoa073059	http://dx.doi.org/10.1056/NEJMoa073059			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288DO	18420500	Green Accepted, Green Submitted			2022-12-28	WOS:000254966600005
J	Psaty, BM; Kronmal, RA				Psaty, Bruce M.; Kronmal, Richard A.			Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment - A case study based on documents from rofecoxib litigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-JOURNAL-EDITORS; CLINICAL-TRIALS; INTERNATIONAL-COMMITTEE; EVENTS; STATEMENT; PUBLICATION	Sponsors have a marketing interest to represent their products in the best light. This approach conflicts with scientific standards that require the symmetric and comparable reporting of safety and efficacy data. Selective reporting of the results of clinical trials can misrepresent the risk- benefit profile of drugs. We summarize how the sponsor represented mortality findings associated with rofecoxib in clinical trials of patients with Alzheimer disease or cognitive impairment. We reviewed documents that became available during litigation related to rofecoxib involving Merck & Co, including internal company analyses and information provided by the sponsor to the FDA. We also evaluated information in 2 published articles that reported results of these trials. In one article ( reporting results of protocol 091) published in 2004,11 "non- drug related deaths" were reported ( 9 deaths among 346 rofecoxib patients and 2 deaths among 346 placebo patients). In another article ( reporting results of protocol 078) published in 2005,39 deaths were reported among patients taking study treatment or within 14 days of the last dose ( 24 among 725 rofecoxib patients and 15 among 732 placebo patients) and an additional 22 deaths in the off- drug period ( 17 in rofecoxib patients and 5 in placebo patients). However, these articles did not include analyses or statistical tests of the mortality data, and the 2 articles concluded that regarding safety, rofecoxib is "well tolerated." In contrast, in April 2001, the company's internal intention- to- treat analyses of pooled data from these 2 trials identified a significant increase in total mortality ( hazard ratio [ HR], 4.43; 95% CI, 1.26- 15.53 for protocol 091, and HR, 2.55; 95% CI, 1.17- 5.56 for protocol 078), with overall mortality of 34 deaths among 1069 rofecoxib patients and 12 deaths among 1078 placebo patients ( HR, 2.99; 95% CI, 1.55- 5.77). These mortality analyses were neither provided to the FDA nor made public in a timely fashion. The data submitted by the sponsor to the FDA in a Safety Update Report in July 2001 used on- treatment analysis methods and reported 29 deaths ( 2.7%) among 1067 rofecoxib patients and 17 deaths ( 1.6%) among 1075 placebo patients. This on- treatment approach to reporting minimized the appearance of any mortality risk. In December 2001, when the FDA raised safety questions about the submitted safety data, the sponsor did not bring these issues to an institutional review board for review and revealed that there was no data and safety monitoring board for the protocol 078 study. The findings from this case study suggest that additional protections for human research participants, including new approaches for the conduct, oversight, and reporting of industry sponsored trials, are necessary.	[Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; [Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA 98101 USA; [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA; [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA; [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; [Kronmal, Richard A.] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Dept Biostat, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; University of Washington; University of Washington Seattle	Psaty, BM (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Ste 1360, Seattle, WA 98101 USA.	psaty@u.washington.edu						Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; De Angelis CD, 2005, JAMA-J AM MED ASSOC, V293, P2927, DOI 10.1001/jama.293.23.jed50037; DeAngelis CD, 2004, JAMA-J AM MED ASSOC, V292, P1363, DOI 10.1001/jama.292.11.1363; Fontanarosa PB, 2008, JAMA-J AM MED ASSOC, V299, P95, DOI 10.1001/jama.2007.28; GRASSLEY CE, 2006, COMMUNICATION   1213; Kerr DJ, 2007, NEW ENGL J MED, V357, P360, DOI 10.1056/NEJMoa071841; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; Korn D, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010001; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; *OFF INSP GEN, 2007, FOOD DRUG ADM OV CLI; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Reines SA, 2004, NEUROLOGY, V62, P66, DOI 10.1212/WNL.62.1.66; Shuchman M, 2007, NEW ENGL J MED, V357, P1365, DOI 10.1056/NEJMp078176; Thal LJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1204, DOI 10.1038/sj.npp.1300690; Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779	15	126	128	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1813	1817		10.1001/jama.299.15.1813	http://dx.doi.org/10.1001/jama.299.15.1813			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18413875				2022-12-28	WOS:000254954800025
J	Kesselheim, AS; Choudhry, NK				Kesselheim, Aaron S.; Choudhry, Niteesh K.			The international pharmaceutical market as a source of low-cost prescription drugs for US patients	ANNALS OF INTERNAL MEDICINE			English	Article							COUNTERFEIT DRUGS; GENERIC DRUGS; UNITED-STATES; PRICES; POLICIES	In response to increasing prescription drug costs, more U.S. patients and policymakers are importing less-expensive pharmaceutical products from other countries. Large-scale prescription drug importation is currently illegal, but the U.S. Food and Drug Administration permits individuals to bring in 90-day supplies of drugs for personal use. As patient use of foreign-bought drugs has increased, federal legislators have continued to debate the full legalization of importation. Three factors help guide whether U.S. patients and policymakers can rely on other countries as sources of imported prescription drugs: whether the safety of the product can be ensured, how the import price compares with domestic prices, and how importation might affect the exporting country's pharmaceutical market. In wealthier countries with active regulatory systems, drug safety can be adequately ensured, and brand-name products are usually less expensive than in the United States (although generic drugs may be more expensive). However, implementing large-scale importation can negatively impact the originating country's market and can diminish the long-term cost savings for U.S. consumers. In low- and middle-income countries, prices may be reduced for both brand-name and generic drugs, but the prevalence of unauthorized products on the market makes ensuring drug safety more difficult. It may be reasonable for individual U.S. consumers to purchase essential medicines from certain international markets, but the most effective way to decrease drug costs overall is the appropriate use of domestic generic drugs, which are available for almost every major therapeutic class.	[Kesselheim, Aaron S.] Brigham & Womens Hosp, Harvard Med Sch, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kesselheim, AS (corresponding author), Brigham & Womens Hosp, Harvard Med Sch, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	akesselheim@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Baker C, 2004, WOULD PRESCRIPTION D; BARRY P, 2004, AARP B           OCT; Choudhry NK, 2007, HEALTH AFFAIR, V26, P186, DOI 10.1377/hlthaff.26.1.186; Choudhry NK, 2005, JAMA-J AM MED ASSOC, V293, P358, DOI 10.1001/jama.293.3.358; Cockburn R, 2005, PLOS MED, V2, P302, DOI 10.1371/journal.pmed.0020100; *CONS REP BEST BUY, 2006, TREAT HEAD TRIPT; CUMMINGS J, 2006, WALL STREET J   0915, V5; FAMILIES USA, 2002, PROFITING PAIN PRESC; Fischer MA, 2004, JAMA-J AM MED ASSOC, V291, P1850, DOI 10.1001/jama.291.15.1850; Frank RG, 2004, NEW ENGL J MED, V351, P1375, DOI 10.1056/NEJMp048158; Frank RG, 2007, NEW ENGL J MED, V357, P1993, DOI 10.1056/NEJMp078193; Gagnon MA, 2008, PLOS MED, V5, P29, DOI 10.1371/journal.pmed.0050001; Hollis A, 2006, AM J LAW MED, V32, P193, DOI 10.1177/009885880603200204; JOHNSON A, 2007, WALL STREET J   0127, pA4; *KAIS FAM FDN, 2005, PRESCR DRUG TRENDS; Kesselheim AS, 2006, HEALTH AFFAIR, V25, P1637, DOI 10.1377/hlthaff.25.6.1637; Kramer Andrew, 2006, NY TIMES        0516, pC1; Liang BA, 2006, AM J LAW MED, V32, P279, DOI 10.1177/009885880603200207; Mueller JM, 2007, NEW ENGL J MED, V356, P541, DOI 10.1056/NEJMp068245; OUTTERSON K, 2006, ALBANY LAW J SCI TEC, V16, P525; Outterson Kevin, 2005, Yale J Health Policy Law Ethics, V5, P193; PEAR R, 2008, NY TIMES        0508, pA1; *PFIZ, 2006, PAT INF LIP; Quon BS, 2005, ANN INTERN MED, V143, P397, DOI 10.7326/0003-4819-143-6-200509200-00004; Rudolf PM, 2004, NEW ENGL J MED, V350, P1384, DOI 10.1056/NEJMp038231; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Soumerai S, 2003, J CLIN PSYCHIAT, V64, P19; *STAT ILL OFF AUD, 2006, MAN AUD FLU VACC PRO; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; THOMAS JR, 2004, PATENTS DRUG IMPORTA; *US DEP HHS SECR T, 2004, STAT N JAC PRES MAGE; *US DEP HHS SERV T, 2004, REP PRESCR DRUG IMP; US Department of Commerce International Trade Administration, 2004, PHARM PRIC CONTR OEC; *US FDA, 2004, FDA WARNS CONS COUNT; *US FDA, 2003, GEN DRUG PRIC US LOW; World Health Organization, 2005, COUNT MED SOME FREQ; 2007, AFX NEWS        0501; INTAS PHARM LIPID LO; 2003, MED LETT DRUGS THER, V45, P100	39	15	15	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2008	148	8					614	619		10.7326/0003-4819-148-8-200804150-00006	http://dx.doi.org/10.7326/0003-4819-148-8-200804150-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290LF	18413623				2022-12-28	WOS:000255123600006
J	Horton, R				Horton, Richard			Countdown to 2015: a report card on maternal, newborn, and child survival	LANCET			English	Editorial Material							HEALTH; MEXICO		Lancet, London NW1 7BY, England		Horton, R (corresponding author), Lancet, London NW1 7BY, England.							*BELL STUD GROUP C, 2003, LANCET, V361, P323; Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6; Boerma JT, 2008, LANCET, V371, P1259, DOI 10.1016/S0140-6736(08)60560-7; Bradshaw D, 2008, LANCET, V371, P1294, DOI 10.1016/S0140-6736(08)60564-4; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Bryce J, 2006, LANCET, V368, P1067, DOI 10.1016/S0140-6736(06)69339-2; Cavagnero E, 2008, LANCET, V371, P1284, DOI 10.1016/S0140-6736(08)60563-2; Chowdhury ME, 2007, LANCET, V370, P1320, DOI 10.1016/S0140-6736(07)61573-6; Filippi V, 2007, LANCET, V370, P1329, DOI 10.1016/S0140-6736(07)61574-8; Greco G, 2008, LANCET, V371, P1268, DOI 10.1016/S0140-6736(08)60561-9; Ijsselmuiden C, 2008, LANCET, V371, P91, DOI 10.1016/S0140-6736(08)60080-X; Lawn JE, 2006, LANCET, V367, P1541, DOI 10.1016/S0140-6736(06)68587-5; Masanja H, 2008, LANCET, V371, P1276, DOI 10.1016/S0140-6736(08)60562-0; Powell-Jackson T, 2006, LANCET, V368, P1077, DOI 10.1016/S0140-6736(06)69338-0; Reich MR, 2008, LANCET, V371, P865, DOI 10.1016/S0140-6736(08)60384-0; Sepulveda J, 2006, LANCET, V368, P2017, DOI 10.1016/S0140-6736(06)69569-X	16	17	21	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1217	1219		10.1016/S0140-6736(08)60533-4	http://dx.doi.org/10.1016/S0140-6736(08)60533-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	286XH	18406841				2022-12-28	WOS:000254878900004
J	Pelton, JN; Logsdon, J				Pelton, Joseph N.; Logsdon, John			Arthur C. Clarke (1917-2008) - Retrospective	SCIENCE			English	Biographical-Item									[Pelton, Joseph N.] George Washington Univ, Space & Adv Commun Res Inst, Washington, DC 20052 USA; [Logsdon, John] George Washington Univ, Inst Space Policy, Washington, DC 20052 USA	George Washington University; George Washington University	Pelton, JN (corresponding author), George Washington Univ, Space & Adv Commun Res Inst, Washington, DC 20052 USA.	logsdon@gwu.edu						CLARKE A, PUBLICATION LIST	1	1	1	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					189	189		10.1126/science.1158220	http://dx.doi.org/10.1126/science.1158220			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403701				2022-12-28	WOS:000254836700031
J	Erez, N; Gordon, G; Nest, M; Kurizki, G				Erez, Noam; Gordon, Goren; Nest, Mathias; Kurizki, Gershon			Thermodynamic control by frequent quantum measurements	NATURE			English	Article							DECAY; WORK; BATH	Heat flow between a large thermal `bath' and a smaller system brings them progressively closer to thermal equilibrium while increasing their entropy(1). Fluctuations involving a small fraction of a statistical ensemble of systems interacting with the bath result in deviations from this trend. In this respect, quantum and classical thermodynamics are in agreement(1-5). Here we predict a different trend in a purely quantum mechanical setting: disturbances of thermal equilibrium between two-level systems (TLSs) and a bath(6), caused by frequent, brief quantum non-demolition(7-10) measurements of the TLS energy states. By making the measurements increasingly frequent, we encounter first the anti-Zeno regime and then the Zeno regime (namely where the TLSs' relaxation respectively speeds up and slows down(11-15)). The corresponding entropy and temperature of both the system and the bath are then found to either decrease or increase depending only on the rate of observation, contrary to the standard thermodynamical rules that hold for memory-less ( Markov) baths(2,5). From a practical viewpoint, these anomalies may offer the possibility of very fast control of heat and entropy in quantum systems, allowing cooling and state purification over an interval much shorter than the time needed for thermal equilibration or for a feedback control loop.	[Erez, Noam; Gordon, Goren; Kurizki, Gershon] Weizmann Inst Sci, Dept Chem Phys, IL-76100 Rehovot, Israel; [Nest, Mathias] Univ Potsdam, D-14476 Potsdam, Germany	Weizmann Institute of Science; University of Potsdam	Kurizki, G (corresponding author), Weizmann Inst Sci, Dept Chem Phys, IL-76100 Rehovot, Israel.	gershon.kurizki@weizmann.ac.il	Nest, Mathias/C-1412-2010; Gordon, Goren/ABB-8100-2021	Gordon, Goren/0000-0002-8351-7034				ALICKI R, 1979, J PHYS A-MATH GEN, V12, pL103, DOI 10.1088/0305-4470/12/5/007; Allahverdyan AE, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.260404; Allahverdyan AE, 2000, PHYS REV LETT, V85, P1799, DOI 10.1103/PhysRevLett.85.1799; BARNETT SM, 1993, NATURE, V362, P113, DOI 10.1038/362113a0; Beck MH, 2000, PHYS REP, V324, P1, DOI 10.1016/S0370-1573(99)00047-2; Braginsky V. B., 1995, QUANTUM MEASUREMENT; Cohen-Tannoudji C., 1998, ATOM PHOTON INTERACT; Facchi P, 2001, PROG OPTICS, V42, P147, DOI 10.1016/S0079-6638(01)80017-2; Gelman D, 2003, CHEM PHYS LETT, V381, P129, DOI 10.1016/j.cplett.2003.09.119; Jarzynski C, 1997, PHYS REV LETT, V78, P2690, DOI 10.1103/PhysRevLett.78.2690; Kofman AG, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.130406; Kofman AG, 2000, NATURE, V405, P546, DOI 10.1038/35014537; LANE AM, 1983, PHYS LETT A, V99, P359, DOI 10.1016/0375-9601(83)90292-X; LINDBLAD G, 1974, COMMUN MATH PHYS, V39, P111, DOI 10.1007/BF01608390; MISRA B, 1977, J MATH PHYS, V18, P756, DOI 10.1063/1.523304; Nest M, 2003, J CHEM PHYS, V119, P24, DOI 10.1063/1.1576384; Schulman LS, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.240405; Scully MO, 2003, SCIENCE, V299, P862, DOI 10.1126/science.1078955; Scully MO, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.220601; SPOHN H, 1978, J MATH PHYS, V19, P1227, DOI 10.1063/1.523789; Stelmachovic P, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.062106; Zurek WH, 2003, REV MOD PHYS, V75, P715, DOI 10.1103/RevModPhys.75.715; [No title captured]	24	156	158	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2008	452	7188					724	727		10.1038/nature06873	http://dx.doi.org/10.1038/nature06873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401404	Green Submitted			2022-12-28	WOS:000254792500039
J	Howard, BV; Roman, MJ; Devereux, RB; Fleg, JL; Galloway, JM; Henderson, JA; Howard, WJ; Lee, ET; Mete, M; Poolaw, B; Ratner, RE; Russell, M; Silverman, A; Stylianou, M; Umans, JG; Wang, WY; Weir, MR; Weissman, NJ; Wilson, C; Yeh, F; Zhu, JH				Howard, Barbara V.; Roman, Mary J.; Devereux, Richard B.; Fleg, Jerome L.; Galloway, James M.; Henderson, Jeffrey A.; Howard, Wm. James; Lee, Elisa T.; Mete, Mihriye; Poolaw, Bryce; Ratner, Robert E.; Russell, Marie; Silverman, Angela; Stylianou, Mario; Umans, Jason G.; Wang, Wenyu; Weir, Matthew R.; Weissman, Neil J.; Wilson, Charlton; Yeh, Fawn; Zhu, Jianhui			Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes - The SANDS randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; INTIMA-MEDIA THICKNESS; LEFT-VENTRICULAR HYPERTROPHY; CARDIOVASCULAR-DISEASE; CAROTID ATHEROSCLEROSIS; SECONDARY PREVENTION; DOUBLE-BLIND; MYOCARDIAL-INFARCTION; REDUCING CHOLESTEROL; SUBGROUP ANALYSIS	Context Individuals with diabetes are at increased risk for cardiovascular disease ( CVD), but more aggressive targets for risk factor control have not been tested. Objective To compare progression of subclinical atherosclerosis in adults with type 2 diabetes treated to reach aggressive targets of low- density lipoprotein cholesterol ( LDL- C) of 70 mg/ dL or lower and systolic blood pressure ( SBP) of 115 mm Hg or lower vs standard targets of LDL- C of 100 mg/ dL or lower and SBP of 130 mm Hg or lower. Design, Setting, and Participants A randomized, open- label, blinded- to- end point, 3- year trial from April 2003- July 2007 at 4 clinical centers in Oklahoma, Arizona, and South Dakota. Participants were 499 American Indian men and women aged 40 years or older with type 2 diabetes and no prior CVD events. Interventions Participants were randomized to aggressive ( n= 252) vs standard ( n= 247) treatment groups with stepped treatment algorithms defined for both. Main Outcome Measures Primary end point was progression of atherosclerosis measured by common carotid artery intimal medial thickness ( IMT). Secondary end points were other carotid and cardiac ultrasonographic measures and clinical events. Results Mean target LDL- C and SBP levels for both groups were reached and maintained. Mean ( 95% confidence interval) levels for LDL- C in the last 12 months were 72 ( 69- 75) and 104 ( 101- 106) mg/ dL and SBP levels were 117 ( 115- 118) and 129 ( 128130) mm Hg in the aggressive vs standard groups, respectively. Compared with baseline, IMT regressed in the aggressive group and progressed in the standard group (- 0.012 mm vs 0.038 mm; P <. 001); carotid arterial cross- sectional area also regressed (- 0.02 mm(2) vs 1.05 mm(2); P <. 001); and there was greater decrease in left ventricular mass index (- 2.4 g/m(2.7) vs - 1.2 g/m(2.7); P =. 03) in the aggressive group. Rates of adverse events ( 38.5% and 26.7%; P=. 005) and serious adverse events ( n= 4 vs 1; P=. 18) related to blood pressure medications were higher in the aggressive group. Clinical CVD events ( 1.6/ 100 and 1.5/ 100 person- years; P=. 87) did not differ significantly between groups. Conclusions Reducing LDL- C and SBP to lower targets resulted in regression of carotid IMT and greater decrease in left ventricular mass in individuals with type 2 diabetes. Clinical events were lower than expected and did not differ significantly between groups. Further follow- up is needed to determine whether these improvements will result in lower long- term CVD event rates and costs and favorable risk- benefit outcomes. Trial Registration clinicaltrials. gov Identifier: NCT00047424.	[Howard, Barbara V.; Mete, Mihriye; Ratner, Robert E.; Silverman, Angela; Umans, Jason G.; Weissman, Neil J.; Zhu, Jianhui] MedStar Res Inst, Hyattsville, MD 20783 USA; [Roman, Mary J.; Devereux, Richard B.] Weill Cornell Med Coll, New York, NY USA; [Fleg, Jerome L.; Stylianou, Mario] NHLBI, Bethesda, MD 20892 USA; [Galloway, James M.] Univ Arizona, Hlth Sci Ctr, Tucson, AZ USA; [Henderson, Jeffrey A.] Black Hills Ctr Amer Indian Hlth, Rapid City, SD USA; [Howard, Wm. James] Washington Hosp Ctr, Washington, DC 20010 USA; [Lee, Elisa T.; Wang, Wenyu; Yeh, Fawn] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; [Poolaw, Bryce] Lawton Indian Hosp, Lawton, OK USA; [Russell, Marie; Wilson, Charlton] Phoenix Indian Med Ctr, Phoenix, AZ USA; [Weir, Matthew R.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Arizona; University of Arizona Health Sciences; MedStar Washington Hospital Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University System of Maryland; University of Maryland Baltimore	Howard, BV (corresponding author), MedStar Res Inst, 6495 New Hampshire Ave,Suite 201, Hyattsville, MD 20783 USA.	barbara.v.howard@medstar.net	Weir, Matthew R/ABC-3654-2021	Weir, Matthew R/0000-0001-8820-5702	NHLBI NIH HHS [U01 HL067031, 1U01 HL67031-01A1, U01 HL067031-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL067031] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; ALLAIN CC, 1974, CLIN CHEM, V20, P470; *ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; BUTLER WJ, 1985, AM J EPIDEMIOL, V121, P541; BYINGTON RP, 1995, AM J CARDIOL, V76, pC54, DOI 10.1016/S0002-9149(99)80471-8; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2003, LANCET, V361, P2005; Crouse JR, 2007, JAMA-J AM MED ASSOC, V297, P1344, DOI 10.1001/jama.297.12.1344; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; de Groot E, 1998, J AM COLL CARDIOL, V31, P1561, DOI 10.1016/S0735-1097(98)00170-3; Devereux RB, 2004, JAMA-J AM MED ASSOC, V292, P2350, DOI 10.1001/jama.292.19.2350; Devereux Richard B., 1995, P1969; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Espeland MA, 2005, CURR CONTR TRIALS C, V6, DOI 10.1186/1468-6708-6-3; Estacio RO, 2000, DIABETES CARE, V23, pB54; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Gavin JR, 1997, DIABETES CARE, V20, P1183; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hedblad B, 2001, CIRCULATION, V103, P1721, DOI 10.1161/01.CIR.103.13.1721; Hodis HN, 1996, ANN INTERN MED, V124, P548, DOI 10.7326/0003-4819-124-6-199603150-00002; Hoogwerf BJ, 1999, DIABETES, V48, P1289, DOI 10.2337/diabetes.48.6.1289; Howard Barbara V., 1996, P792; Howard BV, 2000, ARTERIOSCL THROM VAS, V20, P830, DOI 10.1161/01.ATV.20.3.830; Howard BV, 2006, DIABETES CARE, V29, P391, DOI 10.2337/diacare.29.02.06.dc05-1299; Howard BV, 1999, CIRCULATION, V99, P2389, DOI 10.1161/01.CIR.99.18.2389; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; Keech A, 2003, DIABETES CARE, V26, P2713, DOI 10.2337/diacare.26.10.2713; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; KLEINMAN JC, 1988, AM J EPIDEMIOL, V128, P389, DOI 10.1093/oxfordjournals.aje.a114979; Knopp RH, 2006, DIABETES CARE, V29, P1478, DOI 10.2337/dc05-2415; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; KOSKINEN P, 1992, DIABETES CARE, V15, P820, DOI 10.2337/diacare.15.7.820; Lonn EM, 2001, CIRCULATION, V103, P919; MACK WJ, 1993, STROKE, V24, P1779, DOI 10.1161/01.STR.24.12.1779; MacMahon S, 1998, CIRCULATION, V97, P1784, DOI 10.1161/01.CIR.97.18.1784; Mercuri M, 1996, AM J MED, V101, P627, DOI 10.1016/S0002-9343(96)00333-6; *NIH, 1997, NIH PUBL; Okin PM, 2007, ANN INTERN MED, V147, P311, DOI 10.7326/0003-4819-147-5-200709040-00006; Okin PM, 2006, JAMA-J AM MED ASSOC, V296, P1242, DOI 10.1001/jama.296.10.1242; Okin PM, 2004, JAMA-J AM MED ASSOC, V292, P2343, DOI 10.1001/jama.292.19.2343; Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8; Pedersen TR, 2005, JAMA-J AM MED ASSOC, V294, P2437, DOI 10.1001/jama.294.19.2437; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Quinones MA, 2002, J AM SOC ECHOCARDIOG, V15, P167, DOI 10.1067/mje.2002.120202; Roman MJ, 1998, AM J HYPERTENS, V11, P387, DOI 10.1016/S0895-7061(97)00492-5; Roman MJ, 1996, J AM COLL CARDIOL, V28, P751, DOI 10.1016/0735-1097(96)00225-2; Rubins HB, 2002, ARCH INTERN MED, V162, P2597, DOI 10.1001/archinte.162.22.2597; Russell M, 2006, AM HEART J, V152, P867, DOI 10.1016/j.ahj.2006.05.021; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; Serruys PWJC, 2002, JAMA-J AM MED ASSOC, V287, P3215, DOI 10.1001/jama.287.24.3215; Sever PS, 2005, DIABETES CARE, V28, P1151, DOI 10.2337/diacare.28.5.1151; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Shepherd J, 2006, DIABETES CARE, V29, P1220, DOI 10.2337/dc05-2465; Smilde TJ, 2001, LANCET, V357, P577, DOI 10.1016/S0140-6736(00)04053-8; Taylor AJ, 2002, CIRCULATION, V106, P2055, DOI 10.1161/01.CIR.0000034508.55617.65; Taylor AJ, 2004, CIRCULATION, V110, P3512, DOI 10.1161/01.CIR.0000148955.19792.8D; *US DEP HHS, SERV IND OTH 2 1 2 P; Vakili BA, 2001, AM HEART J, V141, P334, DOI 10.1067/mhj.2001.113218; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; Wachtell K, 2007, CIRCULATION, V116, P700, DOI 10.1161/CIRCULATIONAHA.106.666594; WEI LJ, 1984, J AM STAT ASSOC, V79, P653, DOI 10.2307/2288413; Zanchetti A, 2002, CIRCULATION, V106, P2422, DOI 10.1161/01.CIR.0000039288.86470.DD; Zoghbi WA, 2003, J AM SOC ECHOCARDIOG, V16, P777, DOI 10.1016/S0894-7317(03)00335-3	73	185	196	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2008	299	14					1678	1689		10.1001/jama.299.14.1678	http://dx.doi.org/10.1001/jama.299.14.1678			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285AL	18398080	Green Accepted			2022-12-28	WOS:000254749600024
J	Edwards, M				Edwards, Martin			Historical keyword - Symptoms	LANCET			English	Editorial Material									UCL, Wellcome Trust Ctr Hist Med, London WC1E 6BT, England	University of London; University College London	Edwards, M (corresponding author), UCL, Wellcome Trust Ctr Hist Med, London WC1E 6BT, England.	martin@martinedwards.me.uk							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 5	2008	371	9619					1157	1157		10.1016/S0140-6736(08)60510-3	http://dx.doi.org/10.1016/S0140-6736(08)60510-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395568				2022-12-28	WOS:000254956000014
J	McKinstry, B; Dacre, J				McKinstry, Brian; Dacre, Jane			Are there too many female medical graduates?	BRITISH MEDICAL JOURNAL			English	Editorial Material									[McKinstry, Brian] Univ Edinburgh, Gen Practice Sect, Edinburgh EH8 9DX, Midlothian, Scotland; [Dacre, Jane] UCL, Fac Biomed Sci, London WC1E 6BT, England; [Dacre, Jane] Royal Coll Physicians, London NW1 4LE, England	University of Edinburgh; University of London; University College London; Royal College of Physicians	McKinstry, B (corresponding author), Univ Edinburgh, Gen Practice Sect, Edinburgh EH8 9DX, Midlothian, Scotland.	brian.mckinstry@ed.ac.uk; j.dacre@medsch.ucl.ac.uk		McKinstry, Brian/0000-0001-9581-0468					0	71	71	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 5	2008	336	7647					748	749		10.1136/bmj.39505.491065.94	http://dx.doi.org/10.1136/bmj.39505.491065.94			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	284JW	18390524	Green Published, Green Submitted			2022-12-28	WOS:000254703700029
J	Marte, B; Eccleston, A; Nath, D				Marte, Barbara; Eccleston, Alex; Nath, Deepa			Molecular cancer diagnostics	NATURE			English	Editorial Material																			0	6	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2008	452	7187					547	547		10.1038/452547a	http://dx.doi.org/10.1038/452547a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385727	Bronze			2022-12-28	WOS:000254567200031
J	Stafford, RS				Stafford, Randall S.			Regulating off-label drug use - Rethinking the role of the FDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA	Stanford University	Stafford, RS (corresponding author), Stanford Univ, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA.		Stafford, Randall/F-3974-2017	Stafford, Randall/0000-0003-1805-1271				ADAMS C, 2003, RISKYRX KNIGHT RIDER; Dai CL, 2005, ARCH INTERN MED, V165, P171, DOI 10.1001/archinte.165.2.171; *FOOD DRUG ADM, 2008, GUID IND GOOD REPR P; Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021	4	219	248	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1427	1429		10.1056/NEJMp0802107	http://dx.doi.org/10.1056/NEJMp0802107			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	282CY	18385495	Bronze			2022-12-28	WOS:000254546400003
J	Baron, RJ; Cassel, CK				Baron, Richard J.; Cassel, Christine K.			21st-century primary care - New physician roles need new payment models	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Cassel, Christine K.] Amer Board Internal Med, Philadelphia, PA 19106 USA; [Baron, Richard J.] Greenhouse Internists PC, Philadelphia, PA USA	American Board of Internal Medicine	Cassel, CK (corresponding author), Amer Board Internal Med, 510 Walnut St,Ste 1700, Philadelphia, PA 19106 USA.	ccassel@abim.org						Bodenheimer T, 2007, ANN INTERN MED, V146, P301, DOI 10.7326/0003-4819-146-4-200702200-00011; Bowen JL, 2005, J GEN INTERN MED, V20, P1181, DOI 10.1111/j.1525-1497.2005.0248.x; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Farber J, 2007, ANN INTERN MED, V147, P693, DOI 10.7326/0003-4819-147-10-200711200-00005; Ginsburg PB, 2007, NEW ENGL J MED, V356, P1201, DOI 10.1056/NEJMp068272; Godfrey Marjorie M, 2003, Jt Comm J Qual Saf, V29, P159; Goroll AH, 2007, J GEN INTERN MED, V22, P410, DOI 10.1007/s11606-006-0083-2; Griner PF, 2007, JT COMM J QUAL PATIE, V33, P63, DOI 10.1016/S1553-7250(07)33008-0; Mundinger MO, 2000, JAMA-J AM MED ASSOC, V283, P59, DOI 10.1001/jama.283.1.59; Naylor MD, 2000, PUBLIC HEALTH NURS, V17, P94, DOI 10.1046/j.1525-1446.2000.00094.x; Orszag PR, 2007, NEW ENGL J MED, V357, P1793, DOI 10.1056/NEJMp078190; Pham HH, 2007, HEALTH AFFAIR, V26, pW532, DOI 10.1377/hlthaff.26.4.w532; Sage WM, 2007, J LEGAL MED, V28, P503, DOI 10.1080/01947640701732155; STARCEVIC V, 1992, J PERS DISORD, V6, P213, DOI 10.1521/pedi.1992.6.3.213	14	26	26	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2008	299	13					1595	1597		10.1001/jama.299.13.1595	http://dx.doi.org/10.1001/jama.299.13.1595			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	281RZ	18387933				2022-12-28	WOS:000254517900026
J	Salanti, G; Kavvoura, FK; Ioannidis, JPA				Salanti, Georgia; Kavvoura, Fotini K.; Ioannidis, John P. A.			Exploring the geometry of treatment networks	ANNALS OF INTERNAL MEDICINE			English	Article							DRUG-ELUTING STENTS; CLINICAL-TRIALS; MULTIPLE TREATMENTS; RANDOMIZED-TRIALS; METAANALYSIS; OUTCOMES; DECLARATION; RESISTANCE; HELSINKI; EFFICACY	Background: Several treatment options exist for many conditions. Randomized trial evidence on the relative merits of various options may be missing or biased. Purpose: To examine the patterns of trial evidence (network geometry) and explain their implications for the interpretation of the existing evidence on a treatment's relative effectiveness. Data Sources: PubMed and Thompson ISI Web of Knowledge (last search April 2007). Study Selection: Published networks of randomized trials that included at least 4 treatments were identified. Data Extraction: For each network, data on the number of studies per treatment comparison were extracted by one investigator and verified by a second investigator. Data Synthesis: indices were adopted from the ecological literature that measure diversity (number of treatments and how often they were tested) and co-occurrence (whether some treatment comparisons were preferred and others avoided). Eighteen eligible treatment networks were identified for different diseases, involving 4 to 16 alternative treatment, and 10 to 84 trials. Networks in which 1 option (placebo or no treatment) was the typical comparator were star-shaped, even though several treatments might have had proven effectiveness. Other networks had different shapes. Some showed important co-occurrence that avoided specific head-to-head comparisons. Comparison choices sometimes seemed justified, such as when newer treatments were not compared with older ones already shown to be inferior, whereas other choices seemed to reflect preference bias. Limitations: Networks evolve over time as new trials accumulate, and their geometry may change. Statistical testing for co-occurrence is underpowered when few trials exist. Conclusion: Evaluation of the geometry of a treatment network can offer valuable insights for the interpretation of total evidence when many treatment options are available.	[Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; Tufts Univ, Sch Med, Boston, MA 02111 USA	University of Ioannina; Tufts University	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Ioannidis, John P. A./G-9836-2011	Salanti, Georgia/0000-0002-3830-8508				[Anonymous], 2004, REVELATION, DOI DOI 10.1002/14651858.CD002781.PUB2; Bero L, 2007, PLOS MED, V4, P1001, DOI 10.1371/journal.pmed.0040184; Biondi-Zoccai GL, 2005, INT J CARDIOL, V100, P119, DOI 10.1016/j.ijcard.2004.11.001; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Cooper NJ, 2006, ARCH INTERN MED, V166, P1269, DOI 10.1001/archinte.166.12.1269; Djavan B, 1999, EUR UROL, V36, P1, DOI 10.1159/000019919; Elliott WJ, 2007, LANCET, V369, P201, DOI 10.1016/S0140-6736(07)60108-1; Gartlehner G, 2006, J RHEUMATOL, V33, P2398; Glenny AM, 2005, HEALTH TECHNOL ASSES, V9, P1; GOTELLI NJ, 2004, ECOSIM N MODELS SOFT; Hales G, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010018; Heres S, 2006, AM J PSYCHIAT, V163, P185, DOI 10.1176/appi.ajp.163.2.185; Higgins JPT, 1996, STAT MED, V15, P2733, DOI 10.1002/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; HURLBERT SH, 1971, ECOLOGY, V52, P577, DOI 10.2307/1934145; Ioannidis JPA, 2006, LANCET, V368, P1470, DOI 10.1016/S0140-6736(06)69615-3; Jansen JP, 2006, CURR MED RES OPIN, V22, P671, DOI 10.1185/030079906X96308; Kyrgiou M, 2006, JNCI-J NATL CANCER I, V98, P1655, DOI 10.1093/jnci/djj443; Levine RJ, 1999, NEW ENGL J MED, V341, P531, DOI 10.1056/NEJM199908123410713; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWONTIN RC, 1960, EVOLUTION, V14, P458, DOI 10.2307/2405995; Lilford RJ, 2003, BRIT MED J, V326, P980, DOI 10.1136/bmj.326.7396.980; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; Macfadyen CA, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004618.pub2; Mason Lorna, 2004, BMC Fam Pract, V5, P10, DOI 10.1186/1471-2296-5-10; Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731; Morris MC, 2007, CRIT CARE MED, V35, P940, DOI 10.1097/01.CCM.0000257333.95528.B8; Nixon RM, 2007, STAT MED, V26, P1237, DOI 10.1002/sim.2624; Otoul C, 2005, CLIN NEUROPHARMACOL, V28, P72, DOI 10.1097/01.wnf.0000159956.87511.67; Panidou ET, 2004, AIDS, V18, P2153, DOI 10.1097/00002030-200411050-00007; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Peppercorn J, 2007, CANCER-AM CANCER SOC, V109, P1239, DOI 10.1002/cncr.22528; Playford EG, 2006, EUR J CLIN MICROBIOL, V25, P549, DOI 10.1007/s10096-006-0182-3; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Richy F, 2005, CALCIFIED TISSUE INT, V76, P176, DOI 10.1007/s00223-004-0005-4; Rothman KJ, 2000, BMJ-BRIT MED J, V321, P442, DOI 10.1136/bmj.321.7258.442; Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P1, DOI 10.1002/0470870168; SALANTI G, 2007, STAT METHODS MED RES; Sidhu S, 2006, BRIT J CLIN PHARMACO, V61, P720, DOI 10.1111/j.1365-2125.2006.02614.x; Stettler C, 2007, LANCET, V370, P937, DOI 10.1016/S0140-6736(07)61444-5; Stone GW, 2007, NEW ENGL J MED, V356, P998, DOI 10.1056/NEJMoa067193; Wolinsky H, 2006, EMBO REP, V7, P670, DOI 10.1038/sj.embor.7400743; Wu P, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-300; Zwarenstein M, 2006, J CLIN EPIDEMIOL, V59, P1125, DOI 10.1016/j.jclinepi.2006.05.010	47	152	154	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2008	148	7					544	553		10.7326/0003-4819-148-7-200804010-00011	http://dx.doi.org/10.7326/0003-4819-148-7-200804010-00011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284IV	18378949				2022-12-28	WOS:000254701000007
J	Ferner, R; Beard, K				Ferner, Robin; Beard, Keith			Over the counter medicines: proceed with caution	BRITISH MEDICAL JOURNAL			English	Editorial Material							PARACETAMOL		[Ferner, Robin] City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England; [Beard, Keith] Victoria Infirm, Mansionhouse Unit, Glasgow G41 3DX, Lanark, Scotland	University of Birmingham	Ferner, R (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.	r.e.ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				Bateman DN, 2003, QJM-INT J MED, V96, P125, DOI 10.1093/qjmed/hcg015; CAMPBELL D, 2008, OBSERVER        0217, P1; Choudhry NK, 2005, ANN INTERN MED, V142, P910, DOI 10.7326/0003-4819-142-11-200506070-00009; Cohen JP, 2005, BRIT MED J, V330, P39, DOI 10.1136/bmj.330.7481.39; Glasgow JFT, 2006, DRUG SAFETY, V29, P1111, DOI 10.2165/00002018-200629120-00003; Glasier A, 1998, NEW ENGL J MED, V339, P1, DOI 10.1056/NEJM199807023390101; Hawton K, 2001, BMJ-BRIT MED J, V322, P1203, DOI 10.1136/bmj.322.7296.1203; JENKINS R, 2007, TIMES           1215; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Mansfield PR, 2005, BMJ-BRIT MED J, V330, P5, DOI 10.1136/bmj.330.7481.5; *MED HEALTHC PROD, 2006, LIST A CONS LIST SUB; *MED HEALTHC PROD, 2007, LIST B CONS LIST SUB; *MED HEALTHC PROD, AV MED; *MHRA, 2008, YELL CARD HELP MAK M; Pichichero ME, 2007, JAMA-J AM MED ASSOC, V298, P1772, DOI 10.1001/jama.298.15.1772; Rajkumar SV, 2004, MAYO CLIN PROC, V79, P899, DOI 10.4065/79.7.899; Reeves D, 2007, J ANTIMICROB CHEMOTH, V59, P333, DOI 10.1093/jac/dkl502; *ROYAL PHARM SOC G, 2007, RPS E PIC REF PRESCR; SAUL S, 2007, NY TIMES        1024; WISE J, 1997, BRIT MED J, V314, P1297; 2008, GET BRACKNELL   0111; 2006, CURR PROB PHARMACOVI, V31, P11; 2002, MAIL MHRA UPDATING S, V130, P3	23	19	21	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 29	2008	336	7646					694	696		10.1136/bmj.39504.389676.AD	http://dx.doi.org/10.1136/bmj.39504.389676.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	283ZS	18369225	Green Published			2022-12-28	WOS:000254675600022
J	Amaral, PP; Dinger, ME; Mercer, TR; Mattick, JS				Amaral, Paulo P.; Dinger, Marcel E.; Mercer, Tim R.; Mattick, John S.			The eukaryotic genome as an RNA machine	SCIENCE			English	Editorial Material							LONG NONCODING RNAS; REGULATORY RNAS; MESSENGER-RNA; HUMAN-CELLS; GENE-EXPRESSION; POLYMERASE-II; TRANSCRIPTION; CHROMATIN; ACTIVATION; DROSOPHILA		[Amaral, Paulo P.; Dinger, Marcel E.; Mercer, Tim R.; Mattick, John S.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia	University of Queensland	Mattick, JS (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	j.mattick@imb.uq.edu.au	Mercer, Tim/AAK-5060-2020; Mattick, John/ABH-6130-2020; Mattick, John S/I-7789-2012; Dinger, Marcel/N-1398-2019	Mercer, Tim/0000-0001-8780-894X; Mattick, John/0000-0002-7680-7527; Mattick, John S/0000-0002-7680-7527; Dinger, Marcel/0000-0003-4423-934X; de Paiva Amaral, Paulo/0000-0002-6696-5142				Aravin AA, 2007, SCIENCE, V318, P761, DOI 10.1126/science.1146484; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182; Berezikov E, 2007, MOL CELL, V28, P328, DOI 10.1016/j.molcel.2007.09.028; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Broadbent HM, 2008, HUM MOL GENET, V17, P806, DOI 10.1093/hmg/ddm352; Brower-Toland B, 2007, GENE DEV, V21, P2300, DOI 10.1101/gad.1564307; Buhler M, 2007, NAT STRUCT MOL BIOL, V14, P1041, DOI 10.1038/nsmb1315; Buhler M, 2007, CELL, V129, P707, DOI 10.1016/j.cell.2007.03.038; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Chekanova JA, 2007, CELL, V131, P1340, DOI 10.1016/j.cell.2007.10.056; Chen ES, 2008, NATURE, V451, P734, DOI 10.1038/nature06561; Clamp M, 2007, P NATL ACAD SCI USA, V104, P19428, DOI 10.1073/pnas.0709013104; Davis CA, 2006, P NATL ACAD SCI USA, V103, P3262, DOI 10.1073/pnas.0507783103; Espinoza CA, 2007, RNA, V13, P583, DOI 10.1261/rna.310307; Feng JC, 2006, GENE DEV, V20, P1470, DOI 10.1101/gad.1416106; Folco HD, 2008, SCIENCE, V319, P94, DOI 10.1126/science.1150944; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Hale CJ, 2007, PLOS BIOL, V5, P2156, DOI 10.1371/journal.pbio.0050275; Han J, 2007, P NATL ACAD SCI USA, V104, P12422, DOI 10.1073/pnas.0701635104; Ishii N, 2006, J HUM GENET, V51, P1087, DOI 10.1007/s10038-006-0070-9; Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341; Kawahara Y, 2007, SCIENCE, V315, P1137, DOI 10.1126/science.1138050; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kuwabara T, 2004, CELL, V116, P779, DOI 10.1016/S0092-8674(04)00248-X; Leung AKL, 2007, CELL, V130, P581, DOI 10.1016/j.cell.2007.08.010; Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103; Lin R, 2007, ONCOGENE, V26, P851, DOI 10.1038/sj.onc.1209846; Liu Y, 2007, GENE DEV, V21, P1530, DOI 10.1101/gad.1544207; Lunyak VV, 2007, SCIENCE, V317, P248, DOI 10.1126/science.1140871; Maeda N, 2006, PLOS GENET, V2, P498, DOI 10.1371/journal.pgen.0020062; Makeyev EV, 2008, SCIENCE, V319, P1789, DOI 10.1126/science.1152326; Mariner PD, 2008, MOL CELL, V29, P499, DOI 10.1016/j.molcel.2007.12.013; Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519; Mattick JS, 2007, J EXP BIOL, V210, P1526, DOI 10.1242/jeb.005017; Mercer TR, 2008, P NATL ACAD SCI USA, V105, P716, DOI 10.1073/pnas.0706729105; Murakami H, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000317; NICKERSON JA, 1989, P NATL ACAD SCI USA, V86, P177, DOI 10.1073/pnas.86.1.177; Noma KI, 2006, CELL, V125, P859, DOI 10.1016/j.cell.2006.04.028; Nowacki M, 2008, NATURE, V451, P153, DOI 10.1038/nature06452; Ohno M, 2002, CHROMOSOMA, V111, P201, DOI 10.1007/s00412-002-0198-0; Okamura K, 2007, CELL, V130, P89, DOI 10.1016/j.cell.2007.06.028; Pagano A, 2007, PLOS GENET, V3, P174, DOI 10.1371/journal.pgen.0030001; Pang KC, 2006, TRENDS GENET, V22, P1, DOI 10.1016/j.tig.2005.10.003; Peng JC, 2007, NAT CELL BIOL, V9, P25, DOI 10.1038/ncb1514; Perez DS, 2008, HUM MOL GENET, V17, P642, DOI 10.1093/hmg/ddm336; Pheasant M, 2007, GENOME RES, V17, P1245, DOI 10.1101/gr.6406307; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Pollard KS, 2006, NATURE, V443, P167, DOI 10.1038/nature05113; Ponjavic J, 2007, GENOME RES, V17, P556, DOI 10.1101/gr.6036807; Prasanth KV, 2007, GENE DEV, V21, P11, DOI 10.1101/gad.1484207; Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rodriguez-Campos A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001182; Royo H, 2007, MOL BIOL CELL, V18, P2817, DOI 10.1091/mbc.E06-10-0920; Ruby JG, 2007, NATURE, V448, P83, DOI 10.1038/nature05983; Schoeftner S, 2008, NAT CELL BIOL, V10, P228, DOI 10.1038/ncb1685; Sone M, 2007, J CELL SCI, V120, P2498, DOI 10.1242/jcs.009357; Stark A, 2007, GENOME RES, V17, P1865, DOI 10.1101/gr.6593807; Stephen S, 2008, MOL BIOL EVOL, V25, P402, DOI 10.1093/molbev/msm268; Torarinsson E, 2008, GENOME RES, V18, P242, DOI 10.1101/gr.6887408; Tyler DM, 2008, GENE DEV, V22, P26, DOI 10.1101/gad.1615208; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Willoughby DA, 2000, J BIOL CHEM, V275, P759, DOI 10.1074/jbc.275.2.759; Xu N, 2007, NAT GENET, V39, P1390, DOI 10.1038/ng.2007.5; Yang PK, 2007, CELL, V128, P777, DOI 10.1016/j.cell.2007.01.032; Yin H, 2007, NATURE, V450, P304, DOI 10.1038/nature06263; Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468; Zhang LF, 2007, CELL, V129, P693, DOI 10.1016/j.cell.2007.03.036	71	463	497	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1787	1789		10.1126/science.1155472	http://dx.doi.org/10.1126/science.1155472			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369136				2022-12-28	WOS:000254394000033
J	Montel-Hagen, A; Kinet, S; Manel, N; Mongellaz, C; Prohaska, R; Battini, JL; Delaunay, J; Sitbon, M; Taylor, N				Montel-Hagen, Amelie; Kinet, Sandrina; Manel, Nicolas; Mongellaz, Cedric; Prohaska, Rainer; Battini, Jean-Luc; Delaunay, Jean; Sitbon, Marc; Taylor, Naomi			Erythrocyte glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C	CELL			English	Article							L-ASCORBIC-ACID; GAMMA-LACTONE OXIDASE; RED-BLOOD-CELLS; GLUCOSE-TRANSPORTER; LIPID RAFTS; STOMATIN; BIOSYNTHESIS; RECEPTOR; DOMAINS; BINDING	Of all cells, human erythrocytes express the highest level of the Glut1 glucose transporter. However, the regulation and function of Glut1 during erythropoiesis are not known. Here, we report that glucose transport actually decreases during human erythropoiesis despite a >3-log increase in Glut1 transcripts. In contrast, Glut1-mediated transport of L-dehydroascorbic acid (DHA), an oxidized form of ascorbic acid ( AA), is dramatically enhanced. We identified stomatin, an integral erythrocyte membrane protein, as regulating the switch from glucose to DHA transport. Notably though, we found that erythrocyte Glut1 and associated DHA uptake are unique traits of humans and the few other mammals that have lost the ability to synthesize AA from glucose. Accordingly, we show that mice, a species capable of synthesizing AA, express Glut4 but not Glut1 in mature erythrocytes. Thus, erythrocyte-specific coexpression of Glut1 with stomatin constitutes a compensatory mechanism in mammals that are unable to synthesize vitamin C.	[Montel-Hagen, Amelie; Kinet, Sandrina; Manel, Nicolas; Mongellaz, Cedric; Battini, Jean-Luc; Sitbon, Marc; Taylor, Naomi] Univ Montpellier I, CNRS, Inst Genet Mol Montpellier, Montpellier, France; [Montel-Hagen, Amelie; Kinet, Sandrina; Manel, Nicolas; Mongellaz, Cedric; Battini, Jean-Luc; Sitbon, Marc; Taylor, Naomi] Univ Montpellier 2, Montpellier, France; [Prohaska, Rainer] Med Univ Vienna, Dept Med Biochem, Max F Perutz Labs, Vienna Bioctr, A-1030 Vienna, Austria; [Delaunay, Jean] Hop Bicetre, INSERM, Fac Med Paris Sud, APHP,U Hematol 779, Le Kremlin Bicetre, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Taylor, N (corresponding author), Univ Montpellier I, CNRS, Inst Genet Mol Montpellier, Montpellier, France.	taylor@igmm.cnrs.fr	Taylor, Naomi/H-4016-2014; Manel, Nicolas/E-2128-2011; Sitbon, Marc/A-6771-2010	Manel, Nicolas/0000-0002-1481-4430; Sitbon, Marc/0000-0003-3616-2338; kinet, sandrina/0000-0003-0699-108X; Battini, Jean-Luc/0000-0002-5884-9934	Austrian Science Fund FWF [P 22038] Funding Source: Medline; NIAID NIH HHS [R01 AI059349] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059349] Funding Source: NIH RePORTER	Austrian Science Fund FWF(Austrian Science Fund (FWF)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BIANCHI J, 1986, P SOC EXP BIOL MED, V181, P333; BURNS JJ, 1957, NATURE, V180, P552, DOI 10.1038/180553a0; CHATTERJEE I, 1961, NATURE, V192, P163, DOI 10.1038/192163a0; CHATTERJEE IB, 1973, SCIENCE, V182, P1271, DOI 10.1126/science.182.4118.1271; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P10411, DOI 10.1021/bi953077m; Delaunay J, 2004, SEMIN HEMATOL, V41, P165, DOI 10.1053/j.seminhematol.2004.02.005; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; EVANS RM, 1982, BRIT J NUTR, V47, P473, DOI 10.1079/BJN19820059; Fecchi K, 2006, FASEB J, V20, P705, DOI 10.1096/fj.05-4661fje; Fricke B, 2005, BRIT J HAEMATOL, V131, P265, DOI 10.1111/j.1365-2141.2005.05742.x; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; HELGERSON AL, 1987, J BIOL CHEM, V262, P5464; HORIO F, 1985, J NUTR, V115, P1630, DOI 10.1093/jn/115.12.1630; Huang SH, 2007, CELL METAB, V5, P237, DOI 10.1016/j.cmet.2007.03.006; Huber TB, 2006, P NATL ACAD SCI USA, V103, P17079, DOI 10.1073/pnas.0607465103; Kim Felix J, 2004, Retrovirology, V1, P41, DOI 10.1186/1742-4690-1-41; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kinet S, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-31; Kumar A, 2004, AM J PHYSIOL-ENDOC M, V286, pE568, DOI 10.1152/ajpendo.00372.2003; Leitch JM, 2007, AM J PHYSIOL-CELL PH, V292, pC974, DOI 10.1152/ajpcell.00335.2006; LOWE AG, 1986, BIOCHIM BIOPHYS ACTA, V857, P146, DOI 10.1016/0005-2736(86)90342-1; Maeda N, 2000, P NATL ACAD SCI USA, V97, P841, DOI 10.1073/pnas.97.2.841; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Manel N, 2005, J BIOL CHEM, V280, P29025, DOI 10.1074/jbc.M504549200; Manel N, 2003, BLOOD, V101, P1913, DOI 10.1182/blood-2002-09-2681; May James M., 1998, Frontiers in Bioscience, V3, pD1; May JM, 2001, BBA-GEN SUBJECTS, V1528, P159, DOI 10.1016/S0304-4165(01)00188-X; MIZUSHIMA Y, 1984, EXPERIENTIA, V40, P359, DOI 10.1007/BF01952551; MORGAN PG, 2007, WORMBOOK, V1, P1; Morrow IC, 2005, TRAFFIC, V6, P725, DOI 10.1111/j.1600-0854.2005.00318.x; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAKAJIMA Y, 1969, HISTOCHEMISTRY, V18, P293; NISHIKIMI M, 1994, J BIOL CHEM, V269, P13685; NISHIKIMI M, 1992, J BIOL CHEM, V267, P21967; PAULING L, 1970, P NATL ACAD SCI USA, V67, P1643, DOI 10.1073/pnas.67.4.1643; POLLOCK JI, 1987, AM J PHYS ANTHROPOL, V73, P65, DOI 10.1002/ajpa.1330730106; Rubin D, 2003, AM J PHYSIOL-CELL PH, V285, pC377, DOI 10.1152/ajpcell.00060.2003; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; Salzer U., 2007, DYN CELL BIOL, V1, P20; Santalucia T, 1999, J BIOL CHEM, V274, P17626, DOI 10.1074/jbc.274.25.17626; Sedensky MM, 2006, ANESTHESIOLOGY, V105, P498, DOI 10.1097/00000542-200609000-00013; Seidner G, 1998, NAT GENET, V18, P188, DOI 10.1038/ng0298-188; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; STONE I, 1966, PERSPECT BIOL MED, V10, P133; Swainson L, 2005, P NATL ACAD SCI USA, V102, P12867, DOI 10.1073/pnas.0503603102; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wetzel C, 2007, NATURE, V445, P206, DOI 10.1038/nature05394; Zhang JZ, 1999, ARCH BIOCHEM BIOPHYS, V372, P173, DOI 10.1006/abbi.1999.1489; Zhang JZ, 2001, AM J PHYSIOL-CELL PH, V280, pC1277, DOI 10.1152/ajpcell.2001.280.5.C1277; Zhu YW, 1999, BLOOD, V93, P2404, DOI 10.1182/blood.V93.7.2404.407k13_2404_2410	57	177	182	5	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2008	132	6					1039	1048		10.1016/j.cell.2008.01.042	http://dx.doi.org/10.1016/j.cell.2008.01.042			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358815	Bronze			2022-12-28	WOS:000254273600021
J	Reichman, LB				Reichman, Lee B.			Tuberculosis drug resistance comes full circle	LANCET			English	Editorial Material							PULMONARY TUBERCULOSIS		Univ Med & Dent New Jersey, New Jersey Med Sch, Global TB Inst, Newark, NJ 07101 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Reichman, LB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Global TB Inst, Newark, NJ 07101 USA.	reichmlb@umdnj.edu						Burman WJ, 2006, AM J RESP CRIT CARE, V174, P331, DOI 10.1164/rccm.200603-360OC; Grimaldo ER, 2001, INT J TUBERC LUNG D, V5, P546; LEVIN SB, 1992, ANTIBIOTIC PARADOX M; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Moadebi S, 2007, DRUGS, V67, P2077, DOI 10.2165/00003495-200767140-00007; Reichman L. B., 2002, TIMEBOMB GLOBAL EPID; von Gottberg A, 2008, LANCET, V371, P1108, DOI 10.1016/S0140-6736(08)60350-5; World Health Organization (WHO), 2008, 4 WHOIUATLD	8	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1052	1053		10.1016/S0140-6736(08)60464-X	http://dx.doi.org/10.1016/S0140-6736(08)60464-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18374825				2022-12-28	WOS:000254442700007
J	Kitano, M; Nakaya, M; Nakamura, T; Nagata, S; Matsuda, M				Kitano, Masahiro; Nakaya, Michio; Nakamura, Takeshi; Nagata, Shigekazu; Matsuda, Michiyuki			Imaging of Rab5 activity identifies essential regulators for phagosome maturation	NATURE			English	Article							APOPTOTIC CELLS; PROTEINS; MACROPHAGES; ACTIVATION; DYNAMICS; FUSION; PHAGOCYTOSIS; RECRUITMENT; RHO	Efficient phagocytosis of apoptotic cells is crucial for tissue homeostasis and the immune response(1,2). Rab5 is known as a key regulator of the early endocytic pathway(3) and we have recently shown that Rab5 is also implicated in apoptotic cell engulfment(4); however, the precise spatio- temporal dynamics of Rab5 activity remain unknown. Here, using a newly developed fluorescence resonance energy transfer biosensor, we describe a change in Rab5 activity during the engulfment of apoptotic thymocytes. Rab5 activity on phagosome membranes began to increase on disassembly of the actin coat encapsulating phagosomes. Rab5 activation was either continuous or repetitive for up to 10 min, but it ended before the collapse of engulfed apoptotic cells. Expression of a dominant-negative mutant of Rab5 delayed this collapse of apoptotic thymocytes, showing a role for Rab5 in phagosome maturation. Disruption of microtubules with nocodazole inhibited Rab5 activation on the phagosome membrane without perturbing the engulfment of apoptotic cells. Furthermore, we found that Gapex-5 is the guanine nucleotide exchange factor essential for Rab5 activation during the engulfment of apoptotic cells. Gapex- 5 was bound to a microtubule- tip- associating protein, EB1, whose depletion inhibited Rab5 activation during phagocytosis. We therefore propose a mechanistic model in which the recruitment of Gapex- 5 to phagosomes through the microtubule network induces the transient Rab5 activation.	[Kitano, Masahiro; Nakamura, Takeshi; Matsuda, Michiyuki] Kyoto Univ, Grad Sch Biostudies, Lab Bioimaging & Cell Signaling, Sakyo Ku, Kyoto 6068501, Japan; [Nakaya, Michio; Nagata, Shigekazu] Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; [Kitano, Masahiro] Osaka Univ, Microbial Dis Res Inst, Dept Signal Transduct, Suita, Osaka 5650871, Japan; [Nakaya, Michio; Nagata, Shigekazu] Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Osaka University; Japan Science & Technology Agency (JST)	Nakamura, T (corresponding author), Kyoto Univ, Grad Sch Biostudies, Lab Bioimaging & Cell Signaling, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	tnakamr@path1.med.kyoto-u.ac.jp	Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426; Matsuda, Michiyuki/0000-0002-5876-9969				Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; Diakonova M, 2002, MOL BIOL CELL, V13, P402, DOI 10.1091/mbc.01-05-0273; Duclos S, 2000, J CELL SCI, V113, P3531; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakaya M, 2006, J BIOL CHEM, V281, P8836, DOI 10.1074/jbc.M510972200; Niedergang F, 2004, CURR OPIN CELL BIOL, V16, P422, DOI 10.1016/j.ceb.2004.06.006; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Takaya A, 2004, MOL BIOL CELL, V15, P2549, DOI 10.1091/mbc.E03-11-0857; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Vieira OV, 2003, MOL CELL BIOL, V23, P2501, DOI 10.1128/MCB.23.7.2501-2514.2003; Yoshizaki H, 2007, MOL BIOL CELL, V18, P119, DOI 10.1091/mbc.E06-05-0467; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhou FQ, 2002, J CELL BIOL, V157, P839, DOI 10.1083/jcb.200112014	24	108	114	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2008	453	7192					241	U15		10.1038/nature06857	http://dx.doi.org/10.1038/nature06857			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297BP	18385674	Bronze			2022-12-28	WOS:000255592400044
J	Witze, ES; Litman, ES; Argast, GM; Moon, RT; Ahn, NG				Witze, Eric S.; Litman, Elizabeth S.; Argast, Gretchen M.; Moon, Randall T.; Ahn, Natalie G.			Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors	SCIENCE			English	Article							C-ELEGANS; MELANOMA; DROSOPHILA; INVASION; SIGNALS; KINASE	Mechanisms by which Wnt pathways integrate the organization of receptors, organelles, and cytoskeletal proteins to confer cell polarity and directional cell movement are incompletely understood. We show that acute responses to Wnt5a involve recruitment of actin, myosin IIB, Frizzled 3, and melanoma cell adhesion molecule into an intracellular structure in a melanoma cell line. In the presence of a chemokine gradient, this Wnt- mediated receptor- actin- myosin polarity ( W- RAMP) structure accumulates asymmetrically at the cell periphery, where it triggers membrane contractility and nuclear movement in the direction of membrane retraction. The process requires endosome trafficking, is associated with multivesicular bodies, and is regulated by Wnt5a through the small guanosine triphosphatases Rab4 and RhoB. Thus, cell- autonomous mechanisms allow Wnt5a to control cell orientation, polarity, and directional movement in response to positional cues from chemokine gradients.	[Witze, Eric S.; Litman, Elizabeth S.; Argast, Gretchen M.; Ahn, Natalie G.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Litman, Elizabeth S.; Moon, Randall T.; Ahn, Natalie G.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; [Moon, Randall T.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; [Moon, Randall T.] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Ahn, NG (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	natalie.ahn@colorado.edu	Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408	NCI NIH HHS [R01 CA118972, R01 CA118972-01A2, F32-CA105796, R01-CA118972, R01 CA118972-02, F32 CA105796, F32-CA112847, F32 CA112847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA112847, R01CA118972, F32CA105796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Goldstein B, 2006, DEV CELL, V10, P391, DOI 10.1016/j.devcel.2005.12.016; Gurskaya NG, 2006, NAT BIOTECHNOL, V24, P461, DOI 10.1038/nbt1191; Hilliard MA, 2006, DEV CELL, V10, P379, DOI 10.1016/j.devcel.2006.01.013; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Murakami T, 2002, CANCER RES, V62, P7328; Park FD, 2004, CURR BIOL, V14, P2252, DOI 10.1016/j.cub.2004.12.019; Satyamoorthy K, 2001, ONCOGENE, V20, P4676, DOI 10.1038/sj.onc.1204616; Shimada Y, 2006, DEV CELL, V10, P209, DOI 10.1016/j.devcel.2005.11.016; Ulrich F, 2005, DEV CELL, V9, P555, DOI 10.1016/j.devcel.2005.08.011; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Whangbo J, 1999, MOL CELL, V4, P851, DOI 10.1016/S1097-2765(00)80394-9; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7	18	191	201	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					365	369		10.1126/science.1151250	http://dx.doi.org/10.1126/science.1151250			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420933	Green Accepted			2022-12-28	WOS:000255026100041
J	Leff, B; Finucane, TE				Leff, Bruce; Finucane, Thomas E.			Gizmo idolatry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MYOCARDIAL-INFARCTION; ARTERY		[Leff, Bruce] Johns Hopkins Bayview Med Ctr, Johns Hopkins Care Ctr, Baltimore, MD 21224 USA; [Leff, Bruce; Finucane, Thomas E.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Leff, Bruce] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Leff, B (corresponding author), Johns Hopkins Bayview Med Ctr, Johns Hopkins Care Ctr, John R Burton Pavil,5505 Hopkins Bayview Ctr, Baltimore, MD 21224 USA.	bleff@jhmi.edu						ABELSON R, 2006, NY TIMES        1020, pC6; Abelson Reed, 2006, N Y Times Web, pC4; Arbyn M, 2008, OBSTET GYNECOL, V111, P167, DOI 10.1097/01.AOG.0000296488.85807.b3; Cates CJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000052.pub2; Cullum N., 2004, COCHRANE DB SYST REV, V3, P1735, DOI DOI 10.1002/14651858.CD001735.PUB2; DiSalvo C, 1995, VILLANOVA LAW REV, V40, P1365; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Flum DR, 2006, JAMA-J AM MED ASSOC, V296, P2483, DOI 10.1001/jama.296.20.2483; Garber AM, 2006, NEW ENGL J MED, V355, P337, DOI 10.1056/NEJMp068085; GRIMES DA, 1993, JAMA-J AM MED ASSOC, V269, P3030, DOI 10.1001/jama.269.23.3030; Hillis LD, 2006, NEW ENGL J MED, V355, P2475, DOI 10.1056/NEJMe068251; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; Poldermans D, 2006, J AM COLL CARDIOL, V48, P964, DOI 10.1016/j.jacc.2006.03.059; Saul S, 2006, NY TIMES, pC7; Saul Stephanie, 2006, N Y Times Web, pC7; Spandorfer PR, 2005, PEDIATRICS, V115, P295, DOI 10.1542/peds.2004-0245; Stadtmauer EA, 2000, NEW ENGL J MED, V342, P1069, DOI 10.1056/NEJM200004133421501; Veblen T., 2005, THEORY LEISURE CLASS; Wennberg John E, 2002, Health Aff (Millwood), VSuppl Web Exclusives, pW96; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213	22	64	64	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1830	1832		10.1001/jama.299.15.1830	http://dx.doi.org/10.1001/jama.299.15.1830			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18413879				2022-12-28	WOS:000254954800029
J	Sheppard, SK; McCarthy, ND; Falush, D; Maiden, MCJ				Sheppard, Samuel K.; McCarthy, Noel D.; Falush, Daniel; Maiden, Martin C. J.			Convergence of Campylobacter species: Implications for bacterial evolution	SCIENCE			English	Article							MULTILOCUS GENOTYPE DATA; JEJUNI; SPECIATION; COLI; INFERENCE; MICROEVOLUTION; RECOMBINATION; HYBRIDIZATION; HISTORY	The nature of species boundaries in bacteria remains controversial. In particular, the mechanisms of bacterial speciation and maintenance in the face of frequent genetic exchange are poorly understood. Here, we report patterns of genetic exchange that show two closely related zoonotic pathogenic species, Campylobacter jejuni and Campylobacter coli, are converging as a consequence of recent changes in gene flow. Population expansion into a novel ecological niche generated by human activity is the most probable explanation for the increase in genetic exchange between these species. Bacterial speciation can therefore occur by mechanisms analogous to those seen in metazoans, where genetic diversification and incipient speciation caused by ecological factors have been reported in several genera.	[Sheppard, Samuel K.; McCarthy, Noel D.; Falush, Daniel; Maiden, Martin C. J.] Univ Oxford, Dept Zool, Oxford OX1 3SY, England; [Sheppard, Samuel K.; McCarthy, Noel D.; Falush, Daniel; Maiden, Martin C. J.] Univ Oxford, Dept Stat, Oxford OX1 3SY, England	University of Oxford; University of Oxford	Falush, D (corresponding author), Natl Univ Ireland Univ Coll Cork, Environm Res Inst, Lee Rd, Cork, Ireland.	d.falush@ucc.ie; martin.maiden@zoo.ox.ac.uk	Maiden, Martin C J/C-5055-2014; Maiden, Martin/N-6805-2019; McCarthy, Noel D/K-3314-2012	Maiden, Martin C J/0000-0001-6321-5138; Maiden, Martin/0000-0001-6321-5138; McCarthy, Noel/0000-0003-1113-1017; Sheppard, Samuel/0000-0001-6901-3203	Wellcome Trust [047072] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Achtman M, 2004, P NATL ACAD SCI USA, V101, P17837, DOI 10.1073/pnas.0408026101; Bull SA, 2006, APPL ENVIRON MICROB, V72, P645, DOI 10.1128/AEM.72.1.645-652.2006; Cohan FM, 2002, ANNU REV MICROBIOL, V56, P457, DOI 10.1146/annurev.micro.56.012302.160634; Coker AO, 2002, EMERG INFECT DIS, V8, P237, DOI 10.3201/eid0803.010233; Didelot X, 2007, GENETICS, V175, P1251, DOI 10.1534/genetics.106.063305; Dingle KE, 2005, CAMPYLOBACTER: MOLECULAR AND CELLULAR BIOLOGY, P43; Dingle KE, 2001, J CLIN MICROBIOL, V39, P14, DOI 10.1128/JCM.39.1.14-23.2001; Dingle KE, 2005, J CLIN MICROBIOL, V43, P340, DOI 10.1128/JCM.43.1.340-347.2005; Eggleston AK, 1997, CURR BIOL, V7, pR745, DOI 10.1016/S0960-9822(06)00394-0; Falush D, 2003, GENETICS, V164, P1567; Falush D, 2006, PHILOS T R SOC B, V361, P2045, DOI 10.1098/rstb.2006.1925; Fraser C, 2007, SCIENCE, V315, P476, DOI 10.1126/science.1127573; Gevers D, 2005, NAT REV MICROBIOL, V3, P733, DOI 10.1038/nrmicro1236; GRANT PR, 1992, SCIENCE, V256, P193, DOI 10.1126/science.256.5054.193; Gupta S, 2001, TRENDS MICROBIOL, V9, P181, DOI 10.1016/S0966-842X(01)01986-2; Hanage WP, 2006, PHILOS T R SOC B, V361, P2039, DOI 10.1098/rstb.2006.1926; Jolley KA, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-86; Lawrence JG, 2002, THEOR POPUL BIOL, V61, P449, DOI 10.1006/tpbi.2002.1587; Lo I, 2007, NATURE, V446, P537, DOI 10.1038/nature05624; Mallet J, 2007, NATURE, V446, P279, DOI 10.1038/nature05706; McCarthy ND, 2007, EMERG INFECT DIS, V13, P267, DOI 10.3201/eid1302.060620; Meinersmann RJ, 2003, GENOME LETT, V2, P48, DOI DOI 10.1166/gl.2003.000; Narra HP, 2006, CURR BIOL, V16, pR705, DOI 10.1016/j.cub.2006.08.024; Ochman H, 1994, EXS, V69, P479; Pritchard JK, 2000, GENETICS, V155, P945; Rieseberg LH, 2003, SCIENCE, V301, P1211, DOI 10.1126/science.1086949; ROSEF O, 1983, APPL ENVIRON MICROB, V46, P855, DOI 10.1128/AEM.46.4.855-859.1983; Roumagnac P, 2006, SCIENCE, V314, P1301, DOI 10.1126/science.1134933; Samuel MC, 2004, CLIN INFECT DIS, V38, pS165, DOI 10.1086/381583; Waldenstrom J, 2002, APPL ENVIRON MICROB, V68, P5911, DOI 10.1128/AEM.68.12.5911-5917.2002; Zhu PX, 2001, P NATL ACAD SCI USA, V98, P5234, DOI 10.1073/pnas.061386098	31	179	181	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2008	320	5873					237	239		10.1126/science.1155532	http://dx.doi.org/10.1126/science.1155532			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403712				2022-12-28	WOS:000254836700045
J	Deborde, S; Perret, E; Gravotta, D; Deora, A; Salvarezza, S; Schreiner, R; Rodriguez-Boulan, E				Deborde, Sylvie; Perret, Emilie; Gravotta, Diego; Deora, Ami; Salvarezza, Susana; Schreiner, Ryan; Rodriguez-Boulan, Enrique			Clathrin is a key regulator of basolateral polarity	NATURE			English	Article							DARBY CANINE KIDNEY; EPITHELIAL-CELLS; MDCK CELLS; PLASMA-MEMBRANE; PROTEINS; ENDOSOMES; RECEPTOR; TRAFFICKING; ENDOCYTOSIS; TRANSPORT	Clathrin-coated vesicles are vehicles for intracellular trafficking in all nucleated cells, from yeasts to humans. Many studies have demonstrated their essential roles in endocytosis and cellular signalling processes at the plasma membrane. By contrast, very few of their non-endocytic trafficking roles are known, the best characterized being the transport of hydrolases from the Golgi complex to the lysosome. Here we show that clathrin is required for polarity of the basolateral plasma membrane proteins in the epithelial cell line MDCK. Clathrin knockdown depolarized most basolateral proteins, by interfering with their biosynthetic delivery and recycling, but did not affect the polarity of apical proteins. Quantitative live imaging showed that chronic and acute clathrin knockdown selectively slowed down the exit of basolateral proteins from the Golgi complex, and promoted their mis-sorting into apical carrier vesicles. Our results demonstrate a broad requirement for clathrin in basolateral protein trafficking in epithelial cells.	[Deborde, Sylvie; Perret, Emilie; Gravotta, Diego; Deora, Ami; Salvarezza, Susana; Schreiner, Ryan; Rodriguez-Boulan, Enrique] Cornell Univ, Dept Ophthalmol, Dyson Vis Res Inst, New York, NY 10065 USA; [Rodriguez-Boulan, Enrique] Cornell Univ, Dept Cell & Dev Biol, Weill Med Coll, New York, NY 10065 USA	Cornell University; Dyson; Cornell University	Rodriguez-Boulan, E (corresponding author), Cornell Univ, Dept Ophthalmol, Dyson Vis Res Inst, LC-300,1300 York Ave, New York, NY 10065 USA.	boulan@med.cornell.edu		Schreiner, Ryan/0000-0002-7457-6606; Deborde, Sylvie/0000-0002-6630-4029	NATIONAL EYE INSTITUTE [R01EY008538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008538] Funding Source: Medline; NIGMS NIH HHS [R01 GM034107] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Cancino J, 2007, MOL BIOL CELL, V18, P4872, DOI 10.1091/mbc.E07-06-0563; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Deora AA, 2004, MOL BIOL CELL, V15, P4148, DOI 10.1091/mbc.E04-01-0058; Deora AA, 2007, TRAFFIC, V8, P1304, DOI 10.1111/j.1600-0854.2007.00617.x; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Gan YB, 2002, NAT CELL BIOL, V4, P605, DOI 10.1038/ncb827; Gravotta D, 2007, P NATL ACAD SCI USA, V104, P1564, DOI 10.1073/pnas.0610700104; HERZLINGER DA, 1984, J CELL BIOL, V98, P1777, DOI 10.1083/jcb.98.5.1777; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Iversen TG, 2003, P NATL ACAD SCI USA, V100, P5175, DOI 10.1073/pnas.0534231100; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEMMON SK, 1987, SCIENCE, V238, P504, DOI 10.1126/science.3116672; Li J, 2007, J CELL BIOL, V178, P453, DOI 10.1083/jcb.200608033; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Moskowitz HS, 2003, MOL BIOL CELL, V14, P4437, DOI 10.1091/mbc.e03-04-0230; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Owen DJ, 2004, ANNU REV CELL DEV BI, V20, P153, DOI 10.1146/annurev.cellbio.20.010403.104543; Pagano A, 2004, MOL BIOL CELL, V15, P4990, DOI 10.1091/mbc.E04-04-0355; Pearse BMF, 2000, CURR OPIN STRUC BIOL, V10, P220, DOI 10.1016/S0959-440X(00)00071-3; Raiborg C, 2006, J CELL SCI, V119, P2414, DOI 10.1242/jcs.02978; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; ROTHMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P780, DOI 10.1073/pnas.77.2.780; Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	39	148	150	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	2008	452	7188					719	U3		10.1038/nature06828	http://dx.doi.org/10.1038/nature06828			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401403	Green Accepted			2022-12-28	WOS:000254792500038
J	Isaacs, SL; Schroeder, SA				Isaacs, Stephen L.; Schroeder, Steven A.			California dreamin' - State health care reform and the prospect for national change	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Isaacs, Stephen L.] Isaacs Jellinek, San Francisco, CA USA; [Schroeder, Steven A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Schroeder, Steven A.] Univ Calif San Francisco, Smoking Cessat Leadership Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Isaacs, SL (corresponding author), Isaacs Jellinek, San Francisco, CA USA.							BAILEY S, 2008, BOSTON GLOBE    0206; Cohen JT, 2008, NEW ENGL J MED, V358, P661, DOI 10.1056/NEJMp0708558; DEMBNER A, 2008, BOSTON GLOBE    0203; WEINTRAUB D, 2008, SACRAMENTO BEE  0210, pE4	4	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1537	1540		10.1056/NEJMp0800701	http://dx.doi.org/10.1056/NEJMp0800701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	285NK	18403762				2022-12-28	WOS:000254783300001
J	Mowafi, H; Spiegel, P				Mowafi, Hani; Spiegel, Paul			The Iraqi refugee crisis - Familiar problems and new challenges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH		[Spiegel, Paul] United Nat High Commissioner Refugees, Publ Hlth & HIV Sect, CH-1211 Geneva, Switzerland; [Mowafi, Hani] Boston Univ, Sch Med, Boston, MA 02118 USA; [Mowafi, Hani] Harvard Univ, Harvard Humanitarian Init, Cambridge, MA 02138 USA	Boston University; Harvard University	Spiegel, P (corresponding author), United Nat High Commissioner Refugees, Publ Hlth & HIV Sect, 94 Rue Montbrillant, CH-1211 Geneva, Switzerland.	spiegel@unhcr.org	Mowafi, Hani O/P-1380-2014; Spiegel, Paul/AAL-3238-2021	Mowafi, Hani O/0000-0001-6225-8048; Spiegel, Paul/0000-0002-6158-6661				*CENTR INT AG, 2007, WORLD FACTB; Danish Refugee Council, 2007, IR POP SURV LEB; *FAF I APPL SCI, 2007, IR JORD THEIR NUMB C; International Committee of the Red Cross, IR 1989 1999 DEC SAN; *IRAQ SYRIA, 2007, LACK MON VIS PROBL P; Margesson R, 2007, IRAQI REFUGEES INTER; Saif I., 2007, IRAQ WARS IMPACT GRO; Salama P, 1999, BRIT MED J, V319, P1569, DOI 10.1136/bmj.319.7224.1569; Spiegel P, 2002, LANCET, V360, P1927, DOI 10.1016/S0140-6736(02)11915-5; SPIEGEL P, 2008, DATA BUDGETS IRAQI R; Spiegel PB, 2001, LANCET, V357, P714, DOI 10.1016/S0140-6736(00)04143-X; *UNHCR, 2007, STAT DISPL IR WORLD; United Nations, CONV PROT REL STAT R; *US CDCP, 2 IPS SURV IR REF	14	34	34	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2008	299	14					1713	1715		10.1001/jama.299.14.1713	http://dx.doi.org/10.1001/jama.299.14.1713			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285AL	18398084				2022-12-28	WOS:000254749600028
J	Stepanova, AN; Robertson-Hoyt, J; Yun, J; Benavente, LM; Xie, DY; DoleZal, K; Schlereth, A; Jurgens, G; Alonso, JM				Stepanova, Anna N.; Robertson-Hoyt, Joyce; Yun, Jeonga; Benavente, Larissa M.; Xie, De-Yu; Dolezal, Karel; Schlereth, Alexandra; Juergens, Gerd; Alonso, Jose M.			TAA1-mediated auxin biosynthesis is essential for hormone crosstalk and plant development	CELL			English	Article							YUCCA FLAVIN MONOOXYGENASES; ARABIDOPSIS-THALIANA; RESPONSE PATHWAY; ETHYLENE; TRANSPORT; ENCODES; GENE; TRYPTOPHAN; GRADIENTS; MUTATION	Plants have evolved a tremendous ability to respond to environmental changes by adapting their growth and development. The interaction between hormonal and developmental signals is a critical mechanism in the generation of this enormous plasticity. A good example is the response to the hormone ethylene that depends on tissue type, developmental stage, and environmental conditions. By characterizing the Arabidopsis wei8 mutant, we have found that a small family of genes mediates tissue-specific responses to ethylene. Biochemical studies revealed that WEI8 encodes a long-anticipated tryptophan aminotransferase, TAA1, in the essential, yet genetically uncharacterized, indole-3-pyruvic acid (IPA) branch of the auxin biosynthetic pathway. Analysis of TAA1 and its paralogues revealed a link between local auxin production, tissue-specific ethylene effects, and organ development. Thus, the IPA route of auxin production is key to generating robust auxin gradients in response to environmental and developmental cues.	[Stepanova, Anna N.; Robertson-Hoyt, Joyce; Yun, Jeonga; Benavente, Larissa M.; Alonso, Jose M.] N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA; [Xie, De-Yu] N Carolina State Univ, Dept Plant Biol, Raleigh, NC 27695 USA; [Dolezal, Karel] Palacky Univ, Lab Growth Regulators, CZ-78371 Olomouc, Czech Republic; [Dolezal, Karel] Inst Expt Bot ASCR, CZ-78371 Olomouc, Czech Republic; [Schlereth, Alexandra; Juergens, Gerd] Univ Tubingen, D-72076 Tubingen, Germany	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; Palacky University Olomouc; Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences; Eberhard Karls University of Tubingen	Alonso, JM (corresponding author), N Carolina State Univ, Dept Genet, Box 7614, Raleigh, NC 27695 USA.	jmalonso@unity.ncsu.edu	Alonso, Jose M/K-6826-2014; Doležal, Karel/H-2436-2014	Alonso, Jose M/0000-0001-7087-1571; Doležal, Karel/0000-0003-4938-0350; XIE, DE-YU/0000-0002-3054-1188; STEPANOVA, ANNA/0000-0003-1018-4758				ABEL S, 1995, J BIOL CHEM, V270, P19093, DOI 10.1074/jbc.270.32.19093; Barlier I, 2000, P NATL ACAD SCI USA, V97, P14819, DOI 10.1073/pnas.260502697; Bartel B, 1997, ANNU REV PLANT PHYS, V48, P49; Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3; Bennett M, 2005, PHYSIOL PLANTARUM, V123, P109, DOI 10.1111/j.1399-3054.2005.00483.x; BOERJAN W, 1995, PLANT CELL, V7, P1405, DOI 10.1105/tpc.7.9.1405; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; Cheng YF, 2007, PLANT CELL, V19, P2430, DOI 10.1105/tpc.107.053009; Cheng YF, 2006, GENE DEV, V20, P1790, DOI 10.1101/gad.1415106; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cohen JD, 2003, TRENDS PLANT SCI, V8, P197, DOI 10.1016/S1360-1385(03)00058-X; Dharmasiri N, 2005, DEV CELL, V9, P109, DOI 10.1016/j.devcel.2005.05.014; EDLUND A, 1995, PLANT PHYSIOL, V108, P1043, DOI 10.1104/pp.108.3.1043; FERREIRA GC, 1993, PROTEIN SCI, V2, P1959, DOI 10.1002/pro.5560021117; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Gray WM, 1998, P NATL ACAD SCI USA, V95, P7197, DOI 10.1073/pnas.95.12.7197; Grieneisen VA, 2007, NATURE, V449, P1008, DOI 10.1038/nature06215; Hamann T, 1999, DEVELOPMENT, V126, P1387; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; Jiang K, 2005, ANNU REV CELL DEV BI, V21, P485, DOI 10.1146/annurev.cellbio.21.122303.114753; KANG BG, 1967, SCIENCE, V156, P958, DOI 10.1126/science.156.3777.958; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; Li H, 2004, DEV CELL, V7, P193, DOI 10.1016/j.devcel.2004.07.002; Liepman AH, 2004, CRIT REV PLANT SCI, V23, P73, DOI 10.1080/07352680490273419; Ljung K, 2005, PLANT CELL, V17, P1090, DOI 10.1105/tpc.104.029272; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Muday GK, 2001, J PLANT GROWTH REGUL, V20, P226, DOI 10.1007/s003440010027; Nawy T, 2005, PLANT CELL, V17, P1908, DOI 10.1105/tpc.105.031724; Nemhauser JL, 2000, DEVELOPMENT, V127, P3877; Ortega-Martinez O, 2007, SCIENCE, V317, P507, DOI 10.1126/science.1143409; Pedraza RO, 2004, FEMS MICROBIOL LETT, V233, P15, DOI 10.1016/j.femsle.2004.01.047; Ruzicka K, 2007, PLANT CELL, V19, P2197, DOI 10.1105/tpc.107.052126; Sohlberg JJ, 2006, PLANT J, V47, P112, DOI 10.1111/j.1365-313X.2006.02775.x; Stepanova AN, 2005, PHYSIOL PLANTARUM, V123, P195, DOI 10.1111/j.1399-3054.2005.00447.x; Stepanova AN, 2005, PLANT CELL, V17, P2230, DOI 10.1105/tpc.105.033365; Stepanova AN, 2007, PLANT CELL, V19, P2169, DOI 10.1105/tpc.107.052068; Swarup R, 2002, PLANT MOL BIOL, V49, P411; Swarup R, 2007, PLANT CELL, V19, P2186, DOI 10.1105/tpc.107.052100; Tao Y, 2008, CELL, V133, P164, DOI 10.1016/j.cell.2008.01.049; Till BJ, 2004, NUCLEIC ACIDS RES, V32, P2632, DOI 10.1093/nar/gkh599; Vieten A, 2007, TRENDS PLANT SCI, V12, P160, DOI 10.1016/j.tplants.2007.03.006; Warming S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni035; Weijers D, 2006, DEV CELL, V10, P265, DOI 10.1016/j.devcel.2005.12.001; Weijers D, 2005, PLANT CELL, V17, P2517, DOI 10.1105/tpc.105.034637; Xu J, 2006, SCIENCE, V311, P385, DOI 10.1126/science.1121790; Zhao YD, 2001, SCIENCE, V291, P306, DOI 10.1126/science.291.5502.306; Zhao YD, 2002, GENE DEV, V16, P3100, DOI 10.1101/gad.1035402	48	759	810	12	202	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2008	133	1					177	191		10.1016/j.cell.2008.01.047	http://dx.doi.org/10.1016/j.cell.2008.01.047			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394997	Bronze			2022-12-28	WOS:000254641300018
J	Tao, Y; Ferrer, JL; Ljung, K; Pojer, F; Hong, FX; Long, JA; Li, L; Moreno, JE; Bowman, ME; Ivans, LJ; Cheng, YF; Lim, J; Zhao, YD; Ballare, CL; Sandberg, G; Noel, JP; Chory, J				Tao, Yi; Ferrer, Jean-Luc; Ljung, Karin; Pojer, Florence; Hong, Fangxin; Long, Jeff A.; Li, Lin; Moreno, Javier E.; Bowman, Marianne E.; Ivans, Lauren J.; Cheng, Youfa; Lim, Jason; Zhao, Yunde; Ballare, Carlos L.; Sandberg, Goeran; Noel, Joseph P.; Chory, Joanne			Rapid synthesis of auxin via a new tryptophan-dependent pathway is required for shade avoidance in plants	CELL			English	Article							AMINO-ACID AMINOTRANSFERASES; ENTEROBACTER-CLOACAE; INDOLE-3-ACETIC-ACID BIOSYNTHESIS; INDOLEPYRUVATE DECARBOXYLASE; INDOLE-3-PYRUVIC ACID; ARABIDOPSIS-THALIANA; REACTION SPECIFICITY; INDOLEACETIC-ACID; LIGHT QUALITY; PHYTOCHROME-B	Plants grown at high densities perceive a decrease in the red to far-red (R:FR) ratio of incoming light, resulting from absorption of red light by canopy leaves and reflection of far-red light from neighboring plants. These changes in light quality trigger a series of responses known collectively as the shade avoidance syndrome. During shade avoidance, stems elongate at the expense of leaf and storage organ expansion, branching is inhibited, and flowering is accelerated. We identified several loci in Arabidopsis, mutations in which lead to plants defective in multiple shade avoidance responses. Here we describe TAA1, an aminotransferase, and show that TAA1 catalyzes the formation of indole-3-pyruvic acid (IPA) from L-tryptophan (L-Trp), the first step in a previously proposed, but uncharacterized, auxin biosynthetic pathway. This pathway is rapidly deployed to synthesize auxin at the high levels required to initiate the multiple changes in body plan associated with shade avoidance.	[Tao, Yi; Pojer, Florence; Hong, Fangxin; Bowman, Marianne E.; Lim, Jason; Noel, Joseph P.; Chory, Joanne] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; [Tao, Yi; Hong, Fangxin; Long, Jeff A.; Li, Lin; Ivans, Lauren J.; Lim, Jason; Chory, Joanne] Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; [Ferrer, Jean-Luc] UJF, CNRS, CEA, Inst Biol Struct,Lab Cristallog & Cristallogenese, F-38027 Grenoble, France; [Ferrer, Jean-Luc; Pojer, Florence; Bowman, Marianne E.; Noel, Joseph P.] Salk Inst Biol Studies, Jack H Skirball Ctr Chem Biol & Proteom, La Jolla, CA 92037 USA; [Ljung, Karin] Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, Umea Plant Sci Ctr, SE-90183 Umea, Sweden; [Hong, Fangxin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Moreno, Javier E.; Ballare, Carlos L.] Consejo Nacl Invest Cient & Tecn, Inst Invest Fisiol & Ecol Vinculadas Agr, Buenos Aires, DF, Argentina; [Moreno, Javier E.; Ballare, Carlos L.] Univ Buenos Aires, Buenos Aires, DF, Argentina; [Ivans, Lauren J.; Cheng, Youfa; Zhao, Yunde] Univ Calif San Diego, Sect Cell & Dev Biol, Div Biol Sci, La Jolla, CA 92093 USA; [Sandberg, Goeran] Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, SE-90187 Umea, Sweden	Howard Hughes Medical Institute; Salk Institute; Salk Institute; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Salk Institute; Swedish University of Agricultural Sciences; Umea University; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of California System; University of California San Diego; Umea University	Chory, J (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.	chory@salk.edu	Ballare, Carlos L/F-5141-2011; Ljung, Karin/AAE-8691-2019; Tao, Yi/B-7718-2012; Noel, Joseph P/A-9459-2009; Zhao, Yunde/AAC-5360-2019; Cheng, Youfa/E-4187-2012	Ballare, Carlos L/0000-0001-9129-4531; Ljung, Karin/0000-0003-2901-189X; Li, Lin/0000-0003-4840-5245; Moreno, Javier/0000-0001-9763-5325; Tao, Yi/0000-0002-7460-7927	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [GM52413, R01 GM052413, R01 GM052413-13] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052413] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken SM, 2005, ARCH BIOCHEM BIOPHYS, V433, P166, DOI 10.1016/j.abb.2004.08.024; Aloni R, 2003, PLANTA, V216, P841, DOI 10.1007/s00425-002-0937-8; BACA BE, 1994, SOIL BIOL BIOCHEM, V26, P57, DOI 10.1016/0038-0717(94)90195-3; BADENOCHJONES J, 1982, BIOMED MASS SPECTROM, V9, P429, DOI 10.1002/bms.1200091005; Ballare CL, 1999, TRENDS PLANT SCI, V4, P97, DOI 10.1016/S1360-1385(99)01383-7; Ballare CL, 1997, PLANT CELL ENVIRON, V20, P820, DOI 10.1046/j.1365-3040.1997.d01-112.x; Cerdan PD, 2003, NATURE, V423, P881, DOI 10.1038/nature01636; Cheng YF, 2006, GENE DEV, V20, P1790, DOI 10.1101/gad.1415106; Devlin PF, 2003, PLANT PHYSIOL, V133, P1617, DOI 10.1104/pp.103.034397; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; Franklin KA, 2005, ANN BOT-LONDON, V96, P169, DOI 10.1093/aob/mci165; Gray WM, 1998, P NATL ACAD SCI USA, V95, P7197, DOI 10.1073/pnas.95.12.7197; HALLIDAY KJ, 1994, PLANT PHYSIOL, V104, P1311, DOI 10.1104/pp.104.4.1311; Hisamatsu T, 2005, PLANT PHYSIOL, V138, P1106, DOI 10.1104/pp.104.059055; Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476; Izaguirre MM, 2006, P NATL ACAD SCI USA, V103, P7170, DOI 10.1073/pnas.0509805103; JEFFERSON RA, 1987, EMBO J, V6, P3901; JONES AM, 1991, PLANT PHYSIOL, V97, P352, DOI 10.1104/pp.97.1.352; KANESHIRO T, 1983, CURR MICROBIOL, V8, P301, DOI 10.1007/BF01577732; Kanyuka K, 2003, PLANT J, V35, P57, DOI 10.1046/j.1365-313X.2003.01779.x; Kim BC, 1998, PLANT J, V15, P61, DOI 10.1046/j.1365-313X.1998.00179.x; KOGA J, 1994, BBA-PROTEIN STRUCT M, V1209, P241, DOI 10.1016/0167-4838(94)90191-0; KOGA J, 1992, J BIOL CHEM, V267, P15823; KOGA J, 1991, MOL GEN GENET, V226, P10, DOI 10.1007/BF00273581; Kuettner EB, 2002, ARCH BIOCHEM BIOPHYS, V402, P192, DOI 10.1016/S0003-9861(02)00088-7; Kuettner EB, 2002, J BIOL CHEM, V277, P46402, DOI 10.1074/jbc.M208669200; Kurepin LV, 2007, J EXP BOT, V58, P2145, DOI 10.1093/jxb/erm068; Ljung K, 2005, PLANT CELL, V17, P1090, DOI 10.1105/tpc.104.029272; Luccioni LG, 2002, PLANT PHYSIOL, V128, P173, DOI 10.1104/pp.010668; Lukowitz W, 2000, PLANT PHYSIOL, V123, P795, DOI 10.1104/pp.123.3.795; Mallory AC, 2005, PLANT CELL, V17, P1360, DOI 10.1105/tpc.105.031716; MATHERON ME, 1973, PLANT PHYSIOL, V52, P63, DOI 10.1104/pp.52.1.63; Morelli G, 2000, PLANT PHYSIOL, V122, P621, DOI 10.1104/pp.122.3.621; Morelli G, 2002, TRENDS PLANT SCI, V7, P399, DOI 10.1016/S1360-1385(02)02314-2; Neff MM, 1999, P NATL ACAD SCI USA, V96, P15316, DOI 10.1073/pnas.96.26.15316; Peng J, 1997, PLANT PHYSIOL, V113, P1051, DOI 10.1104/pp.113.4.1051; Pierik R, 2004, PLANT PHYSIOL, V136, P2928, DOI 10.1104/pp.104.045120; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; Salter MG, 2003, NATURE, V426, P680, DOI 10.1038/nature02174; Sessa G, 2005, GENE DEV, V19, P2811, DOI 10.1101/gad.364005; SNUSTAD DP, 1992, PLANT CELL, V4, P549, DOI 10.1105/tpc.4.5.549; Sorin C, 2005, PLANT CELL, V17, P1343, DOI 10.1105/tpc.105.031625; SotoUrzua L, 1996, CAN J MICROBIOL, V42, P294, DOI 10.1139/m96-043; Steindler C, 1999, DEVELOPMENT, V126, P4235; Stepanova AN, 2008, CELL, V133, P177, DOI 10.1016/j.cell.2008.01.047; Tam YY, 1998, J CHROMATOGR A, V800, P101, DOI 10.1016/S0021-9673(97)01051-0; Tanaka SI, 2002, PLANT CELL PHYSIOL, V43, P1171, DOI 10.1093/pcp/pcf133; TRUELSEN TA, 1972, PHYSIOL PLANTARUM, V26, P289, DOI 10.1111/j.1399-3054.1972.tb01110.x; Woodward AW, 2005, ANN BOT-LONDON, V95, P707, DOI 10.1093/aob/mci083; Zhao YD, 2001, SCIENCE, V291, P306, DOI 10.1126/science.291.5502.306; Zhao YD, 2002, GENE DEV, V16, P3100, DOI 10.1101/gad.1035402	52	721	767	11	231	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 4	2008	133	1					164	176		10.1016/j.cell.2008.01.049	http://dx.doi.org/10.1016/j.cell.2008.01.049			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394996	Bronze, Green Accepted			2022-12-28	WOS:000254641300017
J	Loomba, R; Rowley, A; Wesley, R; Liang, TJ; Hoofnagle, JH; Pucino, F; Csako, G				Loomba, Rohit; Rowley, Ayana; Wesley, Robert; Liang, T. Jake; Hoofnagle, Jay H.; Pucino, Frank; Csako, Gyorgy			Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy	ANNALS OF INTERNAL MEDICINE			English	Review							BREAST-CANCER PATIENTS; VIRUS REACTIVATION; CYTOTOXIC CHEMOTHERAPY; PREEMPTIVE LAMIVUDINE; PROPHYLAXIS; THERAPY; INFECTION; CARRIERS; LYMPHOMA; DISEASE	Background: Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen (HBsAg) and are undergoing chemotherapy. Purpose: To determine whether preventive lamivudine reduces chemotherapy-induced hepatitis B virus (HBV)-related morbidity and mortality in patients with cancer who test positive for HBsAg. Data Sources: MEDLINE, Ovid MEDLINE, TOXNET, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched in all languages until June 2007. Study Selection: Clinical trials and cohort studies that reported the efficacy of preventive lamivudine versus control on HBV reactivation in patients who tested positive for HBsAg and were receiving chemotherapy were included. Additional requirements included minimum sample size (>5 participants per treatment group) and reported HBV-related morbidity and mortality data. Data Extraction: Two investigators independently did literature searches and data extraction, and 2 other investigators independently confirmed study eligibility and data retrieval. Data Synthesis: Fourteen studies (2 randomized, controlled trials; 8 prospective cohort studies; and 4 retrospective cohort studies) met the predefined criteria for analysis. There were 275 patients in the preventive lamivudine group and 475 control participants for the primary end point of HBV reactivation. With preventive lamivudine, the relative risk for both HBV reactivation and HBV-related hepatitis ranged from 0.00 to 0.21. None of the patients in the preventive lamivudine group developed HBV-related hepatic failure (0 of 108 patients vs. 21 of 162 patients), and only 4 deaths were attributable to HBV (4 of 208 patients vs. 27 of 394 patients) in the preventive lamivudine group. Lamivudine was well tolerated, and no adverse effects were noted. Limitations: The studies included in the meta-analysis did not consistently report all of the outcomes of interest. Sample sizes were small and only 2 studies had a randomized, controlled design. Conclusion: Preventive therapy with lamivudine for patients who test positive for HBsAg and are undergoing chemotherapy may reduce the risk for HBV reactivation and HBV-associated morbidity and mortality.	[Loomba, Rohit; Rowley, Ayana; Wesley, Robert; Liang, T. Jake; Hoofnagle, Jay H.; Pucino, Frank; Csako, Gyorgy] US Dept HHS, Natl Inst Hlth, Bethesda, MD USA	National Institutes of Health (NIH) - USA	Loomba, R (corresponding author), NIDDKD, NIH, CRC-4-5722,MSC-1614,10 Ctr Dr, Bethesda, MD 20892 USA.	roloomba@ucsd.edu	Loomba, Rohit/AAE-7831-2019	Loomba, Rohit/0000-0002-4845-9991	Intramural NIH HHS [Z01 DK054501-11] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054500, Z01DK054501] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alter MJ, 2003, J HEPATOL, V39, pS64, DOI 10.1016/S0168-8278(03)00141-7; Dai MS, 2004, LIVER INT, V24, P540, DOI 10.1111/j.1478-3231.2004.0964.x; de Franchis R, 2003, J HEPATOL, V39, pS3, DOI 10.1016/S0168-8278(03)00378-7; Esteve M, 2004, GUT, V53, P1363, DOI 10.1136/gut.2004.040675; Euler GL, 2003, PEDIATRICS, V111, P1192; Foont JA, 2007, NAT CLIN PRACT GASTR, V4, P128, DOI 10.1038/ncpgasthep0740; Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087; Hoofnagle JH, 2007, HEPATOLOGY, V45, P1056, DOI 10.1002/hep.21627; HOOFNAGLE JH, 1982, ANN INTERN MED, V96, P447, DOI 10.7326/0003-4819-96-4-447; Hsu C., 2006, GASTROENTEROLOGY, V131, pS297; Hui CK, 2005, GUT, V54, P1597, DOI 10.1136/gut.2005.070763; Hwang LY, 2006, HEPATOLOGY, V44, P341, DOI 10.1002/hep.21252; Idilman R, 2004, J VIRAL HEPATITIS, V11, P141, DOI 10.1046/j.1365-2893.2003.00479.x; Jang JW, 2006, HEPATOLOGY, V43, P233, DOI 10.1002/hep.21024; Jia Jie, 2004, Zhonghua Gan Zang Bing Za Zhi, V12, P628; Kohrt HE, 2006, ALIMENT PHARM THERAP, V24, P1003, DOI 10.1111/j.1365-2036.2006.03081.x; Lau GKK, 2003, GASTROENTEROLOGY, V125, P1742, DOI 10.1053/j.gastro.2003.09.026; Lau GKK, 2002, HEPATOLOGY, V36, P702, DOI 10.1053/jhep.2002.35068; Leaw SJ, 2004, ANN HEMATOL, V83, P270, DOI 10.1007/s00277-003-0825-8; Lee GW, 2003, J KOREAN MED SCI, V18, P849, DOI 10.3346/jkms.2003.18.6.849; Li YH, 2006, CANCER-AM CANCER SOC, V106, P1320, DOI 10.1002/cncr.21701; Lim LL, 2002, ALIMENT PHARM THER, V16, P1939, DOI 10.1046/j.1365-2036.2002.01364.x; Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; Loomba R, 2006, ANTIVIR THER, V11, P1; Mindikoglu AL, 2006, CLIN GASTROENTEROL H, V4, P1076, DOI 10.1016/j.cgh.2006.05.027; Nagamatsu H, 2004, AM J GASTROENTEROL, V99, P2369, DOI 10.1111/j.1572-0241.2004.40069.x; Ries L., 2005, SEER CANC STAT REV 1; Rossi G, 2003, LEUKEMIA LYMPHOMA, V44, P759, DOI 10.1080/104281903100006351; Shibolet O, 2002, BLOOD, V100, P391, DOI 10.1182/blood.V100.2.391; Yeo W, 2006, HEPATOLOGY, V43, P209, DOI 10.1002/hep.21051; Yeo W, 2005, AM J CLIN ONCOL-CANC, V28, P379, DOI 10.1097/01.coc.0000159554.97885.88; Yeo W, 2004, BREAST CANCER RES TR, V88, P209, DOI 10.1007/s10549-004-0725-1; Yeo W, 2004, J CLIN ONCOL, V22, P927, DOI 10.1200/JCO.2004.05.161; Zhong S, 2004, J VIRAL HEPATITIS, V11, P55, DOI 10.1046/j.1352-0504.2003.00467.x	35	353	381	1	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2008	148	7					519	528		10.7326/0003-4819-148-7-200804010-00008	http://dx.doi.org/10.7326/0003-4819-148-7-200804010-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284IV	18378948	Green Accepted			2022-12-28	WOS:000254701000004
J	Coleman, CH; Reis, A				Coleman, Carl H.; Reis, Andreas			Potential penalties for health care professionals who refuse to work during a pandemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ROLES; DUTY		[Coleman, Carl H.] Seton Hall Univ, Sch Law, Hlth Law & Policy Program, Newark, NJ 07102 USA; [Reis, Andreas] WHO, Dept Eth Equ Trade & Human Rights, CH-1211 Geneva, Switzerland	Seton Hall University; World Health Organization	Coleman, CH (corresponding author), Seton Hall Univ, Sch Law, Hlth Law & Policy Program, 1 Newark Ctr, Newark, NJ 07102 USA.	colemaca@shu.edu		Reis, Andreas/0000-0002-8218-2615				Clark CC, 2005, J MED PHILOS, V30, P65, DOI 10.1080/03605310590907066; Gruen RL, 2004, JAMA-J AM MED ASSOC, V291, P94, DOI 10.1001/jama.291.1.94; HEYMAN SJ, 1994, VANDERBILT LAW REV, V47, P673; Hsin DHC, 2004, J INFECTION, V49, P210, DOI 10.1016/j.jinf.2004.06.005; Leroy MH, 2004, ADMIN LAW REV, V56, P585; Nash R, 2007, LANCET, V370, P300, DOI 10.1016/S0140-6736(07)61140-4; RUDERMAN C, 2006, BMC MED ETHICS; *WHO, 2003, CONS DOC EP SEV AC R, P19; World Medical Association, 1948, DECL GEN	9	17	17	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2008	299	12					1471	1473		10.1001/jama.299.12.1471	http://dx.doi.org/10.1001/jama.299.12.1471			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278MY	18364490				2022-12-28	WOS:000254292200022
J	Martin, RW; Connell, PP; Bishop, DK				Martin, Richard W.; Connell, Philip P.; Bishop, Douglas K.			The Yin and Yang of treating BRCA-deficient tumors	CELL			English	Editorial Material							CANCER; RESISTANCE; CISPLATIN; CELLS; RAD51	The myriad changes that occur during the malignant progression of cancer cells present challenges to both clinicians and basic scientists. Two new studies in Nature underscore the central role of genome instability in tumor biology (Edwards et al., 2008; Sakai et al., 2008). These reports describe secondary changes in the BRCA2 locus that restore the wild-type reading frame and contribute to the development of resistance to chemotherapeutic agents.	[Martin, Richard W.; Bishop, Douglas K.] Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; [Connell, Philip P.; Bishop, Douglas K.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Bishop, DK (corresponding author), Univ Chicago, Cummings Life Sci Ctr, Comm Genet, Room 821A,920 E 58th St,Box 13, Chicago, IL 60637 USA.	dbishop@uchicago.edu						Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Foulkes WD, 2006, FAM CANCER, V5, P135, DOI 10.1007/s10689-005-2832-5; Martin RW, 2007, CANCER RES, V67, P9658, DOI 10.1158/0008-5472.CAN-07-0290; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Saeki H, 2006, P NATL ACAD SCI USA, V103, P8768, DOI 10.1073/pnas.0600298103; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087	10	7	8	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2008	132	6					919	920		10.1016/j.cell.2008.03.006	http://dx.doi.org/10.1016/j.cell.2008.03.006			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358803	Bronze			2022-12-28	WOS:000254273600009
J	Mavrich, TN; Jiang, CZ; Ioshikhes, IP; Li, XY; Venters, BJ; Zanton, SJ; Tomsho, LP; Qi, J; Glaser, RL; Schuster, SC; Gilmour, DS; Albert, I; Pugh, BF				Mavrich, Travis N.; Jiang, Cizhong; Ioshikhes, Ilya P.; Li, Xiaoyong; Venters, Bryan J.; Zanton, Sara J.; Tomsho, Lynn P.; Qi, Ji; Glaser, Robert L.; Schuster, Stephan C.; Gilmour, David S.; Albert, Istvan; Pugh, B. Franklin			Nucleosome organization in the Drosophila genome	NATURE			English	Article							RNA-POLYMERASE-II; HIGH-RESOLUTION MAP; PROMOTER ELEMENT; HISTONE H2A.Z; TRANSCRIPTION; CHROMATIN; REPLACEMENT; VARIANT; GENES; ACETYLATION	Comparative genomics of nucleosome positions provides a powerful means for understanding how the organization of chromatin and the transcription machinery co-evolve. Here we produce a high-resolution reference map of H2A.Z and bulk nucleosome locations across the genome of the fly Drosophila melanogaster and compare it to that from the yeast Saccharomyces cerevisiae. Like Saccharomyces, Drosophila nucleosomes are organized around active transcription start sites in a canonical -1, nucleosome-free region, +1 arrangement. However, Drosophila does not incorporate H2A.Z into the -1 nucleosome and does not bury its transcriptional start site in the +1 nucleosome. At thousands of genes, RNA polymerase II engages the +1 nucleosome and pauses. How the transcription initiation machinery contends with the +1 nucleosome seems to be fundamentally different across major eukaryotic lines.	[Mavrich, Travis N.; Jiang, Cizhong; Venters, Bryan J.; Zanton, Sara J.; Gilmour, David S.; Pugh, B. Franklin] Penn State Univ, Ctr Gene Regulat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; [Mavrich, Travis N.; Jiang, Cizhong; Venters, Bryan J.; Zanton, Sara J.; Tomsho, Lynn P.; Qi, Ji; Schuster, Stephan C.; Albert, Istvan; Pugh, B. Franklin] Penn State Univ, Ctr Comparat Genom & Bioinformat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; [Ioshikhes, Ilya P.] Ohio State Univ, Dept Biomed Informat, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; [Ioshikhes, Ilya P.] Ohio State Univ, Dept Mol & Cellular Biochem, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; [Li, Xiaoyong] Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Drosophila Transcript Network Project, Genom Div, Berkeley, CA 94720 USA; [Glaser, Robert L.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; [Glaser, Robert L.] SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Pugh, BF (corresponding author), Penn State Univ, Ctr Gene Regulat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	bfp2@psu.edu	QI, JI/E-2797-2016; Albert, Istvan/J-3734-2015	Mavrich, Travis/0000-0001-9252-5020; Albert, Istvan/0000-0001-8366-984X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004160] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047477] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG004160-01A1, HG004160, R01 HG004160] Funding Source: Medline; NIGMS NIH HHS [GM47477, R01 GM047477] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert I, 2007, NATURE, V446, P572, DOI 10.1038/nature05632; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Bondarenko VA, 2006, MOL CELL, V24, P469, DOI 10.1016/j.molcel.2006.09.009; Brown SA, 1997, GENE DEV, V11, P3116, DOI 10.1101/gad.11.23.3116; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Bruce K, 2005, NUCLEIC ACIDS RES, V33, P5633, DOI 10.1093/nar/gki874; Carey M, 2006, MOL CELL, V24, P481, DOI 10.1016/j.molcel.2006.09.012; David L, 2006, P NATL ACAD SCI USA, V103, P5320, DOI 10.1073/pnas.0601091103; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FYRBERG E, 1994, METHOD CELL BIOL, V44, P1; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Hild M, 2004, GENOME BIOL, V5; Ioshikhes I, 1996, J MOL BIOL, V262, P129, DOI 10.1006/jmbi.1996.0503; Ioshikhes IP, 2006, NAT GENET, V38, P1210, DOI 10.1038/ng1878; Johnson SM, 2006, GENOME RES, V16, P1505, DOI 10.1101/gr.5560806; Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kogan SB, 2006, J BIOMOL STRUCT DYN, V24, P43, DOI 10.1080/07391102.2006.10507097; KORNBERG R, 1981, NATURE, V292, P579, DOI 10.1038/292579a0; KORNBERG RD, 1988, NUCLEIC ACIDS RES, V16, P6677, DOI 10.1093/nar/16.14.6677; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Law A, 1998, NUCLEIC ACIDS RES, V26, P919, DOI 10.1093/nar/26.4.919; Leach TJ, 2000, J BIOL CHEM, V275, P23267, DOI 10.1074/jbc.M910206199; LEE C, IN PRESS MOL CELL BI; Lee W, 2007, NAT GENET, V39, P1235, DOI 10.1038/ng2117; Lehmann M, 2004, TRENDS GENET, V20, P15, DOI 10.1016/j.tig.2003.11.005; Li B, 2005, P NATL ACAD SCI USA, V102, P18385, DOI 10.1073/pnas.0507975102; Li XY, 2008, PLOS BIOL, V6, P365, DOI 10.1371/journal.pbio.0060027; Lieb JD, 2005, CELL, V123, P1187, DOI 10.1016/j.cell.2005.12.010; Lim CY, 2004, GENE DEV, V18, P1606, DOI 10.1101/gad.1193404; Lis JT, 2007, NATURE, V450, P198, DOI 10.1038/nature06324; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637; Mito Y, 2007, SCIENCE, V315, P1408, DOI 10.1126/science.1134004; Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21; Orlando V, 1998, EMBO J, V17, P5141, DOI 10.1093/emboj/17.17.5141; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; Stark A, 2007, NATURE, V450, P219, DOI 10.1038/nature06340; Swaminathan J, 2005, GENE DEV, V19, P65, DOI 10.1101/gad.1259105; Tomancak P, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r145; Updike DL, 2006, PLOS GENET, V2, P1500, DOI 10.1371/journal.pgen.0020161; van Steensel B, 2003, P NATL ACAD SCI USA, V100, P2580, DOI 10.1073/pnas.0438000100; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178; Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26; Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036; Zhang ZH, 2005, NUCLEIC ACIDS RES, V33, P2838, DOI 10.1093/nar/gki583	54	535	552	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2008	453	7193					358	U27		10.1038/nature06929	http://dx.doi.org/10.1038/nature06929			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301AI	18408708	Green Accepted			2022-12-28	WOS:000255868400044
J	Wicher, D; Schafer, R; Bauernfeind, R; Stensmyr, MC; Heller, R; Heinemann, SH; Hansson, BS				Wicher, Dieter; Schaefer, Ronny; Bauernfeind, Rene; Stensmyr, Marcus C.; Heller, Regine; Heinemann, Stefan H.; Hansson, Bill S.			Drosophila odorant receptors are both ligand-gated and cyclic-nucleotide-activated cation channels	NATURE			English	Article							NEUROSECRETORY INSECT NEURONS; OLFACTORY RECEPTOR; MOLECULAR-BASIS; FUNCTIONAL EXPRESSION; IN-VIVO; CAMP; TRANSDUCTION; MELANOGASTER; PROTEINS; ANTENNA	From worm to man, many odorant signals are perceived by the binding of volatile ligands to odorant receptors(1) that belong to the G- protein- coupled receptor ( GPCR) family(2). They couple to heterotrimeric G- proteins, most of which induce cAMP production(3). This second messenger then activates cyclic- nucleotide-gated ion channels to depolarize the olfactory receptor neuron, thus providing a signal for further neuronal processing. Recent findings, however, have challenged this concept of odorant signal transduction in insects, because their odorant receptors, which lack any sequence similarity to other GPCRs(4), are composed of conventional odorant receptors ( for example, Or22a), dimerized with a ubiquitously expressed chaperone protein(5), such as Or83b in Drosophila(6). Or83b has a structure akin to GPCRs, but has an inverted orientation in the plasma membrane(4,7). However, G proteins are expressed in insect olfactory receptor neurons(8), and olfactory perception is modified by mutations affecting the cAMP transduction pathway(9). Here we show that application of odorants to mammalian cells co- expressing Or22a and Or83b results in non- selective cation currents activated by means of an ionotropic and a metabotropic pathway, and a subsequent increase in the intracellular Ca2+ concentration. Expression of Or83b alone leads to functional ion channels not directly responding to odorants, but being directly activated by intracellular cAMP or cGMP. Insect odorant receptors thus form ligand- gated channels as well as complexes of odorant- sensing units and cyclic- nucleotide- activated non- selective cation channels. Thereby, they provide rapid and transient as well as sensitive and prolonged odorant signalling.	[Wicher, Dieter; Schaefer, Ronny; Bauernfeind, Rene; Stensmyr, Marcus C.; Hansson, Bill S.] Max Planck Inst Chem Ecol, Dept Evolutionary Neuroethol, D-07745 Jena, Germany; [Heller, Regine] Univ Jena, Inst Mol Cell Biol, Ctr Mol Biomed, D-07743 Jena, Germany; [Heinemann, Stefan H.] Univ Jena, Dept Biophys, Ctr Mol Biomed, D-07745 Jena, Germany	Max Planck Society; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Wicher, D (corresponding author), Max Planck Inst Chem Ecol, Dept Evolutionary Neuroethol, Hans Knoll St 8, D-07745 Jena, Germany.	dwicher@ice.mpg.de	Hansson, Bill/G-2774-2013; Heller, Regine/AAC-9353-2019	Hansson, Bill/0000-0002-4811-1223; Heinemann, Stefan H./0000-0002-4144-0251; Stensmyr, Marcus/0000-0003-4009-9212				Barry PH, 2003, J GEN PHYSIOL, V122, P247, DOI 10.1085/jgp.200308910; Benton R, 2006, PLOS BIOL, V4, P240, DOI 10.1371/journal.pbio.0040020; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Craven KB, 2006, ANNU REV PHYSIOL, V68, P375, DOI 10.1146/annurev.physiol.68.040104.134728; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Dobritsa AA, 2003, NEURON, V37, P827, DOI 10.1016/S0896-6273(03)00094-1; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Hallem EA, 2004, CELL, V117, P965, DOI 10.1016/j.cell.2004.05.012; Hill, 2001, ION CHANNELS EXCITAB, P441; Katada S, 2003, BIOCHEM BIOPH RES CO, V305, P964, DOI 10.1016/S0006-291X(03)00863-5; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Larsson MC, 2004, NEURON, V43, P703, DOI 10.1016/j.neuron.2004.08.019; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Martin F, 2001, J COMP PHYSIOL A, V187, P359, DOI 10.1007/s003590100208; Messutat S, 2001, CELL CALCIUM, V30, P199, DOI 10.1054/ceca.2001.0227; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; Nagel G, 2002, SCIENCE, V296, P2395, DOI 10.1126/science.1072068; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Neuhaus EM, 2005, NAT NEUROSCI, V8, P15, DOI 10.1038/nn1371; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Pelz D, 2006, J NEUROBIOL, V66, P1544, DOI 10.1002/neu.20333; Ronnett GV, 2002, ANNU REV PHYSIOL, V64, P189, DOI 10.1146/annurev.physiol.64.082701.102219; Rutzler M, 2006, J COMP NEUROL, V499, P533, DOI 10.1002/cne.21083; Wetzel CH, 2001, P NATL ACAD SCI USA, V98, P9377, DOI 10.1073/pnas.151103998; Wicher D, 2006, J NEUROPHYSIOL, V95, P2314, DOI 10.1152/jn.01007.2005; Wicher D, 2006, J BIOL CHEM, V281, P3227, DOI 10.1074/jbc.M511741200; Wistrand M, 2006, PROTEIN SCI, V15, P509, DOI 10.1110/ps.051745906	28	613	662	8	150	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2008	452	7190					1007	U10		10.1038/nature06861	http://dx.doi.org/10.1038/nature06861			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291PF	18408711				2022-12-28	WOS:000255208600042
J	Butte, AJ				Butte, Atul J.			Medicine - The ultimate model organism	SCIENCE			English	Editorial Material							NETWORK; CANCER; PROJECT; MAP		[Butte, Atul J.] Stanford Univ, Sch Med, Stanford Ctr Biomed Informat Res, Stanford, CA 94305 USA; [Butte, Atul J.] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; [Butte, Atul J.] Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Lucile Packard Children's Hospital (LPCH)	Butte, AJ (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Biomed Informat Res, Stanford, CA 94305 USA.	abutte@stanford.edu			NIGMS NIH HHS [R01 GM079719-02, R01 GM079719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Butte AJ, 2006, NAT BIOTECHNOL, V24, P55, DOI 10.1038/nbt1150; Chen David P, 2008, Pac Symp Biocomput, P243; FLISS A, 2008, SUMM TRANSL BIOINF P, P11; Freimer N, 2003, NAT GENET, V34, P15, DOI 10.1038/ng0503-15; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Hunter PJ, 2003, NAT REV MOL CELL BIO, V4, P237, DOI 10.1038/nrm1054; Lage K, 2007, NAT BIOTECHNOL, V25, P309, DOI 10.1038/nbt1295; Payne PRO, 2005, J INVEST MED, V53, P192, DOI 10.2310/6650.2005.00402; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Segal E, 2007, NAT BIOTECHNOL, V25, P675, DOI 10.1038/nbt1306; Stoll M, 2001, SCIENCE, V294, P1723, DOI 10.1126/science.1062117; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278	14	30	30	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					325	327		10.1126/science.1158343	http://dx.doi.org/10.1126/science.1158343			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420921	Green Accepted			2022-12-28	WOS:000255026100028
J	Dolev, M; Heiblum, M; Umansky, V; Stern, A; Mahalu, D				Dolev, M.; Heiblum, M.; Umansky, V.; Stern, Ady; Mahalu, D.			Observation of a quarter of an electron charge at the nu=5/2 quantum Hall state	NATURE			English	Article							FRACTIONAL CHARGE; QUASI-PARTICLE; NOISE	The fractional quantum Hall effect, where plateaus in the Hall resistance at values of h/nu e(2) coexist with zeros in the longitudinal resistance, results from electron correlations in two dimensions under a strong magnetic field. ( Here h is Planck's constant, nu the filling factor and e the electron charge.) Current flows along the sample edges and is carried by charged excitations ( quasiparticles) whose charge is a fraction of the electron charge. Although earlier research concentrated on odd denominator fractional values of nu, the observation of the even denominator nu = 5/2 state sparked much interest. This state is conjectured to be characterized by quasiparticles of charge e/4, whose statistics are 'non- abelian' - in other words, interchanging two quasiparticles may modify the state of the system into a different one, rather than just adding a phase as is the case for fermions or bosons. As such, these quasiparticles may be useful for the construction of a topological quantum computer. Here we report data on shot noise generated by partitioning edge currents in the nu = 5/2 state, consistent with the charge of the quasiparticle being e/4, and inconsistent with other possible values, such as e/2 and e. Although this finding does not prove the non- abelian nature of the nu= 5/2 state, it is the first step towards a full understanding of these new fractional charges.	[Dolev, M.; Heiblum, M.; Umansky, V.; Stern, Ady; Mahalu, D.] Weizmann Inst Sci, Braun Ctr Submicron Res, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Dolev, M (corresponding author), Weizmann Inst Sci, Braun Ctr Submicron Res, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel.	merav.dolev@weizmann.ac.il	Umansky, Vladimir/P-1334-2019; heiblum, moty/Q-1193-2019	Umansky, Vladimir/0000-0001-5727-2064; 				[Anonymous], 1987, QUANTUM HALL EFFECT; Bena C, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.155335; Bonderson P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.016803; Chung YC, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.216804; Chung YC, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.201104; Das Sarma S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.166802; DASSARMA S, 2007, NONABELIAN ANYONS TO; dePicciotto R, 1997, NATURE, V389, P162, DOI 10.1038/38241; Feldman DE, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.085333; Fradkin E, 1998, NUCL PHYS B, V516, P704, DOI 10.1016/S0550-3213(98)00111-4; Griffiths TG, 2000, PHYS REV LETT, V85, P3918, DOI 10.1103/PhysRevLett.85.3918; KANE CL, 1994, PHYS REV LETT, V72, P724, DOI 10.1103/PhysRevLett.72.724; Kitaev AY, 2003, ANN PHYS-NEW YORK, V303, P2, DOI 10.1016/S0003-4916(02)00018-0; LESOVIK GB, 1989, JETP LETT+, V49, P592; MARTIN T, 1992, PHYS REV B, V45, P1742, DOI 10.1103/PhysRevB.45.1742; Miller JB, 2007, NAT PHYS, V3, P561, DOI 10.1038/nphys658; MOORE G, 1991, NUCL PHYS B, V360, P362, DOI 10.1016/0550-3213(91)90407-O; Morf RH, 1998, PHYS REV LETT, V80, P1505, DOI 10.1103/PhysRevLett.80.1505; Pan W, 2001, PHYSICA E, V9, P9, DOI 10.1016/S1386-9477(00)00171-5; Read N, 2000, PHYS REV B, V61, P10267, DOI 10.1103/PhysRevB.61.10267; READ N, 2000, PAIRED FRACTIONAL QU; Reznikov M, 1999, NATURE, V399, P238, DOI 10.1038/20384; Roddaro S, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.156804; Saminadayar L, 1997, PHYS REV LETT, V79, P2526, DOI 10.1103/PhysRevLett.79.2526; STERN A, 2006, PHYS REV LETT, V79; STEVN A, 2008, ANN PHYS, V1, P204; Toke C, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.246805; WILLETT R, 1987, PHYS REV LETT, V59, P1776, DOI 10.1103/PhysRevLett.59.1776	29	277	285	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2008	452	7189					829	U1		10.1038/nature06855	http://dx.doi.org/10.1038/nature06855			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18421345	Green Submitted			2022-12-28	WOS:000255026000039
J	Kesselheim, AS; Avorn, J				Kesselheim, Aaron S.; Avorn, Jerry			Pharmaceutical promotion to physicians and first amendment rights	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DRUG; HYPERTENSION; GABAPENTIN; INDUSTRY; RISK		[Kesselheim, Aaron S.; Avorn, Jerry] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA 02115 USA; [Kesselheim, Aaron S.; Avorn, Jerry] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kesselheim, AS (corresponding author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, 75 Francis St, Boston, MA 02115 USA.		Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Alexopoulos GS, 2004, J CLIN PSYCHIAT, V65, P5; AVORN J, 2000, POWERFUL MED BENEFIT; Avorn J, 2007, NEW ENGL J MED, V356, P1697, DOI 10.1056/NEJMp078041; BERENSON A, 2005, NY TIMES        0819; Fischer MA, 2004, JAMA-J AM MED ASSOC, V291, P1850, DOI 10.1001/jama.291.15.1850; Food and Drug Administration, 2005, FDA ISS PUBL HLTH AD; *FOOD DRUG ADM, 2008, GUID IND GOOD REPR P; Hall RF, 2007, FOOD DRUG LAW J, V62, P1; Henney JE, 2006, ANN INTERN MED, V145, P305, DOI 10.7326/0003-4819-145-4-200608150-00013; Hilts P, 2003, PROTECTING AM HLTH F; Kesselheim AS, 2007, HEALTH AFFAIR, V26, P483, DOI 10.1377/hlthaff.26.2.483; Kesselheim AS, 2007, JAMA-J AM MED ASSOC, V297, P308, DOI 10.1001/jama.297.3.308; Kesselhelm AS, 2006, HEALTH AFFAIR, V25, P1095, DOI 10.1377/hlthaff.25.4.1095; LAGNADO L, 2007, WALL STREET J   1204, pA1, DOI DOI 10.1007/S00228-005-0981-Y; Mason MJ, 2000, J PUBLIC POLICY MARK, V19, P144, DOI 10.1509/jppm.19.1.144.16938; Mathew NT, 2001, HEADACHE, V41, P119, DOI 10.1046/j.1526-4610.2001.111006119.x; MONANE M, 1995, HYPERTENSION, V25, P1045, DOI 10.1161/01.HYP.25.5.1045; Morris CA, 2003, JAMA-J AM MED ASSOC, V290, P1505, DOI 10.1001/jama.290.11.1505; PEAY MY, 1994, SOC SCI MED, V39, P39, DOI 10.1016/0277-9536(94)90164-3; Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021; Steinman MA, 2007, PLOS MED, V4, P743, DOI 10.1371/journal.pmed.0040134; Steinman MA, 2006, ANN INTERN MED, V145, P284, DOI 10.7326/0003-4819-145-4-200608150-00008; Tabarrok A., 2000, INDEP REV, V5, P25; Topol EJ, 2005, NEW ENGL J MED, V353, P113, DOI 10.1056/NEJMp058139; TREAT SA, 2006, WHAT STATES ARE DOIN; Wang PS, 2005, NEW ENGL J MED, V353, P2335, DOI 10.1056/NEJMoa052827; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	27	31	31	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1727	1732		10.1056/NEJMsb0708920	http://dx.doi.org/10.1056/NEJMsb0708920			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288DO	18420505				2022-12-28	WOS:000254966600013
J	Moaddab, MH; Siavash, M				Moaddab, Mohammad Hassan; Siavash, Mansour			Lingual thyroid	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Moaddab, Mohammad Hassan; Siavash, Mansour] Isfahan Univ Med Sci, Esfahan, Iran	Isfahan University Medical Science	Moaddab, MH (corresponding author), Isfahan Univ Med Sci, Esfahan, Iran.	siavash@med.mui.ac.ir	Siavash, Mansour/C-7285-2018; Golshahi, Jafar/C-7236-2018	Siavash, Mansour/0000-0003-0590-6410					0	4	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1712	1712		10.1056/NEJMicm070536	http://dx.doi.org/10.1056/NEJMicm070536			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288DO	18420503				2022-12-28	WOS:000254966600009
J	Valtonen, MJ; Lehto, HJ; Nilsson, K; Heidt, J; Takalo, LO; Sillanpaa, A; Villforth, C; Kidger, M; Poyner, G; Pursimo, T; Zola, S; Wu, JH; Zhou, X; Sadakane, K; Drozdz, M; Koziel, D; Marchev, D; Ogloza, W; Porowski, C; Siwak, M; Stachowski, G; Winiarski, M; Hentunen, VP; Nissinen, M; Liakos, A; Dogru, S				Valtonen, M. J.; Lehto, H. J.; Nilsson, K.; Heidt, J.; Takalo, L. O.; Sillanpaa, A.; Villforth, C.; Kidger, M.; Poyner, G.; Pursimo, T.; Zola, S.; Wu, J. -H.; Zhou, X.; Sadakane, K.; Drozdz, M.; Koziel, D.; Marchev, D.; Ogloza, W.; Porowski, C.; Siwak, M.; Stachowski, G.; Winiarski, M.; Hentunen, V. -P.; Nissinen, M.; Liakos, A.; Dogru, S.			A massive binary black-hole system in OJ 287 and a test of general relativity	NATURE			English	Article							BL-LACERTAE OBJECTS; OJ 287; ACCRETION DISK; MODEL; OUTBURST; PULSAR; OJ287; LENS	Tests of Einstein's general theory of relativity have mostly been carried out in weak gravitational fields where the space- time curvature effects are first- order deviations from Newton's theory(1-6). Binary pulsars(4) provide a means of probing the strong gravitational field around a neutron star, but strong- field effects may be best tested in systems containing black holes(7,8). Here we report such a test in a close binary system of two candidate black holes in the quasar OJ 287. This quasar shows quasi- periodic optical outbursts at 12- year intervals, with two outburst peaks per interval(9,10). The latest outburst occurred in September 2007, within a day of the time predicted by the binary black- hole model and general relativity(11). The observations confirm the binary nature of the system and also provide evidence for the loss of orbital energy in agreement ( within 10 per cent) with the emission of gravitational waves from the system(12). In the absence of gravitational wave emission the outburst would have happened 20 days later(13).	[Valtonen, M. J.; Lehto, H. J.; Takalo, L. O.; Sillanpaa, A.; Villforth, C.] Univ Turku, Dept Phys, FI-21500 Piikkio, Finland; [Valtonen, M. J.; Lehto, H. J.; Nilsson, K.; Takalo, L. O.; Sillanpaa, A.; Villforth, C.] Univ Turku, Tuorla Observ, FI-21500 Piikkio, Finland; [Heidt, J.] Landessternwarte Heidelberg, D-69117 Heidelberg, Germany; [Kidger, M.] European Space Agcy, European Space Astron Ctr, Herschel Sci Ctr, Villafrance Castillo Satellite Tracking Stn, Madrid 28691, Spain; [Kidger, M.] INSA, Madrid 28008, Spain; [Poyner, G.] British Astron Assoc Variable Star Sect, Birmingham B44 0QE, W Midlands, England; [Pursimo, T.] Nord Opt Telescope, E-38700 S C La Palma, Spain; [Zola, S.; Koziel, D.; Porowski, C.; Siwak, M.; Winiarski, M.] Jagiellonian Univ, Astron Observ, PL-30224 Krakow, Poland; [Stachowski, G.] Pedagog Univ, Mt Suhora Observ, PL-30084 Krakow, Poland; [Wu, J. -H.; Zhou, X.] Chinese Acad Sci, Natl Astron Observ, Beijing 100012, Peoples R China; [Sadakane, K.] Osaka Kyoiku Univ, Inst Astron, Kashiwara, Osaka 5828582, Japan; [Marchev, D.] Shoumen Univ, Dept Phys, Shumen, Bulgaria; [Nissinen, M.] Warkauden Kassiopeia Ry, Kangaslampi 79480, Finland; [Liakos, A.] Univ Athens, Fac Phys, Dept Astrophys Astron & Mech, GR-15784 Athens, Greece; [Dogru, S.] Canakkale Onsekiz Mart Univ, Fac Phys, TR-17020 Canakkale, Turkey	University of Turku; University of Turku; Ruprecht Karls University Heidelberg; European Space Agency; Jagiellonian University; Pedagogical University of Cracow; Chinese Academy of Sciences; National Astronomical Observatory, CAS; Osaka University of Education; University of Shumen; National & Kapodistrian University of Athens; Canakkale Onsekiz Mart University	Valtonen, MJ (corresponding author), Univ Turku, Dept Phys, Vaisalantie 20, FI-21500 Piikkio, Finland.	mvaltonen2001@yahoo.com	Doğru, Sertaç Serkan/A-2897-2013; Pursimo, tapio/GLQ-7782-2022; Marchev, Dragomir Valchev/K-3941-2013; Liakos, Alexios/K-4452-2013; Stachowski, Greg/AAY-5570-2021	Marchev, Dragomir Valchev/0000-0001-6394-1121; Liakos, Alexios/0000-0002-0490-1469; Stachowski, Greg/0000-0003-1560-1039; Drozdz, Marek/0000-0001-9587-1615; Villforth, Carolin/0000-0002-8956-6654; Ogloza, Waldemar/0000-0002-6293-9940				Bromley BC, 1998, NATURE, V391, P54, DOI 10.1038/34130; Ciufolini I, 2004, NATURE, V431, P958, DOI 10.1038/nature03007; Cui W, 1998, ASTROPHYS J, V492, pL53, DOI 10.1086/311092; Fiorucci M, 1996, ASTRON ASTROPHYS SUP, V116, P403, DOI 10.1051/aas:1996123; Hughes PA, 1998, ASTROPHYS J, V503, P662, DOI 10.1086/306014; HULSE RA, 1994, REV MOD PHYS, V66, P699, DOI 10.1103/RevModPhys.66.699; Igumenshchev IV, 1999, MON NOT R ASTRON SOC, V303, P309, DOI 10.1046/j.1365-8711.1999.02220.x; Ivanov PB, 1998, ASTROPHYS J, V507, P131, DOI 10.1086/306324; Katz JI, 1997, ASTROPHYS J, V478, P527, DOI 10.1086/303811; Lehto HJ, 1996, ASTROPHYS J, V460, P207, DOI 10.1086/176962; Pietila H, 1998, ASTROPHYS J, V508, P669, DOI 10.1086/306444; POUND RV, 1959, PHYS REV LETT, V3, P439, DOI 10.1103/PhysRevLett.3.439; SMITH PS, 1987, ASTROPHYS J SUPPL S, V64, P459, DOI 10.1086/191203; Sundelius B, 1997, ASTROPHYS J, V484, P180, DOI 10.1086/304331; TAYLOR JH, 1989, ASTROPHYS J, V345, P434, DOI 10.1086/167917; Valtonen M, 2008, ASTRON ASTROPHYS, V477, P407, DOI 10.1051/0004-6361:20066399; Valtonen MJ, 2006, ASTROPHYS J, V643, pL9, DOI 10.1086/505039; Valtonen MJ, 2006, ASTROPHYS J, V646, P36, DOI 10.1086/504884; Valtonen MJ, 2007, ASTROPHYS J, V659, P1074, DOI 10.1086/512801; Valtonen MJ, 1997, ASTROPHYS J, V481, pL5, DOI 10.1086/310642; Vestergaard M, 2008, ASTROPHYS J LETT, V674, pL1, DOI 10.1086/528981; WALSH D, 1979, NATURE, V279, P381, DOI 10.1038/279381a0	23	259	263	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2008	452	7189					851	853		10.1038/nature06896	http://dx.doi.org/10.1038/nature06896			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18421348	Green Submitted			2022-12-28	WOS:000255026000043
J	Bousquet, E; Dawber, M; Stucki, N; Lichtensteiger, C; Hermet, P; Gariglio, S; Triscone, JM; Ghosez, P				Bousquet, Eric; Dawber, Matthew; Stucki, Nicolas; Lichtensteiger, Celine; Hermet, Patrick; Gariglio, Stefano; Triscone, Jean-Marc; Ghosez, Philippe			Improper ferroelectricity in perovskite oxide artificial superlattices	NATURE			English	Article							THIN-FILMS; POLARIZATION ENHANCEMENT; 1ST-PRINCIPLES; BATIO3; SRTIO3	Ferroelectric thin films and superlattices are currently the subject of intensive research(1,2) because of the interest they raise for technological applications and also because their properties are of fundamental scientific importance(3-5). Ferroelectric superlattices(6) allow the tuning of the ferroelectric properties while maintaining perfect crystal structure and a coherent strain, even throughout relatively thick samples. This tuning is achieved in practice by adjusting both the strain(7-10), to enhance the polarization, and the composition, to interpolate between the properties of the combined compounds(11-15). Here we show that superlattices with very short periods possess a new form of interface coupling, based on rotational distortions, which gives rise to 'improper' ferroelectricity. These observations suggest an approach, based on interface engineering, to produce artificial materials with unique properties. By considering ferroelectric/paraelectric PbTiO3/SrTiO3 multilayers, we first show from first principles that the groundstate of the system is not purely ferroelectric but also primarily involves antiferrodistortive rotations of the oxygen atoms in a way compatible with improper ferroelectricity. We then demonstrate experimentally that, in contrast to pure PbTiO3 and SrTiO3 compounds, the multilayer system indeed behaves like a prototypical improper ferroelectric and exhibits a very large dielectric constant of epsilon(r)approximate to 600, which is also fairly temperature-independent. This behaviour, of practical interest for technological applications(16), is distinct from that of normal ferroelectrics, for which the dielectric constant is typically large but strongly evolves around the phase transition temperature and also differs from that of previously known improper ferroelectrics that exhibit a temperature-independent but small dielectric constant only.	[Bousquet, Eric; Hermet, Patrick; Ghosez, Philippe] Univ Liege, B-4000 Sart Tilman Par Liege, Belgium; [Dawber, Matthew; Stucki, Nicolas; Lichtensteiger, Celine; Gariglio, Stefano; Triscone, Jean-Marc] Univ Geneva, DPMC, CH-1211 Geneva 4, Switzerland	University of Liege; University of Geneva	Ghosez, P (corresponding author), Univ Liege, Allee 6 Aout 17 B5, B-4000 Sart Tilman Par Liege, Belgium.	matthew.dawber@stonybrook.edu; philippe.ghosez@ulg.ac.be	Ghosez, Philippe/F-1954-2014	Bousquet, Eric/0000-0002-9290-3463; Gariglio, Stefano/0000-0001-8263-4506				Ahn CH, 2004, SCIENCE, V303, P488, DOI 10.1126/science.1092508; Bungaro C, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.035420; Choi KJ, 2004, SCIENCE, V306, P1005, DOI 10.1126/science.1103218; Dawber M, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.177601; Dawber M, 2005, REV MOD PHYS, V77, P1083, DOI 10.1103/RevModPhys.77.1083; Dawber M, 2007, ADV MATER, V19, P4153, DOI 10.1002/adma.200700965; Dieguez O, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.144101; Eerenstein W, 2006, NATURE, V442, P759, DOI 10.1038/nature05023; Fennie CJ, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.100103; Ghosez P, 1999, PHYS REV B, V60, P836, DOI 10.1103/PhysRevB.60.836; GLAZER AM, 1972, ACTA CRYSTALLOGR B, VB 28, P3384, DOI 10.1107/S0567740872007976; Gonze X, 1997, PHYS REV B, V55, P10355, DOI 10.1103/PhysRevB.55.10355; Gonze X, 2002, COMP MATER SCI, V25, P478, DOI 10.1016/S0927-0256(02)00325-7; Haeni JH, 2004, NATURE, V430, P758, DOI 10.1038/nature02773; Holakovsky J., 1973, Physica Status Solidi B, V56, P615, DOI 10.1002/pssb.2220560224; Junquera J, 2003, NATURE, V422, P506, DOI 10.1038/nature01501; Kingon AI, 2000, NATURE, V406, P1032, DOI 10.1038/35023243; KINGSMITH RD, 1993, PHYS REV B, V47, P1651, DOI 10.1103/PhysRevB.47.1651; Lee HN, 2005, NATURE, V433, P395, DOI 10.1038/nature03261; LEVANYUK AP, 1974, USP FIZ NAUK+, V112, P561, DOI 10.1070/PU1974v017n02ABEH004336; Lichtensteiger C, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.047603; Lin CH, 2006, J APPL PHYS, V100, DOI 10.1063/1.2358305; Martin R.M., 2004, ELECT STRUCTURE BASI; MILLER SC, 1967, TABLES IRREDUCTIBLE; MONKHORST HJ, 1976, PHYS REV B, V13, P5188, DOI 10.1103/PhysRevB.16.1746; Munkholm A, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.016101; Nakhmanson SM, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2042630; Neaton JB, 2003, APPL PHYS LETT, V82, P1586, DOI 10.1063/1.1559651; Pertsev NA, 1998, PHYS REV LETT, V80, P1988, DOI 10.1103/PhysRevLett.80.1988; Pertsev NA, 2000, PHYS REV B, V61, pR825, DOI 10.1103/PhysRevB.61.R825; Rijnders G, 2005, NATURE, V433, P369, DOI 10.1038/433369a; TETER M, 1993, PHYS REV B, V48, P5031, DOI 10.1103/PhysRevB.48.5031; Vasudevarao A, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.257602; ZHONG W, 1995, PHYS REV LETT, V74, P2587, DOI 10.1103/PhysRevLett.74.2587	35	685	692	20	612	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2008	452	7188					732	U4		10.1038/nature06817	http://dx.doi.org/10.1038/nature06817			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401406				2022-12-28	WOS:000254792500041
J	Singh, SN; Wachter, RM				Singh, Sanjiv N.; Wachter, Robert M.			Perspectives on medical outsourcing and telemedicine - Rough edges in a flat world?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TELERADIOLOGY		[Singh, Sanjiv N.; Wachter, Robert M.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Singh, SN (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.			Singh, Sanjiv/0000-0001-5412-2888				*AM COLL RAD, ACR COUNC AD REV STA; BARBOZA D, 2007, NY TIMES        0721; BRIGGS B, 2005, HLTH DATA MANAG, V13, P70; BRIGGS B, 2005, HLTH DATA MANAG, V13, P72; Briggs Bill, 2005, Health Data Manag, V13, ppassim; CHRISTIANSEN JR, 2004, HIT NEWS         SUM, V7, P1; CLABURN T, 2006, INFORMATIONWEEK 0905; Cwiek MA, 2007, TELEMED J E-HEALTH, V13, P141, DOI 10.1089/tmj.2006.0029; Ebbert TL, 2007, AM J ROENTGENOL, V188, pW103, DOI 10.2214/AJR.06.1310; Fleisher L.D., 2004, TELEMEDICINE E HLTH; Friedman T. L., 2006, WORLD IS FLAT BRIEF; GAFFNEY M, 2006, TELERADIOLOGY TELERI; GANESH V, 2007, HINDUSTAN TIMES 0202; *GOV ACC OFF, 2006, PRIV DOM OFFSH OUTS; HARTYGOLDBER B, 2004, MLO MED LAB OBSERVER, V36, P38; HENKEL G, 2006, HOSPITALIST      DEC; *JOINT COMM ACCR H, 2005, JCAHO PROP REV LD 3; KING D, 2005, UC DAVIS BUSINE 0110; KRISHNAN S, INDIA TELERADIOLOGY; Larson DB, 2005, AM J ROENTGENOL, V185, P24, DOI 10.2214/ajr.185.1.01850024; LEVY F, 2006, MILKEN I REV, P64; McLean TR, 2006, HEALTH AFFAIR, V25, P1378, DOI 10.1377/hlthaff.25.5.1378; MILLER NW, 1999, NEWS DIGEST      JUN; Milstein A, 2006, NEW ENGL J MED, V355, P1637, DOI 10.1056/NEJMp068190; MISHRA R, 2005, BOSTON GLOBE    0629; Porter ME, 2007, JAMA-J AM MED ASSOC, V297, P1103, DOI 10.1001/jama.297.10.1103; STEIN R, 2005, WASHINGTON POST 0424; Steinbrook R, 2007, NEW ENGL J MED, V357, P5, DOI 10.1056/NEJMp078059; TRAPKIN LJ, 2006, NEW YORK STATE SOC P; *US OFF CIV RIGHTS, 2003, OCR PRIV BRIEF SUMM; *US OFF TECHN POL, 2004, INN DEM INV TEL; VANMOORE A, REPORT 2003 ACR TASK; WACHTER GW, 2000, INTERSTATE LICENSURE; Wachter RM, 2006, NEW ENGL J MED, V354, P661, DOI 10.1056/NEJMp058258; Wachter RM, 2006, NEW ENGL J MED, V354, P662, DOI 10.1056/NEJMp058286; 2006, HLTH LAW ALERT  0925	36	31	31	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1622	1627		10.1056/NEJMhle0707298	http://dx.doi.org/10.1056/NEJMhle0707298			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285NK	18403771				2022-12-28	WOS:000254783300014
J	Wheeler, R				Wheeler, Robert			Doctors' standard of proof rejected by lawyers?	LANCET			English	Editorial Material									Southampton Gen Hosp, Wessex Reg Ctr Paediat Surg, Southampton SO16 6YD, Hants, England	University of Southampton	Wheeler, R (corresponding author), Southampton Gen Hosp, Wessex Reg Ctr Paediat Surg, Southampton SO16 6YD, Hants, England.	robert.wheeler@suht.swest.nhs.uk						SMITH J, 2004, SAFEGUARDING PATIENT; 2007, LS LAW MED, V7, P418; 1993, QUEENS BENCH REP, P69; 1956, WEEKLY LAW REP, V1, P1442; 2007, LS LAW MED, V7, P429; 2005, ALL ENGL REP, V3, P1116; 2007, LS LAW MED, V7, P1361	7	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 5	2008	371	9619					1148	1149		10.1016/S0140-6736(08)60504-8	http://dx.doi.org/10.1016/S0140-6736(08)60504-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	287ZM	18395565				2022-12-28	WOS:000254956000010
J	Sharma, S; Chakraborty, K; Mueller, BK; Astola, N; Tang, YC; Lamb, DC; Hayer-Hartl, M; Hartl, FU				Sharma, Shruti; Chakraborty, Kausik; Mueller, Barbara K.; Astola, Nagore; Tang, Yun-Chi; Lamb, Don C.; Hayer-Hartl, Manajit; Hartl, F. Ulrich			Monitoring protein conformation along the pathway of chaperonin-assisted folding	CELL			English	Article							MOLECULAR CHAPERONES; GROEL; ATP; INTERMEDIATE; MECHANISM; RELEASE; BINDING; CYTOSOL; STATES; CHAIN	The GroEL/GroES chaperonin system mediates protein folding in the bacterial cytosol. Newly synthesized proteins reach GroEL via transfer from upstream chaperones such as DnaK/DnaJ (Hsp70). Here we employed single molecule and ensemble FRET to monitor the conformational transitions of a model substrate as it proceeds along this chaperone pathway. We find that DnaK/DnaJ stabilizes the protein in collapsed states that fold exceedingly slowly. Transfer to GroEL results in unfolding, with a fraction of molecules reaching locally highly expanded conformations. ATP-induced domain movements in GroEL cause transient further unfolding and rapid mobilization of protein segments with moderate hydrophobicity, allowing partial compaction on the GroEL surface. The more hydrophobic regions are released upon subsequent protein encapsulation in the central GroEL cavity by GroES, completing compaction and allowing rapid folding. Segmental chain release and compaction may be important in avoiding misfolding by proteins that fail to fold efficiently through spontaneous hydrophobic collapse.	[Mueller, Barbara K.; Lamb, Don C.] Univ Munich, Dept Chem & Biochem, D-81377 Munich, Germany; [Mueller, Barbara K.; Lamb, Don C.] Univ Munich, Ctr Nanosci, D-81377 Munich, Germany; [Sharma, Shruti; Chakraborty, Kausik; Astola, Nagore; Tang, Yun-Chi; Hayer-Hartl, Manajit; Hartl, F. Ulrich] Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; [Lamb, Don C.] Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Munich; University of Munich; Max Planck Society; University of Illinois System; University of Illinois Urbana-Champaign	Lamb, DC (corresponding author), Univ Munich, Dept Chem & Biochem, Butenandtstr 11,Haus E, D-81377 Munich, Germany.	don.lamb@cup.uni-muenchen.de; mhartl@biochem.mpg.de; uhartl@biochem.mpg.de	Hayer-Hartl, Manajit/V-8078-2017; Lamb, Don C/G-9501-2014; Chakraborty, Kausik/AAL-5748-2021; Hartl, F. Ulrich/Y-8206-2019; Chakraborty, Kausik/B-2247-2009; Tang, Yun-Chi/GRE-8205-2022	Hayer-Hartl, Manajit/0000-0001-8213-6742; Lamb, Don C/0000-0002-0232-1903; tang, yun qi/0000-0001-9385-2787; chakraborty, kausik/0000-0001-6000-8379				ABRAHAM DJ, 1987, PROTEINS, V2, P130, DOI 10.1002/prot.340020207; Brinker A, 2001, CELL, V107, P223, DOI 10.1016/S0092-8674(01)00517-7; Chang HC, 2005, J MOL BIOL, V353, P397, DOI 10.1016/j.jmb.2005.08.052; Chen JW, 2001, NAT STRUCT BIOL, V8, P721, DOI 10.1038/90443; Coban O, 2006, BIOPHYS J, V90, P4605, DOI 10.1529/biophysj.105.078840; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Elad N, 2007, MOL CELL, V26, P415, DOI 10.1016/j.molcel.2007.04.004; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; Fenton WA, 2003, Q REV BIOPHYS, V36, P229, DOI 10.1017/S0033583503003883; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hayer-Hartl MK, 1999, BIOL CHEM, V380, P531, DOI 10.1515/BC.1999.068; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; Horst R, 2005, P NATL ACAD SCI USA, V102, P12748, DOI 10.1073/pnas.0505642102; Kapanidis AN, 2004, P NATL ACAD SCI USA, V101, P8936, DOI 10.1073/pnas.0401690101; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lin Z, 2004, MOL CELL, V16, P23, DOI 10.1016/j.molcel.2004.09.003; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Merchant KA, 2007, P NATL ACAD SCI USA, V104, P1528, DOI 10.1073/pnas.0607097104; Muller BK, 2005, BIOPHYS J, V89, P3508, DOI 10.1529/biophysj.105.064766; Radford SE, 2000, TRENDS BIOCHEM SCI, V25, P611, DOI 10.1016/S0968-0004(00)01707-2; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Saibil HR, 2002, TRENDS BIOCHEM SCI, V27, P627, DOI 10.1016/S0968-0004(02)02211-9; Schuler B, 2005, P NATL ACAD SCI USA, V102, P2754, DOI 10.1073/pnas.0408164102; Schuler B, 2002, NATURE, V419, P743, DOI 10.1038/nature01060; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; Tang YC, 2006, CELL, V125, P903, DOI 10.1016/j.cell.2006.04.027; Tezuka-Kawakami T, 2006, BIOPHYS J, V91, pL42, DOI 10.1529/biophysj.106.088344; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Zahn R, 1996, J MOL BIOL, V261, P43, DOI 10.1006/jmbi.1996.0440	38	134	136	0	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2008	133	1					142	153		10.1016/j.cell.2008.01.048	http://dx.doi.org/10.1016/j.cell.2008.01.048			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394994	Bronze			2022-12-28	WOS:000254641300015
J	Coombes, R				Coombes, Rebecca			Safety nets	BRITISH MEDICAL JOURNAL			English	Editorial Material												rcoombes@bmj.com							0	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR	2008	336	7648					803	803		10.1136/bmj.39540.565208.AD	http://dx.doi.org/10.1136/bmj.39540.565208.AD			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	292ER	18403542	Green Published			2022-12-28	WOS:000255249800039
J	Chappell, LC; Germain, SJ				Chappell, Lucy C.; Germain, Sarah J.			Commentary: Controversies in management of diabetes from preconception to the postnatal period	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Chappell, Lucy C.] Kings Coll London, Div Reprod & Endocrinol, London SE1 7EH, England; [Germain, Sarah J.] Guys & St Thomas NHS Fdn Trust, Dept Diabet & Endocrinol, London SE1 7EH, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Chappell, LC (corresponding author), Kings Coll London, Div Reprod & Endocrinol, London SE1 7EH, England.	lucy.chappell@kcl.ac.uk						[Anonymous], 2007, DIAB PREGN AR WE PRO; *CONF ENQ MAT CHIL, 2007, SAV MOTH LIV REV MAT; Crowther CA, 2005, NEW ENGL J MED, V352, P2477, DOI 10.1056/NEJMoa042973; Poyhonen-Alho MK, 2005, EUR J OBSTET GYN R B, V121, P34, DOI 10.1016/j.ejogrb.2004.10.008; 1990, DIABET MED, V7, P360	5	2	2	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 29	2008	336	7646					717	718		10.1136/bmj.39518.615058.AE	http://dx.doi.org/10.1136/bmj.39518.615058.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	283ZS	18369228	Green Published			2022-12-28	WOS:000254675600032
J	Capito, RM; Azevedo, HS; Velichko, YS; Mata, A; Stupp, SI				Capito, Ramille M.; Azevedo, Helena S.; Velichko, Yuri S.; Mata, Alvaro; Stupp, Samuel I.			Self-assembly of large and small molecules into hierarchically ordered sacs and membranes	SCIENCE			English	Article							POLYION COMPLEX FIBER; GELLAN; CHITOSAN; FILMS	We report here the self- assembly of macroscopic sacs and membranes at the interface between two aqueous solutions, one containing a megadalton polymer and the other, small self- assembling molecules bearing opposite charge. The resulting structures have a highly ordered architecture in which nanofiber bundles align and reorient by nearly 90 degrees as the membrane grows. The formation of a diffusion barrier upon contact between the two liquids prevents their chaotic mixing. We hypothesize that growth of the membrane is then driven by a dynamic synergy between osmotic pressure of ions and static self- assembly. These robust, self- sealing macroscopic structures offer opportunities in many areas, including the formation of privileged environments for cells, immune barriers, new biological assays, and self- assembly of ordered thick membranes for diverse applications.	[Capito, Ramille M.; Azevedo, Helena S.; Mata, Alvaro; Stupp, Samuel I.] Northwestern Univ, Inst Bionanotechnol Med, Chicago, IL 60611 USA; [Azevedo, Helena S.] Univ Minho, Dept Polymer Engn, 3Bs Res Grp, Braga, Portugal; [Velichko, Yuri S.; Stupp, Samuel I.] Northwestern Univ, Dept Mat Sci & Engn, Chicago, IL 60208 USA; [Stupp, Samuel I.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; [Stupp, Samuel I.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA	Northwestern University; Universidade do Minho; Northwestern University; Northwestern University; Northwestern University	Stupp, SI (corresponding author), Northwestern Univ, Inst Bionanotechnol Med, Chicago, IL 60611 USA.	s-stupp@northwestern.edu	Mata, Alvaro/D-6028-2015; Stupp, Samuel/B-6737-2009; Stupp, Samuel/AGV-1942-2022; Azevedo, Helena/A-8298-2011; Shah, Ramille/E-3737-2010; Velichko, Yuri/D-8596-2011	Mata, Alvaro/0000-0002-6739-9111; Azevedo, Helena/0000-0002-5470-1844; Velichko, Yury S/0000-0002-2287-5727	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB003806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS054287] Funding Source: NIH RePORTER; NIBIB NIH HHS [5-R01-EB003806] Funding Source: Medline; NIDCR NIH HHS [5-R01-DE015920] Funding Source: Medline; NINDS NIH HHS [5-P50-NS054287] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049; Behanna HA, 2005, J AM CHEM SOC, V127, P1193, DOI 10.1021/ja044863u; Blodgett KB, 1935, J AM CHEM SOC, V57, P1007, DOI 10.1021/ja01309a011; Bowden N, 1997, SCIENCE, V276, P233, DOI 10.1126/science.276.5310.233; Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232; Deserno M, 2001, NATO SCI SER II MATH, V46, P27; Deserno M, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.011401; Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187; Hsu L, 2008, J AM CHEM SOC, V130, P3892, DOI 10.1021/ja076553s; Ohkawa K, 2004, MACROMOL MATER ENG, V289, P33, DOI 10.1002/mame.200300188; Pirondini L, 2002, P NATL ACAD SCI USA, V99, P4911, DOI 10.1073/pnas.072612199; Rajangam K, 2006, NANO LETT, V6, P2086, DOI 10.1021/nl0613555; RINGSDORF H, 1988, ANGEW CHEM INT EDIT, V27, P113, DOI 10.1002/anie.198801131; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Storrie H, 2007, BIOMATERIALS, V28, P4608, DOI 10.1016/j.biomaterials.2007.06.026; WEN S, 1991, BIOMATERIALS, V12, P374, DOI 10.1016/0142-9612(91)90005-U; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013; Yamamoto H, 2001, J APPL POLYM SCI, V79, P437, DOI 10.1002/1097-4628(20010118)79:3<437::AID-APP60>3.0.CO;2-Q; Yamamoto H, 2000, MACROMOL CHEM PHYSIC, V201, P84, DOI 10.1002/(SICI)1521-3935(20000101)201:1<84::AID-MACP84>3.0.CO;2-Y; ZASADZINSKI JA, 1994, SCIENCE, V263, P1726, DOI 10.1126/science.8134836	20	486	493	11	501	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1812	1816		10.1126/science.1154586	http://dx.doi.org/10.1126/science.1154586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369143				2022-12-28	WOS:000254394000043
J	Core, LJ; Lis, JT				Core, Leighton J.; Lis, John T.			Transcription regulation through promoter-proximal pausing of RNA polymerase II	SCIENCE			English	Editorial Material							DROSOPHILA-MELANOGASTER; IN-VIVO; ELONGATION; ACTIVATION; RECRUITMENT; GENOME; GENE; ARCHITECTURE; INITIATION; COMPLEXES		[Core, Leighton J.; Lis, John T.] Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Lis, JT (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.	jtl10@cornell.edu			NIGMS NIH HHS [R01 GM025232-32, R01 GM025232] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; Blau J, 1996, MOL CELL BIOL, V16, P2044; Fivaz J, 2000, GENE, V255, P185, DOI 10.1016/S0378-1119(00)00340-1; GARIGLIO P, 1981, NUCLEIC ACIDS RES, V9, P2589, DOI 10.1093/nar/9.11.2589; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21; Pal M, 2001, MOL CELL BIOL, V21, P5815, DOI 10.1128/MCB.21.17.5815-5825.2001; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Roberts JW, 1998, COLD SPRING HARB SYM, V63, P319, DOI 10.1101/sqb.1998.63.319; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; SHOPLAND LS, 1995, GENE DEV, V9, P2756, DOI 10.1101/gad.9.22.2756; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Ujvari A, 2002, J BIOL CHEM, V277, P32527, DOI 10.1074/jbc.M201145200; Wang XL, 2007, GENE DEV, V21, P1031, DOI 10.1101/gad.1521207; Wang YV, 2005, MOL CELL BIOL, V25, P3543, DOI 10.1128/MCB.25.9.3543-3552.2005; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26	25	291	299	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1791	1792		10.1126/science.1150843	http://dx.doi.org/10.1126/science.1150843			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369138	Green Accepted			2022-12-28	WOS:000254394000035
J	Gilbert, MTP; Jenkins, DL; Gotherstrom, A; Naveran, N; Sanchez, JJ; Hofreiter, M; Thomsen, PF; Binladen, J; Higham, TFG; Yohe, RM; Parr, R; Cummings, LS; Willerslev, E				Gilbert, M. Thomas P.; Jenkins, Dennis L.; Gotherstrom, Anders; Naveran, Nuria; Sanchez, Juan J.; Hofreiter, Michael; Thomsen, Philip Francis; Binladen, Jonas; Higham, Thomas F. G.; Yohe, Robert M., II; Parr, Robert; Cummings, Linda Scott; Willerslev, Eske			DNA from pre-Clovis human coprolites in Oregon, North America	SCIENCE			English	Article							ANCIENT DNA; COLONIZATION; CALIBRATION; CHRONOLOGY	The timing of the first human migration into the Americas and its relation to the appearance of the Clovis technological complex in North America at about 11,000 to 10,800 radiocarbon years before the present ( C-14 years B. P.) remains contentious. We establish that humans were present at Paisley 5 Mile Point Caves, in south- central Oregon, by 12,300 C-14 years B. P., through the recovery of human mitochondrial DNA ( mtDNA) from coprolites, directly dated by accelerator mass spectrometry. The mtDNA corresponds to Native American founding haplogroups A2 and B2. The dates of the coprolites are > 1000 C-14 years earlier than currently accepted dates for the Clovis complex.	[Gilbert, M. Thomas P.; Thomsen, Philip Francis; Binladen, Jonas; Willerslev, Eske] Univ Copenhagen, Ctr Ancient Genet, DK-2100 Copenhagen, Denmark; [Jenkins, Dennis L.] Univ Oregon, Museum Nat & Cultural Hist, Eugene, OR 97403 USA; [Gotherstrom, Anders] Uppsala Univ, Dept Evolut Biol, S-74236 Uppsala, Sweden; [Naveran, Nuria] Univ Santiago de Compostela, Inst Med Legal, Fac Med, Santiago De Compostela, Spain; [Sanchez, Juan J.] Natl Inst Toxicol & Forens Sci, Tenerife 38320, Spain; [Hofreiter, Michael] Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; [Higham, Thomas F. G.] Univ Oxford, Archaeol & Hist Art Res Lab, Oxford OX1 3QY, England; [Yohe, Robert M., II; Parr, Robert] Calif State Univ, Dept Sociol Anthropol, Bakersfield, CA 93311 USA; [Cummings, Linda Scott] Palaeo Res Inst, Golden, CO 80401 USA	University of Copenhagen; University of Oregon; Uppsala University; Universidade de Santiago de Compostela; Max Planck Society; University of Oxford; California State University System; California State University Bakersfield	Willerslev, E (corresponding author), Univ Copenhagen, Ctr Ancient Genet, Universitetspk 15, DK-2100 Copenhagen, Denmark.	ewillerslev@bi.ku.dk	Willerslev, Eske/A-9619-2011; Willerslev, Eske/AAA-5686-2019; Gilbert, Marcus TP/A-8936-2013; Thomsen, Philip Francis/AAE-9354-2019; Higham, Tom/Y-2707-2019; Hofreiter, Michael/A-3996-2017	Willerslev, Eske/0000-0002-7081-6748; Gilbert, Marcus TP/0000-0002-5805-7195; Thomsen, Philip Francis/0000-0002-9867-4366; Higham, Tom/0000-0002-5949-598X; Hofreiter, Michael/0000-0003-0441-4705; Gotherstrom, Anders/0000-0001-8579-1304	NERC [NRCF010002] Funding Source: UKRI	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Adovasio J. M., 2004, ENTERING AM NE ASIA; ALLISON IS, 1982, STUDIES GEOLOGY, V11; Dillehay T. D., 1997, ARCHAEOLOGICAL CONTE, VII; Dixon EJ, 2001, QUATERNARY SCI REV, V20, P277; Eshleman JA, 2003, EVOL ANTHROPOL, V12, P7, DOI 10.1002/evan.10048; Falk T, 2004, SCIENCE, V305, P590; Gilbert MTP, 2005, TRENDS ECOL EVOL, V20, P541, DOI 10.1016/j.tree.2005.07.005; Haile J, 2007, MOL BIOL EVOL, V24, P982, DOI 10.1093/molbev/msm016; Hamilton MJ, 2007, P NATL ACAD SCI USA, V104, P15625, DOI 10.1073/pnas.0704215104; Hansen AJ, 2006, GENETICS, V173, P1175, DOI 10.1534/genetics.106.057349; Jenkins D. L., 2007, PALEOINDIAN PALEOARC; Licciardi JM, 2001, J QUATERNARY SCI, V16, P545, DOI 10.1002/jqs.619; Orr P.C., 1968, PREHISTORY SANTA ROS; Ramsey CB, 2001, RADIOCARBON, V43, P355; Reimer PJ, 2004, RADIOCARBON, V46, P1029, DOI 10.1017/S0033822200032999; ROOSEVELT AC, 2002, MEMOIRS CALIFORNIA A, V27, pCH7; Tamm E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000829; Willerslev E, 2005, P ROY SOC B-BIOL SCI, V272, P3, DOI 10.1098/rspb.2004.2813	18	214	220	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2008	320	5877					786	789		10.1126/science.1154116	http://dx.doi.org/10.1126/science.1154116			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VB	18388261				2022-12-28	WOS:000255644400038
J	Osawa, M; Anderson, DE; Erickson, HP				Osawa, Masaki; Anderson, David E.; Erickson, Harold P.			Reconstitution of contractile FtsZ rings in liposomes	SCIENCE			English	Article							CELL-DIVISION PROTEIN; ASSEMBLY DYNAMICS; TUBULIN; HOMOLOG	FtsZ is a tubulin homolog and the major cytoskeletal protein in bacterial cell division. It assembles into the Z ring, which contains FtsZ and a dozen other division proteins, and constricts to divide the cell. We have constructed a membrane- targeted FtsZ ( FtsZ- mts) by splicing an amphipathic helix to its C terminus. When mixed with lipid vesicles, FtsZ- mts was incorporated into the interior of some tubular vesicles. There it formed multiple Z rings that could move laterally in both directions along the length of the liposome and coalesce into brighter Z rings. Brighter Z rings produced visible constrictions in the liposome, suggesting that FtsZ itself can assemble the Z ring and generate a force. No other proteins were needed for assembly and force generation.	[Osawa, Masaki; Anderson, David E.; Erickson, Harold P.] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	h.erickson@cellbio.duke.edu		Anderson, David/0000-0001-9334-6438	NIGMS NIH HHS [R01 GM066014, R01 GM066014-01, GM66014] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066014] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DE, 2004, J BACTERIOL, V186, P5775, DOI 10.1128/JB.186.17.5775-5781.2004; Andrews SS, 2007, BIOPHYS J, V93, P1872, DOI 10.1529/biophysj.106.102343; Chen YD, 2005, J BIOL CHEM, V280, P22549, DOI 10.1074/jbc.M500895200; DAI K, 1991, J BACTERIOL, V173, P3500, DOI 10.1128/jb.173.11.3500-3506.1991; Erickson HP, 2007, BIOESSAYS, V29, P668, DOI 10.1002/bies.20601; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; Feucht A, 2001, MOL MICROBIOL, V40, P115, DOI 10.1046/j.1365-2958.2001.02356.x; Lara B, 2005, MOL MICROBIOL, V55, P699, DOI 10.1111/j.1365-2958.2004.04432.x; Li Z, 2007, EMBO J, V26, P4694, DOI 10.1038/sj.emboj.7601895; Peters PC, 2007, MOL MICROBIOL, V64, P487, DOI 10.1111/j.1365-2958.2007.05673.x; Pichoff S, 2002, EMBO J, V21, P685, DOI 10.1093/emboj/21.4.685; Redick SD, 2005, J BACTERIOL, V187, P2727, DOI 10.1128/JB.187.8.2727-2736.2005; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Thanedar S, 2004, CURR BIOL, V14, P1167, DOI 10.1016/j.cub.2004.06.048	15	390	399	7	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2008	320	5877					792	794		10.1126/science.1154520	http://dx.doi.org/10.1126/science.1154520			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VB	18420899	Green Accepted			2022-12-28	WOS:000255644400040
J	Lam, FH; Steger, DJ; O'Shea, EK				Lam, Felix H.; Steger, David J.; O'Shea, Erin K.			Chromatin decouples promoter threshold from dynamic range	NATURE			English	Article							TRANSCRIPTION FACTOR PHO4; CYCLIN-CDK COMPLEX; SACCHAROMYCES-CEREVISIAE; IN-VIVO; TARGET SITE; NUCLEOSOME; YEAST; BINDING; ACTIVATION; ELEMENTS	Chromatin influences gene expression by restricting access of DNA binding proteins to their cognate sites in the genome(1-3). Large- scale characterization of nucleosome positioning in Saccharomyces cerevisiae has revealed a stereotyped promoter organization in which a nucleosome- free region ( NFR) is present within several hundred base pairs upstream of the translation start site(4,5). Many transcription factors bind within NFRs and nucleate chromatin remodelling events which then expose other cis- regulatory elements(6-9). However, it is not clear how transcription- factor binding and chromatin influence quantitative attributes of gene expression. Here we show that nucleosomes function largely to decouple the threshold of induction from dynamic range. With a series of variants of one promoter, we establish that the affinity of exposed binding sites is a primary determinant of the level of physiological stimulus necessary for substantial gene activation, and sites located within nucleosomal regions serve to scale expression once chromatin is remodelled. Furthermore, we find that the S. cerevisiae phosphate response ( PHO) pathway exploits these promoter designs to tailor gene expression to different environmental phosphate levels. Our results suggest that the interplay of chromatin and binding- site affinity provides a mechanism for fine-tuning responses to the same cellular state. Moreover, these findings may be a starting point for more detailed models of eukaryotic transcriptional control.	[Lam, Felix H.; Steger, David J.; O'Shea, Erin K.] Harvard Univ, Fac Arts & Sci, Ctr Syst Biol, Dept Mol & Cellular Biol,Howard Hughes Med Inst, Cambridge, MA 02138 USA; [Lam, Felix H.; Steger, David J.; O'Shea, Erin K.] Harvard Univ, Fac Arts & Sci, Ctr Syst Biol, Dept Chem & Chem Biol,Howard Hughes Med Inst, Cambridge, MA 02138 USA; [Lam, Felix H.] Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94158 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute; University of California System; University of California San Francisco	O'Shea, EK (corresponding author), Harvard Univ, Fac Arts & Sci, Ctr Syst Biol, Dept Mol & Cellular Biol,Howard Hughes Med Inst, 7 Divin Ave,Bauer 307, Cambridge, MA 02138 USA.	erin_oshea@harvard.edu		Lam, Felix/0000-0001-6585-3360	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R01 GM051377, R01 GM051377-15] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051377] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adkins MW, 2006, MOL CELL, V21, P405, DOI 10.1016/j.molcel.2005.12.010; Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; BARBARIC S, 1992, NUCLEIC ACIDS RES, V20, P1031, DOI 10.1093/nar/20.5.1031; Barbaric S, 1998, MOL CELL BIOL, V18, P2629, DOI 10.1128/MCB.18.5.2629; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Buck MJ, 2006, NAT GENET, V38, P1446, DOI 10.1038/ng1917; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Dhasarathy A, 2005, MOL CELL BIOL, V25, P2698, DOI 10.1128/MCB.25.7.2698-2707.2005; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Korber P, 2004, MOL CELL BIOL, V24, P10965, DOI 10.1128/MCB.24.24.10965-10974.2004; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Liu X, 2006, GENOME RES, V16, P1517, DOI 10.1101/gr.5655606; Maerkl SJ, 2007, SCIENCE, V315, P233, DOI 10.1126/science.1131007; Magbanua JPV, 1997, YEAST, V13, P1299, DOI 10.1002/(SICI)1097-0061(199711)13:14<1299::AID-YEA178>3.0.CO;2-A; Miller JA, 2003, MOL CELL BIOL, V23, P1623, DOI 10.1128/MCB.23.5.1623-1632.2003; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; OGAWA N, 1994, PHOSPHATE IN MICROORGANISMS, P56; Ogawa N, 1995, MOL GEN GENET, V249, P406, DOI 10.1007/BF00287102; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Sekinger EA, 2005, MOL CELL, V18, P735, DOI 10.1016/j.molcel.2005.05.003; Shimizu T, 1997, EMBO J, V16, P4689, DOI 10.1093/emboj/16.15.4689; Springer M, 2003, PLOS BIOL, V1, P261, DOI 10.1371/journal.pbio.0000028; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Thomas MR, 2005, P NATL ACAD SCI USA, V102, P9565, DOI 10.1073/pnas.0501122102; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; Workman JL, 2006, GENE DEV, V20, P2009, DOI 10.1101/gad.1435706; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178	34	192	194	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2008	453	7192					246	U16		10.1038/nature06867	http://dx.doi.org/10.1038/nature06867			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297BP	18418379	Green Accepted, Bronze			2022-12-28	WOS:000255592400045
J	Bourke, J; Wessely, S				Bourke, Julius; Wessely, Simon			Competent novice - Confidentiality	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Bourke, Julius] Maudsley Hosp & Inst Psychiat, London SE5 8AZ, England; [Wessely, Simon] Kings Coll London, Inst Psychiat, Dept Psychol Med, London SE5 8AF, England	South London & Maudsley NHS Trust; University of London; King's College London; University of London; King's College London	Bourke, J (corresponding author), Maudsley Hosp & Inst Psychiat, London SE5 8AZ, England.	Julius.bourke@slam.nhs.uk	Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929				ABBEY SE, 1990, INT J PSYCHIAT MED, V20, P247, DOI 10.2190/2EV1-9TDQ-B61C-5QUV; Ablashi D V, 1991, Can Dis Wkly Rep, V17 Suppl 1E, P33; *BMA, 1999, CONF DISCL HLTH INF; *DEP CONST AFF, 2006, MENT CAP ACT COD PRA; *DEP HLTH, 1974, NHS VEN DIS REG; *DEP HLTH, 2003, NHS CONF COD PRACT; *DEP TRANSP, 1999, MOT VEH DRIV LIC REG; *GEN MED COUNC, CONF PROT PROV INF; *HLTH PROT AG, DIS NOT LOC AUTH PRO; *MED PROT SOC, 2000, GP REGISTRAR, V11, P1; *MIN JUST, 1967, CRIM LAW ACT; O'Brien J, 2003, J MED ETHICS, V29, P36, DOI 10.1136/jme.29.1.36; *OFF PUBL SECT INF, 2000, TERR ACT; *OFF PUBL SECT INF, 1988, ROAD TRAFF ACT; Office of Public Sector Information, 1998, DAT PROT ACT; ONEILL O, 2002, REITH LECT; SOUHAMI R, 2006, PERSONAL DATA PUBLIC; Vigod SN, 2003, BRIT MED J, V327, P1024, DOI 10.1136/bmj.327.7422.1024	18	13	13	1	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 19	2008	336	7649					888	891		10.1136/bmj.39521.357731.BE	http://dx.doi.org/10.1136/bmj.39521.357731.BE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290QH	18420695	Green Published			2022-12-28	WOS:000255136800036
J	McCallum, IJD; King, PM; Bruce, J				McCallum, Iain J. D.; King, Peter M.; Bruce, Julie			Healing by primary closure versus open heating after surgery for pilonidal sinus: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED TRIAL; LIMBERG FLAP; EXCISION	Objective To compare open heating with primary closure for pilonidal sinus and optimal closure method (midline v off-midline). Design Systematic review and meta-analyses of randomised controlled trials. Data sources Cochrane register of controlled trials, Cochrane Wounds Group specialised trials register, Medline (1950-2007), Embase, and CINAHL bibliographic databases, without language restrictions. Data extraction Primary outcomes were time to healing, surgical site infection, and recurrence rate. Secondary outcomes were time to return to work, other complications, cost, length of hospital stay, and wound heating rate. Study selection Randomised controlled trials evaluating surgical treatment of pilonidal sinus in patients aged 14 years or more. Data were extracted independently by two reviewers and assessed for quality. Meta-analyses used fixed and random effects models, dichotomous data were reported as relative risks or Peto odds ratios and continuous data are given as mean differences; all with 95% confidence intervals. Results 18 trials (n=1573) were included. 12 trials compared open heating with primary closure. Time to healing was quicker after primary closure although data were unsuitable for aggregation. Rates of surgical site infection did not differ; recurrence was less likely to occur after open heating (relative risk 0.42, 0.26 to 0.66). 14 patients would require their wound to heal by open heating to prevent one recurrence. Six trials compared surgical closure methods (midline v off-midline). Wounds took longer to heat after midline closure (mean difference 5. 4 days, 95% confidence interval 2.3 to 8.5), rate of infection was higher (relative risk 4.70, 95% confidence interval 1.93 to 11.45), and risk of recurrence was increased (Peto odds ratio 4.95, 95% confidence interval 2.18 to 11.24). Nine patients would need to be treated to prevent one surgical site infection and 11 would need to be treated to prevent one recurrence after off-midline closure. Conclusions Wounds heal more quickly after primary closure but at the expense of increased risk of recurrence. Benefits were clearly shown with off-midline closure than with midline closure. Off-midline closure should become standard management for pilonidal sinus when closure is the desired surgical option.	[Bruce, Julie] Univ Aberdeen, Sch Med, Dept Publ Hlth, Aberdeen AB25 2ZD, Scotland; [McCallum, Iain J. D.; King, Peter M.] Aberdeen Royal Infirm, Dept Gen Surg, Aberdeen, Scotland	University of Aberdeen; University of Aberdeen	Bruce, J (corresponding author), Univ Aberdeen, Sch Med, Dept Publ Hlth, Aberdeen AB25 2ZD, Scotland.	j.bruce@abdn.ac.uk	Bruce, Julie/G-7588-2014	Bruce, Julie/0000-0002-8462-7999	MRC [G106/1178] Funding Source: UKRI; Medical Research Council [G106/1178] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abu Galala KH, 1999, EUR J SURG, V165, P468; Akca T, 2005, BRIT J SURG, V92, P1081, DOI 10.1002/bjs.5074; ALHASSAN HK, 1990, ACTA CHIR SCAND, V156, P695; Berkem H, 2005, INT J COLORECTAL DIS, V20, P343, DOI 10.1007/s00384-004-0699-9; Cihan A, 2006, DIS COLON RECTUM, V49, P244, DOI 10.1007/s10350-005-0253-z; Ertan T, 2005, AM J SURG, V190, P388, DOI 10.1016/j.amjsurg.2004.08.068; Fazeli MS, 2006, DIS COLON RECTUM, V49, P1831, DOI 10.1007/s10350-006-0726-8; FUZUN M, 1994, DIS COLON RECTUM, V37, P1148, DOI 10.1007/BF02049819; Gencosmanoglu R, 2005, INT J COLORECTAL DIS, V20, P415, DOI 10.1007/s00384-004-0710-5; Hameed KK., 2001, MED FORUM MON, V12, P20; KHAWAJA HT, 1992, BRIT MED J, V304, P1282, DOI 10.1136/bmj.304.6837.1282; KRONBORG O, 1985, BRIT J SURG, V72, P303, DOI 10.1002/bjs.1800720418; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; McCallum I, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006213.pub2; Miocinovic Milan, 2000, Acta Medica Croatica, V54, P27; Mohamed HA, 2005, SURG-J R COLL SURG E, V3, P73, DOI 10.1016/S1479-666X(05)80065-4; Petersen S, 2002, DIS COLON RECTUM, V45, P1458, DOI 10.1007/s10350-004-6451-2; RAO M, 2001, INT J COLORECTAL S1, V3; SONDENAA K, 1995, INT J COLORECTAL DIS, V10, P39, DOI 10.1007/BF00337585; SONDENAA K, 1992, EUR J SURG, V158, P351; Sondenaa K, 1996, EUR J SURG, V162, P237; Testini M, 2001, Colorectal Dis, V3, P427; WRIGHT DM, 2001, COLORECTAL DIS S1, V3	23	215	228	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2008	336	7649					868	871		10.1136/bmj.39517.808160.BE	http://dx.doi.org/10.1136/bmj.39517.808160.BE			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290QH	18390914	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000255136800032
J	James, MT; Conley, J; Tonelli, M; Manns, BJ; MacRae, J; Hemmelgarn, BR				James, Matthew T.; Conley, Joslyn; Tonelli, Marcello; Manns, Braden J.; MacRae, Jennifer; Hemmelgarn, Brenda R.		Alberta Kidney Disease Network	Meta-analysis: Antibiotics for prophylaxis against hemodialysis catheter-related infections	ANNALS OF INTERNAL MEDICINE			English	Review							VASCULAR ACCESS; STAPHYLOCOCCUS-AUREUS; DIALYSIS PATIENTS; CONTROLLED-TRIAL; PREVENTION; LOCK; MUPIROCIN; GENTAMICIN; BACTEREMIA; RESISTANCE	Background: Catheter-related infections cause morbidity and mortality in patients undergoing hemodialysis. Purpose: To examine whether topical or intraluminal antibiotics reduce catheter-related bloodstream infection compared with no antibiotic therapy in adults undergoing hemodialysis. Data Sources: Electronic databases, trial registries, bibliographies, and conference proceedings up to October 2007, with no language restrictions. Study Selection: Two reviewers independently selected randomized, controlled trials using topical or intraluminal antibiotics for prophylaxis of infection in adults with catheters who are undergoing hemodialysis. Data Extraction: Two independent reviewers assessed studies for inclusion, quality, and extracted data. Data Synthesis: Fixed-effects models were used to estimate pooled rate ratios for outcomes. Topical antibiotics reduced the rate of bacteremia (rate ratio, 0.22 [95% CI, 0.12 to 0.40]; 0.10 vs. 0.45 case of bacteremia per 100 catheter-days), exit-site infection (rate ratio, 0.17 [CI, 0.08 to 0.381; 0.06 vs. 0.41 case of infection per 100 catheter-days), need for catheter removal, and hospitalization for infection. Intraluminal antibiotics reduced the rate of bacteremia (rate ratio, 0.32 [CI, 0.22 to 0.471; 0.12 vs. 0.32 case of bacteremia per 100 catheter-days) and need for catheter removal. Intraluminal antibiotics did not significantly reduce the rate of exit-site infection, and no hospitalization data were available for these agents. Limitations: The evidence base included only 16 trials, and most had less than 6 months of follow-up. Only one third of studies were blinded. Publication bias was evident. Conclusion: Both topical and intraluminal antibiotics reduced the rate of bacteremia as well as the need for catheter removal secondary to complications. Whether these strategies will lead to antimicrobial resistance and loss of efficacy over longer periods remains unclear.	[Hemmelgarn, Brenda R.] Foothills Med Ctr, Div Nephrol, Calgary, AB T2N 2T9, Canada; Univ Alberta, Edmonton, AB, Canada; Inst Hlth Econ, Edmonton, AB, Canada; Univ Calgary, Calgary, AB, Canada	University of Calgary; University of Alberta; University of Calgary	Hemmelgarn, BR (corresponding author), Foothills Med Ctr, Div Nephrol, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.	Brenda.Hemmelgarn@CalgaryHealthRegion.ca	Manns, Braden J/I-8942-2012; Tonelli, Marcello/B-3028-2009; Hemmelgarn, Brenda R./I-6894-2012; MacRae, Jennifer/AAV-9827-2020	Tonelli, Marcello/0000-0002-0846-3187; MacRae, Jennifer/0000-0002-4711-1440				Al-Hwiesh AK, 2007, SAUDI J KIDNEY DIS T, V18, P239; Allon M, 2004, AM J KIDNEY DIS, V44, P779, DOI [10.1053/j.ajkd.2004.07.005, 10.1016/S0272-6386(04)01078-9]; Annigeri R, 2001, PERITON DIALYSIS INT, V21, P554; Berns JS, 2002, AM J KIDNEY DIS, V40, P886, DOI 10.1053/ajkd.2002.36332; Betjes MGH, 2004, NEPHROL DIAL TRANSPL, V19, P1546, DOI 10.1093/ndt/gfh014; Bleyer AJ, 2005, INFECT CONT HOSP EP, V26, P520, DOI 10.1086/502578; Cavdar Caner, 2004, Adv Perit Dial, V20, P67; Cooper Randy I., 1999, Journal of the American Society of Nephrology, V10, p203A; Dogra GK, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022890.29656.22; Egger M, 2001, SYSTEMATIC REV HLTH; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Ishani A, 2005, KIDNEY INT, V68, P311, DOI 10.1111/j.1523-1755.2005.00414.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jindal Kailash, 2006, J Am Soc Nephrol, V17, pS1; Johnson DW, 2005, J AM SOC NEPHROL, V16, P1456, DOI 10.1681/ASN.2004110997; Johnson DW, 2002, NEPHROL DIAL TRANSPL, V17, P1802, DOI 10.1093/ndt/17.10.1802; Kim SH, 2006, KIDNEY INT, V69, P161, DOI 10.1038/sj.ki.5000012; Krishna M. V. S., 2001, Journal of the American Society of Nephrology, V12, p293A; LEVIN A, 1991, KIDNEY INT, V40, P934, DOI 10.1038/ki.1991.297; Lobbedez T, 2004, NEPHROL DIAL TRANSPL, V19, P3140, DOI 10.1093/ndt/gfh494; Lok CE, 2003, J AM SOC NEPHROL, V14, P169, DOI 10.1097/01.ASN.0000038688.76195.A4; Manns B, 2005, J AM SOC NEPHROL, V16, P201, DOI 10.1681/ASN.2004050355; McIntyre CW, 2004, KIDNEY INT, V66, P801, DOI 10.1111/j.1523-1755.2004.00806.x; Mendelssohn DC, 2006, NEPHROL DIAL TRANSPL, V21, P721, DOI 10.1093/ndt/gfi281; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Nori US, 2006, AM J KIDNEY DIS, V48, P596, DOI 10.1053/j.ajkd.2006.06.012; Pastan S, 2002, KIDNEY INT, V62, P620, DOI 10.1046/j.1523-1755.2002.00460.x; Pervez A, 2002, J Vasc Access, V3, P108; Polkinghorne KR, 2004, J AM SOC NEPHROL, V15, P477, DOI 10.1097/01.ASN.0000109668.05157.05; Ramanathan V, 2007, INFECT CONT HOSP EP, V28, P606, DOI 10.1086/513617; Rayner HC, 2004, AM J KIDNEY DIS, V44, pS22, DOI 10.1053/j.ajkd.2004.08.007; Saxena AK, 2006, KIDNEY INT, V70, P1629, DOI 10.1038/sj.ki.5001776; Saxena AK, 2006, NEPHROLOGY, V11, P299, DOI 10.1111/j.1440-1797.2006.00563.x; Sesso R, 1998, J AM SOC NEPHROL, V9, P1085; *VASC ACC WORK GRO, 2006, AM J KIDNEY DIS S, V48, pS248, DOI DOI 10.1053/J.AJKD.2006.04.040.MEDLINE; von Elm E, 2004, JAMA-J AM MED ASSOC, V291, P974, DOI 10.1001/jama.291.8.974; Zhang P, 2006, J AM SOC NEPHROL, V17, p592A	37	110	115	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2008	148	8					596	605		10.7326/0003-4819-148-8-200804150-00004	http://dx.doi.org/10.7326/0003-4819-148-8-200804150-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290LF	18413621				2022-12-28	WOS:000255123600004
J	Horton, R; Murray, C; Frenk, J				Horton, Richard; Murray, Chris; Frenk, Julio			A new initiative and invitation for health monitoring, tracking, and evaluation	LANCET			English	Editorial Material							CALL		[Horton, Richard] Lancet, London NW1 7BY, England; [Murray, Chris; Frenk, Julio] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; [Frenk, Julio] Bill & Melinda Gates Fdn, Seattle, WA USA; [Frenk, Julio] Carso Hlth Inst, Mexico City, DF, Mexico	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; Bill & Melinda Gates Foundation	Horton, R (corresponding author), Lancet, London NW1 7BY, England.							Beaglehole R, 2007, LANCET, V370, P2152, DOI 10.1016/S0140-6736(07)61700-0; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Boerma JT, 2007, LANCET, V369, P779, DOI 10.1016/S0140-6736(07)60364-X; Filippi V, 2006, LANCET, V368, P1535, DOI 10.1016/S0140-6736(06)69384-7; Glasier A, 2006, LANCET, V368, P1595, DOI 10.1016/S0140-6736(06)69478-6; Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0; Wilkinson P, 2007, LANCET, V370, P965, DOI 10.1016/S0140-6736(07)61252-5	7	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2008	371	9619					1139	1140		10.1016/S0140-6736(08)60498-5	http://dx.doi.org/10.1016/S0140-6736(08)60498-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395559				2022-12-28	WOS:000254956000004
J	Richey, R; Wray, D; Stokes, T				Richey, Roberta; Wray, David; Stokes, Tim		Guideline Dev Grp	Guidelines - Prophylaxis against infective endocarditis: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Wray, David] Glasgow Dent Sch, Glasgow G2 3JZ, Lanark, Scotland; [Richey, Roberta; Stokes, Tim] Natl Inst Hlth & Clin Excellence, Manchester M1 4BD, Lancs, England	University of Glasgow; National Institute for Health & Care Excellence	Wray, D (corresponding author), Glasgow Dent Sch, Glasgow G2 3JZ, Lanark, Scotland.	d.wray@dental.gla.ac.uk	Stokes, Tim/M-9420-2018	Stokes, Tim/0000-0002-1127-1952				*N I HLTH CLIN EXC, 2008, 64 NICE; Prendergast BD, 2006, HEART, V92, P879, DOI 10.1136/hrt.2005.067256	2	109	111	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2008	336	7647					770	771		10.1136/bmj.39510.423148.AD	http://dx.doi.org/10.1136/bmj.39510.423148.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284JW	18390528	Green Published			2022-12-28	WOS:000254703700035
J	Coelho, D; Suormala, T; Stucki, M; Lerner-Ellis, JP; Rosenblatt, DS; Newbold, RF; Baumgartner, MR; Fowler, B				Coelho, David; Suormala, Terttu; Stucki, Martin; Lerner-Ellis, Jordan P.; Rosenblatt, David S.; Newbold, Robert F.; Baumgartner, Matthias R.; Fowler, Brian			Gene identification for the cblD defect of vitamin B-12 metabolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METHYLMALONIC ACIDURIA; COBALAMIN METABOLISM; MEGALOBLASTIC-ANEMIA; ABC TRANSPORTER; ADENOSYLCOBALAMIN; COMPLEMENTATION; DEFICIENCY; GENOME; CELLS; DNA	Background: Vitamin B-12 (cobalamin) is an essential cofactor in several metabolic pathways. Intracellular conversion of cobalamin to its two coenzymes, adenosylcobalamin in mitochondria and methylcobalamin in the cytoplasm, is necessary for the homeostasis of methylmalonic acid and homocysteine. Nine defects of intracellular cobalamin metabolism have been defined by means of somatic complementation analysis. One of these defects, the cblD defect, can cause isolated methylmalonic aciduria, isolated homocystinuria, or both. Affected persons present with multisystem clinical abnormalities, including developmental, hematologic, neurologic, and metabolic findings. The gene responsible for the cblD defect has not been identified. Methods: We studied seven patients with the cblD defect, and skin fibroblasts from each were investigated in cell culture. Microcell-mediated chromosome transfer and refined genetic mapping were used to localize the responsible gene. This gene was transfected into cblD fibroblasts to test for the rescue of adenosylcobalamin and methylcobalamin synthesis. Results: The cblD gene was localized to human chromosome 2q23.2, and a candidate gene, designated MMADHC (methylmalonic aciduria, cblD type, and homocystinuria), was identified in this region. Transfection of wild-type MMADHC rescued the cellular phenotype, and the functional importance of mutant alleles was shown by means of transfection with mutant constructs. The predicted MMADHC protein has sequence homology with a bacterial ATP-binding cassette transporter and contains a putative cobalamin binding motif and a putative mitochondrial targeting sequence. Conclusions: Mutations in a gene we designated MMADHC are responsible for the cblD defect in vitamin B-12 metabolism. Various mutations are associated with each of the three biochemical phenotypes of the disorder.	[Coelho, David; Suormala, Terttu; Lerner-Ellis, Jordan P.; Fowler, Brian] Univ Childrens Hosp Basel, Metab Unit, CH-4005 Basel, Switzerland; [Stucki, Martin; Baumgartner, Matthias R.] Univ Zurich, Childrens Hosp, Div Metab & Mol Pediat, Zurich, Switzerland; [Stucki, Martin] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland; [Lerner-Ellis, Jordan P.; Rosenblatt, David S.] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Lerner-Ellis, Jordan P.; Rosenblatt, David S.] McGill Univ, Ctr Hlth, Div Med Genet, Montreal, PQ, Canada; [Newbold, Robert F.] Brunel Univ, Brunel Inst Canc Genet & Pharmacogenom, Uxbridge UB8 3PH, Middx, England	University of Basel; University Children's Hospital Zurich; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); McGill University; McGill University; Brunel University	Fowler, B (corresponding author), Univ Childrens Hosp Basel, Metab Unit, Roemergasse 8, CH-4005 Basel, Switzerland.	brian.fowler@ukbb.ch	Baumgartner, Matthias/Q-2855-2017; Coelho, David/AAE-9547-2020; Lerner-Ellis, Jordan/J-5559-2016; Coelho, David/F-6680-2011	Baumgartner, Matthias/0000-0002-9270-0826; Coelho, David/0000-0001-7010-5789				Baumgartner MR, 2001, J CLIN INVEST, V107, P495, DOI 10.1172/JCI11948; CARMEL R, 1982, BLOOD, V59, P306; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; COOPER BA, 1990, AM J HEMATOL, V34, P115, DOI 10.1002/ajh.2830340207; Cosma MP, 2004, HUM MUTAT, V23, P576, DOI 10.1002/humu.20040; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Davidson AL, 2002, SCIENCE, V296, P1038, DOI 10.1126/science.1072484; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; FENTON WA, 1978, ARCH BIOCHEM BIOPHYS, V189, P441, DOI 10.1016/0003-9861(78)90232-1; GEBHARD W, 1983, J MOL BIOL, V170, P255, DOI 10.1016/S0022-2836(83)80147-8; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GOODMAN SI, 1970, BIOCHEM MED METAB B, V4, P500, DOI 10.1016/0006-2944(70)90080-3; Hunt JD, 1996, ANAL BIOCHEM, V238, P107, DOI 10.1006/abio.1996.0263; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lerner-Ellis JP, 2006, NAT GENET, V38, P957, DOI 10.1038/ng0806-957a; LITZKAS P, 1984, MOL CELL BIOL, V4, P2549, DOI 10.1128/MCB.4.11.2549; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; MAHONEY MJ, 1975, P NATL ACAD SCI USA, V72, P2799, DOI 10.1073/pnas.72.7.2799; Rosenblatt D. S., 2001, METABOLIC MOL BASES, V8th, P3897; Shultis DD, 2006, SCIENCE, V312, P1396, DOI 10.1126/science.1127694; Suormala T, 2004, J BIOL CHEM, V279, P42742, DOI 10.1074/jbc.M407733200; Tanner SM, 2003, NAT GENET, V33, P426, DOI 10.1038/ng1098; Walker JA, 2004, GENOMICS, V83, P518, DOI 10.1016/j.ygeno.2003.09.003; Watkins D, 2000, J MED GENET, V37, P510, DOI 10.1136/jmg.37.7.510; WILLARD HF, 1978, AM J HUM GENET, V30, P1; Zhang J, 1997, EMBO J, V16, P826, DOI 10.1093/emboj/16.4.826	26	113	119	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1454	1464		10.1056/NEJMoa072200	http://dx.doi.org/10.1056/NEJMoa072200			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282CY	18385497	Green Accepted, Green Published			2022-12-28	WOS:000254546400006
J	Malanchi, I; Peinado, H; Kassen, D; Hussenet, T; Metzger, D; Chambon, P; Huber, M; Hohl, D; Cano, A; Birchmeier, W; Huelsken, J				Malanchi, Ilaria; Peinado, Hector; Kassen, Deepika; Hussenet, Thomas; Metzger, Daniel; Chambon, Pierre; Huber, Marcel; Hohl, Daniel; Cano, Amparo; Birchmeier, Walter; Huelsken, Joerg			Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling	NATURE			English	Article							HAIR FOLLICLE BULGE; SKIN TUMORS; EXPRESSION; GENE; DIFFERENTIATION; EPIDERMIS; MUTATION; RAS; TUMORIGENESIS; POPULATIONS	Continuous turnover of epithelia is ensured by the extensive self-renewal capacity of tissue- specific stem cells(1). Similarly, epithelial tumour maintenance relies on cancer stem cells ( CSCs), which co-opt stem cell properties(2). For most tumours, the cellular origin of these CSCs and regulatory pathways essential for sustaining stemness have not been identified. In murine skin, follicular morphogenesis is driven by bulge stem cells that specifically express CD34. Here we identify a population of cells in early epidermal tumours characterized by phenotypic and functional similarities to normal bulge skin stem cells. This population contains CSCs, which are the only cells with tumour initiation properties. Transplants derived from these CSCs preserve the hierarchical organization of the primary tumour. We describe beta-catenin signalling(3) as being essential in sustaining the CSC phenotype. Ablation of the beta-catenin gene results in the loss of CSCs and complete tumour regression. In addition, we provide evidence for the involvement of increased beta-catenin signalling in malignant human squamous cell carcinomas. Because Wnt/beta-catenin signalling is not essential for normal epidermal homeostasis, such a mechanistic difference may thus be targeted to eliminate CSCs(4) and consequently eradicate squamous cell carcinomas.	[Malanchi, Ilaria; Kassen, Deepika; Hussenet, Thomas; Huelsken, Joerg] EPFL, ISREC Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; [Malanchi, Ilaria; Kassen, Deepika; Hussenet, Thomas; Huelsken, Joerg] NCCR Mol Oncol, CH-1066 Epalinges, Switzerland; [Peinado, Hector; Cano, Amparo] UAM, CSIC, Dept Bioquim, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; [Metzger, Daniel; Chambon, Pierre] CU Strasbourg, IGBMC, F-67404 Illkirch Graffenstaden, France; [Huber, Marcel; Hohl, Daniel] CHU Vaudois, Lab Cutaneous Biol Dermatol, CH-1011 Lausanne, Switzerland; [Huber, Marcel; Hohl, Daniel] FBM UNIL, CH-1011 Lausanne, Switzerland; [Birchmeier, Walter] Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Huelsken, J (corresponding author), EPFL, ISREC Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	joerg.huelsken@epfl.ch	Huber, Marcel/M-8822-2016; Hohl, Daniel M/N-7554-2016; Peinado, Hector/A-6417-2013; Huelsken, Joerg/AAC-9581-2021	Huber, Marcel/0000-0003-3821-2378; Peinado, Hector/0000-0002-4256-3413; Huelsken, Joerg/0000-0003-3105-9606; Metzger, Daniel/0000-0002-5555-046X				Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Brasanac D, 2005, BRIT J DERMATOL, V153, P1166, DOI 10.1111/j.1365-2133.2005.06898.x; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Doglioni C, 2003, AM J PATHOL, V163, P2277, DOI 10.1016/S0002-9440(10)63585-7; GASPAR C, UNPUB NATURE; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Lichti U, 1993, J INVEST DERMATOL, V101, P124; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mackenzie IC, 1997, J INVEST DERMATOL, V109, P377, DOI 10.1111/1523-1747.ep12336255; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Niemann C, 2002, DEVELOPMENT, V129, P95; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Papadavid E, 2002, J PATHOL, V196, P154, DOI 10.1002/path.1019; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Oskarsson T, 2006, GENE DEV, V20, P2024, DOI 10.1101/gad.381206; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Trempus CS, 2007, CANCER RES, V67, P4173, DOI 10.1158/0008-5472.CAN-06-3128; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865	32	467	504	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2008	452	7187					650	U12		10.1038/nature06835	http://dx.doi.org/10.1038/nature06835			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385740				2022-12-28	WOS:000254567200050
J	Richards, T				Richards, Tessa			Purely medicinal?	BRITISH MEDICAL JOURNAL			English	Editorial Material												trichards@bmj.com						Brown H, 2007, BRIT MED J, V334, P664, DOI 10.1136/bmj.39153.511701.BE; 2008, BMJ, V336, P694	2	9	9	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 29	2008	336	7646					693	693		10.1136/bmj.39527.454560.59	http://dx.doi.org/10.1136/bmj.39527.454560.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	283ZS	18369224	Green Published			2022-12-28	WOS:000254675600021
J	Wilson, P; Petticrew, M				Wilson, Paul; Petticrew, Mark			Why promote the findings of single research studies?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Wilson, Paul] Univ York, Ctr Rev & Disseminat, York YO10 5DD, N Yorkshire, England; [Petticrew, Mark] Univ London London Sch Hyg & Trop Med, Publ & Environm Hlth Res Unit, London WC1E 7HT, England	University of York - UK; University of London; London School of Hygiene & Tropical Medicine	Wilson, P (corresponding author), Univ York, Ctr Rev & Disseminat, York YO10 5DD, N Yorkshire, England.	pmw7@york.ac.uk	Petticrew, Mark/AAY-6274-2021	Nazareth, Irwin/0000-0003-2146-9628	Medical Research Council [MC_U130085862, MC_U122797165, MC_U130059812] Funding Source: Medline; Chief Scientist Office [SPHSU1] Funding Source: Medline; MRC [MC_U130085862, MC_U130059812] Funding Source: UKRI; Medical Research Council [UD99999925] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Chief Scientist Office; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)			0	9	11	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	2008	336	7646					722	722		10.1136/bmj.39525.447361.94	http://dx.doi.org/10.1136/bmj.39525.447361.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	283ZS	18369230	Green Submitted, Green Published			2022-12-28	WOS:000254675600034
J	Weinstein, JN				Weinstein, John N.			Biochemistry - A postgenomic visual icon	SCIENCE			English	Editorial Material							CANCER-CELL LINES; MOLECULAR PHARMACOLOGY; EXPRESSION PATTERNS; MICROARRAYS; GENES		Univ Texas Houston, MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Weinstein, JN (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jweinste@mdanderson.org		Weinstein, John/0000-0001-9401-6908				Biron DG, 2006, INSECT MOL BIOL, V15, P731, DOI 10.1111/j.1365-2583.2006.00671.x; Bobe J, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-39; Brauer MJ, 2006, P NATL ACAD SCI USA, V103, P19302, DOI 10.1073/pnas.0609508103; Doxey AC, 2007, MOL BIOL EVOL, V24, P1045, DOI 10.1093/molbev/msm024; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Kluger Y, 2003, GENOME RES, V13, P703, DOI 10.1101/gr.648603; Le Priol Y, 2006, J IMMUNOL, V177, P5145, DOI 10.4049/jimmunol.177.8.5145; Myers TG, 1997, ELECTROPHORESIS, V18, P467; Nesbit J, 2007, SCIENCE, V317, P1857, DOI 10.1126/science.317.5846.1857; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Szakacs G, 2004, CANCER CELL, V6, P129, DOI 10.1016/j.ccr.2004.06.026; Wang XY, 2006, ARCH MICROBIOL, V186, P151, DOI 10.1007/s00203-006-0129-1; Weinstein JN, 2003, CR BIOL, V326, P909, DOI 10.1016/j.crvi.2003.08.005; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343	17	48	50	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1772	1773		10.1126/science.1151888	http://dx.doi.org/10.1126/science.1151888			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369130				2022-12-28	WOS:000254394000028
J	Detrano, R; Guerci, AD; Carr, JJ; Bild, DE; Burke, G; Folsom, AR; Liu, K; Shea, S; Szklo, M; Bluemke, DA; O'Leary, DH; Tracy, R; Watson, K; Wong, ND; Kronmal, RA				Detrano, Robert; Guerci, Alan D.; Carr, J. Jeffrey; Bild, Diane E.; Burke, Gregory; Folsom, Aaron R.; Liu, Kiang; Shea, Steven; Szklo, Moyses; Bluemke, David A.; O'Leary, Daniel H.; Tracy, Russell; Watson, Karol; Wong, Nathan D.; Kronmal, Richard A.			Coronary calcium as a predictor of coronary events in four racial or ethnic groups	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BEAM COMPUTED-TOMOGRAPHY; HEART-DISEASE EVENTS; ARTERY CALCIUM; RISK-FACTORS; CALCIFICATION; ATHEROSCLEROSIS; PREVALENCE; SCORE; CT	Background: In white populations, computed tomographic measurements of coronary-artery calcium predict coronary heart disease independently of traditional coronary risk factors. However, it is not known whether coronary-artery calcium predicts coronary heart disease in other racial or ethnic groups. Methods: We collected data on risk factors and performed scanning for coronary calcium in a population-based sample of 6722 men and women, of whom 38.6% were white, 27.6% were black, 21.9% were Hispanic, and 11.9% were Chinese. The study subjects had no clinical cardiovascular disease at entry and were followed for a median of 3.8 years. Results: There were 162 coronary events, of which 89 were major events (myocardial infarction or death from coronary heart disease). In comparison with participants with no coronary calcium, the adjusted risk of a coronary event was increased by a factor of 7.73 among participants with coronary calcium scores between 101 and 300 and by a factor of 9.67 among participants with scores above 300 (P<0.001 for both comparisons). Among the four racial and ethnic groups, a doubling of the calcium score increased the risk of a major coronary event by 15 to 35% and the risk of any coronary event by 18 to 39%. The areas under the receiver-operating-characteristic curves for the prediction of both major coronary events and any coronary event were higher when the calcium score was added to the standard risk factors. Conclusions: The coronary calcium score is a strong predictor of incident coronary heart disease and provides predictive information beyond that provided by standard risk factors in four major racial and ethnic groups in the United States. No major differences among racial and ethnic groups in the predictive value of calcium scores were detected.	[Detrano, Robert; Wong, Nathan D.] Univ Calif Irvine, Dept Radiol Sci, Irvine, CA 92697 USA; [Guerci, Alan D.] St Francis Hosp, Roslyn, NY USA; [Carr, J. Jeffrey; Burke, Gregory] Wake Forest Baptist Med Ctr, Winston Salem, NC USA; [Bild, Diane E.] NHLBI, Div Prevent & Populat Sci, Bethesda, MD 20892 USA; [Folsom, Aaron R.] Univ Minnesota, Minneapolis, MN USA; [Liu, Kiang] Northwestern Univ, Chicago, IL 60611 USA; [Shea, Steven] Columbia Univ, New York, NY USA; [Szklo, Moyses; Bluemke, David A.] Johns Hopkins Univ, Baltimore, MD USA; [O'Leary, Daniel H.] Caritas Carney Hosp, Dorchester, MA USA; [Tracy, Russell] Univ Vermont, Burlington, VT USA; [Watson, Karol] Univ Calif Los Angeles, Los Angeles, CA USA; [Kronmal, Richard A.] Univ Washington, Seattle, WA 98195 USA	University of California System; University of California Irvine; Wake Forest University; Wake Forest Baptist Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Minnesota System; University of Minnesota Twin Cities; Northwestern University; Columbia University; Johns Hopkins University; University of Vermont; University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle	Detrano, R (corresponding author), Univ Calif Irvine, Dept Radiol Sci, Med Sci Bldg, Irvine, CA 92697 USA.	robert@chinacal.org	Carr, John Jeffrey/A-1938-2012; Carr, John/AAN-7531-2021; Watson, Karol/ABD-7425-2021; Bluemke, David/GYU-8169-2022	Carr, John Jeffrey/0000-0002-4398-8237; Carr, John/0000-0002-4398-8237; Bluemke, David/0000-0002-8323-8086; Szklo, Moyses/0000-0001-9433-6266	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095160, N01HC095162, N01HC095169, N01HC095164, N01HC095159, N01HC095161, N01HC095166, N01HC095163, N01HC095165] Funding Source: NIH RePORTER	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; Arad Y, 2005, J AM COLL CARDIOL, V46, P158, DOI 10.1016/j.jacc.2005.02.088; Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113; Bild DE, 2005, CIRCULATION, V111, P1313, DOI 10.1161/01.CIR.0000157730.94423.4B; Carr JJ, 2005, RADIOLOGY, V234, P35, DOI 10.1148/radiol.2341040439; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; Greenland P, 2004, JAMA-J AM MED ASSOC, V291, P210, DOI 10.1001/jama.291.2.210; Greenland P, 2001, CIRCULATION, V104, P1863, DOI 10.1161/hc4201.097189; Hawthorne V, 2002, HEART, V88, P222; Jain T, 2004, J AM COLL CARDIOL, V44, P1011, DOI 10.1016/j.jacc.2004.05.069; Kondos GT, 2003, CIRCULATION, V107, P2571, DOI 10.1161/01.CIR.0000068341.61180.55; LaMonte MJ, 2005, AM J EPIDEMIOL, V162, P421, DOI 10.1093/aje/kwi228; Lee TC, 2003, J AM COLL CARDIOL, V41, P39, DOI 10.1016/S0735-1097(02)02618-9; Nelson JC, 2005, RADIOLOGY, V235, P403, DOI 10.1148/radiol.2352040515; Newman AB, 2002, ARTERIOSCL THROM VAS, V22, P424, DOI 10.1161/hq0302.105357; O'Malley PG, 2000, AM J CARDIOL, V85, P945, DOI 10.1016/S0002-9149(99)00906-6; Raggi P, 2004, ARTERIOSCL THROM VAS, V24, P1272, DOI 10.1161/01.ATV.0000127024.40516.ef; Raggi P, 2001, AM HEART J, V141, P375, DOI 10.1067/mhj.2001.113220; Shaw LJ, 2003, RADIOLOGY, V228, P826, DOI 10.1148/radiol.2283021006; Smith S C Jr, 2000, Circulation, V101, P111; TANG WY, 1995, AM J CARDIOL, V75, P1088, DOI 10.1016/S0002-9149(99)80735-8; Taylor AJ, 2005, J AM COLL CARDIOL, V46, P807, DOI 10.1016/j.jacc.2005.05.049; Vliegenthart R, 2005, CIRCULATION, V112, P572, DOI 10.1161/CIRCULATIONAHA.104.488916; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wong ND, 2000, AM J CARDIOL, V86, P495, DOI 10.1016/S0002-9149(00)01000-6; Yaghoubi S, 1995, Am J Card Imaging, V9, P231	28	1995	2051	1	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1336	1345		10.1056/NEJMoa072100	http://dx.doi.org/10.1056/NEJMoa072100			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367736				2022-12-28	WOS:000254308400004
J	White, RS; Smith, LK; Roberts, AW; Christie, PAF; Kusznir, NJ				White, R. S.; Smith, L. K.; Roberts, A. W.; Christie, P. A. F.; Kusznir, N. J.		iSIMM Team	Lower-crustal intrusion on the North Atlantic continental margin	NATURE			English	Article							ICELAND MANTLE PLUME; GREENLAND MARGIN; REFRACTION; THICKNESS; REFLECTORS; DIMENSIONS; MAGMATISM; ACCRETION; RIFT	When continents break apart, the rifting is sometimes accompanied by the production of large volumes of molten rock(1-3). The total melt volume, however, is uncertain, because only part of it has erupted at the surface. Furthermore, the cause of the magmatism is still disputed - specifically, whether or not it is due to increased mantle temperatures. We recorded deep- penetration normal-incidence and wide- angle seismic profiles across the Faroe and Hatton Bank volcanic margins in the northeast Atlantic. Here we show that near the Faroe Islands, for every 1 km along strike, 360 - 400 km(3) of basalt is extruded, while 540 - 600 km(3) is intruded into the continent - ocean transition. We find that lower- crustal intrusions are focused mainly into a narrow zone similar to 50 km wide on the transition, although extruded basalts flow more than 100 km from the rift. Seismic profiles show that the melt is intruded into the lower crust as sills, which cross- cut the continental fabric, rather than as an 'underplate' of 100 per cent melt, as has often been assumed. Evidence from the measured seismic velocities and from igneous thicknesses are consistent with the dominant control on melt production being increased mantle temperatures, with no requirement for either significant active small- scale mantle convection under the rift or the presence of fertile mantle at the time of continental break- up, as has previously been suggested for the North Atlantic Ocean(4-6).	[White, R. S.; Smith, L. K.; Roberts, A. W.] Univ Cambridge, Bullard Labs, Cambridge CB3 0EZ, England; [Christie, P. A. F.] Schlumberger Cambridge Res Ltd, Cambridge CB3 0EL, England; [Kusznir, N. J.] Univ Liverpool, Dept Earth Sci, Liverpool L69 3BX, Merseyside, England	University of Cambridge; Schlumberger; University of Liverpool	White, RS (corresponding author), Univ Cambridge, Bullard Labs, Madingley Rd, Cambridge CB3 0EZ, England.	rwhite@esc.cam.ac.uk	Healy, David/G-2005-2010; White, Robert/B-8453-2015	Roberts, Alan/0000-0003-4839-0741	Natural Environment Research Council [NER/T/S/2000/01021] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Barton AJ, 1997, J GEOPHYS RES-SOL EA, V102, P3109, DOI 10.1029/96JB03387; BOWN JW, 1994, EARTH PLANET SC LETT, V121, P435, DOI 10.1016/0012-821X(94)90082-5; Christeson GL, 2007, NATURE, V445, P418, DOI 10.1038/nature05517; COFFIN MF, 1994, REV GEOPHYS, V32, P1, DOI 10.1029/93RG02508; COX KG, 1980, J PETROL, V21, P629, DOI 10.1093/petrology/21.4.629; DORE A. G., 2005, PETROLEUM GEOLOGY N, P947; ELDHOLM O, 1994, J GEOPHYS RES-SOL EA, V99, P2955, DOI 10.1029/93JB02879; Hopper JR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001996; Klingelhofer F, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2005JB003763; Korenaga J, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB001030; Korenaga J, 2000, J GEOPHYS RES-SOL EA, V105, P21591, DOI 10.1029/2000JB900188; Larsen H.C., 1998, PROC OCEAN DRILL SCI, V152, P503, DOI DOI 10.2973/ODP.PROC.SR.152.240.1998; Lunnon Z.C., 2003, 1 BREAK, V21, P51; MARESH J, 2005, 1 BREAK, V23, P27; McBride JH, 2004, TECTONOPHYSICS, V388, P271, DOI 10.1016/j.tecto.2004.07.055; MUTTER JC, 1982, GEOLOGY, V10, P353, DOI 10.1130/0091-7613(1982)10<353:OOSRIO>2.0.CO;2; Nielsen TK, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015681; Park C.-S., 2006, AS PAC C COMM AUG, P1; Parkin CJ, 2007, GEOLOGY, V35, P93, DOI 10.1130/G23273A.1; Roberts A. W., 2005, PETROLEUM GEOLOGY NW, P755; ROBERTS AW, 2007, THESIS U CAMBRIDGE, P1; Sallares V, 2005, GEOPHYS J INT, V161, P763, DOI 10.1111/j.1365-246X.2005.02592.x; Smallwood JR, 1999, J GEOPHYS RES-SOL EA, V104, P22885, DOI 10.1029/1999JB900176; Smallwood JR, 1998, GEOPHYS J INT, V134, P277, DOI 10.1046/j.1365-246x.1998.00593.x; SMITH LK, 2006, THESIS U CAMBRIDGE, P1; WEIGEL W, 1995, MAR GEOPHYS RES, V17, P167, DOI 10.1007/BF01203425; WHITE R, 1989, J GEOPHYS RES-SOLID, V94, P7685, DOI 10.1029/JB094iB06p07685; WHITE RS, 1987, NATURE, V330, P439, DOI 10.1038/330439a0; White RS, 2003, GEOPHYS PROSPECT, V51, P215, DOI 10.1046/j.1365-2478.2003.00364.x; WHITE RS, 1992, J GEOPHYS RES-SOL EA, V97, P19683, DOI 10.1029/92JB01749; Zelt CA, 1998, J GEOPHYS RES-SOL EA, V103, P7187, DOI 10.1029/97JB03536; ZELT CA, 1992, GEOPHYS J INT, V108, P16, DOI 10.1111/j.1365-246X.1992.tb00836.x; [No title captured]	33	234	240	1	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 27	2008	452	7186					460	U6		10.1038/nature06687	http://dx.doi.org/10.1038/nature06687			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279FU	18368115				2022-12-28	WOS:000254341300029
J	Horton, R				Horton, Richard			Danger: people at work	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Horton, R (corresponding author), Lancet, London NW1 7BY, England.							Black C., 2008, WORKING HLTH TOMORRO; Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0	2	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 22	2008	371	9617					971	972		10.1016/S0140-6736(08)60434-1	http://dx.doi.org/10.1016/S0140-6736(08)60434-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358915				2022-12-28	WOS:000254206000010
J	Yokota, S; Imagawa, T; Mori, M; Miyamae, T; Aihara, Y; Takei, S; Iwata, N; Umebayashi, H; Murata, T; Miyoshi, M; Tomiita, M; Nishimoto, N; Kishimoto, T				Yokota, Shumpei; Imagawa, Tomoyuki; Mori, Masaaki; Miyamae, Takoko; Aihara, Yukoh; Takei, Shuji; Iwata, Naomi; Umebayashi, Hiroaki; Murata, Takuji; Miyoshi, Mari; Tomiita, Minako; Nishimoto, Norihiro; Kishimoto, Tadamitsu			Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial	LANCET			English	Article							MACROPHAGE ACTIVATION SYNDROME; RHEUMATOID-ARTHRITIS; RECEPTOR; ETANERCEPT; CHILDREN; METHOTREXATE; ANAKINRA; ANTIBODY; ALPHA	Background Systemic-onset juvenile idiopathic arthritis does not always respond to available treatments, including antitumour necrosis factor agents. We investigated the efficacy and safety of tocilizumab, an anti-interleukin-6-receptor monoclonal antibody, in children with this disorder. Methods 56 children (aged 2-19 years) with disease refractory to conventional treatment were given three doses of tocilizumab 8 mg/kg every 2 weeks during a 6-week open-label lead-in phase. Patients achieving an American College of Rheumatology Pediatric (ACR Pedi) 30 response and a C-reactive protein concentration (CRP) of less than 5 mg/L were randomly assigned to receive placebo or to continue tocilizumab treatment for 12 weeks or until withdrawal for rescue medication in a double-blind phase. The primary endpoint of the double-blind phase was an ACR Pedi 30 response and CRP concentration of less than 15 mg/L. Patients responding to tocilizumab and needing further treatment were enrolled in an open-label extension phase for at least 48 weeks. The analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, numbers NCT00144599 (for the open-label lead-in and double-blind phases) and NCT00144612 (for the open-label extension phase). Findings At the end of the open-label lead-in phase, ACR Pedi 30, 50, and 70 responses were achieved by 51 (91%), 48 (86%), and 38 (68%) patients, respectively. 43 patients continued to the double-blind phase and were included in the efficacy analysis. Four (17%) of 23 patients in the placebo group maintained an ACR Pedi 30 response and a CRP concentration of less than 15 mg/L compared with 16 (80%) of 20 in the tocilizumab group (p<0 . 0001). By week 48 of the open-label extension phase, ACR Pedi 30, 50, and 70 responses were achieved by 47 (98%), 45 (94%), and 43 (90%) of 48 patients, respectively. Serious adverse events wore anaphylactoid reaction, gastrointestinal haemorrhage, bronchitis, and gastroenteritis. Interpretation Tocilizumab is effective in children with systemic-onset juvenile idiopathic arthritis. It might therefore be a suitable treatment in the control of this disorder, which has so far been difficult to manage.	[Yokota, Shumpei; Imagawa, Tomoyuki; Mori, Masaaki; Miyamae, Takoko; Aihara, Yukoh] Yokohama City Univ, Sch Med, Dept Paediat, Kanazawa Ku, Kanagawa 2360004, Japan; [Takei, Shuji] Kagoshima Univ, Dept Paediat, Kagoshima 890, Japan; [Iwata, Naomi] Aichi Childrens Hlth & Med Ctr, Aichi, Japan; [Umebayashi, Hiroaki] Miyagi Childrens Hosp, Miyagi, Japan; [Murata, Takuji] Osaka Med Univ, Dept Paediat, Osaka, Japan; [Miyoshi, Mari] Kobe Childrens Hosp, Kobe, Hyogo, Japan; [Tomiita, Minako] Chiba Univ, Dept Paediat, Chiba, Japan; [Nishimoto, Norihiro; Kishimoto, Tadamitsu] Osaka Univ, Grad Sch Frontier Biosci, Osaka, Japan	Yokohama City University; Kagoshima University; Osaka Medical College; Chiba University; Osaka University	Yokota, S (corresponding author), Yokohama City Univ, Sch Med, Dept Paediat, Kanazawa Ku, 3-9 Fukuura, Kanagawa 2360004, Japan.	syokota@med.yokohama-cu.ac.jp	Kishimoto, Tadamitsu/C-8470-2009					Billiau AD, 2005, BLOOD, V105, P1648, DOI 10.1182/blood-2004-08-2997; Buoncompagni A., 2005, PEDIAT RHEMATOL ONLI, V3, P70; Cortis E, 2006, ACTA PAEDIATR, V95, P38, DOI 10.1080/08035320600649713; de Benedetti F, 2005, ARTHRITIS RHEUM-US, V52, P687, DOI 10.1002/art.20946; DEBENEDETTI F, 1991, ARTHRITIS RHEUM, V34, P1158, DOI 10.1002/art.1780340912; Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308; Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202; Grom AA, 1996, ARTHRITIS RHEUM, V39, P1703, DOI 10.1002/art.1780391013; Henrickson M, 2004, ARTHRITIS RHEUM, V50, pS438; Irigoyen PI, 2004, ARTHRITIS RHEUM, V50, pS437; Kelly A, 2007, CURR OPIN RHEUMATOL, V19, P477, DOI 10.1097/BOR.0b013e32825a6a79; Lieskovska J, 2003, GROWTH HORM IGF RES, V13, P26, DOI 10.1016/S1096-6374(02)00135-1; Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103; Lurati A., 2005, PEDIAT RHEUMATOL ONL, V3, P79; NCI, 2006, CANC THER EV PROGR C; Pascual V, 2005, J EXP MED, V201, P1479, DOI 10.1084/jem.20050473; Petty RE, 2004, J RHEUMATOL, V31, P390; PETTY RE, 2005, TXB PEDIAT RHEUMATOL, P291; Quartier P, 2003, ARTHRITIS RHEUM, V48, P1093, DOI 10.1002/art.10885; Ramanan AV, 2003, J RHEUMATOL, V30, P401; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; STEPHAN JL, 1993, CLIN EXP RHEUMATOL, V11, P451; Verbsky JW, 2004, J RHEUMATOL, V31, P2071; Woo P, 2005, ARTHRITIS RES THER, V7, pR1281, DOI 10.1186/ar1826; Woo P, 2000, ARTHRITIS RHEUM-US, V43, P1849, DOI 10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F; Yokota S, 2004, ARTHRITIS RHEUM, V50, pS438; Yokota S, 2005, ARTHRITIS RHEUM, V52, P818, DOI 10.1002/art.20944	27	549	615	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2008	371	9617					998	1006		10.1016/S0140-6736(08)60454-7	http://dx.doi.org/10.1016/S0140-6736(08)60454-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358927				2022-12-28	WOS:000254206000028
J	Zhang, WW; Luck, SJ				Zhang, Weiwei; Luck, Steven J.			Discrete fixed-resolution representations in visual working memory	NATURE			English	Article							SHORT-TERM-MEMORY; FOURIER DESCRIPTORS; CAPACITY; INFORMATION; NUMBER; ATTENTION; LIMITS; MODEL; SHAPE	Limits on the storage capacity of working memory significantly affect cognitive abilities in a wide range of domains(1), but the nature of these capacity limits has been elusive(2). Some researchers have proposed that working memory stores a limited set of discrete, fixed- resolution representations(3), whereas others have proposed that working memory consists of a pool of resources that can be allocated flexibly to provide either a small number of high-resolution representations or a large number of low- resolution representations(4). Here we resolve this controversy by providing independent measures of capacity and resolution. We show that, when presented with more than a few simple objects, human observers store a high- resolution representation of a subset of the objects and retain no information about the others. Memory resolution varied over a narrow range that cannot be explained in terms of a general resource pool but can be well explained by a small set of discrete, fixed- resolution representations.	[Zhang, Weiwei] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA; [Zhang, Weiwei; Luck, Steven J.] Univ Calif Davis, Ctr Mind & Brain, Davis, CA 95618 USA	University of Iowa; University of California System; University of California Davis	Zhang, WW (corresponding author), Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA.	wwzhang@ucdavis.edu	zhang, weiwei/B-9657-2008; zhang, weiwei/Q-5199-2019	zhang, weiwei/0000-0002-0431-5355	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH076226] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH076226-04, R01 MH076226] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTER I, 1988, PERCEPTION, V17, P191, DOI 10.1068/p170191; Alvarez GA, 2004, PSYCHOL SCI, V15, P106, DOI 10.1111/j.0963-7214.2004.01502006.x; Awh E, 2007, PSYCHOL SCI, V18, P622, DOI 10.1111/j.1467-9280.2007.01949.x; Baddeley A.D., 1986, WORKING MEMORY THOUG; BONNEL AM, 1994, PERCEPT PSYCHOPHYS, V55, P162, DOI 10.3758/BF03211664; Cortese JM, 1996, J EXP PSYCHOL HUMAN, V22, P133, DOI 10.1037/0096-1523.22.1.133; Cousineau D, 2007, TUTORIALS QUANTITATI, V1, P42, DOI DOI 10.20982/TQMP.01.1.P042; Cowan N, 1999, MODELS WORKING MEMOR, P62, DOI [10.1017/CBO9781139174909.006, DOI 10.1017/CBO9781139174909.006]; Fisher NI, 1995, STAT ANAL CIRCULAR D; FRICK RW, 1988, BRIT J PSYCHOL, V79, P289, DOI 10.1111/j.2044-8295.1988.tb02289.x; Luck SJ, 1996, J EXP PSYCHOL HUMAN, V22, P725, DOI 10.1037/0096-1523.22.3.725; Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Myung IJ, 2003, J MATH PSYCHOL, V47, P90, DOI 10.1016/S0022-2496(02)00028-7; Newsome William T., 1995, P401; PALMER J, 1990, J EXP PSYCHOL HUMAN, V16, P332, DOI 10.1037/0096-1523.16.2.332; Prinzmetal W, 1998, J EXP PSYCHOL HUMAN, V24, P261, DOI 10.1037/0096-1523.24.1.261; Raffone A, 2001, J COGNITIVE NEUROSCI, V13, P766, DOI 10.1162/08989290152541430; Sakai K, 2002, PERCEPTION, V31, P579, DOI 10.1068/p3320; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; Sergent C, 2004, PSYCHOL SCI, V15, P720, DOI 10.1111/j.0956-7976.2004.00748.x; SIMON HA, 1974, SCIENCE, V183, P482, DOI 10.1126/science.183.4124.482; Vogel EK, 2006, J EXP PSYCHOL HUMAN, V32, P1436, DOI 10.1037/0096-1523.32.6.1436; Vogel EK, 2005, J COGNITIVE NEUROSCI, V17, P1907, DOI 10.1162/089892905775008599; Wang XJ, 2001, TRENDS NEUROSCI, V24, P455, DOI 10.1016/S0166-2236(00)01868-3; Wilken P, 2004, J VISION, V4, P1120, DOI 10.1167/4.12.11; Xu YD, 2002, J EXP PSYCHOL HUMAN, V28, P458, DOI 10.1037//0096-1523.28.2.458; ZAHN CT, 1972, IEEE T COMPUT, VC 21, P269, DOI 10.1109/TC.1972.5008949	28	1015	1038	15	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2008	453	7192					233	U13		10.1038/nature06860	http://dx.doi.org/10.1038/nature06860			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297BP	18385672	Bronze, Green Accepted			2022-12-28	WOS:000255592400042
J	Bhutta, ZA				Bhutta, Zulfiqar A.			Making a difference - Drug resistant infections in poor countries - A major burden on children	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan	Aga Khan University	Bhutta, ZA (corresponding author), Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan.	zulfiqar.bhutta@aku.edu						BHUTTA ZA, REDUCING ANTIBIOTICS; Bhutta ZA, 2007, ARCH DIS CHILD, V92, P286, DOI 10.1136/adc.2006.111849; Blomberg B, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-43; Brooks WA, 2007, AM J TROP MED HYG, V77, P795, DOI 10.4269/ajtmh.2007.77.795; Capoor MR, 2007, J MED MICROBIOL, V56, P1490, DOI 10.1099/jmm.0.47353-0; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Molstad S, 2008, LANCET INFECT DIS, V8, P125, DOI 10.1016/S1473-3099(08)70017-3; Sneag DB, 2007, PEDIATR INFECT DIS J, V26, P1142, DOI 10.1097/INF.0b013e31814523e4; Zaidi AKM, 2005, LANCET, V365, P1175, DOI 10.1016/S0140-6736(05)71881-X; Zucker JR, 2003, AM J TROP MED HYG, V68, P386, DOI 10.4269/ajtmh.2003.68.386	10	8	8	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	2008	336	7650					948	+		10.1136/bmj.39520.680718.94	http://dx.doi.org/10.1136/bmj.39520.680718.94			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397947	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000255540900035
J	Sato, K; Pellegrino, M; Nakagawa, T; Nakagawa, T; Vosshall, LB; Touhara, K				Sato, Koji; Pellegrino, Maurizio; Nakagawa, Takao; Nakagawa, Tatsuro; Vosshall, Leslie B.; Touhara, Kazushige			Insect olfactory receptors are heteromeric ligand-gated ion channels	NATURE			English	Article							DROSOPHILA-ANTENNA; ODORANT RECEPTOR; MEMBRANE TOPOLOGY; TRANSDUCTION; NEURONS; SYSTEM; MODEL	In insects, each olfactory sensory neuron expresses between one and three ligand- binding members of the olfactory receptor ( OR) gene family, along with the highly conserved and broadly expressed Or83b co-receptor(1-9). The functional insect OR consists of a heteromeric complex of unknown stoichiometry but comprising at least one variable odorant- binding subunit and one constant Or83b family subunit(10-16). Insect ORs lack homology to G- protein-coupled chemosensory receptors in vertebrates(17) and possess a distinct seven- transmembrane topology with the amino terminus located intracellularly(10,18). Here we provide evidence that heteromeric insect ORs comprise a new class of ligand- activated nonselective cation channels. Heterologous cells expressing silkmoth, fruitfly or mosquito heteromeric OR complexes showed extracellular Ca2+ influx and cation- non- selective ion conductance on stimulation with odorant. Odour- evoked OR currents are independent of known G- protein- coupled second messenger pathways. The fast response kinetics and OR- subunit- dependent K+ ion selectivity of the insect OR complex support the hypothesis that the complex between OR and Or83b itself confers channel activity. Direct evidence for odorant- gated channels was obtained by outside- out patch- clamp recording of Xenopus oocyte and HEK293T cell membranes expressing insect OR complexes. The ligand- gated ion channel formed by an insect OR complex seems to be the basis for a unique strategy that insects have acquired to respond to the olfactory environment.	[Sato, Koji; Nakagawa, Takao; Nakagawa, Tatsuro; Touhara, Kazushige] Univ Tokyo, Dept Integrated Biosci, Chiba 2778562, Japan; [Pellegrino, Maurizio; Vosshall, Leslie B.] Rockefeller Univ, Lab Neurogenet & Behav, New York, NY 10065 USA	University of Tokyo; Rockefeller University	Touhara, K (corresponding author), Univ Tokyo, Dept Integrated Biosci, Chiba 2778562, Japan.	touhara@k.u-tokyo.ac.jp		xing zhi, zuo teng/0000-0001-6198-6406; Vosshall, Leslie/0000-0002-6060-8099				Benton R, 2006, PLOS BIOL, V4, P240, DOI 10.1371/journal.pbio.0040020; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Couto A, 2005, CURR BIOL, V15, P1535, DOI 10.1016/j.cub.2005.07.034; de Bruyne M, 1999, J NEUROSCI, V19, P4520; de Bruyne M, 2001, NEURON, V30, P537, DOI 10.1016/S0896-6273(01)00289-6; Dobritsa AA, 2003, NEURON, V37, P827, DOI 10.1016/S0896-6273(03)00094-1; Elmore T, 2003, J NEUROSCI, V23, P9906; FIRESTEIN S, 1990, J PHYSIOL-LONDON, V430, P135, DOI 10.1113/jphysiol.1990.sp018286; Fishilevich E, 2005, CURR BIOL, V15, P1548, DOI 10.1016/j.cub.2005.07.066; Goldman AL, 2005, NEURON, V45, P661, DOI 10.1016/j.neuron.2005.01.025; Halaszovich CR, 2000, J BIOL CHEM, V275, P37423, DOI 10.1074/jbc.M007010200; Hallem EA, 2006, CELL, V125, P143, DOI 10.1016/j.cell.2006.01.050; Hallem EA, 2004, CELL, V117, P965, DOI 10.1016/j.cell.2004.05.012; Hallem EA, 2004, NATURE, V427, P212, DOI 10.1038/427212a; Jones WD, 2005, CURR BIOL, V15, pR119, DOI 10.1016/j.cub.2005.02.007; Kaissling KE, 1996, CHEM SENSES, V21, P257, DOI 10.1093/chemse/21.2.257; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Katada S, 2003, BIOCHEM BIOPH RES CO, V305, P964, DOI 10.1016/S0006-291X(03)00863-5; Krieger J, 2003, J COMP PHYSIOL A, V189, P519, DOI 10.1007/s00359-003-0427-x; LACAMPAGNE A, 1994, BBA-BIOMEMBRANES, V1191, P205, DOI 10.1016/0005-2736(94)90250-X; Larsson MC, 2004, NEURON, V43, P703, DOI 10.1016/j.neuron.2004.08.019; Lundin C, 2007, FEBS LETT, V581, P5601, DOI 10.1016/j.febslet.2007.11.007; Murakami M, 2000, J GEN PHYSIOL, V115, P455, DOI 10.1085/jgp.115.4.455; Nagel G, 2002, SCIENCE, V296, P2395, DOI 10.1126/science.1072068; Nakagawa T, 2005, SCIENCE, V307, P1638, DOI 10.1126/science.1106267; Neuhaus EM, 2005, NAT NEUROSCI, V8, P15, DOI 10.1038/nn1371; Pitts RJ, 2004, P NATL ACAD SCI USA, V101, P5058, DOI 10.1073/pnas.0308146101; Sato K, 2000, J EXP BIOL, V203, P253; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wistrand M, 2006, PROTEIN SCI, V15, P509, DOI 10.1110/ps.051745906; Zagotta WN, 2006, NATURE, V440, P427, DOI 10.1038/440427a	31	722	782	6	225	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2008	452	7190					1002	U9		10.1038/nature06850	http://dx.doi.org/10.1038/nature06850			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291PF	18408712				2022-12-28	WOS:000255208600041
J	Bryce, J; Daelmans, B; Dwivedi, A; Fauveau, V; Lawn, JE; Mason, E; Newby, H; Requejo, J; Salama, P; Shankar, A; Starrs, A; Wardlaw, T				Bryce, Jennifer; Daelmans, Bernadette; Dwivedi, Archana; Fauveau, Vincent; Lawn, Joy E.; Mason, Elizabeth; Newby, Holly; Requejo, Jennifer; Salama, Peter; Shankar, Anuraj; Starrs, Ann; Wardlaw, Tessa		Countdown 2015 Core Grp	Countdown to 2015 for maternal, newborn, and child survival: the 2008 report on tracking coverage of interventions	LANCET			English	Article							HEALTH; DEATH	Background The Countdown to 2015 for Maternal, Newborn, and Child Survival initiative monitors coverage of priority interventions to achieve the Millennium Development Goals (MDG) for reduction of maternal and child mortality. We aimed to report on 68 countries which have 97% of maternal and child deaths worldwide, and on 22 interventions that have been proven to improve maternal, newborn, and child survival. Methods We selected countries with high rates of maternal and child deaths, and interventions with the most potential to avert such deaths. We analysed country-specific data for maternal and child mortality and coverage of selected interventions. We also tracked cause-of-death profiles; indicators of nutritional status; the presence of supportive policies; financial flows to maternal, newborn, and child health; and equity in coverage of interventions. Findings Of the 68 priority countries, 16 were on track to meet MDG 4. Of these, seven had been on track in 2005 when the Countdown initiative was launched, three (including China) moved into the on-track category in 2008, and six were included in the Countdown process for the first time in 2008. Trends in maternal mortality that would indicate progress towards MDG 5 were not available, but in most (56 of 68) countries, maternal mortality was high or very high. Coverage of different interventions varied widely both between and within countries. Interventions that can be routinely scheduled, such as immunisation and antenatal care, had much higher coverage than those that rely on functional health systems and 24-hour availability of clinical services, such as skilled or emergency care at birth and care of ill newborn babies and children. Data for postnatal care were either unavailable or showed poor coverage in almost all 68 countries. The most rapid increases in coverage were seen for immunisation, which also received significant investment during this period. Interpretation Rapid progress is possible, but much more can and must be done. Focused efforts will be needed to improve coverage, especially for priorities such as contraceptive services, care in childbirth, postnatal care, and clinical case management of illnesses in newborn babies and children.	[Bryce, Jennifer] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD 21218 USA; [Daelmans, Bernadette; Mason, Elizabeth; Shankar, Anuraj] WHO, CH-1211 Geneva, Switzerland; [Dwivedi, Archana; Newby, Holly; Salama, Peter; Wardlaw, Tessa] UNICEF, New York, NY USA; [Fauveau, Vincent] UNFPA, Geneva, Switzerland; [Lawn, Joy E.] Save Children US, Cape Town, South Africa; [Starrs, Ann] Family Care Int, New York, NY USA	Johns Hopkins University; World Health Organization; UNICEF; United Nations Population Fund; Save the Children	Bryce, J (corresponding author), 2081 Danby Rd, Ithaca, NY 14850 USA.	jbrycedanby@aol.com	Lawn, Joy/ABE-6382-2020	Lawn, Joy/0000-0002-4573-1443				AbouZahr C, 2005, B WORLD HEALTH ORGAN, V83, P578; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Blanc AK, 2005, B WORLD HEALTH ORGAN, V83, P178; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; BRYCE J, TRACKING PROGR MATER; Bryce J, 2006, LANCET, V368, P1067, DOI 10.1016/S0140-6736(06)69339-2; Bustreo F, 2008, LANCET, V371, P1221, DOI 10.1016/S0140-6736(08)60535-8; Cavagnero E, 2008, LANCET, V371, P1284, DOI 10.1016/S0140-6736(08)60563-2; *COUNTD 2008 EQ AN, 2008, LANCET, P1259; *COUNTD COR GROUP, 2006, TRACK PROGR CHILD SU; Eyakuze C, 2008, DEV WORLD BIOETH, V8, P33, DOI 10.1111/j.1471-8847.2008.00230.x; Graft-Johnson J, 2006, CONTINUUM CARE MATER; Greco G, 2008, LANCET, V371, P1268, DOI 10.1016/S0140-6736(08)60561-9; Hill K, 2007, LANCET, V370, P1311, DOI 10.1016/S0140-6736(07)61572-4; *J HOPK IND I HLTH, AFGH HLTH SURV 2006; KERBER K, LANCET, V370, P1358; Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lawn JE, 2006, INT J EPIDEMIOL, V35, P706, DOI 10.1093/ije/dyl043; McIntyre J, 2005, REPROD HEALTH MATTER, V13, P129, DOI 10.1016/S0968-8080(05)25184-4; *MEAS DHS MACRO IN, DEM HLTH SURV; Setel PW, 2007, LANCET, V370, P1569, DOI 10.1016/S0140-6736(07)61307-5; Stanton C, 2006, LANCET, V367, P1487, DOI 10.1016/S0140-6736(06)68586-3; UNAIDS, 2006, REP GLOB AIDS EP; UNICEF, 2007, PROTECTING THE WORLD'S CHILDREN: IMPACT OF THE CONVENTION ON THE RIGHTS OF THE CHILD IN DIVERSE LEGAL SYSTEMS, P1; *UNICEF, CHILD; *UNICEF WHO, 2006, LEV TRENDS CHILD MOR; United Nations Children's Fund (UNICEF), 2014, STATE WORLDS CHILDRE; United Nations Children's Fund (UNICEF), MULT IND CLUST SURV; Victora CG, 2007, LANCET, V370, P1113, DOI 10.1016/S0140-6736(07)61492-5; *WHO, 2007, INT TRAV HLTH 2007; WHO UNICEF UNFPA and World Bank, 2007, MAT MORT 2005 EST DE; World Health Organization, 2007, WORLD HLTH STAT 2007; World Health Organization, 2006, WHO CHILD GROWTH STA	34	230	239	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1247	1258						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286XH	18406859				2022-12-28	WOS:000254878900026
J	Salama, P; Lawn, J; Bryce, J; Bustreo, F; Fauveau, V; Starrs, A; Mason, E				Salama, Peter; Lawn, Joy; Bryce, Jennifer; Bustreo, Flavia; Fauveau, Vincent; Starrs, Ann; Mason, Elizabeth			Making the Countdown count	LANCET			English	Editorial Material							CHILD SURVIVAL; HEALTH; NEWBORN; COVERAGE		[Salama, Peter] UNICEF, New York, NY 10017 USA; [Bustreo, Flavia; Mason, Elizabeth] WHO, CH-1211 Geneva, Switzerland; [Starrs, Ann] Family Care Int, New York, NY USA; [Lawn, Joy] Saving Newborn Lives Save Children USA, Cape Town, South Africa; [Bryce, Jennifer] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Fauveau, Vincent] UN Populat Fund, New York, NY USA	UNICEF; World Health Organization; Save the Children; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; United Nations Population Fund	Salama, P (corresponding author), UNICEF, New York, NY 10017 USA.	psalama@unicef.org	Lawn, Joy/ABE-6382-2020	Lawn, Joy/0000-0002-4573-1443				*2008 COUNTD 2015, 2008, COUNTD 2015 MAT NEWB; Boerma JT, 2008, LANCET, V371, P1259, DOI 10.1016/S0140-6736(08)60560-7; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Bryce J, 2006, LANCET, V368, P1067, DOI 10.1016/S0140-6736(06)69339-2; Bustreo F, 2008, LANCET, V371, P1221, DOI 10.1016/S0140-6736(08)60535-8; Cavagnero E, 2008, LANCET, V371, P1284, DOI 10.1016/S0140-6736(08)60563-2; Greco G, 2008, LANCET, V371, P1268, DOI 10.1016/S0140-6736(08)60561-9; Madon T, 2007, SCIENCE, V318, P1728, DOI 10.1126/science.1150009; Masanja H, 2008, LANCET, V371, P1276, DOI 10.1016/S0140-6736(08)60562-0; MCNEIL DG, 2007, NY TIMES        0913; Reich MR, 2008, LANCET, V371, P865, DOI 10.1016/S0140-6736(08)60384-0; Stoltenberg J, 2008, LANCET, V371, P1230, DOI 10.1016/S0140-6736(08)60540-1; *WHO, INF M GLOB HLTH LEAD	13	18	18	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 12	2008	371	9620					1219	1221		10.1016/S0140-6736(08)60534-6	http://dx.doi.org/10.1016/S0140-6736(08)60534-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	286XH	18406842				2022-12-28	WOS:000254878900005
J	Crawford, JM; Thomas, PM; Scheerer, JR; Vagstad, AL; Kelleher, NL; Townsend, CA				Crawford, Jason M.; Thomas, Paul M.; Scheerer, Jonathan R.; Vagstad, Anna L.; Kelleher, Neil L.; Townsend, Craig A.			Deconstruction of iterative multidomain polyketide synthase function	SCIENCE			English	Article							IDENTIFICATION; BIOSYNTHESIS; DOMAIN; ACYL	PksA, which initiates biosynthesis of the environmental carcinogen aflatoxin B1, is one of the multidomain iterative polyketide synthases (IPKSs), a large, poorly understood family of biosynthetic enzymes. We found that dissection of PksA and its reconstitution from selected sets of domains allows the accumulation and characterization of advanced octaketide intermediates bound to the enzyme, permitting the reactions controlled by individual catalytic domains to be identified. A product template (PT) domain unites with the ketosynthase and thioesterase in this IPKS system to assemble precisely seven malonyl-derived building blocks to a hexanoyl starter unit and mediate a specific cyclization cascade. Because the PT domain is common among nonreducing IPKSs, these mechanistic features should prove to be general for IPKS-catalyzed production of aromatic polyketides.	[Thomas, Paul M.; Kelleher, Neil L.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA; [Crawford, Jason M.; Scheerer, Jonathan R.; Vagstad, Anna L.; Townsend, Craig A.] Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA	University of Illinois System; University of Illinois Urbana-Champaign; Johns Hopkins University	Kelleher, NL (corresponding author), Univ Illinois, Dept Chem, 1209 W Calif St, Urbana, IL 61801 USA.	kelleher@scs.uiuc.edu; ctownsend@jhu.edu	Thomas, Paul/C-2777-2008; Thomas, Paul M/A-6233-2011	Thomas, Paul M/0000-0003-2887-4765; Vagstad, Anna Lisa/0000-0001-8074-0137	NIAID NIH HHS [R37 AI014937, R37 AI014937-30] Funding Source: Medline; NIEHS NIH HHS [R01 ES001670, ES001670] Funding Source: Medline; NIGMS NIH HHS [F32 GM079408-02, GM070421, T32 GM080189, R01 GM067725, GM067725, F32 GM079408-01, GM079408, R01 GM067725-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES001670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM080189, F32GM079408, T32GM070421, R01GM067725] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN ZG, 1995, PHYTOCHEMISTRY, V38, P299, DOI 10.1016/0031-9422(94)00543-3; Crawford JM, 2008, BIOORG CHEM, V36, P16, DOI 10.1016/j.bioorg.2007.11.002; Crawford JM, 2006, P NATL ACAD SCI USA, V103, P16728, DOI 10.1073/pnas.0604112103; Dorrestein PC, 2006, BIOCHEMISTRY-US, V45, P12756, DOI 10.1021/bi061169d; Fischbach MA, 2006, CHEM REV, V106, P3468, DOI 10.1021/cr0503097; Fujii I, 2001, CHEM BIOL, V8, P189, DOI 10.1016/S1074-5521(00)90068-1; Keatinge-Clay A, 2004, NAT STRUCT MOL BIOL, V11, P888, DOI 10.1038/nsmb808; Ma SM, 2008, J AM CHEM SOC, V130, P38, DOI 10.1021/ja078091o; Ma Y, 2006, CHEMBIOCHEM, V7, P1951, DOI 10.1002/cbic.200600341; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; Sanchez C, 2001, CHEM BIOL, V8, P725, DOI 10.1016/S1074-5521(01)00047-3; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Tang Y, 2003, J AM CHEM SOC, V125, P12708, DOI 10.1021/ja0378759; Udwary DW, 2002, J MOL BIOL, V323, P585, DOI 10.1016/S0022-2836(02)00972-5	14	162	183	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					243	246		10.1126/science.1154711	http://dx.doi.org/10.1126/science.1154711			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403714	Green Accepted			2022-12-28	WOS:000254836700047
J	Kremen, C; Cameron, A; Moilanen, A; Phillips, SJ; Thomas, CD; Beentje, H; Dransfield, J; Fisher, BL; Glaw, F; Good, TC; Harper, GJ; Hijmans, RJ; Lees, DC; Louis, E; Nussbaum, RA; Raxworthy, CJ; Razafimpahanana, A; Schatz, GE; Vences, M; Vieites, DR; Wright, PC; Zjhra, ML				Kremen, C.; Cameron, A.; Moilanen, A.; Phillips, S. J.; Thomas, C. D.; Beentje, H.; Dransfield, J.; Fisher, B. L.; Glaw, F.; Good, T. C.; Harper, G. J.; Hijmans, R. J.; Lees, D. C.; Louis, E., Jr.; Nussbaum, R. A.; Raxworthy, C. J.; Razafimpahanana, A.; Schatz, G. E.; Vences, M.; Vieites, D. R.; Wright, P. C.; Zjhra, M. L.			Aligning conservation priorities across taxa in Madagascar with high-resolution planning tools	SCIENCE			English	Article							SOUTH-AFRICA; STRATEGIES; DISTRIBUTIONS; DIVERSITY; ENDEMISM; RARE	Globally, priority areas for biodiversity are relatively well known, yet few detailed plans exist to direct conservation action within them, despite urgent need. Madagascar, like other globally recognized biodiversity hot spots, has complex spatial patterns of endemism that differ among taxonomic groups, creating challenges for the selection of within-country priorities. We show, in an analysis of wide taxonomic and geographic breadth and high spatial resolution, that multitaxonomic rather than single-taxon approaches are critical for identifying areas likely to promote the persistence of most species. Our conservation prioritization, facilitated by newly available techniques, identifies optimal expansion sites for the Madagascar government's current goal of tripling the land area under protection. Our findings further suggest that high-resolution multitaxonomic approaches to prioritization may be necessary to ensure protection for biodiversity in other global hot spots.	[Kremen, C.; Cameron, A.] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA; [Kremen, C.; Cameron, A.; Razafimpahanana, A.] Wildlife Conservat Soc, Reseau Biodivers Madagascar, Antananarivo, Madagascar; [Moilanen, A.] Univ Helsinki, Metapopulat Res Grp, Dept Biol & Environm Sci, FI-00014 Helsinki, Finland; [Phillips, S. J.] AT&T Labs Res, Florham Pk, NJ 07932 USA; [Thomas, C. D.] Univ York, Dept Biol, Area 18, York YO10 5YW, N Yorkshire, England; [Beentje, H.; Dransfield, J.] Royal Bot Gardens, Richmond TW9 3AB, Surrey, England; [Fisher, B. L.] Calif Acad Sci, Dept Entomol, San Francisco, CA 94103 USA; [Glaw, F.] Zool Staatssammlung, D-81247 Munich, Germany; [Good, T. C.; Zjhra, M. L.] Georgia So Univ, Dept Biol, Statesboro, GA 30460 USA; [Harper, G. J.] Conservat Int, Ctr Appl Biodivers Sci, Arlington, VA 22202 USA; [Hijmans, R. J.] Int Rice Res Inst, Los Banos, Philippines; [Lees, D. C.] Nat Hist Museum, Dept Entomol, London SW7 5BD, England; [Louis, E., Jr.] Henry Doorly Zoo, Ctr Conservat & Res, Omaha, NE 68107 USA; [Nussbaum, R. A.] Univ Michigan, Zool Museum, Ann Arbor, MI 48109 USA; [Raxworthy, C. J.] Amer Museum Nat Hist, New York, NY 10024 USA; [Schatz, G. E.] Missouri Bot Garden, St Louis, MO 63166 USA; [Vences, M.] Tech Univ Carolo Wilhelmina Braunschweig, Inst Zool, D-38106 Braunschweig, Germany; [Vieites, D. R.] Univ Calif Berkeley, Museum Vertebrate Zool, Berkeley, CA 94720 USA; [Vieites, D. R.] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; [Wright, P. C.] SUNY Stony Brook, Dept Anthropol, Stony Brook, NY 11794 USA	University of California System; University of California Berkeley; University of Helsinki; AT&T; University of York - UK; Royal Botanic Gardens, Kew; California Academy of Sciences; University System of Georgia; Georgia Southern University; Conservation International; CGIAR; International Rice Research Institute (IRRI); Natural History Museum London; University of Michigan System; University of Michigan; American Museum of Natural History (AMNH); Missouri Botanical Gardens; Braunschweig University of Technology; University of California System; University of California Berkeley; University of California System; University of California Berkeley; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kremen, C (corresponding author), Univ Calif Berkeley, Dept Environm Sci Policy & Management, 137 Mulford Hall, Berkeley, CA 94720 USA.	ckremen@nature.berkeley.edu	Lees, David/AAD-7382-2021; Vieites, David/B-4481-2009; Hijmans, Robert/N-3299-2016; Moilanen, Atte/A-5005-2011; Fisher, Brian L./S-9374-2019; Vences, Miguel/E-5573-2010; Thomas, Chris D/A-1894-2012; Thomas, Chris D/A-1460-2014; Cameron, Alison/D-3911-2009	Vieites, David/0000-0001-5551-7419; Thomas, Chris D/0000-0003-2822-1334; Thomas, Chris D/0000-0003-2822-1334; Cameron, Alison/0000-0001-8236-7954; Hijmans, Robert/0000-0001-5872-2872; Vences, Miguel/0000-0003-0747-0817; Fisher, Brian/0000-0002-4653-3270				Brooks TM, 2006, SCIENCE, V313, P58, DOI 10.1126/science.1127609; Cowling R. M., 1999, Diversity and Distributions, V5, P51, DOI 10.1046/j.1472-4642.1999.00038.x; Cowling RM, 2003, BIOL CONSERV, V112, P191, DOI 10.1016/S0006-3207(02)00425-1; Elith J, 2006, ECOGRAPHY, V29, P129, DOI 10.1111/j.2006.0906-7590.04596.x; Goodman SM, 2005, ORYX, V39, P73, DOI 10.1017/S0030605305000128; Grenyer R, 2006, NATURE, V444, P93, DOI 10.1038/nature05237; Knight AT, 2006, CONSERV BIOL, V20, P739, DOI 10.1111/j.1523-1739.2006.00452.x; Kohler J, 2005, BIOSCIENCE, V55, P693, DOI 10.1641/0006-3568(2005)055[0693:NAAGCA]2.0.CO;2; Kremen Claire, 2003, P517; Margules CR, 2000, NATURE, V405, P243, DOI 10.1038/35012251; Mittermeier R, 2005, HOTSPOTS REVISITED E; Moilanen A, 2005, P ROY SOC B-BIOL SCI, V272, P1885, DOI 10.1098/rspb.2005.3164; Moilanen A, 2007, BIOL CONSERV, V134, P571, DOI 10.1016/j.biocon.2006.09.008; Moritz C, 2001, P ROY SOC B-BIOL SCI, V268, P1875, DOI 10.1098/rspb.2001.1713; Phillips SJ, 2006, ECOL MODEL, V190, P231, DOI 10.1016/j.ecolmodel.2005.03.026; PRENDERGAST JR, 1993, NATURE, V365, P335, DOI 10.1038/365335a0; Raherilalao MJ, 2005, REV ECOL-TERRE VIE, V60, P355; Raxworthy CJ, 1996, COLLOQ SEMI, P369; Rodrigues ASL, 2004, BIOSCIENCE, V54, P1092, DOI 10.1641/0006-3568(2004)054[1092:GGAPRF]2.0.CO;2; SCHATZ GE, 2000, MEMOIRES SOC BIOGEOG, P1; SCHATZ GE, 2000, DIVERSITE ENDEMISME, P11; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Turner WR, 2006, CONSERV BIOL, V20, P527, DOI 10.1111/j.1523-1739.2006.00333.x; van Jaarsveld AS, 1998, SCIENCE, V279, P2106, DOI 10.1126/science.279.5359.2106	24	403	411	6	199	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					222	226		10.1126/science.1155193	http://dx.doi.org/10.1126/science.1155193			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403708				2022-12-28	WOS:000254836700041
J	Marshall, L; Kenneth, NS; White, RJ				Marshall, Lynne; Kenneth, Niall S.; White, Robert J.			RETRACTED: Elevated tRNA(i)(Met) synthesis can drive cell proliferation and oncogenic transformation (Retracted article. See vol. 151, pg. 455, 2012)	CELL			English	Article; Retracted Publication							RNA-POLYMERASE-III; YEAST SACCHAROMYCES-CEREVISIAE; ELONGATION-FACTOR EEF1A2; RETINOBLASTOMA PROTEIN; MALIGNANT-TRANSFORMATION; IN-VIVO; TRANSCRIPTION; CANCER; TRANSLATION; TFIIIB	Characteristics of transformed and tumor cells include increased levels of protein synthesis and elevated expression of RNA polymerase (pol) III products, such as tRNAs and 5S rRNA. However, whether deregulated pol III transcription contributes to transformation has been unclear. Generating cell lines expressing an inducible pol III-specific transcription factor, Brf1, allowed us to raise tRNA and 5S rRNA levels specifically. Brf1 induction caused an increase in cell proliferation and oncogenic transformation, whereas depletion of Brf1 impeded transformation. Among the gene products induced by Brf1 is the tRNA(i)(Met) that initiates polypeptide synthesis. Overexpression of tRNA(i)(Met) is sufficient to stimulate cell proliferation and allow immortalized fibroblasts to form foci in culture and tumors in mice. The data indicate that elevated tRNA synthesis can promote cellular transformation.	[Marshall, Lynne; Kenneth, Niall S.; White, Robert J.] Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; [Marshall, Lynne; White, Robert J.] Garscube Estate, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Glasgow; Beatson Institute	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	white@beatson.gla.ac.uk						Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Daly NL, 2005, ONCOGENE, V24, P880, DOI 10.1038/sj.onc.1208031; DANIELS GR, 1985, NATURE, V317, P819, DOI 10.1038/317819a0; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fairley JA, 2005, P NATL ACAD SCI USA, V102, P18350, DOI 10.1073/pnas.0506415102; Fairley JA, 2003, EMBO J, V22, P5841, DOI 10.1093/emboj/cdg544; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Felton-Edkins ZA, 2006, J BIOL CHEM, V281, P33871, DOI 10.1074/jbc.M600468200; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; FRANCIS MA, 1990, MOL CELL BIOL, V10, P4486, DOI 10.1128/MCB.10.9.4486; Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Goodfellow SJ, 2006, EMBO J, V25, P1522, DOI 10.1038/sj.emboj.7601040; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirsch HA, 2004, MOL CELL BIOL, V24, P5989, DOI 10.1128/MCB.24.13.5989-5999.2004; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; Jones E, 2000, EXP CELL RES, V254, P163, DOI 10.1006/excr.1999.4739; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Morton JP, 2007, NUCLEIC ACIDS RES, V35, P3046, DOI 10.1093/nar/gkm208; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Sudbery P, 2002, SCIENCE, V297, P351, DOI 10.1126/science.1073042; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Tomlinson VAL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-113; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; ZETTERBE.A, 1965, EXP CELL RES, V40, P1, DOI 10.1016/0014-4827(65)90284-3	57	120	125	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2008	133	1					78	89		10.1016/j.cell.2008.02.035	http://dx.doi.org/10.1016/j.cell.2008.02.035			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394991	Bronze			2022-12-28	WOS:000254641300010
J	Hien, NT; Farrar, J; Horby, P				Hien, Nguyen Tran; Farrar, Jeremy; Horby, Peter			Person-to-person transmission of influenza A (H5N1)	LANCET			English	Editorial Material							VIRUS-INFECTION		[Farrar, Jeremy] Hosp Trop Dis, Ho Chi Minh City, Vietnam; [Farrar, Jeremy] Univ Oxford, Ho Chi Minh City, Vietnam; [Hien, Nguyen Tran] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam; [Horby, Peter] Natl Inst Infect & Trop Dis, Hanoi, Vietnam; [Horby, Peter] Univ Oxford, Hanoi, Vietnam	University of Oxford; National Institute of Hygiene & Epidemiology (NIHE); University of Oxford	Farrar, J (corresponding author), Hosp Trop Dis, Quan 5, Ho Chi Minh City, Vietnam.	jfarrar@oucru.org	Horby, Peter/D-1585-2013; Farrar, Jeremy J./HGA-7610-2022	Farrar, Jeremy/0000-0002-2700-623X; Horby, Peter/0000-0002-9822-1586				Auewarakul P, 2007, J VIROL, V81, P9950, DOI 10.1128/JVI.00468-07; Bridges CB, 2000, J INFECT DIS, V181, P344, DOI 10.1086/315213; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Gilsdorf A, 2006, Euro Surveill, V11, P3, DOI 10.2807/esm.11.05.00620-en; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; Kandun IN, 2006, NEW ENGL J MED, V355, P2186, DOI 10.1056/NEJMoa060930; Katz JM, 1999, J INFECT DIS, V180, P1763, DOI 10.1086/315137; Koopmans M, 2004, LANCET, V363, P587, DOI 10.1016/S0140-6736(04)15589-X; Rollig Christoph, LANCET, V385, P2197, DOI [10.1016/S0140-6736(14)60493-1, DOI 10.1016/S0140-6736(14)60493-1]; Sedyaningsih ER, 2007, J INFECT DIS, V196, P522, DOI 10.1086/519692; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Yen HL, 2007, J VIROL, V81, P6890, DOI 10.1128/JVI.00170-07; 2004, TIMES ONLINE    0202	13	14	14	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR-MAY	2008	371	9622					1392	1394		10.1016/S0140-6736(08)60494-8	http://dx.doi.org/10.1016/S0140-6736(08)60494-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294XW	18400287	Green Published, Bronze			2022-12-28	WOS:000255440600005
J	Lubitz, SA; Fischer, A; Fuster, V				Lubitz, Steven A.; Fischer, Avi; Fuster, Vaentin			Catheter ablation for atrial fibrillation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PULMONARY-VEIN ABLATION; QUALITY-OF-LIFE; RADIOFREQUENCY ABLATION; COST-EFFECTIVENESS; RHYTHM; TACHYARRHYTHMIAS; RECURRENCES; MORTALITY; THERAPY		[Lubitz, Steven A.; Fischer, Avi; Fuster, Vaentin] Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Mariejosee & Henry R Kravis Ctr Cardiovasc Hlth, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Lubitz, SA (corresponding author), Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Mariejosee & Henry R Kravis Ctr Cardiovasc Hlth, Box 1030, New York, NY 10029 USA.	steven.lubitz@mssm.edu	Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				Arentz T, 2007, CIRCULATION, V115, P3057, DOI 10.1161/CIRCULATIONAHA.107.690578; Bertaglia E, 2005, PACE, V28, P366, DOI 10.1111/j.1540-8159.2005.09516.x; Calkins H, 2007, HEART RHYTHM, V4, P816, DOI 10.1016/j.hrthm.2007.04.005; Cappato R, 2005, CIRCULATION, V111, P1100, DOI 10.1161/01.CIR.0000157153.30978.67; Chan PS, 2006, J AM COLL CARDIOL, V47, P2513, DOI 10.1016/j.jacc.2006.01.070; Chen YJ, 1998, J AM COLL CARDIOL, V32, P732, DOI 10.1016/S0735-1097(98)00305-2; Corley SD, 2004, CIRCULATION, V109, P1509, DOI 10.1161/01.CIR.0000121736.16643.11; Fisher JD, 2006, PACE, V29, P523, DOI 10.1111/j.1540-8159.2006.00388.x; Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Hagens VE, 2004, J AM COLL CARDIOL, V43, P241, DOI 10.1016/j.jacc.2003.08.037; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Haissaguerre M, 2000, CIRCULATION, V102, P2463, DOI 10.1161/01.CIR.102.20.2463; Hsu LF, 2004, NEW ENGL J MED, V351, P2373, DOI 10.1056/NEJMoa041018; Jais P, 2006, HEART RHYTHM, V3, P140, DOI 10.1016/j.hrthm.2005.11.012; Karch MR, 2005, CIRCULATION, V111, P2875, DOI 10.1161/CIRCULATIONAHA.104.491530; Khaykin Y, 2007, J CARDIOVASC ELECTR, V18, P907, DOI 10.1111/j.1540-8167.2007.00902.x; KRITTAYAPHONG R, 2003, J MED ASS THAI S1, V86, pS8; Liu XP, 2006, CIRC J, V70, P1392, DOI 10.1253/circj.70.1392; Marshall DA, 2004, ANN INTERN MED, V141, P653, DOI 10.7326/0003-4819-141-9-200411020-00005; Nademanee K, 2004, J AM COLL CARDIOL, V43, P2044, DOI 10.1016/j.jacc.2003.12.054; Natale A, 2007, J CARDIOVASC ELECTR, V18, P560, DOI 10.1111/j.1540-8167.2007.00816.x; NATHAN H, 1966, CIRCULATION, V34, P412, DOI 10.1161/01.CIR.34.3.412; Nilsson B, 2006, AM HEART J, V152, DOI 10.1016/j.ahj.2006.05.029; Oral H, 2003, CIRCULATION, V108, P2355, DOI 10.1161/01.CIR.0000095796.45180.88; Oral H, 2006, CIRCULATION, V113, P1824, DOI 10.1161/CIRCULATIONAHA.105.601898; Oral H, 2004, J CARDIOVASC ELECTR, V15, P920, DOI 10.1046/j.1540-8167.2004.04055.x; Oral H, 2006, NEW ENGL J MED, V354, P934, DOI 10.1056/NEJMoa050955; Oral H, 2002, J AM COLL CARDIOL, V40, P100, DOI 10.1016/S0735-1097(02)01939-3; Oral H, 2006, CIRCULATION, V114, P759, DOI 10.1161/CIRCULATIONAHA.106.641225; Ouyang FF, 2005, CIRCULATION, V111, P127, DOI 10.1161/01.CIR.0000151289.73085.36; Pappone C, 2003, J AM COLL CARDIOL, V42, P185, DOI 10.1016/S0735-1097(03)00577-1; Pappone C, 2004, CIRCULATION, V109, P327, DOI 10.1161/01.CIR.0000112641.16340.C7; Pappone C, 2000, CIRCULATION, V102, P2619; Pappone C, 2006, J AM COLL CARDIOL, V48, P2340, DOI 10.1016/j.jacc.2006.08.037; Stabile G, 2006, EUR HEART J, V27, P216, DOI 10.1093/eurheartj/ehi583; Steinberg JS, 2004, CIRCULATION, V109, P1973, DOI 10.1161/01.CIR.0000118472.77237.FA; Wazni OM, 2005, JAMA-J AM MED ASSOC, V293, P2634, DOI 10.1001/jama.293.21.2634	38	35	38	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR	2008	336	7648					819	826		10.1136/bmj.39513.555150.BE	http://dx.doi.org/10.1136/bmj.39513.555150.BE			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	292ER	18403546	Green Published			2022-12-28	WOS:000255249800046
J	Niewoehner, CB; Schorer, AE				Niewoehner, Catherine B.; Schorer, Anna E.			Gynaecomastia and breast cancer in men	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PROSTATE-CANCER; PUBERTAL GYNECOMASTIA; CONTROLLED-TRIAL; EPIDEMIOLOGY; TAMOXIFEN; EFFICACY; BICALUTAMIDE; ANASTROZOLE; PREVENTION; MANAGEMENT		[Niewoehner, Catherine B.] Vet Adm Med Ctr 111G, Metab Sect, Minneapolis, MN 55417 USA; [Schorer, Anna E.] Vet Adm Med Ctr 111E, Hematol Oncol Sect, Minneapolis, MN 55417 USA		Niewoehner, CB (corresponding author), Vet Adm Med Ctr 111G, Metab Sect, 1 Vet Dr, Minneapolis, MN 55417 USA.	niewo002@umn.edu						Allen EA, 2003, ACTA CYTOL, V47, P183, DOI 10.1159/000326501; ANDERSEN JA, 1982, ACTA PATH MICRO IM A, V90, P191; Anderson WF, 2005, CANCER, V104, P1733, DOI 10.1002/cncr.21353; Boccardo F, 2005, J CLIN ONCOL, V23, P808, DOI 10.1200/JCO.2005.12.013; Dobs A, 2005, J UROLOGY, V174, P1737, DOI 10.1097/01.ju.0000176461.75794.f8; Dobs AS, 1999, J CLIN ENDOCR METAB, V84, P3469, DOI 10.1210/jc.84.10.3469; Evans GFF, 2001, AM J SURG, V181, P96, DOI 10.1016/S0002-9610(00)00571-7; FRIEDL KE, 1989, PHYSICIAN SPORTSMED, V17, P67, DOI 10.1080/00913847.1989.11709731; Fruhstorfer BH, 2003, BRIT J PLAST SURG, V56, P237, DOI 10.1016/S0007-1226(03)00111-5; Goes JCS, 2002, AESTHET PLAST SURG, V26, P1, DOI 10.1007/s00266-001-0037-3; Henley DV, 2007, NEW ENGL J MED, V356, P479, DOI 10.1056/NEJMoa064725; Karlsson CT, 2006, J UROLOGY, V176, P538, DOI 10.1016/j.juro.2006.03.036; Lawrence SE, 2004, J PEDIATR-US, V145, P71, DOI 10.1016/j.jpeds.2004.03.057; NIEWOEHNER CB, 1984, AM J MED, V77, P633, DOI 10.1016/0002-9343(84)90353-X; NUTTALL FQ, 1979, J CLIN ENDOCR METAB, V48, P338, DOI 10.1210/jcem-48-2-338; Perdona S, 2005, LANCET ONCOL, V6, P295, DOI 10.1016/S1470-2045(05)70103-0; Plourde PV, 2004, J CLIN ENDOCR METAB, V89, P4428, DOI 10.1210/jc.2004-0082; Ribeiro GG, 1996, BREAST, V5, P141, DOI 10.1016/S0960-9776(96)90058-2; SASCO AJ, 1993, INT J CANCER, V53, P538, DOI 10.1002/ijc.2910530403; Shozu M, 2003, NEW ENGL J MED, V348, P1855, DOI 10.1056/NEJMoa021559; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Swerdlow AJ, 2005, J NATL CANCER I, V97, P1204, DOI 10.1093/jnci/dji240; TSENG A, 1985, CANCER-AM CANCER SOC, V56, P2534, DOI 10.1002/1097-0142(19851115)56:10<2534::AID-CNCR2820561036>3.0.CO;2-Q; Weiss JR, 2005, CANCER EPIDEM BIOMAR, V14, P20, DOI 10.1158/1055-9965.EPI-05-0414	24	46	48	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	2008	336	7646					709	713		10.1136/bmj.39511.493391.BE	http://dx.doi.org/10.1136/bmj.39511.493391.BE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	283ZS	18369226	Green Published			2022-12-28	WOS:000254675600030
J	Tuch, BB; Li, H; Johnson, AD				Tuch, Brian B.; Li, Hao; Johnson, Alexander D.			Evolution of eukaryotic transcription circuits	SCIENCE			English	Editorial Material							CIS-REGULATORY MUTATIONS; FACTOR-BINDING-SITES; HOX PROTEIN; EVOLVABILITY; NETWORKS; YEAST		[Tuch, Brian B.; Li, Hao; Johnson, Alexander D.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [Tuch, Brian B.; Johnson, Alexander D.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Johnson, AD (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	ajohnson@cgl.ucsf.edu						Bilu Y, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-12-r103; Borneman AR, 2007, SCIENCE, V317, P815, DOI 10.1126/science.1140748; CARROLL SB, 2005, DNA DIVERSITY MOL GE; Davidson E. H., 2001, DEV EVOLUTION; Galant R, 2002, NATURE, V415, P910, DOI 10.1038/nature717; Gasch AP, 2004, PLOS BIOL, V2, P2202, DOI 10.1371/journal.pbio.0020398; Haag ES, 2005, EVOLUTION, V59, P1620, DOI 10.1111/j.0014-3820.2005.tb01813.x; Jeong S, 2008, CELL, V132, P783, DOI 10.1016/j.cell.2008.01.014; Kirschner M, 1998, P NATL ACAD SCI USA, V95, P8420, DOI 10.1073/pnas.95.15.8420; Ludwig MZ, 2000, NATURE, V403, P564, DOI 10.1038/35000615; Lynch M, 2007, NAT REV GENET, V8, P803, DOI 10.1038/nrg2192; Martchenko M, 2007, CURR BIOL, V17, P1007, DOI 10.1016/j.cub.2007.05.017; McGregor AP, 2007, NATURE, V448, P587, DOI 10.1038/nature05988; Odom DT, 2007, NAT GENET, V39, P730, DOI 10.1038/ng2047; Prud'homme B, 2007, P NATL ACAD SCI USA, V104, P8605, DOI 10.1073/pnas.0700488104; Ronshaugen M, 2002, NATURE, V415, P914, DOI 10.1038/nature716; Shapiro MD, 2004, NATURE, V428, P717, DOI 10.1038/nature02415; Tanay A, 2005, P NATL ACAD SCI USA, V102, P7203, DOI 10.1073/pnas.0502521102; Tishkoff SA, 2007, NAT GENET, V39, P31, DOI 10.1038/ng1946; Tsong AE, 2006, NATURE, V443, P415, DOI 10.1038/nature05099; Tuch BB, 2008, PLOS BIOL, V6, P352, DOI 10.1371/journal.pbio.0060038; Wray GA, 2003, MOL BIOL EVOL, V20, P1377, DOI 10.1093/molbev/msg140; Wray GA, 2007, NAT REV GENET, V8, P206, DOI 10.1038/nrg2063; Zuckerkandl E, 1997, J MOL EVOL, V44, pS2, DOI 10.1007/PL00000048	24	123	126	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1797	1799		10.1126/science.1152398	http://dx.doi.org/10.1126/science.1152398			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369141				2022-12-28	WOS:000254394000038
J	Gordon, D; Christensen, L; Dayrit, M; Dela, F; Karle, H; Mercer, H				Gordon, David; Christensen, Leif; Dayrit, Manuel; Dela, Flemming; Karle, Hans; Mercer, Hugo			Educating health professionals: the Avicenna project	LANCET			English	Editorial Material									[Gordon, David; Christensen, Leif; Dela, Flemming; Karle, Hans] Univ Copenhagen, Fac Hlth Sci, World Federat Med Educ, DK-2200 Copenhagen, Denmark; [Dayrit, Manuel; Mercer, Hugo] WHO, Dept Human Resources Hlth, CH-1211 Geneva, Switzerland	University of Copenhagen; World Health Organization	Gordon, D (corresponding author), Univ Copenhagen, Fac Hlth Sci, World Federat Med Educ, DK-2200 Copenhagen, Denmark.	gordoncph@gmail.com	Dayrit, Manuel M./AAJ-6750-2020; Dela, Flemming/AAU-1691-2021; Dela, Flemming/B-3239-2008	Dela, Flemming/0000-0001-9970-9535; Dela, Flemming/0000-0001-9970-9535				*EX COUNC, 2008, MED EDUC, V42, P17; *WORLD FED MED ED, 2004, WHO WFME STRAT PARTN; World Health Organization, 2000, WORLD DIR MED SCH	3	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 22	2008	371	9617					966	967		10.1016/S0140-6736(08)60431-6	http://dx.doi.org/10.1016/S0140-6736(08)60431-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358912				2022-12-28	WOS:000254206000007
J	Greenblatt, JF				Greenblatt, Jack F.			Transcription termination: Pulling out all the stops	CELL			English	Editorial Material							RNA-POLYMERASE; ELONGATION COMPLEX; ESCHERICHIA-COLI; MECHANISM; HYBRID	In this issue, Larson et al. (2008) describe the use of optical traps to pull on the DNA template or RNA transcript and thereby explore the termination mechanism for E. coli RNA polymerase at intrinsic terminators. Their results imply that, depending on the nature of the terminator sequence, RNA polymerase uses either hypertranslocation or RNA: DNA shearing to destabilize the hybrid in the transcription bubble.	[Greenblatt, Jack F.] Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 3E1, Canada; [Greenblatt, Jack F.] Univ Toronto, Dept Mol Genet, Terrence Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada	University of Toronto; University of Toronto	Greenblatt, JF (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 160 Coll St, Toronto, ON M5S 3E1, Canada.	jack.greenblatt@utoronto.ca						Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Komissarova N, 2002, MOL CELL, V10, P1151, DOI 10.1016/S1097-2765(02)00738-4; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; Santangelo TJ, 2004, MOL CELL, V14, P117, DOI 10.1016/S1097-2765(04)00154-6; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611	9	2	2	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 21	2008	132	6					917	918		10.1016/j.cell.2008.03.003	http://dx.doi.org/10.1016/j.cell.2008.03.003			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358802	Bronze			2022-12-28	WOS:000254273600008
J	Gilmore, IT				Gilmore, Ian T.			Making a difference - Excessive drinking in young women - Not just a "lifestyle disease"	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Coll Physicians, London NW1 4LE, England	Royal College of Physicians	Gilmore, IT (corresponding author), Royal Coll Physicians, London NW1 4LE, England.	ian.gilmore@rcplondon.ac.uk						Academy of Medical Sciences (AMS), 2004, CALL TIM NAT DRINK M; Babor TF, 2003, ALCOHOL NO ORDINARY; DONALDSON L, 2001, STATE PUBLIC HLTH; Home Office, 2006, HOM OFF STAT B, V18; O'Malley KD, 2007, ADHD FETAL ALCOHOL S; Office for National Statistics, 2008, GEN HOUS SURV 2006; *SCOTT EX, 2002, 2000 SCOTT CRIM SURV; WILLIAMSON J, 2003, J SUBST USE, V8, P234	8	8	8	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					952	+		10.1136/bmj.39520.716863.94	http://dx.doi.org/10.1136/bmj.39520.716863.94			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397940	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000255540900039
J	Ayi, K; Min-Oo, G; Serghides, L; Crockett, M; Kirby-Allen, M; Quirt, I; Gros, P; Kain, KC				Ayi, Kodjo; Min-Oo, Gundula; Serghides, Lena; Crockett, Maryanne; Kirby-Allen, Melanie; Quirt, Ian; Gros, Philippe; Kain, Kevin C.			Pyruvate kinase deficiency and malaria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; PHAGOCYTOSIS; PROTECTION; PARASITES	Malaria that is caused by Plasmodium falciparum is a significant global health problem. Genetic characteristics of the host influence the severity of disease and the ultimate outcome of infection, and there is evidence of coevolution of the plasmodium parasite with its host. In humans, pyruvate kinase deficiency is the second most common erythrocyte enzyme disorder. Here, we show that pyruvate kinase deficiency provides protection against infection and replication of P. falciparum in human erythrocytes, raising the possibility that mutant pyruvate kinase alleles may confer a protective advantage against malaria in human populations in areas where the disease is endemic.	[Min-Oo, Gundula; Gros, Philippe] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Min-Oo, Gundula; Gros, Philippe] McGill Univ, Ctr Study Host Resistance, Montreal, PQ H3G 1Y6, Canada; [Ayi, Kodjo; Serghides, Lena; Crockett, Maryanne; Kain, Kevin C.] Toronto Gen Hosp, McLaughlin Rotman Ctr Global Hlth, Univ Hlth Network, Toronto, ON, Canada; [Quirt, Ian; Kain, Kevin C.] Toronto Gen Hosp, Dept Med, Univ Hlth Network, Toronto, ON M5G 1L7, Canada; [Kirby-Allen, Melanie] Hosp Sick Children, Hematol Unit, Toronto, ON M5G 1X8, Canada; [Kain, Kevin C.] Univ Toronto, McLaughlin Ctr Mol Med, Toronto, ON, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Gros, P (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler,Rm 907, Montreal, PQ H3G 1Y6, Canada.	philippe.gros@mcgill.ca	Serghides, Lena/C-7968-2018	Serghides, Lena/0000-0002-2817-6134; Crockett, Maryanne/0000-0001-5879-143X; Kain, Kevin/0000-0001-6068-1272				Ayi K, 2004, BLOOD, V104, P3364, DOI 10.1182/blood-2003-11-3820; Ayi K, 2005, INFECT IMMUN, V73, P2559, DOI 10.1128/IAI.73.4.2559-2563.2005; DRONAMRAJU KR, 2006, MALARIA GENETIC EVOL; Haldane J.B.S., 1949, HEREDITAS, V35, P267; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Min-Oo G, 2005, CELL MICROBIOL, V7, P753, DOI 10.1111/j.1462-5822.2005.00524.x; Min-Oo G, 2004, GENES IMMUN, V5, P168, DOI 10.1038/sj.gene.6364069; Min-Oo G, 2003, NAT GENET, V35, P357, DOI 10.1038/ng1260; Mordmuller B, 2006, CURR MOL MED, V6, P247, DOI 10.2174/156652406776055122; Patel SN, 2004, J INFECT DIS, V189, P204, DOI 10.1086/380764; PONGPONRATN E, 1991, AM J TROP MED HYG, V44, P168, DOI 10.4269/ajtmh.1991.44.168; SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Targett GA, 2005, TRENDS PARASITOL, V21, P499, DOI 10.1016/j.pt.2005.08.018; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Williams TN, 2006, CURR OPIN MICROBIOL, V9, P388, DOI 10.1016/j.mib.2006.06.009; Zanella A, 2005, BRIT J HAEMATOL, V130, P11, DOI 10.1111/j.1365-2141.2005.05527.x; Zanella A, 1997, BLOOD, V89, P3847, DOI 10.1182/blood.V89.10.3847.3847_3847_3852; Zanella A, 2000, BEST PRACT RES CL HA, V13, P57, DOI 10.1053/beha.1999.0057	19	69	71	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	2008	358	17					1805	1810		10.1056/NEJMoa072464	http://dx.doi.org/10.1056/NEJMoa072464			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291PL	18420493				2022-12-28	WOS:000255209200006
J	Mendell, JT				Mendell, Joshua T.			miRiad roles for the miR-17-92 cluster in development and disease	CELL			English	Review							CELL-PROLIFERATION; MICRORNAS; EXPRESSION; CANCER; GENE; DIFFERENTIATION; ACTIVATION; LEUKEMIA; TARGETS; FAMILY	MicroRNAs (miRNAs) encoded by the miR-17-92 cluster and its paralogs are known to act as oncogenes. Expression of these miRNAs promotes cell proliferation, suppresses apoptosis of cancer cells, and induces tumor angiogenesis. New work reveals essential functions for these miRNAs not only in tumor formation but also during normal development of the heart, lungs, and immune system.	[Mendell, Joshua T.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Dept Pediat, Baltimore, MD 21205 USA; [Mendell, Joshua T.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Mendell, JT (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Dept Pediat, Baltimore, MD 21205 USA.	jmendell@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA120185] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA120185, R01 CA120185-02, R01 CA120185-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chakraborty T, 2007, MOL CELL, V27, P842, DOI 10.1016/j.molcel.2007.07.010; Cui JW, 2007, BLOOD, V110, P2631, DOI 10.1182/blood-2006-10-053850; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Koralov SB, 2008, CELL, V132, P860, DOI 10.1016/j.cell.2008.02.020; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang CL, 2006, P NATL ACAD SCI USA, V103, P18680, DOI 10.1073/pnas.0609030103; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001	24	887	958	1	52	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 18	2008	133	2					217	222		10.1016/j.cell.2008.04.001	http://dx.doi.org/10.1016/j.cell.2008.04.001			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	289JY	18423194	Green Accepted, Bronze			2022-12-28	WOS:000255052000012
J	Iglehart, JK				Iglehart, John K.			Grassroots activism and the pursuit of an expanded physician supply	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES; REGIONAL-VARIATIONS; WORKFORCE; CARE; SHORTAGES; PERSONNEL; SERVICES; CENTERS; DEMAND; ACCESS											Ahmad OB, 2005, BRIT MED J, V331, P43, DOI 10.1136/bmj.331.7507.43; *AM AC FAM PHYS, 2006, FAM PHYS WORKF REF; *AM MED ASS, 2007, INT MED GRAD US WORK; Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; ARMSTRONG DP, 2007, PHYS RECRUITMENT RET; *ASS AM MED COLL, 2006, AAMC STAT PHYS WORKF; *ASS AM MED COLL, 2005, EC IMP AAMC MEMB MED; *ASS AM MED COLL, 1996, CONS STAT PHYS WORKF; *ASS AM MED COLL, 2008, 2007 SURV MED SCH; *ASS DIR GER AC PR, 2004, GER MED CLIN IMP AG; Blumenthal D, 2004, NEW ENGL J MED, V350, P1780, DOI 10.1056/NEJMhpr033066; *BUR HLTH PROF, 2006, PHYS SUPPL DEM PROJ; *COMM US PHYS SUPP, 1996, NAT PHYS WORKF OPT B; Cook NL, 2007, HEALTH AFFAIR, V26, P1459, DOI 10.1377/hlthaff.26.5.1459; Cooper RA, 2004, ANN INTERN MED, V141, P705, DOI 10.7326/0003-4819-141-9-200411020-00012; Cooper RA, 2004, HEALTH AFFAIR, V23, P243, DOI 10.1377/hlthaff.23.6.243; Cooper RA, 2002, HEALTH AFFAIR, V21, P140, DOI 10.1377/hlthaff.21.1.140; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; Cooper RA, 2007, ANN SURG, V246, P527, DOI 10.1097/SLA.0b013e3181571bc1; Cossman Jeralynn Sittig, 2004, J Miss State Med Assoc, V45, P8; *COUNC GRAD MED ED, 1994, REC IMPR ACC HLTH CA; Council on Graduate Medical Education, 2005, PHYS WORKF POL GUID; *CTR HLTH WORKF ST, 2000, A1 PHYS WORKF REP PR; *CTR HLTH WORKF ST, 2004, CAL PHYS WORKF SUPP; *CTR RUR HLTH, 2004, PHYS WORKF OR SNAPSH; Deal CL, 2007, ARTHRITIS RHEUM, V56, P722, DOI 10.1002/art.22437; Erikson C, 2007, J ONCOL PRACT, V3, P79, DOI 10.1200/JOP.0723601; Ewart GW, 2004, CHEST, V125, P1518, DOI 10.1378/chest.125.4.1518; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; FUHRMANS V, 2007, WALL STREET J   0719, pA1; Fye WB, 2004, CIRCULATION, V109, P813, DOI 10.1161/01.CIR.0000118641.54694.4C; *GEORG BOARD PHYS, 2005, PHYS SUPPL DEM IND G; Goodman DC, 2008, JAMA-J AM MED ASSOC, V299, P335, DOI 10.1001/jama.299.3.335; Goodman DC, 2006, HEALTH AFFAIR, V25, P521, DOI 10.1377/hlthaff.25.2.521; Goodman DC, 2004, HLTH AFF MILLWOOD S, pVAR90; Gottfried ON, 2005, J NEUROSURG, V102, P202, DOI 10.3171/jns.2005.102.2.0202; *GOV ACC OFF, 2006, GAO06704; *GOV HLTH REF COMM, 2007, ROADM VIRG HLTH REP; *GRAD MED ED NAT A, 1981, SUMM REP GRAD MED ED, V1; Grumbach K, 2008, HEALTH AFFAIR, V27, P413, DOI 10.1377/hlthaff.27.2.413; Institute of Medicine, 2007, HOSP BAS EM CAR BREA, DOI [10.17226/11621, DOI 10.17226/11621]; JOHNSON WG, 2005, ARIZONA WORKFORCE S; *KENT I MED, 2007, COMPR STAT PHYS WORK; Kim WJ, 2003, ACAD PSYCHIATR, V27, P277, DOI 10.1176/appi.ap.27.4.277; Korf BR, 2005, GENET MED, V7, P293, DOI 10.1097/01.GIM.0000164551.44846.F6; LEE C, 2007, WASHINGTON POST 0711; LEE C, 2007, WASHINGTON POST 0619, pA2; LEONHARDT D, 2001, NY TIMES        1101, pBU3; Mallon WT, 2007, ACAD MED, V82, P1121, DOI 10.1097/ACM.0b013e318159cca6; MANDSAGER R, 2006, SECURING DEQUATE NUM; *MAR STAT MED SOC, 2007, MAR PHYS WORKF STUD; *MASS MED SOC, 2007, PHYS WORKF STUD; Merritt J, 2004, WILL LAST PHYS AM PL; *MICH STAT MED SOC, 2005, FUT SUPPL DEM PHYS M; Mullan F, 2000, NEW ENGL J MED, V343, P213, DOI 10.1056/NEJM200007203430312; Mullan F, 2005, NEW ENGL J MED, V353, P1810, DOI 10.1056/NEJMsa050004; Munthali AW, 2007, TRAINING PHYS PUBLIC; *N CAR I MED, 2007, NCIOM TASK FORC PRIM; PENDLETON JH, 2007, PRELIMINARY OBSERVAT; Resneck J, 2004, J AM ACAD DERMATOL, V50, P50, DOI 10.1016/j.jaad.2003.07.001; Rizza Robert A, 2003, Endocr Pract, V9, P210; Rosenblatt RA, 2006, JAMA-J AM MED ASSOC, V295, P1042, DOI 10.1001/jama.295.9.1042; SCHNEIDER K, 2007, NY TIMES        0711, pC6; Schubert A, 2003, ANESTH ANALG, V96, P207, DOI 10.1097/00000539-200301000-00043; Scully JH, 2003, ACAD PSYCHIATR, V27, P247, DOI 10.1176/appi.ap.27.4.247; Sheldon GF, 2007, ANN SURG, V246, P541, DOI 10.1097/SLA.0b013e3181571ca1; SONDERMAN J, 2006, TIMES TRIBUNE   0629, P1; Sunshine JH, 2004, AM J ROENTGENOL, V182, P301, DOI 10.2214/ajr.182.2.1820301; TALBOTT C, 2007, WASHINGTON POST 0722, pA1; *TEX HIGH ED COORD, 2002, PROJ NEED MED ED TEX; *U CENTR FLOR, 2005, PRES HITT ASKS STAT; *U IOWA TASK FORC, 2007, REP IOW PHYS WORKF; *UT MED ED COUNC, 2006, UT PHYS WORKF STUD S; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; *WISC HOSP ASS, 2004, WHO WILL CAR OUR PAT; World Health Organization (WHO), 2006, WORLD HLTH REP 2006; 2007, WALL STREET J   0725, pB1	79	50	50	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1741	1749		10.1056/NEJMhpr0800058	http://dx.doi.org/10.1056/NEJMhpr0800058			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288DO	18420508				2022-12-28	WOS:000254966600016
J	Bernstein, S; Say, L; Chowdhury, S				Bernstein, Stan; Say, Lale; Chowdhury, Sadia			Sexual and reproductive health: completing the continuum	LANCET			English	Editorial Material									[Bernstein, Stan] UN Populat Fund, New York, NY 10017 USA; [Say, Lale] WHO, CH-1211 Geneva, Switzerland; [Chowdhury, Sadia] World Bank, Washington, DC 20433 USA	United Nations Population Fund; World Health Organization; The World Bank	Bernstein, S (corresponding author), UN Populat Fund, New York, NY 10017 USA.	bernstein@unfpa.org	, lalesay/AAG-1912-2021					African Union, 2006, MAP PLAN ACT OP CONT; Campbell White A., 2006, REPROD HLTH MISSING; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; Collumbien M., 2004, COMP QUANTIFICATION, P1255; *UN, 2007, A621 UN; UN, 1994, REP INT C POP DEV; *UN MILL PROJ, 2006, PUBL DEC PRIV CHOIC; UN Millennium Project, 2005, WHOS GOT POW TRANSF; *WHO, IN PRESS NATL LEV MO; World Health Organization, 2004, REPR HLTH STRAT	10	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 12	2008	371	9620					1225	1226		10.1016/S0140-6736(08)60537-1	http://dx.doi.org/10.1016/S0140-6736(08)60537-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	286XH	18406845				2022-12-28	WOS:000254878900008
J	Cavagnero, E; Daelmans, B; Gupta, N; Scherpbier, R; Shankar, A				Cavagnero, Eleonora; Daelmans, Bernadette; Gupta, Neeru; Scherpbier, Robert; Shankar, Anuraj		Countdown Working Grp Hlth Policy	Assessment of the health system and policy environment as a critical complement to tracking intervention coverage for maternal, newborn, and child health	LANCET			English	Article							DEVELOPING-COUNTRIES; CARE; MORTALITY; SERVICES; COST	In 2008, the Countdown to 2015 initiative identified 68 priority countries for action on maternal, newborn, and child health. Much attention was paid to monitoring country-level progress in achieving high and equitable coverage with interventions effective in reducing mortality of mothers, newborn infants, and children up to 5 years of age. To have a broader understanding of the environment in which health services are delivered and health outcomes are produced is essential to increase intervention coverage. Programmes to address MNCH rely on health systems to generate information needed for effective decisions and to achieve the expected outcomes. Governance and leadership are needed throughout the process not only to create policies and implement them but also to assure quality and efficiency of care, to finance health services sufficiently and in an equitable way, and to manage the health workforce. We present a systematic approach to assess the wider health system and policy environment needed to achieve positive outcomes for maternal, newborn, and child health. We report on results from 13 indicators and show gaps in policy adoption as well as weaknesses in other health system building blocks. We identify areas for future action in measurement of key indicators and their use to support decision making. We hope that this information will provide an additional dimension to the discussions on feasible and sustainable solutions to accelerate progress towards Millennium Development Goals 4 and 5, both at the global level but most importantly in individual countries.	[Cavagnero, Eleonora; Daelmans, Bernadette; Gupta, Neeru; Scherpbier, Robert; Shankar, Anuraj] WHO, CH-1211 Geneva 27, Switzerland	World Health Organization	Daelmans, B (corresponding author), WHO, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	daelmansb@who.int		Gupta, Neeru/0000-0002-3806-4435				Bhutta ZA, 2004, ARCH DIS CHILD, V89, P483, DOI 10.1136/adc.2003.045732; Boerma JT, 2007, LANCET, V369, P779, DOI 10.1016/S0140-6736(07)60364-X; Borghi J, 2006, LANCET, V368, P1457, DOI 10.1016/S0140-6736(06)69383-5; BRYCE J, TRACKING PROGR MATER; Bryce J, 2006, LANCET, V368, P1067, DOI 10.1016/S0140-6736(06)69339-2; Burnham GM, 2004, B WORLD HEALTH ORGAN, V82, P187; Carlin JB, 2008, LANCET, V371, P135, DOI 10.1016/S0140-6736(08)60106-3; CARRIN G, 2007, B WORLD HEALTH ORGAN, V78, P770; Haines A, 2007, LANCET, V369, P2121, DOI 10.1016/S0140-6736(07)60325-0; ILO, 1952, SOC SEC MIN STAND CO; *ILO, 2007, SAF MAT WORLD WORK; Kaufman J, 2002, REPROD HEALTH MATTER, V10, P108, DOI 10.1016/S0968-8080(02)00090-3; Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9; Kruk ME, 2007, HEALTH POLICY PLANN, V22, P303, DOI 10.1093/heapol/czm027; McNay K, 2004, BUCKING TREND SRI LA; Mullan F, 2007, LANCET, V370, P2158, DOI 10.1016/S0140-6736(07)60785-5; Nahar S, 1998, HEALTH POLICY PLANN, V13, P417, DOI 10.1093/heapol/13.4.417; *ORG AFR UN, AB DECL HIV AIDS TUB; Reich MR, 2008, LANCET, V371, P865, DOI 10.1016/S0140-6736(08)60384-0; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Santos C, 2006, INT J GYNECOL OBSTET, V94, P190, DOI 10.1016/j.ijgo.2006.05.024; Shiffman J, 2007, LANCET, V370, P1370, DOI 10.1016/S0140-6736(07)61579-7; *UNICEF WHO, 2006, TRACK PROGR CHILD SU; *UNICEF WHO UNFPA, 1997, GUID MON AV US OBST; WHO, 2006, INT MAN PREGN CHILDB; *WHO UNICEF, 2006, JOINT STAT MAN PNEUM; *WHO UNICEF, 2006, JOINT STAT CLIN MAN; World Health Organization, 2005, WORLD HLTH REP 2005; World Health Organization, 2007, WORLD HLTH STAT 2007; World Health Organization, 1981, INT COD MARK BREAST; World Health Organization, 2005, TREATM DIARRH MAN PH; World Health Organization, 2007, GLOB ATL HLTH WORKF; World Health Organization, 2001, MACR HLTH INV HLTH E; World Health Organization (WHO), 2007, COMMUNITY HLTH WORKE; World Health Organization (WHO), 2006, WORLD HLTH REP 2006; Xu K., 2005, DESIGNING HLTH FINAN; Zhan SK, 2002, HEALTH POLICY PLANN, V17, P47, DOI 10.1093/heapol/17.suppl_1.47	37	42	45	4	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1284	1293						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286XH	18406863				2022-12-28	WOS:000254878900030
J	Groll, M; Schellenberg, B; Bachmann, AS; Archer, CR; Huber, R; Powell, TK; Lindow, S; Kaiser, M; Dudler, R				Groll, Michael; Schellenberg, Barbara; Bachmann, Andre S.; Archer, Crystal R.; Huber, Robert; Powell, Tracy K.; Lindow, Steven; Kaiser, Markus; Dudler, Robert			A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism	NATURE			English	Article							SYRINGAE PV.-SYRINGAE; CERULENIN-MEDIATED APOPTOSIS; HYPERSENSITIVE CELL-DEATH; III EFFECTOR PROTEINS; PSEUDOMONAS-SYRINGAE; 20S PROTEASOME; BACTERIAL VIRULENCE; INNATE IMMUNITY; POWDERY MILDEW; KEY ROLE	Pathogenic bacteria often use effector molecules to increase virulence. In most cases, the mode of action of effectors remains unknown. Strains of Pseudomonas syringae pv. syringae (Pss) secrete syringolin A (SylA), a product of a mixed non-ribosomal peptide/polyketide synthetase, in planta(1). Here we identify SylA as a virulence factor because a SylA-negative mutant in Pss strain B728a obtained by gene disruption was markedly less virulent on its host, Phaseolus vulgaris (bean). We show that SylA irreversibly inhibits all three catalytic activities of eukaryotic proteasomes, thus adding proteasome inhibition to the repertoire of modes of action of virulence factors. The crystal structure of the yeast proteasome in complex with SylA revealed a novel mechanism of covalent binding to the catalytic subunits. Thus, SylA defines a new class of proteasome inhibitors that includes glidobactin A (GlbA), a structurally related compound from an unknown species of the order Burkholderiales(2), for which we demonstrate a similar proteasome inhibition mechanism. As proteasome inhibitors are a promising class of anti-tumour agents, the discovery of a novel family of inhibitory natural products, which we refer to as syrbactins, may also have implications for the development of anti-cancer drugs(3). Homologues of SylA and GlbA synthetase genes are found in some other pathogenic bacteria, including the human pathogen Burkholderia pseudomallei, the causative agent of melioidosis(4). It is thus possible that these bacteria are capable of producing proteasome inhibitors of the syrbactin class.	[Schellenberg, Barbara; Dudler, Robert] Univ Zurich, Inst Plant Biol, Zurich Basel Plant Sci Ctr, CH-8008 Zurich, Switzerland; [Groll, Michael] Tech Univ Munich, Ctr Integrated Prot Sci, Dept Chem, Lehrstuhl Biochem, D-85747 Garching, Germany; [Bachmann, Andre S.; Archer, Crystal R.] Univ Hawaii Manoa, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA; [Bachmann, Andre S.; Archer, Crystal R.] Univ Hawaii Manoa, Cell & Mol Biol Grad Program, John A Burns Sch Med, Honolulu, HI 96813 USA; [Huber, Robert] Max Planck Inst Biochem, D-82152 Martinsried, Germany; [Huber, Robert] Cardiff Univ, Sch Biosci, Cardiff CF10 3US, Wales; [Huber, Robert] Univ Duisburg Essen, Zentrum Med Biotechnol, D-45117 Essen, Germany; [Powell, Tracy K.; Lindow, Steven] Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; [Kaiser, Markus] Max Planck Soc, Chem Genom Ctr, D-44227 Dortmund, Germany	University of Zurich; Technical University of Munich; Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; Max Planck Society; Cardiff University; University of Duisburg Essen; University of California System; University of California Berkeley; Max Planck Society	Dudler, R (corresponding author), Univ Zurich, Inst Plant Biol, Zurich Basel Plant Sci Ctr, Zollikerstr 107, CH-8008 Zurich, Switzerland.	abachmann@crch.hawaii.edu; markus.kaiser@cgc.mpg.de; rdudler@botinst.uzh.ch	Groll, Michael/F-5572-2015; Groll, Michael/C-1174-2010	Schellenberg, Barbara/0000-0002-4382-8065				Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Amrein H, 2004, MOL PLANT MICROBE IN, V17, P90, DOI 10.1094/MPMI.2004.17.1.90; Borissenko L, 2007, CHEM REV, V107, P687, DOI 10.1021/cr0502504; Brukhin V, 2005, PLANT CELL, V17, P2723, DOI 10.1105/tpc.105.034975; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coleman CS, 2006, CELL PROLIFERAT, V39, P599, DOI 10.1111/j.1365-2184.2006.00402.x; Colon-Carmona A, 1999, PLANT J, V20, P503, DOI 10.1046/j.1365-313x.1999.00620.x; Desveaux D, 2006, CURR OPIN PLANT BIOL, V9, P376, DOI 10.1016/j.pbi.2006.05.005; Doerner P, 1996, NATURE, V380, P520, DOI 10.1038/380520a0; Dong WB, 2006, PLANT CELL, V18, P3321, DOI 10.1105/tpc.106.046326; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Galan JE, 2006, NATURE, V444, P567, DOI 10.1038/nature05272; Geerts D, 2007, CLIN CANCER RES, V13, P6312, DOI 10.1158/1078-0432.CCR-07-0829; Goritschnig S, 2007, PLANT J, V49, P540, DOI 10.1111/j.1365-313X.2006.02978.x; Grant SR, 2006, ANNU REV MICROBIOL, V60, P425, DOI 10.1146/annurev.micro.60.080805.142251; Groll M, 2005, METHOD ENZYMOL, V398, P329, DOI 10.1016/S0076-6879(05)98027-0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heiligtag SJ, 2002, CELL DEATH DIFFER, V9, P1017, DOI 10.1038/sj.cdd.4401055; Hirano SS, 2000, MICROBIOL MOL BIOL R, V64, P624, DOI 10.1128/MMBR.64.3.624-653.2000; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Michel K, 2006, PLANT MOL BIOL, V62, P561, DOI 10.1007/s11103-006-9045-7; Nomura K, 2006, SCIENCE, V313, P220, DOI 10.1126/science.1129523; OKA M, 1988, J ANTIBIOT, V41, P1331, DOI 10.7164/antibiotics.41.1331; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Quinones B, 2005, MOL PLANT MICROBE IN, V18, P682, DOI 10.1094/MPMI-18-0682; RODRIGUESPOUSADA RA, 1993, PLANT CELL, V5, P897, DOI 10.1105/tpc.5.8.897; Rosebrock TR, 2007, NATURE, V448, P370, DOI 10.1038/nature05966; Schellenberg B, 2007, ENVIRON MICROBIOL, V9, P1640, DOI 10.1111/j.1462-2920.2007.01278.x; TURK D, 1992, THESIS TU MUNCHEN; Wallick CJ, 2005, ONCOGENE, V24, P5606, DOI 10.1038/sj.onc.1208808; Waspi U, 1998, MOL PLANT MICROBE IN, V11, P727, DOI 10.1094/MPMI.1998.11.8.727; Waspi U, 2001, PLANT CELL, V13, P153, DOI 10.1105/tpc.13.1.153	36	244	252	0	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2008	452	7188					755	U7		10.1038/nature06782	http://dx.doi.org/10.1038/nature06782			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401409				2022-12-28	WOS:000254792500046
J	Liu, HT; Lalanne, P				Liu, Haitao; Lalanne, Philippe			Microscopic theory of the extraordinary optical transmission	NATURE			English	Article							SUBWAVELENGTH HOLE ARRAYS; EVANESCENT-WAVE MODEL; SURFACE-PLASMONS; DIFFRACTION; RESONANCE; FIELD	The phenomenon of extraordinary light transmission through metallic films perforated by nanohole arrays at optical frequencies was first observed a decade ago(1) and initiated important further experimental and theoretical work. In view of potential applications of such structures-for example, subwavelength optics(2,3), optoelectronics devices(4,5), and chemical sensing(6) - it is important to understand the underlying physical processes in detail. Here we derive a microscopic theory of the transmission through subwavelength hole arrays, by considering the elementary processes associated with scattering of surface-plasmon-polariton (SPP) modes by individual one-dimensional chains of subwavelength holes. Using a SPP coupled-mode model that coherently gathers these elementary processes, we derive analytical expressions for all the transmission spectrum characteristics - such as the resonance wavelength, the peak transmission and the anti-resonance. Further comparisons of the model predictions with fully vectorial computational results allow us quantitatively to check the model accuracy and to discuss the respective impacts of SPP modes and of other electromagnetic fields on producing the extraordinary transmission of light. The model greatly expands our understanding of the phenomenon and may affect further engineering of nanoplasmonic devices.	[Liu, Haitao; Lalanne, Philippe] Univ Paris Sud, Lab Charles Fabry, Inst Opt, CNRS, F-91127 Palaiseau, France; [Liu, Haitao] Nankai Univ, Key Lab Optoelect Informat Sci & Technol, Minist Educ, Inst Modern Opt, Tianjin 300071, Peoples R China	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Nankai University	Lalanne, P (corresponding author), Univ Paris Sud, Lab Charles Fabry, Inst Opt, CNRS, Campus Polytech,RD 128, F-91127 Palaiseau, France.	philippe.lalanne@institutoptique.fr	Liu, Haitao/H-4142-2011; lalanne, philippe/AAE-4888-2020					Aigouy L, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.153902; Alkaisi MM, 1999, APPL PHYS LETT, V75, P3560, DOI 10.1063/1.125388; Barnes WL, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.107401; BOERSMA J, 1977, J MATH PHYS, V18, P321, DOI 10.1063/1.523268; Collin S, 2003, APPL PHYS LETT, V83, P1521, DOI 10.1063/1.1604942; de Abajo FJG, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.233901; Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570; Garcia-Vidal FJ, 2006, NAT PHYS, V2, P790, DOI 10.1038/nphys468a; Gay G, 2006, NAT PHYS, V2, P262, DOI 10.1038/nphys264; Genet C, 2007, NATURE, V445, P39, DOI 10.1038/nature05350; Genet C, 2005, J OPT SOC AM A, V22, P998, DOI 10.1364/JOSAA.22.000998; Lalanne P, 2006, NAT PHYS, V2, P551, DOI 10.1038/nphys364; Lalanne P, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.263902; Lalanne P, 2005, J OPT A-PURE APPL OP, V7, P422, DOI 10.1088/1464-4258/7/8/013; Lezec HJ, 2004, OPT EXPRESS, V12, P3629, DOI 10.1364/OPEX.12.003629; Liu C, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1895481; Luo XG, 2004, JPN J APPL PHYS 1, V43, P4017, DOI 10.1143/JJAP.43.4017; Martin-Moreno L, 2001, PHYS REV LETT, V86, P1114, DOI 10.1103/PhysRevLett.86.1114; PALIK ED, 1985, HDB OPTICAL CONSTAN; Pendry JB, 2004, SCIENCE, V305, P847, DOI 10.1126/science.1098999; Rivas JG, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.201306; Shou X, 2005, OPT EXPRESS, V13, P9834, DOI 10.1364/OPEX.13.009834; Silberstein E, 2001, J OPT SOC AM A, V18, P2865, DOI 10.1364/JOSAA.18.002865; SNYDER AW, 1983, OPTICAL WAVEGUIDE TH, P602; Ye YH, 2004, APPL PHYS LETT, V84, P2977, DOI 10.1063/1.1711166	25	572	593	7	373	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2008	452	7188					728	731		10.1038/nature06762	http://dx.doi.org/10.1038/nature06762			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401405				2022-12-28	WOS:000254792500040
J	Cheng, BQ; Jia, CQ; Liu, CT; Fan, W; Wang, QL; Zhang, ZL; Yi, CH				Cheng, Bao-Quan; Jia, Chong-Qi; Liu, Chun-Tao; Fan, Wei; Wang, Qing-Liang; Zhang, Zong-Li; Yi, Cui-Hua			RETRACTED: Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm - A randomized controlled trial (Retracted article. See vol. 301, pg. 1931, 2009)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Retracted Publication							ETHANOL INJECTION; THERMAL ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION; LIPIODOL CHEMOEMBOLIZATION; ARTERIAL EMBOLIZATION; CLIP SCORE; THERAPY; HCC; VALIDATION; MANAGEMENT	Context Transarterial chemoembolization ( TACE) combined with radiofrequency ablation ( RFA) therapy has been used for patients with large hepatocellular carcinoma tumors, but the survival benefits of combined treatment are not known. Objective To compare rates of survival of patients with large hepatocellular carcinoma tumors who received treatment with TACE combined with RFA therapy ( TACE- RFA), TACE alone, and RFA alone. Design, Setting, and Patients Randomized controlled trial conducted from January 2001 to May 2004 among 291 consecutive patients with hepatocellular carcinoma larger than 3 cm at a single center in China. Intervention Patients were randomly assigned to treatment with combined TACE- RFA ( n= 96), TACE alone ( n= 95), or RFA alone ( n= 100). Main Outcome Measures The primary end point was survival and the secondary end point was objective response rate. Results During a median 28.5 months of follow- up, median survival times were 24 months in the TACE group ( 3.4 courses), 22 months in the RFA group ( 3.6 courses), and 37 months in the TACE- RFA group ( 4.4 courses). Patients treated with TACE-RFA had better overall survival than those treated with TACE alone ( hazard ratio [ HR], 1.87; 95% confidence interval [ CI], 1.33- 2.63; P <. 001) or RFA ( HR, 1.88; 95% CI, 1.34- 2.65; P <. 001). In a preplanned substratification analysis, survival was also better in the TACE- RFA group than in the RFA group for patients with uninodular hepatocellular carcinoma ( HR, 2.50; 95% CI, 1.42- 4.42; P=. 001) and in the TACE- RFA group than the TACE group for patients with multinodular hepatocellular carcinoma ( HR, 1.99; 95% CI, 1.31- 3.00; P <. 001). The rate of objective response sustained for at least 6 months was higher in the TACE- RFA group ( 54%) than with either TACE ( 35%; rate difference, 0.19; 95% CI, 0.06- 0.33; P=. 009) or RFA ( 36%; rate difference, 0.18; 95% CI, 0.05- 0.32; P=. 01) treatment alone. Conclusion In this patient group, TACE- RFA was superior to TACE alone or RFA alone in improving survival for patients with hepatocellular carcinoma larger than 3 cm. Trial Registration clinicaltrials. gov Identifier: NCT00479050.	[Cheng, Bao-Quan; Liu, Chun-Tao; Fan, Wei] Shandong Univ, Qilu Hosp, Dept Gastroenterol, Sch Med, Jinan 250012, Peoples R China; [Wang, Qing-Liang] Qilu Hosp, Sch Med, Dept Radiol, Jinan 250012, Peoples R China; [Zhang, Zong-Li] Qilu Hosp, Sch Med, Dept Surg, Jinan 250012, Peoples R China; [Yi, Cui-Hua] Qilu Hosp, Sch Med, Dept Oncol, Jinan 250012, Peoples R China; [Jia, Chong-Qi] Shandong Univ, Dept Epidemiol & Hlth Stat, Jinan 250100, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University; Shandong University	Cheng, BQ (corresponding author), Shandong Univ, Qilu Hosp, Dept Gastroenterol, Sch Med, Jinan 250012, Peoples R China.	dcbq@sohu.com						Bloomston M, 2002, AM SURGEON, V68, P827; Bruix J, 1998, HEPATOLOGY, V27, P1578, DOI 10.1002/hep.510270617; Bruix J, 2004, GASTROENTEROLOGY, V127, pS179, DOI 10.1053/j.gastro.2004.09.032; Bruix J, 2003, HEPATOLOGY, V37, P507, DOI 10.1053/jhep.2003.50142; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Cai ZH, 2001, CHIN J ULTRASONOGR, V10, P408; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Head HW, 2004, GASTROENTEROLOGY, V127, pS167, DOI 10.1053/j.gastro.2004.09.031; HIGUCHI T, 1994, CANCER, V73, P2259, DOI 10.1002/1097-0142(19940501)73:9<2259::AID-CNCR2820730905>3.0.CO;2-P; KASUGAI H, 1989, GASTROENTEROLOGY, V97, P965, DOI 10.1016/0016-5085(89)91505-9; Kudo M, 2004, HEPATOLOGY, V40, P1396, DOI 10.1002/hep.20486; Lin SM, 2004, GASTROENTEROLOGY, V127, P1714, DOI 10.1053/j.gastro.2004.09.003; Livraghi T, 2000, RADIOLOGY, V214, P761, DOI 10.1148/radiology.214.3.r00mr02761; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; Lu DSK, 2005, HEPATOLOGY, V41, P1130, DOI 10.1002/hep.20688; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; OBERTI F, 1995, NEW ENGL J MED, V332, P1256; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; Omata M, 2004, GASTROENTEROLOGY, V127, pS159, DOI 10.1053/j.gastro.2004.09.030; Perrone F, 2000, HEPATOLOGY, V31, P840; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Rossi S, 2000, RADIOLOGY, V217, P119, DOI 10.1148/radiology.217.1.r00se02119; Rossi S, 1999, TUMORI, V85, P128; SAKURAI M, 1984, CANCER, V54, P387, DOI 10.1002/1097-0142(19840801)54:3<387::AID-CNCR2820540303>3.0.CO;2-W; Shiina S, 2005, GASTROENTEROLOGY, V129, P122, DOI 10.1053/j.gastro.2005.04.009; SORENSEN JB, 1993, BRIT J CANCER, V67, P773, DOI 10.1038/bjc.1993.140; Sturm JW, 2004, ONKOLOGIE, V27, P294, DOI 10.1159/000077982; Takayasu K, 2006, GASTROENTEROLOGY, V131, P461, DOI 10.1053/j.gastro.2006.05.021; Veltri A, 2006, EUR RADIOL, V16, P661, DOI 10.1007/s00330-005-0029-9; Yamakado K, 2004, ONCOL REP, V11, P105	33	143	161	0	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2008	299	14					1669	1677		10.1001/jama.299.14.1669	http://dx.doi.org/10.1001/jama.299.14.1669			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285AL	18398079	Bronze			2022-12-28	WOS:000254749600023
J	Chang, M; Lingner, J				Chang, Michael; Lingner, Joachim			Cell signaling - Tel2 finally tells one story	SCIENCE			English	Editorial Material							TELOMERE LENGTH REGULATION; SACCHAROMYCES-CEREVISIAE; ELEGANS; PROTEIN; GENE; CHECKPOINT; STABILITY		[Chang, Michael; Lingner, Joachim] Swiss Inst Expt Canc Res, Ecole Polytech Fed Lausanne, CH-1066 Epalinges, Switzerland; [Chang, Michael; Lingner, Joachim] Frontiers Genet Natl Ctr Competence Res, CH-1211 Geneva, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; University of Geneva	Chang, M (corresponding author), Swiss Inst Expt Canc Res, Ecole Polytech Fed Lausanne, CH-1066 Epalinges, Switzerland.	michael.chang@epfl.ch; joachim.lingner@epfl.ch	Chang, Michael/B-9279-2012	Chang, Michael/0000-0002-1706-3337; Lingner, Joachim/0000-0002-2853-5803				Ahmed S, 2001, CURR BIOL, V11, P1934, DOI 10.1016/S0960-9822(01)00604-2; ANDERSON CM, 2008, GENES DEV       0311; Benard C, 2001, DEVELOPMENT, V128, P4045; Collis SJ, 2007, NAT CELL BIOL, V9, P391, DOI 10.1038/ncb1555; Garcia-Muse T, 2005, EMBO J, V24, P4345, DOI 10.1038/sj.emboj.7600896; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hayashi T, 2007, GENES CELLS, V12, P1357, DOI 10.1111/j.1365-2443.2007.01141.x; Jiang N, 2003, J BIOL CHEM, V278, P21678, DOI 10.1074/jbc.M300286200; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; Runge KW, 1996, MOL CELL BIOL, V16, P3094; Takai H, 2007, CELL, V131, P1248, DOI 10.1016/j.cell.2007.10.052	11	7	8	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2008	320	5872					60	61		10.1126/science.1155132	http://dx.doi.org/10.1126/science.1155132			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388281				2022-12-28	WOS:000254633000026
J	Williams-Guillen, K; Perfecto, I; Vandermeer, J				Williams-Guillen, Kimberly; Perfecto, Ivette; Vandermeer, John			Bats limit insects in a neotropical agroforestry system	SCIENCE			English	Article							BIRDS		[Williams-Guillen, Kimberly; Perfecto, Ivette; Vandermeer, John] Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA; [Vandermeer, John] Univ Michigan, Dept Ecol & Evolut Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Williams-Guillen, K (corresponding author), Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA.	kimwg@umich.edu						Ceballos G., 2010, ISSUES ECOL, V8, P1821; Cleveland CJ, 2006, FRONT ECOL ENVIRON, V4, P238, DOI 10.1890/1540-9295(2006)004[0238:EVOTPC]2.0.CO;2; GRAHAM GL, 1990, J BIOGEOGR, V17, P657, DOI 10.2307/2845147; GREENBERG R, 1995, J AVIAN BIOL, V26, P260, DOI 10.2307/3677328; Hutson A, 2001, MICROCHIROPTERAN BAT; Schmitz OJ, 2000, AM NAT, V155, P141, DOI 10.1086/303311; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300	7	167	182	2	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					70	70		10.1126/science.1152944	http://dx.doi.org/10.1126/science.1152944			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388285				2022-12-28	WOS:000254633000030
J	Kastelein, JJP; Akdim, F; Stroes, ESG; Zwinderman, AH; Bots, ML; Stalenhoef, AFH; Visseren, FLJ; Sijbrands, EJG; Trip, MD; Stein, EA; Gaudet, D; Duivenvoorden, R; Veltri, EP; Marais, AD; de Groot, E				Kastelein, John J. P.; Akdim, Fatima; Stroes, Erik S. G.; Zwinderman, Aeilko H.; Bots, Michiel L.; Stalenhoef, Anton F. H.; Visseren, Frank L. J.; Sijbrands, Eric J. G.; Trip, Mieke D.; Stein, Evan A.; Gaudet, Daniel; Duivenvoorden, Raphael; Veltri, Enrico P.; Marais, A. David; de Groot, Eric		ENHANCE Investigators	Simvastatin with or without ezetimibe in familial hypercholesterolemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTIMA-MEDIA THICKNESS; ARTERIAL-WALL THICKNESS; HIGH-DOSE ATORVASTATIN; ATHEROSCLEROSIS PROGRESSION; CAROTID ATHEROSCLEROSIS; ENDOTHELIAL FUNCTION; DOUBLE-BLIND; MYOCARDIAL-INFARCTION; REDUCING CHOLESTEROL; SECONDARY PREVENTION	Background: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. Methods: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. Results: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. Conclusions: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097.).	[Kastelein, John J. P.; Akdim, Fatima; Stroes, Erik S. G.; Zwinderman, Aeilko H.; Trip, Mieke D.; Duivenvoorden, Raphael; de Groot, Eric] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands; [Bots, Michiel L.; Visseren, Frank L. J.] Univ Med Ctr, Utrecht, Netherlands; [Stalenhoef, Anton F. H.] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands; [Sijbrands, Eric J. G.] Erasmus Sch Ctr, Rotterdam, Netherlands; [Stein, Evan A.] Metab & Atherosclerosis Res Ctr, Cincinnati, OH USA; [Gaudet, Daniel] Hop Laval, Res Ctr, Quebec Heart Inst, Quebec City, PQ, Canada; [Veltri, Enrico P.] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA; [Marais, A. David] Cape Heart Ctr, Cape Town, South Africa	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; Erasmus University Rotterdam; Laval University; Merck & Company; Schering Plough Corporation	Kastelein, JJP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9,POB 22660, NL-1100 DD Amsterdam, Netherlands.	j.j.kastelein@amc.uva.nl	Stalenhoef, A.F.H./H-8094-2014; Visseren, Frank LJ/I-4855-2013; Kastelein, John/AAF-7950-2020; Duivenvoorden, Raphaël/B-5154-2019; Sijbrands, Eric/A-1065-2009	Duivenvoorden, Raphaël/0000-0003-1446-8336; Sijbrands, Eric/0000-0001-8857-7389; Visseren, Frank/0000-0003-3951-5223				Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Amarenco P, 2004, STROKE, V35, P2902, DOI 10.1161/01.STR.0000147965.52712.fa; Armitage J, 2007, LANCET, V370, P1781, DOI 10.1016/S0140-6736(07)60716-8; Ballantyne CM, 2003, CIRCULATION, V107, P2409, DOI 10.1161/01.CIR.0000068312.21969.C8; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; Buchwald H, 1998, ARCH INTERN MED, V158, P1253, DOI 10.1001/archinte.158.11.1253; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; Bulut D, 2005, CARDIOLOGY, V104, P176, DOI 10.1159/000088105; Cannon CP, 2006, NEW ENGL J MED, V354, P778; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Crouse JR, 2004, CARDIOVASC DRUG THER, V18, P231, DOI 10.1023/B:CARD.0000033645.55138.3d; Davidson MH, 2002, J AM COLL CARDIOL, V40, P2125, DOI 10.1016/S0735-1097(02)02610-4; Davis HR, 2007, ARTERIOSCL THROM VAS, V27, P841, DOI 10.1161/01.ATV.0000257627.40486.46; de Groot E, 2004, CIRCULATION, V109, P33, DOI 10.1161/01.CIR.0000131516.65699.ba; de Groot E, 1998, J AM COLL CARDIOL, V31, P1561, DOI 10.1016/S0735-1097(98)00170-3; Espeland MA, 1999, ANN EPIDEMIOL, V9, P196, DOI 10.1016/S1047-2797(98)00069-6; Fichtlscherer S, 2006, EUR HEART J, V27, P1182, DOI 10.1093/eurheartj/ehi881; Hedblad B, 2001, CIRCULATION, V103, P1721, DOI 10.1161/01.CIR.103.13.1721; Hodis HN, 1996, ANN INTERN MED, V124, P548, DOI 10.7326/0003-4819-124-6-199603150-00002; HOWARD G, 1993, STROKE, V24, P1297, DOI 10.1161/01.STR.24.9.1297; Kastelein JJP, 2007, NEW ENGL J MED, V356, P1620, DOI 10.1056/NEJMoa071359; Kastelein JP, 2005, AM HEART J, V149, P234, DOI 10.1016/j.ahj.2004.06.024; Landmesser U, 2005, CIRCULATION, V111, P2356, DOI 10.1161/01.CIR.0000164260.82417.3F; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; MacMahon S, 1998, CIRCULATION, V97, P1784, DOI 10.1161/01.CIR.97.18.1784; MacMahon S, 1998, CIRCULATION, V97, P2479; Pedersen TR, 2005, JAMA-J AM MED ASSOC, V294, P2437, DOI 10.1001/jama.294.19.2437; PEDERSEN TR, 2005, JAMA-J AM MED ASSOC, V294, P3092; Rader DJ, 2003, J CLIN INVEST, V111, P1795, DOI 10.1172/JCI200318925; Robinson JG, 2005, J AM COLL CARDIOL, V46, P1855, DOI 10.1016/j.jacc.2005.05.085; Schonbeck U, 2004, CIRCULATION, V109, P18, DOI 10.1161/01.CIR.0000129505.34151.23; Smilde TJ, 2001, LANCET, V357, P577, DOI 10.1016/S0140-6736(00)04053-8; Taylor AJ, 2005, CIRCULATION, V111, P1727; Taylor AJ, 2002, CIRCULATION, V106, P2055, DOI 10.1161/01.CIR.0000034508.55617.65; Taylor AJ, 2004, CIRCULATION, V110, P3512, DOI 10.1161/01.CIR.0000148955.19792.8D; van Wissen S, 2005, AM J CARDIOL, V95, P264, DOI 10.1016/j.amjcard.2004.09.015; WHO, 1998, FAM HYP FH REP WHO C; Wiegman A, 2004, LANCET, V363, P369, DOI 10.1016/S0140-6736(04)15467-6	38	962	1018	1	85	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1431	1443		10.1056/NEJMoa0800742	http://dx.doi.org/10.1056/NEJMoa0800742			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282CY	18376000				2022-12-28	WOS:000254546400004
J	Nissen, SE; Nicholls, SJ; Wolski, K; Rodes-Cabau, J; Cannon, CP; Deanfield, JE; Despres, JP; Kastelein, JJP; Steinhubl, SR; Kapadia, S; Yasin, M; Ruzyllo, W; Gaudin, C; Job, B; Hu, B; Bhatt, DL; Lincoff, AM; Tuzcu, EM				Nissen, Steven E.; Nicholls, Stephen J.; Wolski, Kathy; Rodes-Cabau, Josep; Cannon, Christopher P.; Deanfield, John E.; Despres, Jean-Pierre; Kastelein, John J. P.; Steinhubl, Steven R.; Kapadia, Samir; Yasin, Muhammad; Ruzyllo, Witold; Gaudin, Christophe; Job, Bernard; Hu, Bo; Bhatt, Deepak L.; Lincoff, A. Michael; Tuzcu, E. Murat		STRADIVARIUS Investigators	Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease - The STRADIVARIUS randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	57th Annual Scientific Session of the American-College-of-Cardiology	MAR 29-APR 01, 2008	Chicago, IL	Amer Coll Cardiol			CANNABINOID-1 RECEPTOR BLOCKER; INTRAVASCULAR ULTRASOUND; CARDIOVASCULAR-DISEASE; RISK-FACTORS; OVERWEIGHT PATIENTS; STATIN THERAPY; HEART-DISEASE; UNITED-STATES; WEIGHT; PARTICIPANTS	Context Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease. Objective To determine whether weight loss and metabolic effects of the selective cannabinoid type 1 receptor antagonist rimonabant reduces progression of coronary disease in patients with abdominal obesity and the metabolic syndrome. Design, Setting, and Patients Randomized, double- blinded, placebo- controlled, 2- group, parallel- group trial ( enrollment December 2004- December 2005) comparing rimonabant with placebo in 839 patients at 112 centers in North America, Europe, and Australia. Interventions Patients received dietary counseling, were randomized to receive rimonabant ( 20 mg daily) or matching placebo, and underwent coronary intravascular ultrasonography at baseline ( n= 839) and study completion ( n= 676). Main Outcome Measures The primary efficacy parameter was change in percent atheroma volume ( PAV); the secondary efficacy parameter was change in normalized total atheroma volume ( TAV). Results In the rimonabant vs placebo groups, PAV ( 95% confidence interval [ CI]) increased 0.25% (- 0.04% to 0.54%) vs 0.51% ( 0.22% to 0.80%) ( P=. 22), respectively, and TAV decreased 2.2 mm(3) (- 4.09 to - 0.24) vs an increase of 0.88 mm(3) (- 1.03 to 2.79) ( P=. 03). In the rimonabant vs placebo groups, imputingresultsbasedonbaselinecharacteristics for patients not completing the trial, PAV increased 0.25% (- 0.04% to 0.55%) vs 0.57% ( 0.29% to 0.84%) ( P=. 13), and TAV decreased 1.95 mm(3) (- 3.8 to - 0.10) vs an increase of 1.19 mm(3) (- 0.73 to 3.12) ( P=. 02). Rimonabant- treated patients had a larger reduction in body weight ( 4.3 kg [- 5.1 to - 3.5] vs 0.5 kg [- 1.3 to 0.3]) and greater decrease in waist circumference ( 4.5 cm [- 5.4 to - 3.7] vs 1.0 cm [- 1.9 to - 0.2]) ( P <. 001 for both comparisons). In the rimonabant vs placebo groups, high- density lipoprotein cholesterol levels increased 5.8 mg/dL( 4.9 to 6.8) ( 22.4%) vs 1.8 mg/ dL( 0.9 to 2.7) ( 6.9%) ( P <. 001), and median triglyceride levels decreased 24.8mg/ dL(- 35.4 to - 17.3) ( 20.5%) vs 8.9 mg/ dL (- 14.2 to - 1.8) ( 6.2%) ( P <. 001). Rimonabant- treated patients had greater decreases in high- sensitivity C- reactive protein ( 1.3 mg/ dL[- 1.7 to - 1.2] [ 50.3%] vs 0.9 mg/ dL[- 1.4 to - 0.5][ 30.9%]) and less increase in glycated hemoglobin levels( 0.11%[ 0.02% to 0.20%] vs 0.40% [ 0.31% to 0.49%]) ( P <. 001 for both comparisons). Psychiatric adverse effects were more common in the rimonabant group ( 43.4% vs 28.4%, P <. 001). Conclusions After 18 months of treatment, the study failed to show an effect for rimonabant on disease progression for the primary end point ( PAV) but showed a favorable effect on the secondary end point ( TAV). Determining whether rimonabant is useful in management of coronary disease will require additional imaging and outcomes trials, which are currently under way. Trial Registration clinicaltrials. gov Identifier: NCT00124332.	[Nissen, Steven E.; Nicholls, Stephen J.; Wolski, Kathy; Kapadia, Samir; Bhatt, Deepak L.; Lincoff, A. Michael; Tuzcu, E. Murat] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA; [Nissen, Steven E.; Nicholls, Stephen J.; Wolski, Kathy; Kapadia, Samir; Bhatt, Deepak L.; Lincoff, A. Michael; Tuzcu, E. Murat] Cleveland Clin, Lerner Sch Med, Cleveland, OH 44106 USA; [Hu, Bo] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Rodes-Cabau, Josep; Despres, Jean-Pierre] Laval Hosp, Quebec City, PQ, Canada; [Rodes-Cabau, Josep; Despres, Jean-Pierre] Quebec Heart Inst, Quebec City, PQ, Canada; [Cannon, Christopher P.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, Boston, MA 02115 USA; [Cannon, Christopher P.] Harvard Univ, Sch Med, Boston, MA USA; [Deanfield, John E.] UCL, London, England; [Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Steinhubl, Steven R.] Univ Kentucky, Lexington, KY USA; [Yasin, Muhammad] SW Cardiol, Oklahoma City, OK USA; [Ruzyllo, Witold] Inst Kardiol Klin Warsaw 1, Warsaw, Poland; [Gaudin, Christophe; Job, Bernard] Sanofi Aventis, Paris, France	Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of London; University College London; University of Amsterdam; Academic Medical Center Amsterdam; University of Kentucky; Sanofi-Aventis	Nissen, SE (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	nissens@ccf.org	Colquhoun, David M/F-9078-2013; Cannon, Christopher P/AAY-7644-2020; Marroquin, Oscar C/F-2214-2015; Deanfield, John E/C-5178-2008; Kastelein, John/AAF-7950-2020	Cannon, Christopher P/0000-0003-4596-2791; Marroquin, Oscar C/0000-0002-0909-0319; Nicholls, Stephen/0000-0002-9668-4368; TEIGER, emmanuel/0000-0001-7515-4344; Deanfield, John/0000-0001-8806-6052				Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Balkau B, 2007, CIRCULATION, V116, P1942, DOI 10.1161/CIRCULATIONAHA.106.676379; *CDCP, NEW CDC STUD FINDS N; Christensen R, 2007, LANCET, V370, P1706, DOI 10.1016/S0140-6736(07)61721-8; Cota D, 2007, DIABETES-METAB RES, V23, P507, DOI 10.1002/dmrr.764; Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Eriksson KF, 1998, DIABETOLOGIA, V41, P1010, DOI 10.1007/s001250051024; Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001; Grundy SM, 2002, AM J CARDIOL, V90, p11I; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Kim KS, 2000, ANN EPIDEMIOL, V10, P424, DOI 10.1016/S1047-2797(00)00065-X; Klein S, 2004, CIRCULATION, V110, P2952, DOI 10.1161/01.CIR.0000145546.97738.1E; Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5; Nicholls SJ, 2006, NAT REV DRUG DISCOV, V5, P485, DOI 10.1038/nrd2040; Nissen SE, 2007, NEW ENGL J MED, V357, P835; Nissen SE, 2006, NEW ENGL J MED, V355, P638; Nissen SE, 2006, NEW ENGL J MED, V354, P1253, DOI 10.1056/NEJMoa054699; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Nissen SE, 2004, JAMA-J AM MED ASSOC, V292, P2217, DOI 10.1001/jama.292.18.2217; Nissen SE, 2006, JAMA-J AM MED ASSOC, V295, P1556, DOI 10.1001/jama.295.13.jpc60002; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Nissen SE, 2007, NEW ENGL J MED, V356, P1304, DOI 10.1056/NEJMoa070635; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Onyike CU, 2003, AM J EPIDEMIOL, V158, P1139, DOI 10.1093/aje/kwg275; Pi-Sunyer F, 2006, JAMA-J AM MED ASSOC, V295, P761, DOI 10.1001/jama.295.7.761; PISUNYER FX, 2006, JAMA-J AM MED ASSOC, V295, P1252; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; SAUL S, 2007, NY TIMES        0614; Scheen AJ, 2006, LANCET, V368, P1650; Scheen AJ, 2006, LANCET, V368, P1660, DOI 10.1016/S0140-6736(06)69571-8; Schoenhagen P, 2003, J AM SOC ECHOCARDIOG, V16, P277, DOI 10.1067/mje.2003.45; Van Gaal LF, 2005, LANCET, V366, P370; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; Wadden TA, 1999, OBES RES, V7, P170, DOI 10.1002/j.1550-8528.1999.tb00699.x; Yach D, 2006, NAT MED, V12, P367, DOI 10.1038/nm0306-367a; Yach D, 2006, NAT MED, V12, P62, DOI 10.1038/nm0106-62; Yusuf S, 2005, LANCET, V366, P1640, DOI 10.1016/S0140-6736(05)67663-5	39	332	345	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2008	299	13					1547	1560		10.1001/jama.299.13.1547	http://dx.doi.org/10.1001/jama.299.13.1547			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	281RZ	18387931	Bronze			2022-12-28	WOS:000254517900022
J	Platt, OS				Platt, Orah S.			Hydroxyurea for the treatment of sickle cell anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL-HEMOGLOBIN PRODUCTION; CHILDREN; DISEASE; THERAPY; DETERMINANTS; PREVENTION; STROKE; RATES		[Platt, Orah S.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Platt, OS (corresponding author), Childrens Hosp, Dept Lab Med, 300 Longwood Ave, Boston, MA 02115 USA.	orah.platt@childrens.harvard.edu						Ballas SK, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-59; Ballas SK, 1999, BRIT J HAEMATOL, V105, P491, DOI 10.1111/j.1365-2141.1999.01339.x; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Cokic VP, 2003, J CLIN INVEST, V111, P231, DOI 10.1172/JCI200316672; de Montalembert M, 2006, HAEMATOLOGICA, V91, P1685; *DIV BLOOD DIS RES, 2002, NIH PUBL NAT HEART L; Finazzi G, 2005, BLOOD, V105, P2664, DOI 10.1182/blood-2004-09-3426; Franco RS, 2006, BLOOD, V108, P1073, DOI 10.1182/blood-2005-09-008318; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Hankins JS, 2005, BLOOD, V106, P2269, DOI 10.1182/Blood-2004-12-4973; Kinney TR, 1999, BLOOD, V94, P1550; Lanzkron S, 2006, AM J HEMATOL, V81, P927, DOI 10.1002/ajh.20703; LETVIN NL, 1984, NEW ENGL J MED, V310, P869, DOI 10.1056/NEJM198404053101401; Lorey FW, 1996, GENET EPIDEMIOL, V13, P501, DOI 10.1002/(SICI)1098-2272(1996)13:5<501::AID-GEPI6>3.0.CO;2-4; Ma Q, 2007, PHARMACOGENOMICS J, V7, P386, DOI 10.1038/sj.tpj.6500433; Moore RD, 2000, AM J HEMATOL, V64, P26, DOI 10.1002/(SICI)1096-8652(200005)64:1<26::AID-AJH5>3.3.CO;2-6; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Schechter AN, 2003, NEW ENGL J MED, V348, P1483, DOI 10.1056/NEJMcibr023045; SHELBY MD, 2007, NTP CERHR EXPERT PAN; Stamatoyannopoulos G, 2005, EXP HEMATOL, V33, P259, DOI 10.1016/j.exphem.2004.11.007; Steinberg MH, 1997, BLOOD, V89, P1078, DOI 10.1182/blood.V89.3.1078; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V290, P756; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001/jama.289.13.1645; STEINER CA, 2006, 21 AG HEALTHC RES QU; Wang WC, 2002, J PEDIATR-US, V140, P225, DOI 10.1067/mpd.2002.121383; Ware RE, 2004, J PEDIATR-US, V145, P346, DOI 10.1016/j.jpeds.2004.04.058; Ware RE, 1999, BLOOD, V94, P3022, DOI 10.1182/blood.V94.9.3022.421k17_3022_3026; Yan FH, 2005, J CLIN PHARMACOL, V45, P434, DOI 10.1177/0091270004273526; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; Zimmerman SA, 2007, BLOOD, V110, P1043, DOI 10.1182/blood-2006-11-057893; Zumberg MS, 2005, AM J HEMATOL, V79, P107, DOI 10.1002/ajh.20353	34	247	256	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1362	1369		10.1056/NEJMct0708272	http://dx.doi.org/10.1056/NEJMct0708272			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367739				2022-12-28	WOS:000254308400007
J	Yamada, T				Yamada, Tadataka			In search of new ideas for global health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Bill & Melinda Gates Fdn, Global Hlth Program, Seattle, WA 98102 USA	Bill & Melinda Gates Foundation	Yamada, T (corresponding author), Bill & Melinda Gates Fdn, Global Hlth Program, Seattle, WA 98102 USA.								0	12	12	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1324	1325		10.1056/NEJMp0801848	http://dx.doi.org/10.1056/NEJMp0801848			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	278TE	18367734	Bronze			2022-12-28	WOS:000254308400002
J	Gullerova, M; Proudfoot, NJ				Gullerova, Monika; Proudfoot, Nick J.			Cohesin complex promotes transcriptional termination between convergent genes in S. pombe	CELL			English	Article							CELL-CYCLE CONTROL; RNA-POLYMERASE-II; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; SMC PROTEINS; HETEROCHROMATIN; INTERFERENCE; CHROMOSOMES; SITES	Transcription analyses reported in these studies reveal that convergent genes in S. pombe generate overlapping transcripts in the G1 phase of the cell cycle. We show that this double-strand (ds) RNA induces localized RNAi (Dicer and RITS) dependent transient heterochromatin structures including histone H3 lysine 9 trimethylation marks and Swi6 association. Consequently cohesin is recruited to these chromosomal positions through interaction with Swi6. In G2, localized cohesin is further concentrated into the intergenic regions of the convergent genes tested. This results in a block to further dsRNA formation by promoting gene-proximal transcription termination between the convergent genes. Cohesin release at mitosis leads to a new G1 phase with repeated dsRNA formation, transient heterochromatin, and cohesin recruitment. Our results uncover a hitherto unanticipated role for cohesin and further suggest a widespread role for the selective formation of dsRNA, heterochromatin, and subsequent cohesin recruitment in regulated transcriptional termination.	[Gullerova, Monika; Proudfoot, Nick J.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Proudfoot, NJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	nicholas.proudfoot@path.ox.ac.uk		Gullerova, Monika/0000-0002-4512-2779; Proudfoot, Nicholas/0000-0001-8646-3222	MRC [G9826944] Funding Source: UKRI; Medical Research Council [G9826944] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Aranda A, 1999, MOL CELL BIOL, V19, P1251; Bahler J, 2005, ANNU REV GENET, V39, P69, DOI 10.1146/annurev.genet.39.110304.095808; Bernard P, 2008, EMBO J, V27, P111, DOI 10.1038/sj.emboj.7601955; Birse CE, 1997, EMBO J, V16, P3633, DOI 10.1093/emboj/16.12.3633; Camblong J, 2007, CELL, V131, P706, DOI 10.1016/j.cell.2007.09.014; Chen ES, 2008, NATURE, V451, P734, DOI 10.1038/nature06561; Chen SX, 1996, NUCLEIC ACIDS RES, V24, P2885, DOI 10.1093/nar/24.15.2885; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; Glynn EF, 2004, PLOS BIOL, V2, P1325, DOI 10.1371/journal.pbio.0020259; Greger IH, 2000, P NATL ACAD SCI USA, V97, P8415, DOI 10.1073/pnas.140217697; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hansen K, 1998, EMBO J, V17, P3066, DOI 10.1093/emboj/17.11.3066; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Herr AJ, 2005, SCIENCE, V308, P118, DOI 10.1126/science.1106910; Hirano T, 2006, NAT REV MOL CELL BIO, V7, P311, DOI 10.1038/nrm1909; Hongay CF, 2006, CELL, V127, P735, DOI 10.1016/j.cell.2006.09.038; Lengronne A, 2004, NATURE, V430, P573, DOI 10.1038/nature02742; Martin AM, 2004, GENETICS, V167, P1123, DOI 10.1534/genetics.104.026674; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Prescott EM, 2002, P NATL ACAD SCI USA, V99, P8796, DOI 10.1073/pnas.132270899; PROUDFOOD N, 2002, CELL, V131, P649; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Shearwin KE, 2005, TRENDS GENET, V21, P339, DOI 10.1016/j.tig.2005.04.009; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Verdel A, 2005, FEBS LETT, V579, P5872, DOI 10.1016/j.febslet.2005.08.083; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	31	152	158	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2008	132	6					983	995		10.1016/j.cell.2008.02.040	http://dx.doi.org/10.1016/j.cell.2008.02.040			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358811	Bronze			2022-12-28	WOS:000254273600017
J	Capitanio, JP; Emborg, ME				Capitanio, John P.; Emborg, Marina E.			Contributions of non-human primates to neuroscience research	LANCET			English	Review							SIMIAN IMMUNODEFICIENCY VIRUS; NERVE GROWTH-FACTOR; MPTP-TREATED MONKEYS; CHOLINERGIC NEURONAL DEGENERATION; JUVENILE RHESUS-MONKEYS; PRENATAL STRESS DIMINISHES; TRANSPORTER GENE VARIATION; ACUTE SIV INFECTION; STEM-CELLS FUNCTION; PARKINSONS-DISEASE	Non-human primates have a small but important role in basic and translational biomedical research, owing to similarities with human beings in physiology, cognitive capabilities, neuroanatomy, social complexity, reproduction, and development. Although non-human primates have contributed to many areas of biomedical research, we review here their unique contributions to work in neuroscience, and focus on four domains: Alzheimer's disease, neuroAIDS, Parkinson's disease, and stress. Our discussion includes, for example, the role of non-human primates in development of new treatments (eg, stem cells, gene transfer) before phase I clinical trials in patients; basic research on disease pathogenesis; and understanding neurobehavioural outcomes resulting from genotype-environment interactions.	[Capitanio, John P.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; [Capitanio, John P.] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA; [Emborg, Marina E.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI USA; [Emborg, Marina E.] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Capitanio, JP (corresponding author), Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA.	jpcapitanio@ucdavis.edu			NCRR NIH HHS [RR000167, RR000169] Funding Source: Medline; NIMH NIH HHS [MH49033] Funding Source: Medline; NINDS NIH HHS [NS40578] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000167, P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040578] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akwa Y, 2005, ALZ DIS ASSOC DIS, V19, P226, DOI 10.1097/01.wad.0000189053.25817.d6; Albert MS, 2002, ANN NEUROL, V51, P282, DOI 10.1002/ana.10156; Allam MF, 2005, NEUROL RES, V27, P206, DOI 10.1179/016164105X22057; Almirall H, 1999, J NEURAL TRANSM, V106, P1125, DOI 10.1007/s007020050228; *AV, 2005, AV ANN ENC EARL DAT; Babas T, 2003, J VIROL, V77, P208, DOI 10.1128/JVI.77.1.208-216.2003; Bailey MT, 2004, J PEDIATR GASTR NUTR, V38, P414, DOI 10.1097/00005176-200404000-00009; Bankiewicz KS, 2000, EXP NEUROL, V164, P2, DOI 10.1006/exnr.2000.7408; Barcia C, 2003, NEUROENDOCRINOLOGY, V78, P118, DOI 10.1159/000071967; Barker DJP, 2002, TRENDS ENDOCRIN MET, V13, P364, DOI 10.1016/S1043-2760(02)00689-6; Barnes CA, 1999, NEUROBIOL AGING, V20, P349; Baron MS, 2002, J NEUROSCI, V22, P592, DOI 10.1523/JNEUROSCI.22-02-00592.2002; Barr CS, 2004, ARCH GEN PSYCHIAT, V61, P1146, DOI 10.1001/archpsyc.61.11.1146; Barr CS, 2004, BIOL PSYCHIAT, V55, P733, DOI 10.1016/j.biopsych.2003.12.008; Barry PA, 2006, ILAR J, V47, P49, DOI 10.1093/ilar.47.1.49; Baughman RW, 2006, J NEUROSCI, V26, P10329, DOI 10.1523/JNEUROSCI.3979-06.2006; Bennett AJ, 2002, MOL PSYCHIATR, V7, P118, DOI 10.1038/sj/mp/4000949; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Bezard E, 2001, NAT REV NEUROSCI, V2, P577, DOI 10.1038/35086062; *BIRN, NONH PRIM BIRN; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Bjugstad KB, 2005, CELL TRANSPLANT, V14, P183, DOI 10.3727/000000005783983098; BLUM D, 2002, LOVE GOON PARK; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Capitanio J.P., 1986, P411; Capitanio JP, 2008, BRAIN BEHAV IMMUN, V22, P676, DOI 10.1016/j.bbi.2007.05.006; Capitanio JP, 1998, PSYCHOSOM MED, V60, P235, DOI 10.1097/00006842-199805000-00001; Capitanio JP, 2004, PSYCHONEUROENDOCRINO, V29, P1300, DOI 10.1016/j.psyneuen.2004.04.001; Carlsson HE, 2004, AM J PRIMATOL, V63, P225, DOI 10.1002/ajp.20054; CCARBONCORRELL M, 2004, 18 ANN S ET PATH TRE; *CER, CER REP IN PHAS 1 CL; Champoux M, 2002, MOL PSYCHIATR, V7, P1058, DOI 10.1038/sj.mp.4001157; Cinque P, 2005, J NEUROVIROL, V11, P1, DOI 10.1080/13550280600558923; CLARKE AS, 1994, DEV PSYCHOBIOL, V27, P257, DOI 10.1002/dev.420270502; Coe CL, 2003, BIOL PSYCHIAT, V54, P1025, DOI 10.1016/S0006-3223(03)00698-X; Coe CL, 2002, J CLIN ENDOCR METAB, V87, P675, DOI 10.1210/jc.87.2.675; Coe CL, 1996, BRAIN BEHAV IMMUN, V10, P221, DOI 10.1006/brbi.1996.0020; Collier TJ, 2005, EXP NEUROL, V191, pS60, DOI 10.1016/j.expneurol.2004.08.018; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Czub S, 2004, ACTA NEUROPATHOL, V107, P216, DOI 10.1007/s00401-003-0801-3; DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Demuth M, 2000, J NEUROVIROL, V6, P187, DOI 10.3109/13550280009015822; Emborg ME, 2004, J NEUROSCI METH, V139, P121, DOI 10.1016/j.jneumeth.2004.08.004; Emborg ME, 1998, J COMP NEUROL, V401, P253; Eslamboli A, 2003, EXP NEUROL, V184, P536, DOI 10.1016/j.expneurol.2003.08.007; Fahlke C, 2000, ALCOHOL CLIN EXP RES, V24, P644, DOI 10.1111/j.1530-0277.2000.tb02035.x; Fox HS, 2000, J CLIN INVEST, V106, P37, DOI 10.1172/JCI9102; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Fukuda S, 2003, ILAR J, V44, P96, DOI 10.1093/ilar.44.2.96; Fuller RA, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-10; Gaskill PJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-44; Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5; Geinisman Y, 1999, NEUROBIOL AGING, V20, P353; Goetzel RZ, 1998, J OCCUP ENVIRON MED, V40, P843, DOI 10.1097/00043764-199810000-00003; Goldstein DS, 2003, J PHARMACOL EXP THER, V306, P855, DOI 10.1124/jpet.103.051714; Gonzalez RG, 2000, AIDS, V14, P2841, DOI 10.1097/00002030-200012220-00005; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Graziano MSA, 2002, NEURON, V36, P349, DOI 10.1016/S0896-6273(02)01003-6; Greco JB, 2004, MAGN RESON MED, V51, P1108, DOI 10.1002/mrm.20073; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Higley J D, 1997, Recent Dev Alcohol, V13, P191; Hill RS, 2005, NATURE, V437, P64, DOI 10.1038/nature04103; Inder T, 2004, SEMIN PERINATOL, V28, P396, DOI 10.1053/j.semperi.2004.10.002; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Jahng JW, 1997, SYNAPSE, V25, P30; Jenner P, 2003, NEUROLOGY, V61, pS4, DOI 10.1212/WNL.61.6_suppl_3.S4; Jenner P, 2003, PARKINSONISM RELAT D, V9, P131, DOI 10.1016/S1353-8020(02)00115-3; Kalin NH, 2000, BIOL PSYCHIAT, V47, P579, DOI 10.1016/S0006-3223(99)00256-5; Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9; Kapoor A, 2006, J PHYSIOL-LONDON, V572, P31, DOI 10.1113/jphysiol.2006.105254; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Kishima H, 2004, NEUROBIOL DIS, V16, P428, DOI 10.1016/j.nbd.2004.03.012; Kluver H, 1997, J NEUROPSYCH CLIN N, V9, P606; Kordower JH, 2006, ANN NEUROL, V60, P706, DOI 10.1002/ana.21032; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; KORDOWER JH, 1990, J COMP NEUROL, V298, P443, DOI 10.1002/cne.902980406; KORELL M, 2005, PARKINSONS DIS, P39; Koutsilieri E, 1997, NEUROREPORT, V8, P3833, DOI 10.1097/00001756-199712010-00034; Lacreuse A, 2006, NEUROSCIENCE, V138, P859, DOI 10.1016/j.neuroscience.2005.09.006; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, BRAIN RES, V292, P390; Lapchak PA, 1997, EXP NEUROL, V145, P309, DOI 10.1006/exnr.1997.6501; Lemere CA, 2006, REJUV RES, V9, P77, DOI 10.1089/rej.2006.9.77; Lemere CA, 2004, AM J PATHOL, V165, P283, DOI 10.1016/S0002-9440(10)63296-8; Liang GS, 2006, STEREOT FUNCT NEUROS, V84, P221, DOI 10.1159/000096495; Loveman E, 2006, HEALTH TECHNOL ASSES, V10, pIII; Luo J, 2002, SCIENCE, V298, P425, DOI 10.1126/science.1074549; Mandel RJ, 1999, EXP NEUROL, V155, P59, DOI 10.1006/exnr.1998.6961; Maninger N, 2003, AM J PRIMATOL, V61, P73, DOI 10.1002/ajp.10111; Mankowski JL, 1997, J VIROL, V71, P6055, DOI 10.1128/JVI.71.8.6055-6060.1997; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; Masliah E, 2006, J ALZHEIMERS DIS, V9, P91; Mayor S, 2006, BRIT MED J, V332, P195, DOI 10.1136/bmj.332.7535.195; McArthur JC, 2004, J NEUROIMMUNOL, V157, P3, DOI 10.1016/j.jneuroim.2004.08.042; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; Moirano J, 2006, EXP NEUROL, V198, P581, DOI 10.1016/j.expneurol.2006.02.073; Moore TL, 2006, NEUROBIOL AGING, V27, P1484, DOI 10.1016/j.neurobiolaging.2005.08.004; Nesbit CE, 2002, CLIN DIAGN LAB IMMUN, V9, P515, DOI 10.1128/CDLI.9.3.515-524.2002; *NIOSH, DEP HHS PUBL; *NOBL FDN, NOB PRIZ PHYS MED 19; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Olanow CW, 2005, MOVEMENT DISORD, V20, pS3, DOI 10.1002/mds.20457; Orandle MS, 2002, J VIROL, V76, P5797, DOI 10.1128/JVI.76.11.5797-5802.2002; PALMER AM, 1986, NEUROSCI LETT, V66, P199, DOI 10.1016/0304-3940(86)90190-4; PALMER AM, 1987, BRAIN RES, V401, P231, DOI 10.1016/0006-8993(87)91408-9; Peters A, 1996, J NEUROPATH EXP NEUR, V55, P861, DOI 10.1097/00005072-199608000-00001; Price DL, 1991, BRAIN PATHOL, V1, P287, DOI 10.1111/j.1750-3639.1991.tb00672.x; Przedborski S, 2004, J BIOENERG BIOMEMBR, V36, P375, DOI 10.1023/B:JOBB.0000041771.66775.d5; Rajput Alex, 2006, Expert Rev Neurother, V6, P91, DOI 10.1586/14737175.6.1.91; Redmond DE, 2002, NEUROSCIENTIST, V8, P457, DOI 10.1177/107385802237703; Roberts ES, 2004, J NEUROIMMUNOL, V157, P81, DOI 10.1016/j.jneuroim.2004.08.030; Roberts JA, 1997, NEUROREPORT, V8, P2047, DOI 10.1097/00001756-199705260-00048; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Roughton EC, 1998, AM J OCCUP THER, V52, P90, DOI 10.5014/ajot.52.2.90; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; Salvatore MF, 2006, EXP NEUROL, V202, P497, DOI 10.1016/j.expneurol.2006.07.015; Sanchez-Pernaute R, 2005, STEM CELLS, V23, P914, DOI 10.1634/stemcells.2004-0172; Scheller C, 2005, J NEUROCHEM, V95, P377, DOI 10.1111/j.1471-4159.2005.03373.x; Schliebs R, 2005, NEUROCHEM RES, V30, P895, DOI 10.1007/s11064-005-6962-9; SCHNEIDER JS, 1995, NEURODEGENERATION, V4, P245, DOI 10.1016/1055-8330(95)90014-4; Schneider ML, 1998, DEV PSYCHOPATHOL, V10, P427, DOI 10.1017/S0954579498001679; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Serretti A, 2005, J ALZHEIMERS DIS, V7, P331; Shannon C, 2005, AM J PSYCHIAT, V162, P1658, DOI 10.1176/appi.ajp.162.9.1658; Sherer TB, 2006, MOVEMENT DISORD, V21, P136, DOI 10.1002/mds.20861; Sloane JA, 1997, ACTA NEUROPATHOL, V94, P471, DOI 10.1007/s004010050735; Smith DE, 1999, P NATL ACAD SCI USA, V96, P10893, DOI 10.1073/pnas.96.19.10893; Smith DE, 2004, J NEUROSCI, V24, P4373, DOI 10.1523/JNEUROSCI.4289-03.2004; Smith TD, 1999, NEUROBIOL AGING, V20, P357; Sopper S, 2002, J NEURAL TRANSM, V109, P747, DOI 10.1007/s007020200062; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stover NP, 2005, ARCH NEUROL-CHICAGO, V62, P1833, DOI 10.1001/archneur.62.12.1833; Sugaya K, 2003, CELL MOL LIFE SCI, V60, P1891, DOI 10.1007/s00018-002-3014-y; Svendsen CN, 2004, NAT MED, V10, P224, DOI 10.1038/nm0304-224; Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137; TAYLOR JR, 1990, BRAIN, V113, P617, DOI 10.1093/brain/113.3.617; Terry RD, 2006, J ALZHEIMERS DIS, V9, P117; Thomson JA, 1996, BIOL REPROD, V55, P254, DOI 10.1095/biolreprod55.2.254; Tuszynski MH, 1996, GENE THER, V3, P305; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Tuszynski MH, 2004, PROG BRAIN RES, V146, P441; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; UNAIDS, 2005, AIDS EP UPD; *US NAT LIB MED, MIN TREATM DECR MENT; vanRompay KKA, 1996, ANTIMICROB AGENTS CH, V40, P2586, DOI 10.1128/AAC.40.11.2586; VOYTKO ML, 1994, J NEUROSCI, V14, P167; WALKER LC, 1987, NEUROBIOL AGING, V8, P291, DOI 10.1016/0197-4580(87)90067-4; Watts RL, 2003, J NEURAL TRANSM-SUPP, P215; Weed MR, 2004, AIDS RES HUM RETROV, V20, P77, DOI 10.1089/088922204322749521; WENK GL, 1993, BEHAV BRAIN RES, V57, P117, DOI 10.1016/0166-4328(93)90127-C; Williams K, 2005, J CLIN INVEST, V115, P2534, DOI 10.1172/JCI22953; Williams KC, 2001, J EXP MED, V193, P905, DOI 10.1084/jem.193.8.905; Winkler J, 1997, ANN NEUROL, V41, P82, DOI 10.1002/ana.410410114; Winslow JT, 2003, NEUROPSYCHOPHARMACOL, V28, P910, DOI 10.1038/sj.npp.1300128; WISNIEWSKI HM, 1973, J NEUROPATH EXP NEUR, V32, P566, DOI 10.1097/00005072-197310000-00007; Zhang ZM, 2000, J GERONTOL A-BIOL, V55, pB473, DOI 10.1093/gerona/55.10.B473; Zink MC, 2006, CURR HIV RES, V4, P293; Zink MC, 2005, JAMA-J AM MED ASSOC, V293, P2003, DOI 10.1001/jama.293.16.2003	162	144	147	0	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1126	1135		10.1016/S0140-6736(08)60489-4	http://dx.doi.org/10.1016/S0140-6736(08)60489-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18374844				2022-12-28	WOS:000254442700032
J	von Gottberg, A; Klugman, KP; Cohen, C; Wolter, N; de Gouveia, L; du Plessis, M; Mpembe, R; Quan, V; Whitelaw, A; Hoffmann, R; Govender, N; Meiring, S; Smith, AM; Schrag, S				von Gottberg, Anne; Klugman, Keith P.; Cohen, Cheryl; Wolter, Nicole; de Gouveia, Linda; du Plessis, Mignon; Mpembe, Ruth; Quan, Vanessa; Whitelaw, Andrew; Hoffmann, Rena; Govender, Nelesh; Meiring, Susan; Smith, Anthony M.; Schrag, Stephanie		GERMS SA	Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study	LANCET			English	Article							TERM-CARE FACILITY; FLUOROQUINOLONE-RESISTANT; ANTIMICROBIAL RESISTANCE; NASOPHARYNGEAL CARRIAGE; ANTIBIOTIC-RESISTANCE; UNITED-STATES; PNEUMOCOCCI; RISK; OPPORTUNITIES; FAILURE	Background Use of fluoroquinolones to treat paediatric cases of multidrug-resistant tuberculosis could affect the emergence of resistance to this class of drugs. Our aim was to estimate the incidence of, and risk factors for, invasive pneumococcal disease caused by fluoroquinolone-resistant Streptococcus pneumoniae in children in South Africa. Methods 21521 cases of invasive pneumococcal disease were identified by active national surveillance between 2000 and 2006, with enhanced surveillance at 15 sentinel hospitals in seven provinces introduced in 2003. We screened 19 404 isolates (90% of cases) for ofloxacin resistance and measured levofloxacin minimum inhibitory concentrations (MICs) for all isolates that were ofloxacin resistant. Non-susceptibility to levofloxacin was defined as an MIC of 4 mg/L or more. Nasopharyngeal pneumococcal carriage was assessed in 65 children in two tuberculosis hospitals where invasive pneumococcal disease caused by levofloxacin-non-susceptible S pneumoniae had been detected. Findings 12 cases of invasive pneumococcal disease were identified as being non-susceptible to levofloxacin, an in children aged under 15 years. All isolates were rifampicin resistant. Outcome was known for 11 of these patients; five (45%) died. Invasive disease caused by levofloxacin-non-susceptible S pneumoniae was associated with a history of tuberculosis treatment (eight [89%] of nine children with non-susceptible isolates had a history of treatment vs 396 [18%] of 2202 children with susceptible isolates; relative risk [RR] 35 . 78, 95% Cl 4.49-285.30) and nosocomial invasive pneumococcal disease (eight [80%] of ten children with non-susceptible isolates had acquired infection nosocomially vs 109 [4%] of 2709 with susceptible isolates; RR 88.96, 19.10-414.29). 31 (89%) of 35 pneumococcal carriers had bacteria that were non-susceptible to levofloxacin. Interpretation Our data suggest that the use of fluoroquinolones to treat multidrug-resistant tuberculosis in children has led to the emergence of invasive pneumococcal disease caused by levofloxacin-non-susceptible S pneumoniae and its nosocomial spread. Funding National Institute for Communicable Diseases of the National Health Laboratory Service (South Africa), US Agency for International Development Antimicrobial Resistance Initiative, US Centers for Disease Control and Prevention.	[von Gottberg, Anne; Klugman, Keith P.; Cohen, Cheryl; Wolter, Nicole; de Gouveia, Linda; du Plessis, Mignon; Mpembe, Ruth; Quan, Vanessa; Govender, Nelesh; Meiring, Susan; Smith, Anthony M.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa; [von Gottberg, Anne; Klugman, Keith P.; Wolter, Nicole; du Plessis, Mignon; Govender, Nelesh; Smith, Anthony M.] Univ Witwatersrand, Sch Pathol, Fac Hlth Sci, Johannesburg, South Africa; [Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa; [von Gottberg, Anne; Klugman, Keith P.; Wolter, Nicole; de Gouveia, Linda; du Plessis, Mignon; Mpembe, Ruth] MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa; [Klugman, Keith P.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Klugman, Keith P.] Emory Univ, Div Infect Dis, Sch Med, Atlanta, GA 30322 USA; [Whitelaw, Andrew; Hoffmann, Rena] Natl Hlth Lab Serv, Cape Town, South Africa; [Whitelaw, Andrew] Univ Cape Town, Dept Clin & Lab Sci, ZA-7925 Cape Town, South Africa; [Hoffmann, Rena] Univ Stellenbosch, Dept Med Microbiol, ZA-7600 Stellenbosch, South Africa; [Schrag, Stephanie] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA	National Health Laboratory Service; National Institute for Communicable Diseases (NICD); University of Witwatersrand; University of Witwatersrand; Emory University; Rollins School Public Health; Emory University; University of Cape Town; Stellenbosch University; Centers for Disease Control & Prevention - USA	von Gottberg, A (corresponding author), Natl Inst Communicable Dis, Resp & Meningeal Pathogens Res Unit, Private Bag X4, ZA-2131 Johannesburg, Gauteng, South Africa.	annev@nicd.ac.za	Meiring, Susan/M-1463-2019; Govender, Nelesh/ABI-6429-2020	Meiring, Susan/0000-0003-4508-5469; de Gouveia, Linda/0000-0002-1418-8468; Cohen, Cheryl/0000-0003-0376-2302; du Plessis, Mignon/0000-0001-9186-0679; von Gottberg, Anne/0000-0002-0243-7455; Govender, Nelesh/0000-0001-7869-9462; McCarthy, Kerrigan/0000-0001-8958-9795; Whitelaw, Andrew/0000-0001-9070-5247	PHS HHS [U60/CCU022088, U62/CCU022901] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adam HJ, 2007, ANTIMICROB AGENTS CH, V51, P198, DOI 10.1128/AAC.00609-06; APPELBAUM PC, 1977, LANCET, V2, P995; Borer A, 2001, CLIN INFECT DIS, V33, P436, DOI 10.1086/321888; Buie KA, 2004, J INFECT DIS, V189, P1996, DOI 10.1086/386548; Carter RJ, 2005, INFECT CONT HOSP EP, V26, P248, DOI 10.1086/502534; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P800; Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; Clinical and Laboratory Standards Institute (CLSI) C, 2005, M100S15 CLSI NCCLS; Corbett EL, 2006, LANCET, V367, P926, DOI 10.1016/S0140-6736(06)68383-9; Davidson R, 2002, NEW ENGL J MED, V346, P747, DOI 10.1056/NEJMoa012122; Fry AM, 2005, INFECT CONT HOSP EP, V26, P239, DOI 10.1086/502533; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; Gendrel D, 2003, LANCET INFECT DIS, V3, P537, DOI 10.1016/S1473-3099(03)00736-9; Gosling R, 2004, ANTIMICROB AGENTS CH, V48, P3642, DOI 10.1128/AAC.48.9.3642-3643.2004; Ho PL, 2004, EMERG INFECT DIS, V10, P1250, DOI 10.3201/eid1007.030612; Ho PL, 2001, CLIN INFECT DIS, V32, P701, DOI 10.1086/319222; Huang TD, 2006, PEDIATR INFECT DIS J, V25, P1195, DOI 10.1097/01.inf.0000243766.85379.d6; Huebner RE, 1999, S AFR MED J, V89, P924; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; Karstaedt AS, 2001, CLIN INFECT DIS, V33, P610, DOI 10.1086/322589; Klugman K P, 2001, Lancet Infect Dis, V1, P85, DOI 10.1016/S1473-3099(01)00063-9; Klugman KP, 2003, CLIN INFECT DIS, V36, P783, DOI 10.1086/367935; KOORNHOF HJ, 1992, CLIN INFECT DIS, V15, P84, DOI 10.1093/clinids/15.1.84; LEFEVRE JC, 1993, J CLIN MICROBIOL, V31, P2724, DOI 10.1128/JCM.31.10.2724-2728.1993; Linares J, 1999, NEW ENGL J MED, V341, P1546; Low DE, 2005, CLIN INFECT DIS, V40, P236, DOI 10.1086/426822; Mandell LA, 2002, CLIN INFECT DIS, V35, P721, DOI 10.1086/341900; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; McEllistrem MC, 2000, J CLIN MICROBIOL, V38, P351; McGee L, 2002, J ANTIMICROB CHEMOTH, V49, P173, DOI 10.1093/jac/49.1.173; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; O'Brien KL, 2001, J CLIN MICROBIOL, V39, P1021, DOI 10.1128/JCM.39.3.1021-1024.2001; Pletz MWR, 2004, ANTIMICROB AGENTS CH, V48, P3491, DOI 10.1128/AAC.48.9.3491-3497.2004; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Ruoff KL, 2003, MANUAL CLIN MICROBIO, P405; *STAT S AFR, 2005, P03093 MORT CAUS DEA; von Gottberg A, 2003, PEDIATR INFECT DIS J, V22, P1020, DOI 10.1097/01.inf.0000095430.29265.7f; Woolfson A, 1997, B WORLD HEALTH ORGAN, V75, P453; Yew WW, 2002, INT J TUBERC LUNG D, V6, P174	39	45	45	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1108	1113		10.1016/S0140-6736(08)60350-5	http://dx.doi.org/10.1016/S0140-6736(08)60350-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18359074				2022-12-28	WOS:000254442700029
J	Radu, IP; Miller, JB; Marcus, CM; Kastner, MA; Pfeiffer, LN; West, KW				Radu, Iuliana P.; Miller, J. B.; Marcus, C. M.; Kastner, M. A.; Pfeiffer, L. N.; West, K. W.			Quasi-particle properties from tunneling in the nu=5/2 fractional quantum Hall state	SCIENCE			English	Article							2ND LANDAU-LEVEL; EDGE EXCITATIONS; TRANSPORT; CHARGE	Quasi-particles with fractional charge and statistics, as well as modified Coulomb interactions, exist in a two-dimensional electron system in the fractional quantum Hall (FQH) regime. Theoretical models of the FQH state at filling fraction nu = 5/2 make the further prediction that the wave function can encode the interchange of two quasi-particles, making this state relevant for topological quantum computing. We show that bias-dependent tunneling across a narrow constriction at nu = 5/2 exhibits temperature scaling and, from fits to the theoretical scaling form, extract values for the effective charge and the interaction parameter of the quasi-particles. Ranges of values obtained are consistent with those predicted by certain models of the 5/2 state.	[Miller, J. B.; Marcus, C. M.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; [Radu, Iuliana P.; Kastner, M. A.] MIT, Dept Phys, Cambridge, MA 02139 USA; [Pfeiffer, L. N.; West, K. W.] Bell Labs, Alcatel Lucent Technol, Murray Hill, NJ 07974 USA	Harvard University; Massachusetts Institute of Technology (MIT); Alcatel-Lucent; Lucent Technologies; AT&T	Marcus, CM (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	marcus@harvard.edu	Marcus, Charles M./M-4526-2014; Miller, John J/GZG-5663-2022; Kastner, Marc/F-9520-2010	Marcus, Charles M./0000-0003-2420-4692; Radu, Iuliana/0000-0002-7230-7218; Kastner, Marc/0000-0001-7641-5438				BEENAKKER CWJ, 1991, SOLID STATE PHYS, V44, P1; Bishara W, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.165302; Bonderson P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.016803; Das Sarma S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.166802; dePicciotto R, 1997, NATURE, V389, P162, DOI 10.1038/38241; Dolev M, 2008, NATURE, V452, P829, DOI [10.1038/nature06855, 10.1038/natureO6855]; Feldman DE, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.186803; FENDLEY P, 1995, PHYS REV B, V52, P8934, DOI 10.1103/PhysRevB.52.8934; Fendley P, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.036801; Fradkin E, 1998, NUCL PHYS B, V516, P704, DOI 10.1016/S0550-3213(98)00111-4; GOLDMAN VJ, 1995, SCIENCE, V267, P1010, DOI 10.1126/science.267.5200.1010; HALDANE FDM, 1988, PHYS REV LETT, V60, P956, DOI 10.1103/PhysRevLett.60.956; HALPERIN BI, 1993, PHYS REV B, V47, P7312, DOI 10.1103/PhysRevB.47.7312; HALPERIN BI, 1982, PHYS REV B, V25, P2185, DOI 10.1103/PhysRevB.25.2185; HALPERIN BI, 1983, HELV PHYS ACTA, V56, P75; Hou CY, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.146802; Kitaev AY, 2003, ANN PHYS-NEW YORK, V303, P2, DOI 10.1016/S0003-4916(02)00018-0; Lee SS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.236807; Levin M, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.236806; Miller JB, 2007, NAT PHYS, V3, P561, DOI 10.1038/nphys658; Milliken FP, 1996, SOLID STATE COMMUN, V97, P309, DOI 10.1016/0038-1098(95)00181-6; Milovanovic M, 1996, PHYS REV B, V53, P13559, DOI 10.1103/PhysRevB.53.13559; MOORE G, 1991, NUCL PHYS B, V360, P362, DOI 10.1016/0550-3213(91)90407-O; Morf RH, 1998, PHYS REV LETT, V80, P1505, DOI 10.1103/PhysRevLett.80.1505; Roddaro S, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.156804; Roddaro S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.046801; Roddaro S, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.046805; Saminadayar L, 1997, PHYS REV LETT, V79, P2526, DOI 10.1103/PhysRevLett.79.2526; Stern A, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.016802; WEN XG, 1991, PHYS REV LETT, V66, P802, DOI 10.1103/PhysRevLett.66.802; WEN XG, 1991, PHYS REV B, V44, P5708, DOI 10.1103/PhysRevB.44.5708; WEN XG, 1990, PHYS REV B, V41, P9377, DOI 10.1103/PhysRevB.41.9377; Wen XG, 1995, ADV PHYS, V44, P405, DOI 10.1080/00018739500101566; WEN XG, 1993, PHYS REV LETT, V70, P355, DOI 10.1103/PhysRevLett.70.355; WILLETT R, 1987, PHYS REV LETT, V59, P1776, DOI 10.1103/PhysRevLett.59.1776; Xia JS, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.176809	37	262	268	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2008	320	5878					899	902		10.1126/science.1157560	http://dx.doi.org/10.1126/science.1157560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301AH	18420897				2022-12-28	WOS:000255868300034
J	Kaptchuk, TJ; Kelley, JM; Conboy, LA; Davis, RB; Kerr, CE; Jacobson, EE; Kirsch, I; Schyner, RN; Nam, BH; Nguyen, LT; Park, M; Rivers, AL; McManus, C; Kokkotou, E; Drossman, DA; Goldman, P; Lembo, AJ				Kaptchuk, Ted J.; Kelley, John M.; Conboy, Lisa A.; Davis, Roger B.; Kerr, Catherine E.; Jacobson, Eric E.; Kirsch, Irving; Schyner, Rosa N.; Nam, Bong Hyun; Nguyen, Long T.; Park, Min; Rivers, Andrea L.; McManus, Claire; Kokkotou, Efi; Drossman, Douglas A.; Goldman, Peter; Lembo, Anthony J.			Components of placebo effect: randomised controlled trial inpatients with irritable bowel syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROTEIN-CREATININE RATIO; RANDOM URINE PROTEIN; PROTEIN/CREATININE RATIO; ALBUMIN/CREATININE RATIO; END-POINT; HYPERTENSIVE DISORDERS; ADEQUATE RELIEF; KIDNEY-DISEASE; PREGNANCY; EXCRETION	Objective To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components. Design A six week single blind three arm randomised controlled trial. Setting Academic medical centre. Participants 262 adults (76% women), mean (SID) age 39 (14), diagnosed by Rome II criteria for and with a score of >= 150 on the symptom severity scale. Interventions For three weeks either waiting list (observation), placebo acupuncture alone ("limited"), or placebo acupuncture with a patient-practitioner relationship augmented by warmth, attention, and confidence ("augmented"). At three weeks, half of the patients were randomly assigned to continue in their originally assigned group for an additional three weeks. Main outcome measures Global improvement kale (range 1-7), adequate relief of symptoms, symptom severity score, and quality of life. Results At three weeks, scores on the global improvement scale were 3.8 (SID 1.0) v 4.3 (SD 1.4) v 5.0 (SID 1.3) for waiting list versus "limited" versus "augmented," respectively (P<0.001 for trend). The proportion of patients reporting adequate relief showed a similar pattern: 28% on waiting list, 44% in limited group, and 62% in augmented group (P<0.001 for trend). The same trend in response existed in symptom severity score (30 (63) v 42 (67) v 82 (89), P<0.001) and quality of life (3.6 (8.1) v 4.1 (9.4) v 9.3 (14.0), P<0.001). All pairwise comparisons between augmented and limited patient-practitioner relationship were significant: global improvement scale (P<0.001), adequate relief of symptoms (P<.001), symptom severity score (P=0.007), quality of life (P=0.01). Results were similar at six week follow-up. Conclusion Factors contributing to the placebo effect can be progressively combined in a manner resembling a graded dose escalation of component parts. Non-specific effects can produce statistically and clinically significant outcomes and the patient-practitioner relationship is the most robust component. Trial registration Clinical Trials NCTC0065403.	[Kaptchuk, Ted J.; Conboy, Lisa A.; Kerr, Catherine E.; Schyner, Rosa N.; Nam, Bong Hyun; Nguyen, Long T.; Park, Min; Rivers, Andrea L.; McManus, Claire] Harvard Univ, Sch Med, Osher Res Ctr, Boston, MA 02215 USA; [Kelley, John M.] Endicott Coll, Beverly, MA 01915 USA; [Davis, Roger B.; Kokkotou, Efi; Lembo, Anthony J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Jacobson, Eric E.] Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02215 USA; [Kirsch, Irving] Univ Hull, Dept Psychol, Kingston Upon Hull HU6 7RX, N Humberside, England; [Drossman, Douglas A.] Univ N Carolina, Sch Med, Ctr Funct GI & Motil Disorders, Chapel Hill, NC 27699 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Hull; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Osher Res Ctr, 401 Park Dr, Boston, MA 02215 USA.	ted_kaptchuk@hms.harvard.edu	Kerr, Catherine E/D-3299-2009; Conboy, Lisa/ABC-5173-2021; Kirsch, Irving/P-9316-2019	Conboy, Lisa/0000-0003-2218-7841; Casas Gallegos, Isabel/0000-0002-2805-4604	NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT004662] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT002564, R21AT002860, R01AT001414] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT004095] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NCCIH NIH HHS [1R01 AT001414-01, 1R21 AT002860-01, 1K24 AT004095, 1 R21 AT002564, R01 AT004662] Funding Source: Medline; NCRR NIH HHS [RR 01032] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adelberg AM, 2001, AM J OBSTET GYNECOL, V185, P804, DOI 10.1067/mob.2001.117302; Al RA, 2004, OBSTET GYNECOL, V104, P367, DOI 10.1097/01.AOG.0000134788.01016.2a; Allan LG, 2002, EVAL HEALTH PROF, V25, P410, DOI 10.1177/0163278702238054; Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; BOLER L, 1987, OBSTET GYNECOL, V70, P99; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; BROWN MA, 1995, AUST NZ J OBSTET GYN, V35, P366, DOI 10.1111/j.1479-828X.1995.tb02143.x; Brown MA, 2000, AUST NZ J OBSTET GYN, V40, P133, DOI 10.1111/j.1479-828X.2000.tb01136.x; Brown MA, 2001, HYPERTENS PREGNANCY, V20, pIX, DOI 10.1081/PRG-100104165; Camilleri M, 2000, LANCET, V355, P1035, DOI 10.1016/S0140-6736(00)02033-X; Camilleri M, 2007, CLIN GASTROENTEROL H, V5, P534, DOI 10.1016/j.cgh.2007.03.004; Chan P, 2005, BJOG-INT J OBSTET GY, V112, P280, DOI 10.1111/j.1471-0528.2004.00395.x; CHUA S, 1992, EUR J OBSTET GYN R B, V43, P9, DOI 10.1016/0028-2243(92)90236-R; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Deeks JJ., 2001, SYSTEMATIC REV HLTH, P248, DOI DOI 10.1002/9780470693926.CH14; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; Drossman DA, 2000, AM J GASTROENTEROL, V95, P999; Durnwald C, 2003, AM J OBSTET GYNECOL, V189, P848, DOI 10.1067/S0002-9378(03)00849-4; Egger M., 2008, SYSTEMATIC REV HLTH; Evans W, 2000, J Matern Fetal Med, V9, P233; FERRAZZANI S, 1990, AM J OBSTET GYNECOL, V162, P366, DOI 10.1016/0002-9378(90)90387-M; Francis CY, 1997, ALIMENT PHARM THERAP, V11, P395, DOI 10.1046/j.1365-2036.1997.142318000.x; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; GINSBERG JM, 1983, NEW ENGL J MED, V309, P1543, DOI 10.1056/NEJM198312223092503; Gordon S, 2003, DIGEST DIS SCI, V48, P1317, DOI 10.1023/A:1024159226274; Haas D M, 2003, J Matern Fetal Neonatal Med, V14, P233, DOI 10.1080/jmf.14.4.233.236; Hall DR, 2002, INT J GYNECOL OBSTET, V77, P1, DOI 10.1016/S0020-7292(02)00008-5; Helewa ME, 1997, CAN MED ASSOC J, V157, P715; Hrobjartsson A, 2002, J CLIN EPIDEMIOL, V55, P430, DOI 10.1016/S0895-4356(01)00496-6; JASCHEVATZKY OE, 1990, OBSTET GYNECOL, V75, P604; Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011; Kieler H, 2003, BJOG-INT J OBSTET GY, V110, P12, DOI 10.1046/j.1471-0528.2003.01440.x; KUO VS, 1992, AM J OBSTET GYNECOL, V167, P723, DOI 10.1016/S0002-9378(11)91578-6; Lane C, 2006, NEPHROLOGY, V11, P245, DOI 10.1111/j.1440-1797.2006.00564.x; LAO TT, 1988, EUR J OBSTET GYN R B, V29, P121, DOI 10.1016/0028-2243(88)90138-4; Lembo T, 2001, AM J GASTROENTEROL, V96, P2662; LINDHEIMER MD, 1977, KIDNEY FUNCTION DIS, P1; LINDOW SW, 1992, BRIT J OBSTET GYNAEC, V99, P869, DOI 10.1111/j.1471-0528.1992.tb14431.x; Mangel AW, 2006, ALIMENT PHARM THERAP, V23, P879, DOI 10.1111/j.1365-2036.2006.02839.x; Mangel AW, 1998, J INT MED RES, V26, P76, DOI 10.1177/030006059802600203; Menzies J, 2007, HYPERTENS PREGNANCY, V26, P447, DOI 10.1080/10641950701521742; MILLER FG, 2008, IN PRESS J ROY SOC M; Myers GL, 2006, CLIN CHEM, V52, P5, DOI 10.1373/clinchem.2005.0525144; Neithardt AB, 2002, AM J OBSTET GYNECOL, V186, P883, DOI 10.1067/mob.2002.123055; Newman MG, 2003, AM J OBSTET GYNECOL, V188, P264, DOI 10.1067/mob.2003.84; Nisell H, 2006, ACTA OBSTET GYN SCAN, V85, P1327, DOI 10.1080/00016340600808747; Novick J, 2002, ALIMENT PHARM THER, V16, P1877, DOI 10.1046/j.1365-2036.2002.01372.x; PACHECOLOPEZ G, 2006, BRAIN BEHAV IMMUNOL, P403; Patel SM, 2005, NEUROGASTROENT MOTIL, V17, P332, DOI 10.1111/j.1365-2982.2005.00650.x; Phelan LK, 2004, HYPERTENS PREGNANCY, V23, P135, DOI 10.1081/PRG-120028289; Price CP, 2005, CLIN CHEM, V51, P1577, DOI 10.1373/clinchem.2005.049742; QUADRI KHM, 1994, AM J KIDNEY DIS, V24, P416, DOI 10.1016/S0272-6386(12)80897-3; Ramos JGL, 1999, HYPERTENS PREGNANCY, V18, P209, DOI 10.3109/10641959909016194; Rinehart B K, 1999, J Perinatol, V19, P556, DOI 10.1038/sj.jp.7200271; Risberg A, 2004, SCAND J CLIN LAB INV, V64, P17, DOI 10.1080/00365510410003714; Robert M, 1997, OBSTET GYNECOL, V90, P893, DOI 10.1016/S0029-7844(97)00536-X; Rochiguez-Thompson D, 2001, AM J OBSTET GYNECOL, V185, P808; Saudan PJ, 1997, BRIT J OBSTET GYNAEC, V104, P1159, DOI 10.1111/j.1471-0528.1997.tb10940.x; Schiff E, 1996, AM J OBSTET GYNECOL, V175, P1313, DOI 10.1016/S0002-9378(96)70047-9; Skweres Tomasz, 2006, Ginekol Pol, V77, P415; Somanathan N, 2003, J Obstet Gynaecol, V23, P378; Taherian A.A., 2006, J RES MED SCI, V11, P6; Thompson WG, 1999, GUT, V45, P43; UTTENDORFSKY OT, 1988, EUR J OBSTET GYN R B, V27, P221, DOI 10.1016/0028-2243(88)90126-8; Valerio EG, 2005, HYPERTENS PREGNANCY, V24, P213, DOI 10.1080/10641950500281167; Vassalotti JA, 2007, AM J KIDNEY DIS, V50, P169, DOI 10.1053/j.ajkd.2007.06.013; Waugh J, 2005, HYPERTENS PREGNANCY, V24, P291, DOI 10.1080/10641950500281019; Waugh J, 2003, HYPERTENS PREGNANCY, V22, P77, DOI 10.1081/PRG-120017006; Wheeler TL, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.10.892; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Wikstrom AK, 2006, BJOG-INT J OBSTET GY, V113, P930, DOI 10.1111/j.1471-0528.2006.01007.x; Wongkitisophon Kitti, 2003, Journal of the Medical Association of Thailand, V86, P529; Yamasmit Waralak, 2003, J Med Assoc Thai, V86, P69; Young RA, 1996, J FAM PRACTICE, V42, P385; Zadehmodarres S, 2006, AUST NZ J OBSTET GYN, V46, P501, DOI 10.1111/j.1479-828X.2006.00649.x	77	792	803	4	97	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2008	336	7651					999	1003		10.1136/bmj.39524.439618.25	http://dx.doi.org/10.1136/bmj.39524.439618.25			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300EZ	18390493	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000255808400042
J	Heath, I				Heath, Iona			A general practitioner for everyone in the world	BRITISH MEDICAL JOURNAL			English	Editorial Material												iona.heath@dsl.pipex.com							0	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 19	2008	336	7649					861	861		10.1136/bmj.39548.435023.59	http://dx.doi.org/10.1136/bmj.39548.435023.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290QH	18420690	Green Published			2022-12-28	WOS:000255136800029
J	Bradshaw, D; Chopra, M; Kerber, K; Lawn, JE; Bamford, L; Moodley, J; Pattinson, R; Patrick, M; Stephen, C; Velaphi, S				Bradshaw, Debbie; Chopra, Mickey; Kerber, Kate; Lawn, Joy E.; Bamford, Lesley; Moodley, Jack; Pattinson, Robert; Patrick, Mark; Stephen, Cindy; Velaphi, Sithembiso		S Africa Every Death Counts Writin	Every death counts: use of mortality audit data for decision making to save the lives of mothers, babies, and children in South Africa	LANCET			English	Article							MATERNAL MORTALITY; CAPE-TOWN; CARE; HEALTH; QUALITY; TRANSMISSION; SURVIVAL; ACHIEVE; SERVICE; BIRTH	South Africa is one of the few developing countries with a national confidential inquiry into maternal deaths. 164 health facilities obtain audit data for stillbirths and neonatal deaths, and a new audit network does so for child deaths. Three separate reports have been published, providing valuable information about avoidable causes of death for mothers, babies, and children. These reports make health-system recommendations, many of which reports have united to prioritise actions to save the lives of South Africa's mothers, babies, and children. The country is off-track for the health-related Millennium Development Goals. Mortality in children younger than K years has increased, whereas maternal and neonatal mortality remain constant. This situation indicates the challenge of strengthening the health system because of high inequity and HIV/AIDS. Coverage of services is fairly high, but addressing the gaps in quality and equity is essential to increasing the number of lives saved. Consistent leadership and accountability to address crosscutting health system and equity issues, and to prevent mother-to-child transmission of HIV, would save tens of thousands of lives every year. Audit is powerful, but only if the data lead to action.	[Pattinson, Robert; Patrick, Mark; Stephen, Cindy] Univ Pretoria, MRC, Maternal & Infant Hlth Care Strategies Res Unit, ZA-0001 Pretoria, South Africa; [Bradshaw, Debbie] MRC, Burden Dis Res Unit, Cape Town, South Africa; [Chopra, Mickey; Lawn, Joy E.] MRC, Hlth Syst Res Unit, Cape Town, South Africa; [Kerber, Kate; Lawn, Joy E.] Saving Newborn Lives Save Children US, Cape Town, South Africa; [Bamford, Lesley] Univ Pretoria, Sch Hlth Syst & Publ Hlth, ZA-0001 Pretoria, South Africa; [Moodley, Jack] Univ Kwazulu Natal, Womens Hlth & HIV Res Grp, Kwa Zulu, South Africa; [Patrick, Mark; Stephen, Cindy] Univ Pretoria, Pietermaritzburg Hosp Complex, Dept Pediat, Pretoria, South Africa; [Velaphi, Sithembiso] Univ Witwatersrand, Dept Paediat, Johannesburg, South Africa	University of Pretoria; Save the Children; University of Pretoria; University of Kwazulu Natal; University of Pretoria; University of Witwatersrand	Pattinson, R (corresponding author), Univ Pretoria, MRC, Maternal & Infant Hlth Care Strategies Res Unit, Klinikala Bldg,POB 667, ZA-0001 Pretoria, South Africa.	Robert.Pattinson@up.ac.za	Lawn, Joy/ABE-6382-2020	Lawn, Joy/0000-0002-4573-1443; Patrick, Mark/0000-0001-9912-1870				ABOUZAHR C, 2003, MATERNAL MORTALITY 2, P1; [Anonymous], REPORT UNICEF SCALIN; Ashworth A, 2004, LANCET, V363, P1110, DOI 10.1016/S0140-6736(04)15894-7; Baiden F, 2007, B WORLD HEALTH ORGAN, V85, P570, DOI 10.2471/BLT.07.043745; Barron P, 2006, DISTRICT HLTH BAROME; BARRON P, 2008, IN PRESS DISTRICT HL; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Bradshaw D, 2003, SAMJ S AFR MED J, V93, P682; Bradshaw D, 2002, SAMJ S AFR MED J, V92, P618; Bradshaw D, 2007, SAMJ S AFR MED J, V97, P582; BRYCE J, TRACKING PROGR MATER; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Buchmann EJ, 2002, SAMJ S AFR MED J, V92, P897; Burger EH, 2007, SAMJ S AFR MED J, V97, P1077; CASE A, 2003, 38 U NAT DURB CTR SO; Chopra M, 2005, ACTA PAEDIATR, V94, P357, DOI 10.1111/j.1651-2227.2005.tb03080.x; Chopra M, 2005, ARCH DIS CHILD, V90, P397, DOI 10.1136/adc.2004.059147; Daviauda E, 2008, B WORLD HEALTH ORGAN, V86, P46, DOI 10.2471/BLT.07.042283; DORRINGTON R, 2006, DEM IMP HIV AIDS S A; Dorrington Rob, 2004, ESTIMATION MORTALITY; Fawcus SR, 2005, BJOG-INT J OBSTET GY, V112, P1257, DOI 10.1111/j.1471-0528.2005.00601.x; FORDE F, 2007, FRERE HOSP SPOTLIGHT; GREENTHOMPSON R, NATL TASK TEAM REPOR; Hill K, 2007, LANCET, V370, P1311, DOI 10.1016/S0140-6736(07)61572-4; Jackson DJ, 2007, AIDS, V21, P509, DOI 10.1097/QAD.0b013e32801424d2; Jewkes RK, 2005, BJOG-INT J OBSTET GY, V112, P1236, DOI 10.1111/j.1471-0528.2005.00697.x; Kahn K., 2006, DYING MAKE FRESH STA; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Lawn J, 2005, B WORLD HEALTH ORGAN, V83, P409; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lawn JE, 2006, INT J EPIDEMIOL, V35, P706, DOI 10.1093/ije/dyl043; MCINTYRE D, 2007, S AFRICAN HLTH REV 2; Morroni Chelsea, 2006, Reprod Health, V3, P7; *MRC, 2002, 1998 S AFR DEM HLTH; *MRC S AFR, 2007, SAV BAB 2003 05 5 PE; Murray CJL, 2007, LANCET, V370, P1040, DOI 10.1016/S0140-6736(07)61478-0; *NAT DEP HLTH, 2004, 2003 S AFR DEM HLTH; National Department of Health, 2007, SAV MOTH 3 REP CONF; Norman R., 2006, REVISED BURDEN DIS E; PATRICK M, 2007, SAVING CHILDREN 2005; Pattinson RC, 2006, J TROP PEDIATRICS, V52, P438, DOI 10.1093/tropej/fml032; Pattinson RC, 2005, ACTA PAEDIATR, V94, P924, DOI 10.1080/08035250510028399; Pattinson Robert, 2005, Reprod Health, V2, P4, DOI 10.1186/1742-4755-2-4; Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6; *S AFR DEP HLTH, 2007, NAT HIV SYPH ANT SER; *S AFR NAT AIDS CO, 2007, HIV AIDS STI NAT STR; *S AFR STAT COUNC, 2007, MID POP EST 2007; Save the Children, 2003, PARTN DEF QUAL TOOL; Say L., 2007, MATERNAL MORTALITY 2; SCHNEIDER H, 2000, REPROD HEALTH MATTER, V8, P55; Setel PW, 2007, LANCET, V370, P1569, DOI 10.1016/S0140-6736(07)61307-5; *U PRET, 2008, EV DEATH COUNTS WRIT; UNICEF, 2007, PROTECTING THE WORLD'S CHILDREN: IMPACT OF THE CONVENTION ON THE RIGHTS OF THE CHILD IN DIVERSE LEGAL SYSTEMS, P1; *UNICEF, STOCKT REP CHILDR AI; United Nations, 2007, WORLD POP PROSP 2006; United Nations Children's Fund (UNICEF), 2014, STATE WORLDS CHILDRE; *US BUR CENS, COUNTRY SUMM S AFR; WHO, 2006, PER NEON MORT YEAR 2 PER NEON MORT YEAR 2	58	106	108	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1294	1304						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286XH	18406864	Green Submitted			2022-12-28	WOS:000254878900031
J	Burdelya, LG; Krivokrysenko, VI; Tallant, TC; Strom, E; Gleiberman, AS; Gupta, D; Kurnasov, OV; Fort, FL; Osterman, AL; DiDonato, JA; Feinstein, E; Gudkov, AV				Burdelya, Lyudmila G.; Krivokrysenko, Vadim I.; Tallant, Thomas C.; Strom, Evguenia; Gleiberman, Anatoly S.; Gupta, Damodar; Kurnasov, Oleg V.; Fort, Farrel L.; Osterman, Andrei L.; DiDonato, Joseph A.; Feinstein, Elena; Gudkov, Andrei V.			An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTOR-5; FACTOR-KAPPA-B; INDUCED APOPTOSIS; IN-VIVO; IONIZING-RADIATION; ADAPTIVE IMMUNITY; MICE; FLAGELLIN; CANCER	The toxicity of ionizing radiation is associated with massive apoptosis in radiosensitive organs. Here, we investigate whether a drug that activates a signaling mechanism used by tumor cells to suppress apoptosis can protect healthy cells from the harmful effects of radiation. We studied CBLB502, a polypeptide drug derived from Salmonella flagellin that binds to Toll-like receptor 5 (TLR5) and activates nuclear factor-kappa B signaling. A single injection of CBLB502 before lethal total-body irradiation protected mice from both gastrointestinal and hematopoietic acute radiation syndromes and resulted in improved survival. CBLB502 injected after irradiation also enhanced survival, but at lower radiation doses. It is noteworthy that the drug did not decrease tumor radiosensitivity in mouse models. CBLB502 also showed radioprotective activity in lethally irradiated rhesus monkeys. Thus, TLR5 agonists could potentially improve the therapeutic index of cancer radiotherapy and serve as biological protectants in radiation emergencies.	[Krivokrysenko, Vadim I.; Strom, Evguenia; Gleiberman, Anatoly S.; Fort, Farrel L.; Feinstein, Elena; Gudkov, Andrei V.] Cleveland Biolabs Inc CBLI, Buffalo, NY 14203 USA; [Burdelya, Lyudmila G.; Gupta, Damodar; Gudkov, Andrei V.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Tallant, Thomas C.; DiDonato, Joseph A.] Cleveland Clin, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; [Kurnasov, Oleg V.; Osterman, Andrei L.] Burnham Inst, La Jolla, CA 92037 USA	Roswell Park Cancer Institute; Cleveland Clinic Foundation; Sanford Burnham Prebys Medical Discovery Institute	Feinstein, E (corresponding author), Cleveland Biolabs Inc CBLI, Buffalo, NY 14203 USA.	efeinstein@cbiolabs.com; andrei.gudkov@roswellpark.org	Hazen, Stanley L/ABD-5845-2021	Gudkov, Andrei/0000-0003-2548-0154; Strom, Evguenia/0000-0003-1237-2138; gleiberman, anatoli/0000-0001-8491-0826	NATIONAL CANCER INSTITUTE [R01CA084406, R01CA075179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066497] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084406, CA75179, CA84406, R01 CA075179, R01 CA084406-01A1] Funding Source: Medline; NIAID NIH HHS [R01 AI066497, AI066497] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Apetoh Lionel, 2007, Cancer Genomics & Proteomics, V4, P65; ATKINSON K, 1995, CYTOKINES MOL THER, V1, P47; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Dale DC, 2002, DRUGS, V62, P1, DOI 10.2165/00003495-200262001-00001; Dodd Mi., 2001, MANAGING SIDE EFFECT; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Epperly MW, 2002, RADIAT RES, V157, P568, DOI 10.1667/0033-7587(2002)157[0568:MSDSIR]2.0.CO;2; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Honko AN, 2005, IMMUNOL RES, V33, P83, DOI 10.1385/IR:33:1:083; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karkanitsa LV, 1997, STEM CELLS, V15, P95; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Lu T, 2004, CELL CYCLE, V3, P1114; Maaser C, 2004, J IMMUNOL, V172, P5056, DOI 10.4049/jimmunol.172.8.5056; Murthy KGK, 2004, J BIOL CHEM, V279, P5667, DOI 10.1074/jbc.M307759200; NETA R, 1991, J EXP MED, V173, P1177, DOI 10.1084/jem.173.5.1177; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Pasare C, 2005, ADV EXP MED BIOL, V560, P11; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Sebastiani G, 2000, GENOMICS, V64, P230, DOI 10.1006/geno.2000.6115; Stickney DR, 2007, INT IMMUNOPHARMACOL, V7, P500, DOI 10.1016/j.intimp.2006.12.005; Tallant T, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-33; Uematsu S, 2006, NAT IMMUNOL, V7, P868, DOI 10.1038/ni1362; Vidrich A, 2005, AM J PATHOL, V166, P1055, DOI 10.1016/S0002-9440(10)62326-7; Wang Y, 2004, CANCER RES, V64, P6240, DOI 10.1158/0008-5472.CAN-04-0591; Waselenko JK, 2004, ANN INTERN MED, V140, P1037, DOI 10.7326/0003-4819-140-12-200406150-00015; Weiss JF, 2003, TOXICOLOGY, V189, P1, DOI 10.1016/S0300-483X(03)00149-5; Weiss JF, 1997, ENVIRON HEALTH PERSP, V105, P1473, DOI 10.2307/3433654; Whitnall MH, 2000, INT J IMMUNOPHARMACO, V22, P1, DOI 10.1016/S0192-0561(99)00059-4; Yu YM, 2006, J IMMUNOL, V176, P6194, DOI 10.4049/jimmunol.176.10.6194	35	517	630	3	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					226	230		10.1126/science.1154986	http://dx.doi.org/10.1126/science.1154986			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403709	Green Accepted			2022-12-28	WOS:000254836700042
J	Hayashi, M; Thomas, L; Moriya, R; Rettner, C; Parkin, SSP				Hayashi, Masamitsu; Thomas, Luc; Moriya, Rai; Rettner, Charles; Parkin, Stuart S. P.			Current-controlled magnetic domain-wall nanowire shift register	SCIENCE			English	Article							CURRENT PULSES	The controlled motion of a series of domain walls along magnetic nanowires using spin-polarized current pulses is the essential ingredient of the proposed magnetic racetrack memory, a new class of potential non-volatile storage-class memories. Using permalloy nanowires, we achieved the successive creation, motion, and detection of domain walls by using sequences of properly timed, nanosecond-long, spin-polarized current pulses. The cycle time for the writing and shifting of the domain walls was a few tens of nanoseconds. Our results illustrate the basic concept of a magnetic shift register that relies on the phenomenon of spin-momentum transfer to move series of closely spaced domain walls.	[Hayashi, Masamitsu; Thomas, Luc; Moriya, Rai; Rettner, Charles; Parkin, Stuart S. P.] IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA	International Business Machines (IBM)	Parkin, SSP (corresponding author), IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA.	parkin@almaden.ibm.com	Parkin, Stuart/D-2521-2012; Moriya, Rai/P-1460-2016; Hayashi, Masamitsu/N-8033-2019; Hayashi, Masamitsu/H-2809-2011	Parkin, Stuart/0000-0003-4702-6139; Moriya, Rai/0000-0001-7471-7432; Hayashi, Masamitsu/0000-0003-2134-2563; Hayashi, Masamitsu/0000-0003-2134-2563				Barnes SE, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.107204; BERGER L, 1984, J APPL PHYS, V55, P1954, DOI 10.1063/1.333530; BOBECK AH, 1975, P IEEE, V63, P1176, DOI 10.1109/PROC.1975.9912; Feigenson M, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.247204; Hayashi M, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.037204; Hayashi M, 2007, NAT PHYS, V3, P21, DOI 10.1038/nphys464; Klaui M, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.026601; Laribi S, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2746952; Malozemoff A.P., 1979, MAGNETIC DOMAIN WALL; Middelhoek S., 1976, PHYS COMPUTER MEMORY; Nakatani Y, 2005, J MAGN MAGN MATER, V290, P750, DOI 10.1016/j.jmmm.2004.11.355; Ravelosona D, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.117203; Slonczewski JC, 1996, J MAGN MAGN MATER, V159, pL1, DOI 10.1016/0304-8853(96)00062-5; Stiles MD, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.214423; Tatara G, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.086601; Thiaville A, 2007, EUR PHYS J B, V60, P15, DOI 10.1140/epjb/e2007-00320-3; Thomas L, 2007, SCIENCE, V315, P1553, DOI 10.1126/science.1137662; Vernier N, 2004, EUROPHYS LETT, V65, P526, DOI 10.1209/epl/i2003-10112-5; Yamanouchi M, 2004, NATURE, V428, P539, DOI 10.1038/nature02441; Zhang S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.127204	21	547	554	5	209	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					209	211		10.1126/science.1154587	http://dx.doi.org/10.1126/science.1154587			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403706				2022-12-28	WOS:000254836700037
J	Kim, VN				Kim, V. Narry			Sorting out small RNAs	CELL			English	Editorial Material							RECOGNITION	Small RNAs carry out their functions by guiding Argonaute (AGO) proteins to their targets. Diverse types of small RNAs and multiple AGO proteins exist in most eukaryotic species, but how small RNAs are sorted into specific AGO complexes remains unclear. Two papers in this issue (Mi et al., 2008; Montgomery et al., 2008) now reveal the importance of the 5' terminal nucleotide of the small RNA in the sorting process in Arabidopsis.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; [Kim, V. Narry] Seoul Natl Univ, Natl Creat Res Initiat Ctr, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Kim, VN (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	narrykim@snu.ac.kr						Aravin AA, 2007, SCIENCE, V318, P761, DOI 10.1126/science.1146484; Chapman EJ, 2007, NAT REV GENET, V8, P884, DOI 10.1038/nrg2179; Hutvagner G, 2008, NAT REV MOL CELL BIO, V9, P22, DOI 10.1038/nrm2321; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Parker JS, 2005, NATURE, V434, P663, DOI 10.1038/nature03462; Steiner FA, 2007, NAT STRUCT MOL BIOL, V14, P927, DOI 10.1038/nsmb1308; TAKEDA A, 2008, PLANT CELL PHYSL; Tomari Y, 2007, CELL, V130, P299, DOI 10.1016/j.cell.2007.05.057	8	59	64	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 4	2008	133	1					25	26		10.1016/j.cell.2008.03.015	http://dx.doi.org/10.1016/j.cell.2008.03.015			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394983	Bronze			2022-12-28	WOS:000254641300002
J	Hamzah, J; Jugold, M; Kiessling, F; Rigby, P; Manzur, M; Marti, HH; Rabie, T; Kaden, S; Grone, HJ; Hammerling, GJ; Arnold, B; Ganss, R				Hamzah, Juliana; Jugold, Manfred; Kiessling, Fabian; Rigby, Paul; Manzur, Mitali; Marti, Hugo H.; Rabie, Tamer; Kaden, Sylvia; Groene, Hermann-Josef; Haemmerling, Guenter J.; Arnold, Bernd; Ganss, Ruth			Vascular normalization in Rgs5-deficient tumours promotes immune destruction	NATURE			English	Article							HEPATOCELLULAR-CARCINOMA; ANTIANGIOGENIC THERAPY; BLOOD-VESSELS; PERICYTES; PROTEIN; CELLS; MODEL; RGS5; EDEMA; TUMORIGENESIS	The vasculature of solid tumours is morphologically aberrant and characterized by dilated and fragile vessels, intensive vessel sprouting and loss of hierarchical architecture(1). Constant vessel remodelling leads to spontaneous haemorrhages(2) and increased interstitial fluid pressure in the tumour environment(3,4). Tumour-related angiogenesis supports tumour growth and is also a major obstacle for successful immune therapy as it prevents migration of immune effector cells into established tumour parenchyma(2,5,6). The molecular mechanisms for these angiogenic alterations are largely unknown. Here we identify regulator of G-protein signalling 5 (Rgs5) as a master gene responsible for the abnormal tumour vascular morphology in mice. Loss of Rgs5 results in pericyte maturation, vascular normalization and consequent marked reductions in tumour hypoxia and vessel leakiness. These vascular and intratumoral changes enhance influx of immune effector cells into tumour parenchyma and markedly prolong survival of tumour-bearing mice. This is the first demonstration, to our knowledge, of reduced tumour angiogenesis and improved immune therapeutic outcome on loss of a vascular gene function and establishes a previously unrecognized role of G-protein signalling in tumour angiogenesis.	[Hamzah, Juliana; Manzur, Mitali; Ganss, Ruth] Univ Western Australia, Med Res Ctr, Western Australian Inst Med Res, Perth, WA 6000, Australia; [Jugold, Manfred; Kiessling, Fabian] German Canc Res Ctr, Juniorgrp Mol Imaging, Dept Med Phys Radiol, D-69120 Heidelberg, Germany; [Kaden, Sylvia; Groene, Hermann-Josef] German Canc Res Ctr, Dept Cellular & Mol Pathol, D-69120 Heidelberg, Germany; [Haemmerling, Guenter J.; Arnold, Bernd] German Canc Res Ctr, Dept Mol Immunol, D-69120 Heidelberg, Germany; [Rigby, Paul] Univ Western Australia, Ctr Microscopy Characterisat & Anal, Perth, WA 6000, Australia; [Marti, Hugo H.; Rabie, Tamer] Univ Heidelberg, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany	University of Western Australia; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Western Australia; Ruprecht Karls University Heidelberg	Ganss, R (corresponding author), Univ Western Australia, Med Res Ctr, Western Australian Inst Med Res, Perth, WA 6000, Australia.	ganss@waimr.uwa.edu.au	Rabie, Tamer/C-7886-2013; Rigby, Paul/G-5248-2012; hamzah, juliana/G-3114-2013; Kiessling, Fabian/Y-2417-2019	Kiessling, Fabian/0000-0002-7341-0399; Ganss, Ruth/0000-0002-5551-045X; Marti, Hugo/0000-0002-8456-334X; Rabie, Tamer/0000-0001-9060-8797				Allt G, 2001, CELLS TISSUES ORGANS, V169, P1, DOI 10.1159/000047855; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Berger M, 2005, BLOOD, V105, P1094, DOI 10.1182/blood-2004-06-2315; Bondjers C, 2003, AM J PATHOL, V162, P721, DOI 10.1016/S0002-9440(10)63868-0; Boss CN, 2007, CLIN CANCER RES, V13, P3347, DOI 10.1158/1078-0432.CCR-06-2156; BRIX G, 1991, J COMPUT ASSIST TOMO, V15, P621, DOI 10.1097/00004728-199107000-00018; Buckanovich RJ, 2008, NAT MED, V14, P28, DOI 10.1038/nm1699; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen X, 2004, MODERN PATHOL, V17, P1198, DOI 10.1038/modpathol.3800167; Furuya M, 2004, J PATHOL, V203, P551, DOI 10.1002/path.1543; Ganss R, 1998, CANCER RES, V58, P4673; Ganss R, 2002, CANCER RES, V62, P1462; Ganss R, 2004, EUR J IMMUNOL, V34, P2635, DOI 10.1002/eji.200425474; Garbi N, 2004, J IMMUNOL, V172, P5861, DOI 10.4049/jimmunol.172.10.5861; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hata R, 1998, J CEREBR BLOOD F MET, V18, P367, DOI 10.1097/00004647-199804000-00004; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Jain RK, 2007, CANCER RES, V67, P2729, DOI 10.1158/0008-5472.CAN-06-4102; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Manome Y, 2003, CELLS TISSUES ORGANS, V174, P155, DOI 10.1159/000072718; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; Ryschich E, 2006, CANCER RES, V66, P198, DOI 10.1158/0008-5472.CAN-05-1636; Ryschich E, 2002, INT J CANCER, V97, P719, DOI 10.1002/ijc.10074; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011	30	412	432	11	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2008	453	7193					410	U67		10.1038/nature06868	http://dx.doi.org/10.1038/nature06868			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301AI	18418378	Bronze			2022-12-28	WOS:000255868400056
J	Lynn, J				Lynn, Joanne			Making a difference - Palliative care beyond cancer - Reliable comfort and meaningfulness	BRITISH MEDICAL JOURNAL			English	Editorial Material							QUALITY IMPROVEMENT		Ctr Medicare & Medicaid Serv, Off Clin Stand & Qual, Baltimore, MD 21244 USA	Centers for Medicare & Medicaid Services	Lynn, J (corresponding author), Ctr Medicare & Medicaid Serv, Off Clin Stand & Qual, 7500 Secur Blvd, Baltimore, MD 21244 USA.	Joanne.Lynn@cms.hhs.gov						Arnold R, 2005, J PALLIAT MED, V8, P1086, DOI 10.1089/jpm.2005.8.1086; DAVIS K, 2007, MED HOMES COULD IMPR; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Lynn J, 2002, ANN INTERN MED, V137, P117, DOI 10.7326/0003-4819-137-2-200207160-00010; LYNN J, 2007, COMMON SENSE GUIDE I; LYNN J, 2007, IMPROVING CARE END L; LYNN J, 2004, SICK DEATH NOT GOING; Lynn J, 2007, J AM GERIATR SOC, V55, P1663, DOI 10.1111/j.1532-5415.2007.01380.x; Lynn J, 2007, MILBANK Q, V85, P185, DOI 10.1111/j.1468-0009.2007.00483.x	9	11	12	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					958	+		10.1136/bmj.39535.656319.94	http://dx.doi.org/10.1136/bmj.39535.656319.94			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296KC	18397941	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000255540900046
J	Maya-Vetencourt, JF; Sale, A; Viegi, A; Baroncelli, L; De Pasquale, R; O'Leary, OF; Castren, E; Maffei, L				Maya-Vetencourt, Jose Fernando; Sale, Alessandro; Viegi, Alessandro; Baroncelli, Laura; De Pasquale, Roberto; O'Leary, Olivia F.; Castren, Eero; Maffei, Lamberto			The antidepressant fluoxetine restores plasticity in the adult visual cortex	SCIENCE			English	Article							OCULAR DOMINANCE PLASTICITY; CRITICAL-PERIOD; EVOKED-POTENTIALS; RAT HIPPOCAMPUS; MOUSE MODEL; INHIBITION; BRAIN; BDNF; NEUROGENESIS; DEPRESSION	We investigated whether fluoxetine, a widely prescribed medication for treatment of depression, restores neuronal plasticity in the adult visual system of the rat. We found that chronic administration of fluoxetine reinstates ocular dominance plasticity in adulthood and promotes the recovery of visual functions in adult amblyopic animals, as tested electrophysiologically and behaviorally. These effects were accompanied by reduced intracortical inhibition and increased expression of brain- derived neurotrophic factor in the visual cortex. Cortical administration of diazepam prevented the effects induced by fluoxetine, indicating that the reduction of intracortical inhibition promotes visual cortical plasticity in the adult. Our results suggest a potential clinical application for fluoxetine in amblyopia as well as new mechanisms for the therapeutic effects of antidepressants and for the pathophysiology of mood disorders.	[Maya-Vetencourt, Jose Fernando; Sale, Alessandro; Viegi, Alessandro; Baroncelli, Laura; De Pasquale, Roberto; Maffei, Lamberto] Scuola Normale Super Pisa, I-56100 Pisa, Italy; [Maffei, Lamberto] CNR, Inst Neurosci, I-56100 Pisa, Italy; [Castren, Eero] Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland	Scuola Normale Superiore di Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); University of Helsinki	Maya-Vetencourt, JF (corresponding author), Scuola Normale Super Pisa, Piazza Cavalieri, I-56100 Pisa, Italy.	jf.maya@in.cnr.it	Baroncelli, Laura/K-5823-2016; Castrén, Eero/A-4618-2010; Sale, Alessandro/K-7760-2016; Maya-Vetencourt, Jose Fernando/Q-6539-2019; DE PASQUALE, ROBERTO/AAE-2941-2019; O'Leary, Olivia/E-7964-2013	Baroncelli, Laura/0000-0001-6739-2860; Maya-Vetencourt, Jose Fernando/0000-0003-3808-8944; De Pasquale, Roberto/0000-0003-3383-7715; Castren, Eero/0000-0002-1402-2791; O'Leary, Olivia/0000-0002-9171-2032; Sale, Alessandro/0000-0001-7608-4456				ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; Castren E, 2005, NAT REV NEUROSCI, V6, P241, DOI 10.1038/nrn1629; Castren E, 2004, CURR OPIN PHARMACOL, V4, P58, DOI 10.1016/j.coph.2003.10.004; D'Sa C, 2002, BIPOLAR DISORD, V4, P183, DOI 10.1034/j.1399-5618.2002.01203.x; Dani VS, 2005, P NATL ACAD SCI USA, V102, P12560, DOI 10.1073/pnas.0506071102; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; Fernandez F, 2007, NAT NEUROSCI, V10, P411, DOI 10.1038/nn1860; Frenkel MY, 2004, NEURON, V44, P917, DOI 10.1016/j.neuron.2004.12.003; Guire ES, 1999, J NEUROPHYSIOL, V81, P121, DOI 10.1152/jn.1999.81.1.121; Hajszan T, 2005, EUR J NEUROSCI, V21, P1299, DOI 10.1111/j.1460-9568.2005.03968.x; He HY, 2006, J NEUROSCI, V26, P2951, DOI 10.1523/JNEUROSCI.5554-05.2006; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Holmes JM, 2006, LANCET, V367, P1343, DOI 10.1016/S0140-6736(06)68581-4; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; Koponen E, 2005, CELL MOL NEUROBIOL, V25, P973, DOI 10.1007/s10571-005-8468-z; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Nestler EJ, 1998, BIOL PSYCHIAT, V44, P526, DOI 10.1016/S0006-3223(98)00095-X; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Normann C, 2007, BIOL PSYCHIAT, V62, P373, DOI 10.1016/j.biopsych.2006.10.006; Porciatti V, 1999, VISION RES, V39, P3071, DOI 10.1016/S0042-6989(99)00022-X; REYNOLDS JN, 1988, BRAIN RES, V456, P286, DOI 10.1016/0006-8993(88)90230-2; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; Sale A, 2007, NAT NEUROSCI, V10, P679, DOI 10.1038/nn1899; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sawtell NB, 2003, NEURON, V38, P977, DOI 10.1016/S0896-6273(03)00323-4; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002	27	595	600	2	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2008	320	5874					385	388		10.1126/science.1150516	http://dx.doi.org/10.1126/science.1150516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420937				2022-12-28	WOS:000255026100047
J	Heikens, GT; Bunn, J; Amadi, B; Manary, M; Chhagan, M; Berkley, JA; Rollins, N; Kelly, P; Adamczick, C; Maitland, K; Tomkins, A				Heikens, Geert Tom; Bunn, James; Amadi, Beatrice; Manary, Mark; Chhagan, Meera; Berkley, James A.; Rollins, Nigel; Kelly, Paul; Adamczick, Charlotte; Maitland, Kathryn; Tomkins, Andrew		Blantyre Working Grp	Case management of HIV-infected severely malnourished children: challenges in the area of highest prevalence	LANCET			English	Editorial Material							HOME-BASED THERAPY; SEVERE MALNUTRITION; ZAMBIAN CHILDREN; COMMUNITY; MORTALITY; MORBIDITY; DISEASE; IMPACT		[Heikens, Geert Tom; Bunn, James] Univ Malawi, Dept Paediat, Coll Med, Blantyre 3, Malawi; [Bunn, James; Manary, Mark] Univ Malawi, Dept Community Med, Coll Med, Blantyre 3, Malawi; [Bunn, James] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England; [Amadi, Beatrice] Univ Teaching Hosp, Dept Paediat & Child Hlth, Lusaka, Zambia; [Manary, Mark] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Chhagan, Meera] Univ Kwazulu Natal, Nelson R Mandela Sch Med, Dept Paediat & Child Hlth, Durban, South Africa; [Rollins, Nigel] Univ Kwazulu Natal, Nelson R Mandela Sch Med, Ctr Maternal & Child Hlth, Durban, South Africa; [Berkley, James A.; Maitland, Kathryn] Kenya Govt Med Res Ctr, Wellcome Trust Programme, Kilifi, Kenya; [Berkley, James A.] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford, England; [Kelly, Paul] Barts & London Queen Marys Sch Med & Dent, London, England; [Kelly, Paul] Univ Zambia, Sch Med, Trop Gastroenterol & Nutr Grp, Lusaka, Zambia; [Adamczick, Charlotte] Zomba Cent Hosp, Dept Paediat, Zomba, Malawi; [Maitland, Kathryn] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, Div Med, London, England; [Tomkins, Andrew] UCL, Inst Child Hlth, Ctr Int Hlth & Dev, London, England	University of Malawi; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool; University of Zambia; Washington University (WUSTL); University of Kwazulu Natal; University of Kwazulu Natal; Kenya Medical Research Institute; University of Oxford; University of London; Queen Mary University London; University of Zambia; Imperial College London; University of London; University College London	Heikens, GT (corresponding author), Univ Malawi, Dept Paediat, Coll Med, Private Bag 360, Blantyre 3, Malawi.	theikens@medcol.mw	Kerac, Marko/G-1777-2010	Kerac, Marko/0000-0002-3745-7317; Manary, Mark/0000-0003-2733-9568; Maitland, Kathryn/0000-0002-0007-0645; Berkley, James/0000-0002-1236-849X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABIREKEREIRISO E, 2006, ANN TROP PAEDIAT INT, V26, P319; Amadi B, 2002, LANCET, V360, P1375, DOI 10.1016/S0140-6736(02)11401-2; Amadi B, 2001, J PEDIATR GASTR NUTR, V32, P550, DOI 10.1097/00005176-200105000-00011; Andresen E, 2007, J TROP PEDIATRICS, V53, P409, DOI 10.1093/tropej/fmm059; [Anonymous], CAS DEF HIV SURV REV; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Brent AJ, 2006, PEDIATR INFECT DIS J, V25, P230, DOI 10.1097/01.inf.0000202066.02212.ff; Briend A, 2006, FOOD NUTR BULL, V27, pS3, DOI 10.1177/15648265060273S301; Bunn J., 2007, MALAWI MED J, V19, P95; Chhagan MK, 2006, PEDIATR INFECT DIS J, V25, P333, DOI 10.1097/01.inf.0000207400.93627.4c; CHINKUMBHA J, IN PRESS T R SOC TRO; Ciliberto MA, 2005, AM J CLIN NUTR, V81, P864, DOI 10.1093/ajcn/81.4.864; Collins S, 2006, LANCET, V368, P1992, DOI 10.1016/S0140-6736(06)69443-9; Heikens G. T., 2003, REHABILITATION SICK; Heikens GT, 2008, LANCET, V371, P181, DOI 10.1016/S0140-6736(07)61691-2; Heikens GT, 2007, PLOS MED, V4, P222, DOI 10.1371/journal.pmed.0040045; Heikens GT, 2007, LANCET, V369, P2159, DOI 10.1016/S0140-6736(07)61010-1; HEIKENS GT, 1993, EUR J CLIN NUTR, V47, P174; Hsu J..W.C, 2005, MACRONUTRIENTS HIV; HUGHES S, 2006, ARCH DIS CHILD S, V91, pA15; Jackson A. A., 1987, OXFORD TXB MED, P12; KAUFLAFULA G, GASTROENTERITIS ASS; Kessler L, 2000, ANN TROP PAEDIATR, V20, P50, DOI 10.1080/02724930092075; Madhi SA, 2000, CLIN INFECT DIS, V31, P170, DOI 10.1086/313925; Maitland K, 2006, PLOS MED, V3, P2431, DOI 10.1371/journal.pmed.0030500; Manary MJ, 2004, ARCH DIS CHILD, V89, P557, DOI 10.1136/adc.2003.034306; Marais BJ, 2007, PAEDIATR RESPIR REV, V8, P124, DOI 10.1016/j.prrv.2007.04.002; MILLER TL, 1993, AM J CLIN NUTR, V57, P588, DOI 10.1093/ajcn/57.4.588; Victora CG, 2007, LANCET, V370, P1113, DOI 10.1016/S0140-6736(07)61492-5; World Health Organization, 1999, MAN SEV MALN MAN PHY; World Health Organization, 2005, SEV MALN REP CONS RE; Zampoli M, 2007, INT J TUBERC LUNG D, V11, P417; Zar HJ, 2003, J TROP PEDIATRICS, V49, P78, DOI 10.1093/tropej/49.2.78	34	94	97	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1305	1307		10.1016/S0140-6736(08)60565-6	http://dx.doi.org/10.1016/S0140-6736(08)60565-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	286XH	18406865				2022-12-28	WOS:000254878900032
J	Watts, G				Watts, Geoff			An unlikely benefactor	BRITISH MEDICAL JOURNAL			English	Editorial Material												geoff@scileg.freeserve.co.uk						*ENG PHYS SCI RES, EPSRC DEL PLAN 2008; HM TREASURY, 2006, LONG TERM OPP CHALL	2	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 5	2008	336	7647					746	746		10.1136/bmj.39506.495868.AD	http://dx.doi.org/10.1136/bmj.39506.495868.AD			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284JW	18390522	Green Published			2022-12-28	WOS:000254703700027
J	Padua, D; Zhang, XHF; Wang, QQ; Nadal, C; Gerald, WL; Gomis, RR; Massague, J				Padua, David; Zhang, Xiang H. -F.; Wang, Qiongqing; Nadal, Cristina; Gerald, William L.; Gomis, Roger R.; Massague, Joan			TGF beta primes breast tumors for lung metastasis seeding through angiopoietin-like 4	CELL			English	Article							GROWTH-FACTOR-BETA; ENDOTHELIAL-CELL ADHESION; GENE-EXPRESSION SIGNATURE; CANCER METASTASIS; EXTRACELLULAR-MATRIX; C-MYC; RECEPTOR; SMAD; BONE; ANGIOGENESIS	Cells released from primary tumors seed metastases to specific organs by a nonrandom process, implying the involvement of biologically selective mechanisms. Based on clinical, functional, and molecular evidence, we show that the cytokine TGF beta in the breast tumor microenvironment primes cancer cells for metastasis to the lungs. Central to this process is the induction of angiopoietin-like 4 (ANGPTL4) by TGFb via the Smad signaling pathway. TGFb induction of Angptl4 in cancer cells that are about to enter the circulation enhances their subsequent retention in the lungs, but not in the bone. Tumor cell-derived Angptl4 disrupts vascular endothelial cell-cell junctions, increases the permeability of lung capillaries, and facilitates the trans-endothelial passage of tumor cells. These results suggest a mechanism for metastasis whereby a cytokine in the primary tumor microenvironment induces the expression of another cytokine in departing tumor cells, empowering these cells to disrupt lung capillary walls and seed pulmonary metastases.	[Padua, David; Zhang, Xiang H. -F.; Wang, Qiongqing; Massague, Joan] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; [Gerald, William L.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Massague, Joan] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; [Gomis, Roger R.] Inst Res Biomed, Oncol Programme, Barcelona 08028, Spain; [Nadal, Cristina] Hosp Clin IDIBAPS, Inst Malalties Hemato Oncol, Barcelona 08036, Spain	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	j-massague@mskcc.org	Gomis, Roger R/E-9788-2016	Gomis, Roger R/0000-0001-6473-2858; Massague, Joan/0000-0001-9324-8408; Zhang, Xiang/0000-0002-5674-8670; Padua, David/0000-0003-2549-9939	NATIONAL CANCER INSTITUTE [P01CA094060, P30CA008748, R37CA034610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [R37 CA034610, P01 CA094060-01A10002, R37 CA034610-25, P30 CA008748, P01 CA094060] Funding Source: Medline; NIGMS NIH HHS [GM07739, T32 GM007739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Buck MB, 2004, CLIN CANCER RES, V10, P491, DOI 10.1158/1078-0432.CCR-0320-03; Camenisch G, 2002, J BIOL CHEM, V277, P17281, DOI 10.1074/jbc.M109768200; Cazes A, 2006, CIRC RES, V99, P1207, DOI 10.1161/01.RES.0000250758.63358.91; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; DALAL BI, 1993, AM J PATHOL, V143, P381; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hermann LM, 2005, CLIN IMMUNOL, V115, P93, DOI 10.1016/j.clim.2004.12.002; Ito Y, 2003, CANCER RES, V63, P6651; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kielhorn E, 2002, CANCER, V94, P205, DOI 10.1002/cncr.10193; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; OGHISO Y, 1979, JPN J EXP MED, V49, P223; Oike Y, 2004, INT J HEMATOL, V80, P21, DOI 10.1532/ijh97.04034; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678	54	704	735	1	65	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 4	2008	133	1					66	77		10.1016/j.cell.2008.01.046	http://dx.doi.org/10.1016/j.cell.2008.01.046			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394990	Green Accepted, Bronze			2022-12-28	WOS:000254641300009
J	Chu, SY; Bachman, DJ; Callaghan, WM; Whitlock, EP; Dietz, PM; Berg, CJ; O'Keeffe-Rosetti, M; Bruce, FC; Hornbrook, MC				Chu, Susan Y.; Bachman, Donald J.; Callaghan, William M.; Whitlock, Evelyn P.; Dietz, Patricia M.; Berg, Cynthia J.; O'Keeffe-Rosetti, Maureen; Bruce, F. Carol; Hornbrook, Mark C.			Association between obesity during pregnancy and increased use of health care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATERNAL OBESITY; WEIGHT; TRENDS; RISK; IMPACT	Background: In the United States, obesity during pregnancy is common and increases obstetrical risks. An estimate of the increase in use of health care services associated with obesity during pregnancy is needed. Methods: We used electronic data systems of a large U.S. group-practice health maintenance organization to identify 13,442 pregnancies among women 18 years of age or older at the time of conception that resulted in live births or stillbirths. The study period was between January 1, 2000, and December 31, 2004. We assessed associations between measures of use of health care services and body-mass index (BMI, defined as the weight in kilograms divided by the square of the height in meters) before pregnancy or in early pregnancy. The women were categorized as underweight (BMI <18.5), normal (BMI 18.5 to 24.9), overweight (BMI 25.0 to 29.9), obese (BMI 30.0 to 34.9), very obese (BMI 35.0 to 39.9), or extremely obese (BMI greater/equal 40.0). The primary outcome was the mean length of hospital stay for delivery. Results: After adjustment for age, race or ethnic group, level of education, and parity, the mean (+/-SE) length of hospital stay for delivery was significantly (P<0.05) greater among women who were overweight (3.7+/-0.1 days), obese (4.0+/-0.1 days), very obese (4.1+/-0.1 days), and extremely obese (4.4+/-0.1 days) than among women with normal BMI (3.6+/-0.1 days). A higher-than-normal BMI was associated with significantly more prenatal fetal tests, obstetrical ultrasonographic examinations, medications dispensed from the outpatient pharmacy, telephone calls to the department of obstetrics and gynecology, and prenatal visits with physicians. A higher-than-normal BMI was also associated with significantly fewer prenatal visits with nurse practitioners and physician assistants. Most of the increase in length of stay associated with higher BMI was related to increased rates of cesarean delivery and obesity-related high-risk conditions. Conclusions: Obesity during pregnancy is associated with increased use of health care services.	[Chu, Susan Y.; Callaghan, William M.; Dietz, Patricia M.; Berg, Cynthia J.; Bruce, F. Carol] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; [Bachman, Donald J.; Whitlock, Evelyn P.; O'Keeffe-Rosetti, Maureen; Hornbrook, Mark C.] Kaiser Permanente NW, Ctr Hlth Res NW Hawaii SE, Portland, OR USA	Centers for Disease Control & Prevention - USA; Kaiser Permanente	Chu, SY (corresponding author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K-23, Atlanta, GA 30341 USA.	syc1@cdc.gov						American College of Obstetricians and Gynecologists (ACOG), 2005, OBSTET GYNECOL, V106, P671, DOI [10.1097/00006250-200509000-00054, DOI 10.1097/00006250-200509000-00054]; Catalano PM, 2006, BJOG-INT J OBSTET GY, V113, P1126, DOI 10.1111/j.1471-0528.2006.00989.x; Cnattingius S, 1998, NEW ENGL J MED, V338, P147, DOI 10.1056/NEJM199801153380302; Cogswell M E., 2001, Prim Care Update Ob Gyns, V8, P89, DOI 10.1016/S1068-607X(00)00087-1; Ehrenberg HM, 2004, AM J OBSTET GYNECOL, V191, P969, DOI 10.1016/j.ajog.2004.06.057; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Galtier-Dereure F, 2000, AM J CLIN NUTR, V71, p1242S, DOI 10.1093/ajcn/71.5.1242s; GALTIERDEREURE F, 1995, INT J OBESITY, V19, P443; GARBACIAK JA, 1985, AM J OBSTET GYNECOL, V152, P238, DOI 10.1016/S0002-9378(85)80029-6; Hendler I, 2004, INT J OBESITY, V28, P1607, DOI 10.1038/sj.ijo.0802759; Heslehurst N, 2007, BJOG-INT J OBSTET GY, V114, P334, DOI 10.1111/j.1471-0528.2006.01230.x; Hornbrook MC, 2007, HEALTH SERV RES, V42, P908, DOI 10.1111/j.1475-6773.2006.00635.x; Kim SY, 2007, OBESITY, V15, P986, DOI 10.1038/oby.2007.621; Villamor E, 2006, LANCET, V368, P1164, DOI 10.1016/S0140-6736(06)69473-7; Yeh J, 2005, AM J OBSTET GYNECOL, V193, P1994, DOI 10.1016/j.ajog.2005.05.001	15	168	172	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1444	1453		10.1056/NEJMoa0706786	http://dx.doi.org/10.1056/NEJMoa0706786			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282CY	18385496				2022-12-28	WOS:000254546400005
J	Thakur, JK; Arthanari, H; Yang, FJ; Pan, SJ; Fan, XC; Breger, J; Frueh, DP; Gulshan, K; Li, DK; Mylonakis, E; Struhl, K; Moye-Rowley, WS; Cormack, BP; Wagner, G; Naar, AM				Thakur, Jitendra K.; Arthanari, Haribabu; Yang, Fajun; Pan, Shih-Jung; Fan, Xiaochun; Breger, Julia; Frueh, Dominique P.; Gulshan, Kailash; Li, Darrick K.; Mylonakis, Eleftherios; Struhl, Kevin; Moye-Rowley, W. Scott; Cormack, Brendan P.; Wagner, Gerhard; Naar, Anders M.			A nuclear receptor-like pathway regulating multidrug resistance in fungi	NATURE			English	Article							TRANSCRIPTION-FACTOR-BINDING; DRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; TRANSACTIVATION DOMAIN; CASSETTE TRANSPORTER; SECONDARY STRUCTURE; CANDIDA-GLABRATA; NMR-SPECTROSCOPY; AZOLE RESISTANCE; KIX DOMAIN	Multidrug resistance ( MDR) is a serious complication during treatment of opportunistic fungal infections that frequently afflict immunocompromised individuals, such as transplant recipients and cancer patients undergoing cytotoxic chemotherapy. Improved knowledge of the molecular pathways controlling MDR in pathogenic fungi should facilitate the development of novel therapies to combat these intransigent infections. MDR is often caused by upregulation of drug efflux pumps by members of the fungal zinc- cluster transcription- factor family ( for example Pdr1p orthologues). However, the molecular mechanisms are poorly understood. Here we show that Pdr1p family members in Saccharomyces cerevisiae and the human pathogen Candida glabrata directly bind to structurally diverse drugs and xenobiotics, resulting in stimulated expression of drug efflux pumps and induction of MDR. Notably, this is mechanistically similar to regulation of MDR in vertebrates by the PXR nuclear receptor, revealing an unexpected functional analogy of fungal and metazoan regulators of MDR. We have also uncovered a critical and specific role of the Gal11p/ MED15 subunit of the Mediator co- activator and its activator- targeted KIX domain in antifungal/ xenobiotic- dependent regulation of MDR. This detailed mechanistic understanding of a fungal nuclear receptor- like gene regulatory pathway provides novel therapeutic targets for the treatment of multidrug- resistant fungal infections.	[Thakur, Jitendra K.; Yang, Fajun; Li, Darrick K.; Naar, Anders M.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; [Thakur, Jitendra K.; Yang, Fajun; Naar, Anders M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Arthanari, Haribabu; Fan, Xiaochun; Frueh, Dominique P.; Struhl, Kevin; Wagner, Gerhard] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Pan, Shih-Jung; Cormack, Brendan P.] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; [Breger, Julia; Mylonakis, Eleftherios] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Gulshan, Kailash; Moye-Rowley, W. Scott] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Johns Hopkins University; Harvard University; Massachusetts General Hospital; University of Iowa	Naar, AM (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.	naar@helix.mgh.harvard.edu	Moye-Rowley, Scott/AFL-7135-2022; Thakur, Jitendra/AAN-8674-2021; Frueh, Dominique P/A-6462-2008	Moye-Rowley, Scott/0000-0002-7163-1120; Frueh, Dominique P/0000-0003-4605-3776; Arthanari, Haribabu/0000-0002-7281-1289; Thakur, Jitendra Kumar/0000-0001-7874-1923	NCI NIH HHS [CA127990, R01 CA127990] Funding Source: Medline; NIBIB NIH HHS [EB2026] Funding Source: Medline; NIGMS NIH HHS [GM071449, GM30186, GM49825, GM47467] Funding Source: Medline; PHS HHS [A1046223] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA127990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825, R37GM030186, R01GM071449, P01GM047467, R01GM030186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alenquer M, 2006, FEMS YEAST RES, V6, P1130, DOI 10.1111/j.1567-1364.2006.00095.x; Aparicio JG, 2004, MOL CELL BIOL, V24, P4769, DOI 10.1128/MCB.24.11.4769-4780.2004; Aperis G, 2006, EXPERT OPIN INV DRUG, V15, P1319, DOI 10.1517/13543784.15.11.1319; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1994, J BIOL CHEM, V269, P2206; Bertrand W, 2004, MOL BIOL EVOL, V21, P1923, DOI 10.1093/molbev/msh200; Breger J, 2007, PLOS PATHOG, V3, P168, DOI 10.1371/journal.ppat.0030018; Cormack BP, 1999, GENETICS, V151, P979; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; De Guzman RN, 2006, J MOL BIOL, V355, P1005, DOI 10.1016/j.jmb.2005.09.059; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; Fardeau V, 2007, J BIOL CHEM, V282, P5063, DOI 10.1074/jbc.M610197200; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Frueh DP, 2005, J BIOMOL NMR, V33, P187, DOI 10.1007/s10858-005-3204-z; Gao C, 2004, J BIOL CHEM, V279, P42677, DOI 10.1074/jbc.M406363200; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goodman RH, 2000, GENE DEV, V14, P1553; Goto NK, 2002, J BIOL CHEM, V277, P43168, DOI 10.1074/jbc.M207660200; Gulshan K, 2005, J BIOL CHEM, V280, P40524, DOI 10.1074/jbc.M504716200; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; Kepinski S, 2005, NATURE, V435, P446, DOI 10.1038/nature03542; Klepser ME, 2006, PHARMACOTHERAPY, V26, p68S, DOI 10.1592/phco.26.6part2.68S; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; Lucau-Danila A, 2005, MOL CELL BIOL, V25, P1860, DOI 10.1128/MCB.25.5.1860-1868.2005; Mamnun YM, 2004, FEBS LETT, V559, P111, DOI 10.1016/S0014-5793(04)00046-8; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Moye-Rowley WS, 2003, PROG NUCLEIC ACID RE, V73, P251, DOI 10.1016/S0079-6603(03)01008-0; Mylonakis E, 2005, INFECT IMMUN, V73, P3833, DOI 10.1128/IAI.73.7.3833-3841.2005; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Novatchkova M, 2004, CURR BIOL, V14, pR54, DOI 10.1016/j.cub.2003.12.042; Parker D, 1999, MOL CELL BIOL, V19, P5601; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Pfaller MA, 2007, J CLIN MICROBIOL, V45, P1735, DOI 10.1128/JCM.00409-07; Pfaller MA, 2007, CLIN MICROBIOL REV, V20, P133, DOI 10.1128/CMR.00029-06; Phelps C, 2006, P NATL ACAD SCI USA, V103, P7077, DOI 10.1073/pnas.0510080103; Prasad R., 2006, Infectious Disorders - Drug Targets, V6, P69, DOI 10.2174/187152606784112164; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; Richardson MD, 2005, J ANTIMICROB CHEMOTH, V56, P5, DOI 10.1093/jac/dki218; Sherman F., 1986, METHODS YEAST GENETI; Sipos G, 2006, CURR DRUG TARGETS, V7, P471, DOI 10.2174/138945006776359403; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; Taubert S, 2006, GENE DEV, V20, P1137, DOI 10.1101/gad.1395406; Tsai HF, 2006, ANTIMICROB AGENTS CH, V50, P1384, DOI 10.1128/AAC.50.4.1384-1392.2006; van den Hazel HB, 1999, J BIOL CHEM, V274, P1934, DOI 10.1074/jbc.274.4.1934; Vermitsky JP, 2006, MOL MICROBIOL, V61, P704, DOI 10.1111/j.1365-2958.2006.05235.x; Vermitsky JP, 2004, ANTIMICROB AGENTS CH, V48, P3773, DOI 10.1128/AAC.48.10.3773-3781.2004; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Wisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942; Zor T, 2004, J MOL BIOL, V337, P521, DOI 10.1016/j.jmb.2004.01.038	60	237	256	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2008	452	7187					604	U4		10.1038/nature06836	http://dx.doi.org/10.1038/nature06836			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385733				2022-12-28	WOS:000254567200039
J	Hobert, O				Hobert, Oliver			Gene regulation by transcription factors and microRNAs	SCIENCE			English	Editorial Material							PROTEIN-SYNTHESIS; REPRESSION; EXPRESSION; FEEDBACK		Columbia Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Hobert, O (corresponding author), Columbia Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	or38@columbia.edu		Hobert, Oliver/0000-0002-7634-2854	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Alon U., 2006, INTRO SYSTEMS BIOL D; Ashraf SI, 2006, CELL, V124, P191, DOI 10.1016/j.cell.2005.12.017; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Buck MJ, 2006, NAT GENET, V38, P1446, DOI 10.1038/ng1917; Carthew RW, 2006, CURR OPIN GENET DEV, V16, P203, DOI 10.1016/j.gde.2006.02.012; Davidson E. H., 2001, DEV EVOLUTION; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hobert O, 2004, TRENDS BIOCHEM SCI, V29, P462, DOI 10.1016/j.tibs.2004.07.001; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Johnston RJ, 2005, P NATL ACAD SCI USA, V102, P12449, DOI 10.1073/pnas.0505530102; Kawahara Y, 2007, SCIENCE, V315, P1137, DOI 10.1126/science.1138050; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Lee EJ, 2008, RNA, V14, P35, DOI 10.1261/rna.804508; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Martin KC, 2000, CURR OPIN NEUROBIOL, V10, P587, DOI 10.1016/S0959-4388(00)00128-8; Miska EA, 2007, PLOS GENET, V3, P2395, DOI 10.1371/journal.pgen.0030215; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; PTASHNE M, 2002, GENES SIGNALS; Robins H, 2005, P NATL ACAD SCI USA, V102, P4006, DOI 10.1073/pnas.0500775102; Saetrom P, 2007, NUCLEIC ACIDS RES, V35, P2333, DOI 10.1093/nar/gkm133; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Tsang J, 2007, MOL CELL, V26, P753, DOI 10.1016/j.molcel.2007.05.018; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Wray GA, 2003, MOL BIOL EVOL, V20, P1377, DOI 10.1093/molbev/msg140	26	673	714	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1785	1786		10.1126/science.1151651	http://dx.doi.org/10.1126/science.1151651			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369135				2022-12-28	WOS:000254394000032
J	Dedouit, F; Otal, P				Dedouit, Fabrice; Otal, Philippe			Small-bowel obstruction	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Dedouit, Fabrice; Otal, Philippe] CHU Rangueil, F-31059 Toulouse 9, France	CHU de Toulouse	Dedouit, F (corresponding author), CHU Rangueil, F-31059 Toulouse 9, France.	dedouit.f@chu-toulouse.fr	DEDOUIT, Fabrice/AAH-7634-2019						0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1381	1381		10.1056/NEJMicm067566	http://dx.doi.org/10.1056/NEJMicm067566			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367741				2022-12-28	WOS:000254308400009
J	Pesaran, B; Nelson, MJ; Andersen, RA				Pesaran, Bijan; Nelson, Matthew J.; Andersen, Richard A.			Free choice activates a decision circuit between frontal and parietal cortex	NATURE			English	Article							NEURONAL-ACTIVITY; PREMOTOR; SYNCHRONIZATION; REPRESENTATION; PERFORMANCE; POTENTIALS; COHERENCE; ATTENTION; SELECTION; DIRECTION	We often face alternatives that we are free to choose between. Planning movements to select an alternative involves several areas in frontal and parietal cortex(1-11) that are anatomically connected into long-range circuits(12). These areas must coordinate their activity to select a common movement goal, but how neural circuits make decisions remains poorly understood. Here we simultaneously record from the dorsal premotor area (PMd) in frontal cortex and the parietal reach region (PRR) in parietal cortex to investigate neural circuit mechanisms for decision making. We find that correlations in spike and local field potential (LFP) activity between these areas are greater when monkeys are freely making choices than when they are following instructions. We propose that a decision circuit featuring a sub-population of cells in frontal and parietal cortex may exchange information to coordinate activity between these areas. Cells participating in this decision circuit may influence movement choices by providing a common bias to the selection of movement goals.	[Pesaran, Bijan] NYU, Ctr Neural Sci, New York, NY 10003 USA; [Nelson, Matthew J.; Andersen, Richard A.] CALTECH, Computat & Neural Syst Program, Pasadena, CA 91125 USA; [Pesaran, Bijan; Andersen, Richard A.] CALTECH, Div Biol, Pasadena, CA 91125 USA	New York University; California Institute of Technology; California Institute of Technology	Pesaran, B (corresponding author), NYU, Ctr Neural Sci, 550 1St Ave, New York, NY 10003 USA.	bijan@nyu.edu	Nelson, Matthew/K-6635-2018	Nelson, Matthew/0000-0002-2325-4578; Pesaran, Bijan/0000-0003-4116-0038	NEI NIH HHS [R01 EY007492, R01 EY007492-19] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007492] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bogacz R, 2006, PSYCHOL REV, V113, P700, DOI 10.1037/0033-295X.113.4.700; BRESSLER SL, 1993, NATURE, V366, P153, DOI 10.1038/366153a0; Buschman TJ, 2007, SCIENCE, V315, P1860, DOI 10.1126/science.1138071; Cisek P, 2005, NEURON, V45, P801, DOI 10.1016/j.neuron.2005.01.027; Cisek P, 2006, J NEUROSCI, V26, P9761, DOI 10.1523/JNEUROSCI.5605-05.2006; Daw ND, 2006, CURR OPIN NEUROBIOL, V16, P199, DOI 10.1016/j.conb.2006.03.006; Fries P, 2005, TRENDS COGN SCI, V9, P474, DOI 10.1016/j.tics.2005.08.011; Gail A, 2006, J NEUROSCI, V26, P9376, DOI 10.1523/JNEUROSCI.1570-06.2006; Gold JI, 2000, NATURE, V404, P390, DOI 10.1038/35006062; GOLDBERG G, 1985, BEHAV BRAIN SCI, V8, P567, DOI 10.1017/S0140525X00045167; Halliday DM, 1995, PROG BIOPHYS MOL BIO, V64, P237, DOI 10.1016/S0079-6107(96)00009-0; Johnson PB, 1996, CEREB CORTEX, V6, P102, DOI 10.1093/cercor/6.2.102; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; KREPS DM, 1990, MICROECONOMIC THEORY, pCH2; Mitra PP, 1999, BIOPHYS J, V76, P691, DOI 10.1016/S0006-3495(99)77236-X; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; Murthy VN, 1996, J NEUROPHYSIOL, V76, P3968, DOI 10.1152/jn.1996.76.6.3968; Pesaran B, 2002, NAT NEUROSCI, V5, P805, DOI 10.1038/nn890; Pesaran B, 2006, NEURON, V51, P125, DOI 10.1016/j.neuron.2006.05.025; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Quiroga RQ, 2006, J NEUROSCI, V26, P3615, DOI 10.1523/JNEUROSCI.3468-05.2006; Rickert J, 2005, J NEUROSCI, V25, P8815, DOI 10.1523/JNEUROSCI.0816-05.2005; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; ROMO R, 1987, EXP BRAIN RES, V67, P656; Scherberger H, 2005, NEURON, V46, P347, DOI 10.1016/j.neuron.2005.03.004; Scherberger H, 2007, J NEUROSCI, V27, P2001, DOI 10.1523/JNEUROSCI.4274-06.2007; Schmolesky MT, 1998, J NEUROPHYSIOL, V79, P3272, DOI 10.1152/jn.1998.79.6.3272; Sugrue LP, 2004, SCIENCE, V304, P1782, DOI 10.1126/science.1094765; Wise SP, 1997, ANNU REV NEUROSCI, V20, P25, DOI 10.1146/annurev.neuro.20.1.25; Yang T, 2007, NATURE, V447, P1075, DOI 10.1038/nature05852	30	310	314	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2008	453	7193					406	U61		10.1038/nature06849	http://dx.doi.org/10.1038/nature06849			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301AI	18418380	Green Accepted			2022-12-28	WOS:000255868400055
J	Akala, OO; Park, IK; Qian, DL; Pihalja, M; Becker, MW; Clarke, MF				Akala, Omobolaji O.; Park, In-Kyung; Qian, Dalong; Pihalja, Michael; Becker, Michael W.; Clarke, Michael F.			Long-term haematopoietic reconstitution by Trp53(-/-)p16(Ink4a-/-)p19(Arf-/-) multipotent progenitors	NATURE			English	Article							SLAM FAMILY RECEPTORS; LEUKEMIC STEM-CELLS; EX-VIVO EXPANSION; SELF-RENEWAL; BMI-1; P53; P16(INK4A); PROLIFERATION; SENESCENCE; EXPRESSION	Haematopoiesis is maintained by a hierarchical system where haematopoietic stem cells ( HSCs) give rise to multipotent progenitors, which in turn differentiate into all types of mature blood cells1. HSCs maintain themselves for the lifetime of the organism because of their ability to self- renew. However, multipotent progenitors lack the ability to self- renew, therefore their mitotic capacity and expansion potential are limited and they are destined to eventually stop proliferating after a finite number of cell divisions(1,2). The molecular mechanisms that limit the proliferation capacity of multipotent progenitors and other more mature progenitors are not fully understood(2,3). Here we show that bone marrow cells from mice deficient in three genes genetically downstream of Bmi1-p16(Ink4a), p19(Arf) and Trp53 ( triple mutant mice; p16(Ink4a) and p19(Arf) are alternative reading frames of the same gene ( also called Cdkn2a) that encode different proteins) - have an approximately 10-fold increase in cells able to reconstitute the blood long term. This increase is associated with the acquisition of long- term reconstitution capacity by cells of the phenotype c-kit(+)Sca-1(+)Flt3(+)CD150(-)CD48(-)Lin(-), which defines multipotent progenitors in wild- type mice(4-6). The pattern of triple mutant multipotent progenitor response to growth factors resembles that of wild- type multipotent progenitors but not wild- type HSCs. These results demonstrate that p16(Ink4a)/p19(Arf) and Trp53 have a central role in limiting the expansion potential of multipotent progenitors. These pathways are commonly repressed in cancer, suggesting a mechanism by which early progenitor cells could gain the ability to self- renew and become malignant with further oncogenic mutations.	[Akala, Omobolaji O.; Qian, Dalong; Clarke, Michael F.] Stanford Univ, Stanford Inst Stem Cell Biol & Regenerat Med, Palo Alto, CA 94304 USA; [Akala, Omobolaji O.] Univ Michigan, Cellular & Mol Biol Grad Program, Taubman Med Lib 2966, Ann Arbor, MI 48109 USA; [Akala, Omobolaji O.; Qian, Dalong; Clarke, Michael F.] Stanford Univ, Div Hematol Oncol, Palo Alto, CA 94304 USA; [Park, In-Kyung; Pihalja, Michael] Univ Michigan, Dept Hematol Oncol, Ann Arbor, MI 48109 USA; [Becker, Michael W.] Univ Rochester, Div Hematol Oncol, Rochester, NY 14642 USA	Stanford University; University of Michigan System; University of Michigan; Stanford University; University of Michigan System; University of Michigan; University of Rochester	Clarke, MF (corresponding author), Stanford Univ, Stanford Inst Stem Cell Biol & Regenerat Med, 1050 Arastradero Rd, Palo Alto, CA 94304 USA.	mfclarke@stanford.edu		Becker, Michael/0000-0001-9890-8815				Adolfsson J, 2001, IMMUNITY, V15, P659, DOI 10.1016/S1074-7613(01)00220-5; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Berggren P, 2003, CLIN CANCER RES, V9, P235; Burke L, 2005, CLIN CANCER RES, V11, P232; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Dumble M, 2007, BLOOD, V109, P1736, DOI 10.1182/blood-2006-03-010413; Esteller M, 2000, CANCER RES, V60, P129; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kim I, 2006, BLOOD, V108, P737, DOI 10.1182/blood-2005-10-4135; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 2002, J IMMUNOL, V168, P635, DOI 10.4049/jimmunol.168.2.635; Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Stepanova L, 2005, BLOOD, V106, P827, DOI 10.1182/blood-2004-06-2242; Weber A, 2002, VIRCHOWS ARCH, V441, P133, DOI 10.1007/s00428-002-0637-6; Yilmaz OH, 2006, BLOOD, V107, P924, DOI 10.1182/blood-2005-05-2140; Zhang CC, 2006, NAT MED, V12, P240, DOI 10.1038/nm1342; Zhang CC, 2005, BLOOD, V105, P4314, DOI 10.1182/blood-2004-11-4418; Zhang CC, 2004, BLOOD, V103, P2513, DOI 10.1182/blood-2003-08-2955; Zolota V, 2007, PATHOL RES PRACT, V203, P199, DOI 10.1016/j.prp.2007.01.010	27	127	134	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2008	453	7192					228	U12		10.1038/nature06869	http://dx.doi.org/10.1038/nature06869			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297BP	18418377	Bronze, Green Published			2022-12-28	WOS:000255592400041
J	Rathmell, JP; Libman, H				Rathmell, James P.; Libman, Howard			A 50-year-old man with chronic low back pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPINAL-CORD STIMULATION; INTRADISCAL ELECTROTHERMAL THERAPY; CHRONIC NONCANCER PAIN; RANDOMIZED CONTROLLED-TRIAL; NEUROPATHIC PAIN; NONOPERATIVE TREATMENT; INTERVERTEBRAL-DISK; MEDICAL-MANAGEMENT; SURGERY SYNDROME; PRIMARY-CARE	Mr S, a 50- year- old man, has long- standing low back pain. His pain began more than 20 years earlier with a lumbar disk herniation and has persisted despite diskectomy. He has undergone numerous treatments, but he remains disabled with ongoing pain. His treatment course is used to frame the epidemiology and pathophysiology underlying acute and chronic lumbosacral and radicular pain. The roles of neuropathic pain medications, chronic opioid therapy, physical therapy, spinal manipulation, and multidisciplinary pain treatment programs are reviewed. The indications for and outcomes associated with interventional pain treatments, including epidural steroid injection, facet blocks and radiofrequency treatment for facet- related pain, intradiskal electrothermal therapy, spinal cord stimulation, and intrathecal drug delivery, are discussed. Clinicians are given an evidence-based approach to using available treatment options for low back pain.	[Rathmell, James P.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Ctr Pain Med, Boston, MA 02114 USA; [Rathmell, James P.] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Rathmell, JP (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Ctr Pain Med, 15 Parkman St,WACC 333, Boston, MA 02114 USA.	jrathmell@partners.org	Rathmell, James/GQZ-1503-2022					Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Appleby D, 2006, PAIN MED, V7, P308, DOI 10.1111/j.1526-4637.2006.00172.x; Arden NK, 2005, RHEUMATOLOGY, V44, P1399, DOI 10.1093/rheumatology/kei028; Armon C, 2007, NEUROLOGY, V68, P723, DOI 10.1212/01.wnl.0000256734.34238.e7; Backonja MM, 2003, ANESTH ANALG, V97, P785, DOI 10.1213/01.ANE.0000062826.70846.8D; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; BenDebba M, 1999, NEUROL RES, V21, pS37, DOI 10.1080/01616412.1999.11741025; Bogduk N, 2004, CLIN J PAIN, V20, P409, DOI 10.1097/00002508-200411000-00005; BOGDUK N, 2002, PAIN RES CLIN MANAGE, V13, P115; Bronfort Gert, 2004, Spine J, V4, P335, DOI 10.1016/j.spinee.2003.06.002; Carragee EJ, 2006, SPINE, V31, P2115, DOI 10.1097/01.brs.0000231436.30262.dd; Chad DA, 2007, NEUROL CLIN, V25, P407, DOI 10.1016/j.ncl.2007.01.003; Chen HP, 2004, MAYO CLIN PROC, V79, P1533, DOI 10.4065/79.12.1533; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; COHEN S, EFFICACY EPIDURAL ET; Cohen SP, 2007, ANESTHESIOLOGY, V106, P591, DOI 10.1097/00000542-200703000-00024; Cohen SP, 2007, CLIN J PAIN, V23, P45, DOI 10.1097/01.ajp.0000210941.04182.ea; Covington E, 2007, NEUROL CLIN, V25, P539, DOI 10.1016/j.ncl.2007.01.009; Deshpande A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004959.pub3; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Ernst E, 2006, J ROY SOC MED, V99, P192, DOI 10.1258/jrsm.99.4.192; Ferraro MC, 2022, LANCET NEUROL, V21, P405, DOI 10.1016/S1474-4422(22)00096-5; Finnerup NB, 2005, PAIN, V118, P289, DOI 10.1016/j.pain.2005.08.013; Foye PM, 2007, ARCH PHYS MED REHAB, V88, pS14, DOI 10.1016/j.apmr.2006.12.010; Freeman BJC, 2005, SPINE, V30, P2369, DOI 10.1097/01.brs.0000186587.43373.f2; Freeman BJC, 2003, SPINE, V28, P2602, DOI 10.1097/01.BRS.0000097889.01759.05; Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528; Genevay S, 2004, ANN RHEUM DIS, V63, P1120, DOI 10.1136/ard.2003.016451; Geurts JW, 2001, REGION ANESTH PAIN M, V26, P394, DOI 10.1053/rapm.2001.23673; Guzman J, 2001, BMJ-BRIT MED J, V322, P1511, DOI 10.1136/bmj.322.7301.1511; Hagen KB, 2005, SPINE, V30, P542, DOI 10.1097/01.brs.0000154625.02586.95; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; Igarashi T, 2000, SPINE, V25, P2975, DOI 10.1097/00007632-200012010-00003; Jarvik JG, 2002, ANN INTERN MED, V137, P586, DOI 10.7326/0003-4819-137-7-200210010-00010; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Karppinen J, 2003, SPINE, V28, P750, DOI 10.1097/00007632-200304150-00004; Koes BW, 2006, BMJ-BRIT MED J, V332, P1430, DOI 10.1136/bmj.332.7555.1430; Koes B, 2006, AM FAM PHYSICIAN, V74, P803; KOES BW, 1999, PAIN DIGEST, V9, P241; Korhonen T, 2006, SPINE, V31, P2759, DOI 10.1097/01.brs.0000245873.23876.1e; Kornick C, 2004, SPINE, V29, P1352, DOI 10.1097/01.BRS.0000128263.67291.A0; Kumar K, 2007, PAIN, V132, P179, DOI 10.1016/j.pain.2007.07.028; Mackenzie JW, 2006, ANAESTHESIA, V61, P907, DOI 10.1111/j.1365-2044.2006.04763.x; Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; McLain Robert F, 2005, Spine J, V5, P191, DOI 10.1016/j.spinee.2004.10.046; Meeker WC, 2002, ANN INTERN MED, V136, P216, DOI 10.7326/0003-4819-136-3-200202050-00010; Mercadante S, 2007, EUR J PAIN, V11, P823, DOI 10.1016/j.ejpain.2007.01.003; Merskey H., 1994, CLASSIFICATION CHRON, V2nd ed; Michna E, 2004, J PAIN SYMPTOM MANAG, V28, P250, DOI 10.1016/j.jpainsymman.2004.04.007; Mitra S, 2004, ANESTHESIOLOGY, V101, P212, DOI 10.1097/00000542-200407000-00032; Morley-Forster Patricia K, 2003, Pain Res Manag, V8, P189; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nishida K, 1999, SPINE, V24, P2419, DOI 10.1097/00007632-199912010-00002; North RB, 2005, SPINE, V30, P1412, DOI 10.1097/01.brs.0000166502.05449.a8; North RB, 2005, NEUROSURGERY, V56, P98, DOI 10.1227/01NEU.0000144839.65524.E0; Olmarker K, 2001, SCHMERZ, V15, P425, DOI 10.1007/s004820100027; Onesti ST, 2004, NEUROLOGIST, V10, P259, DOI 10.1097/01.nrl.0000138733.09406.39; Ostelo RWJG, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002014.pub2; *OXF CTR EV BAS ME, LEV EV; Pauza Kevin J, 2004, Spine J, V4, P27, DOI 10.1016/j.spinee.2003.07.001; Pope MH, 1999, NEUROL CLIN, V17, P17, DOI 10.1016/S0733-8619(05)70112-2; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Prager JP, 2002, SPINE, V27, P2593, DOI 10.1097/00007632-200211150-00037; Pud D, 2006, DRUG ALCOHOL DEPEN, V82, P218, DOI 10.1016/j.drugalcdep.2005.09.007; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Rauck RL, 2006, J PAIN SYMPTOM MANAG, V31, P393, DOI 10.1016/j.jpainsymman.2005.10.003; Rubin DI, 2007, NEUROL CLIN, V25, P353, DOI 10.1016/j.ncl.2007.01.004; SAAL JA, 1989, SPINE, V14, P431, DOI 10.1097/00007632-198904000-00018; Schofferman J, 2004, SPINE, V29, P2471, DOI 10.1097/01.brs.0000143170.47345.44; SCHWARZER AC, 1995, SPINE, V20, P31, DOI 10.1097/00007632-199501000-00007; SCHWARZER AC, 1995, SPINE, V20, P1878, DOI 10.1097/00007632-199509000-00007; Siddall PJ, 2004, ANESTH ANALG, V99, P510, DOI 10.1213/01.ANE.0000133383.17666.3A; Slipman Curtis W, 2003, Spine J, V3, P310, DOI 10.1016/S1529-9430(03)00025-1; Smith TJ, 2005, ANN ONCOL, V16, P825, DOI 10.1093/annonc/mdi156; SPITZER WO, 1987, SPINE, V12, pS1; Taylor RS, 2005, SPINE, V30, P152, DOI 10.1097/01.brs.0000149199.68381.fe; THOMPSON JP, 1991, SPINE, V16, P253, DOI 10.1097/00007632-199103000-00001; Turner JA, 2004, PAIN, V108, P137, DOI 10.1016/j.pain.2003.12.016; Turner JA, 2007, CLIN J PAIN, V23, P180, DOI 10.1097/01.ajp.0000210955.93878.44; Van Tulder M, 2006, AM FAM PHYSICIAN, V74, P1577; Von Korff M, 1998, SPINE, V23, P2608, DOI 10.1097/00007632-199812010-00016; Wallach CJ, 2003, SPINE, V28, P2331, DOI 10.1097/01.BRS.0000085303.67942.94; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2451, DOI 10.1001/jama.296.20.2451; Wilbourn AJ, 1998, MUSCLE NERVE, V21, P1612, DOI 10.1002/(SICI)1097-4598(199812)21:12<1612::AID-MUS2>3.0.CO;2-0; Wilson-MacDonald J, 2005, J BONE JOINT SURG BR, V87B, P352, DOI 10.1302/0301-620X.87B3.15338	87	16	18	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 7	2008	299	17					2066	2077		10.1001/jama.299.13.jrr80002	http://dx.doi.org/10.1001/jama.299.13.jrr80002			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296NI	18381566				2022-12-28	WOS:000255552700023
J	McQuay, H				McQuay, Henry			Making a difference - Management of chronic pain - Help and hope at the bottom of the pile	BRITISH MEDICAL JOURNAL			English	Editorial Material							LIFE; IMPACT		[McQuay, Henry] The Churchill, Pain Relief Unit, Oxford OX3 7LJ, England; [McQuay, Henry] Univ Oxford, Nuffield Dept Anaesthet, Oxford OX1 2JD, England	University of Oxford; University of Oxford	McQuay, H (corresponding author), The Churchill, Pain Relief Unit, Oxford OX3 7LJ, England.	henry.mcquay@pru.ox.ac.uk						Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Katz WA, 2002, CLIN RHEUMATOL, V21, pS2, DOI 10.1007/s100670200028; Kemler MA, 2002, J PAIN SYMPTOM MANAG, V23, P433, DOI 10.1016/S0885-3924(02)00386-X; Lachaine J, 2007, PAIN RES MANAG, V12, P31, DOI 10.1155/2007/713835; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; McQuay HJ, 2007, HLTH CARE NEEDS ASSE, P519; Sprangers MAG, 2000, J CLIN EPIDEMIOL, V53, P895, DOI 10.1016/S0895-4356(00)00204-3	7	9	9	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					954	+		10.1136/bmj.39520.699190.94	http://dx.doi.org/10.1136/bmj.39520.699190.94			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397945	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000255540900041
J	Kannan, N; Taylor, SS				Kannan, Natarajan; Taylor, Susan S.			Rethinking pseudokinases	CELL			English	Editorial Material							KINASE	Pseudokinases lack conservation of one or more of the catalytic residues in the kinase core and as a consequence are typically thought to be catalytically inactive. New work by Mukherjee et al. (2008) challenges this assumption. They show that the pseudokinase domain of CASK ( Ca2+/calmodulin activated serine-threonine kinase) adopts an active conformation and displays catalytic activity in vivo.	[Kannan, Natarajan; Taylor, Susan S.] Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, La Jolla, CA 92014 USA; [Kannan, Natarajan; Taylor, Susan S.] Univ Calif San Diego, Dept Pharmacol, Howard Hughes Med Inst, La Jolla, CA 92014 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, La Jolla, CA 92014 USA.	staylor@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019301] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R01 GM019301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1993, PROTEIN SCI, V2, P2177, DOI 10.1002/pro.5560021217; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; Kannan N, 2007, PLOS BIOL, V5, P467, DOI 10.1371/journal.pbio.0050017; Madhusudan, 2002, NAT STRUCT BIOL, V9, P273, DOI 10.1038/nsb780; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Min XS, 2004, STRUCTURE, V12, P1303, DOI 10.1016/j.str.2004.04.014; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Waas WF, 2003, BIOCHEMISTRY-US, V42, P2960, DOI 10.1021/bi027171w; Zimmermann B, 2008, BIOCHEM J, V413, P93, DOI 10.1042/BJ20071665	9	33	33	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	2008	133	2					204	205		10.1016/j.cell.2008.04.005	http://dx.doi.org/10.1016/j.cell.2008.04.005			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	289JY	18423189	Bronze, Green Accepted			2022-12-28	WOS:000255052000007
J	Mandl, KD; Kohane, IS				Mandl, Kenneth D.; Kohane, Isaac S.			Tectonic shifts in the health information economy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RECORD; TECHNOLOGY; EXCHANGE; NETWORK		[Mandl, Kenneth D.; Kohane, Isaac S.] Childrens Hosp, Childrens Hosp Informat Program, Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Boston, MA 02115 USA; [Mandl, Kenneth D.; Kohane, Isaac S.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School	Mandl, KD (corresponding author), Childrens Hosp, Childrens Hosp Informat Program, Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, 300 Longwood Ave, Boston, MA 02115 USA.		Kohane, Isaac Kohane/K-3716-2012	Kohane, Isaac Kohane/0000-0003-2192-5160	NATIONAL LIBRARY OF MEDICINE [R01LM009375] Funding Source: NIH RePORTER; NLM NIH HHS [1R01LM009375-01A1] Funding Source: Medline; PHS HHS [R01 CDC 000065-01] Funding Source: Medline; ODCDC CDC HHS [P01 CD000260-01] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); ODCDC CDC HHS		Ackerman Michael J, 2007, J Med Pract Manage, V23, P84; Adler-Milstein J, 2008, HEALTH AFFAIR, V27, pW60, DOI 10.1377/hlthaff.27.1.w60; Annas GJ, 2003, NEW ENGL J MED, V348, P1486, DOI 10.1056/NEJMlim035027; Bradley Colleen A, 2005, MMWR Suppl, V54, P11; *CONN HLTH WORK GR, CONN AM THEIR HLTH C; Conn Joseph, 2006, Mod Healthc, V36, P10; Cupples LA, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S1; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; Flexner A., 1910, FLEXNER REPORT; GLASER J, 2007, HEALTHC FINANC MANAG, V61, P42; Glaser John, 2007, Healthc Financ Manage, V61, P38; Halamka JD, 2008, J AM MED INFORM ASSN, V15, P1, DOI 10.1197/jamia.M2562; *HEALTHC INF TECHN, STAND ACT; Insel TR, 2003, PLOS BIOL, V1, P9, DOI 10.1371/journal.pbio.0000017; Kohane IS, 2005, NEW ENGL J MED, V353, P2074, DOI 10.1056/NEJMsb051220; Kohane IS, 2007, SCIENCE, V316, P836, DOI 10.1126/science.1135489; LOHR S, 2007, NY TIMES        0814; LOHR S, 2007, NY TIMES        1004; Lu SCH, 2007, STUD HEALTH TECHNOL, V127, P58; Malin B, 2004, J BIOMED INFORM, V37, P179, DOI 10.1016/j.jbi.2004.04.005; Mandl KD, 2001, BMJ-BRIT MED J, V322, P283, DOI 10.1136/bmj.322.7281.283; Mandl KD, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-25; MCGEE MK, 2008, INFORMATIONWEEK 0122; MCGEE MK, 2007, INFORMATIONWEEK 0917; *NAT CTR RES RES, 2007, CLIN TRANSL SCI AW; Noor MAF, 2006, PLOS BIOL, V4, P1113, DOI 10.1371/journal.pbio.0040228; Pagliari C, 2007, BMJ-BRIT MED J, V335, P330, DOI 10.1136/bmj.39279.482963.AD; Platt R, 2001, PHARMACOEPIDEM DR S, V10, P373, DOI 10.1002/pds.607; Sax U, 2005, J AM MED INFORM ASSN, V12, P263, DOI 10.1197/jamia.M1681; Simborg DW, 2008, J AM MED INFORM ASSN, V15, P127, DOI 10.1197/jamia.M2573; Sweeney DA, 1997, REV AM HIST, V25, P82, DOI 10.1353/rah.1997.0024; Sweeney L, 1997, J LAW MED ETHICS, V25, P98, DOI 10.1111/j.1748-720X.1997.tb01885.x; Zerhouni EA, 2006, J INVEST MED, V54, P171, DOI 10.2310/6650.2006.X0016	33	98	98	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1732	1737		10.1056/NEJMsb0800220	http://dx.doi.org/10.1056/NEJMsb0800220			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288DO	18420506				2022-12-28	WOS:000254966600014
J	Workowski, KA; Berman, SM; Douglas, JM				Workowski, Kimberly A.; Berman, Stuart M.; Douglas, John M.			Emerging antimicrobial resistance in Neisseria gonorrhoeae: Urgent need to strengthen prevention strategies	ANNALS OF INTERNAL MEDICINE			English	Article							SEXUALLY-TRANSMITTED-DISEASES; DECREASED SUSCEPTIBILITY; PREVALENCE; SEX; MEN; HIV; SURVEILLANCE; MANAGEMENT; CALIFORNIA; MUTATIONS	Prevention and control of gonorrhea is an important public health concern due to the high burden of disease, the recent increase in reported infection rates, and the reproductive and economic consequences of infection. Effective antibiotic treatment is one essential component of an integrated approach to gonorrhea control. Over the past 60 years, however, development of resistance in Neisseria gonorrhoeae to multiple antimicrobial classes challenges this component of gonorrhea control. An integrated, comprehensive prevention strategy should include enhancement of national and international surveillance systems to monitor antimicrobial resistance and new strategies to maximize the benefit and prolong the utility of antimicrobials, including combination regimens, implementation of screening recommendations for individuals at high risk for infection, and the assurance of prompt and effective treatment for infected persons and their sexual partners. Progress in controlling the epidemic and avoiding a resurgence as treatment options wane will require careful attention to all components of a comprehensive prevention strategy.	Emory Univ, Atlanta, GA 30322 USA; Ctr Dis Control & Prevent, Nat Ctr HIV AIDS, Atlanta, GA USA	Emory University; Centers for Disease Control & Prevention - USA	Workowski, KA (corresponding author), 10 Corp Square,Corp Square Blvd,Mailstop E02, Atlanta, GA 30333 USA.	kgw2@cdc.gov						Smith Nicole M., 2006, Morbidity and Mortality Weekly Report, V55, P1; [Anonymous], 2006, MORBIDITY MORTALITY, DOI DOI 10.1001/JAMA.295.19.2245; *ANT AV TASK FORC, 2006, CLIN INFECT DIS, V42, P657; BOSLEGO JW, 1987, NEW ENGL J MED, V317, P272, DOI 10.1056/NEJM198707303170504; Calonge N, 2005, ANN FAM MED, V3, P263, DOI 10.1370/afm.337; *CDC, 2004, MMWR-MORBID MORTAL W, V53, P335; *CDC, 2008, GON IS SURV PROJ GSI; Centers for Disease Control, 1987, MMWR-MORBID MORTAL W, V21, p1S; Centers for Disease Control, 1985, MMWR S, V34, p75S; Centers for Disease Control, 1974, MMWR-MORBID MORTAL W, V23, P341; Centers for Disease Control and Prevention,, 2006, EXP PARTN THER MAN S; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1041; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P833; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1052; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Chandra R, 2007, CLIN PHARMACOKINET, V46, P247, DOI 10.2165/00003088-200746030-00005; Chesson HW, 2005, EVALUATION REV, V29, P3, DOI 10.1177/0193841X04270613; Childs James E., 1993, Morbidity and Mortality Weekly Report, V42, P1; Daly CC, 1997, J CLIN MICROBIOL, V35, P2985, DOI 10.1128/JCM.35.11.2985-2988.1997; del Rio C., 2007, Morbidity and Mortality Weekly Report, V56, P332; Dicker LW, 2007, SEX TRANSM DIS, V34, P41, DOI 10.1097/01.olq.0000222708.70594.8e; ENG TR, 1997, HIDDEN EPIDEMIC CONF; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Gunn RA, 2004, SEX TRANSM DIS, V31, P373, DOI 10.1097/00007435-200406000-00011; HALL C, 2007, 17 INT SOC STD RES S; HANDSFIELD HH, 1992, CLIN INFECT DIS, V15, pS123, DOI 10.1093/clind/15.Supplement_1.S123; Ison CA, 2004, SEX TRANSM INFECT, V80, P386, DOI 10.1136/sti.2004.012757; Ito M, 2004, ANTIMICROB AGENTS CH, V48, P3185, DOI 10.1128/AAC.48.8.3185-3187.2004; Iverson CJ, 2004, SEX TRANSM DIS, V31, P702, DOI 10.1097/01.olq.0000145846.45781.a4; Javanbakht M., 2007, Morbidity and Mortality Weekly Report, V56, P222; Johnson SR, 2003, INT J ANTIMICROB AG, V21, P414, DOI 10.1016/S0924-8579(03)00039-6; *JOINT TASK FORC P, 2005, J ALLERGY CLIN IM S2, V0115, pS 483; KAMPMEIER RH, 1983, SEX TRANSM DIS, V10, P81, DOI 10.1097/00007435-198304000-00007; Kelkar PS, 2001, NEW ENGL J MED, V345, P804, DOI 10.1056/NEJMra993637; Kent CK, 2005, CLIN INFECT DIS, V41, P67, DOI 10.1086/430704; Lafferty WE, 1997, SEX TRANSM DIS, V24, P272, DOI 10.1097/00007435-199705000-00007; Livermore DM, 2005, LANCET INFECT DIS, V5, P450, DOI 10.1016/S1473-3099(05)70166-3; Macomber KE, 2005, EMERG INFECT DIS, V11, P1009, DOI 10.3201/eid1107.041359; Moran John, 2005, Clin Evid, P2016; MORAN JS, 1995, SEX TRANSM DIS, V22, P39, DOI 10.1097/00007435-199501000-00007; MORAN JS, 1995, CLIN INFECT DIS, V20, pS47, DOI 10.1093/clinids/20.Supplement_1.S47; Morris SR, 2006, CLIN INFECT DIS, V43, P1284, DOI 10.1086/508460; Newman LM, 2007, CLIN INFECT DIS, V44, pS84, DOI 10.1086/511422; Peterman TA, 2006, ANN INTERN MED, V145, P564, DOI 10.7326/0003-4819-145-8-200610170-00005; Rottingen JA, 2001, SEX TRANSM DIS, V28, P579; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; Sutrisna A, 2006, INT J STD AIDS, V17, P810, DOI 10.1258/095646206779307595; Takeshita E, 2006, J GASTROENTEROL, V41, P223, DOI 10.1007/s00535-005-1739-0; Tanaka M, 2006, INT J ANTIMICROB AG, V27, P20, DOI 10.1016/j.ijantimicag.2005.08.021; Tapsall John, 2006, Expert Rev Anti Infect Ther, V4, P619, DOI 10.1586/14787210.4.4.619; Tapsall JW, 2006, SEX TRANSM DIS, V33, P8, DOI 10.1097/01.olq.0000194599.97426.a3; Tapsall JW, 2001, ANTIMICROBIAL RESIST; Thomas JC, 2000, INT J STD AIDS, V11, P461, DOI 10.1258/0956462001916254; Wang SA, 2003, CLIN INFECT DIS, V37, P849, DOI 10.1086/377500; Wang SA, 2007, ANN INTERN MED, V147, P81, DOI 10.7326/0003-4819-147-2-200707170-00006; Weinstock H, 2004, PERSPECT SEX REPRO H, V36, P6, DOI 10.1111/j.1931-2393.2004.tb00002.x; *WHO, 2008, IN PRESS COMMUN DIS; Xia MS, 2000, J INFECT DIS, V181, P2080, DOI 10.1086/315510; [No title captured]	59	126	136	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2008	148	8					606	613		10.7326/0003-4819-148-8-200804150-00005	http://dx.doi.org/10.7326/0003-4819-148-8-200804150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290LF	18413622				2022-12-28	WOS:000255123600005
J	Pinaud, F; Dahan, M				Pinaud, Fabien; Dahan, Maxime			Zooming into live cells	SCIENCE			English	Editorial Material							OPTICAL RECONSTRUCTION MICROSCOPY; STIMULATED-EMISSION; NANOSCOPY; ORGANIZATION; PROBES; LIMIT		[Pinaud, Fabien; Dahan, Maxime] Univ Paris 06, Lab Kastler Brossel, CNRS, UMR8552, F-75005 Paris, France; [Pinaud, Fabien; Dahan, Maxime] Univ Paris 06, Phys & Biol Dept, Ecole Normale Super, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; College de France; Ecole Normale Superieure (ENS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Sorbonne Universite	Pinaud, F (corresponding author), Univ Paris 06, Lab Kastler Brossel, CNRS, UMR8552, 46 Rue Ulm, F-75005 Paris, France.	maxime.dahan@lkb.ens.fr	Dahan, Maxime/F-1740-2010; Pinaud, Fabien/F-2306-2010	Pinaud, Fabien/0000-0002-4272-3616; Dahan, Maxime/0000-0002-4943-2491				Bates M, 2007, SCIENCE, V317, P1749, DOI 10.1126/science.1146598; Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344; Donnert G, 2007, BIOPHYS J, V92, pL67, DOI 10.1529/biophysj.107.104497; Giepmans BNG, 2006, SCIENCE, V312, P217, DOI 10.1126/science.1124618; Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395; HELL SW, 1994, OPT LETT, V19, P780, DOI 10.1364/OL.19.000780; Hess ST, 2007, P NATL ACAD SCI USA, V104, P17370, DOI 10.1073/pnas.0708066104; Huang B, 2008, SCIENCE, V319, P810, DOI 10.1126/science.1153529; Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896; Karsenti E, 2008, NAT REV MOL CELL BIO, V9, P255, DOI 10.1038/nrm2357; Kellner RR, 2007, NEUROSCIENCE, V144, P135, DOI 10.1016/j.neuroscience.2006.08.071; Levsky JM, 2003, TRENDS CELL BIOL, V13, P4, DOI 10.1016/S0962-8924(02)00002-8; Manley S, 2008, NAT METHODS, V5, P155, DOI 10.1038/NMETH.1176; Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929; Shroff H, 2007, P NATL ACAD SCI USA, V104, P20308, DOI 10.1073/pnas.0710517105; Westphal V, 2008, SCIENCE, V320, P246, DOI 10.1126/science.1154228; Willig KI, 2006, NATURE, V440, P935, DOI 10.1038/nature04592	17	5	5	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					187	188		10.1126/science.1156510	http://dx.doi.org/10.1126/science.1156510			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403700				2022-12-28	WOS:000254836700030
J	Chen, CW; Jao, SW; Wu, CC; Chao, PC				Chen, Chuang-Wei; Jao, Shu-Wen; Wu, Chang-Chieh; Chao, Pei-Chieh			Red spots on the hands and red blood in the stools	LANCET			English	Editorial Material									[Chen, Chuang-Wei; Jao, Shu-Wen; Wu, Chang-Chieh; Chao, Pei-Chieh] Triserv Gen Hosp, Div Colon & Rectal Surg, Dept Surg, Natl Def Med Ctr, Taipei 114, Taiwan	National Defense Medical Center; Tri-Service General Hospital	Chao, PC (corresponding author), Triserv Gen Hosp, Div Colon & Rectal Surg, Dept Surg, Natl Def Med Ctr, 325 Cheng Kung Rd,Sec 2, Taipei 114, Taiwan.	docallen.tw@yahoo.com.tw							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2008	371	9619					1190	1190		10.1016/S0140-6736(08)60525-5	http://dx.doi.org/10.1016/S0140-6736(08)60525-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395580	Bronze			2022-12-28	WOS:000254956000028
J	Durham, WJ; Aracena-Parks, P; Long, C; Rossi, AE; Goonasekera, SA; Boncompagni, S; Galvan, DL; Gilman, CP; Baker, MR; Shirokova, N; Protasi, F; Dirksen, R; Hamilton, SL				Durham, William J.; Aracena-Parks, Paula; Long, Cheng; Rossi, Ann E.; Goonasekera, Sanjeewa A.; Boncompagni, Simona; Galvan, Daniel L.; Gilman, Charles P.; Baker, Mariah R.; Shirokova, Natalia; Protasi, Feliciano; Dirksen, Robert; Hamilton, Susan L.			RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice	CELL			English	Article							CA2+ RELEASE CHANNEL; SKELETAL-MUSCLE; MALIGNANT HYPERTHERMIA; NITRIC-OXIDE; CALCIUM-RELEASE; RYANODINE BINDING; FUNCTIONAL-STATE; RECEPTOR; EXERCISE; OXIDATION	Mice with a malignant hyperthermia mutation (Y522S) in the ryanodine receptor (RyR1) display muscle contractures, rhabdomyolysis, and death in response to elevated environmental temperatures. We demonstrate that this mutation in RyR1 causes Ca2+ leak, which drives increased generation of reactive nitrogen species (RNS). Subsequent S-nitrosylation of the mutant RyR1 increases its temperature sensitivity for activation, producing muscle contractures upon exposure to elevated temperatures. The Y522S mutation in humans is associated with central core disease. Many mitochondria in the muscle of heterozygous Y522S mice are swollen and misshapen. The mutant muscle displays decreased force production and increased mitochondrial lipid peroxidation with aging. Chronic treatment with N-acetylcysteine protects against mitochondrial oxidative damage and the decline in force generation. We propose a feed-forward cyclic mechanism that increases the temperature sensitivity of RyR1 activation and underlies heat stroke and sudden death. The cycle eventually produces a myopathy with damaged mitochondria.	[Durham, William J.; Aracena-Parks, Paula; Long, Cheng; Galvan, Daniel L.; Gilman, Charles P.; Baker, Mariah R.; Hamilton, Susan L.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Rossi, Ann E.; Goonasekera, Sanjeewa A.; Dirksen, Robert] Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; [Boncompagni, Simona; Protasi, Feliciano] Univ G Dannunzio, Ctr Sci Invecchiamento, Lab Cellular Physiol, I-66013 Chieti, Italy; [Shirokova, Natalia] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, Newark, NJ 07103 USA	Baylor College of Medicine; University of Rochester; G d'Annunzio University of Chieti-Pescara; Rutgers State University New Brunswick; Rutgers State University Medical Center	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza,410B, Houston, TX 77030 USA.	susanh@bcm.edu	Galvan, Daniel L./L-2768-2019; Tuluc, Petronel/C-2527-2011; Aracena, Paula/A-5607-2012	Galvan, Daniel L./0000-0001-7541-6252; Aracena, Paula/0000-0002-2144-6875; Shirokova, Natalia/0000-0003-4648-4592; Hamilton, Susan/0000-0003-0241-9369; Baker, Mariah/0000-0002-1613-9387	NIAMS NIH HHS [R01 AR053349, R01 AR053349-02, P01 AR052354-01A10003, R01 AR044657-12, R01 AR050503-01, R01 AR044657, R01 AR050503, R01 AR050503-05, R01 AR053349-03, AR053349, R29 AR044657, R01 AR053349-01A1, R01 AR050503-03, P01 AR052354-020003, R01 AR041802, R01 AR050503-02, P01 AR052354, AR 050503, R01 AR053349-01A1S1, R01 AR050503-04, 5P01AR052354, AR44657] Funding Source: Medline; NIDCR NIH HHS [T32-DE07202, T32 DE007202] Funding Source: Medline; Telethon [GGP030289] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802, P01AR052354, R01AR053349, R01AR044657, R29AR044657, R01AR050503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007202] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; Aracena-Parks P, 2006, J BIOL CHEM, V281, P40354, DOI 10.1074/jbc.M600876200; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Bellinger AM, 2008, P NATL ACAD SCI USA, V105, P2198, DOI 10.1073/pnas.0711074105; Bendahan D, 2001, ANESTH ANALG, V93, P683, DOI 10.1097/00000539-200109000-00030; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; CARROLL S, 1991, ARCH BIOCHEM BIOPHYS, V290, P239, DOI 10.1016/0003-9861(91)90615-P; Chelu MG, 2006, FASEB J, V20, P329, DOI 10.1096/fj.05-4497fje; CHU A, 1990, MOL PHARMACOL, V37, P735; Clark CB, 2004, RESUSCITATION, V60, P349, DOI 10.1016/j.resuscitation.2004.02.002; Davis M, 2002, BRIT J ANAESTH, V88, P508, DOI 10.1093/bja/88.4.508; Donoso P, 2000, BIOPHYS J, V79, P279, DOI 10.1016/S0006-3495(00)76290-4; Ducreux S, 2004, J BIOL CHEM, V279, P43838, DOI 10.1074/jbc.M403612200; ELLIS FR, 1988, BRIT J ANAESTH, V60, P28, DOI 10.1093/bja/60.1.28; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HACKL W, 1991, BRIT J ANAESTH, V66, P138, DOI 10.1093/bja/66.1.138; Hare JM, 2003, J MOL CELL CARDIOL, V35, P719, DOI 10.1016/S0022-2828(03)00143-3; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; Hopkins PM, 2000, BRIT J ANAESTH, V85, P118, DOI 10.1093/bja/85.1.118; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; Letelier ME, 2005, CHEM-BIOL INTERACT, V151, P71, DOI 10.1016/j.cbi.2004.12.004; Lichtman AD, 2006, ANESTH ANALG, V102, P372, DOI 10.1213/01.ane.0000189596.70694.36; Long C, 2007, HYPERTENSION, V49, P569, DOI 10.1161/01.HYP.0000257914.80918.72; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Oba T, 2002, AM J PHYSIOL-CELL PH, V282, pC684, DOI 10.1152/ajpcell.01273.2000; PAMUKCOGLU T, 1988, AM J FOREN MED PATH, V9, P161, DOI 10.1097/00000433-198806000-00015; Paolini C, 2007, J PHYSIOL-LONDON, V583, P767, DOI 10.1113/jphysiol.2007.138024; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; Pollard JW, 1997, BASIC CELL CULTURE P; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; QUANE KA, 1994, GENOMICS, V23, P236, DOI 10.1006/geno.1994.1483; ROBERTSON S, 1992, VET CLIN N AM-SMALL, V22, P277, DOI 10.1016/S0195-5616(92)50609-X; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; ROSSI AE, 2006, BIOPHYS J, V90, pA269; Ryan JF, 1997, J CLIN ANESTH, V9, P66, DOI 10.1016/S0952-8180(96)00207-3; Sun JH, 2003, J BIOL CHEM, V278, P8184, DOI 10.1074/jbc.M211940200; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Thompson PD, 2007, CIRCULATION, V115, P2358, DOI 10.1161/CIRCULATIONAHA.107.181485; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Treves S, 2005, NEUROMUSCULAR DISORD, V15, P577, DOI 10.1016/j.nmd.2005.06.008; Wappler F, 2001, ANESTHESIOLOGY, V94, P95, DOI 10.1097/00000542-200101000-00019; Wells KE, 2003, NEUROMUSCULAR DISORD, V13, P21, DOI 10.1016/S0960-8966(02)00191-8; Zhang HW, 2003, J BIOL CHEM, V278, P8348, DOI 10.1074/jbc.M209565200	45	248	255	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2008	133	1					53	65		10.1016/j.cell.2008.02.042	http://dx.doi.org/10.1016/j.cell.2008.02.042			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394989	Green Accepted, Bronze			2022-12-28	WOS:000254641300008
J	Katsanis, SH; Javitt, G; Hudson, K				Katsanis, S. H.; Javitt, G.; Hudson, K.			Public health - A case study of personalized medicine	SCIENCE			English	Editorial Material									[Katsanis, S. H.; Javitt, G.; Hudson, K.] Johns Hopkins Univ, Genet & Publ Policy Ctr, Washington, DC 20036 USA	Johns Hopkins University	Hudson, K (corresponding author), Johns Hopkins Univ, Genet & Publ Policy Ctr, Washington, DC 20036 USA.	khudson5@jhu.edu		Katsanis, Sara/0000-0002-5044-8765				Berg AO, 2007, GENET MED, V9, P819, DOI 10.1097/GIM.0b013e31815bf9a3; *DNA DIR INC, 2007, DRUGS TEST FOR; EUGSTER HP, 1993, DRUG METAB DISPOS, V21, P43; EYER JD, 2007, PUBLIC COMMENT BEHAL; *FTC, 2006, FTC FACTS CONS HOM G; *GEN CORP, 2007, PHARM PAX PAR; Hudson K, 2007, AM J HUM GENET, V81, P635, DOI 10.1086/521634; Hudson KL, 2006, SCIENCE, V313, P1853, DOI 10.1126/science.1134996; Hunter DJ, 2008, NEW ENGL J MED, V358, P105, DOI 10.1056/NEJMp0708162; Javitt GH, 2007, FOOD DRUG LAW J, V62, P617; Javitt Gail H, 2004, Oklahoma Law Rev, V57, P251; *LAB CORP AM INC, 2006, LABCORP CAPS CYT P45; MATCHAR DB, 2007, 146 EV REP TECHN ASS, V146, P1; McCabe LL, 2004, GENET MED, V6, P58, DOI 10.1097/01.GIM.0000105753.01536.BE; Nelson DR, 2004, PHARMACOGENETICS, V14, P1, DOI 10.1097/00008571-200401000-00001; *ROCH MOL SYST INC, 2006, AMPLICHIP CYP450 TES; *SACGHS, 2007, US SYST OV GEN TEST; *SACGT, 2000, ENH OV GEN TESTS; *SERYX INC, 2007, DRUG GEN REP; Shurin SB, 2008, NEW ENGL J MED, V358, P1061, DOI 10.1056/NEJMe0800801; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112	21	85	88	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					53	54		10.1126/science.1156604	http://dx.doi.org/10.1126/science.1156604			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	283JR	18388277				2022-12-28	WOS:000254633000022
J	Piccirilli, JA				Piccirilli, Joseph A.			Biochemistry - Toward understanding self-splicing	SCIENCE			English	Editorial Material							METAL-ION COORDINATION; II INTRON CATALYSIS; 2-METAL-ION MECHANISM; RNA; DOMAIN-5; SPLICEOSOME; CONTRIBUTES		[Piccirilli, Joseph A.] Univ Chicago, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; [Piccirilli, Joseph A.] Univ Chicago, Howard Hughes Med Inst, Dept Chem, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Piccirilli, JA (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Biochem & Mol Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	jpicciri@uchicago.edu			Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Chanfreau G, 1996, EMBO J, V15, P3466, DOI 10.1002/j.1460-2075.1996.tb00713.x; Gordon PM, 2007, CHEM BIOL, V14, P607, DOI 10.1016/j.chembiol.2007.05.008; Gordon PM, 2001, NAT STRUCT BIOL, V8, P893, DOI 10.1038/nsb1001-893; Pyle A. M., 2006, RNA WORLD; PYLE AM, 2008, RIBOZYMES RNA CATALY; Shukla GC, 2002, MOL CELL, V9, P1145, DOI 10.1016/S1097-2765(02)00505-1; Sigel RKO, 2004, NAT STRUCT MOL BIOL, V11, P187, DOI 10.1038/nsmb717; Stahley MR, 2005, SCIENCE, V309, P1587, DOI 10.1126/science.1114994; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Toor N, 2008, SCIENCE, V320, P77, DOI 10.1126/science.1153803; Valadkhan S, 2001, NATURE, V413, P701, DOI 10.1038/35099500; Yean SL, 2000, NATURE, V408, P881, DOI 10.1038/35048617; Zhang L, 2002, SCIENCE, V295, P2084, DOI 10.1126/science.1069268	13	1	1	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					56	57		10.1126/science.1156721	http://dx.doi.org/10.1126/science.1156721			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388278				2022-12-28	WOS:000254633000023
J	Nissen, SE; Nicholls, SJ; Wolski, K; Nesto, R; Kupfer, S; Perez, A; Jure, H; De Larochelliere, R; Staniloae, CS; Mavromatis, K; Saw, J; Hu, B; Lincoff, AM; Tuzcu, EM				Nissen, Steven E.; Nicholls, Stephen J.; Wolski, Kathy; Nesto, Richard; Kupfer, Stuart; Perez, Alfonso; Jure, Horacio; De Larochelliere, Robert; Staniloae, Cezar S.; Mavromatis, Kreton; Saw, Jacqueline; Hu, Bo; Lincoff, A. Michael; Tuzcu, E. Murat		PERISCOPE Investigators	Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes - The PERISCOPE randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE MORTALITY; INTRAVASCULAR ULTRASOUND; CARDIOVASCULAR EVENTS; ARTERY-DISEASE; STATIN THERAPY; MELLITUS; RISK; ROSIGLITAZONE; METAANALYSIS; AGENTS	Context No antidiabetic regimen has demonstrated the ability to reduce progression of coronary atherosclerosis. Commonly used oral glucose- lowering agents include sulfonyl-ureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers. Objective To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes. Design, Setting, and Participants Double- blind, randomized, multicenter trial at 97 academic and community hospitals in North and South America ( enrollment August 2003- March 2006) in 543 patients with coronary disease and type 2 diabetes. Interventions A total of 543 patients underwent coronary intravascular ultrasonography and were randomized to receive glimepiride, 1 to 4 mg, or pioglitazone, 15 to 45 mg, for 18 months with titration to maximum dosage, if tolerated. Atherosclerosis progression was measured by repeat intravascular ultrasonography examination in 360 patients at study completion. Main Outcome Measure Change in percent atheroma volume ( PAV) from baseline to study completion. Results Least squares mean PAV increased 0.73%( 95% CI, 0.33% to 1.12%) with glimepiride and decreased 0.16% ( 95% CI, -0.57% to 0.25%) with pioglitazone( P=. 002). An alternative analysis imputing values for noncompleters based on baseline characteristics showed an increase in PAV of 0.64% ( 95% CI, 0.23% to 1.05%) for glimepiride and a decrease of 0.06% (- 0.47% to 0.35%) for pioglitazone ( between- group P=. 02). Mean ( SD) baseline HbA(1c) levels were 7.4% ( 1.0%) in both groups and declined during treatment an average 0.55% ( 95% CI,- 0.68% to -0.42%) with pioglitazone and 0.36%( 95% CI,- 0.48% to- 0.24%) with glimepiride ( between- group P =. 03). In the pioglitazone group, compared with glimepiride, high- density lipoprotein levels increased 5.7 mg/ dL ( 95% CI, 4.4 to 7.0 mg/ dL; 16.0%) vs 0.9 mg/ dL ( 95% CI, - 0.3 to 2.1 mg/ dL; 4.1%), and median triglyceride levels decreased 16.3 mg/ dL ( 95% CI, - 27.7 to - 11.0 mg/ dL; 15.3%) vs an increase of 3.3 mg/ dL( 95% CI,- 10.7 to 11.7 mg/ dL; 0.6%)( P < .001 for both comparisons). Median fasting insulin levels decreased with pioglitazone and increased with glimepiride ( P < .001). Hypoglycemia was more common in the glimepiride group and edema, fractures, and decreased hemoglobin levels occurred more frequently in the pioglitazone group. Conclusion In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride. Trial Registration clinicaltrials. gov Identifier: NCT00225277.	[Nissen, Steven E.; Nicholls, Stephen J.; Wolski, Kathy; Lincoff, A. Michael; Tuzcu, E. Murat] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA; [Hu, Bo] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Nesto, Richard] Lahey Clin Fdn, Dept Cardiovasc Med, Burlington, MA USA; [Kupfer, Stuart; Perez, Alfonso] Takeda Global Res & Dev, Dept Clin Sci, Deerfield, IL USA; [Jure, Horacio] Clin Chutro, Dept Cardiol, Colon, Argentina; [De Larochelliere, Robert] Hop Laval, Dept Cardiol, Quebec Heart Inst, Quebec City, PQ, Canada; [Staniloae, Cezar S.] St Vincents Hosp Manhattan, Div Cardiovasc, New York, NY USA; [Mavromatis, Kreton] Atlanta VA Med Ctr, Dept Med, Div Cardiol, Atlanta, GA USA; [Saw, Jacqueline] Vancouver Gen Hosp, Div Cardiol, Vancouver, BC, Canada	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Lahey Hospital & Medical Center; Laval University; Saint Vincents Hospital Manhattan; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical Center; University of British Columbia	Nissen, SE (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	nissens@ccf.org	Marroquin, Oscar C/F-2214-2015	Marroquin, Oscar C/0000-0002-0909-0319; Mendiz, Oscar/0000-0002-5268-0429; Nicholls, Stephen/0000-0002-9668-4368				[Anonymous], 2007, AV ROS MAL TABL PRES; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Bolen S, 2007, ANN INTERN MED, V147, P386, DOI 10.7326/0003-4819-147-6-200709180-00178; Brener SJ, 2004, CIRCULATION, V109, P2290, DOI 10.1161/01.CIR.0000126826.58526.14; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Eurich DT, 2007, BMJ-BRIT MED J, V335, P497, DOI 10.1136/bmj.39314.620174.80; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; Goldberg RB, 2005, DIABETES CARE, V28, P1547, DOI 10.2337/diacare.28.7.1547; Gu K, 1999, JAMA-J AM MED ASSOC, V281, P1291, DOI 10.1001/jama.281.14.1291; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Lincoff AM, 2007, JAMA-J AM MED ASSOC, V298, P1180, DOI 10.1001/jama.298.10.1180; Mazzone T, 2006, JAMA-J AM MED ASSOC, V296, P2572, DOI 10.1001/jama.296.21.joc60158; Meigs JB, 1997, AM J MED, V102, P38, DOI 10.1016/S0002-9343(96)00383-X; NICHOLLS SJ, IN PRESS J AM COLL C; Nicholls SJ, 2006, NAT REV DRUG DISCOV, V5, P485, DOI 10.1038/nrd2040; Nissen SE, 2007, NEW ENGL J MED, V357, P835; Nissen SE, 2007, NEW ENGL J MED, V357, P100; Nissen SE, 2006, NEW ENGL J MED, V355, P638; Nissen SE, 2006, NEW ENGL J MED, V354, P1253, DOI 10.1056/NEJMoa054699; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Nissen SE, 2004, JAMA-J AM MED ASSOC, V292, P2217, DOI 10.1001/jama.292.18.2217; Nissen SE, 2006, JAMA-J AM MED ASSOC, V295, P1556, DOI 10.1001/jama.295.13.jpc60002; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Nissen SE, 2007, NEW ENGL J MED, V356, P1304, DOI 10.1056/NEJMoa070635; RUBIN R, USA TODAY; Schoenhagen P, 2003, J AM SOC ECHOCARDIOG, V16, P277, DOI 10.1067/mje.2003.45; Scholte AJHA, 2008, HEART, V94, P290, DOI 10.1136/hrt.2007.121921; Staels B, 2005, DIABETES, V54, P2460, DOI 10.2337/diabetes.54.8.2460; Stettler C, 2006, AM HEART J, V152, P27, DOI 10.1016/j.ahj.2005.09.015; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WALLER BF, 1980, AM J MED, V69, P498, DOI 10.1016/S0149-2918(05)80002-5	33	666	698	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2008	299	13					1561	1573		10.1001/jama.299.13.1561	http://dx.doi.org/10.1001/jama.299.13.1561			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	281RZ	18378631	Bronze			2022-12-28	WOS:000254517900023
J	Li, L; Lok, SM; Yu, IM; Zhang, Y; Kuhn, RJ; Chen, J; Rossmann, MG				Li, Long; Lok, Shee-Mei; Yu, I-Mei; Zhang, Ying; Kuhn, Richard J.; Chen, Jue; Rossmann, Michael G.			The flavivirus precursor membrane-envelope protein complex: Structure and maturation	SCIENCE			English	Article							BORNE ENCEPHALITIS-VIRUS; WEST-NILE-VIRUS; DENGUE VIRUS; CRYSTAL-STRUCTURE; E-GLYCOPROTEIN; PRM PROTEIN; PARTICLES; EPITOPES; FUSION; FURIN	Many viruses go through a maturation step in the final stages of assembly before being transmitted to another host. The maturation process of flaviviruses is directed by the proteolytic cleavage of the precursor membrane protein (prM), turning inert virus into infectious particles. We have determined the 2.2 angstrom resolution crystal structure of a recombinant protein in which the dengue virus prM is linked to the envelope glycoprotein E. The structure represents the prM- E heterodimer and fits well into the cryo- electron microscopy density of immature virus at neutral pH. The pr peptide beta-barrel structure covers the fusion loop in E, preventing fusion with host cell membranes. The structure provides a basis for identifying the stages of its pH- directed conformational metamorphosis during maturation, ending with release of pr when budding from the host.	[Li, Long; Lok, Shee-Mei; Yu, I-Mei; Zhang, Ying; Kuhn, Richard J.; Chen, Jue; Rossmann, Michael G.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Rossmann, MG (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	mr@purdue.edu	Li, Long/F-8892-2010; Lok, Shee-mei/I-7050-2012; Kuhn, Richard/AAR-2722-2021	Kuhn, Richard/0000-0003-4148-1026; Lok, Shee-Mei/0000-0003-4631-8041	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055672, U54AI057153] Funding Source: NIH RePORTER; NIAID NIH HHS [1-U54-AI-057153, AI055672] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GUIRAKHOO F, 1992, VIROLOGY, V191, P921, DOI 10.1016/0042-6822(92)90267-S; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Kanai R, 2006, J VIROL, V80, P11000, DOI 10.1128/JVI.01735-06; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Lin YJ, 2005, J VIROL, V79, P8535, DOI 10.1128/JVI.79.13.8535-8544.2005; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Stadler K, 1997, J VIROL, V71, P8475, DOI 10.1128/JVI.71.11.8475-8481.1997; Zhang W, 2003, NAT STRUCT BIOL, V10, P907, DOI 10.1038/nsb990; Zhang Y, 2004, STRUCTURE, V12, P1607, DOI 10.1016/j.str.2004.06.019; Zhang Y, 2003, EMBO J, V22, P2604, DOI 10.1093/emboj/cdg270; Zhang Y, 2007, J VIROL, V81, P6141, DOI 10.1128/JVI.00037-07	17	367	388	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1830	1834		10.1126/science.1153263	http://dx.doi.org/10.1126/science.1153263			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369147				2022-12-28	WOS:000254394000048
J	Carpenter, D; Zucker, EJ; Avorn, J				Carpenter, Daniel; Zucker, Evan James; Avorn, Jerry			Drug-review deadlines and safety problems	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FDA; REFORM	Background: The Prescription Drug User Fee Act (PDUFA) imposes deadlines for the completion of drug reviews by the Food and Drug Administration (FDA). Critics have suggested that these deadlines may result in rushed approvals and the emergence of unanticipated safety problems once a product is in clinical use. Methods: We assessed the association between the PDUFA deadlines and the timing of FDA drug approval by constructing dynamic Cox proportional-hazards models of review times for all new molecular entities approved between 1950 and 2005. To determine whether the deadlines were associated with postmarketing safety problems, we focused on drugs submitted since January 1993, when the deadlines were first imposed. We used exact logistic regression to determine whether drugs approved immediately before the deadlines were associated with a higher rate of postmarketing safety problems (e.g., withdrawals and black-box warnings) than drugs approved at other times. Results: Initiation of the PDUFA requirements concentrated the number of approval decisions made in the weeks immediately preceding the deadlines. As compared with drugs approved at other times, drugs approved in the 2 months before their PDUFA deadlines were more likely to be withdrawn for safety reasons (odds ratio, 5.5; 95% confidence interval [CI], 1.3 to 27.8), more likely to carry a subsequent black-box warning (odds ratio, 4.4; 95% CI, 1.2 to 20.5), and more likely to have one or more dosage forms voluntarily discontinued by the manufacturer (odds ratio, 3.3; 95% CI, 1.5 to 7.5). Conclusions: PDUFA deadlines have appreciably changed the approval decisions of the FDA. Once medications are in clinical use, the discovery of safety problems is more likely for drugs approved immediately before a deadline than for those approved at other times.	[Carpenter, Daniel] Harvard Univ, Dept Govt, Fac Arts & Sci, Cambridge, MA 02138 USA; [Zucker, Evan James; Avorn, Jerry] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Avorn, Jerry] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Carpenter, D (corresponding author), Harvard Univ, Dept Govt, Fac Arts & Sci, N405,1737 Cambridge St, Cambridge, MA 02138 USA.	dcarpenter@gov.harvard.edu						Avorn J, 2004, POWERFUL MED BENEFIT; BACIU A, 2006, FUTURE DRUG SAFETY P; CARPENTER D, 2003, APPROVAL TIMES NEW D; *FDA OFF COMM, PERF FY99 FDAMA GOAL; *FDA OFF PLANN, REP PDUFA GOALS OR N; Fontanarosa PB, 2004, JAMA-J AM MED ASSOC, V292, P2647, DOI 10.1001/jama.292.21.2647; *FOOD DRUG ADM, 2005, PRESCR DRUG US FEE A; *FOOD DRUG ADM, FDA APPR DRUG PROD D; Fung M, 2001, DRUG INF J, V35, P293, DOI 10.1177/009286150103500134; *GOV ACC OFF, 2006, DRUG SAF IMPR NEED F; *HARV U FAC ARTS S, FDA NEW MOL ENT APPR; Horton R, 2001, LANCET, V357, P1544, DOI 10.1016/S0140-6736(00)04776-0; *INF, 2007, PHARM PHARM R D PIP; *KANS U MED CTR, WARN INF PAG; King EN, 2002, AM STAT, V56, P163, DOI 10.1198/00031300283; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; LEWIS C, 2003, FDA CONSUMER     MAY; McClellan M, 2007, NEW ENGL J MED, V356, P1700, DOI 10.1056/NEJMp078057; MEHTA C, 2007, LOGXACT8 STAT SOFTWA; MOFFITT S, 2005, THESIS U MICHIGAN AN; Nissen SE, 2007, NEW ENGL J MED, V357, P100; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Okie S, 2005, NEW ENGL J MED, V352, P2563; Olson MK, 2004, J HEALTH POLIT POLIC, V29, P397, DOI 10.1215/03616878-29-3-397; Ray WA, 2006, NEW ENGL J MED, V354, P194, DOI 10.1056/NEJMsb053432; Ross DB, 2007, NEW ENGL J MED, V356, P1601, DOI 10.1056/NEJMp078032; Therneau TM, 2000, MODELING SURVIVAL DA; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; *UNION CONC SCI, 2006, VOIC SCI FDA PROT PU; WOODCOCK J, 2005, DRUG SAFETY DRUG APP; 2006, PDUFA 3 IND EV FDAS	31	134	138	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1354	1361		10.1056/NEJMsa0706341	http://dx.doi.org/10.1056/NEJMsa0706341			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367738				2022-12-28	WOS:000254308400006
J	Bongartz, T				Bongartz, Tim			Tocilizumab for rheumatoid and juvenile idiopathic arthritis	LANCET			English	Editorial Material							RECEIVING CONCOMITANT METHOTREXATE; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; CORONARY-HEART-DISEASE; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; ETANERCEPT; EFFICACY; RISK; COMBINATION		[Bongartz, Tim] Mayo Clin, Coll Med, Dept Internal Med, Rochester, MN 55905 USA; [Bongartz, Tim] Mayo Clin, Coll Med, Div Rheumatol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Bongartz, T (corresponding author), Mayo Clin, Coll Med, Dept Internal Med, Rochester, MN 55905 USA.	bongartz.tim@mayo.edu						Chung CP, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2098; Cohen S, 2002, ARTHRITIS RHEUM, V46, P614, DOI 10.1002/art.10141; Dixon WG, 2007, ARTHRITIS RHEUM, V56, P2905, DOI 10.1002/art.22809; Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778; GIANNINI EH, 1992, NEW ENGL J MED, V326, P1043, DOI 10.1056/NEJM199204163261602; Gonzalez A, 2008, ANN RHEUM DIS, V67, P64, DOI 10.1136/ard.2006.059980; Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Maradit-Kremers H, 2005, ARTHRITIS RHEUM-US, V52, P402, DOI 10.1002/art.20853; Nishimoto N, 2007, ANN RHEUM DIS, V66, P1162, DOI 10.1136/ard.2006.068064; Nishimoto N, 2006, NAT CLIN PRACT RHEUM, V2, P619, DOI 10.1038/ncprheum0338; Quartier P, 2003, ARTHRITIS RHEUM, V48, P1093, DOI 10.1002/art.10885; Seriolo B, 2006, ANN NY ACAD SCI, V1069, P414, DOI 10.1196/annals.1351.039; Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140-6736(08)60453-5; van der Kooij SM, 2007, ANN RHEUM DIS, V66, P1356, DOI 10.1136/ard.2006.066662; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140-6736(08)60454-7	20	12	15	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 22	2008	371	9617					961	963		10.1016/S0140-6736(08)60428-6	http://dx.doi.org/10.1016/S0140-6736(08)60428-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358909				2022-12-28	WOS:000254206000004
J	Smith, C; Richardus, JH				Smith, Cairns; Richardus, Jan Hendrik			Leprosy strategy is about control, not eradication	LANCET			English	Editorial Material							CHEMOPROPHYLAXIS; TRANSMISSION; PREVENTION		[Smith, Cairns] Univ Aberdeen, Dept Publ Hlth, Sch Med, Aberdeen AB25 2ZD, Scotland; [Richardus, Jan Hendrik] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands	University of Aberdeen; Erasmus University Rotterdam; Erasmus MC	Smith, C (corresponding author), Univ Aberdeen, Dept Publ Hlth, Sch Med, Aberdeen AB25 2ZD, Scotland.	w.c.s.smith@abdn.ac.uk	Richardus, Jan Hendrik/AAE-1278-2021	Richardus, Jan Hendrik/0000-0003-0564-6313				Childs James E., 1993, Morbidity and Mortality Weekly Report, V42, P1; Fine PEM, 2007, B WORLD HEALTH ORGAN, V85, P2, DOI 10.2471/BLT.06.039206; Geluk A, 2006, HUM IMMUNOL, V67, P439, DOI 10.1016/j.humimm.2006.03.009; LEISINGER KM, 2008, 17 INT LEPR C HYD IN; Meima A, 2004, B WORLD HEALTH ORGAN, V82, P373; Moet FJ, 2004, LEPROSY REV, V75, P376; Richardus JH, 2007, LEPROSY REV, V78, P330; Setia MS, 2006, LANCET INFECT DIS, V6, P162, DOI 10.1016/S1473-3099(06)70412-1; Smith CM, 2000, J INFECTION, V41, P137, DOI 10.1053/jinf.2000.0698; *WHO, 2005, GLOB STRAT RED LEPR; *WHO, 2007, WKLY EPIDEMIOL REC, V82, P225; *WHO, 2002, WKLY EPIDEMIOL REC, V77, P1	12	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2008	371	9617					969	970		10.1016/S0140-6736(08)60433-X	http://dx.doi.org/10.1016/S0140-6736(08)60433-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358914				2022-12-28	WOS:000254206000009
J	Kumaran, RI; Thakar, R; Spector, DL				Kumaran, R. Ileng; Thakar, Rajika; Spector, David L.			Chromatin dynamics and gene positioning	CELL			English	Article							X-INACTIVATION; CHROMOSOME TERRITORIES; NUCLEAR ARCHITECTURE; TRANSCRIPTION; EXPRESSION; ACTIN; LOCUS; ORGANIZATION; MOUSE; CELLS	The mammalian cell nucleus provides a landscape where genes are regulated through their organization and association with freely diffusing proteins and nuclear domains. In many cases, specific genes are highly dynamic, and the principles governing their movements and interchromosomal interactions are currently under intensive study. Recent investigations have implicated actin and myosin in chromatin dynamics and gene expression. Here, we discuss our current understanding of the dynamics of the interphase genome and how it impacts nuclear organization and gene activity.	[Kumaran, R. Ileng; Thakar, Rajika; Spector, David L.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Spector, DL (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	spector@cshl.edu		Arora, Rajika/0000-0001-9396-3671	NATIONAL EYE INSTITUTE [PN2EY018244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694] Funding Source: NIH RePORTER; NEI NIH HHS [EY18244, PN2 EY018244] Funding Source: Medline; NIGMS NIH HHS [R01 GM042694-10] Funding Source: Medline; PHS HHS [42694, 71407] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Augui S, 2007, SCIENCE, V318, P1632, DOI 10.1126/science.1149420; Bacher CP, 2006, NAT CELL BIOL, V8, P293, DOI 10.1038/ncb1365; Branco MR, 2006, PLOS BIOL, V4, P780, DOI 10.1371/journal.pbio.0040138; Brown CR, 2007, CURR OPIN GENET DEV, V17, P100, DOI 10.1016/j.gde.2007.02.005; Chuang CH, 2006, CURR BIOL, V16, P825, DOI 10.1016/j.cub.2006.03.059; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; de Lanerolle P, 2005, NAT STRUCT MOL BIOL, V12, P742, DOI 10.1038/nsmb983; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dundr M, 2007, J CELL BIOL, V179, P1095, DOI 10.1083/jcb.200710058; Fraser P, 2007, NATURE, V447, P413, DOI 10.1038/nature05916; Fuss SH, 2007, CELL, V130, P373, DOI 10.1016/j.cell.2007.06.023; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Kumaran RI, 2008, J CELL BIOL, V180, P51, DOI 10.1083/jcb.200706060; Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lanctot C, 2007, EXP CELL RES, V313, P1449, DOI 10.1016/j.yexcr.2007.01.027; Lanctot C, 2007, NAT REV GENET, V8, P104, DOI 10.1038/nrg2041; LANE NJ, 1969, J CELL BIOL, V40, P286, DOI 10.1083/jcb.40.1.286; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191; Lomvardas S, 2006, CELL, V126, P403, DOI 10.1016/j.cell.2006.06.035; Meaburn KJ, 2008, J CELL BIOL, V180, P39, DOI 10.1083/jcb.200708204; Moen PT, 2004, MOL BIOL CELL, V15, P197, DOI 10.1091/mbc.e03-06-0388; Osborne CS, 2007, PLOS BIOL, V5, P1763, DOI 10.1371/journal.pbio.0050192; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Pederson T, 2005, MOL BIOL CELL, V16, P5055, DOI 10.1091/mbc.E05-07-0656; Percipalle P, 2006, J CELL BIOL, V172, P967, DOI 10.1083/jcb.200512083; Ragoczy T, 2006, GENE DEV, V20, P1447, DOI 10.1101/gad.1419506; REDDY KL, 2008, NATURE          0213, V13, P2008, DOI DOI 10.1038/NATURE06727; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Sexton T, 2007, NAT STRUCT MOL BIOL, V14, P1049, DOI 10.1038/nsmb1324; Shykind BM, 2005, HUM MOL GENET, V14, pR33, DOI 10.1093/hmg/ddi105; Skok JA, 2007, NAT IMMUNOL, V8, P378, DOI 10.1038/ni1448; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Spicuglia S, 2006, CURR OPIN IMMUNOL, V18, P158, DOI 10.1016/j.coi.2006.01.003; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Sproul D, 2005, NAT REV GENET, V6, P775, DOI 10.1038/nrg1688; Xu N, 2006, SCIENCE, V311, P1149, DOI 10.1126/science.1122984; Xu N, 2007, NAT GENET, V39, P1390, DOI 10.1038/ng.2007.5	42	117	120	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 21	2008	132	6					929	934		10.1016/j.cell.2008.03.004	http://dx.doi.org/10.1016/j.cell.2008.03.004			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358806	Green Accepted, Bronze			2022-12-28	WOS:000254273600012
J	Troadec, MB; Kaplan, J				Troadec, Marie-Berengere; Kaplan, Jerry			Some vertebrates go with the GLO	CELL			English	Editorial Material							ASCORBIC-ACID; DEHYDROASCORBIC ACID; TRANSPORT	Most vertebrates synthesize vitamin C (ascorbate) de novo from glucose, but humans and certain other mammals cannot. In this issue, Montel-Hagen et al. (2008) demonstrate that erythrocytes from these ascorbate auxotrophs switch the preference of their glucose transporter Glut1 from glucose to dehydroascorbate (DHA), the oxidized form of vitamin C. This substrate preference switch is mediated by the membrane protein stomatin and is an evolutionary adaptation to vitamin C deficiency.	[Troadec, Marie-Berengere; Kaplan, Jerry] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu	Troadec, Marie-Berengere/I-6883-2013	TROADEC, Marie-Berengere/0000-0003-2668-9670				Arrigoni O, 2002, BBA-GEN SUBJECTS, V1569, P1, DOI 10.1016/S0304-4165(01)00235-5; BIANCHI J, 1986, P SOC EXP BIOL MED, V181, P333; FREI B, 1990, ADV EXP MED BIOL, V264, P155; May JM., 1998, FRONT BIOSCI-LANDMRK, V3, P1, DOI [10.2741/a262, DOI 10.2741/A262]; NISHIKIMI M, 1992, J BIOL CHEM, V267, P21967; PAULING L, 1970, P NATL ACAD SCI USA, V67, P1643, DOI 10.1073/pnas.67.4.1643; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Zhang JZ, 2001, AM J PHYSIOL-CELL PH, V280, pC1277, DOI 10.1152/ajpcell.2001.280.5.C1277	9	4	5	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2008	132	6					921	922		10.1016/j.cell.2008.03.005	http://dx.doi.org/10.1016/j.cell.2008.03.005			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358804	Bronze			2022-12-28	WOS:000254273600010
J	Fabry, VJ				Fabry, Victoria J.			Ocean science - Marine calcifiers in a high-CO2 ocean	SCIENCE			English	Editorial Material							EMILIANIA-HUXLEYI; CALCIFICATION; ACIDIFICATION		[Fabry, Victoria J.] Calif State Univ San Marcos, Dept Biol Sci, San Marcos, CA 92096 USA	California State University System; California State University San Marcos	Fabry, VJ (corresponding author), Calif State Univ San Marcos, Dept Biol Sci, San Marcos, CA 92096 USA.	fabry@csusm.edu						Cubillos JC, 2007, MAR ECOL PROG SER, V348, P47, DOI 10.3354/meps07058; Fabry VJ, 2008, ICES J MAR SCI, V65, P414, DOI 10.1093/icesjms/fsn048; FEELY RA, 2008, EOS T AGU; Iglesias-Rodriguez MD, 2008, SCIENCE, V320, P336, DOI 10.1126/science.1154122; Iglesias-Rodriguez MD, 2006, J PHYCOL, V42, P526; Langdon C, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002576; Langer G, 2006, GEOCHEM GEOPHY GEOSY, V7, DOI 10.1029/2005GC001227; Orr JC, 2005, NATURE, V437, P681, DOI 10.1038/nature04095; Paasche E, 2001, PHYCOLOGIA, V40, P503, DOI 10.2216/i0031-8884-40-6-503.1; Riebesell U, 2000, NATURE, V407, P364, DOI 10.1038/35030078; RIES JB, 2008, EOS T AGU; Sabine CL, 2004, SCIENCE, V305, P367, DOI 10.1126/science.1097403; The Royal Society, 2005, 1205 ROYAL SOC; TYRRELL T, 2007, BIOGEOSCIENCES DISCU, V4, P3581; Zondervan I, 2007, DEEP-SEA RES PT II, V54, P521, DOI 10.1016/j.dsr2.2006.12.004	15	125	129	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1020	1022		10.1126/science.1157130	http://dx.doi.org/10.1126/science.1157130			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18420898				2022-12-28	WOS:000256059800026
J	Cote, AM; Brown, MA; Lam, E; von Dadelszen, P; Firoz, T; Liston, RM; Magee, LA				Cote, Anne-Marie; Brown, Mark A.; Lam, Elaine; von Dadelszen, Peter; Firoz, Tabassum; Liston, Robert M.; Magee, Laura A.			Diagnostic accuracy of urinary spot protein : creatinine ratio for proteinuria in hypertensive pregnant women: systematic review	BRITISH MEDICAL JOURNAL			English	Review							SEVERE PREECLAMPSIA; MANAGEMENT; EXCRETION; CLASSIFICATION; DISORDERS	Objective To review the spot protein:creatinine ratio and albumin:creatinine ratio as diagnostic tests for significant proteinuria in hypertensive pregnant women. Design Systematic review. Data sources Medline and Embase, the Cochrane Library, reference lists, and experts. Review methods Literature search (1980-2007) for articles of the spot protein:creatinine ratio or albumin: creatinine ratio in hypertensive pregnancy, with 24 hour proteinuria as the comparator. Results 13 studies concerned the spot protein: creatinine ratio (1214 women with primarily gestational hypertension). Nine studies reported sensitivity and specificity for eight cut-off points, median 24 mg/mmol (range 17-57 mg/mmol; 0.15-0.50 mg/mg). Laboratory assays were not well described. Diagnostic test characteristics were recalculated for a cut-off point of 30,mg/mmol. No significant heterogeneity in cut-off points was found between studies over a range of proteinuria. Pooled values gave a sensitivity of 83.6% (95% confidence interval 77.5% to 89.7%), specificity of 76.3% (72.6% to 80.0%), positive likelihood ratio of 3.53 (2.83 to 4.49), and negative likelihood ratio of 0.21 (0.13 to 0.31) (nine studies, 1003 women). Two studies of the spot albumin:creatinine ratio (225 women) found optimal cut-off points of 2 mg/mmol for proteinuria of 0.3 g/day or more and 27 mg/mmol for albuminuria. Conclusion The spot protein:creatinine ratio is a reasonable "rule-out" test for detecting proteinuria of 0.3 g/day or more in hypertensive pregnancy. Information on use of the spot albumin:creatinine ratio in these women is insufficient.	[Cote, Anne-Marie; Lam, Elaine; Firoz, Tabassum] BC Womens Hosp & Hlth Ctr, Vancouver, BC V6P 1S8, Canada; [Brown, Mark A.] St George Hosp, Sydney, NSW, Australia; [Brown, Mark A.] Univ New S Wales, Sydney, NSW, Australia; [von Dadelszen, Peter; Liston, Robert M.; Magee, Laura A.] Univ British Columbia, Child & Family Res Inst, Vancouver, BC V6H 3N1, Canada	St George Hospital; University of New South Wales Sydney; Child & Family Research Institute; University of British Columbia	Magee, LA (corresponding author), BC Womens Hosp & Hlth Ctr, Vancouver, BC V6P 1S8, Canada.	LMagee@cw.bc.ca	von Dadelszen, Peter/AAP-7480-2021	von Dadelszen, Peter/0000-0003-4136-3070				Brown MA, 2000, AUST NZ J OBSTET GYN, V40, P133, DOI 10.1111/j.1479-828X.2000.tb01136.x; Brown MA, 2001, HYPERTENS PREGNANCY, V20, pIX, DOI 10.1081/PRG-100104165; Chan P, 2005, BJOG-INT J OBSTET GY, V112, P280, DOI 10.1111/j.1471-0528.2004.00395.x; CHUA S, 1992, EUR J OBSTET GYN R B, V43, P9, DOI 10.1016/0028-2243(92)90236-R; Deeks JJ., 2001, SYSTEMATIC REV HLTH, P248, DOI DOI 10.1002/9780470693926.CH14; FERRAZZANI S, 1990, AM J OBSTET GYNECOL, V162, P366, DOI 10.1016/0002-9378(90)90387-M; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; Hall DR, 2002, INT J GYNECOL OBSTET, V77, P1, DOI 10.1016/S0020-7292(02)00008-5; Helewa ME, 1997, CAN MED ASSOC J, V157, P715; Lane C, 2006, NEPHROLOGY, V11, P245, DOI 10.1111/j.1440-1797.2006.00564.x; LAO TT, 1988, EUR J OBSTET GYN R B, V29, P121, DOI 10.1016/0028-2243(88)90138-4; LINDHEIMER MD, 1977, KIDNEY FUNCTION DIS, P1; LINDOW SW, 1992, BRIT J OBSTET GYNAEC, V99, P869, DOI 10.1111/j.1471-0528.1992.tb14431.x; Newman MG, 2003, AM J OBSTET GYNECOL, V188, P264, DOI 10.1067/mob.2003.84; Schiff E, 1996, AM J OBSTET GYNECOL, V175, P1313, DOI 10.1016/S0002-9378(96)70047-9; Skweres Tomasz, 2006, Ginekol Pol, V77, P415; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25	17	126	138	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAY 3	2008	336	7651					1003	1006		10.1136/bmj.39532.543947.BE	http://dx.doi.org/10.1136/bmj.39532.543947.BE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300EZ	18403498	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000255808400043
J	Cristol, DA; Brasso, RL; Condon, AM; Fovargue, RE; Friedman, SL; Hallinger, KK; Monroe, AP; White, AE				Cristol, Daniel A.; Brasso, Rebecka L.; Condon, Anne M.; Fovargue, Rachel E.; Friedman, Scott L.; Hallinger, Kelly K.; Monroe, Adrian P.; White, Ariel E.			The movement of aquatic Mercury through terrestrial food webs	SCIENCE			English	Article							METHYLMERCURY; HEALTH		[Cristol, Daniel A.; Brasso, Rebecka L.; Condon, Anne M.; Fovargue, Rachel E.; Friedman, Scott L.; Hallinger, Kelly K.; Monroe, Adrian P.; White, Ariel E.] Coll William & Mary, Dept Biol, Inst Integrat Bird Behav Studies, Williamsburg, VA 23185 USA	William & Mary	Cristol, DA (corresponding author), Coll William & Mary, Dept Biol, Inst Integrat Bird Behav Studies, Williamsburg, VA 23185 USA.	dacris@wm.edu	Monroe, Adrian/I-4018-2019; Brasso, Rebecka/I-7014-2013	Monroe, Adrian/0000-0003-0934-8225; 				CARTER LJ, 1977, SCIENCE, V198, P1015, DOI 10.1126/science.198.4321.1015; Evers DC, 2008, ECOTOXICOLOGY, V17, P69, DOI 10.1007/s10646-007-0168-7; Haines TA, 2003, ENVIRON MONIT ASSESS, V86, P211, DOI 10.1023/A:1024017329382; Mergler D, 2007, AMBIO, V36, P3, DOI 10.1579/0044-7447(2007)36[3:MEAHEI]2.0.CO;2; Scheulhammer AM, 2007, AMBIO, V36, P12, DOI 10.1579/0044-7447(2007)36[12:EOEMOT]2.0.CO;2	5	308	316	9	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2008	320	5874					335	335		10.1126/science.1154082	http://dx.doi.org/10.1126/science.1154082			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420925				2022-12-28	WOS:000255026100032
J	Nishiyama, M; Ishikawa, T; Rechsteiner, H; Glockshuber, R				Nishiyama, Mireille; Ishikawa, Takashi; Rechsteiner, Helene; Glockshuber, Rudi			Reconstitution of pilus assembly reveals a bacterial outer membrane catalyst	SCIENCE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; FIMH ADHESIN; STRUCTURAL BASIS; TYPE-1 FIMBRIAE; PLATFORM FIMD; BIOGENESIS; COMPLEX; RECOGNITION; MECHANISM; RECEPTOR	Type 1 pili from uropathogenic Escherichia coli are a prototype of adhesive surface organelles assembled and secreted by the conserved chaperone/ usher pathway. We reconstituted type 1 pilus biogenesis from purified pilus proteins. The usher FimD acted as a catalyst to accelerate the ordered assembly of protein subunits independently of cellular energy. Its activity was highly dependent on the adhesin subunit FimH, which triggered the conversion of FimD into a high-efficiency assembly catalyst. Furthermore, a simple kinetic model adequately rationalized usher- catalyzed pilus assembly in vivo. Our results contribute to a mechanistic understanding of protein- catalyzed biogenesis of supramolecular protein complexes at the bacterial outer cell membrane.	[Nishiyama, Mireille; Ishikawa, Takashi; Rechsteiner, Helene; Glockshuber, Rudi] ETH, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Glockshuber, R (corresponding author), ETH, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.	rudi@mol.biol.ethz.ch	Ishikawa, Takashi/E-5023-2017	Ishikawa, Takashi/0000-0002-1976-7477				Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Connell I, 1996, P NATL ACAD SCI USA, V93, P9827, DOI DOI 10.1073/PNAS.93.18.9827; Hahn E, 2002, J MOL BIOL, V323, P845, DOI 10.1016/S0022-2836(02)01005-7; JACOBDUBUISSON F, 1994, J BIOL CHEM, V269, P12447; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; Knight SD, 2007, ADV EXP MED BIOL, V603, P74; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; Munera D, 2007, MOL MICROBIOL, V64, P333, DOI 10.1111/j.1365-2958.2007.05657.x; Nishiyama M, 2005, EMBO J, V24, P2075, DOI 10.1038/sj.emboj.7600693; Nishlyama M, 2003, J MOL BIOL, V330, P513, DOI 10.1016/S0022-2836(03)00591-6; Pinkner JS, 2006, P NATL ACAD SCI USA, V103, P17897, DOI 10.1073/pnas.0606795103; Remaut H, 2006, MOL CELL, V22, P831, DOI 10.1016/j.molcel.2006.05.033; RUSSELL PW, 1992, J BACTERIOL, V174, P5923, DOI 10.1128/jb.174.18.5923-5935.1992; Sauer FG, 2002, CELL, V111, P543, DOI 10.1016/S0092-8674(02)01050-4; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Saulino ET, 1998, EMBO J, V17, P2177, DOI 10.1093/emboj/17.8.2177; Schembri MA, 1996, FEMS MICROBIOL LETT, V137, P257, DOI 10.1016/0378-1097(96)00067-5; Telford JL, 2006, NAT REV MICROBIOL, V4, P509, DOI 10.1038/nrmicro1443; Vetsch M, 2004, NATURE, V431, P329, DOI 10.1038/nature02891; Vetsch M, 2006, EMBO REP, V7, P734, DOI 10.1038/sj.embor.7400722; Zhou G, 2001, J CELL SCI, V114, P4095	22	88	89	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					376	379		10.1126/science.1154994	http://dx.doi.org/10.1126/science.1154994			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18369105				2022-12-28	WOS:000255026100044
J	Ponomarenko, LA; Schedin, F; Katsnelson, MI; Yang, R; Hill, EW; Novoselov, KS; Geim, AK				Ponomarenko, L. A.; Schedin, F.; Katsnelson, M. I.; Yang, R.; Hill, E. W.; Novoselov, K. S.; Geim, A. K.			Chaotic dirac billiard in graphene quantum dots	SCIENCE			English	Article								The exceptional electronic properties of graphene, with its charge carriers mimicking relativistic quantum particles and its formidable potential in various applications, have ensured a rapid growth of interest in this new material. We report on electron transport in quantum dot devices carved entirely from graphene. At large sizes (> 100 nanometers), they behave as conventional single- electron transistors, exhibiting periodic Coulomb blockade peaks. For quantum dots smaller than 100 nanometers, the peaks become strongly nonperiodic, indicating a major contribution of quantum confinement. Random peak spacing and its statistics are well described by the theory of chaotic neutrino billiards. Short constrictions of only a few nanometers in width remain conductive and reveal a confinement gap of up to 0.5 electron volt, demonstrating the possibility of molecular- scale electronics based on graphene.	[Ponomarenko, L. A.; Schedin, F.; Yang, R.; Hill, E. W.; Novoselov, K. S.; Geim, A. K.] Univ Manchester, Manchester Ctr Mesosci & Nanotechnol, Manchester M13 9PL, Lancs, England; [Katsnelson, M. I.] Radboud Univ Nijmegen, Inst Mol & Mat, NL-6525 ED Nijmegen, Netherlands	University of Manchester; Radboud University Nijmegen	Novoselov, KS (corresponding author), Univ Manchester, Manchester Ctr Mesosci & Nanotechnol, Manchester M13 9PL, Lancs, England.	novoselov@manchester.ac.uk	Wang, Yisen/G-5131-2014; Geim, Andre K/J-7888-2012; Katsnelson, Mikhail I./D-4359-2012; Novoselov, Kostya S/G-9581-2014; Ponomarenko, Leonid/AAF-1731-2021; Hill, Ernie/K-6942-2015	Geim, Andre K/0000-0003-2861-8331; Novoselov, Kostya S/0000-0003-4972-5371; Hill, Ernie/0000-0001-9412-6795; hai yan, he/0000-0003-0366-6185	EPSRC [EP/D040264/1, EP/E051227/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/E051227/1, EP/D040264/1, EP/C511875/1] Funding Source: researchfish	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Avouris P, 2007, NAT NANOTECHNOL, V2, P605, DOI 10.1038/nnano.2007.300; Barone V, 2006, NANO LETT, V6, P2748, DOI 10.1021/nl0617033; BERRY MV, 1987, P ROY SOC LOND A MAT, V412, P53, DOI 10.1098/rspa.1987.0080; Bunch JS, 2005, NANO LETT, V5, P287, DOI 10.1021/nl048111+; Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109; Dobisz EA, 2000, J VAC SCI TECHNOL B, V18, P107, DOI 10.1116/1.591242; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Guhr T, 1998, PHYS REP, V299, P190; Gunlycke D, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2718515; Han MY, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.206805; Kouwenhoven L. P., 1997, KLUWER SERIES E, V345, P105; Kuhl U, 2005, J PHYS A-MATH GEN, V38, P10433, DOI 10.1088/0305-4470/38/49/001; Likharev KK, 1999, P IEEE, V87, P606, DOI 10.1109/5.752518; Peres NMR, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.125411; RUZIN IM, 1992, PHYS REV B, V45, P13469, DOI 10.1103/PhysRevB.45.13469; Rycerz A, 2007, NAT PHYS, V3, P172, DOI 10.1038/nphys547; Sols F, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.166803; Son YW, 2006, NATURE, V444, P347, DOI 10.1038/nature05180; Wunsch B, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.035316; Yang L, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.186801	21	1734	1801	19	1230	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2008	320	5874					356	358		10.1126/science.1154663	http://dx.doi.org/10.1126/science.1154663			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420930	Green Submitted			2022-12-28	WOS:000255026100038
J	Watkins, NW; Freeman, MP				Watkins, Nicholas W.; Freeman, Mervyn P.			Geoscience - Natural complexity	SCIENCE			English	Editorial Material							MEMORY		British Antarctic Survey, Cambridge CB3 0ET, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey	Watkins, NW (corresponding author), British Antarctic Survey, High Cross,Madingley Rd, Cambridge CB3 0ET, England.	nww@bas.ac.uk; mpf@bas.ac.uk	Watkins, Nick/GPX-7439-2022; Watkins, Nicholas Wynn/C-5140-2008; Freeman, Mervyn/E-5687-2019	Watkins, Nick/0000-0003-4484-6588; Watkins, Nicholas Wynn/0000-0003-4484-6588; Freeman, Mervyn/0000-0002-8653-8279	Natural Environment Research Council [bas010021] Funding Source: researchfish; NERC [bas010021] Funding Source: UKRI	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Allen MR, 2007, SCIENCE, V318, P582, DOI 10.1126/science.1149988; Avnir D, 1998, SCIENCE, V279, P39, DOI 10.1126/science.279.5347.39; Binder PM, 2008, SCIENCE, V320, P322, DOI 10.1126/science.1156940; BUNDE A, 2002, SCI DISASTERS CLIMAT, P170; Caldarelli G., 2007, SCALE FREE NETWORKS; Couzin ID, 2002, J THEOR BIOL, V218, P1, DOI 10.1006/jtbi.2002.3065; Edwards AM, 2007, NATURE, V449, P1044, DOI 10.1038/nature06199; Maraun D, 2004, NONLINEAR PROC GEOPH, V11, P495, DOI 10.5194/npg-11-495-2004; Neutel AM, 2007, NATURE, V449, P599, DOI 10.1038/nature06154; Roe GH, 2007, SCIENCE, V318, P629, DOI 10.1126/science.1144735; Shalizi Cosma Rohilla, 2006, P33; Smil V., 2002, EARTHS BIOSPHERE EVO, DOI [10.7551/mitpress/2551.001.0001, DOI 10.7551/MITPRESS/2551.001.0001]; SORNETTE D, 2004, SPRINGER SERIES SYNE, P1; Sumpter DJT, 2006, PHILOS T R SOC B, V361, P5, DOI 10.1098/rstb.2005.1733; [No title captured]	15	16	17	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2008	320	5874					323	324		10.1126/science.1151611	http://dx.doi.org/10.1126/science.1151611			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420919				2022-12-28	WOS:000255026100026
J	Rigol, M; Dunjko, V; Olshanii, M				Rigol, Marcos; Dunjko, Vanja; Olshanii, Maxim			Thermalization and its mechanism for generic isolated quantum systems	NATURE			English	Article							EIGENFUNCTIONS; CHAOS; ATOMS; GAS	An understanding of the temporal evolution of isolated many-body quantum systems has long been elusive. Recently, meaningful experimental studies(1,2) of the problem have become possible, stimulating theoretical interest(3-7). In generic isolated systems, non- equilibrium dynamics is expected(8,9) to result in thermalization: a relaxation to states in which the values of macroscopic quantities are stationary, universal with respect to widely differing initial conditions, and predictable using statistical mechanics. However, it is not obvious what feature of many- body quantum mechanics makes quantum thermalization possible in a sense analogous to that in which dynamical chaos makes classical thermalization possible(10). For example, dynamical chaos itself cannot occur in an isolated quantum system, in which the time evolution is linear and the spectrum is discrete(11). Some recent studies(4,5) even suggest that statistical mechanics may give incorrect predictions for the outcomes of relaxation in such systems. Here we demonstrate that a generic isolated quantum many- body system does relax to a state well described by the standard statistical- mechanical prescription. Moreover, we show that time evolution itself plays a merely auxiliary role in relaxation, and that thermalization instead happens at the level of individual eigenstates, as first proposed by Deutsch(12) and Srednicki(13). A striking consequence of this eigenstate- thermalization scenario, confirmed for our system, is that knowledge of a single many- body eigenstate is sufficient to compute thermal averages - any eigenstate in the microcanonical energy window will do, because they all give the same result.	[Rigol, Marcos; Dunjko, Vanja] Univ So Calif, Dept Phys & Astron, Los Angeles, CA 90089 USA; [Rigol, Marcos; Dunjko, Vanja; Olshanii, Maxim] Univ Massachusetts, Dept Phys, Boston, MA 02125 USA	University of Southern California; University of Massachusetts System; University of Massachusetts Boston	Olshanii, M (corresponding author), Univ So Calif, Dept Phys & Astron, Los Angeles, CA 90089 USA.	maxim.olchanyi@umb.edu	Dunjko, Vanja/AAU-3504-2021; Dunjko, Vanja/ABB-2505-2021; Rigol, Marcos/B-3505-2008; Olshanii, Maxim/M-2830-2013	Dunjko, Vanja/0000-0002-1489-8021; Rigol, Marcos/0000-0002-5806-5873; Olshanii, Maxim/0000-0003-3629-6002				Berges J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.142002; BERRY MV, 1977, J PHYS A-MATH GEN, V10, P2083, DOI 10.1088/0305-4470/10/12/016; Calabrese P, 2007, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2007/06/P06008; Cazalilla MA, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.156403; DEUTSCH JM, 1991, PHYS REV A, V43, P2046, DOI 10.1103/PhysRevA.43.2046; DEVERDIERE YC, 1985, COMMUN MATH PHYS, V102, P497; Gallavotti G., 1999, STAT MECH SHORT TREA; Heller EJ, 2007, J PHYS A-MATH THEOR, V40, P9259, DOI 10.1088/1751-8113/40/31/006; HOROI M, 1995, PHYS REV LETT, V74, P5194, DOI 10.1103/PhysRevLett.74.5194; Jin DS, 1996, PHYS REV LETT, V77, P420, DOI 10.1103/PhysRevLett.77.420; JOSE JV, 1998, CLASSICAL DYNAMICS C, P474; Kinoshita T, 2006, NATURE, V440, P900, DOI 10.1038/nature04693; KOREPIN VE, 1993, QUANTUM INVERSE SCAT, P40; KRYLOV NS, 1979, WORKS FDN STAT PHYS; Mandel O, 2003, NATURE, V425, P937, DOI 10.1038/nature02008; Manmana SR, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.210405; Rigol M, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.053616; Rigol M, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.050405; Sengupta K, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.053616; Shnirelman A. I., 1974, USP MAT NAUK, V29, P181; SREDNICKI M, 1994, PHYS REV E, V50, P888, DOI 10.1103/PhysRevE.50.888; Srednicki M, 1996, J PHYS A-MATH GEN, V29, pL75, DOI 10.1088/0305-4470/29/4/003; SREDNICKI M, 1994, DOES QUANTUM CHAOS E; SUTHERLAND B, 2004, BEAUTIFUL MODELS, P27; VOROS A, 1979, STOCHASTIC BEHAV CLA; ZELDITCH S, 1987, DUKE MATH J, V55, P919, DOI 10.1215/S0012-7094-87-05546-3	30	1878	1879	0	120	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2008	452	7189					854	858		10.1038/nature06838	http://dx.doi.org/10.1038/nature06838			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18421349				2022-12-28	WOS:000255026000044
J	Glied, SA				Glied, Sherry A.			Universal coverage one head at a time - The risks and benefits of individual mandates	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-INSURANCE		Columbia Univ, Dept Hlth Policy & Management, Mailman Sch Publ Hlth, New York, NY 10027 USA	Columbia University	Glied, SA (corresponding author), Columbia Univ, Dept Hlth Policy & Management, Mailman Sch Publ Hlth, New York, NY 10027 USA.							Glied SA, 2007, HEALTH AFFAIR, V26, P1612, DOI 10.1377/hlthaff.26.6.1612; Herring B, 2005, J HEALTH ECON, V24, P225, DOI 10.1016/j.jhealeco.2004.08.003; MOFFIT RE, 1994, HEALTH AFFAIR, V13, P101, DOI 10.1377/hlthaff.13.2.101	3	7	7	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1540	1542		10.1056/NEJMp0802027	http://dx.doi.org/10.1056/NEJMp0802027			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	285NK	18403763				2022-12-28	WOS:000254783300002
J	Borer, JS; Gordon, DJ; Geller, NL				Borer, Jeffrey S.; Gordon, David J.; Geller, Nancy L.			When should data and safety monitoring committees share interim results in cardiovascular trials?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL-TRIAL; BENEFIT		[Gordon, David J.; Geller, Nancy L.] NHLBI, Off Biostat Res, NIH, Bethesda, MD 20892 USA; [Borer, Jeffrey S.] Cornell Univ, Weill Cornell Med Coll, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Cornell University	Geller, NL (corresponding author), NHLBI, Off Biostat Res, NIH, 6701 Rockledge Dr, Bethesda, MD 20892 USA.	gellern@nhlbi.nih.gov						Ellenberg SS., 2002, DATA MONITORING COMM; Food and Drug Administration, 2006, GUID CLIN TRIAL SPON; Grant AM, 2005, LANCET, V365, P711; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; *NIAID, 2007, NIAID PRINC US DAT S; Pocock SJ, 2005, JAMA-J AM MED ASSOC, V294, P2228, DOI 10.1001/jama.294.17.2228; PROSCHAN MA, 2006, STAT MONITORING CLIN, P131; Sydes Matthew R, 2004, Clin Trials, V1, P48, DOI 10.1191/1740774504cn003oa; U.S. Securities and Exchange Commission, FIN RUL SEL DISCL IN	9	13	13	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2008	299	14					1710	1712		10.1001/jama.299.14.1710	http://dx.doi.org/10.1001/jama.299.14.1710			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285AL	18398083				2022-12-28	WOS:000254749600027
J	Paerl, HW; Huisman, J				Paerl, Hans W.; Huisman, Jef			Climate - Blooms like it hot	SCIENCE			English	Editorial Material							PHYTOPLANKTON COMMUNITIES; CYANOBACTERIUM		[Paerl, Hans W.] Univ N Carolina, Inst Marine Sci, Morehead City, NC 28557 USA; [Huisman, Jef] Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, NL-1018 WS Amsterdam, Netherlands	University of North Carolina; University of North Carolina Chapel Hill; University of Amsterdam	Paerl, HW (corresponding author), Univ N Carolina, Inst Marine Sci, Morehead City, NC 28557 USA.	hpaerl@email.unc.edu; jef.huisman@science.uva.nl	Huisman, Jef/A-1089-2013	Huisman, Jef/0000-0001-9598-3211				Carmichael WW, 2001, HUM ECOL RISK ASSESS, V7, P1393, DOI 10.1080/20018091095087; Elliott JA, 2006, HYDROBIOLOGIA, V559, P401, DOI 10.1007/s10750-005-1233-y; Guo L, 2007, SCIENCE, V317, P1166, DOI 10.1126/science.317.5842.1166; Honjo M, 2006, J PLANKTON RES, V28, P407, DOI 10.1093/plankt/fbi128; Huisman J., 2005, HARMFUL CYANOBACTERI; Ibelings BW, 2003, ECOL APPL, V13, P1456, DOI 10.1890/01-5345; Johnk KD, 2008, GLOBAL CHANGE BIOL, V14, P495, DOI 10.1111/j.1365-2486.2007.01510.x; KAHRU M, 1993, MAR ECOL PROG SER, V101, P1, DOI 10.3354/meps101001; Kardinaal WEA, 2007, AQUAT MICROB ECOL, V48, P1, DOI 10.3354/ame048001; Moisander PH, 2002, MICROB ECOL, V43, P432, DOI 10.1007/s00248-001-1044-2; Paerl HW, 2006, ECOL STU AN, V189, P95, DOI 10.1007/978-3-540-32210-8_8; Reynolds CS, 2006, ECOL BIODIVERS CONS, P1, DOI 10.2277/ 0521605199; Suikkanen S, 2007, ESTUAR COAST SHELF S, V71, P580, DOI 10.1016/j.ecss.2006.09.004; Tonk L, 2007, AQUAT MICROB ECOL, V46, P117, DOI 10.3354/ame046117; Wiedner C, 2007, OECOLOGIA, V152, P473, DOI 10.1007/s00442-007-0683-5	16	1733	1845	48	939	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					57	58		10.1126/science.1155398	http://dx.doi.org/10.1126/science.1155398			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388279	Green Submitted			2022-12-28	WOS:000254633000024
J	Hanash, SM; Pitteri, SJ; Faca, VM				Hanash, Samir M.; Pitteri, Sharon J.; Faca, Vitor M.			Mining the plasma proteome for cancer biomarkers	NATURE			English	Review							PANCREATIC-CANCER; MASS-SPECTROMETRY; LUNG-CANCER; OVARIAN-CANCER; IMMUNE-RESPONSE; PROSTATE-CANCER; QUANTUM DOTS; PROTEINS; SERUM; IDENTIFICATION	Systematic searches for plasma proteins that are biological indicators, or biomarkers, for cancer are underway. The difficulties caused by the complexity of biological- fluid proteomes and tissue proteomes ( which contribute proteins to plasma) and by the extensive heterogeneity among diseases, subjects and levels of sample procurement are gradually being overcome. This is being achieved through rigorous experimental design and in- depth quantitative studies. The expected outcome is the development of panels of biomarkers that will allow early detection of cancer and prediction of the probable response to therapy. Achieving these objectives requires high- quality specimens with well- matched controls, reagent resources, and an efficient process to confirm discoveries through independent validation studies.	[Hanash, Samir M.; Pitteri, Sharon J.; Faca, Vitor M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Hanash, SM (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	shanash@fhcrc.org	Faça, Vitor M/A-3989-2013	FACA, VITOR MARCEL/0000-0003-3205-7944; Pitteri, Sharon/0000-0002-3119-873X				Barrabes S, 2007, GLYCOBIOLOGY, V17, P388, DOI 10.1093/glycob/cwm002; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; Burg TP, 2007, NATURE, V446, P1066, DOI 10.1038/nature05741; Cerchia L, 2002, FEBS LETT, V528, P12, DOI 10.1016/S0014-5793(02)03275-1; Chatterjee M, 2006, CANCER RES, V66, P1181, DOI 10.1158/0008-5472.CAN-04-2962; Chen R, 2005, GASTROENTEROLOGY, V129, P1187, DOI 10.1053/j.gastro.2005.08.001; Chen R, 2007, MOL CELL PROTEOMICS, V6, P1331, DOI 10.1074/mcp.M700072-MCP200; Chen R, 2007, PANCREAS, V34, P70, DOI 10.1097/01.mpa.0000240615.20474.fd; Chignard N, 2006, GASTROENTEROLOGY, V130, P2010, DOI 10.1053/j.gastro.2006.02.058; Cox J, 2007, CELL, V130, P395, DOI 10.1016/j.cell.2007.07.032; Faca V, 2007, J PROTEOME RES, V6, P3558, DOI 10.1021/pr070233q; Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473; Gao WM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-110; Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994; Hoppe-Seyler F, 2000, J MOL MED, V78, P426, DOI 10.1007/s001090000140; Hu S, 2006, PROTEOMICS, V6, P6326, DOI 10.1002/pmic.200600284; Hudson ME, 2007, P NATL ACAD SCI USA, V104, P17494, DOI 10.1073/pnas.0708572104; Kato K, 2007, ANAL CHEM, V79, P8616, DOI 10.1021/ac071548s; Kim SW, 2007, CANCER RES, V67, P6565, DOI 10.1158/0008-5472.CAN-06-2783; Kingsmore SF, 2006, NAT REV DRUG DISCOV, V5, P310, DOI 10.1038/nrd2006; Kirmiz C, 2007, MOL CELL PROTEOMICS, V6, P43, DOI 10.1074/mcp.M600171-MCP200; Kuhn E, 2004, PROTEOMICS, V4, P1175, DOI 10.1002/pmic.200300670; Kulasingam V, 2007, MOL CELL PROTEOMICS, V6, P1997, DOI 10.1074/mcp.M600465-MCP200; Kyselova Z, 2007, J PROTEOME RES, V6, P1822, DOI 10.1021/pr060664t; Lin Y, 2006, J PROTEOME RES, V5, P2169, DOI 10.1021/pr0600374; Liu T, 2007, CHEM REV, V107, P3621, DOI 10.1021/cr068288j; Liu XY, 2007, J AM SOC MASS SPECTR, V18, P1249, DOI 10.1016/j.jasms.2007.04.012; Lu HL, 2006, CANCER RES, V66, P9754, DOI 10.1158/0008-5472.CAN-06-1083; Ludwig JA, 2005, NAT REV CANCER, V5, P845, DOI 10.1038/nrc1739; Madoz-Gurpide J, 2008, MOL CELL PROTEOMICS, V7, P268, DOI 10.1074/mcp.M700366-MCP200; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Okano T, 2007, CLIN CANCER RES, V13, P799, DOI 10.1158/1078-0432.CCR-06-1654; Pereira-Faca SR, 2007, CANCER RES, V67, P12000, DOI 10.1158/0008-5472.CAN-07-2913; Philip R, 2007, J PROTEOME RES, V6, P2509, DOI 10.1021/pr0606777; Ransohoff DF, 2005, NAT REV CANCER, V5, P142, DOI 10.1038/nrc1550; Shafer MW, 2007, PROSTATE, V67, P255, DOI 10.1002/pros.20514; Stahl-Zeng J, 2007, MOL CELL PROTEOMICS, V6, P1809, DOI 10.1074/mcp.M700132-MCP200; States DJ, 2006, NAT BIOTECHNOL, V24, P333, DOI 10.1038/nbt1183; Syka JEP, 2004, P NATL ACAD SCI USA, V101, P9528, DOI 10.1073/pnas.0402700101; Tada H, 2007, CANCER RES, V67, P1138, DOI 10.1158/0008-5472.CAN-06-1185; Taguchi F, 2007, J NATL CANCER I, V99, P838, DOI 10.1093/jnci/djk195; Villanueva J, 2006, MOL CELL PROTEOMICS, V5, P1840, DOI 10.1074/mcp.M600229-MCP200; Wang XJ, 2005, NEW ENGL J MED, V353, P1224, DOI 10.1056/NEJMoa051931; Wang YH, 2006, GLYCOBIOLOGY, V16, P514, DOI 10.1093/glycob/cwj091; Wu SL, 2006, MOL CELL PROTEOMICS, V5, P1610, DOI 10.1074/mcp.M600105-MCP200; Yasui Y, 2003, BIOSTATISTICS, V4, P449, DOI 10.1093/biostatistics/4.3.449; Yu KH, 2005, J PROTEOME RES, V4, P1742, DOI 10.1021/pr050174l; Zhang H, 2007, MOL CELL PROTEOMICS, V6, P64, DOI 10.1074/mcp.M600160-MCP200; Zhao J, 2007, J PROTEOME RES, V6, P1126, DOI 10.1021/pr0604458	49	629	654	3	193	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2008	452	7187					571	579		10.1038/nature06916	http://dx.doi.org/10.1038/nature06916			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385731				2022-12-28	WOS:000254567200035
J	Jang, MK; Lee, KS				Jang, Myoung Kuk; Lee, Ki Sung			Ascariasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Jang, Myoung Kuk; Lee, Ki Sung] Hallym Univ, Coll Med, Seoul 134701, South Korea	Hallym University	Jang, MK (corresponding author), Hallym Univ, Coll Med, 445 Gildong, Seoul 134701, South Korea.	mkjang2@medimail.co.kr							0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					E16	E16		10.1056/NEJMicm054199	http://dx.doi.org/10.1056/NEJMicm054199			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282CY	18385494				2022-12-28	WOS:000254546400012
J	Kleppner, D				Kleppner, Daniel			Physics - A milestone in time keeping	SCIENCE			English	Editorial Material							NOBEL LECTURE; ATOMS		MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Harvard Ctr Ultracold Atoms, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT)	Kleppner, D (corresponding author), MIT, Dept Phys, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	kleppner@mit.edu						Bergquist JC, 2001, PHYS TODAY, V54, P37, DOI 10.1063/1.1366066; Chu S, 1998, REV MOD PHYS, V70, P685, DOI 10.1103/RevModPhys.70.685; Cohen-Tannoudji CN, 1998, REV MOD PHYS, V70, P707, DOI 10.1103/RevModPhys.70.707; Hansch TW, 2006, REV MOD PHYS, V78, P1297, DOI 10.1103/RevModPhys.78.1297; Hall JL, 2006, REV MOD PHYS, V78, P1279, DOI 10.1103/RevModPhys.78.1279; Ludlow AD, 2008, SCIENCE, V319, P1805, DOI 10.1126/science.1153341; Phillips WD, 1998, REV MOD PHYS, V70, P721, DOI 10.1103/RevModPhys.70.721	7	3	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1768	1769		10.1126/science.1155948	http://dx.doi.org/10.1126/science.1155948			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369127				2022-12-28	WOS:000254394000025
J	Messersmith, PB				Messersmith, Phillip B.			Materials science - Multitasking in tissues and materials	SCIENCE			English	Editorial Material							CHEMISTRY; POLYMERS		Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA; Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; Northwestern Univ, Inst Bionanotechnol Med, Evanston, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University	Messersmith, PB (corresponding author), Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.	philm@northwestern.edu	Messersmith, Phil/B-6695-2009	Messersmith, Phillip/0000-0002-1197-333X				Broomell CC, 2007, J R SOC INTERFACE, V4, P19, DOI 10.1098/rsif.2006.0153; Dalsin JL, 2003, J AM CHEM SOC, V125, P4253, DOI 10.1021/ja0284963; Lee BP, 2006, BIOLOGICAL ADHESIVES, P257, DOI 10.1007/978-3-540-31049-5_13; Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241; Lee H, 2007, NATURE, V448, P338, DOI 10.1038/nature05968; Lee H, 2006, P NATL ACAD SCI USA, V103, P12999, DOI 10.1073/pnas.0605552103; Marshall GW, 2001, J BIOMED MATER RES, V54, P87, DOI 10.1002/1097-4636(200101)54:1<87::AID-JBM10>3.0.CO;2-Z; Miserez A, 2008, SCIENCE, V319, P1816, DOI 10.1126/science.1154117; Moses DN, 2006, J BIOL CHEM, V281, P34826, DOI 10.1074/jbc.M603429200; Paunesku T, 2003, NAT MATER, V2, P343, DOI 10.1038/nmat875; Sagert J, 2006, BIOLOGICAL ADHESIVES, P125, DOI 10.1007/978-3-540-31049-5_7; Statz AR, 2005, J AM CHEM SOC, V127, P7972, DOI 10.1021/ja0522534; Suresh S, 2001, SCIENCE, V292, P2447, DOI 10.1126/science.1059716; Walsh CT, 2005, ANGEW CHEM INT EDIT, V44, P7342, DOI 10.1002/anie.200501023; Xu CJ, 2004, J AM CHEM SOC, V126, P9938, DOI 10.1021/ja0464802; Zurcher S, 2006, J AM CHEM SOC, V128, P1064, DOI 10.1021/ja056256s	16	68	71	2	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1767	1768		10.1126/science.1155122	http://dx.doi.org/10.1126/science.1155122			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369126				2022-12-28	WOS:000254394000024
J	Norris, DJ; Efros, AL; Erwin, SC				Norris, David J.; Efros, Alexander L.; Erwin, Steven C.			Doped nanocrystals	SCIENCE			English	Review							QUANTUM DOTS; SEMICONDUCTOR NANOCRYSTALS; ZNSE NANOCRYSTALS; ELECTRON; IMPURITY; SOLIDS; CELLS; FILMS	The critical role that dopants play in semiconductor devices has stimulated research on the properties and the potential applications of semiconductor nanocrystals, or colloidal quantum dots, doped with intentional impurities. We review advances in the chemical synthesis of doped nanocrystals, in the theoretical understanding of the fundamental mechanisms that control doping, and in the creation of highly conducting nanocrystalline films. Because impurities can be used to alter the properties of nanoscale materials in desirable and controllable ways, doped nanocrystals can address key problems in applications from solar cells to bioimaging.	[Norris, David J.] Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; [Efros, Alexander L.; Erwin, Steven C.] USN, Res Lab, Ctr Computat Mat Sci, Washington, DC 20375 USA	University of Minnesota System; University of Minnesota Twin Cities; United States Department of Defense; United States Navy; Naval Research Laboratory	Norris, DJ (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.	dnorris@umn.edu	Erwin, Steven C/B-1850-2009; Norris, David J/F-4022-2010	Norris, David J/0000-0002-3765-0678				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; BHARGAVA RN, 1994, PHYS REV LETT, V72, P416, DOI 10.1103/PhysRevLett.72.416; BRUS LE, 1983, J CHEM PHYS, V79, P5566, DOI 10.1063/1.445676; Bryan JD, 2005, PROG INORG CHEM, V54, P47, DOI 10.1002/0471725560.ch2; DALPIAN GM, 2006, PHYS REV LETT, DOI UNSP 226802; Efros AL, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.206601; EKIMOV AI, 1990, J LUMIN, V46, P83, DOI 10.1016/0022-2313(90)90010-9; Erwin SC, 2005, NATURE, V436, P91, DOI 10.1038/nature03832; Fujii M, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2135214; Gur I, 2005, SCIENCE, V310, P462, DOI 10.1126/science.1117908; Hanif KM, 2002, J AM CHEM SOC, V124, P11495, DOI 10.1021/ja0262840; HENGLEIN A, 1982, BER BUNSEN PHYS CHEM, V86, P301, DOI 10.1002/bbpc.19820860409; Hoffman DM, 2000, SOLID STATE COMMUN, V114, P547, DOI 10.1016/S0038-1098(00)00089-2; KENNEDY TA, 1995, PHYS REV B, V52, P14356, DOI 10.1103/PhysRevB.52.R14356; Klimov VI, 2007, NATURE, V447, P441, DOI 10.1038/nature05839; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Mikulec FV, 2000, J AM CHEM SOC, V122, P2532, DOI 10.1021/ja991249n; Miller R. J. D., 1995, SURFACE ELECT TRANSF; Mokari T, 2006, ANGEW CHEM INT EDIT, V45, P8001, DOI 10.1002/anie.200602559; Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545; Norris DJ, 2001, NANO LETT, V1, P3, DOI 10.1021/nl005503h; Pradhan N, 2005, J AM CHEM SOC, V127, P17586, DOI 10.1021/ja055557z; Radovanovic PV, 2001, J AM CHEM SOC, V123, P12207, DOI 10.1021/ja0115215; Shim M, 2000, NATURE, V407, P981, DOI 10.1038/35039577; Son DH, 2004, SCIENCE, V306, P1009, DOI 10.1126/science.1103755; Stowell CA, 2003, NANO LETT, V3, P1441, DOI 10.1021/nl034419+; Suyver JF, 2000, PHYS CHEM CHEM PHYS, V2, P5445, DOI 10.1039/b006950g; Swihart MT, 2003, CURR OPIN COLLOID IN, V8, P127, DOI 10.1016/S1359-0294(03)00007-4; Talapin DV, 2005, SCIENCE, V310, P86, DOI 10.1126/science.1116703; TURNBULL D, 1950, J APPL PHYS, V21, P1022, DOI 10.1063/1.1699435; Urban JJ, 2007, NAT MATER, V6, P115, DOI 10.1038/nmat1826; Van de Walle CG, 2003, NATURE, V423, P626, DOI 10.1038/nature01665; Wang CJ, 2004, J PHYS CHEM B, V108, P9027, DOI 10.1021/jp0489830; Wang CJ, 2001, SCIENCE, V291, P2390, DOI 10.1126/science.291.5512.2390; Wehrenberg BL, 2003, J AM CHEM SOC, V125, P7806, DOI 10.1021/ja035369d; Yang YA, 2006, J AM CHEM SOC, V128, P12428, DOI 10.1021/ja064818h; Yin Y, 2005, NATURE, V437, P664, DOI 10.1038/nature04165; Yu D, 2003, SCIENCE, V300, P1277, DOI 10.1126/science.1084424	38	1228	1258	24	802	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1776	1779		10.1126/science.1143802	http://dx.doi.org/10.1126/science.1143802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369131				2022-12-28	WOS:000254394000029
J	Smith, GCS; Celik, E; To, M; Khouri, O; Nicolaides, KH				Smith, Gordon C. S.; Celik, Ebru; To, Meekai; Khouri, Olga; Nicolaides, Kypros H.		Fetal Med Fdn Second Trimester Scr	Cervical length at mid-pregnancy and the risk of primary cesarean delivery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; 23 WEEKS GESTATION; COMMON OUTCOMES; MATERNAL AGE; WOMEN; PREVENTION; DOPPLER; SECTION; BIRTH; RAT	Background: Physiological and biochemical studies suggest that normal parturition at term is dependent on programmed development of the uterus in early pregnancy. It is recognized that a short cervix in mid-pregnancy is associated with an increased risk of spontaneous preterm birth. We hypothesized that a long cervix in mid-pregnancy would be associated with an increased risk of cesarean delivery during labor at term. Methods: We studied 27,472 primiparous women who had a cervical length of 16 mm or more at a median of 23 weeks of gestation and who ultimately delivered a live infant in labor at term. Results: The rate of cesarean delivery at term was lowest (16.0%) among women with a mid-pregnancy cervical length in the lowest quartile (16 to 30 mm) and was significantly greater in the second quartile (18.4%, 31 to 35 mm), third quartile (21.7%, 36 to 39 mm), and fourth quartile (25.7%, 40 to 67 mm) (P<0.001 for trend). The odds ratio for cesarean delivery among women in the fourth quartile, as compared with the first quartile, was 1.81 (95% confidence interval [CI], 1.66 to 1.97), and the odds ratio adjusted for maternal age, body-mass index, smoking status, race or ethnic group, gestational age at birth, spontaneous or induced labor, birth-weight percentile, and hospital of delivery was 1.68 (95% CI, 1.53 to 1.84; P<0.001). The increased risk of cesarean delivery was attributable to procedures performed for poor progress in labor. Conclusions: The cervical length at mid-pregnancy is an independent predictor of the risk of cesarean delivery at term in primiparous women.	[Smith, Gordon C. S.] Univ Cambridge, Dept Obstet & Gynaecol, Cambridge, England; [Celik, Ebru; To, Meekai; Khouri, Olga; Nicolaides, Kypros H.] Kings Coll Hosp London, Sch Med, Harris Birthright Res Ctr, London SE5 8RX, England	University of Cambridge; King's College Hospital NHS Foundation Trust; King's College Hospital	Smith, GCS (corresponding author), Univ Cambridge, Rosie Matern Hosp, Dept Obstet & Gynaecol, Box 223, Cambridge CB2 2SW, England.	gcss2@cam.ac.uk	Celik, Ebru/B-3860-2013; Celik, ebru/X-4343-2019; Smith, Gordon/A-8070-2008	Celik, Ebru/0000-0002-0774-4294; Celik, ebru/0000-0002-0774-4294; Smith, Gordon/0000-0003-2124-0997; Nicolaides, Kypros/0000-0003-1266-0711				Albaiges G, 2000, OBSTET GYNECOL, V96, P559, DOI 10.1016/S0029-7844(00)00946-7; Crane SS, 1997, OBSTET GYNECOL, V89, P213, DOI 10.1016/S0029-7844(96)00449-8; Ecker JL, 2007, NEW ENGL J MED, V356, P885, DOI 10.1056/NEJMp068290; Ecker JL, 2001, AM J OBSTET GYNECOL, V185, P883, DOI 10.1067/mob.2001.117364; FIGUEROA JP, 1985, AM J OBSTET GYNECOL, V151, P524, DOI 10.1016/0002-9378(85)90282-0; Fonseca EB, 2007, NEW ENGL J MED, V357, P462, DOI 10.1056/NEJMoa067815; Garfield RE, 1998, HUM REPROD UPDATE, V4, P673, DOI 10.1093/humupd/4.5.673; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Iams JD, 1996, NEW ENGL J MED, V334, P567, DOI 10.1056/NEJM199602293340904; MACARA LM, 1994, AM J OBSTET GYNECOL, V171, P71, DOI 10.1016/S0002-9378(94)70080-X; Main DM, 2000, AM J OBSTET GYNECOL, V182, P1312, DOI 10.1067/mob.2000.106249; Ramanathan G, 2003, ULTRASOUND OBST GYN, V22, P598, DOI 10.1002/uog.913; Shynlova O, 2006, BIOL REPROD, V74, P839, DOI 10.1095/biolreprod.105.048124; Shynlova O, 2007, BIOL REPROD, V76, P571, DOI 10.1095/biolreprod.106.056929; Smith GCS, 2005, PLOS MED, V2, P871, DOI 10.1371/journal.pmed.0020252; To MS, 2004, LANCET, V363, P1849, DOI 10.1016/S0140-6736(04)16351-4; Yu CKH, 2003, ULTRASOUND OBST GYN, V22, P233, DOI 10.1002/uog.218; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	20	42	42	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1346	1353		10.1056/NEJMoa0706834	http://dx.doi.org/10.1056/NEJMoa0706834			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367737	Bronze			2022-12-28	WOS:000254308400005
J	Swamy, GK; Ostbye, T; Skjaerven, R				Swamy, Geeta K.; Ostbye, Truls; Skjaerven, Rolv			Association of preterm birth with long-term survival, reproduction, and next-generation preterm birth	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUBSEQUENT MARITAL-STATUS; GESTATIONAL-AGE; WEIGHT INFANTS; PRENATAL GROWTH; YOUNG ADULTHOOD; SEX-DIFFERENCES; DEFECTS; RISK; MORTALITY; NORWAY	Context Preterm birth is a major cause of infant morbidity and mortality. Less is known about long- term health among persons born preterm. Objective To determine the long- term effects of preterm birth on survival, reproduction, and next- generation preterm birth. Design, Setting, and Participants Population- based, observational, longitudinal study using registry data from 1 167 506 singleton births in the Medical Birth Registry of Norway in 1967- 1988. The cohort was followed up through 2002 for survival. The cohort was truncated to births from 1967- 1976 for assessment of educational achievement and reproductive outcomes through 2004. Main OutcomeMeasures In relation to sex and gestational age at birth, absolute mortality, risk of fetal, infant, child, and adolescent mortality, and incidence and risk of reproduction and next- generation preterm birth. Singleton term ( 37- 42 weeks) fetal deaths and live births, stratified by sex, served as the reference group for all analyses. Results The percentage who were born preterm was higher among boys ( 5.6%) than among girls ( 4.7%). Preterm participants had an increased risk of mortality throughout childhood. For boys born at 22 to 27 weeks, mortality rates were 1.33% and 1.01% for early and late childhood death, with relative risks ( RRs) of 5.3 ( 95% confidence interval [ CI], 2.0- 14.2) and 7.0 ( 95% CI, 2.3- 22.0), respectively. The mortality rate for girls born at 22 to 27 weeks was 1.71% for early childhood death, with an RR of 9.7 ( 95% CI, 4.0- 23.7); there were no late childhood deaths. For 28 to 32 weeks, the early and late childhood mortality rates among boys were 0.73% and 0.37%, with RRs of 2.5 ( 95% CI, 1.6- 3.7) and 2.3 ( 95% CI, 1.3- 4.1), respectively. Girls born at 28 to 32 weeks did not have a significantly increased risk of childhood mortality. Reproduction was diminished for index participants born preterm. For men and women born at 22 to 27 weeks, absolute reproduction was 13.9% and 25%, with RRs of 0.24 ( 95% CI, 0.17- 0.32) and 0.33 ( 95% CI, 0.26- 0.42), respectively. For 28 to 32 weeks, absolute reproduction was 38.6% and 59.2% for men and women, with RRs of 0.7 ( 95% CI, 0.66- 0.74) and 0.81 ( 95% CI, 0.78- 0.85), respectively. Preterm women but not men were at increased risk of having preterm offspring. Conclusion In persons born in Norway in 1967- 1988, preterm birth was associated with diminished long- term survival and reproduction.	[Swamy, Geeta K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA; [Ostbye, Truls] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA; [Ostbye, Truls] Duke NUS Grad Med Sch, Singapore, Singapore; [Skjaerven, Rolv] Univ Bergen, Sect Epidemiol & Med Stat, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway; [Skjaerven, Rolv] Norwegian Inst Publ Hlth, Med Birth Registry Norway, Bergen, Norway	Duke University; Duke University; National University of Singapore; University of Bergen; Norwegian Institute of Public Health (NIPH)	Swamy, GK (corresponding author), Duke Univ, Med Ctr, Dept Obstet & Gynecol, Box 3967, Durham, NC 27710 USA.	swamy002@mc.duke.edu						ALEXANDER GR, 1995, PUBLIC HEALTH REP, V110, P395; ALLEN MC, 1986, OBSTET GYNECOL, V67, P427; Cui W, 2005, BIRTH DEFECTS RES A, V73, P876, DOI 10.1002/bdra.20196; Dolan SM, 2007, OBSTET GYNECOL, V110, P318, DOI 10.1097/01.AOG.0000275264.78506.63; Ekholm K, 2005, AM J EPIDEMIOL, V161, P725, DOI 10.1093/aje/kwi096; Friedlander Y, 2003, PAEDIATR PERINAT EP, V17, P398, DOI 10.1046/j.1365-3016.2003.00522.x; GEIRSSON RT, 1991, BRIT J OBSTET GYNAEC, V98, P108, DOI 10.1111/j.1471-0528.1991.tb10323.x; Grunau RE, 2004, PEDIATRICS, V114, pE725, DOI 10.1542/peds.2004-0932; Hack M, 2002, NEW ENGL J MED, V346, P149, DOI 10.1056/NEJMoa010856; *HELP AM YOUTH, INCR RISK FACT BOYS; Hoyert Donna L, 2006, Natl Vital Stat Rep, V54, P1; Kalish RB, 2004, AM J OBSTET GYNECOL, V191, P975, DOI 10.1016/j.ajog.2004.06.053; Koppe JGV-VP, 1998, TXB PERINATAL MED, P1362; Kunitz SJ, 2007, INT J EPIDEMIOL, V36, P3, DOI 10.1093/ije/dyl296; Lary JM, 2001, TERATOLOGY, V64, P237, DOI 10.1002/tera.1070; Lefebvre F, 2005, ACTA PAEDIATR, V94, P733, DOI 10.1080/08035250510025987; Li CI, 2003, PAEDIATR PERINAT EP, V17, P164, DOI 10.1046/j.1365-3016.2003.00487.x; Lie RT, 2001, JAMA-J AM MED ASSOC, V285, P755, DOI 10.1001/jama.285.6.755; MacDorman Marian F, 2005, Natl Vital Stat Rep, V53, P1; Majnemer A, 2000, DEV MED CHILD NEUROL, V42, P53; Philip AGS, 2005, PEDIATR RES, V58, P799, DOI 10.1203/01.PDR.0000151693.46655.66; Phillips DIW, 2001, BRIT MED J, V322, P771, DOI 10.1136/bmj.322.7289.771; Phillips Susan P, 2005, Int J Equity Health, V4, P11, DOI 10.1186/1475-9276-4-11; Rasmussen SA, 2001, J PEDIATR-US, V138, P668, DOI 10.1067/mpd.2001.112249; Saigal S, 2006, JAMA-J AM MED ASSOC, V295, P667, DOI 10.1001/jama.295.6.667; Samuelsen SO, 1998, AM J EPIDEMIOL, V148, P983, DOI 10.1093/oxfordjournals.aje.a009575; SELMER ES, 1967, J R STAT SOC SER A-G, V130, P225, DOI 10.2307/2343402; Skjaerven R, 1999, NEW ENGL J MED, V340, P1057, DOI 10.1056/NEJM199904083401401; Skjaerven R, 2000, ACTA OBSTET GYN SCAN, V79, P440, DOI 10.1034/j.1600-0412.2000.079006440.x; *STAT NORW, 2005, IMM EM 1951 2005; Stoelhorst GMSJ, 2005, PEDIATRICS, V115, P396, DOI 10.1542/peds.2004-1497; Vagero D, 2002, BRIT MED J, V324, P398, DOI 10.1136/bmj.324.7334.398; Vatten LJ, 2004, EARLY HUM DEV, V76, P47, DOI 10.1016/j.earlhumdev.2003.10.006; Wilson-Costello D, 2005, PEDIATRICS, V115, P997, DOI 10.1542/peds.2004-0221; Wood NS, 2005, ARCH DIS CHILD-FETAL, V90, P134, DOI 10.1136/adc.2004.052407	35	221	229	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2008	299	12					1429	1436		10.1001/jama.299.12.1429	http://dx.doi.org/10.1001/jama.299.12.1429			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278MY	18364485	Bronze			2022-12-28	WOS:000254292200017
J	Jasper, H				Jasper, Heinrich			SKNy worms and long life	CELL			English	Editorial Material							STRESS-RESPONSE; C-ELEGANS; SPAN; DROSOPHILA; LONGEVITY	Interactions between insulin signaling and stress-response pathways can markedly impact life span. In this issue, Tullet et al. (2008) demonstrate that the worm homolog of Nrf2, called SKN-1, a transcription factor that switches on expression of antioxidant genes, is an important component of such signaling interactions.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Jasper, H (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	henri_jasper@urmc.rochester.edu						An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803; Baumeister R, 2006, J ENDOCRINOL, V190, P191, DOI 10.1677/joe.1.06856; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Giannakou ME, 2007, TRENDS BIOCHEM SCI, V32, P180, DOI 10.1016/j.tibs.2007.02.007; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Niedernhofer LJ, 2006, NATURE, V444, P1038, DOI 10.1038/nature05456; Russell SJ, 2007, NAT REV MOL CELL BIO, V8, P681, DOI 10.1038/nrm2234; Sykiotis GP, 2008, DEV CELL, V14, P76, DOI 10.1016/j.devcel.2007.12.002; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030	9	15	16	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 21	2008	132	6					915	916		10.1016/j.cell.2008.03.002	http://dx.doi.org/10.1016/j.cell.2008.03.002			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358801	Bronze			2022-12-28	WOS:000254273600007
J	Zhou, L; Lopes, JE; Chong, MMW; Ivanov, II; Min, R; Victora, GD; Shen, YL; Du, JG; Rubtsov, YP; Rudensky, AY; Ziegler, SF; Littman, DR				Zhou, Liang; Lopes, Jared E.; Chong, Mark M. W.; Ivanov, Ivaylo I.; Min, Roy; Victora, Gabriel D.; Shen, Yuelei; Du, Jianguang; Rubtsov, Yuri P.; Rudensky, Alexander Y.; Ziegler, Steven F.; Littman, Dan R.			TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing ROR gamma t function	NATURE			English	Article							AUTOIMMUNE INFLAMMATION; GENERATION; CYTOKINE; IL-21; INTERLEUKIN-17; TRANSCRIPTION; ACTIVATION; REPRESSOR; RESPONSES; PATHWAYS	T helper cells that produce IL- 17 (T(H)17 cells) promote autoimmunity in mice and have been implicated in the pathogenesis of human inflammatory diseases. At mucosal surfaces, T(H)17 cells are thought to protect the host from infection, whereas regulatory T ( T-reg) cells control immune responses and inflammation triggered by the resident microflora(1-5). Differentiation of both cell types requires transforming growth factor-beta (TGF-beta), but depends on distinct transcription factors: ROR gamma t ( encoded by Rorc(gamma t)) for T(H)17 cells and Foxp3 for T-reg cells(6-8). How TGF-beta regulates the differentiation of T cells with opposing activities has been perplexing. Here we demonstrate that, together with pro- inflammatory cytokines, TGF-beta orchestrates T(H)17 cell differentiation in a concentration-dependent manner. At low concentrations, TGF-b synergizes with interleukin ( IL)- 6 and IL- 21 ( refs 9 - 11) to promote IL- 23 receptor (Il23r) expression, favouring T(H)17 cell differentiation. High concentrations of TGF-beta repress IL23r expression and favour Foxp3(+) T-reg cells. ROR gamma t and Foxp3 are co- expressed in naive CD4(+) T cells exposed to TGF-beta and in a subset of T cells in the small intestinal lamina propria of the mouse. In vitro, TGF-beta-induced Foxp3 inhibits ROR gamma t function, at least in part through their interaction. Accordingly, lamina propria T cells that co-express both transcription factors produce less IL- 17 ( also known as IL-17a) than those that express ROR gamma t alone. IL- 6, IL- 21 and IL- 23 relieve Foxp3- mediated inhibition of ROR gamma t, thereby promoting TH17 cell differentiation. Therefore, the decision of antigen- stimulated cells to differentiate into either T(H)17 or T-reg cells depends on the cytokine- regulated balance of ROR gamma t and Foxp3.	[Zhou, Liang; Chong, Mark M. W.; Ivanov, Ivaylo I.; Min, Roy; Victora, Gabriel D.; Shen, Yuelei; Littman, Dan R.] NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med, New York, NY 10016 USA; [Min, Roy; Littman, Dan R.] NYU, Sch Med, Dept Microbiol, Howard Hughes Med Inst, New York, NY 10016 USA; [Min, Roy; Littman, Dan R.] NYU, Sch Med, Dept Pathol, Howard Hughes Med Inst, New York, NY 10016 USA; [Lopes, Jared E.; Du, Jianguang; Ziegler, Steven F.] Benaroya Res Inst, Program Immunol, Seattle, WA 98101 USA; [Lopes, Jared E.; Du, Jianguang; Ziegler, Steven F.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA USA; [Rubtsov, Yuri P.; Rudensky, Alexander Y.] Univ Washington, Dept Immunol, Howard Hughes Med Inst, Seattle, WA 98195 USA	New York University; Howard Hughes Medical Institute; New York University; Howard Hughes Medical Institute; New York University; Benaroya Research Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Littman, DR (corresponding author), NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med, New York, NY 10016 USA.	littman@saturn.med.nyu.edu	Rubtsov, Yury P/A-8227-2014; Victora, Gabriel/C-5946-2011; Chong, Mark/H-6684-2016	Rubtsov, Yury P/0000-0001-9175-3013; Chong, Mark/0000-0002-3701-7397; Victora, Gabriel/0000-0001-8807-348X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048779] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI048779, R01 AI048779-05, AI48779] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; DU J, IN PRESS J IMMUNOL; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lee E, 2004, J EXP MED, V199, P125, DOI 10.1084/jem.20030451; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lopes JE, 2006, J IMMUNOL, V177, P3133, DOI 10.4049/jimmunol.177.5.3133; McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Witowski J, 2004, CELL MOL LIFE SCI, V61, P567, DOI 10.1007/s00018-003-3228-z; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	30	1418	1578	4	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 8	2008	453	7192					236	U14		10.1038/nature06878	http://dx.doi.org/10.1038/nature06878			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297BP	18368049	Green Accepted, Bronze			2022-12-28	WOS:000255592400043
J	Jeyaratnam, D; Whitty, CJM; Phillips, K; Liu, DM; Orezzi, C; Ajoku, U; French, GL				Jeyaratnam, Dakshika; Whitty, Christopher J. M.; Phillips, Katie; Liu, Dongmei; Orezzi, Christina; Ajoku, Uchechukwu; French, Gary L.			Impact of rapid screening tests on acquisition of meticillin resistant Staphylococcus aureus: cluster randomised crossover trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NOSOCOMIAL TRANSMISSION; SWAB SPECIMENS; MRSA; CARE; GUIDELINES; HOSPITALS; INFECTION; PCR; COLONIZATION; PREVENTION	Objective To determine whether introducing a rapid test for meticillin resistant Staphylococcus aureus (MRSA) screening leads to a reduction in MRSA acquisition on hospital general wards. Design Cluster randomised crossover trial. Setting Medical, surgical, elderly care, and oncology wards of a London teaching hospital on two sites. Main outcome measure MRSA acquisition rate (proportion of patients negative for MRSA who became MRSA positive). Participants All patients admitted to the study wards who were MRSA negative on admission and screened for MRSA on discharge. Intervention Rapid polymerase chain reaction based screening test for MRSA compared with conventional culture. Results Of 9608 patients admitted to study wards, 8374 met entry criteria and 6888 had full data (82.3%); 3335 in the control arm and 3553 in the rapid test arm. The overall MRSA carriage rate on admission was 6.7%. Rapid tests led to a reduction in median reporting time from admission, from 46 to 22 hours (P<0.001). Rapid testing also reduced the number of inappropriate pre-emptive isolation days between the control and intervention arms (399 v 277, P<0.001). This was not seen in other measurements of resource use. MRSA was acquired by 108 (3.2%) patients in the control arm and 99 (2.8%) in the intervention arm. When predefined confounding factors were taken into account the adjusted odds ratio was 0.91 (95% confidence interval, 0.61 to 1.234). Rates of MRSA transmission, wound infection, and bacteraemia were not statistically different between the two arms. Conclusion A rapid test for MRSA led to the quick receipt of results and had an impact on bed usage. No evidence was found of a significant reduction in MRSA acquisition and on these data it is unlikely that the increased costs of rapid tests can be justified compared with alternative control measures against MRSA. Trial registration Clinical controlled trials.	[Jeyaratnam, Dakshika; Phillips, Katie; Orezzi, Christina; Ajoku, Uchechukwu; French, Gary L.] Guys & St Thomas NHS Fdn Trust, Dept Infect, London, England; [Jeyaratnam, Dakshika; French, Gary L.] Kings Coll London, Sch Med, Dept Infect Dis, London WC2R 2LS, England; [Whitty, Christopher J. M.; Liu, Dongmei] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; London School of Hygiene & Tropical Medicine	Jeyaratnam, D (corresponding author), Kings Coll Hosp NHS Fdn Trust, Hlth Protect Agcy Reg Lab Microbiol, London SE5 9RS, England.	dakshika.jeyaratnam@kcl.ac.uk	Whitty, Christopher/C-7740-2012	Whitty, Christopher/0000-0002-6076-5027	Department of Health Funding Source: Medline	Department of Health		Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253, DOI 10.1016/S0195-6701(98)90293-6; Bishop EJ, 2006, J CLIN MICROBIOL, V44, P2904, DOI 10.1128/JCM.02211-05; Brown DFJ, 2005, J ANTIMICROB CHEMOTH, V56, P1000, DOI 10.1093/jac/dki372; Cepeda JA, 2005, LANCET, V365, P295, DOI 10.1016/S0140-6736(05)17783-6; *CHIEF MED OFF, 2003, WINN WAYS WORK TOG R; COELLO R, 1994, EUR J CLIN MICROBIOL, V13, P74, DOI 10.1007/BF02026130; Coia JE, 2006, J HOSP INFECT, V63, pS1, DOI 10.1016/j.jhin.2006.01.001; Conterno LO, 2007, INFECT CONT HOSP EP, V28, P1134, DOI 10.1086/520099; Cooper BS, 2004, P NATL ACAD SCI USA, V101, P10223, DOI 10.1073/pnas.0401324101; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P53, DOI 10.1086/345476; COSGROVE SE, 2003, CLIN INFECT DIS, V1, P36; Cunningham R, 2007, J HOSP INFECT, V65, P24, DOI 10.1016/j.jhin.2006.09.019; *DEP HLTH, 2007, SCREEN MET RES STAPH; Engemann JJ, 2003, CLIN INFECT DIS, V36, P592, DOI 10.1086/367653; Farrington M, 1998, QJM-MON J ASSOC PHYS, V91, P539, DOI 10.1093/qjmed/91.8.539; Gurran C, 2002, J HOSP INFECT, V52, P148, DOI 10.1053/jhin.2002.1260; Harbarth S, 2008, JAMA-J AM MED ASSOC, V299, P1149, DOI 10.1001/jama.299.10.1149; Harbarth S, 2006, CRIT CARE, V10, DOI 10.1186/cc3982; *HLTH PROT AG, 2007, COMM Q 6 MONTHLY ANN; JEYARATNAM D, 2008, DIAGN MICROBIOL 0115; Keshtgar MRS, 2008, BRIT J SURG, V95, P381, DOI 10.1002/bjs.6013; MacDonald A, 2004, J HOSP INFECT, V56, P56, DOI 10.1016/S0195-6701(03)00293-7; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; Muto CA, 2003, INFECT CONT HOSP EP, V24, P362, DOI 10.1086/502213; Pratt RJ, 2007, J HOSP INFECT, V65, pS1, DOI 10.1016/S0195-6701(07)60002-4; Rao GG, 2007, J HOSP INFECT, V66, P15, DOI 10.1016/j.jhin.2007.01.013; Rioux C, 2007, INFECT CONT HOSP EP, V28, P733, DOI 10.1086/516664; RITCHIE K, 2006, CONSULTATION REPORT; RITCHIE K, 2006, CLIN COST EFFECTIVEN; Robotham JV, 2007, J HOSP INFECT, V65, P93, DOI 10.1016/S0195-6701(07)60023-1; Rubinovitch B, 2001, J HOSP INFECT, V47, P9, DOI 10.1053/jhin.2000.0873; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; Warren DK, 2004, J CLIN MICROBIOL, V42, P5578, DOI 10.1128/JCM.42.12.5578-5581.2004	33	105	105	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	2008	336	7650					927	+		10.1136/bmj.39525.579063.BE	http://dx.doi.org/10.1136/bmj.39525.579063.BE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18417521	Green Accepted, Green Published, Bronze, Green Submitted			2022-12-28	WOS:000255540900029
J	Kush, RD; Helton, E; Rockhold, FW; Hardison, CD				Kush, Rebecca D.; Helton, Edward; Rockhold, Frank W.; Hardison, C. David			Electronic health records, medical research, and the Tower of Babel	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kush, Rebecca D.] Clin Data Interchange Stand Consortium, Austin, TX USA; [Helton, Edward] SAS Inst, Cary, NC USA; [Rockhold, Frank W.] GlaxoSmithKline Inc, King Of Prussia, PA USA; [Hardison, C. David] Sci Applicat Int Corp, San Diego, CA 92121 USA	SAS Institute Inc; GlaxoSmithKline; Science Applications International Corporation (SAIC)	Kush, RD (corresponding author), Clin Data Interchange Stand Consortium, Austin, TX USA.		Rockhold, Frank W./C-7078-2019	Rockhold, Frank W./0000-0003-3732-4765				*CLIN DAT INT STAN, LEV CDISC STAND FAC; *FOOD DRUG ADM, CRIT PATH IN; Rozwell C., 2007, APPL CLIN TRIALS, V16, P70	3	51	51	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1738	1740		10.1056/NEJMsb0800209	http://dx.doi.org/10.1056/NEJMsb0800209			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288DO	18420507	Green Published			2022-12-28	WOS:000254966600015
J	Gostin, LO				Gostin, Lawrence O.			The international migration and recruitment of nurses - Human rights and global justice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH-WORKERS		Georgetown Univ, Ctr Law, Oneill Inst Natl & Global Hlth Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, Oneill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				AIKEN LH, 2007, HLTH AFF MILLWOOD, V20, P43; *AM HOSP ASS, 2007, AM HOSP ASS SURV HOS; BENETAR SR, 2007, CLIN ETHICS, V2, P1; Buchan J, 2004, B WORLD HEALTH ORGAN, V82, P587; Chopra M, 2008, LANCET, V371, P668, DOI 10.1016/S0140-6736(08)60305-0; *DEP HHS, 2002, PROJ SUPPL DEM SHORT; Dwyer J, 2007, HASTINGS CENT REP, V37, P36, DOI 10.1353/hcr.2007.0070; Gostin LO, 2007, JAMA-J AM MED ASSOC, V298, P225, DOI 10.1001/jama.298.2.225; International Council of Nurses, 2006, GLOB NURS SHORT PRIO; International Council of Nurses, 2004, GLOB SHORT REG NURS; Kuehn BM, 2007, JAMA-J AM MED ASSOC, V298, P1853, DOI 10.1001/jama.298.16.1853; Mccoy D, 2008, LANCET, V371, P675, DOI 10.1016/S0140-6736(08)60306-2; Mills EJ, 2008, LANCET, V371, P685, DOI 10.1016/S0140-6736(08)60308-6; Pittman Patricia, 2007, US BASED INT NURSE R; Stanton MW, 2004, HOSP NURSE STAFFING; *WHO, 2004, HIGH LEV FOR HLTH MI; WHO, 2006, WORK TOG HLTH WORLD; *WHO, 2004, HUM RES HLTH REP SEC; *WHO, NEW IN SEEKS PRACT S	19	15	15	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1827	1829		10.1001/jama.299.15.1827	http://dx.doi.org/10.1001/jama.299.15.1827			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18413878				2022-12-28	WOS:000254954800028
J	Brodsky, RA				Brodsky, Robert A.			Narrative review: Paroxysmal nocturnal hemoglobinuria: The physiology of complement-related hemolytic anemia	ANNALS OF INTERNAL MEDICINE			English	Review							GLYCOSYL-PHOSPHATIDYLINOSITOL; PIG-A; INHIBITOR ECULIZUMAB; APLASTIC-ANEMIA; MEMBRANE-GLYCOPROTEINS; SOMATIC MUTATIONS; NATURAL-HISTORY; CELLS; PNH; DEFICIENCY	Clinical Principles Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic stem-cell disorder caused by a somatic mutation in a gene known as phosphatidylinositol glycan class A (PIGA). It may arise de novo or in the setting of acquired aplastic anemia. Clinical presentation can include hemolytic anemia, hemoglobinuria, thrombosis, severe fatigue, abdominal pain, and esophageal spasm. Thrombosis, the leading cause of death from PNH, most commonly occurs in abdominal and cerebral veins. Therapeutic options include supportive care, bone marrow transplantation, and monoclonal antibody therapy with the terminal complement inhibitor eculizumab. Pathophysiologic Principles The product of the PIGA gene is required for the biosynthesis of a glycolipid anchor that attaches a class of membrane proteins known as glycosylphosphatidylinositol (GPI)anchored proteins to the cell surface. The absence of GPI-anchored proteins leads to complement-mediated intravascular hemolysis, because 2 important complement regulatory proteins (CD55 and CD59) are missing from PNH cells. Hemolysis in PNH occurs intravascularly. This leads to release of free hemoglobin, a potent nitric oxide scavenger. Depletion of nitric oxide at the tissue level contributes to fatigue, esophageal spasm, thrombosis, and male erectile dysfunction. Eculizumab decreases hemolysis in PNH by binding to C5 and blocking the terminal portion of the complement cascade.	Johns Hopkins Med Inst, Div Hematol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Brodsky, RA (corresponding author), Johns Hopkins Med Inst, Div Hematol, Ross Res Bldg Room 1025,720 Rutland Ave, Baltimore, MD 21205 USA.	brodsro@jhmi.edu			NATIONAL CANCER INSTITUTE [P01CA070970] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA70970, P01 CA070970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTIN JH, 1985, BLOOD, V66, P1247; Araten DJ, 1999, P NATL ACAD SCI USA, V96, P5209, DOI 10.1073/pnas.96.9.5209; AZIZI E, 1970, CLIN CHIM ACTA, V28, P391, DOI 10.1016/0009-8981(70)90063-X; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; Brodsky R., 2005, HEMATOLOGY BASIC PRI, P419; Brodsky RA, 1999, BLOOD, V93, P1749, DOI 10.1182/blood.V93.5.1749.405k09_1749_1756; Brodsky RA, 2005, LANCET, V365, P1647, DOI 10.1016/S0140-6736(05)66515-4; Brodsky RA, 2000, AM J CLIN PATHOL, V114, P459, DOI 10.1093/ajcp/114.3.459; Brodsky RA, 2008, BLOOD, V111, P1840, DOI 10.1182/blood-2007-06-094136; Carmichael FJL, 2001, TRANSFUS APHER SCI, V24, P17; DAMESHEK W, 1967, BLOOD-J HEMATOL, V30, P251; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Enneking J., 1928, KLIN WOCHENSCHR, V7, P2045; Hall SE, 1996, BLOOD, V87, P5332, DOI 10.1182/blood.V87.12.5332.bloodjournal87125332; Ham TH, 1937, NEW ENGL J MED, V217, P915, DOI 10.1056/NEJM193712022172307; Ham TH, 1939, J CLIN INVEST, V18, P657, DOI 10.1172/JCI101081; HARTMANN RC, 1966, NEW ENGL J MED, V275, P155, DOI 10.1056/NEJM196607212750308; Hillmen P, 2004, NEW ENGL J MED, V350, P552, DOI 10.1056/NEJMoa031688; HILLMEN P, 1995, NEW ENGL J MED, V333, P1253, DOI 10.1056/NEJM199511093331904; Hillmen P, 2007, BLOOD, V110, P4123, DOI 10.1182/blood-2007-06-095646; Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648; Hu R, 2005, BLOOD, V105, P3848, DOI 10.1182/blood-2004-04-1472; Hugel B, 1999, BLOOD, V93, P3451, DOI 10.1182/blood.V93.10.3451.410k27_3451_3456; Inoue N, 2006, BLOOD, V108, P4232, DOI 10.1182/blood-2006-05-025148; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; LEWIS SM, 1967, BRIT J HAEMATOL, V13, P236, DOI 10.1111/j.1365-2141.1967.tb08736.x; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; Luzzatto L, 1997, CELL, V88, P1, DOI 10.1016/S0092-8674(00)81850-4; Maroney SA, 2006, J THROMB HAEMOST, V4, P1114, DOI 10.1111/j.1538-7836.2006.01873.x; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MERI S, 1990, IMMUNOLOGY, V71, P1; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; Morris CR, 2005, JAMA-J AM MED ASSOC, V294, P81, DOI 10.1001/jama.294.1.81; Moyo VM, 2004, BRIT J HAEMATOL, V126, P133, DOI 10.1111/j.1365-2141.2004.04992.x; Mukhina GL, 2001, BRIT J HAEMATOL, V115, P476, DOI 10.1046/j.1365-2141.2001.03127.x; NAGARAJAN S, 1995, BLOOD, V86, P4656, DOI 10.1182/blood.V86.12.4656.bloodjournal86124656; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; PARKER CJ, 1982, J CLIN INVEST, V69, P337, DOI 10.1172/JCI110457; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; PLOUG M, 1992, BLOOD, V79, P1447; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; Rosse WF, 1997, MEDICINE, V76, P63, DOI 10.1097/00005792-199703000-00001; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Saso R, 1999, BRIT J HAEMATOL, V104, P392, DOI 10.1046/j.1365-2141.1999.01195.x; SCHREZENMEIER H, 1995, EXP HEMATOL, V23, P81; Socie G., 1995, Blood, V86, p130A; Socie G, 1996, LANCET, V348, P573, DOI 10.1016/S0140-6736(95)12360-1; Strubing P., 1882, DMW DTSCH MED WOCHEN, V8, P1, DOI [DOI 10.1055/S-0029-1196307, 10.1055/s-0029-1196307]; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; Takahashi Y, 2004, BLOOD, V103, P1383, DOI 10.1182/blood-2003-04-1281; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VANDERSCHOOT CE, 1990, BLOOD, V76, P1853; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wang HB, 2002, BLOOD, V100, P3897, DOI 10.1182/blood-2002-03-0799; WARE RE, 1991, NEW ENGL J MED, V325, P991, DOI 10.1056/NEJM199110033251403; WIEDMER T, 1993, BLOOD, V82, P1192, DOI 10.1182/blood.V82.4.1192.bloodjournal8241192	58	66	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2008	148	8					587	595		10.7326/0003-4819-148-8-200804150-00003	http://dx.doi.org/10.7326/0003-4819-148-8-200804150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290LF	18413620				2022-12-28	WOS:000255123600003
J	Gurm, HS; Yadav, JS; Fayad, P; Katzen, BT; Mishkel, GJ; Bajwa, TK; Ansel, G; Strickman, NE; Wang, H; Cohen, SA; Massaro, JM; Cutlip, DE				Gurm, Hitinder S.; Yadav, Jay S.; Fayad, Pierre; Katzen, Barry T.; Mishkel, Gregory J.; Bajwa, Tanvir K.; Ansel, Gary; Strickman, Neil E.; Wang, Hong; Cohen, Sidney A.; Massaro, Joseph M.; Cutlip, Donald E.		SAPPHIRE Investigators	Long-term results of carotid stenting versus endarterectomy in high-risk patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STENOSIS	Background: We previously reported that, in a randomized trial, carotid stenting with the use of an emboli-protection device is not inferior to carotid endarterectomy for the treatment of carotid artery disease at 30 days and at 1 year. We now report the 3-year results. Methods: The trial evaluated carotid artery stenting with the use of an emboli-protection device as compared with endarterectomy in 334 patients at increased risk for complications from endarterectomy who had either a symptomatic carotid artery stenosis of at least 50% of the luminal diameter or an asymptomatic stenosis of at least 80%. The prespecified major secondary end point at 3 years was a composite of death, stroke, or myocardial infarction within 30 days after the procedure or death or ipsilateral stroke between 31 days and 1080 days (3 years). Results: At 3 years, data were available for 260 patients (77.8%), including 85.6% of patients in the stenting group and 70.1% of those in the endarterectomy group. The prespecified major secondary end point occurred in 41 patients in the stenting group (cumulative incidence, 24.6%; Kaplan-Meier estimate, 26.2%) and 45 patients in the endarterectomy group (cumulative incidence, 26.9%; Kaplan-Meier estimate, 30.3%) (absolute difference in cumulative incidence for the stenting group, -2.3%; 95% confidence interval, -11.8 to 7.0). There were 15 strokes in each of the two groups, of which 11 in the stenting group and 9 in the endarterectomy group were ipsilateral. Conclusions: In our trial of patients with severe carotid artery stenosis and increased surgical risk, no significant difference could be shown in long-term outcomes between patients who underwent carotid artery stenting with an emboli-protection device and those who underwent endarterectomy. (ClinicalTrials.gov number, NCT00231270.).	[Massaro, Joseph M.; Cutlip, Donald E.] Harvard Univ, Sch Med, Harvard Clin Res Inst, Boston, MA 02215 USA; [Cutlip, Donald E.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Gurm, Hitinder S.] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Yadav, Jay S.] Piedmont Cardiovasc Inst, Atlanta, GA USA; [Fayad, Pierre] Univ Nebraska Med Ctr, Omaha, NE USA; [Katzen, Barry T.] Miami Cardiac & Vasc Inst, Miami, FL USA; [Mishkel, Gregory J.] St Johns Hosp, Prairie Heart Inst, Springfield, IL USA; [Bajwa, Tanvir K.] Milwaukee Heart Inst, Milwaukee, WI USA; [Ansel, Gary] Mid Ohio Cardiovasc Consultants, Columbus, OH USA; [Strickman, Neil E.] St Lukes Hosp, Houston, TX USA; [Wang, Hong; Cohen, Sidney A.] Cordis, Warren, NJ USA; [Cohen, Sidney A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Michigan System; University of Michigan; University of Nebraska System; University of Nebraska Medical Center; Baptist Cardiac & Vascular Institute; Johnson & Johnson; Johnson & Johnson USA; University of Pennsylvania	Cutlip, DE (corresponding author), Harvard Univ, Sch Med, Harvard Clin Res Inst, 930 Commonwealth Ave, Boston, MA 02215 USA.	don.cutlip@hcri.harvard.edu	Strickman, Neil/AFS-7515-2022	Hayakawa, Minako/0000-0002-9498-4711; Massaro, Joseph/0000-0002-2682-4812; Gurm, Hitinder/0000-0002-1646-0218				BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711; Brown MM, 2001, LANCET, V357, P1729; Escobar, 1998, STAT METHODS RELIABI; Halliday A, 2004, LANCET, V363, P1491; HALLIDAY A, 2004, LANCET, V364, P416; Halm EA, 2003, STROKE, V34, P1464, DOI 10.1161/01.STR.0000072514.79745.7D; Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302; Kakkos SK, 2005, INT ANGIOL, V24, P221; Lepore MR, 2001, J VASC SURG, V34, P581, DOI 10.1067/mva.2001.118079; Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752; MENDELSOHN FO, 2000, MANAGEMENT ATHEROSCL; Mozes G, 2004, J VASC SURG, V39, P958, DOI 10.1016/j.jvs.2003.12.037; Ouriel K, 2001, J VASC SURG, V33, P728, DOI 10.1067/mva.2001.111981; Ringleb PA, 2006, LANCET, V368, P1239, DOI 10.1016/S0140-6736(06)69122-8; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Roubin GS, 2001, CIRCULATION, V103, P532, DOI 10.1161/01.CIR.103.4.532; Safian RD, 2006, J AM COLL CARDIOL, V47, P2384, DOI 10.1016/j.jacc.2005.12.076; White CJ, 2006, CATHETER CARDIO INTE, V67, P503, DOI 10.1002/ccd.20689; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127; Yadav JS, 1997, CIRCULATION, V95, P376, DOI 10.1161/01.cir.95.2.376	20	546	587	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1572	1579		10.1056/NEJMoa0708028	http://dx.doi.org/10.1056/NEJMoa0708028			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285NK	18403765				2022-12-28	WOS:000254783300006
J	Zimmermann, C; Riechelmann, R; Krzyzanowska, M; Rodin, G; Tannock, I				Zimmermann, Camilla; Riechelmann, Rachel; Krzyzanowska, Monika; Rodin, Gary; Tannock, Ian			Effectiveness of specialized palliative - Care a systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CANCER-PATIENTS; HOME-CARE; CLUSTER RANDOMIZATION; LUNG-CANCER; FAMILY SATISFACTION; COST-EFFECTIVENESS; CONSORT STATEMENT; COORDINATED CARE	Context Specialized palliative care teams are increasingly providing care for the terminally ill. However, the impact of such teams on quality of life, satisfaction with care, and economic cost has not been examined systematically using detailed criteria for study quality. Objective To systematically review the evidence for effectiveness of specialized palliative care. Data Sources We performed a keyword search of the following databases from their inception to January 2008: MEDLINE, Ovid Healthstar, CINAHL, EMBASE, and the Cochrane Central Register of Controlled Trials. Study Selection We included all randomized controlled trials in which specialized palliative care was the intervention and for which outcomes included quality of life, satisfaction with care, or economic cost. Data Extraction Data on population, intervention, outcome, methods, and methodological quality were extracted by 2 investigators using standardized criteria. Results Of 396 reports of randomized controlled trials, 22 met our inclusion criteria. There was most consistent evidence for effectiveness of specialized palliative care in improvement of family satisfaction with care ( 7 of 10 studies favored the intervention). Only 4 of 13 studies assessing quality of life and 1 of 14 assessing symptoms showed a significant benefit of the intervention; however, most studies lacked statistical power to report conclusive results, and quality- of- life measures were not specific for terminally ill patients. There was evidence of significant cost savings of specialized palliative care in only 1 of the 7 studies that assessed this outcome. Methodological limitations were identified in all trials, including contamination of the control group, failure to account for clustering in cluster randomization studies, and substantial problems with recruitment, attrition, and adherence. Conclusions The evidence for benefit from specialized palliative care is sparse and limited by methodological shortcomings. Carefully planned trials, using a standardized palliative care intervention and measures constructed specifically for this population, are needed.	[Zimmermann, Camilla; Rodin, Gary] Princess Margaret Hosp, Palliat Care Serv, Dept Psychosocial Oncol & Palliat Care, Univ Hlth Network, Toronto, ON M5G 2M9, Canada; [Krzyzanowska, Monika; Tannock, Ian] Princess Margaret Hosp, Dept Med Oncol, Univ Hlth Network, Toronto, ON M5G 2M9, Canada; [Riechelmann, Rachel] Albert Einstein Hosp, Dept Med Oncol, Sao Paulo, Brazil; [Zimmermann, Camilla; Krzyzanowska, Monika; Tannock, Ian] Univ Toronto, Div Med Oncol & Hematol, Dept Med, Toronto, ON, Canada; [Zimmermann, Camilla; Rodin, Gary] Univ Toronto, Dept Psychiat, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Hospital Israelita Albert Einstein; University of Toronto; University of Toronto	Zimmermann, C (corresponding author), Princess Margaret Hosp, Palliat Care Serv, Dept Psychosocial Oncol & Palliat Care, Univ Hlth Network, 610 Univ Ave,16-712, Toronto, ON M5G 2M9, Canada.	camilla.zimmermann@uhn.on.ca	Riechelmann, R/Q-6239-2017; Krzyzanowska, Monika K./ABG-3505-2020	Krzyzanowska, Monika K./0000-0001-5533-7418; Rodin, Gary/0000-0002-6626-6974; Zimmermann, Camilla/0000-0003-4889-0244				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; ADDINGTONHALL J, 1995, PALLIATIVE MED, V9, P295, DOI 10.1177/026921639500900404; ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; Ahronheim J C, 2000, J Palliat Med, V3, P265, DOI 10.1089/jpm.2000.3.265; Aiken LS, 2006, J PALLIAT MED, V9, P111, DOI 10.1089/jpm.2006.9.111; Aspinal F, 2003, J ADV NURS, V42, P324, DOI 10.1046/j.1365-2648.2003.02624.x; Baker R, 2000, J AM GERIATR SOC, V48, pS61, DOI 10.1111/j.1532-5415.2000.tb03143.x; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Boni-Saenz AA, 2005, CLIN GERIATR MED, V21, P147, DOI 10.1016/j.cger.2004.08.010; Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Bryce CL, 2004, MED CARE, V42, P423, DOI 10.1097/01.mlr.000012425.62354.57; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Campbell MK, 2004, COMPUT BIOL MED, V34, P113, DOI 10.1016/S0010-4825(03)00039-8; Campbell MK, 2000, FAM PRACT, V17, P192, DOI 10.1093/fampra/17.2.192; Campbell MK, 1998, BMJ-BRIT MED J, V317, P1171, DOI 10.1136/bmj.317.7167.1171; Casarett D, 2005, JAMA-J AM MED ASSOC, V294, P211, DOI 10.1001/jama.294.2.211; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Chochinov HM, 2002, SOC SCI MED, V54, P433, DOI 10.1016/S0277-9536(01)00084-3; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Clark Matthew M, 2006, Am J Hosp Palliat Care, V23, P185, DOI 10.1177/1049909106289074; *COCHR EPOC, DAT ABSTR TEMPL; COHEN SR, 1995, PALLIATIVE MED, V9, P207, DOI 10.1177/026921639500900306; Costantini M, 1999, J PAIN SYMPTOM MANAG, V18, P243, DOI 10.1016/S0885-3924(99)00084-6; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; Desbiens NA, 1996, CRIT CARE MED, V24, P1953, DOI 10.1097/00003246-199612000-00005; Dibble S L, 1998, Oncol Nurs Forum, V25, P577; DONNER A, 1990, INT J EPIDEMIOL, V19, P795, DOI 10.1093/ije/19.4.795; Eldridge Sandra M, 2004, Clin Trials, V1, P80, DOI 10.1191/1740774504cn006rr; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Engelhardt JB, 2006, AM J MANAG CARE, V12, P93; FERRIS FD, 2002, MODEL GUIDE HOSP PAL; Grande GE, 2000, PALLIATIVE MED, V14, P375, DOI 10.1191/026921600701536200; Grande GE, 1999, BRIT MED J, V319, P1472, DOI 10.1136/bmj.319.7223.1472; Grimshaw J, 2003, QUAL SAF HEALTH CARE, V12, P298, DOI 10.1136/qhc.12.4.298; Groenvold M, 2006, EUR J CANCER, V42, P55, DOI 10.1016/j.ejca.2005.06.022; Hanks GW, 2002, BRIT J CANCER, V87, P733, DOI 10.1038/sj.bjc.6600522; Hearn J, 1998, PALLIATIVE MED, V12, P317, DOI 10.1191/026921698676226729; Heyland DK, 2006, CAN MED ASSOC J, V174, P627, DOI 10.1503/cmaj.050626; Higginson IJ, 2003, J PAIN SYMPTOM MANAG, V25, P150, DOI 10.1016/S0885-3924(02)00599-7; Higginson IJ, 2002, J PAIN SYMPTOM MANAG, V23, P96, DOI 10.1016/S0885-3924(01)00406-7; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; Hughes SL, 2000, JAMA-J AM MED ASSOC, V284, P2877, DOI 10.1001/jama.284.22.2877; Huwiler-Muntener K, 2002, JAMA-J AM MED ASSOC, V287, P2801, DOI 10.1001/jama.287.21.2801; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JENICEK M, 1989, J CLIN EPIDEMIOL, V42, P35, DOI 10.1016/0895-4356(89)90023-1; Jordhoy MS, 1999, PALLIATIVE MED, V13, P299, DOI 10.1191/026921699668963873; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Jordhoy MS, 2001, J CLIN ONCOL, V19, P3884, DOI 10.1200/JCO.2001.19.18.3884; Kaasa S, 2003, PALLIATIVE MED, V17, P11, DOI 10.1191/0269216303pm662ra; Kaasa S, 2002, LANCET ONCOL, V3, P175, DOI 10.1016/S1470-2045(02)00682-4; KANE RL, 1985, MED CARE, V23, P189, DOI 10.1097/00005650-198503000-00001; KANE RL, 1986, J CHRON DIS, V39, P735, DOI 10.1016/0021-9681(86)90156-6; KANE RL, 1985, JAMA-J AM MED ASSOC, V253, P2683, DOI 10.1001/jama.253.18.2683; KANE RL, 1984, LANCET, V1, P890; KIRKWOOD BR, 1989, J BIOSOC SCI, P79; Kirkwood BR, 1997, TROP MED INT HEALTH, V2, P1022, DOI 10.1046/j.1365-3156.1997.d01-188.x; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Li Yan-qun, 2006, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V31, P538; Lorenz KA, 2008, ANN INTERN MED, V148, P147, DOI 10.7326/0003-4819-148-2-200801150-00010; Lynn J, 1997, J AM GERIATR SOC, V45, P526; McCarthy EP, 2000, J AM GERIATR SOC, V48, pS110, DOI 10.1111/j.1532-5415.2000.tb03120.x; MCCORKLE R, 1989, CANCER, V64, P1375, DOI 10.1002/1097-0142(19890915)64:6<1375::AID-CNCR2820640634>3.0.CO;2-6; McMillan SC, 2006, CANCER, V106, P214, DOI 10.1002/cncr.21567; McMillan SC, 1998, CANCER PRACT, V6, P282, DOI 10.1046/j.1523-5394.1998.00023.x; McMillan SC, 2007, ONCOL NURS FORUM, V34, P313, DOI 10.1188/07.ONF.313-321; MCWHINNEY IR, 1994, BRIT MED J, V309, P1340, DOI 10.1136/bmj.309.6965.1340; Meyers FJ, 2004, J PAIN SYMPTOM MANAG, V28, P548, DOI 10.1016/j.jpainsymman.2004.03.002; Miller Douglas K, 2005, J Palliat Med, V8, P333, DOI 10.1089/jpm.2005.8.333; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Moore S, 2002, BMJ-BRIT MED J, V325, P1145, DOI 10.1136/bmj.325.7373.1145; Morrison RS, 2000, ARCH INTERN MED, V160, P743, DOI 10.1001/archinte.160.6.743; Paes P, 2005, PALLIATIVE MED, V19, P505, DOI 10.1177/026921630501900614; Pearson, 1969, DEATH DYING, P49; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Rinck GC, 1997, J CLIN ONCOL, V15, P1697, DOI 10.1200/JCO.1997.15.4.1697; Ringdal GI, 2002, J PAIN SYMPTOM MANAG, V24, P53, DOI 10.1016/S0885-3924(02)00417-7; Rodin G, 2007, J PAIN SYMPTOM MANAG, V33, P661, DOI 10.1016/j.jpainsymman.2006.09.034; Rummans TA, 2006, J CLIN ONCOL, V24, P635, DOI 10.1200/JCO.2006.06.209; Salisbury C, 1999, PALLIATIVE MED, V13, P3, DOI 10.1191/026921699677461429; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; SIMPSON JM, 1995, AM J PUBLIC HEALTH, V85, P1378, DOI 10.2105/AJPH.85.10.1378; Smeenk FWJM, 1998, BRIT MED J, V316, P1939, DOI 10.1136/bmj.316.7149.1939; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser Karen E, 2004, Palliat Support Care, V2, P3; Strasser S, 1995, J Health Care Mark, V15, P34; Temel JS, 2007, J CLIN ONCOL, V25, P2377, DOI 10.1200/JCO.2006.09.2627; Torgerson DJ, 2001, BMJ-BRIT MED J, V322, P355, DOI 10.1136/bmj.322.7282.355; TOSELAND RW, 1995, SOC SCI MED, V40, P517, DOI 10.1016/0277-9536(94)E0093-8; WARE JE, 1976, HEALTH SERV RES, V11, P396; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 1993, SF36 HLTH SURVEY MAN; Wilkinson EK, 1999, PALLIATIVE MED, V13, P197, DOI 10.1191/026921699673563105; World Health Organization, 2002, WHO DEF PALL CAR; ZIMMER JG, 1984, J AM GERIATR SOC, V32, P288, DOI 10.1111/j.1532-5415.1984.tb02023.x; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	102	321	327	0	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2008	299	14					1698	1709		10.1001/jama.299.14.1698	http://dx.doi.org/10.1001/jama.299.14.1698			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285AL	18398082				2022-12-28	WOS:000254749600026
J	Michet, CJ; Matteson, EL				Michet, Clement J.; Matteson, Eric L.			Polymyalgia rheumatica	BRITISH MEDICAL JOURNAL			English	Review							GIANT-CELL ARTERITIS; NORTHWESTERN SPAIN; PREDNISONE; MANAGEMENT; SPECTRUM; RELAPSE; TRIAL		[Michet, Clement J.; Matteson, Eric L.] Mayo Clin, Div Rheumatol, Rochester, MN 55905 USA	Mayo Clinic	Matteson, EL (corresponding author), Mayo Clin, Div Rheumatol, Rochester, MN 55905 USA.	matteson.eric@mayo.edu						Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496; CANTANOSO CM, 2007, ARTHRIT CARE RES, V57, P1514; Caporali R, 2004, ANN INTERN MED, V141, P493, DOI 10.7326/0003-4819-141-7-200410050-00005; CATOGGIO LJ, 1991, BRIT J RHEUMATOL, V30, P393; Dasgupta B, 2007, CLIN EXP RHEUMATOL, V25, pS130; Dasgupta B, 2004, OXFORD TXB RHEUMATOL, P977; Doran MF, 2002, J RHEUMATOL, V29, P1694; Gabriel SE, 1997, ARTHRITIS RHEUM, V40, P1873, DOI 10.1002/art.1780401022; Gonzalez-Gay MA, 1999, J RHEUMATOL, V26, P1326; Gonzalez-Gay MA, 2000, J RHEUMATOL, V27, P2179; JONES JG, 1981, ANN RHEUM DIS, V40, P1, DOI 10.1136/ard.40.1.1; Kremers HM, 2005, J RHEUMATOL, V32, P65; KYLE V, 1989, ANN RHEUM DIS, V48, P662, DOI 10.1136/ard.48.8.662; KYLE V, 1993, ANN RHEUM DIS, V52, P847, DOI 10.1136/ard.52.12.847; Leeb BF, 2003, ANN RHEUM DIS, V62, P1189, DOI 10.1136/ard.2002.002618; Martinez-Taboada VM, 2001, SEMIN ARTHRITIS RHEU, V30, P257, DOI 10.1053/sarh.2001.9734; Ostergaard M, 2003, SCAND J RHEUMATOL, V32, P63, DOI 10.1080/03009740310000058; Proven A, 1999, J RHEUMATOL, V26, P1333; Royal College of Physicians and Bone and Tooth Society of Great Britain, 2000, OST CLIN GUID PREV T; Salvarani C, 2002, NEW ENGL J MED, V347, P261, DOI 10.1056/NEJMra011913; Salvarani C, 2007, ANN INTERN MED, V146, P631, DOI 10.7326/0003-4819-146-9-200705010-00005; Smeeth L, 2006, ANN RHEUM DIS, V65, P1093, DOI 10.1136/ard.2005.046912; Weyand CM, 2003, ANN INTERN MED, V139, P505, DOI 10.7326/0003-4819-139-6-200309160-00015	23	40	42	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 5	2008	336	7647					765	769		10.1136/bmj.39514.653588.80	http://dx.doi.org/10.1136/bmj.39514.653588.80			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284JW	18390527	Green Published			2022-12-28	WOS:000254703700034
J	Berns, A				Berns, Anton			A tRNA with oncogenic capacity	CELL			English	Editorial Material							TRANSLATION; CANCER; TUMORS	Overexpression of Brf1, a transcription factor of the RNA polymerase III apparatus, can transform cells in vitro and cause tumor formation in vivo. Marshall et al. (2008) now show that one of the transcriptional products of RNA polymerase III, the initiator tRNAMet, mediates this effect, revealing an unexpected role for this tRNA in tumorigenesis.	Netherlands Canc Inst, Canc Genom Ctr, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Canc Genom Ctr, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl						Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Tomlinson VAL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-113; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Zhang L, 2006, CELL CYCLE, V5, P2216, DOI 10.4161/cc.5.19.3319	9	7	9	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 4	2008	133	1					29	30		10.1016/j.cell.2008.03.017	http://dx.doi.org/10.1016/j.cell.2008.03.017			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394985	Bronze			2022-12-28	WOS:000254641300004
J	Williams, BJ; Jorge, MDJY				Williams, Barbara J.; Jorge y Jorge, Maria del Carmen			Aztec arithmetic revisited: Land-area algorithms and Acolhua congruence arithmetic	SCIENCE			English	Article								Acolhua-Aztec land records depicting areas and side dimensions of agricultural fields provide insight into Aztec arithmetic. Hypothesizing that recorded areas resulted from indigenous calculation, in a study of sample quadrilateral fields we found that 60% of the area values could be reproduced exactly by computation. In remaining cases, discrepancies between computed and recorded areas were consistently small, suggesting use of an unknown indigenous arithmetic. In revisiting the research, we discovered evidence for the use of congruence principles, based on proportions between the standard linear Acolhua measure and their units of shorter length. This procedure substitutes for computation with fractions and is labeled "Acolhua congruence arithmetic." The findings also clarify variance between Acolhua and Tenochca linear units, long an issue in understanding Aztec metrology.	[Jorge y Jorge, Maria del Carmen] Univ Nacl Autonoma Mexico, Inst Invest Matemat Aplicadas & Sist, FENOMEC, Mexico City 04510, DF, Mexico; [Williams, Barbara J.] Univ Wisconsin Rock Cty, Dept Geog & Geol, Janesville, WI USA	Universidad Nacional Autonoma de Mexico; University of Wisconsin System	Jorge, MDJY (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Matemat Aplicadas & Sist, FENOMEC, Mexico City 04510, DF, Mexico.	mcj@mym.iimas.unam.mx						ALONSO MM, 1984, MED INDIGENAS LONGIT; Carrasco Pedro., 1999, TENOCHCA EMPIRE ANCI; CASTILLO VM, 1972, ESTUD CULT NAHUATL, V10, P195; CLINE HF, 1968, ACT MEM 37 INT C AM, V3, P119; GARCIA LR, 1996, 16 CTR INV EST SUP A; Harris, 1990, EMICS ETICS INSIDER; Harvey H. R, 1991, LAND POLITICS VALLEY, P163; HARVEY HR, 1980, SCIENCE, V210, P499, DOI 10.1126/science.210.4469.499; IXTILILXOCHITL FD, 1952, HIST DF ALV IXTL PUB; *MUS NAC ANTR, PAP EMB AM; Nissen Hans J., 1993, ARCHAIC BOOKKEEPING; ROBERTSON D., 1959, MEXICAN MANUSCRIPT P; Robson Eleanor, 1999, OXFORD EDITIONS CUNE; Williams Barbara J., 1997, CODICE SANTA MARIA A; WILLIAMS BJ, 2001, SYMMETRY CULTURE SCI, V12, P185	15	12	15	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					72	77		10.1126/science.1153976	http://dx.doi.org/10.1126/science.1153976			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388287				2022-12-28	WOS:000254633000032
J	Jones, GL; Ledger, W; Mitchell, C				Jones, Georgina Louise; Ledger, William; Mitchell, Caroline			10-minute consultation - Suspected premature menopause	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Jones, Georgina Louise] Univ Sheffield, Hlth Serv Res Sect, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England; [Ledger, William] Univ Sheffield, Jessop Wing Hosp, Sheffield S10 2JT, S Yorkshire, England; [Mitchell, Caroline] Univ Sheffield, No Gen Hosp, Div Primary Med Care, Sheffield S5 7AU, S Yorkshire, England	University of Sheffield; University of Sheffield; Northern General Hospital; University of Sheffield	Jones, GL (corresponding author), Univ Sheffield, Hlth Serv Res Sect, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.	g.l.jones@sheffield.ac.uk	Ledger, William/L-9089-2017	Ledger, William/0000-0001-6465-4343; Mitchell, Caroline/0000-0002-4790-0095; Jones, Georgina/0000-0002-5267-1776					0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR	2008	336	7648					833	833		10.1136/bmj.39371.652604.94	http://dx.doi.org/10.1136/bmj.39371.652604.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	292ER	18403549	Green Published			2022-12-28	WOS:000255249800049
J	Kojodjojo, P; Wong, T; Wright, AR; Kon, OM; Oldfield, W; Kanagaratnam, P; Davies, DW; Peters, NS				Kojodjojo, P.; Wong, T.; Wright, A. R.; Kon, O. M.; Oldfield, W.; Kanagaratnam, P.; Davies, D. W.; Peters, N. S.			Lesson of the week - Pulmonary venous stenosis after treatment for atrial fibrillation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VEIN STENOSIS; RADIOFREQUENCY ABLATION		[Kojodjojo, P.; Wong, T.; Wright, A. R.; Kon, O. M.; Oldfield, W.; Kanagaratnam, P.; Davies, D. W.; Peters, N. S.] St Marys Hosp, Imperial Coll Healthcare NHS Trust, London W2 1NY, England	Imperial College London	Peters, NS (corresponding author), St Marys Hosp, Imperial Coll Healthcare NHS Trust, Praed St, London W2 1NY, England.	n.peters@imperial.ac.uk	Kojodjojo, Pipin/AAA-9739-2020	Kon, Onn Min/0000-0003-2647-4688; Kojodjojo, Pipin/0000-0002-6295-4905; Wong, Tom/0000-0002-6484-4961				Hocini M, 2004, J CARDIOVASC ELECTR, V15, P1467, DOI 10.1046/j.1540-8167.2004.04524.x; MAHAPATRA S, 2004, HEART RHYTHM S, V1, pS88; *NAT I HLTH CLIN E, 2006, PERC RAD CATH ABL AT; Nieuwlaat R, 2005, EUR HEART J, V26, P2422, DOI 10.1093/eurheartj/ehi505; Purerfellner H, 2003, J CARDIOVASC ELECTR, V14, P158; Qureshi AM, 2003, CIRCULATION, V108, P1336, DOI 10.1161/01.CIR.0000086322.21781.6A; Saad EB, 2003, ANN INTERN MED, V138, P634, DOI 10.7326/0003-4819-138-8-200304150-00010; Saad EB, 2003, CIRCULATION, V108, P3102, DOI 10.1161/01.CIR.0000104569.96907.7F; Sauer WH, 2006, HEART RHYTHM, V3, P1024, DOI 10.1016/j.hrthm.2006.05.007; Taylor GW, 2000, CIRCULATION, V101, P1736	10	5	5	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR	2008	336	7648					830	832		10.1136/bmj.39457.764942.47	http://dx.doi.org/10.1136/bmj.39457.764942.47			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	292ER	18403548	Green Published			2022-12-28	WOS:000255249800048
J	Dil, H; Lobo-Checa, J; Laskowski, R; Blaha, P; Berner, S; Osterwalder, J; Greber, T				Dil, Hugo; Lobo-Checa, Jorge; Laskowski, Robert; Blaha, Peter; Berner, Simon; Osterwalder, Juerg; Greber, Thomas			Surface trapping of atoms and molecules with dipole rings	SCIENCE			English	Article							BORON-NITRIDE NANOMESH; ADSORBED XENON; WORK-FUNCTION; PHOTOEMISSION; ADSORPTION; ANISOTROPY; MONOLAYER	The trapping of single molecules on surfaces without the formation of strong covalent bonds is a prerequisite for molecular recognition and the exploitation of molecular function. On nanopatterned surfaces, molecules may be selectively trapped and addressed. In a boron nitride nanomesh formed on Rh( 111), the pattern consisted of holes 2 nanometers in diameter on a hexagonal superlattice, separated by about 3 nanometers. The trapping was further investigated with density functional theory and the photoemission of adsorbed xenon, where the holes were identified as regions of low work function. The analysis showed that the trapping potential was localized at the rims of the holes.	[Dil, Hugo; Lobo-Checa, Jorge; Berner, Simon; Osterwalder, Juerg; Greber, Thomas] Univ Zurich, Inst Phys, CH-8057 Zurich, Switzerland; [Dil, Hugo; Lobo-Checa, Jorge] Paul Scherrer Inst, Swiss Light Source, CH-5232 Villigen, Switzerland; [Laskowski, Robert; Blaha, Peter] Vienna Univ Technol, Inst Mat Chem, A-1060 Vienna, Austria	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Technische Universitat Wien	Greber, T (corresponding author), Univ Zurich, Inst Phys, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	greber@physik.uzh.ch	Greber, Thomas/D-9509-2015; Lobo-Checa, Jorge/D-3570-2009; Dil, Hugo/F-6995-2012; Blaha, Peter/F-2847-2010	Greber, Thomas/0000-0002-5234-1937; Lobo-Checa, Jorge/0000-0003-2698-2543; Dil, Hugo/0000-0002-6016-6120; Blaha, Peter/0000-0001-5849-5788				Ahlund J, 2007, SURF SCI, V601, P3661, DOI 10.1016/j.susc.2007.06.008; Berner S, 2007, ANGEW CHEM INT EDIT, V46, P5115, DOI 10.1002/anie.200700234; Brune H, 1998, NATURE, V394, P451, DOI 10.1038/28804; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Goriachko A, 2007, LANGMUIR, V23, P2928, DOI 10.1021/la062990t; HELLER EJ, 1994, NATURE, V369, P464, DOI 10.1038/369464a0; HERMANN K, 1990, SURF SCI, V251, P289; KAINDL G, 1980, PHYS REV LETT, V45, P1808, DOI 10.1103/PhysRevLett.45.1808; Kerner G, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.205414; KUPPERS J, 1979, PHYS REV LETT, V43, P928, DOI 10.1103/PhysRevLett.43.928; LANG ND, 1982, PHYS REV B, V25, P2940, DOI 10.1103/PhysRevB.25.2940; Laskowski R, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/6/064207; Laskowski R, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.106802; LU KX, 1996, J AM CHEM SOC, V118, P7197; Morgenstern M, 1996, PHYS REV LETT, V77, P703, DOI 10.1103/PhysRevLett.77.703; NAGASHIMA A, 1995, PHYS REV LETT, V75, P3918, DOI 10.1103/PhysRevLett.75.3918; Nony L, 2004, NANO LETT, V4, P2185, DOI 10.1021/nl048693v; Ramprasad R, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2209197; Smoluchowski R, 1941, PHYS REV, V60, P661, DOI 10.1103/PhysRev.60.661; WANDELT K, 1984, J VAC SCI TECHNOL A, V2, P802, DOI 10.1116/1.572509; Widdra W, 1998, PHYS REV B, V57, P4111, DOI 10.1103/PhysRevB.57.4111	21	141	142	1	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1824	1826		10.1126/science.1154179	http://dx.doi.org/10.1126/science.1154179			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369146	Green Accepted			2022-12-28	WOS:000254394000046
J	Murphy, RA; Mondragon, E; Murphy, VA				Murphy, Robin A.; Mondragon, Esther; Murphy, Victoria A.			Rule learning by rats	SCIENCE			English	Article							STIMULI; ANIMALS; INFANTS	Using rules extracted from experience to solve problems in novel situations involves cognitions such as analogical reasoning and language learning and is considered a keystone of humans' unique abilities. Nonprimates, it has been argued, lack such rule transfer. We report that Rattus norvegicus can learn simple rules and apply them to new situations. Rats learned that sequences of stimuli consistent with a rule ( such as XYX) were different from other sequences ( such as XXY or YXX). When novel stimuli were used to construct sequences that did or did not obey the previously learned rule, rats transferred their learning. Therefore, rats, like humans, can transfer structural knowledge from sequential experiences.	[Murphy, Robin A.; Mondragon, Esther] UCL, Dept Psychol, London WC1E 6BT, England; [Murphy, Victoria A.] Univ Oxford, Dept Educ, Oxford OX2 6PY, England	University of London; University College London; University of Oxford	Murphy, RA (corresponding author), UCL, Dept Psychol, Gower St, London WC1E 6BT, England.	robin.murphy@ucl.ac.uk; e.mondragon@ucl.ac.uk	Mondragon, Esther/C-2696-2008	Mondragon, Esther/0000-0003-4180-1261	Biotechnology and Biological Sciences Research Council [S20033] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Conway CM, 2001, TRENDS COGN SCI, V5, P539, DOI 10.1016/S1364-6613(00)01800-3; Elman JL, 1996, RETHINKING INNATENES; Gentner TQ, 2006, NATURE, V440, P1204, DOI 10.1038/nature04675; GUTTMAN N, 1956, J EXP PSYCHOL, V51, P79, DOI 10.1037/h0046219; Hauser MD, 2002, COGNITION, V86, pB15, DOI 10.1016/S0010-0277(02)00139-7; Herbranson WT, 2003, LEARN BEHAV, V31, P98; Honey RC, 1998, J EXP PSYCHOL ANIM B, V24, P325, DOI 10.1037/0097-7403.24.3.325; Mackintosh N. J., 1974, PSYCHOL ANIMAL LEARN; Marcus GF, 1999, SCIENCE, V283, P77, DOI 10.1126/science.283.5398.77; Murphy RA, 2004, BEHAV PROCESS, V67, P303, DOI 10.1016/j.beproc.2004.05.003; Pavlov I.P., 1927, CONDITIONED REFLEXES; Penn DC, 2007, ANNU REV PSYCHOL, V58, P97, DOI 10.1146/annurev.psych.58.110405.085555; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; Spence KW, 1937, PSYCHOL REV, V44, P430, DOI 10.1037/h0062885	15	121	125	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1849	1851		10.1126/science.1151564	http://dx.doi.org/10.1126/science.1151564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369151	Green Accepted			2022-12-28	WOS:000254394000053
J	Scott, C; Lyons, TW; Bekker, A; Shen, Y; Poulton, SW; Chu, X; Anbar, AD				Scott, C.; Lyons, T. W.; Bekker, A.; Shen, Y.; Poulton, S. W.; Chu, X.; Anbar, A. D.			Tracing the stepwise oxygenation of the Proterozoic ocean	NATURE			English	Article							SULFUR; RISE; IRON; MOLYBDENUM; EVOLUTION; ANOXIA; CONSTRAINTS; TRANSITION; CHEMISTRY; OXIDATION	Biogeochemical signatures preserved in ancient sedimentary rocks provide clues to the nature and timing of the oxygenation of the Earth's atmosphere. Geochemical data(1-6) suggest that oxygenation proceeded in two broad steps near the beginning and end of the Proterozoic eon ( 2,500 to 542 million years ago). The oxidation state of the Proterozoic ocean between these two steps and the timing of deep- ocean oxygenation have important implications for the evolutionary course of life on Earth but remain poorly known. Here we present a new perspective on ocean oxygenation based on the authigenic accumulation of the redox- sensitive transition element molybdenum in sulphidic black shales. Accumulation of authigenic molybdenum from sea water is already seen in shales by 2,650 Myr ago; however, the small magnitudes of these enrichments reflect weak or transient(7) sources of dissolved molybdenum before about 2,200 Myr ago, consistent with minimal oxidative weathering of the continents. Enrichments indicative of persistent and vigorous oxidative weathering appear in shales deposited at roughly 2,150 Myr ago, more than 200 million years after the initial rise in atmospheric oxygen(1,2). Subsequent expansion of sulphidic conditions after about 1,800 Myr ago ( refs 8, 9) maintained a mid- Proterozoic molybdenum reservoir below 20 per cent of the modern inventory, which in turn may have acted as a nutrient feedback limiting the spatiotemporal distribution of euxinic ( sulphidic) bottom waters and perhaps the evolutionary and ecological expansion of eukaryotic organisms(10). By 551 Myr ago, molybdenum contents reflect a greatly expanded oceanic reservoir due to oxygenation of the deep ocean and corresponding decrease in sulphidic conditions in the sediments and water column.	[Scott, C.; Lyons, T. W.] Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA; [Bekker, A.] Carnegie Inst Sci, Geophys Lab, Washington, DC 20015 USA; [Shen, Y.] Univ Quebec, Dept Sci Terre & Atmosphere, Montreal, PQ H3C 3P8, Canada; [Poulton, S. W.] Univ Newcastle, Sch Civil Engn & Geosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Chu, X.] Chinese Acad Sci, Key Lab Mineral Resources, Inst Geol & Geophys, Beijing 100029, Peoples R China; [Anbar, A. D.] Arizona State Univ, Sch Earth & Space Explorat, Tempe, AZ 85287 USA; [Anbar, A. D.] Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA	University of California System; University of California Riverside; Carnegie Institution for Science; University of Quebec; University of Quebec Montreal; Newcastle University - UK; Chinese Academy of Sciences; Institute of Geology & Geophysics, CAS; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Scott, C (corresponding author), Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA.	cscot002@ucr.edu	Chu, Xuelei/AAE-6623-2022; Shen, Yanan/L-3724-2018	Chu, Xuelei/0000-0002-2155-7081; Bekker, Andrey/0000-0002-1154-0585; Shen, Yanan/0000-0001-8343-6763; Poulton, Simon/0000-0001-7621-189X	Natural Environment Research Council [NE/C518465/2] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Algeo TJ, 2006, PALEOCEANOGRAPHY, V21, DOI 10.1029/2004PA001112; Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Anbar AD, 2007, SCIENCE, V317, P1903, DOI 10.1126/science.1140325; Arnold GL, 2004, SCIENCE, V304, P87, DOI 10.1126/science.1091785; Bekker A, 2004, NATURE, V427, P117, DOI 10.1038/nature02260; BERTINE KK, 1973, GEOCHIM COSMOCHIM AC, V37, P1415, DOI 10.1016/0016-7037(73)90080-X; Brocks JJ, 2005, NATURE, V437, P866, DOI 10.1038/nature04068; Brocks JJ, 1999, SCIENCE, V285, P1033, DOI 10.1126/science.285.5430.1033; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; CANFIELD DE, 1986, CHEM GEOL, V54, P149, DOI 10.1016/0009-2541(86)90078-1; Canfield DE, 2007, SCIENCE, V315, P92, DOI 10.1126/science.1135013; EMERSON SR, 1991, MAR CHEM, V34, P177, DOI 10.1016/0304-4203(91)90002-E; Farquhar J, 2003, EARTH PLANET SC LETT, V213, P1, DOI 10.1016/S0012-821X(03)00296-6; Fike DA, 2006, NATURE, V444, P744, DOI 10.1038/nature05345; Hannah JL, 2004, EARTH PLANET SC LETT, V225, P43, DOI 10.1016/j.epsl.2004.06.013; Helz GR, 1996, GEOCHIM COSMOCHIM AC, V60, P3631, DOI 10.1016/0016-7037(96)00195-0; Holland HD., 1984, CHEM EVOLUTION ATMOS; Kah LC, 2004, NATURE, V431, P834, DOI 10.1038/nature02974; Karhu JA, 1996, GEOLOGY, V24, P867, DOI 10.1130/0091-7613(1996)024<0867:CIATRO>2.3.CO;2; Kaufman AJ, 2007, SCIENCE, V317, P1900, DOI 10.1126/science.1138700; Lyons TW, 2006, GEOCHIM COSMOCHIM AC, V70, P5698, DOI 10.1016/j.gca.2006.08.021; Lyons TW, 2003, CHEM GEOL, V195, P131, DOI 10.1016/S0009-2541(02)00392-3; LYONS TW, 1992, CHEM GEOL, V99, P1, DOI 10.1016/0009-2541(92)90028-4; Lyons TW, 2000, GEOCHIM COSMOCHIM AC, V64, P427, DOI 10.1016/S0016-7037(99)00323-3; Poulton SW, 2004, NATURE, V431, P173, DOI 10.1038/nature02912; RAISWELL R, 1988, J SEDIMENT PETROL, V58, P812; Rouxel OJ, 2005, SCIENCE, V307, P1088, DOI 10.1126/science.1105692; Shen Y, 2003, NATURE, V423, P632, DOI 10.1038/nature01651; Shen YN, 2002, AM J SCI, V302, P81, DOI 10.2475/ajs.302.2.81; Slack JF, 2007, EARTH PLANET SC LETT, V255, P243, DOI 10.1016/j.epsl.2006.12.018; TAYLOR SR, 1995, REV GEOPHYS, V33, P241, DOI 10.1029/95RG00262; ZERKLE AL, 2006, GEOBIOLOGY, V4, P285	32	717	767	16	263	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 27	2008	452	7186					456	U5		10.1038/nature06811	http://dx.doi.org/10.1038/nature06811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279FU	18368114				2022-12-28	WOS:000254341300028
J	Kopetz, S; Vauthey, JN				Kopetz, Scott; Vauthey, Jean-Nicolas			Perioperative chemotherapy for resectable hepatic metastases	LANCET			English	Editorial Material							COLORECTAL LIVER METASTASES; PREOPERATIVE CHEMOTHERAPY; MAJOR HEPATECTOMY; RESECTION; RECURRENCE; SURVIVAL; OUTCOMES; SURGERY; CANCER		[Vauthey, Jean-Nicolas] Univ Texas Houston, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Kopetz, Scott] Univ Texas Houston, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Vauthey, JN (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jvauthey@mdanderson.org	Kopetz, Scott/AAC-1387-2019	Kopetz, Scott/0000-0001-9647-3416				Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71; Adam R, 2004, ANN SURG, V240, P1052, DOI 10.1097/01.sla.0000145964.08365.01; Aloia T, 2006, J CLIN ONCOL, V24, P4983, DOI 10.1200/JCO.2006.05.8156; Chun YS, 2007, J GASTROINTEST SURG, V11, P1498, DOI 10.1007/s11605-007-0272-2; Karoui M, 2006, ANN SURG, V243, P1, DOI 10.1097/01.sla.0000193603.26265.c3; Nordlinger B, 2008, LANCET, V371, P1007, DOI 10.1016/S0140-6736(08)60455-9; Pawlik TM, 2005, ANN SURG, V241, P715, DOI 10.1097/01.sla.0000160703.75808.7d; Ribero D, 2007, BRIT J SURG, V94, P1386, DOI 10.1002/bjs.5836; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Vauthey JN, 2006, J CLIN ONCOL, V24, P2065, DOI 10.1200/JCO.2005.05.3074; Welsh FKS, 2007, BRIT J CANCER, V96, P1037, DOI 10.1038/sj.bjc.6603670; Zorzi D, 2007, BRIT J SURG, V94, P274, DOI 10.1002/bjs.5719	12	57	60	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 22	2008	371	9617					963	965		10.1016/S0140-6736(08)60429-8	http://dx.doi.org/10.1016/S0140-6736(08)60429-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358910				2022-12-28	WOS:000254206000005
J	Stein, MB; Stein, DJ				Stein, Murray B.; Stein, Dan J.			Social anxiety disorder	LANCET			English	Review							QUALITY-OF-LIFE; NATIONAL EPIDEMIOLOGIC SURVEY; VENLAFAXINE EXTENDED-RELEASE; CEREBRAL-BLOOD-FLOW; DOUBLE-BLIND; PRIMARY-CARE; PSYCHIATRIC-DISORDERS; PERSONALITY-DISORDERS; PHARMACOLOGICAL TREATMENTS; PSYCHOMETRIC PROPERTIES	Our understanding of social anxiety disorder (also known as social phobia) has moved from rudimentary awareness that it is not merely shyness to a much more sophisticated appreciation of its prevalence, its chronic and pernicious nature, and its neurobiological underpinnings. Social anxiety disorder is the most common anxiety disorder; it has an early age of onset-by age 11 years in about 50% and by age 20 years in about 80% of individuals-and it is a risk factor for subsequent depressive illness and substance abuse. Functional neuroimaging studies point to increased activity in amygdala and insula in patients with social anxiety disorder, and genetic studies are increasingly focusing on this and other (eg, personality trait neuroticism) core phenotypes to identify risk loci. A range of effective cognitive behavioural and pharmacological treatments for children and adults now exists; the challenges lie in optimum integration and dissemination of these treatments, and learning how to help the 30-40% of patients for whom treatment does not work.	[Stein, Murray B.] Univ Calif San Diego, Anxiety & Traumat Stress Disorders Res Program, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; [Stein, Murray B.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Stein, Dan J.] Univ Cape Town, Dept Psychiat, ZA-7925 Cape Town, South Africa	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Cape Town	Stein, MB (corresponding author), Univ Calif San Diego, Anxiety & Traumat Stress Disorders Res Program, Dept Psychiat, La Jolla, CA 92093 USA.	mstein@ucsd.edu	Stein, Dan/A-1752-2008	Stein, Dan/0000-0001-7218-7810	NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH064122] Funding Source: NIH RePORTER; NIMH NIH HHS [MH64122] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P38; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Amir N, 2005, BIOL PSYCHIAT, V57, P975, DOI 10.1016/j.biopsych.2005.01.044; Arbelle S, 2003, AM J PSYCHIAT, V160, P671, DOI 10.1176/appi.ajp.160.4.671; Argyropoulos SV, 2004, BIOL PSYCHIAT, V56, P503, DOI 10.1016/j.biopsych.2004.07.006; Bailey KA, 2006, J PEDIATR PSYCHOL, V31, P512, DOI 10.1093/jpepsy/jsj044; Baron-Cohen S, 2005, ANNU REV NEUROSCI, V28, P109, DOI 10.1146/annurev.neuro.27.070203.144137; Bartz JA, 2006, HORM BEHAV, V50, P518, DOI 10.1016/j.yhbeh.2006.06.018; Battaglia M, 2005, ARCH GEN PSYCHIAT, V62, P85, DOI 10.1001/archpsyc.62.1.85; Beesdo K, 2007, ARCH GEN PSYCHIAT, V64, P903, DOI 10.1001/archpsyc.64.8.903; Bienvenu OJ, 2007, AM J PSYCHIAT, V164, P1714, DOI 10.1176/appi.ajp.2007.06101667; Blomhoff S, 2001, BRIT J PSYCHIAT, V179, P23, DOI 10.1192/bjp.179.1.23; Bridge JA, 2007, JAMA-J AM MED ASSOC, V297, P1683, DOI 10.1001/jama.297.15.1683; Cairney J, 2007, AM J GERIAT PSYCHIAT, V15, P224, DOI 10.1097/01.JGP.0000235702.77245.46; Canadian Psychiatric Association, 2006, CAN J PSYCHIAT, V51, p9S; Chavira DA, 2005, CHILD ADOL PSYCH CL, V14, P797, DOI 10.1016/j.chc.2005.05.003; Chavira DA, 2004, DEPRESS ANXIETY, V20, P155, DOI 10.1002/da.20039; Chavira DA, 2007, J AM ACAD CHILD PSY, V46, P1464, DOI 10.1097/chi.0b013e318149366a; Clark DM, 2006, J CONSULT CLIN PSYCH, V74, P568, DOI 10.1037/0022-006X.74.3.568; Cohan SL, 2006, J DEV BEHAV PEDIATR, V27, P341, DOI 10.1097/00004703-200608000-00011; Coles ME, 2006, DEPRESS ANXIETY, V23, P26, DOI 10.1002/da.20132; Connor KM, 2000, BRIT J PSYCHIAT, V176, P379, DOI 10.1192/bjp.176.4.379; Connor KM, 2001, DEPRESS ANXIETY, V14, P137, DOI 10.1002/da.1055; Cooper PJ, 1999, BRIT J PSYCHIAT, V174, P439, DOI 10.1192/bjp.174.5.439; Cox BJ, 2005, BEHAV RES THER, V43, P1019, DOI 10.1016/j.brat.2004.07.006; Cox BJ, 2004, J AFFECT DISORDERS, V82, P227, DOI 10.1016/j.jad.2003.12.012; DAVIDSON JRT, 1993, J CLIN PSYCHOPHARM, V13, P423; Davidson JRT, 2004, ARCH GEN PSYCHIAT, V61, P1005, DOI 10.1001/archpsyc.61.10.1005; Donovan CL, 2000, CLIN PSYCHOL REV, V20, P509, DOI 10.1016/S0272-7358(99)00040-9; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Fedoroff IC, 2001, J CLIN PSYCHOPHARM, V21, P311, DOI 10.1097/00004714-200106000-00011; Furmark T, 2005, BIOL PSYCHIAT, V58, P132, DOI 10.1016/j.biopsych.2005.03.029; Furmark T, 2002, ARCH GEN PSYCHIAT, V59, P425, DOI 10.1001/archpsyc.59.5.425; Gaston JE, 2006, BRIT J CLIN PSYCHOL, V45, P33, DOI 10.1348/014466505X35146; GELERNTER CS, 1991, ARCH GEN PSYCHIAT, V48, P938; Gelernter J, 2004, AM J PSYCHIAT, V161, P59, DOI 10.1176/appi.ajp.161.1.59; Grant BF, 2005, J CLIN PSYCHIAT, V66, P1351, DOI 10.4088/JCP.v66n1102; Grant BF, 2005, J PSYCHIATR RES, V39, P1, DOI 10.1016/j.jpsychires.2004.05.004; Hariri AR, 2006, BIOL PSYCHIAT, V59, P888, DOI 10.1016/j.biopsych.2005.11.005; Heimberg RG, 1999, PSYCHOL MED, V29, P199, DOI 10.1017/S0033291798007879; Heimberg RG, 1998, ARCH GEN PSYCHIAT, V55, P1133, DOI 10.1001/archpsyc.55.12.1133; Hettema JM, 2006, AM J PSYCHIAT, V163, P857, DOI 10.1176/appi.ajp.163.5.857; HIRSHFELDBECKER DR, 2007, J DEV BEHAV PEDIATR, V164, P1714; Hofmann SG, 2006, ARCH GEN PSYCHIAT, V63, P298, DOI 10.1001/archpsyc.63.3.298; Huppert Jonathan D, 2003, Curr Psychiatry Rep, V5, P289, DOI 10.1007/s11920-003-0058-5; Iancu L, 2006, COMPR PSYCHIAT, V47, P399, DOI 10.1016/j.comppsych.2006.01.008; Issakidis C, 2004, PSYCHOL MED, V34, P19, DOI 10.1017/S003329170300881X; Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338; Kasper S, 2005, BRIT J PSYCHIAT, V186, P222, DOI 10.1192/bjp.186.3.222; KATZELNICK DJ, 1995, AM J PSYCHIAT, V152, P1368; Katzelnick DJ, 2001, AM J PSYCHIAT, V158, P1999, DOI 10.1176/appi.ajp.158.12.1999; Kaye WH, 2004, AM J PSYCHIAT, V161, P2215, DOI 10.1176/appi.ajp.161.12.2215; Kessler RC, 1998, AM J PSYCHIAT, V155, P613, DOI 10.1176/ajp.155.5.613; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005; Kobak KA, 2002, J CLIN PSYCHOPHARM, V22, P257, DOI 10.1097/00004714-200206000-00005; Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701; Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004; Lader M, 2004, DEPRESS ANXIETY, V19, P241, DOI 10.1002/da.20014; Lanzenberger RR, 2007, BIOL PSYCHIAT, V61, P1081, DOI 10.1016/j.biopsych.2006.05.022; Liebowitz MR, 2005, ARCH GEN PSYCHIAT, V62, P190, DOI 10.1001/archpsyc.62.2.190; Liebowitz MR, 2005, J CLIN PSYCHIAT, V66, P238, DOI 10.4088/JCP.v66n0213; Liebowitz MR, 2003, J CLIN PSYCHIAT, V64, P785, DOI 10.4088/JCP.v64n0708; LIEBOWITZ MR, 1992, ARCH GEN PSYCHIAT, V49, P290; Liebowitz MR, 2002, J CLIN PSYCHIAT, V63, P66, DOI 10.4088/JCP.v63n0113; MARKS IM, 1966, AM J PSYCHIAT, V123, P218, DOI 10.1176/ajp.123.2.218; Massion AO, 2002, ARCH GEN PSYCHIAT, V59, P434, DOI 10.1001/archpsyc.59.5.434; Matsunaga H, 2001, INT J NEUROPSYCHOPH, V4, P231, DOI 10.1017/S1461145701002474; Means-Christensen AJ, 2006, GEN HOSP PSYCHIAT, V28, P108, DOI 10.1016/j.genhosppsych.2005.08.010; Mennin DS, 2002, J ANXIETY DISORD, V16, P661, DOI 10.1016/S0887-6185(02)00134-2; Meyer-Lindenberg A, 2005, NAT NEUROSCI, V8, P991, DOI 10.1038/nn1494; Mohammadi MR, 2006, DEPRESS ANXIETY, V23, P405, DOI 10.1002/da.20129; Montgomery SA, 2005, J CLIN PSYCHIAT, V66, P1270, DOI 10.4088/JCP.v66n1009; Mortberg E, 2007, ACTA PSYCHIAT SCAND, V115, P142, DOI 10.1111/j.1600-0447.2006.00839.x; Muehlbacher M, 2005, J CLIN PSYCHOPHARM, V25, P580, DOI 10.1097/01.jcp.0000186871.04984.8d; Pallanti S, 2004, AM J PSYCHIAT, V161, P53, DOI 10.1176/appi.ajp.161.1.53; Pande AC, 2004, J CLIN PSYCHOPHARM, V24, P141, DOI 10.1097/01.jcp.0000117423.05703.e7; Pande AC, 1999, J CLIN PSYCHOPHARM, V19, P341, DOI 10.1097/00004714-199908000-00010; Papassotiropoulos A, 2006, SCIENCE, V314, P475, DOI 10.1126/science.1129837; Paulus MP, 2006, BIOL PSYCHIAT, V60, P383, DOI 10.1016/j.biopsych.2006.03.042; Phan KL, 2005, NEUROREPORT, V16, P183, DOI 10.1097/00001756-200502080-00024; Phan KL, 2006, BIOL PSYCHIAT, V59, P424, DOI 10.1016/j.biopsych.2005.08.012; Pollack MH, 2006, BIOL PSYCHIAT, V59, P211, DOI 10.1016/j.biopsych.2005.07.005; Rapee RM, 2004, CLIN PSYCHOL REV, V24, P737, DOI 10.1016/j.cpr.2004.06.004; Rickels K, 2004, J CLIN PSYCHOPHARM, V24, P488, DOI 10.1097/01.jcp.0000138764.31106.60; Rodebaugh TL, 2006, PSYCHOL ASSESSMENT, V18, P231, DOI 10.1037/1040-3590.18.2.231; Roy-Byrne PP, 2006, LANCET, V368, P1023, DOI 10.1016/S0140-6736(06)69418-X; Roy-Byrne PP, 2005, GEN HOSP PSYCHIAT, V27, P155, DOI 10.1016/j.genhosppsych.2005.03.001; Ruscio AM, 2008, PSYCHOL MED, V38, P15, DOI 10.1017/S0033291707001699; Rush AJ, 2005, J AFFECT DISORDERS, V87, P43, DOI 10.1016/j.jad.2005.03.005; Saarni SI, 2007, BRIT J PSYCHIAT, V190, P326, DOI 10.1192/bjp.bp.106.025106; Sareen J, 2007, BIOL PSYCHIAT, V61, P396, DOI 10.1016/j.biopsych.2006.05.043; Sareen J, 2006, PSYCHIAT RES, V142, P11, DOI 10.1016/j.psychres.2006.01.009; Sareen J, 2006, ARCH INTERN MED, V166, P2109, DOI 10.1001/archinte.166.19.2109; Schneier FR, 2000, AM J PSYCHIAT, V157, P457, DOI 10.1176/appi.ajp.157.3.457; Schneier FR, 2001, J CLIN PSYCHIAT, V62, P367, DOI 10.4088/JCP.v62n0511; Schneier FR, 2006, NEW ENGL J MED, V355, P1029, DOI 10.1056/NEJMcp060145; Schwartz CE, 2003, SCIENCE, V300, P1952, DOI 10.1126/science.1083703; Seedat S, 2004, J CLIN PSYCHIAT, V65, P244; Shea MT, 2004, J ABNORM PSYCHOL, V113, P499, DOI 10.1037/0021-843X.113.4.499; Simon NM, 2004, AM J PSYCHIAT, V161, P2222, DOI 10.1176/appi.ajp.161.12.2222; Smoller JW, 2008, ARCH GEN PSYCHIAT, V65, P298, DOI 10.1001/archgenpsychiatry.2007.48; Smoller JW, 2005, BIOL PSYCHIAT, V57, P1485, DOI 10.1016/j.biopsych.2005.02.018; Stein DJ, 2002, ARCH GEN PSYCHIAT, V59, P1111, DOI 10.1001/archpsyc.59.12.1111; Stein DJ, 2002, J CLIN PSYCHIAT, V63, P152, DOI 10.4088/JCP.v63n0211; STEIN DJ, 1991, COMPR PSYCHIAT, V32, P404, DOI 10.1016/0010-440X(91)90017-7; STEIN DJ, 2004, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001206.PUB2; Stein M. B., 2004, SOCIAL ANXIETY DISOR, P197; Stein MB, 2005, PSYCHOPHARMACOLOGY, V177, P280, DOI 10.1007/s00213-004-1957-9; Stein MB, 2000, AM J PSYCHIAT, V157, P1606, DOI 10.1176/appi.ajp.157.10.1606; Stein MB, 2005, MED CARE, V43, P1164, DOI 10.1097/01.mlr.0000185750.18119.fd; Stein MB, 2005, NEUROPSYCHOPHARMACOL, V30, P2092, DOI 10.1038/sj.npp.1300787; Stein MB, 1996, LANCET, V347, P1131, DOI 10.1016/S0140-6736(96)90604-2; Stein MB, 2004, BIOL PSYCHIAT, V56, P217, DOI 10.1016/j.biopsych.2004.05.020; Stein MB, 1996, ARCH GEN PSYCHIAT, V53, P169; STEIN MB, 1990, AM J PSYCHIAT, V147, P217; Stein MB, 1999, AM J PSYCHIAT, V156, P756; Stein MB, 2002, ARCH GEN PSYCHIAT, V59, P1027, DOI 10.1001/archpsyc.59.11.1027; Stein MB, 2002, J NERV MENT DIS, V190, P219, DOI 10.1097/00005053-200204000-00002; Stein MB, 1998, JAMA-J AM MED ASSOC, V280, P708, DOI 10.1001/jama.280.8.708; Stein MB, 2001, AM J PSYCHIAT, V158, P1725, DOI 10.1176/appi.ajp.158.10.1725; Stein MB, 2001, AM J MED GENET, V105, P79, DOI 10.1002/1096-8628(20010108)105:1<79::AID-AJMG1067>3.3.CO;2-6; Stein MB, 1996, AM J PSYCHIAT, V153, P278; Stein MB, 2007, AM J PSYCHIAT, V164, P318, DOI 10.1176/appi.ajp.164.2.318; Stein MB, 2006, PSYCHOPHARMACOLOGY, V187, P68, DOI 10.1007/s00213-006-0349-8; STEINBACH R, 1998, PC WEEK, V15, P90; Tiihonen J, 1997, AM J PSYCHIAT, V154, P239; Van Ameringen MA, 2001, AM J PSYCHIAT, V158, P275, DOI 10.1176/appi.ajp.158.2.275; van der Linden GH, 2000, INT CLIN PSYCHOPHARM, V15, pS15, DOI 10.1097/00004850-200008002-00004; VANVLIET IM, 1994, PSYCHOPHARMACOLOGY, V115, P128, DOI 10.1007/BF02244762; Vythilingum B, 2002, DEPRESS ANXIETY, V16, P84, DOI 10.1002/da.10061; Wagner KD, 2004, ARCH GEN PSYCHIAT, V61, P1153, DOI 10.1001/archpsyc.61.11.1153; Wakefield JC, 2005, CAN J PSYCHIAT, V50, P317, DOI 10.1177/070674370505000604; Walker JR, 2000, J CLIN PSYCHOPHARM, V20, P636, DOI 10.1097/00004714-200012000-00009; Walkup JT, 2001, NEW ENGL J MED, V344, P1279, DOI 10.1056/NEJM200104263441703; Wang PS, 2005, ARCH GEN PSYCHIAT, V62, P629, DOI 10.1001/archpsyc.62.6.629; Westenberg HGM, 2004, J CLIN PSYCHOPHARM, V24, P49, DOI 10.1097/01.jcp.0000104906.75206.8b; World Health Organization, 2019, INT STAT CLASS DIS R, V11th Edn	138	506	517	14	244	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1115	1125		10.1016/S0140-6736(08)60488-2	http://dx.doi.org/10.1016/S0140-6736(08)60488-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	280RA	18374843	Green Submitted			2022-12-28	WOS:000254442700031
J	Kunadian, B; Dunning, J; Roberts, AP; Morley, R; Twomey, D; Hall, JA; Sutton, AGC; Wright, RA; Muir, DF; de Belder, MA				Kunadian, Babu; Dunning, Joel; Roberts, Anthony P.; Morley, Robert; Twomey, Darragh; Hall, James A.; Sutton, Andrew G. C.; Wright, Robert A.; Muir, Douglas F.; de Belder, Mark A.			Cumulative funnel plots for the early detection of interoperator variation: retrospective database analysis of observed versus predicted results of percutaneous coronary intervention	BRITISH MEDICAL JOURNAL			English	Article							ADULT CARDIAC-SURGERY; MULTIVARIATE PREDICTION; OUTCOME DATA; MORTALITY; ENGLAND; PERFORMANCE; VALIDATION	Objective To use funnel plots and cumulative funnel plots to compare in-hospital outcome data for operators undertaking percutaneous coronary interventions with predicted results derived from a validated risk score to allow for early detection of variation in performance. Design Analysis of prospectively collected data. Setting Tertiary centre NHS hospital in the north east of England. Participants Five cardiologists carrying out percutaneous coronary interventions between January 2003 and December 2006. Main outcome measures In-hospitat major adverse cardiovascular and cerebrovascular events (in-hospital death, Q wave myocardial infarction, emergency coronary artery bypass graft surgery, and cerebrovascular accident) analysed against the logistic north west quality improvement programme predicted risk, for each operator. Results are displayed as funnel plots summarising overall performance for each operator and cumulative funnel plots for an individual operator's performance on a case series basis. Results The funnel plots for 5198 patients undergoing percutaneous coronary interventions showed an average observed rate for major adverse cardiovascular and cerebrovascular events of 1.96% overall. This was below the predicted risk of 2.06% by the logistic north west quality improvement programme risk score. Rates of in-hospital major adverse cardiovascular and cerebrovascular events for all operators were within the 3 sigma upper control limit of 2.75% and 2 sigma upper warning limit of 2.49%. Conclusion The overall in-hospital major adverse cardiovascular and cerebrovascular events rates were under the predicted event rate. In-hospital rates after percutaneous coronary intervention procedure can be monitored successfully using funnel and cumulative funnel plots with 3 sigma control limits to display and publish each operator's outcomes. The upper warning limit (2 sigma control limit) could be used for internal monitoring. The main advantage of these charts is their transparency, as they show observed and predicted events separately. By this approach individual operators can monitor their own performance, using the predicted risk for their patients but in a way that is compatible with benchmarking to colleagues, encapsulated by the funnel plot. This methodology is applicable regardless of variations in individual operator case volume and case mix.	[Kunadian, Babu; Dunning, Joel; Roberts, Anthony P.; Morley, Robert; Twomey, Darragh; Hall, James A.; Sutton, Andrew G. C.; Wright, Robert A.; Muir, Douglas F.; de Belder, Mark A.] James Cook Univ Hosp, Dept Cardiol, Middlesbrough TS4 3BW, Cleveland, England	James Cook University Hospital	de Belder, MA (corresponding author), James Cook Univ Hosp, Dept Cardiol, Middlesbrough TS4 3BW, Cleveland, England.	mark.debelder@stees.nhs.uk		Twomey, Darragh/0000-0002-3437-5615; Roberts, Tony/0000-0002-0776-6071; Hall, James/0000-0003-0239-0973				Block PC, 1998, J AM COLL CARDIOL, V32, P275, DOI 10.1016/S0735-1097(98)00208-3; Bolsin S, 2001, LANCET, V358, P2084; Bridgewater B, 2005, BMJ-BRIT MED J, V330, P506, DOI 10.1136/bmj.330.7490.506; Bridgewater B, 2003, BMJ-BRIT MED J, V327, P13, DOI 10.1136/bmj.327.7405.13; Bridgewater B, 2007, HEART, V93, P744, DOI 10.1136/hrt.2006.106393; CAREY RG, 2004, IMPROVING HEALTHCARE; *CENTR CARD AUD DA, COR HEART DIS AUD; Colson M, 2003, INT J QUAL HEALTH C, V15, P445, DOI 10.1093/intqhc/mzg070; DETRE K, 1995, CIRCULATION, V91, P2868, DOI 10.1161/01.CIR.91.12.2868; Gale Christopher P, 2006, BMC Cardiovasc Disord, V6, P34, DOI 10.1186/1471-2261-6-34; Grayson AD, 2006, HEART, V92, P658, DOI 10.1136/hrt.2005.066415; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; KIMMEL SE, 1995, J AM COLL CARDIOL, V26, P931, DOI 10.1016/0735-1097(95)00294-4; King SB, 2007, CIRCULATION, V116, P98, DOI 10.1161/CIRCULATIONAHA.107.185159; KUNADIAN B, 2007, HEART            NOV; McGrath PD, 1999, J AM COLL CARDIOL, V34, P674, DOI 10.1016/S0735-1097(99)00257-0; Moscucci M, 1999, J AM COLL CARDIOL, V34, P692, DOI 10.1016/S0735-1097(99)00266-1; Narins CR, 2005, ARCH INTERN MED, V165, P83, DOI 10.1001/archinte.165.1.83; *NY STAT DEP HLTH, PERC COR INT PCI NEW; *NY STAT DEP HLTH, 2002, PERC COR INT PCI NEW; O'Connor GT, 1999, J AM COLL CARDIOL, V34, P681, DOI 10.1016/S0735-1097(99)00267-3; Spiegelhalter D, 2003, INT J QUAL HEALTH C, V15, P7, DOI 10.1093/intqhc/15.1.7; Spiegelhalter D, 2002, QUAL SAF HEALTH CARE, V11, P390, DOI 10.1136/qhc.11.4.390-a; Spiegelhalter DJ, 2005, STAT MED, V24, P1185, DOI 10.1002/sim.1970; Williams DO, 2000, CIRCULATION, V102, P2945; Wolfe R, 2007, QUAL SAF HEALTH CARE, V16, P192, DOI 10.1136/qshc.2004.012435; 1984, LEARNING BRISTOL REP; 2004, SHIPMAN INQUIRY 5 RE; 2007, GUARDIAN        1020, P10	29	31	31	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					931	+		10.1136/bmj.39512.529120.BE	http://dx.doi.org/10.1136/bmj.39512.529120.BE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18367500	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000255540900030
J	Murray, SA; Sheikh, A				Murray, Scott A.; Sheikh, Aziz			Making a difference - Palliative care beyond cancer - Care for all at the end of life	BRITISH MEDICAL JOURNAL			English	Editorial Material							ILLNESS		[Murray, Scott A.; Sheikh, Aziz] Univ Edinburgh, Div Community Hlth Sci, Gen Practice Sect, Primary Palliat Care Res Grp, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh	Murray, SA (corresponding author), Univ Edinburgh, Div Community Hlth Sci, Gen Practice Sect, Primary Palliat Care Res Grp, Edinburgh EH8 9DX, Midlothian, Scotland.	Scott.Murray@ed.ac.uk	Sheikh, Aziz/D-2818-2009; Ram, Prem/K-4511-2012	Sheikh, Aziz/0000-0001-7022-3056; Harris, Fiona/0000-0003-3258-5624; Grant, Liz/0000-0001-7248-7792				[Anonymous], 2005, PREV CHRON DIS VIT I; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Glare PA, 2008, J PALLIAT MED, V11, P84, DOI 10.1089/jpm.2008.9992; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; MATHERS CD, 2006, UPDATED PROJECTIONS; Murray SA, 2005, BRIT MED J, V330, P611, DOI 10.1136/bmj.330.7492.611; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Reisfeld GM, 2007, J PALLIAT MED, V10, P247, DOI 10.1089/jpm.2007.10.247; World Health Organization, 2004, PALL CAR OLD PEOPL; World Health Organization, 2004, PALL CAR SOL FACTS	10	122	125	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					958	+		10.1136/bmj.39535.491238.94	http://dx.doi.org/10.1136/bmj.39535.491238.94			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397942	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000255540900045
J	Fischer, H; Behrens, M; Bock, M; Richter, U; Schmitt, J; Loulergue, L; Chappellaz, J; Spahni, R; Blunier, T; Leuenberger, M; Stocker, TF				Fischer, Hubertus; Behrens, Melanie; Bock, Michael; Richter, Ulrike; Schmitt, Jochen; Loulergue, Laetitia; Chappellaz, Jerome; Spahni, Renato; Blunier, Thomas; Leuenberger, Markus; Stocker, Thomas F.			Changing boreal methane sources and constant biomass burning during the last termination	NATURE			English	Article							ATMOSPHERIC CH4 GRADIENT; GREENLAND; CLIMATE; ANTARCTICA; OXIDATION; RECORD	Past atmospheric methane concentrations show strong fluctuations in parallel to rapid glacial climate changes in the Northern Hemisphere(1,2) superimposed on a glacial - interglacial doubling of methane concentrations(3-5). The processes driving the observed fluctuations remain uncertain but can be constrained using methane isotopic information from ice cores(6,7). Here we present an ice core record of carbon isotopic ratios in methane over the entire last glacial - interglacial transition. Our data show that the carbon in atmospheric methane was isotopically much heavier in cold climate periods. With the help of a box model constrained by the present data and previously published results(6,8), we are able to estimate the magnitude of past individual methane emission sources and the atmospheric lifetime of methane. We find that methane emissions due to biomass burning were about 45 Tg methane per year, and that these remained roughly constant throughout the glacial termination. The atmospheric lifetime of methane is reduced during cold climate periods. We also show that boreal wetlands are an important source of methane during warm events, but their methane emissions are essentially shut down during cold climate conditions.	[Fischer, Hubertus; Behrens, Melanie; Bock, Michael; Richter, Ulrike; Schmitt, Jochen] Alfred Wegener Inst Polar & Marine Res, D-27568 Bremerhaven, Germany; [Loulergue, Laetitia; Chappellaz, Jerome] UJF, CNRS, Lab Glaciol & Geophys Environm, F-38400 Grenoble, France; [Spahni, Renato; Blunier, Thomas; Leuenberger, Markus; Stocker, Thomas F.] Univ Bern, Inst Phys, CH-3012 Bern, Switzerland	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Bern	Fischer, H (corresponding author), Alfred Wegener Inst Polar & Marine Res, Columbusstr, D-27568 Bremerhaven, Germany.	hubertus.fischer@awi.de	Leuenberger, Markus C/K-9655-2016; Chappellaz, Jérôme A./A-4872-2011; Blunier, Thomas/M-4609-2014; Fischer, Hubertus/A-1211-2014; Stocker, Thomas/B-1273-2013; Schmitt, Jochen/B-7893-2009	Leuenberger, Markus C/0000-0003-4299-6793; Blunier, Thomas/0000-0002-6065-7747; Fischer, Hubertus/0000-0002-2787-4221; Schmitt, Jochen/0000-0003-4695-3029; Behrens, Melanie/0000-0001-9275-4333				Andersen KK, 2004, NATURE, V431, P147, DOI 10.1038/nature02805; Barbante C, 2006, NATURE, V444, P195, DOI 10.1038/nature05301; Brook EJ, 2000, GLOBAL BIOGEOCHEM CY, V14, P559, DOI 10.1029/1999GB001182; CANTRELL CA, 1990, J GEOPHYS RES-ATMOS, V95, P22455, DOI 10.1029/JD095iD13p22455; Chappellaz J, 1997, J GEOPHYS RES-ATMOS, V102, P15987, DOI 10.1029/97JD01017; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; Dallenbach A, 2000, GEOPHYS RES LETT, V27, P1005, DOI 10.1029/1999GL010873; Dueck TA, 2007, NEW PHYTOL, V175, P29, DOI 10.1111/j.1469-8137.2007.02103.x; Ferretti DF, 2005, SCIENCE, V309, P1714, DOI 10.1126/science.1115193; Fluckiger J, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002122; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; Kaplan JO, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2005GB002590; Kaplan JO, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013366; Kennett JP, 2000, SCIENCE, V288, P128, DOI 10.1126/science.288.5463.128; Keppler F, 2006, NATURE, V439, P187, DOI 10.1038/nature04420; Khalil M. A. K., 1993, ATMOSPHERICMETHANE S, P168; Lelieveld J, 1998, TELLUS B, V50, P128, DOI 10.1034/j.1600-0889.1998.t01-1-00002.x; Mahowald N, 1999, J GEOPHYS RES-ATMOS, V104, P15895, DOI 10.1029/1999JD900084; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Quay P, 1999, GLOBAL BIOGEOCHEM CY, V13, P445, DOI 10.1029/1998GB900006; Ruddiman WF, 2003, CLIMATIC CHANGE, V61, P261, DOI 10.1023/B:CLIM.0000004577.17928.fa; SAUERESSIG G, 1995, GEOPHYS RES LETT, V22, P1225, DOI 10.1029/95GL00881; Schaefer H, 2006, SCIENCE, V313, P1109, DOI 10.1126/science.1126562; Sowers T, 2006, SCIENCE, V311, P838, DOI 10.1126/science.1121235; Spahni R, 2005, SCIENCE, V310, P1317, DOI 10.1126/science.1120132; Thonicke K, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002278; TYLER SC, 1994, GEOCHIM COSMOCHIM AC, V58, P1625, DOI 10.1016/0016-7037(94)90564-9; Valdes PJ, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021004; Walter KM, 2007, SCIENCE, V318, P633, DOI 10.1126/science.1142924; WHITICAR MJ, 1993, ATMOSPHERIC METHANE, P138	30	132	136	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2008	452	7189					864	867		10.1038/nature06825	http://dx.doi.org/10.1038/nature06825			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18421351	Green Published			2022-12-28	WOS:000255026000046
J	Ross, JS; Hill, KP; Egilman, DS; Krumholz, HM				Ross, Joseph S.; Hill, Kevin P.; Egilman, David S.; Krumholz, Harlan M.			Guest authorship and ghostwriting in publications related to rofecoxib - A case study of industry documents from rofecoxib litigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; UPPER GASTROINTESTINAL TOXICITY; LARGE OUTCOMES TRIALS; DOUBLE-BLIND; COX-2 INHIBITORS; PAIN MANAGEMENT; RHEUMATOID-ARTHRITIS; SAFETY PROFILE; CYCLOOXYGENASE-2 INHIBITORS; SELECTIVE INHIBITORS	Context Authorship in biomedical publication provides recognition and establishes accountability and responsibility. Recent litigation related to rofecoxib provided a unique opportunity to examine guest authorship and ghostwriting, practices that have been suspected in biomedical publication but for which there is little documentation. Objective To characterize different types and the extent of guest authorship and ghostwriting in 1 case study. Data Sources Court documents originally obtained during litigation related to rofecoxib against Merck & Co Inc. Documents were created predominantly between 1996 and 2004. In addition, publicly available articles related to rofecoxib identified via MEDLINE. Data Extraction All documents were reviewed by one author, with selected review by coauthors, using an iterative process of review, discussion, and rereview of documents to identify information related to guest authorship or ghostwriting. Data Synthesis Approximately 250 documents were relevant to our review. For the publication of clinical trials, documents were found describing Merck employees working either independently or in collaboration with medical publishing companies to prepare manuscripts and subsequently recruiting external, academically affiliated investigators to be authors. Recruited authors were frequently placed in the first and second positions of the authorship list. For the publication of scientific review papers, documents were found describing Merck marketing employees developing plans for manuscripts, contracting with medical publishing companies to ghostwrite manuscripts, and recruiting external, academically affiliated investigators to be authors. Recruited authors were commonly the sole author on the manuscript and offered honoraria for their participation. Among 96 relevant published articles, we found that 92% ( 22 of 24) of clinical trial articles published a disclosure of Merck's financial support, but only 50% ( 36 of 72) of review articles published either a disclosure of Merck sponsorship or a disclosure of whether the author had received any financial compensation from the company. Conclusions This case- study review of industry documents demonstrates that clinical trial manuscripts related to rofecoxib were authored by sponsor employees but often attributed first authorship to academically affiliated investigators who did not always disclose industry financial support. Review manuscripts were often prepared by unacknowledged authors and subsequently attributed authorship to academically affiliated investigators who often did not disclose industry financial support.	[Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; [Hill, Kevin P.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Hill, Kevin P.] McLean Hosp, Belmont, MA 02178 USA; [Egilman, David S.] Brown Univ, Sch Med, Dept Community Hlth, Providence, RI 02912 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson lin Scholars Program, New Haven, CT USA; [Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Sect Cardiovasc Med, Dept Med,Sect Hlth Policy & Adm, New Haven, CT USA; [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA	Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; Harvard University; McLean Hospital; Brown University; Yale University; Yale University; Yale University	Ross, JS (corresponding author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.	joseph.ross@mssm.edu	, Harlan/AAI-2875-2020; Hill, Kevin/GLQ-8874-2022	Ross, Joseph/0000-0002-9218-3320				Aisen PS, 2002, J PAIN SYMPTOM MANAG, V23, pS35, DOI 10.1016/S0885-3924(02)00374-3; Aisen PS, 2002, LANCET NEUROL, V1, P279, DOI 10.1016/S1474-4422(02)00133-3; Anderson SJ, 2006, TOB CONTROL, V15, P254, DOI 10.1136/tc.2005.013854; ARMSTRONG D, ODD GHOSTWRITING OFF; Bell GM, 2001, CLIN GERIATR MED, V17, P489, DOI 10.1016/S0749-0690(05)70082-3; Berenson Alex, 2005, N Y Times Web, pC13; Bingham CO, 2007, RHEUMATOLOGY, V46, P496, DOI 10.1093/rheumatology/kel296; Bingham Clifton O 3rd, 2002, Cleve Clin J Med, V69 Suppl 1, pSI5; Bombardier C, 2006, NEW ENGL J MED, V354, P1196; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Bombardier C, 2002, AM J CARDIOL, V89, p3D; Brater DC, 2002, SEMIN ARTHRITIS RHEU, V32, P33, DOI 10.1053/sarh.2002.37216; Brater DC, 2002, J PAIN SYMPTOM MANAG, V23, pS15, DOI 10.1016/S0885-3924(02)00370-6; Brater DC, 2001, AM J NEPHROL, V21, P1, DOI 10.1159/000046212; Breyer MD, 2001, CURR OPIN NEPHROL HY, V10, P89, DOI 10.1097/00041552-200101000-00014; Buttgereit Frank, 2001, American Journal of Medicine, V110, p13S; Campion EW, 2000, NEW ENGL J MED, V343, P1485, DOI 10.1056/NEJM200011163432009; Cannon Grant W., 2001, American Journal of Medicine, V110, p6S; Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0; Cannon GW, 1999, DRUG TODAY, V35, P487, DOI 10.1358/dot.1999.35.7.548261; Cannon GW, 2000, DRUG TODAY, V36, P255, DOI 10.1358/dot.2000.36.4.570204; Catella-Lawson Francesca, 2001, American Journal of Medicine, V110, p28S; Chen HF, 2003, CURR HYPERTENS REP, V5, P87, DOI 10.1007/s11906-003-0016-y; Crofford LJ, 2000, CURR PHARM DESIGN, V6, P1725, DOI 10.2174/1381612003398753; Cronstein BN, 2002, CLEV CLIN J MED, V69, P13, DOI 10.3949/ccjm.69.Suppl_1.SI13; Curfman GD, 2005, NEW ENGL J MED, V353, P2813, DOI 10.1056/NEJMe058314; Day R, 2000, ARCH INTERN MED, V160, P1781, DOI 10.1001/archinte.160.12.1781; Day RO, 2001, CLIN EXP RHEUMATOL, V19, pS59; DeMaria AN, 2003, J PAIN SYMPTOM MANAG, V25, pS41; Ehrich EW, 1999, J RHEUMATOL, V26, P2438; Ehrich EW, 2001, AM J MANAG CARE, V7, P609; Fendrick AM, 2002, CLEV CLIN J MED, V69, P59, DOI 10.3949/ccjm.69.Suppl_1.SI59; Fendrick AM, 2002, AM J MANAG CARE, V8, pS529; Fine PG, 2002, J PAIN, V3, P272, DOI 10.1054/jpai.2002.125957; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Flanagin A, 1998, JAMA-J AM MED ASSOC, V280, P222, DOI 10.1001/jama.280.3.222; Gajraj NM, 2003, ANESTH ANALG, V96, P1720, DOI 10.1213/01.ANE.0000061461.55712.C5; Gajraj NM, 2003, REGION ANESTH PAIN M, V28, P456, DOI 10.1016/j.rapm.2003.09.001; Gajraj Noor M, 2005, Anesthesiol Clin North Am, V23, P49, DOI 10.1016/j.atc.2004.11.011; Garnett WR, 2001, PHARMACOTHERAPY, V21, P1223, DOI 10.1592/phco.21.15.1223.33891; Geba GP, 2002, JAMA-J AM MED ASSOC, V287, P64, DOI 10.1001/jama.287.1.64; Geusens PP, 2002, SCAND J RHEUMATOL, V31, P230, DOI 10.1080/030097402320318431; Gloth FM, 2001, J AM GERIATR SOC, V49, P188, DOI 10.1046/j.1532-5415.2001.49041.x; Gloth FM, 2001, CLIN GERIATR MED, V17, P553, DOI 10.1016/S0749-0690(05)70086-0; Harris CJ, 2001, CURR OPIN NEPHROL HY, V10, P603, DOI 10.1097/00041552-200109000-00009; Harris RC, 2002, AM J CARDIOL, V89, p10D; Harris RC, 2001, AM J PHYSIOL-RENAL, V281, pF1, DOI 10.1152/ajprenal.2001.281.1.F1; Harris RC, 2000, J AM SOC NEPHROL, V11, P2387, DOI 10.1681/ASN.V11122387; Hawkey C, 2000, ARTHRITIS RHEUM-US, V43, P370, DOI 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D; Hawkey CJ, 2003, GUT, V52, P820, DOI 10.1136/gut.52.6.820; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Hawkey CJ, 2002, GUT, V50, P25; Hawkey CJ, 2001, GASTROENTEROL CLIN N, V30, P921, DOI 10.1016/S0889-8553(05)70220-X; Hawkey CJ, 2001, BEST PRACT RES CL GA, V15, P801, DOI 10.1053/bega.2001.0236; Hawkey CJ, 2001, ALIMENT PHARM THER, V15, P1, DOI 10.1046/j.1365-2036.2001.00894.x; Hawkey CJ, 2001, ALIMENT PHARM THER, V15, P1593, DOI 10.1046/j.1365-2036.2001.01007.x; Hawkey CJ, 2001, CLIN EXP RHEUMATOL, V19, pS23; Healy D, 2003, BRIT J PSYCHIAT, V183, P22, DOI 10.1192/bjp.183.1.22; Hernandez-Diaz Sonia, 2001, American Journal of Medicine, V110, p20S; Hirsch LJ, 2002, SCI ENG ETHICS, V8, P429, DOI 10.1007/s11948-002-0065-7; Hochberg MC, 2002, SEMIN ARTHRITIS RHEU, V32, P4, DOI 10.1053/sarh.2002.37215; Hochberg MC, 2002, AM J MANAG CARE, V8, pS502; Hochberg MC, 2001, CLIN EXP RHEUMATOL, V19, pS15; Hunt RH, 2000, AM J MED, V109, P201, DOI 10.1016/S0002-9343(00)00470-8; Jackson LM, 2000, DRUGS, V59, P1207, DOI 10.2165/00003495-200059060-00001; JOHNSON GE, VIOXX C1 MANUSCRIPT; Katz N, 2003, SPINE, V28, P851, DOI 10.1097/00007632-200305010-00002; Katz N, 2002, SEMIN ARTHRITIS RHEU, V32, P15, DOI 10.1053/sarh.2002.37218; Katz N, 2002, J PAIN SYMPTOM MANAG, V24, pS38, DOI 10.1016/S0885-3924(02)00411-6; Katz WA, 2002, CLEV CLIN J MED, V69, P65; Katz WA, 2002, CURR OPIN RHEUMATOL, V14, P63, DOI 10.1097/00002281-200201000-00012; Kesselheim AS, 2007, JAMA-J AM MED ASSOC, V297, P308, DOI 10.1001/jama.297.3.308; KISTNER U, UPDATE VIOXX MANUSCR; Kivitz AJ, 2004, J AM GERIATR SOC, V52, P666, DOI 10.1111/j.1532-5415.2004.52201.x; Konstam MA, 2002, CLEV CLIN J MED, V69, P47; Krumholz H, 2007, BMJ-BRIT MED J, V334, P120, DOI 10.1136/bmj.39024.487720.68; Kuritzky L, 2003, J PAIN SYMPTOM MANAG, V25, pS6; Laine L, 2003, J PAIN SYMPTOM MANAG, V25, pS32; Laine L, 2002, SEMIN ARTHRITIS RHEU, V32, P25, DOI 10.1053/sarh.2002.37217; Laine L, 2002, J PAIN SYMPTOM MANAG, V23, pS5, DOI 10.1016/S0885-3924(02)00368-8; Lema MJ, 2002, CLEV CLIN J MED, V69, P76; LINES CR, VIOXX PROT 078 PAP; Lipsky Peter E., 2001, American Journal of Medicine, V110, p3S; Lisse JR, 2003, ANN INTERN MED, V139, P539, DOI 10.7326/0003-4819-139-7-200310070-00005; MOAN A, PUBLICATION 901 STUD; Mowatt G, 2002, JAMA-J AM MED ASSOC, V287, P2769, DOI 10.1001/jama.287.21.2769; Myllykangas-Luosujarvi R, 2002, SCAND J RHEUMATOL, V31, P337, DOI 10.1080/030097402320817059; Patrono C, 2001, CLIN EXP RHEUMATOL, V19, pS45; Peloso Paul M., 2001, American Journal of Medicine, V110, p50S; Peura DA, 2002, CLEV CLIN J MED, V69, P31, DOI 10.3949/ccjm.69.Suppl_1.SI31; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Raisz Lawrence G., 2001, American Journal of Medicine, V110, p43S; Reicin A, 2001, Am J Orthop (Belle Mead NJ), V30, P40; Relman AS, 2007, JAMA-J AM MED ASSOC, V298, P2668, DOI 10.1001/jama.298.22.2668; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P469, DOI 10.1001/jama.271.6.469; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; Rex DK, 2002, J PAIN SYMPTOM MANAG, V23, pS41, DOI 10.1016/S0885-3924(02)00375-5; Ruoff G, 2003, J PAIN SYMPTOM MANAG, V25, pS21; Ruoff GE, 2002, SEMIN ARTHRITIS RHEU, V32, P43, DOI 10.1053/sarh.2002.37214; Saag K, 2000, ARCH FAM MED, V9, P1124, DOI 10.1001/archfami.9.10.1124; Scheiman JM, 2003, CURR PHARM DESIGN, V9, P2197, DOI 10.2174/1381612033454018; Scheiman JM, 2002, CLEV CLIN J MED, V69, P40; Scheiman JM, 2002, AM J MANAG CARE, V8, pS518; Schnitzer Thomas J., 2001, American Journal of Medicine, V110, p46S, DOI 10.1016/S0002-9343(00)00650-1; Schnitzer TJ, 1999, CLIN THER, V21, P1688, DOI 10.1016/S0149-2918(99)80048-4; Schnitzer TJ, 2005, J RHEUMATOL, V32, P1093; Schnitzer TJ, 2002, CLEV CLIN J MED, V69, P20; Schnitzer TJ, 2002, J PAIN SYMPTOM MANAG, V23, pS24, DOI 10.1016/S0885-3924(02)00372-X; Schnitzer TJ, 2001, CLIN THER, V23, P313, DOI 10.1016/S0149-2918(01)80041-2; Shamoon Mohammed, 2001, American Journal of Medicine, V110, p46S; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438; Sigthorsson G, 2000, GUT, V47, P527, DOI 10.1136/gut.47.4.527; Steinman MA, 2006, ANN INTERN MED, V145, P284, DOI 10.7326/0003-4819-145-4-200608150-00008; Swan SK, 2000, ANN INTERN MED, V133, P1, DOI 10.7326/0003-4819-133-1-200007040-00002; Thal LJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1204, DOI 10.1038/sj.npp.1300690; Truitt KE, 2001, AGING-CLIN EXP RES, V13, P112, DOI 10.1007/BF03351533; Wayne GF, 2002, TOB CONTROL, V11, pI32, DOI 10.1136/tc.11.suppl_1.i32; Weaver AL, 2006, JCR-J CLIN RHEUMATOL, V12, P17, DOI 10.1097/01.rhu.0000200384.79405.33; Weaver AL, 2001, CLIN THER, V23, P1323, DOI 10.1016/S0149-2918(01)80112-0; Weir MR, 2002, CLEV CLIN J MED, V69, P53; Whelton Andrew, 2001, American Journal of Medicine, V110, p33S; Wight NJ, 2001, GASTROENTEROLOGY, V120, P867, DOI 10.1053/gast.2001.22432; World Assoc Med Editors, 2005, J GEN INTERN MED, V20, P549, DOI 10.1111/j.1525-1497.2005.41015x	123	302	303	0	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1800	1812		10.1001/jama.299.15.1800	http://dx.doi.org/10.1001/jama.299.15.1800			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18413874				2022-12-28	WOS:000254954800024
J	Boerma, JT; Bryce, J; Kinfu, Y; Axelson, H; Victora, CG				Boerma, J. Ties; Bryce, Jennifer; Kinfu, Yohannes; Axelson, Henrik; Victora, Cesar G.		Countdown 2008 Equ Anal Grp	Mind the gap: equity and trends in coverage of maternal, newborn, and child health services in 54 Countdown countries	LANCET			English	Article								Background Increasing the coverage of key maternal, newborn, and child health interventions is essential if Millennium Development Goals (MDG) 4 and 5 are to be reached. We have assessed equity and trends in coverage rates of a key set of interventions through a summary index, to provide overall insight into past performance and progress perspectives. Methods Data from household surveys from 54 countries in the Countdown to 2015 for Maternal, Newborn and Child Survival initiative during 1990-2006 were used to compute an aggregate coverage index based on four intervention areas: family planning, maternal and newborn care, immunisation, and treatment of sick children. The four areas were given equal weight in the computation of the index. Standard measures were applied to assess current levels and trends in the coverage gap measure by wealth quintile. Findings The overall size of the coverage gap ranged from less than 20% in Tajikistan and Peru to over 70% in Ethiopia and Chad, with a mean of 43% for the most recent surveys in the 54 countries. Large intracountry differences were noted, with a country mean coverage gap of 54% for the poorest quintiles of the population and 29% for the wealthiest. Differences between the poorest and the wealthiest were largest for the maternal and newborn health intervention area and smallest for immunisation. In 40 countries with more than one survey, the coverage gap had decreased by an average of 0.9 percentage points per year since the early 1990s. Declines greater than 2 percentage points per year were seen in only three countries after 1995: Cambodia, Mozambique, and Nepal. Country inequity patterns were remarkably persistant over time, with only gradual changes from top inequity (disproportionately smaller gap for the wealthiest) in countries with coverage gaps exceeding 40%, to linear patterns and bottom inequity (disproportionately greater gap for the poorest) in surveys with gaps below 40%. Interpretation Despite most Countdown countries having made gradual progress since 1990, coverage gaps for key interventions remain wide and, in most such countries, the pace of decline needs to be more than doubled to reach levels of coverage of these and other interventions needed in the context of MDG 4 and 5. In general, in-country patterns of inequality are consistant and change only gradually if at all, which has implications for the targeting of interventions.	[Boerma, J. Ties; Kinfu, Yohannes] WHO, CH-1211 Geneva 27, Switzerland; [Bryce, Jennifer] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Axelson, Henrik] Partnership Maternal Newborn & Child Hlth, Geneva, Switzerland; [Victora, Cesar G.] Univ Fed Pelotas, Pelotas, Brazil	World Health Organization; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Universidade Federal de Pelotas	Boerma, JT (corresponding author), WHO, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	boermat@who.int	Victora, Cesar G/D-4476-2013; Victora, Cesar Gomes/Y-2455-2019; Kinfu, Yohannes/AAC-8054-2020	Victora, Cesar G/0000-0002-2465-2180; Victora, Cesar Gomes/0000-0002-2465-2180; Kinfu, Yohannes/0000-0001-9607-6891; Kirkwood, Betty/0000-0001-5274-6072				Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; BRYCE J, TRACKING PROGR MATER; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Bryce J, 2006, LANCET, V368, P1067, DOI 10.1016/S0140-6736(06)69339-2; Fenn B, 2007, ARCH DIS CHILD-FETAL, V92, P361, DOI 10.1136/adc.2006.104836; Gliner J. A., 2000, RES METHODS APPL SET; GWATKIN DR, 2007, SOCIOECONOMIC DIFFER; Houweling Tanja AJ, 2003, Int J Equity Health, V2, P8, DOI 10.1186/1475-9276-2-8; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Lozano R, 2006, LANCET, V368, P1729, DOI 10.1016/S0140-6736(06)69566-4; *MACRO INT, DEM HLTH SURV; Morris SS, 2000, J EPIDEMIOL COMMUN H, V54, P381, DOI 10.1136/jech.54.5.381; Moser K, 2007, INT J EPIDEMIOL, V36, P1285, DOI 10.1093/ije/dym176; Roger E.M, 2003, DIFFUSION INNOVATION, V5th; Russell Bernard H., 1995, RES METHODS ANTHR QU, Vsecond; United Nations Children's Fund (UNICEF), MULT IND CLUST SURV; Victora CG, 2005, LANCET, V366, P1460, DOI 10.1016/S0140-6736(05)67599-X; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; Wagstaff A, 2003, HEALTH ECON, V12, P885, DOI 10.1002/hec.805; Westoff C. F., 1988, International Family Planning Perspectives, V14, P45, DOI 10.2307/2947679; Wirth ME, 2006, B WORLD HEALTH ORGAN, V84, P519, DOI 10.2471/BLT.04.019984; World Health Organization, 2006, WORLD HLTH STAT 2006	22	207	208	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1259	1267						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286XH	18406860				2022-12-28	WOS:000254878900027
J	Weissman, KJ				Weissman, Kira J.			Anatomy of a fungal polyketide synthase	SCIENCE			English	Editorial Material							BIOSYNTHESIS; IDENTIFICATION; AFLATOXIN; PROTEINS; STEPS		Univ Saarland, Dept Pharmaceut Biotechnol, D-60041 Saarbrucken, Germany	Saarland University	Weissman, KJ (corresponding author), Univ Saarland, Dept Pharmaceut Biotechnol, D-60041 Saarbrucken, Germany.	k.weissman@mx.uni-saarland.de						Cox RJ, 2007, ORG BIOMOL CHEM, V5, P2010, DOI 10.1039/b704420h; Crawford JM, 2008, SCIENCE, V320, P243, DOI 10.1126/science.1154711; Crawford JM, 2006, P NATL ACAD SCI USA, V103, P16728, DOI 10.1073/pnas.0604112103; Henry KM, 2005, J AM CHEM SOC, V127, P3724, DOI 10.1021/ja0455188; Ma SM, 2008, J AM CHEM SOC, V130, P38, DOI 10.1021/ja078091o; Ma Y, 2006, CHEMBIOCHEM, V7, P1951, DOI 10.1002/cbic.200600341; Minto RE, 1997, CHEM REV, V97, P2537, DOI 10.1021/cr960032y; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Udwary DW, 2002, J MOL BIOL, V323, P585, DOI 10.1016/S0022-2836(02)00972-5; Watanabe A, 1998, TETRAHEDRON LETT, V39, P7733, DOI 10.1016/S0040-4039(98)01685-2	10	5	6	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					186	187		10.1126/science.1157677	http://dx.doi.org/10.1126/science.1157677			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403699				2022-12-28	WOS:000254836700029
J	Jenkins, NP; Gray, H				Jenkins, Nick P.; Gray, Huon			Pseudoaneurysm of the right internal thoracic artery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Jenkins, Nick P.; Gray, Huon] Wessex Cardiac Unit, Southampton SO16 6YD, Hants, England		Jenkins, NP (corresponding author), Wessex Cardiac Unit, Southampton SO16 6YD, Hants, England.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1603	1603		10.1056/NEJMicm075126	http://dx.doi.org/10.1056/NEJMicm075126			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285NK	18403768				2022-12-28	WOS:000254783300009
J	Meier, F; Zhou, LH; Wiebe, J; Wiesendanger, R				Meier, Focko; Zhou, Lihui; Wiebe, Jens; Wiesendanger, Roland			Revealing magnetic interactions from single-atom magnetization curves	SCIENCE			English	Article							SPIN; ANTIFERROMAGNETISM; ANISOTROPY; MN	The miniaturization of magnetic devices toward the limit of single atoms calls for appropriate tools to study their magnetic properties. We demonstrate the ability to measure magnetization curves of individual magnetic atoms adsorbed on a nonmagnetic metallic substrate with use of a scanning tunneling microscope with a spin- polarized tip. We can map out low- energy magnetic interactions on the atomic scale as evidenced by the oscillating indirect exchange between a Co adatom and a nanowire on Pt( 111). These results are important for the understanding of variations that are found in the magnetic properties of apparently identical adatoms because of different local environments.	[Meier, Focko; Zhou, Lihui; Wiebe, Jens; Wiesendanger, Roland] Univ Hamburg, Inst Appl Phys, D-20355 Hamburg, Germany; [Meier, Focko; Zhou, Lihui; Wiebe, Jens; Wiesendanger, Roland] Univ Hamburg, Microstruct Res Ctr, D-20355 Hamburg, Germany	University of Hamburg; University of Hamburg	Wiebe, J (corresponding author), Univ Hamburg, Inst Appl Phys, D-20355 Hamburg, Germany.	jwiebe@physnet.uni-hamburg.de	Zhou, Lihui/B-5020-2013; Wiesendanger, Roland/P-9726-2016; Wiebe, Jens/C-7580-2018	Wiesendanger, Roland/0000-0002-0472-4183; Wiebe, Jens/0000-0003-1668-6142				BRUNO P, 1992, PHYS REV B, V46, P261, DOI 10.1103/PhysRevB.46.261; Chikazumi S., 1964, PHYS MAGNETISM; FISCHER B, 1975, PHYS REV B, V11, P2025, DOI 10.1103/PhysRevB.11.2025; Gambardella P, 2003, SCIENCE, V300, P1130, DOI 10.1126/science.1082857; Heinze S, 2000, SCIENCE, V288, P1805, DOI 10.1126/science.288.5472.1805; Hirjibehedin CF, 2007, SCIENCE, V317, P1199, DOI 10.1126/science.1146110; IWEBE J, 2005, PHYS REV B, V72; Kaiser U, 2007, NATURE, V446, P522, DOI 10.1038/nature05617; KASUYA T, 1956, PROG THEOR PHYS, V16, P45, DOI 10.1143/PTP.16.45; Kitchen D, 2006, NATURE, V442, P436, DOI 10.1038/nature04971; Krause S, 2007, SCIENCE, V317, P1537, DOI 10.1126/science.1145336; Lee HJ, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.186802; MANASSEN Y, 1989, PHYS REV LETT, V62, P2531, DOI 10.1103/PhysRevLett.62.2531; Meier F, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.195411; RUDERMAN MA, 1954, PHYS REV, V96, P99, DOI 10.1103/PhysRev.96.99; Rugar D, 2004, NATURE, V430, P329, DOI 10.1038/nature02658; Wahl P, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.056601; White RL, 2000, J MAGN MAGN MATER, V209, P1, DOI 10.1016/S0304-8853(99)00632-0; Wiebe J, 2004, REV SCI INSTRUM, V75, P4871, DOI 10.1063/1.1794431; Wortmann D, 2001, PHYS REV LETT, V86, P4132, DOI 10.1103/PhysRevLett.86.4132; YAFET Y, 1987, PHYS REV B, V36, P3948, DOI 10.1103/PhysRevB.36.3948; Yayon Y, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.067202; YOSIDA K, 1957, PHYS REV, V106, P893, DOI 10.1103/PhysRev.106.893	23	277	282	5	140	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					82	86		10.1126/science.1154415	http://dx.doi.org/10.1126/science.1154415			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388289				2022-12-28	WOS:000254633000034
J	Sabin, CA; Worm, SW; Weber, R; Reiss, P; El-Sadr, W; Dabis, F; De Wit, S; Law, M; Monforte, AD; Friis-Moller, N; Kirk, O; Pradier, C; Weller, I; Phillips, AN; Lundgren, JD				Sabin, Caroline A.; Worm, Signe W.; Weber, Rainer; Reiss, Peter; El-Sadr, Wafaa; Dabis, Francois; De Wit, Stephane; Law, Matthew; Monforte, Antonella D'Arminio; Friis-Moller, Nina; Kirk, Ole; Pradier, Christian; Weller, Ian; Phillips, Andrew N.; Lundgren, Jens D.		DAD Study Grp	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D : A : D study: a multi-cohort collaboration	LANCET			English	Article							ANTIRETROVIRAL-NAIVE PATIENTS; INSULIN-RESISTANCE; DIABETES-MELLITUS; CARDIOVASCULAR EVENTS; BODY-COMPOSITION; THERAPY; ASSOCIATION; DISEASE; AIDS; LIPODYSTROPHY	Background Whether nucleoside reverse transcriptase inhibitors increase the risk of myocardial infarction in HIV-infected individuals is unclear. Our aim was to explore whether exposure to such drugs was associated with an excess risk of myocardial infarction in a large, prospective observational cohort of HIV-infected patients. Methods We used Poisson regression models to quantify the relation between cumulative, recent (currently or within the preceding 6 months), and past use of zidovudine, didanosine, stavudine, lamivudine, and abacavir and development of myocardial infarction in 33 347 patients enrolled in the D:A:D study. We adjusted for cardiovascular risk factors that are unlikely to be affected by antiretroviral therapy, cohort, calendar year, and use of other antiretrovirals. Findings Over 157912 person-years, 517 patients had a myocardial infarction. We found no associations between the rate of myocardial infarction and cumulative or recent use of zidovudine, stavudine, or lamivudine. By contrast, recent-but not cumulative use of abacavir or didanosine was associated with an increased rate of myocardial infarction (compared with those with no recent use of the drugs, relative rate 1.90, 95% CI 1.47-2.45 [p=0.0001] with abacavir and 1.49,1.14-1.95 [p=0.003] with didanosine); rates were not significantly increased in those who stopped these drugs more than 6 months previously compared with those who had never received these drugs. After adjustment for predicted 10-year risk of coronary heart disease, recent use of both didanosine and abacavir remained associated with increased rates of myocardial infarction (1.49,1.14-1.95 [p=0.004] with didanosine; 1.89,1.47-2.45 [p=0.0001] with abacavir). Interpretation There exists an increased risk of myocardial infarction in patients exposed to abacavir and didanosine within the preceding 6 months. The excess risk does not seem to be explained by underlying established cardiovascular risk factors and was not present beyond 6 months after drug cessation.	[Sabin, Caroline A.; Worm, Signe W.; Weber, Rainer; Reiss, Peter; El-Sadr, Wafaa; Dabis, Francois; De Wit, Stephane; Law, Matthew; Monforte, Antonella D'Arminio; Friis-Moller, Nina; Kirk, Ole; Pradier, Christian; Weller, Ian; Phillips, Andrew N.; Lundgren, Jens D.] Rigshosp, KMA, Ctr Viral Dis, DK-2200 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Lundgren, JD (corresponding author), Rigshosp, KMA, Ctr Viral Dis, Bldg 21-1, DK-2200 Copenhagen, Denmark.	jdl@cphiv.dk	Phillips, Andrew N/B-4427-2008; Sabin, Caroline/C-2464-2008; Torres, Ferran/D-1296-2011; Pradier, Christian/AFE-8255-2022; Weber, Rainer/D-5175-2012; Morsica, Giulia/AAC-4993-2019; Wiercińska-Drapało, Alicja/V-5930-2018; Pradier, Christian/AAE-9669-2022; Streinu-Cercel, Adrian/M-5835-2017; van der Ven, A.J.A.M./H-8102-2014; DABIS, FRANCOIS/S-9298-2019; Lundgren, Jens/AAE-6876-2019; kirk, ole/ABB-4746-2021	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760; Torres, Ferran/0000-0002-7355-7913; Morsica, Giulia/0000-0003-4891-5376; Wiercińska-Drapało, Alicja/0000-0001-5921-1409; Streinu-Cercel, Adrian/0000-0001-6382-5067; van der Ven, A.J.A.M./0000-0003-1833-3391; DABIS, FRANCOIS/0000-0002-1614-8857; Pezzotti, Patrizio/0000-0002-0805-2927; Collins, Simon/0000-0002-3537-2432; Rijnders, Bart/0000-0003-3343-9610; Chiesi, Antonio/0000-0002-6892-8142; CAUDA, Roberto/0000-0002-1498-4229; Friis-Moller, Nina/0000-0002-7449-7393; Katzenstein, Terese L/0000-0002-2233-500X; Law, Matthew/0000-0002-3540-8837	NIAID NIH HHS [U01 AI069907, 5U01AI046362-03, U01 AI046362, U01 AI042170, 5U01AI042170-10, U01 AI069907-02] Funding Source: Medline; PHS HHS [UOI069907] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI046362, U01AI069907, U01AI042170] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anastos K, 2007, JAIDS-J ACQ IMM DEF, V45, P34, DOI 10.1097/QAI.0b013e318042d5fe; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Brown TT, 2005, AIDS, V19, P1375, DOI 10.1097/01.aids.0000181011.62385.91; Calmy A, 2007, LANCET, V370, P12, DOI 10.1016/S0140-6736(07)61027-7; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; De Wit S, 2008, DIABETES CARE, V31, P1224, DOI 10.2337/dc07-2013; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Fleischman A, 2007, AM J PHYSIOL-ENDOC M, V292, pE1666, DOI 10.1152/ajpendo.00550.2006; Florescu D, 2007, ANTIVIR THER, V12, P149; Fontas E, 2004, J INFECT DIS, V189, P1056, DOI 10.1086/381783; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010; Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723, DOI 10.1056/NEJMoa062744; FRIISMOLLER N, 2007, 14 C RETR OPP INF LO; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Goicoechea M, 2008, J INFECT DIS, V197, P102, DOI 10.1086/524061; Grabar S, 2006, J ANTIMICROB CHEMOTH, V57, P4, DOI 10.1093/jac/dki411; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Jones R, 2005, HIV MED, V6, P396, DOI 10.1111/j.1468-1293.2005.00325.x; Klein D, 2007, 14 C RETR OPP INF LO; Law MG, 2006, HIV MED, V7, P218, DOI 10.1111/j.1468-1293.2006.00362.x; Ledergerber B, 2007, CLIN INFECT DIS, V45, P111, DOI 10.1086/518619; LEWDEN C, 2007, 14 C RETR OPP INF LO; Lorenz MW, 2008, ATHEROSCLEROSIS, V196, P720, DOI 10.1016/j.atherosclerosis.2006.12.022; Mallon PWG, 2007, AIDS REV, V9, P3; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; PARKER WB, 1993, ANTIMICROB AGENTS CH, V37, P1004, DOI 10.1128/AAC.37.5.1004; PHILLIPS AN, IN PRESS ANTIVIR THE; Podzamczer D, 2007, JAIDS-J ACQ IMM DEF, V44, P139, DOI 10.1097/QAI.0b013e31802bf122; SANZ E, 2005, WHO SIGNAL      0504; Shlay JC, 2005, JAIDS-J ACQ IMM DEF, V38, P147, DOI 10.1097/01.qai.0000143599.64234.15; Singh S, 2007, JAMA-J AM MED ASSOC, V298, P1189, DOI 10.1001/jama.298.10.1189; Smieja M, 2007, 16 ANN CAN C HIV AID; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; van Vonderen MGA, 2007, ANTIVIR THER, V12, pL13; Weber R, 2006, ARCH INTERN MED, V166, P1632, DOI 10.1001/archinte.166.15.1632; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	41	660	670	2	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR-MAY	2008	371	9622					1417	1426		10.1016/s0140-6736(08)60423-7	http://dx.doi.org/10.1016/s0140-6736(08)60423-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294XW	18387667	Green Accepted			2022-12-28	WOS:000255440600022
J	Steinberg, MB; Schmelzer, AC; Richardson, DL; Foulds, J				Steinberg, Michael B.; Schmelzer, Amy C.; Richardson, Donna L.; Foulds, Jonathan			The case for treating tobacco dependence as a chronic disease	ANNALS OF INTERNAL MEDICINE			English	Article							SMOKING-CESSATION; NICOTINE REPLACEMENT; PHARMACOTHERAPY; BUPROPION; THERAPY; SAFETY; GUM	Smoking remains the leading cause of preventable death in the United States, yet it is still regarded by many as merely a bad habit. Most smokers want to quit but find it difficult. Behavioral counseling and pharmacotherapies are available; safe, and effective in the treatment of tobacco dependence. Nicotine replacement therapy effectively delivers nicotine in safer doses without exposure to the toxins and chemicals in cigarette smoke. The optimal duration of tobacco dependence treatment is unknown, and some smokers may require extended courses. For smokers using long-term cessation medications, health care providers should encourage treatment and insurance carriers should cover it. Both tobacco dependence and such conditions as diabetes are similar in their potential to exacerbate other diseases, their behavioral components of treatment, and their effectiveness of medications. Despite these similarities, treatments for diabetes are well covered by insurance, whereas tobacco dependence treatments are often limited. Tobacco dependence should share the status of other chronic illnesses, with effective treatments given as long as is necessary to achieve successful clinical outcomes.	[Steinberg, Michael B.] Univ Med & Dent New Jersey, Sch Publ Hlth, Tobacco Dependence Program, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Steinberg, MB (corresponding author), Univ Med & Dent New Jersey, Sch Publ Hlth, Tobacco Dependence Program, 317 George St,Room 210, New Brunswick, NJ 08901 USA.	michael.steinberg@umdnj.edu	Foulds, Jonathan/AAM-6750-2021	Foulds, Jonathan/0000-0003-2296-0726				Bansal MA, 2004, NICOTINE TOB RES, V6, P303, DOI 10.1080/14622200412331320707; Benowitz NL, 1997, J AM COLL CARDIOL, V29, P1422, DOI 10.1016/S0735-1097(97)00079-X; Burani J, 2006, DIABETES EDUCATOR, V32, P78, DOI 10.1177/0145721705284743; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P300; Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P642; Croghan IT, 2007, MAYO CLIN PROC, V82, P186, DOI 10.4065/82.2.186; Etter JF, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015487; FIORE MC, 2008, IN PRESS CLIN PRACTI; Hatsukami D, 2007, PHARMACOL BIOCHEM BE, V86, P132, DOI 10.1016/j.pbb.2006.12.017; Hays JT, 2001, ANN INTERN MED, V135, P423, DOI 10.7326/0003-4819-135-6-200109180-00011; Inzucchi SE, 2002, JAMA-J AM MED ASSOC, V287, P360, DOI 10.1001/jama.287.3.360; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; Murray RP, 1996, CHEST, V109, P438, DOI 10.1378/chest.109.2.438; NIH State-of-the-Science Panel, 2006, ANN INTERN MED, V145, P839, DOI 10.7326/0003-4819-145-11-200612050-00141; Petersen M, 2003, DIABETES CARE, V26, P917; Rigotti NA, 2002, NEW ENGL J MED, V346, P506, DOI 10.1056/NEJMcp012279; Sims TH, 2002, CNS DRUGS, V16, P653, DOI 10.2165/00023210-200216100-00001; Steinberg MB, 2006, PREV MED, V42, P114, DOI 10.1016/j.ypmed.2005.11.013; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; West R, 2000, PSYCHOPHARMACOLOGY, V149, P198, DOI 10.1007/s002130000382; Williams KE, 2007, CURR MED RES OPIN, V23, P793, DOI 10.1185/030079907X182185	21	60	60	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2008	148	7					554	556		10.7326/0003-4819-148-7-200804010-00012	http://dx.doi.org/10.7326/0003-4819-148-7-200804010-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284IV	18378950				2022-12-28	WOS:000254701000008
J	Wang, H; Feng, Z; Shu, Y; Yu, H; Zhou, L; Zu, RQ; Huai, Y; Dong, J; Bao, CJ; Wen, LY; Wang, H; Yang, P; Zhao, W; Dong, LB; Zhou, MH; Liao, QH; Yang, HT; Wang, M; Lu, XJ; Shi, ZY; Wang, W; Gu, L; Zhu, FC; Li, Q; Yin, WD; Yang, WZ; Li, DX; Uyeki, TM; Wang, Y				Wang, Hua; Feng, Zijian; Shu, Yuelong; Yu, Hongjie; Zhou, Lei; Zu, Rongqiang; Huai, Yang; Dong, Jie; Bao, Changjun; Wen, Leying; Wang, Hong; Yang, Peng; Zhao, Wei; Dong, Libo; Zhou, Minghao; Liao, Qiaohong; Yang, Haitao; Wang, Min; Lu, Xiaojun; Shi, Zhiyang; Wang, Wei; Gu, Ling; Zhu, Fengcai; Li, Qun; Yin, Weidong; Yang, Weizhong; Li, Dexin; Uyeki, Timothy M.; Wang, Yu			Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China	LANCET			English	Article							HEALTH-CARE WORKERS; RECEPTOR SPECIFICITY; ANTI-H5 ANTIBODY; INFECTION; HEMAGGLUTININ; DISEASE; EPIDEMIOLOGY; RISK	Bankground in December, 2007, family cluster of two individuals infected with highly pathogenic avian influenza A (H5N1) virus was identified in Jiangsu Province, China. Field and laboratory investigations were implemented immediately by public-health authorities. Methods Epidemiological, clinical, and virological data were collected and analysed. Respiratory specimens from the patients were tested by reverse transcriptase (RT) PCR and by viral culture for the presence of H5N1 virus. Contacts of cases were monitored for symptoms of illness for 10 days. Any contacts who became ill had respiratory specimens collected for H5N1 testing by RT PCR. Sera were obtained from contacts for H5N1 serological testing by microneutralisation and horse red-blood-cell haemagglutinin inhibition assays. Findings The 24-year-old index case died, and the second case, his 52-year-old father, survived after receiving early antiviral treatment and post-vaccination plasma from a participant in an H5N1 vaccine trial. The index case's only plausible exposure to H5N1 virus was a poultry market visit 6 days before the onset of illness. The second case had substantial unprotected close exposure to his ill son. 91 contacts with close exposure to one or both cases without adequate protective equipment provided consent for serological investigation. Of these individuals, 78 (86%) received oseltamivir chemoprophylaxis and two had mild illness. Both ill contacts tested negative for H5N1 by RT PCR. All 91 close contacts tested negative for H5N1 antibodies. HSN1 viruses isolated from the two cases were genetically identical except for one non-synonymous nucleotide substitution. Interpretation Limited, non-sustained person-to-person transmission of H5N1 virus probably occurred in this family cluster. Funding Chinese Ministry of Science and Technology; US National Institute of Allergy and infectious Diseases, National Institutes of Health; China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases.	[Feng, Zijian; Yu, Hongjie; Zhou, Lei; Huai, Yang; Yang, Peng; Liao, Qiaohong; Li, Qun; Yang, Weizhong; Wang, Yu] Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing 100050, Peoples R China; [Wang, Hua; Zu, Rongqiang; Bao, Changjun; Zhou, Minghao; Yang, Haitao; Shi, Zhiyang; Gu, Ling; Zhu, Fengcai] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Peoples R China; [Shu, Yuelong; Dong, Jie; Wen, Leying; Dong, Libo; Wang, Min; Wang, Wei; Li, Dexin] China CDC, State Key Lab Infect Dis Prevent & Control, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China; [Wang, Hong] Jiangsu Prov Peoples Hosp, Nanjing, Peoples R China; [Zhao, Wei] Nanjing Secondary Peoples Hosp, Nanjing, Peoples R China; [Lu, Xiaojun] Nanjing Ctr Dis Control & Prevent, Nanjing, Peoples R China; [Yin, Weidong] Sinovac Biotech Co, Beijing, Peoples R China; [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA	Chinese Center for Disease Control & Prevention; Jiangsu Provincial Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention; National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control & Prevention; Centers for Disease Control & Prevention - USA	Wang, Y (corresponding author), Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, 27 Nanwei Rd, Beijing 100050, Peoples R China.	wangyu@chinacdc.cn	zhou, minghao/GZA-7244-2022; Yu, Hongjie/GZK-5351-2022		NIAID NIH HHS [U19 AI51915] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI051915] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279; [Anonymous], WHO CAS DEF HUM INF; Apisarnthanarak A, 2005, CLIN INFECT DIS, V40, pE16, DOI 10.1086/427034; Auewarakul P, 2007, J VIROL, V81, P9950, DOI 10.1128/JVI.00468-07; Bridges CB, 2000, J INFECT DIS, V181, P344, DOI 10.1086/315213; Chassagne P, 1996, AM J MED, V100, P65, DOI 10.1016/S0002-9343(96)90013-3; Chiu CH, 2004, CLIN MICROBIOL REV, V17, P311, DOI 10.1128/CMR.17.2.311-322.2004; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Gu J, 2007, LANCET, V370, P1137, DOI 10.1016/S0140-6736(07)61515-3; Kandun IN, 2006, NEW ENGL J MED, V355, P2186, DOI 10.1056/NEJMoa060930; Katz JM, 1999, J INFECT DIS, V180, P1763, DOI 10.1086/315137; Liem NT, 2005, EMERG INFECT DIS, V11, P210, DOI 10.3201/eid1102.041075; Mounts AW, 1999, J INFECT DIS, V180, P505, DOI 10.1086/314903; Olsen SJ, 2005, EMERG INFECT DIS, V11, P1799; Oner AF, 2006, NEW ENGL J MED, V355, P2179, DOI 10.1056/NEJMoa060601; Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5; Pitzer VE, 2007, EMERG INFECT DIS, V13, P1074, DOI 10.3201/eid1307.061538; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Schultsz C, 2005, EMERG INFECT DIS, V11, P1158; Scientific Panel on Biological Hazards, 2006, EUR FOOD SAFETY AUTH, V74, P1; Sedyaningsih ER, 2007, J INFECT DIS, V196, P522, DOI 10.1086/519692; Songserm T, 2006, EMERG INFECT DIS, V12, P1744, DOI 10.3201/eid1211.060542; Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002; Stephenson I, 2003, J MED VIROL, V70, P391, DOI 10.1002/jmv.10408; Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Webster RG, 2004, LANCET, V363, P234, DOI 10.1016/S0140-6736(03)15329-9; WHO, CLIN MAN HUM INF AV; WHO, AV INFL SIT IND UPD; *WHO, REC LAB PROC DET AV; WHO, WHO GUID INV HUM CAS; World Health Organization, COLL PRES SHIPP SPEC; World Health Organization, CUM NUMB CONF HUM CA; World Health Organization (WHO), WHO MAN AN INFL DIAG; Yamada S, 2006, NATURE, V444, P378, DOI 10.1038/nature05264; Yu HJ, 2007, EMERG INFECT DIS, V13, P1061, DOI 10.3201/eid1307.061557; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359; 2006, WKLY EPIDEMIOL REC, V81, P183	39	216	249	4	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR-MAY	2008	371	9622					1427	1434		10.1016/S0140-6736(08)60493-6	http://dx.doi.org/10.1016/S0140-6736(08)60493-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294XW	18400288				2022-12-28	WOS:000255440600023
J	Moryl, N; Coyle, N; Foley, KM				Moryl, Natalie; Coyle, Nessa; Foley, Kathleen M.			Managing an acute pain crisis in a patient with advanced cancer - "This is as much of a crisis as a code"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PALLIATIVE CARE; QT-INTERVAL; INTRAVENOUS METHADONE; PARENTERAL METHADONE; TRANSDERMAL FENTANYL; POSTOPERATIVE PAIN; BOWEL OBSTRUCTION; ASSISTED SUICIDE; OPIOID ROTATION; DOUBLE-BLIND	The assessment and management of an acute pain crisis in the setting of advanced illness is challenging. Using the case of Mr X, a 33- year- old man with advanced metastatic mucinous adenocarcinoma of the appendix and "15 out of 10" pain, we explore the issues of acute pain and its management. We define a pain crisis as an event in which the patient reports pain that is severe, uncontrolled, and causing distress for the patient, family members, or both. Our management strategy focuses on making a pain diagnosis, differentiating reversible from intractable causes of pain, and making decisions about further workup; selecting the opioid and monitoring and treating opioid adverse effects; titrating and rotating opioid and coanalgesics; consulting experts to treat a pain crisis as quickly as possible to prevent unnecessary suffering; and co- opting the available institutional resources. The timely intervention of a palliative care team and its expertise can provide the staff, patients, and their families the benefit of an interdisciplinary approach and help the patients address goals of care; understand the benefits and risks of treatment decisions; and meet the psychological, social, and existential needs of the patient and the family commonly seen in this setting.	[Moryl, Natalie; Coyle, Nessa; Foley, Kathleen M.] Mem Sloan Kettering Canc Ctr, Dept Neurol, Pain & Palliat Care Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Foley, KM (corresponding author), Cornell Univ, Weill Med Coll, 1275 York Ave, New York, NY 10021 USA.	foleyk@mskcc.org						Al-Khatib SM, 2003, JAMA-J AM MED ASSOC, V289, P2120, DOI 10.1001/jama.289.16.2120; *AM PAIN SOC, 2007, PRINC AN US TREAT AC; [Anonymous], 2007, NCCN CLIN PRACTICE G; Anthony T, 2007, J PAIN SYMPTOM MANAG, V34, pS49, DOI 10.1016/j.jpainsymman.2007.04.011; Fernandes MDBD, 2007, REV LAT-AM ENFERM, V15, P318, DOI 10.1590/S0104-11692007000200019; Bell RF, 2005, ACTA ANAESTH SCAND, V49, P1405, DOI 10.1111/j.1399-6576.2005.00814.x; Ben-Ari Alon, 2007, J Pain Palliat Care Pharmacother, V21, P7, DOI 10.1300/J354v21n01_04; BERZOFF J, 2004, LIVING DYING; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Boettger Soenke, 2005, Palliat Support Care, V3, P227; Bookbinder M, 2005, J PAIN SYMPTOM MANAG, V29, P529, DOI 10.1016/j.jpainsymman.2004.05.011; Braiteh F, 2007, J PALLIAT MED, V10, P948, DOI 10.1089/jpm.2006.0257; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Bruera E, 2000, J PAIN SYMPTOM MANAG, V19, P427, DOI 10.1016/S0885-3924(00)00138-X; Bruera E, 1991, J Palliat Care, V7, P6; Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Carver AC, 1999, NEUROLOGY, V53, P284, DOI 10.1212/WNL.53.2.284; CHALLONER K R, 1990, Journal of Emergency Medicine, V8, P67, DOI 10.1016/0736-4679(90)90391-8; Cherny N I, 1994, J Palliat Care, V10, P57; Cherny NI, 2006, NAT CLIN PRACT ONCOL, V3, P492, DOI 10.1038/ncponc0583; CHERNY NJ, 1995, CANCER-AM CANCER SOC, V76, P1283, DOI 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0; CODD EE, 1995, J PHARMACOL EXP THER, V274, P1263; Cohen MZ, 2003, J PAIN SYMPTOM MANAG, V25, P519, DOI 10.1016/S0885-3924(03)00068-X; Colucci R D, 2001, Am J Ther, V8, P231, DOI 10.1097/00045391-200107000-00004; Coyle N, 2006, J PAIN SYMPTOM MANAG, V32, P266, DOI 10.1016/j.jpainsymman.2006.04.003; Cranford Ronald E, 2002, HEC Forum, V14, P259, DOI 10.1023/A:1020533215676; CREWS JC, 1993, CANCER-AM CANCER SOC, V72, P2266, DOI 10.1002/1097-0142(19931001)72:7<2266::AID-CNCR2820720734>3.0.CO;2-P; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Davis MP, 2001, SUPPORT CARE CANCER, V9, P73, DOI 10.1007/s005200000180; EDWARDS ND, 1993, ANAESTHESIA, V48, P124; Ehret GB, 2007, EXPERT OPIN DRUG SAF, V6, P289, DOI 10.1517/14740338.6.3.289; Ellershaw JE, 2005, INT J PALLIAT NURS, V11, P132, DOI 10.12968/ijpn.2005.11.3.18032; FEUER DJ, 2004, CORTICOSTEROIDS RESO; Fine PG, 1999, J PAIN SYMPTOM MANAG, V17, P296, DOI 10.1016/S0885-3924(98)00144-4; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; FOLEY KM, 1993, SYMP PAIN R, P331; FOLEY KM, 2005, CANC PRINCIPLES PRAC, P2615; Foley KM, 2001, IMPROVING PALLIATIVE; Gallego AO, 2007, CLIN TRANSL ONCOL, V9, P298, DOI 10.1007/s12094-007-0057-9; Gorman AL, 1997, NEUROSCI LETT, V223, P5; GUTSTEIN BH, 2001, GOODMAN GILLMAN PHAR, P598; HOUDE RW, 1966, INT ENCY PHARM THERA, P59; Kaldjian Lauris C, 2004, Am J Hosp Palliat Care, V21, P381, DOI 10.1177/104990910402100514; Katcher J, 1999, J PAIN SYMPTOM MANAG, V17, P70, DOI 10.1016/S0885-3924(98)00115-8; Katchman AN, 2006, J PHARMACOL EXP THER, V316, P1098, DOI 10.1124/jpet.105.093393; Klepstad P, 2000, ACTA ANAESTH SCAND, V44, P656, DOI 10.1034/j.1399-6576.2000.440605.x; Klepstad P, 2000, EUR J CLIN PHARMACOL, V55, P713, DOI 10.1007/s002280050003; Kloke M, 2000, SUPPORT CARE CANCER, V8, P479, DOI 10.1007/s005200000153; Kornick CA, 2003, PAIN, V105, P499, DOI 10.1016/S0304-3959(03)00205-7; Krantz MJ, 2005, PHARMACOTHERAPY, V25, P1523, DOI 10.1592/phco.2005.25.11.1523; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Lussier D, 2004, ONCOLOGIST, V9, P571, DOI 10.1634/theoncologist.9-5-571; Manfredi PL, 2003, J PAIN SYMPTOM MANAG, V26, P687, DOI 10.1016/S0885-3924(03)00259-8; Marinella MA, 1997, SOUTHERN MED J, V90, P556, DOI 10.1097/00007611-199705000-00022; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; MELZAK R, 1993, PAIN MEASUREMENT ASS; Mercadante S, 1998, PAIN, V74, P5, DOI 10.1016/S0304-3959(97)00090-0; Mercadante S, 1996, PALLIATIVE MED, V10, P225; Mercadante S, 2007, J PALLIAT MED, V10, P338, DOI 10.1089/jpm.2006.0140; Mercadante Sebastiano L, 2007, Am J Hosp Palliat Care, V24, P13, DOI 10.1177/1049909106295431; Meyers FJ, 2004, J PAIN SYMPTOM MANAG, V28, P548, DOI 10.1016/j.jpainsymman.2004.03.002; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Moryl N, 2006, CANC MED, P1113; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Murillo Mauricio, 2004, Palliat Support Care, V2, P65; Nicholson AB, 2004, COCHRANE DB SYST REV, V2; OWEN JA, 1983, CLIN PHARMACOL THER, V34, P364, DOI 10.1038/clpt.1983.180; Pasternak GW, 2005, J PAIN SYMPTOM MANAG, V29, pS2, DOI 10.1016/j.jpainsymman.2005.01.011; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; PORTENOY RK, 1991, PAIN, V47, P13, DOI 10.1016/0304-3959(91)90005-I; Portenoy RK, 2006, J PAIN SYMPTOM MANAG, V32, P532, DOI 10.1016/j.jpainsymman.2006.08.003; Prommer Eric, 2006, J Opioid Manag, V2, P130; Redinbaugh EM, 2003, BMJ-BRIT MED J, V327, P185, DOI 10.1136/bmj.327.7408.185; Reissig JE, 2005, ANN PHARMACOTHER, V39, P727, DOI 10.1345/aph.1E309; Ripamonti C, 1997, PAIN, V70, P109, DOI 10.1016/S0304-3959(96)03286-1; Ripamonti C, 2001, SUPPORT CARE CANCER, V9, P223, DOI 10.1007/s005200000198; Sandner-Kiesling A, 2003, CURR OPIN ANESTHESIO, V16, P535, DOI 10.1097/00001503-200310000-00015; Santiago-Palma J, 2001, CANCER, V92, P1919, DOI 10.1002/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G; Sarhill N, 2001, SUPPORT CARE CANCER, V9, P84, DOI 10.1007/s005200000183; Sekine R, 2007, J PAIN SYMPTOM MANAG, V34, P566, DOI 10.1016/j.jpainsymman.2007.05.001; Smith MT, 2000, CLIN EXP PHARMACOL P, V27, P524, DOI 10.1046/j.1440-1681.2000.03290.x; Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095; SOPALSKI MA, 2007, J HOSP PALLIAT NURS, V9, P13; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Stone P, 1997, PALLIATIVE MED, V11, P140, DOI 10.1177/026921639701100208; Sulmasy Daniel P, 2002, Gerontologist, V42 Spec No 3, P24; Sulmasy DP, 2000, ANN INTERN MED, V133, P564, DOI 10.7326/0003-4819-133-7-200010030-00027; Tarcatu Dana, 2007, J Opioid Manag, V3, P167; Tomalik-Scharte D, 2008, PHARMACOGENOMICS J, V8, P4, DOI 10.1038/sj.tpj.6500462; Ventafridda V, 1990, J Palliat Care, V6, P7; Visser E, 2006, BIOMED PHARMACOTHER, V60, P341, DOI 10.1016/j.biopha.2006.06.021; Wedam EF, 2007, ARCH INTERN MED, V167, P2469, DOI 10.1001/archinte.167.22.2469; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; Wiffen P., 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001133; Wilson KG, 2007, J PAIN SYMPTOM MANAG, V33, P118, DOI 10.1016/j.jpainsymman.2006.07.016; Wilson Robin K, 2004, J Palliat Med, V7, P579, DOI 10.1089/1096621041838425; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	99	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2008	299	12					1457	1467		10.1001/jama.299.12.1457	http://dx.doi.org/10.1001/jama.299.12.1457			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278MY	18364488				2022-12-28	WOS:000254292200020
J	Anvari, M				Anvari, Mehran			Endoscopic treatments for gastro-oesophageal reflux disease	LANCET			English	Editorial Material							ENDOCINCH ENDOLUMINAL GASTROPLICATION; MULTICENTER TRIAL; FOLLOW-UP; GERD; ENTERYX; INJECTION; IMPLANTATION; FAILURE		[Anvari, Mehran] St Josephs Healthcare, Hamilton, ON L8N 4A6, Canada		Anvari, M (corresponding author), St Josephs Healthcare, Hamilton, ON L8N 4A6, Canada.	anvari@mcmaster.ca	Anvari, Mehran/AAQ-1738-2021	Anvari, Mehran/0000-0001-7256-5789				Cohen LB, 2005, GASTROINTEST ENDOSC, V61, P650, DOI 10.1016/S0016-5107(04)02835-4; Fry LC, 2007, EUR J GASTROEN HEPAT, V19, P1125, DOI 10.1097/MEG.0b013e3282f16a21; Houston H, 2003, SURG ENDOSC, V17, P401, DOI 10.1007/s00464-002-8923-6; Johnson DA, 2003, AM J GASTROENTEROL, V98, P250, DOI 10.1016/S0002-9270(02)06013-6; Kahrilas PJ, 2003, GASTROINTEST ENDOSC, V57, P723, DOI 10.1067/mge.2003.203; Noh KW, 2005, AM J GASTROENTEROL, V100, P723, DOI 10.1111/j.1572-0241.2005.41293.x; Pleskow D, 2004, GASTROINTEST ENDOSC, V59, P163, DOI 10.1016/S0016-5107(03)02542-2; Schiefke I, 2005, GUT, V54, P752, DOI 10.1136/gut.2004.058354; Schiefke I, 2005, ENDOSCOPY, V37, P700, DOI 10.1055/s-2005-870128; Tintillier M, 2004, AM J GASTROENTEROL, V99, P1856, DOI 10.1111/j.1572-0241.2004.40554.x; Tuebergen D, 2004, ENDOSCOPY, V36, P663, DOI 10.1055/s-2004-814526; Wong RF, 2005, GASTROINTEST ENDOSC, V61, P753, DOI 10.1016/S0016-5107(04)02645-8	12	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 22	2008	371	9617					965	966		10.1016/S0140-6736(08)60430-4	http://dx.doi.org/10.1016/S0140-6736(08)60430-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358911				2022-12-28	WOS:000254206000006
J	Tattersall, RS; Boulton, JG; Amos, RS				Tattersall, Rachel S.; Boulton, John G.; Amos, Rodney S.			Stiff and partly blind - after a first dose of steroid	LANCET			English	Editorial Material							REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY; LUPUS		[Tattersall, Rachel S.; Boulton, John G.; Amos, Rodney S.] Royal Hallamshire Hosp, Dept Rheumatol, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield	Tattersall, RS (corresponding author), Royal Hallamshire Hosp, Dept Rheumatol, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	rstattersall@doctors.org.uk						Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; Magnano MD, 2006, SEMIN ARTHRITIS RHEU, V35, P396, DOI 10.1016/j.semarthrit.2006.01.002; Mak A, 2008, RHEUMATOLOGY, V47, P256, DOI 10.1093/rheumatology/kem319; Stott VL, 2005, INTERN MED J, V35, P83, DOI 10.1111/j.1445-5994.2004.00750.x	4	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 22	2008	371	9617					1044	1044		10.1016/S0140-6736(08)60458-4	http://dx.doi.org/10.1016/S0140-6736(08)60458-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358931				2022-12-28	WOS:000254206000032
J	Kim, JW; Chu, JL; Shen, XH; Wang, JL; Orkin, SH				Kim, Jonghwan; Chu, Jianlin; Shen, Xiaohua; Wang, Jianlong; Orkin, Stuart H.			An extended transcriptional network for pluripotency of embryonic stem cells	CELL			English	Article							DEVELOPMENTAL REGULATORS; MAMMALIAN-CELLS; SELF-RENEWAL; C-MYC; GENOME; MOUSE; NANOG; FIBROBLASTS; EXPRESSION; SALL4	Much attention has focused on a small set of transcription factors that maintain human or mouse embryonic stem (ES) cells in a pluripotent state. To gain a more complete understanding of the regulatory network that maintains this state, we identified target promoters of nine transcription factors, including somatic cell reprogramming factors (Oct4, Sox2, Klf4, and c-Myc) and others (Nanog, Dax1, Rex1, Zpf281, and Nac1), on a global scale in mouse ES cells. We found that target genes fall into two classes: promoters bound by few factors tend to be inactive or repressed, whereas promoters bound by more than four factors are largely active in the pluripotent state and become repressed upon differentiation. Furthermore, we propose a transcriptional hierarchy for reprogramming factors and broadly distinguish targets of c-Myc versus other factors. Our data provide a resource for exploration of the complex network maintaining pluripotency.	[Kim, Jonghwan; Chu, Jianlin; Shen, Xiaohua; Wang, Jianlong; Orkin, Stuart H.] Dept Pediat Oncol, Boston, MA 02115 USA; [Orkin, Stuart H.] Childrens Hosp, Boston, MA 02115 USA; [Orkin, Stuart H.] Dana Farber Canc Inst, Harvard Stem Cell Inst, Boston, MA 02115 USA; [Kim, Jonghwan; Chu, Jianlin; Shen, Xiaohua; Wang, Jianlong; Orkin, Stuart H.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Kim, Jonghwan; Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Orkin, SH (corresponding author), Dept Pediat Oncol, Boston, MA 02115 USA.	stuart_orkin@dfci.harvard.edu	Wang, Jianlong/GQR-1191-2022; Kim, Jonghwan/AAR-2815-2021; Wang, Jianlong/AAG-9425-2020	Wang, Jianlong/0000-0002-1317-6457; Kim, Jonghwan/0000-0002-9919-9843	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bailey TL, 2006, NUCLEIC ACIDS RES, V34, pW369, DOI 10.1093/nar/gkl198; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; Euskirchen GM, 2007, GENOME RES, V17, P898, DOI 10.1101/gr.5583007; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103; Kim JW, 2005, NAT METHODS, V2, P47, DOI 10.1038/NMETH726; Kuhn RM, 2007, NUCLEIC ACIDS RES, V35, pD668, DOI 10.1093/nar/gkl928; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; MacIsaac KD, 2006, BIOINFORMATICS, V22, P423, DOI 10.1093/bioinformatics/bti815; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Messina DN, 2004, GENOME RES, V14, P2041, DOI 10.1101/gr.2584104; Mi HY, 2007, NUCLEIC ACIDS RES, V35, pD247, DOI 10.1093/nar/gkl869; Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637; Mito Y, 2007, SCIENCE, V315, P1408, DOI 10.1126/science.1134004; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Niakan KK, 2006, MOL GENET METAB, V88, P261, DOI 10.1016/j.ymgme.2005.12.010; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Orkin SH, 2005, CELL, V122, P828, DOI 10.1016/j.cell.2005.09.002; Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Pirity MK, 2005, MOL CELL BIOL, V25, P7193, DOI 10.1128/MCB.25.16.7193-7202.2005; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Roh TY, 2004, NAT BIOTECHNOL, V22, P1013, DOI 10.1038/nbt990; Sakaki-Yumoto M, 2006, DEVELOPMENT, V133, P3005, DOI 10.1242/dev.02457; Silva J, 2006, NATURE, V441, P997, DOI 10.1038/nature04914; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Walhout AJM, 2006, GENOME RES, V16, P1445, DOI 10.1101/gr.5321506; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wernig M, 2008, CELL STEM CELL, V2, P10, DOI 10.1016/j.stem.2007.12.001; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; YOSHIDA K, 1994, MECH DEVELOP, V45, P163, DOI 10.1016/0925-4773(94)90030-2; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004; Zhou Q, 2007, P NATL ACAD SCI USA, V104, P16438, DOI 10.1073/pnas.0701014104	59	1001	1029	0	81	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2008	132	6					1049	1061		10.1016/j.cell.2008.02.039	http://dx.doi.org/10.1016/j.cell.2008.02.039			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358816	Bronze, Green Accepted			2022-12-28	WOS:000254273600022
J	Nunez, E; Kwon, YS; Hutt, KR; Hu, Q; Cardamone, MD; Ohgi, KA; Garcia-Bassets, I; Rose, DW; Glass, CK; Rosenfeld, MG; Fu, XD				Nunez, Esperanza; Kwon, Young-Soo; Hutt, Kasey R.; Hu, Qidong; Cardamone, Maria Dafne; Ohgi, Kenneth A.; Garcia-Bassets, Ivan; Rose, David W.; Glass, Christopher K.; Rosenfeld, Michael G.; Fu, Xiang-Dong			RETRACTED: Nuclear receptor-enhanced transcription requires motor- and LSD1-dependent gene networking in interchromatin granules (Retracted Article. See vol 134, pg 189, 2008)	CELL			English	Article; Retracted Publication							BETA-GLOBIN LOCUS; BINDING-SITES; DEPENDENT TRANSCRIPTION; ESTROGEN RESPONSE; MYOSIN-I; ACTIN; ACTIVATION; DYNAMICS; COMPLEX; GENOME	While the transcriptional machinery has been extensively dissected at the molecular level, little is known about regulation of chromosomal organization in the three-dimensional space of the nucleus to achieve integrated transcriptional responses to diverse signaling events. Here, we report that ligand induces rapid interchromosomal interactions among subsets of estrogen receptor alpha-bound transcription units, with a dramatic reorganization of nuclear territories requiring nuclear actin/myosin-I transport machinery, dynein light chain 1 (DLC1), and a specific subset of transcriptional coactivators and chromatin remodeling complexes. We establish a requirement for the histone lysine demethylase, LSD1, in directing specific interchromosomal interaction loci to distinct interchromatin granules, long thought to be "storage'' sites for splicing machinery, and demonstrate that these three-dimensional motor-dependent interactions are required to achieve enhanced transcription of specific estrogen-receptor target genes. These findings reveal roles for the modulation of nuclear architecture in orchestrating regulated gene-expression programs in the mammalian nucleus.	[Nunez, Esperanza; Hutt, Kasey R.; Hu, Qidong; Cardamone, Maria Dafne; Ohgi, Kenneth A.; Garcia-Bassets, Ivan; Rosenfeld, Michael G.] Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, La Jolla, CA 92093 USA; [Nunez, Esperanza] Univ Calif San Diego, Biomed Sci Grad Program, Sch Med, La Jolla, CA 92093 USA; [Rose, David W.; Fu, Xiang-Dong] Univ Calif San Diego, Dept Med, Sch Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; [Kwon, Young-Soo; Glass, Christopher K.] Univ Calif San Diego, Dept Cellular & Mol Med, Sch Med, La Jolla, CA 92093 USA; [Hutt, Kasey R.] Univ Calif San Diego, Bioinformat Grad Program, Sch Med, La Jolla, CA 92093 USA; [Cardamone, Maria Dafne] Univ Turin, Dept Oncol Sci, Turin, Italy	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Turin	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mrosenfeld@ucsd.edu; xdfu@ucsd.edu	Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; Cardamone, Maria/0000-0003-4591-3447	NATIONAL CANCER INSTITUTE [R01CA052599, R33CA114184, R01CA097134] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039949, R01DK039949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034934] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [CA97134, CA52599, CA114184] Funding Source: Medline; NHLBI NIH HHS [HL088129] Funding Source: Medline; NIDDK NIH HHS [DK39949] Funding Source: Medline; NIGMS NIH HHS [GM049369] Funding Source: Medline; NINDS NIH HHS [NS34934] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Branco MR, 2006, PLOS BIOL, V4, P780, DOI 10.1371/journal.pbio.0040138; Bubb MR, 1998, METHOD ENZYMOL, V298, P26, DOI 10.1016/S0076-6879(98)98005-3; Cai ST, 1999, METHODS, V19, P394, DOI 10.1006/meth.1999.0875; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chuang CH, 2006, CURR BIOL, V16, P825, DOI 10.1016/j.cub.2006.03.059; Cook P, 1998, SCIENCE, V281, P1466, DOI 10.1126/science.281.5382.1466; Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dennis AP, 2005, J STEROID BIOCHEM, V93, P139, DOI 10.1016/j.jsbmb.2004.12.015; Dillon N, 2006, CHROMOSOME RES, V14, P117, DOI 10.1007/s10577-006-1027-8; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; Ghosh MG, 2000, CANCER RES, V60, P6367; Gonsior SM, 1999, J CELL SCI, V112, P797; Gunawardena S, 2000, CURR BIOL, V10, P285, DOI 10.1016/S0960-9822(00)00360-2; Handwerger KE, 2006, TRENDS CELL BIOL, V16, P19, DOI 10.1016/j.tcb.2005.11.005; Hewitt SL, 2004, EUR J IMMUNOL, V34, P3604, DOI 10.1002/eji.200425469; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hofmann WA, 2006, J CELL BIOL, V172, P495, DOI 10.1083/jcb.200601095; Hofmann WA, 2006, BIOCHEM CELL BIOL, V84, P418, DOI 10.1139/O06-069; Holzinger A, 2001, METH MOL B, V161, P109; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Kahle M, 2007, HISTOCHEM CELL BIOL, V127, P139, DOI 10.1007/s00418-006-0231-0; Kosak ST, 2002, SCIENCE, V296, P158, DOI 10.1126/science.1068768; Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191; Lomvardas S, 2006, CELL, V126, P403, DOI 10.1016/j.cell.2006.06.035; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Paixao T, 2007, IMMUNOL CELL BIOL, V85, P315, DOI 10.1038/sj.icb.7100057; Percipalle P, 2006, J CELL BIOL, V172, P967, DOI 10.1083/jcb.200512083; Percipalle P, 2006, CURR OPIN CELL BIOL, V18, P267, DOI 10.1016/j.ceb.2006.03.001; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337; Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417; Rizk RS, 2005, CURR BIOL, V15, pR841, DOI 10.1016/j.cub.2005.10.004; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Saitoh N, 2004, MOL BIOL CELL, V15, P3876, DOI 10.1091/mbc.E04-03-0253; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Vega VB, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r82; Wang Q, 2003, J CELL SCI, V116, P4227, DOI 10.1242/jcs.00709; Williams RRE, 2006, J CELL SCI, V119, P132, DOI 10.1242/jcs.02727; Zhao Z, 2006, NAT GENET, V38, P1341, DOI 10.1038/ng1891; Zink D, 2004, J CELL BIOL, V166, P815, DOI 10.1083/jcb.200404107	62	49	50	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2008	132	6					996	1010		10.1016/j.cell.2008.01.051	http://dx.doi.org/10.1016/j.cell.2008.01.051			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358812	Bronze			2022-12-28	WOS:000254273600018
J	Peric-Hupkes, D; van Steensel, B				Peric-Hupkes, Daniel; van Steensel, Bas			Linking cohesin to gene regulation	CELL			English	Review							CTCF; TRANSCRIPTION; CHROMATIN; REVEALS; REGIONS; ARMS	During cell division the cohesin complex mediates the pairing of sister chromatids. Emerging evidence shows that cohesin also has roles in interphase cells. New studies, including that of Gullerova and Proudfoot (2008) in this issue, reveal how cohesin is targeted to specific sites on chromosomes and implicate cohesin in the regulation of gene expression.	[Peric-Hupkes, Daniel; van Steensel, Bas] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	van Steensel, B (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	b.v.steensel@nki.nl						Bausch C, 2007, MOL CELL BIOL, V27, P8522, DOI 10.1128/MCB.01007-07; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Chang CR, 2005, GENE DEV, V19, P3031, DOI 10.1101/gad.1356305; Dorsett D, 2007, CHROMOSOMA, V116, P1, DOI 10.1007/s00412-006-0072-6; Gerlich D, 2006, CURR BIOL, V16, P1571, DOI 10.1016/j.cub.2006.06.068; Glynn EF, 2004, PLOS BIOL, V2, P1325, DOI 10.1371/journal.pbio.0020259; Hirano M, 2006, MOL CELL, V21, P175, DOI 10.1016/j.molcel.2005.11.026; Horsfield JA, 2007, DEVELOPMENT, V134, P2639, DOI 10.1242/dev.002485; Lengronne A, 2004, NATURE, V430, P573, DOI 10.1038/nature02742; Losada A, 2007, CHROMOSOMA, V116, P321, DOI 10.1007/s00412-007-0104-x; Misulovin Z, 2008, CHROMOSOMA, V117, P89, DOI 10.1007/s00412-007-0129-1; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Parelho V, 2008, CELL, V132, P422, DOI 10.1016/j.cell.2008.01.011; Pauli A, 2008, DEV CELL, V14, P239, DOI 10.1016/j.devcel.2007.12.009; Schuldiner O, 2008, DEV CELL, V14, P227, DOI 10.1016/j.devcel.2007.11.001; Splinter E, 2006, GENE DEV, V20, P2349, DOI 10.1101/gad.399506; Stedman W, 2008, EMBO J, V27, P654, DOI 10.1038/emboj.2008.1; Wendt KS, 2008, NATURE, V451, P796, DOI 10.1038/nature06634; Xu N, 2007, NAT GENET, V39, P1390, DOI 10.1038/ng.2007.5	19	28	29	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2008	132	6					925	928		10.1016/j.cell.2008.03.001	http://dx.doi.org/10.1016/j.cell.2008.03.001			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358805	Bronze			2022-12-28	WOS:000254273600011
J	Alexandroff, A; Kirkham, N; Nayak, N				Alexandroff, Anton; Kirkham, Nigel; Nayak, Neena			A painless, swollen finger (for 20 years)	LANCET			English	Editorial Material									[Alexandroff, Anton] Leicester Royal Infirm, Dept Dermatol, Leicester LE1 5WW, Leics, England; [Kirkham, Nigel] Royal Victoria Hosp, Dept Pathol, Newcastle Upon Tyne, Tyne & Wear, England; [Nayak, Neena] Salisbury Dist Hosp, Dept Dermatol, Salisbury NHS Fdn Trust, Salisbury, Wilts, England	University of Leicester; Salisbury District Hospital	Alexandroff, A (corresponding author), Leicester Royal Infirm, Dept Dermatol, Leicester LE1 5WW, Leics, England.	anton.alexandroff@gmail.com							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR-APR	2008	371	9618					1114	1114		10.1016/S0140-6736(08)60487-0	http://dx.doi.org/10.1016/S0140-6736(08)60487-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18374842				2022-12-28	WOS:000254442700030
J	Kuhara, A; Okumura, M; Kimata, T; Tanizawa, Y; Takano, R; Kimura, KD; Inada, H; Matsumoto, K; Mori, I				Kuhara, Atsushi; Okumura, Masatoshi; Kimata, Tsubasa; Tanizawa, Yoshinori; Takano, Ryo; Kimura, Koutarou D.; Inada, Hitoshi; Matsumoto, Kunihiro; Mori, Ikue			Temperature sensing by an olfactory neuron in a circuit controlling behavior of C-elegans	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; G-PROTEINS; CHEMOSENSATION; THERMOTAXIS; PATHWAY; GENES	Temperature is an unavoidable environmental cue that affects the metabolism and behavior of any creature on Earth, yet how animals perceive temperature is poorly understood. The nematode Caenorhabditis elegans "memorizes" temperatures, and this stored information modifies its subsequent migration along a temperature gradient. We show that the olfactory neuron designated AWC senses temperature. Calcium imaging revealed that AWC responds to temperature changes and that response thresholds differ depending on the temperature to which the animal was previously exposed. In the mutant with impaired heterotrimeric guanine nucleotide- binding protein ( G protein)- mediated signaling, AWC was hyperresponsive to temperature, whereas the AIY interneuron ( which is postsynaptic to AWC) was hyporesponsive to temperature. Thus, temperature sensation exhibits a robust influence on a neural circuit controlling a memory- regulated behavior.	[Kuhara, Atsushi; Okumura, Masatoshi; Kimata, Tsubasa; Tanizawa, Yoshinori; Takano, Ryo; Kimura, Koutarou D.; Inada, Hitoshi; Mori, Ikue] Nagoya Univ, Grad Sch Sci, Grp Mol Neurobiol, Nagoya, Aichi 4648602, Japan; [Matsumoto, Kunihiro] Nagoya Univ, Grad Sch Sci, Grp Signal Transduct, Nagoya, Aichi 4648602, Japan; [Mori, Ikue] Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648602, Japan; [Mori, Ikue] Japan Sci & Technol Agcy, CREST, Tokyo, Japan	Nagoya University; Nagoya University; Nagoya University; Japan Science & Technology Agency (JST)	Mori, I (corresponding author), Nagoya Univ, Grad Sch Sci, Grp Mol Neurobiol, Nagoya, Aichi 4648602, Japan.	m46920a@nucc.cc.nagoya-u.ac.jp	Kimura, Koutarou D./T-9645-2019; Okumura, Masatoshi/AAT-2157-2020; Inada, Hitoshi/GQH-1084-2022; Kuhara, Atsushi/S-5855-2018; Inada, Hitoshi/T-2773-2019	Kimura, Koutarou D./0000-0002-3359-1578; Okumura, Masatoshi/0000-0002-0563-9909; Inada, Hitoshi/0000-0002-6121-3830; Kuhara, Atsushi/0000-0003-2994-8658; Inada, Hitoshi/0000-0002-6121-3830; Tanizawa, Yoshinori/0000-0002-5014-2483				BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Biron D, 2006, NAT NEUROSCI, V9, P1499, DOI 10.1038/nn1796; Chalasani SH, 2007, NATURE, V450, P63, DOI 10.1038/nature06292; Clark DA, 2006, J NEUROSCI, V26, P7444, DOI 10.1523/JNEUROSCI.1137-06.2006; Fukuto HS, 2004, NEURON, V42, P581, DOI 10.1016/S0896-6273(04)00252-1; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; HEDGECOCK EM, 1975, P NATL ACAD SCI USA, V72, P4061, DOI 10.1073/pnas.72.10.4061; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; Inada H, 2006, GENETICS, V172, P2239, DOI 10.1534/genetics.105.050013; Ito H, 2006, J NEUROSCI METH, V154, P45, DOI 10.1016/j.jneumeth.2005.11.011; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Kimura KD, 2004, CURR BIOL, V14, P1291, DOI 10.1016/j.cub.2004.06.060; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; L'Etoile ND, 2000, NEURON, V25, P575, DOI 10.1016/S0896-6273(00)81061-2; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mohri A, 2005, GENETICS, V169, P1437, DOI 10.1534/genetics.104.036111; MORI I, 1995, NATURE, V376, P344, DOI 10.1038/376344a0; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Tanizawa Y, 2006, GENE DEV, V20, P3296, DOI 10.1101/gad.1497806; Tomioka M, 2006, NEURON, V51, P613, DOI 10.1016/j.neuron.2006.07.024; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Zwaal RR, 1997, GENETICS, V145, P715	22	128	144	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 9	2008	320	5877					803	807		10.1126/science.1148922	http://dx.doi.org/10.1126/science.1148922			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VB	18403676				2022-12-28	WOS:000255644400044
J	Politi, A; Cryan, MJ; Rarity, JG; Yu, SY; O'Brien, JL				Politi, Alberto; Cryan, Martin J.; Rarity, John G.; Yu, Siyuan; O'Brien, Jeremy L.			Silica-on-silicon waveguide quantum circuits	SCIENCE			English	Article							ENTANGLEMENT; PHOTONS; INTERFERENCE; LIMIT; STATE	Quantum technologies based on photons will likely require an integrated optics architecture for improved performance, miniaturization, and scalability. We demonstrate high- fidelity silica- on- silicon integrated optical realizations of key quantum photonic circuits, including two- photon quantum interference with a visibility of 94.8 +/- 0.5%; a controlled- NOT gate with an average logical basis fidelity of 94.3 +/- 0.2%; and a path- entangled state of two photons with fidelity of >92%. These results show that it is possible to directly "write" sophisticated photonic quantum circuits onto a silicon chip, which will be of benefit to future quantum technologies based on photons, including information processing, communication, metrology, and lithography, as well as the fundamental science of quantum optics.	[Politi, Alberto; Cryan, Martin J.; Rarity, John G.; Yu, Siyuan; O'Brien, Jeremy L.] Univ Bristol, HH Wills Phys Lab, Ctr Quantum Photon, Bristol BS8 1UB, Avon, England; [Politi, Alberto; Cryan, Martin J.; Rarity, John G.; Yu, Siyuan; O'Brien, Jeremy L.] Univ Bristol, Dept Elect & Elect Engn, Bristol BS8 1UB, Avon, England	University of Bristol; University of Bristol	O'Brien, JL (corresponding author), Univ Bristol, HH Wills Phys Lab, Ctr Quantum Photon, Merchant Venturers Bldg,Woodland Rd, Bristol BS8 1UB, Avon, England.	Jeremy.OBrien@bristol.ac.uk	Yu, Siyuan/G-5713-2017; Politi, Alberto/D-7134-2011; O'Brien, Jeremy L/A-6290-2008	Yu, Siyuan/0000-0002-2550-8201; Politi, Alberto/0000-0002-3668-9474; O'Brien, Jeremy/0000-0002-3576-8285; Dekker, Peter/0000-0001-9284-5403; Ams, Martin/0000-0002-4359-0480; Withford, Michael/0000-0002-6414-8739	EPSRC [EP/F008023/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [GR/S82176/01, EP/F008023/1] Funding Source: researchfish	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Gasparoni S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.020504; Gisin N, 2002, REV MOD PHYS, V74, P145, DOI 10.1103/RevModPhys.74.145; GRANGLER P, 2004, NEW J PHYS, V6; Higgins BL, 2007, NATURE, V450, P393, DOI 10.1038/nature06257; Hofmann HF, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.024308; HONG CK, 1987, PHYS REV LETT, V59, P2044, DOI 10.1103/PhysRevLett.59.2044; Kawabe Y, 2007, OPT EXPRESS, V15, P14244, DOI 10.1364/OE.15.014244; Kiesel N, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.210502; Kiesel N, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.210505; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Langford NK, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.210504; Lu CY, 2007, NAT PHYS, V3, P91, DOI 10.1038/nphys507; MIGDAL A, 2004, J MOD OPT, V51; Mitchell MW, 2004, NATURE, V429, P161, DOI 10.1038/nature02493; Nagata T, 2007, SCIENCE, V316, P726, DOI 10.1126/science.1138007; Nielsen Michael A., 2002, QUANTUM COMPUTATION; O'Brien JL, 2007, SCIENCE, V318, P1393, DOI 10.1126/science.1152581; O'Brien JL, 2007, SCIENCE, V318, P1567, DOI 10.1126/science.1142892; O'Brien JL, 2003, NATURE, V426, P264, DOI 10.1038/nature02054; Okamoto R, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.210506; Pittman TB, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.032316; Pryde GJ, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.190402; Ralph TC, 2006, PHYS REV A, V73, DOI 10.1103/PhysRevA.73.012113; Ralph TC, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.062324; Resch KJ, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.223601; Rohde PP, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.032306; Sun FW, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.033812; Walther P, 2004, NATURE, V429, P158, DOI 10.1038/nature02552; Walther P, 2005, NATURE, V434, P169, DOI 10.1038/nature03347	30	750	770	8	257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2008	320	5876					646	649		10.1126/science.1155441	http://dx.doi.org/10.1126/science.1155441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	295DD	18369104	Green Submitted			2022-12-28	WOS:000255454300040
J	Beckett, NS; Peters, R; Fletcher, AE; Staessen, JA; Liu, LS; Dumitrascu, D; Stoyanovsky, V; Antikainen, RL; Nikitin, Y; Anderson, C; Belhani, A; Forette, F; Rajkumar, C; Thijs, L; Banya, W; Bulpitt, CJ				Beckett, Nigel S.; Peters, Ruth; Fletcher, Astrid E.; Staessen, Jan A.; Liu, Lisheng; Dumitrascu, Dan; Stoyanovsky, Vassil; Antikainen, Riitta L.; Nikitin, Yuri; Anderson, Craig; Belhani, Alli; Forette, Francoise; Rajkumar, Chakravarthi; Thijs, Lutgarde; Banya, Winston; Bulpitt, Christopher J.		HYVET Study Grp	Treatment of hypertension in patients 80 years of age or older	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-PRESSURE; HEART-FAILURE; SHORT-TERM; MORTALITY; SURVIVAL; TRIAL; POPULATION; INDAPAMIDE; STROKE; METAANALYSIS	Background: Whether the treatment of patients with hypertension who are 80 years of age or older is beneficial is unclear. It has been suggested that antihypertensive therapy may reduce the risk of stroke, despite possibly increasing the risk of death. Methods: We randomly assigned 3845 patients from Europe, China, Australasia, and Tunisia who were 80 years of age or older and had a sustained systolic blood pressure of 160 mm Hg or more to receive either the diuretic indapamide (sustained release, 1.5 mg) or matching placebo. The angiotensin-converting-enzyme inhibitor perindopril (2 or 4 mg), or matching placebo, was added if necessary to achieve the target blood pressure of 150/80 mm Hg. The primary end point was fatal or nonfatal stroke. Results: The active-treatment group (1933 patients) and the placebo group (1912 patients) were well matched (mean age, 83.6 years; mean blood pressure while sitting, 173.0/90.8 mm Hg); 11.8% had a history of cardiovascular disease. Median follow-up was 1.8 years. At 2 years, the mean blood pressure while sitting was 15.0/6.1 mm Hg lower in the active-treatment group than in the placebo group. In an intention-to-treat analysis, active treatment was associated with a 30% reduction in the rate of fatal or nonfatal stroke (95% confidence interval [CI], -1 to 51; P=0.06), a 39% reduction in the rate of death from stroke (95% CI, 1 to 62; P=0.05), a 21% reduction in the rate of death from any cause (95% CI, 4 to 35; P=0.02), a 23% reduction in the rate of death from cardiovascular causes (95% CI, -1 to 40; P=0.06), and a 64% reduction in the rate of heart failure (95% CI, 42 to 78; P<0.001). Fewer serious adverse events were reported in the active-treatment group (358, vs. 448 in the placebo group; P=0.001). Conclusions: The results provide evidence that antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older is beneficial. (ClinicalTrials.gov number, NCT00122811.).	[Beckett, Nigel S.; Peters, Ruth; Antikainen, Riitta L.; Banya, Winston; Bulpitt, Christopher J.] Univ London Imperial Coll Sci Technol & Med, Div Med, London W12 0NN, England; [Fletcher, Astrid E.] London Sch Hyg & Trop Med, London WC1, England; [Staessen, Jan A.; Thijs, Lutgarde] Univ Louvain, Louvain, Belgium; [Liu, Lisheng] Beijing Hypertens League Inst, Beijing, Peoples R China; [Dumitrascu, Dan] Spitalul Judetean Cluj, Med Clin 2, Cluj Napoca, Romania; [Stoyanovsky, Vassil] Natl Transport Multi Profile Hosp, Sofia, Bulgaria; [Antikainen, Riitta L.] Univ Oulu, Oulu, Finland; [Nikitin, Yuri] State Sci Res Inst Internal Med, Novosibirsk, Russia; [Anderson, Craig] George Inst Int Hlth, Sydney, NSW, Australia; [Belhani, Alli] Etab Publ Sante Charles Nicolle, Serv Cardiol, Tunis, Tunisia; [Forette, Francoise] Univ Paris 05, Hop Broca, Paris, France; [Rajkumar, Chakravarthi] Brighton & Sussex Med Sch, Brighton, E Sussex, England	Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Chinese Hypertension League; University of Oulu; University of Sydney; Universite de Tunis-El-Manar; Hopital Charles Nicolle; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Broca - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Brighton; University of Sussex	Beckett, NS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Med, Du Cane Rd, London W12 0NN, England.		Ripp, Tatiana M./P-6586-2015; Karpov, Rostislav S./F-5406-2014; Staessen, Jan A/A-1065-2011; Nedogoda, Sergey V/O-4656-2014; Zadionchenko, Vladimir/A-7445-2016; Peters, Ruth/D-4047-2011; Nikitin, Yuri/D-2774-2018	Ripp, Tatiana M./0000-0001-5898-0361; Karpov, Rostislav S./0000-0002-7011-4316; Staessen, Jan A/0000-0002-3026-1637; Nedogoda, Sergey V/0000-0001-5981-1754; Zadionchenko, Vladimir/0000-0003-2377-5266; Peters, Ruth/0000-0003-0148-3617; Thijs, Lutgarde/0000-0002-8108-2356; Gommans, John/0000-0003-3750-765X; Waldman, Adam D/0000-0003-4398-6431; Narkiewicz, Krzysztof/0000-0001-5949-5018; Beckett, Nigel/0000-0002-7736-3817; Woodward, Mark/0000-0001-9800-5296; Anderson, Craig/0000-0002-7248-4863; Nikitin, Yuri/0000-0002-3932-2299				Ambrosioni E, 1998, J HYPERTENS, V16, P1677, DOI 10.1097/00004872-199816110-00015; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; Bulpitt C, 2001, DRUG AGING, V18, P151, DOI 10.2165/00002512-200118030-00001; Bulpitt CJ, 2003, J HYPERTENS, V21, P2409, DOI 10.1097/00004872-200312000-00030; Callow AD, 2006, VASC PHARMACOL, V45, P302, DOI 10.1016/j.vph.2006.08.010; Chalmers J, 1999, J HYPERTENS, V17, P151; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Dahlof B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1; Davis BR, 2006, CIRCULATION, V113, P2201, DOI 10.1161/CIRCULATIONAHA.105.544031; de Jong G, 2003, J CLIN EPIDEMIOL, V56, P262, DOI 10.1016/S0895-4356(02)00572-3; Emeriau JP, 2001, J HYPERTENS, V19, P343, DOI 10.1097/00004872-200102000-00023; Gueyffier F, 1999, LANCET, V353, P793, DOI 10.1016/S0140-6736(98)08127-6; Hollander M, 2003, J NEUROL NEUROSUR PS, V74, P317, DOI 10.1136/jnnp.74.3.317; Kammersgaard LP, 2004, AGE AGEING, V33, P149, DOI 10.1093/ageing/afh052; LANGER RD, 1993, HYPERTENSION, V22, P551, DOI 10.1161/01.HYP.22.4.551; Lawes CMM, 2004, STROKE, V35, P1024, DOI 10.1161/01.STR.0000126208.14181.DD; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mancia G, 2007, J HYPERTENS, V25, P1751, DOI 10.1097/HJH.0b013e3282f0580f; Mancia G, 2007, J HYPERTENS, V25, P1105, DOI 10.1097/01.hjh.0000280180.80455.83; MATTILA K, 1988, BRIT MED J, V296, P887, DOI 10.1136/bmj.296.6626.887; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Neal B, 2000, LANCET, V356, P1955; Oates DJ, 2007, J AM GERIATR SOC, V55, P383, DOI 10.1111/j.1532-5415.2007.01069.x; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; PROGRESS Collaborative Grp, 2002, LANCET, V359, P2120; Puig JG, 2007, AM J HYPERTENS, V20, P90, DOI 10.1016/j.amjhyper.2006.05.018; Rastas S, 2006, J AM GERIATR SOC, V54, P912, DOI 10.1111/j.1532-5415.2006.00742.x; Satish S, 2001, J AM GERIATR SOC, V49, P367, DOI 10.1046/j.1532-5415.2001.49078.x; Shapiro AP, 1997, JAMA-J AM MED ASSOC, V277, P157; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Stewart S, 2003, HEART, V89, P49, DOI 10.1136/heart.89.1.49; The Criteria Committee of the New York Heart Association, 1994, NOM CRIT DIAGN DIS H; van Bemmel T, 2006, J AM SOC NEPHROL, V17, P2561, DOI 10.1681/ASN.2005090902; Zuliani G, 2006, GERONTOLOGY, V52, P231, DOI 10.1159/000093655	37	2017	2178	3	109	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2008	358	18					1887	1898		10.1056/NEJMoa0801369	http://dx.doi.org/10.1056/NEJMoa0801369			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294ER	18378519	Green Published, Green Accepted			2022-12-28	WOS:000255387900003
J	Spinewine, A				Spinewine, Anne			Making a difference - Adverse drug reactions in elderly people - The challenge of safer prescribing	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							OLDER; HOMES		Clin Univ Mt Godinne, Yvoir, Belgium	Universite Catholique Louvain; Universite Catholique Louvain Hospital	Spinewine, A (corresponding author), Clin Univ Mt Godinne, Yvoir, Belgium.	anne.spinewine@uclouvain.be						Carnes D, 2008, BRIT MED J, V336, P142, DOI 10.1136/bmj.39401.699063.BE; Elliott RA, 2007, J GEN INTERN MED, V22, P805, DOI 10.1007/s11606-007-0193-5; Glintborg B, 2008, BRIT J CLIN PHARMACO, V65, P265, DOI 10.1111/j.1365-2125.2007.03017.x; Hanlon JT, 2001, J AM GERIATR SOC, V49, P200, DOI 10.1046/j.1532-5415.2001.49042.x; Hughes CM, 2007, DRUG AGING, V24, P81, DOI 10.2165/00002512-200724020-00001; Patterson SM, 2007, PHARM WORLD SCI, V29, P517, DOI 10.1007/s11096-006-9044-4; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Witherington EMA, 2008, QUAL SAF HEALTH CARE, V17, P71, DOI 10.1136/qshc.2006.020842	8	15	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	2008	336	7650					956	+		10.1136/bmj.39520.686458.94	http://dx.doi.org/10.1136/bmj.39520.686458.94			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397946	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000255540900044
J	Dornan, AJ; Goodwin, SF				Dornan, Anthony J.; Goodwin, Stephen F.			Fly courtship song: Triggering the light fantastic	CELL			English	Editorial Material							NEURAL CIRCUITRY; DROSOPHILA; FRUITLESS; BEHAVIOR	In a study in this issue, Clyne and Miesenbock (2008) apply an ingenious optogenetic technology to activate neurons that generate male-specific courtship song in flies. This work sheds new light on the neural circuitry underlying sexually dimorphic behaviors in Drosophila.	[Dornan, Anthony J.; Goodwin, Stephen F.] Univ Glasgow, IBLS, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	Goodwin, SF (corresponding author), Univ Glasgow, IBLS, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland.	s.goodwin@bio.gla.ac.uk		Goodwin, Stephen/0000-0002-0552-4140; Dornan, Anthony/0000-0002-5228-2893				Billeter JC, 2006, CURR BIOL, V16, pR766, DOI 10.1016/j.cub.2006.08.025; Billeter JC, 2006, CURR BIOL, V16, P1063, DOI 10.1016/j.cub.2006.04.039; Datta SR, 2008, NATURE, V452, P473, DOI 10.1038/nature06808; Demir E, 2005, CELL, V121, P785, DOI 10.1016/j.cell.2005.04.027; Kimura KI, 2005, NATURE, V438, P229, DOI 10.1038/nature04229; Kvitsiani D, 2006, CURR BIOL, V16, pR355, DOI 10.1016/j.cub.2006.04.025; Lima SQ, 2005, CELL, V121, P141, DOI 10.1016/j.cell.2005.02.004; Rideout EJ, 2007, CURR BIOL, V17, P1473, DOI 10.1016/j.cub.2007.07.047; Stockinger P, 2005, CELL, V121, P795, DOI 10.1016/j.cell.2005.04.026; VONSCHILCHER F, 1979, J COMP PHYSIOL, V129, P85, DOI 10.1007/BF00679915	10	4	4	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	2008	133	2					210	212		10.1016/j.cell.2008.04.008	http://dx.doi.org/10.1016/j.cell.2008.04.008			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	289JY	18423192	Bronze			2022-12-28	WOS:000255052000010
J	Eichenwald, EC; Stark, AR				Eichenwald, Eric C.; Stark, Ann R.			Medical progress: Management and outcomes of very low birth weight	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INHALED NITRIC-OXIDE; POSITIVE AIRWAY PRESSURE; CHRONIC LUNG-DISEASE; PATENT DUCTUS-ARTERIOSUS; PREVENT BRONCHOPULMONARY DYSPLASIA; NEONATAL RESEARCH NETWORK; NECROTIZING ENTEROCOLITIS; NEURODEVELOPMENTAL OUTCOMES; PREMATURE-INFANTS; PRETERM INFANTS		[Eichenwald, Eric C.; Stark, Ann R.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Eichenwald, Eric C.; Stark, Ann R.] Texas Childrens Hosp, Baylor Coll Med, Sect Neonatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Eichenwald, EC (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, 6621 Fannin,Mail Code WT 6-104, Houston, TX 77030 USA.	eichenwa@bcm.edu		Stark, Ann/0000-0002-6051-1190				Aly H, 2005, PEDIATRICS, V115, P1660, DOI 10.1542/peds.2004-2493; Aly H, 2007, PEDIATRICS, V119, P818, DOI 10.1542/peds.2006-3026; Anderson P, 2003, JAMA-J AM MED ASSOC, V289, P3264, DOI 10.1001/jama.289.24.3264; Askie LM, 2003, NEW ENGL J MED, V349, P959, DOI 10.1056/NEJMoa023080; AVERY ME, 1987, PEDIATRICS, V79, P26; Ballard PL, 2006, PEDIATR RES, V59, P157, DOI 10.1203/01.pdr.0000190664.69081.f1; Ballard RA, 2007, NEW ENGL J MED, V357, P1444, DOI 10.1056/NEJMc076350; Ballard RA, 2006, NEW ENGL J MED, V355, P343, DOI 10.1056/NEJMoa061088; Bancalari E, 2005, BIOL NEONATE, V88, P192, DOI 10.1159/000087582; Banks BA, 1999, PEDIATRICS, V103, P610, DOI 10.1542/peds.103.3.610; Baraldi E, 2007, NEW ENGL J MED, V357, P1946, DOI 10.1056/NEJMra067279; Barrington KJ, 2001, PEDIATRICS, V107, P638, DOI 10.1542/peds.107.4.638; Bartels DB, 2006, PEDIATRICS, V117, P2206, DOI 10.1542/peds.2005-1624; Baveja R, 2006, SEMIN PERINATOL, V30, P209, DOI 10.1053/j.semperi.2006.05.008; Behrman RE, 2007, PRETERM BIRTH CAUSES; Bin-Nun A, 2005, J PEDIATR-US, V147, P192, DOI 10.1016/j.jpeds.2005.03.054; Blackmon LR, 2002, PEDIATRICS, V109, P330; Blakely ML, 2006, PEDIATRICS, V117, pE680, DOI 10.1542/peds.2005-1273; Bland RD, 2005, AM J RESP CRIT CARE, V172, P899, DOI 10.1164/rccm.200503-384OC; Booth C, 2006, ARCH DIS CHILD-FETAL, V91, pF398, DOI 10.1136/adc.2005.092478; Boyd CA, 2007, ARCH DIS CHILD-FETAL, V92, pF169, DOI 10.1136/adc.2005.089490; Butel MJ, 2002, BRIT J NUTR, V87, pS213, DOI 10.1079/BJN/2002540; Carlo WA, 2002, J PEDIATR-US, V141, P370, DOI 10.1067/mpd.2002.127507; Chow LC, 2003, PEDIATRICS, V111, P339, DOI 10.1542/peds.111.2.339; Cole CH, 2003, PEDIATRICS, V112, P1415, DOI 10.1542/peds.112.6.1415; Costeloe K, 2000, PEDIATRICS, V106, P659, DOI 10.1542/peds.106.4.659; Dani C, 2004, PEDIATRICS, V113, pE560, DOI 10.1542/peds.113.6.e560; Deulofeut R, 2006, J PERINATOL, V26, P700, DOI 10.1038/sj.jp.7211608; Eichenwald EC, 2007, ARCH DIS CHILD-FETAL, V92, P334, DOI 10.1136/adc.2006.106583; Ellsbury DL, 2002, J PEDIATR-US, V140, P247, DOI 10.1067/mpd.2002.121933; Evans N, 2006, ARCH DIS CHILD-FETAL, V91, pF213, DOI 10.1136/adc.2005.071829; Fanaroff Avroy A, 2007, Am J Obstet Gynecol, V196, DOI 10.1016/j.ajog.2006.09.014; Fanaroff JM, 2006, PEDIATRICS, V117, P1131, DOI 10.1542/peds.2005-1230; Finer N, 2006, ARCH DIS CHILD-FETAL, V91, pF392, DOI 10.1136/adc.2006.099754; GARLAND JS, 1995, ARCH PEDIAT ADOL MED, V149, P617, DOI 10.1001/archpedi.1995.02170190027005; Guillet R, 2006, PEDIATRICS, V117, pE137, DOI 10.1542/peds.2005-1543; Hack M, 2005, JAMA-J AM MED ASSOC, V294, P318, DOI 10.1001/jama.294.3.318; Hack M, 2002, NEW ENGL J MED, V346, P149, DOI 10.1056/NEJMoa010856; Hammerman C, 2004, CLIN PERINATOL, V31, P489, DOI 10.1016/j.clp.2004.04.015; Hintz SR, 2005, PEDIATRICS, V115, P696, DOI 10.1542/peds.2004-0569; Hovi P, 2007, NEW ENGL J MED, V356, P2053, DOI 10.1056/NEJMoa067187; Inder TE, 2005, PEDIATRICS, V115, P286, DOI 10.1542/peds.2004-0326; Kabra NS, 2007, J PEDIATR-US, V150, P229, DOI 10.1016/j.jpeds.2006.11.039; Keszler M, 2006, PEDIATR PULM, V41, P364, DOI 10.1002/ppul.20384; Keszler M, 2004, PEDIATR PULM, V38, P240, DOI 10.1002/ppul.20063; Keszler M, 2007, CLIN PERINATOL, V34, P107, DOI 10.1016/j.clp.2006.12.011; Kinsella JP, 2006, NEW ENGL J MED, V355, P354, DOI 10.1056/NEJMoa060442; Land MH, 2005, PEDIATRICS, V115, P178, DOI 10.1542/peds.2004-2137; Lefebvre F, 2005, ACTA PAEDIATR, V94, P733, DOI 10.1080/08035250510025987; Lemons JA, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.1.e1; Limperopoulos C, 2007, PEDIATRICS, V120, P966, DOI 10.1542/peds.2007-0075; Lin HC, 2005, PEDIATRICS, V115, P1, DOI 10.1542/peds.2004-1463; Lucey JF, 2004, PEDIATRICS, V113, P1559, DOI 10.1542/peds.113.6.1559; McGrath MM, 2000, PEDIATRICS, V106, P1397, DOI 10.1542/peds.106.6.1397; Ment LR, 2003, JAMA-J AM MED ASSOC, V289, P705, DOI 10.1001/jama.289.6.705; Mestan KKL, 2005, NEW ENGL J MED, V353, P23, DOI 10.1056/NEJMoa043514; Miller JD, 2007, CURR OPIN PEDIATR, V19, P142, DOI 10.1097/MOP.0b013e3280895e12; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Moss RL, 2006, NEW ENGL J MED, V355, P856; Moss RL, 2006, NEW ENGL J MED, V354, P2225, DOI 10.1056/NEJMoa054605; Patole S. K., 2005, Archives of Disease in Childhood Fetal and Neonatal Edition, V90, pF147, DOI 10.1136/adc.2004.059741; Phibbs CS, 2007, NEW ENGL J MED, V356, P2165, DOI 10.1056/NEJMsa065029; Platt MJ, 2007, LANCET, V369, P43, DOI 10.1016/S0140-6736(07)60030-0; Rademaker KJ, 2007, J PEDIATR-US, V150, P351, DOI 10.1016/j.jpeds.2006.10.051; Reber KM, 2004, CLIN PERINATOL, V31, P157, DOI 10.1016/j.clp.2004.03.002; Rees CM, 2007, ARCH DIS CHILD-FETAL, V92, pF193, DOI 10.1136/adc.2006.099929; Saigal S, 2000, PEDIATRICS, V105, P325, DOI 10.1542/peds.105.2.325; Saigal S, 2006, JAMA-J AM MED ASSOC, V295, P667, DOI 10.1001/jama.295.6.667; Saugstad OD, 2006, J PERINATOL, V26, pS46, DOI 10.1038/sj.jp.7211475; Schmidt B, 2006, NEW ENGL J MED, V354, P2112, DOI 10.1056/NEJMoa054065; Schmidt B, 2003, JAMA-J AM MED ASSOC, V289, P1124, DOI 10.1001/jama.289.9.1124; Schmidt B, 2001, NEW ENGL J MED, V344, P1966, DOI 10.1056/NEJM200106283442602; Schmidt B, 2007, NEW ENGL J MED, V357, P1893, DOI 10.1056/NEJMoa073679; Schmidt B, 2006, J PEDIATR-US, V148, P730, DOI 10.1016/j.jpeds.2006.01.047; Schreiber MD, 2003, NEW ENGL J MED, V349, P2099, DOI 10.1056/NEJMoa031154; Schulzke SM, 2007, ARCH PEDIAT ADOL MED, V161, P583, DOI 10.1001/archpedi.161.6.583; Shah PS, 2005, J PEDIATR-US, V146, P626, DOI 10.1016/j.jpeds.2005.01.030; Short EJ, 2003, PEDIATRICS, V112, pE359, DOI 10.1542/peds.112.5.e359; Speer CP, 2006, J PERINATOL, V26, pS57, DOI 10.1038/sj.jp.7211476; Speer CP, 2006, SEMIN FETAL NEONAT M, V11, P354, DOI 10.1016/j.siny.2006.03.004; Stark AR, 2001, NEW ENGL J MED, V344, P95, DOI 10.1056/NEJM200101113440203; Stoll BJ, 2004, JAMA-J AM MED ASSOC, V292, P2357, DOI 10.1001/jama.292.19.2357; ter Horst SAJ, 2007, AM J PHYSIOL-LUNG C, V293, P35, DOI 10.1152/ajplung.00381.2006; Thome UH, 2005, ARCH DIS CHILD-FETAL, V90, pF466, DOI 10.1136/adc.2004.068437; Tin W, 2001, ARCH DIS CHILD-FETAL, V84, pF106, DOI 10.1136/fn.84.2.F106; Tyson JE, 1999, NEW ENGL J MED, V340, P1962, DOI 10.1056/NEJM199906243402505; TYSON JE, 2005, COCHRANE DB SYST REV, V2; Tyson JE, 2008, NEW ENGL J MED, V358, P1672, DOI 10.1056/NEJMoa073059; Van Marter LJ, 2000, PEDIATRICS, V105, P1194, DOI 10.1542/peds.105.6.1194; Van Marter LJ, 2002, J PEDIATR-US, V140, P171, DOI 10.1067/mpd.2002.121381; Van Meurs KP, 2005, NEW ENGL J MED, V353, P13, DOI 10.1056/NEJMoa043927; VanderVeen DK, 2006, J AAPOS, V10, P445, DOI 10.1016/j.jaapos.2006.04.010; Viscardi RM, 2004, PEDIATR RES, V55, P1009, DOI 10.1203/01.pdr.0000127015.60185.8a; Vohr BR, 2005, PEDIATRICS, V116, P635, DOI 10.1542/peds.2004-2247; Vohr BR, 2004, PEDIATRICS, V113, P781, DOI 10.1542/peds.113.4.781; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; Walsh MC, 2004, PEDIATRICS, V114, P1305, DOI 10.1542/peds.2004-0204; Walsh MC, 2006, PEDIATRICS, V118, pE1328, DOI 10.1542/peds.2006-0359; Watterberg KL, 2004, PEDIATRICS, V114, P1649, DOI 10.1542/peds.2004-1159; Watterberg KL, 2001, PEDIATR RES, V50, P190, DOI 10.1203/00006450-200108000-00005; Watterberg KL, 2007, PEDIATRICS, V120, P40, DOI 10.1542/peds.2006-3158; Wilson-Costello D, 2005, PEDIATRICS, V115, P997, DOI 10.1542/peds.2004-0221; Wilson-Costello D, 2007, PEDIATRICS, V119, P37, DOI 10.1542/peds.2006-1416; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601	104	228	243	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1700	1711		10.1056/NEJMra0707601	http://dx.doi.org/10.1056/NEJMra0707601			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288DO	18420502				2022-12-28	WOS:000254966600008
J	Goodman, DC; Fisher, ES				Goodman, David C.; Fisher, Elliott S.			Physician workforce crisis? Wrong diagnosis, wrong prescription	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							REGIONAL-VARIATIONS; CARE; QUALITY		[Goodman, David C.; Fisher, Elliott S.] Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Ctr Hlth Policy Res, Hanover, NH 03755 USA	Dartmouth College	Goodman, DC (corresponding author), Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Ctr Hlth Policy Res, Hanover, NH 03755 USA.		Goodman, David/AAG-7497-2020					Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Goodman DC, 2002, NEW ENGL J MED, V346, P1538, DOI 10.1056/NEJMoa011921; GOODMAN DC, 2004, 20 YEAR TRENDS REGIO; *MASS MED SOC, 2007, 2007 MMS PHYS WORKF; Sirovich BE, 2006, ANN INTERN MED, V144, P641, DOI 10.7326/0003-4819-144-9-200605020-00007	5	87	87	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1658	1661		10.1056/NEJMp0800319	http://dx.doi.org/10.1056/NEJMp0800319			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288DO	18420498				2022-12-28	WOS:000254966600003
J	Fishman, JA; Gonzalez, RG; Branda, JA; Rosenberg, ES				Fishman, Jay A.; Gonzalez, R. Gilberto; Branda, John A.; Rosenberg, Eric S.			A man with changes in mental status after liver transplantation - Disseminated cryptococcosis with cryptococcal meningitis in a liver-allograft recipient	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VISCERAL LEISHMANIASIS; ORGAN DONOR; NEOFORMANS INFECTION; TRANSMISSION; VIRUS; THERAPY; MANAGEMENT; DISEASE; IMPACT; AGENTS		[Fishman, Jay A.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA; [Fishman, Jay A.] Massachusetts Gen Hosp, Transplant Infect Dis & Compromised Host Host Pro, Boston, MA 02114 USA; [Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Branda, John A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Fishman, Jay A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Gonzalez, R. Gilberto] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Branda, John A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Fishman, JA (corresponding author), Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.		Branda, John/ABD-5620-2020					Angelis M, 2003, LIVER TRANSPLANT, V9, P451, DOI 10.1053/jlts.2003.50094; Basset D, 2005, MICROBES INFECT, V7, P1370, DOI 10.1016/j.micinf.2005.06.002; Boletis JN, 1999, CLIN INFECT DIS, V28, P1308, DOI 10.1086/514784; Brouwer AE, 2004, LANCET, V363, P1764, DOI 10.1016/S0140-6736(04)16301-0; Campdera FG, 1998, AM J NEPHROL, V18, P171, DOI 10.1159/000013329; Delmonico FL, 2000, CLIN INFECT DIS, V31, P781, DOI 10.1086/314000; Delmonico FL, 1998, TRANSPLANTATION, V65, P603, DOI 10.1097/00007890-199803150-00001; Fischer SA, 2006, NEW ENGL J MED, V354, P2235, DOI 10.1056/NEJMoa053240; Fishman JA, 2003, J INFECT DIS, V188, P1405, DOI 10.1086/379256; Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407; Fishman JA, 2007, NEW ENGL J MED, V357, P2601, DOI 10.1056/NEJMra064928; Frapier JM, 2001, J HEART LUNG TRANSPL, V20, P912, DOI 10.1016/S1053-2498(01)00263-7; Freeman RB, 1999, TRANSPLANTATION, V68, P1107, DOI 10.1097/00007890-199910270-00008; Graybill JR, 2000, CLIN INFECT DIS, V30, P47, DOI 10.1086/313603; Horn DL, 2007, DIAGN MICR INFEC DIS, V59, P407, DOI 10.1016/j.diagmicrobio.2007.06.008; Husain S, 2001, EMERG INFECT DIS, V7, P375; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Jabbour N, 1996, TRANSPLANTATION, V61, P146, DOI 10.1097/00007890-199601150-00027; Jean SS, 2002, QJM-INT J MED, V95, P511, DOI 10.1093/qjmed/95.8.511; Kapoor A, 1999, Transpl Infect Dis, V1, P213, DOI 10.1034/j.1399-3062.1999.010309.x; Macsween KF, 2005, J INFECTION, V51, pE221, DOI 10.1016/j.jinf.2005.02.010; Mehrenberger Marion, 2006, Exp Clin Transplant, V4, P525; Mueller N J, 2003, Transpl Infect Dis, V5, P140, DOI 10.1034/j.1399-3062.2003.00026.x; Palau LA, 1997, AM J TROP MED HYG, V57, P413, DOI 10.4269/ajtmh.1997.57.413; Pfaller MA, 1999, ANTIMICROB AGENTS CH, V43, P169, DOI 10.1093/oxfordjournals.jac.a020873; PORTOLES J, 1994, TRANSPLANTATION, V57, P1677; Saag MS, 2000, CLIN INFECT DIS, V30, P710, DOI 10.1086/313757; SCOGGIN CH, 1977, ANN INTERN MED, V87, P456, DOI 10.7326/0003-4819-87-4-456; Shelburne SA, 2005, CLIN INFECT DIS, V40, P1049, DOI 10.1086/428618; Singh N, 2005, CLIN INFECT DIS, V40, P1756, DOI 10.1086/430606; Singh N, 2007, J INFECT DIS, V195, P756, DOI 10.1086/511438; Srinivasan A, 2005, NEW ENGL J MED, V352, P1103, DOI 10.1056/NEJMoa043018; Wilck M, 2005, CURR OPIN ORGAN TRAN, V10, P301, DOI 10.1097/01.mot.0000183245.66967.b3; Wu G, 2002, Transpl Infect Dis, V4, P183, DOI 10.1034/j.1399-3062.2002.t01-1-02005.x; 2002, MMWR MORB MORTAL WKL, V51, P210	35	14	14	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1604	1613		10.1056/NEJMcpc0801192	http://dx.doi.org/10.1056/NEJMcpc0801192			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285NK	18403769				2022-12-28	WOS:000254783300011
J	Feagan, BG; Sandborn, WJ; Mittmann, U; Bar-Meir, S; D'Haens, G; Bradette, M; Cohen, A; Dallaire, C; Ponich, TP; McDonald, JWD; Hebuterne, X; Pare, P; Klvana, P; Niv, Y; Ardizzone, S; Alexeeva, O; Rostom, A; Kiudelis, G; Spleiss, J; Gilgen, D; Vandervoort, MK; Wong, CJ; Zou, GY; Donner, A; Rutgeerts, P				Feagan, Brian G.; Sandborn, William J.; Mittmann, Ulrich; Bar-Meir, Simon; D'Haens, Geert; Bradette, Marc; Cohen, Albert; Dallaire, Chrystian; Ponich, Terry P.; McDonald, John W. D.; Hebuterne, Xavier; Pare, Pierre; Klvana, Pavel; Niv, Yaron; Ardizzone, Sandro; Alexeeva, Olga; Rostom, Alaa; Kiudelis, Gediminas; Spleiss, Johannes; Gilgen, Denise; Vandervoort, Margaret K.; Wong, Cindy J.; Zou, Guang Yong; Donner, Allan; Rutgeerts, Paul			Omega-3 free fatty acids for the maintenance of remission in Crohn disease - The EPIC randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLAMMATORY-BOWEL-DISEASE; COMPLEMENTARY MEDICINE USE; CORONARY HEART-DISEASE; OF-THE-LITERATURE; DOSE OMEGA-3-FATTY-ACIDS; RHEUMATOID-ARTHRITIS; ALTERNATIVE MEDICINE; CERTOLIZUMAB PEGOL; ORAL BUDESONIDE; QUALITY	Context Maintenance therapy for Crohn disease features the use of immunosuppressive drugs, which are associated with an increased risk of infection. Identification of safe and effective maintenance strategies is a priority. Objective To determine whether the oral administration of omega- 3 free fatty acids is more effective than placebo for prevention of relapse of Crohn disease. Design, Setting, and Patients Two randomized, double- blind, placebo-controlled studies ( Epanova Program in Crohn's Study 1 [ EPIC- 1] and EPIC- 2) conducted between January 2003 and February 2007 at 98 centers in Canada, Europe, Israel, and the United States. Data from 363 and 375 patients with quiescent Crohn disease were evaluated in EPIC- 1 and EPIC- 2, respectively. Interventions Patients with a Crohn's Disease Activity Index ( CDAI) score of less than 150 were randomly assigned to receive either 4 g/ d of omega- 3 free fatty acids or placebo for up to 58 weeks. No other treatments for Crohn disease were permitted. Main Outcome Measure Clinical relapse, as defined by a CDAI score of 150 points or greater and an increase of more than 70 points from the baseline value, or initiation of treatment for active Crohn disease. Results For EPIC- 1, 188 patients were assigned to receive omega- 3 free fatty acids and 186 patients to receive placebo. Corresponding numbers for EPIC- 2 were 189 and 190 patients, respectively. The rate of relapse at 1 year in EPIC- 1 was 31.6% in patients who received omega- 3 free fatty acids and 35.7% in those who received placebo ( hazard ratio, 0.82; 95% confidence interval, 0.51- 1.19; P=. 30). Corresponding values for EPIC- 2 were 47.8% and 48.8% ( hazard ratio, 0.90; 95% confidence interval, 0.67- 1.21; P=. 48). Serious adverse events were uncommon and mostly related to Crohn disease. Conclusion In these trials, treatment with omega- 3 free fatty acids was not effective for the prevention of relapse in Crohn disease. Trial Registration clinicaltrials. gov Identifiers: EPIC- 1: NCT00613197, EPIC- 2: NCT00074542.	[Feagan, Brian G.; Vandervoort, Margaret K.; Wong, Cindy J.; Zou, Guang Yong; Donner, Allan] Univ Western Ontario, Robarts Res Inst, London, ON N6A 5K8, Canada; [Feagan, Brian G.; Zou, Guang Yong; Donner, Allan] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON N6A 5K8, Canada; [Sandborn, William J.] Mayo Clin, Rochester, MN USA; [Mittmann, Ulrich] MP Consulting, Basel, Switzerland; [Bar-Meir, Simon] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; [D'Haens, Geert] Imelda Gen Hosp, Imeldalaan Bonheiden, Belgium; [Bradette, Marc] Pavillon Hotel Dieu Quebec, Quebec City, PQ, Canada; [Cohen, Albert] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada; [Dallaire, Chrystian] Pavillon St Francois Assise, Quebec City, PQ, Canada; [Ponich, Terry P.; McDonald, John W. D.] London Hlth Sci Ctr, London, ON, Canada; [Hebuterne, Xavier] Univ Nice Sophia Antipolis, Ctr Hosp Univ, Nice, France; [Pare, Pierre] Hop St Sacrement, Quebec City, PQ, Canada; [Klvana, Pavel] Univ Ostrava, Univ Hosp Ostrava, Ostrava, Czech Republic; [Niv, Yaron] Rabin Med Ctr, Petah Tiqwa, Israel; [Ardizzone, Sandro] Osped L Sacco, Milan, Italy; [Alexeeva, Olga] Reg Clin Hosp, Nizhnii Novgorod, Russia; [Rostom, Alaa] Univ Calgary, Calgary, AB, Canada; [Kiudelis, Gediminas] Kaunas Med Univ, Kaunas, Lithuania; [Spleiss, Johannes; Gilgen, Denise] Tillotts Pharma AG, Ziefen, Switzerland; [Rutgeerts, Paul] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium	Western University (University of Western Ontario); Western University (University of Western Ontario); Mayo Clinic; Chaim Sheba Medical Center; Imeldaziekenhuis; Laval University; McGill University; London Health Sciences Centre; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Laval University; University Hospital Ostrava; University of Ostrava; Rabin Medical Center; University of Milan; Luigi Sacco Hospital; University of Calgary; Lithuanian University of Health Sciences; KU Leuven; University Hospital Leuven	Feagan, BG (corresponding author), Univ Western Ontario, Robarts Res Inst, 100 Perth Dr, London, ON N6A 5K8, Canada.	bfeagan@robarts.ca	Ardizzone, Sandro/J-3251-2017; Sandborn, William/ABE-8342-2020; Feagan, Brian G/M-4283-2015; Zou, Guangyong/K-6408-2013; Feagan, Brian/G-3292-2011	Ardizzone, Sandro/0000-0001-9915-2992; Zou, Guangyong/0000-0001-5773-4185; 				Akobeng AK, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003715.pub2; [Anonymous], 2001, SAS STAT SOFTW VERS; [Anonymous], 1996, INT C HARM TECHN REQ; Bays H, 2006, AM J CARDIOL, V98, p71I, DOI 10.1016/j.amjcard.2005.12.029; Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Bucher HC, 2002, AM J MED, V112, P298, DOI 10.1016/S0002-9343(01)01114-7; CANDY S, 1995, GUT, V37, P674, DOI 10.1136/gut.37.5.674; Colombel JF, 2007, GASTROENTEROLOGY, V132, P52, DOI 10.1053/j.gastro.2006.11.041; *CYT INC, 2007, STATXACT VERS VERS 8; Donadio JV, 2001, J AM SOC NEPHROL, V12, P791, DOI 10.1681/ASN.V124791; Durrington PN, 2001, HEART, V85, P544, DOI 10.1136/heart.85.5.544; Feagan BG, 2000, NEW ENGL J MED, V342, P1627, DOI 10.1056/NEJM200006013422202; Gluud LL, 2006, AM J EPIDEMIOL, V163, P493, DOI 10.1093/aje/kwj069; Goldberg RJ, 2007, PAIN, V129, P210, DOI 10.1016/j.pain.2007.01.020; Greenberg GR, 1996, GASTROENTEROLOGY, V110, P45, DOI 10.1053/gast.1996.v110.pm8536887; GREENBERG GR, 1994, NEW ENGL J MED, V331, P836, DOI 10.1056/NEJM199409293311303; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; HARVEY RF, 1980, LANCET, V1, P514; Heuschkel R, 2002, AM J GASTROENTEROL, V97, P382, DOI 10.1111/j.1572-0241.2002.05474.x; Hilsden RJ, 1998, AM J GASTROENTEROL, V93, P697; *INT FED PHARM MAN, 2007, MED DICT REG ACT MED; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Kirschner BS, 1998, GASTROENTEROLOGY, V115, P813, DOI 10.1016/S0016-5085(98)70251-3; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Kjaergard LL, 1999, HEPATOLOGY, V30, P1134, DOI 10.1002/hep.510300510; KNAPP HR, 1986, NEW ENGL J MED, V314, P937, DOI 10.1056/NEJM198604103141501; Langmead L, 2006, ALIMENT PHARM THER, V23, P341, DOI 10.1111/j.1365-2036.2006.02761.x; Leong RWL, 2004, DIGEST DIS SCI, V49, P1672, DOI 10.1023/B:DDAS.0000043384.26092.f4; Li FX, 2005, CAN J GASTROENTEROL, V19, P567, DOI 10.1155/2005/943547; LorenzMeyer H, 1996, SCAND J GASTROENTERO, V31, P778, DOI 10.3109/00365529609010352; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; McClaskey EM, 2007, PHARMACOTHERAPY, V27, P152, DOI 10.1592/phco.27.1.152; Nurmohamed MT, 2005, DRUGS, V65, P661, DOI 10.2165/00003495-200565050-00006; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; Sandborn WJ, 2007, NEW ENGL J MED, V357, P228, DOI 10.1056/NEJMoa067594; Sandborn WJ, 2005, NEW ENGL J MED, V353, P1912, DOI 10.1056/NEJMoa043335; Schreiber S, 2007, NEW ENGL J MED, V357, P239, DOI 10.1056/NEJMoa062897; Stalenhoef AFH, 2000, ATHEROSCLEROSIS, V153, P129, DOI 10.1016/S0021-9150(00)00381-6; Stamp LK, 2005, SEMIN ARTHRITIS RHEU, V35, P77, DOI 10.1016/j.semarthrit.2005.05.001; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yokoyama M, 2007, LANCET, V369, P1090, DOI 10.1016/S0140-6736(07)60527-3	43	193	205	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2008	299	14					1690	1697		10.1001/jama.299.14.1690	http://dx.doi.org/10.1001/jama.299.14.1690			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285AL	18398081				2022-12-28	WOS:000254749600025
J	Linhares, AC; Velazquez, FR; Perez-Schael, I; Saez-Llorens, X; Abate, H; Espinoza, F; Lopez, P; Macias-Parra, M; Ortega-Barria, E; Rivera-Medina, DM; Rivera, L; Pavia-Ruz, N; Nunez, E; Damaso, S; Ruiz-Palacios, GM; De Vos, B; O'Ryan, M; Gillard, P; Bouckenooghe, A				Linhares, Alexandre C.; Velazquez, F. Raul; Perez-Schael, Irene; Saez-Llorens, Xavier; Abate, Hector; Espinoza, Felix; Lopez, Pio; Macias-Parra, Mercedes; Ortega-Barria, Eduardo; Rivera-Medina, Doris Maribel; Rivera, Luis; Pavia-Ruz, Noris; Nunez, Ernesto; Damaso, Silvia; Ruiz-Palacios, Guillermo M.; De Vos, Beatrice; O'Ryan, Miguel; Gillard, Paul; Bouckenooghe, Alain		Human Rotavirus Vaccine Study Grp	Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study	LANCET			English	Article							CHILDREN; PROTECTION; INFECTION	Background Peak incidence of rotavirus gastroenteritis is seen in infants between 6 and 24 months of age. We therefore aimed to assess the 2-year efficacy and safety of an oral live attenuated human rotavirus vaccine for prevention of severe gastroenteritis in infants. Methods 15183 healthy infants aged 6-13 weeks from ten Latin American countries randomly assigned in a 1 to 1 ratio to receive two oral doses of RIX4414 or placebo at about 2 and 4 months of age in a double-blind, placebo-controlled phase III study were followed up until about 2 years of age. Primary endpoint was vaccine efficacy from 2 weeks after dose two until 1 year of age. Treatment allocation was concealed from investigators and parents of participating infants. Efficacy follow-up for gastroenteritis episodes was undertaken from 2 weeks after dose two until about 2 years of age. Analysis was according to protocol. This study is registered with ClinicalTrials.gov, number NCT00140673 (eTrack444563-023). Findings 897 infants were excluded from the according-to-protocol analysis. Fewer cases (p<0.0001) of severe rotavirus gastroenteritis were recorded for the combined 2-year period in the RIX4414 group (32 [0.4%] of 7205; 95% CI 0 . 3-0.6) than in the placebo group (161 [2.3%] of 7081; 1 . 9-2.6), resulting in a vaccine efficacy of 80.5% (71.3-87. 1) to 82.1% (64.6-91.9) against wild-type G1, 77.5% (64.7-86.2) against pooled non-G1 strains, and 80.5% (67.9-88 . 8) against pooled non-G1 P[81 strains. Vaccine efficacy for hospital admission for rotavirus gastroenteritis was 83. 0% (73.1-89.7) and for admission for diarrhoea of any cause was 39.3% (29.1-48 . 1). No cases of intussusception were reported during the second year of follow-up. Interpretation Two doses of RIX4414 were effective against severe rotavirus gastroenteritis during the first 2 years of life in a Latin American setting. Inclusion of RIX4414 in routine paediatric immunisations should reduce the burden of rotavirus gastroenteritis worldwide.	[O'Ryan, Miguel] Univ Chile, Microbiol & Mycol Programme, Inst Biomed Sci, Fac Med, Santiago, Chile; [Linhares, Alexandre C.] Minist Hlth, Inst Evandro Chagas, Secretaria Vigilancia Saude, Belem, Para, Brazil; [Velazquez, F. Raul] Inst Mexicano Seguro Social, Med Res Unit Infect Dis, Paediat Hosp, Natl Med Ctr SXXI, Mexico City, DF, Mexico; [Perez-Schael, Irene] Inst Biomed Fuvesin, Secc Enfermedades Entericas, Caracas, Venezuela; [Saez-Llorens, Xavier] Hosp Nino, Panama City, Panama; [Abate, Hector] Hosp Dr Humberto Notti, Mendoza, Argentina; [Espinoza, Felix] Univ Nacl Autonoma Leon, Leon, Nicaragua; [Lopez, Pio] Clin Materno Infantil Farallones, Cali, Colombia; [Macias-Parra, Mercedes] Inst Nacl Pediat, Mexico City, DF, Mexico; [Ortega-Barria, Eduardo] Inst Invest Cientificas Avanzadas & Serv Alta Tec, Panama City, Panama; [Rivera-Medina, Doris Maribel] Hosp Especialidades Ctr Med La Raza, Inst Hondureno Seguridad Social, Tegucigalpa, Honduras; [Rivera, Luis] Hosp Nuestra Senora Altagracia, Santo Domingo, Dominican Rep; [Pavia-Ruz, Noris] Univ Nacl Autonoma Mexico, Dept Expt Med, Mexico City 04510, DF, Mexico; [Nunez, Ernesto] Univ Concepcion, Concepcion, Chile; [Ruiz-Palacios, Guillermo M.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico; [Damaso, Silvia; De Vos, Beatrice; Gillard, Paul; Bouckenooghe, Alain] GlaxoSmithKline Biol, Rixensart, Belgium	Universidad de Chile; Instituto Evandro Chagas; Instituto Mexicano del Seguro Social; Universidad Nacional Autonoma de Mexico; Universidad de Concepcion; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; GlaxoSmithKline	O'Ryan, M (corresponding author), Univ Chile, Microbiol & Mycol Programme, Inst Biomed Sci, Fac Med, Santiago, Chile.	moryan@med.uchile.cl	Ruiz-Palacios, Guillermo/GYQ-5462-2022; O'Ryan, Miguel/H-3478-2013	O'Ryan, Miguel/0000-0002-7926-2163; SAEZ LLORENS, XAVIER/0000-0002-1149-5905; Aguiar Justino, Maria Cleonice/0000-0003-3248-5893; Macias, Mercedes/0000-0002-3538-2550				Bernstein DI, 2006, PEDIATR ANN, V35, P38, DOI 10.3928/0090-4481-20060101-12; Bines JE, 2004, VACCINE, V22, P569, DOI 10.1016/j.vaccine.2003.09.016; Castello Alejandro A, 2004, Pediatr Infect Dis J, V23, pS168, DOI 10.1097/01.inf.0000142466.57262.2a; Glass RI, 2006, LANCET, V368, P323, DOI 10.1016/S0140-6736(06)68815-6; Gurgel RQ, 2007, EMERG INFECT DIS, V13, P1571, DOI 10.3201/eid1310.070412; Kane EM, 2004, REV PANAM SALUD PUBL, V16, P371, DOI 10.1590/S1020-49892004001200002; Keating Gillian M, 2006, Paediatr Drugs, V8, P389, DOI 10.2165/00148581-200608060-00006; Linhares A C, 2000, Cad Saude Publica, V16, P629, DOI 10.1590/S0102-311X2000000300012; Linhares A C, 2000, Rev Panam Salud Publica, V8, P305, DOI 10.1590/S1020-49892000001000002; Linhares Alexandre C., 2006, J. Pediatr. (Rio J.), V82, ps25, DOI 10.2223/JPED.1492; ORYAN ML, 1994, J INFECT DIS, V169, P504, DOI 10.1093/infdis/169.3.504; Parashar UD, 2006, EMERG INFECT DIS, V12, P304; Rheingans RD, 2007, REV PANAM SALUD PUBL, V21, P192, DOI 10.1590/S1020-49892007000300002; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; Ruiz-Palacios GM, 2007, PEDIATRICS, V120, pE253, DOI 10.1542/peds.2006-2630; RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046; Santos N, 2005, REV MED VIROL, V15, P29, DOI 10.1002/rmv.448; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; Velazquez FR, 2000, J INFECT DIS, V182, P1602, DOI 10.1086/317619; Vesikari T, 2007, LANCET, V370, P1757, DOI 10.1016/S0140-6736(07)61744-9; World Health Organization, 2007, Wkly Epidemiol Rec, V82, P285; Zahn M, 2006, PEDIATR ANN, V35, P23, DOI 10.3928/0090-4481-20060101-10	22	303	317	0	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2008	371	9619					1181	1189		10.1016/S0140-6736(08)60524-3	http://dx.doi.org/10.1016/S0140-6736(08)60524-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395579				2022-12-28	WOS:000254956000027
J	Bieber, T				Bieber, Thomas			Mechanisms of disease: Atopic dermatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FC-EPSILON-RI; EPIDERMAL LANGERHANS CELLS; SINGLE NUCLEOTIDE POLYMORPHISMS; PLASMACYTOID DENDRITIC CELLS; CORNEUM CHYMOTRYPTIC ENZYME; HIGH-AFFINITY RECEPTOR; OF-FUNCTION MUTATIONS; SKIN BARRIER FUNCTION; PATCH TEST REACTIONS; T-CELLS		Univ Bonn, Med Ctr, Dept Dermatol & Allergy, D-53105 Bonn, Germany	University of Bonn	Bieber, T (corresponding author), Univ Bonn, Med Ctr, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53105 Bonn, Germany.	thomas.bieber@ukb.uni-bonn.de						Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Aichberger KJ, 2005, J IMMUNOL, V175, P1286, DOI 10.4049/jimmunol.175.2.1286; Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P724; Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Bieber T, 2007, IMMUNOBIOLOGY, V212, P499, DOI 10.1016/j.imbio.2007.03.001; Bowcock AM, 2004, HUM MOL GENET, V13, pR43, DOI 10.1093/hmg/ddh094; Braff MH, 2006, CURR TOP MICROBIOL, V306, P91; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; BRUYNZEELKOOMEN C, 1986, ARCH DERMATOL RES, V278, P199, DOI 10.1007/BF00412924; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; Cao W, 2007, CURR OPIN IMMUNOL, V19, P24, DOI 10.1016/j.coi.2006.11.004; Cardona ID, 2006, J ALLERGY CLIN IMMUN, V117, P688, DOI 10.1016/j.jaci.2005.11.037; Cardona ID, 2006, AM J CLIN DERMATOL, V7, P273, DOI 10.2165/00128071-200607050-00001; CHAN SC, 1993, J IMMUNOL, V151, P3345; Clark RA, 2006, J IMMUNOL, V176, P4431, DOI 10.4049/jimmunol.176.7.4431; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Denburg JA, 2006, EUR RESPIR J, V27, P441, DOI 10.1183/09031936.06.00000706; Diepgen TL, 2002, PEDIAT ALLERG IMM-UK, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Gilliet M, 2003, J EXP MED, V197, P1059, DOI 10.1084/jem.20030240; Gombert M, 2005, J IMMUNOL, V174, P8219, DOI 10.4049/jimmunol.174.12.8219; Gombert M, 2005, J IMMUNOL, V174, P5082, DOI 10.4049/jimmunol.174.8.5082; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Haagerup A, 2004, ACTA DERM-VENEREOL, V84, P346, DOI 10.1080/00015550410034426; Hallstrand TS, 2004, BLOOD, V104, P3086, DOI 10.1182/blood-2004-05-1775; Hansson L, 2002, J INVEST DERMATOL, V118, P444, DOI 10.1046/j.0022-202x.2001.01684.x; Hoffjan S, 2005, J MOL MED, V83, P682, DOI 10.1007/s00109-005-0672-2; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Ingordo V, 2002, J EUR ACAD DERMATOL, V16, P450, DOI 10.1046/j.1468-3083.2002.00525.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kerschenlohr K, 2004, CURR ALLERGY ASTHM R, V4, P285, DOI 10.1007/s11882-004-0072-7; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Lange J, 2005, PEDIAT ALLERG IMM-UK, V16, P456, DOI 10.1111/j.1399-3038.2005.00277.x; LARSEN FVS, 1985, ACTA DERM-VENEREOL, P159; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; Mittermann I, 2004, CURR OPIN ALLERGY CL, V4, P367, DOI 10.1097/00130832-200410000-00007; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Mothes N, 2005, J ALLERGY CLIN IMMUN, V116, P706, DOI 10.1016/j.jaci.2005.06.025; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Novak N, 2005, J AM ACAD DERMATOL, V53, pS171, DOI 10.1016/j.jaad.2005.04.060; Novak N, 2005, J ALLERGY CLIN IMMUN, V115, P828, DOI 10.1016/j.jaci.2005.01.030; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2002, J INVEST DERMATOL, V119, P870, DOI 10.1046/j.1523-1747.2002.00191.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer LJ, 2005, LANCET, V366, P1223, DOI 10.1016/S0140-6736(05)67485-5; Paus R, 2006, J CLIN INVEST, V116, P1174, DOI 10.1172/JCI28553; Peng WM, 2007, J INVEST DERMATOL, V127, P1261, DOI 10.1038/sj.jid.5700657; Proksch E, 2003, CLIN DERMATOL, V21, P134, DOI 10.1016/S0738-081X(02)00370-X; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Reich K, 2001, J IMMUNOL, V167, P6321, DOI 10.4049/jimmunol.167.11.6321; Rieg S, 2005, J IMMUNOL, V174, P8003, DOI 10.4049/jimmunol.174.12.8003; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Schmid-Wendtner MH, 2006, SKIN PHARMACOL PHYS, V19, P296, DOI 10.1159/000094670; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Taha RA, 1998, J ALLERGY CLIN IMMUN, V102, P245, DOI 10.1016/S0091-6749(98)70093-4; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; von Bubnoff D, 2004, ALLERGY, V59, P933, DOI 10.1111/j.1398-9995.2004.00546.x; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P922; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P724; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P277, DOI 10.1016/j.jaci.2006.04.034; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547; Zutavern A, 2005, CLIN EXP ALLERGY, V35, P1301, DOI 10.1111/j.1365-2222.2005.02350.x	101	1401	1487	10	208	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1483	1494		10.1056/NEJMra074081	http://dx.doi.org/10.1056/NEJMra074081			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282CY	18385500				2022-12-28	WOS:000254546400009
J	Li, CH; Benedick, AJ; Fendel, P; Glenday, AG; Kartner, FX; Phillips, DF; Sasselov, D; Szentgyorgyi, A; Walsworth, RL				Li, Chih-Hao; Benedick, Andrew J.; Fendel, Peter; Glenday, Alexander G.; Kartner, Franz X.; Phillips, David F.; Sasselov, Dimitar; Szentgyorgyi, Andrew; Walsworth, Ronald L.			A laser frequency comb that enables radial velocity measurements with a precision of 1 cm s(-1)	NATURE			English	Article							ATOMIC VAPOR; PLANETS; DECELERATION; SYSTEM; STARS	Searches for extrasolar planets using the periodic Doppler shift of stellar spectral lines have recently achieved a precision of 60 cm s(-1) ( ref. 1), which is sufficient to find a 5- Earth- mass planet in a Mercury- like orbit around a Sun- like star. To find a 1- Earth-mass planet in an Earth- like orbit, a precision of similar to 5 cm s(-1) is necessary. The combination of a laser frequency comb with a Fabry-Perot filtering cavity has been suggested as a promising approach to achieve such Doppler shift resolution via improved spectrograph wavelength calibration(2-4), with recent encouraging results(5). Here we report the fabrication of such a filtered laser comb with up to 40-GHz ( similar to 1-angstrom ) line spacing, generated from a 1-GHz repetition- rate source, without compromising long- term stability, reproducibility or spectral resolution. This wide- linespacing comb, or 'astro- comb', is well matched to the resolving power of high- resolution astrophysical spectrographs. The astro-comb should allow a precision as high as 1 cm s(-1) in astronomical radial velocity measurements.	[Li, Chih-Hao; Glenday, Alexander G.; Phillips, David F.; Sasselov, Dimitar; Szentgyorgyi, Andrew; Walsworth, Ronald L.] Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; [Li, Chih-Hao; Glenday, Alexander G.; Walsworth, Ronald L.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; [Benedick, Andrew J.; Fendel, Peter; Kartner, Franz X.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; [Benedick, Andrew J.; Fendel, Peter; Kartner, Franz X.] MIT, Elect Res Lab, Cambridge, MA 02139 USA; [Fendel, Peter] MenloSyst Inc, Newton, NJ 07860 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Walsworth, RL (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.	rwalsworth@cfa.harvard.edu						ARAUJOHAUCK C, 2007, ESO MESSENGER, V129, P24; Bartels A, 2007, OPT LETT, V32, P2553, DOI 10.1364/OL.32.002553; BENEDICK A, CLEO EUR 2007 MUN 17; Butler RP, 1996, PUBL ASTRON SOC PAC, V108, P500, DOI 10.1086/133755; Corwin KL, 1998, APPL OPTICS, V37, P3295, DOI 10.1364/AO.37.003295; Loeb A, 1998, ASTROPHYS J, V499, pL111, DOI 10.1086/311375; LOVIS C, 2006, P SOC PHOTO-OPT INS, V6269, P23; Murphy MT, 2007, MON NOT R ASTRON SOC, V380, P839, DOI 10.1111/j.1365-2966.2007.12147.x; OSTERMAN S, 2007, P SOC PHOTO-OPT INS, V6693; Reeves JM, 2006, APPL OPTICS, V45, P372, DOI 10.1364/AO.45.000372; SANDAGE A, 1962, ASTROPHYS J, V136, P319, DOI 10.1086/147385; SCHMIDT PO, P 2007 ESO INSTR CAL; STORM J, 1994, ASTRON ASTROPHYS, V290, P443; Szentgyorgyi A, 1998, P SOC PHOTO-OPT INS, V3355, P242, DOI 10.1117/12.316766; Tarter JC, 2007, ASTROBIOLOGY, V7, P30, DOI 10.1089/ast.2006.0124; Udem T, 2002, NATURE, V416, P233, DOI 10.1038/416233a; Udry S, 2007, ASTRON ASTROPHYS, V469, pL43, DOI 10.1051/0004-6361:20077612	18	333	352	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2008	452	7187					610	612		10.1038/nature06854	http://dx.doi.org/10.1038/nature06854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385734	Green Submitted			2022-12-28	WOS:000254567200040
J	Weissleder, R; Pittet, MJ				Weissleder, Ralph; Pittet, Mikael J.			Imaging in the era of molecular oncology	NATURE			English	Review							CIRCULATING TUMOR-CELLS; REGULATORY T-CELLS; PROTEIN-PROTEIN INTERACTIONS; BREAST-CANCER METASTASIS; IN-VIVO; LIVING CELLS; LUNG-CANCER; CARCINOEMBRYONIC ANTIGEN; GENE-EXPRESSION; FLOW-CYTOMETRY	New technologies for imaging molecules, particularly optical technologies, are increasingly being used to understand the complexity, diversity and in vivo behaviour of cancers. 'Omic' approaches are providing comprehensive 'snapshots' of biological indicators, or biomarkers, of cancer, but imaging can take this information a step further, showing the activity of these markers in vivo and how their location changes over time. Advances in experimental and clinical imaging are likely to improve how cancer is understood at a systems level and, ultimately, should enable doctors not only to locate tumours but also to assess the activity of the biological processes within these tumours and to provide 'on the spot' treatment.	[Weissleder, Ralph; Pittet, Mikael J.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA; [Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Weissleder, R (corresponding author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA.	rweissleder@mgh.harvard.edu	Pittet, Mikael/ABD-6300-2021	/0000-0003-0828-4143	NATIONAL CANCER INSTITUTE [P01CA069246, P50CA086355, U24CA092782] Funding Source: NIH RePORTER; NCI NIH HHS [U24 CA092782, P01 CA069246, P50 CA086355, P50 CA086355-01, U24 CA092782-07, P01 CA069246-070006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbab AS, 2006, EXPERT REV MED DEVIC, V3, P427, DOI 10.1586/17434440.3.4.427; AULER H., 1942, Z. Krebsforsck, V53, P65, DOI 10.1007/BF01792783; Avril N, 2005, J CLIN ONCOL, V23, P7445, DOI 10.1200/JCO.2005.06.965; Blankenberg FG, 2006, NAT PROTOC, V1, P108, DOI 10.1038/nprot.2006.17; Boissonnas A, 2007, J EXP MED, V204, P345, DOI 10.1084/jem.20061890; Boon T, 2006, ANNU REV IMMUNOL, V24, P175, DOI 10.1146/annurev.immunol.24.021605.090733; Boutrus S, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2722733; Brindle K, 2008, NAT REV CANCER, V8, P94, DOI 10.1038/nrc2289; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Bulte Jeff W M, 2006, Methods Mol Med, V124, P419; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHANCE B, 1991, ANNU REV BIOPHYS BIO, V20, P1; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Deisseroth K, 2006, J NEUROSCI, V26, P10380, DOI 10.1523/JNEUROSCI.3863-06.2006; DEKKER E, 2005, ENDOSC CLIN N AM, V15, P703; Drahl C, 2005, ANGEW CHEM INT EDIT, V44, P5788, DOI 10.1002/anie.200500900; DREXLER B, 1985, RADIOLOGY, V157, P41, DOI 10.1148/radiology.157.1.4034975; Evans CL, 2005, P NATL ACAD SCI USA, V102, P16807, DOI 10.1073/pnas.0508282102; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Figueiredo JL, 2006, INT J CANCER, V118, P2672, DOI 10.1002/ijc.21713; Flusberg BA, 2005, NAT METHODS, V2, P941, DOI 10.1038/NMETH820; FOLLI S, 1992, P NATL ACAD SCI USA, V89, P7973, DOI 10.1073/pnas.89.17.7973; Georgakoudi I, 2004, CANCER RES, V64, P5044, DOI 10.1158/0008-5472.CAN-04-1058; Giepmans BNG, 2006, SCIENCE, V312, P217, DOI 10.1126/science.1124618; Granot D, 2007, CANCER RES, V67, P9180, DOI 10.1158/0008-5472.CAN-07-0684; Grimm J, 2005, P NATL ACAD SCI USA, V102, P14404, DOI 10.1073/pnas.0503920102; Gross S, 2005, CANCER CELL, V7, P5, DOI 10.1016/j.ccr.2004.12.011; Halin C, 2005, ANNU REV CELL DEV BI, V21, P581, DOI 10.1146/annurev.cellbio.21.122303.133159; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; He W, 2007, P NATL ACAD SCI USA, V104, P11760, DOI 10.1073/pnas.0703875104; Herth FJF, 2006, RESPIRATION, V73, P399, DOI 10.1159/000093369; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; KELLY K, IN PRESS PLOS MED; Kelly KA, 2006, NEOPLASIA, V8, P1011, DOI 10.1593/neo.06610; Kiesslich R, 2007, NAT CLIN PRACT ONCOL, V4, P480, DOI 10.1038/ncponc0881; Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Koyama Y, 2007, CLIN CANCER RES, V13, P2936, DOI 10.1158/1078-0432.CCR-06-2240; Laxman B, 2002, P NATL ACAD SCI USA, V99, P16551, DOI 10.1073/pnas.252644499; LEE H, IN PRESS NATURE MED; Lee KC, 2007, CLIN CANCER RES, V13, P1839, DOI 10.1158/1078-0432.CCR-06-1657; Liu Y, 2007, CLIN CANCER RES, V13, P4392, DOI 10.1158/1078-0432.CCR-06-1648; Lordick F, 2007, LANCET ONCOL, V8, P797, DOI 10.1016/S1470-2045(07)70244-9; Marten K, 2002, GASTROENTEROLOGY, V122, P406, DOI 10.1053/gast.2002.30990; McCarthy JR, 2006, SMALL, V2, P983, DOI 10.1002/smll.200600139; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Mempel TR, 2006, IMMUNITY, V25, P129, DOI 10.1016/j.immuni.2006.04.015; Montet X, 2005, CANCER RES, V65, P6330, DOI 10.1158/0008-5472.CAN-05-0382; MOORE GE, 1948, J NEUROSURG, V5, P392, DOI 10.3171/jns.1948.5.4.0392; Mrass P, 2006, J EXP MED, V203, P2749, DOI 10.1084/jem.20060710; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagaraj S, 2007, NAT MED, V13, P828, DOI 10.1038/nm1609; Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385; Neves AA, 2006, BBA-REV CANCER, V1766, P242, DOI 10.1016/j.bbcan.2006.10.002; Ntziachristos V, 2000, P NATL ACAD SCI USA, V97, P2767, DOI 10.1073/pnas.040570597; Ntziachristos V, 2004, P NATL ACAD SCI USA, V101, P12294, DOI 10.1073/pnas.0401137101; Ntziachristos V, 2005, NAT BIOTECHNOL, V23, P313, DOI 10.1038/nbt1074; Ntziachristos V, 2002, NAT MED, V8, P757, DOI 10.1038/nm729; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Paulmurugan R, 2004, CANCER RES, V64, P2113, DOI 10.1158/0008-5472.CAN-03-2972; PELEGRIN A, 1991, CANCER, V67, P2529, DOI 10.1002/1097-0142(19910515)67:10<2529::AID-CNCR2820671024>3.0.CO;2-B; Perez JM, 2002, NAT BIOTECHNOL, V20, P816, DOI 10.1038/nbt720; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Pittet MJ, 2007, P NATL ACAD SCI USA, V104, P12457, DOI 10.1073/pnas.0704460104; Pittet MJ, 2006, NAT PROTOC, V1, P73, DOI 10.1038/nprot.2006.11; Policard A, 1924, CR SOC BIOL, V91, P1423; Quon A, 2005, J CLIN ONCOL, V23, P1664, DOI 10.1200/JCO.2005.11.024; Ray P, 2002, P NATL ACAD SCI USA, V99, P3105, DOI 10.1073/pnas.052710999; Roberti MJ, 2007, NAT METHODS, V4, P345, DOI 10.1038/NMETH1026; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; Rontgen WC, 1896, NATURE, V53, P274; Rudin M, 2003, NAT REV DRUG DISCOV, V2, P123, DOI 10.1038/nrd1007; Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110; Shojaei F, 2007, NATURE, V450, P825, DOI 10.1038/nature06348; Soon L, 2007, MICROSC RES TECHNIQ, V70, P252, DOI 10.1002/jemt.20411; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; Swirski FK, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001075; TATSUTA M, 1989, LASER SURG MED, V9, P422, DOI 10.1002/lsm.1900090415; Veiga-Fernandes H, 2000, NAT IMMUNOL, V1, P47, DOI 10.1038/76907; Venkatraman P, 2007, NAT CHEM BIOL, V3, P222, DOI 10.1038/nchembio868; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wagner R., 1839, ERLAUTERUNGSTAFELN P; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Yelin D, 2006, NATURE, V443, P765, DOI 10.1038/443765a; Yun SH, 2006, NAT MED, V12, P1429, DOI 10.1038/nm1450; Zacharakis G, 2005, P NATL ACAD SCI USA, V102, P18252, DOI 10.1073/pnas.0504628102; Zhang HF, 2006, NAT BIOTECHNOL, V24, P848, DOI 10.1038/nbt1220; Zippelius A, 2004, CANCER RES, V64, P2865, DOI 10.1158/0008-5472.CAN-03-3066	100	1824	1885	26	867	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2008	452	7187					580	589		10.1038/nature06917	http://dx.doi.org/10.1038/nature06917			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385732	Green Accepted			2022-12-28	WOS:000254567200036
J	Hill, JA; Olson, EN				Hill, Joseph A.; Olson, Eric N.			Mechanisms of disease: Cardiac plasticity	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEFT-VENTRICULAR MASS; HUMAN HEART-FAILURE; PRESSURE-OVERLOAD HYPERTROPHY; FOXO TRANSCRIPTION FACTORS; SKELETAL-MUSCLE ATROPHY; IN-VIVO; ESSENTIAL-HYPERTENSION; SYSTOLIC FUNCTION; GENE-EXPRESSION; WALL STRESS		[Hill, Joseph A.; Olson, Eric N.] Univ Texas SW Med Ctr Dallas, Div Cardiol, Donald W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX 75390 USA; [Hill, Joseph A.] Univ Texas SW Med Ctr Dallas, Dept Internal Med Cardiol, Dallas, TX 75390 USA; [Hill, Joseph A.; Olson, Eric N.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Hill, JA (corresponding author), Univ Texas SW Med Ctr Dallas, Div Cardiol, Donald W Reynolds Cardiovasc Clin Res Ctr, 6000 Harry Hines Blvd,NB11-200, Dallas, TX 75390 USA.	joseph.hill@utsouthwestern.edu						Ago T, 2007, ANTIOXID REDOX SIGN, V9, P679, DOI 10.1089/ars.2007.1529; Andersen JB, 2005, NATURE, V434, P37, DOI 10.1038/434037a; Berenji K, 2005, AM J PHYSIOL-HEART C, V289, pH8, DOI 10.1152/ajpheart.01303.2004; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; BOTTINI PB, 1995, AM J HYPERTENS, V8, P221, DOI 10.1016/0895-7061(94)00178-E; Bristow M R, 1998, Lancet, V352 Suppl 1, pSI8, DOI 10.1016/S0140-6736(98)90311-7; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Burkhoff D, 2006, J CARD FAIL, V12, P227, DOI 10.1016/j.cardfail.2005.10.012; CALDERONE A, 1995, CIRCULATION, V92, P2385, DOI 10.1161/01.CIR.92.9.2385; Chien KR, 2000, J CLIN INVEST, V105, P1339, DOI 10.1172/JCI10079; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; de Groot PC, 2006, ARCH PHYS MED REHAB, V87, P1195, DOI 10.1016/j.apmr.2006.05.023; Devereux RB, 2001, HYPERTENSION, V38, P417, DOI 10.1161/01.HYP.38.3.417; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; Diedrichs H, 2004, EUR J HEART FAIL, V6, P823, DOI 10.1016/j.ejheart.2004.10.001; Diedrichs H, 2004, EUR J HEART FAIL, V6, P3, DOI 10.1016/j.ejheart.2003.07.007; Diffee GM, 2003, AM J PHYSIOL-HEART C, V284, pH830, DOI 10.1152/ajpheart.00761.2002; Dorn GW, 2007, HYPERTENSION, V49, P962, DOI 10.1161/HYPERTENSIONAHA.106.079426; Dorn GW, 2003, CIRC RES, V92, P1171, DOI 10.1161/01.RES.0000077012.11088.BC; Drazner MH, 2005, CIRCULATION, V112, P936, DOI 10.1161/CIRCULATIONAHA.105.558734; Drazner MH, 2004, J AM COLL CARDIOL, V43, P2207, DOI 10.1016/j.jacc.2003.11.064; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; FAGARD R, 1983, CIRCULATION, V67, P896, DOI 10.1161/01.CIR.67.4.896; Fagard R, 2003, HEART, V89, P1455, DOI 10.1136/heart.89.12.1455; Fazio S, 2007, J CLIN ENDOCR METAB, V92, P4218, DOI 10.1210/jc.2007-1189; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB; FROHLICH ED, 1992, NEW ENGL J MED, V327, P1768; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; GAASCH WH, 1989, CIRCULATION, V79, P872, DOI 10.1161/01.CIR.79.4.872; GANAU A, 1992, J AM COLL CARDIOL, V19, P1550, DOI 10.1016/0735-1097(92)90617-V; Glass DJ, 2003, TRENDS MOL MED, V9, P344, DOI 10.1016/S1471-4914(03)00138-2; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; GUNTHER S, 1979, CIRCULATION, V59, P679, DOI 10.1161/01.CIR.59.4.679; Haq S, 2001, CIRCULATION, V103, P670; Hardt SE, 2004, CARDIOVASC RES, V63, P500, DOI 10.1016/j.cardiores.2004.03.015; Haunstetter A, 2000, CIRC RES, V86, P371, DOI 10.1161/01.RES.86.4.371; Hein S, 2003, CIRCULATION, V107, P984, DOI 10.1161/01.CIR.0000051865.66123.B7; Heineke J, 2006, NAT REV MOL CELL BIO, V7, P589, DOI 10.1038/nrm1983; Hilfiker-Klemer D, 2006, J AM COLL CARDIOL, V48, pA56, DOI 10.1016/j.jacc.2006.07.007; Hill JA, 2000, CIRCULATION, V101, P2863, DOI 10.1161/01.CIR.101.24.2863; Hill JA, 2003, TRENDS CARDIOVAS MED, V13, P316, DOI 10.1016/j.tcm.2003.08.002; Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200; HOOD WP, 1968, AM J CARDIOL, V22, P550, DOI 10.1016/0002-9149(68)90161-6; HUBER D, 1981, CIRCULATION, V64, P126, DOI 10.1161/01.CIR.64.1.126; IMAMURA T, 1994, CIRC RES, V75, P418, DOI 10.1161/01.RES.75.3.418; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Katz AM, 2002, CARDIOVASC DRUG THER, V16, P245, DOI 10.1023/A:1020604623427; Kerkela R, 2007, TRENDS CARDIOVAS MED, V17, P91, DOI 10.1016/j.tcm.2007.01.004; Kinugawa K, 2001, CIRC RES, V89, P591, DOI 10.1161/hh1901.096706; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KRAYENBUEHL HP, 1989, CIRCULATION, V79, P744, DOI 10.1161/01.CIR.79.4.744; KRAYENBUEHL HP, 1988, EUR HEART J, V9, P19, DOI 10.1093/eurheartj/9.suppl_E.19; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Li HH, 2004, J CLIN INVEST, V114, P1058, DOI 10.1172/JCl200422220; Lim HW, 1999, NAT MED, V5, P246, DOI 10.1038/6430; Lisy O, 2005, AM J PHYSIOL-REG I, V288, pR158, DOI 10.1152/ajpregu.00444.2004; Lorell BH, 2000, CIRCULATION, V102, P470; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Margulies KB, 2005, CIRC RES, V96, P592, DOI 10.1161/01.RES.0000159390.03503.c3; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; McMullen JR, 2007, P NATL ACAD SCI USA, V104, P612, DOI 10.1073/pnas.0606663104; MEERSON F Z, 1961, Cor Vasa, V3, P161; Mesa A, 1999, CIRCULATION, V99, P511, DOI 10.1161/01.CIR.99.4.511; MILLIKEN MC, 1988, AM J CARDIOL, V62, P301, DOI 10.1016/0002-9149(88)90228-7; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; Moens AL, 2006, ARTERIOSCL THROM VAS, V26, P2439, DOI 10.1161/01.ATV.0000243924.00970.cb; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nakai A, 2007, NAT MED, V13, P619, DOI 10.1038/nm1574; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Neubauer S, 2007, NEW ENGL J MED, V356, P1140, DOI 10.1056/NEJMra063052; Ni YG, 2006, CIRCULATION, V114, P1159, DOI 10.1161/CIRCULATIONAHA.106.637124; Olson Eric N, 2006, Novartis Found Symp, V274, P3; Opie LH, 2006, LANCET, V367, P356, DOI 10.1016/S0140-6736(06)68074-4; Osler W, 1892, PRINCIPLES PRACTICE; Packer M, 2002, J CARD FAIL, V8, P193, DOI 10.1054/jcaf.2002.128001; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; Perhonen MA, 2001, J APPL PHYSIOL, V91, P645, DOI 10.1152/jappl.2001.91.2.645; Perrino C, 2006, J CLIN INVEST, V116, P1547, DOI 10.1172/JCI25397; Potthoff MJ, 2007, J CLIN INVEST, V117, P2459, DOI 10.1172/JCI31960; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Razeghi P, 2006, ANN NY ACAD SCI, V1080, P110, DOI 10.1196/annals.1380.011; Ritter O, 2002, CIRCULATION, V105, P2265, DOI 10.1161/01.CIR.0000016044.19527.96; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P9907; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Rothermel BA, 2007, AUTOPHAGY, V3, P632, DOI 10.4161/auto.4913; Sadler DB, 1997, HYPERTENSION, V30, P777, DOI 10.1161/01.HYP.30.4.777; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SANDLER H, 1963, CIRC RES, V13, P91, DOI 10.1161/01.RES.13.2.91; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sano M, 2007, NATURE, V446, P444, DOI 10.1038/nature05602; SCHEUER J, 1982, J CLIN INVEST, V70, P1300, DOI 10.1172/JCI110729; Schillaci G, 2000, HYPERTENSION, V35, P580, DOI 10.1161/01.HYP.35.2.580; SEMELKA RC, 1990, AM HEART J, V119, P1367, DOI 10.1016/S0002-8703(05)80187-5; Serneri GGN, 1999, CIRC RES, V85, P57; Shiojima I, 2005, J CLIN INVEST, V115, P2108, DOI 10.1172/JCI24682; Shiojima I, 2006, GENE DEV, V20, P3347, DOI 10.1101/gad.1492806; Sides MB, 2005, AVIAT SPACE ENVIR MD, V76, P877; Skurk C, 2005, J BIOL CHEM, V280, P20814, DOI 10.1074/jbc.M500528200; SPIRITO P, 1987, AM J CARDIOL, V60, P123, DOI 10.1016/0002-9149(87)90998-2; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Sugden PH, 2001, ANN MED, V33, P611; Sussman MA, 2004, ANNU REV PHYSIOL, V66, P29, DOI 10.1146/annurev.physiol.66.032102.140723; Takimoto E, 2007, HYPERTENSION, V49, P241, DOI 10.1161/01.HYP.0000254415.31362.a7; TANNOUS P, IN PRESS CIRCULATION; Thompson PD, 2004, MED SCI SPORT EXER, V36, P363, DOI 10.1249/01.MSS.0000117117.67849.F6; Tomaselli GF, 2004, CIRC RES, V95, P754, DOI 10.1161/01.RES.0000145047.14691.db; Tsao LN, 2000, NAT MED, V6, P2, DOI 10.1038/71478; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; Vasan RS, 1997, NEW ENGL J MED, V336, P1350, DOI 10.1056/NEJM199705083361903; VERDECCHIA P, 1995, J AM COLL CARDIOL, V25, P871, DOI 10.1016/0735-1097(94)00424-O; Verdecchia P, 2001, J AM COLL CARDIOL, V38, P1829, DOI 10.1016/S0735-1097(01)01663-1; VILLARI B, 1995, CIRCULATION, V91, P2353, DOI 10.1161/01.CIR.91.9.2353; Wachtell K, 2001, AM J CARDIOL, V87, P54, DOI 10.1016/S0002-9149(00)01272-8; Weber KT, 1997, CIRCULATION, V96, P4065; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Zhu HX, 2007, J CLIN INVEST, V117, P1782, DOI 10.1172/JCI27523; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137; 1898, BR MED J, V1, P908	130	839	870	5	72	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1370	1380		10.1056/NEJMra072139	http://dx.doi.org/10.1056/NEJMra072139			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367740				2022-12-28	WOS:000254308400008
J	Smolen, JS; Beaulieu, A; Rubbert-Roth, A; Ramos-Remus, C; Rovensky, J; Alecock, E; Woodworth, T; Alten, R				Smolen, Josef S.; Beaulieu, Andre; Rubbert-Roth, Andrea; Ramos-Remus, Cesar; Rovensky, Josef; Alecock, Emma; Woodworth, Thasia; Alten, Rieke		OPTION Investigators	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial	LANCET			English	Article; Proceedings Paper	Annual European Congress of Rheumatology (EULAR 2007)	JUN 13-16, 2007	Barcelona, SPAIN	European League Against Rheumatism			RECEIVING CONCOMITANT METHOTREXATE; CARDIOVASCULAR RISK-FACTORS; COLLEGE-OF-RHEUMATOLOGY; ACUTE-PHASE REACTANTS; LIPID PROFILE; MONOCLONAL-ANTIBODY; INFLIXIMAB THERAPY; ACTIVITY SCORE; DISEASE; VALIDATION	Background Interleukin 6 is involved in the pathogenesis of rheumatoid arthritis via its broad effects on immune and inflammatory responses. Our aim was to assess the therapeutic effects of blocking interleukin 6 by inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis. Methods In this double-blind, randomised, placebo-controlled, parallel group phase III study, 623 patients with moderate to severe active rheumatoid arthritis were randomly assigned with an interactive voice response system, stratified by site with a randomisation list provided by the study sponsor, to receive tocilizumab 8 mg/kg (n=205), tocilizumab 4 mg/kg (214), or placebo (204) intravenously every 4 weeks, with methortrexate at stable pre-study doses (10-25 mg/week). Rescue therapy with tocilizumab 8 mg/kg was offered at week 16 to patients with less than 20% improvement in both swollen and tender joint counts. The primary endpoint was the proportion of patients with 20% improvement in signs and symptoms of rheumatoid arthritis according to American College of Rheumatology criteria (ACR20 response) at week 24. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00106548. Findings The intention-to-treat analysis population consisted of 622 patients: one patient in the 4 mg/kg group did not receive study treatment and was thus excluded. At 24 weeks, ACR20 responses were seen in more patients receiving tocilizumab than in those receiving placebo (120 [59%] patients in the 8 mg/kg group, 102 [48%] in the 4 mg/kg group, 54 [26%] in the placebo group; odds ratio 4.0 [95% CI 2.6-6.1], p<0.0001 for 8 mg/kg vs placebo; and 2.6 [1.7-3.9], p<0 . 0001 for 4 mg/kg vs placebo). More people receiving tocilizumab than those receiving placebo had at least one adverse event (143 [69%] in the 8 mg/kg group; 151 [71%] in the 4 mg/kg group; 129 [63%] in the placebo group). The most common serious adverse events were serious infections or infestations, reported by six patients in the 8 mg/kg group, three in the 4 mg/kg group, and two in the placebo group. Interpretation Tocilizumab could be an effective therapeutic approach in patients with moderate to severe active rheumatoid arthritis.	[Smolen, Josef S.] Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, Vienna, Austria; [Smolen, Josef S.] Hietzing Hosp, Dept Med 2, Vienna, Austria; [Beaulieu, Andre] Univ Laval, Fac Med, Laval, PQ, Canada; [Rubbert-Roth, Andrea] Univ Cologne, Med Clin 1, Cologne, Germany; [Ramos-Remus, Cesar] Res Unit Chron Dis, Guadalajara, Jalisco, Mexico; [Rovensky, Josef] Natl Inst Rheumat Dis, Piestany, Slovakia; [Alecock, Emma; Woodworth, Thasia] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England; [Alten, Rieke] Univ Med Berlin, Dept Internal Med 2, Schlosspk Clin, Berlin, Germany	Medical University of Vienna; Hietzing Hospital; Laval University; University of Cologne; Roche Holding; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Smolen, JS (corresponding author), Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, Vienna, Austria.	josef.smolen@meduniwien.ac.at	Alten, Rieke/M-1045-2019; Khraishi, Majed/HDN-4826-2022; Puéchal, Xavier/P-1555-2017; ABU-SHAKRA, MAHMOUD/F-1892-2012	Khraishi, Majed/0000-0003-0293-5128; Puéchal, Xavier/0000-0003-3573-9203; ABU-SHAKRA, MAHMOUD/0000-0001-6954-0839; Abud-Mendoza, Carlos/0000-0002-3749-5831; scali, jacqueline/0000-0003-2844-7499; Ramos-Remus, Cesar/0000-0002-4898-4219				Aletaha D, 2005, ARTHRITIS RES THER, V7, pR796, DOI 10.1186/ar1740; Allanore Y, 2006, CLIN CHIM ACTA, V365, P143, DOI 10.1016/j.cca.2005.08.010; ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315; Bruce B, 2003, J RHEUMATOL, V30, P167; Cella D, 2005, J RHEUMATOL, V32, P811; Cella D, 2002, CANCER-AM CANCER SOC, V94, P528, DOI 10.1002/cncr.10245; Choi HK, 2002, LANCET, V359, P1173, DOI 10.1016/S0140-6736(02)08213-2; Dahlqvist SR, 2006, SCAND J RHEUMATOL, V35, P107, DOI 10.1080/03009740500474578; Dursunoglu D, 2005, RHEUMATOL INT, V25, P241, DOI 10.1007/s00296-004-0438-0; Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778; EMERY P, 1995, ANN RHEUM DIS, V54, P944, DOI 10.1136/ard.54.12.944; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347; Fransen J, 2004, RHEUMATOLOGY, V43, P1252, DOI 10.1093/rheumatology/keh297; Jacobsson LTH, 2001, ARTHRITIS RHEUM-US, V44, P1170, DOI 10.1002/1529-0131(200105)44:5<1170::AID-ANR200>3.3.CO;2-K; Jiang YB, 2000, ARTHRITIS RHEUM, V43, P1001, DOI 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P; Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217; Kremer JM, 2006, ANN INTERN MED, V144, P865, DOI 10.7326/0003-4819-144-12-200606200-00003; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Maini RN, 2006, ARTHRITIS RHEUM-US, V54, P2817, DOI 10.1002/art.22033; Mierau M, 2007, RHEUMATOLOGY, V46, P975, DOI 10.1093/rheumatology/kem007; Nagabhushanam V, 2003, J IMMUNOL, V171, P4750, DOI 10.4049/jimmunol.171.9.4750; Naka T, 2002, ARTHRITIS RES THER, V4, pS233, DOI 10.1186/ar565; National Cholesterol Education Program, 2002, DET EV TREATM HIGH B; Nishimoto N, 2004, ARTHRITIS RHEUM-US, V50, P1761, DOI 10.1002/art.20303; Nishimoto N, 2007, ANN RHEUM DIS, V66, P1162, DOI 10.1136/ard.2006.068064; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Sattar N, 2003, CIRCULATION, V108, P2957, DOI 10.1161/01.CIR.0000099844.31524.05; Sattar N, 2007, ARTHRITIS RHEUM-US, V56, P831, DOI 10.1002/art.22447; Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140-6736(07)60784-3; Steiner G, 1999, RHEUMATOLOGY, V38, P202, DOI 10.1093/rheumatology/38.3.202; Turesson C, 2007, CURR OPIN RHEUMATOL, V19, P190, DOI 10.1097/BOR.0b013e3280147107; vanGestel AM, 1996, ARTHRITIS RHEUM, V39, P34, DOI 10.1002/art.1780390105; VANLEEUWEN MA, 1994, J RHEUMATOL, V21, P425; Vis M, 2005, J RHEUMATOL, V32, P252; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WELLS GA, 1993, J RHEUMATOL, V20, P557; Wolfe F, 2004, AM J MED, V116, P305, DOI 10.1016/j.amjmed.2003.09.039; Wolfe F, 2003, J RHEUMATOL, V30, P36; Wolfe F, 2006, J RHEUMATOL, V33, P1516	42	1066	1184	0	53	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 22	2008	371	9617					987	997		10.1016/S0140-6736(08)60453-5	http://dx.doi.org/10.1016/S0140-6736(08)60453-5			11	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358926				2022-12-28	WOS:000254206000027
J	Kahn, RS; Fleischhacker, WW; Boter, H; Davidson, M; Vergouwe, Y; Keet, IPM; Gheorghe, MD; Rybakowski, JK; Galderisi, S; Libiger, J; Hummer, M; Dollfus, S; Lopez-Ibor, JJ; Hranov, LG; Gaebel, W; Peuskens, J; Lindefors, N; Riecher-Rossler, A; Grobbee, DE				Kahn, Rene S.; Fleischhacker, W. Wolfgang; Boter, Han; Davidson, Michael; Vergouwe, Yvonne; Keet, Ireneus P. M.; Gheorghe, Mihai D.; Rybakowski, Janusz K.; Galderisi, Silvana; Libiger, Jan; Hummer, Martina; Dollfus, Sonia; Lopez-Ibor, Juan J.; Hranov, Luchezar G.; Gaebel, Wolfgang; Peuskens, Joseph; Lindefors, Nils; Riecher-Roessler, Anita; Grobbee, Diederick E.		EUFEST Study Grp	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial	LANCET			English	Article							DOUBLE-BLIND; CONVENTIONAL ANTIPSYCHOTICS; RECEPTOR OCCUPANCY; RATING-SCALE; HALOPERIDOL; OLANZAPINE; PSYCHOSIS; EFFICACY; RELIABILITY; RISPERIDONE	Background Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated. We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia. Methods We did an open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries. Eligible patients were aged 18-40 years, and met diagnostic criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder. 498 patients were randomly assigned by a web-based online system to haloperidol (1-4 mg per day; n=103), amisulpride (200-800 mg per day; n=104), olanzapine (5-20 mg per day; n=105), quetiapine (200-750 mg per day; n=104), or ziprasidone (40-160 mg per day; n=82); follow-up was at 1 year. The primary outcome measure was all-cause treatment discontinuation. Patients and their treating physicians were not blinded to the assigned treatment. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN68736636. Findings The number of patients who discontinued treatment for any cause within 12 months was 63 (Kaplan-Meier estimate 72%) for haloperidol, 32 (40%) for amisulpride, 30 (33%) for olanzapine, 51 (53%) for quetiapine, and 31 (45%) for ziprasidone. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride (hazard ratio [HR] 0 . 37, [95% Cl 0. 24-0.57]), olanzapine (HR 0 . 28 [0.18-0.43]), quetiapine (HR 0 . 52 [0 . 35-0.76]), and ziprasidone (HR 0 . 51 [0.32-0.81]). However, symptom reductions were virtually the same in all the groups, at around 60%. Interpretation This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year. However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement. Funding AstraZeneca, Pfizer, Sanofi-Aventis.	[Kahn, Rene S.; Boter, Han] Univ Med Ctr Utrecht, Dept Psychiat, Rudolf Magnus Inst Neurosci, NL-3508 GA Utrecht, Netherlands; [Vergouwe, Yvonne; Grobbee, Diederick E.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; [Fleischhacker, W. Wolfgang; Hummer, Martina] Med Univ Innsbruck, Dept Biol Psychiat, Innsbruck, Austria; [Davidson, Michael] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; [Keet, Ireneus P. M.] AMC de Meren, Amsterdam, Netherlands; [Gheorghe, Mihai D.] Cent Mil Hosp, Dept Psychiat, Bucharest, Romania; [Rybakowski, Janusz K.] Univ Med Sci, Dept Adult Psychiat, Poznan, Poland; [Galderisi, Silvana] Univ Naples SUN, Dept Psychiat, Naples, Italy; [Libiger, Jan] Charles Univ Prague, Med Sch & Fac Hosp, Dept & Clin Psychiat, Hradec Kralove, Czech Republic; [Dollfus, Sonia] CHU Caen, Ctr Esquirol, F-14000 Caen, France; [Lopez-Ibor, Juan J.] Hosp Clin San Carlos, Inst Psychiat & Mental Hlth, Madrid, Spain; [Hranov, Luchezar G.] Univ Hosp Neurol & Psychiat St Naum, Dept & Clin Psychiat, Sofia, Bulgaria; [Gaebel, Wolfgang] Univ Dusseldorf, Dept Psychiat & Psychotherapy, Dusseldorf, Germany; [Peuskens, Joseph] Katholieke Univ Leuven, Univ Psychiat Ctr, Louvain, Belgium; [Lindefors, Nils] Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, Stockholm, Sweden; [Riecher-Roessler, Anita] Univ Basel Hosp, Dept Psychiat, CH-4031 Basel, Switzerland	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Medical University of Innsbruck; Chaim Sheba Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; Universita della Campania Vanvitelli; Charles University Prague; CHU de Caen NORMANDIE; Universite de Caen Normandie; Hospital Clinico San Carlos; Medical University Sofia; Heinrich Heine University Dusseldorf; KU Leuven; Karolinska Institutet; University of Basel	Kahn, RS (corresponding author), Univ Med Ctr Utrecht, Dept Psychiat, Rudolf Magnus Inst Neurosci, POB 85500, NL-3508 GA Utrecht, Netherlands.	r.kahn@umcutrecht.nl	Grobbee, Diederick/C-7651-2014; Dollfus, Sonia/L-4551-2013; Riecher-Rössler, Anita/ABF-5752-2020; Lencer, Rebekka/A-4994-2009; LIBIGER, JAN/N-6884-2017; Dollfus, Sonia/B-8186-2008	Grobbee, Diederick/0000-0003-4472-4468; Riecher-Rössler, Anita/0000-0001-6361-8789; Lencer, Rebekka/0000-0003-4032-7297; Dollfus, Sonia/0000-0002-6051-1748; LIBIGER, JAN/0000-0002-6354-8634; Vita, Antonio/0000-0002-3621-6394; Galderisi, Silvana/0000-0002-1592-7656; Muehlbacher, Moritz/0000-0002-3398-3889				ADDINGTON D, 1992, SCHIZOPHR RES, V6, P201, DOI 10.1016/0920-9964(92)90003-N; Aleman A, 2003, ARCH GEN PSYCHIAT, V60, P565, DOI 10.1001/archpsyc.60.6.565; Arato M, 2002, INT CLIN PSYCHOPHARM, V17, P207, DOI 10.1097/00004850-200209000-00001; Davis JM, 2003, ARCH GEN PSYCHIAT, V60, P553, DOI 10.1001/archpsyc.60.6.553; Fleischhacker WW, 2005, SCHIZOPHR RES, V78, P147, DOI 10.1016/j.schres.2005.06.004; Geddes J, 2000, BRIT MED J, V321, P1371, DOI 10.1136/bmj.321.7273.1371; GERLACH J, 1993, ACTA PSYCHIAT SCAND, V87, P244, DOI 10.1111/j.1600-0447.1993.tb03366.x; GOLDSTEIN H, 1994, STAT MED, V13, P1643, DOI 10.1002/sim.4780131605; Green AI, 2006, SCHIZOPHR RES, V86, P234, DOI 10.1016/j.schres.2006.06.021; Guy W, 2000, HDB PSYCHIAT MEASURE, P100; JONES SH, 1995, BRIT J PSYCHIAT, V166, P654, DOI 10.1192/bjp.166.5.654; Kapur S, 2000, AM J PSYCHIAT, V157, P514, DOI 10.1176/appi.ajp.157.4.514; Kapur S, 1997, PSYCHOPHARMACOLOGY, V131, P148, DOI 10.1007/s002130050277; Kapur S, 1996, AM J PSYCHIAT, V153, P948; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kemmler G, 2005, ARCH GEN PSYCHIAT, V62, P1305, DOI 10.1001/archpsyc.62.12.1305; Kemp R, 1996, BRIT MED J, V312, P345; Leucht S, 1999, SCHIZOPHR RES, V35, P51, DOI 10.1016/S0920-9964(98)00105-4; Leucht S, 2003, LANCET, V361, P1581, DOI 10.1016/S0140-6736(03)13306-5; Leucht S, 2006, NEUROPSYCHOPHARMACOL, V31, P2318, DOI 10.1038/sj.npp.1301147; Lieberman JA, 2003, AM J PSYCHIAT, V160, P1396, DOI 10.1176/appi.ajp.160.8.1396; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Lingjaerde O, 1987, Acta Psychiatr Scand Suppl, V334, P1; McEvoy JP, 2007, AM J PSYCHIAT, V164, P1050, DOI 10.1176/appi.ajp.164.7.1050; MCEVOY JP, 1991, ARCH GEN PSYCHIAT, V48, P739; Pocock S, 1993, CLIN TRIALS PRACTICA; Priebe S, 1999, INT J SOC PSYCHIATR, V45, P7, DOI 10.1177/002076409904500102; Remington G, 1998, BRIT J PSYCHIAT, V172, P66, DOI 10.1192/S0007125000297687; Rummel C, 2003, COCHRANE DB SYST REV, V4; Schooler N, 2005, AM J PSYCHIAT, V162, P947, DOI 10.1176/appi.ajp.162.5.947; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; STONE CK, 1995, AM J PSYCHIAT, V152, P1210; Stroup TS, 2006, NAT REV DRUG DISCOV, V5, P133, DOI 10.1038/nrd1956; Suhara T, 2002, ARCH GEN PSYCHIAT, V59, P25, DOI 10.1001/archpsyc.59.1.25	34	780	814	1	71	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1085	1097		10.1016/S0140-6736(08)60486-9	http://dx.doi.org/10.1016/S0140-6736(08)60486-9			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18374841	Green Accepted			2022-12-28	WOS:000254442700027
J	Das, SB; Joughin, I; Behn, MD; Howat, IM; King, MA; Lizarralde, D; Bhatia, MP				Das, Sarah B.; Joughin, Ian; Behn, Mark D.; Howat, Ian M.; King, Matt A.; Lizarralde, Dan; Bhatia, Maya P.			Fracture propagation to the base of the Greenland Ice Sheet during supraglacial lake drainage	SCIENCE			English	Article							SURFACE MELT; EVOLUTION; SCENARIOS	Surface meltwater that reaches the base of an ice sheet creates a mechanism for the rapid response of ice flow to climate change. The process whereby such a pathway is created through thick, cold ice has not, however, been previously observed. We describe the rapid (< 2 hours) drainage of a large supraglacial lake down 980 meters through to the bed of the Greenland Ice Sheet initiated by water- driven fracture propagation evolving into moulin flow. Drainage coincided with increased seismicity, transient acceleration, ice- sheet uplift, and horizontal displacement. Subsidence and deceleration occurred over the subsequent 24 hours. The short- lived dynamic response suggests that an efficient drainage system dispersed the meltwater subglacially. The integrated effect of multiple lake drainages could explain the observed net regional summer ice speedup.	[Das, Sarah B.; Behn, Mark D.; Lizarralde, Dan] Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA; [Joughin, Ian; Howat, Ian M.] Univ Washington, Appl Phys Lab, Polar Sci Ctr, Seattle, WA 98105 USA; [Howat, Ian M.] Ohio State Univ, Sch Earth Sci, Columbus, OH 43210 USA; [Howat, Ian M.] Ohio State Univ, Byrd Polar Res Ctr, Columbus, OH 43210 USA; [King, Matt A.] Univ Newcastle, Sch Civil Engn & Geosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Bhatia, Maya P.] MIT, Woods Hole Oceanog Inst Joint Program, Dept Geol & Geophys, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution; University of Washington; University of Washington Seattle; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Newcastle University - UK; Massachusetts Institute of Technology (MIT)	Das, SB (corresponding author), Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA.	sdas@whoi.edu	King, Matt/B-4622-2008; Joughin, Ian R/A-2998-2008; Howat, Ian M/A-3474-2008; Joughin, Ian/AAR-7778-2021; Behn, Mark D/F-5813-2012	King, Matt/0000-0001-5611-9498; Joughin, Ian R/0000-0001-6229-679X; Howat, Ian M/0000-0002-8072-6260; Joughin, Ian/0000-0001-6229-679X; Behn, Mark D/0000-0002-2001-1335; Lizarralde, Daniel/0000-0001-6152-6039; Bhatia, Maya/0000-0002-5236-8689	Natural Environment Research Council [NE/C002121/1] Funding Source: researchfish; NERC [NE/C002121/1] Funding Source: UKRI	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		ALLEY RB, 2005, ANN GLACIOL, V40; BARNBER JL, 2007, EARTH PLANET SC LETT, V257, P1; Boon S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018034; Box JE, 2007, J GLACIOL, V53, P257, DOI 10.3189/172756507782202883; Gogineni S, 2001, J GEOPHYS RES-ATMOS, V106, P33761, DOI 10.1029/2001JD900183; Greve R, 1997, J CLIMATE, V10, P901, DOI 10.1175/1520-0442(1997)010<0901:AOAPTD>2.0.CO;2; IPCC (Intergovernmental Panel on Climate Change), 2007, CLIM CHANG 2007 PHYS; Joughin I, 2008, SCIENCE, V320, P781, DOI 10.1126/science.1153288; Luthje M, 2006, J GLACIOL, V52, P608, DOI 10.3189/172756506781828386; Marshall SJ, 2005, EARTH PLANET SC LETT, V240, P191, DOI 10.1016/j.epsl.2005.08.016; McMillan M, 2007, EARTH PLANET SC LETT, V262, P484, DOI 10.1016/j.epsl.2007.08.002; Parizek BR, 2004, QUATERNARY SCI REV, V23, P1013, DOI 10.1016/j.quascirev.2003.12.024; van der Veen CJ, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028385; WEERTMAN J, 1973, S HYDR GLAC CAMBR 7, P139; Zwally HJ, 2002, SCIENCE, V297, P218, DOI 10.1126/science.1072708	15	391	397	3	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2008	320	5877					778	781		10.1126/science.1153360	http://dx.doi.org/10.1126/science.1153360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VB	18420900	Green Submitted			2022-12-28	WOS:000255644400035
J	Brearley, S; Johnson, JN				Brearley, Stephen; Johnson, James N.			Should we screen for abdominal aortic aneurysm?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Brearley, Stephen] Whipps Cross Univ Hosp, London E11 1NR, England; [Johnson, James N.] Halton Gen Hosp, Runcorn WA7 2DA, Cheshire, England	University of London; Queen Mary University London	Brearley, S (corresponding author), Whipps Cross Univ Hosp, London E11 1NR, England.	vascusurg@btconnect.com; jnjohnson33@hotmail.com							0	8	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2008	336	7649					862	863		10.1136/bmj.39517.443796.AD	http://dx.doi.org/10.1136/bmj.39517.443796.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290QH	18420691	Green Published			2022-12-28	WOS:000255136800030
J	Wiviott, SD; Braunwald, E; McCabe, CH; Horvath, I; Keltai, M; Herrman, JPR; Van de Werf, F; Downey, WE; Scirica, BM; Murphy, SA; Antman, EM				Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Horvath, Ivan; Keltai, Matyas; Herrman, Jean-Paul R.; Van de Werf, Frans; Downey, William E.; Scirica, Benjamin M.; Murphy, Sabina A.; Antman, Elliott M.		TRITON TIMI 38 Investigators	Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial	LANCET			English	Article							DRUG-ELUTING STENTS; ACUTE MYOCARDIAL-INFARCTION; BARE-METAL STENTS; ARTERY-DISEASE; PLATELET INHIBITION; OFF-LABEL; BALLOON ANGIOPLASTY; CLINICAL-OUTCOMES; UNCOATED STENTS; INCREASED RISK	Background Intracoronary stenting can improve procedural success and reduce restenosis compared with balloon angioplasty in patients with acute coronary syndromes, but can also increase the rate of thrombotic complications including stent thrombosis. The TRITON-TIMI 38 trial has shown that prasugrel-a novel, potent thienopyridine-can reduce ischaemic events compared with standard clopidogrel therapy. We assessed the rate, outcomes, and prevention of ischaemic events in patients treated with prasugrel or clopidogrel with stents in the TRITON-TIMI 38 study. Methods patients with moderate-risk to high-risk coronary syndromes ware included in our analysis if they had received at least one coronary stent at the time of the index procedure following randomisation in TRITON-TIMI 38, and were further subdivided by type of stent received. Patients were randomly assigned in a 1 to 1 fashion to receive a loading dose of study drug (prasugrel 60 mg or clopidogrel 300 mg) as soon as possible after randomisation, followed by daily maintenance therapy (prasugrel 10 mg or clopidogrel 75 mg). All patients were to receive aspirin therapy. Treatment was to be continued for a minimum of 6 months and a maximum of 15 months. Randomisation was not stratified by stents used or stent type. The primary endpoint was the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Stent thrombosis was assessed using Academic Research Consortium definitions, and analysis was by intention to treat. TRITON-TIMI 38 is registered with ClinicalTrials.gov, number NCT 00097591. Findings 12 844 patients received at least one coronary stent; 5743 received only drug-eluting stents, and 6461 received only bare-metal stents. Prasugrel compared with clopidogrel reduced the primary endpoint (9.7 vs 11.9%, HR 0.81, p=0.0001) in the stented cohort, in patients with only drug-eluting stents (9.0 vs 11.1%, HR 0.82, p=0.019), and in pateints with only bare-metal stents (10.0 vs 12.2%, HR 0.80, p=0.003). Stent thrombosis was associated with death or myocardial infarction in 89% (186/210) of patients. Stent thrombosis was reduced with prasugrel overall (1.13 vs 2.35%, HR 0.48, p<0.0001), in patients with drug-eluting stents only (0.84 vs 2.31%, HR 0.36, p<0.0001), and in those with bare-metal stents only (1.27 vs 2.41%, HR 0.52, p=0.0009). Interpretation Intensive antiplatelet therapy with prasugrel resulted in fewer ischaemic outcomes including stent thrombosis than with standard clopidogrel. These findings were statistically robust irrespective of stent type, and the data affirm the importance of intensive platelet inhibition in patients with intracoronary stents. Funding TRITON-TIMI 38 was supported by research grants from Daiichi Sankyo and Eli Lilly.	[Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Scirica, Benjamin M.; Murphy, Sabina A.; Antman, Elliott M.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA; [Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Scirica, Benjamin M.; Murphy, Sabina A.; Antman, Elliott M.] Harvard Univ, Sch Med, Boston, MA USA; [Horvath, Ivan] Univ Pecs, Inst Heart, Pecs, Hungary; [Keltai, Matyas] Semmelweis Univ, Hungarian Inst Cardiol, H-1085 Budapest, Hungary; [Herrman, Jean-Paul R.] Onze Lieve Vrouw Hosp, Dept Cardiol, Amsterdam, Netherlands; [Van de Werf, Frans] Univ Louvain, Dept Cardiovasc Dis, Louvain, Belgium; [Downey, William E.] LeBauer Cardiovasc Res Fdn, Greensboro, NC USA; [Downey, William E.] Moses Cone Heart & Vasc Ctr, Greensboro, NC USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Pecs; Semmelweis University; Onze Lieve Vrouwe Gasthuis Hospital; LeBauer-Brodie Center for Cardiovascular Research & Education	Wiviott, SD (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.	swiviott@partners.org	Wiviott, Stephen/HIK-2534-2022	Van de Werf, Frans/0000-0001-9479-7767				Awata M, 2007, CIRCULATION, V116, P910, DOI 10.1161/CIRCULATIONAHA.105.609057; Beohar N, 2007, JAMA-J AM MED ASSOC, V297, P1992, DOI 10.1001/jama.297.18.1992; Bertrand ME, 2000, CIRCULATION, V102, P624, DOI 10.1161/01.CIR.102.6.624; Bertrand ME, 1998, CIRCULATION, V98, P1597, DOI 10.1161/01.CIR.98.16.1597; Brandt JT, 2007, AM HEART J, V153, DOI 10.1016/j.ahj.2006.10.010; Buonamici P, 2007, J AM COLL CARDIOL, V49, P2312, DOI 10.1016/j.jacc.2007.01.094; Cuisset T, 2006, J THROMB HAEMOST, V4, P542, DOI 10.1111/j.1538-7836.2005.01751.x; Eisenstein EL, 2007, JAMA-J AM MED ASSOC, V297, P159, DOI 10.1001/jama.297.2.joc60179; Farb A, 2007, NEW ENGL J MED, V356, P984, DOI 10.1056/NEJMp068304; Finn AV, 2007, CIRCULATION, V115, P2435, DOI 10.1161/CIRCULATIONAHA.107.693739; Finn AV, 2005, CIRCULATION, V112, P270, DOI 10.1161/CIRCULATIONAHA.104.508937; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GALLOE AM, 1920, JAMA-J AM MED ASSOC, V299, P409; Grines CL, 2007, CIRCULATION, V115, P813, DOI 10.1161/CIRCULATIONAHA.106.180944; Gurbel PA, 2003, AM J CARDIOL, V91, P1123, DOI 10.1016/S0002-9149(03)00163-2; Gurbel PA, 2005, J AM COLL CARDIOL, V46, P1827, DOI 10.1016/j.jacc.2005.07.056; Ho PM, 2008, JAMA-J AM MED ASSOC, V299, P532, DOI 10.1001/jama.299.5.532; Ho PM, 2007, AM HEART J, V154, P489, DOI 10.1016/j.ahj.2007.05.018; Jakubowski JA, 2007, CARDIOVASC DRUG REV, V25, P357, DOI 10.1111/j.1527-3466.2007.00027.x; Jakubowski JA, 2007, BRIT J CLIN PHARMACO, V63, P421, DOI 10.1111/j.1365-2125.2006.02792.x; Laarman GJ, 2006, NEW ENGL J MED, V355, P1105, DOI 10.1056/NEJMoa062598; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Lincoff AM, 1999, NEW ENGL J MED, V341, P319, DOI 10.1056/NEJM199907293410503; Maisel WH, 2007, NEW ENGL J MED, V356, P981, DOI 10.1056/NEJMp068305; Marroquin OC, 2008, NEW ENGL J MED, V358, P342, DOI 10.1056/NEJMoa0706258; Matetzky S, 2004, CIRCULATION, V109, P3171, DOI 10.1161/01.CIR.0000130846.46168.03; Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Pfisterer M, 2006, J AM COLL CARDIOL, V48, P2584, DOI 10.1016/j.jacc.2006.10.026; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Serebruany VL, 2005, J AM COLL CARDIOL, V45, P246, DOI 10.1016/j.jacc.2004.09.067; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Silber S, 2005, EUR HEART J, V26, P804, DOI 10.1093/eurheartj/ehi138; SMITH SC, 2005, CATHETER CARDIO 1214; Spaulding C, 2007, NEW ENGL J MED, V356, P989, DOI 10.1056/NEJMoa066633; Spaulding C, 2006, NEW ENGL J MED, V355, P1093, DOI 10.1056/NEJMoa062006; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Stettler C, 2007, LANCET, V370, P937, DOI 10.1016/S0140-6736(07)61444-5; Stone GW, 2007, CIRCULATION, V115, P2842, DOI 10.1161/CIRCULATIONAHA.106.687186; Stone GW, 2004, CIRCULATION, V109, P1942, DOI 10.1161/01.CIR.0000127110.49192.72; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Templin Christian, 2006, Clin Res Cardiol, V95, P122, DOI 10.1007/s00392-006-0332-8; Urban P, 1998, CIRCULATION, V98, P2126, DOI 10.1161/01.CIR.98.20.2126; Wallentin L, 2008, EUR HEART J, V29, P21, DOI 10.1093/eurheartj/ehm545; Win HK, 2007, JAMA-J AM MED ASSOC, V297, P2001, DOI 10.1001/jama.297.18.2001; Wiviott SD, 2007, CIRCULATION, V116, P2923, DOI 10.1161/CIRCULATIONAHA.107.740324; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Wiviott SD, 2006, AM HEART J, V152, P627, DOI 10.1016/j.ahj.2006.04.012; Yusuf S, 2001, NEW ENGL J MED, V345, P494	50	360	382	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 19	2008	371	9621					1353	1363		10.1016/S0140-6736(08)60422-5	http://dx.doi.org/10.1016/S0140-6736(08)60422-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291PE	18377975				2022-12-28	WOS:000255208500026
J	Alexander, JH; Emery, RW; Carrier, M; Ellis, SJ; Mehta, RH; Hasselblad, V; Menasche, P; Khalil, A; Cote, R; Bennett-Guerrero, E; Mack, MJ; Schuler, G; Harrington, RA; Tardif, JC				Alexander, John H.; Emery, Robert W., Jr.; Carrier, Michel; Ellis, Stephen J.; Mehta, Rajendra H.; Hasselblad, Vic; Menasche, Philippe; Khalil, Ahmad; Cote, Robert; Bennett-Guerrero, Elliott; Mack, Michael J.; Schuler, Gerhard; Harrington, Robert A.; Tardif, Jean-Claude		MEND-CABG II Investigators	Efficacy and safety of pyridoxal 5 '-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery - The MEND-CABG II randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; CARDIOPULMONARY BYPASS; ISCHEMIC-INJURY; ADENOSINE; MORTALITY; DATABASE; OUTCOMES; SOCIETY; REVASCULARIZATION; CARDIOPLEGIA	Context Coronary artery bypass graft ( CABG) surgery is frequently performed and effective; however, perioperative complications related to ischemia- reperfusion injury, including myocardial infarction ( MI), remain common and result in significant morbidity and mortality. MC- 1, a naturally occurring pyridoxine metabolite and purinergic receptor antagonist, prevents cellular calcium overload and may reduce ischemia-reperfusion injury. Phase 2 trial data suggest that MC- 1 may reduce death or MI in high- risk patients undergoing CABG surgery. Objective To assess the efficacy and safety of MC- 1 administered immediately before and for 30 days after surgery in patients undergoing CABG surgery. Design, Setting, and Participants The MC- 1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery II Trial, a phase 3, multicenter, randomized, double- blind, placebo- controlled trial, with 3023 intermediate- to high- risk patients undergoing CABG surgery with cardiopulmonary bypass enrolled between October 2006 and September 2007 at 130 sites in Canada, the United States, and Germany. Interventions Patients received either MC- 1, 250 mg/ d ( n= 1519), or matching placebo ( n= 1504) immediately before and for 30 days after CABG surgery. Main Outcome Measures The primary efficacy outcome was cardiovascular death or nonfatal MI, defined as a creatine kinase ( CK) MB fraction of at least 100 ng/ mL or new Q waves through postoperative day 30. Results The primary efficacy outcome occurred in 140 of 1510 patients ( 9.3%) in the MC- 1 group and 133 of 1486 patients ( 9.0%) in the placebo group ( risk ratio, 1.04; 95% confidence interval, 0.83- 1.30; P=. 76). All- cause mortality was higher among patients assigned to MC- 1 than placebo at 4 days ( 1.0% vs 0.3%; P=. 03) but was similar at 30 days ( 1.9% vs 1.5%; P=. 44). There was no difference in the 8- to 24- hour CK- MB area under the curve between the MC- 1 and placebo groups ( median, 270 [ interquartile range, 175- 492] vs 268 [ interquartile range, 170- 456] hours x ng/ mL; P=. 11). Conclusion In this population of intermediate- to high- risk patients undergoing CABG surgery, MC- 1 did not reduce the composite of cardiovascular death or nonfatal MI. Trial Registration clinicaltrials. gov Identifier: NCT00402506.	[Alexander, John H.; Ellis, Stephen J.; Mehta, Rajendra H.; Hasselblad, Vic; Bennett-Guerrero, Elliott; Harrington, Robert A.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27715 USA; [Emery, Robert W., Jr.] Minnesota Heart & Vasc Ctr, Edina, MN USA; [Carrier, Michel; Cote, Robert; Tardif, Jean-Claude] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; [Menasche, Philippe] Hosp European George Pompidou, Paris, France; [Khalil, Ahmad] Medicure Int Inc, Winnipeg, MB, Canada; [Mack, Michael J.] Cardiothorac Surg Assoc N Texas, Dallas, TX USA; [Schuler, Gerhard] Univ Leipzig, Leipzig, Germany	Duke University; Universite de Montreal; UDICE-French Research Universities; Universite Paris Cite; Leipzig University	Alexander, JH (corresponding author), Duke Univ, Med Ctr, Duke Clin Res Inst, DUMC Box 3850, Durham, NC 27715 USA.	john.h.alexander@duke.edu	Alexander, John/GVS-7271-2022	Shaher, Motaz/0000-0003-3248-708X; Alexander, John/0000-0002-1444-2462				Alexander JH, 2005, JAMA-J AM MED ASSOC, V294, P2446; Brener SJ, 2002, J AM COLL CARDIOL, V40, P1961, DOI 10.1016/S0735-1097(02)02538-X; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Costa MA, 2001, CIRCULATION, V104, P2689, DOI 10.1161/hc4701.099789; Desai ND, 2004, NEW ENGL J MED, V351, P2302, DOI 10.1056/NEJMoa040982; Eagle Kim A, 2004, Circulation, V110, pe340; EDWARDS FH, 1994, ANN THORAC SURG, V57, P12, DOI 10.1016/0003-4975(94)90358-1; Ferguson TB, 2002, ANN THORAC SURG, V73, P480, DOI 10.1016/S0003-4975(01)03339-2; Fremes SE, 1996, CIRCULATION, V94, P370; Kandzari DE, 2005, EXPERT OPIN INV DRUG, V14, P1435, DOI 10.1517/13543784.14.11.1435; Kandzari DE, 2003, AM J CARDIOL, V92, P660, DOI 10.1016/S0002-9149(03)00818-X; Klatte K, 2001, J AM COLL CARDIOL, V38, P1070, DOI 10.1016/S0735-1097(01)01481-4; LACOURCIERE Y, 2006, AM SOC HYP 21 ANN SC; LANCASTER H, 1961, J AM STAT ASSOC, V56, P223, DOI 10.2307/2282247; LEE HT, 1995, J CARDIAC SURG, V10, P665, DOI 10.1111/j.1540-8191.1995.tb00657.x; LEFEBVRE J, 2006, AM SOC HYP 21 ANN SC; Mangano DT, 2006, J AM COLL CARDIOL, V48, P206, DOI 10.1016/j.jacc.2006.04.044; Mangano DT, 1997, JAMA-J AM MED ASSOC, V277, P325, DOI 10.1001/jama.277.4.325; Mehta RH, 2008, CIRCULATION, V117, P876, DOI 10.1161/CIRCULATIONAHA.107.728147; MEHTA RH, AM HEART J; Mentzer RM, 1999, ANN SURG, V229, P643, DOI 10.1097/00000658-199905000-00006; Mentzer RM, 1997, AM J CARDIOL, V79, P38, DOI 10.1016/S0002-9149(97)00262-2; MENTZER RM, 2003, AM HEART ASS SCI SES; Plume SK, 2001, ANN THORAC SURG, V72, P314, DOI 10.1016/S0003-4975(01)02453-5; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Shernan SK, 2004, ANN THORAC SURG, V77, P942, DOI 10.1016/j.athoracsur.2003.08.054; Tardif JC, 2007, J THORAC CARDIOV SUR, V133, P1604, DOI 10.1016/j.jtcvs.2007.01.049; Theroux P, 2000, CIRCULATION, V102, P3032; Thygesen K, 2007, EUR HEART J, V28, P2525; Verrier ED, 2004, JAMA-J AM MED ASSOC, V291, P2319, DOI 10.1001/jama.291.19.2319; Wang CX, 2005, J NEUROSURG, V103, P165, DOI 10.3171/jns.2005.103.1.0165; Wang X, 1999, J MOL CELL CARDIOL, V31, P1063, DOI 10.1006/jmcc.1999.0936; Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667	33	41	44	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1777	1787						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18381567	Bronze			2022-12-28	WOS:000254954800022
J	Vivo, RP				Vivo, Rey P.			Rediscovery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												rey.vivo@ttuhsc.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1753	1754		10.1001/jama.299.15.1753	http://dx.doi.org/10.1001/jama.299.15.1753			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18413864				2022-12-28	WOS:000254954800001
J	Masanja, H; de Savigny, D; Smithson, P; Schellenberg, J; John, T; Mbuya, C; Upunda, G; Boerma, T; Victora, C; Smith, T; Mshinda, H				Masanja, Honorati; de Savigny, Don; Smithson, Paul; Schellenberg, Joanna; John, Theopista; Mbuya, Conrad; Upunda, Gabriel; Boerma, Ties; Victora, Cesar; Smith, Tom; Mshinda, Hassan			Child survival gains Tanzania: analysis of data from demographic and health surveys	LANCET			English	Article							UNDER-5 MORTALITY; RURAL TANZANIA; IMPACT; COUNTRIES; COVERAGE; STRATEGY; TRENDS	Background A recent national survey in Tanzania reported that mortality in children younger than 5 years dropped by 24% over the 5 years between 2000 and 2004. We aimed to investigate yearly changes to identify what might have contributed to this reduction and to investigate the prospects for meeting the Millennium Development Goal for child survival (MDG 4). Methods We analysed data from the four demographic and health surveys done in Tanzania since 1990 to generate estimates of mortality in children younger than 5 years for every 1-year period before each survey back to 1990. We estimated trends in mortality between 1990 and 2004 by fitting Lowess regression, and forecasted trends in mortality in 2005 to 2015. We aimed to investigate contextual factors, whether part of Tanzania's health system or not, that could have affected child mortality. Findings Disaggregated estimates of mortality showed a sharp acceleration in the reduction in mortality in children younger than 5 years in Tanzania between 2000 and 2004. In 1990, the point estimate of mortality was 141.5 (95% CI 141.5-141. 5) deaths per 1000 livebirths. This was reduced by 40%, to reach a point estimate of 83.2 (95% CI 70.1-96-3) deaths per 1000 livebirths in 2004. The change in absolute risk was 58.4 (95% CI 32 . 7-83 . 8; p< 0 . 0001). Between 1999 and 2004 we noted important improvements in Tanzania's health system, including doubled public expenditure on health; decentralisation and sector-wide basket funding; and increased coverage of key child-survival interventions, such as integrated management of childhood illness, insecticide-treated nets, vitamin A supplementation, immunisation, and exclusive breastfeeding. Other determinants of child survival that are not related to the health system did not change between 1999 and 2004, except for a slow increase in the HIV/AIDS burden. Interpretation Tanzania could attain MDG 4 if this trend of improved child survival were to be sustained. Investment in health systems and scaling up interventions can produce rapid gains in child survival. Funding Government of Norway.	[Masanja, Honorati; de Savigny, Don; Smithson, Paul; Schellenberg, Joanna; Mshinda, Hassan] Ifakara Hlth Res & Dev Ctr, Dar Es Salaam, Tanzania; [de Savigny, Don; Smith, Tom] Swiss Trop Inst, CH-4002 Basel, Switzerland; [Schellenberg, Joanna] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [John, Theopista; Boerma, Ties] WHO, Dar Es Salaam, Tanzania; [Mbuya, Conrad; Upunda, Gabriel] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania; [Victora, Cesar] Univ Pelotas, Pelotas, Brazil	Ifakara Health Institute; University of Basel; Swiss Tropical & Public Health Institute; University of London; London School of Hygiene & Tropical Medicine; World Health Organization	Masanja, H (corresponding author), Ifakara Hlth Res & Dev Ctr, Kiko Ave,Plot N 463, Dar Es Salaam, Tanzania.	hmasanja@ihrdc.or.tz	Smith, Thomas/B-5569-2015; Victora, Cesar G/D-4476-2013; Victora, Cesar Gomes/Y-2455-2019	Smith, Thomas/0000-0002-3650-9381; Victora, Cesar G/0000-0002-2465-2180; Victora, Cesar Gomes/0000-0002-2465-2180; Schellenberg, Joanna/0000-0002-0708-3676				Abdullah S, 2007, AM J TROP MED HYG, V77, P99; Adult Morbidity and Mortality Project, 2004, POL IMPL TANZ MORT B; Armspach D, 2004, J IRAN CHEM SOC, V1, P10, DOI 10.1007/BF03245765; *BANK TANZ, TANZ EC FIN IND; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Bryce J, 2006, LANCET, V368, P1067, DOI 10.1016/S0140-6736(06)69339-2; Bryce J, 2006, LANCET, V368, P817, DOI 10.1016/S0140-6736(06)69299-4; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Collet D., 1994, MODELLING SURVIVAL D; DESAVIGNY D, 2004, FIXING HLTH SYSTEMS; *FUT GROUP INT, 2008, SPECTR POL MOD SYST; *GOV TANZ, 2001, POV RED STRAT PAP; *GOV UN REP TANZ V, 2005, NAT STRAT GROWTH RED; Habicht JP, 1999, INT J EPIDEMIOL, V28, P10, DOI 10.1093/ije/28.1.10; Heston A., 2006, PENN WORLD TABLE VER; Horton R, 2006, LANCET, V367, P3, DOI 10.1016/S0140-6736(06)67899-9; Horton R, 2006, LANCET, V368, P1041, DOI 10.1016/S0140-6736(06)69331-8; Houweling TAJ, 2005, INT J EPIDEMIOL, V34, P1257, DOI 10.1093/ije/dyi190; Janson A, 2007, ACTA PAEDIATR, V96, P781, DOI 10.1111/j.1651-2227.2007.00293.x; Korenromp EL, 2004, INT J EPIDEMIOL, V33, P1293, DOI 10.1093/ije/dyh182; Lawn JE, 2004, LANCET, V364, P399, DOI 10.1016/S0140-6736(04)16783-4; Martines J, 2005, LANCET, V365, P1189, DOI 10.1016/S0140-6736(05)71882-1; Masanja H, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-142; *MIN HLTH SOC WELF, 2006, ANN HLTH STAT ABSTR; *MIN HLTH TANZ, 2006, PUBL EXP REV PER 200; Morris SS, 2003, INT J EPIDEMIOL, V32, P1041, DOI 10.1093/ije/dyg241; Murray CJL, 2007, LANCET, V370, P1040, DOI 10.1016/S0140-6736(07)61478-0; *NAT BUR STAT TANZ, 2000, TANZ REPR CHILD HLTH; *NAT BUR STAT TANZ, 2005, TANZ HIV AIDS IND SU; *NAT BUR STAT TANZ, 2003, TANZ HOUS BUDG SURV; *NAT BUR STAT TANZ, 2005, TANZ DEM HLTH SURV 2; National Bureau of Statistics of Tanzania ICF Macro, 1993, TANZ DEM HLTH SURV 1; National Bureau of Statistics of Tanzania Macro International, 1996, TANZ DEM HLTH SURV 1; National Bureau of Statistics Tanzania and Macro International, 2007, TANZ SERV PROV ASS S; Ng'weshemi J, 2003, JAIDS-J ACQ IMM DEF, V33, P393, DOI 10.1097/00126334-200307010-00015; Schellenberg JRMA, 2004, LANCET, V364, P1583, DOI 10.1016/S0140-6736(04)17311-X; Schellenberg JRMA, 2001, LANCET, V357, P1241, DOI 10.1016/S0140-6736(00)04404-4; Smith L. C., 2006, FOOD INSECURITY SUBS, V146; *UN REP TANZ RES A, 2005, POV HUM DEV REP 2005; *UNICEF, 2005, COUNTD 2015 CHILD SU; *UNICEF ROLL MAL, 2007, MAL CHILDR PROGR INT; Vega JC, 2007, TROP MED INT HEALTH, V12, P1524, DOI 10.1111/j.1365-3156.2007.01961.x; Victora CG, 2005, HEALTH POLICY PLANN, V20, pI18, DOI 10.1093/heapol/czi050; Victora CG, 2005, LANCET, V366, P1460, DOI 10.1016/S0140-6736(05)67599-X; World Health Organization, 2007, WORLD HLTH STAT 2007	45	107	109	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1276	1283		10.1016/S0140-6736(08)60562-0	http://dx.doi.org/10.1016/S0140-6736(08)60562-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286XH	18406862				2022-12-28	WOS:000254878900029
J	Richter, J; Lux, J; Reinecke, P; Mueller-Mattheis, V				Richter, Joachim; Lux, Joerg; Reinecke, Petra; Mueller-Mattheis, Volker			Of flukes and fistulae	LANCET			English	Editorial Material							SCHISTOSOMIASIS; HEALTH		[Richter, Joachim] Univ Dusseldorf, Trop Med Unit, Univ Hosp Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany; [Lux, Joerg] Univ Dusseldorf, Univ Hosp Gynaecol & Obstet, Dusseldorf, Germany; [Reinecke, Petra] Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany; [Mueller-Mattheis, Volker] Univ Dusseldorf, Univ Hosp Urol, D-4000 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Richter, J (corresponding author), Univ Dusseldorf, Tropenmed Ambulanz, Klin Gastroenterol Hepatol & Infektiol, Universitatsklinikum Dusseldorf, Moorenstr 5, D-40225 Dusseldorf, Germany.	joachim.richter@med.uni-duesseldorf.de						BLAND KG, 1970, T ROY SOC TROP MED H, V64, P588, DOI 10.1016/0035-9203(70)90081-7; EDINGTON GM, 1975, T ROY SOC TROP MED H, V69, P153, DOI 10.1016/0035-9203(75)90027-9; Swai B, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-134; Wall LL, 2006, LANCET, V368, P1201, DOI 10.1016/S0140-6736(06)69476-2; WRIGHT ED, 1982, T ROY SOC TROP MED H, V76, P822, DOI 10.1016/0035-9203(82)90118-3	5	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 12	2008	371	9620					1308	1308		10.1016/S0140-6736(08)60566-8	http://dx.doi.org/10.1016/S0140-6736(08)60566-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286XH	18406866				2022-12-28	WOS:000254878900033
J	Chereau, D; Boczkowska, M; Skwarek-Maruszewska, A; Fujiwara, I; Hayes, DB; Rebowski, G; Lappalainen, P; Pollard, TD; Dominguez, R				Chereau, David; Boczkowska, Malgorzata; Skwarek-Maruszewska, Aneta; Fujiwara, Ikuko; Hayes, David B.; Rebowski, Grzegorz; Lappalainen, Pekka; Pollard, Thomas D.; Dominguez, Roberto			Leiomodin is an actin filament nucleator in muscle cells	SCIENCE			English	Article							ARP2/3 COMPLEX; TROPOMODULIN; END	Initiation of actin polymerization in cells requires nucleation factors. Here we describe an actin-binding protein, leiomodin, that acted as a strong filament nucleator in muscle cells. Leiomodin shared two actin-binding sites with the filament pointed end-capping protein tropomodulin: a flexible N-terminal region and a leucine-rich repeat domain. Leiomodin also contained a C-terminal extension of 150 residues. The smallest fragment with strong nucleation activity included the leucine-rich repeat and C-terminal extension. The N-terminal region enhanced the nucleation activity threefold and recruited tropomyosin, which weakly stimulated nucleation and mediated localization of leiomodin to the middle of muscle sarcomeres. Knocking down leiomodin severely compromised sarcomere assembly in cultured muscle cells, which suggests a role for leiomodin in the nucleation of tropomyosin-decorated filaments in muscles.	[Boczkowska, Malgorzata; Rebowski, Grzegorz; Dominguez, Roberto] Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; [Chereau, David; Hayes, David B.] Boston Biomed Res Inst, Watertown, MA 02472 USA; [Skwarek-Maruszewska, Aneta; Lappalainen, Pekka] Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; [Fujiwara, Ikuko; Pollard, Thomas D.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	University of Pennsylvania; Boston Biomedical Research Institute; University of Helsinki; Yale University	Dominguez, R (corresponding author), Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA.	droberto@mail.med.upenn.edu	Fujiwara, Ikuko/H-5717-2016; Hayes, David B/CAH-1880-2022	Fujiwara, Ikuko/0000-0002-9361-636X; Hayes, David B/0000-0002-1133-3471; Lappalainen, Pekka/0000-0001-6227-0354	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL086655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073791, R01GM026338] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL086655, HL086655, P01 HL086655-01A10004] Funding Source: Medline; NIGMS NIH HHS [R01 GM073791-04, R01 GM073791, GM073791, GM026338] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Clarkson E, 2004, J PATHOL, V204, P407, DOI 10.1002/path.1648; Conley CA, 2001, GENOMICS, V73, P127, DOI 10.1006/geno.2000.6501; Fischer RS, 2003, TRENDS CELL BIOL, V13, P593, DOI 10.1016/j.tcb.2003.09.007; Fowler VM, 2003, J BIOL CHEM, V278, P40000, DOI 10.1074/jbc.M306895200; HITCHCOCKDEGREGORI SE, 1988, BIOCHEMISTRY-US, V27, P9182, DOI 10.1021/bi00426a016; Kostyukova AS, 2007, J MOL BIOL, V372, P608, DOI 10.1016/j.jmb.2007.05.084; Krieger I, 2002, BIOPHYS J, V83, P2716, DOI 10.1016/S0006-3495(02)75281-8; Mahaffy RE, 2006, BIOPHYS J, V91, P3519, DOI 10.1529/biophysj.106.080937; Pollard TD, 2007, ANNU REV BIOPH BIOM, V36, P451, DOI 10.1146/annurev.biophys.35.040405.101936; Quinlan ME, 2005, NATURE, V433, P382, DOI 10.1038/nature03241	10	165	170	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					239	243		10.1126/science.1155313	http://dx.doi.org/10.1126/science.1155313			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403713	Green Accepted			2022-12-28	WOS:000254836700046
J	Pasupathy, AN; Pushp, A; Gomes, KK; Parker, CV; Wen, JS; Xu, ZJ; Gu, GD; Ono, S; Ando, Y; Yazdani, A				Pasupathy, Abhay N.; Pushp, Aakash; Gomes, Kenjiro K.; Parker, Colin V.; Wen, Jinsheng; Xu, Zhijun; Gu, Genda; Ono, Shimpei; Ando, Yoichi; Yazdani, Ali			Electronic origin of the inhomogeneous pairing interaction in the high-T-c superconductor Bi2Sr2CaCu2O8+delta	SCIENCE			English	Article							TRANSITION-TEMPERATURE; ATOMIC-SCALE; STATE; MECHANISM; DYNAMICS; MODEL; GLUE	Identifying the mechanism of superconductivity in the high-temperature cuprate superconductors is one of the major outstanding problems in physics. We report local measurements of the onset of superconducting pairing in the high-transition temperature (T-c) superconductor Bi2Sr2CaCu2O8+delta using a lattice-tracking spectroscopy technique with a scanning tunneling microscope. We can determine the temperature dependence of the pairing energy gaps, the electronic excitations in the absence of pairing, and the effect of the local coupling of electrons to bosonic excitations. Our measurements reveal that the strength of pairing is determined by the unusual electronic excitations of the normal state, suggesting that strong electron-electron interactions rather than low-energy (< 0.1 volts) electron-boson interactions are responsible for superconductivity in the cuprates.	[Pasupathy, Abhay N.; Pushp, Aakash; Gomes, Kenjiro K.; Parker, Colin V.; Yazdani, Ali] Princeton Univ, Joseph Henry Labs, Princeton, NJ 08544 USA; [Pushp, Aakash; Gomes, Kenjiro K.] Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; [Wen, Jinsheng; Xu, Zhijun; Gu, Genda] Brookhaven Natl Lab, Upton, NY 11973 USA; [Ono, Shimpei] Cent Res Inst Elect Power Ind, Tokyo 2018511, Japan; [Ando, Yoichi] Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan	Princeton University; Princeton University; United States Department of Energy (DOE); Brookhaven National Laboratory; Central Research Institute of Electric Power Industry - Japan; Osaka University	Yazdani, A (corresponding author), Princeton Univ, Joseph Henry Labs, Princeton, NJ 08544 USA.	yazdani@princeton.edu	Pushp, Aakash/G-6626-2011; Parker, Colin/AAK-6766-2021; Ando, Yoichi/B-8163-2013; Ono, Shimpei/D-2918-2017; xu, zhijun/A-3264-2013; Wen, Jinsheng/F-4209-2010	Ando, Yoichi/0000-0002-3553-3355; xu, zhijun/0000-0001-7486-2015; Wen, Jinsheng/0000-0001-5864-1466; Yazdani, Ali/0000-0003-4996-8904; XU, ZHIJUN/0000-0002-4960-3801; Parker, Colin/0000-0001-6902-4471; Ono, Shimpei/0000-0003-1514-8879				Anderson PW, 2006, NAT PHYS, V2, P626, DOI 10.1038/nphys388; Anderson PW, 2007, SCIENCE, V316, P1705, DOI 10.1126/science.1140970; Anderson PW, 2004, J PHYS-CONDENS MAT, V16, pR755, DOI 10.1088/0953-8984/16/24/R02; ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; BARDEEN J, 1973, SCIENCE, V181, P1209, DOI 10.1126/science.181.4106.1209; BICKERS NE, 1989, PHYS REV LETT, V62, P961, DOI 10.1103/PhysRevLett.62.961; Boyer MC, 2007, NAT PHYS, V3, P802, DOI 10.1038/nphys725; Campuzano JC, 2004, PHYSICS OF SUPERCONDUCTORS, VOL II, P167; Carbotte JP, 1999, NATURE, V401, P354, DOI 10.1038/43843; CARBOTTE JP, 1990, REV MOD PHYS, V62, P1027, DOI 10.1103/RevModPhys.62.1027; Chubukov AV, 2003, PHYSICS OF SUPERCONDUCTORS, VOL I, P495; Cuk T, 2005, PHYS STATUS SOLIDI B, V242, P11, DOI 10.1002/pssb.200404959; Dagotto E, 2005, SCIENCE, V309, P257, DOI 10.1126/science.1107559; Damascelli A, 2003, REV MOD PHYS, V75, P473, DOI 10.1103/RevModPhys.75.473; Demler E, 1998, NATURE, V396, P733, DOI 10.1038/25482; DYNES RC, 1978, PHYS REV LETT, V41, P1509, DOI 10.1103/PhysRevLett.41.1509; DYNES RC, 1975, PHYS REV B, V11, P1884, DOI 10.1103/PhysRevB.11.1884; ELIASHBERG GM, 1960, SOV PHYS JETP-USSR, V11, P696; Eschrig M, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.144503; Fang AC, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.017007; Fink J., 2007, VERY HIGH RESOLUTION, P295, DOI [10.1007/3-540-68133-7, DOI 10.1007/3-540-68133-7]; Gomes KK, 2007, NATURE, V447, P569, DOI 10.1038/nature05881; Graf J, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.067004; Howald C, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.100504; Hwang J, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.207002; Hwang J, 2004, NATURE, V427, P714, DOI 10.1038/nature02347; KIHLSTROM KE, 1981, PHYS REV B, V24, P4101, DOI 10.1103/PhysRevB.24.4101; Lanzara A, 2001, NATURE, V412, P510, DOI 10.1038/35087518; Le Tacon M, 2006, NAT PHYS, V2, P537, DOI 10.1038/nphys362; Lee J, 2006, NATURE, V442, P546, DOI 10.1038/nature04973; McElroy K, 2005, SCIENCE, V309, P1048, DOI 10.1126/science.1113095; McMillan W., 1969, SUPERCONDUCTIVITY, V1, P561; MCMILLAN WL, 1965, PHYS REV LETT, V14, P108, DOI 10.1103/PhysRevLett.14.108; Meevasana W, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.174506; MILLIS AJ, 1990, PHYS REV B, V42, P167, DOI 10.1103/PhysRevB.42.167; Niestemski FC, 2007, NATURE, V450, P1058, DOI 10.1038/nature06430; Norman MR, 1998, PHYS REV B, V57, pR11093, DOI 10.1103/PhysRevB.57.R11093; Pan SH, 2001, NATURE, V413, P282, DOI 10.1038/35095012; Paramekanti A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.217002; Pilgram S, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.117003; Scalapino DJ, 2006, NAT PHYS, V2, P593, DOI 10.1038/nphys398; SCALAPINO DJ, 1966, PHYS REV, V148, P263, DOI 10.1103/PhysRev.148.263; Schrieffer J. R., 1964, THEORY SUPERCONDUCTI; Sidis Y, 2004, PHYS STATUS SOLIDI B, V241, P1204, DOI 10.1002/pssb.200304498; VALLES JM, 1994, PHYSICA B, V197, P522, DOI 10.1016/0921-4526(94)90252-6; van der Marel D, 2003, NATURE, V425, P271, DOI 10.1038/nature01978; Varma CM, 1997, PHYS REV B, V55, P14554, DOI 10.1103/PhysRevB.55.14554; Zasadzinski JF, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.067005	49	168	170	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2008	320	5873					196	201		10.1126/science.1154700	http://dx.doi.org/10.1126/science.1154700			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403704	Green Submitted			2022-12-28	WOS:000254836700034
J	Bell, JJ; Bhandoola, A				Bell, J. Jeremiah; Bhandoola, Avinash			The earliest thymic progenitors for T cells possess myeloid lineage potential	NATURE			English	Article							COMMON LYMPHOID PROGENITORS; HEMATOPOIETIC STEM-CELLS; BONE-MARROW; DENDRITIC CELLS; IDENTIFICATION; PRECURSOR; DIFFERENTIATION; TRANSCRIPTION; MACROPHAGES; COMMITMENT	There exists controversy over the nature of haematopoietic progenitors of T cells. Most T cells develop in the thymus, but the lineage potential of thymus-colonizing progenitors is unknown. One approach to resolving this question is to determine the lineage potentials of the earliest thymic progenitors (ETPs). Previous work has shown that ETPs possess T and natural killer lymphoid potentials, and rare subsets of ETPs also possess B lymphoid potential(1), suggesting an origin from lymphoid-restricted progenitor cells. However, whether ETPs also possess myeloid potential is unknown. Here we show that nearly all ETPs in adult mice possess both T and myeloid potential in clonal assays. The existence of progenitors possessing T and myeloid potential within the thymus is incompatible with the current dominant model of haematopoiesis, in which T cells are proposed to arise from lymphoid-restricted progenitors(2). Our results indicate that alternative models for lineage commitment during haematopoiesis must be considered.	[Bell, J. Jeremiah; Bhandoola, Avinash] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Bhandoola, A (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	bhandooa@mail.med.upenn.edu						Adolfsson J, 2001, IMMUNITY, V15, P659, DOI 10.1016/S1074-7613(01)00220-5; Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Allman D, 2003, NAT IMMUNOL, V4, P168, DOI 10.1038/ni878; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; Balciunaite G, 2005, BLOOD, V105, P1930, DOI 10.1182/blood-2004-08-3087; Benz C, 2005, J EXP MED, V202, P21, DOI 10.1084/jem.20050146; Bhandoola A, 2007, IMMUNITY, V26, P678, DOI 10.1016/j.immuni.2007.05.009; Borghesi L, 2004, J EXP MED, V199, P491, DOI 10.1084/jem.20031800; Ceredig R, 2007, EUR J IMMUNOL, V37, P830, DOI 10.1002/eji.200636728; Faust N, 2000, BLOOD, V96, P719; Franco CB, 2006, P NATL ACAD SCI USA, V103, P11993, DOI 10.1073/pnas.0601188103; Igarashi H, 2002, IMMUNITY, V17, P117, DOI 10.1016/S1074-7613(02)00366-7; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kondo M, 2001, CURR OPIN GENET DEV, V11, P520, DOI 10.1016/S0959-437X(00)00227-6; Laiosa CV, 2006, IMMUNITY, V25, P731, DOI 10.1016/j.immuni.2006.09.011; Lu M, 2005, J IMMUNOL, V175, P5848, DOI 10.4049/jimmunol.175.9.5848; MATSUZAKI Y, 1993, J EXP MED, V178, P1283, DOI 10.1084/jem.178.4.1283; Min H, 2004, J IMMUNOL, V173, P245, DOI 10.4049/jimmunol.173.1.245; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Porritt HE, 2004, IMMUNITY, V20, P735, DOI 10.1016/j.immuni.2004.05.004; Sambandam A, 2005, NAT IMMUNOL, V6, P663, DOI 10.1038/ni1216; Schmitt TM, 2006, IMMUNOL REV, V209, P95, DOI 10.1111/j.0105-2896.2006.00353.x; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Taghon TN, 2005, GENE DEV, V19, P965, DOI 10.1101/gad.1298305; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; Ye M, 2003, IMMUNITY, V19, P689, DOI 10.1016/S1074-7613(03)00299-1; Yoshida T, 2006, NAT IMMUNOL, V7, P382, DOI 10.1038/ni1314	29	314	330	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2008	452	7188					764	U9		10.1038/nature06840	http://dx.doi.org/10.1038/nature06840			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401411				2022-12-28	WOS:000254792500048
J	Gabut, M; Chaudhry, S; Blencowe, BJ				Gabut, Mathieu; Chaudhry, Sidharth; Blencowe, Benjamin J.			SnapShot: The splicing regulatory machinery	CELL			English	Editorial Material							RNA-BINDING PROTEINS		[Gabut, Mathieu; Chaudhry, Sidharth; Blencowe, Benjamin J.] Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 3E1, Canada	University of Toronto	Gabut, M (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 3E1, Canada.		GABUT, Mathieu/M-7624-2017	GABUT, Mathieu/0000-0001-7343-5361				Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LIN S, 2007, ALTERNATIVE SPLICING, P108; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Moroy T, 2007, RNA, V13, P1155, DOI 10.1261/rna.554607; Musunuru K, 2003, TRENDS CARDIOVAS MED, V13, P188, DOI 10.1016/S1050-1738(03)00075-6; Park JW, 2004, P NATL ACAD SCI USA, V101, P15974, DOI 10.1073/pnas.0407004101; Pascual M, 2006, DIFFERENTIATION, V74, P65, DOI 10.1111/j.1432-0436.2006.00060.x; Ranum LPW, 2006, ANNU REV NEUROSCI, V29, P259, DOI 10.1146/annurev.neuro.29.051605.113014; Singh R, 2005, NAT STRUCT MOL BIOL, V12, P645, DOI 10.1038/nsmb961; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Ule J, 2006, CURR OPIN NEUROBIOL, V16, P102, DOI 10.1016/j.conb.2006.01.003	13	45	45	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 4	2008	133	1					192	U1		10.1016/j.cell.2008.03.010	http://dx.doi.org/10.1016/j.cell.2008.03.010			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394998	Bronze			2022-12-28	WOS:000254641300019
J	Kalka, MB; Smith, AR; Kalko, EKV				Kalka, Margareta B.; Smith, Adam R.; Kalko, Elisabeth K. V.			Bats limit arthropods and herbivory in a tropical forest	SCIENCE			English	Article							TREES		[Kalka, Margareta B.; Smith, Adam R.; Kalko, Elisabeth K. V.] Smithsonian Trop Res Inst, Balboa 03092, Panama; [Kalko, Elisabeth K. V.] Univ Ulm, Inst Expt Ecol, D-89069 Ulm, Germany	Smithsonian Institution; Smithsonian Tropical Research Institute; Ulm University	Kalka, MB (corresponding author), Smithsonian Trop Res Inst, Apdo 0843, Balboa 03092, Panama.	mbkalka@gmail.com	Smith, Adam/GPS-8322-2022					Cleveland CJ, 2006, FRONT ECOL ENVIRON, V4, P238, DOI 10.1890/1540-9295(2006)004[0238:EVOTPC]2.0.CO;2; Fine PVA, 2004, SCIENCE, V305, P663, DOI 10.1126/science.1098982; Greenberg R, 2000, ECOLOGY, V81, P1750, DOI 10.1890/0012-9658(2000)081[1750:TIOAIO]2.0.CO;2; HOLMES RT, 1979, SCIENCE, V206, P462, DOI 10.1126/science.206.4417.462; Kalka M, 2006, J TROP ECOL, V22, P1, DOI 10.1017/S0266467405002920; Van Bael SA, 2003, P NATL ACAD SCI USA, V100, P8304, DOI 10.1073/pnas.1431621100	6	195	208	2	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					71	71		10.1126/science.1153352	http://dx.doi.org/10.1126/science.1153352			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388286				2022-12-28	WOS:000254633000031
J	Hung, RJ; Mckay, JD; Gaborieau, V; Boffetta, P; Hashibe, M; Zaridze, D; Mukeria, A; Szeszenia-Dabrowska, N; Lissowska, J; Rudnai, P; Fabianova, E; Mates, D; Bencko, V; Foretova, L; Janout, V; Chen, C; Goodman, G; Field, JK; Liloglou, T; Xinarianos, G; Cassidy, A; McLaughlin, J; Liu, G; Narod, S; Krokan, HE; Skorpen, F; Elvestad, MB; Hveem, K; Vatten, L; Linseisen, J; Clavel-Chapelon, F; Vineis, P; Bueno-De-Mesquita, HB; Lund, E; Martinez, C; Bingham, S; Rasmuson, T; Hainaut, P; Riboli, E; Ahrens, W; Benhamou, S; Lagiou, P; Trichopoulos, D; Holcatova, I; Merletti, F; Kjaerheim, K; Agudo, A; Macfarlane, G; Talamini, R; Simonato, L; Lowry, R; Conway, DI; Znaor, A; Healy, C; Zelenika, D; Boland, A; Delepine, M; Foglio, M; Lechner, D; Matsuda, F; Blanche, H; Gut, I; Heath, S; Lathrop, M; Brennan, P				Hung, Rayjean J.; Mckay, James D.; Gaborieau, Valerie; Boffetta, Paolo; Hashibe, Mia; Zaridze, David; Mukeria, Anush; Szeszenia-Dabrowska, Neonilia; Lissowska, Jolanta; Rudnai, Peter; Fabianova, Eleonora; Mates, Dana; Bencko, Vladimir; Foretova, Lenka; Janout, Vladimir; Chen, Chu; Goodman, Gary; Field, John K.; Liloglou, Triantafillos; Xinarianos, George; Cassidy, Adrian; McLaughlin, John; Liu, Geoffrey; Narod, Steven; Krokan, Hans E.; Skorpen, Frank; Elvestad, Maiken Bratt; Hveem, Kristian; Vatten, Lars; Linseisen, Jakob; Clavel-Chapelon, Francoise; Vineis, Paolo; Bueno-de-Mesquita, H. Bas; Lund, Eiliv; Martinez, Carmen; Bingham, Sheila; Rasmuson, Torgny; Hainaut, Pierre; Riboli, Elio; Ahrens, Wolfgang; Benhamou, Simone; Lagiou, Pagona; Trichopoulos, Dimitrios; Holcatova, Ivana; Merletti, Franco; Kjaerheim, Kristina; Agudo, Antonio; Macfarlane, Gary; Talamini, Renato; Simonato, Lorenzo; Lowry, Ray; Conway, David I.; Znaor, Ariana; Healy, Claire; Zelenika, Diana; Boland, Anne; Delepine, Marc; Foglio, Mario; Lechner, Doris; Matsuda, Fumihiko; Blanche, Helene; Gut, Ivo; Heath, Simon; Lathrop, Mark; Brennan, Paul			A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25	NATURE			English	Article							FAGERSTROM TOLERANCE QUESTIONNAIRE; GENOME-WIDE ASSOCIATION; HAPLOTYPE MAP; DEPENDENCE; EXPRESSION; SMOKERS; CELLS; SNPS	Lung cancer is the most common cause of cancer death worldwide, with over one million cases annually(1). To identify genetic factors that modify disease risk, we conducted a genome- wide association study by analysing 317,139 single- nucleotide polymorphisms in 1,989 lung cancer cases and 2,625 controls from six central European countries. We identified a locus in chromosome region 15q25 that was strongly associated with lung cancer ( P= 9 x 10(-10)). This locus was replicated in five separate lung cancer studies comprising an additional 2,513 lung cancer cases and 4,752 controls ( P = 5 x 10(-20) overall), and it was found to account for 14%( attributable risk) of lung cancer cases. Statistically similar risks were observed irrespective of smoking status or propensity to smoke tobacco. The association region contains several genes, including three that encode nicotinic acetylcholine receptor subunits ( CHRNA5, CHRNA3 and CHRNB4). Such subunits are expressed in neurons and other tissues, in particular alveolar epithelial cells, pulmonary neuroendocrine cells and lung cancer cell lines(2,3), and they bind to N'- nitrosonornicotine and potential lung carcinogens(4). A non- synonymous variant of CHRNA5 that induces an amino acid substitution ( D398N) at a highly conserved site in the second intracellular loop of the protein is among the markers with the strongest disease associations. Our results provide compelling evidence of a locus at 15q25 predisposing to lung cancer, and reinforce interest in nicotinic acetylcholine receptors as potential disease candidates and chemopreventative targets(5).	[Hung, Rayjean J.; Mckay, James D.; Gaborieau, Valerie; Boffetta, Paolo; Hashibe, Mia; Hainaut, Pierre; Brennan, Paul] IARC, F-69008 Lyon, France; [Hung, Rayjean J.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Zaridze, David; Mukeria, Anush] Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia; [Szeszenia-Dabrowska, Neonilia] Inst Occupat Med, Dept Epidemiol, PL-90950 Lodz, Poland; [Lissowska, Jolanta] M Sklodowska Curie Mem Canc Ctr & Inst Oncol, PL-02781 Warsaw, Poland; [Rudnai, Peter] Natl Inst Environm Hlth, H-1097 Budapest, Hungary; [Fabianova, Eleonora] Specialized Inst Hyg & Epidemiol, Banska Bystrica 97556, Slovakia; [Mates, Dana] Inst Publ Hlth, Bucharest 050463, Romania; [Bencko, Vladimir] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague 12800 2, Czech Republic; [Foretova, Lenka] Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno 65653, Czech Republic; [Janout, Vladimir] Palacky Univ, Olomouc 77515, Czech Republic; [Chen, Chu; Goodman, Gary] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Field, John K.; Liloglou, Triantafillos; Xinarianos, George; Cassidy, Adrian] Univ Liverpool, Canc Res Ctr, Roy Castle Lung Canc Res Programme, Liverpool L3 9TA, Merseyside, England; [McLaughlin, John] Canc Care Ontario, Toronto, ON M5G 2L7, Canada; [McLaughlin, John] Samuel Lunenfeld Res Inst, Toronto, ON M5G 2L7, Canada; [Liu, Geoffrey] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; [Narod, Steven] Womens Coll Res Inst, Toronto, ON M5G 1N8, Canada; [Krokan, Hans E.; Skorpen, Frank; Elvestad, Maiken Bratt; Hveem, Kristian; Vatten, Lars] Norwegian Univ Sci & Technol, N-7489 Trondheim, Norway; [Linseisen, Jakob] German Canc Res Ctr, Div Canc Epidemiol, D-69120 Heidelberg, Germany; [Clavel-Chapelon, Francoise] Inst Gustave Roussy, INSERM, ER120, F-94805 Villejuif, France; [Vineis, Paolo; Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England; [Vineis, Paolo] ISI, I-10133 Turin, Italy; [Bueno-de-Mesquita, H. Bas] Natl Inst Publ Hlth & Environm, Ctr Nutr & Hlth, NL-3710 BA Bilthoven, Netherlands; [Lund, Eiliv] Univ Tromso, Inst Community Med, N-9037 Tromso, Norway; [Martinez, Carmen] Andalusian Sch Publ Hlth & Ciber Epidemiol & Salu, Granada 18011, Spain; [Bingham, Sheila] Univ Cambridge, MRC Ctr Nutr & Canc, Dept Publ Hlth & Primary Care, Cambridge CB2 0XY, England; [Bingham, Sheila] MRC Dunn Human Nutr Unit, Cambridge CB2 0XY, England; [Rasmuson, Torgny] Umea Univ, Dept Radiat Sci, S-90187 Umea, Sweden; [Ahrens, Wolfgang] Bremen Inst Prevent Res & Social Med, D-28359 Bremen, Germany; [Benhamou, Simone] Fdn Jean Dausset CEPH, INSERM, U794, F-75010 Paris, France; [Benhamou, Simone] Inst Gustave Roussy, CNRS, FRE2939, F-94805 Villejuif, France; [Lagiou, Pagona; Trichopoulos, Dimitrios] Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens 11527, Greece; [Lagiou, Pagona; Trichopoulos, Dimitrios] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Holcatova, Ivana] Inst Hyg & Epidemiol, Prague 12800 2, Czech Republic; [Merletti, Franco] Univ Turin, I-10126 Turin, Italy; [Kjaerheim, Kristina] Canc Registry Norway, N-0310 Oslo, Norway; [Agudo, Antonio] Inst Catala Oncol, Barcelona 08907, Spain; [Macfarlane, Gary] Univ Aberdeen, Sch Med, Aberdeen AB25 2ZD, Scotland; [Talamini, Renato] Aviano Canc Ctr, I-33081 Aviano, Italy; [Simonato, Lorenzo] Univ Padua, Dept Environm Med & Publ Hlth, I-35131 Padua, Italy; [Lowry, Ray] Univ Newcastle, Sch Dent, Newcastle Upon Tyne NE2 4BW, Tyne & Wear, England; [Conway, David I.] Univ Glasgow, Sch Dent, Glasgow G2 3JZ, Lanark, Scotland; [Znaor, Ariana] Natl Inst Publ Hlth, Croatian Natl Canc Registry, Zagreb 10000, Croatia; [Healy, Claire] Univ Dublin Trinity Coll, Sch Dent Sci, Dublin 2, Ireland; [Zelenika, Diana; Boland, Anne; Delepine, Marc; Foglio, Mario; Lechner, Doris; Matsuda, Fumihiko; Gut, Ivo; Lathrop, Mark] Commiss Energie Atom, Ctr Natl Genotype, Inst Genom, F-91000 Evry, France; [Blanche, Helene; Heath, Simon; Lathrop, Mark] Ctr Etud Polymorphisme Humain, Fdn Jean Dausset, F-75010 Paris, France	World Health Organization; International Agency for Research on Cancer (IARC); University of California System; University of California Berkeley; Nofer Institute of Occupational Medicine; Maria Sklodowska-Curie National Research Institute of Oncology; Charles University Prague; Masaryk Memorial Cancer Institute; Palacky University Olomouc; Fred Hutchinson Cancer Center; University of Liverpool; Cancer Care Ontario; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Womens College Hospital; Norwegian University of Science & Technology (NTNU); Helmholtz Association; German Cancer Research Center (DKFZ); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Imperial College London; Netherlands National Institute for Public Health & the Environment; UiT The Arctic University of Tromso; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Escuela Andaluza de Salud Publica; University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Umea University; Leibniz Institute for Prevention Research & Epidemiology (BIPS); Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Athens Medical School; National & Kapodistrian University of Athens; Harvard University; Harvard T.H. Chan School of Public Health; University of Turin; University of Oslo; Catalan Institute of Oncology; University of Aberdeen; University of Padua; Newcastle University - UK; University of Glasgow; Trinity College Dublin; CEA; UDICE-French Research Universities; Universite Paris Saclay; Foundation Jean Dausset-CEPH	Brennan, P (corresponding author), IARC, F-69008 Lyon, France.	brennan@iarc.fr	Hung, Rayjean J/A-7439-2013; Janout, Vladimir/M-5133-2014; Vatten, Lars/AFK-2073-2022; Xinarianos, George/B-7534-2012; Benhamou, Simone/K-6554-2015; Matsuda, Fumihiko/B-9893-2009; Znaor, A/H-6718-2019; Agudo, Antonio/J-1805-2016; Boffetta, Paolo/AAI-7767-2021; Lissowska, Jolanta/AAH-3252-2020; Szeszenia-Dabrowska, Neonila/F-7190-2010; Gut, Ivo/ABF-3188-2020; Narod, Steven A/AAA-6112-2022; Bencko, Vladimir/H-8598-2017; Healy, Claire M/AGL-9755-2022; Linseisen, Jakob/B-5353-2014; Field, John K./AAD-5674-2020; Hveem, Kristian/AFV-4683-2022; Liu, Geoffrey/N-4421-2016; Benhamou, Simone/ABD-2590-2020; Zaridze, David/K-5605-2013; Holcatova, Ivana/C-8327-2017; Heath, Simon C/J-4138-2012; Vatten, Lars/AAF-9380-2022; Clavel-Chapelon, Francoise/G-6733-2014; Foglio, mary A./B-9149-2012; McLaughlin, John R/E-4577-2013; Macfarlane, Gary J/I-9521-2014; Hainaut, Pierre/B-6018-2012; Ahrens, Wolfgang/A-2740-2012	Agudo, Antonio/0000-0001-9900-5677; Boffetta, Paolo/0000-0002-3811-2791; Lissowska, Jolanta/0000-0003-2695-5799; Gut, Ivo/0000-0001-7219-632X; Bencko, Vladimir/0000-0003-1935-2228; Healy, Claire M/0000-0003-0583-6360; Linseisen, Jakob/0000-0002-9386-382X; Field, John K./0000-0003-3951-6365; Holcatova, Ivana/0000-0002-1366-0337; Heath, Simon C/0000-0002-9550-0897; Foglio, mary A./0000-0001-7715-4452; Macfarlane, Gary J/0000-0003-2322-3314; Hainaut, Pierre/0000-0002-1303-1610; SIMONATO, LORENZO/0000-0002-9914-1000; Hung, Rayjean/0000-0002-4486-7496; Ahrens, Wolfgang/0000-0003-3777-570X; Xinarianos, George/0000-0001-9185-5554; Riboli, Elio/0000-0001-6795-6080; mates, dana/0000-0002-6219-9807; BENHAMOU, Simone/0000-0001-5853-8047; Foretova, Lenka/0000-0003-0494-2620; Kjaerheim, Kristina/0000-0003-0691-3735; Skorpen, Frank/0000-0001-7093-8000; Conway, David/0000-0001-7762-4063; Liu, Geoffrey/0000-0002-2603-7296; Healy, Claire M/0000-0001-7940-4611; Lund, Eiliv/0000-0002-8071-8711	NATIONAL CANCER INSTITUTE [R01CA092039] Funding Source: NIH RePORTER; MRC [G9900432] Funding Source: UKRI; Medical Research Council [G9900432] Funding Source: Medline; NCI NIH HHS [R01 CA092039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801; BERRETINI W, 2008, MOL PSYCHIAT    0429; Chabrol H, 2005, ADDICT BEHAV, V30, P1474, DOI 10.1016/j.addbeh.2005.02.001; Coleman MP, 2003, ANN ONCOL, V14, pV128, DOI 10.1093/annonc/mdg756; Dasgupta P, 2006, CELL CYCLE, V5, P2324, DOI 10.4161/cc.5.20.3366; de Bakker PIW, 2006, NAT GENET, V38, P1166, DOI 10.1038/ng1885; FAGERSTROM KO, 1989, J BEHAV MED, V12, P159, DOI 10.1007/BF00846549; Falush D, 2003, GENETICS, V164, P1567; Ferlay J., 2004, GLOBOCAN 2002 IARC C; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; *INT AG RES CANC, 2007, IARC HDB CANC PREV, V11, P15; International Agency for Research on Cancer, 2004, IARC MONOGRAPHS EVAL, V83, P33; Lam DCL, 2007, CANCER RES, V67, P4638, DOI 10.1158/0008-5472.CAN-06-4628; Matakidou A, 2005, BRIT J CANCER, V93, P825, DOI 10.1038/sj.bjc.6602769; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Russo P, 2006, CURR MED CHEM, V13, P3493, DOI 10.2174/092986706779026192; Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438; Schuller HM, 2007, LIFE SCI, V80, P2274, DOI 10.1016/j.lfs.2007.03.006; Tritto T, 2002, PHARMACOGENETICS, V12, P197, DOI 10.1097/00008571-200204000-00004; Wang Y, 2001, MOL PHARMACOL, V60, P1201, DOI 10.1124/mol.60.6.1201; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147	23	967	1011	0	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2008	452	7187					633	637		10.1038/nature06885	http://dx.doi.org/10.1038/nature06885			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385738	Green Submitted, Green Published			2022-12-28	WOS:000254567200046
J	van Seters, M; van Beurden, M; ten Kate, FJW; Beckmann, I; Ewing, PC; Eijkemans, MJC; Kagie, MJ; Meijer, CJM; Aaronson, NK; KleinJan, A; Heijmans-Antonissen, C; Zijlstra, FJ; Burger, MPM; Helmerhorst, TJM				van Seters, Manon; van Beurden, Marc; ten Kate, Fiebo J. W.; Beckmann, Ilse; Ewing, Patricia C.; Eijkemans, Marinus J. C.; Kagie, Marjolein J.; Meijer, Chris J. M.; Aaronson, Neil K.; KleinJan, Alex; Heijmans-Antonissen, Claudia; Zijlstra, Freek J.; Burger, Matthe P. M.; Helmerhorst, Theo J. M.			Treatment of vulvar intraepithelial neoplasia with topical imiquimod	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-PAPILLOMAVIRUS; SOMATOPSYCHIC REACTIONS; EUROPEAN-ORGANIZATION; NATURAL-HISTORY; IMMUNE-RESPONSE; SEXUAL FUNCTION; LOCAL EXCISION; CANCER; TERMINOLOGY; RECURRENCE	Background: Alternatives to surgery are needed for the treatment of vulvar intraepithelial neoplasia. We investigated the effectiveness of imiquimod 5% cream, a topical immune-response modulator, for the treatment of this condition. Methods: Fifty-two patients with grade 2 or 3 vulvar intraepithelial neoplasia were randomly assigned to receive either imiquimod or placebo, applied twice weekly for 16 weeks. The primary outcome was a reduction of more than 25% in lesion size at 20 weeks. Secondary outcomes were histologic regression, clearance of human papillomavirus (HPV) from the lesion, changes in immune cells in the epidermis and dermis of the vulva, relief of symptoms, improvement of quality of life, and durability of response. Reduction in lesion size was classified as complete response (elimination), strong partial response (76 to 99% reduction), weak partial response (26 to 75% reduction), or no response (lessthan/equal 25% reduction). The follow-up period was 12 months. Results: Lesion size was reduced by more than 25% at 20 weeks in 21 of the 26 patients (81%) treated with imiquimod and in none of those treated with placebo (P<0.001). Histologic regression was significantly greater in the imiquimod group than in the placebo group (P<0.001). At baseline, 50 patients (96%) tested positive for HPV DNA. HPV cleared from the lesion in 15 patients in the imiquimod group (58%), as compared with 2 in the placebo group (8%) (P<0.001). The number of immune epidermal cells increased significantly and the number of immune dermal cells decreased significantly with imiquimod as compared with placebo. Imiquimod reduced pruritus and pain at 20 weeks (P=0.008 and P=0.004, respectively) and at 12 months (P=0.04 and P=0.02, respectively). The lesion progressed to invasion (to a depth of <1 mm) in 3 of 49 patients (6%) followed for 12 months (2 in the placebo group and 1 in the imiquimod group). Nine patients, all treated with imiquimod, had a complete response at 20 weeks and remained free from disease at 12 months. Conclusions: Imiquimod is effective in the treatment of vulvar intraepithelial neoplasia. (Current Controlled Trials number, ISRCTN11290871.).	[van Seters, Manon; Beckmann, Ilse; Helmerhorst, Theo J. M.] Erasmus Univ, Med Ctr, Dept Gynecol, Rotterdam, Netherlands; [KleinJan, Alex] Erasmus Univ, Med Ctr, Dept Pulmonol, Rotterdam, Netherlands; [Heijmans-Antonissen, Claudia; Zijlstra, Freek J.] Erasmus Univ, Med Ctr, Dept Anesthesiol, Rotterdam, Netherlands; [Ewing, Patricia C.] Erasmus Univ, Med Ctr, Dept Pathol, Rotterdam, Netherlands; [Eijkemans, Marinus J. C.] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [van Seters, Manon; van Beurden, Marc; Burger, Matthe P. M.] Univ Amsterdam, Acad Med Ctr, Dept Gynecol, NL-1105 AZ Amsterdam, Netherlands; [ten Kate, Fiebo J. W.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [van Beurden, Marc] Netherlands Canc Inst, Dept Gynecol, Amsterdam, Netherlands; [Aaronson, Neil K.] Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, Amsterdam, Netherlands; [Kagie, Marjolein J.] Med Ctr Haaglanden, The Hague, Netherlands; [Meijer, Chris J. M.] Free Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Netherlands Cancer Institute; Haaglanden Medical Center; Vrije Universiteit Amsterdam	Helmerhorst, TJM (corresponding author), Erasmus MC, Dept Obstet & Gynecol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	t.helmerhorst@erasmusmc.nl	Aaronson, Neil K/AAV-8194-2021					Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; ANDERSEN BL, 1983, OBSTET GYNECOL, V62, P457; ANDERSEN BL, 1988, OBSTET GYNECOL, V71, P15; ANDREASSON B, 1986, ACTA OBSTET GYN SCAN, V65, P7, DOI 10.3109/00016348609158221; Beutner KR, 1998, ANTIMICROB AGENTS CH, V42, P789, DOI 10.1128/AAC.42.4.789; Davis G, 2000, J REPROD MED, V45, P619; Diaz-Arrastia C, 2001, CLIN CANCER RES, V7, P3031; Iversen T, 1998, OBSTET GYNECOL, V91, P969, DOI 10.1016/S0029-7844(98)00101-X; Jacobs MV, 2000, BRIT J CANCER, V82, P1421, DOI 10.1054/bjoc.1999.1128; Jayne CJ, 2002, J REPROD MED, V47, P395; Jones RW, 2005, OBSTET GYNECOL, V106, P1319, DOI 10.1097/01.AOG.0000187301.76283.7f; Kanodia S, 2007, CURR CANCER DRUG TAR, V7, P79, DOI 10.2174/156800907780006869; KAUFMAN RH, 1995, GYNECOL ONCOL, V56, P8, DOI 10.1006/gyno.1995.1003; Modesitt SC, 1998, OBSTET GYNECOL, V92, P962, DOI 10.1016/S0029-7844(98)00350-0; Preti M, 2000, BRIT J OBSTET GYNAEC, V107, P594, DOI 10.1111/j.1471-0528.2000.tb13298.x; Sanders ME, 2004, ACSMS HEALTH FIT J, V8, P3, DOI 10.1097/00135124-200401000-00004; Schon MP, 2004, APOPTOSIS, V9, P291, DOI 10.1023/B:APPT.0000025805.55340.c3; Sideri M, 2005, J REPROD MED, V50, P807; Sprangers MAG, 1996, J CLIN ONCOL, V14, P2756, DOI 10.1200/JCO.1996.14.10.2756; THUESEN B, 1992, ACTA OBSTET GYN SCAN, V71, P126, DOI 10.3109/00016349209007969; van Beurden M, 1999, J CLIN PATHOL, V52, P820, DOI 10.1136/jcp.52.11.820; van den Brule AJC, 2002, J CLIN MICROBIOL, V40, P779, DOI 10.1128/JCM.40.3.779-787.2002; van Poelgeest MIE, 2005, CLIN CANCER RES, V11, P5273, DOI 10.1158/1078-0432.CCR-05-0616; van Seters M, 2005, GYNECOL ONCOL, V97, P645, DOI 10.1016/j.ygyno.2005.02.012; van Seters M, 2002, J REPROD MED, V47, P701; VANBEURDEN M, 1995, CANCER, V75, P2879, DOI 10.1002/1097-0142(19950615)75:12<2879::AID-CNCR2820751214>3.0.CO;2-W; Ware JE, 1993, SF36 HLTH SURVEY MAN; WILKINSON EJ, 1986, J REPROD MED, V31, P973; WILKINSON EJ, 1992, DERMATOL CLIN, V10, P283; WOLCOTT HD, 1984, AM J OBSTET GYNECOL, V150, P695, DOI 10.1016/0002-9378(84)90669-0	31	216	219	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1465	1473		10.1056/NEJMoa072685	http://dx.doi.org/10.1056/NEJMoa072685			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282CY	18385498				2022-12-28	WOS:000254546400007
J	Driessen, E; van Tartwijk, J; Dornan, T				Driessen, Erik; van Tartwijk, Jan; Dornan, Tim			Teaching rounds - The self critical doctor: helping students become more reflective	BRITISH MEDICAL JOURNAL			English	Editorial Material							MEDICAL-EDUCATION; PORTFOLIOS; FEEDBACK; LEARNER		[Driessen, Erik] Maastricht Univ, Dept Educ Dev & Res, Fac Hlth Med & Life Sci, Maastricht, Netherlands; [van Tartwijk, Jan] Leiden Univ, ICLON Grad Sch Teaching, Leiden, Netherlands; [Dornan, Tim] Univ Manchester, Hope Hosp, Salford M6 8HD, Lancs, England; [Dornan, Tim] Salford Royal Hosp, Salford M6 8HD, Lancs, England	Maastricht University; Leiden University; Leiden University - Excl LUMC; University of Manchester; Salford Royal NHS Foundation Trust; Salford Royal Hospital	Driessen, E (corresponding author), Maastricht Univ, Dept Educ Dev & Res, Fac Hlth Med & Life Sci, Maastricht, Netherlands.	e.driessen@educ.unimaas.nl	van Tartwijk, Jan/H-3837-2011					Aagaard E, 2004, ACAD MED, V79, P42, DOI 10.1097/00001888-200401000-00010; Branch WT, 2002, ACAD MED, V77, P1185, DOI 10.1097/00001888-200212000-00005; Davis DA, 2006, JAMA-J AM MED ASSOC, V296, P1094, DOI 10.1001/jama.296.9.1094; Dewey J., 1933, LATER WORKS J DEWEY; Driessen E, 2007, MED EDUC, V41, P1224, DOI 10.1111/j.1365-2923.2007.02944.x; Driessen EW, 2005, MED EDUC, V39, P1230, DOI 10.1111/j.1365-2929.2005.02337.x; Ericsson KA, 2006, CAMBRIDGE HANDBOOK OF EXPERTISE AND EXPERT PERFORMANCE, P683; ERICSSON KA, 1994, AM PSYCHOL, V49, P725, DOI 10.1037/0003-066X.49.8.725; Ertmer PA, 1996, INSTR SCI, V24, P1, DOI 10.1007/BF00156001; Eva KW, 2005, ACAD MED, V80, pS46, DOI 10.1097/00001888-200510001-00015; *GEN MED COUNC, 1993, 63 GMC ROYAL COLL GE; *GEN MED COUNC, 2003, TOM DOCT REC UND MED; General Medical Council, 2000, REV DOCT ENS STAND S; Grant A, 2006, MED EDUC, V40, P379, DOI 10.1111/j.1365-2929.2006.02415.x; Hattie J, 2007, REV EDUC RES, V77, P81, DOI 10.3102/003465430298487; Jarvis P, 1992, Nurse Educ Today, V12, P174, DOI 10.1016/0260-6917(92)90059-W; Korthagen Fred A. J., 2001, LINKING THEORY PRACT; Mamede S, 2004, MED EDUC, V38, P1302, DOI 10.1111/j.1365-2929.2004.01917.x; Norcini JJ, 2003, ANN INTERN MED, V138, P476, DOI 10.7326/0003-4819-138-6-200303180-00012; O'Donnell M., 1997, SCEPTICS MED DICT; Teunissen PW, 2007, MED EDUC, V41, P763, DOI 10.1111/j.1365-2923.2007.02778.x; Van Tartwijk J, 2007, QUAL HIGH EDUC, V13, P69, DOI 10.1080/13538320701272813; Woodward HM, 2006, WELD J, V85, P91	23	94	95	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR	2008	336	7648					827	830		10.1136/bmj.39503.608032.AD	http://dx.doi.org/10.1136/bmj.39503.608032.AD			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	292ER	18403547	Green Published			2022-12-28	WOS:000255249800047
J	Cahoon, JF; Sawyer, KR; Schlegel, JP; Harris, CB				Cahoon, James F.; Sawyer, Karma R.; Schlegel, Jacob P.; Harris, Charles B.			Determining transition-state geometries in liquids using 2D-IR	SCIENCE			English	Article							2D IR SPECTROSCOPY; METAL-CARBONYL COMPOUNDS; HYDROGEN-BOND; TEMPERATURE; SPECTRA; FREQUENCY; DYNAMICS; EXCHANGE; FE(CO)5; RELAXATION	Many properties of chemical reactions are determined by the transition state connecting reactant and product, yet it is difficult to directly obtain any information about these short- lived structures in liquids. We show that two- dimensional infrared ( 2D- IR) spectroscopy can provide direct information about transition states by tracking the transformation of vibrational modes as a molecule crossed a transition state. We successfully monitored a simple chemical reaction, the fluxional rearrangement of Fe(CO)(5), in which the exchange of axial and equatorial CO ligands causes an exchange of vibrational energy between the normal modes of the molecule. This energy transfer provides direct evidence regarding the time scale, transition state, and mechanism of the reaction.	[Cahoon, James F.; Sawyer, Karma R.; Schlegel, Jacob P.; Harris, Charles B.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Cahoon, James F.; Sawyer, Karma R.; Schlegel, Jacob P.; Harris, Charles B.] Lawrence Berkeley Lab, Div Chem Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Harris, CB (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	cbharris@berkeley.edu						BAKKER HJ, 1993, J CHEM PHYS, V98, P8496, DOI 10.1063/1.464508; Barone V, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1824881; BECKERLE JD, 1992, CHEM PHYS, V160, P487, DOI 10.1016/0301-0104(92)80015-N; BERRY RS, 1960, J CHEM PHYS, V32, P933, DOI 10.1063/1.1730820; BRAMLEY R, 1962, T FARADAY SOC, V58, P1893, DOI 10.1039/tf9625801893; Bredenbeck J, 2004, J CHEM PHYS, V121, P5943, DOI 10.1063/1.1779575; BURDETT JK, 1976, J AM CHEM SOC, V98, P5728, DOI 10.1021/ja00434a070; COTTON FA, 1958, J CHEM PHYS, V29, P1427, DOI 10.1063/1.1744746; Frisch M.J., 2016, GAUSSIAN16 REV B01; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; GONZALEZ C, 1989, J CHEM PHYS, V90, P2154, DOI 10.1063/1.456010; Grevels FW, 1998, J AM CHEM SOC, V120, P10423, DOI 10.1021/ja973897h; Khalil M, 2004, J CHEM PHYS, V121, P362, DOI 10.1063/1.1756870; Khalil M, 2003, J PHYS CHEM A, V107, P5258, DOI 10.1021/jp0219247; Kim YS, 2006, J PHYS CHEM B, V110, P8531, DOI 10.1021/jp060935n; Kim YS, 2005, P NATL ACAD SCI USA, V102, P11185, DOI 10.1073/pnas.0504865102; Kim YS, 2007, J PHYS CHEM B, V111, P9697, DOI 10.1021/jp074267x; Kurochkin DV, 2007, P NATL ACAD SCI USA, V104, P14209, DOI 10.1073/pnas.0700560104; Lambert J. B., 2004, NUCL MAGNETIC RESONA; Londergan CH, 2003, CHEM-EUR J, V9, P5962, DOI 10.1002/chem.200305028; Mukamel S., 1995, PRINCIPLES NONLINEAR, V1st; Nibbering ETJ, 2005, ANNU REV PHYS CHEM, V56, P337, DOI 10.1146/annurev.physchem.56.092503.141314; SHELINE RK, 1975, ANGEW CHEM INT EDIT, V14, P314, DOI 10.1002/anie.197503141; SPIESS HW, 1974, CHEM PHYS, V6, P226, DOI 10.1016/0301-0104(74)85063-9; Steinfeld J.I., 1999, CHEM KINETICS DYNAMI; STRAUSS HL, 1992, J AM CHEM SOC, V114, P905, DOI 10.1021/ja00029a017; TOKMAKOFF A, 1994, J CHEM PHYS, V100, P9035, DOI 10.1063/1.466709; UGI I, 1971, ACCOUNTS CHEM RES, V4, P288, DOI 10.1021/ar50044a004; Woutersen S, 2001, CHEM PHYS, V266, P137, DOI 10.1016/S0301-0104(01)00224-5; Zheng JR, 2006, SCIENCE, V313, P1951, DOI 10.1126/science.1132178	30	138	139	2	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1820	1823		10.1126/science.1154041	http://dx.doi.org/10.1126/science.1154041			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369145	Green Submitted			2022-12-28	WOS:000254394000045
J	Makeyev, EV; Maniatis, T				Makeyev, Eugene V.; Maniatis, Tom			Multilevel regulation of gene expression by microRNAs	SCIENCE			English	Editorial Material							MIR-124; NPTB		[Makeyev, Eugene V.; Maniatis, Tom] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Makeyev, EV (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	makeyev@mcb.harvard.edu; maniatis@mcb.harvard.edu		Makeyev, Eugene/0000-0001-6034-6896	NINDS NIH HHS [2R01NS043915-27, R01 NS043915, R01 NS043915-27] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043915] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Boutz PL, 2007, GENE DEV, V21, P71, DOI 10.1101/gad.1500707; Cao XW, 2007, GENE DEV, V21, P531, DOI 10.1101/gad.1519207; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Conaco C, 2006, P NATL ACAD SCI USA, V103, P2422, DOI 10.1073/pnas.0511041103; Davidson EH, 2006, REG GEN GEN REG; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Hobert O, 2008, SCIENCE, V319, P1785, DOI 10.1126/science.1151651; Karginov FV, 2007, P NATL ACAD SCI USA, V104, P19291, DOI 10.1073/pnas.0709971104; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Niwa R, 2007, CURR OPIN GENET DEV, V17, P145, DOI 10.1016/j.gde.2007.02.004; Spellman R, 2007, MOL CELL, V27, P420, DOI 10.1016/j.molcel.2007.06.016; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Visvanathan J, 2007, GENE DEV, V21, P744, DOI 10.1101/gad.1519107; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006	19	228	242	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2008	319	5871					1789	1790		10.1126/science.1152326	http://dx.doi.org/10.1126/science.1152326			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369137	Green Accepted			2022-12-28	WOS:000254394000034
J	Cheung, AM; Detsky, AS				Cheung, Angela M.; Detsky, Allan S.			Osteoporosis and fractures - Missing the bridge?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; ELDERLY-WOMEN; FALLS; RISK; MORTALITY; BMD; QUALITY; HEALTH; MEN		[Cheung, Angela M.; Detsky, Allan S.] Univ Hlth Network, Toronto, ON M5G 2C4, Canada; [Cheung, Angela M.; Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 2C4, Canada; [Cheung, Angela M.; Detsky, Allan S.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Cheung, Angela M.; Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto	Cheung, AM (corresponding author), Univ Hlth Network, 200 Elizabeth St,7 Eaton N 221, Toronto, ON M5G 2C4, Canada.	angela.cheung@uhn.on.ca		Cheung, Angela M./0000-0001-8332-0744	CIHR [44917] Funding Source: Medline	CIHR(Canadian Institutes of Health Research (CIHR))		Adachi JD, 2001, OSTEOPOROSIS INT, V12, P903, DOI 10.1007/s001980170017; Cauley JA, 2007, JAMA-J AM MED ASSOC, V298, P2761, DOI 10.1001/jama.298.23.2761; Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001-9002; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532-5415.2000.tb02641.x; GREENDALE GA, 1995, J AM GERIATR SOC, V43, P955, DOI 10.1111/j.1532-5415.1995.tb05557.x; Jarvinen TLN, 2008, BRIT MED J, V336, P124, DOI 10.1136/bmj.39428.470752.AD; Kanis JA, 2007, OSTEOPOROSIS INT, V18, P1033, DOI 10.1007/s00198-007-0343-y; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006; Kaptoge S, 2005, BONE, V36, P387, DOI 10.1016/j.bone.2004.11.012; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941; McCloskey EV, 2007, J BONE MINER RES, V22, P135, DOI 10.1359/JBMR.061008; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; *NAT OST FDN, NOFS NEW CLIN GUID P; Nyberg L, 1996, J AM GERIATR SOC, V44, P156, DOI 10.1111/j.1532-5415.1996.tb02432.x; Pasco JA, 2006, OSTEOPOROSIS INT, V17, P1404, DOI 10.1007/s00198-006-0135-9; Robbins JA, 2006, J AM GERIATR SOC, V54, P1885, DOI 10.1111/j.1532-5415.2006.00985.x; Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077; Siminoski K, 2005, CAN ASSOC RADIOL J, V56, P178; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; 2000, NIH CONSENS STATEMEN, V17, P1	23	63	68	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2008	299	12					1468	1470		10.1001/jama.299.12.1468	http://dx.doi.org/10.1001/jama.299.12.1468			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278MY	18364489				2022-12-28	WOS:000254292200021
J	Hawkins, SS; Lamb, K; Cole, TJ; Law, C				Hawkins, Summer Sherburne; Lamb, Kate; Cole, Tim J.; Law, Catherine		Millennium Cohort Study Child Hlth	Influence of moving to the UK on maternal health behaviours: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-FEEDING INITIATION; UNITED-STATES; PREGNANCY; SMOKING; WOMEN; ACCULTURATION; EXPOSURE; ALCOHOL; RACE/ETHNICITY; DETERMINANTS	Objective To compare health behaviours during pregnancy (smoking and alcohol consumption) and afterbirth (initiation and duration of breast feeding) between British/Irish white mothers and mothers from ethnic minority groups; and, in mothers from ethnic minority groups, to examine whether indicators of acculturation (generational status, language spoken at home, tench of residency in the United Kingdom) were associated with these health behaviours. Design Prospective nationally representative cohort study. Setting England. Participants 6478 British/Irish white mothers and 2110 mothers from ethnic minority groups. Main outcome measures Any smoking during pregnancy; any alcohol consumption during pregnancy; initiation of breast feeding; breast feeding for at least four months. Results Compared with British/Irish white mothers, mothers from ethnic minority groups were less likely to smoke (15% v 37%) or consume alcohol (14% v 37%) during pregnancy but more likely to initiate breast feeding (86% v 69%) and breast feed for at least four months (40% v 27%). Among mothers from ethnic minority groups, first and second generation mothers were more likely to smoke during pregnancy (odds ratio 3.85, 95% confidence interval 2.50 to 5.93, and 4.70, 2.49 to 8.90, respectively), less likely to initiate breast feeding (0.92,0.88 to 0.97, and 0.86, 0.75 to 0.99), and less likely to breast feed for at least four months (0.72, 0.62 to 0.83, and 0.52, 0.30 to 0.89) than immigrants, after adjustment for sociodemographic characteristics. There were no consistent differences in alcohol consumption. Among immigrants, for every additional five years spent in the UK the likelihood of mothers smoking during pregnancy increased by 31% (4% to 66%) and they were 5% (0% to 10%) less likely to breast feed for at least four months. Conclusions After immigration, maternal health behaviours worsen with length of residency in the UK. Health professionals should not underestimate women's likelihood of engaging in risky health behaviours because of their ethnicity.	[Hawkins, Summer Sherburne; Lamb, Kate; Cole, Tim J.; Law, Catherine; Millennium Cohort Study Child Hlth] UCL, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England	University of London; University College London	Hawkins, SS (corresponding author), UCL, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England.	s.hawkins@ich.ucl.ac.uk	Cole, Tim J/B-7883-2008; Law, Catherine/A-1353-2009	Cole, Tim J/0000-0001-5711-8200; Hawkins, Summer/0000-0002-1099-362X; Law, Catherine/0000-0002-1777-9386	Medical Research Council [G9827821, G9827821(62595)] Funding Source: Medline; MRC [G9827821] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abraido-Lanza AF, 2006, AM J PUBLIC HEALTH, V96, P1342, DOI 10.2105/AJPH.2005.064980; Bolling K, 2007, INFANT FEEDING SURVE; Bonuck KA, 2005, J HUM LACT, V21, P320, DOI 10.1177/0890334405278249; *BREASTF MAN COAL, BREASTF MAN; Butler S., 2004, New Zealand Medical Journal, P908; BUTLER S, 2004, NZ MED J, V117, P1171; Ceti AC, 2005, ARCH PEDIAT ADOL MED, V159, P255, DOI 10.1001/archpedi.159.3.255; Colvin L, 2007, ALCOHOL CLIN EXP RES, V31, P276, DOI 10.1111/j.1530-0277.2006.00303.x; *DEP HLTH HOM OFF, 2007, SAF SENS SOC NEXT ST; Department of Health, 1998, SMOK KILLS WHIT PAP; Department of Health, 2006, PREGN BOOK; EISNER MD, 2006, JAMA-J AM MED ASSOC, V296, P1178; ERENS B, 2007, HLTH SURVEY ENGLAND; Ford RPK, 1997, J EPIDEMIOL COMMUN H, V51, P246, DOI 10.1136/jech.51.3.246; Gibson MV, 2005, BIRTH-ISS PERINAT C, V32, P93, DOI 10.1111/j.0730-7659.2005.00351.x; Gibson-Davis CM, 2006, AM J PUBLIC HEALTH, V96, P641, DOI 10.2105/AJPH.2005.064840; Gill P. S., 2007, HLTH CARE NEEDS ASSE; Griffiths LJ, 2005, INT J EPIDEMIOL, V34, P1378, DOI 10.1093/ije/dyi162; HANSEN K, 2006, MILLENNIUM COHORT ST; Harley K, 2007, MATERN CHILD HLTH J, V11, P119, DOI 10.1007/s10995-006-0152-5; Harley K, 2006, SOC SCI MED, V62, P3048, DOI 10.1016/j.socscimed.2005.11.036; Hofhuis W, 2003, ARCH DIS CHILD, V88, P1086, DOI 10.1136/adc.88.12.1086; *INT CTR ALC POL, 2007, INT GUID DRINK PREGN; Lara M, 2005, ANNU REV PUBL HEALTH, V26, P367, DOI 10.1146/annurev.publhealth.26.021304.144615; Leslie JC, 2006, MATERN CHILD HLTH J, V10, P33, DOI 10.1007/s10995-005-0028-0; Li RW, 2005, NUTR REV, V63, P103, DOI 10.1111/j.1753-4887.2005.tb00128.x; Madan A, 2006, J PEDIATR-US, V148, P341, DOI 10.1016/j.jpeds.2005.11.028; Mattson SN, 1998, ALCOHOL CLIN EXP RES, V22, P279, DOI 10.1111/j.1530-0277.1998.tb03651.x; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Merewood A, 2006, PEDIATRICS, V118, pE1048, DOI 10.1542/peds.2005-2637; MICHAELSEN KF, 2000, FEEDING NUTR FINANTS; Mohsin M, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-138; Office for National Statistics, 2003, ETHN GROUP STAT GUID; PERREIRA KM, 2004, AJPH, V96, P1629; Phares Tanya M, 2004, MMWR Surveill Summ, V53, P1; Plewis I, 2004, MILLENNIUM COHORT ST; Plewis I, 2006, MILLENNIUM COHORT ST; RAO JNK, 1984, ANN STAT, V12, P46, DOI 10.1214/aos/1176346391; *RENDALL M, 2005, FOCUS PEOPLE MIGRATI; Rose D., 2003, RES GUIDE NATL STAT; *SCOTT PARL, 2005, BREASTF ETC SCOTL AC; Section on Breastfeeding, 2012, Pediatrics, V129, pe827, DOI 10.1542/peds.2011-3552; Singh GK, 2007, PEDIATRICS, V119, pS38, DOI 10.1542/peds.2006-2089G; *STAT OFF, 2006, SMOK FREE PREM ENF R; Stoler JM, 1998, J PEDIATR-US, V133, P346, DOI 10.1016/S0022-3476(98)70267-7; United States Department of Health and Human Services, 2000, HLTH PEOPL 2010, V1; United States Department of Health and Human Services, 2000, HLTH PEOPL 2010, V2; Ventura SJ, 2003, PEDIATRICS, V111, P1176; Walsh RA, 1996, ADDICT BEHAV, V21, P675, DOI 10.1016/0306-4603(95)00097-6; WHITE A, 2000, SOCIAL FOCUS BRIEF E; WHITE A, 2002, SOCIAL FOCUS BRIEF E; *WHO, WHO GLOB DAT BANK BR; World Health Organization, 2002, GLOB STRAT INF YOUNG; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	54	107	107	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2008	336	7652					1052	+		10.1136/bmj.39532.688877.25	http://dx.doi.org/10.1136/bmj.39532.688877.25			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	304IN	18403500	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000256103300028
J	Godlee, F				Godlee, Fiona			Running the gauntlet to improve patient care	BRITISH MEDICAL JOURNAL			English	Editorial Material												fgodlee@bmj.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					947	947		10.1136/bmj.39541.660289.94	http://dx.doi.org/10.1136/bmj.39541.660289.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296KC	18397949	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000255540900034
J	Bernheim, JL; Deschepper, R; Distelmans, W; Mullie, A; Bilsen, J; Deliens, L				Bernheim, Jan L.; Deschepper, Reginald; Distelmans, Wim; Mullie, Arsene; Bilsen, Johan; Deliens, Luc			Development of palliative care and legalisation of euthanasia: antagonism or synergy?	BRITISH MEDICAL JOURNAL			English	Editorial Material							EUROPEAN COUNTRIES; TASK-FORCE; BELGIUM; NETHERLANDS; ETHICS		[Bernheim, Jan L.; Deschepper, Reginald; Distelmans, Wim; Mullie, Arsene; Bilsen, Johan; Deliens, Luc] Vrije Univ Brussels, Dept Med Sociol & Hlth Sci, End Life Care Res Grp, B-1090 Brussels, Belgium	Vrije Universiteit Brussel	Bernheim, JL (corresponding author), Vrije Univ Brussels, Dept Med Sociol & Hlth Sci, End Life Care Res Grp, Laarbeeklaan 103, B-1090 Brussels, Belgium.	jan.bernheim@vub.ac.be	Deschepper, Reginald/B-8103-2013	Deschepper, Reginald/0000-0002-4222-3945; Bernheim, Jan/0000-0003-1610-5790; Deliens, Luc/0000-0002-8158-2422				*BELG MED DISC BOA, 2003, REC REG PALL CAR EUT; Bernheim J. L., 1996, WAARDIG STERVEN, P67; Bernheim JL, 1990, BIOETHIEK, P103; BILSEN J, 2007, SOC SCI MED     0507; Broeckaert B, 2001, EUR J HEALTH LAW, V8, P95; Broeckaert Bert, 2002, Ethical Perspect, V9, P156, DOI 10.2143/EP.9.2.503854; Broekaert B., 2005, EUTHANASIA PALLIATIV, P35; *CATH U LEUV AC CT, 2003, POS MED END OF LIF D; Centeno C, 2007, PALLIATIVE MED, V21, P463, DOI 10.1177/0269216307081942; CHILDRESS JF, 1998, REGULATING WE DIE ET, P120; Clark D, 2000, PALLIATIVE MED, V14, P479, DOI 10.1191/026921600701536408; DEKEYSER E, 2003, NIEUW JURIDISCH WEEK, V2, P1067; Deliens L, 2003, LANCET, V362, P1239, DOI 10.1016/S0140-6736(03)14520-5; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; DESCHEPPER R, 2003, CAREFULLY DYING HOME; DISTELMANS W, 2008, BELG J MED ONCOL, V2, P16; DISTELMANS W, 2004, TIJDSCHR VR GK, V60, P232; DISTELMANS W, 2005, EUR J PALLIAT CARE, V12, P170; *EUR ASS PALL CAR, EAPC TASKF PALL CAR; *FLEM PALL CAR FED, 2003, DEAL EUTH OTH KINDS; Gastmans C, 2004, J MED ETHICS, V30, P212, DOI 10.1136/jme.2003.005082; Gastmans Chris, 2002, Ethical Perspect, V9, P134, DOI 10.2143/EP.9.2.503852; Hamel R, 1998, Health Prog, V79, P54; HOTTOIS G, 1988, BIOETHIQUE LIBRE EXA; Hurst SA, 2006, PALLIATIVE MED, V20, P107, DOI 10.1191/0269216306pm1109oa; LEONTINE S, 1996, WHY EUTHANASIA YET; Loop J, 2003, PALLIATIVE MED, V17, P174, DOI 10.1191/0269216303pm727op; Materstvedt LJ, 2003, PALLIATIVE MED, V17, P97, DOI 10.1191/0269216303pm673oa; Schotsmans P, 2005, EUTHANASIA PALLIATIV; SUZANNE C, 1990, EUTHANASIE; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143	32	68	70	5	19	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 19	2008	336	7649					864	867		10.1136/bmj.39497.397257.AD	http://dx.doi.org/10.1136/bmj.39497.397257.AD			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	290QH	18420693	Green Published			2022-12-28	WOS:000255136800031
J	Iglesias-Rodriguez, MD; Halloran, PR; Rickaby, REM; Hall, IR; Colmenero-Hidalgo, E; Gittins, JR; Green, DRH; Tyrrell, T; Gibbs, SJ; von Dassow, P; Rehm, E; Armbrust, EV; Boessenkool, KP				Iglesias-Rodriguez, M. Debora; Halloran, Paul R.; Rickaby, Rosalind E. M.; Hall, Ian R.; Colmenero-Hidalgo, Elena; Gittins, John R.; Green, Darryl R. H.; Tyrrell, Toby; Gibbs, Samantha J.; von Dassow, Peter; Rehm, Eric; Armbrust, E. Virginia; Boessenkool, Karin P.			Phytoplankton calcification in a high-CO2 world	SCIENCE			English	Article							EMILIANIA-HUXLEYI; CARBONATE; CO2; SEDIMENTS; OCEAN; FEEDBACK; LIGHT	Ocean acidification in response to rising atmospheric CO2 partial pressures is widely expected to reduce calcification by marine organisms. From the mid- Mesozoic, coccolithophores have been major calcium carbonate producers in the world's oceans, today accounting for about a third of the total marine CaCO3 production. Here, we present laboratory evidence that calcification and net primary production in the coccolithophore species Emiliania huxleyi are significantly increased by high CO2 partial pressures. Field evidence from the deep ocean is consistent with these laboratory conclusions, indicating that over the past 220 years there has been a 40% increase in average coccolith mass. Our findings show that coccolithophores are already responding and will probably continue to respond to rising atmospheric CO2 partial pressures, which has important implications for biogeochemical modeling of future oceans and climate.	[Iglesias-Rodriguez, M. Debora; Green, Darryl R. H.; Tyrrell, Toby; Gibbs, Samantha J.] Univ Southampton, Natl Oceanog Ctr, Southampton SO14 3ZH, Hants, England; [Halloran, Paul R.; Rickaby, Rosalind E. M.] Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; [Hall, Ian R.; Colmenero-Hidalgo, Elena; Boessenkool, Karin P.] Cardiff Univ, Sch Earth Ocean & Planetary Sci, Cardiff CF10 3YE, S Glam, Wales; [von Dassow, Peter] Stn Biol Roscoff, F-29682 Roscoff, France; [Armbrust, E. Virginia] Univ Washington, Sch Oceanog, Seattle, WA 98195 USA	NERC National Oceanography Centre; University of Southampton; University of Oxford; Cardiff University; UDICE-French Research Universities; Sorbonne Universite; University of Washington; University of Washington Seattle	Iglesias-Rodriguez, MD (corresponding author), Univ Southampton, Natl Oceanog Ctr, Waterfront Campus,European Way, Southampton SO14 3ZH, Hants, England.		von Dassow, Peter/A-5399-2012; Hall, Ian R/C-2755-2009; Colmenero-Hidalgo, Elena/I-1634-2015; Halloran, Paul R/G-3965-2012	Hall, Ian R/0000-0001-6960-1419; Colmenero-Hidalgo, Elena/0000-0002-5449-2739; Halloran, Paul R/0000-0002-9227-0678; von Dassow, Peter/0000-0002-1858-1953; Rickaby, Rosalind/0000-0002-6095-8419; Boessenkool, Karin/0000-0003-0887-4864; Rehm, Eric/0000-0002-8417-538X	NERC [soc010008, soc010007] Funding Source: UKRI; Natural Environment Research Council [soc010008, NER/T/S/2002/00436, NE/C002407/1, soc010007] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Anderson TR, 2003, DEEP-SEA RES PT I, V50, P573, DOI 10.1016/S0967-0637(03)00034-7; ARCHER D, 1994, NATURE, V367, P260, DOI 10.1038/367260a0; Barker S, 2003, PHILOS T R SOC A, V361, P1977, DOI 10.1098/rsta.2003.1238; Baumann Karl-Heinz, 2005, Palaeontologische Zeitschrift, V79, P93; BEAUFORT L, GEOCHEM GEOPHY GEOSY, V8, DOI DOI 10.1029/2006GC00149; Bijma J., 1999, USE PROXIES PALEOCEA, DOI DOI 10.1007/978-3-642-58646-0_20; Boessenkool KP, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030285; Bollmann J, 2007, EARTH PLANET SC LETT, V255, P273, DOI 10.1016/j.epsl.2006.12.029; Burkhardt S, 1999, LIMNOL OCEANOGR, V44, P683, DOI 10.4319/lo.1999.44.3.0683; Caldeira K, 2003, NATURE, V425, P365, DOI 10.1038/425365a; Delille B, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002318; Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329; Flores JA, 1997, MICROPALEONTOLOGY, V43, P321, DOI 10.2307/1485832; FRANKIGNOULLE M, 1994, LIMNOL OCEANOGR, V39, P458, DOI 10.4319/lo.1994.39.2.0458; Frenz M, 2005, J SEDIMENT RES, V75, P464, DOI 10.2110/jsr.2005.036; Frenz M, 2007, SEDIMENTOLOGY, V54, P391, DOI 10.1111/j.1365-3091.2006.00841.x; Gibbs SJ, 2006, SCIENCE, V314, P1770, DOI 10.1126/science.1133902; Hill M.E. III., 1975, Micropalaeontology, V21, P227, DOI 10.2307/1485025; Keeling C.D., 2005, TRENDS COMPENDIUM DA; Kleypas JA, 1999, SCIENCE, V284, P118, DOI 10.1126/science.284.5411.118; Kolber ZS, 1998, BBA-BIOENERGETICS, V1367, P88, DOI 10.1016/S0005-2728(98)00135-2; Langer G, 2006, GEOCHEM GEOPHY GEOSY, V7, DOI 10.1029/2005GC001227; McCave IN, 2006, GEOCHEM GEOPHY GEOSY, V7, DOI 10.1029/2006GC001284; MCINTYRE A, 1967, DEEP-SEA RES, V14, P561, DOI 10.1016/0011-7471(67)90065-4; NIMER NA, 1993, NEW PHYTOL, V123, P673, DOI 10.1111/j.1469-8137.1993.tb03776.x; Paasche E, 2001, PHYCOLOGIA, V40, P503, DOI 10.2216/i0031-8884-40-6-503.1; Poulton AJ, 2007, DEEP-SEA RES PT II, V54, P538, DOI 10.1016/j.dsr2.2006.12.003; Riebesell U, 2000, NATURE, V407, P364, DOI 10.1038/35030078; ROYER DL, GSA TODAY, V14, DOI DOI 10.1130/1052-5173(2004)0142.0.CO;2; Sciandra A, 2003, MAR ECOL PROG SER, V261, P111, DOI 10.3354/meps261111; Trimborn S, 2007, LIMNOL OCEANOGR, V52, P2285, DOI 10.4319/lo.2007.52.5.2285; Tyrrell T, 2004, GEOCHIM COSMOCHIM AC, V68, P3521, DOI 10.1016/j.gca.2004.02.018; VANBLEIJSWIJK JDL, 1994, J PHYCOL, V30, P230; WANG HZ, 1990, J GEOL SOC LONDON, V147, P373, DOI 10.1144/gsjgs.147.2.0373; Young JR, 2000, DEEP-SEA RES PT II, V47, P1679, DOI 10.1016/S0967-0645(00)00003-5; Zachos JC, 2005, SCIENCE, V308, P1611, DOI 10.1126/science.1109004; Ziveri P, 2004, COCCOLITHOPHORES: FROM MOLECULAR PROCESSES TO GLOBAL IMPACT, P403; Zondervan I, 2001, GLOBAL BIOGEOCHEM CY, V15, P507, DOI 10.1029/2000GB001321	38	562	588	9	480	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2008	320	5874					336	340		10.1126/science.1154122	http://dx.doi.org/10.1126/science.1154122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420926				2022-12-28	WOS:000255026100033
J	Kiers, ET; Leakey, RRB; Izac, AM; Heinemann, JA; Rosenthal, E; Nathan, D; Jiggins, J				Kiers, E. Toby; Leakey, Roger R. B.; Izac, Anne-Marie; Heinemann, Jack A.; Rosenthal, Erika; Nathan, Dev; Jiggins, Janice			Ecology - Agriculture at a crossroads	SCIENCE			English	Editorial Material							AFRICA; IMPACT; WORLD		[Kiers, E. Toby] Free Univ Amsterdam, Inst Ecol Sci, Fac Earth & Life Sci, NL-1081 HV Amsterdam, Netherlands; [Leakey, Roger R. B.] James Cook Univ N Queensland, Sch Marine & Trop Biol, Cairns, Qld, Australia; [Izac, Anne-Marie] IFAD, Alliance CGIAR Ctr, Rome, Italy; [Heinemann, Jack A.] Univ Canterbury, Sch Biol Sci, Christchurch, New Zealand; [Rosenthal, Erika] Ctr Int Environm Law, Washington, DC USA; [Nathan, Dev] Inst Human Dev, New Delhi, India; [Jiggins, Janice] Wageningen Univ Res, Wageningen, Netherlands	Vrije Universiteit Amsterdam; James Cook University; CGIAR; University of Canterbury; Wageningen University & Research	Kiers, ET (corresponding author), Free Univ Amsterdam, Inst Ecol Sci, Fac Earth & Life Sci, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	ekiers@falw.vu.nl	Toby, Kiers/H-4819-2017	Toby, Kiers/0000-0002-0597-1653				Alston J, 2002, 113 IFPRI; [Anonymous], 2007, WATER FOOD WATER LIF; [Anonymous], 2007, IPCC 4 ASS REP CLIM; [Anonymous], 2006, FOOD SECURITY HUNGER; Delmer DP, 2005, P NATL ACAD SCI USA, V102, P15739, DOI 10.1073/pnas.0505895102; Dingkuhn M, 2006, AGR WATER MANAGE, V80, P241, DOI 10.1016/j.agwat.2005.07.016; Evans LT, 2005, J AGR SCI, V143, P7, DOI 10.1017/S0021859604004460; Evenson RE, 2003, SCIENCE, V300, P758, DOI 10.1126/science.1078710; *FAO, 2004, MILK DAIR PROD POST; FAO, 2007, STAT FOOD AGR 2007 P; *FAO, 2007, FOOD OUTL 2007 GLOB; Green RE, 2005, SCIENCE, V307, P550, DOI 10.1126/science.1106049; JANE TS, 1994, ZIMBABWES AGR REVOLU; Lilja N, 2008, EXP AGR, V44, P3, DOI 10.1017/S0014479707005972; Lobell DB, 2008, SCIENCE, V319, P607, DOI 10.1126/science.1152339; Millennium Ecosystem Assessment, 2005, EC HUM WELL BEING GL; Morrison Jamie, 2007, WTO RULES AGR COMPAT; Nederlof E. S., 2007, International Journal of Agricultural Sustainability, V5, P247; Pardey P., 2007, SCI TECHNOLOGY SKILL; Pardey P. G., 2006, Agricultural research: a growing global divide?; Pray CE, 2007, J DEV STUD, V43, P192, DOI 10.1080/00220380601055676; Sanchez PA, 2002, SCIENCE, V295, P2019, DOI 10.1126/science.1065256; Stokstad E, 2008, SCIENCE, V319, P1474, DOI 10.1126/science.319.5869.1474; *SUST DEV DEP FAO, 2007, SUST RUR DEV PROGR C; *SUST RIC PROD FOO, 2003, P 20 SESS INT RIC CO; Tilman D, 2001, SCIENCE, V292, P281, DOI 10.1126/science.1057544; UNEP (United Nations Environment Programme), 2007, GLOB ENV OUTL GEO 4, DOI 10.1227/01.NEU.0000108643.94730.21; Van Mele P, 2008, AGR FOREST ENTOMOL, V10, P13, DOI 10.1111/j.1461-9563.2007.00350.x; 2008, NAT BIOTECHNOL, V26, P247; 2008, NATURE, V451, P223; 2008, INT ASSESSMENT AGR S	32	79	84	1	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					320	321		10.1126/science.1158390	http://dx.doi.org/10.1126/science.1158390			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420917				2022-12-28	WOS:000255026100024
J	Le Hir, H; Seraphin, B				Le Hir, Herve; Seraphin, Bertrand			EJCs at the heart of translational control	CELL			English	Review							EXON-JUNCTION COMPLEX; MESSENGER-RNA DECAY; NONSENSE-MEDIATED DECAY; MAMMALIAN-CELLS; YEAST; MRNPS	In mammalian cells, the splicing machinery deposits the exon junction complex (EJC) on mRNA splice junctions. Two studies in this issue now link the EJC to different aspects of translational control. Ma et al. (2008) show that the EJC activates translation downstream of the mTOR signaling pathway, whereas Isken et al. (2008) establish that translation is repressed by partners of the EJC that are implicated in nonsense mediated decay (NMD).	[Le Hir, Herve; Seraphin, Bertrand] CNRS, Euipe lablisee La Ligue, Ctr Genet Mol, UPR 2167, F-91198 Gif Sur Yvette, France; [Le Hir, Herve; Seraphin, Bertrand] Univ Paris 11, F-91405 Orsay, France; [Le Hir, Herve; Seraphin, Bertrand] Univ Paris 06, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Sorbonne Universite	Seraphin, B (corresponding author), CNRS, Euipe lablisee La Ligue, Ctr Genet Mol, UPR 2167, F-91198 Gif Sur Yvette, France.	seraphin@cgm.cnrs-gif.fr		Le Hir, Herve/0000-0001-7964-9221; Seraphin, Bertrand/0000-0002-5168-1921				Amrani N, 2004, NATURE, V432, P112, DOI 10.1038/nature03060; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909; Conti E, 2005, CURR OPIN CELL BIOL, V17, P316, DOI 10.1016/j.ceb.2005.04.005; Diem MD, 2007, NAT STRUCT MOL BIOL, V14, P1173, DOI 10.1038/nsmb1321; Giorgi C, 2007, SEMIN CELL DEV BIOL, V18, P186, DOI 10.1016/j.semcdb.2007.01.002; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Juneau K, 2006, GENETICS, V174, P511, DOI 10.1534/genetics.106.058560; Kashima I, 2006, GENE DEV, V20, P355, DOI 10.1101/gad.1389006; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Merz C, 2007, RNA, V13, P116, DOI 10.1261/rna.336807; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Muhlrad D, 1999, MOL BIOL CELL, V10, P3971, DOI 10.1091/mbc.10.11.3971; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Pisarev AV, 2007, CELL, V131, P286, DOI 10.1016/j.cell.2007.08.041; Richardson CJ, 2004, CURR BIOL, V14, P1540, DOI 10.1016/j.cub.2004.08.061; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012	18	96	98	2	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	2008	133	2					213	216		10.1016/j.cell.2008.04.002	http://dx.doi.org/10.1016/j.cell.2008.04.002			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	289JY	18423193	Bronze			2022-12-28	WOS:000255052000011
J	Bustreo, F; Johnsson, AB				Bustreo, Flavia; Johnsson, Anders B.			Parliamentarians: leading the change for maternal, newborn, and child survival?	LANCET			English	Editorial Material							COUNTDOWN		[Bustreo, Flavia] Partnership Maternal Newborn & Child Hlth, CH-1211 Geneva, Switzerland; [Johnsson, Anders B.] Interparliamentary Union, Geneva, Switzerland		Bustreo, F (corresponding author), Partnership Maternal Newborn & Child Hlth, CH-1211 Geneva, Switzerland.	bustreof@who.int						Boerma JT, 2008, LANCET, V371, P1259, DOI 10.1016/S0140-6736(08)60560-7; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Greco G, 2008, LANCET, V371, P1268, DOI 10.1016/S0140-6736(08)60561-9; Salama P, 2008, LANCET, V371, P1219, DOI 10.1016/S0140-6736(08)60534-6; Sibbald B, 2007, CAN MED ASSOC J, V177, P244, DOI 10.1503/cmaj.070883	5	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1221	1222		10.1016/S0140-6736(08)60535-8	http://dx.doi.org/10.1016/S0140-6736(08)60535-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	286XH	18406843				2022-12-28	WOS:000254878900006
J	Shankar, A; Sebayang, S; Guarenti, L; Utomo, B; Islam, M; Fauveau, V; Jalal, F				Shankar, Anuraj; Sebayang, Susy; Guarenti, Laura; Utomo, Budi; Islam, Monir; Fauveau, Vincent; Jalal, Fasli			The village-based midwife programme in Indonesia	LANCET			English	Editorial Material							WELL		[Shankar, Anuraj; Guarenti, Laura; Islam, Monir] WHO, CH-1211 Geneva, Switzerland; [Sebayang, Susy] Summit Inst Dev, Mataram, Indonesia; [Utomo, Budi] Univ Indonesia, Jakarta, Indonesia; [Fauveau, Vincent] United Nat Populat Fund, Geneva, Switzerland; [Jalal, Fasli] Andalas Univ, Padang, Indonesia	World Health Organization; University of Indonesia; United Nations Population Fund; Universitas Andalas	Shankar, A (corresponding author), WHO, CH-1211 Geneva, Switzerland.	shankara@who.int	Sebayang, Susy/ABI-1686-2022; Shankar, Anuraj/U-3764-2018	Shankar, Anuraj/0000-0001-7268-6708; , Yusnita/0000-0003-1094-3195				*BPS NFPCB, 1994, IND DEM HLTH SURV 19; *BPS NFPCB, 1991, IND DEM HLTH SURV 19; *BPS ORC MACR 2003, 2003, IND DEM HLTH SURV 20; Ensor T, 2008, EUR J HEALTH ECON, V9, P385, DOI 10.1007/s10198-007-0094-x; Frankenberg E, 2005, POP STUD-J DEMOG, V59, P5, DOI 10.1080/0032472052000332674; GEEFHUYSEN CJ, 1999, SAFE MOTHERHOOD INIT, P62; Hatt L, 2007, B WORLD HEALTH ORGAN, V85, P774, DOI 10.2471/BLT.06.033472; Kristiansen S, 2006, HEALTH POLICY, V77, P247, DOI 10.1016/j.healthpol.2005.07.013; Makowiecka K, 2008, HEALTH POLICY PLANN, V23, P67, DOI 10.1093/heapol/czm036; McDermott J, 2001, J MIDWIFERY WOM HEAL, V46, P217, DOI 10.1016/S1526-9523(01)00137-4; Milne L, 2004, J MIDWIFERY WOM HEAL, V49, P338, DOI 10.1016/j.jmwh.2004.04.002; *MIN HLTH, 2000, IND 3 EV HFA 2000; Ministry of Health, 1997, IND HLTH PROF; RONSMANS C, 2001, SAFE MOTHERHOOD STRA, P317; Shankar AH, 2008, LANCET, V371, P215, DOI 10.1016/S0140-6736(08)60133-6; Shiffman J, 2007, AM J PUBLIC HEALTH, V97, P796, DOI 10.2105/AJPH.2006.095455; Simms C, 2003, LANCET, V361, P1382, DOI 10.1016/S0140-6736(03)13076-0; Supratikto G, 2002, B WORLD HEALTH ORGAN, V80, P228	18	36	36	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1226	1229		10.1016/S0140-6736(08)60538-3	http://dx.doi.org/10.1016/S0140-6736(08)60538-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	286XH	18406846				2022-12-28	WOS:000254878900009
J	Cauchemez, S; Valleron, AJ; Boelle, PY; Flahault, A; Ferguson, NM				Cauchemez, Simon; Valleron, Alain-Jacques; Boelle, Pierre-Yves; Flahault, Antoine; Ferguson, Neil M.			Estimating the impact of school closure on influenza transmission from Sentinel data	NATURE			English	Article							PANDEMIC INFLUENZA; NONPHARMACEUTICAL INTERVENTIONS; COMMUNICABLE DISEASES; US CITIES; SURVEILLANCE; STRATEGIES; HOUSEHOLD	The threat posed by the highly pathogenic H5N1 influenza virus requires public health authorities to prepare for a human pandemic. Although pre-pandemic vaccines and antiviral drugs might significantly reduce illness rates(1,2), their stockpiling is too expensive to be practical for many countries. Consequently, alternative control strategies, based on non-pharmaceutical interventions, are a potentially attractive policy option. School closure is the measure most often considered. The high social and economic costs of closing schools for months make it an expensive and therefore controversial policy, and the current absence of quantitative data on the role of schools during influenza epidemics means there is little consensus on the probable effectiveness of school closure in reducing the impact of a pandemic. Here, from the joint analysis of surveillance data and holiday timing in France, we quantify the role of schools in influenza epidemics and predict the effect of school closure during a pandemic. We show that holidays lead to a 20 - 29% reduction in the rate at which influenza is transmitted to children, but that they have no detectable effect on the contact patterns of adults. Holidays prevent 16 - 18% of seasonal influenza cases (18 - 21% in children). By extrapolation, we find that prolonged school closure during a pandemic might reduce the cumulative number of cases by 13 - 17% (18 - 23% in children) and peak attack rates by up to 39 - 45% (47 - 52% in children). The impact of school closure would be reduced if it proved difficult to maintain low contact rates among children for a prolonged period.	[Cauchemez, Simon; Ferguson, Neil M.] Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, London W2 1PG, England; [Valleron, Alain-Jacques; Boelle, Pierre-Yves; Flahault, Antoine] Univ Paris 06, UMR S707, F-75012 Paris, France; [Valleron, Alain-Jacques; Boelle, Pierre-Yves; Flahault, Antoine] INSERM, UMR S 707, F-75012 Paris, France; [Valleron, Alain-Jacques; Boelle, Pierre-Yves] Hop St Antoine, AP HP, F-75012 Paris, France; [Flahault, Antoine] French Sch Publ Hlth EHESP, F-75004 Paris, France	Imperial College London; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Cauchemez, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, Norfolk Pl, London W2 1PG, England.	s.cauchemez@imperial.ac.uk	Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093; Boelle, Pierre-Yves/0000-0002-5367-8232	Medical Research Council [G0600719B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Bell D, 2006, EMERG INFECT DIS, V12, P88; Bootsma MCJ, 2007, P NATL ACAD SCI USA, V104, P7588, DOI 10.1073/pnas.0611071104; Cauchemez S, 2004, STAT MED, V23, P3469, DOI 10.1002/sim.1912; Denoeud L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000464; Doucet A., 2001, SEQUENTIAL MONTE CAR; Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795; Finkenstadt BF, 2005, STAT MED, V24, P3447, DOI 10.1002/sim.2196; Flahault A, 2006, STAT METHODS MED RES, V15, P413, DOI 10.1177/0962280206071639; Germann TC, 2006, P NATL ACAD SCI USA, V103, P5935, DOI 10.1073/pnas.0601266103; Gilks W. R., 1996, MARKOV CHAIN MONTE C; Glass RJ, 2006, EMERG INFECT DIS, V12, P1671, DOI 10.3201/eid1211.060255; GLEZEN WP, 1991, AM J EPIDEMIOL, V133, P296, DOI 10.1093/oxfordjournals.aje.a115874; Hatchett RJ, 2007, P NATL ACAD SCI USA, V104, P7582, DOI 10.1073/pnas.0610941104; Heymann A, 2004, PEDIATR INFECT DIS J, V23, P675, DOI 10.1097/01.inf.0000128778.54105.06; Liu J.S., 2001, MONTE CARLO STRATEGI; LONGINI IM, 1988, AM J EPIDEMIOL, V128, P845, DOI 10.1093/oxfordjournals.aje.a115038; Markel H, 2007, JAMA-J AM MED ASSOC, V298, P644, DOI 10.1001/jama.298.6.644; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; Olson DR, 2007, PLOS MED, V4, P1349, DOI 10.1371/journal.pmed.0040247; VALLERON AJ, 1986, AM J PUBLIC HEALTH, V76, P1289, DOI 10.2105/AJPH.76.11.1289; VALLERON AJ, 2003, INT C OPT CONTR INFL, V5; Xia YC, 2005, J R STAT SOC C-APPL, V54, P659, DOI 10.1111/j.1467-9876.2005.05383.x	22	452	462	4	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2008	452	7188					750	U6		10.1038/nature06732	http://dx.doi.org/10.1038/nature06732			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401408				2022-12-28	WOS:000254792500045
J	Lagakos, SW; Gable, AR				Lagakos, Stephen W.; Gable, Alicia R.			Focus on research: Challenges to HIV prevention - Seeking effective measures in the absence of a vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lagakos, Stephen W.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Lagakos, Stephen W.; Gable, Alicia R.] IOM Comm Methodol Challenges Biomed HIV Prevent, Washington, DC USA	Harvard University; Harvard T.H. Chan School of Public Health	Lagakos, SW (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.							Joint United Nations Programme on HIV/AIDS and the World Health Organization, 2007, 2007 AIDS EP UPD; Lagakos SW, 2008, METHODOLOGICAL CHALL	2	42	42	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1543	1545		10.1056/NEJMp0802028	http://dx.doi.org/10.1056/NEJMp0802028			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	285NK	18403764	Bronze			2022-12-28	WOS:000254783300003
J	Taylor, BS; Sobieszczyk, ME; McCutchan, FE; Hammer, SM				Taylor, Barbara S.; Sobieszczyk, Magdalena E.; McCutchan, Francine E.; Hammer, Scott M.			Medical progress: The challenge of HIV-1 subtype diversity	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANCE-ASSOCIATED MUTATIONS; INJECTING DRUG-USERS; FORMER SOVIET-UNION; INTERSUBTYPE RECOMBINANT VIRUSES; LENGTH GENOME SEQUENCES; WEST-CENTRAL-AFRICA; T-CELL RESPONSES; NON-B SUBTYPES; ANTIRETROVIRAL THERAPY		[Taylor, Barbara S.; Sobieszczyk, Magdalena E.; McCutchan, Francine E.; Hammer, Scott M.] Columbia Univ, Med Ctr, Dept Med, Div Infect Dis, New York, NY 10032 USA	Columbia University	Taylor, BS (corresponding author), Columbia Univ, Med Ctr, Dept Med, Div Infect Dis, 630 W 168th St,P&S Box 82, New York, NY 10032 USA.	bs2026@columbia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069470, T32AI049821] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI069470, UO1 AI069470-01, T32 AI049821, T32 AI049821-06] Funding Source: Medline; PHS HHS [T32 A149821-06] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aghokeng AF, 2005, AIDS RES HUM RETROV, V21, P430, DOI 10.1089/aid.2005.21.430; Alaeus A, 1999, AIDS, V13, P901, DOI 10.1097/00002030-199905280-00005; Alexander CS, 2002, ANTIVIR THER, V7, P31; Baeten JM, 2007, J INFECT DIS, V195, P1177, DOI 10.1086/512682; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Bellocchi MC, 2005, J MED VIROL, V76, P452, DOI 10.1002/jmv.20382; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Blackard JT, 2002, CLIN INFECT DIS, V34, P1108, DOI 10.1086/339547; Bocket L, 2005, ANTIVIR THER, V10, P247; Brenner BG, 2006, AIDS, V20, pF9, DOI 10.1097/01.aids.0000232228.88511.0b; Brown SA, 2006, AIDS RES HUM RETROV, V22, P188, DOI 10.1089/aid.2006.22.188; Carr JK, 1996, J VIROL, V70, P5935, DOI 10.1128/JVI.70.9.5935-5943.1996; Catanzaro AT, 2006, J INFECT DIS, V194, P1638, DOI 10.1086/509258; Cilliers T, 2003, J VIROL, V77, P4449, DOI 10.1128/JVI.77.7.4449-4456.2003; Cohen J, 2007, SCIENCE, V318, P1048, DOI 10.1126/science.318.5853.1048; Costello C, 2005, INT J EPIDEMIOL, V34, P577, DOI 10.1093/ije/dyi023; de Brito A, 2006, CLIN INFECT DIS, V43, P1476, DOI 10.1086/508875; de Parga EV, 2005, J MED VIROL, V77, P337, DOI 10.1002/jmv.20461; Delgado E, 2002, J ACQ IMMUN DEF SYND, V29, P536, DOI 10.1097/00126334-200204150-00016; Deroo S, 2002, AIDS, V16, P2461, DOI 10.1097/00002030-200212060-00012; Descamps D, 2005, JAIDS-J ACQ IMM DEF, V38, P545, DOI 10.1097/01.qai.0000155201.51232.2e; Descamps D, 1997, J VIROL, V71, P8893, DOI 10.1128/JVI.71.11.8893-8898.1997; Deshpande A, 2004, AIDS RES HUM RETROV, V20, P1032, DOI 10.1089/aid.2004.20.1032; Doualla-Bell F, 2006, ANTIMICROB AGENTS CH, V50, P4182, DOI 10.1128/AAC.00714-06; Douek DC, 2006, CELL, V124, P677, DOI 10.1016/j.cell.2006.02.005; Duerr A, 2006, CLIN INFECT DIS, V43, P500, DOI 10.1086/505979; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Frater AJ, 2001, AIDS, V15, P1493, DOI 10.1097/00002030-200108170-00006; Frost SDW, 2005, P NATL ACAD SCI USA, V102, P18514, DOI 10.1073/pnas.0504658102; Gao F, 1996, J VIROL, V70, P7013, DOI 10.1128/JVI.70.10.7013-7029.1996; Girard MP, 2006, VACCINE, V24, P4062, DOI 10.1016/j.vaccine.2006.02.031; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Graham BS, 2006, J INFECT DIS, V194, P1650, DOI 10.1086/509259; Gray CM, 2005, AIDS RES HUM RETROV, V21, P285, DOI 10.1089/aid.2005.21.285; Grossman Z, 2004, ANTIMICROB AGENTS CH, V48, P2159, DOI 10.1128/AAC.48.6.2159-2165.2004; Grossman Z, 2004, AIDS, V18, P909, DOI 10.1097/00002030-200404090-00008; Grossman Z, 2001, AIDS, V15, P1453, DOI 10.1097/00002030-200108170-00001; Grossman Z, 2001, AIDS, V15, P2209; Hemelaar J, 2006, AIDS, V20, pW13, DOI 10.1097/01.aids.0000247564.73009.bc; Holguin A, 2004, J CLIN VIROL, V31, P215, DOI 10.1016/j.jcv.2004.03.015; Hu DJ, 2002, J ACQ IMMUN DEF SYND, V30, P240, DOI [10.1097/00042560-200206010-00013, 10.1097/01.QAI.0000014770.35851.44]; Hu DJ, 2001, AIDS, V15, P683, DOI 10.1097/00002030-200104130-00003; Huang W, 2007, J VIROL, V81, P7885, DOI 10.1128/JVI.00218-07; Hudgens MG, 2002, AM J EPIDEMIOL, V155, P159, DOI 10.1093/aje/155.2.159; John-Stewart GC, 2005, J INFECT DIS, V192, P492, DOI 10.1086/431514; Johnston MI, 2007, NEW ENGL J MED, V356, P2073, DOI 10.1056/NEJMra066267; Kaleebu P, 2002, J INFECT DIS, V185, P1244, DOI 10.1086/340130; Kanki PJ, 1999, J INFECT DIS, V179, P68, DOI 10.1086/314557; Kantor R, 2005, PLOS MED, V2, P325, DOI 10.1371/journal.pmed.0020112; Kantor R, 2004, J CLIN VIROL, V29, P152, DOI 10.1016/S1386-6532(03)00115-X; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Keele BF, 2006, SCIENCE, V313, P523, DOI 10.1126/science.1126531; Kijak GH, 2007, VIROLOGY, V358, P178, DOI 10.1016/j.virol.2006.07.055; Kiwanuka N, 2008, J INFECT DIS, V197, P707, DOI 10.1086/527416; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; LAEYENDECKER O, 2006, 13 C RETR OPP INF DE; Laurent C, 2002, J INFECT DIS, V186, P486, DOI 10.1086/341833; LEITNER T, 2005, HIV SEQUENCE COMPEND; Letourneau S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000984; Ly N, 2005, AIDS RES HUM RETROV, V21, P971, DOI 10.1089/aid.2005.21.971; Maljkovic I, 2003, AIDS RES HUM RETROV, V19, P989, DOI 10.1089/088922203322588341; McCutchan FE, 2002, AIDS RES HUM RETROV, V18, P1135, DOI 10.1089/088922202320567879; MCCUTCHAN FE, 1992, AIDS RES HUM RETROV, V8, P1887, DOI 10.1089/aid.1992.8.1887; McKinnon LR, 2005, JAIDS-J ACQ IMM DEF, V40, P245, DOI 10.1097/01.qai.0000184858.16447.04; Miller MD, 2007, AIDS, V21, P265, DOI 10.1097/QAD.0b013e32801199ee; Nabatov AA, 2002, AIDS RES HUM RETROV, V18, P891, DOI 10.1089/08892220260190380; Naderi H R, 2006, Infect Agent Cancer, V1, P4, DOI 10.1186/1750-9378-1-4; Njai HF, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-40; Nkengafac AD, 2007, ANTIVIR THER, V12, pS50; Palma AC, 2007, INFECT GENET EVOL, V7, P391, DOI 10.1016/j.meegid.2007.01.009; Paraskevis D, 2005, VIRUS RES, V112, P115, DOI 10.1016/j.virusres.2005.03.004; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Pillay D, 2002, J INFECT DIS, V186, P617, DOI 10.1086/342680; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; Piyasirisilp S, 2000, J VIROL, V74, P11286, DOI 10.1128/JVI.74.23.11286-11295.2000; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rainwater S, 2005, AIDS RES HUM RETROV, V21, P1060, DOI 10.1089/aid.2005.21.1060; Renjifo B, 2004, AIDS, V18, P1629, DOI 10.1097/01.aids.0000131392.68597.34; Renjifo B, 2001, J HUMAN VIROL, V4, P16; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Robertson M., 2008, 15 C RETR OPP INF BO, P3; Roudinskii NI, 2004, J VIROL, V78, P11276, DOI 10.1128/JVI.78.20.11276-11287.2004; Saad MD, 2006, AIDS RES HUM RETROV, V22, P796, DOI 10.1089/aid.2006.22.796; Sagar M, 2006, J VIROL, V80, P9586, DOI 10.1128/JVI.00141-06; Sanders-Buell E, 2007, AIDS RES HUM RETROV, V23, P953, DOI 10.1089/aid.2007.0299a; Sanders-Buell E, 2007, AIDS RES HUM RETROV, V23, P834, DOI 10.1089/aid.2006.0299; Snoeck J, 2006, ANTIMICROB AGENTS CH, V50, P694, DOI 10.1128/AAC.50.2.694-701.2006; Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012; Tang JM, 2002, J VIROL, V76, P8276, DOI 10.1128/JVI.76.16.8276-8284.2002; Tee KK, 2006, AIDS RES HUM RETROV, V22, P121, DOI 10.1089/aid.2006.22.121; Thakar MR, 2005, J INFECT DIS, V192, P749, DOI 10.1086/432547; Thomson MM, 2004, AIDS RES HUM RETROV, V20, P1126, DOI 10.1089/aid.2004.20.1126; Thomson MM, 2002, J GEN VIROL, V83, P107, DOI 10.1099/0022-1317-83-1-107; Tovanabutra S, 2004, AIDS RES HUM RETROV, V20, P465, DOI 10.1089/088922204323087705; Tuaillon E, 2004, JAIDS-J ACQ IMM DEF, V37, P1543, DOI 10.1097/00126334-200412150-00001; Van Heuverswyn F, 2006, NATURE, V444, P164, DOI 10.1038/444164a; Weaver EA, 2006, J VIROL, V80, P6745, DOI 10.1128/JVI.02484-05; Wensing AMJ, 2005, J INFECT DIS, V192, P1501; Wensing AMJ, 2005, J INFECT DIS, V192, P958, DOI 10.1086/432916; Westby M, 2007, J VIROL, V81, P2359, DOI 10.1128/JVI.02006-06; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	102	354	367	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1590	1602		10.1056/NEJMra0706737	http://dx.doi.org/10.1056/NEJMra0706737			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285NK	18403767	Green Accepted			2022-12-28	WOS:000254783300008
J	Yusuf, S; Teo, KK; Pogue, J; Dyal, L; Copland, I; Schumacher, H; Ingelheim, B; Dagenais, G; Sleight, P; Anderson, C				Yusuf, Salim; Teo, Koon K.; Pogue, Janice; Dyal, Leanne; Copland, Ingrid; Schumacher, Helmut; Ingelheim, Boehringer; Dagenais, Gilles; Sleight, Peter; Anderson, Craig		ONTARGET Investigators	Telmisartan, ramipril, or both in patients at high risk for vascular events	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONVERTING-ENZYME-INHIBITORS; LEFT-VENTRICULAR DYSFUNCTION; CHRONIC HEART-FAILURE; MYOCARDIAL-INFARCTION; SYSTOLIC DYSFUNCTION; RANDOMIZED TRIAL; DOUBLE-BLIND; COMBINATION; CANDESARTAN; DISEASE	Background: In patients who have vascular disease or high-risk diabetes without heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown. We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes. Methods: After a 3-week, single-blind run-in period, patients underwent double-blind randomization, with 8576 assigned to receive 10 mg of ramipril per day, 8542 assigned to receive 80 mg of telmisartan per day, and 8502 assigned to receive both drugs (combination therapy). The primary composite outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure. Results: Mean blood pressure was lower in both the telmisartan group (a 0.9/0.6 mm Hg greater reduction) and the combination-therapy group (a 2.4/1.4 mm Hg greater reduction) than in the ramipril group. At a median follow-up of 56 months, the primary outcome had occurred in 1412 patients in the ramipril group (16.5%), as compared with 1423 patients in the telmisartan group (16.7%; relative risk, 1.01; 95% confidence interval [CI], 0.94 to 1.09). As compared with the ramipril group, the telmisartan group had lower rates of cough (1.1% vs. 4.2%, P<0.001) and angioedema (0.1% vs. 0.3%, P=0.01) and a higher rate of hypotensive symptoms (2.6% vs. 1.7%, P<0.001); the rate of syncope was the same in the two groups (0.2%). In the combination-therapy group, the primary outcome occurred in 1386 patients (16.3%; relative risk, 0.99; 95% CI, 0.92 to 1.07); as compared with the ramipril group, there was an increased risk of hypotensive symptoms (4.8% vs. 1.7%, P<0.001), syncope (0.3% vs. 0.2%, P=0.03), and renal dysfunction (13.5% vs. 10.2%, P<0.001). Conclusions: Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema. The combination of the two drugs was associated with more adverse events without an increase in benefit. (ClinicalTrials.gov number, NCT00153101.).	[Yusuf, Salim; Teo, Koon K.; Pogue, Janice; Dyal, Leanne; Copland, Ingrid] McMaster Univ, Populat Hlth Res Inst, Hamilton Hlth Sci, Hamilton, ON L8L 2X2, Canada; [Dagenais, Gilles] Univ Laval, Heart & Lung Inst, Laval Hosp, Quebec City, PQ, Canada; [Sleight, Peter] Univ Oxford, Oxford, England; [Anderson, Craig] George Inst Int Hlth, Sydney, NSW, Australia	McMaster University; Population Health Research Institute; Laval University; Quebec Heart & Lung Institute; University of Oxford; University of Sydney	Yusuf, S (corresponding author), McMaster Univ, Populat Hlth Res Inst, Hamilton Hlth Sci, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca	Yusof, Zurkurnai/AAA-5893-2021; Davis, Stephen M/L-5260-2013; Verheugt, F.W.A./H-8105-2014; Maia, Lilia/B-8116-2008; Selvetella, Giulio/J-4342-2012; Arnolda, Leonard F/B-7986-2008; Holaj, Robert/D-4241-2017; Force, Rex W/K-4094-2012; Sedurante, Myrna Buenaluz/AAJ-9932-2020; bladin, chris/B-9136-2013; Chazova, Irina/B-8688-2017; Böhm, Michael/C-3638-2011; Parsons, Mark W./G-3750-2014; Jennings, Garry/B-3914-2009; Thompson, Peter L/P-1071-2014; Belenkov, Yury N/B-4159-2018; Stanton, Alice V/F-4697-2012; Walters, Darren/A-7069-2011; Vanhooren, Geert/H-4433-2011; Munzel, Thomas/A-2912-2014; Plavnik, Frida L/I-6068-2012; Hug, Balthasar L./G-1568-2010; Granger, Christopher B/D-3458-2014; Stefanadis, Christodoulos/ABH-2232-2020; JARDIM, PAULO CESAR/C-4574-2015	Davis, Stephen M/0000-0003-0962-2300; Holaj, Robert/0000-0002-9488-9706; Sedurante, Myrna Buenaluz/0000-0001-9172-5477; Chazova, Irina/0000-0002-9822-4357; Vanhooren, Geert/0000-0001-6818-9346; Munzel, Thomas/0000-0001-5503-4150; Granger, Christopher B/0000-0002-0045-3291; Stefanadis, Christodoulos/0000-0001-5974-6454; Anderson, Craig/0000-0002-7248-4863; da Silva Franco, Roberto Jorge/0000-0001-9787-4393; Stanton, Alice/0000-0002-4961-165X; Volpe, Massimo/0000-0002-9642-8380; McEneaney, David/0000-0002-1734-0736; Williams, Bryan/0000-0002-8094-1841; ELISAF, MOSES/0000-0003-0505-078X; Held, Claes/0000-0001-9402-7404; Seo, Hong Seog/0000-0002-3228-7988; Ruilope, Luis M/0000-0001-6278-7951; Yusuf, Salim/0000-0003-4776-5601; Maher, Vincent/0000-0002-3592-4508; Redon, Josep/0000-0001-8777-6773; Radchenko, Ganna/0000-0002-3651-3014; Liang, Chang-seng/0000-0002-0328-0277; JARDIM, PAULO CESAR/0000-0002-5333-013X				Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Connolly S, 2006, AM HEART J, V151, P1187, DOI 10.1016/j.ahj.2005.06.026; Cox D. R., 1984, ANAL SURVIVAL DATA; COX DR, 1972, J R STAT SOC B, V34, P187; Dagenais GR, 2006, LANCET, V368, P581, DOI 10.1016/S0140-6736(06)69201-5; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; Diener HC, 2007, CEREBROVASC DIS, V23, P368, DOI 10.1159/000100105; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Fox KM, 2003, LANCET, V362, P782; Gerstein HC, 2000, LANCET, V355, P253; Granger CB, 2003, LANCET, V362, P772, DOI 10.1016/S0140-6736(03)14284-5; Hasselblad V, 2001, DRUG INF J, V35, P435, DOI 10.1177/009286150103500212; *HEART OUTC PREV E, 2000, LANCET, V356, P860; *HEART OUTC PREV E, 2000, NEW ENGL J MED, V342, P784; Jong P, 2003, LANCET, V361, P1843, DOI 10.1016/S0140-6736(03)13501-5; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Phillips CO, 2007, ARCH INTERN MED, V167, P1930, DOI 10.1001/archinte.167.18.1930; Teo KK, 2004, AM HEART J, V148, P52, DOI 10.1016/j.ahj.2004.03.020; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2000, NEW ENGL J MED, V342, P145	26	2455	2567	6	107	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1547	1559						13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285NK	18378520	Bronze, Green Published			2022-12-28	WOS:000254783300004
J	Christakis, NA				Christakis, Nicholas A.			Don't just blame the system	BRITISH MEDICAL JOURNAL			English	Editorial Material									Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Mt Auburn Hosp, Cambridge, MA USA	Harvard University; Harvard University; Mount Auburn Hospital	Christakis, NA (corresponding author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.	christak@hcp.med.harvard.edu	Christakis, Nicholas A/B-6690-2008; Christakis, Nicholas A/C-3205-2009						0	3	5	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 5	2008	336	7647					747	747		10.1136/bmj.39534.461134.59	http://dx.doi.org/10.1136/bmj.39534.461134.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	284JW	18390523	Green Published			2022-12-28	WOS:000254703700028
J	Dawlaty, MM; Malureanu, L; Jeganathan, KB; Kao, E; Sustmann, C; Tahk, S; Shuai, K; Grosschedl, R; van Deursen, JM				Dawlaty, Meelad M.; Malureanu, Liviu; Jeganathan, Karthik B.; Kao, Esther; Sustmann, Claudio; Tahk, Samuel; Shuai, Ke; Grosschedl, Rudolf; van Deursen, Jan M.			Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase II alpha	CELL			English	Article							NUCLEAR-PORE COMPLEX; CHROMATID SEGREGATION; GENE-EXPRESSION; PROTEIN EXPORT; E3 LIGASE; RAN-GTP; IN-VIVO; NUCLEOPORIN; RANGAP1; PIASY	RanBP2 is a nucleoporin with SUMO E3 ligase activity that functions in both nucleocytoplasmic transport and mitosis. However, the biological relevance of RanBP2 and the in vivo targets of its E3 ligase activity are unknown. Here we show that animals with low amounts of RanBP2 develop severe aneuploidy in the absence of overt transport defects. The main chromosome segregation defect in cells from these mice is anaphase-bridge formation. Topoisomerase II alpha (Topo II alpha), which decatenates sister centromeres prior to anaphase onset to prevent bridges, fails to accumulate at inner centromeres when RanBP2 levels are low. We find that RanBP2 sumoylates Topo II alpha in mitosis and that this modification is required for its proper localization to inner centromeres. Furthermore, mice with low amounts of RanBP2 are highly sensitive to tumor formation. Together, these data identify RanBP2 as a chromosomal instability gene that regulates Topo II alpha by sumoylation and suppresses tumorigenesis.	[Dawlaty, Meelad M.; van Deursen, Jan M.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Malureanu, Liviu; Jeganathan, Karthik B.; Kao, Esther; van Deursen, Jan M.] Mayo Clin, Coll Med, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; [Sustmann, Claudio; Grosschedl, Rudolf] Max Planck Inst Immunobiol, Dept Cellular & Mol Immunol, D-79108 Freiburg, Germany; [Tahk, Samuel] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; [Shuai, Ke] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	Mayo Clinic; Mayo Clinic; Max Planck Society; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	van Deursen, JM (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.	vandeursen.jan@mayo.edu		Jeganathan, KARTHIK/0000-0001-5587-1266	NCI NIH HHS [R01 CA077262, R01 CA077262-11, R01-CA077262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077262] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnaoutov A, 2005, NAT CELL BIOL, V7, P626, DOI 10.1038/ncb1263; Aslanukov A, 2006, PLOS GENET, V2, P1653, DOI 10.1371/journal.pgen.0020177; Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Azuma Y, 2005, EMBO J, V24, P2172, DOI 10.1038/sj.emboj.7600700; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bernad R, 2004, MOL CELL BIOL, V24, P2373, DOI 10.1128/MCB.24.6.2373-2384.2004; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; CLARKE DJ, 1993, J CELL SCI, V105, P563; Dawlaty MM, 2006, METHODS, V39, P370, DOI 10.1016/j.ymeth.2006.06.009; Diaz-Martinez LA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000053; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Hutten S, 2006, MOL CELL BIOL, V26, P6772, DOI 10.1128/MCB.00342-06; Jeganathan KB, 2005, NATURE, V438, P1036, DOI 10.1038/nature04221; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Joseph J, 2002, J CELL BIOL, V156, P595, DOI 10.1083/jcb.200110109; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Matunis MJ, 2005, NAT STRUCT MOL BIOL, V12, P565, DOI 10.1038/nsmb0705-565; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Michor F, 2005, SEMIN CANCER BIOL, V15, P43, DOI 10.1016/j.semcancer.2004.09.007; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Pichler A, 2004, NAT STRUCT MOL BIOL, V11, P984, DOI 10.1038/nsmb834; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Roth W, 2004, J IMMUNOL, V173, P6189, DOI 10.4049/jimmunol.173.10.6189; Salina D, 2003, J CELL BIOL, V162, P991, DOI 10.1083/jcb.200304080; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Takahashi Y, 2006, GENETICS, V172, P783, DOI 10.1534/genetics.105.047167; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Wong KA, 2004, MOL CELL BIOL, V24, P5577, DOI 10.1128/MCB.24.12.5577-5586.2004; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	33	244	253	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 4	2008	133	1					103	115		10.1016/j.cell.2008.01.045	http://dx.doi.org/10.1016/j.cell.2008.01.045			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394993	Green Accepted, Bronze			2022-12-28	WOS:000254641300012
J	Acharya, CR; Hsu, DS; Anders, CK; Anguiano, A; Salter, KH; Walters, KS; Redman, RC; Tuchman, SA; Moylan, CA; Mukherjee, S; Barry, WT; Dressman, HK; Ginsburg, GS; Marcom, KP; Garman, KS; Lyman, GH; Nevins, JR; Potti, A				Acharya, Chaitanya R.; Hsu, David S.; Anders, Carey K.; Anguiano, Ariel; Salter, Kelly H.; Walters, Kelli S.; Redman, Richard C.; Tuchman, Sascha A.; Moylan, Cynthia A.; Mukherjee, Sayan; Barry, William T.; Dressman, Holly K.; Ginsburg, Geoffrey S.; Marcom, Kelly P.; Garman, Katherine S.; Lyman, Gary H.; Nevins, Joseph R.; Potti, Anil			Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RETRACTED ARTICLE. SEE; PROFILES; INFORMATION; METASTASIS; VALIDATION; PREDICTION; ADJUVANT; SUBTYPES; BIOLOGY; WOMEN	Context Gene expression profiling may be useful for prognostic and therapeutic strategies in breast carcinoma. Objectives To demonstrate the value in integrating genomic information with clinical and pathological risk factors, to refine prognosis, and to improve therapeutic strategies for early stage breast cancer. Design, Setting, and Patients Retrospective study of patients with early stage breast carcinoma who were candidates for adjuvant chemotherapy; 964 clinically annotated breast tumor samples ( 573 in the initial discovery set and 391 in the validation cohort) with corresponding microarray data were used. All patients were assigned relapse risk scores based on their respective clinicopathological features. Signatures representing oncogenic pathway activation and tumor biology/ microenvironment status were applied to these samples to obtain patterns of deregulation that correspond with relapse risk scores to refine prognosis with the clinicopathological prognostic model alone. Predictors of chemotherapeutic response were also applied to further characterize clinically relevant heterogeneity in early stage breast cancer. Main Outcome Measures Gene expression signatures and clinicopathological variables in early stage breast cancer to determine a refined estimation of relapse- free survival and sensitivity to chemotherapy. Results In the initial data set of 573 patients, prognostically significant clusters representing patterns of oncogenic pathway activation and tumor biology/ microenvironment states were identified within the low- risk ( log- rank P=. 004), intermediate-risk ( log- rank P=. 01), and high- risk ( log- rank P=. 003) model cohorts, representing clinically important genomic subphenotypes of breast cancer. As an example, in the low- risk cohort, of 6 prognostically significant clusters, patients in cluster 4 had an inferior relapse- free survival vs patients in cluster 1 ( log- rank P=. 004) and cluster 5 ( log- rank P=. 03). Median relapse- free survival for patients in cluster 4 was 16 months less than for patients in cluster 1 ( 95% CI, 7.5- 24.5 months) and 19 months less than for patients in cluster 5 ( 95% CI, 10.5- 27.5 months). Multivariate analyses confirmed the independent prognostic value of the genomic clusters ( low risk, P=. 05; high risk, P=. 02). The reproducibility and validity of these patterns of pathway deregulation in predicting relapse risk was established using related but not identical clusters in the independent validation cohort. The prognostic clinicogenomic clusters also have unique sensitivity patterns to commonly used cytotoxic therapies. Conclusions These results provide preliminary evidence that incorporation of gene expression signatures into clinical risk stratification can refine prognosis. Prospective studies are needed to determine the value of this approach for individualizing therapeutic strategies.	[Acharya, Chaitanya R.; Hsu, David S.; Anguiano, Ariel; Salter, Kelly H.; Walters, Kelli S.; Redman, Richard C.; Tuchman, Sascha A.; Moylan, Cynthia A.; Mukherjee, Sayan; Barry, William T.; Dressman, Holly K.; Ginsburg, Geoffrey S.; Garman, Katherine S.; Nevins, Joseph R.; Potti, Anil] Duke Univ, Duke Inst Genome Sci & Policy, Durham, NC 27708 USA; [Mukherjee, Sayan; Barry, William T.] Duke Univ, Inst Stat & Decis Sci, Durham, NC 27706 USA; [Hsu, David S.; Anders, Carey K.; Anguiano, Ariel; Redman, Richard C.; Tuchman, Sascha A.; Moylan, Cynthia A.; Marcom, Kelly P.; Garman, Katherine S.; Lyman, Gary H.; Potti, Anil] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Potti, A (corresponding author), Duke Univ, Duke Inst Genome Sci & Policy, 101 Sci Dr,Box 3382, Durham, NC 27708 USA.	anil.potti@duke.edu	Lyman, Gary H/K-5227-2019; Acharya, Chaitanya/T-3510-2019	Lyman, Gary H/0000-0002-0823-8086; Tuchman, Sascha/0000-0003-2109-1573				Anders CK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001373; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bild AH, 2006, NAT REV CANCER, V6, P735, DOI 10.1038/nrc1976; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Golub TR, 2001, NEW ENGL J MED, V344, P601, DOI 10.1056/NEJM200102223440809; Gyorffy B, 2006, INT J CANCER, V118, P1699, DOI 10.1002/ijc.21570; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Massague J, 2007, NEW ENGL J MED, V356, P294, DOI 10.1056/NEJMe068292; Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137; Olivotto IA, 2005, J CLIN ONCOL, V23, P2716, DOI 10.1200/JCO.2005.06.178; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paik S, 2006, CURR OPIN OBSTET GYN, V18, P59, DOI 10.1097/01.gco.0000192970.52320.29; Pittman J, 2004, P NATL ACAD SCI USA, V101, P8431, DOI 10.1073/pnas.0401736101; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467; Ravdin PM, 2001, J CLIN ONCOL, V19, P980, DOI 10.1200/JCO.2001.19.4.980; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Scharpf R, 2003, BIOTECHNIQUES, P22; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; van't Veer LJ, 2005, J CLIN ONCOL, V23, P1631, DOI 10.1200/JCO.2005.12.005; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; Viemann D, 2006, J LEUKOCYTE BIOL, V80, P174, DOI 10.1189/jlb.0905530; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Weinberg R. A., 1989, ONCOGENES MOL ORIGIN; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941	41	86	92	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2008	299	13					1574	1587		10.1001/jama.299.13.1574	http://dx.doi.org/10.1001/jama.299.13.1574			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	281RZ	18387932				2022-12-28	WOS:000254517900024
J	Sykes, MV				Sykes, Mark V.			Planetary science - The planet debate continues	SCIENCE			English	Editorial Material							PLUTO		Planetary Sci Inst, Tucson, AZ 85719 USA		Sykes, MV (corresponding author), Planetary Sci Inst, 1700 E Fort Lowell,Suite 106, Tucson, AZ 85719 USA.	sykes@psi.edu						Hogan J, 2006, NATURE, V442, P965, DOI 10.1038/442965a; LEVISON H, 2006, HAND WAVING DERIVATI; Schilling G, 2006, SCIENCE, V313, P1214, DOI 10.1126/science.313.5791.1214	3	5	5	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1765	1765		10.1126/science.1155743	http://dx.doi.org/10.1126/science.1155743			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369125				2022-12-28	WOS:000254394000023
J	Duffy, HS				Duffy, Heather S.			Cardiac connections - The antiarrhythmic solution?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STEM-CELLS		[Duffy, Heather S.] Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University	Duffy, HS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.							Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Mills WR, 2007, J MOL CELL CARDIOL, V42, P304, DOI 10.1016/j.yjmcc.2006.09.011; Murry CE, 2006, J AM COLL CARDIOL, V47, P1777, DOI 10.1016/j.jacc.2006.02.002; Roell W, 2007, NATURE, V450, P819, DOI 10.1038/nature06321; Rosen MR, 2006, CIRCULATION, V114, P1992, DOI 10.1161/CIRCULATIONAHA.106.641670	5	10	10	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1397	1398		10.1056/NEJMcibr0708922	http://dx.doi.org/10.1056/NEJMcibr0708922			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367745				2022-12-28	WOS:000254308400014
J	Losonczy, A; Makara, JK; Magee, JC				Losonczy, Attila; Makara, Judit K.; Magee, Jeffrey C.			Compartmentalized dendritic plasticity and input feature storage in neurons	NATURE			English	Article							CA1 PYRAMIDAL NEURONS; ACTION-POTENTIALS; EXCITABILITY; HIPPOCAMPUS; PATTERNS; SPIKES; MEMORY; CELLS; KV4.2; RAT	Although information storage in the central nervous system is thought to be primarily mediated by various forms of synaptic plasticity, other mechanisms, such as modifications in membrane excitability, are available. Local dendritic spikes are nonlinear voltage events that are initiated within dendritic branches by spatially clustered and temporally synchronous synaptic input. That local spikes selectively respond only to appropriately correlated input allows them to function as input feature detectors and potentially as powerful information storage mechanisms. However, it is currently unknown whether any effective form of local dendritic spike plasticity exists. Here we show that the coupling between local dendritic spikes and the soma of rat hippocampal CA1 pyramidal neurons can be modified in a branch- specific manner through an N- methyl- D- aspartate receptor ( NMDAR)- dependent regulation of dendritic Kv4.2 potassium channels. These data suggest that compartmentalized changes in branch excitability could store multiple complex features of synaptic input, such as their spatio- temporal correlation. We propose that this 'branch strength potentiation' represents a previously unknown form of information storage that is distinct from that produced by changes in synaptic efficacy both at the mechanistic level and in the type of information stored.	[Losonczy, Attila; Makara, Judit K.; Magee, Jeffrey C.] Howard Hughes Med Inst, Ashburn, VA 20147 USA	Howard Hughes Medical Institute	Losonczy, A (corresponding author), Howard Hughes Med Inst, Janelia Farm Res Campus,19700 Helix Dr, Ashburn, VA 20147 USA.	losonczya@janelia.hhmi.org; makaraj@janelia.hhmi.org						Ariav G, 2003, J NEUROSCI, V23, P7750; BANNISTER NJ, 1995, J COMP NEUROL, V360, P150, DOI 10.1002/cne.903600111; Chen XX, 2006, J NEUROSCI, V26, P12143, DOI 10.1523/JNEUROSCI.2667-06.2006; Csicsvari J, 2000, NEURON, V28, P585, DOI 10.1016/S0896-6273(00)00135-5; Frick A, 2004, NAT NEUROSCI, V7, P126, DOI 10.1038/nn1178; Fusi S, 2005, NEURON, V45, P599, DOI 10.1016/j.neuron.2005.02.001; Gasparini S, 2006, J NEUROSCI, V26, P2088, DOI 10.1523/JNEUROSCI.4428-05.2006; Gasparini S, 2004, J NEUROSCI, V24, P11046, DOI 10.1523/JNEUROSCI.2520-04.2004; Gasparini S, 2007, J PHYSIOL-LONDON, V580, P787, DOI 10.1113/jphysiol.2006.121343; Golding NL, 1998, NEURON, V21, P1189, DOI 10.1016/S0896-6273(00)80635-2; Govindarajan A, 2006, NAT REV NEUROSCI, V7, P575, DOI 10.1038/nrn1937; Guo WN, 2005, CIRC RES, V97, P1342, DOI 10.1161/01.RES.0000196559.63223.aa; Harvey CD, 2007, NATURE, V450, P1195, DOI 10.1038/nature06416; Hasselmo ME, 2006, J MOL NEUROSCI, V30, P133, DOI 10.1385/JMN:30:1:133; Hoffman DA, 1999, J NEUROPHYSIOL, V81, P408, DOI 10.1152/jn.1999.81.1.408; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; Kim JY, 2007, NEURON, V54, P933, DOI 10.1016/j.neuron.2007.05.026; Larkum ME, 2001, J PHYSIOL-LONDON, V533, P447, DOI 10.1111/j.1469-7793.2001.0447a.x; Lee AK, 2002, NEURON, V36, P1183, DOI 10.1016/S0896-6273(02)01096-6; London M, 2005, ANNU REV NEUROSCI, V28, P503, DOI 10.1146/annurev.neuro.28.061604.135703; Losonczy A, 2006, NEURON, V50, P291, DOI 10.1016/j.neuron.2006.03.016; Magee JC, 2005, CURR OPIN NEUROBIOL, V15, P334, DOI 10.1016/j.conb.2005.05.013; Nadasdy Z, 1999, J NEUROSCI, V19, P9497; O'Neill J, 2006, NEURON, V49, P143, DOI 10.1016/j.neuron.2005.10.037; Poirazi P, 2001, NEURON, V29, P779, DOI 10.1016/S0896-6273(01)00252-5; Poirazi P, 2003, NEURON, V37, P989, DOI 10.1016/S0896-6273(03)00149-1; Polsky A, 2004, NAT NEUROSCI, V7, P621, DOI 10.1038/nn1253; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; Yasuda R, 2006, NAT NEUROSCI, V9, P283, DOI 10.1038/nn1635; Zhang W, 2003, NAT REV NEUROSCI, V4, P885, DOI 10.1038/nrn1248	30	410	414	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2008	452	7186					436	U3		10.1038/nature06725	http://dx.doi.org/10.1038/nature06725			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279FU	18368112				2022-12-28	WOS:000254341300024
J	Quintana, FJ; Basso, AS; Iglesias, AH; Korn, T; Farez, MF; Bettelli, E; Caccamo, M; Oukka, M; Weiner, HL				Quintana, Francisco J.; Basso, Alexandre S.; Iglesias, Antonio H.; Korn, Thomas; Farez, Mauricio F.; Bettelli, Estelle; Caccamo, Mario; Oukka, Mohamed; Weiner, Howard L.			Control of T-reg and TH17 cell differentiation by the aryl hydrocarbon receptor	NATURE			English	Article							TGF-BETA; INDEPENDENT REGULATION; MICROARRAY ANALYSIS; AH RECEPTOR; ACTIVATION; EXPRESSION; INDUCTION; DIOXIN; T(H)17; LIGAND	Regulatory T cells (T-reg) expressing the transcription factor Foxp3 control the autoreactive components of the immune system. The development of T-reg cells is reciprocally related to that of pro- inflammatory T cells producing interleukin- 17 ( T(H)17). Although T-reg cell dysfunction and/ or T(H)17 cell dysregulation are thought to contribute to the development of autoimmune disorders, little is known about the physiological pathways that control the generation of these cell lineages. Here we report the identification of the ligand- activated transcription factor aryl hydrocarbon receptor ( AHR) as a regulator of T-reg and T(H)17 cell differentiation in mice. AHR activation by its ligand 2,3,7,8- tetrachlorodibenzo- p- dioxin induced functional Treg cells that suppressed experimental autoimmune encephalomyelitis. On the other hand, AHR activation by 6- formylindolo[ 3,2- b] carbazole interfered with T-reg cell development, boosted T(H)17 cell differentiation and increased the severity of experimental autoimmune encephalomyelitis in mice. Thus, AHR regulates both T-reg and T(H)17 cell differentiation in a ligand- specific fashion, constituting a unique target for therapeutic immunomodulation.	[Quintana, Francisco J.; Basso, Alexandre S.; Iglesias, Antonio H.; Korn, Thomas; Farez, Mauricio F.; Bettelli, Estelle; Weiner, Howard L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; [Caccamo, Mario] European Bioinformat Inst, EMBL Outstn Hinxton, Cambridge CB10 1SD, England; [Oukka, Mohamed] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; European Molecular Biology Laboratory (EMBL); Harvard University; Brigham & Women's Hospital	Weiner, HL (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	hweiner@rics.bwh.harvard.edu	Korn, Thomas/AAE-6960-2019; Basso, Alexandre S/K-2281-2012; Quintana, Francisco Javier/AAB-6915-2020	Korn, Thomas/0000-0002-3633-0955; Basso, Alexandre S/0000-0002-3302-4792; 	NIAID NIH HHS [R01AI073542-01, R01 AI073542-02, R01 AI073542, AI435801, R01 AI073542-01] Funding Source: Medline; NINDS NIH HHS [NS38037, R01 NS059996, P01 NS038037] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS038037, R01NS059996] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baccarelli A, 2002, ENVIRON HEALTH PERSP, V110, P1169, DOI 10.1289/ehp.021101169; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Burchill MA, 2007, J IMMUNOL, V178, P280, DOI 10.4049/jimmunol.178.1.280; Chang XQ, 2007, MOL CELL BIOL, V27, P6127, DOI 10.1128/MCB.00323-07; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Frericks M, 2007, TOXICOL APPL PHARM, V220, P320, DOI 10.1016/j.taap.2007.01.014; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Funatake CJ, 2005, J IMMUNOL, V175, P4184, DOI 10.4049/jimmunol.175.7.4184; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Hestermann EV, 2003, MOL CELL BIOL, V23, P7920, DOI 10.1128/MCB.23.21.7920-7925.2003; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518; Mantel PY, 2006, J IMMUNOL, V176, P3593, DOI 10.4049/jimmunol.176.6.3593; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Murphy KA, 2004, J BIOL CHEM, V279, P25284, DOI 10.1074/jbc.M402168200; Oesch-Bartlomowicz B, 2005, P NATL ACAD SCI USA, V102, P9218, DOI 10.1073/pnas.0503488102; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; OKEY AB, 1989, MOL PHARMACOL, V35, P823; Okino ST, 2007, MOL PHARMACOL, V72, P1457, DOI 10.1124/mol.107.039826; Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935; Ovcharenko I, 2005, GENOME RES, V15, P184, DOI 10.1101/gr.3007205; Quintana FJ, 2004, P NATL ACAD SCI USA, V101, P14615, DOI 10.1073/pnas.0404848101; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Song JS, 2002, P NATL ACAD SCI USA, V99, P14694, DOI 10.1073/pnas.232562899; Stekel D, 2003, MICROARRAY BIOINFORM; Tai P, 2008, J CELL PHYSIOL, V214, P456, DOI 10.1002/jcp.21221; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716; Zhang S, 2008, TOXICOL APPL PHARM, V227, P196, DOI 10.1016/j.taap.2007.10.019	41	1239	1311	4	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2008	453	7191					65	+		10.1038/nature06880	http://dx.doi.org/10.1038/nature06880			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294ID	18362915				2022-12-28	WOS:000255398800039
J	Kim, DH; Ahn, JH; Choi, WM; Kim, HS; Kim, TH; Song, JZ; Huang, YGY; Liu, ZJ; Lu, C; Rogers, JA				Kim, Dae-Hyeong; Ahn, Jong-Hyun; Choi, Won Mook; Kim, Hoon-Sik; Kim, Tae-Ho; Song, Jizhou; Huang, Yonggang Y.; Liu, Zhuangjian; Lu, Chun; Rogers, John A.			Stretchable and foldable silicon integrated circuits	SCIENCE			English	Article							THIN-FILM TRANSISTORS; HIGH-PERFORMANCE ELECTRONICS; SINGLE-CRYSTAL-SILICON; TECHNOLOGY; FORM	We have developed a simple approach to high- performance, stretchable, and foldable integrated circuits. The systems integrate inorganic electronic materials, including aligned arrays of nanoribbons of single crystalline silicon, with ultrathin plastic and elastomeric substrates. The designs combine multilayer neutral mechanical plane layouts and "wavy" structural configurations in silicon complementary logic gates, ring oscillators, and differential amplifiers. We performed three- dimensional analytical and computational modeling of the mechanics and the electronic behaviors of these integrated circuits. Collectively, the results represent routes to devices, such as personal health monitors and other biomedical devices, that require extreme mechanical deformations during installation/ use and electronic properties approaching those of conventional systems built on brittle semiconductor wafers.	[Huang, Yonggang Y.] Northwestern Univ, Dept Civil & Environm Engn, Evanston, IL 60208 USA; [Huang, Yonggang Y.] Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA; [Liu, Zhuangjian; Lu, Chun] Inst High Performance Comp, Singapore 117528, Singapore; [Kim, Dae-Hyeong; Choi, Won Mook; Kim, Hoon-Sik; Kim, Tae-Ho; Rogers, John A.] Univ Illinois, Dept Mat Sci & Engn, Beckman Inst, Urbana, IL 61801 USA; [Kim, Dae-Hyeong; Choi, Won Mook; Kim, Hoon-Sik; Kim, Tae-Ho; Rogers, John A.] Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA; [Ahn, Jong-Hyun] Sungkyunkwan Univ, Sch Adv Mat Sci & Engn, Suwon 440746, South Korea; [Song, Jizhou; Rogers, John A.] Univ Illinois, Dept Mech Sci & Engn, Urbana, IL 61801 USA; [Rogers, John A.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA; [Rogers, John A.] Univ Illinois, Dept Elect & Comp Engn, Urbana, IL 61801 USA	Northwestern University; Northwestern University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of High Performance Computing (IHPC); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Sungkyunkwan University (SKKU); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Huang, YGY (corresponding author), Northwestern Univ, Dept Civil & Environm Engn, Evanston, IL 60208 USA.	y-huang@northwestern.edu; jrogers@uiuc.edu	Ahn, Jong-Hyun/L-9825-2016; Rogers, John/L-2798-2016; huang, yonggang/O-6236-2019; Huang, Yonggang/B-6998-2009; Song, Jizhou/B-1935-2008; LU, Chun/A-4653-2010	Ahn, Jong-Hyun/0000-0002-8135-7719; Song, Jizhou/0000-0003-2821-9429; LU, Chun/0000-0001-7941-4879; Kim, Dae-Hyeong/0000-0002-4722-1893				Ahn JH, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2742294; Ahn JH, 2006, SCIENCE, V314, P1754, DOI 10.1126/science.1132394; Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530; Da Silva VD, 2005, MECH STRENGTH MAT; Dodabalapur A, 2006, MATER TODAY, V9, P24, DOI 10.1016/S1369-7021(06)71444-4; Jacobs HO, 2002, SCIENCE, V296, P323, DOI 10.1126/science.1069153; Jiang HQ, 2007, P NATL ACAD SCI USA, V104, P15607, DOI 10.1073/pnas.0702927104; Khang DY, 2006, SCIENCE, V311, P208, DOI 10.1126/science.1121401; Lacour SP, 2005, P IEEE, V93, P1459, DOI 10.1109/JPROC.2005.851502; Lee CH, 2006, INT EL DEVICES MEET, P29; Lu XM, 2006, NAT NANOTECHNOL, V1, P163, DOI 10.1038/nnano.2006.157; Mack S, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2206688; Maikap S, 2004, IEEE INTERNATIONAL ELECTRON DEVICES MEETING 2004, TECHNICAL DIGEST, P233, DOI 10.1109/IEDM.2004.1419117; McAlpine MC, 2003, NANO LETT, V3, P1531, DOI 10.1021/nl0346427; Meitl MA, 2006, NAT MATER, V5, P33, DOI 10.1038/nmat1532; Menard E, 2004, APPL PHYS LETT, V84, P5398, DOI 10.1063/1.1767591; Moroz V, 2003, MAT SCI SEMICON PROC, V6, P27, DOI 10.1016/S1369-8001(03)00068-4; Reuss RH, 2005, P IEEE, V93, P1239, DOI 10.1109/JPROC.2005.851237; Serikawa T, 2000, JPN J APPL PHYS 2, V39, pL393, DOI 10.1143/JJAP.39.L393; Servati P, 2005, P IEEE, V93, P1257, DOI 10.1109/JPROC.2005.851534; Someya T, 2004, P NATL ACAD SCI USA, V101, P9966, DOI 10.1073/pnas.0401918101; STREETMAN SG, 1981, SOLID STATE ELECT DE; Sun YG, 2007, ADV MATER, V19, P1897, DOI 10.1002/adma.200602223; Sun YG, 2007, J MATER CHEM, V17, P832, DOI 10.1039/b614793c; Sun YG, 2006, NAT NANOTECHNOL, V1, P201, DOI 10.1038/nnano.2006.131; Sun YG, 2006, ADV MATER, V18, P2857, DOI 10.1002/adma.200600646; Talapin DV, 2005, SCIENCE, V310, P86, DOI 10.1126/science.1116703; Thompson SE, 2004, IEEE T ELECTRON DEV, V51, P1790, DOI 10.1109/TED.2004.836648; Wu M, 2002, IEEE T ELECTRON DEV, V49, P1993, DOI 10.1109/TED.2002.804702; Yuan HC, 2006, J APPL PHYS, V100, DOI 10.1063/1.2214301	30	1279	1429	38	1065	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2008	320	5875					507	511		10.1126/science.1154367	http://dx.doi.org/10.1126/science.1154367			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292EM	18369106				2022-12-28	WOS:000255249300044
J	Mayer, EA				Mayer, Emeran A.			Irritable bowel syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FUNCTIONAL GASTROINTESTINAL DISORDERS; DRUG DEVELOPMENT; CONSTIPATION; SEROTONIN; ALOSETRON; EFFICACY; DIARRHEA; ARTICLE; HISTORY; CARE		Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis,Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis,Dept Psychiat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mayer, EA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Div Digest Dis,Dept Med, Peter Ueberroth Bldg,Ste 2338 F,10945 Leconte Ave, Los Angeles, CA 90095 USA.	emayer@ucla.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R24AT002681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK064539, R01DK048351, R01DK058173] Funding Source: NIH RePORTER; NCCIH NIH HHS [R24 AT002681-04, R24 AT002681] Funding Source: Medline; NIDDK NIH HHS [P50 DK064539, R01 DK048351, P50 DK64539, R01 DK058173, R01 DK048351-10A2, R01 DK058173-05, P50 DK064539-06, R01 DK48351, R01 DK58173] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andresen V, 2007, GASTROENTEROLOGY, V133, P761, DOI 10.1053/j.gastro.2007.06.067; Bradesi Sylvie, 2006, Expert Opin Emerg Drugs, V11, P293, DOI 10.1517/14728214.11.2.293; Brandt LJ, 2002, AM J GASTROENTEROL, V97, pS7; Cash BD, 2002, AM J GASTROENTEROL, V97, P2812; Chang L, 2005, AM J GASTROENTEROL, V100, P115, DOI 10.1111/j.1572-0241.2005.40365.x; Chang L, 2006, AM J GASTROENTEROL, V101, P1069, DOI 10.1111/j.1572-0241.2006.00459.x; Clouse RE, 2005, GUT, V54, P1332, DOI 10.1136/gut.2004.048884; DILORENZO C, 2006, ROME, V3, P723; Drossman DA, 2003, GASTROENTEROLOGY, V125, P19, DOI 10.1016/S0016-5085(03)00669-3; Drossman DA, 2002, GASTROENTEROLOGY, V123, P2108, DOI 10.1053/gast.2002.37095; Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002; Halder SLS, 2007, GASTROENTEROLOGY, V133, P799, DOI 10.1053/j.gastro.2007.06.010; Hamm LR, 1999, AM J GASTROENTEROL, V94, P1279, DOI 10.1016/S0002-9270(99)00133-1; Ilnyckyj A, 2003, ALIMENT PHARM THER, V17, P871, DOI 10.1046/j.1365-2036.2003.01523.x; Jackson JL, 2000, AM J MED, V108, P65, DOI 10.1016/S0002-9343(99)00299-5; JOHANSON JF, IN PRESS ALIMENT PHA; Kassinen A, 2007, GASTROENTEROLOGY, V133, P24, DOI 10.1053/j.gastro.2007.04.005; Lackner JA, 2004, J CONSULT CLIN PSYCH, V72, P1100, DOI 10.1037/0022-006X.72.6.1100; LACKNER JM, IN PRESS CLIN GASTRO; Lesbros-Pantoflickova D, 2004, ALIMENT PHARM THER, V20, P1253, DOI 10.1111/j.1365-2036.2004.02267.x; Levy RL, 2001, AM J GASTROENTEROL, V96, P3122; Longstreth GF, 2006, ROME 3 FUNCTIONAL GA, VIII, P487; Mayer EA, 2006, ALIMENT PHARM THER, V24, P919, DOI 10.1111/j.1365-2036.2006.03078.x; MAYER EA, 1994, GASTROENTEROLOGY, V107, P271, DOI 10.1016/0016-5085(94)90086-8; Mayey EA, 2001, J CLIN PSYCHIAT, V62, P28; O'Mahony L, 2005, GASTROENTEROLOGY, V128, P541, DOI 10.1053/j.gastro.2004.11.050; Pasricha PJ, 2007, GASTROENTEROLOGY, V132, P2287, DOI 10.1053/j.gastro.2007.04.057; Pimentel M, 2006, ANN INTERN MED, V145, P557, DOI 10.7326/0003-4819-145-8-200610170-00004; Quigley EMM, 2007, NEUROGASTROENT MOTIL, V19, P166, DOI 10.1111/j.1365-2982.2006.00879.x; SAARTO T, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD005454; Spiegel BMR, 2004, ARCH INTERN MED, V164, P1773, DOI 10.1001/archinte.164.16.1773; Spiegel BMR, 2004, GASTROENTEROLOGY, V126, P1721, DOI 10.1053/j.gastro.2004.03.012; Spiegel BM, 2006, GASTROENTEROLOGY, V130, pA112; Spiller R, 2007, GUT, V56, P1770, DOI 10.1136/gut.2007.119446; Spiller R, 2006, CURR OPIN GASTROEN, V22, P13, DOI 10.1097/01.mog.0000194792.36466.5c; Tack J, 2006, ALIMENT PHARM THER, V24, P183, DOI 10.1111/j.1365-2036.2006.02938.x; Wessely S, 2004, BRIT J PSYCHIAT, V185, P95, DOI 10.1192/bjp.185.2.95; Whitehead WE, 2002, GASTROENTEROLOGY, V122, P1140, DOI 10.1053/gast.2002.32392; Whorwell PJ, 2005, ALIMENT PHARM THER, V22, P1061, DOI 10.1111/j.1365-2036.2005.02697.x	39	196	204	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1692	1699		10.1056/NEJMcp0801447	http://dx.doi.org/10.1056/NEJMcp0801447			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288DO	18420501	Green Accepted			2022-12-28	WOS:000254966600007
J	Erikson, SL				Erikson, Susan L.			Getting political: fighting for global health	LANCET			English	Editorial Material									Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Erikson, SL (corresponding author), Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada.	slerikson@sfu.ca						Buse K, 1997, SOC SCI MED, V45, P449, DOI 10.1016/S0277-9536(96)00365-6; Drager N, 2007, B WORLD HEALTH ORGAN, V85, P162, DOI 10.2471/BLT.07.041079; GROWN C, 2006, TRADING WOMENS HLTH; Kickbusch I, 2006, SCAND J PUBLIC HEALT, V34, P561, DOI 10.1080/14034940600973059; Klarevas L, 2004, HARVARD INT REV, V26, P18; Lee K, 2002, HLTH POLICY GLOBALIZ; MCINNES C, 2005, HLTH FOREIGN POLICY; OKIE S, 2004, NEW ENGL J MED, V355, P1084; [No title captured]	9	16	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 12	2008	371	9620					1229	1230		10.1016/S0140-6736(08)60539-5	http://dx.doi.org/10.1016/S0140-6736(08)60539-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	286XH	18406847	Green Published, Bronze			2022-12-28	WOS:000254878900010
J	Shankar, A; Bartlett, L; Fauveau, V; Islam, M; Terreri, N				Shankar, Anuraj; Bartlett, Linda; Fauveau, Vincent; Islam, Monir; Terreri, Nancy		Countdown 2015 Maternal Hlth Grp	Delivery of MDG 5 by active management with data	LANCET			English	Editorial Material							MATERNAL HEALTH; QUALITY		[Shankar, Anuraj; Islam, Monir] WHO, CH-1211 Geneva, Switzerland; [Bartlett, Linda] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Fauveau, Vincent] UN Populat Fund, Geneva, Switzerland; [Terreri, Nancy] UNICEF, New York, NY USA	World Health Organization; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; United Nations Population Fund; UNICEF	Shankar, A (corresponding author), WHO, CH-1211 Geneva, Switzerland.	shankara@who.int	Shankar, Anuraj/U-3764-2018	Shankar, Anuraj/0000-0001-7268-6708				Bradshaw D, 2008, LANCET, V371, P1294, DOI 10.1016/S0140-6736(08)60564-4; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Dott MM, 2005, J MIDWIFERY WOM HEAL, V50, P296, DOI 10.1016/j.jmwh.2005.02.013; Fauveau V, 2007, LANCET, V370, P1310, DOI 10.1016/S0140-6736(07)61571-2; Filippi V, 2005, ACTA OBSTET GYN SCAN, V84, P11, DOI 10.1111/j.0001-6349.2005.00636.x; Filippi V, 2006, LANCET, V368, P1535, DOI 10.1016/S0140-6736(06)69384-7; Harvey SA, 2007, B WORLD HEALTH ORGAN, V85, P783, DOI 10.2471/BLT.06.038455; Hill K, 2007, LANCET, V370, P1311, DOI 10.1016/S0140-6736(07)61572-4; Hulton LA, 2007, SOC SCI MED, V64, P2083, DOI 10.1016/j.socscimed.2007.01.019; Reich MR, 2008, LANCET, V371, P865, DOI 10.1016/S0140-6736(08)60384-0; Sanders D, 2006, PLOS MED, V3, P719, DOI 10.1371/journal.pmed.0030186; Stanton C, 2006, LANCET, V367, P1487, DOI 10.1016/S0140-6736(06)68586-3; *UN, 2007, REP SECR GEN WORK OR; Villar J, 2007, BRIT MED J, V335, P1025, DOI 10.1136/bmj.39363.706956.55; Wilson Ronee E, 2007, Int J Fertil Womens Med, V52, P121	15	24	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1223	1224		10.1016/S0140-6736(08)60536-X	http://dx.doi.org/10.1016/S0140-6736(08)60536-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286XH	18406844				2022-12-28	WOS:000254878900007
J	Stoltenberg, J				Stoltenberg, Jens			Delivering for women and children	LANCET			English	Editorial Material									Norwegian Govt, NO-0030 Oslo, Norway		Stoltenberg, J (corresponding author), Norwegian Govt, NO-0030 Oslo, Norway.	Tore.Godal@smk.dep.no						*UN UNICEF, 2002, UN SPEC SESS CHILDR; United Nations Children's Fund (UNICEF), 2014, STATE WORLDS CHILDRE	2	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2008	371	9620					1230	1232		10.1016/S0140-6736(08)60540-1	http://dx.doi.org/10.1016/S0140-6736(08)60540-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	286XH	18406848				2022-12-28	WOS:000254878900011
J	Paquay, FS; Ravizza, GE; Dalai, TK; Peucker-Ehrenbrink, B				Paquay, Francois S.; Ravizza, Gregory E.; Dalai, Tarun K.; Peucker-Ehrenbrink, Bernhard			Determining chondritic impactor size from the marine osmium isotope record	SCIENCE			English	Article							CRETACEOUS-TERTIARY BOUNDARY; IRIDIUM; EOCENE; CHEMOSTRATIGRAPHY; SIDEROPHILE; SYSTEMATICS; METEORITE; SEDIMENTS; ELEMENTS; RHENIUM	Decreases in the seawater Os-187/Os-188 ratio caused by the impact of a chondritic meteorite are indicative of projectile size, if the soluble fraction of osmium carried by the impacting body is known. Resulting diameter estimates of the Late Eocene and Cretaceous/Paleogene projectiles are within 50% of independent estimates derived from iridium data, assuming total vaporization and dissolution of osmium in seawater. The variations of Os-187/Os-188 and Os/Ir across the Late Eocene impact-event horizon support the main assumptions required to estimate the projectile diameter. Chondritic impacts as small as 2 kilometers in diameter should produce observable excursions in the marine osmium isotope record, suggesting that previously unrecognized impact events can be identified by this method.	[Paquay, Francois S.; Ravizza, Gregory E.; Dalai, Tarun K.] Univ Hawaii, Dept Geol & Geophys, Honolulu, HI 96822 USA; [Peucker-Ehrenbrink, Bernhard] Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA	University of Hawaii System; Woods Hole Oceanographic Institution	Paquay, FS (corresponding author), Univ Hawaii, Dept Geol & Geophys, Honolulu, HI 96822 USA.	paquay@hawaii.edu	Dalai, Tarun/AAF-5804-2020; Ravizza, Greg/J-5104-2013	Peucker-Ehrenbrink, Bernhard/0000-0002-3819-992X				ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; Anbar AD, 1996, SCIENCE, V273, P1524, DOI 10.1126/science.273.5281.1524; Channell JET, 2003, GEOL SOC AM BULL, V115, P607, DOI 10.1130/0016-7606(2003)115<0607:ETMMBA>2.0.CO;2; Claeys P, 2002, GEOL SOC AM SPEC PAP, V356, P55; Collins GS, 2005, METEORIT PLANET SCI, V40, P817, DOI 10.1111/j.1945-5100.2005.tb00157.x; Collins GS, 2005, GEOLOGY, V33, P925, DOI 10.1130/G21854.1; Dalai TK, 2006, GEOCHIM COSMOCHIM AC, V70, P3928, DOI 10.1016/j.gca.2006.06.002; Dalai TK, 2006, EARTH PLANET SC LETT, V241, P477, DOI 10.1016/j.epsl.2005.11.035; DONALDSON S, 2001, METEORIT PLANET SCI, V36, pA50; Ebel DS, 2005, GEOLOGY, V33, P293, DOI 10.1130/G21136.1; Farley KA, 1998, SCIENCE, V280, P1250, DOI 10.1126/science.280.5367.1250; Frei R, 2002, EARTH PLANET SC LETT, V203, P691, DOI 10.1016/S0012-821X(02)00865-8; Horan MF, 2003, CHEM GEOL, V196, P5, DOI 10.1016/S0009-2541(02)00405-9; Ivanov BA, 2005, SOLAR SYST RES+, V39, P381, DOI 10.1007/s11208-005-0051-0; Koeberl C, 1997, PALAEOGEOGR PALAEOCL, V132, P25, DOI 10.1016/S0031-0182(97)00045-X; Kyte FT, 2002, DEEP-SEA RES PT II, V49, P1049, DOI 10.1016/S0967-0645(01)00139-4; Kyte FT, 1998, NATURE, V396, P237, DOI 10.1038/24322; KYTE FT, 2002, LUNAR PLANET SCI, V33, P1981; Lee CTA, 2003, GEOCHIM COSMOCHIM AC, V67, P655, DOI 10.1016/S0016-7037(02)01135-3; Levasseur S, 1999, EARTH PLANET SC LETT, V174, P7, DOI 10.1016/S0012-821X(99)00259-9; Levasseur S, 1998, SCIENCE, V282, P272, DOI 10.1126/science.282.5387.272; LUCK JM, 1983, SCIENCE, V222, P613, DOI 10.1126/science.222.4624.613; MEISEL T, 1995, GEOLOGY, V23, P313, DOI 10.1130/0091-7613(1995)023<0313:COASIS>2.3.CO;2; MORGAN JW, 1995, GEOCHIM COSMOCHIM AC, V59, P2331, DOI 10.1016/0016-7037(95)00109-D; Oxburgh R, 1998, EARTH PLANET SC LETT, V159, P183, DOI 10.1016/S0012-821X(98)00057-0; PALIKE H, 2005, SCI RES P OCEAN DRIL, V199; PEARSON DG, 1999, GEOL SOC AM ABSTR, V31, P123; PEUCKEREHRENBRINK B, 1995, EARTH PLANET SC LETT, V130, P155, DOI 10.1016/0012-821X(95)00003-U; Quitte G, 2007, METEORIT PLANET SCI, V42, P1567, DOI 10.1111/j.1945-5100.2007.tb00591.x; Ravizza G, 2003, SCIENCE, V302, P1392, DOI 10.1126/science.1089209; Tagle R, 2005, GEOCHIM COSMOCHIM AC, V69, P2877, DOI 10.1016/j.gca.2004.11.024; WASSON JT, 1988, PHILOS T R SOC A, V325, P535, DOI 10.1098/rsta.1988.0066; Whitehead J, 2000, EARTH PLANET SC LETT, V181, P473, DOI 10.1016/S0012-821X(00)00225-9	33	51	51	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2008	320	5873					214	218		10.1126/science.1152860	http://dx.doi.org/10.1126/science.1152860			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403707				2022-12-28	WOS:000254836700039
J	Vartanian, JP; Guetard, D; Henry, M; Wain-Hobson, S				Vartanian, Jean-Pierre; Guetard, Denise; Henry, Michel; Wain-Hobson, Simon			Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions	SCIENCE			English	Article							CYTIDINE DEAMINASE; SOMATIC HYPERMUTATION; ANTIRETROVIRAL FACTOR; HIV-1 DNA; PROTEINS; FAMILY; VIF; EXPRESSION; EVOLUTION; VIRUS	Cytidine deaminases of the APOBEC3 family all have specificity for single-stranded DNA, which may become exposed during replication or transcription of double-stranded DNA. Three human APOBEC3A (hA3A), hA3B, and hA3H genes are expressed in keratinocytes and skin, leading us to determine whether genetic editing of human papillomavirus (HPV) DNA occurred. In a study of HPV1a plantar warts and HPV16 precancerous cervical biopsies, hyperedited HPV1a and HPV16 genomes were found. Strictly analogous results were obtained from transfection experiments with HPV plasmid DNA and the three nuclear localized enzymes: hA3A, hA3C, and hA3H. Thus, stochastic or transient overexpression of APOBEC3 genes may expose the genome to a broad spectrum of mutations that could influence the development of tumors.	[Vartanian, Jean-Pierre; Guetard, Denise; Henry, Michel; Wain-Hobson, Simon] Inst Pasteur, Mol Retrovirol Unit, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Wain-Hobson, S (corresponding author), Inst Pasteur, Mol Retrovirol Unit, 28 Rue Dr Roux, F-75724 Paris 15, France.	simon@pasteur.fr		Vartanian, Jean-Pierre/0000-0001-8079-8814				Arbyn M, 2007, J CLIN VIROL, V38, P189, DOI 10.1016/j.jcv.2006.12.009; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Cogliano V, 2005, LANCET ONCOL, V6, P204, DOI 10.1016/S1470-2045(05)70086-3; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Dang Y, 2006, J VIROL, V80, P10522, DOI 10.1128/JVI.01123-06; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Goodman Myron F, 2007, Adv Immunol, V94, P127, DOI 10.1016/S0065-2776(06)94005-X; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kinomoto M, 2007, NUCLEIC ACIDS RES, V35, P2955, DOI 10.1093/nar/gkm181; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Madsen P, 1999, J INVEST DERMATOL, V113, P162, DOI 10.1046/j.1523-1747.1999.00682.x; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; OhAinle M, 2006, J VIROL, V80, P3853, DOI 10.1128/JVI.80.8.3853-3862.2006; Okazaki Il-mi, 2007, Adv Immunol, V94, P245, DOI 10.1016/S0065-2776(06)94008-5; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Stunkel W, 1999, J VIROL, V73, P1918; Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102; Suspene R, 2005, J GEN VIROL, V86, P125, DOI 10.1099/vir.0.80426-0; Suspene R, 2004, NUCLEIC ACIDS RES, V32, P2421, DOI 10.1093/nar/gkh554; Trivedi NR, 2006, J INVEST DERMATOL, V126, P1071, DOI 10.1038/sj.jid.5700213; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	27	238	248	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					230	233		10.1126/science.1153201	http://dx.doi.org/10.1126/science.1153201			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403710				2022-12-28	WOS:000254836700043
J	Kleinman, ME; Yamada, K; Takeda, A; Chandrasekaran, V; Nozaki, M; Baffi, JZ; Albuquerque, RJC; Yamasaki, S; Itaya, M; Pan, YZ; Appukuttan, B; Gibbs, D; Yang, ZL; Kariko, K; Ambati, BK; Wilgus, TA; DiPietro, LA; Sakurai, E; Zhang, K; Smith, JR; Taylor, EW; Ambati, J				Kleinman, Mark E.; Yamada, Kiyoshi; Takeda, Atsunobu; Chandrasekaran, Vasu; Nozaki, Miho; Baffi, Judit Z.; Albuquerque, Romulo J. C.; Yamasaki, Satoshi; Itaya, Masahiro; Pan, Yuzhen; Appukuttan, Binoy; Gibbs, Daniel; Yang, Zhenglin; Kariko, Katalin; Ambati, Balamurali K.; Wilgus, Traci A.; DiPietro, Luisa A.; Sakurai, Eiji; Zhang, Kang; Smith, Justine R.; Taylor, Ethan W.; Ambati, Jayakrishna			Sequence- and target-independent angiogenesis suppression by siRNA via TLR3	NATURE			English	Article							TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; SMALL INTERFERING RNAS; IN-VIVO DELIVERY; NF-KAPPA-B; CHOROIDAL NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION; NEGATIVE REGULATOR; ENDOTHELIAL-CELLS; SIGNALING PATHWAY	Clinical trials of small interfering RNA ( siRNA) targeting vascular endothelial growth factor-A ( VEGFA) or its receptor VEGFR1 ( also called FLT1), in patients with blinding choroidal neovascularization ( CNV) from age- related macular degeneration, are premised on gene silencing by means of intracellular RNA interference ( RNAi). Weshow instead that CNV inhibition is a siRNA- class effect: 21- nucleotide or longer siRNAs targeting non- mammalian genes, non- expressed genes, non- genomic sequences, pro- and anti- angiogenic genes, and RNAi- incompetent siRNAs all suppressed CNV in mice comparably to siRNAs targeting Vegfa or Vegfr1 without off- target RNAi or interferon-alpha/beta activation. Non- targeted ( against non- mammalian genes) and targeted ( against Vegfa or Vegfr1) siRNA suppressed CNV via cell- surface toll- like receptor 3 ( TLR3), its adaptor TRIF, and induction of interferon-gamma and interleukin- 12. Non- targeted siRNA suppressed dermal neovascularization in mice as effectively as Vegfa siRNA. siRNA- induced inhibition of neovascularization required a minimum length of 21 nucleotides, a bridging necessity in a modelled 2: 1 TLR3 - RNA complex. Choroidal endothelial cells from people expressing the TLR3 coding variant 412FF were refractory to extracellular siRNA- induced cytotoxicity, facilitating individualized pharmacogenetic therapy. Multiple human endothelial cell types expressed surface TLR3, indicating that generic siRNAs might treat angiogenic disorders that affect 8% of the world's population, and that siRNAs might induce unanticipated vascular or immune effects.	[Kleinman, Mark E.; Yamada, Kiyoshi; Takeda, Atsunobu; Nozaki, Miho; Baffi, Judit Z.; Albuquerque, Romulo J. C.; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA; [Albuquerque, Romulo J. C.; Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY 40506 USA; [Chandrasekaran, Vasu] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; [Yamasaki, Satoshi; Itaya, Masahiro; Sakurai, Eiji] Nagoya City Univ, Sch Med, Dept Ophthalmol, Nagoya, Aichi 4678601, Japan; [Pan, Yuzhen; Appukuttan, Binoy; Smith, Justine R.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA; [Gibbs, Daniel; Yang, Zhenglin; Ambati, Balamurali K.; Zhang, Kang] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT 84132 USA; [Gibbs, Daniel; Yang, Zhenglin; Zhang, Kang] Univ Utah, Sch Med, Program Human Mol Biol & Genet, Eccles Inst Human Genet, Salt Lake City, UT 84132 USA; [Kariko, Katalin] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Ambati, Balamurali K.] Vet Affairs Salt Lake City Healthcare Syst, Salt Lake City, UT 84148 USA; [Wilgus, Traci A.; DiPietro, Luisa A.] Univ Illinois, Coll Dent, Ctr Wound Healing & Tissue Regenerat, Chicago, IL 60612 USA; [Taylor, Ethan W.] Univ N Carolina, Mol Med Lab, Greensboro, NC 27402 USA	University of Kentucky; University of Kentucky; University of North Carolina; University of North Carolina Chapel Hill; Nagoya City University; Oregon Health & Science University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Pennsylvania; US Department of Veterans Affairs; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of North Carolina; University of North Carolina Greensboro	Ambati, J (corresponding author), Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.	jamba2@email.uky.edu	Smith, Justine/Y-9044-2019; Peng, Chunwei/F-6788-2010; Zhang, Kang/Y-2740-2019	Smith, Justine/0000-0002-4756-5493; Zhang, Kang/0000-0002-4549-1697; Kleinman, Mark/0000-0001-8557-7949	NATIONAL EYE INSTITUTE [R01EY015422, R01EY018350, R01EY018836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050875] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY018350, R01 EY018836, R01 EY015422, R01 EY015422-04, R01 EY018836-01, R01 EY018350-02] Funding Source: Medline; NIGMS NIH HHS [R01 GM050875] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Battle TE, 2006, CANCER RES, V66, P3649, DOI 10.1158/0008-5472.CAN-05-3612; Bell JK, 2006, P NATL ACAD SCI USA, V103, P8792, DOI 10.1073/pnas.0603245103; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Cameron JS, 2007, J NEUROSCI, V27, P13033, DOI 10.1523/JNEUROSCI.4290-06.2007; Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Corey DR, 2007, NAT CHEM BIOL, V3, P8, DOI 10.1038/nchembio0107-8; de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310; Gay NJ, 2006, NAT REV IMMUNOL, V6, P693, DOI 10.1038/nri1916; Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103; Gowen BB, 2007, J IMMUNOL, V178, P5200, DOI 10.4049/jimmunol.178.8.5200; Heidel JD, 2004, NAT BIOTECHNOL, V22, P1579, DOI 10.1038/nbt1038; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; Lang KS, 2006, J CLIN INVEST, V116, P2456, DOI 10.1172/JCI28349; Lee HK, 2006, IMMUNITY, V24, P153, DOI 10.1016/j.immuni.2005.12.012; Lin Y, 2006, J IMMUNOL, V176, P4147, DOI 10.4049/jimmunol.176.7.4147; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237; Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103; Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P17696, DOI 10.1074/jbc.M700209200; Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P7668, DOI 10.1074/jbc.M610946200; Reich S, 2003, MOL VIS, V9, P210; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Saleh MC, 2006, NAT CELL BIOL, V8, P793, DOI 10.1038/ncb1439; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Smith JR, 2007, INVEST OPHTH VIS SCI, V48, P2676, DOI 10.1167/iovs.06-0598; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Takada E, 2007, MOL IMMUNOL, V44, P3633, DOI 10.1016/j.molimm.2007.04.021; VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581; Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang L, 2002, BIOCHEM BIOPH RES CO, V292, P860, DOI 10.1006/bbrc.2002.6710	55	722	789	5	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2008	452	7187					591	U1		10.1038/nature06765	http://dx.doi.org/10.1038/nature06765			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18368052	Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000254567200037
J	Alakeson, V				Alakeson, Vidhya			Let patients control the purse strings	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												vidhya.alakeson@hhs.gov						Alakeson V, 2007, CONTRIBUTION SELF DI; Alakeson V., 2007, PUTTING PATIENTS CON; *CAR SERV IMPR PRO, IND BUDG PIL PROGR; *COMM CROSS QUAL C, 2005, IMPR QUAL HLTH CAR M; Corben S, 2005, SELF MANAGEMENT LONG; *FLOR DEP CHILDR F, 2007, REP EFF SELF DIR CAR; *FLOR SELF DIR CAR, ABOUT FL SDC; Glasby J., 2006, DEV DIRECT PAYMENTS; GLASBY J, 2004, HLTH OPTION DIRECT P; Glendinning C, 2000, HEALTH SOC CARE COMM, V8, P192, DOI 10.1046/j.1365-2524.2000.00244.x; Grand JL, 2007, OTHER INVISIBLE HAND: DELIVERING PUBLIC SERVICES THROUGH CHOICE AND COMPETITION, P1; *HM GOV, 2007, PUTT PEOPL 1, P3; Leadbeater C., 2008, MAKING IT PERSONAL; LIPSEY D, 2007, OTHER INVISIBLE HAND, P182; *NAT CTR IND LIV, 2003, CLAR EV DIR PAYM PRA; PHILLIPS B, 2005, AC HLTH ANN RES M; Poll C., 2006, REPORT CONTROLS 1 PH; RANKIN J, 2005, GOOD CHOICE MENTAL H; *RW JOHNS FDN, 2006, CHOOS IND OV CASH CO	19	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR	2008	336	7648					807	809		10.1136/bmj.39524.400498.AD	http://dx.doi.org/10.1136/bmj.39524.400498.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	292ER	18403545	Green Published			2022-12-28	WOS:000255249800042
J	Yu, IM; Zhang, W; Holdaway, HA; Li, L; Kostyuchenko, VA; Chipman, PR; Kuhn, RJ; Rossmann, MG; Chen, J				Yu, I-Mei; Zhang, Wei; Holdaway, Heather A.; Li, Long; Kostyuchenko, Victor A.; Chipman, Paul R.; Kuhn, Richard J.; Rossmann, Michael G.; Chen, Jue			Structure of the immature dengue virus at low pH primes proteolytic maturation	SCIENCE			English	Article							BORNE ENCEPHALITIS-VIRUS; WEST-NILE-VIRUS; ENVELOPE GLYCOPROTEIN; MEMBRANE-FUSION; HETERODIMERIC ASSOCIATION; INFLUENZA HEMAGGLUTININ; CRYSTAL-STRUCTURE; CELL-SURFACE; FLAVIVIRUS; PROTEIN	Intracellular cleavage of immature flaviviruses is a critical step in assembly that generates the membrane fusion potential of the E glycoprotein. With cryo- electron microscopy we show that the immature dengue particles undergo a reversible conformational change at low pH that renders them accessible to furin cleavage. At a pH of 6.0, the E proteins are arranged in a herringbone pattern with the pr peptides docked onto the fusion loops, a configuration similar to that of the mature virion. After cleavage, the dissociation of pr is pH- dependent, suggesting that in the acidic environment of the trans- Golgi network pr is retained on the virion to prevent membrane fusion. These results suggest a mechanism by which flaviviruses are processed and stabilized in the host cell secretory pathway.	[Yu, I-Mei; Zhang, Wei; Holdaway, Heather A.; Li, Long; Kostyuchenko, Victor A.; Chipman, Paul R.; Kuhn, Richard J.; Rossmann, Michael G.; Chen, Jue] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chen, J (corresponding author), Purdue Univ, Dept Biol Sci, 915 W State St, W Lafayette, IN 47907 USA.	chenjue@purdue.edu	Kuhn, Richard/AAR-2722-2021; Li, Long/F-8892-2010	Kuhn, Richard/0000-0003-4148-1026; Chipman, Paul/0000-0003-3652-4087	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055672, U54AI057153] Funding Source: NIH RePORTER; NIAID NIH HHS [AI055672, 1-U54-AI-057153] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON SL, 1995, J VIROL, V69, P695, DOI 10.1128/JVI.69.2.695-700.1995; CIAMPOR F, 1992, VIROLOGY, V188, P14, DOI 10.1016/0042-6822(92)90730-D; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; GUIRAKHOO F, 1991, J GEN VIROL, V72, P1323, DOI 10.1099/0022-1317-72-6-1323; HEINZ FX, 1994, VIROLOGY, V198, P109, DOI 10.1006/viro.1994.1013; Kanai R, 2006, J VIROL, V80, P11000, DOI 10.1128/JVI.01735-06; Kielian M, 2006, NAT REV MICROBIOL, V4, P67, DOI 10.1038/nrmicro1326; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Li L, 2008, SCIENCE, V319, P1830, DOI 10.1126/science.1153263; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Nybakken GE, 2006, J VIROL, V80, P11467, DOI 10.1128/JVI.01125-06; Paroutis P, 2004, PHYSIOLOGY, V19, P207, DOI 10.1152/physiol.00005.2004; RANDOLPH VB, 1990, VIROLOGY, V174, P450, DOI 10.1016/0042-6822(90)90099-D; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; SARIOLA M, 1995, J CELL SCI, V108, P2465; SCHLESINGER S, 2001, FIELDS VIROLOGY, P895; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Stadler K, 1997, J VIROL, V71, P8475, DOI 10.1128/JVI.71.11.8475-8481.1997; Stiasny K, 1996, J VIROL, V70, P8142, DOI 10.1128/JVI.70.11.8142-8147.1996; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; WAHLBERG JM, 1989, J VIROL, V63, P4991, DOI 10.1128/JVI.63.12.4991-4997.1989; WENGLER G, 1989, J VIROL, V63, P2521, DOI 10.1128/JVI.63.6.2521-2526.1989; Zhang Y, 2004, STRUCTURE, V12, P1607, DOI 10.1016/j.str.2004.06.019; Zhang Y, 2003, EMBO J, V22, P2604, DOI 10.1093/emboj/cdg270; Zhang Y, 2007, J VIROL, V81, P6141, DOI 10.1128/JVI.00037-07	28	440	456	3	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1834	1837		10.1126/science.1153264	http://dx.doi.org/10.1126/science.1153264			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369148				2022-12-28	WOS:000254394000049
J	Levine, S; Nguyen, T; Taylor, N; Friscia, ME; Budak, MT; Rothenberg, P; Zhu, JL; Sachdeva, R; Sonnad, S; Kaiser, LR; Rubinstein, NA; Powers, SK; Shrager, JB				Levine, Sanford; Nguyen, Taitan; Taylor, Nyali; Friscia, Michael E.; Budak, Murat T.; Rothenberg, Pamela; Zhu, Jianliang; Sachdeva, Rajeev; Sonnad, Seema; Kaiser, Larry R.; Rubinstein, Neal A.; Powers, Scott K.; Shrager, Joseph B.			Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; UBIQUITIN-PROTEASOME PATHWAY; SKELETAL-MUSCLE; OXIDATIVE STRESS; INJURY; MECHANISMS; EXPRESSION; CYTOKINES; FAILURE; MYOSIN	Background: The combination of complete diaphragm inactivity and mechanical ventilation (for more than 18 hours) elicits disuse atrophy of myofibers in animals. We hypothesized that the same may also occur in the human diaphragm. Methods: We obtained biopsy specimens from the costal diaphragms of 14 brain-dead organ donors before organ harvest (case subjects) and compared them with intraoperative biopsy specimens from the diaphragms of 8 patients who were undergoing surgery for either benign lesions or localized lung cancer (control subjects). Case subjects had diaphragmatic inactivity and underwent mechanical ventilation for 18 to 69 hours; among control subjects diaphragmatic inactivity and mechanical ventilation were limited to 2 to 3 hours. We carried out histologic, biochemical, and gene-expression studies on these specimens. Results: As compared with diaphragm-biopsy specimens from controls, specimens from case subjects showed decreased cross-sectional areas of slow-twitch and fast-twitch fibers of 57% (P=0.001) and 53% (P=0.01), respectively, decreased glutathione concentration of 23% (P=0.01), increased active caspase-3 expression of 100% (P=0.05), a 200% higher ratio of atrogin-1 messenger RNA (mRNA) transcripts to MBD4 (a housekeeping gene) (P=0.002), and a 590% higher ratio of MuRF-1 mRNA transcripts to MBD4 (P=0.001). Conclusions: The combination of 18 to 69 hours of complete diaphragmatic inactivity and mechanical ventilation results in marked atrophy of human diaphragm myofibers. These findings are consistent with increased diaphragmatic proteolysis during inactivity.	[Levine, Sanford; Nguyen, Taitan; Taylor, Nyali; Friscia, Michael E.; Budak, Murat T.; Rothenberg, Pamela; Zhu, Jianliang; Sonnad, Seema; Kaiser, Larry R.; Shrager, Joseph B.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Rubinstein, Neal A.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; [Levine, Sanford; Budak, Murat T.; Rubinstein, Neal A.; Shrager, Joseph B.] Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA; [Levine, Sanford] Gift Life Donor Program, Philadelphia, PA USA; [Levine, Sanford; Nguyen, Taitan; Sachdeva, Rajeev; Shrager, Joseph B.] Dept Vet Affairs Med Ctr, Med Res Surg & Lab Med Serv, Philadelphia, PA 19104 USA; [Powers, Scott K.] Univ Florida, Ctr Exercise Sci, Gainesville, FL 32611 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; State University System of Florida; University of Florida	Levine, S (corresponding author), 1495 Wesleys Run, Gladwyne, PA 19035 USA.	sdlevine@mail.med.upenn.edu	Kaiser, Larry/L-7940-2019; Budak, Murat/I-8358-2013	Budak, Murat/0000-0002-5059-9651	NHLBI NIH HHS [R01-HL-078834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams GR, 2003, J APPL PHYSIOL, V95, P2185, DOI 10.1152/japplphysiol.00346.2003; AMADO JA, 1995, METABOLISM, V44, P812, DOI 10.1016/0026-0495(95)90198-1; Belperio JA, 2006, SEMIN RESP CRIT CARE, V27, P350, DOI 10.1055/s-2006-948289; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Castro MJ, 1999, J APPL PHYSIOL, V86, P350, DOI 10.1152/jappl.1999.86.1.350; Conover W.J., 1999, PRACTICAL NONPARAMET, V350; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Falk DJ, 2006, J APPL PHYSIOL, V101, P1017, DOI 10.1152/japplphysiol.00104.2006; Gayan-Ramirez G, 2005, CRIT CARE MED, V33, P2804, DOI 10.1097/01.CCM.0000191250.32988.A3; Hudson NJ, 2002, J EXP BIOL, V205, P2297; Laghi F, 2003, AM J RESP CRIT CARE, V167, P120, DOI 10.1164/rccm.200210-1246OC; Larionov A, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-62; Lawler JM, 1998, CAN J APPL PHYSIOL, V23, P23, DOI 10.1139/h98-002; Levine S, 2003, AM J RESP CRIT CARE, V168, P706, DOI 10.1164/rccm.200209-1070OC; Levine S, 2006, J APPL PHYSIOL, V101, P1297, DOI 10.1152/japplphysiol.01607.2005; MacIntyre NR, 2005, CHEST, V128, P3937, DOI 10.1378/chest.128.6.3937; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Moore AJ, 2006, J APPL PHYSIOL, V101, P1400, DOI 10.1152/japplphysiol.01614.2005; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; NAUMANN K, 1994, DIFFERENTIATION, V55, P203, DOI 10.1046/j.1432-0436.1994.5530203.x; Ohira Y, 2000, JPN J PHYSIOL, V50, P41, DOI 10.2170/jjphysiol.50.41; Powers SK, 2005, AM J PHYSIOL-REG I, V288, pR337, DOI 10.1152/ajpregu.00469.2004; Reid MB, 2005, AM J PHYSIOL-REG I, V288, pR1423, DOI 10.1152/ajpregu.00545.2004; Sacheck JM, 2007, FASEB J, V21, P140, DOI 10.1096/fj.06-6604com; Shanely RA, 2002, AM J RESP CRIT CARE, V166, P1369, DOI 10.1164/rccm.200202-088OC; Trapp R.G., 2004, BASIC CLIN BIOSTATIS, V4th; Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP; VATER R, 1994, HISTOCHEM J, V26, P916	29	884	969	4	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1327	1335		10.1056/NEJMoa070447	http://dx.doi.org/10.1056/NEJMoa070447			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367735				2022-12-28	WOS:000254308400003
J	Satoh, T; Arii, J; Suenaga, T; Wang, J; Kogure, A; Uehori, J; Arase, N; Shiratori, I; Tanaka, S; Kawaguchi, Y; Spear, PG; Lanier, LL; Arase, H				Satoh, Takeshi; Arii, Jun; Suenaga, Tadahiro; Wang, Jing; Kogure, Amane; Uehori, Junji; Arase, Noriko; Shiratori, Ikuo; Tanaka, Shinya; Kawaguchi, Yasushi; Spear, Patricia G.; Lanier, Lewis L.; Arase, Hisashi			PILR alpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B	CELL			English	Article							CELL-SURFACE RECEPTORS; HEPARAN-SULFATE; ARTIFICIAL CHROMOSOME; CRYSTAL-STRUCTURE; TYPE-1; PROTEIN; CONSTRUCTION; FUSION; BETA; HERPES-SIMPLEX-VIRUS-1	Glycoprotein B(gB) is one of the essential components for infection by herpes simplex virus-1 (HSV-1). Although several cellular receptors that associate with glycoprotein D(gD), such as herpes virus entry mediator (HVEM) and Nectin-1, have been identified, specific molecules that mediate HSV-1 infection by associating with gB have not been elucidated. Here, we found that paired immunoglobulin-like type 2 receptor (PILR) alpha associates with gB, and cells transduced with PILR alpha become susceptible to HSV-1 infection. Furthermore, HSV-1 infection of human primary cells expressing both HVEM and PILR alpha was blocked by either anti-PILR alpha or anti-HVEM antibody. Our results demonstrate that cellular receptors for both gB and gD are required for HSV-1 infection and that PILR alpha plays an important role in HSV-1 infection as a coreceptor that associates with gB. These findings uncover a crucial aspect of the mechanism underlying HSV-1 infection.	[Arase, Hisashi] Japan Sci & Technol Agcy, SORST, Kawaguchi, Saitama 3320012, Japan; [Satoh, Takeshi; Suenaga, Tadahiro; Wang, Jing; Kogure, Amane; Uehori, Junji; Arase, Noriko; Shiratori, Ikuo; Arase, Hisashi] Osaka Univ, Dept Immunochem, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; [Satoh, Takeshi; Suenaga, Tadahiro; Arase, Hisashi] Osaka Univ, WPI Immunl Frontier Res Ctr, Suita, Osaka 5650871, Japan; [Arii, Jun; Kawaguchi, Yasushi] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Dept Infect Dis Control,Minato Ku, Tokyo 1088639, Japan; [Tanaka, Shinya] Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido 0608638, Japan; [Spear, Patricia G.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; [Lanier, Lewis L.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Lanier, Lewis L.] Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94143 USA	Japan Science & Technology Agency (JST); Osaka University; Osaka University; University of Tokyo; Hokkaido University; Northwestern University; Feinberg School of Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Arase, H (corresponding author), Japan Sci & Technol Agcy, SORST, Kawaguchi, Saitama 3320012, Japan.	arase@biken.osaka-u.ac.jp	Lanier, Lewis L/E-2139-2014; Arase, Hisashi/C-8442-2009; Tanaka, Shinya/D-3586-2011; Satoh, Takeshi/O-3549-2014	Lanier, Lewis L/0000-0003-1308-3952; Arase, Hisashi/0000-0002-1153-3166; Satoh, Takeshi/0000-0001-8544-7423; Arase, Noriko/0000-0003-3966-3437; Wang, Jing/0000-0001-8758-1693; Shiratori, Ikuo/0000-0003-3713-4910; Kawaguchi, Yasushi/0000-0001-8232-6925	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036293, R01AI068129, P01AI064520, R01AI036293] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI036293-10, AI36293, R37 AI036293-08, R37 AI036293-13, R37 AI036293, R01 AI068129-08, R37 AI036293-12, R01 AI068129-06, R37 AI036293-06, AI64520, P01 AI064520, R01 AI068129-07, R37 AI036293-07, R37 AI036293-09, R37 AI036293-15, R37 AI036293-14, R37 AI036293-11, R01 AI068129] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; Bender FC, 2005, J VIROL, V79, P11588, DOI 10.1128/JVI.79.18.11588-11597.2005; CAL WH, 1988, J VIROL, V62, P2596, DOI 10.1128/JVI.62.8.2596-2604.1988; Chapman TL, 1999, J BIOL CHEM, V274, P6911, DOI 10.1074/jbc.274.11.6911; de Zarate IBO, 2004, J VIROL, V78, P1540, DOI 10.1128/JVI.78.3.1540-1551-2004; FORRESTER A, 1992, J VIROL, V66, P341, DOI 10.1128/JVI.66.1.341-348.1992; Fournier N, 2000, J IMMUNOL, V165, P1197, DOI 10.4049/jimmunol.165.3.1197; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Gianni T, 2005, J VIROL, V79, P2931, DOI 10.1128/JVI.79.5.2931-2940.2005; Heldwein EE, 2006, SCIENCE, V313, P217, DOI 10.1126/science.1126548; HEROLD BC, 1994, J GEN VIROL, V75, P1211, DOI 10.1099/0022-1317-75-6-1211; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; Kawaguchi Y, 1997, J VIROL, V71, P7328, DOI 10.1128/JVI.71.10.7328-7336.1997; Krummenacher C, 2005, EMBO J, V24, P4144, DOI 10.1038/sj.emboj.7600875; Laquerre S, 1998, J VIROL, V72, P6119, DOI 10.1128/JVI.72.7.6119-6130.1998; LIGAS MW, 1988, J VIROL, V62, P1486, DOI 10.1128/JVI.62.5.1486-1494.1988; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Mousseau DD, 2000, J BIOL CHEM, V275, P4467, DOI 10.1074/jbc.275.6.4467; Narayanan K, 1999, GENE THER, V6, P442, DOI 10.1038/sj.gt.3300901; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Roche S, 2006, SCIENCE, V313, P187, DOI 10.1126/science.1127683; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; Shiratori I, 2005, J IMMUNOL, V175, P4441, DOI 10.4049/jimmunol.175.7.4441; Shiratori I, 2004, J EXP MED, V199, P525, DOI 10.1084/jem.20031885; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; Subramanian RP, 2007, P NATL ACAD SCI USA, V104, P2903, DOI 10.1073/pnas.0608374104; Tanaka M, 2005, VIROLOGY, V341, P301, DOI 10.1016/j.virol.2005.07.010; Tanaka M, 2004, MICROBES INFECT, V6, P485, DOI 10.1016/j.micinf.2004.01.011; Tanaka M, 2003, J VIROL, V77, P1382, DOI 10.1128/JVI.77.2.1382-1391.2003; Turner A, 1998, J VIROL, V72, P873, DOI 10.1128/JVI.72.1.873-875.1998; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Whitley RJ, 2001, LANCET, V357, P1513, DOI 10.1016/S0140-6736(00)04638-9; Wilson MD, 2006, PHYSIOL GENOMICS, V27, P201, DOI 10.1152/physiolgenomics.00284.2005	35	210	234	2	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2008	132	6					935	944		10.1016/j.cell.2008.01.043	http://dx.doi.org/10.1016/j.cell.2008.01.043			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358807	Green Accepted, Bronze			2022-12-28	WOS:000254273600013
J	Feachem, R; Sabot, O				Feachem, Richard; Sabot, Oliver			A new global malaria eradication strategy	LANCET			English	Editorial Material							MOZAMBIQUE		[Sabot, Oliver] Clinton Fdn HIV AID Initiat, New York, NY USA; [Feachem, Richard] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Sabot, O (corresponding author), Clinton Fdn HIV AID Initiat, Quincy, MA 02169 USA.	osabot@clintonfoundation.org						*ALLAFRICA COM, 2006, NAM CROSS BORD IN LA; Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6; CHOUDHURY D S, 1985, Indian Journal of Pediatrics, V52, P243, DOI 10.1007/BF02754849; FEACHEM R, 2002, FINAL REPORT EXTERNA; Feachem RGA, 2007, JAMA-J AM MED ASSOC, V297, P2281, DOI 10.1001/jama.297.20.2281; Fegan GW, 2007, LANCET, V370, P1035, DOI 10.1016/S0140-6736(07)61477-9; Harrison G, 1978, MOSQUITOES MALARIA M; Humphreys M., 2001, MALARIA POVERTY RACE; *MAL NO MOR, 2008, WE CANT AFF WAIT BUS; Nyarango PM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-33; *PAC MAL IN, 2007, UNPUB 2 M MAL REF GR; Sharp BL, 2007, AM J TROP MED HYG, V76, P42, DOI 10.4269/ajtmh.2007.76.42; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; *SO AFR DEV COMM, 2007, SADC MAL STRAT PLAN; *UNICEF, 2007, ROLL BACK MAL PARTN; *WHO, 1956, INT ORGAN, V10, P642; World Health Organization, 2007, MAL EL FIELD MAN LOW	17	147	147	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 10	2008	371	9624					1633	1635		10.1016/S0140-6736(08)60424-9	http://dx.doi.org/10.1016/S0140-6736(08)60424-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	298VO	18374409	Green Submitted			2022-12-28	WOS:000255715400031
J	Dostert, C; Petrilli, V; Van Bruggen, R; Steele, C; Mossman, BT; Tschopp, J				Dostert, Catherine; Petrilli, Virginie; Van Bruggen, Robin; Steele, Chad; Mossman, Brooke T.; Tschopp, Jurg			Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica	SCIENCE			English	Article							CASPASE-1 ACTIVATION; PATHOGENESIS; MACROPHAGES; ANTAGONIST; MECHANISMS; RECEPTOR; GOUT; MICE; ATP	The inhalation of airborne pollutants, such as asbestos or silica, is linked to inflammation of the lung, fibrosis, and lung cancer. How the presence of pathogenic dust is recognized and how chronic inflammatory diseases are triggered are poorly understood. Here, we show that asbestos and silica are sensed by the Nalp3 inflammasome, whose subsequent activation leads to interleukin-1 beta secretion. Inflammasome activation is triggered by reactive oxygen species, which are generated by a NADPH oxidase upon particle phagocytosis. ( NADPH is the reduced form of nicotinamide adenine dinucleotide phosphate.) In a model of asbestos inhalation, Nalp3(-/-) mice showed diminished recruitment of inflammatory cells to the lungs, paralleled by lower cytokine production. Our findings implicate the Nalp3 inflammasome in particulate matter- related pulmonary diseases and support its role as a major proinflammatory "danger" receptor.	[Dostert, Catherine; Petrilli, Virginie; Tschopp, Jurg] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; [Van Bruggen, Robin] Sanquin Res, Dept Blood Cell Res, Amsterdam, Netherlands; [Van Bruggen, Robin] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; [Steele, Chad] Univ Alabama, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA; [Mossman, Brooke T.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA	University of Lausanne; University of Amsterdam; Academic Medical Center Amsterdam; University of Alabama System; University of Alabama Birmingham; University of Vermont	Tschopp, J (corresponding author), Univ Lausanne, Dept Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	jurg.tschopp@unil.ch	Petrilli, Virginie/ABI-8199-2020; Dostert, Catherine/AAJ-5473-2020	Petrilli, Virginie/0000-0001-8502-6979	NATIONAL CANCER INSTITUTE [P01CA114047] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067004] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA114047, P01 CA114047-01A10002] Funding Source: Medline; NHLBI NIH HHS [P01HL67004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Amer A, 2006, J BIOL CHEM, V281, P35217, DOI 10.1074/jbc.M604933200; Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Franchi L, 2007, J BIOL CHEM, V282, P18810, DOI 10.1074/jbc.M610762200; Haegens A, 2007, J IMMUNOL, V178, P1800, DOI 10.4049/jimmunol.178.3.1800; HANSEN K, 1987, CANCER RES, V47, P1681; Hawkins PN, 2003, NEW ENGL J MED, V348, P2583, DOI 10.1056/NEJM200306193482523; Kamp DW, 1999, THORAX, V54, P638, DOI 10.1136/thx.54.7.638; Krelin Y, 2007, CANCER RES, V67, P1062, DOI 10.1158/0008-5472.CAN-06-2956; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2004, CURR BIOL, V14, P1929, DOI 10.1016/j.cub.2004.10.027; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; PIGUET PF, 1993, CYTOKINE, V5, P57, DOI 10.1016/1043-4666(93)90024-Y; Ramos-Nino ME, 2006, J CELL BIOCHEM, V98, P723, DOI 10.1002/jcb.20828; Rimal B, 2005, CURR OPIN PULM MED, V11, P169, DOI 10.1097/01.mcp.0000152998.11335.24; Robledo RF, 2000, AM J PATHOL, V156, P1307, DOI 10.1016/S0002-9440(10)65001-8; Sabo-Attwood T, 2005, AM J PATHOL, V167, P1243, DOI 10.1016/S0002-9440(10)61212-6; Shukla A, 2003, FREE RADICAL BIO MED, V34, P1117, DOI 10.1016/S0891-5849(03)00060-1; So A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2143; Wang YH, 2004, INT J ONCOL, V25, P173	24	1916	1990	9	235	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2008	320	5876					674	677		10.1126/science.1156995	http://dx.doi.org/10.1126/science.1156995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	295DD	18403674	Green Submitted, Green Accepted			2022-12-28	WOS:000255454300049
J	Kummamuru, RK; Soh, YA				Kummamuru, Ravi K.; Soh, Yeong-Ah			Electrical effects of spin density wave quantization and magnetic domain walls in chromium	NATURE			English	Article							FIELD DEPENDENCE; CR(001) FILMS; LAYERS; ANTIFERROMAGNETISM; MAGNETORESISTANCE; TEMPERATURE; MULTILAYERS	The role of magnetic domains ( and the walls between domains) in determining the electrical properties of ferromagnetic materials(1) has been investigated in great detail for many years, not least because control over domains offers a means of manipulating electron spin to control charge transport in 'spintronic' devices(2). In contrast, much less attention has been paid to the effects of domains and domain walls on the electrical properties of antiferromagnets: antiferromagnetic domains show no net external magnetic moment, and so are difficult to manipulate or probe. Here we describe electrical measurements on chromium - a simple metal and quintessential spin density wave antiferromagnet(3) - that show behaviour directly related to spin density wave formation and the presence of antiferromagnetic domains. Two types of thermal hysteresis are seen in both longitudinal and Hall resistivity: the first can be explained by the quantization of spin density waves due to the finite film thickness ( confirmed by X- ray diffraction measurements) and the second by domain- wall scattering of electrons(4,5). We also observe the striking influence of the electrical lead configuration ( a mesoscopic effect) on the resistivity of macroscopic samples in the spin density wave state. Our results are potentially of practical importance, in that they reveal tunable electrical effects of film thickness and domain walls that are as large as the highest seen for ferromagnets(6,7).	[Kummamuru, Ravi K.; Soh, Yeong-Ah] Dartmouth Coll, Dept Phys & Astron, Hanover, NH 03755 USA	Dartmouth College	Soh, YA (corresponding author), Univ Illinois, Dept Mat Sci & Engn, 1304 W Green St, Urbana, IL 61801 USA.	yeong-ah.soh@dartmouth.edu	Kummamuru, Ravi K/C-3890-2009					ARKO AJ, 1968, PHYS REV, V1, P671; BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; Bazaliy YB, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.144423; Bode M, 2006, NAT MATER, V5, P477, DOI 10.1038/nmat1646; Bodeker P, 1998, PHYS REV LETT, V81, P914, DOI 10.1103/PhysRevLett.81.914; Ebels U, 2000, PHYS REV LETT, V84, P983, DOI 10.1103/PhysRevLett.84.983; Evans PG, 2002, SCIENCE, V295, P1042, DOI 10.1126/science.1066870; FAWCETT E, 1988, REV MOD PHYS, V60, P209, DOI 10.1103/RevModPhys.60.209; Fishman RS, 1999, PHYS REV B, V59, P13849, DOI 10.1103/PhysRevB.59.13849; Fullerton EE, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.237201; FURUYA Y, 1976, J PHYS SOC JPN, V40, P490, DOI 10.1143/JPSJ.40.490; HILL JP, 1995, PHYS REV B, V51, P10336, DOI 10.1103/PhysRevB.51.10336; Jaramillo R, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.117206; LAURENT DG, 1981, PHYS REV B, V23, P4977, DOI 10.1103/PhysRevB.23.4977; Lee M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.187201; LOMER WM, 1962, P PHYS SOC LOND, V80, P489, DOI 10.1088/0370-1328/80/2/316; Marrows CH, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.097206; Marrows CH, 2005, ADV PHYS, V54, P585, DOI 10.1080/00018730500442209; Mibu K, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.287202; MICHEL RP, 1991, PHYS REV B, V44, P7413, DOI 10.1103/PhysRevB.44.7413; MUIR WB, 1971, PHYS REV B, V4, P988, DOI 10.1103/PhysRevB.4.988; Niklasson AMN, 1999, PHYS REV LETT, V82, P4544, DOI 10.1103/PhysRevLett.82.4544; Norman MR, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.116601; ROTENBERG E, 2005, J PHYS; Shi ZP, 1997, PHYS REV LETT, V78, P1351, DOI 10.1103/PhysRevLett.78.1351; Shpyrko OG, 2007, NATURE, V447, P68, DOI 10.1038/nature05776; Sonntag P, 1998, J MAGN MAGN MATER, V183, P5, DOI 10.1016/S0304-8853(97)01056-1; Takeda M, 2000, J PHYS SOC JPN, V69, P1590, DOI 10.1143/JPSJ.69.1590; WERNER SA, 1967, PHYS REV, V155, P528, DOI 10.1103/PhysRev.155.528; Yeh A, 2002, NATURE, V419, P459, DOI 10.1038/nature01044; Zutic I, 2004, REV MOD PHYS, V76, P323, DOI 10.1103/RevModPhys.76.323	32	40	43	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2008	452	7189					859	U4		10.1038/nature06826	http://dx.doi.org/10.1038/nature06826			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18421350				2022-12-28	WOS:000255026000045
J	Murai, KK; Pasquale, EB				Murai, Keith K.; Pasquale, Elena B.			Axons seek neighborly advice	SCIENCE			English	Editorial Material							TYROSINE KINASE; MOTOR-NEURONS; CHICK HINDLIMB; EXPRESSION; LIMB; PROJECTIONS; LIGANDS		[Murai, Keith K.] McGill Univ, Ctr Hlth, Montreal Gen Hosp, Ctr Res Neurosci,Dept Neurol & Neurosurg, Montreal, PQ H3G 1A4, Canada; [Pasquale, Elena B.] Burnham Inst, La Jolla, CA 92037 USA; [Pasquale, Elena B.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	McGill University; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Murai, KK (corresponding author), McGill Univ, Ctr Hlth, Montreal Gen Hosp, Ctr Res Neurosci,Dept Neurol & Neurosurg, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	keith.murai@mcgill.ca; elenap@burnham.org						Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Eberhart J, 2004, J NEUROSCI, V24, P1070, DOI 10.1523/JNEUROSCI.4719-03.2004; Gallarda BW, 2008, SCIENCE, V320, P233, DOI 10.1126/science.1153758; Helmbacher F, 2000, DEVELOPMENT, V127, P3313; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Honig MG, 1998, DEVELOPMENT, V125, P995; Iwamasa H, 1999, DEV GROWTH DIFFER, V41, P685; Kania A, 2003, NEURON, V38, P581, DOI 10.1016/S0896-6273(03)00292-7; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; LANDMESSER L, 1986, DEV BIOL, V118, P511, DOI 10.1016/0012-1606(86)90023-0; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Luo LQ, 2007, NEURON, V56, P284, DOI 10.1016/j.neuron.2007.10.014; Marquardt T, 2005, CELL, V121, P127, DOI 10.1016/j.cell.2005.01.020; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Serizawa S, 2006, CELL, V127, P1057, DOI 10.1016/j.cell.2006.10.031; SOANS C, 1994, ONCOGENE, V9, P3353	16	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2008	320	5873					185	186		10.1126/science.1157605	http://dx.doi.org/10.1126/science.1157605			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403698				2022-12-28	WOS:000254836700028
J	Boesz, C; Lloyd, N				Boesz, Christine; Lloyd, Nigel			Collaborations: Investigating international misconduct	NATURE			English	Editorial Material									[Boesz, Christine] Natl Sci Fdn, Arlington, VA 22230 USA; [Lloyd, Nigel] Nat Sci & Engn Res Council Canada, Ottawa, ON K1A 1H5, Canada	National Science Foundation (NSF)	Boesz, C (corresponding author), Natl Sci Fdn, 4201 Wilson Blvd, Arlington, VA 22230 USA.								0	13	13	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2008	452	7188					686	687		10.1038/452686a	http://dx.doi.org/10.1038/452686a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401384				2022-12-28	WOS:000254792500019
J	Oertel, YC; Odegbile, A				Oertel, Yolanda C.; Odegbile, Adedotun			Fine-needle aspiration in rural areas	LANCET			English	Editorial Material							FNA CYTOLOGY; DIAGNOSIS; COST		[Oertel, Yolanda C.; Odegbile, Adedotun] Washington Hosp Ctr, Washington, DC 20010 USA	MedStar Washington Hospital Center	Oertel, YC (corresponding author), Washington Hosp Ctr, Washington, DC 20010 USA.	Yolanda.C.Oertel@medstar.net						FOX CH, 1979, LANCET, V1, P1387; HAAS S, 1993, AM J MED, V94, P357, DOI 10.1016/0002-9343(93)90145-F; Lahiri S K, 2001, Indian J Public Health, V45, P43; Malami S, 2006, CANCER CYTOPATHOL, V108, P433; Malami S, 2006, CANCER CYTOPATHOL, V108, P424; Mayall F, 1998, J CLIN PATHOL, V51, P541, DOI 10.1136/jcp.51.7.541; MELKERT PWJ, 1990, ACTA CYTOL, V34, P677; OERTEL YC, 1993, SOUTHERN MED J, V86, P282, DOI 10.1097/00007611-199303000-00004; Reyes CV, 2005, AM J CLIN PATHOL, V124, P631; Smith BR, 2006, THYROID, V16, P109, DOI 10.1089/thy.2006.16.109; Spillane AJ, 1999, AUST NZ J SURG, V69, P178, DOI 10.1046/j.1440-1622.1999.01518.x; Thomas JO, 1999, CYTOPATHOLOGY, V10, P206, DOI 10.1046/j.1365-2303.1999.00187.x; Zardawi IM, 1998, ACTA CYTOL, V42, P899, DOI 10.1159/000331965	13	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2008	371	9619					1147	1148		10.1016/S0140-6736(08)60503-6	http://dx.doi.org/10.1016/S0140-6736(08)60503-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395564				2022-12-28	WOS:000254956000009
J	Bang, AG; Carpenter, MK				Bang, Anne G.; Carpenter, Melissa K.			Development - Deconstructing pluripotency	SCIENCE			English	Editorial Material							STEM-CELLS; DNA METHYLATION; FIBROBLASTS; MOUSE; GENERATION; MICRORNAS		[Bang, Anne G.; Carpenter, Melissa K.] Novocell Inc, San Diego, CA 92121 USA		Bang, AG (corresponding author), Novocell Inc, 3550 Gen Atom Court, San Diego, CA 92121 USA.	mcarpenter@novocell.com						AOI T, 2008, SCIENCE         0214, DOI DOI 10.1126/SCIENCE.1154884; Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P268, DOI 10.1038/nsmb.1399; Brambrink T, 2008, CELL STEM CELL, V2, P151, DOI 10.1016/j.stem.2008.01.004; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Meissner A, 2007, NAT BIOTECHNOL, V25, P1177, DOI 10.1038/nbt1335; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Polesskaya A, 2007, GENE DEV, V21, P1125, DOI 10.1101/gad.415007; Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391; Stadler BM, 2008, CELL, V132, P563, DOI 10.1016/j.cell.2008.02.005; Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	21	11	12	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					58	59		10.1126/science.1157042	http://dx.doi.org/10.1126/science.1157042			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388280				2022-12-28	WOS:000254633000025
J	Benford, G				Benford, Gregory			Arthur C. Clarke (1917-2008) - Obituary	NATURE			English	Biographical-Item									[Benford, Gregory] Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA	University of California System; University of California Irvine	Benford, G (corresponding author), Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA.	xbenford@aol.com							0	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2008	452	7187					546	546		10.1038/452546a	http://dx.doi.org/10.1038/452546a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385726	Bronze			2022-12-28	WOS:000254567200030
J	Lambert, F; Delmonte, B; Petit, JR; Bigler, M; Kaufmann, PR; Hutterli, MA; Stocker, TF; Ruth, U; Steffensen, JP; Maggi, V				Lambert, F.; Delmonte, B.; Petit, J. R.; Bigler, M.; Kaufmann, P. R.; Hutterli, M. A.; Stocker, T. F.; Ruth, U.; Steffensen, J. P.; Maggi, V.			Dust-climate couplings over the past 800,000 years from the EPICA Dome C ice core	NATURE			English	Article							LAST GLACIAL MAXIMUM; EAST ANTARCTICA; SOUTHERN-OCEAN; PRODUCTIVITY; TRANSPORT; RECORD; RECONSTRUCTION; TEMPERATURE; CYCLE	Dust can affect the radiative balance of the atmosphere by absorbing or reflecting incoming solar radiation(1); it can also be a source of micronutrients, such as iron, to the ocean(2). It has been suggested that production, transport and deposition of dust is influenced by climatic changes on glacial-interglacial timescales(3-6). Here we present a high- resolution record of aeolian dust from the EPICA Dome C ice core in East Antarctica, which provides an undisturbed climate sequence over the past eight climatic cycles(7,8). We find that there is a significant correlation between dust flux and temperature records during glacial periods that is absent during interglacial periods. Our data suggest that dust flux is increasingly correlated with Antarctic temperature as the climate becomes colder. We interpret this as progressive coupling of the climates of Antarctic and lower latitudes. Limited changes in glacial-interglacial atmospheric transport time(4,9,10) suggest that the sources and lifetime of dust are the main factors controlling the high glacial dust input. We propose that the observed similar to 25-fold increase in glacial dust flux over all eight glacial periods can be attributed to a strengthening of South American dust sources, together with a longer lifetime for atmospheric dust particles in the upper troposphere resulting from a reduced hydrological cycle during the ice ages.	[Petit, J. R.] Univ Grenoble 1, CNRS, Lab Glaciol & Geophys Environm, F-38402 St Martin Dheres, France; [Lambert, F.; Bigler, M.; Kaufmann, P. R.; Stocker, T. F.] Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; [Lambert, F.; Kaufmann, P. R.; Stocker, T. F.] Univ Bern, Oeschger Ctr Climate Change Res, CH-3012 Bern, Switzerland; [Delmonte, B.; Maggi, V.] Univ Milano Bicocca, Dept Environm Sci, I-20126 Milan, Italy; [Bigler, M.; Steffensen, J. P.] Univ Copenhagen, Niels Bohr Inst, Ctr Ice & Climate, DK-2100 Copenhagen OE, Denmark; [Hutterli, M. A.] British Antarctic Survey, Cambridge CB3 0ET, England; [Ruth, U.] Alfred Wegener Inst Polar & Marine Res, D-27568 Bremerhaven, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Bern; University of Bern; University of Milano-Bicocca; University of Copenhagen; Niels Bohr Institute; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Petit, JR (corresponding author), Univ Grenoble 1, CNRS, Lab Glaciol & Geophys Environm, BP96, F-38402 St Martin Dheres, France.	petit@lgge.obs.ujf-grenoble.fr	Lambert, Fabrice/M-2003-2014; Delmonte, Barbara/L-2555-2015; Maggi, Valter/AAX-5728-2020; Maggi, Valter/E-1878-2014; Stocker, Thomas/B-1273-2013	Lambert, Fabrice/0000-0002-2192-024X; Maggi, Valter/0000-0001-6287-1213; Steffensen, Jorgen Peder/0000-0002-5516-1093; Delmonte, Barbara/0000-0002-9074-2061	NERC [bas010016] Funding Source: UKRI; Natural Environment Research Council [bas010016] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Augustin L, 2004, NATURE, V429, P623, DOI 10.1038/nature02599; Chase Z, 2001, PALEOCEANOGRAPHY, V16, P468, DOI 10.1029/2000PA000542; Delmonte B, 2004, CLIM DYNAM, V23, P427, DOI 10.1007/s00382-004-0450-9; Delmonte B, 2002, CLIM DYNAM, V18, P647, DOI 10.1007/s00382-001-0193-9; Fischer H, 2007, EARTH PLANET SC LETT, V260, P340, DOI 10.1016/j.epsl.2007.06.014; Fujii Y., 2003, MEM NATL I PLR R SI, V57, P46; Fung IY, 2000, GLOBAL BIOGEOCHEM CY, V14, P281, DOI 10.1029/1999GB900059; Gersonde R, 2005, QUATERNARY SCI REV, V24, P869, DOI 10.1016/j.quascirev.2004.07.015; Iriondo M, 2000, QUATERN INT, V68, P83, DOI 10.1016/S1040-6182(00)00035-5; Jouzel J, 2007, SCIENCE, V317, P793, DOI 10.1126/science.1141038; Kohfeld KE, 2001, EARTH-SCI REV, V54, P81, DOI 10.1016/S0012-8252(01)00042-3; Krinner G, 2003, TELLUS B, V55, P54, DOI 10.1034/j.1600-0889.2003.00004.x; Kukla G., 1994, T ROY SOC EDIN-EARTH, V81, P263; KUMAR N, 1995, NATURE, V378, P675, DOI 10.1038/378675a0; LISIECKI LE, 2005, PALEOCEANOGRAPHY, V0020; Lunt DJ, 2001, GEOPHYS RES LETT, V28, P295, DOI 10.1029/2000GL012170; Mahowald N, 1999, J GEOPHYS RES-ATMOS, V104, P15895, DOI 10.1029/1999JD900084; Mahowald NM, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006653; Markgraf V, 2000, QUATERNARY SCI REV, V19, P125, DOI 10.1016/S0277-3791(99)00058-X; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Revel-Rolland M, 2006, EARTH PLANET SC LETT, V249, P1, DOI 10.1016/j.epsl.2006.06.028; Steffensen JP, 1997, J GEOPHYS RES-OCEANS, V102, P26755, DOI 10.1029/97JC01490; Stenni B, 2004, EARTH PLANET SC LETT, V217, P183, DOI 10.1016/S0012-821X(03)00574-0; Stuut JBW, 2004, QUATERNARY RES, V62, P301, DOI 10.1016/j.yqres.2004.08.001; Sun YB, 2006, QUATERNARY SCI REV, V25, P33, DOI 10.1016/j.quascirev.2005.07.005; Tegen I, 2003, QUATERNARY SCI REV, V22, P1821, DOI 10.1016/S0277-3791(03)00163-X; Werner M, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002365; Wolff EW, 2006, NATURE, V440, P491, DOI 10.1038/nature04614; Yung YL, 1996, SCIENCE, V271, P962, DOI 10.1126/science.271.5251.962	29	461	477	2	170	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2008	452	7187					616	619		10.1038/nature06763	http://dx.doi.org/10.1038/nature06763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385736	Bronze, Green Published			2022-12-28	WOS:000254567200042
J	Vinokur, VM; Baturina, TI; Fistul, MV; Mironov, AY; Baklanov, MR; Strunk, C				Vinokur, Valerii M.; Baturina, Tatyana I.; Fistul, Mikhail V.; Mironov, Aleksey Yu.; Baklanov, Mikhail R.; Strunk, Christoph			Superinsulator and quantum synchronization	NATURE			English	Article							TUNNEL-JUNCTIONS; ARRAYS; CHARGE	Synchronized oscillators are ubiquitous in nature(1), and synchronization plays a key part in various classical and quantum phenomena. Several experiments(2-4) have shown that in thin superconducting films, disorder enforces the droplet- like electronic texture - superconducting islands immersed into a normal matrix - and that tuning disorder drives the system from superconducting to insulating behaviour. In the vicinity of the transition, a distinct state(4) forms: a Cooper- pair insulator, with thermally activated conductivity. It results from synchronization of the phase of the superconducting order parameter at the islands across the whole system(5). Here we show that at a certain finite temperature, a Cooper- pair insulator undergoes a transition to a superinsulating state with infinite resistance. We present experimental evidence of this transition in titanium nitride films and show that the superinsulating state is dual to the superconducting state: it is destroyed by a sufficiently strong critical magnetic field, and breaks down at some critical voltage that is analogous to the critical current in superconductors.	[Vinokur, Valerii M.; Baturina, Tatyana I.] Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; [Baturina, Tatyana I.; Mironov, Aleksey Yu.] Russian Acad Sci, Inst Semicond Phys, Novosibirsk 630090, Russia; [Baturina, Tatyana I.; Mironov, Aleksey Yu.; Strunk, Christoph] Univ Regensburg, Inst Expt Angew Phys, D-93040 Regensburg, Germany; [Fistul, Mikhail V.] Ruhr Univ Bochum, D-44801 Bochum, Germany; [Baklanov, Mikhail R.] IMEC, B-3001 Louvain, Belgium	United States Department of Energy (DOE); Argonne National Laboratory; Russian Academy of Sciences; Rzhanov Institute of Semiconductor Physics, Siberian Branch, Russian Academy of Sciences; University of Regensburg; Ruhr University Bochum; IMEC	Vinokur, VM (corresponding author), Argonne Natl Lab, Div Mat Sci, 9700 S Cass Ave, Argonne, IL 60439 USA.	vinokour@anl.gov	Fistul, Mikhail/AAD-2185-2022; Strunk, Christoph/AFT-9823-2022; Baturina, Tatyana/AAA-1588-2022; Vinokur, Valerii M/J-7299-2013; Baklanov, Mikhail/D-4672-2016; Mironov, Alexey Yu/F-7555-2017; Mironov, Alexey/AAD-5670-2021	Strunk, Christoph/0000-0001-9982-0022; Baklanov, Mikhail/0000-0002-9677-1293; Mironov, Alexey/0000-0003-4148-0752				Altland A, 2006, ANN PHYS-NEW YORK, V321, P2566, DOI 10.1016/j.aop.2005.12.012; Averin D., 1991, MESOSCOPIC PHENOMENA, P173, DOI DOI 10.1016/B978-0-444-88454-1.50012-7; Baturina TI, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.127003; Baturina TI, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.257003; Beloborodov IS, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.014502; Efetov KB, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.174205; FAZIO R, 1991, PHYS REV B, V43, P5307, DOI 10.1103/PhysRevB.43.5307; Fistul MV, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.086805; GANTMAKHER VF, 1996, SOV PHYS JETP, V82, P951; INGOLD GL, 1992, NATO ADV SCI I B-PHY, V294, P21; INGOLD GL, 1998, QUANTUM TRANSPORT DI, P213; Koval Y, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.087004; KOWAL D, 1994, SOLID STATE COMMUN, V90, P783, DOI 10.1016/0038-1098(94)90242-9; LANDAU LD, 2003, QUANTUM MECH, P142; Lopatin AV, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.092201; Lotkhov SV, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.197002; MATVEEV KA, 1993, PHYS REV LETT, V70, P2940, DOI 10.1103/PhysRevLett.70.2940; MOOIJ JE, 1990, PHYS REV LETT, V65, P645, DOI 10.1103/PhysRevLett.65.645; Pikovsky A, 2001, SYNCHRONIZATION UNIV; TINKHAM M, 1996, INTRO SUPERCONDUCTIV, pCH6	21	168	170	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2008	452	7187					613	U5		10.1038/nature06837	http://dx.doi.org/10.1038/nature06837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385735	Green Published			2022-12-28	WOS:000254567200041
J	Haver, KE; Hartnick, CJ; Ryan, DP; Shailam, R; Mark, EJ; Pasternack, MS; Pilch, BZ; Harris, NL				Haver, Kenan E.; Hartnick, Christopher J.; Ryan, Daniel P.; Shailam, Randheer; Mark, Eugene J.; Pasternack, Mark S.; Pilch, Ben Z.; Harris, Nancy Lee			A girl with dyspnea on exertion - Glomus tumor of the trachea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									[Haver, Kenan E.] Massachusetts Gen Hosp, Pediat Pulm Unit, Boston, MA 02114 USA; [Ryan, Daniel P.] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA; [Shailam, Randheer] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Mark, Eugene J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Hartnick, Christopher J.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA; [Haver, Kenan E.] Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; [Hartnick, Christopher J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Cambridge, MA 02138 USA; [Ryan, Daniel P.] Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA; [Shailam, Randheer] Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; [Mark, Eugene J.] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard University; Harvard University; Harvard University; Harvard University	Haver, KE (corresponding author), Massachusetts Gen Hosp, Pediat Pulm Unit, Boston, MA 02114 USA.							Altinok T, 2006, J THORAC CARDIOV SUR, V132, P201, DOI 10.1016/j.jtcvs.2006.03.032; Chan J, 2005, ANZ J SURG, V75, P252, DOI 10.1111/j.1445-2197.2005.03341.x; Doody DP, 2004, SURG TRACHEA BRONCHI; FABICH DR, 1980, CANCER-AM CANCER SOC, V45, P2337, DOI 10.1002/1097-0142(19800501)45:9<2337::AID-CNCR2820450917>3.0.CO;2-3; Folpe AL, 2001, AM J SURG PATHOL, V25, P1, DOI 10.1097/00000478-200101000-00001; Fridlender ZG, 2005, CHEST, V128, P1057, DOI 10.1378/chest.128.2.1057; Gaissert HA, 2006, ANN THORAC SURG, V82, P268, DOI 10.1016/j.athoracsur.2006.01.065; GAISSERT HA, 1994, J PEDIATR SURG, V29, P192, DOI 10.1016/0022-3468(94)90316-6; GARCIAPRATS MD, 1991, HISTOPATHOLOGY, V19, P459, DOI 10.1111/j.1365-2559.1991.tb00237.x; Gowan RT, 2001, ANN THORAC SURG, V72, P598, DOI 10.1016/S0003-4975(00)02278-5; GRILLO HC, 1990, ANN THORAC SURG, V49, P69, DOI 10.1016/0003-4975(90)90358-D; HEARD BE, 1982, THORAX, V37, P97, DOI 10.1136/thx.37.2.97; ITO H, 1988, PATHOL RES PRACT, V183, P778, DOI 10.1016/S0344-0338(88)80065-7; Kayser K, 2001, VIRCHOWS ARCH, V438, P192, DOI 10.1007/s004280000287; Kim TS, 2005, J COMPUT ASSIST TOMO, V29, P633, DOI 10.1097/01.rct.0000168363.60191.f8; Menaissy YM, 2000, ANN THORAC SURG, V70, P295, DOI 10.1016/S0003-4975(00)01285-6; Naiman AN, 2004, INT J PEDIATR OTORHI, V68, P1469, DOI 10.1016/j.ijporl.2004.06.006; SHIN DH, 1990, CHEST, V98, P1021, DOI 10.1378/chest.98.4.1021	18	12	12	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1382	1390		10.1056/NEJMcpc0800629	http://dx.doi.org/10.1056/NEJMcpc0800629			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367742				2022-12-28	WOS:000254308400011
J	Tullet, JMA; Hertweck, M; An, JH; Baker, J; Hwang, JY; Liu, S; Oliveira, RP; Baumeister, R; Blackwell, TK				Tullet, Jennifer M. A.; Hertweck, Maren; An, Jae Hyung; Baker, Joseph; Hwang, Ji Yun; Liu, Shu; Oliveira, Riva P.; Baumeister, Ralf; Blackwell, T. Keith			Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans	CELL			English	Article							RESTRICTION-INDUCED LONGEVITY; EXTENDS LIFE-SPAN; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; DIETARY RESTRICTION; DAF-16; GENE; RESISTANCE; PROTEINS; MUTATION	Insulin/IGF-1-like signaling (IIS) is central to growth and metabolism and has a conserved role in aging. In C. elegans, reductions in IIS increase stress resistance and longevity, effects that require the IIS-inhibited FOXO protein DAF-16. The C. elegans transcription factor SKN-1 also defends against oxidative stress by mobilizing the conserved phase 2 detoxification response. Here we show that IIS not only opposes DAF-16 but also directly inhibits SKN-1 in parallel. The IIS kinases AKT-1, -2, and SGK-1 phosphorylate SKN-1, and reduced IIS leads to constitutive SKN-1 nuclear accumulation in the intestine and SKN-1 target gene activation. SKN-1 contributes to the increased stress tolerance and longevity resulting from reduced IIS and delays aging when expressed transgenically. Furthermore, SKN-1 that is constitutively active increases life span independently of DAF-16. Our findings indicate that the transcription network regulated by SKN-1 promotes longevity and is an important direct target of IIS.	[Tullet, Jennifer M. A.; An, Jae Hyung; Baker, Joseph; Oliveira, Riva P.; Blackwell, T. Keith] Harvard Univ, Sch Med, Harvard Stem Cell Inst,Dept Pathol, Joslin Diabet Ctr,Sect Dev & Stem Cell Biol, Boston, MA 02215 USA; [Hertweck, Maren; Liu, Shu; Baumeister, Ralf] Univ Freiburg, ZBMZ, Ctr Biochem & Mol Cell Res, Fac Med,Bioinformat & Mol Genet Fac Biol, D-79104 Freiburg, Germany; [An, Jae Hyung; Hwang, Ji Yun] Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea; [Baumeister, Ralf] Univ Freiburg, Ctr Syst Biol ZBSA, D-79104 Freiburg, Germany	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of Freiburg; Yonsei University; University of Freiburg	Blackwell, TK (corresponding author), Harvard Univ, Sch Med, Harvard Stem Cell Inst,Dept Pathol, Joslin Diabet Ctr,Sect Dev & Stem Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA.	keith.blackwell@joslin.harvard.edu	Oliveira, Riva/J-8408-2013; Tullet, Jennifer/C-1779-2008	Oliveira, Riva/0000-0002-4917-7646; de Paula Oliveira, Riva/0000-0002-6092-6142; Tullet, Jennifer/0000-0002-2037-526X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062891, F32GM070088] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK07260] Funding Source: Medline; NIGMS NIH HHS [R01 GM062891-08, R01 GM062891-05, R01 GM062891, 2 R01 GM062891, R01 GM062891-06, 5 F32 GM070088-02, R01 GM062891-07] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803; An JH, 2005, P NATL ACAD SCI USA, V102, P16275, DOI 10.1073/pnas.0508105102; Antebi A, 2007, PLOS GENET, V3, P1565, DOI 10.1371/journal.pgen.0030129; Arantes-Oliveira N, 2002, SCIENCE, V295, P502, DOI 10.1126/science.1065768; Berdichevsky A, 2006, CELL, V125, P1165, DOI 10.1016/j.cell.2006.04.036; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FRIEDMAN DB, 1988, GENETICS, V118, P75; Gems D, 1998, GENETICS, V150, P129; Goldstein BJ, 2005, DIABETES, V54, P311, DOI 10.2337/diabetes.54.2.311; Gottesmann B., 1994, HALLESCHES JB GEOWIS, V16, P23; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Houthoofd K, 2002, EXP GERONTOL, V37, P1371, DOI 10.1016/S0531-5565(02)00173-0; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Inoue H, 2005, GENE DEV, V19, P2278, DOI 10.1101/gad.1324805; Kell A, 2007, FREE RADICAL BIO MED, V43, P1560, DOI 10.1016/j.freeradbiomed.2007.08.025; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lithgow GJ, 2002, MECH AGEING DEV, V123, P765, DOI 10.1016/S0047-6374(01)00422-5; McMahon M, 2001, CANCER RES, V61, P3299; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Rea SL, 2007, PLOS BIOL, V5, P2312, DOI 10.1371/journal.pbio.0050259; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190	42	620	649	2	84	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2008	132	6					1025	1038		10.1016/j.cell.2008.01.030	http://dx.doi.org/10.1016/j.cell.2008.01.030			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358814	Green Accepted, Bronze			2022-12-28	WOS:000254273600020
J	Boutin, AT; Weidemann, A; Fu, ZX; Mesropian, L; Gradin, K; Jamora, C; Wiesener, M; Eckardt, KU; Koch, CJ; Ellies, LG; Haddad, G; Haase, VH; Simon, MC; Poellinger, L; Powell, FL; Johnson, RS				Boutin, Adam T.; Weidemann, Alexander; Fu, Zhenxing; Mesropian, Lernik; Gradin, Katarina; Jamora, Colin; Wiesener, Michael; Eckardt, Kai-Uwe; Koch, Cameron J.; Ellies, Lesley G.; Haddad, Gabriel; Haase, Volker H.; Simon, M. Celeste; Poellinger, Lorenz; Powell, Frank L.; Johnson, Randall S.			Epidermal sensing of oxygen is essential for systemic hypoxic response	CELL			English	Article							NITRIC-OXIDE; TUMOR-SUPPRESSOR; ERYTHROPOIETIN PRODUCTION; GENE-EXPRESSION; BLOOD-FLOW; HUMAN SKIN; MICE; VHL; HIF; VASOCONSTRICTION	Skin plays an essential role, mediated in part by its remarkable vascular plasticity, in adaptation to environmental stimuli. Certain vertebrates, such as amphibians, respond to hypoxia in part through the skin; but it is unknown whether this tissue can influence mammalian systemic adaptation to low oxygen levels. We have found that epidermal deletion of the hypoxia-responsive transcription factor HIF-1 alpha inhibits renal erythropoietin (EPO) synthesis in response to hypoxia. Conversely, mice with an epidermal deletion of the vonHippel-Lindau (VHL) factor, a negative regulator of HIF, have increased EPO synthesis and polycythemia. We show that nitric oxide release induced by the HIF pathway acts on cutaneous vascular flow to increase systemic erythropoietin expression. These results demonstrate that in mice the skin is a critical mediator of systemic responses to environmental oxygen.	[Boutin, Adam T.; Weidemann, Alexander; Mesropian, Lernik; Jamora, Colin; Johnson, Randall S.] Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, La Jolla, CA 92093 USA; [Gradin, Katarina; Poellinger, Lorenz] Karolinska Inst, S-17177 Stockholm, Sweden; [Wiesener, Michael; Eckardt, Kai-Uwe] Univ Erlangen Nurnberg, D-91054 Erlangen, Germany; [Koch, Cameron J.; Haase, Volker H.; Simon, M. Celeste] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Fu, Zhenxing; Ellies, Lesley G.; Haddad, Gabriel; Powell, Frank L.] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; [Fu, Zhenxing; Ellies, Lesley G.; Haddad, Gabriel; Powell, Frank L.] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; [Fu, Zhenxing; Ellies, Lesley G.; Haddad, Gabriel; Powell, Frank L.] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Karolinska Institutet; University of Erlangen Nuremberg; University of Pennsylvania; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Johnson, RS (corresponding author), Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, La Jolla, CA 92093 USA.	rsjohnson@ucsd.edu	Simon, Celeste/AAG-3941-2021; Haase, Volker Hans/AAJ-5061-2021; Johnson, Randall/AAM-1189-2021; Haase, Volker Hans/A-6758-2013	Johnson, Randall/0000-0002-4084-6639; Haase, Volker Hans/0000-0002-7051-8994	NCI NIH HHS [R01 CA082515, R01CA082515, K22CA118182, R01 CA082515-09, R01 CA100787] Funding Source: Medline; NHLBI NIH HHS [R01 HL081823] Funding Source: Medline; NIAID NIH HHS [R01AI060840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA118182, R01CA100787, R01CA082515] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBRECHT PH, 1972, J APPL PHYSIOL, V32, P54, DOI 10.1152/jappl.1972.32.1.54; Bergmann C., 1847, GOTTINGER STUDIEN, V3, P595; Bozzini CE, 2005, HIGH ALT MED BIOL, V6, P238, DOI 10.1089/ham.2005.6.238; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; DURAND J, 1969, FED PROC, V28, P1124; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Evans SM, 2006, J INVEST DERMATOL, V126, P2596, DOI 10.1038/sj.jid.5700451; Fandrey J, 2004, AM J PHYSIOL-REG I, V286, pR977, DOI 10.1152/ajpregu.00577.2003; Fikree FF, 2005, SOC SCI MED, V60, P911, DOI 10.1016/j.socscimed.2004.06.034; Gassmann M, 2003, ADV EXP MED BIOL, V543, P323; Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104; Haase VH, 2005, SEMIN CELL DEV BIOL, V16, P564, DOI 10.1016/j.semcdb.2005.03.006; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Harbrecht BG, 2006, CURR PHARM DESIGN, V12, P3543, DOI 10.2174/138161206778343000; Houghton BL, 2006, J PHYSIOL-LONDON, V572, P811, DOI 10.1113/jphysiol.2005.104067; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; KUWAHIRA I, 1993, J APPL PHYSIOL, V74, P211, DOI 10.1152/jappl.1993.74.1.211; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Lewis LD, 2004, SEMIN HEMATOL, V41, P17, DOI 10.1053/j.seminhematol.2004.09.004; Lezon C, 1995, HAEMATOLOGICA, V80, P491; Malvin GM, 2001, AM J PHYSIOL-REG I, V280, pR1308, DOI 10.1152/ajpregu.2001.280.5.R1308; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; Maxwell PH, 2001, ADV EXP MED BIOL, V502, P365; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Minson CT, 2003, ADV EXP MED BIOL, V543, P249; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Moudgil R, 2005, J APPL PHYSIOL, V98, P390, DOI 10.1152/japplphysiol.00733.2004; Moudgil R, 2006, MICROCIRCULATION, V13, P615, DOI 10.1080/10739680600930222; Mullany LC, 2005, J TROP PEDIATRICS, V51, P82, DOI 10.1093/tropej/fmh083; Powell FL, 1998, RESP PHYSIOL, V112, P123, DOI 10.1016/S0034-5687(98)00026-7; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rubner M., 1883, Z BIOL, V19, P535; Russell RC, 2007, CELL CYCLE, V6, P56, DOI 10.4161/cc.6.1.3668; Scortegagna M, 2005, BLOOD, V105, P3133, DOI 10.1182/blood-2004-05-1695; Semenza GL, 2004, J APPL PHYSIOL, V96, P1173, DOI 10.1152/japplphysiol.00770.2003; Soliz J, 2007, J PHYSIOL-LONDON, V583, P329, DOI 10.1113/jphysiol.2007.133454; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stucker M, 2002, J PHYSIOL-LONDON, V538, P985, DOI 10.1013/jphysiol.2001.013067; Tam BYY, 2006, NAT MED, V12, P793, DOI 10.1038/nm1428; Tobin DJ, 2006, CHEM SOC REV, V35, P52, DOI 10.1039/b505793k; Todorov V, 2000, PFLUG ARCH EUR J PHY, V439, P445, DOI 10.1007/s004240050961; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; WEIL JV, 1969, FED PROC, V28, P1160; Weir EK, 2005, NEW ENGL J MED, V353, P2042, DOI 10.1056/NEJMra050002; Whitman EM, 2008, AM J PHYSIOL-LUNG C, V294, pL309, DOI 10.1152/ajplung.00091.2007	52	135	139	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	2008	133	2					223	234		10.1016/j.cell.2008.02.038	http://dx.doi.org/10.1016/j.cell.2008.02.038			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	289JY	18423195	Green Accepted, Bronze			2022-12-28	WOS:000255052000013
J	Bowerman, B				Bowerman, Bruce			Cell signaling - Wnt moves beyond the Canon	SCIENCE			English	Editorial Material							CAENORHABDITIS-ELEGANS; BETA-CATENIN; POLARITY; DIVISION; INVASION; MELANOMA		[Bowerman, Bruce] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Bowerman, B (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	bbowerman@molbio.uoregon.edu			NIGMS NIH HHS [R01 GM049869] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049869] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Goldstein B, 2006, DEV CELL, V10, P391, DOI 10.1016/j.devcel.2005.12.016; Herman MA, 2004, FRONT BIOSCI-LANDMRK, V9, P1530, DOI 10.2741/1306; Kaletta T, 1997, NATURE, V390, P294, DOI 10.1038/36869; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mizumoto K, 2007, TRENDS CELL BIOL, V17, P465, DOI 10.1016/j.tcb.2007.08.004; Park FD, 2004, CURR BIOL, V14, P2252, DOI 10.1016/j.cub.2004.12.019; Satyamoorthy K, 2001, ONCOGENE, V20, P4676, DOI 10.1038/sj.onc.1204616; Thorpe CJ, 2000, TRENDS CELL BIOL, V10, P10, DOI 10.1016/S0962-8924(99)01672-4; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Witze ES, 2008, SCIENCE, V320, P365, DOI 10.1126/science.1151250	12	10	12	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					327	328		10.1126/science.1157590	http://dx.doi.org/10.1126/science.1157590			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420922	Green Accepted			2022-12-28	WOS:000255026100029
J	Feng, M; Zhao, J; Petek, H				Feng, Min; Zhao, Jin; Petek, Hrvoje			Atomlike, hollow-core-bound molecular orbitals of C-60	SCIENCE			English	Article							STATES	The atomic electron orbitals that underlie molecular bonding originate from the central Coulomb potential of the atomic core. We used scanning tunneling microscopy and density functional theory to explore the relation between the nearly spherical shape and unoccupied electronic structure of buckminsterfullerene ( C-60) molecules adsorbed on copper surfaces. Besides the known pi* antibonding molecular orbitals of the carbon- atom framework, above 3.5 electron volts we found atomlike orbitals bound to the core of the hollow C-60 cage. These "superatom" states hybridize like the s and p orbitals of hydrogen and alkali atoms into diatomic molecule- like dimers and free- electron bands of one- dimensional wires and two- dimensional quantum wells in C-60 aggregates. We attribute the superatom states to the central potential binding an electron to its screening charge, a property expected for hollow- shell molecules derived from layered materials.	[Feng, Min; Zhao, Jin; Petek, Hrvoje] Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA; [Feng, Min; Zhao, Jin; Petek, Hrvoje] Univ Pittsburgh, Petersen Inst NanoSci & Engn, Pittsburgh, PA 15260 USA; [Feng, Min; Zhao, Jin] Donostia Int Phys Ctr, San Sebastian 20018, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Petek, H (corresponding author), Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA.	petek@pitt.edu	Zhao, Jin/E-2735-2016; Feng, Min/A-3546-2011; Petek, Hrvoje/A-3912-2009	Zhao, Jin/0000-0003-1346-5280; Petek, Hrvoje/0000-0001-9605-2590				BLASE X, 1995, PHYS REV B, V51, P6868, DOI 10.1103/PhysRevB.51.6868; Boyle M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.273401; CEPERLEY DM, 1980, PHYS REV LETT, V45, P566, DOI 10.1103/PhysRevLett.45.566; Coropceanu V, 2007, CHEM REV, V107, P926, DOI 10.1021/cr050140x; Crain JN, 2005, SCIENCE, V307, P703, DOI 10.1126/science.1106911; Delaney P, 2004, APPL PHYS LETT, V84, P431, DOI 10.1063/1.1640783; Dougherty DB, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.125428; Dougherty DB, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.236806; ECHENIQUE PM, 1978, J PHYS C SOLID STATE, V11, P2065, DOI 10.1088/0022-3719/11/10/017; Feng M, 2007, J AM CHEM SOC, V129, P12394, DOI 10.1021/ja075239v; Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575; HASHIZUME T, 1993, PHYS REV LETT, V71, P2959, DOI 10.1103/PhysRevLett.71.2959; Lu XH, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.115418; Margine ER, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.196803; MARTINS JL, 1991, CHEM PHYS LETT, V180, P457, DOI 10.1016/0009-2614(91)85149-Q; Miyamoto Y, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.041402; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; POSTERNAK M, 1983, PHYS REV LETT, V50, P761, DOI 10.1103/PhysRevLett.50.761; Shinohara H, 2000, REP PROG PHYS, V63, P843, DOI 10.1088/0034-4885/63/6/201; Tautz FS, 2007, PROG SURF SCI, V82, P479, DOI 10.1016/j.progsurf.2007.09.001; Tsuei KD, 1997, SOLID STATE COMMUN, V101, P337, DOI 10.1016/S0038-1098(96)00590-X; Wachowiak A, 2005, SCIENCE, V310, P468, DOI 10.1126/science.1117303; Wang YY, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.086402; Zhu XY, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.241401	24	232	238	5	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2008	320	5874					359	362		10.1126/science.1155866	http://dx.doi.org/10.1126/science.1155866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420931				2022-12-28	WOS:000255026100039
J	Martin, TR; Wurfel, MM				Martin, Thomas R.; Wurfel, Mark M.			A TRIFfic perspective on acute lung injury	CELL			English	Editorial Material							RESPIRATORY-DISTRESS-SYNDROME	Acute lung injury (ALI) is a leading cause of death in people infected with H5N1 avian influenza virus or the SARS-coronavirus. Imai et al. (2008) now report that ALI is triggered by the signaling of oxidized phospholipids through Toll-like receptor 4 (TLR4) and the adaptor protein TRIF. These findings provide insight into the molecular pathogenesis of ALI, a condition for which treatment options are currently very limited.	[Martin, Thomas R.; Wurfel, Mark M.] Univ Washington, Med Res Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA; [Martin, Thomas R.; Wurfel, Mark M.] Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA 98108 USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Martin, TR (corresponding author), Univ Washington, Med Res Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.	trmartin@u.washington.edu			NHLBI NIH HHS [HL073996, HL081764, P50 HL073996, HL629063, R01 HL081764] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL073996, R01HL081764] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; DOSSANTOS CC, 2006, ANNU REV PHYSIOL, V68, P685; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Martin TR, 1997, AM J RESP CRIT CARE, V155, P937, DOI 10.1164/ajrccm.155.3.9117029; Nonas S, 2006, AM J RESP CRIT CARE, V173, P1130, DOI 10.1164/rccm.200511-1737OC; Oppenheim JJ, 2007, ADV EXP MED BIOL, V601, P185; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Sittipunt C, 2001, AM J RESP CRIT CARE, V163, P503, DOI 10.1164/ajrccm.163.2.2004187; Skerrett SJ, 2007, AM J PHYSIOL-LUNG C, V292, pL312, DOI 10.1152/ajplung.00250.2006	11	20	23	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 18	2008	133	2					208	210		10.1016/j.cell.2008.04.006	http://dx.doi.org/10.1016/j.cell.2008.04.006			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	289JY	18423191	Green Published, Bronze			2022-12-28	WOS:000255052000009
J	Singh, S				Singh, Seema			India takes an open source approach to drug discovery	CELL			English	Editorial Material								Open source software may have been around for 17 years, but using an open source model to speed up drug discovery is a relatively new idea. This month, India is launching a new open source initiative for developing drugs to treat diseases such as tuberculosis, malaria, and HIV.											0	21	22	1	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 18	2008	133	2					201	203		10.1016/j.cell.2008.04.003	http://dx.doi.org/10.1016/j.cell.2008.04.003			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	289JY	18423188	Bronze			2022-12-28	WOS:000255052000006
J	Oppenheim, RE; Felsberg, GJ				Oppenheim, Ronald E.; Felsberg, Gary J.			Cerebral embolism of probable aortic origin	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Oppenheim, Ronald E.; Felsberg, Gary J.] Florida Hosp, Orlando, FL 32803 USA	Adventist Health Services; AdventHealth	Oppenheim, RE (corresponding author), Florida Hosp, Orlando, FL 32803 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					E17	E17		10.1056/NEJMicm070396	http://dx.doi.org/10.1056/NEJMicm070396			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285NK	18403761				2022-12-28	WOS:000254783300010
J	Lafta, RK				Lafta, Riyadh K.			Intimate-partner violence and women's health	LANCET			English	Editorial Material									Mustansiriya Med Sch, Baghdad, Iraq		Lafta, RK (corresponding author), Mustansiriya Med Sch, Baghdad, Iraq.	riyadhlafta@yahoo.com						Ellsberg M, 2008, LANCET, V371, P1165, DOI 10.1016/S0140-6736(08)60522-X; Kulwicki Anahid Devartanian, 2002, Issues Ment Health Nurs, V23, P77, DOI 10.1080/01612840252825491; Schwartz MD, 2005, J INTERPERS VIOLENCE, V20, P7, DOI 10.1177/0886260504268087; *WHO, 1997, VIOL WOM PRIOR HLTH; World Health Organization, 2005, WHO MULT STUD WOM HL; World Health Organization, 2002, WORLD REPORT VIOLENC; Xu X, 2005, AM J PUBLIC HEALTH, V95, P78, DOI 10.2105/AJPH.2003.023978; 2003, WOMEN IRAQ WOMENS RI	8	13	13	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 5	2008	371	9619					1140	1142		10.1016/S0140-6736(08)60499-7	http://dx.doi.org/10.1016/S0140-6736(08)60499-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	287ZM	18395560				2022-12-28	WOS:000254956000005
J	Oliver, A				Oliver, Adam			Public-sector health-care reforms that work? A case study of the US Veterans Health Administration	LANCET			English	Editorial Material							QUALITY-OF-CARE		[Oliver, Adam] Univ London London Sch Econ & Polit Sci, London WC2A 2AE, England	University of London; London School Economics & Political Science	Oliver, A (corresponding author), Univ London London Sch Econ & Polit Sci, Houghton St, London WC2A 2AE, England.	a.j.oliver@lse.ac.uk	Oliver, Adam/CAG-2031-2022					Asch SM, 2004, ANN INTERN MED, V141, P938, DOI 10.7326/0003-4819-141-12-200412210-00010; Brown SH, 2003, INT J MED INFORM, V69, P135, DOI 10.1016/S1386-5056(02)00131-4; Evans DC, 2006, HEALTH ECON POLICY L, V1, P163, DOI 10.1017/S1744133105001210; Evans L., 2005, RECOGNIZING 75 ANNIV; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; Kizer KW, 1995, VISION CHANGE PLAN R; KRUGMAN P, 2006, NY TIMES        0227, P23; *NCQA, 2005, STAT HLTH CAR QUAL R; Oliver A, 2007, MILBANK Q, V85, P5, DOI 10.1111/j.1468-0009.2007.00475.x; Perlin JB, 2004, AM J MANAG CARE, V10, P828; PERLIN JB, 2005, TRANSFORMATIONAL STR; PERLIN JB, 2006, PRESIDENTS FY 2007 B; Perlin JB, 2006, HEALTH ECON POLICY L, V1, P99, DOI 10.1017/S1744133105001222; *PITAC, 2004, REV HLTH CAR INF TEC; Sales MM, 2005, AM J MANAG CARE, V11, P104; VA Office of Quality and Performance, 2005, VAS PERF COMP NON VA	16	20	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 5	2008	371	9619					1211	1213		10.1016/S0140-6736(08)60528-0	http://dx.doi.org/10.1016/S0140-6736(08)60528-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	287ZM	18395583				2022-12-28	WOS:000254956000031
J	Anderson, GM; Juurlink, D; Detsky, AS				Anderson, Geoffrey M.; Juurlink, David; Detsky, Allan S.			Newly approved does not always mean new and improved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ATYPICAL ANTIPSYCHOTIC-DRUGS; OLDER-ADULTS; RISK; INHIBITORS; DEATH		[Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Anderson, Geoffrey M.; Juurlink, David; Detsky, Allan S.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Juurlink, David; Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Juurlink, David] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada; [Detsky, Allan S.] Univ Hlth Network, Dept Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, 427-600 Univ Ave, Toronto, ON M5G 1X5, Canada.	adetsky@mtsinai.on.ca						Bronskill SE, 2004, J AM GERIATR SOC, V52, P749, DOI 10.1111/j.1532-5415.2004.52212.x; Gill SS, 2007, ANN INTERN MED, V146, P775, DOI 10.7326/0003-4819-146-11-200706050-00006; Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140-6736(05)17864-7; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Lee PE, 2004, BMJ-BRIT MED J, V329, P75, DOI 10.1136/bmj.38125.465579.55; Mamdani M, 2002, CAN MED ASSOC J, V167, P1125; Mamdani M, 2006, CAN MED ASSOC J, V175, P1535, DOI 10.1503/cmaj.050192; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; Polinski JM, 2007, HEALTH AFFAIR, V26, P750, DOI 10.1377/hlthaff.26.3.750; Psaty BM, 2007, JAMA-J AM MED ASSOC, V298, P2185, DOI 10.1001/jama.298.18.2185; Rochon PA, 2007, ARCH INTERN MED, V167, P676, DOI 10.1001/archinte.167.7.676; Schneeweiss S, 2007, CAN MED ASSOC J, V176, P627, DOI 10.1503/cmaj.061250; Schultz WB, 2007, NEW ENGL J MED, V357, P2217, DOI 10.1056/NEJMp078212; Steinman MA, 2007, PLOS MED, V4, P743, DOI 10.1371/journal.pmed.0040134; U.S. Food and Drug Administration, 2005, J Pain Palliat Care Pharmacother, V19, P83	16	15	15	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2008	299	13					1598	1600		10.1001/jama.299.13.1598	http://dx.doi.org/10.1001/jama.299.13.1598			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	281RZ	18387934				2022-12-28	WOS:000254517900027
J	Thiessen, MEW				Thiessen, Molly E. W.			Someone else's sister	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												molly.welch@uchsc.edu							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2008	299	13					1523	1524		10.1001/jama.299.13.jpo80009	http://dx.doi.org/10.1001/jama.299.13.jpo80009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	281RZ	18387921				2022-12-28	WOS:000254517900001
J	Cassidy, J				Cassidy, Jane			UKCAT among the pigeons	BRITISH MEDICAL JOURNAL			English	Editorial Material							MEDICAL-SCHOOL					janecassi@yahoo.co.uk						Donnon T, 2007, ACAD MED, V82, P100, DOI 10.1097/01.ACM.0000249878.25186.b7; McManus IC, 2005, BRIT MED J, V331, P555, DOI 10.1136/bmj.331.7516.555; *SUPP PROF ADM PRO, ADM TESTS	3	9	9	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 29	2008	336	7646					691	692		10.1136/bmj.39519.621111.59	http://dx.doi.org/10.1136/bmj.39519.621111.59			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	283ZS	18369223	Green Published			2022-12-28	WOS:000254675600020
J	Cruess, SR; Cruess, RL; Steinert, Y				Cruess, Sylvia R.; Cruess, Richard L.; Steinert, Yvonne			Teaching rounds - Role modelling - making the most of a powerful teaching strategy	BRITISH MEDICAL JOURNAL			English	Editorial Material							RESIDENTS; STUDENTS; MEDICINE		[Cruess, Sylvia R.; Cruess, Richard L.; Steinert, Yvonne] McGill Univ, Ctr Med Educ, Montreal, PQ H3A 1A3, Canada	McGill University	Cruess, SR (corresponding author), McGill Univ, Ctr Med Educ, 1110 Pine Ave W, Montreal, PQ H3A 1A3, Canada.	sylvia.cruess@mcgill.ca						Althouse LA, 1999, ADV HEALTH SCI EDUC, V4, P111, DOI 10.1023/A:1009768526142; Baldwin DC, 1998, ACAD MED, V73, P1195, DOI 10.1097/00001888-199811000-00019; Cote L, 2000, ACAD MED, V75, P1117, DOI 10.1097/00001888-200011000-00020; Epstein RM, 1998, ARCH FAM MED, V7, P149, DOI 10.1001/archfami.7.2.149; Hafferty FW, 1998, ACAD MED, V73, P403, DOI 10.1097/00001888-199804000-00013; Inui T, 2003, FLAG WIND ED PROFESS; Kenny NP, 2003, ACAD MED, V78, P1203, DOI 10.1097/00001888-200312000-00002; Ludmerer KM, 1999, TIME HEAL; Paice E, 2002, BMJ-BRIT MED J, V325, P707, DOI 10.1136/bmj.325.7366.707; Ricer R E, 1998, Fam Med, V30, P328; Schon D.A., 1987, ED REFLECTIVE PRACTI; SKEFF KM, 1992, ARCH INTERN MED, V152, P1156, DOI 10.1001/archinte.1992.00400180028004; Skeff KM, 1998, NEW ENGL J MED, V339, P2015, DOI 10.1056/NEJM199812313392710; STEINERT Y, ACAD MED, V82, P1057; Steinert Y, 2006, MED TEACH, V28, P497, DOI 10.1080/01421590600902976; TOSTESON DC, 1979, NEW ENGL J MED, V301, P690, DOI 10.1056/NEJM197909273011304; Wright S, 1997, J GEN INTERN MED, V12, P53, DOI 10.1007/s11606-006-0007-1; Wright S, 1996, ACAD MED, V71, P290, DOI 10.1097/00001888-199603000-00024; Wright SM, 1998, NEW ENGL J MED, V339, P1986, DOI 10.1056/NEJM199812313392706	19	276	283	1	37	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 29	2008	336	7646					718	721		10.1136/bmj.39503.757847.BE	http://dx.doi.org/10.1136/bmj.39503.757847.BE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	283ZS	18369229	Green Published, Green Submitted			2022-12-28	WOS:000254675600033
J	Holroyd-Leduc, JM; Tannenbaum, C; Thorpe, KE; Straus, SE				Holroyd-Leduc, Jayna M.; Tannenbaum, Cara; Thorpe, Kevin E.; Straus, Sharon E.			What type of urinary incontinence does this woman have?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							Q-TIP TEST; URETHRAL SPHINCTER DYSFUNCTION; OVERACTIVE BLADDER SYMPTOMS; SCORED UROLOGICAL HISTORY; SUPINE STRESS TEST; URODYNAMIC INVESTIGATIONS; DIFFERENTIAL-DIAGNOSIS; DETRUSOR INSTABILITY; WOMEN; QUESTIONNAIRE	Context Urinary incontinence is a prevalent condition and treatment options can depend on what type of incontinence is present. Objective To systematically review the evidence about the most accurate way to determine the type of urinary incontinence during an office assessment. Data Sources A search of MEDLINE using Ovid ( 1966- July 2007) and EMBASE ( 1980-July 2007), and the bibliographies of retrieved articles to identify relevant studies. Search terms included urinary incontinence, diagnostic tests, medical history taking, physical examination, cough stress test, and urodynamics. Study Selection English- language articles were identified that addressed the office diagnosis of urinary incontinence in adults, in which data was not limited to case reports. Cohort studies of patients undergoing history, physical examination, and/ or office procedures ( excluding urodynamics) for diagnosing the type of urinary incontinence were included. Case- control studies were considered when there was insufficient data available from cohort studies. The accepted reference standard for categorization of incontinence type was diagnosis confirmed by an expert, urodynamic studies, or both. Data Extraction Two investigators independently appraised study quality and extracted relevant data. Minimum inclusion criteria were completion of an appropriate reference standard in all patients and the ability to extract relevant data. Data Synthesis Forty articles were identified for inclusion. A random- effects model was used for quantitative synthesis. Minimal data was available for men. In women, simple questions modestly helped diagnose stress urinary incontinence ( summary positive likelihood ratio [ LR], 2.2; 95% confidence interval [ CI], 1.6- 3.2; summary negative LR, 0.39; 95% CI, 0.25- 0.61) but are more helpful in diagnosing urge urinary incontinence ( summary positive LR, 4.2; 95% CI, 2.3- 7.6; summary negative LR, 0.48; 95% CI, 0.36- 0.62). A positive bladder stress test may help diagnose stress urinary incontinence ( summary LR, 3.1; 95% CI, 1.7- 5.5); however, a negative test is not as useful ( summary LR, 0.36; 95% CI, 0.21- 0.60). A systematic assessment combining the history, physical examination, and results of bedside tests to establish a clinical diagnosis appears to be of modest value in diagnosing stress urinary incontinence ( summary positive LR, 3.7; 95% CI, 2.6- 5.2; summary negative LR, 0.20; 95% CI, 0.08-0.51). The systematic assessment is less helpful in diagnosing urge urinary incontinence ( summary positive LR, 2.2; 95% CI, 0.55- 8.7; summary negative LR, 0.63; 95% CI, 0.34- 1.17). Conclusions The most helpful component for diagnosing urge urinary incontinence is a history of urine loss associated with urgency. A bladder stress test may be helpful for diagnosing stress urinary incontinence.	[Holroyd-Leduc, Jayna M.; Straus, Sharon E.] Univ Calgary, Div Geriatr & Gen Internal Med, Calgary, AB, Canada; [Holroyd-Leduc, Jayna M.; Straus, Sharon E.] Univ Calgary, Div Knowledge Translat Program, Calgary, AB, Canada; [Tannenbaum, Cara] Inst Univ Geriatr Montreal, Montreal, PQ, Canada; [Thorpe, Kevin E.; Straus, Sharon E.] Univ Toronto, St Michaels Hosp, Knowledge Translat Program, Toronto, ON M5B 1W8, Canada; [Thorpe, Kevin E.] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	University of Calgary; University of Calgary; Universite de Montreal; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Holroyd-Leduc, JM (corresponding author), Foothills Med Ctr, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.	jayna.holroyd-leduc@calgaryhealthregion.ca		Thorpe, Kevin/0000-0002-7586-3893				ABRAMS P, 2005, INCONTINENCE, V2; American College of Obstetricians and Gynecologists, 2005, OBSTET GYNECOL, V105, P1533; Bai SW, 2004, YONSEI MED J, V45, P287, DOI 10.3349/ymj.2004.45.2.287; Basra R, 2007, EUR UROL, V52, P230, DOI 10.1016/j.eururo.2006.11.015; BENT AE, 1983, AM J OBSTET GYNECOL, V145, P218, DOI 10.1016/0002-9378(83)90495-7; BERGMAN A, 1987, J REPROD MED, V32, P273; Bradley CS, 2005, AM J OBSTET GYNECOL, V192, P66, DOI 10.1016/j.ajog.2004.07.037; Brown JS, 2006, ANN INTERN MED, V144, P715, DOI 10.7326/0003-4819-144-10-200605160-00005; CANTOR TJ, 1980, BRIT J OBSTET GYNAEC, V87, P889, DOI 10.1111/j.1471-0528.1980.tb04442.x; Carey MP, 1997, AUST NZ J OBSTET GYN, V37, P436, DOI 10.1111/j.1479-828X.1997.tb02455.x; CRYSTLE CD, 1971, OBSTET GYNECOL, V38, P313; Cundiff GW, 1997, AM J OBSTET GYNECOL, V177, P262, DOI 10.1016/S0002-9378(97)70185-6; DEMUYLDER X, 1992, EUR J OBSTET GYN R B, V44, P205, DOI 10.1016/0028-2243(92)90100-D; Digesu GA, 2003, NEUROUROL URODYNAM, V22, P105, DOI 10.1002/nau.10099; Diokno AC, 1999, J UROLOGY, V161, P1263, DOI 10.1016/S0022-5347(01)61652-5; DIOKNO AC, 1990, UROLOGY, V36, P431, DOI 10.1016/S0090-4295(90)80291-T; FANTL JA, 1990, AM J OBSTET GYNECOL, V162, P946, DOI 10.1016/0002-9378(90)91295-N; FANTL JA, 1996, AHCPR PUBLICATION; FitzGerald MP, 2002, NEUROUROL URODYNAM, V21, P30, DOI 10.1002/nau.2116; GLEZERMAN M, 1986, EUR J OBSTET GYN R B, V21, P159, DOI 10.1016/0028-2243(86)90030-4; HAEUSLER G, 1995, ACTA OBSTET GYN SCAN, V74, P635, DOI 10.3109/00016349509013477; Holroyd-Leduc JM, 2004, JAMA-J AM MED ASSOC, V291, P996, DOI 10.1001/jama.291.8.996; Holroyd-Leduc JM, 2004, JAMA-J AM MED ASSOC, V291, P986, DOI 10.1001/jama.291.8.986; Hsu THS, 1999, J UROLOGY, V162, P460, DOI 10.1016/S0022-5347(05)68589-8; Ishiko O, 2000, INT J GYNECOL OBSTET, V68, P131, DOI 10.1016/S0020-7292(99)00182-4; KADAR N, 1988, BRIT J OBSTET GYNAEC, V95, P698, DOI 10.1111/j.1471-0528.1988.tb06533.x; Khan MS, 2004, BJOG-INT J OBSTET GY, V111, P468, DOI 10.1111/j.1471-0528.2004.00126.x; Kirschner-Hermanns R, 1998, J UROLOGY, V159, P1903, DOI 10.1016/S0022-5347(01)63191-4; Klovning A, 1996, ACTA OBSTET GYN SCAN, V75, P941, DOI 10.3109/00016349609055032; KUJANSUU E, 1982, ANN CHIR GYNAECOL FE, V71, P197; LAGROJANSSEN ALM, 1991, BRIT J UROL, V67, P569, DOI 10.1111/j.1464-410X.1991.tb15217.x; Larsson G, 1994, INT UROGYNECOL J PEL, V5, P273; LECOUTOUR X, 1990, EUR J OBSTET GYN R B, V37, P279, DOI 10.1016/0028-2243(90)90036-Z; Lemack GE, 1999, UROLOGY, V54, P461, DOI 10.1016/S0090-4295(99)00246-0; Lobel RW, 1996, OBSTET GYNECOL, V88, P128, DOI 10.1016/0029-7844(96)00087-7; McLennan MT, 1998, NEUROUROL URODYNAM, V17, P121, DOI 10.1002/(SICI)1520-6777(1998)17:2<121::AID-NAU5>3.0.CO;2-F; ORTIZ OC, 1993, ZENTRALBL GYNAKOL, V115, P446; OUSLANDER J, 1986, WORLD J UROL, V4, P16, DOI 10.1007/BF00326735; RESNICK NM, 1987, JAMA-J AM MED ASSOC, V257, P3076, DOI 10.1001/jama.257.22.3076; Rohr G, 2004, ACTA OBSTET GYN SCAN, V83, P969, DOI 10.1111/j.0001-6349.2004.00557.x; SAND PK, 1988, OBSTET GYNECOL, V71, P257; SANDVIK H, 1995, J CLIN EPIDEMIOL, V48, P339, DOI 10.1016/0895-4356(94)00147-I; STASKIN D, 2005, INCONTINENCE, V1; Swift SE, 1999, OBSTET GYNECOL, V94, P99, DOI 10.1016/S0029-7844(99)00314-2; Thom D, 1998, J AM GERIATR SOC, V46, P473, DOI 10.1111/j.1532-5415.1998.tb02469.x; Tincello D G, 1998, Int Urogynecol J Pelvic Floor Dysfunct, V9, P391, DOI 10.1007/BF02199573; van Brummen HJ, 2004, NEUROUROL URODYNAM, V23, P38, DOI 10.1002/nau.10162; Versi E, 1996, BRIT J OBSTET GYNAEC, V103, P162, DOI 10.1111/j.1471-0528.1996.tb09669.x; VERSI E, 1991, BRIT J OBSTET GYNAEC, V98, P815, DOI 10.1111/j.1471-0528.1991.tb13488.x; WALL LL, 1994, AM J OBSTET GYNECOL, V171, P1472, DOI 10.1016/0002-9378(94)90390-5; Walsh LP, 2006, J UROLOGY, V176, P646, DOI 10.1016/j.juro.2006.03.091; Walter AJ, 2004, INT UROGYNECOL J, V15, P298, DOI 10.1007/s00192-004-1172-6; Weidner AC, 2001, AM J OBSTET GYNECOL, V184, P20, DOI 10.1067/mob.2001.108171	53	66	68	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2008	299	12					1446	1456		10.1001/jama.299.12.1446	http://dx.doi.org/10.1001/jama.299.12.1446			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278MY	18364487				2022-12-28	WOS:000254292200019
J	Pui, CH; Robison, LL; Look, AT				Pui, Ching-Hon; Robison, Leslie L.; Look, A. Thomas			Acute lymphoblastic leukaemia	LANCET			English	Review							CENTRAL-NERVOUS-SYSTEM; STEM-CELL TRANSPLANTATION; CHILDRENS-CANCER-GROUP; ESCHERICHIA-COLI-ASPARAGINASE; TRANSGENIC ZEBRAFISH MODEL; GENE-EXPRESSION SIGNATURES; TRAUMATIC LUMBAR PUNCTURE; EARLY TREATMENT RESPONSE; 1ST COMPLETE REMISSION; UMBILICAL-CORD BLOOD	Acute lymphoblastic leukaemia, a malignant disorder of lymphoid progenitor cells, affects both children and adults, with peak prevalence between the ages of 2 and 5 years. Steady progress in development of effective treatments has led to a cure rate of more than 80% in children, creating opportunities for innovative approaches that would preserve past gains in leukaemia-firee survival while reducing the toxic side-effects of current intensive regimens. Advances in our understanding of the pathobiology of acute lymphoblastic leukaemia, fuelled by emerging molecular technologies, suggest that drugs specifically targeting the genetic defects of leukaemic cells could revolutionise management of this disease. Meanwhile, studies are underway to ascertain the precise events that take place in the genesis of acute lymphoblastic leukaemia, to enhance the clinical application of known risk factors and antileukaemic agents, and to identify treatment regimens that might boost the generally low cure rates in adults and subgroups of children with high-risk leukaemia.	[Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Robison, Leslie L.] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA; Univ Tennessee, Memphis, TN USA; [Look, A. Thomas] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Look, A. Thomas] Harvard Univ, Sch Med, Boston, MA USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Pui, CH (corresponding author), St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	ching-hon.pui@stjude.org	Robison, Leslie/N-8122-2018; Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NCI NIH HHS [CA90246, CA36401, CA78224, CA21765, CA68484, CA52259, CA60419, CA06516, CA51001, P30 CA006516] Funding Source: Medline; NIGMS NIH HHS [GM61393] Funding Source: Medline; NINR NIH HHS [NR07610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA060419, R01CA051001, P01CA068484, R01CA052259, P30CA021765, P30CA006516, R01CA078224, R01CA090246, R01CA036401, R29CA051001, R37CA036401, R01CA060419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR007610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Ahlbom A, 2000, BRIT J CANCER, V83, P692, DOI 10.1054/bjoc.2000.1376; Amatruda JF, 2002, CANCER CELL, V1, P229, DOI 10.1016/S1535-6108(02)00052-1; Arico M, 2000, NEW ENGL J MED, V342, P998, DOI 10.1056/NEJM200004063421402; Armstrong SA, 2005, J CLIN ONCOL, V23, P6306, DOI 10.1200/JCO.2005.05.047; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Avramis VI, 2002, BLOOD, V99, P1986, DOI 10.1182/blood.V99.6.1986; Balduzzi A, 2005, LANCET, V366, P635, DOI 10.1016/S0140-6736(05)66998-X; Barredo JC, 2006, J CLIN ONCOL, V24, P3142, DOI 10.1200/JCO.2005.03.3373; Barry E, 2007, J CLIN ONCOL, V25, P813, DOI 10.1200/JCO.2006.08.6397; Biondi A, 2000, BLOOD, V96, P24, DOI 10.1182/blood.V96.1.24; Boissel N, 2003, J CLIN ONCOL, V21, P774, DOI 10.1200/JCO.2003.02.053; Bostrom BC, 2003, BLOOD, V101, P3809, DOI 10.1182/blood-2002-08-2454; Breit S, 2006, BLOOD, V108, P1151, DOI 10.1182/blood-2005-12-4956; Bruggemann M, 2006, BLOOD, V107, P1116, DOI 10.1182/blood-2005-07-2708; Buffler PA, 2005, CANCER INVEST, V23, P60, DOI 10.1081/CNV-200046402; Burger B, 2003, J CLIN ONCOL, V21, P184, DOI 10.1200/JCO.2003.04.096; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Butturini AM, 2007, J CLIN ONCOL, V25, P2063, DOI 10.1200/JCO.2006.07.7792; Chauvenet AR, 2007, BLOOD, V110, P1105, DOI 10.1182/blood-2006-12-061689; Cheng Q, 2005, NAT GENET, V37, P878, DOI 10.1038/ng1612; Cheok MH, 2003, NAT GENET, V34, P85, DOI 10.1038/ng1151; Conter V, 2007, LANCET, V369, P123, DOI 10.1016/S0140-6736(07)60073-7; Coustan-Smith E, 2002, BLOOD, V100, P52, DOI 10.1182/blood-2002-01-0006; Coustan-Smith E, 2006, BLOOD, V108, P97, DOI 10.1182/blood-2006-01-0066; Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367; de Bont JM, 2004, LEUKEMIA, V18, P2032, DOI 10.1038/sj.leu.2403538; de Labarthe A, 2007, BLOOD, V109, P1408, DOI 10.1182/blood-2006-03-011908; Delannoy A, 2006, LEUKEMIA, V20, P1526, DOI 10.1038/sj.leu.2404320; Dhedin N, 2006, LEUKEMIA, V20, P336, DOI 10.1038/sj.leu.2404065; Douer D, 2007, BLOOD, V109, P2744, DOI 10.1182/blood-2006-07-035006; Druker BJ, 2004, ADV CANCER RES, V91, P1, DOI 10.1016/S0065-230X(04)91001-9; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Duval M, 2002, BLOOD, V99, P2734, DOI 10.1182/blood.V99.8.2734; Dworzak MN, 2002, BLOOD, V99, P1952, DOI 10.1182/blood.V99.6.1952; Eapen M, 2007, LANCET, V369, P1947, DOI 10.1016/S0140-6736(07)60915-5; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Evans WE, 2004, NATURE, V429, P464, DOI 10.1038/nature02626; Evans WE, 2001, J CLIN ONCOL, V19, P2293, DOI 10.1200/JCO.2001.19.8.2293; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gajjar A, 2000, BLOOD, V96, P3381; Gast A, 2007, LEUKEMIA, V21, P320, DOI 10.1038/sj.leu.2404474; Gleissner B, 2005, BLOOD, V106, P4054, DOI 10.1182/blood-2005-05-1866; Gleissner B, 2002, BLOOD, V99, P1536, DOI 10.1182/blood.V99.5.1536; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Greaves M, 2006, NAT REV CANCER, V6, P193, DOI 10.1038/nrc1816; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Hallbook H, 2006, CANCER-AM CANCER SOC, V107, P1551, DOI 10.1002/cncr.22189; Harms DO, 2003, BLOOD, V102, P2736, DOI 10.1182/blood-2002-08-2372; Healy J, 2007, BLOOD, V109, P683, DOI 10.1182/blood-2006-02-003236; Hijiya N, 2007, JAMA-J AM MED ASSOC, V297, P1207, DOI 10.1001/jama.297.11.1207; Hijiya N, 2006, BLOOD, V108, P3997, DOI 10.1182/blood-2006-05-024414; Hilden JM, 2006, BLOOD, V108, P441, DOI 10.1182/blood-2005-07-3011; Hjalgrim LH, 2003, AM J EPIDEMIOL, V158, P724, DOI 10.1093/aje/kwg210; Hock H, 2004, GENE DEV, V18, P2336, DOI 10.1101/gad.1239604; Hoelzer D, 2000, SEMIN ONCOL, V27, P540; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Hunault M, 2004, BLOOD, V104, P3028, DOI 10.1182/blood-2003-10-3560; Hutchinson RJ, 2003, J CLIN ONCOL, V21, P1790, DOI 10.1200/JCO.2003.03.009; Igarashi S, 2005, J CLIN ONCOL, V23, P6489, DOI 10.1200/JCO.2005.01.982; Iwamoto S, 2007, J CLIN INVEST, V117, P1049, DOI 10.1172/JCI30235; Jacobs SS, 2007, PEDIATR BLOOD CANCER, V49, P250, DOI 10.1002/pbc.20964; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kadan-Lottick NS, 2003, JAMA-J AM MED ASSOC, V290, P2008, DOI 10.1001/jama.290.15.2008; Kager L, 2005, J CLIN INVEST, V115, P110, DOI 10.1172/JCI200522477; Kantarjian H, 2004, CANCER-AM CANCER SOC, V101, P2788, DOI 10.1002/cncr.20668; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Kawamata N, 2008, BLOOD, V111, P776, DOI 10.1182/blood-2007-05-088310; Kinlen L, 2004, ONCOGENE, V23, P6341, DOI 10.1038/sj.onc.1207898; Kishi S, 2007, BLOOD, V109, P4151, DOI 10.1182/blood-2006-10-054528; Kosaka Y, 2004, BLOOD, V104, P3527, DOI 10.1182/blood-2004-04-1390; Krajinovic M, 2002, PHARMACOGENETICS, V12, P655, DOI 10.1097/00008571-200211000-00010; Krause DS, 2006, NAT MED, V12, P1175, DOI 10.1038/nm1489; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Lanciotti M, 2005, LEUKEMIA, V19, P214, DOI 10.1038/sj.leu.2403613; Landau Heather, 2006, Curr Hematol Malig Rep, V1, P171, DOI 10.1007/s11899-996-0005-8; Lange BJ, 2002, BLOOD, V99, P825, DOI 10.1182/blood.V99.3.825; Langenau DM, 2005, P NATL ACAD SCI USA, V102, P6068, DOI 10.1073/pnas.0408708102; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Larson RA, 2006, SEMIN HEMATOL, V43, P126, DOI 10.1053/j.seminhematol.2006.01.007; Lazarus HM, 2006, BLOOD, V108, P465, DOI 10.1182/blood-2005-11-4666; Lee EJ, 2001, J CLIN ONCOL, V19, P4014, DOI 10.1200/JCO.2001.19.20.4014; Lennard L, 2006, CLIN PHARMACOL THER, V80, P375, DOI 10.1016/j.clpt.2006.07.002; Linker C, 2002, J CLIN ONCOL, V20, P2464, DOI 10.1200/JCO.2002.07.116; Loh ML, 2006, BLOOD, V107, P4508, DOI 10.1182/blood-2005-08-3451; Lowe EJ, 2005, PEDIATR BLOOD CANCER, V45, P10, DOI 10.1002/pbc.20178; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maia AT, 2003, LEUKEMIA, V17, P2202, DOI 10.1038/sj.leu.2403101; Mancini M, 2005, BLOOD, V105, P3434, DOI 10.1182/blood-2004-07-2922; Matloub Y, 2006, BLOOD, V108, P1165, DOI 10.1182/blood-2005-12-011809; Mi SL, 2007, P NATL ACAD SCI USA, V104, P19971, DOI 10.1073/pnas.0709313104; Mitchell CD, 2005, BRIT J HAEMATOL, V129, P734, DOI 10.1111/j.1365-2141.2005.05509.x; Moghrabi A, 2007, BLOOD, V109, P896, DOI 10.1182/blood-2006-06-027714; Moorman AV, 2007, BLOOD, V109, P3189, DOI 10.1182/blood-2006-10-051912; Moorman AV, 2007, BLOOD, V109, P2327, DOI 10.1182/blood-2006-08-040436; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nachman JB, 2007, BLOOD, V110, P1112, DOI 10.1182/blood-2006-07-038299; Nachman JB, 1998, NEW ENGL J MED, V338, P1663, DOI 10.1056/NEJM199806043382304; Nathan PC, 2006, LEUKEMIA LYMPHOMA, V47, P2488, DOI 10.1080/10428190600942769; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Panzer-Grumayer ER, 2000, BLOOD, V95, P790, DOI 10.1182/blood.V95.3.790.003k48_790_794; Patte C, 2001, BLOOD, V97, P3370, DOI 10.1182/blood.V97.11.3370; Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X; Pinheiro JPV, 2004, BRIT J HAEMATOL, V125, P117, DOI 10.1111/j.1365-2141.2004.04863.x; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; Pui CH, 2001, LANCET ONCOL, V2, P597, DOI 10.1016/S1470-2045(01)00516-2; Pui CH, 2003, J CLIN ONCOL, V21, P179, DOI 10.1200/JCO.2003.10.032; Pui CH, 2003, NEW ENGL J MED, V349, P640, DOI 10.1056/NEJMoa035091; Pui CH, 2004, BLOOD, V104, P2690, DOI 10.1182/blood-2004-04-1616; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Pui CH, 2000, BRIT J HAEMATOL, V109, P13, DOI 10.1046/j.1365-2141.2000.01843.x; Pui CH, 2003, JAMA-J AM MED ASSOC, V290, P2001, DOI 10.1001/jama.290.15.2001; Pui Ching-Hon, 2006, Hematology Am Soc Hematol Educ Program, P142; Pui CH, 2007, NAT REV DRUG DISCOV, V6, P149, DOI 10.1038/nrd2240; Pui CH, 2006, LEUKEMIA LYMPHOMA, V47, P2431, DOI 10.1080/10428190600955837; Raff T, 2007, BLOOD, V109, P910, DOI 10.1182/blood-2006-07-037093; Ramanujachar R, 2007, PEDIATR BLOOD CANCER, V48, P254, DOI 10.1002/PBC.20749; Relling MV, 2006, BLOOD, V107, P843, DOI 10.1182/blood-2005-08-3379; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Ribera JM, 2007, J CLIN ONCOL, V25, P16, DOI 10.1200/JCO.2006.06.8312; Rizzari C, 2006, HAEMATOLOGICA, V91, P24; Rocha JCC, 2005, BLOOD, V105, P4752, DOI 10.1182/blood-2004-11-4544; Rocha V, 2004, NEW ENGL J MED, V351, P2276, DOI 10.1056/NEJMoa041469; Roman-Gomez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood-2006-09-047043; Rowe JM, 2005, BLOOD, V106, P3760, DOI 10.1182/blood-2005-04-1623; Sabaawy HE, 2006, P NATL ACAD SCI USA, V103, P15166, DOI 10.1073/pnas.0603349103; Sanders JE, 2005, BLOOD, V105, P3749, DOI 10.1182/blood-2004-08-3312; Schrappe M, 2000, BLOOD, V95, P3310; Schrauder A, 2006, J CLIN ONCOL, V24, P5742, DOI 10.1200/JCO.2006.06.2679; Schultz KR, 2007, BLOOD, V109, P926, DOI 10.1182/blood-2006-01-024729; Sharma VM, 2006, MOL CELL BIOL, V26, P8022, DOI 10.1128/MCB.01091-06; Silverman LB, 2001, BLOOD, V97, P1211, DOI 10.1182/blood.V97.5.1211; Skarby TVC, 2006, LEUKEMIA, V20, P1955, DOI 10.1038/sj.leu.2404404; Skibola CF, 2002, BLOOD, V99, P3786, DOI 10.1182/blood.V99.10.3786; Skibola CF, 1999, P NATL ACAD SCI USA, V96, P12810, DOI 10.1073/pnas.96.22.12810; Spector LG, 2005, CANCER EPIDEM BIOMAR, V14, P651, DOI 10.1158/1055-9965.EPI-04-0602; Stanulla M, 2005, JAMA-J AM MED ASSOC, V293, P1485, DOI 10.1001/jama.293.12.1485; Stork LC, 2002, BLOOD, V100, p156A; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; te Loo DMWM, 2006, J CLIN ONCOL, V24, P2332, DOI 10.1200/JCO.2005.03.9727; Thomas X, 2004, J CLIN ONCOL, V22, P4075, DOI 10.1200/JCO.2004.10.050; Tissing WJE, 2007, BLOOD, V109, P3929, DOI 10.1182/blood-2006-11-056366; Toyoda Y, 2000, J CLIN ONCOL, V18, P1508, DOI 10.1200/JCO.2000.18.7.1508; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Vey N, 2006, LEUKEMIA, V20, P2155, DOI 10.1038/sj.leu.2404420; Vitale A, 2006, CURR OPIN ONCOL, V18, P652, DOI 10.1097/01.cco.0000245317.82391.1b; Vora A, 2006, LANCET, V368, P1339, DOI 10.1016/S0140-6736(06)69558-5; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wetzler M, 2007, BLOOD, V109, P4164, DOI 10.1182/blood-2006-09-045351; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Woessmann W, 2005, BLOOD, V105, P948, DOI 10.1182/blood-2004-03-0973; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Yanada M, 2006, J CLIN ONCOL, V24, P460, DOI 10.1200/JCO.2005.03.2177; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Zaza G, 2005, BLOOD, V106, P1778, DOI 10.1182/blood-2005-01-0143; Zhou JB, 2007, BLOOD, V110, P1607, DOI 10.1182/blood-2006-09-045369; Zhu YM, 2006, CLIN CANCER RES, V12, P3043, DOI 10.1158/1078-0432.CCR-05-2832	171	1020	1099	2	187	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2008	371	9617					1030	1043		10.1016/S0140-6736(08)60457-2	http://dx.doi.org/10.1016/S0140-6736(08)60457-2			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358930				2022-12-28	WOS:000254206000031
J	Walker, IA; Wilson, IH				Walker, Isabeau A.; Wilson, Iain H.			Anaesthesia in developing countries - a risk for patients	LANCET			English	Editorial Material							MORTALITY		[Walker, Isabeau A.] Great Ormond St Hosp NHS Trust, Dept Anaesthesia, London WC1N 3JH, England; [Wilson, Iain H.] Royal Devon & Exeter NHS Fdn Trust, Dept Anaesthesia, Exeter, Devon, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Exeter	Walker, IA (corresponding author), Great Ormond St Hosp NHS Trust, Dept Anaesthesia, London WC1N 3JH, England.	walkei@gosh.nhs.uk						Buck N, 1987, REPORT CONFIDENTIAL; Enohumah KO, 2006, ACTA ANAESTH SCAND, V50, P206, DOI 10.1111/j.1399-6576.2006.00945.x; Glenshaw M, 2005, Cent Afr J Med, V51, P39; Hansen D, 2000, TROP DOCT, V30, P146, DOI 10.1177/004947550003000311; HEYWOOD AJ, 1989, ANN ROY COLL SURG, V71, P354; Hodges SC, 2007, ANAESTHESIA, V62, P4, DOI 10.1111/j.1365-2044.2006.04907.x; Maman AFOB, 2005, TROP DOCT, V35, P220, DOI 10.1258/004947505774938666; Mbonye AK, 2007, INT J GYNECOL OBSTET, V98, P285, DOI 10.1016/j.ijgo.2007.05.019; *NAT COMM CONF ENQ, SAV MOTH REP CONF EN; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; WHO, 2006, WORK TOG HLTH WORLD	11	81	83	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2008	371	9617					968	969		10.1016/S0140-6736(08)60432-8	http://dx.doi.org/10.1016/S0140-6736(08)60432-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277IN	18358913				2022-12-28	WOS:000254206000008
J	Hsu, TY; Tsai, TC; Yang, CC; Hwang, TZ; Tseng, CC; Wang, CC				Hsu, Tun-Yen; Tsai, Ting-Chou; Yang, Chuan-Chien; Hwang, Tzer-Zen; Tseng, Chih-Chieh; Wang, Chih-Chun			Near-fatal sore throat	LANCET			English	Editorial Material							RETROPHARYNGEAL HEMATOMA		[Hsu, Tun-Yen; Tsai, Ting-Chou; Yang, Chuan-Chien; Hwang, Tzer-Zen; Tseng, Chih-Chieh; Wang, Chih-Chun] I Shou Univ, Dept Otolaryngol, E DA Hosp, Kaohsiung 82445, Taiwan	E-Da Hospital; I Shou University	Hsu, TY (corresponding author), I Shou Univ, Dept Otolaryngol, E DA Hosp, 1 Yida Rd, Kaohsiung 82445, Taiwan.	dunyen@yahoo.com.tw						Amitrano L, 2002, SEMIN LIVER DIS, V22, P83, DOI 10.1055/s-2002-23205; Chiti-Batelli S, 2005, ACTA OTO-LARYNGOL, V125, P443, DOI 10.1080/00016480410017233; COLEMAN JA, 1986, OTOLARYNG HEAD NECK, V94, P387, DOI 10.1177/019459988609400326; WHOLEY MH, 1958, RADIOLOGY, V71, P350, DOI 10.1148/71.3.350	4	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1136	1136		10.1016/S0140-6736(08)60490-0	http://dx.doi.org/10.1016/S0140-6736(08)60490-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18374845				2022-12-28	WOS:000254442700033
J	Rosenheck, RA				Rosenheck, Robert A.			Pharmacotherapy of first-episode schizophrenia	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; 2ND-GENERATION ANTIPSYCHOTICS; COST-EFFECTIVENESS; DRUGS		[Rosenheck, Robert A.] VA Connecticut Hlth Care Syst, West Haven, CT 06516 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Rosenheck, RA (corresponding author), VA Connecticut Hlth Care Syst, West Haven, CT 06516 USA.	robert.rosenheck@yale.edu						Jones PB, 2006, ARCH GEN PSYCHIAT, V63, P1079, DOI 10.1001/archpsyc.63.10.1079; Kahn RS, 2008, LANCET, V371, P1085, DOI 10.1016/S0140-6736(08)60486-9; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Moore TA, 2007, J CLIN PSYCHIAT, V68, P1751, DOI 10.4088/JCP.v68n1115; Rosenheck R, 2003, JAMA-J AM MED ASSOC, V290, P2693, DOI 10.1001/jama.290.20.2693; Rosenheck RA, 2007, BRIT J PSYCHIAT, V191, P238, DOI 10.1192/bjp.bp.106.035063; Rosenheck RA, 2006, AM J PSYCHIAT, V163, P2080, DOI 10.1176/appi.ajp.163.12.2080	7	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR-APR	2008	371	9618					1048	1049		10.1016/S0140-6736(08)60463-8	http://dx.doi.org/10.1016/S0140-6736(08)60463-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18374824				2022-12-28	WOS:000254442700005
J	Heath, I				Heath, Iona			Making a difference - Multiple health problems in elderly people - Never had it so good?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GENERAL-PRACTICE; DISEASE; CARE		Caversham Grp Practice, London NW5 2UP, England		Heath, I (corresponding author), Caversham Grp Practice, Kentish Town, London NW5 2UP, England.	iona.heath@dsl.pipex.com						ATHILL D, 2002, YESTERDAY MORNING VE, P5; Auerbach AD, 2007, NEW ENGL J MED, V357, P608, DOI 10.1056/NEJMsb070738; Drennan V, 2007, FAM PRACT, V24, P454, DOI 10.1093/fampra/cmm034; LINK BG, 1995, J HEALTH SOC BEHAV, V35, P80, DOI 10.2307/2626958; Mangin D, 2007, BMJ-BRIT MED J, V335, P285, DOI 10.1136/bmj.39241.630741.BE1; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Tinetti ME, 2004, AM J MED, V116, P179, DOI 10.1016/j.amjmed.2003.09.031; Watt G, 2004, BRIT J GEN PRACT, V54, P939; World Health Organization, 2002, ACT AG POL FRAM	9	7	8	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	2008	336	7650					950	+		10.1136/bmj.39532.671319.94	http://dx.doi.org/10.1136/bmj.39532.671319.94			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397944	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000255540900037
J	Richards, S; Gibbs, RA; Weinstock, GM; Brown, SJ; Denell, R; Beeman, RW; Gibbs, R; Bucher, G; Friedrich, M; Grimmelikhuijzen, CJP; Klingler, M; Lorenzen, MD; Roth, S; Schroder, R; Tautz, D; Zdobnov, EM; Muzny, D; Attaway, T; Bell, S; Buhay, CJ; Chandrabose, MN; Chavez, D; Clerk-Blankenburg, KP; Cree, A; Dao, M; Davis, C; Chacko, J; Dinh, H; Dugan-Rocha, S; Fowler, G; Garner, TT; Garnes, J; Gnirke, A; Hawes, A; Hernandez, J; Hines, S; Holder, M; Hume, J; Jhangiani, SN; Joshi, V; Khan, ZM; Jackson, L; Kovar, C; Kowis, A; Lee, S; Lewis, LR; Margolis, J; Morgan, M; Nazareth, LV; Nguyen, N; Okwuonu, G; Parker, D; Ruiz, SJ; Santibanez, J; Savard, J; Scherer, SE; Schneider, B; Sodergren, E; Vattahil, S; Villasana, D; White, CS; Wright, R; Park, Y; Lord, J; Oppert, B; Brown, S; Wang, LJ; Savard, J; Liu, Y; Worley, K; Elsik, CG; Reese, JT; Elhaik, E; Landan, G; Graur, D; Arensburger, P; Atkinson, P; Beidler, J; Demuth, JP; Drury, DW; Du, YZ; Fujiwara, H; Maselli, V; Osanai, M; Robertson, HM; Tu, Z; Wang, JJ; Wang, SZ; Song, H; Zhang, L; Sodergren, E; Werner, D; Stanke, M; Morgenstern, B; Solovyev, V; Kosarev, P; Brown, G; Chen, HC; Ermolaeva, O; Hlavina, W; Kapustin, Y; Kiryutin, B; Kitts, P; Maglott, D; Pruitt, K; Sapojnikov, V; Souvorov, A; Mackey, AJ; Waterhouse, RM; Wyder, S; Zdobnov, EM; Kriventseva, EV; Kadowaki, T; Bork, P; Aranda, M; Bao, RY; Beermann, A; Berns, N; Bolognesi, R; Bonneton, F; Bopp, D; Butts, T; Chaumot, A; Denell, RE; Ferrier, DEK; Gordon, CM; Jindra, M; Klingler, M; Lan, Q; Lattorff, HMG; Laudet, V; von Levetsow, C; Liu, ZY; Lutz, R; Lynch, JA; da Fonseca, RN; Posnien, N; Reuter, R; Roth, S; Schinko, JB; Schmitt, C; Schoppmeier, M; Shippy, TD; Simonnet, F; Marques-Souza, H; Tomoyasu, Y; Trauner, J; Van der Zee, M; Vervoort, M; Wittkopp, N; Wimmer, EA; Yang, XY; Jones, AK; Sattelle, DB; Ebert, PR; Nelson, D; Scott, JG; Muthukrishnan, S; Kramer, KJ; Arakane, Y; Zhu, QS; Hogenkamp, D; Dixit, R; Jiang, HB; Zou, Z; Marshall, J; Elpidina, E; Vinokurov, K; Oppert, C; Evans, J; Lu, ZQ; Zhao, PC; Sumathipala, N; Altincicek, B; Vilcinskas, A; Williams, M; Hultmark, D; Hetru, C; Hauser, F; Cazzamali, G; Williamson, M; Li, B; Tanaka, Y; Predel, R; Neupert, S; Schachtner, J; Verleyen, P; Raible, F; Walden, KKO; Robertson, HM; Angeli, S; Foret, S; Schuetz, S; Maleszka, R; Miller, SC; Grossmann, D				Richards, Stephen; Gibbs, Richard A.; Weinstock, George M.; Brown, Susan J.; Denell, Robin; Beeman, Richard W.; Gibbs, Richard; Bucher, Gregor; Friedrich, Markus; Grimmelikhuijzen, Cornelis J. P.; Klingler, Martin; Lorenzen, Marce D.; Roth, Siegfried; Schroeder, Reinhard; Tautz, Diethard; Zdobnov, Evgeny M.; Muzny, Donna; Attaway, Tony; Bell, Stephanie; Buhay, Christian J.; Chandrabose, Mimi N.; Chavez, Dean; Clerk-Blankenburg, Kerstin P.; Cree, Andrew; Dao, Marvin; Davis, Clay; Chacko, Joseph; Dinh, Huyen; Dugan-Rocha, Shannon; Fowler, Gerald; Garner, Toni T.; Garnes, Jeffrey; Gnirke, Andreas; Hawes, Alica; Hernandez, Judith; Hines, Sandra; Holder, Michael; Hume, Jennifer; Jhangiani, Shalini N.; Joshi, Vandita; Khan, Ziad Mohid; Jackson, LaRonda; Kovar, Christie; Kowis, Andrea; Lee, Sandra; Lewis, Lora R.; Margolis, Jon; Morgan, Margaret; Nazareth, Lynne V.; Nguyen, Ngoc; Okwuonu, Geoffrey; Parker, David; Ruiz, San-Juana; Santibanez, Jireh; Savard, Joel; Scherer, Steven E.; Schneider, Brian; Sodergren, Erica; Vattahil, Selina; Villasana, Donna; White, Courtney S.; Wright, Rita; Park, Yoonseong; Lord, Jeff; Oppert, Brenda; Brown, Susan; Wang, Liangjiang; Savard, Joel; Liu, Yue; Worley, Kim; Elsik, Christine G.; Reese, Justin T.; Elhaik, Eran; Landan, Giddy; Graur, Dan; Arensburger, Peter; Atkinson, Peter; Beidler, Jim; Demuth, Jeffery P.; Drury, Douglas W.; Du, Yu-Zhou; Fujiwara, Haruhiko; Maselli, Vincenza; Osanai, Mizuko; Robertson, Hugh M.; Tu, Zhijian; Wang, Jian-Jun; Wang, Suzhi; Song, Henry; Zhang, Lan; Sodergren, Erica; Werner, Doreen; Stanke, Mario; Morgenstern, Burkhard; Solovyev, Victor; Kosarev, Peter; Brown, Garth; Chen, Hsiu-Chuan; Ermolaeva, Olga; Hlavina, Wratko; Kapustin, Yuri; Kiryutin, Boris; Kitts, Paul; Maglott, Donna; Pruitt, Kim; Sapojnikov, Victor; Souvorov, Alexandre; Mackey, Aaron J.; Waterhouse, Robert M.; Wyder, Stefan; Zdobnov, Evgeny M.; Kriventseva, Evgenia V.; Kadowaki, Tatsuhiko; Bork, Peer; Aranda, Manuel; Bao, Riyue; Beermann, Anke; Berns, Nicola; Bolognesi, Renata; Bonneton, Francois; Bopp, Daniel; Butts, Thomas; Chaumot, Arnaud; Denell, Robin E.; Ferrier, David E. K.; Gordon, Cassondra M.; Jindra, Marek; Klingler, Martin; Lan, Que; Lattorff, H. Michael G.; Laudet, Vincent; von Levetsow, Cornelia; Liu, Zhenyi; Lutz, Rebekka; Lynch, Jeremy A.; da Fonseca, Rodrigo Nunes; Posnien, Nico; Reuter, Rolf; Roth, Siegfried; Schinko, Johannes B.; Schmitt, Christian; Schoppmeier, Michael; Shippy, Teresa D.; Simonnet, Franck; Marques-Souza, Henrique; Tomoyasu, Yoshinori; Trauner, Jochen; Van der Zee, Maurijn; Vervoort, Michel; Wittkopp, Nadine; Wimmer, Ernst A.; Yang, Xiaoyun; Jones, Andrew K.; Sattelle, David B.; Ebert, Paul R.; Nelson, David; Scott, Jeffrey G.; Muthukrishnan, Subbaratnam; Kramer, Karl J.; Arakane, Yasuyuki; Zhu, Qingsong; Hogenkamp, David; Dixit, Radhika; Jiang, Haobo; Zou, Zhen; Marshall, Jeremy; Elpidina, Elena; Vinokurov, Konstantin; Oppert, Cris; Evans, Jay; Lu, Zhiqiang; Zhao, Picheng; Sumathipala, Niranji; Altincicek, Boran; Vilcinskas, Andreas; Williams, Michael; Hultmark, Dan; Hetru, Charles; Hauser, Frank; Cazzamali, Giuseppe; Williamson, Michael; Li, Bin; Tanaka, Yoshiaki; Predel, Reinhard; Neupert, Susanne; Schachtner, Joachim; Verleyen, Peter; Raible, Florian; Walden, Kimberly K. O.; Robertson, Hugh M.; Angeli, Sergio; Foret, Sylvain; Schuetz, Stefan; Maleszka, Ryszard; Miller, Sherry C.; Grossmann, Daniela		Tribolium Genome Sequencing Consortium	The genome of the model beetle and pest Tribolium castaneum	NATURE			English	Article							SHORT-GERM INSECT; RED FLOUR BEETLE; DROSOPHILA-MELANOGASTER; GENE SUPERFAMILY; APIS-MELLIFERA; MESSENGER-RNA; BOMBYX-MORI; HONEY-BEE; PROTEIN; SEGMENTATION	Tribolium castaneum is a member of the most species-rich eukaryotic order, a powerful model organism for the study of generalized insect development, and an important pest of stored agricultural products. We describe its genome sequence here. This omnivorous beetle has evolved the ability to interact with a diverse chemical environment, as shown by large expansions in odorant and gustatory receptors, as well as P450 and other detoxification enzymes. Development in Tribolium is more representative of other insects than is Drosophila, a fact reflected in gene content and function. For example, Tribolium has retained more ancestral genes involved in cell - cell communication than Drosophila, some being expressed in the growth zone crucial for axial elongation in short- germ development. Systemic RNA interference in T. castaneum functions differently from that in Caenorhabditis elegans, but nevertheless offers similar power for the elucidation of gene function and identification of targets for selective insect control.	[Richards, Stephen; Gibbs, Richard A.; Weinstock, George M.; Gibbs, Richard; Bucher, Gregor; Muzny, Donna; Attaway, Tony; Bell, Stephanie; Buhay, Christian J.; Chandrabose, Mimi N.; Chavez, Dean; Clerk-Blankenburg, Kerstin P.; Cree, Andrew; Dao, Marvin; Davis, Clay; Chacko, Joseph; Dinh, Huyen; Dugan-Rocha, Shannon; Fowler, Gerald; Garner, Toni T.; Hawes, Alica; Hernandez, Judith; Hines, Sandra; Holder, Michael; Hume, Jennifer; Jhangiani, Shalini N.; Joshi, Vandita; Khan, Ziad Mohid; Jackson, LaRonda; Kovar, Christie; Kowis, Andrea; Lee, Sandra; Lewis, Lora R.; Morgan, Margaret; Nazareth, Lynne V.; Nguyen, Ngoc; Okwuonu, Geoffrey; Parker, David; Ruiz, San-Juana; Santibanez, Jireh; Scherer, Steven E.; Schneider, Brian; Sodergren, Erica; Vattahil, Selina; Villasana, Donna; White, Courtney S.; Wright, Rita; Liu, Yue; Worley, Kim; Song, Henry; Zhang, Lan; Sodergren, Erica] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [Richards, Stephen; Gibbs, Richard A.; Weinstock, George M.; Gibbs, Richard; Bucher, Gregor; Muzny, Donna; Attaway, Tony; Bell, Stephanie; Buhay, Christian J.; Chandrabose, Mimi N.; Chavez, Dean; Clerk-Blankenburg, Kerstin P.; Cree, Andrew; Dao, Marvin; Davis, Clay; Chacko, Joseph; Dinh, Huyen; Dugan-Rocha, Shannon; Fowler, Gerald; Garner, Toni T.; Hawes, Alica; Hernandez, Judith; Hines, Sandra; Holder, Michael; Hume, Jennifer; Jhangiani, Shalini N.; Joshi, Vandita; Khan, Ziad Mohid; Jackson, LaRonda; Kovar, Christie; Kowis, Andrea; Lee, Sandra; Lewis, Lora R.; Morgan, Margaret; Nazareth, Lynne V.; Nguyen, Ngoc; Okwuonu, Geoffrey; Parker, David; Ruiz, San-Juana; Santibanez, Jireh; Scherer, Steven E.; Schneider, Brian; Sodergren, Erica; Vattahil, Selina; Villasana, Donna; White, Courtney S.; Wright, Rita; Liu, Yue; Worley, Kim; Song, Henry; Zhang, Lan; Sodergren, Erica] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Brown, Susan J.; Denell, Robin; Lorenzen, Marce D.; Brown, Susan; Wang, Liangjiang; Wang, Suzhi; Bolognesi, Renata; Denell, Robin E.; Gordon, Cassondra M.; Shippy, Teresa D.; Tomoyasu, Yoshinori; Marshall, Jeremy; Miller, Sherry C.] Kansas State Univ, Div Biol, Manhattan, KS 66506 USA; [Beeman, Richard W.; Lorenzen, Marce D.; Lord, Jeff; Oppert, Brenda; Kramer, Karl J.; Arakane, Yasuyuki; Oppert, Cris] ARS, Grain Mkt & Prod Res Ctr, USDA, Manhattan, KS 66502 USA; [Posnien, Nico; Schinko, Johannes B.; Simonnet, Franck; Wimmer, Ernst A.; Schuetz, Stefan; Grossmann, Daniela] Univ Gottingen, Johann Friedrich Blumenbach Inst, Dept Dev Biol, D-37077 Gottingen, Germany; [Friedrich, Markus; Bao, Riyue; Yang, Xiaoyun] Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; [Grimmelikhuijzen, Cornelis J. P.; Hauser, Frank; Cazzamali, Giuseppe; Williamson, Michael] Univ Copenhagen, Ctr Funct & Comparat Insect Genom, DK-2100 Copenhagen, Denmark; [Hauser, Frank; Cazzamali, Giuseppe; Williamson, Michael] Univ Copenhagen, Dept Cell Biol & Comparat Zool, Inst Biol, DK-2100 Copenhagen, Denmark; [Klingler, Martin; Klingler, Martin; Schmitt, Christian; Schoppmeier, Michael; Trauner, Jochen] Friedrich Alexander Univ Erlangen, Dept Dev Biol, Inst Biol, D-91058 Erlangen, Germany; [Roth, Siegfried; von Levetsow, Cornelia; Lynch, Jeremy A.; da Fonseca, Rodrigo Nunes; Roth, Siegfried] Univ Cologne, Inst Dev Biol, D-50674 Cologne, Germany; [Schroeder, Reinhard; Beermann, Anke; Berns, Nicola; Lutz, Rebekka; Reuter, Rolf; Wittkopp, Nadine] Univ Tubingen, Interfac Inst Cell Biol, D-72076 Tubingen, Germany; [Tautz, Diethard; Savard, Joel; Savard, Joel; Aranda, Manuel; Marques-Souza, Henrique; Van der Zee, Maurijn] Univ Cologne, Dept Genet, D-50674 Cologne, Germany; [Zdobnov, Evgeny M.; Wyder, Stefan; Zdobnov, Evgeny M.; Kriventseva, Evgenia V.] Univ Geneva, Med Sch, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland; [Zdobnov, Evgeny M.; Zdobnov, Evgeny M.] Swiss Inst Bioinformat, CH-1211 Geneva, Switzerland; [Zdobnov, Evgeny M.; Waterhouse, Robert M.; Zdobnov, Evgeny M.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; Childrens Hosp Oakland, Res Inst, BACPAC Resources, Oakland, CA 94609 USA; [Garnes, Jeffrey] MIT, Broad Inst, Cambridge, MA 02142 USA; [Garnes, Jeffrey] Harvard Univ, Cambridge Ctr 7, Cambridge, MA 02142 USA; [Gnirke, Andreas; Margolis, Jon] AgraQuest Inc, Davis, CA 95616 USA; [Park, Yoonseong; Li, Bin] Kansas State Univ, Dept Entomol, Manhattan, KS 66506 USA; [Elsik, Christine G.; Reese, Justin T.] Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA; [Elhaik, Eran; Landan, Giddy; Graur, Dan] Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; [Arensburger, Peter; Atkinson, Peter] Univ Calif, Dept Entomol, Riverside, CA 92521 USA; [Beidler, Jim; Tu, Zhijian] Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA; [Demuth, Jeffery P.] Univ Texas Arlington, Dept Biol, Arlington, TX 76019 USA; [Drury, Douglas W.] Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; [Du, Yu-Zhou; Wang, Jian-Jun] Yangzhou Univ, Dept Plant Protect, Yangzhou 225009, Peoples R China; [Fujiwara, Haruhiko; Osanai, Mizuko] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan; [Maselli, Vincenza] European Sch Mol Med, I-80131 Naples, Italy; Telethon Inst Genet & Med, I-80131 Naples, Italy; [Robertson, Hugh M.; Walden, Kimberly K. O.; Robertson, Hugh M.] Univ Illinois, Dept Entomol, Urbana, IL 61801 USA; [Werner, Doreen; Stanke, Mario; Morgenstern, Burkhard] Univ Gottingen, Dept Bioinformat, Inst Microbiol & Genet, D-37077 Gottingen, Germany; [Solovyev, Victor] Univ London, Dept Comp Sci, Surrey TW20 0EX, England; [Kosarev, Peter] Softberry Inc, Mt Kisco, NY 10549 USA; [Brown, Garth; Chen, Hsiu-Chuan; Ermolaeva, Olga; Hlavina, Wratko; Kapustin, Yuri; Kiryutin, Boris; Kitts, Paul; Maglott, Donna; Pruitt, Kim; Sapojnikov, Victor; Souvorov, Alexandre] Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; [Mackey, Aaron J.] GlaxoSmithKline, Collegeville, PA 19426 USA; [Kriventseva, Evgenia V.] Univ Geneva, Dept Struct Biol & Bioinformat, Sch Med, CH-1211 Geneva, Switzerland; [Kadowaki, Tatsuhiko] Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; [Bork, Peer; Raible, Florian] European Mol Biol Lab, D-69117 Heidelberg, Germany; [Bork, Peer] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; [Bonneton, Francois; Laudet, Vincent] Univ Lyon 1, Inst Genom Fonctionnelle Lyon, Equipe Zool Mol, ENS Lyon,CNRS,UMR 5242,INRA,IFR128, F-69364 Lyon 07, France; [Bopp, Daniel] Univ Zurich, Zool Inst, CH-8057 Zurich, Switzerland; [Butts, Thomas; Ferrier, David E. K.] Univ Oxford, Dept Zool, Oxford OX1 3PS, England; [Chaumot, Arnaud] Irstea, Lab Ecotoxicol, F-69336 Lyon 09, France; [Jindra, Marek] Inst Entomol ASCR, Ceske Budejovice 37005, Czech Republic; [Lan, Que] Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA; [Lattorff, H. Michael G.] Univ Halle Wittenberg, Inst Biol, D-06099 Halle, Saale, Germany; [Liu, Zhenyi] Washington Univ, Dept Mol Biol & Pharmacol, Sch Med, St Louis, MO 63110 USA; [Vervoort, Michel] Univ Paris 07, Ctr Genet Mol, CNRS UPR 2167, F-91198 Gif Sur Yvette, France; [Jones, Andrew K.; Sattelle, David B.] Univ Oxford, MRC Funct Genet Unit, Dept Physiol Anat & Genet, Oxford OX1 3QX, England; [Ebert, Paul R.] Univ Queensland, Sch Integrat Biol, St Lucia, Qld 4072, Australia; [Ebert, Paul R.] Univ Queensland, Sch Mol & Microbial Sci, St Lucia, Qld 4072, Australia; [Nelson, David] Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA; [Nelson, David] Univ Tennessee, Ct Excellence Genom & Bioinformat, Memphis, TN 38163 USA; [Scott, Jeffrey G.] Cornell Univ, Dept Entomol, Ithaca, NY 14853 USA; [Muthukrishnan, Subbaratnam; Kramer, Karl J.; Arakane, Yasuyuki; Zhu, Qingsong; Hogenkamp, David; Dixit, Radhika] Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; [Jiang, Haobo; Zou, Zhen; Lu, Zhiqiang; Zhao, Picheng; Sumathipala, Niranji] Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA; [Elpidina, Elena; Vinokurov, Konstantin] Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119992, Russia; [Evans, Jay] ARS, USDA, Bee Res Lab, Beltsville, MD 20705 USA; [Altincicek, Boran; Vilcinskas, Andreas] Univ Giessen, Inst Phytopathol & Appl Zool, Interdisciplinary Res Ctr, D-35392 Giessen, Germany; [Williams, Michael; Hultmark, Dan] Umea Univ, Umea Ctr Mol Pathogenesis, SE-90187 Umea, Sweden; [Hetru, Charles] CNRS, Inst Biol Molec Cell, F-67084 Strasbourg, France; [Tanaka, Yoshiaki] Natl Inst Agrobiol Sci, Div Insect Sci, Tsukuba, Ibaraki 3058634, Japan; [Predel, Reinhard; Neupert, Susanne] Univ Jena, Inst Gen Zool, D-07743 Jena, Germany; [Schachtner, Joachim] Univ Marburg, Dept Anim Physiol, D-35032 Marburg, Germany; [Verleyen, Peter] Univ Louvain, Dept Anim Physiol & Neurobiol, BE-3000 Louvain, Belgium; [Angeli, Sergio] Inst Forest Zool & Forest Conservat, D-37077 Gottingen, Germany; [Foret, Sylvain; Maleszka, Ryszard] Australian Natl Univ, Visual Sci & ARC Ctr Mol Genet Dev, Res Sch Biol Sci, Canberra, ACT 0200, Australia	Baylor College of Medicine; Baylor College of Medicine; Kansas State University; United States Department of Agriculture (USDA); University of Gottingen; Wayne State University; University of Copenhagen; University of Copenhagen; University of Erlangen Nuremberg; University of Cologne; Eberhard Karls University of Tubingen; University of Cologne; University of Geneva; Swiss Institute of Bioinformatics; Imperial College London; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Kansas State University; Texas A&M University System; Texas A&M University College Station; University of Houston System; University of Houston; University of California System; University of California Riverside; Virginia Polytechnic Institute & State University; University of Texas System; University of Texas Arlington; Indiana University System; Indiana University Bloomington; Yangzhou University; University of Tokyo; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Illinois System; University of Illinois Urbana-Champaign; University of Gottingen; University of London; Royal Holloway University London; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); GlaxoSmithKline; University of Geneva; Nagoya University; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); University of Zurich; University of Oxford; INRAE; Czech Academy of Sciences; University of Wisconsin System; University of Wisconsin Madison; Martin Luther University Halle Wittenberg; Washington University (WUSTL); UDICE-French Research Universities; Universite Paris Cite; University of Oxford; University of Queensland; University of Queensland; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Cornell University; Kansas State University; Oklahoma State University System; Oklahoma State University - Stillwater; Lomonosov Moscow State University; United States Department of Agriculture (USDA); Justus Liebig University Giessen; Umea University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National Institute of Agrobiological Sciences - Japan; Friedrich Schiller University of Jena; Philipps University Marburg; Australian National University	Richards, S (corresponding author), Baylor Coll Med, Human Genome Sequencing Ctr, 1 Baylor Plaza, Houston, TX 77030 USA.		ZHAO, PICHENG/G-3737-2014; Klingler, Martin/J-8383-2013; Lattorff, Michael/F-6287-2010; Bucher, Gregor/B-9004-2015; Bao, Riyue/G-8765-2014; Ferrier, David E.K./D-7595-2013; Maselli, Vincenza/H-4672-2014; Elhaik, Eran/H-6838-2019; Evans, Jay D/C-8408-2012; Z., Q./I-4446-2013; Aranda Lastra, Manuel/D-9530-2011; Angeli, Sergio/A-7720-2008; zou, zhen/C-6134-2016; Roth, Siegfried/E-8241-2010; Posnien, Nico/D-1639-2012; Marshall, Jeremy/D-1436-2013; Bork, Peer/F-1813-2013; Zdobnov, Evgeny/AAB-2745-2022; Morgenstern, Burkhard/A-7486-2008; Marques-Souza, Henrique/X-5865-2019; Vinokurov, Konstantin S/F-9521-2011; Jindra, Marek/H-2082-2014; Schachtner, Joachim/D-5522-2009; Bopp, Daniel/L-3517-2018; Tautz, Diethard/H-8436-2014; Fonseca, Rodrigo/B-2981-2009; Altincicek, Boran/C-1191-2009; Nunes-da-Fonseca, Rodrigo/ABI-1404-2022; Elsik, Christine G/C-4120-2017; Nguyen, Ngoc/HHZ-0886-2022; Tomoyasu, Yoshinori/D-3061-2017; Landan, Giddy/C-1086-2019; Liu, Zhenyi/H-5673-2011; Solovyev, Victor/C-4614-2013; da Fonseca, Rodrigo Nunes/S-3964-2018; FORET, Sylvain/B-9207-2012; Zdobnov, Evgeny M/K-1133-2012; Raible, Florian/G-6019-2011; Weinstock, George M/C-6314-2013; Waterhouse, Robert M/A-1858-2010; Stanke, Mario/P-7876-2019; Wimmer, Ernst A./I-3333-2019; Elpidina, Elena/D-5646-2012; Hultmark, Dan/C-5058-2013; Hauser, Frank/M-2952-2014; Maleszka, Ryszard/A-6078-2008; Foret, Sylvain/C-7661-2011; Schachtner, Joachim/AAG-1101-2020; Tautz, Diethard/D-4304-2011; Vervoort, Michel/S-1448-2019; Predel, Reinhard/O-5243-2015; Park, Yoonseong/J-5861-2013	Klingler, Martin/0000-0001-8859-1965; Lattorff, Michael/0000-0002-8603-6332; Bucher, Gregor/0000-0002-4615-6401; Bao, Riyue/0000-0002-6105-1704; Ferrier, David E.K./0000-0003-3247-6233; Maselli, Vincenza/0000-0002-9877-3751; Elhaik, Eran/0000-0003-4795-1084; Evans, Jay D/0000-0002-0036-4651; Aranda Lastra, Manuel/0000-0001-6673-016X; Angeli, Sergio/0000-0002-8463-7476; zou, zhen/0000-0003-3550-7656; Roth, Siegfried/0000-0001-5772-3558; Posnien, Nico/0000-0003-0700-5595; Bork, Peer/0000-0002-2627-833X; Zdobnov, Evgeny/0000-0002-5178-1498; Morgenstern, Burkhard/0000-0002-7431-2862; Jindra, Marek/0000-0002-2196-9924; Bopp, Daniel/0000-0002-0740-9672; Tautz, Diethard/0000-0002-0460-5344; Fonseca, Rodrigo/0000-0003-3063-7806; Altincicek, Boran/0000-0003-2019-452X; Nunes-da-Fonseca, Rodrigo/0000-0001-9576-2849; Elsik, Christine G/0000-0002-4248-7713; Tomoyasu, Yoshinori/0000-0001-9824-3454; Landan, Giddy/0000-0002-2502-8750; Solovyev, Victor/0000-0001-8885-493X; da Fonseca, Rodrigo Nunes/0000-0001-9576-2849; Weinstock, George M/0000-0002-2997-4592; Waterhouse, Robert M/0000-0003-4199-9052; Stanke, Mario/0000-0001-8696-0384; Wimmer, Ernst A./0000-0002-2480-2804; Elpidina, Elena/0000-0002-4988-4842; Hultmark, Dan/0000-0002-6506-5855; Hauser, Frank/0000-0001-5563-2345; Maleszka, Ryszard/0000-0003-1855-555X; Schachtner, Joachim/0000-0001-7268-0699; Lorenzen, Marce/0000-0003-2318-1388; Park, Yoonseong/0000-0003-1191-7335; Ebert, Paul/0000-0002-4435-0737; Bonneton, Francois/0000-0002-6500-1931; Nelson, David/0000-0003-0583-5421; Jiang, Haobo/0000-0003-1357-1315; chaumot, arnaud/0000-0001-9132-3419; Jones, Andrew/0000-0002-7835-0890; Wyder, Stefan/0000-0002-3412-0292; Grimmelikhuijzen, Cornelis Johannes Pieter/0000-0001-6486-2046; Shippy, Teresa/0000-0003-2305-7432; Pruitt, Kim/0000-0001-7950-1374; Brown, Susan/0000-0002-7984-0445; Worley, Kim/0000-0002-0282-1000; Schroder, Reinhard/0000-0002-3483-1916; Marques-Souza, Henrique/0000-0002-5008-8413; Walden, Kimberly/0000-0002-5799-8639; Butts, Thomas/0000-0002-1781-5287	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058634] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BBS/B/12067/2, BBS/B/12067] Funding Source: Medline; Intramural NIH HHS Funding Source: Medline; NICHD NIH HHS [R01 HD029594, R01 HD029594-16] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bankir L, 2001, CARDIOVASC RES, V51, P372, DOI 10.1016/S0008-6363(01)00328-5; Beermann A, 2001, DEVELOPMENT, V128, P287; BEERMANN A, IN PRESS DEV GENES E; BOLOGNESI R, IN PRESS DEV GENES E; BROWN SJ, 1990, INSECT BIOCHEM, V20, P185, DOI 10.1016/0020-1790(90)90011-I; Bucher G, 2004, DEVELOPMENT, V131, P1729, DOI 10.1242/dev.01073; Bucher G, 2002, CURR BIOL, V12, pR85, DOI 10.1016/S0960-9822(02)00666-8; Cerny AC, 2005, DEVELOPMENT, V132, P5353, DOI 10.1242/dev.02154; Choe CP, 2006, P NATL ACAD SCI USA, V103, P6560, DOI 10.1073/pnas.0510440103; Ciccarelli FD, 2005, GENOME RES, V15, P343, DOI 10.1101/gr.3266405; Clyne PJ, 2000, SCIENCE, V287, P1830, DOI 10.1126/science.287.5459.1830; Daborn PJ, 2002, SCIENCE, V297, P2253, DOI 10.1126/science.1074170; Demuth JP, 2007, MOL ECOL NOTES, V7, P1189, DOI 10.1111/j.1471-8286.2007.01826.x; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; ENGSONTIA P, IN PRESS INSECT BIOC; ffrench-Constant RH, 2004, TRENDS GENET, V20, P163, DOI 10.1016/j.tig.2004.01.003; FONSECA RN, IN PRESS DEV CELL; Fujiwara H, 2005, CHROMOSOME RES, V13, P455, DOI 10.1007/s10577-005-0990-9; Hauser F, 2006, PROG NEUROBIOL, V80, P1, DOI 10.1016/j.pneurobio.2006.07.005; Hill CA, 2002, SCIENCE, V298, P176, DOI 10.1126/science.1076196; Hunt T, 2007, SCIENCE, V318, P1913, DOI 10.1126/science.1146954; Jackowska M, 2007, FRONT ZOOL, V4, DOI 10.1186/1742-9994-4-24; Jones AK, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-327; Jones WD, 2007, NATURE, V445, P86, DOI 10.1038/nature05466; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Lorenzen MD, 2007, INSECT MOL BIOL, V16, P265, DOI 10.1111/j.1365-2583.2007.00727.x; Lorenzen MD, 2005, GENETICS, V170, P741, DOI 10.1534/genetics.104.032227; Ono H, 2006, DEV BIOL, V298, P555, DOI 10.1016/j.ydbio.2006.07.023; Osanai M, 2006, GENE, V376, P281, DOI 10.1016/j.gene.2006.04.022; Raymond-Delpech Valerie, 2005, Invertebrate Neuroscience, V5, P119; Robertson HM, 2003, P NATL ACAD SCI USA, V100, P14537, DOI 10.1073/pnas.2335847100; Robertson HM, 2006, GENOME RES, V16, P1345, DOI 10.1101/gr.5085606; Savard J, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-7; Savard J, 2006, GENOME RES, V16, P1334, DOI 10.1101/gr.5204306; Savard J, 2006, CELL, V126, P559, DOI 10.1016/j.cell.2006.05.053; Schroder R, 2003, NATURE, V422, P621, DOI 10.1038/nature01536; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Sokoloff A, 1972, BIOL TRIBOLIUM SPECI, V1; SOKOLOFF A, 1974, BIOL TRIBOLIUM SPECI, V1; SOKOLOFF A, 1977, BIOL TRIBOLIUM SPECI, V1; TAUTZ D, 1994, DEVELOPMENT, P193; Tautz D, 2004, DEV CELL, V7, P301, DOI 10.1016/j.devcel.2004.08.008; Tomoyasu Y, 2004, DEV GENES EVOL, V214, P575, DOI 10.1007/s00427-004-0434-0; TOMOYASU Y, IN PRESS GENOME BIOL; Ugarkovic D, 1996, MOL BIOL EVOL, V13, P1059, DOI 10.1093/oxfordjournals.molbev.a025668; van der Zee M, 2006, P NATL ACAD SCI USA, V103, P16307, DOI 10.1073/pnas.0605154103; Vinokurov KS, 2006, COMP BIOCHEM PHYS B, V145, P126, DOI 10.1016/j.cbpb.2006.05.005; WANG S, IN PRESS GENOME BIOL; Wong MD, 2005, ANNU REV GENET, V39, P173, DOI 10.1146/annurev.genet.39.073003.105855; Wyder S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r242; XIONG Y, 1988, MOL CELL BIOL, V8, P114, DOI 10.1128/MCB.8.1.114	51	988	1047	12	311	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2008	452	7190					949	955		10.1038/nature06784	http://dx.doi.org/10.1038/nature06784			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291PF	18362917	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000255208600030
J	Hillenmeyer, ME; Fung, E; Wildenhain, J; Pierce, SE; Hoon, S; Lee, W; Proctor, M; St Onge, RP; Tyers, M; Koller, D; Altman, RB; Davis, RW; Nislow, C; Giaever, G				Hillenmeyer, Maureen E.; Fung, Eula; Wildenhain, Jan; Pierce, Sarah E.; Hoon, Shawn; Lee, William; Proctor, Michael; St Onge, Robert P.; Tyers, Mike; Koller, Daphne; Altman, Russ B.; Davis, Ronald W.; Nislow, Corey; Giaever, Guri			The chemical genomic portrait of yeast: Uncovering a phenotype for all genes	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; SMALL MOLECULES; MULTIDRUG-RESISTANCE; BIOACTIVE COMPOUNDS; METABOLIC NETWORK; MEMBRANE; ROBUSTNESS; PROTEINS; DRUGS	Genetics aims to understand the relation between genotype and phenotype. However, because complete deletion of most yeast genes (similar to 80%) has no obvious phenotypic consequence in rich medium, it is difficult to study their functions. To uncover phenotypes for this nonessential fraction of the genome, we performed 1144 chemical genomic assays on the yeast whole- genome heterozygous and homozygous deletion collections and quantified the growth fitness of each deletion strain in the presence of chemical or environmental stress conditions. We found that 97% of gene deletions exhibited a measurable growth phenotype, suggesting that nearly all genes are essential for optimal growth in at least one condition.	[Hillenmeyer, Maureen E.; Fung, Eula; Pierce, Sarah E.; Hoon, Shawn; Lee, William; Proctor, Michael; St Onge, Robert P.] Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA; [Hillenmeyer, Maureen E.; Altman, Russ B.; Davis, Ronald W.] Stanford Univ, Program Biomed Informat, Palo Alto, CA 94304 USA; [Wildenhain, Jan; Tyers, Mike] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Pierce, Sarah E.; Hoon, Shawn; Lee, William; Altman, Russ B.; Davis, Ronald W.] Stanford Univ, Dept Genet, Palo Alto, CA 94304 USA; [Tyers, Mike; Nislow, Corey; Giaever, Guri] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada; [Koller, Daphne] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Nislow, Corey; Giaever, Guri] Univ Toronto, Donelley Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada; [Giaever, Guri] Univ Toronto, Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada	Stanford University; Stanford University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Stanford University; University of Toronto; Stanford University; University of Toronto; University of Toronto	Giaever, G (corresponding author), Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA.	guri.giaever@utoronto.ca	Hoon, Shawn/Q-2472-2016; Wildenhain, Jan/E-5597-2011; Tyers, Michael/ABE-3194-2021; Giaever, Guri/D-3930-2009; Wildenhain, Jan/Q-6596-2019	Hoon, Shawn/0000-0002-3892-3332; Wildenhain, Jan/0000-0002-5461-3828; Wildenhain, Jan/0000-0002-5461-3828	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061374] Funding Source: NIH RePORTER; NIGMS NIH HHS [U01 GM061374-09, U01 GM061374] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagshaw RD, 2005, MOL CELL PROTEOMICS, V4, P133, DOI 10.1074/mcp.M400128-MCP200; Blower P. E., 2002, Pharmacogenomics Journal, V2, P259, DOI 10.1038/sj.tpj.6500116; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Chua G, 2004, CURR OPIN MICROBIOL, V7, P638, DOI 10.1016/j.mib.2004.10.009; David L, 2006, P NATL ACAD SCI USA, V103, P5320, DOI 10.1073/pnas.0601091103; Deutschbauer AM, 2005, GENETICS, V169, P1915, DOI 10.1534/genetics.104.036871; Deutscher D, 2006, NAT GENET, V38, P993, DOI 10.1038/ng1856; DUDLEY AM, 2005, MOL SYSTEMS BIOL, V1; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; Ferte J, 2000, EUR J BIOCHEM, V267, P277, DOI 10.1046/j.1432-1327.2000.01046.x; Fry RC, 2005, ANNU REV MICROBIOL, V59, P357, DOI 10.1146/annurev.micro.59.031805.133658; Giaever G, 2004, P NATL ACAD SCI USA, V101, P793, DOI 10.1073/pnas.0307490100; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gong YP, 2003, J BIOL CHEM, V278, P50234, DOI 10.1074/jbc.M306606200; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; Jungwirth H, 2006, FEBS LETT, V580, P1131, DOI 10.1016/j.febslet.2005.12.050; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; Liang XJ, 2006, CANCER RES, V66, P2346, DOI 10.1158/0008-5472.CAN-05-3436; Papp B, 2004, NATURE, V429, P661, DOI 10.1038/nature02636; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Parsons AB, 2006, CELL, V126, P611, DOI 10.1016/j.cell.2006.06.040; Schrader M, 2004, HISTOCHEM CELL BIOL, V122, P383, DOI 10.1007/s00418-004-0673-1; Schreiber SL, 2005, NAT CHEM BIOL, V1, P64, DOI 10.1038/nchembio0705-64; Sharom JR, 2004, CURR OPIN CHEM BIOL, V8, P81, DOI 10.1016/j.cbpa.2003.12.007; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	28	710	728	1	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					362	365		10.1126/science.1150021	http://dx.doi.org/10.1126/science.1150021			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420932	Green Accepted			2022-12-28	WOS:000255026100040
J	Russell, CA; Jones, TC; Barr, IG; Cox, NJ; Garten, RJ; Gregory, V; Gust, ID; Hampson, AW; Hay, AJ; Hurt, AC; de Jong, JC; Kelso, A; Klimov, AI; Kageyama, T; Komadina, N; Lapedes, AS; Lin, YP; Mosterin, A; Obuchi, M; Odagiri, T; Osterhaus, ADME; Rimmelzwaan, GF; Shaw, MW; Skepner, E; Stohr, K; Tashiro, M; Fouchier, RAM; Smith, DJ				Russell, Colin A.; Jones, Terry C.; Barr, Ian G.; Cox, Nancy J.; Garten, Rebecca J.; Gregory, Vicky; Gust, Ian D.; Hampson, Alan W.; Hay, Alan J.; Hurt, Aeron C.; de Jong, Jan C.; Kelso, Anne; Klimov, Alexander I.; Kageyama, Tsutomu; Komadina, Naomi; Lapedes, Alan S.; Lin, Yi P.; Mosterin, Ana; Obuchi, Masatsugu; Odagiri, Takato; Osterhaus, Albert D. M. E.; Rimmelzwaan, Guus F.; Shaw, Michael W.; Skepner, Eugene; Stohr, Klaus; Tashiro, Masato; Fouchier, Ron A. M.; Smith, Derek J.			The global circulation of seasonal influenza A (H3N2) viruses	SCIENCE			English	Article							SURVEILLANCE; EPIDEMICS; EVOLUTION; REASSORTMENT; HIERARCHIES; INFECTIONS; REVEALS; BRAZIL	Antigenic and genetic analysis of the hemagglutinin of similar to 13,000 human influenza A ( H3N2) viruses from six continents during 2002- 2007 revealed that there was continuous circulation in east and Southeast Asia ( E- SE Asia) via a region- wide network of temporally overlapping epidemics and that epidemics in the temperate regions were seeded from this network each year. Seed strains generally first reached Oceania, North America, and Europe, and later South America. This evidence suggests that once A ( H3N2) viruses leave E- SE Asia, they are unlikely to contribute to long- term viral evolution. If the trends observed during this period are an accurate representation of overall patterns of spread, then the antigenic characteristics of A ( H3N2) viruses outside E- SE Asia may be forecast each year based on surveillance within E- SE Asia, with consequent improvements to vaccine strain selection.	[Russell, Colin A.; Jones, Terry C.; Mosterin, Ana; Skepner, Eugene; Smith, Derek J.] Univ Cambridge, Dept Zool, Cambridge, England; [Jones, Terry C.; Osterhaus, Albert D. M. E.; Rimmelzwaan, Guus F.; Fouchier, Ron A. M.; Smith, Derek J.] Erasmus MC, Dept Virol, Rotterdam, Netherlands; [Jones, Terry C.] Univ Pompeu Fabra, Barcelona, Spain; [Barr, Ian G.; Gust, Ian D.; Hampson, Alan W.; Hurt, Aeron C.; Kelso, Anne; Komadina, Naomi] WHO, Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia; [Cox, Nancy J.; Garten, Rebecca J.; Klimov, Alexander I.; Shaw, Michael W.] Ctr Dis Control & Prevent, WHO Collaborating Ctr Influenza, Atlanta, GA USA; [Obuchi, Masatsugu; Odagiri, Takato; Tashiro, Masato] Natl Inst Med Res, WHO Collaborating Ctr Influenza, London NW7 1AA, England; [Gregory, Vicky; Lin, Yi P.] Natl Inst Infect Dis, WHO Collaborating Ctr Influenza, Tokyo, Japan; [Lapedes, Alan S.] Los Alamos Natl Lab, Div Theoret, Los Alamos, NM USA; [Stohr, Klaus] Novartis Vaccines & Diagnost, Cambridge, MA USA	University of Cambridge; Erasmus University Rotterdam; Erasmus MC; Pompeu Fabra University; World Health Organization; Centers for Disease Control & Prevention - USA; MRC National Institute for Medical Research; National Institute of Infectious Diseases (NIID); United States Department of Energy (DOE); Los Alamos National Laboratory; Novartis	Smith, DJ (corresponding author), Univ Cambridge, Dept Zool, Cambridge, England.	dsmith@zoo.cam.ac.uk	Russell, Colin/ABE-7106-2020; Fouchier, Ron A/A-1911-2014; Russell, Colin/B-2226-2008; Smith, Derek/Z-3075-2019	Fouchier, Ron A/0000-0001-8095-2869; Smith, Derek/0000-0002-2393-1890; Kelso, Anne/0000-0002-3166-3267; Osterhaus, Albert/0000-0002-6074-1172; Barr, Ian/0000-0002-7351-418X; Russell, Colin/0000-0002-2113-162X; Hurt, Aeron/0000-0003-1826-4314	Medical Research Council [MC_U117512723] Funding Source: Medline; NIH HHS [DP1-OD000490-01] Funding Source: Medline; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD000490] Funding Source: NIH RePORTER; MRC [MC_U117512723] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alonso WJ, 2007, AM J EPIDEMIOL, V165, P1434, DOI 10.1093/aje/kwm012; Chew FT, 1998, EPIDEMIOL INFECT, V121, P121, DOI 10.1017/S0950268898008905; *COMM AC RESP DIS, 1948, AM J HYG, V47, P290; Cox NJ, 2000, ANNU REV MED, V51, P407, DOI 10.1146/annurev.med.51.1.407; COX NJ, 1994, EUR J EPIDEMIOL, V10, P467, DOI 10.1007/BF01719678; DAVIDWEST TS, 1974, B WORLD HEALTH ORGAN, V51, P103; DEARRUDA E, 1991, J INFECT DIS, V164, P252, DOI 10.1093/infdis/164.2.252; DORAISINGHAM S, 1988, B WORLD HEALTH ORGAN, V66, P57; Dosseh A, 2000, AM J TROP MED HYG, V62, P639, DOI 10.4269/ajtmh.2000.62.639; DUDGEON JA, 1946, LANCET, V248, P627; Fitzner K. A., 1999, Hong Kong Medical Journal, V5, P87; Ghedin E, 2005, NATURE, V437, P1162, DOI 10.1038/nature04239; GLEZEN WP, 1989, VIRAL INFECTIONS HUM, P419; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; Grenfell BT, 1998, ECOL LETT, V1, P63; Holmes EC, 2005, PLOS BIOL, V3, P1579, DOI 10.1371/journal.pbio.0030300; Hufnagel L, 2004, P NATL ACAD SCI USA, V101, P15124, DOI 10.1073/pnas.0308344101; Monto AS, 2004, INT CONGR SER, V1263, P3, DOI 10.1016/j.ics.2004.02.049; Nelson MI, 2007, PLOS PATHOG, V3, P1220, DOI 10.1371/journal.ppat.0030131; Nelson MI, 2006, PLOS PATHOG, V2, P1144, DOI 10.1371/journal.ppat.0020125; Nelson MI, 2007, NAT REV GENET, V8, P196, DOI 10.1038/nrg2053; Nguyen-Van-Tam JS, 1998, TXB INFLUENZA, P181; Shih SR, 2005, J CLIN MICROBIOL, V43, P1651, DOI 10.1128/JCM.43.4.1651-1661.2005; Shortridge KF, 1997, CHINESE MED J-PEKING, V110, P637; Simmerman JM, 2004, VACCINE, V23, P182, DOI 10.1016/j.vaccine.2004.05.025; Simonsen L, 2007, MOL BIOL EVOL, V24, P1811, DOI 10.1093/molbev/msm103; Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211; Stohr K, 2002, LANCET INFECT DIS, V2, P517, DOI 10.1016/S1473-3099(02)00366-3; Taylor RM, 1949, AM J PUBLIC HEALTH N, V39, P171, DOI 10.2105/AJPH.39.2.171; THACKER SB, 1986, EPIDEMIOL REV, V8, P129, DOI 10.1093/oxfordjournals.epirev.a036291; Viboud C, 2004, EMERG INFECT DIS, V10, P32, DOI 10.3201/eid1001.020705; Viboud C, 2006, PLOS MED, V3, P468, DOI 10.1371/journal.pmed.0030089; Wong CM, 2006, PLOS MED, V3, P485, DOI 10.1371/journal.pmed.0030121	33	512	542	1	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					340	346		10.1126/science.1154137	http://dx.doi.org/10.1126/science.1154137			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420927				2022-12-28	WOS:000255026100034
J	Westervelt, RM				Westervelt, R. M.			Applied physics - Graphene nanoelectronics	SCIENCE			English	Editorial Material							QUANTUM; BILLIARDS; PHASE		[Westervelt, R. M.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Westervelt, R. M.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University; Harvard University	Westervelt, RM (corresponding author), Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.	westervelt@seas.harvard.edu						BERRY MV, 1987, P ROY SOC LOND A MAT, V412, P53, DOI 10.1098/rspa.1987.0080; Bunch JS, 2005, NANO LETT, V5, P287, DOI 10.1021/nl048111+; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Han MY, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.206805; Katsnelson MI, 2006, NAT PHYS, V2, P620, DOI 10.1038/nphys384; Miao F, 2007, SCIENCE, V317, P1530, DOI 10.1126/science.1144359; Novoselov KS, 2007, SCIENCE, V315, P1379, DOI 10.1126/science.1137201; Novoselov KS, 2005, P NATL ACAD SCI USA, V102, P10451, DOI 10.1073/pnas.0502848102; Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Ponomarenko LA, 2008, SCIENCE, V320, P356, DOI 10.1126/science.1154663; Stampfer C, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2827188; WALLACE PR, 1947, PHYS REV, V71, P622, DOI 10.1103/PhysRev.71.622; Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235	14	275	285	0	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					324	325		10.1126/science.1156936	http://dx.doi.org/10.1126/science.1156936			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420920				2022-12-28	WOS:000255026100027
J	Ball, P				Ball, Philip			Triumph of the medieval mind	NATURE			English	Editorial Material																		Duby Georges., 1981, AGE CATHEDRALS ART S; Haskins Charles H., 1927, RENAISSANCE 12 CENTU; Le Goff Jacques, 1993, INTELLECTUALS MIDDLE; PANOFSKY E, 1957, ARCHITECTURE SCHOLAS; von Simson Otto, 1964, GOTHIC CATHEDRAL	5	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2008	452	7189					816	818		10.1038/452816a	http://dx.doi.org/10.1038/452816a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18421336	Bronze			2022-12-28	WOS:000255026000030
J	Ober, C; Tan, Z; Sun, Y; Possick, JD; Pan, L; Nicolae, R; Radford, S; Parry, RR; Heinzmann, A; Deichmann, KA; Lester, LA; Gern, JE; Lemanske, RF; Nicolae, DL; Elias, JA; Chupp, GL				Ober, Carole; Tan, Zheng; Sun, Ying; Possick, Jennifer D.; Pan, Lin; Nicolae, Raluca; Radford, Sadie; Parry, Rodney R.; Heinzmann, Andrea; Deichmann, Klaus A.; Lester, Lucille A.; Gern, James E.; Lemanske, Robert F., Jr.; Nicolae, Dan L.; Elias, Jack A.; Chupp, Geoffrey L.			Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOUNDER POPULATION; QUANTITATIVE TRAITS; COMPLEX PEDIGREES; CHITINASE; SUSCEPTIBILITY; PROTEIN; MARKER; CELLS	Background: The chitinase-like protein YKL-40 is involved in inflammation and tissue remodeling. We recently showed that serum YKL-40 levels were elevated in patients with asthma and were correlated with severity, thickening of the subepithelial basement membrane, and pulmonary function. We hypothesized that single-nucleotide polymorphisms (SNPs) that affect YKL-40 levels also influence asthma status and lung function. Methods: We carried out a genomewide association study of serum YKL-40 levels in a founder population of European descent, the Hutterites, and then tested for an association between an implicated SNP and asthma and lung function. One associated variant was genotyped in a birth cohort at high risk for asthma, in which YKL-40 levels were measured from birth through 5 years of age, and in two populations of unrelated case patients of European descent with asthma and controls. Results: A promoter SNP (-131C-->G) in CHI3L1, the chitinase 3-like 1 gene encoding YKL-40, was associated with elevated serum YKL-40 levels (P=1.1 x 10(-13)), asthma (P=0.047), bronchial hyperresponsiveness (P=0.002), and measures of pulmonary function (P=0.046 to 0.002) in the Hutterites. The same SNP could be used to predict the presence of asthma in the two case-control populations (combined P=1.2 x 10(-5)) and serum YKL-40 levels at birth (in cord-blood specimens) through 5 years of age in the birth cohort (P=8.9 x 10(-3) to 2.5 x 10(-4)). Conclusions CHI3L1 is a susceptibility gene for asthma, bronchial hyperresponsiveness, and reduced lung function, and elevated circulating YKL-40 levels are a biomarker for asthma and decline in lung function.	[Ober, Carole; Tan, Zheng; Sun, Ying; Pan, Lin; Nicolae, Raluca; Radford, Sadie; Lester, Lucille A.; Nicolae, Dan L.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Madison, WI USA; [Possick, Jennifer D.; Elias, Jack A.; Chupp, Geoffrey L.] Yale Univ, Sch Med, New Haven, CT USA; [Parry, Rodney R.] Univ S Dakota, Sch Med, Sioux Falls, SD USA; [Heinzmann, Andrea; Deichmann, Klaus A.] Univ Freiburg, Freiburg, Germany	University of Chicago; University of Wisconsin System; University of Wisconsin Madison; Yale University; University of South Dakota; University of Freiburg	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St, Chicago, IL 60637 USA.	c-ober@genetics.uchicago.edu	Possick, Jennifer/AFG-1039-2022	Ober, Carole/0000-0003-4626-9809; Nicolae, Dan/0000-0002-0918-4630	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000055] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066533, R01HL061879, P01HL056389, P50HL056389, U01HL049596, R01HL085197, R01HL072414, P01HL070831, P50HL056399] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000055, M01 RR00055] Funding Source: Medline; NHLBI NIH HHS [P01 HL070831, R01 HL066533, HL61879, HL70831, U01 HL049596, R01 HL072414, P50 HL056399, HL66533, HL56399, HL85197, P50 HL056389, HL56389, R01 HL085197, HL72414, P01 HL056389, HL81638, R01 HL085197-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abney M, 2002, AM J HUM GENET, V70, P920, DOI 10.1086/339705; Abney M, 2001, AM J HUM GENET, V68, P1302, DOI 10.1086/320112; Bourgain C, 2004, GENETICS, V168, P2349, DOI 10.1534/genetics.104.031617; Bourgain C, 2003, AM J HUM GENET, V73, P612, DOI 10.1086/378208; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; Johansen JS, 2006, DAN MED BULL, V53, P172; Kelleher TB, 2005, J HEPATOL, V43, P78, DOI 10.1016/j.jhep.2005.02.025; Kruit A, 2007, RESP MED, V101, P1563, DOI 10.1016/j.rmed.2006.12.006; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; McPeek MS, 2004, BIOMETRICS, V60, P359; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2001, AM J HUM GENET, V69, P1068, DOI 10.1086/324025; Pan L, 2007, GENET EPIDEMIOL, V31, P338, DOI 10.1002/gepi.20214; Rabbee N, 2006, BIOINFORMATICS, V22, P7, DOI 10.1093/bioinformatics/bti741; Zhao XZ, 2007, AM J HUM GENET, V80, P12, DOI 10.1086/510438; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	21	380	396	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1682	1691		10.1056/NEJMoa0708801	http://dx.doi.org/10.1056/NEJMoa0708801			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288DO	18403759	Green Accepted			2022-12-28	WOS:000254966600006
J	Wada, H; Masuda, K; Satoh, R; Kakugawa, K; Ikawa, T; Katsura, Y; Kawamoto, H				Wada, Haruka; Masuda, Kyoko; Satoh, Rumi; Kakugawa, Kiyokazu; Ikawa, Tomokatsu; Katsura, Yoshimoto; Kawamoto, Hiroshi			Adult T-cell progenitors retain myeloid potential	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; NATURAL-KILLER-CELL; MURINE FETAL LIVER; LYMPHOID PROGENITORS; B-LINEAGE; THYMUS; PRECURSOR; MOUSE; IDENTIFICATION; SUBPOPULATION	During haematopoiesis, pluripotent haematopoietic stem cells are sequentially restricted to give rise to a variety of lineage-committed progenitors. The classical model of haematopoiesis postulates that, in the first step of differentiation, the stem cell generates common myelo-erythroid progenitors and common lymphoid progenitors (CLPs). However, our previous studies in fetal mice showed that myeloid potential persists even as the lineage branches segregate towards T and B cells(1-6). We therefore proposed the 'myeloid-based' model of haematopoiesis(7,8), in which the stem cell initially generates common myelo-erythroid progenitors and common myelo-lymphoid progenitors. T-cell and B-cell progenitors subsequently arise from common myelo-lymphoid progenitors through myeloid-T and myeloid-B stages, respectively. However, it has been unclear whether this myeloid-based model is also valid for adult haematopoiesis. Here we provide clonal evidence that the early cell populations in the adult thymus contain progenitors that have lost the potential to generate B cells but retain substantial macrophage potential as well as T-cell, natural killer (NK)-cell and dendritic-cell potential. We also show that such T-cell progenitors can give rise to macrophages in the thymic environment in vivo. Our findings argue against the classical dichotomy model in which T cells are derived from CLPs; instead, they support the validity of the 'myeloid-based' model for both adult and fetal haematopoiesis.	[Wada, Haruka; Masuda, Kyoko; Satoh, Rumi; Kakugawa, Kiyokazu; Ikawa, Tomokatsu; Katsura, Yoshimoto; Kawamoto, Hiroshi] RIKEN Res Ctr Allergy & Immunol, Lab Lymphocyte Dev, Yokohama, Kanagawa 2300045, Japan; [Katsura, Yoshimoto] Nihon Univ, Sch Med, Div Cell Regenerat & Transplantat, Adv Med Res Ctr, Tokyo 1738610, Japan	RIKEN; Nihon University	Kawamoto, H (corresponding author), RIKEN Res Ctr Allergy & Immunol, Lab Lymphocyte Dev, Yokohama, Kanagawa 2300045, Japan.	kawamoto@rcai.riken.jp	Wada, Haruka/F-8828-2012	Kakugawa, Kiyokazu/0000-0002-2560-5562				Anderson MK, 2002, IMMUNITY, V16, P285, DOI 10.1016/S1074-7613(02)00277-7; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; Balciunaite G, 2005, BLOOD, V105, P1930, DOI 10.1182/blood-2004-08-3087; Benz C, 2005, J EXP MED, V202, P21, DOI 10.1084/jem.20050146; Buza-Vidas N, 2007, CURR OPIN HEMATOL, V14, P315, DOI 10.1097/MOH.0b013e3281de72bb; HOLLANDER GA, 1995, NATURE, V373, P350, DOI 10.1038/373350a0; Ikawa M, 1998, FEBS LETT, V430, P83, DOI 10.1016/S0014-5793(98)00593-6; Ikawa T, 2004, BLOOD, V103, P530, DOI 10.1182/blood-2003-06-1797; Katsura Y, 2002, NAT REV IMMUNOL, V2, P127, DOI 10.1038/nri721; Kawamoto H, 2006, TRENDS IMMUNOL, V27, P169, DOI 10.1016/j.it.2006.02.004; Kawamoto H, 2000, IMMUNITY, V12, P441, DOI 10.1016/S1074-7613(00)80196-X; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; Kawamoto H, 1998, J IMMUNOL, V161, P3799; Kincade PW, 2002, IMMUNOL REV, V187, P116, DOI 10.1034/j.1600-065X.2002.18710.x; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Laiosa CV, 2006, ANNU REV IMMUNOL, V24, P705, DOI 10.1146/annurev.immunol.24.021605.090742; Lee CK, 2001, J IMMUNOL, V166, P5964, DOI 10.4049/jimmunol.166.10.5964; Lind EF, 2001, J EXP MED, V194, P127, DOI 10.1084/jem.194.2.127; Lu M, 2005, J IMMUNOL, V175, P5848, DOI 10.4049/jimmunol.175.9.5848; Lu M, 2002, J IMMUNOL, V169, P3519, DOI 10.4049/jimmunol.169.7.3519; Masuda K, 2005, EMBO J, V24, P4052, DOI 10.1038/sj.emboj.7600878; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; Ohmura K, 1999, J IMMUNOL, V163, P4788; Spangrude GJ, 2002, IMMUNOL REV, V187, P40, DOI 10.1034/j.1600-065X.2002.18704.x; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; WANG BP, 1994, P NATL ACAD SCI USA, V91, P9402, DOI 10.1073/pnas.91.20.9402	26	262	276	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2008	452	7188					768	U10		10.1038/nature06839	http://dx.doi.org/10.1038/nature06839			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401412				2022-12-28	WOS:000254792500049
J	Hiyama, E; Iehara, T; Sugimoto, T; Fukuzawa, M; Hayashi, Y; Sasaki, F; Sugiyama, M; Kondo, S; Yoneda, A; Yamaoka, H; Tajiri, T; Akazawa, K; Ohtaki, M				Hiyama, Eiso; Iehara, Tomoko; Sugimoto, Tohru; Fukuzawa, Masahiro; Hayashi, Yutaka; Sasaki, Fumiaki; Sugiyama, Masahiko; Kondo, Satoshi; Yoneda, Akihiro; Yamaoka, Hiroaki; Tajiri, Tatsuro; Akazawa, Kohei; Ohtaki, Mequ			Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study	LANCET			English	Article							TEXAS OUTREACH PROGRAM; NEURO-BLASTOMA; UNITED-STATES; JAPAN; MORTALITY; SURVIVAL; DECREASE; CHILDREN; INFANTS; CANCER	Background In Japan, a nationwide programme between 1984 and 2003 screened all infants for urinary catecholamine metabolites as a marker for neuroblastoma. Before 1989, this was done by qualitative spot tests for vanillylmandelic acid in urine, and subsequently by quantitative assay with high-performance liquid chromatography (HPLC). However, the Japanese government stopped the mass-screening programme in 2003, after reports that it did not reduce mortality due to neuroblastoma. We aimed to assess the effectiveness of the programme, by comparing the rates of incidence and mortality from neuroblastomas diagnosed before 6 years of age in three cohorts. Methods We did a retrospective population-based cohort study on all children born between 1980 and 1998, except for a 2-year period from 1984. We divided these 22 289 695 children into three cohorts: children born before screening in 1980-83 (n=6 130 423); those born during qualitative screening in 1986-89 (n=5 290 412); and those born during quantitative screening 1990-98 (n=10 868 860). We used databases from hospitals, screening centres, and national cancer registries. Cases of neuroblastoma were followed up for a mean of 78.7 months. Findings 21.56 cases of neuroblastorna per 100 000 births over 72 months were identified in the qualitatively screened group (relative risk [RR] 1 . 87, 95% Cl 1 . 66-2. 10), and 29.80 cases per 100 000 births over 72 months in the quantitatively screened group (RR 2.58, 2.33-2.86). The cumulative incidence of neuroblastorna in the prescreening cohort (11 . 56 cases per 100 000 births over 72 months) was lower than that in other cohorts (p<0 . 0001 for all comparisons), but more neuroblastomas were diagnosed after 24 months of age in this cohort (p=0 . 0002 for qualitative screening vs prescreening, p<0 . 0001 for quantitative screening vs prescreening). Cumulative mortality was lower in the qualititative screening (3.90 cases per 100 000 livebirths over 72 months) and quantitative screening cohorts (2.83 cases) than in the prescreening cohort (5.38 cases). Compared with the prescreening cohort, the relative risk of mortality was 0 . 73 (95% Cl 0 . 58-0.90) for qualitative screening, and 0 . 53 (0.42-0.63) for quantitative screening. Mortality rates for both the qualitative and quantitative screening groups were lower than were those for the prescreening cohort (p=0 . 0041 for prescreening vs qualitative screening, p<0. 0001 for prescreening vs quantitative screening). Interpretation More infantile neuroblastomas were recorded in children who were screened for neuroblastoma at 6 months of age than in those who were not. The mortality rate from neuroblastoma in children who were screened at 6 months was lower than that in the prescreening cohort, especially in children screened by quantitative HPLC. Any new screening programme should aim to decrease mortality but also to minimise overdiagnosis of turnours with favourable prognoses (eg, by screening children at 18 months).	[Hiyama, Eiso] Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Minami Ku, Hiroshima 7348551, Japan; [Hiyama, Eiso; Yamaoka, Hiroaki] Hiroshima Univ Hosp, Dept Paediat Surg, Hiroshima, Japan; [Ohtaki, Mequ] Hiroshima Univ, Dept Environmetr & Biometr, Res Inst Radiat Biol & Med, Hiroshima 7348551, Japan; [Iehara, Tomoko; Sugimoto, Tohru] Kyoto Prefectural Univ Med, Dept Paediat, Kyoto, Japan; [Fukuzawa, Masahiro; Yoneda, Akihiro] Osaka Univ, Grad Sch Med, Dept Paediat Surg, Osaka, Japan; [Hayashi, Yutaka] Tohoku Univ, Sch Med, Dept Paediat Surg, Sendai, Miyagi 980, Japan; [Sasaki, Fumiaki] Hokkaido Univ, Grad Sch Med, Dept Paediat Surg, Sapporo, Hokkaido, Japan; [Sugiyama, Masahiko] Univ Tokyo, Grad Sch Med, Dept Paediat Surg, Tokyo, Japan; [Kondo, Satoshi] Nagoya City Univ, Grad Sch Med Sci, Dept Oncol Immunol & Surg, Nagoya, Aichi, Japan; [Tajiri, Tatsuro] Kyushu Univ, Dept Pediat Surg, Grad Sch Med Sci, Fukuoka 812, Japan; [Akazawa, Kohei] Niigata Univ, Med & Dent Hosp, Dept Med Informat, Niigata, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Kyoto Prefectural University of Medicine; Osaka University; Tohoku University; Hokkaido University; University of Tokyo; Nagoya City University; Kyushu University; Niigata University	Hiyama, E (corresponding author), Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	eiso@hiroshima-u.ac.jp	Hiyama, Eiso/A-2013-2019; Ohtaki, Megu/S-9927-2018	Hiyama, Eiso/0000-0001-9179-5037; 				Ajiki W, 1998, CANCER CAUSE CONTROL, V9, P631, DOI 10.1023/A:1008897123707; Ater JL, 1998, CANCER, V82, P1593, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1593::AID-CNCR23>3.0.CO;2-Z; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; Berthold F, 1999, J CLIN ONCOL, V17, P1200, DOI 10.1200/JCO.1999.17.4.1200; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Dobrovoljski G, 2003, J PEDIAT HEMATOL ONC, V25, P14, DOI 10.1097/00043426-200301000-00005; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; HAYASHI K, 2004, ADV NEUR RES C GEN I, P95; HISASHIGE A, 2000, EVALUATION MASS SCRE; Honjo S, 2003, INT J CANCER, V103, P538, DOI 10.1002/ijc.10859; *JAP SOC MASS SCRE, 1999, J JPN SOC MASS SCREE, V9, P81; Kerbl R, 1998, CANCER, V83, P2047, DOI 10.1002/(SICI)1097-0142(19981101)83:9<2047::AID-CNCR27>3.0.CO;2-N; Mathieu P, 1996, EARLY HUM DEV, V46, P177, DOI 10.1016/0378-3782(96)01763-X; Nishi M, 1998, ONCOL REP, V5, P1399; Nishi M, 2002, J EXP CLIN CANC RES, V21, P73; Nishi M, 1998, CANCER, V82, P1973, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1973::AID-CNCR22>3.0.CO;2-P; Oue T, 2005, J PEDIATR SURG, V40, P359, DOI 10.1016/j.jpedsurg.2004.10.062; PARKIN DM, 1988, INT J CANCER, V42, P511, DOI 10.1002/ijc.2910420408; Powell JE, 1998, LANCET, V352, P682, DOI 10.1016/S0140-6736(97)11239-9; SAWADA T, 1984, LANCET, V2, P271; SAWADA T, 1982, AM J DIS CHILD, V136, P710, DOI 10.1001/archpedi.1982.03970440054015; SAWADA T, 1988, LANCET, V2, P1134; SAWADA T, 1984, MED PEDIATR ONCOL, V12, P101, DOI 10.1002/mpo.2950120208; SAWAGUCHI S, 1990, CANCER, V66, P1879, DOI 10.1002/1097-0142(19901101)66:9<1879::AID-CNCR2820660905>3.0.CO;2-L; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; SCHILLING FH, 1994, LANCET, V344, P1157, DOI 10.1016/S0140-6736(94)90665-3; TREUNER J, 1995, EUR J CANCER, V31A, P565, DOI 10.1016/0959-8049(95)00034-G; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; Woods WG, 2002, NEW ENGL J MED, V346, P1041, DOI 10.1056/NEJMoa012387; Yamamoto K, 1998, J CLIN ONCOL, V16, P1265, DOI 10.1200/JCO.1998.16.4.1265; Yamamoto K, 2002, J CLIN ONCOL, V20, P1209, DOI 10.1200/JCO.2002.20.5.1209; Yoneda A, 2001, MED PEDIATR ONCOL, V36, P160, DOI 10.1002/1096-911X(20010101)36:1<160::AID-MPO1039>3.0.CO;2-G; YOUNG JL, 1987, CANCER, V56, P598; 1999, MED PEDIAT ONCOL, V33, P357	34	57	60	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 5	2008	371	9619					1173	1180		10.1016/S0140-6736(08)60523-1	http://dx.doi.org/10.1016/S0140-6736(08)60523-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395578				2022-12-28	WOS:000254956000026
J	Kluger, N; Cohen-Valensi, R; Nezri, M				Kluger, Nicolas; Cohen-Valensi, Rolande; Nezri, Meyer			Black lymph nodes - and a colourful skin	LANCET			English	Editorial Material							TATTOO; PATIENT		[Kluger, Nicolas] Univ Montpellier I, Dept Dermatol, Hop St Eloi, CHU Montpellier, F-34295 Montpellier 5, France; [Cohen-Valensi, Rolande; Nezri, Meyer] Ctr Hosp Gen, Dept Internal Med, Martigues, France	Universite de Montpellier; CHU de Montpellier	Kluger, N (corresponding author), Univ Montpellier I, Dept Dermatol, Hop St Eloi, CHU Montpellier, 80 Ave Augustin Fliche, F-34295 Montpellier 5, France.	nicolaskluger@yahoo.fr	Kluger, Nicolas/L-4220-2019	Kluger, Nicolas/0000-0002-5225-8316				Jack C M, 2005, Int Semin Surg Oncol, V2, P28; Mangas C, 2007, DERMATOL SURG, V33, P766, DOI 10.1111/j.1524-4725.2007.33161.x; Nam H, 2007, LANCET ONCOL, V8, P1147, DOI 10.1016/S1470-2045(07)70382-0; SPERRY K, 1992, AM J FOREN MED PATH, V13, P7, DOI 10.1097/00000433-199203000-00003; Zirkin HJ, 2001, CUTIS, V67, P471	5	18	18	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2008	371	9619					1214	1214		10.1016/S0140-6736(08)60529-2	http://dx.doi.org/10.1016/S0140-6736(08)60529-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395584				2022-12-28	WOS:000254956000032
J	Welm, AL				Welm, Alana L.			TGF beta primes breast tumor cells for metastasis	CELL			English	Editorial Material							CANCER METASTASIS; PROGRESSION; INVASION	The microenvironment of a tumor is known to influence tumor progression and spread to distant sites (metastasis). Padua et al. (2008) now show that transient exposure of breast cancer cells to the signaling molecule transforming growth factor beta (TGF beta) promotes their extravasation from blood vessels and entry into the lung by upregulation of the adipokine angiopoietin-like 4 (ANGPTL4). Their work shows that the later stages of metastasis can be influenced by transient signals produced in the primary tumor microenvironment.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Welm, AL (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA.	alana.welm@hci.utah.edu						Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; McSherry EA, 2007, CELL MOL LIFE SCI, V64, P3201, DOI 10.1007/s00018-007-7388-0; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Olumi AF, 1999, CANCER RES, V59, P5002; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0	10	21	21	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 4	2008	133	1					27	28		10.1016/j.cell.2008.03.012	http://dx.doi.org/10.1016/j.cell.2008.03.012			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394984	Bronze			2022-12-28	WOS:000254641300003
J	Safdar, N; Abad, CL; Kaul, DR; Jarrard, D; Saint, S				Safdar, Nasia; Abad, Cybele L.; Kaul, Daniel R.; Jarrard, David; Saint, Sanjay			An unintended consequence	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BACILLUS-CALMETTE-GUERIN; SUPERFICIAL BLADDER-CANCER; MYCOTIC-ANEURYSM; THERAPY; IMMUNOTHERAPY; COMPLICATIONS; BCG		[Abad, Cybele L.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA; [Jarrard, David] Univ Wisconsin, Sch Med, Dept Surg, Madison, WI USA; [Kaul, Daniel R.; Saint, Sanjay] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; [Saint, Sanjay] Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Michigan System; University of Michigan	Safdar, N (corresponding author), Univ Wisconsin, Clin Sci Ctr H4 572, Div Infect Dis, 600 Highland Ave, Madison, WI 53792 USA.	ns2@medicine.wisc.edu	Saint, Sanjay/AAF-5126-2019					*AM CANC SOC, 2007, CANC FACTS FIG 2007; Bohle A, 2000, EUR UROL, V37, P1, DOI 10.1159/000052375; BORNET P, 1989, J VASC SURG, V10, P688, DOI 10.1067/mva.1989.15576; Damm O, 1998, J UROLOGY, V159, P984, DOI 10.1016/S0022-5347(01)63796-0; Elkabani M, 2000, Cancer Control, V7, P476; Kamphuis JT, 2001, NETH J MED, V58, P71, DOI 10.1016/S0300-2977(00)00098-X; LAMM DL, 1992, J UROLOGY, V147, P596, DOI 10.1016/S0022-5347(17)37316-0; Mack D, 2001, J UROLOGY, V165, P401, DOI 10.1097/00005392-200102000-00011; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; MORALES A, 1992, UROL CLIN N AM, V19, P549; Seelig MH, 1999, J VASC SURG, V29, P377, DOI 10.1016/S0741-5214(99)70391-5; Shelley MD, 2004, BJU INT, V93, P485, DOI 10.1111/j.1464-410X.2003.04655.x; VANDERMEIJDEN APM, 1995, EUR UROL, V27, P23; VANDERMEIJDEN APM, 1991, J UROLOGY, V146, P444, DOI 10.1016/S0022-5347(17)37821-7; Vegt PDJ, 1997, J UROLOGY, V157, P1246, DOI 10.1016/S0022-5347(01)64936-X	15	23	23	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1496	1501		10.1056/NEJMcps0706711	http://dx.doi.org/10.1056/NEJMcps0706711			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282CY	18385502				2022-12-28	WOS:000254546400013
J	Steinberger, B; Torsvik, TH				Steinberger, Bernhard; Torsvik, Trond H.			Absolute plate motions and true polar wander in the absence of hotspot tracks	NATURE			English	Article							AXIS	The motion of continents relative to the Earth's spin axis may be due either to rotation of the entire Earth relative to its spin axis true polar wander(1,2) - or to the motion of individual plates(3). In order to distinguish between these over the past 320 Myr ( since the formation of the Pangaea supercontinent), we present here computations of the global average of continental motion and rotation through time(4) in a palaeomagnetic reference frame. Two components are identified: a steady northward motion and, during certain time intervals, clockwise and anticlockwise rotations, interpreted as evidence for true polar wander. We find 186 anti-clockwise rotation about 250-220 Myr ago and the same amount of clockwise rotation about 195-145 Myr ago. In both cases the rotation axis is located at about 10-20 degrees W, 0 degrees N, near the site that became the North American - South American - African triple junction at the break- up of Pangaea. This was followed by 106 clockwise rotation about 145-135 Myr ago, followed again by the same amount of anticlockwise rotation about 110-100 Myr ago, with a rotation axis in both cases similar to 25-50 degrees E in the reconstructed area of North Africa and Arabia. These rotation axes mark the maxima of the degree- two non- hydrostatic geoid during those time intervals, and the fact that the overall net rotation since 320 Myr ago is nearly zero is an indication of long- term stability of the degree- two geoid and related mantle structure(5,6). We propose a new reference frame, based on palaeomagnetism, but corrected for the true polar wander identified in this study, appropriate for relating surface to deep mantle processes from 320 Myr ago until hotspot tracks can be used ( about 130 Myr ago).	[Steinberger, Bernhard; Torsvik, Trond H.] Geol Survey Norway, Ctr Geodynam, N-7491 Trondheim, Norway; [Torsvik, Trond H.] Univ Oslo, N-0316 Oslo, Norway; [Torsvik, Trond H.] Univ Witwatersrand, Sch Geosci, ZA-2050 Johannesburg, South Africa	Geological Survey of Norway; University of Oslo; University of Witwatersrand	Steinberger, B (corresponding author), Geol Survey Norway, Ctr Geodynam, Leiv Eirikssons Vei 39, N-7491 Trondheim, Norway.	bernhard.steinberger@ngu.no	Steinberger, Bernhard/ABB-9204-2021; Steinberger, Bernhard/AAG-7148-2019	Steinberger, Bernhard/0000-0002-3643-3049				Becker TW, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000168; Besse J, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000050; CHANG T, 1990, GEOPHYS J INT, V101, P649, DOI 10.1111/j.1365-246X.1990.tb05576.x; DEMETS C, 1990, GEOPHYS J INT, V101, P425, DOI 10.1111/j.1365-246X.1990.tb06579.x; Evans DAD, 2003, TECTONOPHYSICS, V362, P303, DOI 10.1016/S0040-1951(02)000642-X; GOLD T, 1955, NATURE, V175, P526, DOI 10.1038/175526a0; GOLDREICH P, 1969, J GEOPHYS RES, V74, P2555, DOI 10.1029/JB074i010p02555; HAGER BH, 1984, J GEOPHYS RES, V89, P6003, DOI 10.1029/JB089iB07p06003; JURDY DM, 1975, SCIENCE, V187, P1193, DOI 10.1126/science.187.4182.1193; Kirschvink JL, 1997, SCIENCE, V277, P541, DOI 10.1126/science.277.5325.541; Maloof AC, 2006, GEOL SOC AM BULL, V118, P1099, DOI 10.1130/B25892.1; Marcano MC, 1999, J GEODYN, V28, P75, DOI 10.1016/S0264-3707(98)00026-X; McCarthy D, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004535; MORGAN WJ, 1971, NATURE, V230, P42, DOI 10.1038/230042a0; Mound JE, 2001, GEOPHYS RES LETT, V28, P2057, DOI 10.1029/2000GL012369; O'Neill C, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2004GC000784; RICHARDS MA, 1984, J GEOPHYS RES, V89, P5987, DOI 10.1029/JB089iB07p05987; Steinberger B, 1997, NATURE, V387, P169, DOI 10.1038/387169a0; Steinberger B, 2002, GEODYNAMICS, V29, P233; Steinberger B, 2004, NATURE, V430, P167, DOI 10.1038/nature02660; Torsvik TH, 2004, J GEOL SOC LONDON, V161, P555, DOI 10.1144/0016-764903-098; Torsvik TH, 2002, EARTH PLANET SC LETT, V202, P185, DOI 10.1016/S0012-821X(02)00807-5; Torsvik TH, 1999, COMPUT GEOSCI-UK, V25, P395, DOI 10.1016/S0098-3004(98)00143-5; TORSVIK TH, IN PRESS REV GEOPHYS; Torsvik TH, 2006, GEOPHYS J INT, V167, P1447, DOI 10.1111/j.1365-246X.2006.03158.x; Tsai VC, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2005JB003923; Wegener A, 2001, J GEODYN, V32, P31; Wegener A, 1912, PETERMANNS MITT, V58, P185; Wegener A, 1912, PETERMANNS MITT, V58, P253; Wegener A, 1912, PETERMANNS MITT, V58, P305; Wessel P, 1991, EOS T AM GEOPHYS UN, V72, P445, DOI [10.1029/90EO00319, DOI 10.1029/90EO00319, DOI 10.1029/90E000319]; WILSON JT, 1963, CAN J PHYS, V41, P863, DOI 10.1139/p63-094	32	175	177	4	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2008	452	7187					620	U6		10.1038/nature06824	http://dx.doi.org/10.1038/nature06824			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385737				2022-12-28	WOS:000254567200043
J	Iglehart, JK				Iglehart, John K.			Spreading the safety net - Obstacles to the expansion of community health centers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE											Cook NL, 2007, HEALTH AFFAIR, V26, P1459, DOI 10.1377/hlthaff.26.5.1459; Isaacs SL, 2007, HEALTH AFFAIR, V26, P871, DOI 10.1377/hlthaff.26.3.871; *PFIZ, 2007, MOM LEAD CAS STUD PU; *R GRAH CTR, 2007, ACC DEN LOOK AM MED; Rosenblatt RA, 2006, JAMA-J AM MED ASSOC, V295, P1042, DOI 10.1001/jama.295.9.1042	5	18	18	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1321	1323		10.1056/NEJMp0801332	http://dx.doi.org/10.1056/NEJMp0801332			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367733				2022-12-28	WOS:000254308400001
J	Kudva, YC; Montori, VM				Kudva, Yogish C.; Montori, Victor M.			Patient-centred treatments for type 2 diabetes	LANCET			English	Editorial Material							HYPERGLYCEMIA; INSULIN; COMPLICATIONS; METFORMIN; CONSENSUS; THERAPY		[Kudva, Yogish C.; Montori, Victor M.] Mayo Clin, Div Endocrinol & Metab, Rochester, MN 55905 USA	Mayo Clinic	Kudva, YC (corresponding author), Mayo Clin, Div Endocrinol & Metab, Rochester, MN 55905 USA.	kudva.yogish@mayo.edu		Montori, Victor/0000-0003-0595-2898				Bretzel RG, 2008, LANCET, V371, P1073, DOI 10.1016/S0140-6736(08)60485-7; Camastra S, 2007, DIABETES CARE, V30, P1002, DOI 10.2337/dc06-1845; Holman RR, 2007, NEW ENGL J MED, V357, P1716, DOI 10.1056/NEJMoa075392; Huang ES, 2007, DIABETES CARE, V30, P2478, DOI 10.2337/dc07-0499; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Monnier L, 2003, DIABETES CARE, V26, P881, DOI 10.2337/diacare.26.3.881; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Montori VM, 2007, LANCET, V370, P1104, DOI 10.1016/S0140-6736(07)61489-5; Nathan DM, 2006, DIABETES CARE, V29, P1963, DOI 10.2337/dc06-9912; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6	11	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR-APR	2008	371	9618					1047	1048		10.1016/S0140-6736(08)60462-6	http://dx.doi.org/10.1016/S0140-6736(08)60462-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18374823				2022-12-28	WOS:000254442700004
J	Rajagopal, A; Rao, AU; Amigo, J; Tian, M; Upadhyay, SK; Hall, C; Uhm, S; Mathew, MK; Fleming, MD; Paw, BH; Krause, M; Hamza, I				Rajagopal, Abbhirami; Rao, Anita U.; Amigo, Julio; Tian, Meng; Upadhyay, Sanjeev K.; Hall, Caitlin; Uhm, Suji; Mathew, M. K.; Fleming, Mark D.; Paw, Barry H.; Krause, Michael; Hamza, Iqbal			Haem homeostasis is regulated by the conserved and concerted functions of HRG-1 proteins	NATURE			English	Article							TRANSPORTER; ZEBRAFISH; BIOSYNTHESIS; DISORDERS; SENSOR	Haems are metalloporphyrins that serve as prosthetic groups for various biological processes including respiration, gas sensing, xenobiotic detoxification, cell differentiation, circadian clock control, metabolic reprogramming and microRNA processing(1-4). With a few exceptions, haem is synthesized by a multistep biosynthetic pathway comprising defined intermediates that are highly conserved throughout evolution(5). Despite our extensive knowledge of haem biosynthesis and degradation, the cellular pathways and molecules that mediate intracellular haem trafficking are unknown. The experimental setback in identifying haem trafficking pathways has been the inability to dissociate the highly regulated cellular synthesis and degradation of haem from intracellular trafficking events(6). Caenorhabditis elegans and related helminths are natural haem auxotrophs that acquire environmental haem for incorporation into haemoproteins, which have vertebrate orthologues(7). Here we show, by exploiting this auxotrophy to identify HRG-1 proteins in C. elegans, that these proteins are essential for haem homeostasis and normal development in worms and vertebrates. Depletion of hrg-1, or its paralogue hrg-4, in worms results in the disruption of organismal haem sensing and an abnormal response to haem analogues. HRG-1 and HRG-4 are previously unknown transmembrane proteins, which reside in distinct intracellular compartments. Transient knockdown of hrg-1 in zebrafish leads to hydrocephalus, yolk tube malformations and, most strikingly, profound defects in erythropoiesis-phenotypes that are fully rescued by worm HRG-1. Human and worm proteins localize together, and bind and transport haem, thus establishing an evolutionarily conserved function for HRG-1. These findings reveal conserved pathways for cellular haem trafficking in animals that define the model for eukaryotic haem transport. Thus, uncovering the mechanisms of haem transport in C. elegans may provide insights into human disorders of haem metabolism and reveal new drug targets for developing anthelminthics to combat worm infestations.	[Rajagopal, Abbhirami; Rao, Anita U.; Uhm, Suji; Hamza, Iqbal] Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA; [Rajagopal, Abbhirami; Rao, Anita U.; Hall, Caitlin; Uhm, Suji; Hamza, Iqbal] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; [Amigo, Julio; Paw, Barry H.] Harvard Univ, Sch Med, Div Hematol, Dept Med,Brigham & Womens Hosp, Boston, MA 02115 USA; [Tian, Meng; Fleming, Mark D.] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; [Upadhyay, Sanjeev K.; Mathew, M. K.] Univ Agr Sci Bangalore, Natl Ctr Biol Sci, Tata Inst Fundamental Res, Bangalore 560065, Karnataka, India; [Krause, Michael] NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); University of Agricultural Sciences Bangalore; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hamza, I (corresponding author), Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA.	hamza@umd.edu		amigo, julio/0000-0002-6481-8034; Krause, Michael/0000-0001-6127-3940; Fleming, Mark/0000-0003-0948-4024; Paw, Barry/0000-0002-0492-1419; Hamza, Iqbal/0000-0003-0045-0610	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036134, R01DK074797] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [R01 DK074797-01, R01 DK074797] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett CM, 2001, BLOOD, V98, P643, DOI 10.1182/blood.V98.3.643; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Dailey HA, 2002, BIOCHEM SOC T, V30, P590, DOI 10.1042/bst0300590; De Domenico I, 2008, NAT REV MOL CELL BIO, V9, P72, DOI 10.1038/nrm2295; Faller M, 2007, NAT STRUCT MOL BIOL, V14, P23, DOI 10.1038/nsmb1182; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hamza I, 2006, ACS CHEM BIOL, V1, P627, DOI 10.1021/cb600442b; Kaasik K, 2004, NATURE, V430, P467, DOI 10.1038/nature02724; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Lin HF, 2005, BLOOD, V106, P3803, DOI 10.1182/blood-2005-01-0179; Mao XQ, 2007, J BIOL CHEM, V282, P6992, DOI 10.1074/jbc.M610552200; McGhee JD, 2007, DEV BIOL, V302, P627, DOI 10.1016/j.ydbio.2006.10.024; MEDLOCK AE, 2007, TETRAPYRROLES, P116; NASS R, 2007, CURRENT PROTOCOLS TO; Pellicena P, 2004, P NATL ACAD SCI USA, V101, P12854, DOI 10.1073/pnas.0405188101; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Rao AU, 2005, P NATL ACAD SCI USA, V102, P4270, DOI 10.1073/pnas.0500877102; Rees EM, 2004, CURR OPIN MICROBIOL, V7, P175, DOI 10.1016/j.mib.2004.02.004; Schmidt PM, 2005, EUR J PHARMACOL, V513, P67, DOI 10.1016/j.ejphar.2005.02.046; Shafizadeh E, 2004, CURR OPIN HEMATOL, V11, P255, DOI 10.1097/01.moh.0000138686.15806.71; Yin L, 2007, SCIENCE, V318, P1786, DOI 10.1126/science.1150179	23	223	238	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2008	453	7198					1127	1131		10.1038/nature06934	http://dx.doi.org/10.1038/nature06934			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WM	18418376	Green Accepted			2022-12-28	WOS:000256839900062
J	Guo, Y; Walther, TC; Rao, M; Stuurman, N; Goshima, G; Terayama, K; Wong, JS; Vale, RD; Walter, P; Farese, RV				Guo, Yi; Walther, Tobias C.; Rao, Meghana; Stuurman, Nico; Goshima, Gohta; Terayama, Koji; Wong, Jinny S.; Vale, Ronald D.; Walter, Peter; Farese, Robert V., Jr.			Functional genomic screen reveals genes involved in lipid-droplet formation and utilization	NATURE			English	Article							DROSOPHILA; PROTEINS; ROLES; PHOSPHORYLATION; ENDOCYTOSIS; PERILIPIN; RECEPTOR; RNA	Eukaryotic cells store neutral lipids in cytoplasmic lipid droplets(1,2) enclosed in a monolayer of phospholipids and associated proteins(3,4). These dynamic organelles(5) serve as the principal reservoirs for storing cellular energy and for the building blocks for membrane lipids. Excessive lipid accumulation in cells is a central feature of obesity, diabetes and atherosclerosis, yet remarkably little is known about lipid- droplet cell biology. Here we show, by means of a genome- wide RNA interference ( RNAi) screen in Drosophila S2 cells that about 1.5% of all genes function in lipid- droplet formation and regulation. The phenotypes of the gene knockdowns sorted into five distinct phenotypic classes. Genes encoding enzymes of phospholipid biosynthesis proved to be determinants of lipid- droplet size and number, suggesting that the phospholipid composition of the monolayer profoundly affects droplet morphology and lipid utilization. A subset of the Arf1 - COPI vesicular transport proteins also regulated droplet morphology and lipid utilization, thereby identifying a previously unrecognized function for this machinery. These phenotypes are conserved in mammalian cells, suggesting that insights from these studies are likely to be central to our understanding of human diseases involving excessive lipid storage.	[Guo, Yi; Walther, Tobias C.; Walter, Peter; Farese, Robert V., Jr.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; [Stuurman, Nico; Goshima, Gohta; Vale, Ronald D.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Farese, Robert V., Jr.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; [Guo, Yi; Rao, Meghana; Terayama, Koji; Wong, Jinny S.; Farese, Robert V., Jr.] Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; [Walther, Tobias C.] Max Planck Inst Biochem, D-12852 Martinsried, Germany; [Vale, Ronald D.; Walter, Peter] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; Max Planck Society; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Farese, RV (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA.	twalther@biochem.mpg.de; bfarese@gladstone.ucsf.edu	Stuurman, Nico/AAV-4894-2021; Lai, Michael M. C./I-7001-2012	Stuurman, Nico/0000-0002-6179-8613; Terayama, Koji/0000-0002-0740-9074; Walther, Tobias/0000-0003-1442-1327	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK078254] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIDDK NIH HHS [R21 DK078254-01, R21 DK078254] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bard F, 2006, NATURE, V439, P604, DOI 10.1038/nature04377; Bartz R, 2007, J LIPID RES, V48, P837, DOI 10.1194/jlr.M600413-JLR200; Bartzt R, 2007, J PROTEOME RES, V6, P3256, DOI 10.1021/pr070158j; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; Goshima G, 2007, SCIENCE, V316, P417, DOI 10.1126/science.1141314; Hafez IM, 2001, ADV DRUG DELIVER REV, V47, P139, DOI 10.1016/S0169-409X(01)00103-X; Hojjati MR, 2006, J LIPID RES, V47, P673, DOI 10.1194/jlr.D500040-JLR200; Kent C, 2005, BBA-MOL CELL BIOL L, V1733, P53, DOI 10.1016/j.bbalip.2004.12.008; Kulkarni MM, 2006, NAT METHODS, V3, P833, DOI 10.1038/nmeth935; Kumar Y, 2006, CURR BIOL, V16, P1646, DOI 10.1016/j.cub.2006.06.060; Ma Y, 2006, NATURE, V443, P359, DOI 10.1038/nature05179; Marcinkiewicz A, 2006, J BIOL CHEM, V281, P11901, DOI 10.1074/jbc.M600171200; Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Miyanari Y, 2007, NAT CELL BIOL, V9, P1089, DOI 10.1038/ncb1631; Monetti M, 2007, CELL METAB, V6, P69, DOI 10.1016/j.cmet.2007.05.005; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; Nakamura N, 2005, BIOCHEM BIOPH RES CO, V335, P117, DOI 10.1016/j.bbrc.2005.07.050; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Ulvila J, 2006, J BIOL CHEM, V281, P14370, DOI 10.1074/jbc.M513868200; Verghese PB, 2007, MOL CELL BIOCHEM, V302, P241, DOI 10.1007/s11010-007-9447-0; Weber U, 2003, DEV CELL, V5, P559, DOI 10.1016/S1534-5807(03)00273-9	30	532	541	5	124	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					657	661		10.1038/nature06928	http://dx.doi.org/10.1038/nature06928			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18408709	Green Accepted			2022-12-28	WOS:000256185200045
J	Wang, PYT; Caspi, L; Lam, CKL; Chari, M; Li, XS; Light, PE; Gutierrez-Juarez, R; Ang, M; Schwartz, GJ; Lam, TKT				Wang, Penny Y. T.; Caspi, Liora; Lam, Carol K. L.; Chari, Madhu; Li, Xiaosong; Light, Peter E.; Gutierrez-Juarez, Roger; Ang, Michelle; Schwartz, Gary J.; Lam, Tony K. T.			Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production	NATURE			English	Article							D-ASPARTATE RECEPTORS; FOOD-INTAKE; OBESITY; ENERGY; MECHANISMS; HOMEOSTASIS; NUCLEUS; BALANCE; SIGNALS; WEIGHT	Energy and glucose homeostasis are regulated by food intake and liver glucose production, respectively. The upper intestine has a critical role in nutrient digestion and absorption. However, studies indicate that upper intestinal lipids inhibit food intake as well in rodents and humans by the activation of an intestine - brain axis(1-4). In parallel, a brain - liver axis has recently been proposed to detect blood lipids to inhibit glucose production in rodents(5). Thus, we tested the hypothesis that upper intestinal lipids activate an intestine - brain - liver neural axis to regulate glucose homeostasis. Here we demonstrate that direct administration of lipids into the upper intestine increased upper intestinal long- chain fatty acyl-coenzyme A ( LCFA- CoA) levels and suppressed glucose production. Co- infusion of the acyl- CoA synthase inhibitor triacsin C or the anaesthetic tetracaine with duodenal lipids abolished the inhibition of glucose production, indicating that upper intestinal LCFA- CoAs regulate glucose production in the preabsorptive state. Subdiaphragmatic vagotomy or gut vagal deafferentation interrupts the neural connection between the gut and the brain, and blocks the ability of upper intestinal lipids to inhibit glucose production. Direct administration of the N- methyl- D- aspartate ion channel blocker MK- 801 into the fourth ventricle or the nucleus of the solitary tract where gut sensory fibres terminate abolished the upper- intestinal- lipid- induced inhibition of glucose production. Finally, hepatic vagotomy negated the inhibitory effects of upper intestinal lipids on glucose production. These findings indicate that upper intestinal lipids activate an intestine - brain - liver neural axis to inhibit glucose production, and thereby reveal a previously unappreciated pathway that regulates glucose homeostasis.	[Wang, Penny Y. T.; Caspi, Liora; Lam, Carol K. L.; Chari, Madhu; Ang, Michelle; Lam, Tony K. T.] Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON M5G 1L7, Canada; [Lam, Carol K. L.; Chari, Madhu; Lam, Tony K. T.] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; [Lam, Tony K. T.] Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; [Li, Xiaosong; Gutierrez-Juarez, Roger; Schwartz, Gary J.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Li, Xiaosong; Gutierrez-Juarez, Roger; Schwartz, Gary J.] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; [Light, Peter E.] Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Alberta	Lam, TKT (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON M5G 1L7, Canada.	tony.lam@uhnres.utoronto.ca		Lam, Carol/0000-0002-9736-3347	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045024, R29DK045024, R01DK047208] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45024, DK47208] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aicher SA, 1999, NEUROSCIENCE, V91, P119, DOI 10.1016/S0306-4522(98)00530-2; Badman MK, 2005, SCIENCE, V307, P1909, DOI 10.1126/science.1109951; Bence KK, 2006, NAT MED, V12, P917, DOI 10.1038/nm1435; Berthoud HR, 2001, BRAIN RES, V915, P143, DOI 10.1016/S0006-8993(01)02826-8; Caspi L, 2007, CELL METAB, V6, P99, DOI 10.1016/j.cmet.2007.07.005; Coll AP, 2007, CELL, V129, P251, DOI 10.1016/j.cell.2007.04.001; Coppari R, 2005, CELL METAB, V1, P63, DOI 10.1016/j.cmet.2004.12.004; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Covasa M, 2004, AM J PHYSIOL-REG I, V287, pR1462, DOI 10.1152/ajpregu.00471.2004; Cummings DE, 2007, J CLIN INVEST, V117, P13, DOI 10.1172/JCI30227; Cummings David E., 2004, Journal of Clinical Endocrinology & Metabolism, V89, P2608, DOI 10.1210/jc.2004-0433; GREENBERG D, 1995, AM J PHYSIOL-REG I, V269, pR432, DOI 10.1152/ajpregu.1995.269.2.R432; GREENBERG D, 1990, AM J PHYSIOL, V259, pR110, DOI 10.1152/ajpregu.1990.259.1.R110; Lam TKT, 2005, SCIENCE, V309, P943, DOI 10.1126/science.1112085; Lam TKT, 2005, NAT NEUROSCI, V8, P579, DOI 10.1038/nn1456; Lam TKT, 2005, NAT MED, V11, P320, DOI 10.1038/nm1201; Lam TKT, 2007, NAT MED, V13, P171, DOI 10.1038/nm1540; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Matzinger D, 2000, GUT, V46, P688, DOI 10.1136/gut.46.5.689; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Monnikes H, 1997, AM J PHYSIOL-REG I, V273, pR2059, DOI 10.1152/ajpregu.1997.273.6.R2059; MORAN TP, 1994, HUM-COMPUT INTERACT, V9, P1, DOI 10.1207/s15327051hci0901_1; Murphy KG, 2006, NATURE, V444, P854, DOI 10.1038/nature05484; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Pocai A, 2006, J CLIN INVEST, V116, P1081, DOI 10.1172/JCI26640; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; Sclafani A, 2003, PHYSIOL BEHAV, V78, P285, DOI 10.1016/S0031-9384(02)00968-X; Treece BR, 1998, BRAIN RES, V810, P34, DOI 10.1016/S0006-8993(98)00867-1; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414	30	211	221	5	62	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 24	2008	452	7190					1012	1016		10.1038/nature06852	http://dx.doi.org/10.1038/nature06852			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291PF	18401341				2022-12-28	WOS:000255208600043
J	Lenzer, J; Brownlee, S				Lenzer, Jeanne; Brownlee, Shannon			Knowing me, knowing you	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Brownlee, Shannon] New Amer Fdn, Washington, DC USA			jeanne.lenzer@gmail.com						[Anonymous], 2007, MOR GEN DIR; Bach PB, 2007, JAMA-J AM MED ASSOC, V297, P953, DOI 10.1001/jama.297.9.953; Barrette SP, 2006, J CLIN ONCOL, V24, P1542, DOI 10.1200/JCO.2005.04.4602; Berg AO, 2007, GENET MED, V9, P819, DOI 10.1097/GIM.0b013e31815bf9a3; Feero WG, 2008, JAMA-J AM MED ASSOC, V299, P1351, DOI 10.1001/jama.299.11.1351; Goldstein NM, 2001, ARCH INTERN MED, V161, P567, DOI 10.1001/archinte.161.4.567; HERPER M, 2007, FORBES COM      0618; HUDSON K, 2006, PUBLIC CITIZEN  0926; LU E, 2007, PUBLIC CITIZEN  1221; *NCI, US CANC STAT 2004 IN; SCHEUNER MT, 2008, JAMA-J AM MED ASSOC, V229, P1320; Welch HG, 1998, JAMA-J AM MED ASSOC, V280, P1525, DOI 10.1001/jama.280.17.1525; Woods WG, 2002, NEW ENGL J MED, V346, P1041, DOI 10.1056/NEJMoa012387	13	8	8	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2008	336	7649					858	860		10.1136/bmj.39534.451458.AD	http://dx.doi.org/10.1136/bmj.39534.451458.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290QH	18420689	Green Published			2022-12-28	WOS:000255136800028
J	Nordtveit, TI; Melve, KK; Albrechtsen, S; Skjaerven, R				Nordtveit, Tone Irene; Melve, Kari Klungsoyr; Albrechtsen, Susanne; Skjaerven, Rolv			Maternal and paternal contribution to intergenerational recurrence of breech delivery: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							GESTATIONAL-AGE; BIRTH-WEIGHT; RISK-FACTORS; TERM; MORTALITY; SURVIVAL; CHILDREN; DEFECTS; NORWAY	Objective To investigate intergenerational recurrence of breech delivery, with a hypothesis that both women and men delivered in breech presentation contribute to increased risk of breech delivery in their offspring. Design Population based cohort study for two generations. Setting Data from the medical birth registry of Norway, based on all births in Norway 1967-2004 (2.2 million births). Participants Generational data were provided through linkage by national identification numbers, forming 451393 mother-offspring units and 295 253 father-offspring units. We included units where both parents and offspring were singletons and offspring were first born, forming 232 704 mother-offspring units and 154 851 father-offspring units for our analyses. Main outcome measure Breech delivery in the second generation. Results Men and women who themselves were delivered in breech presentation had more than twice the risk of breech delivery in their own first pregnancies compared with men and women who had been cephalic presentations (odds ratios 2.2, 95% confidence interval 1.8 to 2.7, and 2.2, 1.9 to 2.5, for men and women, respectively). The strongest risks of recurrence were found for vaginally delivered offspring and were equally strong for men and women. Increased risk of recurrence of breech delivery in offspring was present only for parents delivered at term. Conclusion Intergenerational recurrence risk of breech delivery in offspring was equally high when transmitted through fathers and mothers. It seems reasonable to attribute the observed pattern of familial predisposition to term breech delivery to genetic inheritance, predominantly through the fetus.	[Nordtveit, Tone Irene; Melve, Kari Klungsoyr; Skjaerven, Rolv] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Sect Epidemiol & Med Stat, N-5018 Bergen, Norway; [Melve, Kari Klungsoyr; Skjaerven, Rolv] Norwegian Inst Publ Hlth, Med Birth Registry, Bergen, Norway; [Albrechtsen, Susanne] Haukeland Hosp, Dept Obstet & Gynaecol, N-5021 Bergen, Norway	University of Bergen; Norwegian Institute of Public Health (NIPH); University of Bergen; Haukeland University Hospital	Nordtveit, TI (corresponding author), Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Sect Epidemiol & Med Stat, Kalfarveien 31, N-5018 Bergen, Norway.	Tone.Nordtveit@isf.uib.no	Klungsøyr, Kari/ABC-6147-2020; Albrechtsen, Susanne/H-4680-2019	Klungsøyr, Kari/0000-0003-2482-1690; 				Albrechtsen S, 1998, OBSTET GYNECOL, V92, P775, DOI 10.1016/S0029-7844(98)00307-X; Albrechtsen S, 1998, ACTA OBSTET GYN SCAN, V77, P410, DOI 10.1034/j.1600-0412.1998.770409.x; Albrechtsen S, 1998, OBSTET GYNECOL, V92, P345, DOI 10.1016/S0029-7844(98)00176-8; BACKE B, 1993, BRIT J OBSTET GYNAEC, V100, P727, DOI 10.1111/j.1471-0528.1993.tb14263.x; BARTLETT D, 1994, DEV MED CHILD NEUROL, V36, P833; BENRAFAEL Z, 1991, J REPROD MED, V36, P723; BLOOMBERG L, 1994, HEALTH EDUC QUART, V21, P447, DOI 10.1177/109019819402100407; BRAUN FHT, 1975, J PEDIATR-US, V86, P419, DOI 10.1016/S0022-3476(75)80977-2; Cartledge LJ, 1942, J HERED, V33, P409, DOI 10.1093/oxfordjournals.jhered.a105106; CRUIKSHANK DP, 1986, CLIN OBSTET GYNECOL, V29, P255, DOI 10.1097/00003081-198606000-00008; Danielian PJ, 1996, BRIT MED J, V312, P1451, DOI 10.1136/bmj.312.7044.1451; DUNN LJ, 1965, OBSTET GYNECOL, V25, P170; Herbst A, 2005, ACTA OBSTET GYN SCAN, V84, P593, DOI 10.1111/j.0001-6349.2005.00852.x; Jaquet D, 2005, BJOG-INT J OBSTET GY, V112, P153, DOI 10.1111/j.1471-0528.2004.00313.x; Kramer MS, 2000, PAEDIATR PERINAT EP, V14, P194, DOI 10.1046/j.1365-3016.2000.00266.x; Lie RT, 2007, PAEDIATR PERINAT EP, V21, P13, DOI 10.1111/j.1365-3016.2007.00832.x; Lie RT, 2001, JAMA-J AM MED ASSOC, V285, P755, DOI 10.1001/jama.285.6.755; LUBCHENCO LO, 1963, PEDIATRICS, V32, P793; LUTERKORT M, 1984, OBSTET GYNECOL, V64, P55; MAGNUS P, 1993, ANN HUM BIOL, V20, P231, DOI 10.1080/03014469300002662; Rayl J, 1996, AM J OBSTET GYNECOL, V174, P28, DOI 10.1016/S0002-9378(96)70368-X; Skjaerven R, 1999, NEW ENGL J MED, V340, P1057, DOI 10.1056/NEJM199904083401401; Skjaerven R, 2000, ACTA OBSTET GYN SCAN, V79, P440, DOI 10.1034/j.1600-0412.2000.079006440.x; *STAT NORW, 2000, NORW STAND ED GROUP; TOMPKINS P, 1946, AM J OBSTET GYNECOL, V51, P595, DOI 10.1016/S0002-9378(15)30116-2	25	18	19	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 19	2008	336	7649					872	876		10.1136/bmj.39505.436539.BE	http://dx.doi.org/10.1136/bmj.39505.436539.BE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290QH	18369204	Green Published, Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000255136800033
J	Binder, PM				Binder, P. -M.			Mathematics - Frustration in complexity	SCIENCE			English	Editorial Material							MODELS		[Binder, P. -M.] Univ Hawaii, Dept Phys & Astron, Hilo, HI 96720 USA	University of Hawaii System; University Hawaii Hilo	Binder, PM (corresponding author), Univ Hawaii, Dept Phys & Astron, Hilo, HI 96720 USA.	pbinder@hawaii.edu	Binder, P. -M./L-9889-2015					BADII R, 1997, COMPLEXITY; Bar-Yam Y., 2005, MAKING THINGS WORK; BARYAM Y, 2003, INTRO COMPLEX SYSTEM; Chomsky Noam, 1959, INFORM CONTR, V2, DOI [10.1016/S0019-9958(59)90362-6, DOI 10.1016/S0019-9958(59)90362-6]; Erdi P., 2007, COMPLEXITY EXPLAINED; Koiran P, 1999, THEOR COMPUT SCI, V210, P217, DOI 10.1016/S0304-3975(98)00117-0; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MITCHELL M, 1993, INTRO GENETIC ALGORI; Strogatz S. H., 2001, NONLINEAR DYNAMICS C; Szabo G, 2007, PHYS REP, V446, P97, DOI 10.1016/j.physrep.2007.04.004; TOULOUSE G, 1977, COMMUN PHYS, V2, P115; Watkins NW, 2008, SCIENCE, V320, P323, DOI 10.1126/science.1151611; WOLFRAM S, 1984, NATURE, V311, P419, DOI 10.1038/311419a0; 1999, SCIENCE         0402, V284	14	27	28	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					322	323		10.1126/science.1156940	http://dx.doi.org/10.1126/science.1156940			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420918				2022-12-28	WOS:000255026100025
J	Redline, RW; Sagar, P; King, ME; Krishnamoorthy, KS; Grabowski, EF; Roberts, DJ; Harris, NL				Redline, Raymond W.; Sagar, Pallavi; King, Mary Etta; Krishnamoorthy, Kalpathy S.; Grabowski, Eric F.; Roberts, Drucilla J.; Harris, Nancy Lee			A newborn infant with intermittent apnea and seizures - Severe acute chorioamnionitis with umbilical-cord phlebitis and intense chorionic-plate vasculitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL INFLAMMATORY RESPONSE; PLACENTAL REACTION PATTERNS; NEUROLOGIC IMPAIRMENT; ARTERIAL STROKE; TERM INFANTS; INFECTION; CHILDREN; REPRODUCIBILITY; VASCULOPATHY; NOSOLOGY		[Redline, Raymond W.] Univ Hosp Case Med Ctr, Dept Pathol, Cleveland, OH USA; [Sagar, Pallavi] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [King, Mary Etta] Massachusetts Gen Hosp, Dept Pediat Cardiol, Boston, MA 02114 USA; [Krishnamoorthy, Kalpathy S.] Massachusetts Gen Hosp, Dept Pediat Neurol, Boston, MA 02114 USA; [Grabowski, Eric F.] Massachusetts Gen Hosp, Dept Pediat Hematol Oncol, Boston, MA 02114 USA; [Roberts, Drucilla J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Redline, Raymond W.] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Sagar, Pallavi] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [King, Mary Etta; Krishnamoorthy, Kalpathy S.; Grabowski, Eric F.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Roberts, Drucilla J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Case Western Reserve University; Case Western Reserve University Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Case Western Reserve University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Redline, RW (corresponding author), Univ Hosp Case Med Ctr, Dept Pathol, Cleveland, OH USA.		Roberts, Drucilla/AAB-6379-2022					Kim CJ, 2001, AM J OBSTET GYNECOL, V185, P496, DOI 10.1067/mob.2001.116689; King EL, 2004, HUM PATHOL, V35, P412, DOI 10.1016/j.humpath.2003.12.002; Kurnik K, 2003, STROKE, V34, P2887, DOI 10.1161/01.STR.0000103745.03393.39; Lee J, 2005, JAMA-J AM MED ASSOC, V293, P723, DOI 10.1001/jama.293.6.723; MILLER MJ, 2006, FANAROFF MARTINS NEO, P1135; Mittendorf R, 2003, AM J OBSTET GYNECOL, V188, P1438, DOI 10.1067/mob.2003.380; Raju TNK, 2007, PEDIATRICS, V120, P609, DOI 10.1542/peds.2007-0336; REDLINE RW, 1995, HUM PATHOL, V26, P80, DOI 10.1016/0046-8177(95)90118-3; Redline RW, 2005, AM J OBSTET GYNECOL, V192, P452, DOI 10.1016/j.ajog.2004.07.030; Redline RW, 2004, PEDIATR DEVEL PATHOL, V7, P443, DOI 10.1007/s10024-004-2020-x; Redline RW, 2003, PEDIATR DEVEL PATHOL, V6, P435, DOI 10.1007/s10024-003-7070-y; Redline RW, 2000, PEDIATR RES, V47, P721, DOI 10.1203/00006450-200006000-00007; Rogers BB, 2002, HUM PATHOL, V33, P335, DOI 10.1053/hupa.2002.32214; Scher MS, 2006, FANAROFF MARTINS NEO, P956; Soper DE, 1996, AM J OBSTET GYNECOL, V175, P304, DOI 10.1016/S0002-9378(96)70139-4; West SL, 2006, DEV MED CHILD NEUROL, V48, P991, DOI 10.1017/S0012162206002179; Wu YW, 2003, JAMA-J AM MED ASSOC, V290, P2677, DOI 10.1001/jama.290.20.2677	17	12	12	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1713	1723		10.1056/NEJMcpc0801164	http://dx.doi.org/10.1056/NEJMcpc0801164			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288DO	18420504				2022-12-28	WOS:000254966600011
J	Makita, T; Sucov, HM; Gariepy, CE; Yanagisawa, M; Ginty, DD				Makita, Takako; Sucov, Henry M.; Gariepy, Cheryl E.; Yanagisawa, Masashi; Ginty, David D.			Endothelins are vascular-derived axonal guidance cues for developing sympathetic neurons	NATURE			English	Article							CARDIAC NEURAL CREST; B-RECEPTOR; GENE; EXPRESSION; DISRUPTION; ANTAGONIST; PROFILE; CLONING; POTENT; ECE-1	During development, sympathetic neurons extend axons along a myriad of distinct trajectories, often consisting of arteries, to innervate one of a large variety of distinct final target tissues. Whether or not subsets of neurons within complex sympathetic ganglia are predetermined to innervate select end-organs is unknown. Here we demonstrate in mouse embryos that the endothelin family member Edn3 (ref. 1), acting through the endothelin receptor EdnrA (refs 2, 3), directs extension of axons of a subset of sympathetic neurons from the superior cervical ganglion to a preferred intermediate target, the external carotid artery, which serves as the gateway to select targets, including the salivary glands. These findings establish a previously unknown mechanism of axonal pathfinding involving vascular-derived endothelins, and have broad implications for endothelins as general mediators of axonal growth and guidance in the developing nervous system. Moreover, they suggest a model in which newborn sympathetic neurons distinguish and choose between distinct vascular trajectories to innervate their appropriate end organs.	[Makita, Takako; Ginty, David D.] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Howard Hughes Med Inst, Baltimore, MD 21205 USA; [Sucov, Henry M.] Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; [Gariepy, Cheryl E.] Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; [Yanagisawa, Masashi] Univ Texas Dallas, SW Med Ctr, Dept Mol Genet, Howard Hughes Med Inst, Dallas, TX 75235 USA	Howard Hughes Medical Institute; Johns Hopkins University; University of Southern California; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ginty, DD (corresponding author), Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Howard Hughes Med Inst, Baltimore, MD 21205 USA.	dginty@jhmi.edu	Gariepy, Cheryl/AAQ-3441-2021; Gariepy, Cheryl/C-6141-2012	Sucov, Henry/0000-0002-3792-3795	Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [R01 HL078891, R01 HL078891-01A1, R01 HL078891-03, R01 HL078891-02] Funding Source: Medline; NINDS NIH HHS [R37 NS034814-11, R37 NS034814-13, R37 NS034814-11S1, R37 NS034814-12, R37 NS034814] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034814] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Choudhary B, 2006, DEV BIOL, V289, P420, DOI 10.1016/j.ydbio.2005.11.008; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; FIRTH JD, 1992, J CLIN INVEST, V90, P1023, DOI 10.1172/JCI115915; Gariepy CE, 1996, P NATL ACAD SCI USA, V93, P867, DOI 10.1073/pnas.93.2.867; GUTHRIE S, 1994, NEUROPROTOCOLS, V4, P116; Hiruma T, 2002, J ANAT, V201, P15, DOI 10.1046/j.1469-7580.2002.00071.x; IHARA M, 1992, J CARDIOVASC PHARM, V20, pS11, DOI 10.1097/00005344-199204002-00005; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; Jiang XB, 2000, DEVELOPMENT, V127, P1607; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHOTZINGER RJ, 1988, NATURE, V335, P637, DOI 10.1038/335637a0; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yanagisawa H, 2000, J CLIN INVEST, V105, P1373, DOI 10.1172/JCI7447	19	137	140	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2008	452	7188					759	U8		10.1038/nature06859	http://dx.doi.org/10.1038/nature06859			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401410	Green Published, Green Accepted			2022-12-28	WOS:000254792500047
J	Sila, CA; Higashida, RT; Clagett, GP				Sila, Cathy A.; Higashida, Randall T.; Clagett, G. Patrick			Management of carotid stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; ARTERY STENOSIS; ENDARTERECTOMY; STROKE		[Sila, Cathy A.] Case Western Reserve Univ, Sch Med, Neurol Inst, Case Med Ctr, Cleveland, OH 44106 USA; [Higashida, Randall T.] Univ Calif San Francisco, Med Ctr, Div Intervent Neurovasc Radiol, San Francisco, CA 94143 USA; [Higashida, Randall T.] Univ Calif San Francisco, Med Ctr, Dept Radiol, San Francisco, CA 94143 USA; [Higashida, Randall T.] Univ Calif San Francisco, Med Ctr, Dept Neurol, San Francisco, CA 94143 USA; [Higashida, Randall T.] Univ Calif San Francisco, Med Ctr, Dept Neurol Surg, San Francisco, CA 94143 USA; [Higashida, Randall T.] Univ Calif San Francisco, Med Ctr, Dept Anesthesiol, San Francisco, CA 94143 USA; [Clagett, G. Patrick] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Vasc & Endovasc Surg, Dallas, TX 75390 USA	Case Western Reserve University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Southwestern Medical Center Dallas	Sila, CA (corresponding author), Case Western Reserve Univ, Sch Med, Neurol Inst, Case Med Ctr, Cleveland, OH 44106 USA.							Abbott AL, 2007, INT J STROKE, V2, P27, DOI 10.1111/j.1747-4949.2007.00096.x; Adams RJ, 2003, CIRCULATION, V108, P1278, DOI 10.1161/01.CIR.0000090444.87006.CF; COHEN SN, 1993, J VASC SURG, V18, P1002, DOI 10.1016/0741-5214(93)90555-Z; Coward LJ, 2005, STROKE, V36, P905, DOI 10.1161/01.STR.0000158921.51037.64; *CTR MED MED SERV, MED COV PERC TRANSL; Feasby TE, 2007, ARCH NEUROL-CHICAGO, V64, P1496, DOI 10.1001/archneur.64.10.1496; Halliday A, 2004, LANCET, V363, P1491; HALLIDAY A, 2004, LANCET, V364, P416; Matsen SL, 2006, J VASC SURG, V44, P488, DOI 10.1016/j.jvs.2006.05.017; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; Wolff T, 2007, ANN INTERN MED, V147, P860, DOI 10.7326/0003-4819-147-12-200712180-00006; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127	12	13	15	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1617	1621						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285NK	18403770				2022-12-28	WOS:000254783300013
J	Pielke, R; Wigley, T; Green, C				Pielke, Roger, Jr.; Wigley, Tom; Green, Christopher			Dangerous assumptions	NATURE			English	Editorial Material							ENERGY		[Pielke, Roger, Jr.] Univ Colorado, Ctr Sci & Technol Policy Res, Boulder, CO 80309 USA; [Wigley, Tom] Natl Ctr Atmospher Res, Boulder, CO 80305 USA; [Green, Christopher] McGill Univ, Dept Econ, Montreal, PQ H3A 2T7, Canada	University of Colorado System; University of Colorado Boulder; National Center Atmospheric Research (NCAR) - USA; McGill University	Pielke, R (corresponding author), Univ Colorado, Ctr Sci & Technol Policy Res, Boulder, CO 80309 USA.							AUFFHAMMER M, IN PRESS J ENV EC MA; Baksi S, 2007, ENERG POLICY, V35, P6457, DOI 10.1016/j.enpol.2007.08.018; Edmonds J.A., 2006, AVOIDING DANGEROUS C, P385; Edmonds JA, 2001, GLOBAL ENERGY TECHNO; FISHER BS, 2007, CLIMATE CHANGE 2007, P218; GREEN C, 2002, MAKING CLIMATE STABI, P6; Hanaoka TR, 2006, GREENHOUSE GAS EMISS; Hoffert MI, 2002, SCIENCE, V298, P981, DOI 10.1126/science.1072357; Hoffert MI, 1998, NATURE, V395, P881, DOI 10.1038/27638; Nakicenovic N., 2000, SPECIAL REPORT EMISS; Nakicenovic N, 2006, ENVIRON ECON POLICY, V7, P137, DOI 10.1007/BF03353998	11	139	151	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2008	452	7187					531	532		10.1038/452531a	http://dx.doi.org/10.1038/452531a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282KR	18385715				2022-12-28	WOS:000254567200021
J	Dyudina, UA; Ingersoll, AP; Ewald, SP; Vasavada, AR; West, RA; Del Genio, AD; Barbara, JM; Porco, CC; Achterberg, RK; Flasar, FM; Simon-Miller, AA; Fletcher, LN				Dyudina, Ulyana A.; Ingersoll, Andrew P.; Ewald, Shawn P.; Vasavada, Ashwin R.; West, Robert A.; Del Genio, Anthony D.; Barbara, John M.; Porco, Carolyn C.; Achterberg, Richard K.; Flasar, F. Michael; Simon-Miller, Amy A.; Fletcher, Leigh N.			Dynamics of Saturn's south polar vortex	SCIENCE			English	Article									[Dyudina, Ulyana A.; Ingersoll, Andrew P.; Ewald, Shawn P.] CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; [Vasavada, Ashwin R.; West, Robert A.; Fletcher, Leigh N.] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; [Del Genio, Anthony D.; Barbara, John M.] NASA, Goddard Inst Space Studies, New York, NY 10025 USA; [Porco, Carolyn C.] Space Sci Inst, Boulder, CO 80301 USA; [Achterberg, Richard K.; Flasar, F. Michael; Simon-Miller, Amy A.] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Fletcher, Leigh N.] Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England	California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Oxford	Dyudina, UA (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.	ulyana@gps.caltech.edu	Del Genio, Anthony/D-4663-2012; Fletcher, Leigh/D-6093-2011; Simon, Amy/C-8020-2012; Flasar, F Michael/C-8509-2012	Del Genio, Anthony/0000-0001-7450-1359; Fletcher, Leigh/0000-0001-5834-9588; Simon, Amy/0000-0003-4641-6186; Achterberg, Richard/0000-0002-7643-7626; Barbara, John/0000-0002-2190-4290				BAGENAL F, 2001, JUPITER PLANET SATEL; Fletcher LN, 2008, SCIENCE, V319, P79, DOI 10.1126/science.1149514; Holton J., 2004, INTRO DYNAMIC METEOR; Orton GS, 2007, ASTRON ASTROPHYS, V473, pL5, DOI 10.1051/0004-6361:20078277; Piccioni G, 2007, NATURE, V450, P637, DOI 10.1038/nature06209	5	45	45	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1801	1801		10.1126/science.1153633	http://dx.doi.org/10.1126/science.1153633			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369142				2022-12-28	WOS:000254394000039
J	Riddihough, G; Purnell, BA; Travis, J				Riddihough, Guy; Purnell, Beverly A.; Travis, John			Introduction - Freedom of expression	SCIENCE			English	Editorial Material																			0	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1781	1781		10.1126/science.319.5871.1781	http://dx.doi.org/10.1126/science.319.5871.1781			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369132				2022-12-28	WOS:000254394000030
J	Kutik, S; Stojanovski, D; Becker, L; Becker, T; Meinecke, M; Kruger, V; Prinz, C; Meisinger, C; Guiard, B; Wagner, R; Pfanner, N; Wiedemann, N				Kutik, Stephan; Stojanovski, Diana; Becker, Lars; Becker, Thomas; Meinecke, Michael; Krueger, Vivien; Prinz, Claudia; Meisinger, Chris; Guiard, Bernard; Wagner, Richard; Pfanner, Nikolaus; Wiedemann, Nils			Dissecting membrane insertion of mitochondrial beta-barrel proteins	CELL			English	Article							OUTER-MEMBRANE; ESSENTIAL COMPONENT; ASSEMBLY MACHINERY; TOM COMPLEX; IMPORT; BIOGENESIS; TRANSLOCASE; DOMAIN; MUTATIONS; CHANNEL	Communication of mitochondria with the rest of the cell requires beta-barrel proteins of the outer membrane. All beta-barrel proteins are synthesized as precursors in the cytosol and imported into mitochondria by the general translocase TOM and the sorting machinery SAM. The SAM complex contains two proteins essential for cell viability, the channel-forming Sam50 and Sam35. We have identified the sorting signal of mitochondrial beta-barrel proteins that is universal in all eukaryotic kingdoms. The beta-signal initiates precursor insertion into a hydrophilic, proteinaceous membrane environment by forming a ternary complex with Sam35 and Sam50. Sam35 recognizes the beta-signal, inducing a major conductance increase of the Sam50 channel. Subsequent precursor release from SAM is coupled to integration into the lipid phase. We propose that a two-stage mechanism of signal-driven insertion into a membrane protein complex and subsequent integration into the lipid phase may represent a general mechanism for biogenesis of beta-barrel proteins.	[Kutik, Stephan; Stojanovski, Diana; Becker, Thomas; Krueger, Vivien; Prinz, Claudia; Meisinger, Chris; Pfanner, Nikolaus; Wiedemann, Nils] Univ Freiburg, Inst Biochem & Mol Biol, Zentrum Biochem & Mol Zellforsch, D-79014 Freiburg, Germany; [Kutik, Stephan] Univ Freiburg, Fak Biol, D-79014 Freiburg, Germany; [Becker, Lars; Meinecke, Michael; Krueger, Vivien; Wagner, Richard] Univ Osnabruck, FB Biol Chem, D-49034 Osnabruck, Germany; [Guiard, Bernard] CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Freiburg; University Osnabruck; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Zentrum Biochem & Mol Zellforsch, D-79014 Freiburg, Germany.	nikolaus.pfanner@biochemie.uni-freiburg.de	Meisinger, Chris/J-1110-2014; Pfanner, Nikolaus/AAV-7878-2021; Becker, Thomas/AAS-9404-2020; Meinecke, Michael/C-4833-2013	Meisinger, Chris/0000-0002-8326-3548; Meinecke, Michael/0000-0003-1414-6951; Stojanovski, Diana/0000-0002-0199-3222; Wiedemann, Nils/0000-0001-8305-6728				Becker L, 2005, J MOL BIOL, V353, P1011, DOI 10.1016/j.jmb.2005.09.019; Bos MP, 2007, EMBO REP, V8, P1149, DOI 10.1038/sj.embor.7401092; Chan NC, 2008, MOL BIOL CELL, V19, P126, DOI 10.1091/mbc.E07-08-0796; Court DA, 1996, FEBS LETT, V390, P73, DOI 10.1016/0014-5793(96)00629-1; Dolezal P, 2006, SCIENCE, V313, P314, DOI 10.1126/science.1127895; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; Habib SJ, 2007, J CELL BIOL, V176, P77, DOI 10.1083/jcb.200602050; Habib SJ, 2005, J BIOL CHEM, V280, P6434, DOI 10.1074/jbc.M411510200; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; Humphries AD, 2005, J BIOL CHEM, V280, P11535, DOI 10.1074/jbc.M413816200; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; Johnson AE, 2004, NAT STRUCT MOL BIOL, V11, P113, DOI 10.1038/nsmb0204-113; Kim S, 2007, SCIENCE, V317, P961, DOI 10.1126/science.1143993; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Milenkovic D, 2004, J BIOL CHEM, V279, P22781, DOI 10.1074/jbc.C400120200; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Robert V, 2006, PLOS BIOL, V4, P1984, DOI 10.1371/journal.pbio.0040377; Ryan MT, 2004, CURR BIOL, V14, pR207, DOI 10.1016/j.cub.2004.02.024; Sanchez-Pulido L, 2003, TRENDS BIOCHEM SCI, V28, P523, DOI 10.1016/j.tibs.2003.08.003; Schleiff E, 2005, EMBO REP, V6, P1023, DOI 10.1038/sj.embor.7400563; Sherman EL, 2006, J BIOL CHEM, V281, P22554, DOI 10.1074/jbc.M601630200; Sklar JG, 2007, P NATL ACAD SCI USA, V104, P6400, DOI 10.1073/pnas.0701579104; Taylor RD, 2003, J BIOL CHEM, V278, P765, DOI 10.1074/jbc.M208083200; Tommassen J, 2007, SCIENCE, V317, P903, DOI 10.1126/science.1146518; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; Waizenegger T, 2004, EMBO REP, V5, P704, DOI 10.1038/sj.embor.7400183; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753	33	229	254	1	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 21	2008	132	6					1011	1024		10.1016/j.cell.2008.01.028	http://dx.doi.org/10.1016/j.cell.2008.01.028			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358813	Bronze			2022-12-28	WOS:000254273600019
J	Rambaut, A; Pybus, OG; Nelson, MI; Viboud, C; Taubenberger, JK; Holmes, EC				Rambaut, Andrew; Pybus, Oliver G.; Nelson, Martha I.; Viboud, Cecile; Taubenberger, Jeffery K.; Holmes, Edward C.			The genomic and epidemiological dynamics of human influenza A virus	NATURE			English	Article							PHYLOGENETIC ANALYSIS; MEMBRANE ASSOCIATION; GENETIC EVOLUTION; MATRIX PROTEIN; M(2) PROTEIN; H3N2 VIRUSES; HEMAGGLUTININ; REASSORTMENT; H1N1; GLYCOPROTEINS	The evolutionary interaction between influenza A virus and the human immune system, manifest as 'antigenic drift' of the viral haemagglutinin, is one of the best described patterns in molecular evolution. However, little is known about the genome- scale evolutionary dynamics of this pathogen. Similarly, how genomic processes relate to global influenza epidemiology, in which the A/ H3N2 and A/ H1N1 subtypes co- circulate, is poorly understood. Here through an analysis of 1,302 complete viral genomes sampled from temperate populations in both hemispheres, we show that the genomic evolution of influenza A virus is characterized by a complex interplay between frequent reassortment and periodic selective sweeps. The A/ H3N2 and A/ H1N1 subtypes exhibit different evolutionary dynamics, with diverse lineages circulating in A/ H1N1, indicative of weaker antigenic drift. These results suggest a sink - source model of viral ecology in which new lineages are seeded from a persistent influenza reservoir, which we hypothesize to be located in the tropics, to sink populations in temperate regions.	[Rambaut, Andrew] Univ Edinburgh, Inst Evolutionary Biol, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland; [Pybus, Oliver G.] Univ Oxford, Dept Zool, Oxford OX1 3PS, England; [Nelson, Martha I.; Holmes, Edward C.] Penn State Univ, Ctr Infect Dis Dynam, Dept Biol, Mueller Lab, University Pk, PA 16802 USA; [Viboud, Cecile; Holmes, Edward C.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA; [Taubenberger, Jeffery K.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA	University of Edinburgh; University of Oxford; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rambaut, A (corresponding author), Univ Edinburgh, Inst Evolutionary Biol, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland.	a.rambaut@ed.ac.uk; ech15@psu.edu	Taubenberger, Jeffery/AAQ-1407-2021; Pybus, Oliver G/B-2640-2012; Holmes, Edward/GVR-9499-2022; Rambaut, Andrew/B-2481-2009; Holmes, Edward/Y-2789-2019	Pybus, Oliver G/0000-0002-8797-2667; Rambaut, Andrew/0000-0003-4337-3707; Holmes, Edward/0000-0001-9596-3552; Rambaut FRSE, Professor Andrew/0000-0002-1278-598X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000996] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000996-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ali A, 2000, J VIROL, V74, P8709, DOI 10.1128/JVI.74.18.8709-8719.2000; Alonso WJ, 2007, AM J EPIDEMIOL, V165, P1434, DOI 10.1093/aje/kwm012; Barman S, 2001, VIRUS RES, V77, P61, DOI 10.1016/S0168-1702(01)00266-0; Berkhoff EGM, 2005, J VIROL, V79, P11239, DOI 10.1128/JVI.79.17.11239-11246.2005; Bush RM, 1999, MOL BIOL EVOL, V16, P1457, DOI 10.1093/oxfordjournals.molbev.a026057; Carrington CVF, 2005, J VIROL, V79, P14680, DOI 10.1128/JVI.79.23.14680-14687.2005; Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/mss075; Drummond AJ, 2002, GENETICS, V161, P1307; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Enami M, 1996, J VIROL, V70, P6653, DOI 10.1128/JVI.70.10.6653-6657.1996; Ferguson NM, 2003, NATURE, V422, P428, DOI 10.1038/nature01509; Finkelman BS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001296; FITCH WM, 1991, P NATL ACAD SCI USA, V88, P4270, DOI 10.1073/pnas.88.10.4270; Gerhard W, 2006, EMERG INFECT DIS, V12, P569, DOI 10.3201/eid1204.051020; Ghedin E, 2005, NATURE, V437, P1162, DOI 10.1038/nature04239; Gregory V, 2002, VIROLOGY, V300, P1, DOI 10.1006/viro.2002.1513; Hay AJ, 2001, PHILOS T R SOC B, V356, P1861, DOI 10.1098/rstb.2001.0999; Holmes EC, 2005, PLOS BIOL, V3, P1579, DOI 10.1371/journal.pbio.0030300; Kaji M, 2003, RESPIROLOGY, V8, P231, DOI 10.1046/j.1440-1843.2003.00457.x; Kingman JFC., 1982, STOCH PROC APPL, V13, P235, DOI [DOI 10.1016/0304-4149(82)90011-4, 10.1016/0304-4149(82)90011-4]; Krug RM, 2003, VIROLOGY, V309, P181, DOI 10.1016/S0042-6822(03)00119-3; Lavenu A, 2006, EPIDEMIOL INFECT, V134, P514, DOI 10.1017/S0950268805005686; Lemey P, 2006, AIDS REV, V8, P125; Lindstrom SE, 1998, J VIROL, V72, P8021, DOI 10.1128/JVI.72.10.8021-8031.1998; Lindstrom SE, 2004, VIROLOGY, V328, P101, DOI 10.1016/j.virol.2004.06.009; LUDWIG S, 1991, VIROLOGY, V183, P566, DOI 10.1016/0042-6822(91)90985-K; Macken CA, 2006, J GEN VIROL, V87, P2803, DOI 10.1099/vir.0.81454-0; Mitnaul LJ, 2000, J VIROL, V74, P6015, DOI 10.1128/JVI.74.13.6015-6020.2000; Nelson MI, 2007, PLOS PATHOG, V3, P1220, DOI 10.1371/journal.ppat.0030131; Nelson MI, 2006, PLOS PATHOG, V2, P1144, DOI 10.1371/journal.ppat.0020125; OHUCHI M, 1994, J VIROL, V68, P920, DOI 10.1128/JVI.68.2.920-926.1994; Rambaut A, 2000, BIOINFORMATICS, V16, P395, DOI 10.1093/bioinformatics/16.4.395; Reid AH, 2004, NAT REV MICROBIOL, V2, P909, DOI 10.1038/nrmicro1027; SCHOLTISSEK C, 1978, VIROLOGY, V89, P613, DOI 10.1016/0042-6822(78)90203-9; Schweiger B, 2006, VACCINE, V24, P6683, DOI 10.1016/j.vaccine.2006.05.105; Shapiro B, 2006, MOL BIOL EVOL, V23, P7, DOI 10.1093/molbev/msj021; Shih ACC, 2007, P NATL ACAD SCI USA, V104, P6283, DOI 10.1073/pnas.0701396104; Shortridge KF, 1997, CHINESE MED J-PEKING, V110, P637; Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211; SONOGUCHI T, 1985, J INFECT DIS, V151, P81, DOI 10.1093/infdis/151.1.81; TAKEUCHI K, 1994, J VIROL, V68, P911, DOI 10.1128/JVI.68.2.911-919.1994; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979; Viboud C, 2006, SCIENCE, V312, P447, DOI 10.1126/science.1125237; Viboud C, 2006, PLOS MED, V3, P468, DOI 10.1371/journal.pmed.0030089; *WHO, 2003, INFL; Wolf YI, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-34; WRIGHT PF, 1980, AM J EPIDEMIOL, V112, P814, DOI 10.1093/oxfordjournals.aje.a113053; YOUNG JF, 1979, P NATL ACAD SCI USA, V76, P6547, DOI 10.1073/pnas.76.12.6547	49	674	708	1	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					615	U2		10.1038/nature06945	http://dx.doi.org/10.1038/nature06945			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18418375	Bronze, Green Accepted			2022-12-28	WOS:000256185200035
J	Joughin, I; Das, SB; King, MA; Smith, BE; Howat, IM; Moon, T				Joughin, Ian; Das, Sarah B.; King, Matt A.; Smith, Ben E.; Howat, Ian M.; Moon, Twila			Seasonal speedup along the western flank of the Greenland Ice Sheet	SCIENCE			English	Article							SUBGLACIAL WATER-PRESSURE; JAKOBSHAVN ISBRAE; SURFACE MELT; GLACIER; VELOCITY	It has been widely hypothesized that a warmer climate in Greenland would increase the volume of lubricating surface meltwater reaching the ice- bedrock interface, accelerating ice flow and increasing mass loss. We have assembled a data set that provides a synoptic- scale view, spanning ice- sheet to outlet- glacier flow, with which to evaluate this hypothesis. On the ice sheet, these data reveal summer speedups ( 50 to 100%) consistent with, but somewhat larger than, earlier observations. The relative speedup of outlet glaciers, however, is far smaller (< 15%). Furthermore, the dominant seasonal influence on Jakobshavn Isbrae's flow is the calving front's annual advance and retreat. With other effects producing outlet- glacier speedups an order of magnitude larger, seasonal melt's influence on ice flow is likely confined to those regions dominated by ice- sheet flow.	[Joughin, Ian; Smith, Ben E.; Howat, Ian M.; Moon, Twila] Univ Washington, Polar Sci Ctr, Appl Phys Lab, Seattle, WA 98105 USA; [Das, Sarah B.] Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA; [King, Matt A.] Univ Newcastle, Sch Civil Engn & Geosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Washington; University of Washington Seattle; Woods Hole Oceanographic Institution; Newcastle University - UK	Joughin, I (corresponding author), Univ Washington, Polar Sci Ctr, Appl Phys Lab, 1013 NE 40th St, Seattle, WA 98105 USA.	ian@apl.washington.edu	Howat, Ian M/A-3474-2008; Moon, Twila/AAZ-9302-2021; Joughin, Ian/AAR-7778-2021; King, Matt/B-4622-2008; Joughin, Ian R/A-2998-2008	Howat, Ian M/0000-0002-8072-6260; Joughin, Ian/0000-0001-6229-679X; King, Matt/0000-0001-5611-9498; Joughin, Ian R/0000-0001-6229-679X; Moon, Twila/0000-0003-0968-7008	NERC [NE/C002121/1] Funding Source: UKRI; Natural Environment Research Council [NE/C002121/1] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Box JE, 2006, J CLIMATE, V19, P2783, DOI 10.1175/JCLI3738.1; Chylek P, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026510; Das SB, 2008, SCIENCE, V320, P778, DOI 10.1126/science.1153360; ECHELMEYER K, 1990, J GLACIOL, V36, P82, DOI 10.3189/S0022143000005591; Gore A. L., 2006, INCONVENIENT TRUTH P; Harper JT, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030233; Howat IM, 2007, SCIENCE, V315, P1559, DOI 10.1126/science.1138478; Howat IM, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024737; IKEN A, 1986, J GLACIOL, V32, P101, DOI 10.3189/S0022143000006936; IKEN A, 1983, J GLACIOL, V29, P28, DOI 10.3189/S0022143000005128; IKEN A, 1981, J GLACIOL, V27, P407, DOI 10.3189/S0022143000011448; IPCC (Intergovernmental Panel on Climate Change), 2007, CLIM CHANG 2007 PHYS; Joughin I, 2004, NATURE, V432, P608, DOI 10.1038/nature03130; Joughin I, 1996, SCIENCE, V274, P228, DOI 10.1126/science.274.5285.228; KAMB B, 1994, J GEOPHYS RES-SOL EA, V99, P15231, DOI 10.1029/94JB00467; Luckman A, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025428; Luckman A, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022519; Parizek BR, 2004, QUATERNARY SCI REV, V23, P1013, DOI 10.1016/j.quascirev.2003.12.024; Paterson W.S.B., 1994, PHYS GLACIERS, Vthird; Rignot E, 2006, SCIENCE, V311, P986, DOI 10.1126/science.1121381; Sohn HG, 1998, GEOPHYS RES LETT, V25, P2699, DOI 10.1029/98GL01973; Thomas RH, 2003, J GLACIOL, V49, P231, DOI 10.3189/172756503781830764; Zwally HJ, 2002, SCIENCE, V297, P218, DOI 10.1126/science.1072708	23	312	318	1	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 9	2008	320	5877					781	783		10.1126/science.1153288	http://dx.doi.org/10.1126/science.1153288			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297VB	18420901				2022-12-28	WOS:000255644400036
J	Wasson, JH				Wasson, John H.			Making a difference - Multiple health problems in elderly people - Adapting what is known	BRITISH MEDICAL JOURNAL			English	Editorial Material							CARE; QUALITY		Dartmouth Med Sch, Lebanon, NH 03766 USA	Dartmouth College	Wasson, JH (corresponding author), Dartmouth Med Sch, 35 Centerra Pkwy,Suite 300, Lebanon, NH 03766 USA.	John.H.Wasson@Dartmouth.edu						Boyd CM, 2007, GERONTOLOGIST, V47, P697, DOI 10.1093/geront/47.5.697; Luck J, 2007, J GEN INTERN MED, V22, P396, DOI 10.1007/s11606-007-0293-2; Moore LG, 2006, J AMBUL CARE MANAG, V29, P195, DOI 10.1097/00004479-200607000-00003; Reuben DB, 2007, JAMA-J AM MED ASSOC, V298, P2673, DOI 10.1001/jama.298.22.2673; Sirovich BE, 2006, ANN INTERN MED, V144, P641, DOI 10.7326/0003-4819-144-9-200605020-00007; Vogeli C, 2007, J GEN INTERN MED, V22, P391, DOI 10.1007/s11606-007-0322-1; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; Wasson JH, 2006, J AMBUL CARE MANAG, V29, P233, DOI 10.1097/00004479-200607000-00010; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007	9	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					950	+		10.1136/bmj.39532.671597.94	http://dx.doi.org/10.1136/bmj.39532.671597.94			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397938	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000255540900038
J	Anderson, CNK; Hsieh, CH; Sandin, SA; Hewitt, R; Hollowed, A; Beddington, J; May, RM; Sugihara, G				Anderson, Christian N. K.; Hsieh, Chih-Hao; Sandin, Stuart A.; Hewitt, Roger; Hollowed, Anne; Beddington, John; May, Robert M.; Sugihara, George			Why fishing magnifies fluctuations in fish abundance	NATURE			English	Article							COD GADUS-MORHUA; NATURAL-POPULATIONS; AGE STRUCTURE; LIFE-HISTORY; FISHERIES; SIZE; SUSTAINABILITY; VARIABILITY; ECOLOGY; BIOMASS	It is now clear that fished populations can fluctuate more than unharvested stocks. However, it is not clear why. Here we distinguish among three major competing mechanisms for this phenomenon, by using the 50- year California Cooperative Oceanic Fisheries Investigations ( CalCOFI) larval fish record. First, variable fishing pressure directly increases variability in exploited populations. Second, commercial fishing can decrease the average body size and age of a stock, causing the truncated population to track environmental fluctuations directly. Third, age- truncated or juvenescent populations have increasingly unstable population dynamics because of changing demographic parameters such as intrinsic growth rates. We find no evidence for the first hypothesis, limited evidence for the second and strong evidence for the third. Therefore, in California Current fisheries, increased temporal variability in the population does not arise from variable exploitation, nor does it reflect direct environmental tracking. More fundamentally, it arises from increased instability in dynamics. This finding has implications for resource management as an empirical example of how selective harvesting can alter the basic dynamics of exploited populations, and lead to unstable booms and busts that can precede systematic declines in stock levels.	[Anderson, Christian N. K.; Hsieh, Chih-Hao; Sandin, Stuart A.; Sugihara, George] Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; [Hsieh, Chih-Hao] Kyoto Univ, Ctr Ecol Res, Otsu, Shiga 5202113, Japan; [Hsieh, Chih-Hao] Natl Taiwan Univ, Inst Oceanog, Taipei 10617, Taiwan; [Hsieh, Chih-Hao] Natl Taiwan Ocean Univ, Inst Marine Environm Chem & Ecol, Chilung 20224, Taiwan; [Hewitt, Roger] Natl Marine Fisheries Serv, SW Fisheries Sci Ctr, La Jolla, CA 92037 USA; [Hollowed, Anne] NOAA, Natl Marine Fisheries Serv, Alaska Fisheries Sci Ctr, Seattle, WA 98115 USA; [Beddington, John] Univ London Imperial Coll Sci Technol & Med, Div Biol, Fac Nat Sci, London SW7 2AZ, England; [May, Robert M.] Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of California System; University of California San Diego; Scripps Institution of Oceanography; Kyoto University; National Taiwan University; National Taiwan Ocean University; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; Imperial College London; University of Oxford	Sugihara, G (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	gsugihara@ucsd.edu	Hsieh, Chih-hao/B-3797-2008	Hsieh, Chih-hao/0000-0001-5935-7272				ARMSTRONG M, 2006, 200607 FISH SCI PART; BEDDINGTON JR, 1977, SCIENCE, V197, P463, DOI 10.1126/science.197.4302.463; Berkeley SA, 2004, FISHERIES, V29, P23, DOI 10.1577/1548-8446(2004)29[23:FSVPOA]2.0.CO;2; Bobko SJ, 2004, FISH B-NOAA, V102, P418; Clark FN, 1955, CAL COOP OCEAN FISH, V4, P11; Conover DO, 2002, SCIENCE, V297, P94, DOI 10.1126/science.1074085; Dixon PA, 1999, SCIENCE, V283, P1528, DOI 10.1126/science.283.5407.1528; Gunderson DR., 1993, SURVEYS FISHERIES RE; Halley JM, 1996, TRENDS ECOL EVOL, V11, P33, DOI 10.1016/0169-5347(96)81067-6; Harvey CJ, 2006, ECOL APPL, V16, P1502, DOI 10.1890/1051-0761(2006)016[1502:CIBSAA]2.0.CO;2; HASTINGS A, 1991, ECOLOGY, V72, P896, DOI 10.2307/1940591; HILBORN R, 1992; Hsieh CH, 2005, PROG OCEANOGR, V67, P160, DOI 10.1016/j.pocean.2005.05.002; Hsieh CH, 2005, NATURE, V435, P336, DOI 10.1038/nature03553; HSIEH CH, IN PRESS CAN J FISH; Hsieh CH, 2008, AM NAT, V171, P71, DOI 10.1086/524202; Hsieh CH, 2006, NATURE, V443, P859, DOI 10.1038/nature05232; HUNTER JR, 1993, B MAR SCI, V53, P723; Hutchings JA, 2005, PHILOS T R SOC B, V360, P315, DOI 10.1098/rstb.2004.1586; Hutchings JA, 2004, BIOSCIENCE, V54, P297, DOI 10.1641/0006-3568(2004)054[0297:MFPCCF]2.0.CO;2; HUTCHINGS JA, 1993, CAN J FISH AQUAT SCI, V50, P2468, DOI 10.1139/f93-271; *ICCAT, 2006, STOCK STAT REP SWORD; Jonzen N, 2002, AM NAT, V159, P427, DOI 10.1086/339456; Jonzen N, 2001, MAR ECOL PROG SER, V210, P291, DOI 10.3354/meps210291; Jorgensen C, 2007, SCIENCE, V318, P1247, DOI 10.1126/science.1148089; Kuparinen A, 2007, TRENDS ECOL EVOL, V22, P652, DOI 10.1016/j.tree.2007.08.011; LAMBERT TC, 1987, MAR ECOL PROG SER, V39, P209, DOI 10.3354/meps039209; Lande R., 2003, OXFORD SERIES ECOLOG; Longhurst A, 2006, FISH RES, V81, P107, DOI 10.1016/j.fishres.2006.06.022; Marr JC, 1960, P WORLD SCI M BIOL S, P667; Marteinsdottir G, 1998, J FISH BIOL, V52, P1241, DOI 10.1111/j.1095-8649.1998.tb00969.x; MAY RM, 1978, MATH BIOSCI, V42, P219, DOI 10.1016/0025-5564(78)90097-4; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; Murawski SA, 2001, ICES J MAR SCI, V58, P1002, DOI 10.1006/jmsc.2001.1097; MURPHY GARTH L, 1966, PROC CALIF ACAD SCI, V34, P1; MURPHY GI, 1968, AM NAT, V102, P391, DOI 10.1086/282553; MURPHY GI, 1967, ECOLOGY, V48, P731, DOI 10.2307/1933730; Poulsen RT, 2007, FISH RES, V87, P196, DOI 10.1016/j.fishres.2007.07.002; RICKER WE, 1981, CAN J FISH AQUAT SCI, V38, P1636, DOI 10.1139/f81-213; Rykaczewski RR, 2008, P NATL ACAD SCI USA, V105, P1965, DOI 10.1073/pnas.0711777105; Sibert J, 2006, SCIENCE, V314, P1773, DOI 10.1126/science.1135347; Spencer P, 2007, LOW WAKE FI, V23, P513; STEELE JH, 1985, NATURE, V313, P355, DOI 10.1038/313355a0; STEELE JH, 1984, SCIENCE, V224, P985, DOI 10.1126/science.224.4652.985; Stefansson G, 2005, PHILOS T R SOC B, V360, P133, DOI 10.1098/rstb.2004.1579; Sugihara G, 1999, P NATL ACAD SCI USA, V96, P14210, DOI 10.1073/pnas.96.25.14210; SUGIHARA G, 1990, PHILOS T R SOC B, V330, P235, DOI 10.1098/rstb.1990.0195; SUGIHARA G, 1994, PHILOS T R SOC A, V348, P477, DOI 10.1098/rsta.1994.0106; Vasseur DA, 2004, ECOLOGY, V85, P1146, DOI 10.1890/02-3122; 2004, ALASKA GROUNDFISH FI	50	500	517	4	269	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2008	452	7189					835	839		10.1038/nature06851	http://dx.doi.org/10.1038/nature06851			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18421346	Green Published			2022-12-28	WOS:000255026000040
J	Blow, N				Blow, Nathan			Nanotechnology: Could it be a small world after all?	NATURE			English	Editorial Material																			0	3	3	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2008	452	7189					901	906		10.1038/452901a	http://dx.doi.org/10.1038/452901a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18421356	Bronze			2022-12-28	WOS:000255026000057
J	Dayan, GH; Quinlisk, MP; Parker, AA; Barskey, AE; Harris, ML; Schwartz, JMH; Hunt, K; Finley, CG; Leschinsky, DP; O'Keefe, AL; Clayton, J; Kightlinger, LK; Dietle, EG; Berg, J; Kenyon, CL; Goldstein, ST; Stokley, SK; Redd, SB; Rota, PA; Rota, J; Bi, DL; Roush, SW; Bridges, CB; Santibanez, TA; Parashar, U; Bellini, WJ; Seward, JF				Dayan, Gustavo H.; Quinlisk, M. Patricia; Parker, Amy A.; Barskey, Albert E.; Harris, Meghan L.; Schwartz, Jennifer M. Hill; Hunt, Kae; Finley, Carol G.; Leschinsky, Dennis P.; O'Keefe, Anne L.; Clayton, Joshua; Kightlinger, Lon K.; Dietle, Eden G.; Berg, Jeffrey; Kenyon, Cynthia L.; Goldstein, Susan T.; Stokley, Shannon K.; Redd, Susan B.; Rota, Paul A.; Rota, Jennifer; Bi, Daoling; Roush, Sandra W.; Bridges, Carolyn B.; Santibanez, Tammy A.; Parashar, Umesh; Bellini, William J.; Seward, Jane F.			Recent resurgence of mumps in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VACCINATION; VIRUS; OUTBREAK; DIAGNOSIS; POPULATION; ANTIBODIES; SPECIMENS	Background: The widespread use of a second dose of mumps vaccine among U.S. schoolchildren beginning in 1990 was followed by historically low reports of mumps cases. A 2010 elimination goal was established, but in 2006 the largest mumps outbreak in two decades occurred in the United States. Methods: We examined national data on mumps cases reported during 2006, detailed case data from the most highly affected states, and vaccination-coverage data from three nationwide surveys. Results: A total of 6584 cases of mumps were reported in 2006, with 76% occurring between March and May. There were 85 hospitalizations, but no deaths were reported; 85% of patients lived in eight contiguous midwestern states. The national incidence of mumps was 2.2 per 100,000, with the highest incidence among persons 18 to 24 years of age (an incidence 3.7 times that of all other age groups combined). In a subgroup analysis, 83% of these patients reported current college attendance. Among patients in eight highly affected states with known vaccination status, 63% overall and 84% between the ages of 18 and 24 years had received two doses of mumps vaccine. For the 12 years preceding the outbreak, national coverage of one-dose mumps vaccination among preschoolers was 89% or more nationwide and 86% or more in highly affected states. In 2006, the national two-dose coverage among adolescents was 87%, the highest in U.S. history. Conclusions: Despite a high coverage rate with two doses of mumps-containing vaccine, a large mumps outbreak occurred, characterized by two-dose vaccine failure, particularly among midwestern college-age adults who probably received the second dose as schoolchildren. A more effective mumps vaccine or changes in vaccine policy may be needed to avert future outbreaks and achieve the elimination of mumps.	[Dayan, Gustavo H.; Parker, Amy A.; Barskey, Albert E.; Goldstein, Susan T.; Redd, Susan B.; Rota, Paul A.; Rota, Jennifer; Bi, Daoling; Parashar, Umesh; Bellini, William J.; Seward, Jane F.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, MS A-47, Atlanta, GA 30333 USA; [Stokley, Shannon K.; Santibanez, Tammy A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA; [Roush, Sandra W.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA; [Bridges, Carolyn B.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA; [Quinlisk, M. Patricia; Harris, Meghan L.] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA; [Schwartz, Jennifer M. Hill] Kansas Dept Hlth & Environm, Topeka, KS USA; [Hunt, Kae; Finley, Carol G.] Illinois Dept Publ Hlth, Springfield, IL 62761 USA; [Leschinsky, Dennis P.; O'Keefe, Anne L.] Nebraska Dept Hlth & Human Serv, Lincoln, NE USA; [Clayton, Joshua; Kightlinger, Lon K.] S Dakota Dept Hlth, Pierre, SD USA; [Dietle, Eden G.] Missouri Dept Hlth & Sr Serv, Jefferson City, MO USA; [Berg, Jeffrey] Wisconsin Dept Hlth & Family Serv, Madison, WI USA; [Kenyon, Cynthia L.] Minnesota Dept Hlth, St Paul, MN USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Minnesota Department of Health (MHD)	Parker, AA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, MS A-47, Atlanta, GA 30333 USA.			Santibanez, Tammy A./0000-0002-5784-7427				*ACIP, 1989, MMWR-MORBID MORTAL W, V38, P1; ANDERSON R M, 1991; ANDERSON RM, 1985, NATURE, V318, P323, DOI 10.1038/318323a0; [Anonymous], 2005, Wkly Epidemiol Rec, V80, P418; [Anonymous], STAT SURV IMM COV US; BRISS PA, 1994, J INFECT DIS, V169, P77, DOI 10.1093/infdis/169.1.77; *CENS BUR, POP EST; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P629; CHEEK JE, 1995, ARCH PEDIAT ADOL MED, V149, P774, DOI 10.1001/archpedi.1995.02170200064010; Cohen C, 2007, EMERG INFECT DIS, V13, P12; CORTESE MM, IN PRESS CLIN INFECT; DATE A, 2006, IN PRESS J INFECT DI; DAVIDKIN I, 1995, VACCINE, V13, P1617, DOI 10.1016/0264-410X(95)00064-8; *DEP ED NAT CTR ED, 2005, 2004 2005 INT POSTS; *DEP ED NAT CTR ED, 2006, 2004 2005 INT POSTS; Galazka AM, 1999, B WORLD HEALTH ORGAN, V77, P3; Gershman K., 2006, Morbidity and Mortality Weekly Report, V55, P559; GUT JP, 1985, J CLIN MICROBIOL, V21, P346, DOI 10.1128/JCM.21.3.346-352.1985; Harling R, 2005, VACCINE, V23, P4070, DOI 10.1016/j.vaccine.2004.10.020; HERSH BS, 1991, J PEDIATR-US, V119, P187, DOI 10.1016/S0022-3476(05)80726-7; Jin L, 2004, J INFECT DIS, V189, P1001, DOI 10.1086/382134; Kolasa MS, 2004, J INFECT DIS, V189, pS98, DOI 10.1086/374720; Krause CH, 2006, J CLIN VIROL, V37, P184, DOI 10.1016/j.jcv.2006.07.009; Nojd J, 2001, VACCINE, V19, P1727, DOI 10.1016/S0264-410X(00)00392-3; Novek J, 2000, J NURS CARE QUAL, V14, P1, DOI 10.1097/00001786-200001000-00003; PLOTKIN S A, 2004, VACCINES, P441; RUBIN SA, IN PRESS J INFECT DI; Sanz JC, 2006, APMIS, V114, P788, DOI 10.1111/j.1600-0463.2006.apm_463.x; Schaffzin JK, 2007, PEDIATRICS, V120, pE862, DOI 10.1542/peds.2006-3451; Simpson DM, 2001, AM J PREV MED, V20, P6, DOI 10.1016/S0749-3797(01)00286-0; STOKLEY S, 2006, 40 NAT IMM C ATL MAR; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; WERNER CA, 1950, ANN INTERN MED, V32, P1066, DOI 10.7326/0003-4819-32-6-1066; WHARTON M, 1988, J INFECT DIS, V158, P1253, DOI 10.1093/infdis/158.6.1253; [No title captured]; 2006, MMWR MORB MORTAL WKL, V55, P173; 2006, MMWR MORB MORTAL WKL, V55, P401; 1977, MMWR MORB MORTAL WKL, V26, P393; 2006, MMWR MORB MORTAL WKL, V55, P366; 2006, MMWR MORB MORTAL WKL, V55, P434; 2007, WKLY EPIDEMIOL REC, V82, P51	41	272	282	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1580	1589		10.1056/NEJMoa0706589	http://dx.doi.org/10.1056/NEJMoa0706589			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285NK	18403766				2022-12-28	WOS:000254783300007
J	Goldston, D				Goldston, David			Hazy reasoning behind clean air	NATURE			English	Editorial Material											Goldston, D (corresponding author), Harvard Univ, Ctr Environm, Cambridge, MA 02138 USA.	partyofonecolumn@gmail.com							0	1	1	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2008	452	7187					519	519		10.1038/452519a	http://dx.doi.org/10.1038/452519a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	282KR	18385707	Bronze			2022-12-28	WOS:000254567200013
J	Mongan, JJ; Ferris, TG; Lee, TH				Mongan, James J.; Ferris, Timothy G.; Lee, Thomas H.			Options for slowing the growth of health care costs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INFORMATION-TECHNOLOGY; QUALITY; SYSTEMS		[Mongan, James J.; Ferris, Timothy G.; Lee, Thomas H.] Partners Healthcare Syst, Boston, MA USA	Partners Healthcare System	Mongan, JJ (corresponding author), Partners Healthcare Syst, Boston, MA USA.							*AM COLL PHYS, SYST NEED CHANG REST; Blumenthal D, 2007, NEW ENGL J MED, V356, P2527, DOI 10.1056/NEJMhpr066212; Bodenheimer T, 2005, ANN INTERN MED, V142, P932, DOI 10.7326/0003-4819-142-11-200506070-00012; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Cutler DM, 2004, YOUR MONEY YOUR LIFE; *DARTM ATL PROJ, 2006, CAR PAT SEV CHRON IL; Davis K, 2007, NEW ENGL J MED, V356, P1166, DOI 10.1056/NEJMe078007; Eggleston K, 2005, J HEALTH ECON, V24, P211, DOI 10.1016/j.jhealeco.2004.09.001; Fireman B, 2004, HEALTH AFFAIR, V23, P63, DOI 10.1377/hlthaff.23.6.63; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; Ginsburg Paul B, 2007, Issue Brief Cent Stud Health Syst Change, P1; GUTERMAN S, 2007, ENHANCING VALUE MED; Hillestad R, 2005, HEALTH AFFAIR, V24, P1103, DOI 10.1377/hlthaff.24.5.1103; HOTZBAKIN D, 2004, ANAL LIT DIS MANAGEM; Huskamp HA, 2003, HEALTH AFFAIR, V22, P149, DOI 10.1377/hlthaff.22.3.149; Iezzoni LI, 1998, NEW ENGL J MED, V339, P1933, DOI 10.1056/NEJM199812243392613; Institute of Medicine, 2006, REW PROV PERF AL INC; MARTIN JP, 2003, EXPERIENCE OECD COUN; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; ORSZAG PR, 2007, RES COMP EFFECTIVENE; Pham HH, 2007, HEALTH AFFAIR, V26, pW532, DOI 10.1377/hlthaff.26.4.w532; RUBIN RJ, 1994, J AM HEALTH POLICY, V4, P7; Studdert DM, 2006, NEW ENGL J MED, V354, P2024, DOI 10.1056/NEJMsa054479; Thorpe KE, 2005, HEALTH AFFAIR, V24, P1436, DOI 10.1377/hlthaff.24.6.1436; Woolhandler S, 2003, NEW ENGL J MED, V349, P768, DOI 10.1056/NEJMsa022033	25	99	99	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1509	1514		10.1056/NEJMsb0707912	http://dx.doi.org/10.1056/NEJMsb0707912			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	282CY	18385503				2022-12-28	WOS:000254546400017
J	Finning, K; Martin, P; Summers, J; Massey, E; Poole, G; Daniels, G				Finning, Kirstin; Martin, Pete; Summers, Joanna; Massey, Edwin; Poole, Geoff; Daniels, Geoff			Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study	BRITISH MEDICAL JOURNAL			English	Article								Objectives To assess the feasibility of applying a high throughput method, with an automated robotic technique, for predicting fetal RhD phenotype from fetal DNA in the plasma of RhD negative pregnant women to avoid unnecessary treatment with anti-RhD immunoglobulin. Design Prospective comparison of fetal RHD genotype determined from fetal DNA in maternal plasma with the serologically determined fetal RhD phenotype from cord blood. Setting Antenatal clinics and antenatal testing laboratories in the Midlands and north of England and an international blood group reference laboratory. Participants Pregnant women of known gestation identified as RhD negative by an antenatal testing laboratory. Samples from 1997 women were taken at or before the 28 week antenatal visit. Main outcome measures Detection rate of fetal RhD from maternal plasma, error rate, false positive rate, and the odds of being affected given a positive result. Results Serologically determined RhD phenotypes were obtained from 1869 cord blood samples. In 95.7% (n=1788) the correct fetal RhD phenotype was predicted by the genotyping tests. In 3.4% (n=64) results were either unobtainable or inconclusive. A false positive result was obtained in 0.8% (14 samples), probably because of unexpressed or weakly expressed fetal RHD genes. In only three samples (0.2%) were false negative results obtained. If these results had been applied as a guide to treatment, only 2% of the women would have received anti-RhD unnecessarily, compared with 38% without he genotyping. Conclusions High throughput RHD genotyping of fetuses in all RhD negative women is feasible and would substantially reduce unnecessary administration of anti-RhD immunoglobulin to RhD negative pregnant women with an RhD negative fetus.	[Finning, Kirstin; Martin, Pete; Summers, Joanna; Massey, Edwin; Daniels, Geoff] NHS Blood & Transplant, Int Blood Grp Reference Lab, Bristol BS10 5ND, Avon, England; [Poole, Geoff] NHS Blood & Transplant, Bristol, Avon, England		Daniels, G (corresponding author), NHS Blood & Transplant, Int Blood Grp Reference Lab, Bristol BS10 5ND, Avon, England.	geoff.daniels@nbs.nhs.uk			Department of Health Funding Source: Medline	Department of Health		Daniels G., 2002, HUMAN BLOOD GROUPS; Denomme GA, 2005, TRANSFUSION, V45, P1554, DOI 10.1111/j.1537-2995.2005.00586.x; *NAT I CLIN EXCL, 2002, TECHN APPR GUID 41 G; Van der Schoot CE, 2006, TRANSFUS CLIN BIOL, V13, P53, DOI 10.1016/j.tracli.2006.02.021; Wagner FF, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-10	5	169	188	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR	2008	336	7648					816	818		10.1136/bmj.39518.463206.25	http://dx.doi.org/10.1136/bmj.39518.463206.25			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	292ER	18390496	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000255249800045
J	Klein, R				Klein, Rudolf			Does the NHS really need a constitution?	BRITISH MEDICAL JOURNAL			English	Editorial Material											Klein, R (corresponding author), London Sch Econ, London, England.	Rudolfklein30@aol.com							0	1	1	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR	2008	336	7648					804	804		10.1136/bmj.39545.432407.59	http://dx.doi.org/10.1136/bmj.39545.432407.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	292ER	18403543	Green Published, Green Accepted			2022-12-28	WOS:000255249800040
J	Nair, RR; Blake, P; Grigorenko, AN; Novoselov, KS; Booth, TJ; Stauber, T; Peres, NMR; Geim, AK				Nair, R. R.; Blake, P.; Grigorenko, A. N.; Novoselov, K. S.; Booth, T. J.; Stauber, T.; Peres, N. M. R.; Geim, A. K.			Fine structure constant defines visual transparency of graphene	SCIENCE			English	Article									[Nair, R. R.; Blake, P.; Grigorenko, A. N.; Novoselov, K. S.; Booth, T. J.; Geim, A. K.] Univ Manchester, Manchester Ctr Mesosci & Nanotechnol, Manchester M13 9PL, Lancs, England; [Stauber, T.; Peres, N. M. R.] Univ Minho, Dept Phys, P-4710057 Braga, Portugal	University of Manchester; Universidade do Minho	Geim, AK (corresponding author), Univ Manchester, Manchester Ctr Mesosci & Nanotechnol, Manchester M13 9PL, Lancs, England.	geim@man.ac.uk	Geim, Andre K/J-7888-2012; Raveendran Nair, Rahul/G-5839-2010; Stauber, Tobias/K-6731-2014; Booth, Timothy J/A-5847-2012; Blake, Peter/E-8556-2010; Peres, Nuno M R/B-9537-2008; Novoselov, Kostya S/G-9581-2014; Nair, Rahul Raveendran/Z-1566-2019	Geim, Andre K/0000-0003-2861-8331; Booth, Timothy J/0000-0002-9784-989X; Novoselov, Kostya S/0000-0003-4972-5371; hai yan, he/0000-0003-0366-6185; Peres, Nuno/0000-0002-7928-8005; Stauber, Tobias/0000-0003-0983-2420	Engineering and Physical Sciences Research Council [EP/E051227/1] Funding Source: researchfish; EPSRC [EP/E051227/1] Funding Source: UKRI	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Ando T, 2002, J PHYS SOC JPN, V71, P1318, DOI 10.1143/JPSJ.71.1318; Bunch JS, 2007, SCIENCE, V315, P490, DOI 10.1126/science.1136836; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; GUYSNIN VP, 2006, PHYS REV LETT, V96; Kuzmenko AB, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.117401	5	6774	7070	104	3363	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1308	1308		10.1126/science.1156965	http://dx.doi.org/10.1126/science.1156965			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18388259	Green Submitted			2022-12-28	WOS:000256441100035
J	Jackevicius, CA; Tu, JV; Ross, JS; Ko, DT; Krumholz, HM				Jackevicius, Cynthia A.; Tu, Jack V.; Ross, Joseph S.; Ko, Dennis T.; Krumholz, Harlan M.			Use of ezetimibe in the United States and Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPY; SAFETY; PREVENTION; TRIALS; TRENDS	Background: Ezetimibe lowers low-density lipoprotein cholesterol, but current lipid-lowering guidelines in the United States and Canada do not recommend it as a first option for either primary or secondary prevention. We sought to describe the adoption of ezetimibe relative to that of other lipid-lowering agents and compare its use in the two countries. Methods: We conducted a population-level, cohort study using data from January 2002 to December 2006, provided by IMS Health, to describe prescribing practices and expenditures for lipid-lowering agents and ezetimibe in the United States and Canada. Results: From 2002 to 2006, the monthly number of prescriptions for lipid-lowering agents rose from 3719 to 7401 per 100,000 population in Canada and from 3927 to 6827 per 100,000 population in the United States. Of these prescriptions, the proportion for ezetimibe rose from 0.2% in 2003 to 3.4% in 2006 in Canada and from 0.1% in 2002 to 15.2% in 2006 in the United States. Statin use was relatively constant between 2002 and 2006 in Canada, whereas the proportion of statin prescriptions decreased from 86.5 to 80.8% in the United States. In 2006, the ratio of prescriptions for statins to those for ezetimibe was 26:1 in Canada and 5:1 in the United States. In 2006, expenditures for ezetimibe per 100,000 population were higher in the United States than in Canada by a factor of more than 4. Conclusions: Distinct patterns of use of ezetimibe emerged in the United States and Canada from 2002 to 2006, a difference that markedly altered the approach to the treatment of hyperlipidemia in the United States. The U.S. pattern increased overall costs, but the effect on clinical outcomes is uncertain. N Engl J Med 2008;358:1819-28.	[Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA 91766 USA; [Ross, Joseph S.] Mt Sinai Sch Med, New York, NY USA; [Ross, Joseph S.] James J Peters Vet Affairs Med Ctr, New York, NY USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA; [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; [Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT USA; [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Univ Hlth Network, Toronto, ON, Canada; [Jackevicius, Cynthia A.; Tu, Jack V.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Fac Med, Toronto, ON, Canada; [Tu, Jack V.; Ko, Dennis T.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Cardiol, Schulich Heart Ctr, Toronto, ON, Canada; [Tu, Jack V.; Ko, Dennis T.] Inst Clin Evaluat Sci, Toronto, ON, Canada	Western University of Health Sciences; Icahn School of Medicine at Mount Sinai; Yale University; Yale University; Yale University; Yale University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Jackevicius, CA (corresponding author), Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, 309 E 2nd St, Pomona, CA 91766 USA.	cjackevicius@westernu.edu	, Harlan/AAI-2875-2020	Tu, Jack/0000-0003-0111-722X; Ross, Joseph/0000-0002-9218-3320; Ko, Dennis/0000-0001-6840-8051				Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Bruckert E, 2003, CIRCULATION, V107, P3124, DOI 10.1161/01.CIR.0000072345.98581.24; Carroll MD, 2005, JAMA-J AM MED ASSOC, V294, P1773, DOI 10.1001/jama.294.14.1773; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; Grundy, 2004, CIRCULATION, V110, P763, DOI 10.1161/01.CIR.0000140446.06098.6B; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Heart and Stroke Foundation of Canada, 2003, GROW BURD HEART DIS; Hollon MF, 2005, JAMA-J AM MED ASSOC, V293, P2030, DOI 10.1001/jama.293.16.2030; Iglehart JK, 2000, NEW ENGL J MED, V342, P2007, DOI 10.1056/NEJM200006293422624; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Jackevicius CA, 2003, CAN J CARDIOL, V19, P1359; Kashani A, 2006, CIRCULATION, V114, P2788, DOI 10.1161/CIRCULATIONAHA.106.624890; Kastelein JJP, 2008, NEW ENGL J MED, V358, P1431, DOI 10.1056/NEJMoa0800742; Majumdar SR, 2003, AM J MED, V115, P467, DOI 10.1016/S0002-9343(03)00422-4; Marra CA, 2006, ARTHRIT RHEUM-ARTHR, V55, P9, DOI 10.1002/art.21709; McPherson R, 2006, CAN J CARDIOL, V22, P913, DOI 10.1016/S0828-282X(06)70310-5; *MERCK FROSST SCHE, 2007, PROD MON EZ; *MERCK SCHER PLOUG, 2007, PROD INF VYT; *MERCK SCHER PLOUG, 2007, PROD INF ZET; Mintzes B, 2002, BRIT MED J, V324, P1131; Morgan S, 2004, HEALTH AFFAIR, V23, P269, DOI 10.1377/hlthaff.23.3.269; Rawson NSB, 2003, ANN PHARMACOTHER, V37, P1403, DOI 10.1345/aph.1D110; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; *STAT CAN, 2001 CENS CAN; Tu K, 2003, CAN MED ASSOC J, V168, P553; Vachris MA, 1999, MON LABOR REV, V122, P3; Waxman HA, 2005, NEW ENGL J MED, V352, P2576, DOI 10.1056/NEJMp058136	27	68	68	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	2008	358	17					1819	1828		10.1056/NEJMsa0801461	http://dx.doi.org/10.1056/NEJMsa0801461			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291PL	18375999				2022-12-28	WOS:000255209200008
J	Samuel, DG				Samuel, David Gwynfor			The tale of an anorexic male medical student	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Cardiff Univ, Cardiff, Wales	Cardiff University	Samuel, DG (corresponding author), Cardiff Univ, Cardiff, Wales.	welshsledge@hotmail.com							0	1	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2008	336	7649					892	892		10.1136/bmj.39546.715347.94	http://dx.doi.org/10.1136/bmj.39546.715347.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	290QH	18420696	Green Published			2022-12-28	WOS:000255136800037
J	White, NJ				White, N. J.			Qinghaosu (Artemisinin): The price of success	SCIENCE			English	Review							UNCOMPLICATED FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; IN-VITRO; COMBINATION THERAPY; SCHISTOSOMA-MANSONI; ARTESUNATE; ARTEMETHER; MEFLOQUINE; RESISTANT; BURDEN	Artemisinin and its derivatives have become essential components of antimalarial treatment. These plant- derived peroxides are unique among antimalarial drugs in killing the young intraerythrocytic malaria parasites, thereby preventing their development to more pathological mature stages. This results in rapid clinical and parasitological responses to treatment and life- saving benefit in severe malaria. Artemisinin combination treatments ( ACTs) are now first- line drugs for uncomplicated falciparum malaria, but access to ACTs is still limited in most malaria- endemic countries. Improved agricultural practices, selection of high- yielding hybrids, microbial production, and the development of synthetic peroxides will lower prices. A global subsidy would make these drugs more affordable and available. ACTs are central to current malaria elimination initiatives, but there are concerns that tolerance to artemisinins may be emerging in Cambodia.	[White, N. J.] Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England; [White, N. J.] Mahidol Univ, Fac Trop Med, Bangkok, Thailand	University of Oxford; Mahidol University	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, Bangkok, Thailand.	nickw@tropmedres.ac	White, Nick/AAC-6527-2019; Hua, QX/HGE-3640-2022; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; [Anonymous], 2007, Wkly Epidemiol Rec, V82, P360; [Anonymous], 1979, CHINESE MED J-PEKING, V92, P811; Ashton M, 1998, CLIN PHARMACOL THER, V63, P482, DOI 10.1016/S0009-9236(98)90044-3; Asimus S, 2007, FUND CLIN PHARMACOL, V21, P307, DOI 10.1111/j.1472-8206.2007.00471.x; Barnes KI, 2004, LANCET, V363, P1598, DOI 10.1016/S0140-6736(04)16203-X; Barnes KI, 2005, PLOS MED, V2, P1123, DOI 10.1371/journal.pmed.0020330; Benoit-Vical F, 2007, ANTIMICROB AGENTS CH, V51, P1463, DOI 10.1128/AAC.00967-06; Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309; BREWER TG, 1994, T ROY SOC TROP MED H, V88, P33, DOI 10.1016/0035-9203(94)90469-3; Carrara VI, 2006, PLOS MED, V3, P856, DOI 10.1371/journal.pmed.0030183; Chang MCY, 2007, NAT CHEM BIOL, V3, P274, DOI 10.1038/nchembio875; CHEN PQ, 1994, CHINESE MED J-PEKING, V107, P709; Chotivanich K, 2002, J INFECT DIS, V185, P1538, DOI 10.1086/340213; Denis MB, 2006, TROP MED INT HEALTH, V11, P1360, DOI 10.1111/j.1365-3156.2006.01690.x; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; Faiz MA, 2005, LANCET, V366, P717; Genovese RF, 2008, ARCH TOXICOL, V82, P379, DOI 10.1007/s00204-007-0252-z; Haynes RK, 2007, CHEMMEDCHEM, V2, P1480, DOI 10.1002/cmdc.200700108; Hien TT, 2004, ANTIMICROB AGENTS CH, V48, P4234, DOI 10.1128/AAC.48.11.4234-4239.2004; Hien TT, 2003, LANCET, V362, P295, DOI 10.1016/S0140-6736(03)13974-8; Hunt P, 2007, MOL MICROBIOL, V65, P27, DOI 10.1111/j.1365-2958.2007.05753.x; Institute of Medicine (US) Committee on the Economics of Antimalarial Drugs, 2004, SAVING LIVES BUYING, P1125; Jambou R, 2005, LANCET, V366, P1960, DOI 10.1016/S0140-6736(05)67787-2; JIANG JB, 1982, LANCET, V2, P285; Keiser J, 2007, ANTIMICROB AGENTS CH, V51, P1096, DOI 10.1128/AAC.01366-06; Kindermans JM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-125; Kissinger E, 2000, AM J TROP MED HYG, V63, P48, DOI 10.4269/ajtmh.2000.63.48; Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1; KYLE DE, 2007, KEYST S GLOB HLTH SE; LI G, 1982, Journal of Traditional Chinese Medicine, V2, P125; Longo M, 2006, REPROD TOXICOL, V21, P83, DOI 10.1016/j.reprotox.2005.05.005; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Mishina YV, 2007, ANTIMICROB AGENTS CH, V51, P1852, DOI 10.1128/AAC.01544-06; Murphy SA, 1997, T ROY SOC TROP MED H, V91, P331, DOI 10.1016/S0035-9203(97)90097-3; Nakase I, 2008, INT J PHARM, V354, P28, DOI 10.1016/j.ijpharm.2007.09.003; Newton PN, 2008, PLOS MED, V5, P209, DOI 10.1371/journal.pmed.0050032; Newton PN, 2006, PLOS MED, V3, P752, DOI 10.1371/journal.pmed.0030197; NOSTEN F, 1994, J INFECT DIS, V170, P971, DOI 10.1093/infdis/170.4.971; Nyunt MM, 2007, CLIN PHARMACOL THER, V82, P601, DOI 10.1038/sj.clpt.6100361; PETERS W, 1990, PHARMACOL THERAPEUT, V47, P499, DOI 10.1016/0163-7258(90)90067-C; Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640; SCHMID G, 1983, J AM CHEM SOC, V105, P624, DOI 10.1021/ja00341a054; Stepniewska K, 2001, T ROY SOC TROP MED H, V95, P637, DOI 10.1016/S0035-9203(01)90104-X; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; Toovey S, 2004, T ROY SOC TROP MED H, V98, P261, DOI 10.1016/j.trstmh.2003.11.001; Udomsangpetch R, 1996, J INFECT DIS, V173, P691, DOI 10.1093/infdis/173.3.691; Uhlemann AC, 2007, ANTIMICROB AGENTS CH, V51, P667, DOI 10.1128/AAC.01064-06; Utzinger J, 2000, LANCET, V355, P1320, DOI 10.1016/S0140-6736(00)02114-0; Van Vugt M, 2000, AM J TROP MED HYG, V62, P65, DOI 10.4269/ajtmh.2000.62.65; Vennerstrom JL, 2004, NATURE, V430, P900, DOI 10.1038/nature02779; White NJ, 1997, ANTIMICROB AGENTS CH, V41, P1413, DOI 10.1128/AAC.41.7.1413; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; White TEK, 2006, BIRTH DEFECTS RES B, V77, P413, DOI 10.1002/bdrb.20092; *WHO, 2006, TREATM MAL; Xu H, 2007, RHEUMATOLOGY, V46, P920, DOI 10.1093/rheumatology/kem014; Yang HL, 2003, T ROY SOC TROP MED H, V97, P226, DOI 10.1016/S0035-9203(03)90127-1	57	663	695	13	360	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2008	320	5874					330	334		10.1126/science.1155165	http://dx.doi.org/10.1126/science.1155165			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420924				2022-12-28	WOS:000255026100031
J	Goldstein, NE; Genden, E; Morrison, RS				Goldstein, Nathan E.; Genden, Eric; Morrison, R. Sean			Palliative care for patients with head and neck cancer - "I would like a quick return to a normal lifestyle"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; RADIATION-INDUCED XEROSTOMIA; SQUAMOUS-CELL CARCINOMA; INDUCED ORAL MUCOSITIS; HUMAN-PAPILLOMAVIRUS; PROGNOSTIC-FACTORS; LARYNGEAL-CANCER; PHASE-III; MANAGEMENT	Head and neck cancers constitute a diverse group of diseases including malignancies of the oral cavity, oropharynx, larynx, sinuses, and skull base. Treatment of these cancers includes a combination of surgical resection, chemotherapy, and radiation. Due to both the patterns of disease recurrence and the adverse effects of treatments, patients with head and neck cancer often have a complex and prolonged course of illness that is marked by periods of freedom from disease and symptoms interspersed with bouts of serious illness, debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia. Thus, management of this disease is best provided by an interdisciplinary team that includes individuals from the disciplines of otolaryngology, palliative care, radiation oncology, oncology, nutrition, speech, and physical and occupational therapy. Using the case of Mr K, we describe the symptoms encountered by patients with head and neck cancer and suggest options for management. We discuss the psychological aspects that affect these patients, including issues such as changes in body image, quality of life, anxiety, and guilt. Finally, we discuss the importance of the interdisciplinary team in the care of these patients and outline the roles of each team member. By providing comprehensive care to patients with malignancies of the head and neck, clinicians can increase the likelihood that patients and their families will be able to obtain the best possible outcomes and quality of life.	[Goldstein, Nathan E.; Morrison, R. Sean] Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA; [Genden, Eric] Mt Sinai Sch Med, Dept Otolaryngol, New York, NY 10029 USA; [Goldstein, Nathan E.; Morrison, R. Sean] James J Peters VA Med Ctr, Bronx, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center	Goldstein, NE (corresponding author), Mt Sinai Sch Med, Dept Geriatr, Box 1070,1 Gustave Levy Pl, New York, NY 10029 USA.	nathan.goldstein@mssm.edu			NIA NIH HHS [K23AG025933, K24AG22345] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K23AG025933, K24AG022345] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abuksis G, 2000, AM J GASTROENTEROL, V95, P128; Agar MH., 2004, CLIN PRACT GUID QUAL, DOI 10.4135/9781848608191; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Babin E, 2008, EUR ARCH OTO-RHINO-L, V265, P265, DOI 10.1007/s00405-007-0561-0; Baghi M, 2007, LARYNGOSCOPE, V117, P712, DOI 10.1097/mlg.0b013e318031d0b4; Ballonoff A, 2006, OTOLARYNG CLIN N AM, V39, P365, DOI 10.1016/j.otc.2005.11.004; Birkhaug EJ, 2002, EUR ARCH OTO-RHINO-L, V259, P197, DOI 10.1107/s00405-001-0444-8; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Boffetta P, 1997, AM J EPIDEMIOL, V145, P1100; Bolderston A, 2006, SUPPORT CARE CANCER, V14, P802, DOI 10.1007/s00520-006-0063-4; Boldt AM, 2006, J PALLIAT MED, V9, P1128, DOI 10.1089/jpm.2006.9.1128; Bourhis J, 2002, SEMIN ONCOL, V29, P61, DOI 10.1053/sonc.2002.37349; Brizel DM, 2000, J CLIN ONCOL, V18, P3339, DOI 10.1200/JCO.2000.18.19.3339; Brosky Mary Elizabeth, 2007, J Support Oncol, V5, P215; Buentzel J, 2006, INT J RADIAT ONCOL, V64, P684, DOI 10.1016/j.ijrobp.2005.08.005; Callahan C, 2004, SOC WORK HEALTH CARE, V40, P73, DOI 10.1300/J010v40n02_05; Carvalho AL, 2005, INT J CANCER, V114, P806, DOI 10.1002/ijc.20740; Chambers MS, 2007, HEAD NECK-J SCI SPEC, V29, P58, DOI 10.1002/hed.20456; Chan Alexandre, 2005, J Oncol Pharm Pract, V11, P139, DOI 10.1191/1078155205jp166oa; Clarkson JE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001973.pub3; Cohen James, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P110, DOI 10.1097/00020840-200404000-00010; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497; DAHLIN C, 2001, TXB PALLIATIVE NURSI, P122; de Bree R, 2008, EUR ARCH OTO-RHINO-L, V265, P1, DOI 10.1007/s00405-007-0413-y; Dikshit RP, 2005, INT J CANCER, V117, P992, DOI 10.1002/ijc.21244; Dirix P, 2006, CANCER-AM CANCER SOC, V107, P2525, DOI 10.1002/cncr.22302; Dropkin M J, 1989, Semin Oncol Nurs, V5, P213, DOI 10.1016/0749-2081(89)90095-8; Duffy SA, 2007, PSYCHOSOMATICS, V48, P142, DOI 10.1176/appi.psy.48.2.142; Ellershaw J, 2003, BRIT MED J, V326, P30, DOI 10.1136/bmj.326.7379.30; EMANUEL LL, 1999, EPEC PARTICIPANTS HD; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Foley KM, 2001, IMPROVING PALLIATIVE; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Forastiere AA, 2000, ONCOLOGY-NY, V14, P163; Frampton M, 2001, BRIT J ORAL MAX SURG, V39, P67, DOI 10.1054/bjom.2000.0547; Ganzini L, 2003, NEW ENGL J MED, V349, P359, DOI 10.1056/NEJMsa035086; Genden EM, 2006, AURIS NASUS LARYNX, V33, P1, DOI 10.1016/j.anl.2005.09.008; Genden EM, 2007, ORAL ONCOL, V43, P431, DOI 10.1016/j.oraloncology.2006.08.007; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Goldstein NE, 2005, CRIT REV ONCOL HEMAT, V54, P157, DOI 10.1016/j.critrevonc.2005.01.001; Gould Lisa, 2006, Br J Nurs, V15, P1091; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Hammerlid E, 2001, BRIT J CANCER, V84, P149, DOI 10.1054/bjoc.2000.1576; HANKS G, 2005, OXFORD TXB PALLIATIV, P316; Hearn J, 1998, PALLIATIVE MED, V12, P317, DOI 10.1191/026921698676226729; Higginson IJ, 2003, J PAIN SYMPTOM MANAG, V25, P150, DOI 10.1016/S0885-3924(02)00599-7; Himmerich H, 2006, DIABETES CARE, V29, P170, DOI 10.2337/diacare.29.1.170; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551; Laimer M, 2006, J CLIN PSYCHIAT, V67, P421, DOI 10.4088/JCP.v67n0313; Lazarus C L, 2000, Semin Speech Lang, V21, P293, DOI 10.1055/s-2000-8383; Ledeboer QCP, 2005, CLIN OTOLARYNGOL, V30, P303, DOI 10.1111/j.1365-2273.2005.01035.x; Lussier D, 2004, ONCOLOGIST, V9, P571, DOI 10.1634/theoncologist.9-5-571; MEIER D, 2005, OXFORD TXB PALLIATIV, P935; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; MURPHY BA, 2005, OXFORD TXB PALLIATIV, P658; Murphy BA, 2007, CRIT REV ONCOL HEMAT, V62, P251, DOI 10.1016/j.critrevonc.2006.07.005; Ouwens MMMTJ, 2007, HEAD NECK-J SCI SPEC, V29, P378, DOI 10.1002/hed.20532; Pandey M, 2007, PSYCHO-ONCOL, V16, P582, DOI 10.1002/pon.1123; PAYNE R, 2005, OXFORD TXB PALLIATIV, P288; Posner M, 2007, ONCOLOGIST, V12, P967, DOI 10.1634/theoncologist.12-8-967; Rodriguez KL, 2007, J PALLIAT MED, V10, P99, DOI 10.1089/jpm.2006.0155; Rosenquist Kerstin, 2005, Swed Dent J Suppl, P1; Sanders DS, 2000, AM J GASTROENTEROL, V95, P1472, DOI 10.1111/j.1572-0241.2000.02079.x; Scharloo M, 2005, HEAD NECK-J SCI SPEC, V27, P857, DOI 10.1002/hed.20251; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Schulz R, 1997, ANN BEHAV MED, V19, P110, DOI 10.1007/BF02883327; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Scully C, 2004, HEAD NECK-J SCI SPEC, V26, P77, DOI 10.1002/hed.10326; Shiboski CH, 2007, ORAL SURG ORAL MED O, V103, pS66, DOI 10.1016/j.tripleo.2006.11.013; Stalfors J, 2007, ACTA OTO-LARYNGOL, V127, P82, DOI 10.1080/00016480600740589; Stokman MA, 2006, J DENT RES, V85, P690, DOI 10.1177/154405910608500802; Tagay S, 2006, QUAL LIFE RES, V15, P695, DOI 10.1007/s11136-005-3689-7; Treister Nathaniel, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P123, DOI 10.1097/MOO.0b013e3280523ad6; Twaddle ML, 2007, J PALLIAT MED, V10, P86, DOI 10.1089/jpm.2006.0048; Vakharia KT, 2007, OTOLARYNG HEAD NECK, V136, P405, DOI 10.1016/j.otohns.2006.10.018; Verdonck-de Leeuw IM, 2007, LARYNGOSCOPE, V117, P238, DOI 10.1097/01.mlg.0000250169.10241.58; Worthington HV, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000978.pub3	81	32	34	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1818	1825		10.1001/jama.299.15.1818	http://dx.doi.org/10.1001/jama.299.15.1818			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18413876				2022-12-28	WOS:000254954800026
J	Kirshenbaum, SR; Mooney, C; Otto, SL; Chapman, M; Dacey, A; Holt, R; Krauss, L				Kirshenbaum, Sheril R.; Mooney, Chris; Otto, Shawn Lawrence; Chapman, Matthew; Dacey, Austin; Holt, Rush; Krauss, Lawrence			Science and government: Science and the candidates	SCIENCE			English	Editorial Material									[Kirshenbaum, Sheril R.] Duke Univ, Nicholas Inst Environm Policy Solut, Durham, NC 27708 USA; [Mooney, Chris] Sci Progress, Washington, DC 20005 USA; [Dacey, Austin] Ctr Inquiry, Amherst, NY 14228 USA; [Holt, Rush] US House Representatives, Washington, DC 20515 USA; [Krauss, Lawrence] Case Western Reserve Univ, Ctr Educ & Res Cosmol & Astrophys, Cleveland, OH 44106 USA	Duke University; Case Western Reserve University	Kirshenbaum, SR (corresponding author), Duke Univ, Nicholas Inst Environm Policy Solut, Durham, NC 27708 USA.	sheril.kirshenbaum@duke.edu						Business Roundtable, 2005, TAPP AM POT ED INN I; IPCC Apndice, 2007, AR4 CLIMATE CHANGE 2; MOONEY C, 2007, SEED            1023; National Academy of Sciences, 2005, RIS GATH STORM EN EM; Nisbet MC, 2007, SCIENCE, V316, P56, DOI 10.1126/science.1142030; SHULMAN S, 2004, SCI INTEGRITY POLICY; TULIP P, 2007, 585 ORG EC COOP DEV	7	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					182	182		10.1126/science.1158281	http://dx.doi.org/10.1126/science.1158281			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403695				2022-12-28	WOS:000254836700025
J	Kump, LR; Pollard, D				Kump, Lee R.; Pollard, David			Amplification of cretaceous warmth by biological cloud feedbacks	SCIENCE			English	Article							CLIMATES		[Kump, Lee R.] Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; [Kump, Lee R.] Penn State Univ, Ctr Earth Syst Sci, University Pk, PA 16802 USA; [Pollard, David] Penn State Univ, Earth & Environm Syst Inst, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Kump, LR (corresponding author), Penn State Univ, Dept Geosci, University Pk, PA 16802 USA.	lkump@psu.edu	Kump, Lee/H-8287-2012					Andreae MO, 2007, SCIENCE, V315, P50, DOI 10.1126/science.1136529; Bice KL, 2006, PALEOCEANOGRAPHY, V21, DOI 10.1029/2005PA001203; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; Francis JE, 2002, PALAEOGEOGR PALAEOCL, V182, P47, DOI 10.1016/S0031-0182(01)00452-7; Sloan LC, 1998, GEOPHYS RES LETT, V25, P3517, DOI 10.1029/98GL02492; SPICER RA, 1992, GEOL MAG, V129, P169, DOI 10.1017/S0016756800008268	6	93	95	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					195	195		10.1126/science.1153883	http://dx.doi.org/10.1126/science.1153883			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403703				2022-12-28	WOS:000254836700033
J	Biddle, L; Donovan, J; Hawton, K; Kapur, N; Gunnell, D				Biddle, Lucy; Donovan, Jenny; Hawton, Keith; Kapur, Navneet; Gunnell, David			Suicide and the Internet	BRITISH MEDICAL JOURNAL			English	Editorial Material							EPIDEMIOLOGY; PREVENTION; TESTS; RATES		[Biddle, Lucy; Donovan, Jenny; Gunnell, David] Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; [Hawton, Keith] Univ Oxford, Ctr Suicide Res, Dept Psychiat, Oxford OX3 7JX, England; [Kapur, Navneet] Univ Manchester, Ctr Suicide Prevent, Manchester M13 9PL, Lancs, England	University of Bristol; University of Oxford; University of Manchester	Biddle, L (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	d.j.gunnell@bristol.ac.uk	Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470				Baume P, 1997, Crisis, V18, P73, DOI 10.1027/0227-5910.18.2.73; Beatson S, 2000, PSYCHIAT B, V24, P434; Becker K, 2004, J AM ACAD CHILD PSY, V43, P246, DOI 10.1097/00004583-200403000-00002; Biddle L, 2008, BRIT MED J, V336, P539, DOI 10.1136/bmj.39475.603935.25; Eysenbach G, 2002, BMJ-BRIT MED J, V324, P573, DOI 10.1136/bmj.324.7337.573; Gunnell D, 2005, INT J EPIDEMIOL, V34, P433, DOI 10.1093/ije/dyh398; Hansen DL, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e25; Hawton K, 2002, BRIT MED J, V325, P1374, DOI 10.1136/bmj.325.7377.1374; HAWTON K, 2005, PREVENTION TREATMENT, P279; Mehlum L, 2000, Crisis, V21, P186, DOI 10.1027//0227-5910.21.4.186; Miller M, 2004, ANN EMERG MED, V43, P723, DOI 10.1016/j.annemergmed.2004.01.018; MISHARA BL, ETHICAL LEGAL PRACTI; PHILLIPS DP, 1974, AM SOCIOL REV, V39, P340, DOI 10.2307/2094294; Pirkis J, 2001, Crisis, V22, P146, DOI 10.1027//0227-5910.22.4.146; Pirkis J, 2001, Crisis, V22, P155, DOI 10.1027//0227-5910.22.4.155; PRASAD V, 2001, PSYCHIAT B, V25, P222, DOI DOI 10.1192/PB.25.6.222; Prior TI, 2004, AM J PSYCHIAT, V161, P1500, DOI 10.1176/appi.ajp.161.8.1500-a; Rajagopal S, 2004, BRIT MED J, V329, P1298, DOI 10.1136/bmj.329.7478.1298; Ryan A, 2006, J PUBLIC HEALTH, V28, P370, DOI 10.1093/pubmed/fdl051; Thompson S, 1999, PSYCHIAT B, V23, P449, DOI DOI 10.1192/PB.23.8.449; Yip PSF, 2007, CRISIS, V28, P21, DOI 10.1027/0227-5910.28.S1.21	21	158	163	0	19	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR	2008	336	7648					800	802		10.1136/bmj.39525.442674.AD	http://dx.doi.org/10.1136/bmj.39525.442674.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	292ER	18403541	Green Published			2022-12-28	WOS:000255249800038
J	Kuemmeth, F; Ilani, S; Ralph, DC; McEuen, PL				Kuemmeth, F.; Ilani, S.; Ralph, D. C.; McEuen, P. L.			Coupling of spin and orbital motion of electrons in carbon nanotubes	NATURE			English	Article							QUANTUM DOTS; TRANSPORT	Electrons in atoms possess both spin and orbital degrees of freedom. In non- relativistic quantum mechanics, these are independent, resulting in large degeneracies in atomic spectra. However, relativistic effects couple the spin and orbital motion, leading to the well- known fine structure in their spectra. The electronic states in defect- free carbon nanotubes are widely believed to be four- fold degenerate(1-10), owing to independent spin and orbital symmetries, and also to possess electron - hole symmetry(11). Here we report measurements demonstrating that in clean nanotubes the spin and orbital motion of electrons are coupled, thereby breaking all of these symmetries. This spin - orbit coupling is directly observed as a splitting of the four- fold degeneracy of a single electron in ultra- clean quantum dots. The coupling favours parallel alignment of the orbital and spin magnetic moments for electrons and antiparallel alignment for holes. Our measurements are consistent with recent theories(12,13) that predict the existence of spin - orbit coupling in curved graphene and describe it as a spin-dependent topological phase in nanotubes. Our findings have important implications for spin- based applications in carbon-based systems, entailing new design principles for the realization of quantum bits ( qubits) in nanotubes and providing a mechanism for all- electrical control of spins(14) in nanotubes.	[Kuemmeth, F.; Ilani, S.; Ralph, D. C.; McEuen, P. L.] Cornell Univ, Atom & Solid State Phys Lab, Dept Phys, Ithaca, NY 14853 USA	Cornell University	McEuen, PL (corresponding author), Cornell Univ, Atom & Solid State Phys Lab, Dept Phys, Ithaca, NY 14853 USA.	mceuen@ccmr.cornell.edu	Ralph, Daniel C/G-3251-2010; ILANI, SHAHAL/K-1377-2012; Kuemmeth, Ferdinand/M-7232-2014	ILANI, SHAHAL/0000-0001-8589-7723; Kuemmeth, Ferdinand/0000-0003-3675-7331				Ando T, 2000, J PHYS SOC JPN, V69, P1757, DOI 10.1143/JPSJ.69.1757; Awschalom DD, 2007, NAT PHYS, V3, P153, DOI 10.1038/nphys551; BULAEV DV, 2007, SPIN ORBIT INTERACTI; Cao J, 2005, NAT MATER, V4, P745, DOI 10.1038/nmat1478; Cobden DH, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.046803; Cobden DH, 1998, PHYS REV LETT, V81, P681, DOI 10.1103/PhysRevLett.81.681; Elzerman JM, 2004, NATURE, V430, P431, DOI 10.1039/nature02693; Huertas-Hernando D, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.155426; Jarillo-Herrero P, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.156802; Jarillo-Herrero P, 2005, NATURE, V434, P484, DOI 10.1038/nature03422; Jarillo-Herrero P, 2004, NATURE, V429, P389, DOI 10.1038/nature02568; Kane CL, 1997, PHYS REV LETT, V78, P1932, DOI 10.1103/PhysRevLett.78.1932; Liang WJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.126801; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Makarovski A, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.241407; Makarovski A, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.155431; Minot ED, 2004, NATURE, V428, P536, DOI 10.1038/nature02425; Moriyama S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.186806; Nowack KC, 2007, SCIENCE, V318, P1430, DOI 10.1126/science.1148092; Oreg Y, 2000, PHYS REV LETT, V85, P365, DOI 10.1103/PhysRevLett.85.365; Petta JR, 2005, SCIENCE, V309, P2180, DOI 10.1126/science.1116955; Ralchenko Yu, ATOMIC SPECTRA DATAB; Sahoo S, 2005, NAT PHYS, V1, P99, DOI 10.1038/nphys149; Sapmaz S, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.153402; Tombros N, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.233403; Tombros N, 2007, NATURE, V448, P571, DOI 10.1038/nature06037	27	472	475	7	166	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2008	452	7186					448	452		10.1038/nature06822	http://dx.doi.org/10.1038/nature06822			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279FU	18368113	Green Published, Green Submitted			2022-12-28	WOS:000254341300026
J	Psaty, BM; Lumley, T				Psaty, Bruce M.; Lumley, Thomas			Surrogate end points and FDA approval - A tale of 2 lipid-altering drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ESTER TRANSFER PROTEIN; CHOLESTEROL ABSORPTION INHIBITOR; PRIMARY HYPERCHOLESTEROLEMIA; MYOCARDIAL-INFARCTION; TORCETRAPIB; EZETIMIBE; EFFICACY; SAFETY; RISK; ROSIGLITAZONE		[Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98101 USA; [Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98101 USA; [Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Hlth Serv, Seattle, WA 98101 USA; [Lumley, Thomas] Univ Washington, Cardiovasc Hlth Res Unit, Dept Biostat, Seattle, WA 98101 USA; [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative	Psaty, BM (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, 1730 Minor Ave,Ste 1360, Seattle, WA 98101 USA.	psaty@u.washington.edu						Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; BERENSON A, 2008, NY TIMES        0115, pA1; Bots ML, 2007, LANCET, V370, P153, DOI 10.1016/S0140-6736(07)61088-5; Brousseau ME, 2004, NEW ENGL J MED, V350, P1505, DOI 10.1056/NEJMoa031766; Carroll MD, 2005, JAMA-J AM MED ASSOC, V294, P1773, DOI 10.1001/jama.294.14.1773; Davidson MH, 2002, J AM COLL CARDIOL, V40, P2125, DOI 10.1016/S0735-1097(02)02610-4; Davidson MH, 2006, J AM COLL CARDIOL, V48, P1774, DOI 10.1016/j.jacc.2006.06.067; Dujovne CA, 2002, AM J CARDIOL, V90, P1092, DOI 10.1016/S0002-9149(02)02798-4; Gagne C, 2002, AM J CARDIOL, V90, P1084, DOI 10.1016/S0002-9149(02)02774-1; Greenland P, 2008, JAMA-J AM MED ASSOC, V299, P953, DOI 10.1001/jama.299.8.953; Hellings WE, 2008, JAMA-J AM MED ASSOC, V299, P547, DOI 10.1001/jama.299.5.547; Joffe HV, 2007, NEW ENGL J MED, V357, P1775; Knopp RH, 2003, EUR HEART J, V24, P729, DOI 10.1016/S0195-668X(02)00807-2; McKenney JM, 2006, J AM COLL CARDIOL, V48, P1782, DOI 10.1016/j.jacc.2006.06.066; *MERCK SCHER PLOUG, 2008, PROD NEWS MERCK SHER; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Nissen SE, 2007, NEW ENGL J MED, V356, P1304, DOI 10.1056/NEJMoa070635; Psaty BM, 1999, JAMA-J AM MED ASSOC, V282, P786, DOI 10.1001/jama.282.8.786; Psaty BM, 2004, J AM GERIATR SOC, V52, P1639, DOI 10.1111/j.1532-5415.2004.52455.x; *US FDA, 1990, GUID CLIN EV LIP ALT	20	33	33	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2008	299	12					1474	1476		10.1001/jama.299.12.1474	http://dx.doi.org/10.1001/jama.299.12.1474			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278MY	18364491				2022-12-28	WOS:000254292200023
J	Wang, JS				Wang, Judy S.			A practical pact for the pure land	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2008	299	12					1405	1406		10.1001/jama.299.12.1405	http://dx.doi.org/10.1001/jama.299.12.1405			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278MY	18364475				2022-12-28	WOS:000254292200001
J	Watanabe, T; Totoki, Y; Toyoda, A; Kaneda, M; Kuramochi-Miyagawa, S; Obata, Y; Chiba, H; Kohara, Y; Kono, T; Nakano, T; Surani, MA; Sakaki, Y; Sasaki, H				Watanabe, Toshiaki; Totoki, Yasushi; Toyoda, Atsushi; Kaneda, Masahiro; Kuramochi-Miyagawa, Satomi; Obata, Yayoi; Chiba, Hatsune; Kohara, Yuji; Kono, Tomohiro; Nakano, Toru; Surani, M. Azim; Sakaki, Yoshiyuki; Sasaki, Hiroyuki			Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes	NATURE			English	Article							SMALL RNAS; C-ELEGANS; MICRORNAS; GENE; ANTISENSE; GERMLINE; GENOME; TESTES; PIWI; RETROTRANSPOSON	RNA interference (RNAi) is a mechanism by which doublestranded RNAs (dsRNAs) suppress specific transcripts in a sequence-dependent manner. dsRNAs are processed by Dicer to 21-24-nucleotide small interfering RNAs (siRNAs) and then incorporated into the argonaute (Ago) proteins(1-4). Gene regulation by endogenous siRNAs has been observed only in organisms possessing RNA- dependent RNA polymerase (RdRP)(5-10). In mammals, where no RdRP activity has been found, biogenesis and function of endogenous siRNAs remain largely unknown. Here we show, using mouse oocytes, that endogenous siRNAs are derived from naturally occurring dsRNAs and have roles in the regulation of gene expression. By means of deep sequencing, we identify a large number of both similar to 25-27-nucleotide Piwi-interacting RNAs (piRNAs) and similar to 21-nucleotide siRNAs corresponding to messenger RNAs or retrotransposons in growing oocytes. piRNAs are bound to Mili and have a role in the regulation of retrotransposons. siRNAs are exclusively mapped to retrotransposons or other genomic regions that produce transcripts capable of forming dsRNA structures. Inverted repeat structures, bidirectional transcription and antisense transcripts from various loci are sources of the dsRNAs. Some precursor transcripts of siRNAs are derived from expressed pseudogenes, indicating that one role of pseudogenes is to adjust the level of the founding source mRNA through RNAi. Loss of Dicer or Ago2 results in decreased levels of siRNAs and increased levels of retrotransposon and protein-coding transcripts complementary to the siRNAs. Thus, the RNAi pathway regulates both protein-coding transcripts and retrotransposons in mouse oocytes. Our results reveal a role for endogenous siRNAs in mammalian oocytes and show that organisms lacking RdRP activity can produce functional endogenous siRNAs from naturally occurring dsRNAs.	[Watanabe, Toshiaki; Chiba, Hatsune; Sasaki, Hiroyuki] Res Org Informat & Syst, Div Human Genet, Dept Integrated Genet, Natl Inst Genet, Mishima, Shizuoka 4118540, Japan; [Watanabe, Toshiaki; Chiba, Hatsune; Kohara, Yuji; Sasaki, Hiroyuki] Grad Univ Adv Studies, SOKENDAI, Dept Genet, Sch Life Sci, Mishima, Shizuoka 4118540, Japan; [Totoki, Yasushi; Sakaki, Yoshiyuki] RIKEN, Genome Sci Ctr, Genome Annotat & Comparat Anal Team, Computat & Expt Syst Biol Grp, Yokohama, Kanagawa 2300045, Japan; [Toyoda, Atsushi; Sakaki, Yoshiyuki] RIKEN, Genome Sci Ctr, Sequence Technol Team, Yokohama, Kanagawa 2300045, Japan; [Kaneda, Masahiro] Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst Canc Dev B, Cambridge CB2 1QN, England; [Kaneda, Masahiro] Natl Agr & Food Res Org, Reprod Biol & Technol Res Team, Natl Inst Livestock & Grassland Sci, Tsukuba, Ibaraki 3050901, Japan; [Kuramochi-Miyagawa, Satomi; Nakano, Toru] Osaka Univ, Dept Pathol, Grad Sch Med & Frontier Biosci, Suita, Osaka 5650871, Japan; [Obata, Yayoi; Kono, Tomohiro; Surani, M. Azim] Tokyo Univ Agr, Dept Biosci, Tokyo 1568502, Japan; [Kohara, Yuji] Res Org Informat & Syst, Genome Biol Lab, Ctr Genet Resources Informat, Natl Inst Genet, Mishima, Shizuoka 4118540, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; RIKEN; RIKEN; University of Cambridge; National Agriculture & Food Research Organization - Japan; Osaka University; Tokyo University of Agriculture; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Watanabe, T (corresponding author), Res Org Informat & Syst, Div Human Genet, Dept Integrated Genet, Natl Inst Genet, Mishima, Shizuoka 4118540, Japan.	toshwata@lab.nig.ac.jp; hisasaki@lab.nig.ac.jp	Kaneda, Masahiro/E-3117-2010	Kaneda, Masahiro/0000-0003-0660-7156; Surani, Azim/0000-0002-8640-4318	Grants-in-Aid for Scientific Research [19061001] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ambros V, 2007, DEVELOPMENT, V134, P1635, DOI 10.1242/dev.002006; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Chen JJ, 2004, NUCLEIC ACIDS RES, V32, P4812, DOI 10.1093/nar/gkh818; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Filipowicz W, 2005, CURR OPIN STRUC BIOL, V15, P331, DOI 10.1016/j.sbi.2005.05.006; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Gray TA, 2006, P NATL ACAD SCI USA, V103, P12039, DOI 10.1073/pnas.0602216103; Grivna ST, 2006, GENE DEV, V20, P1709, DOI 10.1101/gad.1434406; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Kuramochi-Miyagawa S, 2004, DEVELOPMENT, V131, P839, DOI 10.1242/dev.00973; Lau NC, 2006, SCIENCE, V313, P363, DOI 10.1126/science.1130164; Lavorgna G, 2004, TRENDS BIOCHEM SCI, V29, P88, DOI 10.1016/j.tibs.2003.12.002; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Pak J, 2007, SCIENCE, V315, P241, DOI 10.1126/science.1132839; Peaston AE, 2004, DEV CELL, V7, P597, DOI 10.1016/j.devcel.2004.09.004; Ruby JG, 2006, CELL, V127, P1193, DOI 10.1016/j.cell.2006.10.040; Saito K, 2006, GENE DEV, V20, P2214, DOI 10.1101/gad.1454806; Sijen T, 2007, SCIENCE, V315, P244, DOI 10.1126/science.1136699; Tang F, 2007, GENE DEV, V21, P644, DOI 10.1101/gad.418707; Vagin VV, 2006, SCIENCE, V313, P320, DOI 10.1126/science.1129333; Vaucheret H, 2006, GENE DEV, V20, P759, DOI 10.1101/gad.1410506; Watanabe T, 2006, GENE DEV, V20, P1732, DOI 10.1101/gad.1425706; Yang N, 2006, NAT STRUCT MOL BIOL, V13, P763, DOI 10.1038/nsmb1141; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Yigit E, 2006, CELL, V127, P747, DOI 10.1016/j.cell.2006.09.033	29	817	889	2	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2008	453	7194					539	U9		10.1038/nature06908	http://dx.doi.org/10.1038/nature06908			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18404146				2022-12-28	WOS:000256023700046
J	Morita, H; Rehm, HL; Menesses, A; McDonough, B; Roberts, AE; Kucherlapati, R; Towbin, JA; Seidman, JG; Seidman, CE				Morita, Hiroyuki; Rehm, Heidi L.; Menesses, Andres; McDonough, Barbara; Roberts, Amy E.; Kucherlapati, Raju; Towbin, Jeffrey A.; Seidman, J. G.; Seidman, Christine E.			Shared genetic causes of cardiac hypertrophy in children and adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; BINDING PROTEIN-C; PEDIATRIC CARDIOMYOPATHY; ALPHA-TROPOMYOSIN; TROPONIN-T; MUTATIONS; EPIDEMIOLOGY; EXPRESSION; COMPOUND; DISTINCT	Background: The childhood onset of idiopathic cardiac hypertrophy that occurs without a family history of cardiomyopathy can portend a poor prognosis. Despite morphologic similarities to genetic cardiomyopathies of adulthood, the contribution of genetics to childhood-onset hypertrophy is unknown. Methods: We assessed the family and medical histories of 84 children (63 boys and 21 girls) with idiopathic cardiac hypertrophy diagnosed before 15 years of age (mean [+/-SD] age, 6.99+/-6.12 years). We sequenced eight genes: MYH7, MYBPC3, TNNT2, TNNI3, TPM1, MYL3, MYL2, and ACTC. These genes encode sarcomere proteins that, when mutated, cause adult-onset cardiomyopathies. We also sequenced PRKAG2 and LAMP2, which encode metabolic proteins; mutations in these genes can cause early-onset ventricular hypertrophy. Results: We identified mutations in 25 of 51 affected children without family histories of cardiomyopathy and in 21 of 33 affected children with familial cardiomyopathy. Among 11 of the 25 children with presumed sporadic disease, 4 carried new mutations and 7 inherited the mutations. Mutations occurred predominantly (in >75% of the children) in MYH7 and MYBPC3; significantly more MYBPC3 missense mutations were detected than occur in adult-onset cardiomyopathy (P<0.005). Neither hypertrophic severity nor contractile function correlated with familial or genetic status. Cardiac transplantation and sudden death were more prevalent among mutation-positive than among mutation-negative children; implantable cardioverter-defibrillators were more frequent (P=0.007) in children with family histories that were positive for the mutation. Conclusions: Genetic causes account for about half of presumed sporadic cases and nearly two thirds of familial cases of childhood-onset hypertrophy. Childhood-onset hypertrophy should prompt genetic analyses and family evaluations.	[Morita, Hiroyuki; McDonough, Barbara; Kucherlapati, Raju; Seidman, J. G.; Seidman, Christine E.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Rehm, Heidi L.; Roberts, Amy E.; Kucherlapati, Raju; Seidman, J. G.] Harvard Univ, Sch Med, Partners HealthCare Ctr Genet & Genom, Boston, MA USA; [McDonough, Barbara; Seidman, Christine E.] Howard Hughes Med Inst, Boston, MA 02115 USA; [McDonough, Barbara; Seidman, Christine E.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Roberts, Amy E.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; [Menesses, Andres; Towbin, Jeffrey A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Partners Healthcare System; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Baylor College of Medicine	Seidman, CE (corresponding author), Harvard Univ, Sch Med, Dept Genet, Rm 256 NRB,77 Ave Louis Pasteur, Boston, MA 02115 USA.	cseidman@genetics.med.harvard.edu	Kucherlapati, Raju/ABC-8807-2021; Towbin, Jeffrey A./J-5595-2019	Towbin, Jeffrey A./0000-0002-6585-714X; Rehm, Heidi L./0000-0002-6025-0015	Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [R01 HL087000-02, R01 HL087000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087000] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alders M, 2003, EUR HEART J, V24, P1848, DOI 10.1016/S0195-668X(03)00466-4; Anan R, 2007, AM J CARDIOL, V99, P1750, DOI 10.1016/j.amjcard.2007.01.066; Arad M, 2005, NEW ENGL J MED, V352, P362, DOI 10.1056/NEJMoa033349; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Burwinkel B, 2005, AM J HUM GENET, V76, P1034, DOI 10.1086/430840; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Colan SD, 2007, CIRCULATION, V115, P773, DOI 10.1161/CIRCULATIONAHA.106.621185; CONSEVAGE MW, 1994, HUM MOL GENET, V3, P1025, DOI 10.1093/hmg/3.6.1025; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; FANANAPAZIR L, 1994, CIRCULATION, V89, P22, DOI 10.1161/01.CIR.89.1.22; Flavigny J, 1999, J MOL BIOL, V294, P443, DOI 10.1006/jmbi.1999.3276; Gruver EJ, 1999, AM J CARDIOL, V83, p13H; Ingles J, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.033886; Lind Joanne M, 2006, Expert Rev Cardiovasc Ther, V4, P927, DOI 10.1586/14779072.4.6.927; Lipshultz SE, 2003, NEW ENGL J MED, V348, P1647, DOI 10.1056/NEJMoa021715; Maron BJ, 2004, PEDIATR CLIN N AM, V51, P1305, DOI 10.1016/j.pcl.2004.04.017; Maron BJ, 2003, J AM COLL CARDIOL, V42, P882, DOI 10.1016/S0735-1097(03)00855-6; Morita H, 2002, COLD SPRING HARB SYM, V67, P383, DOI 10.1101/sqb.2002.67.383; Morita H, 2006, CIRCULATION, V113, P2697, DOI 10.1161/CIRCULATIONAHA.105.593558; Niimura H, 2002, CIRCULATION, V105, P446, DOI 10.1161/hc0402.102990; Niimura H, 1998, NEW ENGL J MED, V338, P1248, DOI 10.1056/NEJM199804303381802; Nugent AW, 2003, NEW ENGL J MED, V348, P1639, DOI 10.1056/NEJMoa021737; Nugent AW, 2005, CIRCULATION, V112, P1332, DOI 10.1161/CIRCULATIONAHA.104.530303; Osio A, 2007, CIRC RES, V100, P766, DOI 10.1161/01.RES.0000263008.66799.aa; Probst V, 2003, J AM COLL CARDIOL, V41, P643, DOI 10.1016/S0735-1097(02)02864-4; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; Roberts AE, 2005, AM J MED GENET A, V132A, P333, DOI 10.1002/ajmg.a.30405; SAS Institute, 2000, SAS STAT US GUID REL; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Van Driest SL, 2004, J AM COLL CARDIOL, V44, P1903, DOI 10.1016/j.jacc.2004.07.045; Van Driest SL, 2004, J AM COLL CARDIOL, V44, P602, DOI 10.1016/j.jacc.2004.04.039; Van Driest SL, 2002, CIRCULATION, V106, P3085, DOI 10.1161/01.CIR.0000042675.59901.14; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; Yetman AT, 2005, CURR OPIN CARDIOL, V20, P80, DOI 10.1097/01.hco.0000153452.45341.36	37	266	286	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2008	358	18					1899	1908		10.1056/NEJMoa075463	http://dx.doi.org/10.1056/NEJMoa075463			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294ER	18403758	Green Accepted, Bronze			2022-12-28	WOS:000255387900004
J	Avorn, J; Shrank, WH				Avorn, Jerry; Shrank, William H.			Making a difference - Adverse drug reactions in elderly people - A substantial cause of preventable illness	BRITISH MEDICAL JOURNAL			English	Editorial Material							PHARMACOLOGICAL CARE; QUALITY		[Avorn, Jerry; Shrank, William H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Avorn, J (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA.	javorn@medsoc.harvard.edu						AVORN J, 1995, AM J MED, V99, P48, DOI 10.1016/S0002-9343(99)80104-1; AVORN J, 2003, GERIATRIC MED EVIDEN; Avorn J, 2004, POWERFUL MED BENEFIT; Benner JS, 2002, JAMA-J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Higashi T, 2004, ANN INTERN MED, V140, P714, DOI 10.7326/0003-4819-140-9-200405040-00011; Peterson JF, 2005, ARCH INTERN MED, V165, P802, DOI 10.1001/archinte.165.7.802; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Shrank WH, 2006, MED CARE, V44, P936, DOI 10.1097/01.mlr.0000223460.60033.79	9	23	24	1	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					956	+		10.1136/bmj.39520.671053.94	http://dx.doi.org/10.1136/bmj.39520.671053.94			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397948	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000255540900043
J	Bardy, GH; Lee, KL; Mark, DB; Poole, JE; Toff, WD; Tonkin, AM; Smith, W; Dorian, P; Packer, DL; White, RD; Longstreth, WT; Anderson, J; Johnson, G; Bischoff, E; Yallop, JJ; McNulty, S; Ray, LD; Clapp-Channing, NE; Rosenberg, Y; Schron, EB				Bardy, Gust H.; Lee, Kerry L.; Mark, Daniel B.; Poole, Jeanne E.; Toff, William D.; Tonkin, Andrew M.; Smith, Warren; Dorian, Paul; Packer, Douglas L.; White, Roger D.; Longstreth, W. T., Jr.; Anderson, Jill; Johnson, George; Bischoff, Eric; Yallop, Julie J.; McNulty, Steven; Ray, Linda Davidson; Clapp-Channing, Nancy E.; Rosenberg, Yves; Schron, Eleanor B.		HAT Investigators	Home use of automated external defibrillators for sudden cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; CARDIOVERTER-DEFIBRILLATOR; SURVIVAL; IMPLANTATION; ASSOCIATION; COMMITTEE; VICTIMS; RATES; WAVE	Background: The most common location of out-of-hospital sudden cardiac arrest is the home, a situation in which emergency medical services are challenged to provide timely care. Consequently, home use of an automated external defibrillator (AED) might offer an opportunity to improve survival for patients at risk. Methods: We randomly assigned 7001 patients with previous anterior-wall myocardial infarction who were not candidates for an implantable cardioverter-defibrillator to receive one of two responses to sudden cardiac arrest occurring at home: either the control response (calling emergency medical services and performing cardiopulmonary resuscitation [CPR]) or the use of an AED, followed by calling emergency medical services and performing CPR. The primary outcome was death from any cause. Results: The median age of the patients was 62 years; 17% were women. The median follow-up was 37.3 months. Overall, 450 patients died: 228 of 3506 patients (6.5%) in the control group and 222 of 3495 patients (6.4%) in the AED group (hazard ratio, 0.97; 95% confidence interval, 0.81 to 1.17; P=0.77). Mortality did not differ significantly in major prespecified subgroups. Only 160 deaths (35.6%) were considered to be from sudden cardiac arrest from tachyarrhythmia. Of these deaths, 117 occurred at home; 58 at-home events were witnessed. AEDs were used in 32 patients. Of these patients, 14 received an appropriate shock, and 4 survived to hospital discharge. There were no documented inappropriate shocks. Conclusions: For survivors of anterior-wall myocardial infarction who were not candidates for implantation of a cardioverter-defibrillator, access to a home AED did not significantly improve overall survival, as compared with reliance on conventional resuscitation methods.	[Bardy, Gust H.; Anderson, Jill; Johnson, George; Bischoff, Eric] Seattle Inst Cardiac Res, Seattle, WA 98103 USA; [Poole, Jeanne E.; Longstreth, W. T., Jr.] Univ Washington, Seattle, WA 98195 USA; [Lee, Kerry L.; Mark, Daniel B.; McNulty, Steven; Ray, Linda Davidson; Clapp-Channing, Nancy E.] Duke Univ, Clin Res Inst, Durham, NC USA; [Toff, William D.] Univ Leicester, Leicester, Leics, England; [Tonkin, Andrew M.; Yallop, Julie J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Smith, Warren; Yallop, Julie J.] Auckland City Hosp, Auckland, New Zealand; [Dorian, Paul] Univ Toronto, Toronto, ON, Canada; [Packer, Douglas L.; White, Roger D.] Mayo Clin, Rochester, MN USA; [Rosenberg, Yves; Schron, Eleanor B.] NHLBI, NIH, Bethesda, MD 20892 USA	University of Washington; University of Washington Seattle; Duke University; University of Leicester; Monash University; Auckland City Hospital; University of Toronto; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bardy, GH (corresponding author), Seattle Inst Cardiac Res, 7900 E Green Lake Dr N,302, Seattle, WA 98103 USA.	gbardy@sicr.org		Toff, William/0000-0001-5631-4496; Mark, Daniel/0000-0001-6340-8087; Raitt, Merritt/0000-0001-5638-7732; Rinaldi, christopher/0000-0002-3930-1957	NCRR NIH HHS [K23 RR018298] Funding Source: Medline; NHLBI NIH HHS [U01 HL067972, U01-HL67972] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR018298] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL067972] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bardy GH, 2005, NEW ENGL J MED, V352, P2146; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Bardy GH, 2008, AM HEART J, V155, P445, DOI 10.1016/j.ahj.2007.12.008; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; Califf RM, 1996, CIRCULATION, V94, P1233, DOI 10.1161/01.CIR.94.6.1233; Cappato R, 2006, EUR HEART J, V27, P553, DOI 10.1093/eurheartj/ehi654; Capucci A, 2002, CIRCULATION, V106, P1065, DOI 10.1161/01.CIR.0000028148.62305.69; COX DR, 1972, J R STAT SOC B, V34, P187; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; Furman MI, 2001, J AM COLL CARDIOL, V37, P1571, DOI 10.1016/S0735-1097(01)01203-7; Gliner BE, 1999, RESUSCITATION, V41, P133, DOI 10.1016/S0300-9572(99)00040-4; Goldenberg I, 2008, J AM COLL CARDIOL, V51, P288, DOI 10.1016/j.jacc.2007.08.058; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Nichol G, 1999, ANN EMERG MED, V34, P517, DOI 10.1016/S0196-0644(99)80054-7; Norris RM, 2005, HEART, V91, P1537, DOI 10.1136/hrt.2004.057018; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Pell JP, 2002, BRIT MED J, V325, P515, DOI 10.1136/bmj.325.7363.515; Poole JE, 1997, J CARDIOVASC ELECTR, V8, P1373, DOI 10.1111/j.1540-8167.1997.tb01034.x; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Saxon LA, 2008, NEW ENGL J MED, V358, P77, DOI 10.1056/NEJMe0707823; Singh M, 2007, J AM COLL CARDIOL, V50, P1752, DOI 10.1016/j.jacc.2007.04.101; The American Heart Association in Collaboration with the International Liaison Committee on Resuscitation, 2000, CIRCULATION, V102, pI60; The American Heart Association in collaboration with the International Liaison Committee On Resuscitation (ILCOR), 2000, CIRCULATION S1, V102, pI12; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; White RD, 2005, RESUSCITATION, V65, P279, DOI 10.1016/j.resuscitation.2004.10.018; Zipes DP, 2006, CIRCULATION, V114, pE385, DOI 10.1161/CIRCULATIONAHA.106.178233	31	181	184	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	2008	358	17					1793	1804		10.1056/NEJMoa0801651	http://dx.doi.org/10.1056/NEJMoa0801651			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291PL	18381485	Green Published			2022-12-28	WOS:000255209200005
J	Steinbrook, R				Steinbrook, Robert			Personally controlled online health data - The next big thing in medical care?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RECORDS					rsteinbrook@attglobal.net						BRIGHT B, 2009, WALL STREET J   1129; Halamka JD, 2008, J AM MED INFORM ASSN, V15, P1, DOI 10.1197/jamia.M2562; HING ES, 2007, ADV DATA VITAL HLTH, V393; Pagliari C, 2007, BMJ-BRIT MED J, V335, P330, DOI 10.1136/bmj.39279.482963.AD	4	103	104	1	81	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1653	1656		10.1056/NEJMp0801736	http://dx.doi.org/10.1056/NEJMp0801736			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288DO	18420496				2022-12-28	WOS:000254966600001
J	Heine, M; Groc, L; Frischknecht, R; Beique, JC; Lounis, B; Rumbaugh, G; Huganir, RL; Cognet, L; Choquet, D				Heine, Martin; Groc, Laurent; Frischknecht, Renato; Beique, Jean-Claude; Lounis, Brahim; Rumbaugh, Gavin; Huganir, Richard L.; Cognet, Laurent; Choquet, Daniel			Surface mobility of postsynaptic AMPARs tunes synaptic transmission	SCIENCE			English	Article							CENTRAL GLUTAMATERGIC SYNAPSES; CA1 PYRAMIDAL NEURONS; RECEPTOR DESENSITIZATION; MOSSY FIBER; RELEASE; TRAFFICKING; MECHANISM; CYCLOTHIAZIDE; TRANSPORTERS; VARIABILITY	AMPA glutamate receptors (AMPARs) mediate fast excitatory synaptic transmission. Upon fast consecutive synaptic stimulation, transmission can be depressed. Recuperation from fast synaptic depression has been attributed solely to recovery of transmitter release and/or AMPAR desensitization. We show that AMPAR lateral diffusion, observed in both intact hippocampi and cultured neurons, allows fast exchange of desensitized receptors with naive functional ones within or near the postsynaptic density. Recovery from depression in the tens of millisecond time range can be explained in part by this fast receptor exchange. Preventing AMPAR surface movements through cross-linking, endogenous clustering, or calcium rise all slow recovery from depression. Physiological regulation of postsynaptic receptor mobility affects the fidelity of synaptic transmission by shaping the frequency dependence of synaptic responses.	[Heine, Martin; Groc, Laurent; Choquet, Daniel] Univ Bordeaux 1, CNRS, UMR 5091, Bordeaux, France; [Lounis, Brahim; Cognet, Laurent] Univ Bordeaux 1, Ctr Phys Mol Opt & Hertzienne, CNRS, F-33405 Talence, France; [Beique, Jean-Claude; Rumbaugh, Gavin; Huganir, Richard L.] Johns Hopkins Univ, Dept Neurosci, Baltimore, MD USA; [Frischknecht, Renato] Leibniz Inst Neurobiol, Magdeburg, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Johns Hopkins University; Leibniz Institut fur Neurobiologie (LIN)	Choquet, D (corresponding author), Univ Bordeaux 1, CNRS, UMR 5091, Bordeaux, France.	dchoquet@u-bordeaux2.fr	Choquet, Daniel/E-4203-2013; Choquet, Daniel/GOJ-8825-2022; Choquet, Daniel/K-7893-2018; Cognet, Laurent/F-4163-2011; Lounis, Brahim/I-7862-2016; Cognet, Laurent/M-4505-2019	Choquet, Daniel/0000-0003-4726-9763; Choquet, Daniel/0000-0003-4726-9763; Cognet, Laurent/0000-0002-3573-5387; Lounis, Brahim/0000-0001-7501-0236; 	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Adesnik H, 2005, NEURON, V48, P977, DOI 10.1016/j.neuron.2005.11.030; Andrasfalvy BK, 2001, J NEUROSCI, V21, P9151, DOI 10.1523/JNEUROSCI.21-23-09151.2001; Arai A, 1998, BRAIN RES, V799, P230, DOI 10.1016/S0006-8993(98)00446-6; Ashby MC, 2006, J NEUROSCI, V26, P7046, DOI 10.1523/JNEUROSCI.1235-06.2006; Bats C, 2007, NEURON, V53, P719, DOI 10.1016/j.neuron.2007.01.030; Beique JC, 2006, P NATL ACAD SCI USA, V103, P19535, DOI 10.1073/pnas.0608492103; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525; Diamond JS, 1997, J NEUROSCI, V17, P4672; DIAMOND JS, 1995, NEURON, V15, P1097, DOI 10.1016/0896-6273(95)90098-5; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Ehlers MD, 2007, NEURON, V54, P447, DOI 10.1016/j.neuron.2007.04.010; Fortune ES, 2001, TRENDS NEUROSCI, V24, P381, DOI 10.1016/S0166-2236(00)01835-X; Franks KM, 2003, J NEUROSCI, V23, P3186; Franks KM, 2002, BIOPHYS J, V83, P2333, DOI 10.1016/S0006-3495(02)75248-X; Groc L, 2004, NAT NEUROSCI, V7, P695, DOI 10.1038/nn1270; Groc L, 2007, J NEUROSCI, V27, P12433, DOI 10.1523/JNEUROSCI.3349-07.2007; Grosskreutz J, 2003, EUR J NEUROSCI, V17, P1173, DOI 10.1046/j.1460-9568.2003.02531.x; Hjelmstad GO, 1999, J NEUROPHYSIOL, V81, P3096, DOI 10.1152/jn.1999.81.6.3096; Ishikawa T, 2001, J PHYSIOL-LONDON, V533, P423, DOI 10.1111/j.1469-7793.2001.0423a.x; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; Lisman JE, 2007, NAT REV NEUROSCI, V8, P597, DOI 10.1038/nrn2191; Liu GS, 1999, NEURON, V22, P395, DOI 10.1016/S0896-6273(00)81099-5; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; RAMAN IM, 1995, BIOPHYS J, V68, P137, DOI 10.1016/S0006-3495(95)80168-2; Scheuss V, 2002, J NEUROSCI, V22, P728, DOI 10.1523/JNEUROSCI.22-03-00728.2002; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Smith MA, 2003, J PHYSIOL-LONDON, V548, P245, DOI 10.1113/jphysiol.2002.036376; Sugiyama Y, 2005, NAT METHODS, V2, P677, DOI 10.1038/NMETH783; Tardin C, 2003, EMBO J, V22, P4656, DOI 10.1093/emboj/cdg463; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; Xie XP, 1997, P NATL ACAD SCI USA, V94, P6983, DOI 10.1073/pnas.94.13.6983; Xu-Friedman MA, 2003, J NEUROSCI, V23, P2182; YAMADA KA, 1993, J NEUROSCI, V13, P3904; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	37	342	346	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2008	320	5873					201	205		10.1126/science.1152089	http://dx.doi.org/10.1126/science.1152089			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403705	Green Accepted			2022-12-28	WOS:000254836700035
J	Silver, RA; Kanichay, RT				Silver, R. Angus; Kanichay, Roby T.			Refreshing connections	SCIENCE			English	Editorial Material							AMPA RECEPTORS; GLUTAMATE; DESENSITIZATION; TRANSMISSION; DEPRESSION; SYNAPSE; SLICES		[Silver, R. Angus; Kanichay, Roby T.] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England	University of London; University College London	Silver, RA (corresponding author), UCL, Dept Neurosci Physiol & Pharmacol, Gower St, London WC1E 6BT, England.	a.silver@ucl.ac.uk		Silver, Robin/0000-0002-5480-6638	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; BETZ WJ, 1970, J PHYSIOL-LONDON, V206, P629, DOI 10.1113/jphysiol.1970.sp009034; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DiGregorio DA, 2002, NEURON, V35, P521, DOI 10.1016/S0896-6273(02)00787-0; DiGregorio DA, 2007, J NEUROSCI, V27, P8344, DOI 10.1523/JNEUROSCI.2399-07.2007; Heine M, 2008, SCIENCE, V320, P201, DOI 10.1126/science.1152089; Liu GS, 1999, NEURON, V22, P395, DOI 10.1016/S0896-6273(00)81099-5; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; Saviane C, 2006, NATURE, V439, P983, DOI 10.1038/nature04509; Silver RA, 1998, J PHYSIOL-LONDON, V510, P881, DOI 10.1111/j.1469-7793.1998.881bj.x; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2	12	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2008	320	5873					183	184		10.1126/science.1157589	http://dx.doi.org/10.1126/science.1157589			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286HJ	18403696				2022-12-28	WOS:000254836700026
J	Gilbert, RE; Marsden, PA				Gilbert, Richard E.; Marsden, Philip A.			Activated protein C and diabetic nephropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SEPSIS		[Gilbert, Richard E.; Marsden, Philip A.] Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada; [Gilbert, Richard E.; Marsden, Philip A.] St Michaels Hosp, Div Endocrinol, Toronto, ON M5B 1W8, Canada; [Gilbert, Richard E.; Marsden, Philip A.] St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1W8, Canada; [Gilbert, Richard E.; Marsden, Philip A.] Univ Toronto, Toronto, ON, Canada	University of Toronto; Li Ka Shing Knowledge Institute; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Gilbert, RE (corresponding author), Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada.		Marsden, Philip A/B-1441-2012					Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Isermann B, 2007, NAT MED, V13, P1349, DOI 10.1038/nm1667; Kerschen EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884	4	10	12	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2008	358	15					1628	1630		10.1056/NEJMcibr0801042	http://dx.doi.org/10.1056/NEJMcibr0801042			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285NK	18403772				2022-12-28	WOS:000254783300015
J	Lelieveld, J; Butler, TM; Crowley, JN; Dillon, TJ; Fischer, H; Ganzeveld, L; Harder, H; Lawrence, MG; Martinez, M; Taraborrelli, D; Williams, J				Lelieveld, J.; Butler, T. M.; Crowley, J. N.; Dillon, T. J.; Fischer, H.; Ganzeveld, L.; Harder, H.; Lawrence, M. G.; Martinez, M.; Taraborrelli, D.; Williams, J.			Atmospheric oxidation capacity sustained by a tropical forest	NATURE			English	Article							ISOPRENE; CHEMISTRY; EMISSION; MODEL; THERMOTOLERANCE; HYDROCARBONS; TERRESTRIAL; SIMULATION; OZONE	Terrestrial vegetation, especially tropical rain forest, releases vast quantities of volatile organic compounds (VOCs) to the atmosphere(1-3), which are removed by oxidation reactions and deposition of reaction products(4-6). The oxidation is mainly initiated by hydroxyl radicals (OH), primarily formed through the photodissociation of ozone(4). Previously it was thought that, in unpolluted air, biogenic VOCs deplete OH and reduce the atmospheric oxidation capacity(5-10). Conversely, in polluted air VOC oxidation leads to noxious oxidant build-up by the catalytic action of nitrogen oxides(5-10) (NOx = NO + NO2). Here we report aircraft measurements of atmospheric trace gases performed over the pristine Amazon forest. Our data reveal unexpectedly high OH concentrations. We propose that natural VOC oxidation, notably of isoprene, recycles OH efficiently in low-NOx air through reactions of organic peroxy radicals. Computations with an atmospheric chemistry model and the results of laboratory experiments suggest that an OH recycling efficiency of 40-80 per cent in isoprene oxidation may be able to explain the high OH levels we observed in the field. Although further laboratory studies are necessary to explore the chemical mechanism responsible for OH recycling in more detail, our results demonstrate that the biosphere maintains a remarkable balance with the atmospheric environment.	[Lelieveld, J.; Butler, T. M.; Crowley, J. N.; Dillon, T. J.; Fischer, H.; Ganzeveld, L.; Harder, H.; Lawrence, M. G.; Martinez, M.; Taraborrelli, D.; Williams, J.] Max Planck Inst Chem, D-55128 Mainz, Germany	Max Planck Society	Lelieveld, J (corresponding author), Max Planck Inst Chem, 27 Becherweg, D-55128 Mainz, Germany.	lelieveld@mpch-mainz.mpg.de	Lelieveld, Jos/A-1986-2013; Taraborrelli, Domenico/O-8668-2015; Butler, Tim/G-1139-2011; Dillon, Terry J/A-3921-2011; Harder, Hartwig D/L-2511-2014; Harder, Hartwig/AAE-8557-2019; Williams, Jonathan/K-7686-2017	Lelieveld, Jos/0000-0001-6307-3846; Taraborrelli, Domenico/0000-0003-2213-6307; Dillon, Terry J/0000-0001-8974-9410; Harder, Hartwig D/0000-0002-6868-714X; Harder, Hartwig/0000-0002-6868-714X; Williams, Jonathan/0000-0001-9421-1703; Butler, Timothy/0000-0002-2219-4657; Lawrence, Mark/0000-0002-2178-4903				Ciccioli P, 1999, J GEOPHYS RES-ATMOS, V104, P8077, DOI 10.1029/1998JD100026; Di Carlo P, 2004, SCIENCE, V304, P722, DOI 10.1126/science.1094392; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; Ganzeveld LN, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001289; Goldstein AH, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021259; Goldstein AH, 2007, ENVIRON SCI TECHNOL, V41, P1514, DOI 10.1021/es072476p; Granier C, 2000, ATMOS ENVIRON, V34, P5255, DOI 10.1016/S1352-2310(00)00299-5; Guenther A, 2006, ATMOS CHEM PHYS, V6, P3181, DOI 10.5194/acp-6-3181-2006; Hasson AS, 2004, J PHYS CHEM A, V108, P5979, DOI 10.1021/jp048873t; Jenkin ME, 2007, PHYS CHEM CHEM PHYS, V9, P3149, DOI 10.1039/b702757e; Jockel P, 2006, ATMOS CHEM PHYS, V6, P5067; Karl T, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2007JD008539; Kesselmeier J, 1999, J ATMOS CHEM, V33, P23, DOI 10.1023/A:1006127516791; Kuhn U, 2007, ATMOS CHEM PHYS, V7, P2855, DOI 10.5194/acp-7-2855-2007; Lawrence MG, 1999, J GEOPHYS RES-ATMOS, V104, P26245, DOI 10.1029/1999JD900425; Lelieveld J, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002272; LEVY H, 1971, SCIENCE, V173, P141, DOI 10.1126/science.173.3992.141; Penuelas J, 2005, PLANT CELL ENVIRON, V28, P278, DOI 10.1111/j.1365-3040.2004.01250.x; Poschl U, 2000, J ATMOS CHEM, V37, P29, DOI 10.1023/A:1006391009798; Sander R, 2005, ATMOS CHEM PHYS, V5, P445, DOI 10.5194/acp-5-445-2005; Saunders SM, 2003, ATMOS CHEM PHYS, V3, P161, DOI 10.5194/acp-3-161-2003; Singsaas EL, 1997, PLANT PHYSIOL, V115, P1413, DOI 10.1104/pp.115.4.1413; Tan D, 2001, J GEOPHYS RES-ATMOS, V106, P24407, DOI 10.1029/2001JD900016; TERRY GM, 1995, J EXP BOT, V46, P1629, DOI 10.1093/jxb/46.10.1629; Thornton JA, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000932; von Kuhlmann R, 2004, ATMOS CHEM PHYS, V4, P1, DOI 10.5194/acp-4-1-2004; Wang YH, 1998, J GEOPHYS RES-ATMOS, V103, P10757, DOI 10.1029/98JD00156; Wildermuth MC, 1996, PLANT PHYSIOL, V112, P171, DOI 10.1104/pp.112.1.171; Williams J, 2007, ATMOS CHEM PHYS, V7, P973, DOI 10.5194/acp-7-973-2007	29	591	599	11	435	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	2008	452	7188					737	740		10.1038/nature06870	http://dx.doi.org/10.1038/nature06870			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	285QY	18401407				2022-12-28	WOS:000254792500042
J	Connaughton, M				Connaughton, Mark			Commentary: Controversies in NICE guidance on infective endocarditis	BRITISH MEDICAL JOURNAL			English	Editorial Material									St Marys Hosp, Newport PO30 5TG, Wight, England		Connaughton, M (corresponding author), St Marys Hosp, Newport PO30 5TG, Wight, England.	mconnaughton@doctors.org.uk						*BRIT CARD SOC, 2006, END GUID; Gould FK, 2006, J ANTIMICROB CHEMOTH, V57, P1035, DOI 10.1093/jac/dkl121	2	9	9	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 5	2008	336	7647					771	771		10.1136/bmj.39512.666412.AD	http://dx.doi.org/10.1136/bmj.39512.666412.AD			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284JW	18390529	Green Published			2022-12-28	WOS:000254703700036
J	Maris, JM; Woods, WG				Maris, John M.; Woods, William G.			Screening for neuroblastoma: a resurrected idea?	LANCET			English	Editorial Material									[Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Woods, William G.] Emory Univ, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Children's Healthcare of Atlanta (CHOA); Emory University	Maris, JM (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA.	maris@chop.edu						Barrette SP, 2006, J CLIN ONCOL, V24, P1542, DOI 10.1200/JCO.2005.04.4602; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Dobrovoljski G, 2003, J PEDIAT HEMATOL ONC, V25, P14, DOI 10.1097/00043426-200301000-00005; Hiyama E, 2008, LANCET, V371, P1173, DOI 10.1016/S0140-6736(08)60523-1; Maris JM, 2005, CURR OPIN PEDIATR, V17, P7, DOI 10.1097/01.mop.0000150631.60571.89; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; NISHI M, 1987, CANCER, V60, P433, DOI 10.1002/1097-0142(19870801)60:3<433::AID-CNCR2820600326>3.0.CO;2-H; Nishihira H, 2000, J CLIN ONCOL, V18, P3012, DOI 10.1200/JCO.2000.18.16.3012; Riley RD, 2004, CLIN CANCER RES, V10, P4, DOI 10.1158/1078-0432.CCR-1051-2; SAWADA T, 1984, LANCET, V2, P271; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Soderstrom L, 2005, J NATL CANCER I, V97, P1118, DOI 10.1093/jnci/dji203; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5	13	15	15	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 5	2008	371	9619					1142	1143		10.1016/S0140-6736(08)60500-0	http://dx.doi.org/10.1016/S0140-6736(08)60500-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395561				2022-12-28	WOS:000254956000006
J	An, SG; Kumar, R; Sheets, ED; Benkovic, SJ				An, Songon; Kumar, Ravindra; Sheets, Erin D.; Benkovic, Stephen J.			Reversible compartmentalization of de novo purine biosynthetic complexes in living cells	SCIENCE			English	Article							FOLATE-REQUIRING ENZYMES; HUMAN-FIBROBLASTS; AMIDOPHOSPHORIBOSYLTRANSFERASE; METABOLISM; GROWTH; DENOVO; PHOSPHORIBOSYLPYROPHOSPHATE; PURIFICATION; PYRIMIDINE; NUCLEOTIDE	Purines are synthesized de novo in 10 chemical steps that are catalyzed by six enzymes in eukaryotes. Studies in vitro have provided little evidence of anticipated protein- protein interactions that would enable substrate channeling and regulation of the metabolic flux. We applied fluorescence microscopy to HeLa cells and discovered that all six enzymes colocalize to form clusters in the cellular cytoplasm. The association and dissociation of these enzyme clusters can be regulated dynamically, by either changing the purine levels of or adding exogenous agents to the culture media. Collectively, the data provide strong evidence for the formation of a multi- enzyme complex, the "purinosome," to carry out de novo purine biosynthesis in cells.	[An, Songon; Kumar, Ravindra; Sheets, Erin D.; Benkovic, Stephen J.] Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	An, SG (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.	sua13@psu.edu; eds11@psu.edu; sjb1@psu.edu	An, Songon/A-6714-2009	An, Songon/0000-0003-2189-7374; Sheets, Erin/0000-0002-5980-3225	NIA NIH HHS [R21 AG030949, R21 AG030949-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R21AG030949] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECKER MA, 1987, J BIOL CHEM, V262, P14531; Campanella ME, 2005, P NATL ACAD SCI USA, V102, P2402, DOI 10.1073/pnas.0409741102; CAPERELLI CA, 1980, J BIOL CHEM, V255, P1885; Constantine CZ, 2006, BIOCHEMISTRY-US, V45, P8193, DOI 10.1021/bi060465n; Gooljarsingh LT, 2001, P NATL ACAD SCI USA, V98, P6565, DOI 10.1073/pnas.121182998; Howarth M, 2005, P NATL ACAD SCI USA, V102, P7583, DOI 10.1073/pnas.0503125102; IWAHANA H, 1995, BBA-GENE STRUCT EXPR, V1261, P369, DOI 10.1016/0167-4781(95)00036-G; Kondo M, 2000, J BIOCHEM, V128, P57, DOI 10.1093/oxfordjournals.jbchem.a022730; Li SX, 2007, J MOL BIOL, V366, P1603, DOI 10.1016/j.jmb.2006.12.027; PAGLIARO L, 1988, J CELL BIOL, V107, P981, DOI 10.1083/jcb.107.3.981; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; RUDOLPH J, 1995, BIOCHEMISTRY-US, V34, P2241, DOI 10.1021/bi00007a019; SMITH GK, 1980, BIOCHEMISTRY-US, V19, P4313, DOI 10.1021/bi00559a026; Stasolla C, 2003, J PLANT PHYSIOL, V160, P1271, DOI 10.1078/0176-1617-01169; THOMPSON LF, 1978, P NATL ACAD SCI USA, V75, P3722, DOI 10.1073/pnas.75.8.3722; WASSERMAN GF, 1984, BIOCHEMISTRY-US, V23, P6704, DOI 10.1021/bi00321a065; Yamaoka T, 1997, J BIOL CHEM, V272, P17719, DOI 10.1074/jbc.272.28.17719; Yamaoka T, 2001, J BIOL CHEM, V276, P21285, DOI 10.1074/jbc.M011103200; Zrenner R, 2006, ANNU REV PLANT BIOL, V57, P805, DOI 10.1146/annurev.arplant.57.032905.105421	19	340	348	6	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					103	106		10.1126/science.1152241	http://dx.doi.org/10.1126/science.1152241			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388293				2022-12-28	WOS:000254633000041
J	Harris, TD; Buzby, PR; Babcock, H; Beer, E; Bowers, J; Braslavsky, I; Causey, M; Colonell, J; Dimeo, J; Efcavitch, JW; Giladi, E; Gill, J; Healy, J; Jarosz, M; Lapen, D; Moulton, K; Quake, SR; Steinmann, K; Thayer, E; Tyurina, A; Ward, R; Weiss, H; Xie, Z				Harris, Timothy D.; Buzby, Phillip R.; Babcock, Hazen; Beer, Eric; Bowers, Jayson; Braslavsky, Ido; Causey, Marie; Colonell, Jennifer; DiMeo, James; Efcavitch, J. William; Giladi, Eldar; Gill, Jaime; Healy, John; Jarosz, Mirna; Lapen, Dan; Moulton, Keith; Quake, Stephen R.; Steinmann, Kathleen; Thayer, Edward; Tyurina, Anastasia; Ward, Rebecca; Weiss, Howard; Xie, Zheng			Single-molecule DNA sequencing of a viral genome	SCIENCE			English	Article							POLYMERASE	The full promise of human genomics will be realized only when the genomes of thousands of individuals can be sequenced for comparative analysis. A reference sequence enables the use of short read length. We report an amplification- free method for determining the nucleotide sequence of more than 280,000 individual DNA molecules simultaneously. A DNA polymerase adds labeled nucleotides to surface- immobilized primer-template duplexes in stepwise fashion, and the asynchronous growth of individual DNA molecules was monitored by fluorescence imaging. Read lengths of > 25 bases and equivalent phred software program quality scores approaching 30 were achieved. We used this method to sequence the M13 virus to an average depth of > 150x and with 100% coverage; thus, we resequenced the M13 genome with high-sensitivity mutation detection. This demonstrates a strategy for high- throughput low- cost resequencing.	[Harris, Timothy D.; Buzby, Phillip R.; Babcock, Hazen; Beer, Eric; Bowers, Jayson; Causey, Marie; Colonell, Jennifer; DiMeo, James; Efcavitch, J. William; Giladi, Eldar; Gill, Jaime; Healy, John; Jarosz, Mirna; Lapen, Dan; Moulton, Keith; Steinmann, Kathleen; Thayer, Edward; Tyurina, Anastasia; Ward, Rebecca; Weiss, Howard; Xie, Zheng] Helicos Biosci Corp, Cambridge, MA 02139 USA; [Braslavsky, Ido] Ohio Univ, Dept Phys & Astron, Athens, OH 45701 USA; [Quake, Stephen R.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Quake, Stephen R.] Howard Hughes Med Inst, Stanford, CA 94305 USA	University System of Ohio; Ohio University; Stanford University; Howard Hughes Medical Institute	Harris, TD (corresponding author), Helicos Biosci Corp, 1 Kendall Sq, Cambridge, MA 02139 USA.	tharris@helicosbio.com	Braslavsky, Ido/O-1859-2013	Braslavsky, Ido/0000-0001-8985-8211; Babcock, Hazen/0000-0003-4835-3692	Howard Hughes Medical Institute Funding Source: Medline; NHGRI NIH HHS [R01 HG004144-01] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004144] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BARNES WM, 1992, GENE, V112, P29, DOI 10.1016/0378-1119(92)90299-5; Braslavsky I, 2003, P NATL ACAD SCI USA, V100, P3960, DOI 10.1073/pnas.0230489100; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Greenleaf WJ, 2006, SCIENCE, V313, P801, DOI 10.1126/science.1130105; Hillier LW, 2008, NAT METHODS, V5, P183, DOI 10.1038/NMETH.1179; JETT JH, 1989, J BIOMOL STRUCT DYN, V7, P301, DOI 10.1080/07391102.1989.10507773; Ju JY, 2006, P NATL ACAD SCI USA, V103, P19635, DOI 10.1073/pnas.0609513103; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; STADEN R, 1979, NUCLEIC ACIDS RES, V6, P2601, DOI 10.1093/nar/6.7.2601; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	14	467	869	3	219	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					106	109		10.1126/science.1150427	http://dx.doi.org/10.1126/science.1150427			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388294				2022-12-28	WOS:000254633000042
J	Palme, K; Nagy, F				Palme, Klaus; Nagy, Ferenc			A new gene for auxin synthesis	CELL			English	Editorial Material							ARABIDOPSIS; TRANSPORT; GROWTH	There is much interest in understanding the pathways that trigger biosynthesis of the plant hormone auxin. In this issue, Stepanova et al. (2008) and Tao et al. (2008) reveal that a small family of tryptophan aminotransferases catalyze formation of indole-3-pyruvic acid (IPA) from L-tryptophan (L-Trp), the first step in a pathway for auxin biosynthesis.	[Palme, Klaus] Univ Freiburg, Fac Biol, Inst Biol 2, D-79104 Freiburg, Germany; [Nagy, Ferenc] Inst Plant Biol, Biol Res Ctr, Szeged, Hungary	University of Freiburg; Hungarian Academy of Sciences; Hungarian Biological Research Center	Palme, K (corresponding author), Univ Freiburg, Fac Biol, Inst Biol 2, D-79104 Freiburg, Germany.	klaus.palme@biologie.uni-freiburg.de	Palme, Klaus/A-9524-2013; Nagy, Ferenc/D-3532-2015	Palme, Klaus/0000-0002-2728-3835; Nagy, Ferenc/0000-0002-6157-9269				Bartel Bonnie, 1997, Annu Rev Plant Physiol Plant Mol Biol, V48, P51, DOI 10.1146/annurev.arplant.48.1.51; Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; Carabelli M, 2007, GENE DEV, V21, P1863, DOI 10.1101/gad.432607; Cheng YF, 2006, GENE DEV, V20, P1790, DOI 10.1101/gad.1415106; Franklin KA, 2005, ANN BOT-LONDON, V96, P169, DOI 10.1093/aob/mci165; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Paponov IA, 2005, TRENDS PLANT SCI, V10, P170, DOI 10.1016/j.tplants.2005.02.009; Sessa G, 2005, GENE DEV, V19, P2811, DOI 10.1101/gad.364005; Teale WD, 2008, MOL PLANT, V1, P229, DOI 10.1093/mp/ssn006; Teale WD, 2006, NAT REV MOL CELL BIO, V7, P847, DOI 10.1038/nrm2020	10	14	14	1	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 4	2008	133	1					31	32		10.1016/j.cell.2008.03.014	http://dx.doi.org/10.1016/j.cell.2008.03.014			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394986	Bronze			2022-12-28	WOS:000254641300005
J	Toor, N; Keating, KS; Taylor, SD; Pyle, AM				Toor, Navtej; Keating, Kevin S.; Taylor, Sean D.; Pyle, Anna Marie			Crystal structure of a self-spliced group II intron	SCIENCE			English	Article							METAL-ION COORDINATION; ACTIVE-SITE; IN-VIVO; CONSERVED DINUCLEOTIDE; 2-METAL-ION MECHANISM; TERTIARY INTERACTION; EXON-BINDING; RNA; DOMAIN-5; CATALYSIS	Group II introns are self- splicing ribozymes that catalyze their own excision from precursor transcripts and insertion into new genetic locations. Here we report the crystal structure of an intact, self- spliced group II intron from Oceanobacillus iheyensis at 3.1 angstrom resolution. An extensive network of tertiary interactions facilitates the ordered packing of intron subdomains around a ribozyme core that includes catalytic domain V. The bulge of domain V adopts an unusual helical structure that is located adjacent to a major groove triple helix ( catalytic triplex). The bulge and catalytic triplex jointly coordinate two divalent metal ions in a configuration that is consistent with a two- metal ion mechanism for catalysis. Structural and functional analogies support the hypothesis that group II introns and the spliceosome share a common ancestor.	[Toor, Navtej; Pyle, Anna Marie] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA; [Keating, Kevin S.] Yale Univ, Interdept Program Computat Biol & Bioinformat, New Haven, CT 06511 USA; [Taylor, Sean D.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA; [Pyle, Anna Marie] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Yale University; Yale University; Yale University; Howard Hughes Medical Institute	Toor, N (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave,Bass Bldg, New Haven, CT 06511 USA.	navtej.toor@yale.edu; anna.pyle@yale.edu		Toor, Navtej/0000-0002-6134-163X; Keating, Kevin/0000-0001-5855-6739	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050313] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007056] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [GM50313, R01 GM050313] Funding Source: Medline; NLM NIH HHS [T15 LM07056] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Adams PL, 2004, NATURE, V430, P45, DOI 10.1038/nature02642; Baeyens KJ, 1996, P NATL ACAD SCI USA, V93, P12851, DOI 10.1073/pnas.93.23.12851; Boudvillain M, 2000, NATURE, V406, P315, DOI 10.1038/35018589; Boudvillain M, 1998, EMBO J, V17, P7091, DOI 10.1093/emboj/17.23.7091; BOULANGER SC, 1995, MOL CELL BIOL, V15, P4479; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHANFREAU G, 1994, SCIENCE, V266, P1383, DOI 10.1126/science.7973729; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; Costa M, 2000, EMBO J, V19, P5007, DOI 10.1093/emboj/19.18.5007; Costa M, 1997, J MOL BIOL, V267, P520, DOI 10.1006/jmbi.1996.0882; de Lencastre A, 2005, NAT STRUCT MOL BIOL, V12, P626, DOI 10.1038/nsmb957; Fedorova O, 2005, EMBO J, V24, P3906, DOI 10.1038/sj.emboj.7600852; Fedorova O, 2003, J MOL BIOL, V330, P197, DOI 10.1016/S0022-2836(03)00594-1; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; Gordon PM, 2007, CHEM BIOL, V14, P607, DOI 10.1016/j.chembiol.2007.05.008; Gordon PM, 2001, NAT STRUCT BIOL, V8, P893, DOI 10.1038/nsb1001-893; Granlund M, 2001, J BACTERIOL, V183, P2560, DOI 10.1128/JB.183.8.2560-2569.2001; HARRISKERR CL, 1993, P NATL ACAD SCI USA, V90, P10658, DOI 10.1073/pnas.90.22.10658; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P41; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; Keel AY, 2007, STRUCTURE, V15, P761, DOI 10.1016/j.str.2007.06.003; Leontis NB, 2001, RNA, V7, P499, DOI 10.1017/S1355838201002515; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; Martin W, 2006, NATURE, V440, P41, DOI 10.1038/nature04531; Mikheeva S, 2000, RNA, V6, P1509, DOI 10.1017/S1355838200000972; Podar M, 1998, RNA, V4, P151; Podar M, 1998, NATURE, V391, P915, DOI 10.1038/36142; PODAR M, 1995, RNA, V1, P828; Podar M, 1999, RNA, V5, P318, DOI 10.1017/S1355838299981724; Pyle A. M., 2006, RNA WORLD; Pyle AM, 2007, TRENDS BIOCHEM SCI, V32, P138, DOI 10.1016/j.tibs.2007.01.005; Rest JS, 2003, MOL BIOL EVOL, V20, P1134, DOI 10.1093/molbev/msg135; Robart AR, 2007, P NATL ACAD SCI USA, V104, P6620, DOI 10.1073/pnas.0700561104; Schmidt U, 1996, RNA, V2, P1161; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; Shukla GC, 2002, MOL CELL, V9, P1145, DOI 10.1016/S1097-2765(02)00505-1; Sigel RKO, 2004, NAT STRUCT MOL BIOL, V11, P187, DOI 10.1038/nsmb717; Stahley MR, 2005, SCIENCE, V309, P1587, DOI 10.1126/science.1114994; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Tamura M, 2002, J MOL BIOL, V320, P455, DOI 10.1016/S0022-2836(02)00515-6; Toor N, 2001, RNA, V7, P1142, DOI 10.1017/S1355838201010251; Toor N, 2006, NUCLEIC ACIDS RES, V34, P6461, DOI 10.1093/nar/gkl820; Valles Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001488; Wank H, 1999, MOL CELL, V4, P239, DOI 10.1016/S1097-2765(00)80371-8; Yean SL, 2000, NATURE, V408, P881, DOI 10.1038/35048617; Zhang L, 2002, SCIENCE, V295, P2084, DOI 10.1126/science.1069268; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	48	361	367	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2008	320	5872					77	82		10.1126/science.1153803	http://dx.doi.org/10.1126/science.1153803			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388288	Green Accepted			2022-12-28	WOS:000254633000033
J	Mason, WJ; Nickols, HH				Mason, William J.; Nickols, Hilary H.			Crystalluria from acyclovir use	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Mason, William J.; Nickols, Hilary H.] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University	Mason, WJ (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA.	jeff.mason@vanderbilt.edu							0	13	15	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					E14	E14		10.1056/NEJMicm066726	http://dx.doi.org/10.1056/NEJMicm066726			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367732				2022-12-28	WOS:000254308400010
J	Mullighan, CG; Miller, CB; Radtke, I; Phillips, LA; Dalton, J; Ma, J; White, D; Hughes, TP; Le Beau, MM; Pui, CH; Relling, MV; Shurtleff, SA; Downing, JR				Mullighan, Charles G.; Miller, Christopher B.; Radtke, Ina; Phillips, Letha A.; Dalton, James; Ma, Jing; White, Deborah; Hughes, Timothy P.; Le Beau, Michelle M.; Pui, Ching-Hon; Relling, Mary V.; Shurtleff, Sheila A.; Downing, James R.			BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros	NATURE			English	Article							POLYMERASE-CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA; DNA-BINDING PROTEINS; GENE ENCODES; EXPRESSION; ISOFORMS; FAMILY; CELLS; PHENOTYPE; MUTATION	The Philadelphia chromosome, a chromosomal abnormality that encodes BCR - ABL1, is the defining lesion of chronic myelogenous leukaemia ( CML) and a subset of acute lymphoblastic leukaemia (ALL)(1-3). To define oncogenic lesions that cooperate with BCR ABL1 to induce ALL, we performed a genome- wide analysis of diagnostic leukaemia samples from 304 individuals with ALL, including 43 BCR - ABL1 B- progenitor ALLs and 23 CML cases. IKZF1 ( encoding the transcription factor Ikaros) was deleted in 83.7% of BCR - ABL1 ALL, but not in chronic- phase CML. Deletion of IKZF1 was also identified as an acquired lesion at the time of transformation of CML to ALL ( lymphoid blast crisis). The IKZF1 deletions resulted in haploin sufficiency, expression of a dominant- negative Ikaros isoform, or the complete loss of Ikaros expression. Sequencing of IKZF1 deletion breakpoints suggested that aberrant RAG- mediated recombination is responsible for the deletions. These findings suggest that genetic lesions resulting in the loss of Ikaros function are an important event in the development of BCR - ABL1 ALL.	[Mullighan, Charles G.; Miller, Christopher B.; Radtke, Ina; Phillips, Letha A.; Dalton, James; Shurtleff, Sheila A.; Downing, James R.] St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA; [Pui, Ching-Hon] St Jude Childrens Hosp, Dept Oncol, Memphis, TN 38105 USA; [Relling, Mary V.] St Jude Childrens Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; [Ma, Jing] St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; [White, Deborah; Hughes, Timothy P.] Inst Med & Vet Sci, Div Haematol, Adelaide, SA 5000, Australia; [Le Beau, Michelle M.] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; Institute Medical & Veterinary Science Australia; University of Chicago	Downing, JR (corresponding author), St Jude Childrens Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA.	james.downing@stjude.org	Downing, James R./N-8102-2018; Relling, Mary/N-5032-2018; Mullighan, Charles/H-3253-2011; Hughes, Tim/AAO-9975-2021; Pui, Ching-Hon/N-8076-2018	Mullighan, Charles/0000-0002-1871-1850; Pui, Ching-Hon/0000-0003-0303-5658; White, Deborah/0000-0003-4844-333X; Hughes, Timothy/0000-0002-0910-3730				DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Drexler HG., 2001, LEUKEMIA LYMPHOMA CE, P2, DOI [10.1016/B978-012221970-2/50002-4, DOI 10.1016/B978-012221970-2/50002-4]; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Gleissner B, 2002, BLOOD, V99, P1536, DOI 10.1182/blood.V99.5.1536; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Kirstetter P, 2002, EUR J IMMUNOL, V32, P720, DOI 10.1002/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P; Klein F, 2006, ONCOGENE, V25, P1118, DOI 10.1038/sj.onc.1209133; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; MANABE A, 1994, BLOOD, V83, P1731, DOI 10.1182/blood.V83.7.1731.bloodjournal8371731; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Molnar A, 1996, J IMMUNOL, V156, P585; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nakase K, 2000, CANCER RES, V60, P4062; Nishii K, 2000, INT J HEMATOL, V71, P372; Olivero S, 2000, BRIT J HAEMATOL, V110, P826, DOI 10.1046/j.1365-2141.2000.02297.x; Rebollo A, 2003, IMMUNOL CELL BIOL, V81, P171, DOI 10.1046/j.1440-1711.2003.01159.x; RIBEIRO RC, 1987, BLOOD, V70, P948; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; Takanashi M, 2002, BRIT J HAEMATOL, V117, P525, DOI 10.1046/j.1365-2141.2002.03487.x; Tonnelle Cecile, 2003, Hematol J, V4, P104, DOI 10.1038/sj.thj.6200235; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1	32	759	797	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2008	453	7191					110	+		10.1038/nature06866	http://dx.doi.org/10.1038/nature06866			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294ID	18408710				2022-12-28	WOS:000255398800049
J	Hoddinott, P; Tappin, D; Wright, C				Hoddinott, Pat; Tappin, David; Wright, Charlotte			Breast feeding	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEALTH		[Hoddinott, Pat] Univ Aberdeen, Ctr Rural Hlth, Inverness IV2 3BL, Scotland; [Tappin, David; Wright, Charlotte] Univ Glasgow, Royal Hosp Sick Children, Sect Child Hlth, Paediat Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland	University of Aberdeen; University of Glasgow	Hoddinott, P (corresponding author), Univ Aberdeen, Ctr Rural Hlth, Inverness IV2 3BL, Scotland.	p.hoddinott@abdn.ac.uk	Hoddinott, Pat/F-9090-2011	Hoddinott, Pat/0000-0002-4372-9681				Abdulwadud OA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006177; Aillet S, 2002, EUR J OBSTET GYN R B, V101, P79, DOI 10.1016/S0301-2115(01)00517-6; Anderson PO, 2003, CLIN PEDIATR, V42, P325, DOI 10.1177/000992280304200405; [Anonymous], 2005, DIV ANK TONG TIE BRE; [Anonymous], 2002, COCHRANE DB SYST REV; Bolling K, 2007, INFANT FEEDING SURVE; Britton C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001141.pub3; Brown S Lori, 2006, J Long Term Eff Med Implants, V16, P281; de Onis M, 2007, J NUTR, V137, P144, DOI 10.1093/jn/137.1.144; DEMOTT K, 2006, ROUTINE POSTNATAL CA; Donnelly A, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002075; Dyson L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001688.pub2; Edmond K, 2006, OPTIMAL FEEDING LOW; Gagnon AJ, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002869.pub2; Hawkins SS, 2008, BMJ-BRIT MED J, V336, P1052, DOI 10.1136/bmj.39532.688877.25; Henderson G, 2007, COCHRANE DB SYST REV, V2007, DOI DOI 10.1002/14651858.CD002972.PUB2; Hodnett E D, 2005, Cochrane Database Syst Rev, pCD000012; Horta BL, 2007, EVIDENCE LONG TERM E; Ip Stanley, 2007, Evid Rep Technol Assess (Full Rep), P1; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Jones V, 2006, BMJ-BRIT MED J, V332, P777, DOI 10.1136/bmj.332.7544.777; Moore ER, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub3; *NAT I HLTH CLIN E, 2008, GUID MIDW HLTH VIS P; Quigley MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002971.pub2; Quigley MA, 2007, PEDIATRICS, V119, pE837, DOI 10.1542/peds.2006-2256; RENFREW M, 2005, EFFECTIVENESS PUBLIC; Shah PS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004950.pub2; Snowden H. H. M., 2001, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000046.PUB2, 10.1002/14651858.CD000046.pub2]; van Dommelen P, 2007, ARCH DIS CHILD, V92, P490, DOI 10.1136/adc.2006.104331; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; WRIGHT C, 2007, ARCH DIS CHILD  1001	31	145	149	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2008	336	7649					881	887		10.1136/bmj.39521.566296.BE	http://dx.doi.org/10.1136/bmj.39521.566296.BE			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290QH	18420694	Green Published, Green Submitted			2022-12-28	WOS:000255136800035
J	Anthony, RM; Nimmerjahn, F; Ashline, DJ; Reinhold, VN; Paulson, JC; Ravetch, JV				Anthony, Robert M.; Nimmerjahn, Falk; Ashline, David J.; Reinhold, Vernon N.; Paulson, James C.; Ravetch, Jeffrey V.			Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG fc	SCIENCE			English	Article							IMMUNOGLOBULIN-G; AUTOIMMUNE-DISEASE; BINDING; RECEPTOR; GLYCOSYLATION; SPECIFICITY; SIALYLTRANSFERASE; OLIGOSACCHARIDES; SIALYLATION; PROTECTION	It is well established that high doses of monomeric immunoglobulin G ( IgG) purified from pooled human plasma [ intravenous immunoglobulin ( IVIG)] confer anti- inflammatory activity in a variety of autoimmune settings. However, exactly how those effects are mediated is not clear because of the heterogeneity of IVIG. Recent studies have demonstrated that the anti- inflammatory activity of IgG is completely dependent on sialylation of the N- linked glycan of the IgG Fc fragment. Here we determine the precise glycan requirements for this anti- inflammatory activity, allowing us to engineer an appropriate IgG1 Fc fragment, and thus generate a fully recombinant, sialylated IgG1 Fc with greatly enhanced potency. This therapeutic molecule precisely defines the biologically active component of IVIG and helps guide development of an IVIG replacement with improved activity and availability.	[Anthony, Robert M.; Nimmerjahn, Falk; Ravetch, Jeffrey V.] Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10021 USA; [Ashline, David J.; Reinhold, Vernon N.] Univ New Hampshire, Dept Biochem & Mol Biol, Glycom Ctr, Durham, NH 03824 USA; [Paulson, James C.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA; [Paulson, James C.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Nimmerjahn, Falk] Univ Erlangen Nurnberg, Lab Expt Immunol & Immunotherapy, D-91054 Erlangen, Germany	Rockefeller University; University System Of New Hampshire; University of New Hampshire; Scripps Research Institute; Scripps Research Institute; University of Erlangen Nuremberg	Ravetch, JV (corresponding author), Rockefeller Univ, Lab Mol Genet & Immunol, 1230 York Ave, New York, NY 10021 USA.	ravetch@rockefeller.edu	Ravetch, Jeffrey/Z-1596-2019; Nimmerjahn, Falk/J-4986-2013; Paulson, James/AAG-3565-2019	Ravetch, Jeffrey/0000-0003-2024-9041; Nimmerjahn, Falk/0000-0002-5418-316X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054045, R01GM060938] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM060938-09, R01 GM054045-11, R01 GM054045, R01 GM060938, GM60938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Arnold JN, 2004, J IMMUNOL, V173, P6831, DOI 10.4049/jimmunol.173.11.6831; Bruhns P, 2003, IMMUNITY, V18, P573, DOI 10.1016/S1074-7613(03)00080-3; Dalziel M, 1999, GLYCOCONJUGATE J, V16, P801, DOI 10.1023/A:1007183915921; HANISCH FG, 1993, INFECT IMMUN, V61, P2108, DOI 10.1128/IAI.61.5.2108-2115.1993; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Ibricevic A, 2006, J VIROL, V80, P7469, DOI 10.1128/JVI.02677-05; JEFFERIS R, 1990, BIOCHEM J, V268, P529, DOI 10.1042/bj2680529; Kaneko Y, 2006, J EXP MED, V203, P789, DOI 10.1084/jem.20051900; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Lehmann F, 2006, CELL MOL LIFE SCI, V63, P1331, DOI 10.1007/s00018-005-5589-y; Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Nimmerjahn F, 2007, J EXP MED, V204, P11, DOI 10.1084/jem.20061788; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Scallon BJ, 2007, MOL IMMUNOL, V44, P1524, DOI 10.1016/j.molimm.2006.09.005; TAKAHASHI N, 1987, BIOCHEMISTRY-US, V26, P1137, DOI 10.1021/bi00378a023; Tumpey TM, 2007, SCIENCE, V315, P655, DOI 10.1126/science.1136212; Varki A, 2007, NATURE, V446, P1023, DOI 10.1038/nature05816; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472	23	604	689	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2008	320	5874					373	376		10.1126/science.1154315	http://dx.doi.org/10.1126/science.1154315			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZZ	18420934	Green Accepted			2022-12-28	WOS:000255026100043
J	Isalan, M; Lemerle, C; Michalodimitrakis, K; Horn, C; Beltrao, P; Raineri, E; Garriga-Canut, M; Serrano, L				Isalan, Mark; Lemerle, Caroline; Michalodimitrakis, Konstantinos; Horn, Carsten; Beltrao, Pedro; Raineri, Emanuele; Garriga-Canut, Mireia; Serrano, Luis			Evolvability and hierarchy in rewired bacterial gene networks	NATURE			English	Article							ESCHERICHIA-COLI; REGULATORY NETWORK; TRANSCRIPTIONAL REGULATION; OPERON ORGANIZATION; BIOFILM FORMATION; GROWTH; EXPRESSION; TOLERANCE; RPOS; PHENOTYPES	Sequencing DNA from several organisms has revealed that duplication and drift of existing genes have primarily moulded the contents of a given genome. Though the effect of knocking out or overexpressing a particular gene has been studied in many organisms, no study has systematically explored the effect of adding new links in a biological network. To explore network evolvability, we constructed 598 recombinations of promoters ( including regulatory regions) with different transcription or sigma-factor genes in Escherichia coli, added over a wild- type genetic background. Here we show that similar to 95% of new networks are tolerated by the bacteria, that very few alter growth, and that expression level correlates with factor position in the wild- type network hierarchy. Most importantly, we find that certain networks consistently survive over the wild type under various selection pressures. Therefore new links in the network are rarely a barrier for evolution and can even confer a fitness advantage.	[Isalan, Mark; Michalodimitrakis, Konstantinos; Raineri, Emanuele; Garriga-Canut, Mireia; Serrano, Luis] UPF, CRG, EMBL, CRG Syst Biol, Barcelona 08003, Spain; [Lemerle, Caroline; Horn, Carsten; Beltrao, Pedro] European Mol Biol Lab, D-69117 Heidelberg, Germany	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Isalan, M (corresponding author), UPF, CRG, EMBL, CRG Syst Biol, Barcelona 08003, Spain.	isalan@crg.es	Serrano, Luis/B-3355-2013; Beltrao, Pedro/B-3342-2010; Raineri, Emanuele/AAX-7874-2020	Serrano, Luis/0000-0002-5276-1392; Beltrao, Pedro/0000-0002-2724-7703; Isalan, Mark/0000-0002-4652-0365	Wellcome Trust [066543] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Babu MM, 2006, J MOL BIOL, V358, P614, DOI 10.1016/j.jmb.2006.02.019; Babu MM, 2004, CURR OPIN STRUC BIOL, V14, P283, DOI 10.1016/j.sbi.2004.05.004; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Cheville AM, 1996, APPL ENVIRON MICROB, V62, P1822, DOI 10.1128/AEM.62.5.1822-1824.1996; COSMA CL, 1995, MOL MICROBIOL, V18, P491, DOI 10.1111/j.1365-2958.1995.mmi_18030491.x; Dekel E, 2005, NATURE, V436, P588, DOI 10.1038/nature03842; DELANEY JM, 1992, J BACTERIOL, V174, P1240, DOI 10.1128/jb.174.4.1240-1247.1992; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Fong SS, 2005, GENOME RES, V15, P1365, DOI 10.1101/gr.3832305; Foster JW, 1999, NOVART FDN SYMP, V221, P55; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Guelzim N, 2002, NAT GENET, V31, P60, DOI 10.1038/ng873; Hasty J, 2002, NATURE, V420, P224, DOI 10.1038/nature01257; HOLM S, 1979, SCAND J STAT, V6, P65; Hooper SD, 2003, MOL BIOL EVOL, V20, P945, DOI 10.1093/molbev/msg101; Isalan M, 2005, PLOS BIOL, V3, P488, DOI 10.1371/journal.pbio.0030064; Isalan M, 2005, NAT METHODS, V2, P113, DOI 10.1038/NMETH732; Keseler IM, 2005, NUCLEIC ACIDS RES, V33, pD334, DOI 10.1093/nar/gki108; LANGE R, 1994, MOL MICROBIOL, V13, P733, DOI 10.1111/j.1365-2958.1994.tb00466.x; Loewen PC, 1998, CAN J MICROBIOL, V44, P707, DOI 10.1139/cjm-44-8-707; Lozada-Chavez I, 2006, NUCLEIC ACIDS RES, V34, P3434, DOI 10.1093/nar/gkl423; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; MADAN BM, 2003, NUCLEIC ACIDS RES, V31, P1234, DOI DOI 10.1093/NAR/GKG210; Mangan MW, 2006, MOL MICROBIOL, V59, P1831, DOI 10.1111/j.1365-2958.2006.05062.x; Martinez-Antonio A, 2003, CURR OPIN MICROBIOL, V6, P482, DOI 10.1016/j.mib.2003.09.002; Perez-Rueda E, 2000, NUCLEIC ACIDS RES, V28, P1838, DOI 10.1093/nar/28.8.1838; Poelwijk FJ, 2006, PLOS COMPUT BIOL, V2, P467, DOI 10.1371/journal.pcbi.0020058; Pratt LA, 1996, MOL MICROBIOL, V20, P911, DOI 10.1111/j.1365-2958.1996.tb02532.x; Prigent-Combaret C, 2001, J BACTERIOL, V183, P7213, DOI 10.1128/JB.183.24.7213-7223.2001; Pruss BM, 1996, J BACTERIOL, V178, P668; Romling U, 1998, J BACTERIOL, V180, P722; Salgado H, 2001, NUCLEIC ACIDS RES, V29, P72, DOI 10.1093/nar/29.1.72; Salgado H, 2006, NUCLEIC ACIDS RES, V34, pD394, DOI 10.1093/nar/gkj156; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Slonczewski JL, 1999, NOVART FDN SYMP, V221, P75; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Solano C, 2002, MOL MICROBIOL, V43, P793, DOI 10.1046/j.1365-2958.2002.02802.x; Sopko R, 2006, MOL CELL, V21, P319, DOI 10.1016/j.molcel.2005.12.011; Teichmann SA, 2004, NAT GENET, V36, P492, DOI 10.1038/ng1340; Teichmann SA, 1998, P NATL ACAD SCI USA, V95, P14658, DOI 10.1073/pnas.95.25.14658; Vidal O, 1998, J BACTERIOL, V180, P2442, DOI 10.1128/JB.180.9.2442-2449.1998; Zaslaver A, 2006, NAT METHODS, V3, P623, DOI 10.1038/NMETH895	45	225	234	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2008	452	7189					840	U2		10.1038/nature06847	http://dx.doi.org/10.1038/nature06847			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288ZY	18421347	Green Accepted			2022-12-28	WOS:000255026000041
J	Losick, R; Desplan, C				Losick, Richard; Desplan, Claude			Stochasticity and cell fate	SCIENCE			English	Review							DOUBLE-NEGATIVE FEEDBACK; BACILLUS-SUBTILIS; GENE-EXPRESSION; FLUCTUATING ENVIRONMENTS; PHOTORECEPTOR CELLS; POSITIVE FEEDBACK; PLANAR POLARITY; DROSOPHILA EYE; COLOR-VISION; DIFFERENTIATION	Fundamental to living cells is the capacity to differentiate into subtypes with specialized attributes. Understanding the way cells acquire their fates is a major challenge in developmental biology. How cells adopt a particular fate is usually thought of as being deterministic, and in the large majority of cases it is. That is, cells acquire their fate by virtue of their lineage or their proximity to an inductive signal from another cell. In some cases, however, and in organisms ranging from bacteria to humans, cells choose one or another pathway of differentiation stochastically, without apparent regard to environment or history. Stochasticity has important mechanistic requirements. We speculate on why stochasticity is advantageous- and even critical in some circumstances- to the individual, the colony, or the species.	[Losick, Richard] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Desplan, Claude] NYU, Dept Biol, Ctr Dev Genet, New York, NY 10003 USA	Harvard University; New York University	Losick, R (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.			Desplan, Claude/0000-0002-6914-1413	NATIONAL EYE INSTITUTE [R01EY013010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018568, R01GM018568] Funding Source: NIH RePORTER; NEI NIH HHS [EY13010, R01 EY013010-11, R01 EY013010] Funding Source: Medline; NIGMS NIH HHS [R01 GM018568-36, R01 GM018568, GM18568, R37 GM018568] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Bell ML, 2007, J COMP NEUROL, V502, P75, DOI 10.1002/cne.21298; Campos JA, 1997, CURR BIOL, V7, pR726, DOI 10.1016/S0960-9822(06)00367-8; Doe CQ, 1996, CURR OPIN NEUROBIOL, V6, P18, DOI 10.1016/S0959-4388(96)80004-3; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; FRANCESCHINI N, 1981, SCIENCE, V213, P1264, DOI 10.1126/science.7268434; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Gonzalez-Pastor JE, 2003, SCIENCE, V301, P510, DOI 10.1126/science.1086462; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Holtzendorff J, 2004, SCIENCE, V304, P983, DOI 10.1126/science.1095191; Johnston RJ, 2005, P NATL ACAD SCI USA, V102, P12449, DOI 10.1073/pnas.0505530102; Kearns DB, 2005, GENE DEV, V19, P3083, DOI 10.1101/gad.1373905; Kussell E, 2005, SCIENCE, V309, P2075, DOI 10.1126/science.1114383; Lewis K, 2007, NAT REV MICROBIOL, V5, P48, DOI 10.1038/nrmicro1557; Maamar H, 2005, MOL MICROBIOL, V56, P615, DOI 10.1111/j.1365-2958.2005.04592.x; Maamar H, 2007, SCIENCE, V317, P526, DOI 10.1126/science.1140818; Mikeladze-Dvali T, 2005, CELL, V122, P775, DOI 10.1016/j.cell.2005.07.026; Mombaerts P, 2004, CURR OPIN NEUROBIOL, V14, P31, DOI 10.1016/j.conb.2004.01.014; Nathans J, 1999, NEURON, V24, P299, DOI 10.1016/S0896-6273(00)80845-4; Palmer AR, 1996, P NATL ACAD SCI USA, V93, P14279, DOI 10.1073/pnas.93.25.14279; Ptashne M, 2007, CURR BIOL, V17, pR233, DOI 10.1016/j.cub.2007.02.030; Raser JM, 2005, SCIENCE, V309, P2010, DOI 10.1126/science.1105891; RINE J, 1981, COLD SPRING HARB SYM, V45, P951; Smallwood PM, 2002, P NATL ACAD SCI USA, V99, P1008, DOI 10.1073/pnas.022629799; Suel GM, 2007, SCIENCE, V315, P1716, DOI 10.1126/science.1137455; Suel GM, 2006, NATURE, V440, P545, DOI 10.1038/nature04588; Thattai M, 2004, GENETICS, V167, P523, DOI 10.1534/genetics.167.1.523; Veening JW, 2005, MOL MICROBIOL, V56, P1481, DOI 10.1111/j.1365-2958.2005.04659.x; WEHRLI M, 1995, DEVELOPMENT, V121, P2451; Wernet MF, 2006, NATURE, V440, P174, DOI 10.1038/nature04615; Yang CH, 2002, CELL, V108, P675, DOI 10.1016/S0092-8674(02)00658-X	31	420	426	3	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2008	320	5872					65	68		10.1126/science.1147888	http://dx.doi.org/10.1126/science.1147888			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388284	Green Accepted			2022-12-28	WOS:000254633000029
J	Reyes-Lamothe, R; Possoz, C; Danilova, O; Sherratt, DJ				Reyes-Lamothe, Rodrigo; Possoz, Christophe; Danilova, Olessia; Sherratt, David J.			Independent positioning and action of Escherichia coli replisomes in live cells	CELL			English	Article							CHROMOSOME SEGREGATION; DNA-REPLICATION; FLUORESCENT PROTEIN; BACILLUS-SUBTILIS; TEMPORAL ORGANIZATION; FACTORY MODEL; LOCALIZATION; MOVEMENT; HALVES; ARMS	A prevalent view of DNA replication has been that it is carried out in fixed "replication factories.'' By tracking the progression of sister replication forks with respect to genetic loci in live Escherichia coli, we show that at initiation replisomes assemble at replication origins irrespective of where the origins are positioned within the cell. Sister replisomes separate and move to opposite cell halves shortly after initiation, migrating outwards as replication proceeds and both returning to midcell as replication termination approaches. DNA polymerase is maintained at stalled replication forks, and over short intervals of time replisomes are more dynamic than genetic loci. The data are inconsistent with models in which replisomes associated with sister forks act within a fixed replication factory. We conclude that independent replication forks follow the path of the compacted chromosomal DNA, with no structure other than DNA anchoring the replisome to any particular cellular region.	[Reyes-Lamothe, Rodrigo; Possoz, Christophe; Danilova, Olessia; Sherratt, David J.] Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Sherratt, DJ (corresponding author), Univ Oxford, Dept Biochem, Oxford OX1 3QU, England.	sherratt@bioch.ox.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adachi S, 2005, MOL GENET GENOMICS, V274, P264, DOI 10.1007/s00438-005-0023-6; Bates D, 2005, CELL, V121, P899, DOI 10.1016/j.cell.2005.04.013; Berkmen MB, 2006, MOL MICROBIOL, V62, P57, DOI 10.1111/j.1365-2958.2006.05356.x; Breier AM, 2005, P NATL ACAD SCI USA, V102, P3942, DOI 10.1073/pnas.0500812102; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Danilova O, 2007, MOL MICROBIOL, V65, P1485, DOI 10.1111/j.1365-2958.2007.05881.x; den Blaauwen T, 2006, MOL MICROBIOL, V62, P695, DOI 10.1111/j.1365-2958.2006.05417.x; Deng S, 2005, MOL MICROBIOL, V57, P1511, DOI 10.1111/j.1365-2958.2005.04796.x; DINGMAN CW, 1974, J THEOR BIOL, V43, P187, DOI 10.1016/S0022-5193(74)80052-4; Elmore S, 2005, J STRUCT BIOL, V151, P275, DOI 10.1016/j.jsb.2005.06.004; Fekete RA, 2005, MOL MICROBIOL, V55, P175, DOI 10.1111/j.1365-2958.2004.04392.x; Fiebig A, 2006, MOL MICROBIOL, V60, P1164, DOI 10.1111/j.1365-2958.2006.05175.x; Hearst JE, 1998, TRENDS GENET, V14, P244, DOI 10.1016/S0168-9525(98)01481-4; Hiraga S, 2000, GENES CELLS, V5, P327, DOI 10.1046/j.1365-2443.2000.00334.x; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Jensen RB, 2001, EMBO J, V20, P4952, DOI 10.1093/emboj/20.17.4952; Kitamura E, 2006, CELL, V125, P1297, DOI 10.1016/j.cell.2006.04.041; Kongsuwan K, 2002, FEMS MICROBIOL LETT, V216, P255, DOI 10.1111/j.1574-6968.2002.tb11444.x; Lau IF, 2003, MOL MICROBIOL, V49, P731, DOI 10.1046/j.1365-2958.2003.03640.x; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lemon KP, 2000, MOL CELL, V6, P1321, DOI 10.1016/S1097-2765(00)00130-1; Maisnier-Patin S, 2001, MOL MICROBIOL, V42, P1371, DOI 10.1046/j.1365-2958.2001.02718.x; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Meile JC, 2006, PROTEOMICS, V6, P2135, DOI 10.1002/pmic.200500512; Migocki MD, 2004, MOL MICROBIOL, V54, P452, DOI 10.1111/j.1365-2958.2004.04267.x; Molina F, 2004, MOL MICROBIOL, V52, P1597, DOI 10.1111/j.1365-2958.2004.04097.x; Nguyen AW, 2005, NAT BIOTECHNOL, V23, P355, DOI 10.1038/nbt1066; Nielsen HJ, 2006, MOL MICROBIOL, V62, P331, DOI 10.1111/j.1365-2958.2006.05346.x; Nielsen HJ, 2006, MOL MICROBIOL, V61, P383, DOI 10.1111/j.1365-2958.2006.05245.x; O'Donnell M, 2006, J BIOL CHEM, V281, P10653, DOI 10.1074/jbc.R500028200; Possoz C, 2006, EMBO J, V25, P2596, DOI 10.1038/sj.emboj.7601155; Postow L, 2004, GENE DEV, V18, P1766, DOI 10.1101/gad.1207504; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Sawitzke J, 2001, MOL MICROBIOL, V40, P786, DOI 10.1046/j.1365-2958.2001.02350.x; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Sunako Y, 2001, MOL MICROBIOL, V42, P1233, DOI 10.1046/j.1365-2958.2001.02680.x; Viollier PH, 2004, P NATL ACAD SCI USA, V101, P9257, DOI 10.1073/pnas.0402606101; Wang XD, 2005, GENE DEV, V19, P2367, DOI 10.1101/gad.345305; Wang XD, 2006, GENE DEV, V20, P1727, DOI 10.1101/gad.388406; Withers HL, 1998, J BACTERIOL, V180, P1624, DOI 10.1128/JB.180.7.1624-1631.1998; Woldringh CL, 2006, J STRUCT BIOL, V156, P273, DOI 10.1016/j.jsb.2006.04.013; Zimmerman SB, 2006, J STRUCT BIOL, V156, P255, DOI 10.1016/j.jsb.2006.03.022	43	199	199	3	28	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 4	2008	133	1					90	102		10.1016/j.cell.2008.01.044	http://dx.doi.org/10.1016/j.cell.2008.01.044			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	283MW	18394992	Green Published, hybrid			2022-12-28	WOS:000254641300011
J	Chan, CC; Chiu, HC				Chan, Chih-Chieh; Chiu, Hsien-Ching			Vestibular papillomatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Chan, Chih-Chieh; Chiu, Hsien-Ching] Natl Taiwan Univ Hosp, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital	Chan, CC (corresponding author), Natl Taiwan Univ Hosp, Taipei 100, Taiwan.	hcchiu1003@ntu.edu.tw		CHIU, HSIEN-CHING/0000-0002-1409-8470					0	3	3	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1495	1495		10.1056/NEJMicm076056	http://dx.doi.org/10.1056/NEJMicm076056			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282CY	18385501				2022-12-28	WOS:000254546400011
J	Ham, C				Ham, Chris			Competition and integration in the English National Health Service	BRITISH MEDICAL JOURNAL			English	Editorial Material							NHS; CARE		[Ham, Chris] Univ Birmingham, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Ham, C (corresponding author), Univ Birmingham, Birmingham B15 2RT, W Midlands, England.	c.j.ham@bham.ac.uk						*AUD COMM, 2007, PUTT COMM PRACT; BROWN G, 2003, MODERN AGENDA PROSPE; CHRISTIE S, 2007, HLTH SERV J     0426, P17; Coase RH, 1937, ECONOMICA-NEW SER, V4, P386, DOI 10.1111/j.1468-0335.1937.tb00002.x; Dixon J, 2007, JAMA-J AM MED ASSOC, V298, P1445, DOI 10.1001/jama.298.12.1445; Donaldson C, 2005, BMJ-BRIT MED J, V331, P1328, DOI 10.1136/bmj.331.7528.1328; Enthoven AC, 2002, BRIT MED J, V324, P143; Ham C., 2006, DEV INTEGRATED CARE; Ham C, 2007, CLIN INTEGRATED SYST; Ham C, 2008, J HEALTH SERV RES PO, V13, P116, DOI 10.1258/jhsrp.2008.007177; Ham C, 2008, BRIT MED J, V336, P53, DOI 10.1136/bmj.39455.385868.80; Le Grand J, 1998, LEARNING NHS INTERNA; Light D, 2004, BRIT MED J, V328, P763, DOI 10.1136/bmj.328.7442.763; Porter M.E., 2006, REDEFINING HLTH CARE; Williamson O.E., 1975, MARKETS HIERARCHIES	15	21	21	2	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR	2008	336	7648					805	807		10.1136/bmj.39532.445197.AD	http://dx.doi.org/10.1136/bmj.39532.445197.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	292ER	18403544	Green Published			2022-12-28	WOS:000255249800041
J	Breaker, RR				Breaker, Ronald R.			Complex riboswitches	SCIENCE			English	Editorial Material							GENE-EXPRESSION; S-ADENOSYLMETHIONINE; STRUCTURAL BASIS; MESSENGER-RNA; BINDING; BACTERIA; LIGAND; SPEED		Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Breaker, RR (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	ronald.breaker@yale.edu		Breaker, Ronald/0000-0002-2165-536X	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Barrick JE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r239; Bocobza S, 2007, GENE DEV, V21, P2874, DOI 10.1101/gad.443907; Breaker RR, 2006, COLD SPRING HARB MON, V43, P89; Breaker RR, 2003, RNA, V9, P949, DOI 10.1261/rna.5670703; Cheah MT, 2007, NATURE, V447, P497, DOI 10.1038/nature05769; Cochrane JC, 2007, CHEM BIOL, V14, P97, DOI 10.1016/j.chembiol.2006.12.005; Coppins RL, 2007, CURR OPIN MICROBIOL, V10, P176, DOI 10.1016/j.mib.2007.03.006; Croft MT, 2007, P NATL ACAD SCI USA, V104, P20770, DOI 10.1073/pnas.0705786105; Edwards TE, 2007, CURR OPIN STRUC BIOL, V17, P273, DOI 10.1016/j.sbi.2007.05.004; Fuchs RT, 2006, NAT STRUCT MOL BIOL, V13, P226, DOI 10.1038/nsmb1059; Gallivan JP, 2007, CURR OPIN CHEM BIOL, V11, P612, DOI 10.1016/j.cbpa.2007.10.004; Gilbert SD, 2008, NAT STRUCT MOL BIOL, V15, P177, DOI 10.1038/nsmb.1371; Greenleaf WJ, 2008, SCIENCE, V319, P630, DOI 10.1126/science.1151298; Gutierrez-Preciado A, 2005, TRENDS GENET, V21, P432, DOI 10.1016/j.tig.2005.06.001; Kazanov MD, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-347; Klein DJ, 2006, SCIENCE, V313, P1752, DOI 10.1126/science.1129666; Kubodera T, 2003, FEBS LETT, V555, P516, DOI 10.1016/S0014-5793(03)01335-8; Mandal M, 2004, SCIENCE, V306, P275, DOI 10.1126/science.1100829; Montange RK, 2006, NATURE, V441, P1172, DOI 10.1038/nature04819; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Osborne SE, 1997, CHEM REV, V97, P349, DOI 10.1021/cr960009c; Rieder R, 2007, CHEMBIOCHEM, V8, P896, DOI 10.1002/cbic.200700057; Serganov A, 2006, NATURE, V441, P1167, DOI 10.1038/nature04740; Stoddard CD, 2006, ACS CHEM BIOL, V1, P751, DOI 10.1021/cb600458w; Sudarsan N, 2006, SCIENCE, V314, P300, DOI 10.1126/science.1130716; Thore S, 2006, SCIENCE, V312, P1208, DOI 10.1126/science.1128451; Vitreschak AG, 2004, TRENDS GENET, V20, P44, DOI 10.1016/j.tig.2003.11.008; Wachter A, 2007, PLANT CELL, V19, P3437, DOI 10.1105/tpc.107.053645; Weinberg Z, 2007, NUCLEIC ACIDS RES, V35, P4809, DOI 10.1093/nar/gkm487; Welz R, 2007, RNA, V13, P573, DOI 10.1261/rna.407707; Wickiser JK, 2005, MOL CELL, V18, P49, DOI 10.1016/j.molcel.2005.02.032	31	79	89	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2008	319	5871					1795	1797		10.1126/science.1152621	http://dx.doi.org/10.1126/science.1152621			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279ZF	18369140				2022-12-28	WOS:000254394000037
J	Blumberg, BS				Blumberg, Baruch S.			Joshua Lederberg (1925-2008) - Obituary	NATURE			English	Biographical-Item									Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Blumberg, BS (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	baruch.blumberg@fccc.edu							0	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2008	452	7186					422	422		10.1038/452422a	http://dx.doi.org/10.1038/452422a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	279FU	18368111				2022-12-28	WOS:000254341300021
J	Bretzel, RG; Nuber, U; Landgraf, W; Owens, DR; Bradley, C; Linn, T				Bretzel, Reinhard G.; Nuber, Ulrike; Landgraf, Wolfgang; Owens, David R.; Bradley, Clare; Linn, Thomas			Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial	LANCET			English	Article							META-REGRESSION ANALYSIS; HUMAN NPH INSULIN; GLYCEMIC CONTROL; MICROVASCULAR COMPLICATIONS; GLYCOSYLATED HEMOGLOBIN; BEDTIME NPH; THERAPY; GLUCOSE; MELLITUS; PHARMACOKINETICS	Background As type 2 diabetes mellitus progresses, oral hypoglycaemic agents often fail to maintain blood glucose control and insulin is needed. We investigated whether the addition of once-daily insulin glargine is non-inferior to three-times daily prandial insulin lispro in overall glycaemic control in adults with inadequately controlled type 2 diabetes mellitus taking oral hypoglycaemic agents. Methods In the 44-week, parallel, open study that was undertaken in 69 study sites across Europe and Australia, 418 patients with type 2 diabetes mellitus that was inadequately controlled by oral hypoglycaemic agents were randomly assigned to either insulin glargine taken once daily at the same time every day or to insulin lispro administered three times per day. The primary objective was to compare the change in haemoglobin A(1c) from baseline to endpoint (week 44) between the two regimens. Randomisation was done with a central randomisation service. Analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT00311818. Findings 205 patients were randomly assigned to insulin glargine and 210 to insulin lispro. Mean haemoglobin A(1c) decrease in the insulin glargine group was -1 . 7% (from 8.7% [SD 1 . 0] to 7.0% [0.71]) and -1 . 9% in the insulin lispro group (from 8.7% [1.0] to 6.8% [0.9]), which was within the predefined limit of 0.4% for non-inferiority (difference=0.157; 95% Cl -0.008 to 0.322).106 (57%) patients reached haemoglobin A(1c) of 7% or less in the glargine group and 131 (69%) in the lispro group. In the glargine group, the fall in mean fasting blood glucose (-4.3 [SD 2.3] mmol/L vs -1 . 8 [2.3] mmol/L; p<0 . 0001) and nocturnal blood glucose (-3.3 [2.8] mmol/L vs -2.6 [2.9] mmol/L; p=0.0041) was better than it was in the insulin lispro group, whereas insulin lispro better controlled postprandial blood glucose throughout the day (p<0 .0001). The incidence of hypoglycaemic events was less with insulin glargine than with lispro (5 . 2 [95% CI 1 . 9-8.9] vs 24.0 [21-28] events per patient per year; p<0 .0001). Respective mean weight gains were 3 . 01 (S D 4.33) kg and 3.54 (4.48) kg. The improvement of treatment satisfaction was greater for insulin glargine than for insulin lispro (mean difference 3.13; 95% CI 2.04-4.22). Interpretation A therapeutic regimen involving the addition of either basal or prandial insulin analogue is equally effective in lowering haemoglobin A(1c). We conclude that insulin glargine provides a simple and effective option that is more satisfactory to patients than is lispro for early initiation of insulin therapy, since it was associated with a lower risk of hypoglycaemia, fewer injections, less blood glucose self monitoring, and greater patient satisfaction than was insulin lispro.	[Bretzel, Reinhard G.; Nuber, Ulrike; Linn, Thomas] Univ Giessen, Med Klin & Poliklin 3, D-35392 Giessen, Germany; [Landgraf, Wolfgang] Sanofi Aventis Deutschland GmbH, Med Affairs, Berlin, Germany; [Owens, David R.] Llandough Univ Hosp, Diabet Res Unit, Cardiff, Wales; [Bradley, Clare] Univ London Royal Holloway & Bedford New Coll, Surrey, England	Justus Liebig University Giessen; Sanofi-Aventis; University of London; Royal Holloway University London	Linn, T (corresponding author), Univ Giessen, Med Klin & Poliklin 3, Rodthohl 6, D-35392 Giessen, Germany.	Thomas.linn@innere.med.uni-giessen.de	Landgraf, Wolfgang/AAD-2624-2019	Landgraf, Wolfgang/0000-0001-5321-7164; Bradley, Clare/0000-0002-4079-0364				Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4; [Anonymous], 1999, Diabet Med, V16, P716; Bastyr EJ, 2000, DIABETES CARE, V23, P1236, DOI 10.2337/diacare.23.9.1236; Bonora E, 2001, DIABETES CARE, V24, P2023, DOI 10.2337/diacare.24.12.2023; Boye KS, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-80; BRADLEY C, 1990, DIABETIC MED, V7, P445, DOI 10.1111/j.1464-5491.1990.tb01421.x; Bradley C., 1994, HDB PSYCHOL DIABETES, P111; Cefalu WT, 2002, AM J MED, V113, p23S; Cryer PE, 2002, DIABETOLOGIA, V45, P937, DOI 10.1007/s00125-002-0822-9; Davidson JA, 2004, CURR MED RES OPIN, V20, P1919, DOI 10.1185/030079904X6291; Davies M, 2005, DIABETES CARE, V28, P1282, DOI 10.2337/diacare.28.6.1282; DAVIS RE, 2006, PRACTICAL DIABETES I, V23, P171; DeWitt DE, 2003, JAMA-J AM MED ASSOC, V289, P2254, DOI 10.1001/jama.289.17.2254; Eliaschewitz FG, 2006, ARCH MED RES, V37, P495, DOI 10.1016/j.arcmed.2005.10.015; GRAF RJ, 1978, DIABETES, V27, P834, DOI 10.2337/diabetes.27.8.834; Heine RJ, 2005, ANN INTERN MED, V143, P559, DOI 10.7326/0003-4819-143-8-200510180-00006; Heinemann L, 2000, DIABETES CARE, V23, P644, DOI 10.2337/diacare.23.5.644; Holman RR, 2007, NEW ENGL J MED, V357, P1716, DOI 10.1056/NEJMoa075392; *INT DIAB FED, 2005, GLOB GUID TYP 1 DIAB; Janka HU, 2005, DIABETES CARE, V28, P254, DOI 10.2337/diacare.28.2.254; Jovanovic L, 2004, CLIN THER, V26, P1492, DOI 10.1016/j.clinthera.2004.09.001; LANDSTEDTHALLIN L, 1995, DIABETES CARE, V18, P1183, DOI 10.2337/diacare.18.8.1183; Lepore M, 2000, DIABETES, V49, P2142, DOI 10.2337/diabetes.49.12.2142; MCCANCE DR, 1988, DIABETES CARE, V11, P512, DOI 10.2337/diacare.11.6.512; MCCRIMMON RJ, 1994, DIABETES METAB, V20, P503; Monnier L, 2003, DIABETES CARE, V26, P881, DOI 10.2337/diacare.26.3.881; Mullins P, 2007, CLIN THER, V29, P1607, DOI 10.1016/j.clinthera.2007.08.020; Nathan DM, 2006, DIABETOLOGIA, V49, P1711, DOI 10.1007/s00125-006-0316-2; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Peyrot M, 2005, DIABETES CARE, V28, P2673, DOI 10.2337/diacare.28.11.2673; Polonsky WH, 2005, DIABETES CARE, V28, P2543, DOI 10.2337/diacare.28.10.2543; Porcellati F, 2007, DIABETES CARE, V30, P2447, DOI 10.2337/dc07-0002; Riddle MC, 2003, DIABETES CARE, V26, P3080, DOI 10.2337/diacare.26.11.3080; RIEDEL AA, 2006, DIABETES S1, V55, pA132; Rosenstock J, 2005, DIABETES CARE, V28, P950, DOI 10.2337/diacare.28.4.950; Rosenstock J, 2001, DIABETES CARE, V24, P631, DOI 10.2337/diacare.24.4.631; Scholtz HE, 2005, DIABETOLOGIA, V48, P1988, DOI 10.1007/s00125-005-1916-y; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Surwit RS, 2005, DIABETES RES CLIN PR, V69, P78, DOI 10.1016/j.diabres.2004.11.002; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; Wright AD, 1998, DIABETES CARE, V21, P87; Yki-Jarvinen H, 2006, DIABETOLOGIA, V49, P442, DOI 10.1007/s00125-005-0132-0; Yki-Jarvinen H, 2003, DIABETES, V52, pA149; Yki-Jarvinen H, 2000, DIABETES CARE, V23, P1130, DOI 10.2337/diacare.23.8.1130	46	234	246	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1073	1084		10.1016/S0140-6736(08)60485-7	http://dx.doi.org/10.1016/S0140-6736(08)60485-7			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18374840				2022-12-28	WOS:000254442700026
J	O'Kane, MJ; Bunting, B; Copeland, M; Coates, VE				O'Kane, Maurice J.; Bunting, Brendan; Copeland, Margaret; Coates, Vivien E.		ESMON Study Grp	Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; METABOLIC-CONTROL; INSULIN; MELLITUS; IMPACT; CARE; COMPLICATIONS	Objectives To assess the effect of self monitoring of blood glucose concentrations on glycaemic control and psychological indices in patients with newly diagnosed type 2 diabetes mellitus. Design Prospective randomised controlled trial of self monitoring versus no monitoring (control). Setting Hospital diabetes clinics. Participants 184 (111 men) people aged <70 with newly diagnosed type 2 diabetes referred to the participating diabetes clinics. Major exclusion criteria were secondary diabetes, insulin treatment, previous self monitoring of blood glucose. Interventions Participants were randomised to self monitoring or no monitoring (control) groups for one year with follow-up at three monthly intervals. Both groups underwent an identical structured core education programme. The self monitoring group received additional education on monitoring. Main outcome measures Between group differences in HbA(1c), psychological indices, use of oral hypoglycaemic drugs, body mass index (BMI), and reported hypoglycaemia rates. Results 96 patients (55 men) were randomised to monitoring and 88 (56 men) to control. There were no baseline differences in mean (SD) age (57.7 (11.0) in monitoring group v 60.9 (11.5) in control group) or HbA(1c) (8.8 (2.1)% v 8.6 (2.3)%, respectively). Those in the monitoring group had a higher baseline BMI (34 (7) v 32 (6.2)). There were no significant differences between groups at any time point (12 months values given) in HbA(1c) (6.9 (0.8)% v 6.9 (1.2)%, P=0.69; 95% confidence interval for difference -0.25% to 0.38%), BMI (33.1 (6.4) v 31.8 (6.0); adjusted for baseline BMI, P=0.32), use of oral hypoglycaemic drugs, or reported incidence of hypoglycaemia. Monitoring was associated with a 6% higher score on the depression subscale of the well-being questionnaire (P=0.01). Conclusions In patients with newly diagnosed type 2 diabetes self monitoring of blood glucose concentration has no effect on glycaemic control but is associated with higher scores on a depression subscale. Trial registration ISRCTN 49814766.	[O'Kane, Maurice J.] Western Hlth & Social Care Trust, Dept Clin Chem, Altnagelvin Hosp, Coleraine, Londonderry, North Ireland; [Bunting, Brendan] Univ Ulster, Psychol Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland; [Copeland, Margaret; Coates, Vivien E.] Univ Ulster, Inst Nursing Res, Coleraine BT52 1SA, Londonderry, North Ireland	Ulster University; Ulster University	O'Kane, MJ (corresponding author), Western Hlth & Social Care Trust, Dept Clin Chem, Altnagelvin Hosp, Coleraine, Londonderry, North Ireland.	Maurice.OKane@westerntrust.hscni.net						ALLEN BT, 1990, DIABETES CARE, V13, P1044, DOI 10.2337/diacare.13.10.1044; ANDERSON RM, 1990, PATIENT EDUC COUNS, V16, P231, DOI 10.1016/0738-3991(90)90072-S; Bradley C., 1994, HDB PSYCHOL DIABETES, VFirst; Bradley C., 1994, HDB PSYCHOL DIABETES, P111; Davidson MB, 2005, AM J MED, V118, P422, DOI 10.1016/j.amjmed.2004.12.006; Farmer A, 2007, BMJ-BRIT MED J, V335, P132, DOI 10.1136/bmj.39247.447431.BE; FONTBONNE A, 1989, DIABETES METAB, V15, P255; Franciosi M, 2001, DIABETES CARE, V24, P1870, DOI 10.2337/diacare.24.11.1870; GALLICHAN MJ, 1994, PRACTICAL DIABETES, V11, P28; Guerci B, 2003, DIABETES METAB, V29, P587, DOI 10.1016/S1262-3636(07)70073-3; Gulliford M, 2004, DIABETIC MED, V21, P685, DOI 10.1111/j.1464-5491.2004.01238.x; Heller SR, 2007, BMJ-BRIT MED J, V335, P105, DOI 10.1136/bmj.39276.549109.47; Home P, 2006, DIABETIC MED, V23, P579; KARTER AJ, 1996, AM J MED, V100, P157; Martin S, 2006, DIABETOLOGIA, V49, P271, DOI 10.1007/s00125-005-0083-5; Miles P, 1997, BRIT MED J, V315, P348; MUCHMORE DB, 1994, ACTA DIABETOL, V31, P215, DOI 10.1007/BF00571954; Muthen LK., 2017, MPLUS, VEight; Peel E, 2007, BMJ-BRIT MED J, V335, P493, DOI 10.1136/bmj.39302.444572.DE; Schwedes U, 2002, DIABETES CARE, V25, P1928, DOI 10.2337/diacare.25.11.1928; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Soumerai SB, 2004, ARCH INTERN MED, V164, P645, DOI 10.1001/archinte.164.6.645; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Watkins KW, 2000, DIABETES CARE, V23, P1511, DOI 10.2337/diacare.23.10.1511; Welschen LMC, 2005, DIABETES CARE, V28, P1510, DOI 10.2337/diacare.28.6.1510	25	210	217	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2008	336	7654					1174	+		10.1136/bmj.39534.571644.BE	http://dx.doi.org/10.1136/bmj.39534.571644.BE			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308WJ	18420662	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000256420900040
J	Simon, J; Gray, A; Clarke, P; Wade, A; Neil, A; Farmer, A				Simon, Judit; Gray, Alastair; Clarke, Philip; Wade, Aisha; Neil, Andrew; Farmer, Andrew		Diabet Glycaem Educ & Monitoring T	Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial	BRITISH MEDICAL JOURNAL			English	Article							METAANALYSIS; THERAPY; CARE	Objective To assess the cost effectiveness of self monitoring of blood glucose alone or with additional training in incorporating the results into self care, in addition to standardised usual care for patients with non-insulin treated type 2 diabetes. Design Incremental cost utility analysis from a healthcare perspective. Data on resource use from the randomised controlled diabetes glycaemic education and monitoring (DiGEM) trial covered 12 months before baseline and 12 months of trial follow-up. Quality of life was measured at baseline and 12 months using the EuroQol EQ-5D questionnaire. Setting Primary care in the United Kingdom. Participants 453 patients with non-insulin treated type 2 diabetes. Interventions Standardised usual care (control) compared with additional self monitoring of blood glucose alone (less intensive self monitoring) or with training in self interpretation of the results (more intensive self monitoring). Main outcome measures Quality adjusted life years and healthcare costs (sterling in 2005-6 prices). Results The average costs of intervention were 89 pound ((euro)113; $179) for standardised usual care, 181 pound for less intensive self monitoring, and 173 pound for more intensive self monitoring, showing an additional cost per patient of 92 pound (95% confidence interval 80 pound to 103) pound in the less intensive group and 84 pound (73 pound to 96) pound in the more intensive group. No other significant cost difference was detected between the groups. An initial negative impact of self monitoring on quality of life occurred, averaging -0.027 (95% confidence interval-0.069 to 0.015) for the less intensive self monitoring group and -0.075 (-0.119 to -0.031) for the more intensive group. Conclusions Self monitoring of blood glucose with or without additional training in incorporating the results into self care was associated with higher costs and lower quality of life in patients with non-insulin treated type 2 diabetes. In light of this, and no clinically significant differences in other outcomes, self monitoring of blood glucose is unlikely to be cost effective in addition to standardised usual care. Trial registration Current Controlled Trials ISRCTN47464659.	[Simon, Judit; Gray, Alastair] Univ Oxford, Dept Publ Hlth, Hlth Econ Res Ctr, Oxford OX3 7LF, England; [Clarke, Philip] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; [Wade, Aisha] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Neil, Andrew] Univ Oxford, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England; [Farmer, Andrew] Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England	University of Oxford; University of Sydney; Johns Hopkins University; University of Oxford; University of Oxford	Simon, J (corresponding author), Univ Oxford, Dept Publ Hlth, Hlth Econ Res Ctr, Oxford OX3 7LF, England.	judit.simon@dphpcox.ac.uk	Jiwa, Moyez/A-1325-2008; Wade, Alisha/A-8180-2011	Simon, Judit/0000-0001-9279-8627; Clarke, Philip/0000-0002-7555-5348; Wade, Alisha/0000-0002-1158-2523				Bang H, 2000, BIOMETRIKA, V87, P329, DOI 10.1093/biomet/87.2.329; *BRIT MED ASS ROYA, 2006, 52 BNF; Coster S, 2000, DIABETIC MED, V17, P755, DOI 10.1046/j.1464-5491.2000.00390.x; CURTIS L, 2006, COSTS HLTH SOCIAL CA; Davidson MB, 2005, DIABETES CARE, V28, P1531, DOI 10.2337/diacare.28.6.1531; *DEP HLTH, 2007, DEP REP GOV EXP PLAN; *DEP HLTH, 2004, REV BOD DOCT DENT RE; Department of Health, 2007, NHS REF COSTS 2005 0; Diabetes UK, 2004, DIAB UK 2004; Dolan P, 1995, SOCIAL TARIFF EUROQO; Drummond MF, 2015, METHODS EC EVALUATIO; Farmer A, 2005, DIABETIC MED, V22, P511, DOI 10.1111/j.1464-5491.2005.01530.x; Farmer A, 2007, BMJ-BRIT MED J, V335, P132, DOI 10.1136/bmj.39247.447431.BE; Farmer Andrew, 2005, BMC Fam Pract, V6, P25, DOI 10.1186/1471-2296-6-25; Fleming DM, 2005, BRIT J GEN PRACT, V55, P589; Gerich JE, 2006, DIABETES EDUCATOR, V32, P513, DOI 10.1177/0145721706290832; Gray A, 2002, BRIT MED J, V325, P860, DOI 10.1136/bmj.325.7369.860; *NAT HLTH SERV, 2007, ANN FIN RET NHS TRUS; NETTEN A, 2002, UNIT COSTS HLTH SOCI; OWENS DR, 2004, DIABETES PRIMARY CAR, V6, P398; Palmer AJ, 2006, CURR MED RES OPIN, V22, P861, DOI 10.1185/030079906X104669; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Sarol JN, 2005, CURR MED RES OPIN, V21, P173, DOI 10.1185/030079904X20286; Welschen LMC, 2005, DIABETES CARE, V28, P1510, DOI 10.2337/diacare.28.6.1510	25	135	140	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2008	336	7654					1177	+		10.1136/bmj.39526.674873.BE	http://dx.doi.org/10.1136/bmj.39526.674873.BE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308WJ	18420663	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000256420900041
J	Veldhoen, M; Hirota, K; Westendorf, AM; Buer, J; Dumoutier, L; Renauld, JC; Stockinger, B				Veldhoen, Marc; Hirota, Keiji; Westendorf, Astrid M.; Buer, Jan; Dumoutier, Laure; Renauld, Jean-Christophe; Stockinger, Brigitta			The aryl hydrocarbon receptor links T(H)17-cell-mediated autoimmunity to environmental toxins	NATURE			English	Article							NF-KAPPA-B; AH RECEPTOR; TH17 CELLS; MICE LACKING; DIFFERENTIATION; INTERLEUKIN-22; IL-22; ENCEPHALOMYELITIS; INFLAMMATION; HEPATOCYTES	The aryl hydrocarbon receptor ( AHR) is a ligand- dependent transcription factor best known for mediating the toxicity of dioxin(1). Environmental factors are believed to contribute to the increased prevalence of autoimmune diseases, many of which are due to the activity of T(H)17 T cells, a new helper T- cell subset characterized by the production of the cytokine IL- 17. Here we show that in the CD4(+) T- cell lineage of mice AHR expression is restricted to the T(H)17 cell subset and its ligation results in the production of the T(H)17 cytokine interleukin ( IL)- 22. AHR is also expressed in human T(H)17 cells. Activation of AHR by a high-affinity ligand during T(H)17 cell development markedly increases the proportion of T(H)17 T cells and their production of cytokines. CD4(+) T cells from AHR- deficient mice can develop T(H)17 cell responses, but when confronted with AHR ligand fail to produce IL- 22 and do not show enhanced T(H)17 cell development. AHR activation during induction of experimental autoimmune encephalomyelitis causes accelerated onset and increased pathology in wild- type mice, but not AHR- deficient mice. AHR ligands may therefore represent co- factors in the development of autoimmune diseases.	[Veldhoen, Marc; Hirota, Keiji; Stockinger, Brigitta] Natl Inst Med Res, MRC, Div Mol Immunol, London NW7 1AA, England; [Westendorf, Astrid M.; Buer, Jan] Univ Hosp Essen, Inst Med Microbiol, D-45122 Essen, Germany; [Westendorf, Astrid M.] Helmholtz Ctr Infect Res, D-38124 Braunschweig, Germany; [Dumoutier, Laure; Renauld, Jean-Christophe] Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium; [Dumoutier, Laure; Renauld, Jean-Christophe] Catholic Univ Louvain, Expt Med Unit, B-1200 Brussels, Belgium	MRC National Institute for Medical Research; University of Duisburg Essen; Helmholtz Association; Helmholtz-Center for Infection Research; Ludwig Institute for Cancer Research; Universite Catholique Louvain	Stockinger, B (corresponding author), Natl Inst Med Res, MRC, Div Mol Immunol, Ridgeway,Mill Hill, London NW7 1AA, England.	bstocki@nimr.mrc.ac.uk	Westendorf, Astrid M./AAX-1937-2020; Veldhoen, Marc/AAJ-2759-2020; Veldhoen, Marc/AAM-5357-2021; Renauld, Jean-Christophe/B-7268-2012	Veldhoen, Marc/0000-0002-1478-9562; Hirota, Keiji/0000-0002-4737-0661; Renauld, Jean-Christophe/0000-0003-1736-2131; Dumoutier, Laure/0000-0002-6645-684X; Stockinger, Brigitta/0000-0001-8781-336X; Buer, Jan/0000-0002-7602-1698	Medical Research Council Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Cox AL, 2005, EUR J IMMUNOL, V35, P3332, DOI 10.1002/eji.200535075; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Funatake CJ, 2005, J IMMUNOL, V175, P4184, DOI 10.4049/jimmunol.175.7.4184; Harper PA, 2006, BIOCHEM PHARMACOL, V72, P267, DOI 10.1016/j.bcp.2006.01.007; Hilliard B, 1999, J IMMUNOL, V163, P2937; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Katiyar SK, 2000, J INVEST DERMATOL, V114, P328, DOI 10.1046/j.1523-1747.2000.00876.x; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kerkvliet NI, 2002, INT IMMUNOPHARMACOL, V2, P277, DOI 10.1016/S1567-5769(01)00179-5; Kreymborg K, 2007, J IMMUNOL, V179, P8098, DOI 10.4049/jimmunol.179.12.8098; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Minamimura K, 2006, J IMMUNOL, V176, P4125, DOI 10.4049/jimmunol.176.7.4125; Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965; Okey AB, 2007, TOXICOL SCI, V98, P5, DOI 10.1093/toxsci/kfm096; Radaeva S, 2004, HEPATOLOGY, V39, P1332, DOI 10.1002/hep.20184; Rannug A, 2006, BIOL CHEM, V387, P1149, DOI 10.1515/BC.2006.143; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Tian YN, 2002, CHEM-BIOL INTERACT, V141, P97, DOI 10.1016/S0009-2797(02)00068-6; Uyttenhove C, 2006, EUR J IMMUNOL, V36, P2868, DOI 10.1002/eji.200636662; Veldhoen M, 2006, NAT IMMUNOL, V7, P1151, DOI 10.1038/ni1391; Zenewicz LA, 2007, IMMUNITY, V27, P647, DOI 10.1016/j.immuni.2007.07.023; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	30	1201	1264	2	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2008	453	7191					106	+		10.1038/nature06881	http://dx.doi.org/10.1038/nature06881			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294ID	18362914	Green Submitted			2022-12-28	WOS:000255398800048
J	Zhou, ZF; Zhu, GS; Hariri, AR; Enoch, MA; Scott, D; Sinha, R; Virkkunen, M; Mash, DC; Lipsky, RH; Hu, XZ; Hodgkinson, CA; Xu, K; Buzas, B; Yuan, QP; Shen, PH; Ferrell, RE; Manuck, SB; Brown, SM; Hauger, RL; Stohler, CS; Zubieta, JK; Goldman, D				Zhou, Zhifeng; Zhu, Guanshan; Hariri, Ahmad R.; Enoch, Mary-Anne; Scott, David; Sinha, Rajita; Virkkunen, Matti; Mash, Deborah C.; Lipsky, Robert H.; Hu, Xian-Zhang; Hodgkinson, Colin A.; Xu, Ke; Buzas, Beata; Yuan, Qiaoping; Shen, Pei-Hong; Ferrell, Robert E.; Manuck, Stephen B.; Brown, Sarah M.; Hauger, Richard L.; Stohler, Christian S.; Zubieta, Jon-Kar; Goldman, David			Genetic variation in human NPY expression affects stress response and emotion	NATURE			English	Article							NEUROPEPTIDE-Y DISTRIBUTION; HUMAN AMYGDALA; SEROTONIN TRANSPORTER; POLYMORPHISM; BRAIN; GENOTYPE; DISEASE; ANXIETY; PAIN; ASSOCIATION	Understanding inter- individual differences in stress response requires the explanation of genetic influences at multiple phenotypic levels, including complex behaviours and the metabolic responses of brain regions to emotional stimuli. Neuropeptide Y ( NPY) is anxiolytic(1,2) and its release is induced by stress(3). NPY is abundantly expressed in regions of the limbic system that are implicated in arousal and in the assignment of emotional valences to stimuli and memories(4-6). Here we show that haplotype- driven NPY expression predicts brain responses to emotional and stress challenges and also inversely correlates with trait anxiety. NPY haplotypes predicted levels of NPY messenger RNA in postmortem brain and lymphoblasts, and levels of plasma NPY. Lower haplotype- driven NPY expression predicted higher emotion- induced activation of the amygdala, as well as diminished resiliency as assessed by pain/ stress- induced activations of endogenous opioid neurotransmission in various brain regions. A single nucleotide polymorphism ( SNP rs16147) located in the promoter region alters NPY expression in vitro and seems to account for more than half of the variation in expression in vivo. These convergent findings are consistent with the function of NPY as an anxiolytic peptide and help to explain inter- individual variation in resiliency to stress, a risk factor for many diseases.	[Zhou, Zhifeng; Zhu, Guanshan; Enoch, Mary-Anne; Lipsky, Robert H.; Hu, Xian-Zhang; Hodgkinson, Colin A.; Xu, Ke; Buzas, Beata; Yuan, Qiaoping; Shen, Pei-Hong; Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; [Hariri, Ahmad R.; Ferrell, Robert E.; Manuck, Stephen B.; Brown, Sarah M.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15261 USA; [Hariri, Ahmad R.; Ferrell, Robert E.; Manuck, Stephen B.; Brown, Sarah M.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA; [Hariri, Ahmad R.; Ferrell, Robert E.; Manuck, Stephen B.; Brown, Sarah M.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15261 USA; [Scott, David; Zubieta, Jon-Kar] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA; [Scott, David; Zubieta, Jon-Kar] Univ Michigan, Sch Med, Dept Radiol, Ann Arbor, MI 48109 USA; [Sinha, Rajita] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06510 USA; [Virkkunen, Matti] Univ Helsinki, Dept Psychiat, Helsinki 00014, Finland; [Mash, Deborah C.] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33124 USA; [Hauger, Richard L.] San Diego VA Healthcare Syst, Dept Psychiat, San Diego, CA 92161 USA; [Hauger, Richard L.] Univ Calif San Diego, San Diego, CA 92161 USA; [Stohler, Christian S.] Univ Maryland, Sch Dent, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yale University; University of Helsinki; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University System of Maryland; University of Maryland Baltimore	Goldman, D (corresponding author), NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA.	davidgoldman@mail.nih.gov	Hariri, Ahmad/D-5761-2011; Goldman, David/F-9772-2010; STOHLER, CHRISTIAN/AAQ-7539-2020; Zubieta, Jon-Kar/AAB-5565-2022; Majid, Salma/AAT-2616-2020	Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405; Yuan, Qiaoping/0000-0002-5880-8702; Lipsky, Robert/0000-0001-7753-1473; Hodgkinson, Colin/0000-0002-5365-8119; Shen, Pei-Hong/0000-0002-8031-9374; Stohler, Christian S/0000-0003-0443-6146	Intramural NIH HHS [Z01 AA000301-09, Z99 AA999999] Funding Source: Medline; NHLBI NIH HHS [R01 HL065137, P01 HL040962] Funding Source: Medline; NIAAA NIH HHS [R01 AA013892, R01-AA13892] Funding Source: Medline; NIDA NIH HHS [R01 DA 016423, P50 DA016556, PL1 DA024859-02, K02 DA017232, R01 DA016423, K02-DA17232, P50-DA16556, PL1 DA024859] Funding Source: Medline; NIDCR NIH HHS [R01 DE015396, R01 DE 15396] Funding Source: Medline; NIMH NIH HHS [R01 MH074697, K01 MH072837, R01 MH074697-04A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040962, R01HL065137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH074697, K01MH072837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013892, Z01AA000305, Z01AA000301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA017232, R01DA016423, PL1DA024859, P50DA016556] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADRIAN TE, 1983, NATURE, V306, P584, DOI 10.1038/306584a0; ALLEN R, 1991, CLIN EXP PHARMACOL P, V18, P825, DOI 10.1111/j.1440-1681.1991.tb01402.x; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Britton KT, 2001, PEPTIDES, V22, P607, DOI 10.1016/S0196-9781(01)00371-0; BROQUA P, 1995, BEHAV PHARMACOL, V6, P215; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Enoch Mary-Anne, 2006, J Psychopharmacol, V20, P19, DOI 10.1177/1359786806066041; Haas BW, 2007, BEHAV NEUROSCI, V121, P249, DOI 10.1037/0735-7044.121.2.249; Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829; Hariri AR, 2005, ARCH GEN PSYCHIAT, V62, P146, DOI 10.1001/archpsyc.62.2.146; HEILIG M, 1989, PSYCHOPHARMACOLOGY, V98, P524, DOI 10.1007/BF00441953; Heinz A, 2005, NAT NEUROSCI, V8, P20, DOI 10.1038/nn1366; Horsell A, 1999, NEUROREPORT, V10, P3003, DOI 10.1097/00001756-199909290-00024; Karvonen MK, 1998, NAT MED, V4, P1434, DOI 10.1038/4027; Li Y, 2002, BRAIN RES, V940, P69, DOI 10.1016/S0006-8993(02)02594-5; McEwen BS, 2000, NEUROPSYCHOPHARMACOL, V22, P108, DOI 10.1016/S0893-133X(99)00129-3; MCEWEN BS, 1993, ARCH INTERN MED, V153, P2093, DOI 10.1001/archinte.153.18.2093; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Moles A, 2004, SCIENCE, V304, P1983, DOI 10.1126/science.1095943; Niskanen L, 2000, EXP CLIN ENDOCR DIAB, V108, P235, DOI 10.1055/s-2000-7748; Pezawas L, 2005, NAT NEUROSCI, V8, P828, DOI 10.1038/nn1463; Rosenberg NA, 2003, AM J HUM GENET, V73, P1402, DOI 10.1086/380416; Sen S, 2004, AM J MED GENET B, V127B, P85, DOI 10.1002/ajmg.b.20158; Sinha R, 2006, ARCH GEN PSYCHIAT, V63, P324, DOI 10.1001/archpsyc.63.3.324; Somerville LH, 2004, BIOL PSYCHIAT, V55, P897, DOI 10.1016/j.biopsych.2004.01.007; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TEMPLETON AR, 1995, GENETICS, V140, P403; Tessitore A, 2002, J NEUROSCI, V22, P9099, DOI 10.1523/jneurosci.22-20-09099.2002; WATKINS LR, 1982, SCIENCE, V216, P1185, DOI 10.1126/science.6281891; Zhu GS, 2004, PSYCHOPHARMACOLOGY, V177, P178, DOI 10.1007/s00213-004-1938-z; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	35	327	336	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2008	452	7190					997	U8		10.1038/nature06858	http://dx.doi.org/10.1038/nature06858			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	291PF	18385673	Green Accepted, Green Published			2022-12-28	WOS:000255208600040
J	Bland, PA				Bland, Philip A.			Astronomy - Small-scale observations tell a cosmological story	SCIENCE			English	Editorial Material									[Bland, Philip A.] Univ London Imperial Coll Sci Technol & Med, Dept Earth Sci & Engn, Impacts & Astromat Res Ctr, London SW7 2AZ, England	Imperial College London; Natural History Museum London	Bland, PA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Earth Sci & Engn, Impacts & Astromat Res Ctr, London SW7 2AZ, England.	p.a.bland@imperial.ac.uk	Bland, Phil/M-9392-2018	Bland, Phil/0000-0002-4681-7898				Aguirre AN, 1999, ASTROPHYS J, V512, pL19, DOI 10.1086/311862; Amelin Y, 2002, SCIENCE, V297, P1678, DOI 10.1126/science.1073950; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Dwek E, 2004, ASTROPHYS J, V611, pL109, DOI 10.1086/423893; Fries M, 2008, SCIENCE, V320, P91, DOI 10.1126/science.1153578; Huss G. R., 2005, ASP C SERIES, V341, P701; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; Riess AG, 2004, ASTROPHYS J, V607, P665, DOI 10.1086/383612; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Robaina AR, 2007, ASTRON ASTROPHYS, V464, P465, DOI 10.1051/0004-6361:20065292; Russell S.S., 2005, CHONDRITES PROTOPLAN, P317; WICKRAMASINGHE NC, 1994, NATURE, V368, P695, DOI 10.1038/368695a0; Zinner EK, 2005, TREATISE GEOCHEM, V1, P17	13	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2008	320	5872					61	62		10.1126/science.1155284	http://dx.doi.org/10.1126/science.1155284			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388282				2022-12-28	WOS:000254633000027
J	Roberts, WA; Feeney, MC; MacPherson, K; Petter, M; McMillan, N; Musolino, E				Roberts, William A.; Feeney, Miranda C.; MacPherson, Krista; Petter, Mark; McMillan, Neil; Musolino, Evanya			Episodic-like memory in rats: Is it based on when or how long ago?	SCIENCE			English	Article							SCRUB JAYS; TIME; DISCRIMINATION; REMEMBER	Recent experiments with rats suggest that they show episodic- like or what- where- when memory for a preferred food found on a radial maze. Although memory for when a salient event occurred suggests that rats can mentally travel in time to a moment in the past, an alternative possibility is that they remember how long ago the food was found. Three groups of rats were tested for memory of previously encountered food. The different groups could use only the cues of when, how long ago, or when + how long ago. Only the cue of how long ago food was encountered was used successfully. These results suggest that episodic- like memory in rats is qualitatively different from human episodic memory.	[Roberts, William A.; Feeney, Miranda C.; MacPherson, Krista; McMillan, Neil; Musolino, Evanya] Univ Western Ontario, Dept Psychol, London, ON N6A 5C2, Canada; [Petter, Mark] Dalhousie Univ, Dept Psychol, Halifax, NS B3H 4J1, Canada	Western University (University of Western Ontario); Dalhousie University	Roberts, WA (corresponding author), Univ Western Ontario, Dept Psychol, London, ON N6A 5C2, Canada.	roberts@uwo.ca	McMillan, Neil/AAD-7675-2020	McMillan, Neil/0000-0003-0027-3095				[Anonymous], 1983, CANADIAN PSYCHOL; Babb SJ, 2005, LEARN MOTIV, V36, P177, DOI 10.1016/j.lmot.2005.02.009; Babb SJ, 2006, LEARN BEHAV, V34, P124, DOI 10.3758/BF03193188; Babb SJ, 2006, CURR BIOL, V16, P1317, DOI 10.1016/j.cub.2006.05.025; CHURCH RM, 1990, COGNITION, V37, P55, DOI 10.1016/0010-0277(90)90018-F; Clayton NS, 1998, NATURE, V395, P272, DOI 10.1038/26216; Clayton NS, 1999, J COMP PSYCHOL, V113, P403, DOI 10.1037/0735-7036.113.4.403; Clayton NS, 2001, J EXP PSYCHOL-ANIM B, V27, P17, DOI 10.1037//0097-7403.27.1.17; Crystal JD, 2006, BEHAV PROCESS, V72, P149, DOI 10.1016/j.beproc.2006.01.010; FRIEDMAN WJ, 1993, PSYCHOL BULL, V113, P44, DOI 10.1037/0033-2909.113.1.44; GIBBON J, 1991, LEARN MOTIV, V22, P3, DOI 10.1016/0023-9690(91)90015-Z; Griffiths D, 1999, TRENDS COGN SCI, V3, P74, DOI 10.1016/S1364-6613(98)01272-8; KILLEEN PR, 1988, PSYCHOL REV, V95, P274, DOI 10.1037/0033-295X.95.2.274; Naqshbandi M, 2007, BEHAV PROCESS, V74, P217, DOI 10.1016/j.beproc.2006.10.010; Roberts WA, 2002, PSYCHOL BULL, V128, P473, DOI 10.1037//0033-2909.128.3.473; Staddon JER, 1999, J EXP ANAL BEHAV, V71, P215, DOI 10.1901/jeab.1999.71-215; Suddendorf T, 1997, GENET SOC GEN PSYCH, V123, P133; Suddendorf T, 2007, BEHAV BRAIN SCI, V30, P299, DOI 10.1017/S0140525X07001975; TULVING E, 1985, AM PSYCHOL, V40, P385, DOI 10.1037/0003-066x.40.4.385; Tulving E., 1972, ORG MEMORY, DOI DOI 10.1017/S0140525X00047257	20	103	104	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2008	320	5872					113	115		10.1126/science.1152709	http://dx.doi.org/10.1126/science.1152709			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	283JR	18388296				2022-12-28	WOS:000254633000044
J	Stein, JH; Currier, JS				Stein, James H.; Currier, Judith S.			Risk of myocardial infarction and nucleoside analogues	LANCET			English	Editorial Material							PROTEASE INHIBITORS; ABACAVIR		[Stein, James H.] Univ Wisconsin, Sch Med & Publ Hlth, Div Cardiovasc Med, Madison, WI 53717 USA; [Currier, Judith S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, UCLA Ctr Clin AIDS Res & Educ, Los Angeles, CA 90095 USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Stein, JH (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Div Cardiovasc Med, Madison, WI 53717 USA.	jhs@medicine.wisc.edu		Stein, James/0000-0002-2770-8223				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Clumeck N, 2001, AIDS, V15, P1517, DOI 10.1097/00002030-200108170-00009; CUTRELL A, 2008, LANCET          0402; *DAD STUD GROUP, 2008, LANCET          0402; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723, DOI 10.1056/NEJMoa062744; Keiser PH, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-2; Martinez E, 2003, NEW ENGL J MED, V349, P1036, DOI 10.1056/NEJMoa021589; STEIN JH, 2005, CIRCULATIONS, V112, P23	9	7	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR-MAY	2008	371	9622					1391	1392		10.1016/S0140-6736(08)60491-2	http://dx.doi.org/10.1016/S0140-6736(08)60491-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294XW	18387666				2022-12-28	WOS:000255440600004
J	Larson, MH; Greenleaf, WJ; Landick, R; Block, SM				Larson, Matthew H.; Greenleaf, William J.; Landick, Robert; Block, Steven M.			Applied force reveals mechanistic and energetic details of transcription termination	CELL			English	Article							RNA-POLYMERASE MOLECULES; ESCHERICHIA-COLI RNA; SINGLE-MOLECULE; ELONGATION COMPLEX; STRUCTURAL BASIS; NUCLEIC-ACID; REGULATORY STRATEGY; NASCENT RNA; SEQUENCE; ATTENUATION	Transcription termination by bacterial RNA polymerase (RNAP) occurs at sequences coding for a GC-rich RNA hairpin followed by a U-rich tract. We used single-molecule techniques to investigate the mechanism by which three representative terminators (his, t500, and tR2) destabilize the elongation complex (EC). For his and tR2 terminators, loads exerted to bias translocation did not affect termination efficiency (TE). However, the force-dependent kinetics of release and the force-dependent TE of a mutant imply a forward translocation mechanism for the t500 terminator. Tension on isolated U-tracts induced transcript release in a manner consistent with RNA: DNA hybrid shearing. We deduce that different mechanisms, involving hypertranslocation or shearing, operate at terminators with different U-tracts. Tension applied to RNA at terminators suggests that closure of the final 2-3 hairpin bases destabilizes the hybrid and that competing RNA structures modulate TE. We propose a quantitative, energetic model that predicts the behavior for these terminators and mutant variants.	[Greenleaf, William J.; Block, Steven M.] Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; [Larson, Matthew H.] Stanford Univ, Biophys Program, Stanford, CA 94305 USA; [Block, Steven M.] Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; [Landick, Robert] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Stanford University; Stanford University; Stanford University; University of Wisconsin System; University of Wisconsin Madison	Block, SM (corresponding author), Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.	sblock@stanford.edu	Larson, Matthew/C-8289-2014	Larson, Matthew/0000-0002-6778-2604	NIGMS NIH HHS [R01 GM057035-03, R37 GM038660, R01 GM057035-11, R01 GM038660, R37 GM057035, R01 GM057035, GM38660, GM057035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038660, R29GM038660, R01GM057035, R01GM038660, R37GM057035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbondanzieri EA, 2005, NATURE, V438, P460, DOI 10.1038/nature04268; Adelman K, 2002, P NATL ACAD SCI USA, V99, P13538, DOI 10.1073/pnas.212358999; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; Dalal RV, 2006, MOL CELL, V23, P231, DOI 10.1016/j.molcel.2006.06.023; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Greenleaf WJ, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.208102; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Herbert KM, 2006, CELL, V125, P1083, DOI 10.1016/j.cell.2006.04.032; Komissarova N, 2002, MOL CELL, V10, P1151, DOI 10.1016/S1097-2765(02)00738-4; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Korzheva N, 1998, COLD SPRING HARB SYM, V63, P337, DOI 10.1101/sqb.1998.63.337; Lang MJ, 2004, NAT METHODS, V1, P133, DOI 10.1038/NMETH714; Lesnik EA, 2001, NUCLEIC ACIDS RES, V29, P3583, DOI 10.1093/nar/29.17.3583; Liphardt J, 2001, SCIENCE, V292, P733, DOI 10.1126/science.1058498; MACDONALD LE, 1993, NUCLEIC ACIDS RES, V8, P2295; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Merino E, 2005, TRENDS GENET, V21, P260, DOI 10.1016/j.tig.2005.03.002; Neuman KC, 1999, BIOPHYS J, V77, P2856, DOI 10.1016/S0006-3495(99)77117-1; Neuman KC, 2003, CELL, V115, P437, DOI 10.1016/S0092-8674(03)00845-6; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; ODIJK T, 1995, MACROMOLECULES, V28, P7016, DOI 10.1021/ma00124a044; PLATT T, 1981, CELL, V24, P10, DOI 10.1016/0092-8674(81)90496-7; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; Santangelo TJ, 2004, MOL CELL, V14, P117, DOI 10.1016/S1097-2765(04)00154-6; Seol Y, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.118102; Shaevitz JW, 2003, NATURE, V426, P684, DOI 10.1038/nature02191; Shundrovsky A, 2004, BIOPHYS J, V87, P3945, DOI 10.1529/biophysj.104.044081; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Toulokhonov I, 2003, MOL CELL, V12, P1125, DOI 10.1016/S1097-2765(03)00439-8; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; Vassylyev DG, 2007, NATURE, V448, P163, DOI 10.1038/nature05931; Vassylyev DG, 2007, NATURE, V448, P157, DOI 10.1038/nature05932; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; Woodside MT, 2006, SCIENCE, V314, P1001, DOI 10.1126/science.1133601; Woodside MT, 2006, P NATL ACAD SCI USA, V103, P6190, DOI 10.1073/pnas.0511048103; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; Yanofsky C, 2000, J BACTERIOL, V182, P1, DOI 10.1128/JB.182.1.1-8.2000; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	43	121	126	0	29	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 21	2008	132	6					971	982		10.1016/j.cell.2008.01.027	http://dx.doi.org/10.1016/j.cell.2008.01.027			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	278GR	18358810	Green Accepted, Bronze			2022-12-28	WOS:000254273600016
J	Altman, DG; Simera, I; Hoey, J; Moher, D; Schutz, K				Altman, Douglas G.; Simera, Iveta; Hoey, John; Moher, David; Schutz, Ken			EQUATOR: reporting guidelines for health research	LANCET			English	Editorial Material							QUALITY; INSTRUCTIONS; ENDORSEMENT; STATEMENT; JOURNALS; TRIALS		[Altman, Douglas G.; Simera, Iveta] Univ Oxford, Ctr Stat Med, Oxford OX2 6UD, England; [Hoey, John] Queens Univ, Kingston, ON, Canada; [Moher, David] Univ Ottawa, Chalmers Res Grp, Ottawa, ON, Canada; [Schutz, Ken] Family Hlth Int, Quantitat Sci, Durham, NC USA	University of Oxford; Queens University - Canada; University of Ottawa	Simera, I (corresponding author), Univ Oxford, Ctr Stat Med, Oxford OX2 6UD, England.	iveta.simera@cancer.org.uk	Simera, Iveta/AFN-5638-2022	Simera, Iveta/0000-0001-5785-6756; Moher, David/0000-0003-2434-4206	MRC [MC_qA137931] Funding Source: UKRI; Medical Research Council [MC_qA137931] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Altman DG, 2005, BMJ-BRIT MED J, V330, P1056, DOI 10.1136/bmj.330.7499.1056; Bossuyt PM, 2003, CLIN CHEM, V49, P1, DOI 10.1373/49.1.1; Chan AW, 2005, LANCET, V365, P1159, DOI 10.1016/S0140-6736(05)71879-1; Mallett S, 2006, BMJ-BRIT MED J, V333, P413, DOI 10.1136/bmj.38895.467130.55; Mills E, 2004, BRIT J CLIN PHARMACO, V58, P61, DOI 10.1111/j.1365-2125.2004.2092.x; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Pocock SJ, 2004, BMJ-BRIT MED J, V329, P883, DOI 10.1136/bmj.38250.571088.55; Riley RD, 2003, BRIT J CANCER, V88, P1191, DOI 10.1038/sj.bjc.6600886; Smidt N, 2005, RADIOLOGY, V235, P347, DOI 10.1148/radiol.2352040507; Smidt N, 2007, CLIN CHEM, V53, P1983, DOI 10.1373/clinchem.2007.090167; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]	12	166	167	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2008	371	9619					1149	1150		10.1016/S0140-6736(08)60505-X	http://dx.doi.org/10.1016/S0140-6736(08)60505-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZM	18395566	Green Submitted			2022-12-28	WOS:000254956000011
